[
  {
    "id": "7",
    "Sentence": "Prevention of <\\entity><\\entity> in patients with primary brain tumors: preliminary experience with oxcarbazepine.Early postoperative seizures are defined as those that appear within the first week after surgery and are a well-known and feared complication in patients with supratentorial brain tumors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8",
    "Sentence": "Prevention of early postoperative seizures in patients with <\\entity><\\entity>: preliminary experience with oxcarbazepine.Early postoperative seizures are defined as those that appear within the first week after surgery and are a well-known and feared complication in patients with supratentorial brain tumors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9",
    "Sentence": "Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with <\\entity><\\entity>.Early postoperative seizures are defined as those that appear within the first week after surgery and are a well-known and feared complication in patients with supratentorial brain tumors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10",
    "Sentence": "Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine.<\\entity><\\entity> are defined as those that appear within the first week after surgery and are a well-known and feared complication in patients with supratentorial brain tumors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11",
    "Sentence": "Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine.Early postoperative seizures are defined as those that appear within the first week after surgery and are a well-known and feared <\\entity><\\entity> in patients with supratentorial brain tumors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12",
    "Sentence": "Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine.Early postoperative seizures are defined as those that appear within the first week after surgery and are a well-known and feared complication in patients with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13",
    "Sentence": "Few studies have investigated the value of pharmacological prophylaxis in the prevention of <\\entity><\\entity> in these patients and their outcome has not been consistent.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14",
    "Sentence": "Furthermore, the efficacy of the new generation of <\\entity><\\entity> in the prophylaxis of perioperative seizures has not been assessed so far.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15",
    "Sentence": "Furthermore, the efficacy of the new generation of antiepileptic agents in the prophylaxis of <\\entity><\\entity> has not been assessed so far.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16",
    "Sentence": "We analyzed the data related to 150 patients harboring <\\entity><\\entity> with the aim to assess the efficacy of oxcarbazepine in preventing the occurrence or the recurrence of early postoperative seizures and its tolerability when it is rapidly titrated.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17",
    "Sentence": "We analyzed the data related to 150 patients harboring supratentorial brain gliomas with the aim to assess the efficacy of <\\entity><\\entity> in preventing the occurrence or the recurrence of early postoperative seizures and its tolerability when it is rapidly titrated.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "18",
    "Sentence": "We analyzed the data related to 150 patients harboring supratentorial brain gliomas with the aim to assess the efficacy of oxcarbazepine in preventing the occurrence or the recurrence of <\\entity><\\entity> and its tolerability when it is rapidly titrated.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "19",
    "Sentence": "Only four patients (2.7%) experienced <\\entity><\\entity> within the first week after surgery.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "20",
    "Sentence": "Regarding adverse events in the first week, six patients (4%) showed <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "21",
    "Sentence": "Persistent symptomatic <\\entity><\\entity> never occurred.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "22",
    "Sentence": "Our data showed that <\\entity><\\entity> can be a good alternative to traditional antiepileptic agents in the prevention of perioperative seizures being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "23",
    "Sentence": "Our data showed that oxcarbazepine can be a good alternative to traditional <\\entity><\\entity> in the prevention of perioperative seizures being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "24",
    "Sentence": "Our data showed that oxcarbazepine can be a good alternative to traditional antiepileptic agents in the prevention of <\\entity><\\entity> being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "25",
    "Sentence": "Our data showed that oxcarbazepine can be a good alternative to traditional antiepileptic agents in the prevention of perioperative seizures being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no <\\entity><\\entity> during titration and during the first postoperative week) the key factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "26",
    "Sentence": "Moreover, <\\entity><\\entity> can be a valid choice when long-term therapy is required because of the low interaction with other drugs and the low hematological side effects.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "27",
    "Sentence": "Moreover, oxcarbazepine can be a valid choice when long-term therapy is required because of the low interaction with other drugs and the low <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "28",
    "Sentence": "Furthermore, the efficacy of the new generation of <\\entity><\\entity> in the prophylaxis of perioperative seizures has not been assessed so far.",
    "Label": ""
  },
  {
    "id": "29",
    "Sentence": "Furthermore, the efficacy of the new generation of antiepileptic agents in the prophylaxis of <\\entity><\\entity> has not been assessed so far.",
    "Label": ""
  },
  {
    "id": "31",
    "Sentence": "Our data showed that <\\entity><\\entity> can be a good alternative to traditional antiepileptic agents in the prevention of perioperative seizures being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors.",
    "Label": ""
  },
  {
    "id": "32",
    "Sentence": "Our data showed that oxcarbazepine can be a good alternative to traditional antiepileptic agents in the prevention of <\\entity><\\entity> being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors.",
    "Label": ""
  },
  {
    "id": "34",
    "Sentence": "Our data showed that <\\entity><\\entity> can be a good alternative to traditional antiepileptic agents in the prevention of perioperative seizures being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors.",
    "Label": ""
  },
  {
    "id": "35",
    "Sentence": "Our data showed that oxcarbazepine can be a good alternative to traditional antiepileptic agents in the prevention of perioperative seizures being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no <\\entity><\\entity> during titration and during the first postoperative week) the key factors.",
    "Label": ""
  },
  {
    "id": "37",
    "Sentence": "Moreover, <\\entity><\\entity> can be a valid choice when long-term therapy is required because of the low interaction with other drugs and the low hematological side effects.",
    "Label": ""
  },
  {
    "id": "38",
    "Sentence": "Moreover, oxcarbazepine can be a valid choice when long-term therapy is required because of the low interaction with other drugs and the low <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "40",
    "Sentence": "Our data showed that oxcarbazepine can be a good alternative to traditional <\\entity><\\entity> in the prevention of perioperative seizures being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors.",
    "Label": ""
  },
  {
    "id": "41",
    "Sentence": "Our data showed that oxcarbazepine can be a good alternative to traditional antiepileptic agents in the prevention of <\\entity><\\entity> being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors.",
    "Label": ""
  },
  {
    "id": "43",
    "Sentence": "Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with <\\entity><\\entity>.Early postoperative seizures are defined as those that appear within the first week after surgery and are a well-known and feared complication in patients with supratentorial brain tumors.",
    "Label": ""
  },
  {
    "id": "44",
    "Sentence": "Prevention of <\\entity><\\entity> in patients with primary brain tumors: preliminary experience with oxcarbazepine.Early postoperative seizures are defined as those that appear within the first week after surgery and are a well-known and feared complication in patients with supratentorial brain tumors.",
    "Label": ""
  },
  {
    "id": "46",
    "Sentence": "Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with <\\entity><\\entity>.Early postoperative seizures are defined as those that appear within the first week after surgery and are a well-known and feared complication in patients with supratentorial brain tumors.",
    "Label": ""
  },
  {
    "id": "47",
    "Sentence": "Prevention of early postoperative seizures in patients with <\\entity><\\entity>: preliminary experience with oxcarbazepine.Early postoperative seizures are defined as those that appear within the first week after surgery and are a well-known and feared complication in patients with supratentorial brain tumors.",
    "Label": ""
  },
  {
    "id": "49",
    "Sentence": "We analyzed the data related to 150 patients harboring supratentorial brain gliomas with the aim to assess the efficacy of <\\entity><\\entity> in preventing the occurrence or the recurrence of early postoperative seizures and its tolerability when it is rapidly titrated.",
    "Label": ""
  },
  {
    "id": "50",
    "Sentence": "We analyzed the data related to 150 patients harboring supratentorial brain gliomas with the aim to assess the efficacy of oxcarbazepine in preventing the occurrence or the recurrence of <\\entity><\\entity> and its tolerability when it is rapidly titrated.",
    "Label": ""
  },
  {
    "id": "52",
    "Sentence": "We analyzed the data related to 150 patients harboring supratentorial brain gliomas with the aim to assess the efficacy of <\\entity><\\entity> in preventing the occurrence or the recurrence of early postoperative seizures and its tolerability when it is rapidly titrated.",
    "Label": ""
  },
  {
    "id": "53",
    "Sentence": "We analyzed the data related to 150 patients harboring <\\entity><\\entity> with the aim to assess the efficacy of oxcarbazepine in preventing the occurrence or the recurrence of early postoperative seizures and its tolerability when it is rapidly titrated.",
    "Label": ""
  },
  {
    "id": "55",
    "Sentence": "Our data showed that <\\entity><\\entity> can be a good alternative to traditional antiepileptic agents in the prevention of perioperative seizures being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors.",
    "Label": ""
  },
  {
    "id": "56",
    "Sentence": "Our data showed that oxcarbazepine can be a good alternative to traditional antiepileptic agents in the prevention of perioperative seizures being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no <\\entity><\\entity> during titration and during the first postoperative week) the key factors.",
    "Label": ""
  },
  {
    "id": "62",
    "Sentence": "<\\entity><\\entity> and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (pSS), and changes in B cell biomarkers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "63",
    "Sentence": "Tolerance and efficacy of <\\entity><\\entity> and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of <\\entity><\\entity> (RTX) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (pSS), and changes in B cell biomarkers.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "64",
    "Sentence": "Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic <\\entity><\\entity> of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (pSS), and changes in B cell biomarkers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "65",
    "Sentence": "Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of <\\entity><\\entity>.OBJECTIVE: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with <\\entity><\\entity> (pSS), and changes in B cell biomarkers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "66",
    "Sentence": "Tolerance and efficacy of <\\entity><\\entity> and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of <\\entity><\\entity> (RTX) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (pSS), and changes in B cell biomarkers.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "67",
    "Sentence": "Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of rituximab (<\\entity><\\entity>) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (pSS), and changes in B cell biomarkers.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "68",
    "Sentence": "Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of rituximab (RTX) for <\\entity><\\entity> in patients with primary SjÃ¶gren's syndrome (pSS), and changes in B cell biomarkers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "69",
    "Sentence": "Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of <\\entity><\\entity>.OBJECTIVE: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with <\\entity><\\entity> (pSS), and changes in B cell biomarkers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "70",
    "Sentence": "Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (<\\entity><\\entity>), and changes in B cell biomarkers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "71",
    "Sentence": "PATIENTS AND METHODS: The records of 16 patients with <\\entity><\\entity> according to the American European consensus group criteria were reviewed retrospectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "72",
    "Sentence": "RESULTS: Patients, all women, had a median age of 58.5 (range 41-71) years and a <\\entity><\\entity> duration of 9.5 (range 0-25) years.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "73",
    "Sentence": "<\\entity><\\entity> was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "74",
    "Sentence": "RTX was prescribed for <\\entity><\\entity> (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "75",
    "Sentence": "RTX was prescribed for lymphoma (n = 5), <\\entity><\\entity> (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "76",
    "Sentence": "RTX was prescribed for lymphoma (n = 5), refractory <\\entity><\\entity> with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "77",
    "Sentence": "RTX was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), <\\entity><\\entity> (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "78",
    "Sentence": "RTX was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), <\\entity><\\entity> (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "79",
    "Sentence": "RTX was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), <\\entity><\\entity> (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "80",
    "Sentence": "RTX was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and <\\entity><\\entity> (n = 1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "81",
    "Sentence": "Three patients experienced adverse events, including one mild <\\entity><\\entity> with the presence of human antichimeric antibodies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "82",
    "Sentence": "Efficacy of treatment was observed in 4 of 5 patients with <\\entity><\\entity> and in 9 of 11 patients with systemic involvement.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "83",
    "Sentence": "<\\entity><\\entity> was improved in only a minority of patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "84",
    "Sentence": "<\\entity><\\entity> dose was reduced in 11 patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "85",
    "Sentence": "<\\entity><\\entity> induced decreased rheumatoid factor, gamma-globulin and beta2-microglobulin levels, and the level of B cell activating factor of the tumour necrosis factor family (BAFF) increased concomitantly with B cell depletion.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "86",
    "Sentence": "RTX induced decreased rheumatoid factor, gamma-globulin and beta2-microglobulin levels, and the level of B cell activating factor of the <\\entity><\\entity> factor family (BAFF) increased concomitantly with B cell depletion.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "87",
    "Sentence": "Five patients were re-treated, with good efficacy and <\\entity><\\entity>, except for one with probable serum sickness-like reaction.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "88",
    "Sentence": "Five patients were re-treated, with good efficacy and tolerance, except for one with probable <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "89",
    "Sentence": "CONCLUSION: This study shows good efficacy and fair <\\entity><\\entity> of RTX for systemic features.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "90",
    "Sentence": "CONCLUSION: This study shows good efficacy and fair tolerance of <\\entity><\\entity> for systemic features.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "91",
    "Sentence": "In addition, <\\entity><\\entity> allows for a marked reduction in corticosteroid use.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "92",
    "Sentence": "In addition, RTX allows for a marked reduction in <\\entity><\\entity> use.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "93",
    "Sentence": "Except for BAFF, the level of which increases, serum B cell biomarker levels decrease after taking <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "94",
    "Sentence": "Controlled trials should be performed to confirm the efficacy of <\\entity><\\entity> in pSS.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "95",
    "Sentence": "Controlled trials should be performed to confirm the efficacy of RTX in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "96",
    "Sentence": "<\\entity><\\entity> was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": ""
  },
  {
    "id": "97",
    "Sentence": "RTX was prescribed for <\\entity><\\entity> (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": ""
  },
  {
    "id": "99",
    "Sentence": "<\\entity><\\entity> was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": ""
  },
  {
    "id": "100",
    "Sentence": "RTX was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), <\\entity><\\entity> (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": ""
  },
  {
    "id": "102",
    "Sentence": "<\\entity><\\entity> was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": ""
  },
  {
    "id": "103",
    "Sentence": "RTX was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), <\\entity><\\entity> (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": ""
  },
  {
    "id": "105",
    "Sentence": "<\\entity><\\entity> was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": ""
  },
  {
    "id": "106",
    "Sentence": "RTX was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and <\\entity><\\entity> (n = 1).",
    "Label": ""
  },
  {
    "id": "108",
    "Sentence": "<\\entity><\\entity> was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": ""
  },
  {
    "id": "109",
    "Sentence": "RTX was prescribed for lymphoma (n = 5), <\\entity><\\entity> (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": ""
  },
  {
    "id": "111",
    "Sentence": "<\\entity><\\entity> was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": ""
  },
  {
    "id": "112",
    "Sentence": "RTX was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), <\\entity><\\entity> (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1).",
    "Label": ""
  },
  {
    "id": "114",
    "Sentence": "Controlled trials should be performed to confirm the efficacy of <\\entity><\\entity> in pSS.",
    "Label": ""
  },
  {
    "id": "115",
    "Sentence": "Controlled trials should be performed to confirm the efficacy of RTX in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "117",
    "Sentence": "<\\entity><\\entity> induced decreased rheumatoid factor, gamma-globulin and beta2-microglobulin levels, and the level of B cell activating factor of the tumour necrosis factor family (BAFF) increased concomitantly with B cell depletion.",
    "Label": ""
  },
  {
    "id": "118",
    "Sentence": "RTX induced decreased rheumatoid factor, gamma-globulin and beta2-microglobulin levels, and the level of B cell activating factor of the <\\entity><\\entity> factor family (BAFF) increased concomitantly with B cell depletion.",
    "Label": ""
  },
  {
    "id": "120",
    "Sentence": "Tolerance and efficacy of <\\entity><\\entity> and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of <\\entity><\\entity> (RTX) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (pSS), and changes in B cell biomarkers.",
    "Label": ""
  },
  {
    "id": "121",
    "Sentence": "Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic <\\entity><\\entity> of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (pSS), and changes in B cell biomarkers.",
    "Label": ""
  },
  {
    "id": "123",
    "Sentence": "Tolerance and efficacy of <\\entity><\\entity> and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of <\\entity><\\entity> (RTX) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (pSS), and changes in B cell biomarkers.",
    "Label": ""
  },
  {
    "id": "124",
    "Sentence": "Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of <\\entity><\\entity>.OBJECTIVE: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with <\\entity><\\entity> (pSS), and changes in B cell biomarkers.",
    "Label": ""
  },
  {
    "id": "126",
    "Sentence": "Tolerance and efficacy of <\\entity><\\entity> and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of <\\entity><\\entity> (RTX) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (pSS), and changes in B cell biomarkers.",
    "Label": ""
  },
  {
    "id": "127",
    "Sentence": "Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of <\\entity><\\entity>.OBJECTIVE: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with <\\entity><\\entity> (pSS), and changes in B cell biomarkers.",
    "Label": ""
  },
  {
    "id": "129",
    "Sentence": "Tolerance and efficacy of <\\entity><\\entity> and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of <\\entity><\\entity> (RTX) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (pSS), and changes in B cell biomarkers.",
    "Label": ""
  },
  {
    "id": "130",
    "Sentence": "Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of rituximab (RTX) for <\\entity><\\entity> in patients with primary SjÃ¶gren's syndrome (pSS), and changes in B cell biomarkers.",
    "Label": ""
  },
  {
    "id": "132",
    "Sentence": "Tolerance and efficacy of <\\entity><\\entity> and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of <\\entity><\\entity> (RTX) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (pSS), and changes in B cell biomarkers.",
    "Label": ""
  },
  {
    "id": "133",
    "Sentence": "Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (<\\entity><\\entity>), and changes in B cell biomarkers.",
    "Label": ""
  },
  {
    "id": "135",
    "Sentence": "Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of rituximab (<\\entity><\\entity>) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (pSS), and changes in B cell biomarkers.",
    "Label": ""
  },
  {
    "id": "136",
    "Sentence": "Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary SjÃ¶gren's syndrome.OBJECTIVE: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with primary SjÃ¶gren's syndrome (<\\entity><\\entity>), and changes in B cell biomarkers.",
    "Label": ""
  },
  {
    "id": "142",
    "Sentence": "Differential effects of <\\entity><\\entity> and activated beta-catenin mutations in human hepatocellular carcinomas.Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "143",
    "Sentence": "Differential effects of <\\entity><\\entity> and activated beta-catenin mutations in human hepatocellular carcinomas.Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "144",
    "Sentence": "Differential effects of inactivated Axin1 and <\\entity><\\entity> in human hepatocellular carcinomas.Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "145",
    "Sentence": "Differential effects of inactivated Axin1 and activated <\\entity><\\entity> mutations in human hepatocellular carcinomas.Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "146",
    "Sentence": "Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.Perturbations to the <\\entity><\\entity> signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "147",
    "Sentence": "<\\entity><\\entity> and loss of function mutations in Axin1 are thought to be functionally equivalent.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "148",
    "Sentence": "Activating <\\entity><\\entity> mutations and loss of function mutations in Axin1 are thought to be functionally equivalent.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "149",
    "Sentence": "Activating beta-catenin mutations and <\\entity><\\entity> are thought to be functionally equivalent.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "150",
    "Sentence": "Activating beta-catenin mutations and <\\entity><\\entity> are thought to be functionally equivalent.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "151",
    "Sentence": "We examined the <\\entity><\\entity> pathway in HCC by comparing the expression of beta-catenin target genes and the level of beta-catenin-dependent transcriptional activation, in 45 HCC tumors and four cell lines.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "152",
    "Sentence": "We examined the Wnt pathway in <\\entity><\\entity> by comparing the expression of beta-catenin target genes and the level of beta-catenin-dependent transcriptional activation, in 45 <\\entity><\\entity> tumors and four cell lines.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "153",
    "Sentence": "We examined the Wnt pathway in HCC by comparing the expression of <\\entity><\\entity> target genes and the level of <\\entity><\\entity>-dependent transcriptional activation, in 45 HCC tumors and four cell lines.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "154",
    "Sentence": "We examined the Wnt pathway in HCC by comparing the expression of <\\entity><\\entity> target genes and the level of <\\entity><\\entity>-dependent transcriptional activation, in 45 HCC tumors and four cell lines.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "155",
    "Sentence": "We examined the Wnt pathway in <\\entity><\\entity> by comparing the expression of beta-catenin target genes and the level of beta-catenin-dependent transcriptional activation, in 45 <\\entity><\\entity> tumors and four cell lines.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "156",
    "Sentence": "Among these samples, <\\entity><\\entity> and AXIN1 were mutated in 20 and seven cases, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "157",
    "Sentence": "Among these samples, beta-catenin and <\\entity><\\entity> were mutated in 20 and seven cases, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "158",
    "Sentence": "We found a significant correlation between <\\entity><\\entity> and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "159",
    "Sentence": "We found a significant correlation between activated <\\entity><\\entity> mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "160",
    "Sentence": "We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes <\\entity><\\entity> (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "161",
    "Sentence": "We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (<\\entity><\\entity>), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "162",
    "Sentence": "We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), <\\entity><\\entity> (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "163",
    "Sentence": "We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (<\\entity><\\entity> and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "164",
    "Sentence": "We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and <\\entity><\\entity> (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "165",
    "Sentence": "We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (<\\entity><\\entity> (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "166",
    "Sentence": "We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes <\\entity><\\entity>, LECT2, c-myc and cyclin D1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "167",
    "Sentence": "We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, <\\entity><\\entity>, c-myc and cyclin D1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "168",
    "Sentence": "We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, <\\entity><\\entity> and cyclin D1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "169",
    "Sentence": "We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "170",
    "Sentence": "We also showed that <\\entity><\\entity> is a good immunohistochemical marker of beta-catenin activation in HCC.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "171",
    "Sentence": "We also showed that GS is a good immunohistochemical marker of <\\entity><\\entity> activation in HCC.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "172",
    "Sentence": "We also showed that GS is a good immunohistochemical marker of beta-catenin activation in <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "173",
    "Sentence": "However, we observed no induction of <\\entity><\\entity>, GPR49 or GLT-1 in the five inactivated Axin1 tumors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "174",
    "Sentence": "However, we observed no induction of GS, <\\entity><\\entity> or GLT-1 in the five inactivated Axin1 tumors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "175",
    "Sentence": "However, we observed no induction of GS, GPR49 or <\\entity><\\entity> in the five inactivated Axin1 tumors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "176",
    "Sentence": "However, we observed no induction of GS, GPR49 or GLT-1 in the five <\\entity><\\entity> tumors.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "177",
    "Sentence": "However, we observed no induction of GS, GPR49 or GLT-1 in the five <\\entity><\\entity> tumors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "178",
    "Sentence": "<\\entity><\\entity>-dependent transcriptional activation in two Axin1-mutated HCC cell lines was much weaker than in beta-catenin-mutated cell lines.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "179",
    "Sentence": "Beta-catenin-dependent transcriptional activation in two <\\entity><\\entity>-mutated HCC cell lines was much weaker than in beta-catenin-mutated cell lines.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "180",
    "Sentence": "Beta-catenin-dependent transcriptional activation in two Axin1-mutated <\\entity><\\entity> cell lines was much weaker than in beta-catenin-mutated cell lines.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "181",
    "Sentence": "Beta-catenin-dependent transcriptional activation in two Axin1-mutated HCC cell lines was much weaker than in <\\entity><\\entity>-mutated cell lines.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "182",
    "Sentence": "Our results strongly suggest that in <\\entity><\\entity>, contrary to expectation, the loss of function of Axin1 is not equivalent to the gain of function of beta-catenin.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "183",
    "Sentence": "Our results strongly suggest that in HCC, contrary to expectation, the loss of function of <\\entity><\\entity> is not equivalent to the gain of function of beta-catenin.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "184",
    "Sentence": "Our results strongly suggest that in HCC, contrary to expectation, the loss of function of Axin1 is not equivalent to the gain of function of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "185",
    "Sentence": "Our results also suggest that the tumor suppressor function of <\\entity><\\entity> in HCC may be related to another, non-Wnt pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "186",
    "Sentence": "Our results also suggest that the tumor suppressor function of Axin1 in <\\entity><\\entity> may be related to another, non-Wnt pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "187",
    "Sentence": "Our results also suggest that the tumor suppressor function of Axin1 in HCC may be related to another, non-<\\entity><\\entity> pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "192",
    "Sentence": "<\\entity><\\entity> regulates ionizing radiation-induced disruption of HDAC1:PP1:Rb complexes.Ionizing radiation elicits signaling events that coordinate DNA repair and interruption of cell cycle progression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "193",
    "Sentence": "ATM regulates ionizing radiation-induced disruption of <\\entity><\\entity> complexes.Ionizing radiation elicits signaling events that coordinate DNA repair and interruption of cell cycle progression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "194",
    "Sentence": "ATM regulates ionizing radiation-induced disruption of HDAC1:<\\entity><\\entity>:Rb complexes.Ionizing radiation elicits signaling events that coordinate DNA repair and interruption of cell cycle progression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "195",
    "Sentence": "We previously demonstrated that ionizing radiation (IR) of cells activates nuclear protein <\\entity><\\entity>-1 (PP1) by promoting dephosphorylation of Thr320, an inhibitory site in the enzyme and that the ATM kinase is required for this response.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "196",
    "Sentence": "We previously demonstrated that ionizing radiation (IR) of cells activates nuclear protein phosphatase-1 (<\\entity><\\entity>) by promoting dephosphorylation of Thr320, an inhibitory site in the enzyme and that the ATM kinase is required for this response.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "197",
    "Sentence": "We previously demonstrated that ionizing radiation (IR) of cells activates nuclear protein phosphatase-1 (PP1) by promoting dephosphorylation of Thr320, an inhibitory site in the enzyme and that the <\\entity><\\entity> is required for this response.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "198",
    "Sentence": "We sought to identify potential targets of IR-activated <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "199",
    "Sentence": "Untreated and IR-treated Jurkat cells were labeled with <\\entity><\\entity>, and nuclear extracts were subjected to microcystin affinity chromatography to recover phosphatase complexes that were analyzed by 2D-PAGE and mass spectrometry.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "200",
    "Sentence": "Untreated and IR-treated Jurkat cells were labeled with (32)P orthophosphate, and nuclear extracts were subjected to microcystin affinity chromatography to recover <\\entity><\\entity> complexes that were analyzed by 2D-PAGE and mass spectrometry.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "201",
    "Sentence": "Several proteins associated with protein <\\entity><\\entity> demonstrated a significant decrease in (32)P intensity following IR, and one of these was identified as HDAC1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "202",
    "Sentence": "Several proteins associated with protein phosphatases demonstrated a significant decrease in <\\entity><\\entity> intensity following IR, and one of these was identified as HDAC1.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "203",
    "Sentence": "Several proteins associated with protein phosphatases demonstrated a significant decrease in (32)P intensity following IR, and one of these was identified as <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "204",
    "Sentence": "Co-immunoprecipitation revealed complexes containing <\\entity><\\entity> with HDAC1 and Rb in cell extracts.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "205",
    "Sentence": "Co-immunoprecipitation revealed complexes containing PP1 with <\\entity><\\entity> and Rb in cell extracts.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "206",
    "Sentence": "Co-immunoprecipitation revealed complexes containing PP1 with HDAC1 and <\\entity><\\entity> in cell extracts.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "207",
    "Sentence": "In response to IR, there was an <\\entity><\\entity>-dependent activation of PP1, dephosphorylation of HDAC1, dissociation of HDAC1-PP1-Rb complexes and increased HDAC1 activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "208",
    "Sentence": "In response to IR, there was an ATM-dependent activation of <\\entity><\\entity>, dephosphorylation of HDAC1, dissociation of HDAC1-<\\entity><\\entity>-Rb complexes and increased HDAC1 activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "209",
    "Sentence": "In response to IR, there was an ATM-dependent activation of PP1, dephosphorylation of <\\entity><\\entity>, dissociation of <\\entity><\\entity>-PP1-Rb complexes and increased <\\entity><\\entity> activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "210",
    "Sentence": "In response to IR, there was an ATM-dependent activation of PP1, dephosphorylation of HDAC1, dissociation of <\\entity><\\entity> complexes and increased HDAC1 activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "211",
    "Sentence": "In response to IR, there was an ATM-dependent activation of PP1, dephosphorylation of <\\entity><\\entity>, dissociation of <\\entity><\\entity>-PP1-Rb complexes and increased <\\entity><\\entity> activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "212",
    "Sentence": "These results suggest that IR regulates <\\entity><\\entity> phosphorylation and activity through ATM-dependent activation of PP1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "213",
    "Sentence": "These results suggest that IR regulates HDAC1 phosphorylation and activity through <\\entity><\\entity>-dependent activation of PP1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "214",
    "Sentence": "These results suggest that IR regulates HDAC1 phosphorylation and activity through ATM-dependent activation of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "219",
    "Sentence": "<\\entity><\\entity> polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for non-Hodgkin's lymphoma (NHL).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "220",
    "Sentence": "Ala394Thr polymorphism in the <\\entity><\\entity> gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for non-Hodgkin's lymphoma (NHL).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "221",
    "Sentence": "Ala394Thr polymorphism in the clock gene <\\entity><\\entity>: a circadian modifier for the risk of non-Hodgkin's lymphoma.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for non-Hodgkin's lymphoma (NHL).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "222",
    "Sentence": "Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of <\\entity><\\entity>.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for <\\entity><\\entity> (NHL).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "223",
    "Sentence": "Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of <\\entity><\\entity>.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for <\\entity><\\entity> (NHL).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "224",
    "Sentence": "Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for non-Hodgkin's lymphoma (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "225",
    "Sentence": "Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for non-Hodgkin's lymphoma (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "226",
    "Sentence": "Genes responsible for circadian rhythm are also involved in <\\entity><\\entity>-related biological pathways as potential tumor suppressors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "227",
    "Sentence": "Genes responsible for circadian rhythm are also involved in cancer-related biological pathways as potential <\\entity><\\entity> suppressors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "228",
    "Sentence": "However, no previous studies have examined associations between <\\entity><\\entity> and NHL risk.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "229",
    "Sentence": "However, no previous studies have examined associations between circadian genes and <\\entity><\\entity> risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "230",
    "Sentence": "However, no previous studies have examined associations between circadian genes and <\\entity><\\entity> risk.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "231",
    "Sentence": "In this population-based case control study (n = 455 cases; 527 controls), we examined the only identified nonsynonymous polymorphism (<\\entity><\\entity>; rs2305160) in the largest circadian gene, neuronal PAS domain protein 2 (NPAS2), in order to examine its impact on NHL risk.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "232",
    "Sentence": "In this population-based case control study (n = 455 cases; 527 controls), we examined the only identified nonsynonymous polymorphism (Ala394Thr; <\\entity><\\entity>) in the largest circadian gene, neuronal PAS domain protein 2 (NPAS2), in order to examine its impact on NHL risk.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "233",
    "Sentence": "In this population-based case control study (n = 455 cases; 527 controls), we examined the only identified nonsynonymous polymorphism (Ala394Thr; rs2305160) in the largest <\\entity><\\entity>, neuronal PAS domain protein 2 (NPAS2), in order to examine its impact on NHL risk.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "234",
    "Sentence": "In this population-based case control study (n = 455 cases; 527 controls), we examined the only identified nonsynonymous polymorphism (Ala394Thr; rs2305160) in the largest circadian gene, <\\entity><\\entity> (NPAS2), in order to examine its impact on NHL risk.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "235",
    "Sentence": "In this population-based case control study (n = 455 cases; 527 controls), we examined the only identified nonsynonymous polymorphism (Ala394Thr; rs2305160) in the largest circadian gene, neuronal PAS domain protein 2 (<\\entity><\\entity>), in order to examine its impact on NHL risk.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "236",
    "Sentence": "In this population-based case control study (n = 455 cases; 527 controls), we examined the only identified nonsynonymous polymorphism (Ala394Thr; rs2305160) in the largest circadian gene, neuronal PAS domain protein 2 (NPAS2), in order to examine its impact on <\\entity><\\entity> risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "237",
    "Sentence": "In this population-based case control study (n = 455 cases; 527 controls), we examined the only identified nonsynonymous polymorphism (Ala394Thr; rs2305160) in the largest circadian gene, neuronal PAS domain protein 2 (NPAS2), in order to examine its impact on <\\entity><\\entity> risk.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "238",
    "Sentence": "Our results demonstrate a robust association of the variant <\\entity><\\entity> (Ala/Thr and Thr/Thr) with reduced risk of NHL (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "239",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (<\\entity><\\entity> and Thr/Thr) with reduced risk of NHL (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "240",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (Ala/Thr and <\\entity><\\entity>) with reduced risk of NHL (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "241",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (Ala/Thr and Thr/Thr) with reduced risk of <\\entity><\\entity> (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "242",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (Ala/Thr and Thr/Thr) with reduced risk of <\\entity><\\entity> (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "243",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (Ala/Thr and Thr/Thr) with reduced risk of NHL (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially <\\entity><\\entity> (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "244",
    "Sentence": "These findings provide the first molecular epidemiologic evidence supporting a role of <\\entity><\\entity> in lymphomagenesis, which suggests that genetic variations in <\\entity><\\entity> might be a novel panel of promising biomarkers for NHL and warrants further investigation.CI - (c) 2006 Wiley-Liss, Inc.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "245",
    "Sentence": "These findings provide the first molecular epidemiologic evidence supporting a role of circadian genes in <\\entity><\\entity>, which suggests that genetic variations in circadian genes might be a novel panel of promising biomarkers for NHL and warrants further investigation.CI - (c) 2006 Wiley-Liss, Inc.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "246",
    "Sentence": "These findings provide the first molecular epidemiologic evidence supporting a role of <\\entity><\\entity> in lymphomagenesis, which suggests that genetic variations in <\\entity><\\entity> might be a novel panel of promising biomarkers for NHL and warrants further investigation.CI - (c) 2006 Wiley-Liss, Inc.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "247",
    "Sentence": "These findings provide the first molecular epidemiologic evidence supporting a role of circadian genes in lymphomagenesis, which suggests that genetic variations in circadian genes might be a novel panel of promising biomarkers for <\\entity><\\entity> and warrants further investigation.CI - (c) 2006 Wiley-Liss, Inc.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "248",
    "Sentence": "These findings provide the first molecular epidemiologic evidence supporting a role of circadian genes in lymphomagenesis, which suggests that genetic variations in circadian genes might be a novel panel of promising biomarkers for <\\entity><\\entity> and warrants further investigation.CI - (c) 2006 Wiley-Liss, Inc.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "249",
    "Sentence": "Our results demonstrate a robust association of the variant <\\entity><\\entity> (Ala/Thr and Thr/Thr) with reduced risk of NHL (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": ""
  },
  {
    "id": "250",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (Ala/Thr and Thr/Thr) with reduced risk of <\\entity><\\entity> (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": ""
  },
  {
    "id": "252",
    "Sentence": "Our results demonstrate a robust association of the variant <\\entity><\\entity> (Ala/Thr and Thr/Thr) with reduced risk of NHL (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": ""
  },
  {
    "id": "253",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (Ala/Thr and Thr/Thr) with reduced risk of NHL (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially <\\entity><\\entity> (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": ""
  },
  {
    "id": "255",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (<\\entity><\\entity> and Thr/Thr) with reduced risk of NHL (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": ""
  },
  {
    "id": "256",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (Ala/Thr and Thr/Thr) with reduced risk of <\\entity><\\entity> (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": ""
  },
  {
    "id": "258",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (<\\entity><\\entity> and Thr/Thr) with reduced risk of NHL (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": ""
  },
  {
    "id": "259",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (Ala/Thr and Thr/Thr) with reduced risk of NHL (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially <\\entity><\\entity> (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": ""
  },
  {
    "id": "261",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (Ala/Thr and <\\entity><\\entity>) with reduced risk of NHL (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": ""
  },
  {
    "id": "262",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (Ala/Thr and Thr/Thr) with reduced risk of <\\entity><\\entity> (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": ""
  },
  {
    "id": "264",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (Ala/Thr and <\\entity><\\entity>) with reduced risk of NHL (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": ""
  },
  {
    "id": "265",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (Ala/Thr and Thr/Thr) with reduced risk of NHL (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially <\\entity><\\entity> (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": ""
  },
  {
    "id": "267",
    "Sentence": "These findings provide the first molecular epidemiologic evidence supporting a role of <\\entity><\\entity> in lymphomagenesis, which suggests that genetic variations in <\\entity><\\entity> might be a novel panel of promising biomarkers for NHL and warrants further investigation.CI - (c) 2006 Wiley-Liss, Inc.",
    "Label": ""
  },
  {
    "id": "268",
    "Sentence": "These findings provide the first molecular epidemiologic evidence supporting a role of circadian genes in lymphomagenesis, which suggests that genetic variations in circadian genes might be a novel panel of promising biomarkers for <\\entity><\\entity> and warrants further investigation.CI - (c) 2006 Wiley-Liss, Inc.",
    "Label": ""
  },
  {
    "id": "270",
    "Sentence": "These findings provide the first molecular epidemiologic evidence supporting a role of <\\entity><\\entity> in lymphomagenesis, which suggests that genetic variations in <\\entity><\\entity> might be a novel panel of promising biomarkers for NHL and warrants further investigation.CI - (c) 2006 Wiley-Liss, Inc.",
    "Label": ""
  },
  {
    "id": "271",
    "Sentence": "These findings provide the first molecular epidemiologic evidence supporting a role of circadian genes in <\\entity><\\entity>, which suggests that genetic variations in circadian genes might be a novel panel of promising biomarkers for NHL and warrants further investigation.CI - (c) 2006 Wiley-Liss, Inc.",
    "Label": ""
  },
  {
    "id": "273",
    "Sentence": "Ala394Thr polymorphism in the <\\entity><\\entity> gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for non-Hodgkin's lymphoma (NHL).",
    "Label": ""
  },
  {
    "id": "274",
    "Sentence": "Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of <\\entity><\\entity>.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for <\\entity><\\entity> (NHL).",
    "Label": ""
  },
  {
    "id": "276",
    "Sentence": "Ala394Thr polymorphism in the clock gene <\\entity><\\entity>: a circadian modifier for the risk of non-Hodgkin's lymphoma.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for non-Hodgkin's lymphoma (NHL).",
    "Label": ""
  },
  {
    "id": "277",
    "Sentence": "Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of <\\entity><\\entity>.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for <\\entity><\\entity> (NHL).",
    "Label": ""
  },
  {
    "id": "279",
    "Sentence": "Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for non-Hodgkin's lymphoma (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "280",
    "Sentence": "Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of <\\entity><\\entity>.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for <\\entity><\\entity> (NHL).",
    "Label": ""
  },
  {
    "id": "282",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (Ala/Thr and Thr/Thr) with reduced risk of <\\entity><\\entity> (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially B-cell lymphoma (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": ""
  },
  {
    "id": "283",
    "Sentence": "Our results demonstrate a robust association of the variant Thr genotypes (Ala/Thr and Thr/Thr) with reduced risk of NHL (OR = 0.66, 95% CI: 0.51-0.85, p = 0.001), especially <\\entity><\\entity> (OR = 0.61, 95% CI: 0.47-0.80, p <or= 0.0001).",
    "Label": ""
  },
  {
    "id": "285",
    "Sentence": "These findings provide the first molecular epidemiologic evidence supporting a role of circadian genes in lymphomagenesis, which suggests that genetic variations in circadian genes might be a novel panel of promising biomarkers for <\\entity><\\entity> and warrants further investigation.CI - (c) 2006 Wiley-Liss, Inc.",
    "Label": ""
  },
  {
    "id": "286",
    "Sentence": "These findings provide the first molecular epidemiologic evidence supporting a role of circadian genes in <\\entity><\\entity>, which suggests that genetic variations in circadian genes might be a novel panel of promising biomarkers for NHL and warrants further investigation.CI - (c) 2006 Wiley-Liss, Inc.",
    "Label": ""
  },
  {
    "id": "288",
    "Sentence": "<\\entity><\\entity> polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for non-Hodgkin's lymphoma (NHL).",
    "Label": ""
  },
  {
    "id": "289",
    "Sentence": "Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of <\\entity><\\entity>.Circadian disruption is theorized to cause immune dysregulation, which is the only established risk factor for <\\entity><\\entity> (NHL).",
    "Label": ""
  },
  {
    "id": "291",
    "Sentence": "In this population-based case control study (n = 455 cases; 527 controls), we examined the only identified nonsynonymous polymorphism (Ala394Thr; rs2305160) in the largest circadian gene, neuronal PAS domain protein 2 (<\\entity><\\entity>), in order to examine its impact on NHL risk.",
    "Label": ""
  },
  {
    "id": "292",
    "Sentence": "In this population-based case control study (n = 455 cases; 527 controls), we examined the only identified nonsynonymous polymorphism (Ala394Thr; rs2305160) in the largest circadian gene, neuronal PAS domain protein 2 (NPAS2), in order to examine its impact on <\\entity><\\entity> risk.",
    "Label": ""
  },
  {
    "id": "294",
    "Sentence": "In this population-based case control study (n = 455 cases; 527 controls), we examined the only identified nonsynonymous polymorphism (<\\entity><\\entity>; rs2305160) in the largest circadian gene, neuronal PAS domain protein 2 (NPAS2), in order to examine its impact on NHL risk.",
    "Label": ""
  },
  {
    "id": "295",
    "Sentence": "In this population-based case control study (n = 455 cases; 527 controls), we examined the only identified nonsynonymous polymorphism (Ala394Thr; rs2305160) in the largest circadian gene, neuronal PAS domain protein 2 (NPAS2), in order to examine its impact on <\\entity><\\entity> risk.",
    "Label": ""
  },
  {
    "id": "297",
    "Sentence": "In this population-based case control study (n = 455 cases; 527 controls), we examined the only identified nonsynonymous polymorphism (Ala394Thr; <\\entity><\\entity>) in the largest circadian gene, neuronal PAS domain protein 2 (NPAS2), in order to examine its impact on NHL risk.",
    "Label": ""
  },
  {
    "id": "298",
    "Sentence": "In this population-based case control study (n = 455 cases; 527 controls), we examined the only identified nonsynonymous polymorphism (Ala394Thr; rs2305160) in the largest circadian gene, neuronal PAS domain protein 2 (NPAS2), in order to examine its impact on <\\entity><\\entity> risk.",
    "Label": ""
  },
  {
    "id": "304",
    "Sentence": "Association study of putative <\\entity><\\entity> gene and schizophrenia.A previous study revealed a number of methamphetamine (METH) and phencyclidine (PCP)-reactive tags in a rat brain through serial analysis of gene expression.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "305",
    "Sentence": "Association study of putative <\\entity><\\entity> gene and schizophrenia.A previous study revealed a number of methamphetamine (METH) and phencyclidine (PCP)-reactive tags in a rat brain through serial analysis of gene expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "306",
    "Sentence": "Association study of putative promoter polymorphisms in the neuroplastin gene and <\\entity><\\entity>.A previous study revealed a number of methamphetamine (METH) and phencyclidine (PCP)-reactive tags in a rat brain through serial analysis of gene expression.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "307",
    "Sentence": "Association study of putative promoter polymorphisms in the neuroplastin gene and schizophrenia.A previous study revealed a number of <\\entity><\\entity> (METH) and phencyclidine (PCP)-reactive tags in a rat brain through serial analysis of gene expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "308",
    "Sentence": "Association study of putative promoter polymorphisms in the neuroplastin gene and schizophrenia.A previous study revealed a number of methamphetamine (<\\entity><\\entity>) and phencyclidine (PCP)-reactive tags in a rat brain through serial analysis of gene expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "309",
    "Sentence": "Association study of putative promoter polymorphisms in the neuroplastin gene and schizophrenia.A previous study revealed a number of methamphetamine (METH) and <\\entity><\\entity> (PCP)-reactive tags in a rat brain through serial analysis of gene expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "310",
    "Sentence": "Association study of putative promoter polymorphisms in the neuroplastin gene and schizophrenia.A previous study revealed a number of methamphetamine (METH) and phencyclidine (<\\entity><\\entity> in a rat brain through serial analysis of gene expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "311",
    "Sentence": "Association study of putative promoter polymorphisms in the neuroplastin gene and schizophrenia.A previous study revealed a number of methamphetamine (METH) and phencyclidine (<\\entity><\\entity> in a rat brain through serial analysis of gene expression.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "312",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from <\\entity><\\entity>, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "313",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from <\\entity><\\entity>, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "314",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/<\\entity><\\entity>-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "315",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/<\\entity><\\entity>-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "316",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the <\\entity><\\entity> (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "317",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, <\\entity><\\entity> (NPTN) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "318",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (<\\entity><\\entity>) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "319",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and <\\entity><\\entity> (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "320",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (<\\entity><\\entity>), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "321",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to <\\entity><\\entity> by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "322",
    "Sentence": "There were nominally significant differences between the two groups in their allelic frequencies (<\\entity><\\entity>, chi2=4.910, d.f.=1, P=0.040) and genotypic distributions (T/T or T/Del, chi2=5.116, d.f.=1, P=0.036) of rs3840846 in the 5'-upstream of NPTN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "323",
    "Sentence": "There were nominally significant differences between the two groups in their allelic frequencies (T Ins/Del, chi2=4.910, d.f.=1, P=0.040) and genotypic distributions (<\\entity><\\entity> or T/Del, chi2=5.116, d.f.=1, P=0.036) of rs3840846 in the 5'-upstream of NPTN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "324",
    "Sentence": "There were nominally significant differences between the two groups in their allelic frequencies (T Ins/Del, chi2=4.910, d.f.=1, P=0.040) and genotypic distributions (T/T or <\\entity><\\entity>, chi2=5.116, d.f.=1, P=0.036) of rs3840846 in the 5'-upstream of NPTN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "325",
    "Sentence": "There were nominally significant differences between the two groups in their allelic frequencies (T Ins/Del, chi2=4.910, d.f.=1, P=0.040) and genotypic distributions (T/T or T/Del, chi2=5.116, d.f.=1, P=0.036) of <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "326",
    "Sentence": "There were nominally significant differences between the two groups in their allelic frequencies (T Ins/Del, chi2=4.910, d.f.=1, P=0.040) and genotypic distributions (T/T or T/Del, chi2=5.116, d.f.=1, P=0.036) of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "327",
    "Sentence": "The two groups differed significantly also in their allelic frequencies (<\\entity><\\entity>, chi2=4.229, d.f.=1, P=0.044), but not genotypic distributions of rs3743500 in the 5'-upstream of NPTN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "328",
    "Sentence": "The two groups differed significantly also in their allelic frequencies (G/T, chi2=4.229, d.f.=1, P=0.044), but not genotypic distributions of <\\entity><\\entity> in the 5'-upstream of NPTN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "329",
    "Sentence": "The two groups differed significantly also in their allelic frequencies (G/T, chi2=4.229, d.f.=1, P=0.044), but not genotypic distributions of rs3743500 in the 5'-upstream of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "330",
    "Sentence": "The haplotypes constructed from the three SNPs (<\\entity><\\entity>, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with schizophrenia (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "331",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, <\\entity><\\entity> and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with schizophrenia (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "332",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and <\\entity><\\entity>, in order) in the 5'-upstream of NPTN showed a significant association with schizophrenia (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "333",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of <\\entity><\\entity> showed a significant association with schizophrenia (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "334",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with <\\entity><\\entity> (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "335",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with schizophrenia (permutation P=0.036), in that <\\entity><\\entity> (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "336",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with schizophrenia (permutation P=0.036), in that T-G-T (permutation P=0.028) and <\\entity><\\entity> (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "337",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with <\\entity><\\entity> (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "338",
    "Sentence": "Notably, a reporter construct containing a haplotype <\\entity><\\entity> had significantly lower transcriptional activity as compared with one having a haplotype T-G-G or T-A-G.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "339",
    "Sentence": "Notably, a reporter construct containing a haplotype T-G-T had significantly lower transcriptional activity as compared with one having a haplotype <\\entity><\\entity> or T-A-G.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "340",
    "Sentence": "Notably, a reporter construct containing a haplotype T-G-T had significantly lower transcriptional activity as compared with one having a haplotype T-G-G or <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "341",
    "Sentence": "There was no significant difference between the two groups regarding allelic frequencies, genotypic distribution or the adopted SNP-combinatory haplotype for <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "342",
    "Sentence": "These results suggest that <\\entity><\\entity> may be involved in genetic susceptibility to schizophrenia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "343",
    "Sentence": "These results suggest that NPTN may be involved in genetic susceptibility to <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "344",
    "Sentence": "The haplotypes constructed from the three SNPs (<\\entity><\\entity>, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with schizophrenia (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia.",
    "Label": ""
  },
  {
    "id": "345",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with <\\entity><\\entity> (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "347",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, <\\entity><\\entity> and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with schizophrenia (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia.",
    "Label": ""
  },
  {
    "id": "348",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with <\\entity><\\entity> (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "350",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and <\\entity><\\entity>, in order) in the 5'-upstream of NPTN showed a significant association with schizophrenia (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia.",
    "Label": ""
  },
  {
    "id": "351",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with <\\entity><\\entity> (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "353",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with schizophrenia (permutation P=0.036), in that <\\entity><\\entity> (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia.",
    "Label": ""
  },
  {
    "id": "354",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with <\\entity><\\entity> (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "356",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with schizophrenia (permutation P=0.036), in that T-G-T (permutation P=0.028) and <\\entity><\\entity> (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia.",
    "Label": ""
  },
  {
    "id": "357",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with <\\entity><\\entity> (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "359",
    "Sentence": "These results suggest that <\\entity><\\entity> may be involved in genetic susceptibility to schizophrenia.",
    "Label": ""
  },
  {
    "id": "360",
    "Sentence": "These results suggest that NPTN may be involved in genetic susceptibility to <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "362",
    "Sentence": "Association study of putative <\\entity><\\entity> gene and schizophrenia.A previous study revealed a number of methamphetamine (METH) and phencyclidine (PCP)-reactive tags in a rat brain through serial analysis of gene expression.",
    "Label": ""
  },
  {
    "id": "363",
    "Sentence": "Association study of putative promoter polymorphisms in the neuroplastin gene and <\\entity><\\entity>.A previous study revealed a number of methamphetamine (METH) and phencyclidine (PCP)-reactive tags in a rat brain through serial analysis of gene expression.",
    "Label": ""
  },
  {
    "id": "365",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (<\\entity><\\entity>) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": ""
  },
  {
    "id": "366",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to <\\entity><\\entity> by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": ""
  },
  {
    "id": "368",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (<\\entity><\\entity>) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": ""
  },
  {
    "id": "369",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from <\\entity><\\entity>, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": ""
  },
  {
    "id": "371",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/<\\entity><\\entity>-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": ""
  },
  {
    "id": "372",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to <\\entity><\\entity> by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": ""
  },
  {
    "id": "374",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/<\\entity><\\entity>-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": ""
  },
  {
    "id": "375",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from <\\entity><\\entity>, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": ""
  },
  {
    "id": "377",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (<\\entity><\\entity>), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": ""
  },
  {
    "id": "378",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to <\\entity><\\entity> by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": ""
  },
  {
    "id": "380",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (<\\entity><\\entity>), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": ""
  },
  {
    "id": "381",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from <\\entity><\\entity>, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": ""
  },
  {
    "id": "383",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of <\\entity><\\entity> showed a significant association with schizophrenia (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in schizophrenia.",
    "Label": ""
  },
  {
    "id": "384",
    "Sentence": "The haplotypes constructed from the three SNPs (rs3840846, rs3826047 and rs3743500, in order) in the 5'-upstream of NPTN showed a significant association with <\\entity><\\entity> (permutation P=0.036), in that T-G-T (permutation P=0.028) and del-G-G (permutation P=0.040) were under-represented and over-represented, respectively, in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "386",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the <\\entity><\\entity> (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to schizophrenia by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": ""
  },
  {
    "id": "387",
    "Sentence": "The present study extends this previous study by investigating whether two genes, which deduced from METH/PCP-reactive tags, were identified as those encoding human transmembrane proteins of the immunoglobulin (Ig) superfamily, neuroplastin (NPTN) and basigin (BSG), confer genetic susceptibility to <\\entity><\\entity> by analyzing single nucleotide polymorphisms (SNPs).",
    "Label": ""
  },
  {
    "id": "393",
    "Sentence": "<\\entity><\\entity> regulates catalytic activity and scaffolding functions of the protein tyrosine phosphatase PEST, a novel modulator of the apoptotic response.The protein tyrosine phosphatase PEST (PTP-PEST) is involved in the regulation of the actin cytoskeleton.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "394",
    "Sentence": "Caspase-3 regulates catalytic activity and scaffolding functions of the <\\entity><\\entity>, a novel modulator of the apoptotic response.The <\\entity><\\entity> (PTP-PEST) is involved in the regulation of the actin cytoskeleton.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "395",
    "Sentence": "Caspase-3 regulates catalytic activity and scaffolding functions of the protein <\\entity><\\entity> PEST, a novel modulator of the apoptotic response.The protein <\\entity><\\entity> PEST (PTP-PEST) is involved in the regulation of the actin cytoskeleton.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "396",
    "Sentence": "Caspase-3 regulates catalytic activity and scaffolding functions of the <\\entity><\\entity>, a novel modulator of the apoptotic response.The <\\entity><\\entity> (PTP-PEST) is involved in the regulation of the actin cytoskeleton.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "397",
    "Sentence": "Caspase-3 regulates catalytic activity and scaffolding functions of the protein <\\entity><\\entity> PEST, a novel modulator of the apoptotic response.The protein <\\entity><\\entity> PEST (PTP-PEST) is involved in the regulation of the actin cytoskeleton.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "398",
    "Sentence": "Caspase-3 regulates catalytic activity and scaffolding functions of the protein tyrosine phosphatase PEST, a novel modulator of the apoptotic response.The protein tyrosine phosphatase PEST (<\\entity><\\entity>) is involved in the regulation of the actin cytoskeleton.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "399",
    "Sentence": "Caspase-3 regulates catalytic activity and scaffolding functions of the protein tyrosine phosphatase PEST, a novel modulator of the apoptotic response.The protein tyrosine phosphatase PEST (PTP-PEST) is involved in the regulation of the <\\entity><\\entity> cytoskeleton.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "400",
    "Sentence": "Despite the emerging functions attributed to both <\\entity><\\entity> and the actin cytoskeleton in apoptosis, the involvement of PTP-PEST in apoptotic cell death remains to be established.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "401",
    "Sentence": "Despite the emerging functions attributed to both PTPs and the <\\entity><\\entity> cytoskeleton in apoptosis, the involvement of PTP-PEST in apoptotic cell death remains to be established.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "402",
    "Sentence": "Despite the emerging functions attributed to both PTPs and the actin cytoskeleton in apoptosis, the involvement of <\\entity><\\entity> in apoptotic cell death remains to be established.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "403",
    "Sentence": "Using several cell-based assays, we showed that <\\entity><\\entity> participates in the regulation of apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "404",
    "Sentence": "As apoptosis progressed, a pool of <\\entity><\\entity> localized to the edge of retracting lamellipodia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "405",
    "Sentence": "Expression of <\\entity><\\entity> also sensitized cells to receptor-mediated apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "406",
    "Sentence": "Concertedly, specific degradation of <\\entity><\\entity> was observed during apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "407",
    "Sentence": "Pharmacological inhibitors, immunodepletion experiments, and in vitro cleavage assays identified <\\entity><\\entity> as the primary regulator of PTP-PEST processing during apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "408",
    "Sentence": "Pharmacological inhibitors, immunodepletion experiments, and in vitro cleavage assays identified caspase-3 as the primary regulator of <\\entity><\\entity> processing during apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "409",
    "Sentence": "<\\entity><\\entity> specifically cleaved PTP-PEST at the (549)DSPD motif and generated fragments, some of which displayed increased catalytic activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "410",
    "Sentence": "Caspase-3 specifically cleaved <\\entity><\\entity> at the (549)DSPD motif and generated fragments, some of which displayed increased catalytic activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "411",
    "Sentence": "Caspase-3 specifically cleaved PTP-PEST at the <\\entity><\\entity> motif and generated fragments, some of which displayed increased catalytic activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "412",
    "Sentence": "Moreover, <\\entity><\\entity> regulated PTP-PEST interactions with paxillin, leupaxin, Shc, and PSTPIP.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "413",
    "Sentence": "Moreover, caspase-3 regulated <\\entity><\\entity> interactions with paxillin, leupaxin, Shc, and PSTPIP.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "414",
    "Sentence": "Moreover, caspase-3 regulated PTP-PEST interactions with <\\entity><\\entity>, leupaxin, Shc, and PSTPIP.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "415",
    "Sentence": "Moreover, caspase-3 regulated PTP-PEST interactions with paxillin, <\\entity><\\entity>, Shc, and PSTPIP.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "416",
    "Sentence": "Moreover, caspase-3 regulated PTP-PEST interactions with paxillin, leupaxin, <\\entity><\\entity>, and PSTPIP.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "417",
    "Sentence": "Moreover, caspase-3 regulated PTP-PEST interactions with paxillin, leupaxin, Shc, and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "418",
    "Sentence": "<\\entity><\\entity> acted as a scaffolding molecule connecting PSTPIP to additional partners: paxillin, Shc, Csk, and activation of caspase-3 correlated with the modulation of the <\\entity><\\entity> adaptor function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "419",
    "Sentence": "PTP-PEST acted as a scaffolding molecule connecting <\\entity><\\entity> to additional partners: paxillin, Shc, Csk, and activation of caspase-3 correlated with the modulation of the PTP-PEST adaptor function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "420",
    "Sentence": "PTP-PEST acted as a scaffolding molecule connecting PSTPIP to additional partners: <\\entity><\\entity>, Shc, Csk, and activation of caspase-3 correlated with the modulation of the PTP-PEST adaptor function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "421",
    "Sentence": "PTP-PEST acted as a scaffolding molecule connecting PSTPIP to additional partners: paxillin, <\\entity><\\entity>, Csk, and activation of caspase-3 correlated with the modulation of the PTP-PEST adaptor function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "422",
    "Sentence": "PTP-PEST acted as a scaffolding molecule connecting PSTPIP to additional partners: paxillin, Shc, <\\entity><\\entity>, and activation of caspase-3 correlated with the modulation of the PTP-PEST adaptor function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "423",
    "Sentence": "PTP-PEST acted as a scaffolding molecule connecting PSTPIP to additional partners: paxillin, Shc, Csk, and activation of <\\entity><\\entity> correlated with the modulation of the PTP-PEST adaptor function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "424",
    "Sentence": "<\\entity><\\entity> acted as a scaffolding molecule connecting PSTPIP to additional partners: paxillin, Shc, Csk, and activation of caspase-3 correlated with the modulation of the <\\entity><\\entity> adaptor function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "425",
    "Sentence": "In addition, cleavage of <\\entity><\\entity> facilitated cellular detachment during apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "426",
    "Sentence": "Together, our data demonstrate that <\\entity><\\entity> actively contributes to the cellular apoptotic response and reveal the importance of caspases as regulators of PTPs in apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "427",
    "Sentence": "Together, our data demonstrate that PTP-PEST actively contributes to the cellular apoptotic response and reveal the importance of <\\entity><\\entity> as regulators of PTPs in apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "428",
    "Sentence": "Together, our data demonstrate that PTP-PEST actively contributes to the cellular apoptotic response and reveal the importance of caspases as regulators of <\\entity><\\entity> in apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "433",
    "Sentence": "The 2nd ADAO <\\entity><\\entity> Conference.On National <\\entity><\\entity> Awareness Day 2006, a conference was held at Mount Sinai, the home ground of Dr.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "434",
    "Sentence": "The 2nd ADAO <\\entity><\\entity> Conference.On National <\\entity><\\entity> Awareness Day 2006, a conference was held at Mount Sinai, the home ground of Dr.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "435",
    "Sentence": "Four decades after the pioneering conference on the Biological Effects of <\\entity><\\entity> was organized by Drs.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "436",
    "Sentence": "Selikoff and Churg, <\\entity><\\entity> victims and their relatives, public health campaigners, medical professionals, journalists and community representatives convened in New York City to assess the progress that had been made in raising public, professional and political awareness of <\\entity><\\entity>-related diseases.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "437",
    "Sentence": "Selikoff and Churg, asbestos victims and their relatives, public health campaigners, medical professionals, journalists and community representatives convened in New York City to assess the progress that had been made in raising public, professional and political awareness of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "438",
    "Sentence": "Selikoff and Churg, asbestos victims and their relatives, public health campaigners, medical professionals, journalists and community representatives convened in New York City to assess the progress that had been made in raising public, professional and political awareness of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "439",
    "Sentence": "Selikoff and Churg, <\\entity><\\entity> victims and their relatives, public health campaigners, medical professionals, journalists and community representatives convened in New York City to assess the progress that had been made in raising public, professional and political awareness of <\\entity><\\entity>-related diseases.",
    "Label": ""
  },
  {
    "id": "440",
    "Sentence": "Selikoff and Churg, asbestos victims and their relatives, public health campaigners, medical professionals, journalists and community representatives convened in New York City to assess the progress that had been made in raising public, professional and political awareness of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "446",
    "Sentence": "Novel <\\entity><\\entity> monoclonal antibodies with potent and broad-spectrum anti-HIV activities.To identify monoclonal antibodies (mAbs) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human <\\entity><\\entity> mAbs ROAb12, ROAb13, ROAb14, and ROAb18 showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "447",
    "Sentence": "Novel CCR5 <\\entity><\\entity> with potent and broad-spectrum anti-HIV activities.To identify <\\entity><\\entity> (mAbs) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human CCR5 mAbs ROAb12, ROAb13, ROAb14, and ROAb18 showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "448",
    "Sentence": "Novel CCR5 <\\entity><\\entity> with potent and broad-spectrum anti-HIV activities.To identify <\\entity><\\entity> (mAbs) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human CCR5 mAbs ROAb12, ROAb13, ROAb14, and ROAb18 showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "449",
    "Sentence": "Novel CCR5 <\\entity><\\entity> with potent and broad-spectrum anti-HIV activities.To identify <\\entity><\\entity> (mAbs) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human CCR5 mAbs ROAb12, ROAb13, ROAb14, and ROAb18 showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "450",
    "Sentence": "Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.To identify monoclonal antibodies (<\\entity><\\entity>) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human CCR5 <\\entity><\\entity> ROAb12, ROAb13, ROAb14, and ROAb18 showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "451",
    "Sentence": "Novel <\\entity><\\entity> monoclonal antibodies with potent and broad-spectrum anti-HIV activities.To identify monoclonal antibodies (mAbs) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human <\\entity><\\entity> mAbs ROAb12, ROAb13, ROAb14, and ROAb18 showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "452",
    "Sentence": "Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.To identify monoclonal antibodies (<\\entity><\\entity>) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human CCR5 <\\entity><\\entity> ROAb12, ROAb13, ROAb14, and ROAb18 showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "453",
    "Sentence": "Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.To identify monoclonal antibodies (<\\entity><\\entity>) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human CCR5 <\\entity><\\entity> ROAb12, ROAb13, ROAb14, and ROAb18 showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "454",
    "Sentence": "Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.To identify monoclonal antibodies (mAbs) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human CCR5 mAbs <\\entity><\\entity>, ROAb13, ROAb14, and ROAb18 showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "455",
    "Sentence": "Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.To identify monoclonal antibodies (mAbs) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human CCR5 mAbs <\\entity><\\entity>, ROAb13, ROAb14, and ROAb18 showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "456",
    "Sentence": "Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.To identify monoclonal antibodies (mAbs) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human CCR5 mAbs ROAb12, <\\entity><\\entity>, ROAb14, and ROAb18 showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "457",
    "Sentence": "Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.To identify monoclonal antibodies (mAbs) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human CCR5 mAbs ROAb12, <\\entity><\\entity>, ROAb14, and ROAb18 showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "458",
    "Sentence": "Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.To identify monoclonal antibodies (mAbs) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human CCR5 mAbs ROAb12, ROAb13, <\\entity><\\entity>, and ROAb18 showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "459",
    "Sentence": "Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.To identify monoclonal antibodies (mAbs) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human CCR5 mAbs ROAb12, ROAb13, <\\entity><\\entity>, and ROAb18 showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "460",
    "Sentence": "Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.To identify monoclonal antibodies (mAbs) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human CCR5 mAbs ROAb12, ROAb13, ROAb14, and <\\entity><\\entity> showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "461",
    "Sentence": "Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.To identify monoclonal antibodies (mAbs) with high potency and novel recognition sites, more than 25,000 of mouse hybridomas were screened and 4 novel anti-human CCR5 mAbs ROAb12, ROAb13, ROAb14, and <\\entity><\\entity> showing potent activity in cell-cell fusion (CCF) assay were identified.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "462",
    "Sentence": "These <\\entity><\\entity> demonstrated potent antiviral activities in both single-cycle HIV infection (IC(50) range: 0.16-4.3 microg/ml) and PBMC viral replication (IC(50) range: 0.02-0.04 microg/ml) assays.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "463",
    "Sentence": "All 4 <\\entity><\\entity> were also highly potent in the PhenoSense assay against 29 HIV isolates covering clade A through G.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "464",
    "Sentence": "In all antiviral assays, these <\\entity><\\entity> showed potency superior to the previously reported mAb 2D7 in side-by-side comparison studies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "465",
    "Sentence": "In all antiviral assays, these <\\entity><\\entity>s showed potency superior to the previously reported <\\entity><\\entity> 2D7 in side-by-side comparison studies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "466",
    "Sentence": "In all antiviral assays, these mAbs showed potency superior to the previously reported mAb <\\entity><\\entity> in side-by-side comparison studies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "467",
    "Sentence": "In all antiviral assays, these mAbs showed potency superior to the previously reported mAb <\\entity><\\entity> in side-by-side comparison studies.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "468",
    "Sentence": "All 4 <\\entity><\\entity> were also fully active against viruses resistant to HIV fusion inhibitor enfuvirtide and CCR5 antagonist maraviroc.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "469",
    "Sentence": "All 4 mAbs were also fully active against viruses resistant to <\\entity><\\entity> enfuvirtide and CCR5 antagonist maraviroc.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "470",
    "Sentence": "All 4 mAbs were also fully active against viruses resistant to HIV fusion inhibitor <\\entity><\\entity> and CCR5 antagonist maraviroc.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "471",
    "Sentence": "All 4 mAbs were also fully active against viruses resistant to HIV fusion inhibitor enfuvirtide and <\\entity><\\entity> maraviroc.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "472",
    "Sentence": "All 4 mAbs were also fully active against viruses resistant to HIV fusion inhibitor enfuvirtide and <\\entity><\\entity> maraviroc.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "473",
    "Sentence": "All 4 mAbs were also fully active against viruses resistant to HIV fusion inhibitor enfuvirtide and CCR5 antagonist <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "474",
    "Sentence": "Although <\\entity><\\entity>, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "475",
    "Sentence": "Although <\\entity><\\entity>, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "476",
    "Sentence": "Although ROAb12, <\\entity><\\entity>, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "477",
    "Sentence": "Although ROAb12, <\\entity><\\entity>, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "478",
    "Sentence": "Although ROAb12, ROAb14, and <\\entity><\\entity> inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "479",
    "Sentence": "Although ROAb12, ROAb14, and <\\entity><\\entity> inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "480",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited <\\entity><\\entity>, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "481",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, <\\entity><\\entity> and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "482",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and <\\entity><\\entity> binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "483",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel <\\entity><\\entity> ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "484",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb <\\entity><\\entity> was inactive in inhibiting cell activation by these three ligands.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "485",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb <\\entity><\\entity> was inactive in inhibiting cell activation by these three ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "486",
    "Sentence": "Furthermore, highly synergistic antiviral effects were found between <\\entity><\\entity> ROAb13 and 2D7 or ROAb12.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "487",
    "Sentence": "Furthermore, highly synergistic antiviral effects were found between mAb <\\entity><\\entity> and 2D7 or ROAb12.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "488",
    "Sentence": "Furthermore, highly synergistic antiviral effects were found between mAb <\\entity><\\entity> and 2D7 or ROAb12.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "489",
    "Sentence": "Furthermore, highly synergistic antiviral effects were found between mAb ROAb13 and <\\entity><\\entity> or ROAb12.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "490",
    "Sentence": "Furthermore, highly synergistic antiviral effects were found between mAb ROAb13 and <\\entity><\\entity> or ROAb12.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "491",
    "Sentence": "Furthermore, highly synergistic antiviral effects were found between mAb ROAb13 and 2D7 or <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "492",
    "Sentence": "Furthermore, highly synergistic antiviral effects were found between mAb ROAb13 and 2D7 or <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "493",
    "Sentence": "In addition, none of these <\\entity><\\entity> showed agonist activity or caused internalization of the CCR5 receptor.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "494",
    "Sentence": "In addition, none of these mAbs showed agonist activity or caused internalization of the <\\entity><\\entity> receptor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "495",
    "Sentence": "Although <\\entity><\\entity>, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "496",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited <\\entity><\\entity>, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "498",
    "Sentence": "Although <\\entity><\\entity>, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "499",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, <\\entity><\\entity> and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "501",
    "Sentence": "Although <\\entity><\\entity>, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "502",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and <\\entity><\\entity> binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "504",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb <\\entity><\\entity> was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "505",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited <\\entity><\\entity>, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "507",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb <\\entity><\\entity> was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "508",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, <\\entity><\\entity> and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "510",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb <\\entity><\\entity> was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "511",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and <\\entity><\\entity> binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "513",
    "Sentence": "Although ROAb12, <\\entity><\\entity>, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "514",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited <\\entity><\\entity>, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "516",
    "Sentence": "Although ROAb12, <\\entity><\\entity>, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "517",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, <\\entity><\\entity> and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "519",
    "Sentence": "Although ROAb12, <\\entity><\\entity>, and ROAb18 inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "520",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and <\\entity><\\entity> binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "522",
    "Sentence": "Although ROAb12, ROAb14, and <\\entity><\\entity> inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "523",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited <\\entity><\\entity>, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "525",
    "Sentence": "Although ROAb12, ROAb14, and <\\entity><\\entity> inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "526",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, <\\entity><\\entity> and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "528",
    "Sentence": "Although ROAb12, ROAb14, and <\\entity><\\entity> inhibited RANTES, MIP1alpha and MIP1beta binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "529",
    "Sentence": "Although ROAb12, ROAb14, and ROAb18 inhibited RANTES, MIP1alpha and <\\entity><\\entity> binding and cell activation, the other novel mAb ROAb13 was inactive in inhibiting cell activation by these three ligands.",
    "Label": ""
  },
  {
    "id": "531",
    "Sentence": "In addition, none of these <\\entity><\\entity> showed agonist activity or caused internalization of the CCR5 receptor.",
    "Label": ""
  },
  {
    "id": "532",
    "Sentence": "In addition, none of these mAbs showed agonist activity or caused internalization of the <\\entity><\\entity> receptor.",
    "Label": ""
  },
  {
    "id": "534",
    "Sentence": "All 4 mAbs were also fully active against viruses resistant to HIV fusion inhibitor <\\entity><\\entity> and CCR5 antagonist maraviroc.",
    "Label": ""
  },
  {
    "id": "535",
    "Sentence": "All 4 mAbs were also fully active against viruses resistant to HIV fusion inhibitor enfuvirtide and <\\entity><\\entity> maraviroc.",
    "Label": ""
  },
  {
    "id": "537",
    "Sentence": "All 4 mAbs were also fully active against viruses resistant to HIV fusion inhibitor enfuvirtide and CCR5 antagonist <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "538",
    "Sentence": "All 4 mAbs were also fully active against viruses resistant to HIV fusion inhibitor enfuvirtide and <\\entity><\\entity> maraviroc.",
    "Label": ""
  },
  {
    "id": "544",
    "Sentence": "Neuroprotective efficacy of the <\\entity><\\entity> in vitro and in vivo.Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily and function as ligand-modulated transcription factors that regulate gene expression in many important biological processes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "545",
    "Sentence": "Neuroprotective efficacy of the <\\entity><\\entity> in vitro and in vivo.Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily and function as ligand-modulated transcription factors that regulate gene expression in many important biological processes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "546",
    "Sentence": "Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.<\\entity><\\entity> (PPARs) are members of the nuclear receptor superfamily and function as ligand-modulated transcription factors that regulate gene expression in many important biological processes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "547",
    "Sentence": "Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.Peroxisome proliferator-activated receptors (<\\entity><\\entity>) are members of the nuclear receptor superfamily and function as ligand-modulated transcription factors that regulate gene expression in many important biological processes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "548",
    "Sentence": "The <\\entity><\\entity> subtype has the highest expression in the brain and is postulated to play a major role in neuronal cell function; however, the precise physiological roles of this receptor remain to be elucidated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "549",
    "Sentence": "Herein, we show that the high-affinity <\\entity><\\entity> L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "550",
    "Sentence": "Herein, we show that the high-affinity <\\entity><\\entity> L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "551",
    "Sentence": "Herein, we show that the high-affinity PPARdelta agonists <\\entity><\\entity> [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "552",
    "Sentence": "Herein, we show that the high-affinity PPARdelta agonists L-165041 [<\\entity><\\entity>] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "553",
    "Sentence": "Herein, we show that the high-affinity PPARdelta agonists L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and <\\entity><\\entity> [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "554",
    "Sentence": "Herein, we show that the high-affinity PPARdelta agonists L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [<\\entity><\\entity>] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "555",
    "Sentence": "Herein, we show that the high-affinity PPARdelta agonists L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and <\\entity><\\entity> (MPTP) neurotoxicity in vivo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "556",
    "Sentence": "Herein, we show that the high-affinity PPARdelta agonists L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (<\\entity><\\entity>) neurotoxicity in vivo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "557",
    "Sentence": "In the SH-SY5Y studies, treatment with <\\entity><\\entity> or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "558",
    "Sentence": "In the SH-SY5Y studies, treatment with L-165041 or <\\entity><\\entity> significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "559",
    "Sentence": "In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following <\\entity><\\entity>, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "560",
    "Sentence": "In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, <\\entity><\\entity>, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "561",
    "Sentence": "In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or <\\entity><\\entity> exposure, with the extent of damage correlated with the level of caspase-3 inhibition.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "562",
    "Sentence": "In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of <\\entity><\\entity> inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "563",
    "Sentence": "infusion of <\\entity><\\entity> or GW501516 significantly attenuated the ischemic brain damage measured 24 h after reperfusion.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "564",
    "Sentence": "infusion of L-165041 or <\\entity><\\entity> significantly attenuated the ischemic brain damage measured 24 h after reperfusion.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "565",
    "Sentence": "Moreover, the <\\entity><\\entity> also significantly attenuated MPTP-induced depletion of striatal dopamine and related metabolite contents in mouse brain.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "566",
    "Sentence": "Moreover, the <\\entity><\\entity> also significantly attenuated MPTP-induced depletion of striatal dopamine and related metabolite contents in mouse brain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "567",
    "Sentence": "Moreover, the PPARdelta agonists also significantly attenuated <\\entity><\\entity>-induced depletion of striatal dopamine and related metabolite contents in mouse brain.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "568",
    "Sentence": "Moreover, the PPARdelta agonists also significantly attenuated MPTP-induced depletion of striatal <\\entity><\\entity> and related metabolite contents in mouse brain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "569",
    "Sentence": "Moreover, the PPARdelta agonists also significantly attenuated MPTP-induced depletion of striatal <\\entity><\\entity> and related metabolite contents in mouse brain.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "570",
    "Sentence": "These results demonstrate that subtype-selective <\\entity><\\entity> possess antiapoptotic properties in vitro, which may underlie their potential neuroprotective potential in in vivo experimental models of cerebral ischemia and Parkinson's disease (PD).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "571",
    "Sentence": "These results demonstrate that subtype-selective <\\entity><\\entity> possess antiapoptotic properties in vitro, which may underlie their potential neuroprotective potential in in vivo experimental models of cerebral ischemia and Parkinson's disease (PD).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "572",
    "Sentence": "These findings suggest that <\\entity><\\entity> could be useful tools for understanding the role of PPARdelta in other neurodegenerative disorders, as well as attractive therapeutic candidates for stroke and neurodegenerative diseases such as PD.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "573",
    "Sentence": "These findings suggest that <\\entity><\\entity> could be useful tools for understanding the role of PPARdelta in other neurodegenerative disorders, as well as attractive therapeutic candidates for stroke and neurodegenerative diseases such as PD.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "574",
    "Sentence": "These findings suggest that <\\entity><\\entity> agonists could be useful tools for understanding the role of <\\entity><\\entity> in other neurodegenerative disorders, as well as attractive therapeutic candidates for stroke and neurodegenerative diseases such as PD.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "575",
    "Sentence": "In the SH-SY5Y studies, treatment with <\\entity><\\entity> or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition.",
    "Label": ""
  },
  {
    "id": "576",
    "Sentence": "In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of <\\entity><\\entity> inhibition.",
    "Label": ""
  },
  {
    "id": "578",
    "Sentence": "In the SH-SY5Y studies, treatment with L-165041 or <\\entity><\\entity> significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition.",
    "Label": ""
  },
  {
    "id": "579",
    "Sentence": "In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of <\\entity><\\entity> inhibition.",
    "Label": ""
  },
  {
    "id": "581",
    "Sentence": "Moreover, the PPARdelta agonists also significantly attenuated <\\entity><\\entity>-induced depletion of striatal dopamine and related metabolite contents in mouse brain.",
    "Label": ""
  },
  {
    "id": "582",
    "Sentence": "Moreover, the PPARdelta agonists also significantly attenuated MPTP-induced depletion of striatal <\\entity><\\entity> and related metabolite contents in mouse brain.",
    "Label": ""
  },
  {
    "id": "584",
    "Sentence": "These findings suggest that <\\entity><\\entity> could be useful tools for understanding the role of PPARdelta in other neurodegenerative disorders, as well as attractive therapeutic candidates for stroke and neurodegenerative diseases such as PD.",
    "Label": ""
  },
  {
    "id": "585",
    "Sentence": "These findings suggest that <\\entity><\\entity> agonists could be useful tools for understanding the role of <\\entity><\\entity> in other neurodegenerative disorders, as well as attractive therapeutic candidates for stroke and neurodegenerative diseases such as PD.",
    "Label": ""
  },
  {
    "id": "587",
    "Sentence": "Herein, we show that the high-affinity PPARdelta agonists <\\entity><\\entity> [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": ""
  },
  {
    "id": "588",
    "Sentence": "Herein, we show that the high-affinity <\\entity><\\entity> L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": ""
  },
  {
    "id": "590",
    "Sentence": "Herein, we show that the high-affinity PPARdelta agonists L-165041 [<\\entity><\\entity>] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": ""
  },
  {
    "id": "591",
    "Sentence": "Herein, we show that the high-affinity <\\entity><\\entity> L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": ""
  },
  {
    "id": "593",
    "Sentence": "Herein, we show that the high-affinity PPARdelta agonists L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and <\\entity><\\entity> [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": ""
  },
  {
    "id": "594",
    "Sentence": "Herein, we show that the high-affinity <\\entity><\\entity> L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": ""
  },
  {
    "id": "596",
    "Sentence": "Herein, we show that the high-affinity PPARdelta agonists L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [<\\entity><\\entity>] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": ""
  },
  {
    "id": "597",
    "Sentence": "Herein, we show that the high-affinity <\\entity><\\entity> L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": ""
  },
  {
    "id": "599",
    "Sentence": "Herein, we show that the high-affinity PPARdelta agonists L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and <\\entity><\\entity> (MPTP) neurotoxicity in vivo.",
    "Label": ""
  },
  {
    "id": "600",
    "Sentence": "Herein, we show that the high-affinity <\\entity><\\entity> L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": ""
  },
  {
    "id": "602",
    "Sentence": "Herein, we show that the high-affinity PPARdelta agonists L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (<\\entity><\\entity>) neurotoxicity in vivo.",
    "Label": ""
  },
  {
    "id": "603",
    "Sentence": "Herein, we show that the high-affinity <\\entity><\\entity> L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo.",
    "Label": ""
  },
  {
    "id": "605",
    "Sentence": "Moreover, the PPARdelta agonists also significantly attenuated MPTP-induced depletion of striatal <\\entity><\\entity> and related metabolite contents in mouse brain.",
    "Label": ""
  },
  {
    "id": "606",
    "Sentence": "Moreover, the <\\entity><\\entity> also significantly attenuated MPTP-induced depletion of striatal dopamine and related metabolite contents in mouse brain.",
    "Label": ""
  },
  {
    "id": "608",
    "Sentence": "Moreover, the PPARdelta agonists also significantly attenuated <\\entity><\\entity>-induced depletion of striatal dopamine and related metabolite contents in mouse brain.",
    "Label": ""
  },
  {
    "id": "609",
    "Sentence": "Moreover, the <\\entity><\\entity> also significantly attenuated MPTP-induced depletion of striatal dopamine and related metabolite contents in mouse brain.",
    "Label": ""
  },
  {
    "id": "611",
    "Sentence": "In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following <\\entity><\\entity>, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition.",
    "Label": ""
  },
  {
    "id": "612",
    "Sentence": "In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of <\\entity><\\entity> inhibition.",
    "Label": ""
  },
  {
    "id": "614",
    "Sentence": "In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, <\\entity><\\entity>, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition.",
    "Label": ""
  },
  {
    "id": "615",
    "Sentence": "In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of <\\entity><\\entity> inhibition.",
    "Label": ""
  },
  {
    "id": "617",
    "Sentence": "In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or <\\entity><\\entity> exposure, with the extent of damage correlated with the level of caspase-3 inhibition.",
    "Label": ""
  },
  {
    "id": "618",
    "Sentence": "In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of <\\entity><\\entity> inhibition.",
    "Label": ""
  },
  {
    "id": "624",
    "Sentence": "<\\entity><\\entity> secondary to cocaine use.A 27-yr-old woman recreationally inhaled cocaine.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "625",
    "Sentence": "Spinal cord infarction <\\entity><\\entity> to cocaine use.A 27-yr-old woman recreationally inhaled cocaine.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "626",
    "Sentence": "Spinal cord infarction secondary to <\\entity><\\entity> use.A 27-yr-old woman recreationally inhaled <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "627",
    "Sentence": "Spinal cord infarction secondary to <\\entity><\\entity> use.A 27-yr-old woman recreationally inhaled <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "628",
    "Sentence": "Several hours later, she noted <\\entity><\\entity>, back and neck pain, and later bilateral upper-extremity weakness.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "629",
    "Sentence": "Several hours later, she noted chest tightness, back and <\\entity><\\entity>, and later bilateral upper-extremity weakness.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "630",
    "Sentence": "Several hours later, she noted chest tightness, back and neck pain, and later bilateral upper-extremity <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "631",
    "Sentence": "Physical examination revealed <\\entity><\\entity> of the upper extremities.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "632",
    "Sentence": "<\\entity><\\entity> at 2 mos after injury, but no detectable weakness, developed in the lower extremities.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "633",
    "Sentence": "Spasticity at 2 <\\entity><\\entity> after injury, but no detectable weakness, developed in the lower extremities.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "634",
    "Sentence": "Spasticity at 2 mos after injury, but no detectable <\\entity><\\entity>, developed in the lower extremities.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "635",
    "Sentence": "<\\entity><\\entity> was detected in her urine.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "636",
    "Sentence": "Cocaine was detected in <\\entity><\\entity> urine.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "637",
    "Sentence": "Magnetic resonance imaging showed hyperintensity in the <\\entity><\\entity> cervicothoracic spinal cord.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "638",
    "Sentence": "Electrodiagnostic studies of the upper extremities were consistent with <\\entity><\\entity> horn cell death.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "639",
    "Sentence": "<\\entity><\\entity> abuse is associated with cerebrovascular events; spinal cord effects are rarely reported.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "640",
    "Sentence": "<\\entity><\\entity> abuse is associated with cerebrovascular events; spinal cord effects are rarely reported.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "641",
    "Sentence": "Cocaine abuse is associated with <\\entity><\\entity>; spinal cord effects are rarely reported.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "642",
    "Sentence": "Cocaine abuse is associated with cerebrovascular events; <\\entity><\\entity> are rarely reported.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "643",
    "Sentence": "The patient seems to have an <\\entity><\\entity> in the anterior spinal artery distribution, with clinical, imaging, and electrodiagnostic findings of upper-extremity lower-motor neuron injury, accompanied by spasticity of the lower extremities.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "644",
    "Sentence": "The patient seems to have an infarct in the <\\entity><\\entity> spinal artery distribution, with clinical, imaging, and electrodiagnostic findings of upper-extremity lower-motor neuron injury, accompanied by spasticity of the lower extremities.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "645",
    "Sentence": "The patient seems to have an infarct in the anterior spinal <\\entity><\\entity> distribution, with clinical, imaging, and electrodiagnostic findings of upper-extremity lower-motor neuron injury, accompanied by spasticity of the lower extremities.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "646",
    "Sentence": "The patient seems to have an infarct in the anterior spinal artery distribution, with clinical, imaging, and electrodiagnostic findings of upper-extremity lower-motor neuron injury, accompanied by <\\entity><\\entity> of the lower extremities.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "647",
    "Sentence": "Gray matter has increased susceptibility to <\\entity><\\entity> compared with white matter, producing flaccid weakness in the cervical region with isolated arm weakness.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "648",
    "Sentence": "Gray matter has increased susceptibility to ischemia compared with white matter, producing flaccid <\\entity><\\entity> in the cervical region with isolated arm <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "649",
    "Sentence": "Gray matter has increased susceptibility to ischemia compared with white matter, producing flaccid weakness in the cervical region with isolated <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "650",
    "Sentence": "Although uncommon, <\\entity><\\entity> abuse can cause spinal cord infarction.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "651",
    "Sentence": "Although uncommon, <\\entity><\\entity> abuse can cause spinal cord infarction.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "652",
    "Sentence": "Although uncommon, cocaine abuse can cause <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "653",
    "Sentence": "Spinal cord infarction secondary to <\\entity><\\entity> use.A 27-yr-old woman recreationally inhaled <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "654",
    "Sentence": "<\\entity><\\entity> secondary to cocaine use.A 27-yr-old woman recreationally inhaled cocaine.",
    "Label": ""
  },
  {
    "id": "656",
    "Sentence": "<\\entity><\\entity> abuse is associated with cerebrovascular events; spinal cord effects are rarely reported.",
    "Label": ""
  },
  {
    "id": "657",
    "Sentence": "Cocaine abuse is associated with <\\entity><\\entity>; spinal cord effects are rarely reported.",
    "Label": ""
  },
  {
    "id": "659",
    "Sentence": "<\\entity><\\entity> abuse is associated with cerebrovascular events; spinal cord effects are rarely reported.",
    "Label": ""
  },
  {
    "id": "660",
    "Sentence": "Cocaine abuse is associated with cerebrovascular events; <\\entity><\\entity> are rarely reported.",
    "Label": ""
  },
  {
    "id": "662",
    "Sentence": "Although uncommon, <\\entity><\\entity> abuse can cause spinal cord infarction.",
    "Label": ""
  },
  {
    "id": "663",
    "Sentence": "Although uncommon, cocaine abuse can cause <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "665",
    "Sentence": "Spinal cord infarction secondary to <\\entity><\\entity> use.A 27-yr-old woman recreationally inhaled <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "666",
    "Sentence": "Spinal cord infarction <\\entity><\\entity> to cocaine use.A 27-yr-old woman recreationally inhaled cocaine.",
    "Label": ""
  },
  {
    "id": "672",
    "Sentence": "The variation in <\\entity><\\entity> localization and the changes in <\\entity><\\entity> expression level upon stimulation with growth factors.Although <\\entity><\\entity> (APO-1/CD95) is well known as a death receptor, its stimulation occasionally fails to induce apoptosis in malignant cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "673",
    "Sentence": "The variation in <\\entity><\\entity> localization and the changes in <\\entity><\\entity> expression level upon stimulation with growth factors.Although <\\entity><\\entity> (APO-1/CD95) is well known as a death receptor, its stimulation occasionally fails to induce apoptosis in malignant cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "674",
    "Sentence": "The variation in <\\entity><\\entity> localization and the changes in <\\entity><\\entity> expression level upon stimulation with growth factors.Although <\\entity><\\entity> (APO-1/CD95) is well known as a death receptor, its stimulation occasionally fails to induce apoptosis in malignant cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "675",
    "Sentence": "The variation in Fas localization and the changes in Fas expression level upon stimulation with growth factors.Although Fas (<\\entity><\\entity>) is well known as a death receptor, its stimulation occasionally fails to induce apoptosis in malignant cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "676",
    "Sentence": "On the contrary, <\\entity><\\entity> is reported to advance the cell cycle in cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "677",
    "Sentence": "Therefore, we investigated roles of <\\entity><\\entity> in cell growth and apoptosis using human lung cancer cell lines.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "678",
    "Sentence": "<\\entity><\\entity> was localized in the cytoplasm in exponentially growing cells, whereas only confluent cells expressed <\\entity><\\entity> on the cell membrane.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "679",
    "Sentence": "<\\entity><\\entity> was localized in the cytoplasm in exponentially growing cells, whereas only confluent cells expressed <\\entity><\\entity> on the cell membrane.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "680",
    "Sentence": "A stimulation of confluent cells by either of <\\entity><\\entity>, IGF-I or V<\\entity><\\entity> induced once a decrease in Fas expression level and its sequential recovery.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "681",
    "Sentence": "A stimulation of confluent cells by either of <\\entity><\\entity>, IGF-I or V<\\entity><\\entity> induced once a decrease in Fas expression level and its sequential recovery.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "682",
    "Sentence": "A stimulation of confluent cells by either of EGF, <\\entity><\\entity> or VEGF induced once a decrease in Fas expression level and its sequential recovery.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "683",
    "Sentence": "A stimulation of confluent cells by either of EGF, <\\entity><\\entity> or VEGF induced once a decrease in Fas expression level and its sequential recovery.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "684",
    "Sentence": "A stimulation of confluent cells by either of EGF, IGF-I or <\\entity><\\entity> induced once a decrease in Fas expression level and its sequential recovery.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "685",
    "Sentence": "A stimulation of confluent cells by either of EGF, IGF-I or <\\entity><\\entity> induced once a decrease in Fas expression level and its sequential recovery.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "686",
    "Sentence": "A stimulation of confluent cells by either of EGF, IGF-I or VEGF induced once a decrease in <\\entity><\\entity> expression level and its sequential recovery.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "687",
    "Sentence": "<\\entity><\\entity> expression levels in confluent cells were negatively correlated with cell doubling times (r=0.757, p=0.0088).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "688",
    "Sentence": "<\\entity><\\entity> remained on the cell membrane of IgM-treated cells even after the growth factor stimulation, leading to apoptosis with abnormal mitosis, whereas the same stimulation induced <\\entity><\\entity> internalization in IgG(1)-treated cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "689",
    "Sentence": "Fas remained on the cell membrane of <\\entity><\\entity>-treated cells even after the growth factor stimulation, leading to apoptosis with abnormal mitosis, whereas the same stimulation induced Fas internalization in IgG(1)-treated cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "690",
    "Sentence": "Fas remained on the cell membrane of IgM-treated cells even after the <\\entity><\\entity> stimulation, leading to apoptosis with abnormal mitosis, whereas the same stimulation induced Fas internalization in IgG(1)-treated cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "691",
    "Sentence": "<\\entity><\\entity> remained on the cell membrane of IgM-treated cells even after the growth factor stimulation, leading to apoptosis with abnormal mitosis, whereas the same stimulation induced <\\entity><\\entity> internalization in IgG(1)-treated cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "692",
    "Sentence": "Fas remained on the cell membrane of IgM-treated cells even after the growth factor stimulation, leading to apoptosis with abnormal mitosis, whereas the same stimulation induced Fas internalization in <\\entity><\\entity>-treated cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "693",
    "Sentence": "From these results, we suggest that <\\entity><\\entity> remaining on the cell membrane amplifies to induce apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "694",
    "Sentence": "Conversely, <\\entity><\\entity> internalization may enable cancer cells to escape from apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "695",
    "Sentence": "Our results suggest that <\\entity><\\entity> may contribute to the resistance of cancer cells to Fas-mediated apoptosis in an autocrine or paracrine fashion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "696",
    "Sentence": "Our results suggest that growth factor may contribute to the resistance of cancer cells to <\\entity><\\entity>-mediated apoptosis in an autocrine or paracrine fashion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "697",
    "Sentence": "A stimulation of confluent cells by either of <\\entity><\\entity>, IGF-I or V<\\entity><\\entity> induced once a decrease in Fas expression level and its sequential recovery.",
    "Label": ""
  },
  {
    "id": "698",
    "Sentence": "A stimulation of confluent cells by either of EGF, IGF-I or VEGF induced once a decrease in <\\entity><\\entity> expression level and its sequential recovery.",
    "Label": ""
  },
  {
    "id": "700",
    "Sentence": "A stimulation of confluent cells by either of EGF, <\\entity><\\entity> or VEGF induced once a decrease in Fas expression level and its sequential recovery.",
    "Label": ""
  },
  {
    "id": "701",
    "Sentence": "A stimulation of confluent cells by either of EGF, IGF-I or VEGF induced once a decrease in <\\entity><\\entity> expression level and its sequential recovery.",
    "Label": ""
  },
  {
    "id": "703",
    "Sentence": "A stimulation of confluent cells by either of EGF, IGF-I or <\\entity><\\entity> induced once a decrease in Fas expression level and its sequential recovery.",
    "Label": ""
  },
  {
    "id": "704",
    "Sentence": "A stimulation of confluent cells by either of EGF, IGF-I or VEGF induced once a decrease in <\\entity><\\entity> expression level and its sequential recovery.",
    "Label": ""
  },
  {
    "id": "710",
    "Sentence": "Gene expression profiling of human primary astrocytes exposed to <\\entity><\\entity> chloride indicates selective effects on several functions of the cells.Exposure of adult humans to <\\entity><\\entity> (Mn) has long been known to cause neurotoxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "711",
    "Sentence": "Gene expression profiling of human primary astrocytes exposed to <\\entity><\\entity> chloride indicates selective effects on several functions of the cells.Exposure of adult humans to <\\entity><\\entity> (Mn) has long been known to cause neurotoxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "712",
    "Sentence": "Gene expression profiling of human primary astrocytes exposed to manganese chloride indicates selective effects on several functions of the cells.Exposure of adult humans to manganese (<\\entity><\\entity>) has long been known to cause neurotoxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "713",
    "Sentence": "Recent evidence also suggests that exposure of children to <\\entity><\\entity> is associated with developmental neurotoxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "714",
    "Sentence": "In this report, to help elucidate the molecular events underlying <\\entity><\\entity> neurotoxicity, we systematically identified the molecular targets of <\\entity><\\entity> in primary human astrocytes at a genome-wide level, by using microarray gene expression profiling and computational data analysis algorithms.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "715",
    "Sentence": "In this report, to help elucidate the molecular events underlying <\\entity><\\entity> neurotoxicity, we systematically identified the molecular targets of <\\entity><\\entity> in primary human astrocytes at a genome-wide level, by using microarray gene expression profiling and computational data analysis algorithms.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "716",
    "Sentence": "We found that <\\entity><\\entity> altered the expression of diverse genes ranging from those encoding cytokines and transporters to signal transducers and transcriptional regulators.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "717",
    "Sentence": "We found that Mn altered the expression of diverse genes ranging from those encoding <\\entity><\\entity> and transporters to signal transducers and transcriptional regulators.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "718",
    "Sentence": "We found that Mn altered the expression of diverse genes ranging from those encoding cytokines and <\\entity><\\entity> to signal transducers and transcriptional regulators.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "719",
    "Sentence": "We found that Mn altered the expression of diverse genes ranging from those encoding cytokines and transporters to <\\entity><\\entity> and transcriptional regulators.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "720",
    "Sentence": "We found that Mn altered the expression of diverse genes ranging from those encoding cytokines and transporters to signal transducers and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "721",
    "Sentence": "Particularly, 28 genes encoding <\\entity><\\entity>, cytokines and related functions were up-regulated, whereas 15 genes encoding functions involved in DNA replication and repair and cell cycle checkpoint control were down-regulated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "722",
    "Sentence": "Particularly, 28 genes encoding proinflammatory chemokines, <\\entity><\\entity> and related functions were up-regulated, whereas 15 genes encoding functions involved in DNA replication and repair and cell cycle checkpoint control were down-regulated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "723",
    "Sentence": "Consistent with the increased expression of proinflammatory factors, analysis of common regulators revealed that 16 targets known to be positively affected by the interferon-gamma signaling pathway were up-regulated by <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "724",
    "Sentence": "In addition, 68 genes were found to be similarly up- or down-regulated by both <\\entity><\\entity> and hypoxia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "725",
    "Sentence": "Together, these analyses show that <\\entity><\\entity> selectively affects cell cycle progression, the expression of hypoxia-responsive genes, and the expression of proinflammatory factors in primary human astrocytes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "726",
    "Sentence": "These results provide important insights into the molecular mechanisms underlying <\\entity><\\entity> neurotoxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "727",
    "Sentence": "We found that <\\entity><\\entity> altered the expression of diverse genes ranging from those encoding cytokines and transporters to signal transducers and transcriptional regulators.",
    "Label": ""
  },
  {
    "id": "728",
    "Sentence": "We found that Mn altered the expression of diverse genes ranging from those encoding <\\entity><\\entity> and transporters to signal transducers and transcriptional regulators.",
    "Label": ""
  },
  {
    "id": "730",
    "Sentence": "We found that <\\entity><\\entity> altered the expression of diverse genes ranging from those encoding cytokines and transporters to signal transducers and transcriptional regulators.",
    "Label": ""
  },
  {
    "id": "731",
    "Sentence": "We found that Mn altered the expression of diverse genes ranging from those encoding cytokines and <\\entity><\\entity> to signal transducers and transcriptional regulators.",
    "Label": ""
  },
  {
    "id": "733",
    "Sentence": "We found that <\\entity><\\entity> altered the expression of diverse genes ranging from those encoding cytokines and transporters to signal transducers and transcriptional regulators.",
    "Label": ""
  },
  {
    "id": "734",
    "Sentence": "We found that Mn altered the expression of diverse genes ranging from those encoding cytokines and transporters to <\\entity><\\entity> and transcriptional regulators.",
    "Label": ""
  },
  {
    "id": "736",
    "Sentence": "We found that <\\entity><\\entity> altered the expression of diverse genes ranging from those encoding cytokines and transporters to signal transducers and transcriptional regulators.",
    "Label": ""
  },
  {
    "id": "737",
    "Sentence": "We found that Mn altered the expression of diverse genes ranging from those encoding cytokines and transporters to signal transducers and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "743",
    "Sentence": "The histone deacetylase inhibitors depsipeptide and MS-275, enhance <\\entity><\\entity> gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.Gene therapy of cancer using adenovirus as a single treatment modality has met limited success and efforts to enhance therapeutic outcomes have included combination of gene therapy with chemotherapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "744",
    "Sentence": "The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP <\\entity><\\entity> cells without adverse effects in normal prostate epithelial cells.Gene therapy of cancer using adenovirus as a single treatment modality has met limited success and efforts to enhance therapeutic outcomes have included combination of gene therapy with chemotherapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "745",
    "Sentence": "The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without <\\entity><\\entity> in normal prostate epithelial cells.Gene therapy of cancer using adenovirus as a single treatment modality has met limited success and efforts to enhance therapeutic outcomes have included combination of gene therapy with chemotherapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "746",
    "Sentence": "The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate <\\entity><\\entity> cells without adverse effects in normal prostate epithelial cells.Gene therapy of <\\entity><\\entity> using adenovirus as a single treatment modality has met limited success and efforts to enhance therapeutic outcomes have included combination of gene therapy with chemotherapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "747",
    "Sentence": "The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.Gene therapy of cancer using <\\entity><\\entity> as a single treatment modality has met limited success and efforts to enhance therapeutic outcomes have included combination of gene therapy with chemotherapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "748",
    "Sentence": "The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.Gene therapy of cancer using adenovirus as a single treatment modality has <\\entity><\\entity> limited success and efforts to enhance therapeutic outcomes have included combination of gene therapy with chemotherapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "749",
    "Sentence": "The goal of this study was to investigate which chemotherapeutic agents may be suitable for combination with gene therapy of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "750",
    "Sentence": "Using an <\\entity><\\entity> expressing green fluorescent protein (GFP), we determined the effect of cisplatin, gemcitabine, doxorubicin, depsipeptide and MS-275 on adenoviral infectivity and transgene expression in LNCaP cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "751",
    "Sentence": "Using an adenovirus expressing <\\entity><\\entity> (GFP), we determined the effect of cisplatin, gemcitabine, doxorubicin, depsipeptide and MS-275 on adenoviral infectivity and transgene expression in LNCaP cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "752",
    "Sentence": "Using an adenovirus expressing green fluorescent protein (<\\entity><\\entity>), we determined the effect of cisplatin, gemcitabine, doxorubicin, depsipeptide and MS-275 on adenoviral infectivity and transgene expression in LNCaP cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "753",
    "Sentence": "The increase in infectivity but not transgene expression correlated to increased surface expression of <\\entity><\\entity> (CAR).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "754",
    "Sentence": "The increase in infectivity but not transgene expression correlated to increased surface expression of coxsackie and <\\entity><\\entity> receptor (CAR).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "755",
    "Sentence": "The increase in infectivity but not transgene expression correlated to increased surface expression of coxsackie and adenovirus receptor (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "756",
    "Sentence": "The increase in infectivity but not transgene expression correlated to increased surface expression of coxsackie and adenovirus receptor (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "757",
    "Sentence": "Increased transgene expression following <\\entity><\\entity> expressing tumor necrosis factor-related apoptosis inducing ligand (TRAIL) was observed only in LNCaP cells treated with depsipeptide or MS-275.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "758",
    "Sentence": "Increased transgene expression following infection with an adenovirus expressing <\\entity><\\entity>(TRAIL) was observed only in LNCaP cells treated with depsipeptide or MS-275.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "759",
    "Sentence": "Increased transgene expression following infection with an adenovirus expressing tumor necrosis factor-related apoptosis inducing ligand (<\\entity><\\entity>) was observed only in LNCaP cells treated with depsipeptide or MS-275.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "760",
    "Sentence": "Combination of <\\entity><\\entity> gene therapy with HDACi but not doxorubicin resulted in increased induction of apoptosis in LNCaP cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "761",
    "Sentence": "These results suggest that combination of HDACi with adenoviral <\\entity><\\entity> gene therapy may be a new therapeutic approach for the treatment of prostate cancer that warrants further investigation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "762",
    "Sentence": "These results suggest that combination of HDACi with adenoviral TRAIL gene therapy may be a new therapeutic approach for the treatment of <\\entity><\\entity> that warrants further investigation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "763",
    "Sentence": "Increased transgene expression following infection with an adenovirus expressing <\\entity><\\entity>(TRAIL) was observed only in LNCaP cells treated with depsipeptide or MS-275.",
    "Label": ""
  },
  {
    "id": "764",
    "Sentence": "Increased transgene expression following <\\entity><\\entity> expressing tumor necrosis factor-related apoptosis inducing ligand (TRAIL) was observed only in LNCaP cells treated with depsipeptide or MS-275.",
    "Label": ""
  },
  {
    "id": "766",
    "Sentence": "The histone deacetylase inhibitors depsipeptide and MS-275, enhance <\\entity><\\entity> gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.Gene therapy of cancer using adenovirus as a single treatment modality has met limited success and efforts to enhance therapeutic outcomes have included combination of gene therapy with chemotherapy.",
    "Label": ""
  },
  {
    "id": "767",
    "Sentence": "The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP <\\entity><\\entity> cells without adverse effects in normal prostate epithelial cells.Gene therapy of cancer using adenovirus as a single treatment modality has met limited success and efforts to enhance therapeutic outcomes have included combination of gene therapy with chemotherapy.",
    "Label": ""
  },
  {
    "id": "769",
    "Sentence": "The increase in infectivity but not transgene expression correlated to increased surface expression of coxsackie and adenovirus receptor (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "770",
    "Sentence": "The increase in infectivity but not transgene expression correlated to increased surface expression of coxsackie and <\\entity><\\entity> receptor (CAR).",
    "Label": ""
  },
  {
    "id": "772",
    "Sentence": "Increased transgene expression following infection with an adenovirus expressing tumor necrosis factor-related apoptosis inducing ligand (<\\entity><\\entity>) was observed only in LNCaP cells treated with depsipeptide or MS-275.",
    "Label": ""
  },
  {
    "id": "773",
    "Sentence": "Increased transgene expression following <\\entity><\\entity> expressing tumor necrosis factor-related apoptosis inducing ligand (TRAIL) was observed only in LNCaP cells treated with depsipeptide or MS-275.",
    "Label": ""
  },
  {
    "id": "775",
    "Sentence": "These results suggest that combination of HDACi with adenoviral <\\entity><\\entity> gene therapy may be a new therapeutic approach for the treatment of prostate cancer that warrants further investigation.",
    "Label": ""
  },
  {
    "id": "776",
    "Sentence": "These results suggest that combination of HDACi with adenoviral TRAIL gene therapy may be a new therapeutic approach for the treatment of <\\entity><\\entity> that warrants further investigation.",
    "Label": ""
  },
  {
    "id": "782",
    "Sentence": "The Connectivity Map: a new tool for biomedical research.The ultimate objective of biomedical research is to connect human <\\entity><\\entity> with the genes that underlie them and drugs that treat them.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "783",
    "Sentence": "But this remains a daunting task, and even the most inspired researchers <\\entity><\\entity> have to resort to laborious screens of genetic or chemical libraries.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "788",
    "Sentence": "<\\entity><\\entity>.A 21-year-old student developed an acute, symmetrical, predominantly motor polyneuropathy within 48 h of walking through a patch of nettles (Urtica ferox).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "789",
    "Sentence": "<\\entity><\\entity>.A 21-year-old student developed an acute, symmetrical, predominantly motor polyneuropathy within 48 h of walking through a patch of nettles (Urtica ferox).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "790",
    "Sentence": "Urtica ferox neuropathy.A 21-year-old student developed an acute, symmetrical, predominantly <\\entity><\\entity> within 48 h of walking through a patch of nettles (Urtica ferox).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "791",
    "Sentence": "Urtica ferox neuropathy.A 21-year-old student developed an acute, symmetrical, predominantly motor polyneuropathy within 48 h of walking through a <\\entity><\\entity> of nettles (Urtica ferox).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "792",
    "Sentence": "<\\entity><\\entity> neuropathy.A 21-year-old student developed an acute, symmetrical, predominantly motor polyneuropathy within 48 h of walking through a patch of nettles (<\\entity><\\entity>).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "793",
    "Sentence": "Two companions had similar but less severe <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "794",
    "Sentence": "This case demonstrates that cutaneous exposure to <\\entity><\\entity> can cause an acute polyneuropathy and that its stinging hairs contain an unidentified neurotoxin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "795",
    "Sentence": "This case demonstrates that cutaneous exposure to Urtica ferox can cause an <\\entity><\\entity> and that its stinging hairs contain an unidentified neurotoxin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "796",
    "Sentence": "This case demonstrates that cutaneous exposure to Urtica ferox can cause an acute polyneuropathy and that its <\\entity><\\entity> hairs contain an unidentified neurotoxin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "797",
    "Sentence": "This case demonstrates that cutaneous exposure to Urtica ferox can cause an acute polyneuropathy and that its stinging hairs contain an <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "798",
    "Sentence": "This case demonstrates that cutaneous exposure to Urtica ferox can cause an acute polyneuropathy and that its stinging hairs contain an <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "799",
    "Sentence": "This case demonstrates that cutaneous exposure to Urtica ferox can cause an <\\entity><\\entity> and that its stinging hairs contain an unidentified neurotoxin.",
    "Label": ""
  },
  {
    "id": "801",
    "Sentence": "<\\entity><\\entity> neuropathy.A 21-year-old student developed an acute, symmetrical, predominantly motor polyneuropathy within 48 h of walking through a patch of nettles (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "802",
    "Sentence": "Urtica ferox neuropathy.A 21-year-old student developed an acute, symmetrical, predominantly <\\entity><\\entity> within 48 h of walking through a patch of nettles (Urtica ferox).",
    "Label": ""
  },
  {
    "id": "804",
    "Sentence": "This case demonstrates that cutaneous exposure to <\\entity><\\entity> can cause an acute polyneuropathy and that its stinging hairs contain an unidentified neurotoxin.",
    "Label": ""
  },
  {
    "id": "805",
    "Sentence": "This case demonstrates that cutaneous exposure to Urtica ferox can cause an <\\entity><\\entity> and that its stinging hairs contain an unidentified neurotoxin.",
    "Label": ""
  },
  {
    "id": "811",
    "Sentence": "Effect of <\\entity><\\entity> on tear production after treatment of lateral canthal rhytids.PURPOSE: To evaluate the incidence of temporary dry eye and the effects on lacrimal gland tear production after treatment of lateral canthal rhytids with botulinum toxin type A injections.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "812",
    "Sentence": "Effect of botulinum toxin type a on <\\entity><\\entity> production after treatment of lateral canthal rhytids.PURPOSE: To evaluate the incidence of temporary dry eye and the effects on lacrimal gland <\\entity><\\entity> production after treatment of lateral canthal rhytids with botulinum toxin type A injections.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "813",
    "Sentence": "Effect of botulinum toxin type a on tear production after treatment of <\\entity><\\entity>.PURPOSE: To evaluate the incidence of temporary dry eye and the effects on lacrimal gland tear production after treatment of <\\entity><\\entity> with botulinum toxin type A injections.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "814",
    "Sentence": "Effect of botulinum toxin type a on tear production after treatment of lateral canthal rhytids.PURPOSE: To evaluate the incidence of temporary <\\entity><\\entity> and the effects on lacrimal gland tear production after treatment of lateral canthal rhytids with botulinum toxin type A injections.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "815",
    "Sentence": "Effect of botulinum toxin type a on <\\entity><\\entity> production after treatment of lateral canthal rhytids.PURPOSE: To evaluate the incidence of temporary dry eye and the effects on lacrimal gland <\\entity><\\entity> production after treatment of lateral canthal rhytids with botulinum toxin type A injections.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "816",
    "Sentence": "Effect of botulinum toxin type a on tear production after treatment of <\\entity><\\entity>.PURPOSE: To evaluate the incidence of temporary dry eye and the effects on lacrimal gland tear production after treatment of <\\entity><\\entity> with botulinum toxin type A injections.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "817",
    "Sentence": "Effect of botulinum toxin type a on tear production after treatment of lateral canthal rhytids.PURPOSE: To evaluate the incidence of temporary dry eye and the effects on lacrimal gland tear production after treatment of lateral canthal rhytids with <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "818",
    "Sentence": "METHODS: Twenty-six crow's feet areas were injected with <\\entity><\\entity> in 13 women with an age range of 31 to 58 years.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "819",
    "Sentence": "A total of 10 units of <\\entity><\\entity> was injected per side, with two separate injections.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "820",
    "Sentence": "Only one patient reported <\\entity><\\entity> symptoms at the 4-month follow-up.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "821",
    "Sentence": "Only one patient reported dry-eye <\\entity><\\entity> at the 4-month follow-up.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "822",
    "Sentence": "CONCLUSIONS: <\\entity><\\entity> for lateral canthal rhytids usually does not suppress tear production.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "823",
    "Sentence": "CONCLUSIONS: Botulinum toxin for <\\entity><\\entity> usually does not suppress tear production.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "824",
    "Sentence": "CONCLUSIONS: Botulinum toxin for lateral canthal rhytids usually does not suppress <\\entity><\\entity> production.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "825",
    "Sentence": "However, decreased <\\entity><\\entity> after botulinum toxin injection for crow's feet is a possible complication and patients should be advised of the small but definite risk of a temporary dry eye.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "826",
    "Sentence": "However, decreased tear production after <\\entity><\\entity> injection for crow's feet is a possible complication and patients should be advised of the small but definite risk of a temporary dry eye.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "827",
    "Sentence": "However, decreased tear production after botulinum toxin injection for crow's feet is a possible <\\entity><\\entity> and patients should be advised of the small but definite risk of a temporary dry eye.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "828",
    "Sentence": "However, decreased tear production after botulinum toxin injection for crow's feet is a possible complication and patients should be advised of the small but definite risk of a temporary <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "829",
    "Sentence": "Effect of botulinum toxin type a on tear production after treatment of lateral canthal rhytids.PURPOSE: To evaluate the incidence of temporary dry eye and the effects on lacrimal gland tear production after treatment of lateral canthal rhytids with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "830",
    "Sentence": "Effect of botulinum toxin type a on tear production after treatment of <\\entity><\\entity>.PURPOSE: To evaluate the incidence of temporary dry eye and the effects on lacrimal gland tear production after treatment of <\\entity><\\entity> with botulinum toxin type A injections.",
    "Label": ""
  },
  {
    "id": "832",
    "Sentence": "CONCLUSIONS: <\\entity><\\entity> for lateral canthal rhytids usually does not suppress tear production.",
    "Label": ""
  },
  {
    "id": "833",
    "Sentence": "CONCLUSIONS: Botulinum toxin for <\\entity><\\entity> usually does not suppress tear production.",
    "Label": ""
  },
  {
    "id": "835",
    "Sentence": "However, decreased tear production after <\\entity><\\entity> injection for crow's feet is a possible complication and patients should be advised of the small but definite risk of a temporary dry eye.",
    "Label": ""
  },
  {
    "id": "836",
    "Sentence": "However, decreased tear production after botulinum toxin injection for crow's feet is a possible complication and patients should be advised of the small but definite risk of a temporary <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "838",
    "Sentence": "Effect of <\\entity><\\entity> on tear production after treatment of lateral canthal rhytids.PURPOSE: To evaluate the incidence of temporary dry eye and the effects on lacrimal gland tear production after treatment of lateral canthal rhytids with botulinum toxin type A injections.",
    "Label": ""
  },
  {
    "id": "839",
    "Sentence": "Effect of botulinum toxin type a on <\\entity><\\entity> production after treatment of lateral canthal rhytids.PURPOSE: To evaluate the incidence of temporary dry eye and the effects on lacrimal gland <\\entity><\\entity> production after treatment of lateral canthal rhytids with botulinum toxin type A injections.",
    "Label": ""
  },
  {
    "id": "841",
    "Sentence": "Effect of botulinum toxin type a on tear production after treatment of lateral canthal rhytids.PURPOSE: To evaluate the incidence of temporary dry eye and the effects on lacrimal gland tear production after treatment of lateral canthal rhytids with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "842",
    "Sentence": "Effect of botulinum toxin type a on <\\entity><\\entity> production after treatment of lateral canthal rhytids.PURPOSE: To evaluate the incidence of temporary dry eye and the effects on lacrimal gland <\\entity><\\entity> production after treatment of lateral canthal rhytids with botulinum toxin type A injections.",
    "Label": ""
  },
  {
    "id": "844",
    "Sentence": "Effect of botulinum toxin type a on tear production after treatment of lateral canthal rhytids.PURPOSE: To evaluate the incidence of temporary dry eye and the effects on lacrimal gland tear production after treatment of lateral canthal rhytids with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "845",
    "Sentence": "Effect of botulinum toxin type a on tear production after treatment of lateral canthal rhytids.PURPOSE: To evaluate the incidence of temporary <\\entity><\\entity> and the effects on lacrimal gland tear production after treatment of lateral canthal rhytids with botulinum toxin type A injections.",
    "Label": ""
  },
  {
    "id": "847",
    "Sentence": "CONCLUSIONS: <\\entity><\\entity> for lateral canthal rhytids usually does not suppress tear production.",
    "Label": ""
  },
  {
    "id": "848",
    "Sentence": "CONCLUSIONS: Botulinum toxin for lateral canthal rhytids usually does not suppress <\\entity><\\entity> production.",
    "Label": ""
  },
  {
    "id": "850",
    "Sentence": "However, decreased tear production after <\\entity><\\entity> injection for crow's feet is a possible complication and patients should be advised of the small but definite risk of a temporary dry eye.",
    "Label": ""
  },
  {
    "id": "851",
    "Sentence": "However, decreased tear production after botulinum toxin injection for crow's feet is a possible <\\entity><\\entity> and patients should be advised of the small but definite risk of a temporary dry eye.",
    "Label": ""
  },
  {
    "id": "853",
    "Sentence": "However, decreased tear production after <\\entity><\\entity> injection for crow's feet is a possible complication and patients should be advised of the small but definite risk of a temporary dry eye.",
    "Label": ""
  },
  {
    "id": "854",
    "Sentence": "However, decreased <\\entity><\\entity> after botulinum toxin injection for crow's feet is a possible complication and patients should be advised of the small but definite risk of a temporary dry eye.",
    "Label": ""
  },
  {
    "id": "860",
    "Sentence": "<\\entity><\\entity> (LRP5) gene polymorphisms are associated with bone mass in both Chinese and whites.In this study, the associations of novel LRP5 variants with BMD variation were detected and some replicated in the two ethnic groups of Chinese and white origins, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "861",
    "Sentence": "Low-density lipoprotein receptor-related protein 5 <\\entity><\\entity> are associated with bone mass in both Chinese and whites.In this study, the associations of novel LRP5 variants with BMD variation were detected and some replicated in the two ethnic groups of Chinese and white origins, respectively.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "862",
    "Sentence": "Low-density lipoprotein receptor-related protein 5 (<\\entity><\\entity>) gene polymorphisms are associated with bone mass in both Chinese and whites.In this study, the associations of novel <\\entity><\\entity> variants with BMD variation were detected and some replicated in the two ethnic groups of Chinese and white origins, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "863",
    "Sentence": "Low-density lipoprotein receptor-related protein 5 (LRP5) gene polymorphisms are associated with <\\entity><\\entity> in both Chinese and whites.In this study, the associations of novel LRP5 variants with BMD variation were detected and some replicated in the two ethnic groups of Chinese and white origins, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "864",
    "Sentence": "Low-density lipoprotein receptor-related protein 5 (LRP5) gene polymorphisms are associated with bone mass in both Chinese and whites.In this study, the associations of novel <\\entity><\\entity> with BMD variation were detected and some replicated in the two ethnic groups of Chinese and white origins, respectively.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "865",
    "Sentence": "Low-density lipoprotein receptor-related protein 5 (LRP5) gene polymorphisms are associated with bone mass in both Chinese and whites.In this study, the associations of novel <\\entity><\\entity> with BMD variation were detected and some replicated in the two ethnic groups of Chinese and white origins, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "866",
    "Sentence": "Low-density lipoprotein receptor-related protein 5 (LRP5) gene polymorphisms are associated with bone mass in both Chinese and whites.In this study, the associations of novel LRP5 variants with <\\entity><\\entity> variation were detected and some replicated in the two ethnic groups of Chinese and white origins, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "867",
    "Sentence": "These data support the concept that <\\entity><\\entity> can contribute to minor and major variation in bone structure.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "868",
    "Sentence": "These data support the concept that <\\entity><\\entity> can contribute to minor and major variation in bone structure.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "869",
    "Sentence": "These data support the concept that LRP5 variation can contribute to <\\entity><\\entity> and major variation in bone structure.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "870",
    "Sentence": "These data support the concept that LRP5 variation can contribute to minor and major variation in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "871",
    "Sentence": "INTRODUCTION: <\\entity><\\entity> (LRP5) gene have been shown to cause both high and low bone mass.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "872",
    "Sentence": "INTRODUCTION: <\\entity><\\entity> (LRP5) gene have been shown to cause both high and low bone mass.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "873",
    "Sentence": "INTRODUCTION: <\\entity><\\entity> (LRP5) gene have been shown to cause both high and low bone mass.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "874",
    "Sentence": "INTRODUCTION: Mutations in the low-density lipoprotein receptor-related protein 5 (<\\entity><\\entity>) gene have been shown to cause both high and low bone mass.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "875",
    "Sentence": "INTRODUCTION: Mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) gene have been shown to cause both <\\entity><\\entity> and low bone mass.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "876",
    "Sentence": "INTRODUCTION: Mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) gene have been shown to cause both high and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "877",
    "Sentence": "However, it is <\\entity><\\entity> controversial whether LRP5 is associated with normal BMD variation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "878",
    "Sentence": "However, it is still controversial whether <\\entity><\\entity> is associated with normal BMD variation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "879",
    "Sentence": "However, it is still controversial whether LRP5 is associated with normal <\\entity><\\entity> variation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "880",
    "Sentence": "This study explored the association of <\\entity><\\entity> with BMD phenotypes at three clinically important skeletal sites-the spine, hip, and ultradistal radius (UD)-in two independent populations of Chinese and white ethnicities, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "881",
    "Sentence": "This study explored the association of LRP5 with <\\entity><\\entity> phenotypes at three clinically important skeletal sites-the spine, hip, and ultradistal radius (UD)-in two independent populations of Chinese and white ethnicities, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "882",
    "Sentence": "<\\entity><\\entity>-density single nucleotide polymorphisms (SNPs) across the whole LRP5 gene were genotyped and analyzed in both samples.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "883",
    "Sentence": "High-density single nucleotide polymorphisms (SNPs) across the whole <\\entity><\\entity> gene were genotyped and analyzed in both samples.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "884",
    "Sentence": "RESULTS: Linkage disequilibrium (LD) analyses showed that the haplotype structures of <\\entity><\\entity> between Chinese and whites were in good agreement.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "885",
    "Sentence": "Association tests showed that <\\entity><\\entity> significantly associated with spine BMD variation in both samples.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "886",
    "Sentence": "Association tests showed that <\\entity><\\entity> significantly associated with spine BMD variation in both samples.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "887",
    "Sentence": "Association tests showed that polymorphisms in <\\entity><\\entity> 5 spanning intron 7 to intron 19 of LRP5 significantly associated with spine BMD variation in both samples.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "888",
    "Sentence": "Association tests showed that polymorphisms in <\\entity><\\entity> 5 spanning intron 7 to intron 19 of LRP5 significantly associated with spine BMD variation in both samples.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "889",
    "Sentence": "Association tests showed that polymorphisms in block 5 spanning intron 7 to intron 19 of LRP5 significantly associated with spine <\\entity><\\entity> variation in both samples.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "890",
    "Sentence": "Particularly, the significant association of SNP <\\entity><\\entity> with spine BMD in the Chinese sample (p=0.002) was replicated in whites, even after adjusting for multiple testing (p=0.005).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "891",
    "Sentence": "Particularly, the significant association of SNP rs491347 in intron 7 with spine <\\entity><\\entity> in the Chinese sample (p=0.002) was replicated in whites, even after adjusting for multiple testing (p=0.005).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "892",
    "Sentence": "Its strongly associated SNP <\\entity><\\entity> could cause the loss of an estrogen receptor alpha (ERalpha) binding site in LRP5, which could partially explain the above replicated association.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "893",
    "Sentence": "Its strongly associated SNP rs1784235 could cause the loss of an <\\entity><\\entity> (ERalpha) binding site in LRP5, which could partially explain the above replicated association.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "894",
    "Sentence": "Its strongly associated SNP rs1784235 could cause the loss of an estrogen receptor alpha (<\\entity><\\entity> in LRP5, which could partially explain the above replicated association.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "895",
    "Sentence": "Its strongly associated SNP rs1784235 could cause the loss of an estrogen receptor alpha (ERalpha) binding site in <\\entity><\\entity>, which could partially explain the above replicated association.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "896",
    "Sentence": "However, we did not observe any significant replication with <\\entity><\\entity> variation at the hip and UD.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "897",
    "Sentence": "After accounting for multiple testing, associations with <\\entity><\\entity> variation at these two sites were mainly found in Chinese.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "898",
    "Sentence": "Sex-stratified analyses further revealed that the <\\entity><\\entity> associations with BMD in Chinese and whites were driven by male and female subjects, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "899",
    "Sentence": "Sex-stratified analyses further revealed that the LRP5 associations with <\\entity><\\entity> in Chinese and whites were driven by male and female subjects, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "900",
    "Sentence": "CONCLUSIONS: Our work supported <\\entity><\\entity> genetic variants as possible susceptibility factors for osteoporosis and fractures in humans.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "901",
    "Sentence": "CONCLUSIONS: Our work supported LRP5 genetic variants as possible susceptibility factors for <\\entity><\\entity> and fractures in humans.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "902",
    "Sentence": "CONCLUSIONS: Our work supported LRP5 genetic variants as possible susceptibility factors for osteoporosis and <\\entity><\\entity> in humans.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "903",
    "Sentence": "Especially, the SNP <\\entity><\\entity> and its strongly associated SNPs (e.g., rs1784235) could be important to human osteoporosis phenotypes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "904",
    "Sentence": "Especially, the SNP rs491347 and its strongly associated SNPs (e.g., <\\entity><\\entity>) could be important to human osteoporosis phenotypes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "905",
    "Sentence": "Especially, the SNP rs491347 and its strongly associated SNPs (e.g., rs1784235) could be important to human <\\entity><\\entity> phenotypes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "906",
    "Sentence": "INTRODUCTION: <\\entity><\\entity> (LRP5) gene have been shown to cause both high and low bone mass.",
    "Label": ""
  },
  {
    "id": "907",
    "Sentence": "INTRODUCTION: Mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) gene have been shown to cause both high and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "909",
    "Sentence": "INTRODUCTION: <\\entity><\\entity> (LRP5) gene have been shown to cause both high and low bone mass.",
    "Label": ""
  },
  {
    "id": "910",
    "Sentence": "INTRODUCTION: Mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) gene have been shown to cause both <\\entity><\\entity> and low bone mass.",
    "Label": ""
  },
  {
    "id": "912",
    "Sentence": "CONCLUSIONS: Our work supported <\\entity><\\entity> genetic variants as possible susceptibility factors for osteoporosis and fractures in humans.",
    "Label": ""
  },
  {
    "id": "913",
    "Sentence": "CONCLUSIONS: Our work supported LRP5 genetic variants as possible susceptibility factors for <\\entity><\\entity> and fractures in humans.",
    "Label": ""
  },
  {
    "id": "915",
    "Sentence": "Especially, the SNP rs491347 and its strongly associated SNPs (e.g., <\\entity><\\entity>) could be important to human osteoporosis phenotypes.",
    "Label": ""
  },
  {
    "id": "916",
    "Sentence": "Especially, the SNP rs491347 and its strongly associated SNPs (e.g., rs1784235) could be important to human <\\entity><\\entity> phenotypes.",
    "Label": ""
  },
  {
    "id": "918",
    "Sentence": "Especially, the SNP <\\entity><\\entity> and its strongly associated SNPs (e.g., rs1784235) could be important to human osteoporosis phenotypes.",
    "Label": ""
  },
  {
    "id": "919",
    "Sentence": "Especially, the SNP rs491347 and its strongly associated SNPs (e.g., rs1784235) could be important to human <\\entity><\\entity> phenotypes.",
    "Label": ""
  },
  {
    "id": "921",
    "Sentence": "Low-density lipoprotein receptor-related protein 5 (<\\entity><\\entity>) gene polymorphisms are associated with bone mass in both Chinese and whites.In this study, the associations of novel <\\entity><\\entity> variants with BMD variation were detected and some replicated in the two ethnic groups of Chinese and white origins, respectively.",
    "Label": ""
  },
  {
    "id": "922",
    "Sentence": "Low-density lipoprotein receptor-related protein 5 (LRP5) gene polymorphisms are associated with <\\entity><\\entity> in both Chinese and whites.In this study, the associations of novel LRP5 variants with BMD variation were detected and some replicated in the two ethnic groups of Chinese and white origins, respectively.",
    "Label": ""
  },
  {
    "id": "924",
    "Sentence": "Low-density lipoprotein receptor-related protein 5 (LRP5) gene polymorphisms are associated with bone mass in both Chinese and whites.In this study, the associations of novel <\\entity><\\entity> with BMD variation were detected and some replicated in the two ethnic groups of Chinese and white origins, respectively.",
    "Label": ""
  },
  {
    "id": "925",
    "Sentence": "Low-density lipoprotein receptor-related protein 5 (LRP5) gene polymorphisms are associated with bone mass in both Chinese and whites.In this study, the associations of novel LRP5 variants with <\\entity><\\entity> variation were detected and some replicated in the two ethnic groups of Chinese and white origins, respectively.",
    "Label": ""
  },
  {
    "id": "927",
    "Sentence": "These data support the concept that <\\entity><\\entity> can contribute to minor and major variation in bone structure.",
    "Label": ""
  },
  {
    "id": "928",
    "Sentence": "These data support the concept that LRP5 variation can contribute to <\\entity><\\entity> and major variation in bone structure.",
    "Label": ""
  },
  {
    "id": "930",
    "Sentence": "INTRODUCTION: Mutations in the low-density lipoprotein receptor-related protein 5 (<\\entity><\\entity>) gene have been shown to cause both high and low bone mass.",
    "Label": ""
  },
  {
    "id": "931",
    "Sentence": "INTRODUCTION: <\\entity><\\entity> (LRP5) gene have been shown to cause both high and low bone mass.",
    "Label": ""
  },
  {
    "id": "933",
    "Sentence": "However, it is still controversial whether <\\entity><\\entity> is associated with normal BMD variation.",
    "Label": ""
  },
  {
    "id": "934",
    "Sentence": "However, it is still controversial whether LRP5 is associated with normal <\\entity><\\entity> variation.",
    "Label": ""
  },
  {
    "id": "936",
    "Sentence": "However, it is still controversial whether <\\entity><\\entity> is associated with normal BMD variation.",
    "Label": ""
  },
  {
    "id": "937",
    "Sentence": "However, it is <\\entity><\\entity> controversial whether LRP5 is associated with normal BMD variation.",
    "Label": ""
  },
  {
    "id": "939",
    "Sentence": "This study explored the association of <\\entity><\\entity> with BMD phenotypes at three clinically important skeletal sites-the spine, hip, and ultradistal radius (UD)-in two independent populations of Chinese and white ethnicities, respectively.",
    "Label": ""
  },
  {
    "id": "940",
    "Sentence": "This study explored the association of LRP5 with <\\entity><\\entity> phenotypes at three clinically important skeletal sites-the spine, hip, and ultradistal radius (UD)-in two independent populations of Chinese and white ethnicities, respectively.",
    "Label": ""
  },
  {
    "id": "942",
    "Sentence": "Association tests showed that <\\entity><\\entity> significantly associated with spine BMD variation in both samples.",
    "Label": ""
  },
  {
    "id": "943",
    "Sentence": "Association tests showed that polymorphisms in block 5 spanning intron 7 to intron 19 of LRP5 significantly associated with spine <\\entity><\\entity> variation in both samples.",
    "Label": ""
  },
  {
    "id": "945",
    "Sentence": "Association tests showed that <\\entity><\\entity> significantly associated with spine BMD variation in both samples.",
    "Label": ""
  },
  {
    "id": "946",
    "Sentence": "Association tests showed that polymorphisms in <\\entity><\\entity> 5 spanning intron 7 to intron 19 of LRP5 significantly associated with spine BMD variation in both samples.",
    "Label": ""
  },
  {
    "id": "948",
    "Sentence": "Sex-stratified analyses further revealed that the <\\entity><\\entity> associations with BMD in Chinese and whites were driven by male and female subjects, respectively.",
    "Label": ""
  },
  {
    "id": "949",
    "Sentence": "Sex-stratified analyses further revealed that the LRP5 associations with <\\entity><\\entity> in Chinese and whites were driven by male and female subjects, respectively.",
    "Label": ""
  },
  {
    "id": "951",
    "Sentence": "These data support the concept that <\\entity><\\entity> can contribute to minor and major variation in bone structure.",
    "Label": ""
  },
  {
    "id": "952",
    "Sentence": "These data support the concept that LRP5 variation can contribute to minor and major variation in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "954",
    "Sentence": "Association tests showed that polymorphisms in <\\entity><\\entity> 5 spanning intron 7 to intron 19 of LRP5 significantly associated with spine BMD variation in both samples.",
    "Label": ""
  },
  {
    "id": "955",
    "Sentence": "Association tests showed that polymorphisms in block 5 spanning intron 7 to intron 19 of LRP5 significantly associated with spine <\\entity><\\entity> variation in both samples.",
    "Label": ""
  },
  {
    "id": "957",
    "Sentence": "Particularly, the significant association of SNP <\\entity><\\entity> with spine BMD in the Chinese sample (p=0.002) was replicated in whites, even after adjusting for multiple testing (p=0.005).",
    "Label": ""
  },
  {
    "id": "958",
    "Sentence": "Particularly, the significant association of SNP rs491347 in intron 7 with spine <\\entity><\\entity> in the Chinese sample (p=0.002) was replicated in whites, even after adjusting for multiple testing (p=0.005).",
    "Label": ""
  },
  {
    "id": "960",
    "Sentence": "CONCLUSIONS: Our work supported <\\entity><\\entity> genetic variants as possible susceptibility factors for osteoporosis and fractures in humans.",
    "Label": ""
  },
  {
    "id": "961",
    "Sentence": "CONCLUSIONS: Our work supported LRP5 genetic variants as possible susceptibility factors for osteoporosis and <\\entity><\\entity> in humans.",
    "Label": ""
  },
  {
    "id": "967",
    "Sentence": "A randomized, placebo-controlled trial of <\\entity><\\entity> as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that <\\entity><\\entity> (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "968",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a <\\entity><\\entity>-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "969",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for <\\entity><\\entity>.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control <\\entity><\\entity> (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "970",
    "Sentence": "A randomized, placebo-controlled trial of <\\entity><\\entity> as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that <\\entity><\\entity> (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "971",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (<\\entity><\\entity>) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "972",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for <\\entity><\\entity>.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control <\\entity><\\entity> (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "973",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (<\\entity><\\entity>) in patients with anorexia, vomiting, and diarrhea.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "974",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with <\\entity><\\entity>, vomiting, and diarrhea.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "975",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, <\\entity><\\entity>, and diarrhea.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "976",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "977",
    "Sentence": "Patients were randomized to <\\entity><\\entity> for 10 days and either oral BDP 8 mg/d (n = 62) or placebo (n = 67) tablets for 50 days.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "978",
    "Sentence": "Patients were randomized to prednisone for 10 days and either oral <\\entity><\\entity> 8 mg/d (n = 62) or placebo (n = 67) tablets for 50 days.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "979",
    "Sentence": "At study day 10, <\\entity><\\entity> was rapidly tapered while continuing study drug.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "980",
    "Sentence": "On an intent-to-treat basis, the risk of <\\entity><\\entity>-treatment failure was reduced for the BDP group at study day 50 (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.35-1.13) and at 30 days follow-up (HR 0.55, 95% CI 0.32-0.93).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "981",
    "Sentence": "On an intent-to-treat basis, the risk of GVHD-treatment failure was reduced for the <\\entity><\\entity> group at study day 50 (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.35-1.13) and at 30 days follow-up (HR 0.55, 95% CI 0.32-0.93).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "982",
    "Sentence": "Among patients eligible for <\\entity><\\entity> taper at study day 10, the risk of GVHD-treatment failure was significantly reduced at both study days 50 and 80 (HR 0.39 and 0.38, respectively).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "983",
    "Sentence": "Among patients eligible for prednisone taper at study day 10, the risk of <\\entity><\\entity>-treatment failure was significantly reduced at both study days 50 and 80 (HR 0.39 and 0.38, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "984",
    "Sentence": "By day 200 after transplantation, 5 patients randomized to <\\entity><\\entity> had died compared with 16 deaths on placebo, a 67% reduction in the hazard of mortality (HR 0.33, P = .03).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "985",
    "Sentence": "By day 200 after transplantation, 5 patients randomized to BDP had died compared with 16 deaths on placebo, a 67% reduction in the hazard of <\\entity><\\entity> (HR 0.33, P = .03).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "986",
    "Sentence": "In 47 recipients of unrelated and HLA-mismatched stem cells, <\\entity><\\entity> at transplantation day 200 was reduced by 91% in the BDP group compared with placebo (HR 0.09, P = .02).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "987",
    "Sentence": "In 47 recipients of unrelated and HLA-mismatched stem cells, mortality at transplantation day 200 was reduced by 91% in the <\\entity><\\entity> group compared with placebo (HR 0.09, P = .02).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "988",
    "Sentence": "Oral <\\entity><\\entity> prevents relapses of gastrointestinal GVHD following tapering of prednisone; survival is statistically significantly better among patients receiving <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "989",
    "Sentence": "Oral BDP prevents <\\entity><\\entity> following tapering of prednisone; survival is statistically significantly better among patients receiving BDP.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "990",
    "Sentence": "Oral BDP prevents relapses of gastrointestinal GVHD following tapering of <\\entity><\\entity>; survival is statistically significantly better among patients receiving BDP.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "991",
    "Sentence": "Oral <\\entity><\\entity> prevents relapses of gastrointestinal GVHD following tapering of prednisone; survival is statistically significantly better among patients receiving <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "992",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (<\\entity><\\entity>) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "993",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (<\\entity><\\entity>) in patients with anorexia, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "995",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (<\\entity><\\entity>) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "996",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for <\\entity><\\entity>.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control <\\entity><\\entity> (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "998",
    "Sentence": "A randomized, placebo-controlled trial of <\\entity><\\entity> as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that <\\entity><\\entity> (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "999",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (<\\entity><\\entity>) in patients with anorexia, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "1001",
    "Sentence": "Oral <\\entity><\\entity> prevents relapses of gastrointestinal GVHD following tapering of prednisone; survival is statistically significantly better among patients receiving <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1002",
    "Sentence": "Oral BDP prevents <\\entity><\\entity> following tapering of prednisone; survival is statistically significantly better among patients receiving BDP.",
    "Label": ""
  },
  {
    "id": "1004",
    "Sentence": "On an intent-to-treat basis, the risk of GVHD-treatment failure was reduced for the <\\entity><\\entity> group at study day 50 (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.35-1.13) and at 30 days follow-up (HR 0.55, 95% CI 0.32-0.93).",
    "Label": ""
  },
  {
    "id": "1005",
    "Sentence": "On an intent-to-treat basis, the risk of <\\entity><\\entity>-treatment failure was reduced for the BDP group at study day 50 (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.35-1.13) and at 30 days follow-up (HR 0.55, 95% CI 0.32-0.93).",
    "Label": ""
  },
  {
    "id": "1007",
    "Sentence": "Among patients eligible for <\\entity><\\entity> taper at study day 10, the risk of GVHD-treatment failure was significantly reduced at both study days 50 and 80 (HR 0.39 and 0.38, respectively).",
    "Label": ""
  },
  {
    "id": "1008",
    "Sentence": "Among patients eligible for prednisone taper at study day 10, the risk of <\\entity><\\entity>-treatment failure was significantly reduced at both study days 50 and 80 (HR 0.39 and 0.38, respectively).",
    "Label": ""
  },
  {
    "id": "1010",
    "Sentence": "Oral BDP prevents relapses of gastrointestinal GVHD following tapering of <\\entity><\\entity>; survival is statistically significantly better among patients receiving BDP.",
    "Label": ""
  },
  {
    "id": "1011",
    "Sentence": "Oral BDP prevents <\\entity><\\entity> following tapering of prednisone; survival is statistically significantly better among patients receiving BDP.",
    "Label": ""
  },
  {
    "id": "1013",
    "Sentence": "A randomized, placebo-controlled trial of <\\entity><\\entity> as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that <\\entity><\\entity> (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "1014",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for <\\entity><\\entity>.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control <\\entity><\\entity> (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "1016",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (<\\entity><\\entity>) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "1017",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with <\\entity><\\entity>, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "1019",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (<\\entity><\\entity>) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "1020",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, <\\entity><\\entity>, and diarrhea.",
    "Label": ""
  },
  {
    "id": "1022",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (<\\entity><\\entity>) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "1023",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1025",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a <\\entity><\\entity>-sparing therapy for gastrointestinal graft-versus-host disease.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "1026",
    "Sentence": "A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for <\\entity><\\entity>.We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control <\\entity><\\entity> (GVHD) in patients with anorexia, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "1028",
    "Sentence": "By day 200 after transplantation, 5 patients randomized to <\\entity><\\entity> had died compared with 16 deaths on placebo, a 67% reduction in the hazard of mortality (HR 0.33, P = .03).",
    "Label": ""
  },
  {
    "id": "1029",
    "Sentence": "By day 200 after transplantation, 5 patients randomized to BDP had died compared with 16 deaths on placebo, a 67% reduction in the hazard of <\\entity><\\entity> (HR 0.33, P = .03).",
    "Label": ""
  },
  {
    "id": "1031",
    "Sentence": "In 47 recipients of unrelated and HLA-mismatched stem cells, mortality at transplantation day 200 was reduced by 91% in the <\\entity><\\entity> group compared with placebo (HR 0.09, P = .02).",
    "Label": ""
  },
  {
    "id": "1032",
    "Sentence": "In 47 recipients of unrelated and HLA-mismatched stem cells, <\\entity><\\entity> at transplantation day 200 was reduced by 91% in the BDP group compared with placebo (HR 0.09, P = .02).",
    "Label": ""
  },
  {
    "id": "1038",
    "Sentence": "<\\entity><\\entity> and susceptibility to psychosis and mania.Previous studies have identified a putative gene locus for both schizophrenia and bipolar disorder in the chromosome 18q21 region.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1039",
    "Sentence": "Malic enzyme 2 and susceptibility to <\\entity><\\entity> and mania.Previous studies have identified a putative gene locus for both schizophrenia and bipolar disorder in the chromosome 18q21 region.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1040",
    "Sentence": "Malic enzyme 2 and susceptibility to psychosis and <\\entity><\\entity>.Previous studies have identified a putative gene locus for both schizophrenia and bipolar disorder in the chromosome 18q21 region.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1041",
    "Sentence": "Malic enzyme 2 and susceptibility to psychosis and mania.Previous studies have identified a putative gene locus for both <\\entity><\\entity> and bipolar disorder in the chromosome 18q21 region.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1042",
    "Sentence": "Malic enzyme 2 and susceptibility to psychosis and mania.Previous studies have identified a putative gene locus for both schizophrenia and <\\entity><\\entity> in the chromosome 18q21 region.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1043",
    "Sentence": "Malic enzyme 2 and susceptibility to psychosis and mania.Previous studies have identified a putative gene locus for both schizophrenia and bipolar disorder in the chromosome <\\entity><\\entity> region.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1044",
    "Sentence": "Malic enzyme 2 and susceptibility to psychosis and mania.Previous studies have identified a putative gene locus for both schizophrenia and bipolar disorder in the chromosome <\\entity><\\entity> region.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "1045",
    "Sentence": "To identify candidate genes associated with these <\\entity><\\entity> we completed fine mapping analyses (using microsatellite markers) in 152 families from the Central Valley of Costa Rica (CVCR) (376 total subjects, 151 with a history of psychosis, 97 with a history of mania).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1046",
    "Sentence": "To identify candidate genes associated with these disorders we completed fine mapping analyses (using microsatellite markers) in 152 families from the Central Valley of Costa Rica (CVCR) (376 total subjects, 151 with a history of <\\entity><\\entity>, 97 with a history of mania).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1047",
    "Sentence": "To identify candidate genes associated with these disorders we completed fine mapping analyses (using microsatellite markers) in 152 families from the Central Valley of Costa Rica (CVCR) (376 total subjects, 151 with a history of psychosis, 97 with a history of <\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1048",
    "Sentence": "In a corollary gene expression study, one of these genes, <\\entity><\\entity> (ME2), showed levels of gene expression 5.6-fold lower in anterior cingulate tissue from post-mortem bipolar brains.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1049",
    "Sentence": "In a corollary gene expression study, one of these genes, malic enzyme 2 (<\\entity><\\entity>), showed levels of gene expression 5.6-fold lower in anterior cingulate tissue from post-mortem bipolar brains.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1050",
    "Sentence": "In a corollary gene expression study, one of these genes, malic enzyme 2 (ME2), showed levels of gene expression 5.6-fold lower in <\\entity><\\entity> cingulate tissue from post-mortem bipolar brains.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1051",
    "Sentence": "In a corollary gene expression study, one of these genes, malic enzyme 2 (ME2), showed levels of gene expression 5.6-fold lower in anterior cingulate tissue from post-mortem <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1052",
    "Sentence": "Subsequent analysis of individual SNPs in strong linkage disequilibrium with the <\\entity><\\entity> gene revealed one SNP and one haplotype associated with the phenotype of psychosis in the CVCR sample.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1053",
    "Sentence": "Subsequent analysis of individual SNPs in strong linkage disequilibrium with the ME2 gene revealed one SNP and one haplotype associated with the phenotype of <\\entity><\\entity> in the CVCR sample.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1054",
    "Sentence": "<\\entity><\\entity> interacts directly with the malate shuttle system, which has been shown to be altered in schizophrenia and bipolar disorder, and has roles in neuronal synthesis of glutamate and gamma-amino butyric acid.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1055",
    "Sentence": "ME2 interacts directly with the <\\entity><\\entity> shuttle system, which has been shown to be altered in schizophrenia and bipolar disorder, and has roles in neuronal synthesis of glutamate and gamma-amino butyric acid.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1056",
    "Sentence": "ME2 interacts directly with the malate shuttle system, which has been shown to be altered in <\\entity><\\entity> and bipolar disorder, and has roles in neuronal synthesis of glutamate and gamma-amino butyric acid.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1057",
    "Sentence": "ME2 interacts directly with the malate shuttle system, which has been shown to be altered in schizophrenia and <\\entity><\\entity>, and has roles in neuronal synthesis of glutamate and gamma-amino butyric acid.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1058",
    "Sentence": "ME2 interacts directly with the malate shuttle system, which has been shown to be altered in schizophrenia and bipolar disorder, and has roles in neuronal synthesis of <\\entity><\\entity> and gamma-amino butyric acid.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1059",
    "Sentence": "ME2 interacts directly with the malate shuttle system, which has been shown to be altered in schizophrenia and bipolar disorder, and has roles in neuronal synthesis of glutamate and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1060",
    "Sentence": "The present study suggests that genetic variation in or near the <\\entity><\\entity> gene is associated with both psychotic and manic disorders, including schizophrenia and bipolar disorder.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1061",
    "Sentence": "The present study suggests that genetic variation in or near the ME2 gene is associated with both <\\entity><\\entity> and manic disorders, including schizophrenia and bipolar disorder.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1062",
    "Sentence": "The present study suggests that genetic variation in or near the ME2 gene is associated with both psychotic and <\\entity><\\entity>, including schizophrenia and bipolar disorder.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1063",
    "Sentence": "The present study suggests that genetic variation in or near the ME2 gene is associated with both psychotic and manic disorders, including <\\entity><\\entity> and bipolar disorder.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1064",
    "Sentence": "The present study suggests that genetic variation in or near the ME2 gene is associated with both psychotic and manic disorders, including schizophrenia and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1065",
    "Sentence": "Malic enzyme 2 and susceptibility to psychosis and mania.Previous studies have identified a putative gene locus for both schizophrenia and bipolar disorder in the chromosome <\\entity><\\entity> region.",
    "Label": ""
  },
  {
    "id": "1066",
    "Sentence": "Malic enzyme 2 and susceptibility to psychosis and mania.Previous studies have identified a putative gene locus for both <\\entity><\\entity> and bipolar disorder in the chromosome 18q21 region.",
    "Label": ""
  },
  {
    "id": "1068",
    "Sentence": "Malic enzyme 2 and susceptibility to psychosis and mania.Previous studies have identified a putative gene locus for both schizophrenia and bipolar disorder in the chromosome <\\entity><\\entity> region.",
    "Label": ""
  },
  {
    "id": "1069",
    "Sentence": "Malic enzyme 2 and susceptibility to psychosis and mania.Previous studies have identified a putative gene locus for both schizophrenia and <\\entity><\\entity> in the chromosome 18q21 region.",
    "Label": ""
  },
  {
    "id": "1071",
    "Sentence": "In a corollary gene expression study, one of these genes, malic enzyme 2 (<\\entity><\\entity>), showed levels of gene expression 5.6-fold lower in anterior cingulate tissue from post-mortem bipolar brains.",
    "Label": ""
  },
  {
    "id": "1072",
    "Sentence": "In a corollary gene expression study, one of these genes, malic enzyme 2 (ME2), showed levels of gene expression 5.6-fold lower in anterior cingulate tissue from post-mortem <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1074",
    "Sentence": "Subsequent analysis of individual SNPs in strong linkage disequilibrium with the <\\entity><\\entity> gene revealed one SNP and one haplotype associated with the phenotype of psychosis in the CVCR sample.",
    "Label": ""
  },
  {
    "id": "1075",
    "Sentence": "Subsequent analysis of individual SNPs in strong linkage disequilibrium with the ME2 gene revealed one SNP and one haplotype associated with the phenotype of <\\entity><\\entity> in the CVCR sample.",
    "Label": ""
  },
  {
    "id": "1077",
    "Sentence": "ME2 interacts directly with the <\\entity><\\entity> shuttle system, which has been shown to be altered in schizophrenia and bipolar disorder, and has roles in neuronal synthesis of glutamate and gamma-amino butyric acid.",
    "Label": ""
  },
  {
    "id": "1078",
    "Sentence": "ME2 interacts directly with the malate shuttle system, which has been shown to be altered in <\\entity><\\entity> and bipolar disorder, and has roles in neuronal synthesis of glutamate and gamma-amino butyric acid.",
    "Label": ""
  },
  {
    "id": "1080",
    "Sentence": "ME2 interacts directly with the <\\entity><\\entity> shuttle system, which has been shown to be altered in schizophrenia and bipolar disorder, and has roles in neuronal synthesis of glutamate and gamma-amino butyric acid.",
    "Label": ""
  },
  {
    "id": "1081",
    "Sentence": "ME2 interacts directly with the malate shuttle system, which has been shown to be altered in schizophrenia and <\\entity><\\entity>, and has roles in neuronal synthesis of glutamate and gamma-amino butyric acid.",
    "Label": ""
  },
  {
    "id": "1083",
    "Sentence": "The present study suggests that genetic variation in or near the <\\entity><\\entity> gene is associated with both psychotic and manic disorders, including schizophrenia and bipolar disorder.",
    "Label": ""
  },
  {
    "id": "1084",
    "Sentence": "The present study suggests that genetic variation in or near the ME2 gene is associated with both psychotic and manic disorders, including <\\entity><\\entity> and bipolar disorder.",
    "Label": ""
  },
  {
    "id": "1086",
    "Sentence": "The present study suggests that genetic variation in or near the <\\entity><\\entity> gene is associated with both psychotic and manic disorders, including schizophrenia and bipolar disorder.",
    "Label": ""
  },
  {
    "id": "1087",
    "Sentence": "The present study suggests that genetic variation in or near the ME2 gene is associated with both psychotic and manic disorders, including schizophrenia and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1089",
    "Sentence": "The present study suggests that genetic variation in or near the <\\entity><\\entity> gene is associated with both psychotic and manic disorders, including schizophrenia and bipolar disorder.",
    "Label": ""
  },
  {
    "id": "1090",
    "Sentence": "The present study suggests that genetic variation in or near the ME2 gene is associated with both <\\entity><\\entity> and manic disorders, including schizophrenia and bipolar disorder.",
    "Label": ""
  },
  {
    "id": "1092",
    "Sentence": "The present study suggests that genetic variation in or near the <\\entity><\\entity> gene is associated with both psychotic and manic disorders, including schizophrenia and bipolar disorder.",
    "Label": ""
  },
  {
    "id": "1093",
    "Sentence": "The present study suggests that genetic variation in or near the ME2 gene is associated with both psychotic and <\\entity><\\entity>, including schizophrenia and bipolar disorder.",
    "Label": ""
  },
  {
    "id": "1095",
    "Sentence": "<\\entity><\\entity> and susceptibility to psychosis and mania.Previous studies have identified a putative gene locus for both schizophrenia and bipolar disorder in the chromosome 18q21 region.",
    "Label": ""
  },
  {
    "id": "1096",
    "Sentence": "Malic enzyme 2 and susceptibility to <\\entity><\\entity> and mania.Previous studies have identified a putative gene locus for both schizophrenia and bipolar disorder in the chromosome 18q21 region.",
    "Label": ""
  },
  {
    "id": "1098",
    "Sentence": "In a corollary gene expression study, one of these genes, malic enzyme 2 (<\\entity><\\entity>), showed levels of gene expression 5.6-fold lower in anterior cingulate tissue from post-mortem bipolar brains.",
    "Label": ""
  },
  {
    "id": "1099",
    "Sentence": "In a corollary gene expression study, one of these genes, malic enzyme 2 (ME2), showed levels of gene expression 5.6-fold lower in <\\entity><\\entity> cingulate tissue from post-mortem bipolar brains.",
    "Label": ""
  },
  {
    "id": "1101",
    "Sentence": "<\\entity><\\entity> interacts directly with the malate shuttle system, which has been shown to be altered in schizophrenia and bipolar disorder, and has roles in neuronal synthesis of glutamate and gamma-amino butyric acid.",
    "Label": ""
  },
  {
    "id": "1102",
    "Sentence": "ME2 interacts directly with the malate shuttle system, which has been shown to be altered in <\\entity><\\entity> and bipolar disorder, and has roles in neuronal synthesis of glutamate and gamma-amino butyric acid.",
    "Label": ""
  },
  {
    "id": "1104",
    "Sentence": "<\\entity><\\entity> interacts directly with the malate shuttle system, which has been shown to be altered in schizophrenia and bipolar disorder, and has roles in neuronal synthesis of glutamate and gamma-amino butyric acid.",
    "Label": ""
  },
  {
    "id": "1105",
    "Sentence": "ME2 interacts directly with the malate shuttle system, which has been shown to be altered in schizophrenia and <\\entity><\\entity>, and has roles in neuronal synthesis of glutamate and gamma-amino butyric acid.",
    "Label": ""
  },
  {
    "id": "1107",
    "Sentence": "<\\entity><\\entity> and susceptibility to psychosis and mania.Previous studies have identified a putative gene locus for both schizophrenia and bipolar disorder in the chromosome 18q21 region.",
    "Label": ""
  },
  {
    "id": "1108",
    "Sentence": "Malic enzyme 2 and susceptibility to psychosis and <\\entity><\\entity>.Previous studies have identified a putative gene locus for both schizophrenia and bipolar disorder in the chromosome 18q21 region.",
    "Label": ""
  },
  {
    "id": "1114",
    "Sentence": "<\\entity><\\entity> and the pathogenesis of skin cancer.The <\\entity><\\entity> tumor suppressor gene and gene product are among the most diverse and complex molecules involved in cellular functions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1115",
    "Sentence": "p53 and the <\\entity><\\entity> of skin cancer.The p53 tumor suppressor gene and gene product are among the most diverse and complex molecules involved in cellular functions.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1116",
    "Sentence": "p53 and the pathogenesis of <\\entity><\\entity>.The p53 tumor suppressor gene and gene product are among the most diverse and complex molecules involved in cellular functions.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1117",
    "Sentence": "p53 and the pathogenesis of skin cancer.The <\\entity><\\entity> gene and gene product are among the most diverse and complex molecules involved in cellular functions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1118",
    "Sentence": "<\\entity><\\entity> within the p53 gene have been shown to have a direct correlation with cancer development and have been shown to occur in nearly 50% of all cancers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1119",
    "Sentence": "Genetic alterations within the <\\entity><\\entity> gene have been shown to have a direct correlation with cancer development and have been shown to occur in nearly 50% of all cancers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1120",
    "Sentence": "Genetic alterations within the p53 gene have been shown to have a direct correlation with <\\entity><\\entity> development and have been shown to occur in nearly 50% of all <\\entity><\\entity>s.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1121",
    "Sentence": "Genetic alterations within the p53 gene have been shown to have a direct correlation with cancer development and have been shown to occur in nearly 50% of all <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1122",
    "Sentence": "<\\entity><\\entity> are particularly common in skin cancers and UV irradiation has been shown to be a primary cause of specific 'signature' mutations that can result in oncogenic transformation.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "1123",
    "Sentence": "<\\entity><\\entity> are particularly common in skin cancers and UV irradiation has been shown to be a primary cause of specific 'signature' mutations that can result in oncogenic transformation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1124",
    "Sentence": "<\\entity><\\entity> are particularly common in skin cancers and UV irradiation has been shown to be a primary cause of specific 'signature' mutations that can result in oncogenic transformation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1125",
    "Sentence": "p53 mutations are particularly common in <\\entity><\\entity> and UV irradiation has been shown to be a primary cause of specific 'signature' mutations that can result in oncogenic transformation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1126",
    "Sentence": "p53 <\\entity><\\entity> are particularly common in skin cancers and UV irradiation has been shown to be a primary cause of specific 'signature' <\\entity><\\entity> that can result in oncogenic transformation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1127",
    "Sentence": "p53 mutations are particularly common in skin cancers and UV irradiation has been shown to be a primary cause of specific 'signature' mutations that can result in oncogenic <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1128",
    "Sentence": "There are certain 'hot-spots' in the <\\entity><\\entity> gene where mutations are commonly found that result in a mutated dipyrimidine site.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1129",
    "Sentence": "There are certain 'hot-spots' in the p53 gene where <\\entity><\\entity> are commonly found that result in a mutated dipyrimidine site.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1130",
    "Sentence": "There are certain 'hot-spots' in the p53 gene where mutations are commonly found that result in a mutated <\\entity><\\entity> site.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1131",
    "Sentence": "This review discusses the role of <\\entity><\\entity> from normal function and its dysfunction in pre-cancerous lesions and non-melanoma skin cancers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1132",
    "Sentence": "This review discusses the role of p53 from normal function and its <\\entity><\\entity> in pre-cancerous lesions and non-melanoma skin cancers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1133",
    "Sentence": "This review discusses the role of p53 from normal function and its dysfunction in <\\entity><\\entity> and non-melanoma skin cancers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1134",
    "Sentence": "This review discusses the role of p53 from normal function and its dysfunction in pre-cancerous lesions and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1135",
    "Sentence": "Additionally, special situations are explored, such as <\\entity><\\entity> in which there is an inherited p53 mutation, and the consequences of immune suppression on p53 mutations and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1136",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited <\\entity><\\entity>, and the consequences of immune suppression on <\\entity><\\entity>s and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "1137",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited <\\entity><\\entity>, and the consequences of immune suppression on <\\entity><\\entity>s and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1138",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited <\\entity><\\entity>, and the consequences of immune suppression on <\\entity><\\entity>s and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1139",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited p53 mutation, and the consequences of <\\entity><\\entity> on p53 mutations and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1140",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited p53 mutation, and the consequences of immune suppression on <\\entity><\\entity> and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "1141",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited p53 mutation, and the consequences of immune suppression on <\\entity><\\entity> and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1142",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited p53 mutation, and the consequences of immune suppression on <\\entity><\\entity> and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1143",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited p53 mutation, and the consequences of immune suppression on p53 mutations and the resulting increase in <\\entity><\\entity> in these patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1144",
    "Sentence": "Genetic alterations within the <\\entity><\\entity> gene have been shown to have a direct correlation with cancer development and have been shown to occur in nearly 50% of all cancers.",
    "Label": ""
  },
  {
    "id": "1145",
    "Sentence": "Genetic alterations within the p53 gene have been shown to have a direct correlation with cancer development and have been shown to occur in nearly 50% of all <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1147",
    "Sentence": "<\\entity><\\entity> are particularly common in skin cancers and UV irradiation has been shown to be a primary cause of specific 'signature' mutations that can result in oncogenic transformation.",
    "Label": ""
  },
  {
    "id": "1148",
    "Sentence": "p53 mutations are particularly common in <\\entity><\\entity> and UV irradiation has been shown to be a primary cause of specific 'signature' mutations that can result in oncogenic transformation.",
    "Label": ""
  },
  {
    "id": "1150",
    "Sentence": "<\\entity><\\entity> and the pathogenesis of skin cancer.The <\\entity><\\entity> tumor suppressor gene and gene product are among the most diverse and complex molecules involved in cellular functions.",
    "Label": ""
  },
  {
    "id": "1151",
    "Sentence": "p53 and the <\\entity><\\entity> of skin cancer.The p53 tumor suppressor gene and gene product are among the most diverse and complex molecules involved in cellular functions.",
    "Label": ""
  },
  {
    "id": "1153",
    "Sentence": "<\\entity><\\entity> and the pathogenesis of skin cancer.The <\\entity><\\entity> tumor suppressor gene and gene product are among the most diverse and complex molecules involved in cellular functions.",
    "Label": ""
  },
  {
    "id": "1154",
    "Sentence": "p53 and the pathogenesis of <\\entity><\\entity>.The p53 tumor suppressor gene and gene product are among the most diverse and complex molecules involved in cellular functions.",
    "Label": ""
  },
  {
    "id": "1156",
    "Sentence": "<\\entity><\\entity> are particularly common in skin cancers and UV irradiation has been shown to be a primary cause of specific 'signature' mutations that can result in oncogenic transformation.",
    "Label": ""
  },
  {
    "id": "1157",
    "Sentence": "<\\entity><\\entity> within the p53 gene have been shown to have a direct correlation with cancer development and have been shown to occur in nearly 50% of all cancers.",
    "Label": ""
  },
  {
    "id": "1159",
    "Sentence": "<\\entity><\\entity> are particularly common in skin cancers and UV irradiation has been shown to be a primary cause of specific 'signature' mutations that can result in oncogenic transformation.",
    "Label": ""
  },
  {
    "id": "1160",
    "Sentence": "p53 <\\entity><\\entity> are particularly common in skin cancers and UV irradiation has been shown to be a primary cause of specific 'signature' <\\entity><\\entity> that can result in oncogenic transformation.",
    "Label": ""
  },
  {
    "id": "1162",
    "Sentence": "<\\entity><\\entity> are particularly common in skin cancers and UV irradiation has been shown to be a primary cause of specific 'signature' mutations that can result in oncogenic transformation.",
    "Label": ""
  },
  {
    "id": "1163",
    "Sentence": "p53 mutations are particularly common in skin cancers and UV irradiation has been shown to be a primary cause of specific 'signature' mutations that can result in oncogenic <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1165",
    "Sentence": "There are certain 'hot-spots' in the <\\entity><\\entity> gene where mutations are commonly found that result in a mutated dipyrimidine site.",
    "Label": ""
  },
  {
    "id": "1166",
    "Sentence": "There are certain 'hot-spots' in the p53 gene where <\\entity><\\entity> are commonly found that result in a mutated dipyrimidine site.",
    "Label": ""
  },
  {
    "id": "1168",
    "Sentence": "This review discusses the role of <\\entity><\\entity> from normal function and its dysfunction in pre-cancerous lesions and non-melanoma skin cancers.",
    "Label": ""
  },
  {
    "id": "1169",
    "Sentence": "This review discusses the role of p53 from normal function and its <\\entity><\\entity> in pre-cancerous lesions and non-melanoma skin cancers.",
    "Label": ""
  },
  {
    "id": "1171",
    "Sentence": "This review discusses the role of <\\entity><\\entity> from normal function and its dysfunction in pre-cancerous lesions and non-melanoma skin cancers.",
    "Label": ""
  },
  {
    "id": "1172",
    "Sentence": "This review discusses the role of p53 from normal function and its dysfunction in pre-cancerous lesions and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1174",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited p53 mutation, and the consequences of immune suppression on <\\entity><\\entity> and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": ""
  },
  {
    "id": "1175",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited p53 mutation, and the consequences of immune suppression on <\\entity><\\entity> and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": ""
  },
  {
    "id": "1177",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited p53 mutation, and the consequences of immune suppression on <\\entity><\\entity> and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": ""
  },
  {
    "id": "1178",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited p53 mutation, and the consequences of immune suppression on p53 mutations and the resulting increase in <\\entity><\\entity> in these patients.",
    "Label": ""
  },
  {
    "id": "1180",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited p53 mutation, and the consequences of immune suppression on <\\entity><\\entity> and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": ""
  },
  {
    "id": "1181",
    "Sentence": "Additionally, special situations are explored, such as <\\entity><\\entity> in which there is an inherited p53 mutation, and the consequences of immune suppression on p53 mutations and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": ""
  },
  {
    "id": "1183",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited p53 mutation, and the consequences of immune suppression on <\\entity><\\entity> and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": ""
  },
  {
    "id": "1184",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited p53 mutation, and the consequences of <\\entity><\\entity> on p53 mutations and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": ""
  },
  {
    "id": "1186",
    "Sentence": "This review discusses the role of <\\entity><\\entity> from normal function and its dysfunction in pre-cancerous lesions and non-melanoma skin cancers.",
    "Label": ""
  },
  {
    "id": "1187",
    "Sentence": "This review discusses the role of p53 from normal function and its dysfunction in <\\entity><\\entity> and non-melanoma skin cancers.",
    "Label": ""
  },
  {
    "id": "1189",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited <\\entity><\\entity>, and the consequences of immune suppression on <\\entity><\\entity>s and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": ""
  },
  {
    "id": "1190",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited p53 mutation, and the consequences of immune suppression on p53 mutations and the resulting increase in <\\entity><\\entity> in these patients.",
    "Label": ""
  },
  {
    "id": "1192",
    "Sentence": "Additionally, special situations are explored, such as Li-Fraumeni syndrome in which there is an inherited <\\entity><\\entity>, and the consequences of immune suppression on <\\entity><\\entity>s and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": ""
  },
  {
    "id": "1193",
    "Sentence": "Additionally, special situations are explored, such as <\\entity><\\entity> in which there is an inherited p53 mutation, and the consequences of immune suppression on p53 mutations and the resulting increase in non-melanoma skin cancer in these patients.",
    "Label": ""
  },
  {
    "id": "1199",
    "Sentence": "<\\entity><\\entity> and its receptors ET(A) and ET(B) in drug-induced gingival overgrowth.BACKGROUND: The purpose of this study was to study the expression of endothelin-1 (ET-1) and its receptors ETA and ETB in normal human gingiva and cyclosporin-induced gingival fibroblasts.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1200",
    "Sentence": "Endothelin-1 and its receptors ET(A) and ET(B) in <\\entity><\\entity>.BACKGROUND: The purpose of this study was to study the expression of endothelin-1 (ET-1) and its receptors ETA and ETB in normal human gingiva and cyclosporin-induced gingival fibroblasts.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1201",
    "Sentence": "Endothelin-1 and its receptors ET(A) and ET(B) in drug-induced gingival overgrowth.BACKGROUND: The purpose of this study was to study the expression of <\\entity><\\entity> (ET-1) and its receptors ETA and ETB in normal human gingiva and cyclosporin-induced gingival fibroblasts.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1202",
    "Sentence": "Endothelin-1 and its receptors ET(A) and ET(B) in drug-induced gingival overgrowth.BACKGROUND: The purpose of this study was to study the expression of endothelin-1 (ET-1) and its receptors <\\entity><\\entity> and ETB in normal human gingiva and cyclosporin-induced gingival fibroblasts.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1203",
    "Sentence": "Endothelin-1 and its receptors ET(A) and ET(B) in drug-induced gingival overgrowth.BACKGROUND: The purpose of this study was to study the expression of endothelin-1 (ET-1) and its receptors ETA and ETB in normal human gingiva and <\\entity><\\entity>-induced gingival fibroblasts.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1204",
    "Sentence": "METHODS: Gingival samples were collected from eight normal healthy individuals, eight patients with <\\entity><\\entity>, and eight patients with cyclosporin A (CsA)-induced gingival overgrowth.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1205",
    "Sentence": "METHODS: Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with <\\entity><\\entity> (CsA)-induced gingival overgrowth.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1206",
    "Sentence": "METHODS: Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with cyclosporin A (<\\entity><\\entity>)-induced gingival overgrowth.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1207",
    "Sentence": "METHODS: Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with cyclosporin A (CsA)-induced <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1208",
    "Sentence": "Total RNA was extracted from tissue samples, and reverse transcriptase-polymerase chain reaction was performed for ET-1, <\\entity><\\entity>, and ETB.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1209",
    "Sentence": "The expression of ET-1 and its receptors was also examined in gingival fibroblast cells treated with <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1210",
    "Sentence": "RESULTS: ET-1 mRNA expression was significantly higher in patients with <\\entity><\\entity>-induced gingival overgrowth (P <0.001) than in patients with periodontitis and the controls.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1211",
    "Sentence": "RESULTS: ET-1 mRNA expression was significantly higher in patients with CsA-induced <\\entity><\\entity> (P <0.001) than in patients with periodontitis and the controls.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1212",
    "Sentence": "RESULTS: ET-1 mRNA expression was significantly higher in patients with CsA-induced gingival overgrowth (P <0.001) than in patients with <\\entity><\\entity> and the controls.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1213",
    "Sentence": "<\\entity><\\entity> mRNA was expressed more than the ETB in all examined samples.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1214",
    "Sentence": "In human gingival fibroblasts, ET-1 expression was increased with <\\entity><\\entity> incorporation compared to controls (P <0.001).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1215",
    "Sentence": "CONCLUSION: These results suggest that <\\entity><\\entity> can modulate the expression of ET-1 in gingival fibroblasts and <\\entity><\\entity>-induced gingival overgrowth.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1216",
    "Sentence": "CONCLUSION: These results suggest that <\\entity><\\entity> can modulate the expression of ET-1 in gingival fibroblasts and <\\entity><\\entity>-induced gingival overgrowth.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1217",
    "Sentence": "CONCLUSION: These results suggest that CsA can modulate the expression of ET-1 in gingival fibroblasts and CsA-induced <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1218",
    "Sentence": "METHODS: Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with <\\entity><\\entity> (CsA)-induced gingival overgrowth.",
    "Label": ""
  },
  {
    "id": "1219",
    "Sentence": "METHODS: Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with cyclosporin A (CsA)-induced <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1221",
    "Sentence": "METHODS: Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with cyclosporin A (<\\entity><\\entity>)-induced gingival overgrowth.",
    "Label": ""
  },
  {
    "id": "1222",
    "Sentence": "METHODS: Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with cyclosporin A (CsA)-induced <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1224",
    "Sentence": "METHODS: Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with cyclosporin A (<\\entity><\\entity>)-induced gingival overgrowth.",
    "Label": ""
  },
  {
    "id": "1225",
    "Sentence": "METHODS: Gingival samples were collected from eight normal healthy individuals, eight patients with <\\entity><\\entity>, and eight patients with cyclosporin A (CsA)-induced gingival overgrowth.",
    "Label": ""
  },
  {
    "id": "1227",
    "Sentence": "RESULTS: ET-1 mRNA expression was significantly higher in patients with <\\entity><\\entity>-induced gingival overgrowth (P <0.001) than in patients with periodontitis and the controls.",
    "Label": ""
  },
  {
    "id": "1228",
    "Sentence": "RESULTS: ET-1 mRNA expression was significantly higher in patients with CsA-induced <\\entity><\\entity> (P <0.001) than in patients with periodontitis and the controls.",
    "Label": ""
  },
  {
    "id": "1230",
    "Sentence": "CONCLUSION: These results suggest that <\\entity><\\entity> can modulate the expression of ET-1 in gingival fibroblasts and <\\entity><\\entity>-induced gingival overgrowth.",
    "Label": ""
  },
  {
    "id": "1231",
    "Sentence": "CONCLUSION: These results suggest that CsA can modulate the expression of ET-1 in gingival fibroblasts and CsA-induced <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1233",
    "Sentence": "RESULTS: ET-1 mRNA expression was significantly higher in patients with <\\entity><\\entity>-induced gingival overgrowth (P <0.001) than in patients with periodontitis and the controls.",
    "Label": ""
  },
  {
    "id": "1234",
    "Sentence": "RESULTS: ET-1 mRNA expression was significantly higher in patients with CsA-induced gingival overgrowth (P <0.001) than in patients with <\\entity><\\entity> and the controls.",
    "Label": ""
  },
  {
    "id": "1236",
    "Sentence": "METHODS: Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with <\\entity><\\entity> (CsA)-induced gingival overgrowth.",
    "Label": ""
  },
  {
    "id": "1237",
    "Sentence": "METHODS: Gingival samples were collected from eight normal healthy individuals, eight patients with <\\entity><\\entity>, and eight patients with cyclosporin A (CsA)-induced gingival overgrowth.",
    "Label": ""
  },
  {
    "id": "1239",
    "Sentence": "<\\entity><\\entity> and its receptors ET(A) and ET(B) in drug-induced gingival overgrowth.BACKGROUND: The purpose of this study was to study the expression of endothelin-1 (ET-1) and its receptors ETA and ETB in normal human gingiva and cyclosporin-induced gingival fibroblasts.",
    "Label": ""
  },
  {
    "id": "1240",
    "Sentence": "Endothelin-1 and its receptors ET(A) and ET(B) in <\\entity><\\entity>.BACKGROUND: The purpose of this study was to study the expression of endothelin-1 (ET-1) and its receptors ETA and ETB in normal human gingiva and cyclosporin-induced gingival fibroblasts.",
    "Label": ""
  },
  {
    "id": "1246",
    "Sentence": "<\\entity><\\entity> suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.<\\entity><\\entity> (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1247",
    "Sentence": "Paeonol suppresses <\\entity><\\entity> expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.Paeonol (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1248",
    "Sentence": "Paeonol suppresses intercellular adhesion molecule-1 expression in <\\entity><\\entity>-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.Paeonol (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1249",
    "Sentence": "Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking <\\entity><\\entity>, ERK and nuclear factor-kappaB signaling pathways.Paeonol (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1250",
    "Sentence": "Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, <\\entity><\\entity> and nuclear factor-kappaB signaling pathways.Paeonol (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1251",
    "Sentence": "Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and <\\entity><\\entity> signaling pathways.Paeonol (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1252",
    "Sentence": "<\\entity><\\entity> suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.<\\entity><\\entity> (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1253",
    "Sentence": "Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.Paeonol (<\\entity><\\entity>), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1254",
    "Sentence": "Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.Paeonol (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb <\\entity><\\entity>, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1255",
    "Sentence": "We studied how the levels of <\\entity><\\entity> (ICAM-1), one of the key molecules in the development of atherosclerosis, might be affected by paeonol in tumor necrosis factor-alpha (TNF-alpha)-activated human umbilical vein endothelial cells (HUVECs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1256",
    "Sentence": "We studied how the levels of intercellular adhesion molecule-1 (<\\entity><\\entity>), one of the key molecules in the development of atherosclerosis, might be affected by paeonol in tumor necrosis factor-alpha (TNF-alpha)-activated human umbilical vein endothelial cells (HUVECs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1257",
    "Sentence": "We studied how the levels of intercellular adhesion molecule-1 (ICAM-1), one of the key molecules in the development of atherosclerosis, might be affected by <\\entity><\\entity> in tumor necrosis factor-alpha (TNF-alpha)-activated human umbilical vein endothelial cells (HUVECs).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1258",
    "Sentence": "We studied how the levels of intercellular adhesion molecule-1 (ICAM-1), one of the key molecules in the development of atherosclerosis, might be affected by paeonol in <\\entity><\\entity> (TNF-alpha)-activated human umbilical vein endothelial cells (HUVECs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1259",
    "Sentence": "We studied how the levels of intercellular adhesion molecule-1 (ICAM-1), one of the key molecules in the development of atherosclerosis, might be affected by paeonol in tumor necrosis factor-alpha (<\\entity><\\entity>)-activated human umbilical vein endothelial cells (HUVECs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1260",
    "Sentence": "<\\entity><\\entity> concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1261",
    "Sentence": "Paeonol concentration-dependently inhibited the production of <\\entity><\\entity>; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1262",
    "Sentence": "Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited <\\entity><\\entity> (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1263",
    "Sentence": "Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (<\\entity><\\entity>) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1264",
    "Sentence": "Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) <\\entity><\\entity> translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1265",
    "Sentence": "Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of <\\entity><\\entity> (IkappaBalpha).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1266",
    "Sentence": "Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1267",
    "Sentence": "It also blocked the <\\entity><\\entity>-induced phosphorylation of p38 and extracellular signal-regulated kinase (ERK), which are involved in regulating ICAM-1 production by <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1268",
    "Sentence": "It also blocked the TNF-alpha-induced phosphorylation of <\\entity><\\entity> and extracellular signal-regulated kinase (ERK), which are involved in regulating ICAM-1 production by TNF-alpha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1269",
    "Sentence": "It also blocked the TNF-alpha-induced phosphorylation of p38 and <\\entity><\\entity> (ERK), which are involved in regulating ICAM-1 production by TNF-alpha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1270",
    "Sentence": "It also blocked the TNF-alpha-induced phosphorylation of p38 and extracellular signal-regulated kinase (<\\entity><\\entity>), which are involved in regulating ICAM-1 production by TNF-alpha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1271",
    "Sentence": "It also blocked the TNF-alpha-induced phosphorylation of p38 and extracellular signal-regulated kinase (ERK), which are involved in regulating <\\entity><\\entity> production by TNF-alpha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1272",
    "Sentence": "It also blocked the <\\entity><\\entity>-induced phosphorylation of p38 and extracellular signal-regulated kinase (ERK), which are involved in regulating ICAM-1 production by <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1273",
    "Sentence": "<\\entity><\\entity> inhibited U937 monocyte adhesion to HUVECs stimulated by TNF-alpha, suggesting that it may inhibit the binding of monocytes to endothelium by regulating the production of critical adhesion molecules by TNF-alpha.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1274",
    "Sentence": "Paeonol inhibited U937 monocyte adhesion to HUVECs stimulated by <\\entity><\\entity>, suggesting that it may inhibit the binding of monocytes to endothelium by regulating the production of critical adhesion molecules by <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1275",
    "Sentence": "Paeonol inhibited U937 monocyte adhesion to HUVECs stimulated by <\\entity><\\entity>, suggesting that it may inhibit the binding of monocytes to endothelium by regulating the production of critical adhesion molecules by <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1276",
    "Sentence": "The inhibitory effect of <\\entity><\\entity> on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1277",
    "Sentence": "The inhibitory effect of paeonol on <\\entity><\\entity> production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced <\\entity><\\entity> production.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1278",
    "Sentence": "The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting <\\entity><\\entity>, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1279",
    "Sentence": "The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, <\\entity><\\entity> and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1280",
    "Sentence": "The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and <\\entity><\\entity> signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1281",
    "Sentence": "The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in <\\entity><\\entity>-induced ICAM-1 production.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1282",
    "Sentence": "The inhibitory effect of paeonol on <\\entity><\\entity> production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced <\\entity><\\entity> production.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1283",
    "Sentence": "Thus, <\\entity><\\entity> may be beneficial in the treatment of cardiovascular disorders such as atherosclerosis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1284",
    "Sentence": "<\\entity><\\entity> suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.<\\entity><\\entity> (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": ""
  },
  {
    "id": "1285",
    "Sentence": "Paeonol suppresses <\\entity><\\entity> expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.Paeonol (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": ""
  },
  {
    "id": "1287",
    "Sentence": "<\\entity><\\entity> suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.<\\entity><\\entity> (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": ""
  },
  {
    "id": "1288",
    "Sentence": "Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking <\\entity><\\entity>, ERK and nuclear factor-kappaB signaling pathways.Paeonol (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": ""
  },
  {
    "id": "1290",
    "Sentence": "<\\entity><\\entity> suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.<\\entity><\\entity> (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": ""
  },
  {
    "id": "1291",
    "Sentence": "Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, <\\entity><\\entity> and nuclear factor-kappaB signaling pathways.Paeonol (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": ""
  },
  {
    "id": "1293",
    "Sentence": "<\\entity><\\entity> suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.<\\entity><\\entity> (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": ""
  },
  {
    "id": "1294",
    "Sentence": "Paeonol suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and <\\entity><\\entity> signaling pathways.Paeonol (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": ""
  },
  {
    "id": "1296",
    "Sentence": "We studied how the levels of intercellular adhesion molecule-1 (ICAM-1), one of the key molecules in the development of atherosclerosis, might be affected by <\\entity><\\entity> in tumor necrosis factor-alpha (TNF-alpha)-activated human umbilical vein endothelial cells (HUVECs).",
    "Label": ""
  },
  {
    "id": "1297",
    "Sentence": "We studied how the levels of intercellular adhesion molecule-1 (<\\entity><\\entity>), one of the key molecules in the development of atherosclerosis, might be affected by paeonol in tumor necrosis factor-alpha (TNF-alpha)-activated human umbilical vein endothelial cells (HUVECs).",
    "Label": ""
  },
  {
    "id": "1299",
    "Sentence": "<\\entity><\\entity> concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": ""
  },
  {
    "id": "1300",
    "Sentence": "Paeonol concentration-dependently inhibited the production of <\\entity><\\entity>; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": ""
  },
  {
    "id": "1302",
    "Sentence": "<\\entity><\\entity> concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": ""
  },
  {
    "id": "1303",
    "Sentence": "Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (<\\entity><\\entity>) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": ""
  },
  {
    "id": "1305",
    "Sentence": "<\\entity><\\entity> concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": ""
  },
  {
    "id": "1306",
    "Sentence": "Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) <\\entity><\\entity> translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": ""
  },
  {
    "id": "1308",
    "Sentence": "<\\entity><\\entity> concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": ""
  },
  {
    "id": "1309",
    "Sentence": "Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "1311",
    "Sentence": "<\\entity><\\entity> concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": ""
  },
  {
    "id": "1312",
    "Sentence": "Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited <\\entity><\\entity> (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": ""
  },
  {
    "id": "1314",
    "Sentence": "<\\entity><\\entity> concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of inhibitory factor kappaBalpha (IkappaBalpha).",
    "Label": ""
  },
  {
    "id": "1315",
    "Sentence": "Paeonol concentration-dependently inhibited the production of ICAM-1; it inhibited nuclear factor-kappaB (NF-kappaB) p65 translocation into the nucleus and the phosphorylation of <\\entity><\\entity> (IkappaBalpha).",
    "Label": ""
  },
  {
    "id": "1317",
    "Sentence": "<\\entity><\\entity> inhibited U937 monocyte adhesion to HUVECs stimulated by TNF-alpha, suggesting that it may inhibit the binding of monocytes to endothelium by regulating the production of critical adhesion molecules by TNF-alpha.",
    "Label": ""
  },
  {
    "id": "1318",
    "Sentence": "Paeonol inhibited U937 monocyte adhesion to HUVECs stimulated by <\\entity><\\entity>, suggesting that it may inhibit the binding of monocytes to endothelium by regulating the production of critical adhesion molecules by <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1320",
    "Sentence": "The inhibitory effect of <\\entity><\\entity> on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production.",
    "Label": ""
  },
  {
    "id": "1321",
    "Sentence": "The inhibitory effect of paeonol on <\\entity><\\entity> production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced <\\entity><\\entity> production.",
    "Label": ""
  },
  {
    "id": "1323",
    "Sentence": "The inhibitory effect of <\\entity><\\entity> on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production.",
    "Label": ""
  },
  {
    "id": "1324",
    "Sentence": "The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting <\\entity><\\entity>, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production.",
    "Label": ""
  },
  {
    "id": "1326",
    "Sentence": "The inhibitory effect of <\\entity><\\entity> on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production.",
    "Label": ""
  },
  {
    "id": "1327",
    "Sentence": "The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and <\\entity><\\entity> signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production.",
    "Label": ""
  },
  {
    "id": "1329",
    "Sentence": "The inhibitory effect of <\\entity><\\entity> on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production.",
    "Label": ""
  },
  {
    "id": "1330",
    "Sentence": "The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, <\\entity><\\entity> and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production.",
    "Label": ""
  },
  {
    "id": "1332",
    "Sentence": "<\\entity><\\entity> suppresses intercellular adhesion molecule-1 expression in tumor necrosis factor-alpha-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.<\\entity><\\entity> (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": ""
  },
  {
    "id": "1333",
    "Sentence": "Paeonol suppresses intercellular adhesion molecule-1 expression in <\\entity><\\entity>-stimulated human umbilical vein endothelial cells by blocking p38, ERK and nuclear factor-kappaB signaling pathways.Paeonol (2'-hydroxy-4'-methoxyacetophenone), the main active compound of the traditionally used Chinese herb Paeonia lactiflora Pallas, has anti-inflammatory, antioxidant and cardiovascular protective activities.",
    "Label": ""
  },
  {
    "id": "1335",
    "Sentence": "We studied how the levels of intercellular adhesion molecule-1 (ICAM-1), one of the key molecules in the development of atherosclerosis, might be affected by <\\entity><\\entity> in tumor necrosis factor-alpha (TNF-alpha)-activated human umbilical vein endothelial cells (HUVECs).",
    "Label": ""
  },
  {
    "id": "1336",
    "Sentence": "We studied how the levels of intercellular adhesion molecule-1 (ICAM-1), one of the key molecules in the development of atherosclerosis, might be affected by paeonol in <\\entity><\\entity> (TNF-alpha)-activated human umbilical vein endothelial cells (HUVECs).",
    "Label": ""
  },
  {
    "id": "1338",
    "Sentence": "We studied how the levels of intercellular adhesion molecule-1 (ICAM-1), one of the key molecules in the development of atherosclerosis, might be affected by <\\entity><\\entity> in tumor necrosis factor-alpha (TNF-alpha)-activated human umbilical vein endothelial cells (HUVECs).",
    "Label": ""
  },
  {
    "id": "1339",
    "Sentence": "We studied how the levels of intercellular adhesion molecule-1 (ICAM-1), one of the key molecules in the development of atherosclerosis, might be affected by paeonol in tumor necrosis factor-alpha (<\\entity><\\entity>)-activated human umbilical vein endothelial cells (HUVECs).",
    "Label": ""
  },
  {
    "id": "1341",
    "Sentence": "The inhibitory effect of <\\entity><\\entity> on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in TNF-alpha-induced ICAM-1 production.",
    "Label": ""
  },
  {
    "id": "1342",
    "Sentence": "The inhibitory effect of paeonol on ICAM-1 production might be mediated by inhibiting p38, ERK and NF-kappaB signaling pathways, which are involved in <\\entity><\\entity>-induced ICAM-1 production.",
    "Label": ""
  },
  {
    "id": "1348",
    "Sentence": "<\\entity><\\entity>: a rare pulmonary toxicity of sirolimus.The aim of our paper is to describe an unusual pulmonary toxicity of sirolimus (SRL) in a kidney transplant recipient.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1349",
    "Sentence": "Pulmonary alveolar proteinosis: a rare <\\entity><\\entity> of sirolimus.The aim of our paper is to describe an unusual <\\entity><\\entity> of sirolimus (SRL) in a kidney transplant recipient.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1350",
    "Sentence": "Pulmonary alveolar proteinosis: a rare pulmonary toxicity of <\\entity><\\entity>.The aim of our paper is to describe an unusual pulmonary toxicity of <\\entity><\\entity> (SRL) in a kidney transplant recipient.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1351",
    "Sentence": "Pulmonary alveolar proteinosis: a rare <\\entity><\\entity> of sirolimus.The aim of our paper is to describe an unusual <\\entity><\\entity> of sirolimus (SRL) in a kidney transplant recipient.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1352",
    "Sentence": "Pulmonary alveolar proteinosis: a rare pulmonary toxicity of <\\entity><\\entity>.The aim of our paper is to describe an unusual pulmonary toxicity of <\\entity><\\entity> (SRL) in a kidney transplant recipient.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1353",
    "Sentence": "Pulmonary alveolar proteinosis: a rare pulmonary toxicity of sirolimus.The aim of our paper is to describe an unusual pulmonary toxicity of sirolimus (<\\entity><\\entity>) in a kidney transplant recipient.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1354",
    "Sentence": "We present a 34-year-old woman with a second renal transplantation, complicated with <\\entity><\\entity> and chronic allograft dysfunction.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1355",
    "Sentence": "We present a 34-year-old woman with a second renal transplantation, complicated with <\\entity><\\entity> and chronic allograft dysfunction.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1356",
    "Sentence": "We present a 34-year-old woman with a second renal transplantation, complicated with steroid-resistant acute rejection and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1357",
    "Sentence": "Two years after initiating <\\entity><\\entity>, she presented complaints of progressive dyspnoea, nonproductive cough, chest pain and low-grade fever of 1 month duration.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1358",
    "Sentence": "Two years after initiating SRL, she presented complaints of progressive <\\entity><\\entity>, nonproductive cough, chest pain and low-grade fever of 1 month duration.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1359",
    "Sentence": "Two years after initiating SRL, she presented complaints of progressive dyspnoea, <\\entity><\\entity>, chest pain and low-grade fever of 1 month duration.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1360",
    "Sentence": "Two years after initiating SRL, she presented complaints of progressive dyspnoea, nonproductive cough, <\\entity><\\entity> and low-grade fever of 1 month duration.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1361",
    "Sentence": "Two years after initiating SRL, she presented complaints of progressive dyspnoea, nonproductive cough, chest pain and <\\entity><\\entity> of 1 month duration.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1362",
    "Sentence": "She had <\\entity><\\entity> and slight elevation of lactic dehydrogenase levels.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1363",
    "Sentence": "Diagnosis of <\\entity><\\entity> (PAP) was made and drug-induced toxicity was suspected.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1364",
    "Sentence": "Diagnosis of pulmonary alveolar proteinosis (<\\entity><\\entity>) was made and drug-induced toxicity was suspected.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1365",
    "Sentence": "<\\entity><\\entity> was withdrawn with marked improvement in the patients' clinical and radiological status.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1366",
    "Sentence": "<\\entity><\\entity> resolved within 3 months without further therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1367",
    "Sentence": "<\\entity><\\entity> is a very rare complication of SRL therapy with only a few cases described.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1368",
    "Sentence": "PAP is a very rare <\\entity><\\entity> of SRL therapy with only a few cases described.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1369",
    "Sentence": "PAP is a very rare complication of <\\entity><\\entity> therapy with only a few cases described.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1370",
    "Sentence": "Withdrawal of <\\entity><\\entity> with conversion to another immunosuppressant seems to be an appropriate procedure in this condition.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1371",
    "Sentence": "Withdrawal of SRL with conversion to another <\\entity><\\entity> seems to be an appropriate procedure in this condition.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1372",
    "Sentence": "Pulmonary alveolar proteinosis: a rare pulmonary toxicity of <\\entity><\\entity>.The aim of our paper is to describe an unusual pulmonary toxicity of <\\entity><\\entity> (SRL) in a kidney transplant recipient.",
    "Label": ""
  },
  {
    "id": "1373",
    "Sentence": "<\\entity><\\entity>: a rare pulmonary toxicity of sirolimus.The aim of our paper is to describe an unusual pulmonary toxicity of sirolimus (SRL) in a kidney transplant recipient.",
    "Label": ""
  },
  {
    "id": "1375",
    "Sentence": "PAP is a very rare complication of <\\entity><\\entity> therapy with only a few cases described.",
    "Label": ""
  },
  {
    "id": "1376",
    "Sentence": "<\\entity><\\entity> is a very rare complication of SRL therapy with only a few cases described.",
    "Label": ""
  },
  {
    "id": "1378",
    "Sentence": "Two years after initiating <\\entity><\\entity>, she presented complaints of progressive dyspnoea, nonproductive cough, chest pain and low-grade fever of 1 month duration.",
    "Label": ""
  },
  {
    "id": "1379",
    "Sentence": "Two years after initiating SRL, she presented complaints of progressive dyspnoea, <\\entity><\\entity>, chest pain and low-grade fever of 1 month duration.",
    "Label": ""
  },
  {
    "id": "1381",
    "Sentence": "Two years after initiating <\\entity><\\entity>, she presented complaints of progressive dyspnoea, nonproductive cough, chest pain and low-grade fever of 1 month duration.",
    "Label": ""
  },
  {
    "id": "1382",
    "Sentence": "Two years after initiating SRL, she presented complaints of progressive dyspnoea, nonproductive cough, <\\entity><\\entity> and low-grade fever of 1 month duration.",
    "Label": ""
  },
  {
    "id": "1384",
    "Sentence": "Two years after initiating <\\entity><\\entity>, she presented complaints of progressive dyspnoea, nonproductive cough, chest pain and low-grade fever of 1 month duration.",
    "Label": ""
  },
  {
    "id": "1385",
    "Sentence": "Two years after initiating SRL, she presented complaints of progressive dyspnoea, nonproductive cough, chest pain and <\\entity><\\entity> of 1 month duration.",
    "Label": ""
  },
  {
    "id": "1387",
    "Sentence": "Pulmonary alveolar proteinosis: a rare pulmonary toxicity of <\\entity><\\entity>.The aim of our paper is to describe an unusual pulmonary toxicity of <\\entity><\\entity> (SRL) in a kidney transplant recipient.",
    "Label": ""
  },
  {
    "id": "1388",
    "Sentence": "Pulmonary alveolar proteinosis: a rare <\\entity><\\entity> of sirolimus.The aim of our paper is to describe an unusual <\\entity><\\entity> of sirolimus (SRL) in a kidney transplant recipient.",
    "Label": ""
  },
  {
    "id": "1390",
    "Sentence": "Pulmonary alveolar proteinosis: a rare pulmonary toxicity of <\\entity><\\entity>.The aim of our paper is to describe an unusual pulmonary toxicity of <\\entity><\\entity> (SRL) in a kidney transplant recipient.",
    "Label": ""
  },
  {
    "id": "1391",
    "Sentence": "Pulmonary alveolar proteinosis: a rare <\\entity><\\entity> of sirolimus.The aim of our paper is to describe an unusual <\\entity><\\entity> of sirolimus (SRL) in a kidney transplant recipient.",
    "Label": ""
  },
  {
    "id": "1393",
    "Sentence": "Pulmonary alveolar proteinosis: a rare pulmonary toxicity of sirolimus.The aim of our paper is to describe an unusual pulmonary toxicity of sirolimus (<\\entity><\\entity>) in a kidney transplant recipient.",
    "Label": ""
  },
  {
    "id": "1394",
    "Sentence": "Pulmonary alveolar proteinosis: a rare <\\entity><\\entity> of sirolimus.The aim of our paper is to describe an unusual <\\entity><\\entity> of sirolimus (SRL) in a kidney transplant recipient.",
    "Label": ""
  },
  {
    "id": "1396",
    "Sentence": "Two years after initiating <\\entity><\\entity>, she presented complaints of progressive dyspnoea, nonproductive cough, chest pain and low-grade fever of 1 month duration.",
    "Label": ""
  },
  {
    "id": "1397",
    "Sentence": "Two years after initiating SRL, she presented complaints of progressive <\\entity><\\entity>, nonproductive cough, chest pain and low-grade fever of 1 month duration.",
    "Label": ""
  },
  {
    "id": "1403",
    "Sentence": "Production of polyclonal antibodies against the human respiratory syncytial <\\entity><\\entity> nucleoprotein and phosphoprotein expressed in Escherichia coli.The nucleoprotein (N) and the phosphoprotein (P) of the human respiratory syncytial <\\entity><\\entity> (HRSV), A2 strain, were cloned into pMAL-c2e vector.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1404",
    "Sentence": "Production of polyclonal antibodies against the human respiratory syncytial <\\entity><\\entity> nucleoprotein and phosphoprotein expressed in Escherichia coli.The nucleoprotein (N) and the phosphoprotein (P) of the human respiratory syncytial <\\entity><\\entity> (HRSV), A2 strain, were cloned into pMAL-c2e vector.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1405",
    "Sentence": "Production of polyclonal antibodies against the human respiratory syncytial virus <\\entity><\\entity> and phosphoprotein expressed in Escherichia coli.The <\\entity><\\entity> (N) and the phosphoprotein (P) of the human respiratory syncytial virus (HRSV), A2 strain, were cloned into pMAL-c2e vector.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1406",
    "Sentence": "Production of polyclonal antibodies against the human respiratory syncytial virus nucleoprotein and <\\entity><\\entity> expressed in Escherichia coli.The nucleoprotein (N) and the <\\entity><\\entity> (P) of the human respiratory syncytial virus (HRSV), A2 strain, were cloned into pMAL-c2e vector.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1407",
    "Sentence": "Production of polyclonal antibodies against the human respiratory syncytial virus nucleoprotein and phosphoprotein expressed in <\\entity><\\entity> coli.The nucleoprotein (N) and the phosphoprotein (P) of the human respiratory syncytial virus (HRSV), A2 strain, were cloned into pMAL-c2e vector.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1408",
    "Sentence": "Production of polyclonal antibodies against the human respiratory syncytial virus nucleoprotein and phosphoprotein expressed in <\\entity><\\entity> coli.The nucleoprotein (N) and the phosphoprotein (P) of the human respiratory syncytial virus (HRSV), A2 strain, were cloned into pMAL-c2e vector.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1409",
    "Sentence": "Production of polyclonal antibodies against the human respiratory syncytial virus <\\entity><\\entity> and phosphoprotein expressed in Escherichia coli.The <\\entity><\\entity> (N) and the phosphoprotein (P) of the human respiratory syncytial virus (HRSV), A2 strain, were cloned into pMAL-c2e vector.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1410",
    "Sentence": "Production of polyclonal antibodies against the human respiratory syncytial virus nucleoprotein and phosphoprotein expressed in Escherichia coli.The nucleoprotein (<\\entity><\\entity>) and the phosphoprotein (P) of the human respiratory syncytial virus (HRSV), A2 strain, were cloned into pMAL-c2e vector.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1411",
    "Sentence": "Production of polyclonal antibodies against the human respiratory syncytial virus nucleoprotein and <\\entity><\\entity> expressed in Escherichia coli.The nucleoprotein (N) and the <\\entity><\\entity> (P) of the human respiratory syncytial virus (HRSV), A2 strain, were cloned into pMAL-c2e vector.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1412",
    "Sentence": "<\\entity><\\entity>roduction of polyclonal antibodies against the human respiratory syncytial virus nucleoprotein and phosphoprotein expressed in Escherichia coli.The nucleoprotein (N) and the phosphoprotein (<\\entity><\\entity>) of the human respiratory syncytial virus (HRSV), A2 strain, were cloned into pMAL-c2e vector.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1413",
    "Sentence": "Production of polyclonal antibodies against the human respiratory syncytial <\\entity><\\entity> nucleoprotein and phosphoprotein expressed in Escherichia coli.The nucleoprotein (N) and the phosphoprotein (P) of the human respiratory syncytial <\\entity><\\entity> (HRSV), A2 strain, were cloned into pMAL-c2e vector.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1414",
    "Sentence": "Production of polyclonal antibodies against the human respiratory syncytial <\\entity><\\entity> nucleoprotein and phosphoprotein expressed in Escherichia coli.The nucleoprotein (N) and the phosphoprotein (P) of the human respiratory syncytial <\\entity><\\entity> (HRSV), A2 strain, were cloned into pMAL-c2e vector.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1415",
    "Sentence": "Production of polyclonal antibodies against the human respiratory syncytial virus nucleoprotein and phosphoprotein expressed in Escherichia coli.The nucleoprotein (N) and the phosphoprotein (P) of the human respiratory syncytial virus (HRSV), A2 <\\entity><\\entity>, were cloned into pMAL-c2e vector.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1416",
    "Sentence": "Production of polyclonal antibodies against the human respiratory syncytial virus nucleoprotein and phosphoprotein expressed in Escherichia coli.The nucleoprotein (N) and the phosphoprotein (P) of the human respiratory syncytial virus (HRSV), A2 <\\entity><\\entity>, were cloned into pMAL-c2e vector.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1417",
    "Sentence": "The proteins were expressed fused with the <\\entity><\\entity> (MBP) and were preferentially found in the soluble fraction of the bacterial lysate.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1418",
    "Sentence": "The proteins were expressed fused with the maltose-binding protein (<\\entity><\\entity>) and were preferentially found in the soluble fraction of the bacterial lysate.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1419",
    "Sentence": "The fused proteins were cleaved by digestion with <\\entity><\\entity> and then used as antigens for BALB/c mice immunization.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1420",
    "Sentence": "The obtained polyclonal antibodies were tested against <\\entity><\\entity> cells in immunofluorescence assays.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1421",
    "Sentence": "The results indicate that the antibodies generated against the recombinant proteins were able to recognize the <\\entity><\\entity> proteins.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1422",
    "Sentence": "We now intend to purify the cleaved <\\entity><\\entity> and P proteins and use them in structural studies.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1423",
    "Sentence": "We now intend to purify the cleaved N and <\\entity><\\entity> proteins and use them in structural studies.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1424",
    "Sentence": "The recombinant proteins will also be tested as potential inducers of a protective immunity against the <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1429",
    "Sentence": "Sequential metabolism is responsible for <\\entity><\\entity>-induced time-dependent loss of CYP3A.Kinetic parameters (k(inact) and K(I)) obtained in microsomes are often used to predict time-dependent inactivation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1430",
    "Sentence": "Sequential metabolism is responsible for diltiazem-induced time-dependent loss of <\\entity><\\entity>.Kinetic parameters (k(inact) and K(I)) obtained in microsomes are often used to predict time-dependent inactivation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1431",
    "Sentence": "We previously reported that microsomal inactivation kinetic parameters of <\\entity><\\entity> underpredicted CYP3A inactivation in hepatocytes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1432",
    "Sentence": "We previously reported that microsomal inactivation kinetic parameters of diltiazem underpredicted <\\entity><\\entity> inactivation in hepatocytes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1433",
    "Sentence": "In this study, we evaluated the contributions of inactivation and reversible inhibition of <\\entity><\\entity> by diltiazem and its N-desmethyl (MA) and N,N-didesmethyl (MD) metabolites.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1434",
    "Sentence": "In this study, we evaluated the contributions of inactivation and reversible inhibition of CYP3A by <\\entity><\\entity> and its N-desmethyl (MA) and N,N-didesmethyl (MD) metabolites.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1435",
    "Sentence": "In this study, we evaluated the contributions of inactivation and reversible inhibition of CYP3A by diltiazem and its <\\entity><\\entity> (MA) and N,N-didesmethyl (MD) metabolites.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1436",
    "Sentence": "In this study, we evaluated the contributions of inactivation and reversible inhibition of CYP3A by diltiazem and its N-desmethyl (<\\entity><\\entity>) and N,N-didesmethyl (MD) metabolites.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1437",
    "Sentence": "In this study, we evaluated the contributions of inactivation and reversible inhibition of CYP3A by diltiazem and its N-desmethyl (MA) and <\\entity><\\entity> (MD) metabolites.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1438",
    "Sentence": "In this study, we evaluated the contributions of inactivation and reversible inhibition of CYP3A by diltiazem and its N-desmethyl (MA) and N,N-didesmethyl (<\\entity><\\entity>) metabolites.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1439",
    "Sentence": "In human liver microsomes, <\\entity><\\entity> was a more potent time-dependent inactivator of CYP3A than its parent drug, with apparent k(inact) approximately 4-fold higher than that of diltiazem at a microsomal protein concentration of 0.2 mg/ml.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1440",
    "Sentence": "In human liver microsomes, MA was a more potent time-dependent inactivator of <\\entity><\\entity> than its parent drug, with apparent k(inact) approximately 4-fold higher than that of diltiazem at a microsomal protein concentration of 0.2 mg/ml.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1441",
    "Sentence": "In human liver microsomes, MA was a more potent time-dependent inactivator of CYP3A than its parent drug, with apparent k(inact) approximately 4-fold higher than that of <\\entity><\\entity> at a microsomal protein concentration of 0.2 mg/ml.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1442",
    "Sentence": "<\\entity><\\entity> did not inactivate CYP3A.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1443",
    "Sentence": "MD did not inactivate <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1444",
    "Sentence": "Inactivation of <\\entity><\\entity> by diltiazem was dependent on microsomal protein concentration (25, 36, and 41% decrease in <\\entity><\\entity> activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM diltiazem over 20 min), whereas inactivation by MA did not seem to be protein concentration-dependent.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1445",
    "Sentence": "Inactivation of CYP3A by <\\entity><\\entity> was dependent on microsomal protein concentration (25, 36, and 41% decrease in CYP3A activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM <\\entity><\\entity> over 20 min), whereas inactivation by MA did not seem to be protein concentration-dependent.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1446",
    "Sentence": "Inactivation of <\\entity><\\entity> by diltiazem was dependent on microsomal protein concentration (25, 36, and 41% decrease in <\\entity><\\entity> activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM diltiazem over 20 min), whereas inactivation by MA did not seem to be protein concentration-dependent.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1447",
    "Sentence": "Inactivation of CYP3A by <\\entity><\\entity> was dependent on microsomal protein concentration (25, 36, and 41% decrease in CYP3A activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM <\\entity><\\entity> over 20 min), whereas inactivation by MA did not seem to be protein concentration-dependent.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1448",
    "Sentence": "Inactivation of CYP3A by diltiazem was dependent on microsomal protein concentration (25, 36, and 41% decrease in CYP3A activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM diltiazem over 20 min), whereas inactivation by <\\entity><\\entity> did not seem to be protein concentration-dependent.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1449",
    "Sentence": "<\\entity><\\entity> and MD were reversible inhibitors of CYP3A with competitive Ki values of 2.7 and 0.2 microM, respectively.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1450",
    "Sentence": "MA and <\\entity><\\entity> were reversible inhibitors of CYP3A with competitive Ki values of 2.7 and 0.2 microM, respectively.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1451",
    "Sentence": "MA and MD were reversible inhibitors of <\\entity><\\entity> with competitive Ki values of 2.7 and 0.2 microM, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1452",
    "Sentence": "In cryopreserved hepatocytes incubated with <\\entity><\\entity>, time-dependent loss of CYP3A was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher <\\entity><\\entity> concentrations.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1453",
    "Sentence": "In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of <\\entity><\\entity> was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher diltiazem concentrations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1454",
    "Sentence": "In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of CYP3A was accompanied by increased formation of <\\entity><\\entity> and MD, with the <\\entity><\\entity> level similar to its K(I) at higher diltiazem concentrations.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1455",
    "Sentence": "In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of CYP3A was accompanied by increased formation of MA and <\\entity><\\entity>, with the MA level similar to its K(I) at higher diltiazem concentrations.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1456",
    "Sentence": "In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of CYP3A was accompanied by increased formation of <\\entity><\\entity> and MD, with the <\\entity><\\entity> level similar to its K(I) at higher diltiazem concentrations.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1457",
    "Sentence": "In cryopreserved hepatocytes incubated with <\\entity><\\entity>, time-dependent loss of CYP3A was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher <\\entity><\\entity> concentrations.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1458",
    "Sentence": "In summary, time-dependent <\\entity><\\entity> inactivation by MA seems to be the major contributor responsible for the loss of <\\entity><\\entity> in human liver microsomes and human hepatocytes incubated with diltiazem.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1459",
    "Sentence": "In summary, time-dependent CYP3A inactivation by <\\entity><\\entity> seems to be the major contributor responsible for the loss of CYP3A in human liver microsomes and human hepatocytes incubated with diltiazem.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1460",
    "Sentence": "In summary, time-dependent <\\entity><\\entity> inactivation by MA seems to be the major contributor responsible for the loss of <\\entity><\\entity> in human liver microsomes and human hepatocytes incubated with diltiazem.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1461",
    "Sentence": "In summary, time-dependent CYP3A inactivation by MA seems to be the major contributor responsible for the loss of CYP3A in human liver microsomes and human hepatocytes incubated with <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1462",
    "Sentence": "These findings suggest that prediction of <\\entity><\\entity> loss based solely on microsomal inactivation parameters of parent drug may be inadequate.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1463",
    "Sentence": "Sequential metabolism is responsible for <\\entity><\\entity>-induced time-dependent loss of CYP3A.Kinetic parameters (k(inact) and K(I)) obtained in microsomes are often used to predict time-dependent inactivation.",
    "Label": ""
  },
  {
    "id": "1464",
    "Sentence": "Sequential metabolism is responsible for diltiazem-induced time-dependent loss of <\\entity><\\entity>.Kinetic parameters (k(inact) and K(I)) obtained in microsomes are often used to predict time-dependent inactivation.",
    "Label": ""
  },
  {
    "id": "1466",
    "Sentence": "In human liver microsomes, MA was a more potent time-dependent inactivator of CYP3A than its parent drug, with apparent k(inact) approximately 4-fold higher than that of <\\entity><\\entity> at a microsomal protein concentration of 0.2 mg/ml.",
    "Label": ""
  },
  {
    "id": "1467",
    "Sentence": "In human liver microsomes, MA was a more potent time-dependent inactivator of <\\entity><\\entity> than its parent drug, with apparent k(inact) approximately 4-fold higher than that of diltiazem at a microsomal protein concentration of 0.2 mg/ml.",
    "Label": ""
  },
  {
    "id": "1469",
    "Sentence": "In human liver microsomes, <\\entity><\\entity> was a more potent time-dependent inactivator of CYP3A than its parent drug, with apparent k(inact) approximately 4-fold higher than that of diltiazem at a microsomal protein concentration of 0.2 mg/ml.",
    "Label": ""
  },
  {
    "id": "1470",
    "Sentence": "In human liver microsomes, MA was a more potent time-dependent inactivator of <\\entity><\\entity> than its parent drug, with apparent k(inact) approximately 4-fold higher than that of diltiazem at a microsomal protein concentration of 0.2 mg/ml.",
    "Label": ""
  },
  {
    "id": "1472",
    "Sentence": "<\\entity><\\entity> did not inactivate CYP3A.",
    "Label": ""
  },
  {
    "id": "1473",
    "Sentence": "MD did not inactivate <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1475",
    "Sentence": "Inactivation of CYP3A by <\\entity><\\entity> was dependent on microsomal protein concentration (25, 36, and 41% decrease in CYP3A activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM <\\entity><\\entity> over 20 min), whereas inactivation by MA did not seem to be protein concentration-dependent.",
    "Label": ""
  },
  {
    "id": "1476",
    "Sentence": "Inactivation of <\\entity><\\entity> by diltiazem was dependent on microsomal protein concentration (25, 36, and 41% decrease in <\\entity><\\entity> activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM diltiazem over 20 min), whereas inactivation by MA did not seem to be protein concentration-dependent.",
    "Label": ""
  },
  {
    "id": "1478",
    "Sentence": "Inactivation of CYP3A by diltiazem was dependent on microsomal protein concentration (25, 36, and 41% decrease in CYP3A activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM diltiazem over 20 min), whereas inactivation by <\\entity><\\entity> did not seem to be protein concentration-dependent.",
    "Label": ""
  },
  {
    "id": "1479",
    "Sentence": "Inactivation of <\\entity><\\entity> by diltiazem was dependent on microsomal protein concentration (25, 36, and 41% decrease in <\\entity><\\entity> activity at 0.2, 0.4, and 0.8 mg/ml microsomal protein, respectively, incubated with 10 microM diltiazem over 20 min), whereas inactivation by MA did not seem to be protein concentration-dependent.",
    "Label": ""
  },
  {
    "id": "1481",
    "Sentence": "MA and <\\entity><\\entity> were reversible inhibitors of CYP3A with competitive Ki values of 2.7 and 0.2 microM, respectively.",
    "Label": ""
  },
  {
    "id": "1482",
    "Sentence": "MA and MD were reversible inhibitors of <\\entity><\\entity> with competitive Ki values of 2.7 and 0.2 microM, respectively.",
    "Label": ""
  },
  {
    "id": "1484",
    "Sentence": "<\\entity><\\entity> and MD were reversible inhibitors of CYP3A with competitive Ki values of 2.7 and 0.2 microM, respectively.",
    "Label": ""
  },
  {
    "id": "1485",
    "Sentence": "MA and MD were reversible inhibitors of <\\entity><\\entity> with competitive Ki values of 2.7 and 0.2 microM, respectively.",
    "Label": ""
  },
  {
    "id": "1487",
    "Sentence": "In cryopreserved hepatocytes incubated with <\\entity><\\entity>, time-dependent loss of CYP3A was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher <\\entity><\\entity> concentrations.",
    "Label": ""
  },
  {
    "id": "1488",
    "Sentence": "In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of <\\entity><\\entity> was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher diltiazem concentrations.",
    "Label": ""
  },
  {
    "id": "1490",
    "Sentence": "In summary, time-dependent CYP3A inactivation by <\\entity><\\entity> seems to be the major contributor responsible for the loss of CYP3A in human liver microsomes and human hepatocytes incubated with diltiazem.",
    "Label": ""
  },
  {
    "id": "1491",
    "Sentence": "In summary, time-dependent <\\entity><\\entity> inactivation by MA seems to be the major contributor responsible for the loss of <\\entity><\\entity> in human liver microsomes and human hepatocytes incubated with diltiazem.",
    "Label": ""
  },
  {
    "id": "1493",
    "Sentence": "We previously reported that microsomal inactivation kinetic parameters of <\\entity><\\entity> underpredicted CYP3A inactivation in hepatocytes.",
    "Label": ""
  },
  {
    "id": "1494",
    "Sentence": "We previously reported that microsomal inactivation kinetic parameters of diltiazem underpredicted <\\entity><\\entity> inactivation in hepatocytes.",
    "Label": ""
  },
  {
    "id": "1496",
    "Sentence": "In this study, we evaluated the contributions of inactivation and reversible inhibition of CYP3A by <\\entity><\\entity> and its N-desmethyl (MA) and N,N-didesmethyl (MD) metabolites.",
    "Label": ""
  },
  {
    "id": "1497",
    "Sentence": "In this study, we evaluated the contributions of inactivation and reversible inhibition of <\\entity><\\entity> by diltiazem and its N-desmethyl (MA) and N,N-didesmethyl (MD) metabolites.",
    "Label": ""
  },
  {
    "id": "1499",
    "Sentence": "In this study, we evaluated the contributions of inactivation and reversible inhibition of CYP3A by diltiazem and its N-desmethyl (MA) and N,N-didesmethyl (<\\entity><\\entity>) metabolites.",
    "Label": ""
  },
  {
    "id": "1500",
    "Sentence": "In this study, we evaluated the contributions of inactivation and reversible inhibition of <\\entity><\\entity> by diltiazem and its N-desmethyl (MA) and N,N-didesmethyl (MD) metabolites.",
    "Label": ""
  },
  {
    "id": "1502",
    "Sentence": "In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of CYP3A was accompanied by increased formation of MA and <\\entity><\\entity>, with the MA level similar to its K(I) at higher diltiazem concentrations.",
    "Label": ""
  },
  {
    "id": "1503",
    "Sentence": "In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of <\\entity><\\entity> was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher diltiazem concentrations.",
    "Label": ""
  },
  {
    "id": "1505",
    "Sentence": "In summary, time-dependent CYP3A inactivation by MA seems to be the major contributor responsible for the loss of CYP3A in human liver microsomes and human hepatocytes incubated with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1506",
    "Sentence": "In summary, time-dependent <\\entity><\\entity> inactivation by MA seems to be the major contributor responsible for the loss of <\\entity><\\entity> in human liver microsomes and human hepatocytes incubated with diltiazem.",
    "Label": ""
  },
  {
    "id": "1508",
    "Sentence": "In this study, we evaluated the contributions of inactivation and reversible inhibition of CYP3A by diltiazem and its N-desmethyl (<\\entity><\\entity>) and N,N-didesmethyl (MD) metabolites.",
    "Label": ""
  },
  {
    "id": "1509",
    "Sentence": "In this study, we evaluated the contributions of inactivation and reversible inhibition of <\\entity><\\entity> by diltiazem and its N-desmethyl (MA) and N,N-didesmethyl (MD) metabolites.",
    "Label": ""
  },
  {
    "id": "1511",
    "Sentence": "<\\entity><\\entity> did not inactivate CYP3A.",
    "Label": ""
  },
  {
    "id": "1512",
    "Sentence": "MD did not inactivate <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1514",
    "Sentence": "In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of CYP3A was accompanied by increased formation of <\\entity><\\entity> and MD, with the <\\entity><\\entity> level similar to its K(I) at higher diltiazem concentrations.",
    "Label": ""
  },
  {
    "id": "1515",
    "Sentence": "In cryopreserved hepatocytes incubated with diltiazem, time-dependent loss of <\\entity><\\entity> was accompanied by increased formation of MA and MD, with the MA level similar to its K(I) at higher diltiazem concentrations.",
    "Label": ""
  },
  {
    "id": "1521",
    "Sentence": "Response to <\\entity><\\entity> in a child with familial cold autoinflammatory syndrome.Familial cold auto-inflammatory syndrome, Muckle-Wells syndrome and chronic infantile neurologic, cutaneous, articular syndrome are related disorders associated with mutations in the CIAS1 gene.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1522",
    "Sentence": "Response to IL-1-receptor antagonist in a child with <\\entity><\\entity>.Familial cold auto-inflammatory syndrome, Muckle-Wells syndrome and chronic infantile neurologic, cutaneous, articular syndrome are related disorders associated with mutations in the CIAS1 gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1523",
    "Sentence": "Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome.Familial cold auto-inflammatory syndrome, <\\entity><\\entity> and chronic infantile neurologic, cutaneous, articular syndrome are related disorders associated with mutations in the CIAS1 gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1524",
    "Sentence": "Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome.Familial cold auto-inflammatory syndrome, Muckle-Wells syndrome and chronic infantile neurologic, cutaneous, articular syndrome are related disorders associated with <\\entity><\\entity> gene.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "1525",
    "Sentence": "Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome.Familial cold auto-inflammatory syndrome, Muckle-Wells syndrome and chronic infantile neurologic, cutaneous, articular syndrome are related disorders associated with <\\entity><\\entity> gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1526",
    "Sentence": "They appear to represent a continuum of one disease characterized by <\\entity><\\entity>-mediated inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1527",
    "Sentence": "Until recently, these conditions have been difficult to treat; however, with the advent of <\\entity><\\entity> therapy, many reports of successful treatment of patients with these autoinflammatory diseases have emerged in the past 2 years.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1528",
    "Sentence": "We describe an 8-year-old <\\entity><\\entity>, diagnosed with Familial cold auto-inflammatory syndrome, confirmed by presence of a novel CIAS1 mutation, who was refractory to symptomatic treatment.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1529",
    "Sentence": "We describe an 8-year-old girl, diagnosed with Familial cold auto-inflammatory syndrome, confirmed by presence of a novel <\\entity><\\entity>, who was refractory to symptomatic treatment.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "1530",
    "Sentence": "We describe an 8-year-old girl, diagnosed with Familial cold auto-inflammatory syndrome, confirmed by presence of a novel <\\entity><\\entity>, who was refractory to symptomatic treatment.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1531",
    "Sentence": "As frequent attacks of urticaria and associated arthralgia had a debilitating effect on the child's lifestyle, a trial of <\\entity><\\entity> (anakinra) was instituted.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1532",
    "Sentence": "As frequent attacks of urticaria and associated arthralgia had a debilitating effect on the child's lifestyle, a trial of IL-1-receptor antagonist (<\\entity><\\entity>) was instituted.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1533",
    "Sentence": "Dramatic sustained clinical improvement was evident within days and serum <\\entity><\\entity> and C-reactive protein levels normalized within a month.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1534",
    "Sentence": "Dramatic sustained clinical improvement was evident within days and serum amyloid and <\\entity><\\entity> levels normalized within a month.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1535",
    "Sentence": "Although several authors have reported successful use of this agent in children with chronic infantile neurologic, cutaneous, articular syndrome, we believe ours is the first report of successful treatment with <\\entity><\\entity> in a young child with familial cold auto-inflammatory syndrome.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1536",
    "Sentence": "We describe an 8-year-old <\\entity><\\entity>, diagnosed with Familial cold auto-inflammatory syndrome, confirmed by presence of a novel CIAS1 mutation, who was refractory to symptomatic treatment.",
    "Label": ""
  },
  {
    "id": "1537",
    "Sentence": "We describe an 8-year-old girl, diagnosed with Familial cold auto-inflammatory syndrome, confirmed by presence of a novel <\\entity><\\entity>, who was refractory to symptomatic treatment.",
    "Label": ""
  },
  {
    "id": "1543",
    "Sentence": "Effect of <\\entity><\\entity> on pharmacokinetics of paroxetine: the role of gut transporters.A recent in vitro study has shown that paroxetine is a substrate of P-glycoprotein.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1544",
    "Sentence": "Effect of itraconazole on pharmacokinetics of <\\entity><\\entity>: the role of gut transporters.A recent in vitro study has shown that <\\entity><\\entity> is a substrate of P-glycoprotein.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1545",
    "Sentence": "Effect of itraconazole on pharmacokinetics of paroxetine: the role of <\\entity><\\entity>.A recent in vitro study has shown that paroxetine is a substrate of P-glycoprotein.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1546",
    "Sentence": "Effect of itraconazole on pharmacokinetics of <\\entity><\\entity>: the role of gut transporters.A recent in vitro study has shown that <\\entity><\\entity> is a substrate of P-glycoprotein.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1547",
    "Sentence": "Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters.A recent in vitro study has shown that paroxetine is a substrate of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1548",
    "Sentence": "However, there was no in vivo information indicating the involvement of <\\entity><\\entity> on the pharmacokinetics of paroxetine.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1549",
    "Sentence": "However, there was no in vivo information indicating the involvement of P-glycoprotein on the pharmacokinetics of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1550",
    "Sentence": "The aim of this study was to examine the effects of <\\entity><\\entity>, a P-glycoprotein inhibitor, on the pharmacokinetics of paroxetine.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1551",
    "Sentence": "The aim of this study was to examine the effects of itraconazole, a <\\entity><\\entity>, on the pharmacokinetics of paroxetine.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1552",
    "Sentence": "The aim of this study was to examine the effects of itraconazole, a <\\entity><\\entity>, on the pharmacokinetics of paroxetine.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1553",
    "Sentence": "The aim of this study was to examine the effects of itraconazole, a P-glycoprotein inhibitor, on the pharmacokinetics of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1554",
    "Sentence": "Two 6 day courses of either 200 mg <\\entity><\\entity> daily or placebo with at least a 4 week washout period were conducted.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1555",
    "Sentence": "Thirteen volunteers took a single oral 20 mg dose of <\\entity><\\entity> on day 6 of both courses.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1556",
    "Sentence": "Plasma concentrations of <\\entity><\\entity> were monitored up to 48 hours after the dosing.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1557",
    "Sentence": "Compared with placebo, <\\entity><\\entity> treatment significantly increased the peak plasma concentration (Cmax) of paroxetine by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of paroxetine by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1558",
    "Sentence": "Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of <\\entity><\\entity> by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of <\\entity><\\entity> by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1559",
    "Sentence": "Compared with placebo, itraconazole treatment significantly increased the peak plasma concentration (Cmax) of <\\entity><\\entity> by 1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P < 0.05) and the area under the plasma concentration-time curve from zero to 48 hours [AUC (0-48)] of <\\entity><\\entity> by 1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P < 0.01).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1560",
    "Sentence": "The present study demonstrated that the bioavailability of <\\entity><\\entity> was increased by itraconazole, suggesting a possible involvement of P-glycoprotein in the pharmacokinetics of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1561",
    "Sentence": "The present study demonstrated that the bioavailability of paroxetine was increased by <\\entity><\\entity>, suggesting a possible involvement of P-glycoprotein in the pharmacokinetics of paroxetine.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1562",
    "Sentence": "The present study demonstrated that the bioavailability of paroxetine was increased by itraconazole, suggesting a possible involvement of <\\entity><\\entity> in the pharmacokinetics of paroxetine.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1563",
    "Sentence": "The present study demonstrated that the bioavailability of <\\entity><\\entity> was increased by itraconazole, suggesting a possible involvement of P-glycoprotein in the pharmacokinetics of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1564",
    "Sentence": "Effect of itraconazole on pharmacokinetics of <\\entity><\\entity>: the role of gut transporters.A recent in vitro study has shown that <\\entity><\\entity> is a substrate of P-glycoprotein.",
    "Label": ""
  },
  {
    "id": "1565",
    "Sentence": "Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters.A recent in vitro study has shown that paroxetine is a substrate of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1567",
    "Sentence": "However, there was no in vivo information indicating the involvement of P-glycoprotein on the pharmacokinetics of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1568",
    "Sentence": "However, there was no in vivo information indicating the involvement of <\\entity><\\entity> on the pharmacokinetics of paroxetine.",
    "Label": ""
  },
  {
    "id": "1570",
    "Sentence": "The present study demonstrated that the bioavailability of <\\entity><\\entity> was increased by itraconazole, suggesting a possible involvement of P-glycoprotein in the pharmacokinetics of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1571",
    "Sentence": "The present study demonstrated that the bioavailability of paroxetine was increased by itraconazole, suggesting a possible involvement of <\\entity><\\entity> in the pharmacokinetics of paroxetine.",
    "Label": ""
  },
  {
    "id": "1573",
    "Sentence": "Effect of <\\entity><\\entity> on pharmacokinetics of paroxetine: the role of gut transporters.A recent in vitro study has shown that paroxetine is a substrate of P-glycoprotein.",
    "Label": ""
  },
  {
    "id": "1574",
    "Sentence": "Effect of itraconazole on pharmacokinetics of paroxetine: the role of <\\entity><\\entity>.A recent in vitro study has shown that paroxetine is a substrate of P-glycoprotein.",
    "Label": ""
  },
  {
    "id": "1576",
    "Sentence": "Effect of itraconazole on pharmacokinetics of <\\entity><\\entity>: the role of gut transporters.A recent in vitro study has shown that <\\entity><\\entity> is a substrate of P-glycoprotein.",
    "Label": ""
  },
  {
    "id": "1577",
    "Sentence": "Effect of itraconazole on pharmacokinetics of paroxetine: the role of <\\entity><\\entity>.A recent in vitro study has shown that paroxetine is a substrate of P-glycoprotein.",
    "Label": ""
  },
  {
    "id": "1579",
    "Sentence": "The aim of this study was to examine the effects of <\\entity><\\entity>, a P-glycoprotein inhibitor, on the pharmacokinetics of paroxetine.",
    "Label": ""
  },
  {
    "id": "1580",
    "Sentence": "The aim of this study was to examine the effects of itraconazole, a <\\entity><\\entity>, on the pharmacokinetics of paroxetine.",
    "Label": ""
  },
  {
    "id": "1582",
    "Sentence": "The aim of this study was to examine the effects of itraconazole, a P-glycoprotein inhibitor, on the pharmacokinetics of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1583",
    "Sentence": "The aim of this study was to examine the effects of itraconazole, a <\\entity><\\entity>, on the pharmacokinetics of paroxetine.",
    "Label": ""
  },
  {
    "id": "1585",
    "Sentence": "The present study demonstrated that the bioavailability of paroxetine was increased by <\\entity><\\entity>, suggesting a possible involvement of P-glycoprotein in the pharmacokinetics of paroxetine.",
    "Label": ""
  },
  {
    "id": "1586",
    "Sentence": "The present study demonstrated that the bioavailability of paroxetine was increased by itraconazole, suggesting a possible involvement of <\\entity><\\entity> in the pharmacokinetics of paroxetine.",
    "Label": ""
  },
  {
    "id": "1592",
    "Sentence": "A facile lentiviral vector system for expression of <\\entity><\\entity>-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha.RNA interference (RNAi) is a powerful genetic tool for loss-of-function studies in mammalian cells and is also considered a potentially powerful therapeutic modality for the treatment of a variety of human diseases.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1593",
    "Sentence": "A facile lentiviral vector system for expression of doxycycline-inducible <\\entity><\\entity>: knockdown of the pre-miRNA processing enzyme Drosha.RNA interference (RNAi) is a powerful genetic tool for loss-of-function studies in mammalian cells and is also considered a potentially powerful therapeutic modality for the treatment of a variety of human diseases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1594",
    "Sentence": "A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-<\\entity><\\entity> processing enzyme Drosha.RNA interference (RNAi) is a powerful genetic tool for loss-of-function studies in mammalian cells and is also considered a potentially powerful therapeutic modality for the treatment of a variety of human diseases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1595",
    "Sentence": "A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme <\\entity><\\entity>.RNA interference (RNAi) is a powerful genetic tool for loss-of-function studies in mammalian cells and is also considered a potentially powerful therapeutic modality for the treatment of a variety of human diseases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1596",
    "Sentence": "A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha.<\\entity><\\entity> (RNAi) is a powerful genetic tool for loss-of-function studies in mammalian cells and is also considered a potentially powerful therapeutic modality for the treatment of a variety of human diseases.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1597",
    "Sentence": "A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha.RNA interference (<\\entity><\\entity>) is a powerful genetic tool for loss-of-function studies in mammalian cells and is also considered a potentially powerful therapeutic modality for the treatment of a variety of human diseases.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1598",
    "Sentence": "During the past 3 years a number of systems for conditional <\\entity><\\entity> have been developed that allow controlled expression of short hairpin RNA (shRNA) triggers of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1599",
    "Sentence": "During the past 3 years a number of systems for conditional RNAi have been developed that allow controlled expression of <\\entity><\\entity> (shRNA) triggers of RNAi.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1600",
    "Sentence": "During the past 3 years a number of systems for conditional RNAi have been developed that allow controlled expression of short hairpin RNA (<\\entity><\\entity>) triggers of RNAi.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1601",
    "Sentence": "During the past 3 years a number of systems for conditional <\\entity><\\entity> have been developed that allow controlled expression of short hairpin RNA (shRNA) triggers of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1602",
    "Sentence": "The simplest strategy relies on <\\entity><\\entity>-promoted shRNAs and co-expression of the tetracycline regulatory protein, TetR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1603",
    "Sentence": "The simplest strategy relies on tet-operable polymerase III-promoted <\\entity><\\entity> and co-expression of the tetracycline regulatory protein, TetR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1604",
    "Sentence": "The simplest strategy relies on tet-operable polymerase III-promoted shRNAs and co-expression of the <\\entity><\\entity>, TetR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1605",
    "Sentence": "The simplest strategy relies on tet-operable polymerase III-promoted shRNAs and co-expression of the <\\entity><\\entity>, TetR.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1606",
    "Sentence": "The simplest strategy relies on tet-operable polymerase III-promoted shRNAs and co-expression of the tetracycline regulatory protein, <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1607",
    "Sentence": "In this study we have combined these features into a single lentiviral vector that upon delivery to target cells allows robust induction of <\\entity><\\entity>, even with low levels of doxycycline; importantly, we show minimal leakiness in the absence of inducer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1608",
    "Sentence": "In this study we have combined these features into a single lentiviral vector that upon delivery to target cells allows robust induction of shRNAs, even with low levels of <\\entity><\\entity>; importantly, we show minimal leakiness in the absence of inducer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1609",
    "Sentence": "We have exploited the regulatory properties of our system by targeting an essential cellular gene, the <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1610",
    "Sentence": "We have exploited the regulatory properties of our system by targeting an essential cellular gene, the nuclear <\\entity><\\entity> Drosha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1611",
    "Sentence": "<\\entity><\\entity> is the core catalytic component of the \"microprocessor complex\" and cleaves the primary microRNA (miRNA) transcripts into their pre-miRNA hairpin intermediates.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1612",
    "Sentence": "Drosha is the core catalytic component of the \"microprocessor complex\" and cleaves the primary <\\entity><\\entity> (miRNA) transcripts into their pre-miRNA hairpin intermediates.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1613",
    "Sentence": "Drosha is the core catalytic component of the \"microprocessor complex\" and cleaves the primary microRNA (<\\entity><\\entity>) transcripts into their pre-<\\entity><\\entity> hairpin intermediates.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1614",
    "Sentence": "Drosha is the core catalytic component of the \"microprocessor complex\" and cleaves the primary microRNA (<\\entity><\\entity>) transcripts into their pre-<\\entity><\\entity> hairpin intermediates.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1615",
    "Sentence": "We anticipate that our vector will facilitate functional studies of <\\entity><\\entity> biogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1616",
    "Sentence": "During the past 3 years a number of systems for conditional <\\entity><\\entity> have been developed that allow controlled expression of short hairpin RNA (shRNA) triggers of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1617",
    "Sentence": "During the past 3 years a number of systems for conditional RNAi have been developed that allow controlled expression of <\\entity><\\entity> (shRNA) triggers of RNAi.",
    "Label": ""
  },
  {
    "id": "1619",
    "Sentence": "During the past 3 years a number of systems for conditional <\\entity><\\entity> have been developed that allow controlled expression of short hairpin RNA (shRNA) triggers of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1620",
    "Sentence": "During the past 3 years a number of systems for conditional RNAi have been developed that allow controlled expression of short hairpin RNA (<\\entity><\\entity>) triggers of RNAi.",
    "Label": ""
  },
  {
    "id": "1622",
    "Sentence": "In this study we have combined these features into a single lentiviral vector that upon delivery to target cells allows robust induction of shRNAs, even with low levels of <\\entity><\\entity>; importantly, we show minimal leakiness in the absence of inducer.",
    "Label": ""
  },
  {
    "id": "1623",
    "Sentence": "In this study we have combined these features into a single lentiviral vector that upon delivery to target cells allows robust induction of <\\entity><\\entity>, even with low levels of doxycycline; importantly, we show minimal leakiness in the absence of inducer.",
    "Label": ""
  },
  {
    "id": "1625",
    "Sentence": "A facile lentiviral vector system for expression of <\\entity><\\entity>-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha.RNA interference (RNAi) is a powerful genetic tool for loss-of-function studies in mammalian cells and is also considered a potentially powerful therapeutic modality for the treatment of a variety of human diseases.",
    "Label": ""
  },
  {
    "id": "1626",
    "Sentence": "A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme <\\entity><\\entity>.RNA interference (RNAi) is a powerful genetic tool for loss-of-function studies in mammalian cells and is also considered a potentially powerful therapeutic modality for the treatment of a variety of human diseases.",
    "Label": ""
  },
  {
    "id": "1628",
    "Sentence": "A facile lentiviral vector system for expression of <\\entity><\\entity>-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha.RNA interference (RNAi) is a powerful genetic tool for loss-of-function studies in mammalian cells and is also considered a potentially powerful therapeutic modality for the treatment of a variety of human diseases.",
    "Label": ""
  },
  {
    "id": "1629",
    "Sentence": "A facile lentiviral vector system for expression of doxycycline-inducible <\\entity><\\entity>: knockdown of the pre-miRNA processing enzyme Drosha.RNA interference (RNAi) is a powerful genetic tool for loss-of-function studies in mammalian cells and is also considered a potentially powerful therapeutic modality for the treatment of a variety of human diseases.",
    "Label": ""
  },
  {
    "id": "1631",
    "Sentence": "The simplest strategy relies on tet-operable polymerase III-promoted shRNAs and co-expression of the <\\entity><\\entity>, TetR.",
    "Label": ""
  },
  {
    "id": "1632",
    "Sentence": "The simplest strategy relies on tet-operable polymerase III-promoted shRNAs and co-expression of the tetracycline regulatory protein, <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1638",
    "Sentence": "<\\entity><\\entity> and ATR: components of an integrated circuit.The phosphatidylinositol 3-kinase-like kinases (PIKKs) <\\entity><\\entity> and ATR activate a complex signaling network in response to diverse forms of DNA damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1639",
    "Sentence": "ATM and <\\entity><\\entity>: components of an integrated circuit.The phosphatidylinositol 3-kinase-like kinases (PIKKs) ATM and <\\entity><\\entity> activate a complex signaling network in response to diverse forms of DNA damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1640",
    "Sentence": "ATM and ATR: components of an integrated circuit.The <\\entity><\\entity> (PIKKs) ATM and ATR activate a complex signaling network in response to diverse forms of DNA damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1641",
    "Sentence": "ATM and ATR: components of an integrated circuit.The phosphatidylinositol 3-kinase-like kinases (<\\entity><\\entity>) ATM and ATR activate a complex signaling network in response to diverse forms of DNA damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1642",
    "Sentence": "<\\entity><\\entity> and ATR: components of an integrated circuit.The phosphatidylinositol 3-kinase-like kinases (PIKKs) <\\entity><\\entity> and ATR activate a complex signaling network in response to diverse forms of DNA damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1643",
    "Sentence": "ATM and <\\entity><\\entity>: components of an integrated circuit.The phosphatidylinositol 3-kinase-like kinases (PIKKs) ATM and <\\entity><\\entity> activate a complex signaling network in response to diverse forms of DNA damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1644",
    "Sentence": "ATM and ATR: components of an integrated circuit.The phosphatidylinositol 3-kinase-like kinases (PIKKs) ATM and ATR activate a complex signaling network in response to diverse forms of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1645",
    "Sentence": "Initial characterization of these signaling molecules focused on the individual role that each plays in response to specific types of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1646",
    "Sentence": "<\\entity><\\entity>- and ATR-activated signaling pathways once appeared parallel, but new findings suggest that this cellular circuitry is highly interconnected.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1647",
    "Sentence": "ATM- and <\\entity><\\entity>-activated signaling pathways once appeared parallel, but new findings suggest that this cellular circuitry is highly interconnected.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1648",
    "Sentence": "Communication between <\\entity><\\entity> and ATR enables the cell to respond to DNA strand breaks and inhibition of DNA synthesis with coordinated, highly modulated outputs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1649",
    "Sentence": "Communication between ATM and <\\entity><\\entity> enables the cell to respond to DNA strand breaks and inhibition of DNA synthesis with coordinated, highly modulated outputs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1650",
    "Sentence": "ATM and <\\entity><\\entity>: components of an integrated circuit.The phosphatidylinositol 3-kinase-like kinases (PIKKs) ATM and <\\entity><\\entity> activate a complex signaling network in response to diverse forms of DNA damage.",
    "Label": ""
  },
  {
    "id": "1651",
    "Sentence": "ATM and ATR: components of an integrated circuit.The phosphatidylinositol 3-kinase-like kinases (PIKKs) ATM and ATR activate a complex signaling network in response to diverse forms of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1653",
    "Sentence": "<\\entity><\\entity> and ATR: components of an integrated circuit.The phosphatidylinositol 3-kinase-like kinases (PIKKs) <\\entity><\\entity> and ATR activate a complex signaling network in response to diverse forms of DNA damage.",
    "Label": ""
  },
  {
    "id": "1654",
    "Sentence": "ATM and ATR: components of an integrated circuit.The phosphatidylinositol 3-kinase-like kinases (PIKKs) ATM and ATR activate a complex signaling network in response to diverse forms of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1660",
    "Sentence": "Development of methods for coordinate measurement of total cell-associated and integrated <\\entity><\\entity> type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.We have adapted our established Alu PCR assay for proviral DNA and PCR for total cellular DNA to a real-time PCR format and applied these to <\\entity><\\entity> (HIV)-positive specimens collected for routine determination of the plasma viral load (pVL).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1661",
    "Sentence": "Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (<\\entity><\\entity>) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated <\\entity><\\entity> DNA may be prognostic for continued successful therapy.We have adapted our established Alu PCR assay for proviral DNA and PCR for total cellular DNA to a real-time PCR format and applied these to human immunodeficiency virus (HIV)-positive specimens collected for routine determination of the plasma viral load (pVL).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1662",
    "Sentence": "Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (<\\entity><\\entity>) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated <\\entity><\\entity> DNA may be prognostic for continued successful therapy.We have adapted our established Alu PCR assay for proviral DNA and PCR for total cellular DNA to a real-time PCR format and applied these to human immunodeficiency virus (HIV)-positive specimens collected for routine determination of the plasma viral load (pVL).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1663",
    "Sentence": "Development of methods for coordinate measurement of total cell-associated and integrated <\\entity><\\entity> type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.We have adapted our established Alu PCR assay for proviral DNA and PCR for total cellular DNA to a real-time PCR format and applied these to <\\entity><\\entity> (HIV)-positive specimens collected for routine determination of the plasma viral load (pVL).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1664",
    "Sentence": "Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (<\\entity><\\entity>-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated <\\entity><\\entity>-1 DNA may be prognostic for continued successful therapy.We have adapted our established Alu PCR assay for proviral DNA and PCR for total cellular DNA to a real-time PCR format and applied these to human immunodeficiency virus (<\\entity><\\entity>)-positive specimens collected for routine determination of the plasma viral load (pVL).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1665",
    "Sentence": "In a cohort of five patients, measurements of integrated viral load (iVL) and cell-associated viral load (cVL) in <\\entity><\\entity>(+) cells isolated by a single positive selection step were not indicative of HIV DNA levels in the circulation, and further analysis was performed on peripheral blood mononuclear cells (PBMC).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1666",
    "Sentence": "In a cohort of five patients, measurements of integrated viral load (iVL) and cell-associated viral load (cVL) in CD4(+) cells isolated by a single positive selection <\\entity><\\entity> were not indicative of HIV DNA levels in the circulation, and further analysis was performed on peripheral blood mononuclear cells (PBMC).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1667",
    "Sentence": "In a cohort of five patients, measurements of integrated viral load (iVL) and cell-associated viral load (cVL) in CD4(+) cells isolated by a single positive selection step were not indicative of <\\entity><\\entity> DNA levels in the circulation, and further analysis was performed on peripheral blood mononuclear cells (PBMC).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1668",
    "Sentence": "In a cohort of 46 samples total cVL was quantitated in most samples, but iVL could be quantitated in only 47.8%, since in 26% iVL was undetectable and in 21.7% the results were invalid due to high levels of unintegrated <\\entity><\\entity> DNA.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1669",
    "Sentence": "There was no correlation of cVL or iVL with pVL, <\\entity><\\entity> count, or duration of successful antiretroviral treatment.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1670",
    "Sentence": "These results show that cVL and iVL can be coordinately measured in PBMC from clinical samples but do not correlate with pVL, <\\entity><\\entity> counts, or length of suppressive antiretroviral therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1671",
    "Sentence": "In a cohort of five patients, measurements of integrated viral load (iVL) and cell-associated viral load (cVL) in CD4(+) cells isolated by a single positive selection <\\entity><\\entity> were not indicative of HIV DNA levels in the circulation, and further analysis was performed on peripheral blood mononuclear cells (PBMC).",
    "Label": ""
  },
  {
    "id": "1672",
    "Sentence": "In a cohort of five patients, measurements of integrated viral load (iVL) and cell-associated viral load (cVL) in CD4(+) cells isolated by a single positive selection step were not indicative of <\\entity><\\entity> DNA levels in the circulation, and further analysis was performed on peripheral blood mononuclear cells (PBMC).",
    "Label": ""
  },
  {
    "id": "1678",
    "Sentence": "Development of <\\entity><\\entity> in etanercept-treated rheumatoid arthritis patients.We report two rheumatoid arthritis patients developing <\\entity><\\entity> possibly induced by etanercept.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1679",
    "Sentence": "Development of sarcoidosis in <\\entity><\\entity>-treated rheumatoid arthritis patients.We report two rheumatoid arthritis patients developing sarcoidosis possibly induced by <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1680",
    "Sentence": "Development of sarcoidosis in etanercept-treated <\\entity><\\entity> patients.We report two <\\entity><\\entity> patients developing sarcoidosis possibly induced by etanercept.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1681",
    "Sentence": "Development of sarcoidosis in etanercept-treated <\\entity><\\entity> patients.We report two <\\entity><\\entity> patients developing sarcoidosis possibly induced by etanercept.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1682",
    "Sentence": "Development of <\\entity><\\entity> in etanercept-treated rheumatoid arthritis patients.We report two rheumatoid arthritis patients developing <\\entity><\\entity> possibly induced by etanercept.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1683",
    "Sentence": "Development of sarcoidosis in <\\entity><\\entity>-treated rheumatoid arthritis patients.We report two rheumatoid arthritis patients developing sarcoidosis possibly induced by <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1684",
    "Sentence": "Both women, aged 46 and 53, had erosive, <\\entity><\\entity> (RA) for 7 and 6 years, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1685",
    "Sentence": "Both women, aged 46 and 53, had erosive, rheumatoid-factor-positive rheumatoid arthritis (<\\entity><\\entity>) for 7 and 6 years, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1686",
    "Sentence": "The eldest had received <\\entity><\\entity> for over a year with good response, which was stopped because of a perfusion reaction.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1687",
    "Sentence": "She developed a <\\entity><\\entity> and dyspnea after 6 months of etanercept treatment.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1688",
    "Sentence": "She developed a cough and <\\entity><\\entity> after 6 months of etanercept treatment.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1689",
    "Sentence": "She developed a cough and dyspnea after 6 months of <\\entity><\\entity> treatment.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1690",
    "Sentence": "The other developed <\\entity><\\entity> and a plaque lesion on the right arm after 1 year of etanercept.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1691",
    "Sentence": "The other developed erythema nodosum and a <\\entity><\\entity> on the right arm after 1 year of etanercept.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1692",
    "Sentence": "The other developed erythema nodosum and a plaque lesion on the right arm after 1 year of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1693",
    "Sentence": "Imaging showed, in both cases, <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1694",
    "Sentence": "Biopsies were compatible with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1695",
    "Sentence": "<\\entity><\\entity> withdrawal led to a complete remission.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1696",
    "Sentence": "Recently, there have been reports of <\\entity><\\entity> in patients receiving etanercept for a variety of diseases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1697",
    "Sentence": "Recently, there have been reports of noninfectious granulomatous syndromes in patients receiving <\\entity><\\entity> for a variety of diseases.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1698",
    "Sentence": "Recently, there have been reports of noninfectious granulomatous syndromes in patients receiving etanercept for a variety of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1699",
    "Sentence": "In our cases, the temporal association with <\\entity><\\entity> therapy and the complete remission after suspension of <\\entity><\\entity> suggest a triggering role of this agent.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1700",
    "Sentence": "In our cases, the temporal association with <\\entity><\\entity> therapy and the complete remission after suspension of <\\entity><\\entity> suggest a triggering role of this agent.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1701",
    "Sentence": "Development of sarcoidosis in <\\entity><\\entity>-treated rheumatoid arthritis patients.We report two rheumatoid arthritis patients developing sarcoidosis possibly induced by <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1702",
    "Sentence": "Development of sarcoidosis in etanercept-treated <\\entity><\\entity> patients.We report two <\\entity><\\entity> patients developing sarcoidosis possibly induced by etanercept.",
    "Label": ""
  },
  {
    "id": "1704",
    "Sentence": "Development of sarcoidosis in <\\entity><\\entity>-treated rheumatoid arthritis patients.We report two rheumatoid arthritis patients developing sarcoidosis possibly induced by <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1705",
    "Sentence": "Development of <\\entity><\\entity> in etanercept-treated rheumatoid arthritis patients.We report two rheumatoid arthritis patients developing <\\entity><\\entity> possibly induced by etanercept.",
    "Label": ""
  },
  {
    "id": "1707",
    "Sentence": "Recently, there have been reports of noninfectious granulomatous syndromes in patients receiving <\\entity><\\entity> for a variety of diseases.",
    "Label": ""
  },
  {
    "id": "1708",
    "Sentence": "Recently, there have been reports of noninfectious granulomatous syndromes in patients receiving etanercept for a variety of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1710",
    "Sentence": "Recently, there have been reports of noninfectious granulomatous syndromes in patients receiving <\\entity><\\entity> for a variety of diseases.",
    "Label": ""
  },
  {
    "id": "1711",
    "Sentence": "Recently, there have been reports of <\\entity><\\entity> in patients receiving etanercept for a variety of diseases.",
    "Label": ""
  },
  {
    "id": "1713",
    "Sentence": "Development of sarcoidosis in <\\entity><\\entity>-treated rheumatoid arthritis patients.We report two rheumatoid arthritis patients developing sarcoidosis possibly induced by <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1714",
    "Sentence": "Development of <\\entity><\\entity> in etanercept-treated rheumatoid arthritis patients.We report two rheumatoid arthritis patients developing <\\entity><\\entity> possibly induced by etanercept.",
    "Label": ""
  },
  {
    "id": "1716",
    "Sentence": "The other developed erythema nodosum and a plaque lesion on the right arm after 1 year of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1717",
    "Sentence": "The other developed <\\entity><\\entity> and a plaque lesion on the right arm after 1 year of etanercept.",
    "Label": ""
  },
  {
    "id": "1719",
    "Sentence": "Development of sarcoidosis in <\\entity><\\entity>-treated rheumatoid arthritis patients.We report two rheumatoid arthritis patients developing sarcoidosis possibly induced by <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1720",
    "Sentence": "Development of sarcoidosis in etanercept-treated <\\entity><\\entity> patients.We report two <\\entity><\\entity> patients developing sarcoidosis possibly induced by etanercept.",
    "Label": ""
  },
  {
    "id": "1722",
    "Sentence": "She developed a cough and dyspnea after 6 months of <\\entity><\\entity> treatment.",
    "Label": ""
  },
  {
    "id": "1723",
    "Sentence": "She developed a <\\entity><\\entity> and dyspnea after 6 months of etanercept treatment.",
    "Label": ""
  },
  {
    "id": "1725",
    "Sentence": "She developed a cough and dyspnea after 6 months of <\\entity><\\entity> treatment.",
    "Label": ""
  },
  {
    "id": "1726",
    "Sentence": "She developed a cough and <\\entity><\\entity> after 6 months of etanercept treatment.",
    "Label": ""
  },
  {
    "id": "1728",
    "Sentence": "The other developed erythema nodosum and a plaque lesion on the right arm after 1 year of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1729",
    "Sentence": "The other developed erythema nodosum and a <\\entity><\\entity> on the right arm after 1 year of etanercept.",
    "Label": ""
  },
  {
    "id": "1735",
    "Sentence": "<\\entity><\\entity> inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1736",
    "Sentence": "Flavonoids inhibit <\\entity><\\entity>-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), <\\entity><\\entity> (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1737",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: <\\entity><\\entity> (ABC) transporters, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1738",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (<\\entity><\\entity>, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1739",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (<\\entity><\\entity>, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1740",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (ABC) transporters, such as <\\entity><\\entity> (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1741",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (<\\entity><\\entity>), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1742",
    "Sentence": "Flavonoids inhibit <\\entity><\\entity>-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), <\\entity><\\entity> (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1743",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), breast cancer resistance protein (<\\entity><\\entity>), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1744",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and <\\entity><\\entity> (MRP1), confer resistance to various anticancer agents.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1745",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (<\\entity><\\entity>), confer resistance to various anticancer agents.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1746",
    "Sentence": "We previously reported that some <\\entity><\\entity> have BCRP-inhibitory activity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1747",
    "Sentence": "We previously reported that some flavonoids have <\\entity><\\entity>-inhibitory activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1748",
    "Sentence": "Here we show the reversal effects of an extensive panel of <\\entity><\\entity> upon BCRP-, P-gp-, and MRP1-mediated drug resistance.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1749",
    "Sentence": "Here we show the reversal effects of an extensive panel of flavonoids upon <\\entity><\\entity>-, P-gp-, and MRP1-mediated drug resistance.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1750",
    "Sentence": "Here we show the reversal effects of an extensive panel of flavonoids upon BCRP-, <\\entity><\\entity>-, and MRP1-mediated drug resistance.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1751",
    "Sentence": "Here we show the reversal effects of an extensive panel of flavonoids upon BCRP-, P-gp-, and <\\entity><\\entity>-mediated drug resistance.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1752",
    "Sentence": "METHODS: Reversal effects of <\\entity><\\entity> upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1753",
    "Sentence": "METHODS: Reversal effects of flavonoids upon <\\entity><\\entity>-, P-gp-, or MRP1-mediated drug resistance were examined in the <\\entity><\\entity>- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1754",
    "Sentence": "METHODS: Reversal effects of flavonoids upon BCRP-, <\\entity><\\entity>-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1755",
    "Sentence": "METHODS: Reversal effects of flavonoids upon BCRP-, P-gp-, or <\\entity><\\entity>-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the <\\entity><\\entity>-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1756",
    "Sentence": "METHODS: Reversal effects of flavonoids upon <\\entity><\\entity>-, P-gp-, or MRP1-mediated drug resistance were examined in the <\\entity><\\entity>- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1757",
    "Sentence": "METHODS: Reversal effects of flavonoids upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or <\\entity><\\entity>-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1758",
    "Sentence": "The reversal of <\\entity><\\entity> activity was tested by measuring the fluorescence of intracellular topotecan.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1759",
    "Sentence": "The reversal of BCRP activity was tested by measuring the fluorescence of intracellular <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1760",
    "Sentence": "RESULTS: The <\\entity><\\entity>-inhibitory activity of 32 compounds was screened, and 20 were found to be active.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1761",
    "Sentence": "Among these active compounds, <\\entity><\\entity> showed the strongest anti-BCRP activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for mitoxantrone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1762",
    "Sentence": "Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-<\\entity><\\entity> activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for mitoxantrone.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1763",
    "Sentence": "Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-BCRP activity with RI(50) values of 0.012 microM for <\\entity><\\entity> and 0.044 muM for mitoxantrone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1764",
    "Sentence": "Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-BCRP activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1765",
    "Sentence": "We next examined the effects of a panel of 11 compounds on <\\entity><\\entity>- and MRP1-mediated drug resistance.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1766",
    "Sentence": "We next examined the effects of a panel of 11 compounds on P-gp- and <\\entity><\\entity>-mediated drug resistance.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1767",
    "Sentence": "Two of the flavones, <\\entity><\\entity> and acacetin, showed only low anti-P-gp activity, with the remainder displaying no suppressive effects against P-gp.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1768",
    "Sentence": "Two of the flavones, 3',4',7-trimethoxyflavone and <\\entity><\\entity>, showed only low anti-P-gp activity, with the remainder displaying no suppressive effects against P-gp.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1769",
    "Sentence": "Two of the flavones, 3',4',7-trimethoxyflavone and acacetin, showed only low anti-<\\entity><\\entity> activity, with the remainder displaying no suppressive effects against <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1770",
    "Sentence": "Two of the flavones, 3',4',7-trimethoxyflavone and acacetin, showed only low anti-<\\entity><\\entity> activity, with the remainder displaying no suppressive effects against <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1771",
    "Sentence": "None of the <\\entity><\\entity> that we tested inhibited MRP1.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1772",
    "Sentence": "None of the flavonoids that we tested inhibited <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1773",
    "Sentence": "CONCLUSION: Our present results thus indicate that many <\\entity><\\entity> selectively inhibit BCRP only.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1774",
    "Sentence": "CONCLUSION: Our present results thus indicate that many flavonoids selectively inhibit <\\entity><\\entity> only.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1775",
    "Sentence": "Moreover, we examined the structure-<\\entity><\\entity> inhibitory activity relationship from our current study.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1776",
    "Sentence": "<\\entity><\\entity> inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": ""
  },
  {
    "id": "1777",
    "Sentence": "Flavonoids inhibit <\\entity><\\entity>-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), <\\entity><\\entity> (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": ""
  },
  {
    "id": "1779",
    "Sentence": "We previously reported that some <\\entity><\\entity> have BCRP-inhibitory activity.",
    "Label": ""
  },
  {
    "id": "1780",
    "Sentence": "We previously reported that some flavonoids have <\\entity><\\entity>-inhibitory activity.",
    "Label": ""
  },
  {
    "id": "1782",
    "Sentence": "Here we show the reversal effects of an extensive panel of <\\entity><\\entity> upon BCRP-, P-gp-, and MRP1-mediated drug resistance.",
    "Label": ""
  },
  {
    "id": "1783",
    "Sentence": "Here we show the reversal effects of an extensive panel of flavonoids upon BCRP-, P-gp-, and <\\entity><\\entity>-mediated drug resistance.",
    "Label": ""
  },
  {
    "id": "1785",
    "Sentence": "Here we show the reversal effects of an extensive panel of <\\entity><\\entity> upon BCRP-, P-gp-, and MRP1-mediated drug resistance.",
    "Label": ""
  },
  {
    "id": "1786",
    "Sentence": "Here we show the reversal effects of an extensive panel of flavonoids upon <\\entity><\\entity>-, P-gp-, and MRP1-mediated drug resistance.",
    "Label": ""
  },
  {
    "id": "1788",
    "Sentence": "Here we show the reversal effects of an extensive panel of <\\entity><\\entity> upon BCRP-, P-gp-, and MRP1-mediated drug resistance.",
    "Label": ""
  },
  {
    "id": "1789",
    "Sentence": "Here we show the reversal effects of an extensive panel of flavonoids upon BCRP-, <\\entity><\\entity>-, and MRP1-mediated drug resistance.",
    "Label": ""
  },
  {
    "id": "1791",
    "Sentence": "The reversal of BCRP activity was tested by measuring the fluorescence of intracellular <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1792",
    "Sentence": "The reversal of <\\entity><\\entity> activity was tested by measuring the fluorescence of intracellular topotecan.",
    "Label": ""
  },
  {
    "id": "1794",
    "Sentence": "Among these active compounds, <\\entity><\\entity> showed the strongest anti-BCRP activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for mitoxantrone.",
    "Label": ""
  },
  {
    "id": "1795",
    "Sentence": "Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-<\\entity><\\entity> activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for mitoxantrone.",
    "Label": ""
  },
  {
    "id": "1797",
    "Sentence": "Two of the flavones, <\\entity><\\entity> and acacetin, showed only low anti-P-gp activity, with the remainder displaying no suppressive effects against P-gp.",
    "Label": ""
  },
  {
    "id": "1798",
    "Sentence": "Two of the flavones, 3',4',7-trimethoxyflavone and acacetin, showed only low anti-<\\entity><\\entity> activity, with the remainder displaying no suppressive effects against <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1800",
    "Sentence": "Two of the flavones, 3',4',7-trimethoxyflavone and <\\entity><\\entity>, showed only low anti-P-gp activity, with the remainder displaying no suppressive effects against P-gp.",
    "Label": ""
  },
  {
    "id": "1801",
    "Sentence": "Two of the flavones, 3',4',7-trimethoxyflavone and acacetin, showed only low anti-<\\entity><\\entity> activity, with the remainder displaying no suppressive effects against <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1803",
    "Sentence": "None of the <\\entity><\\entity> that we tested inhibited MRP1.",
    "Label": ""
  },
  {
    "id": "1804",
    "Sentence": "None of the flavonoids that we tested inhibited <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1806",
    "Sentence": "CONCLUSION: Our present results thus indicate that many <\\entity><\\entity> selectively inhibit BCRP only.",
    "Label": ""
  },
  {
    "id": "1807",
    "Sentence": "CONCLUSION: Our present results thus indicate that many flavonoids selectively inhibit <\\entity><\\entity> only.",
    "Label": ""
  },
  {
    "id": "1809",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (<\\entity><\\entity>, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": ""
  },
  {
    "id": "1810",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), breast cancer resistance protein (<\\entity><\\entity>), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": ""
  },
  {
    "id": "1812",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (<\\entity><\\entity>, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": ""
  },
  {
    "id": "1813",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (<\\entity><\\entity>), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": ""
  },
  {
    "id": "1815",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (<\\entity><\\entity>, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": ""
  },
  {
    "id": "1816",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and <\\entity><\\entity> (MRP1), confer resistance to various anticancer agents.",
    "Label": ""
  },
  {
    "id": "1818",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (<\\entity><\\entity>, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (MRP1), confer resistance to various anticancer agents.",
    "Label": ""
  },
  {
    "id": "1819",
    "Sentence": "Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.PURPOSE: ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-related protein 1 (<\\entity><\\entity>), confer resistance to various anticancer agents.",
    "Label": ""
  },
  {
    "id": "1821",
    "Sentence": "METHODS: Reversal effects of <\\entity><\\entity> upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.",
    "Label": ""
  },
  {
    "id": "1822",
    "Sentence": "METHODS: Reversal effects of flavonoids upon BCRP-, P-gp-, or <\\entity><\\entity>-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the <\\entity><\\entity>-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.",
    "Label": ""
  },
  {
    "id": "1824",
    "Sentence": "METHODS: Reversal effects of <\\entity><\\entity> upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.",
    "Label": ""
  },
  {
    "id": "1825",
    "Sentence": "METHODS: Reversal effects of flavonoids upon <\\entity><\\entity>-, P-gp-, or MRP1-mediated drug resistance were examined in the <\\entity><\\entity>- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.",
    "Label": ""
  },
  {
    "id": "1827",
    "Sentence": "METHODS: Reversal effects of <\\entity><\\entity> upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.",
    "Label": ""
  },
  {
    "id": "1828",
    "Sentence": "METHODS: Reversal effects of flavonoids upon BCRP-, <\\entity><\\entity>-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.",
    "Label": ""
  },
  {
    "id": "1830",
    "Sentence": "METHODS: Reversal effects of <\\entity><\\entity> upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or MDR1-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.",
    "Label": ""
  },
  {
    "id": "1831",
    "Sentence": "METHODS: Reversal effects of flavonoids upon BCRP-, P-gp-, or MRP1-mediated drug resistance were examined in the BCRP- or <\\entity><\\entity>-transduced human leukemia K562 cells or in the MRP1-transfected human epidermoid carcinoma KB-3-1 cells using cell growth inhibition assays.",
    "Label": ""
  },
  {
    "id": "1833",
    "Sentence": "Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-BCRP activity with RI(50) values of 0.012 microM for <\\entity><\\entity> and 0.044 muM for mitoxantrone.",
    "Label": ""
  },
  {
    "id": "1834",
    "Sentence": "Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-<\\entity><\\entity> activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for mitoxantrone.",
    "Label": ""
  },
  {
    "id": "1836",
    "Sentence": "Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-BCRP activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1837",
    "Sentence": "Among these active compounds, 3',4',7-trimethoxyflavone showed the strongest anti-<\\entity><\\entity> activity with RI(50) values of 0.012 microM for SN-38 and 0.044 muM for mitoxantrone.",
    "Label": ""
  },
  {
    "id": "1839",
    "Sentence": "Two of the flavones, <\\entity><\\entity> and acacetin, showed only low anti-P-gp activity, with the remainder displaying no suppressive effects against P-gp.",
    "Label": ""
  },
  {
    "id": "1840",
    "Sentence": "Two of the flavones, 3',4',7-trimethoxyflavone and acacetin, showed only low anti-<\\entity><\\entity> activity, with the remainder displaying no suppressive effects against <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1842",
    "Sentence": "Two of the flavones, 3',4',7-trimethoxyflavone and <\\entity><\\entity>, showed only low anti-P-gp activity, with the remainder displaying no suppressive effects against P-gp.",
    "Label": ""
  },
  {
    "id": "1843",
    "Sentence": "Two of the flavones, 3',4',7-trimethoxyflavone and acacetin, showed only low anti-<\\entity><\\entity> activity, with the remainder displaying no suppressive effects against <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "1849",
    "Sentence": "An open multicenter phase II trial of weekly <\\entity><\\entity> for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly <\\entity><\\entity> monotherapy in frail elderly patients with advanced-stage non-small-cell lung cancer, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1850",
    "Sentence": "An open multicenter phase II trial of weekly docetaxel for <\\entity><\\entity> in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly docetaxel monotherapy in frail elderly patients with <\\entity><\\entity>, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1851",
    "Sentence": "An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or <\\entity><\\entity>: The GFPC 02-02b study.CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly docetaxel monotherapy in frail elderly patients with advanced-stage non-small-cell lung cancer, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1852",
    "Sentence": "An open multicenter phase II trial of weekly <\\entity><\\entity> for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly <\\entity><\\entity> monotherapy in frail elderly patients with advanced-stage non-small-cell lung cancer, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1853",
    "Sentence": "An open multicenter phase II trial of weekly docetaxel for <\\entity><\\entity> in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly docetaxel monotherapy in frail elderly patients with <\\entity><\\entity>, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1854",
    "Sentence": "An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly docetaxel monotherapy in frail elderly patients with advanced-stage non-small-cell lung cancer, selected on the basis of their precise age, general condition, and number of <\\entity><\\entity> (Charlson score).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1855",
    "Sentence": "METHODS: Analysis of the response rate, toxicity, quality of life, median survival and 1-year survival rates after 1-3 six-week cycles of <\\entity><\\entity> 30mg/m(2) weekly.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1856",
    "Sentence": "The main grade 3-4 toxicity was <\\entity><\\entity> (30%).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1857",
    "Sentence": "CONCLUSION: In frail elderly patients selected on the basis of their age, general condition and comorbidity, weekly <\\entity><\\entity> monotherapy has acceptable toxicity and does not negatively affect quality of life.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1858",
    "Sentence": "An open multicenter phase II trial of weekly <\\entity><\\entity> for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly <\\entity><\\entity> monotherapy in frail elderly patients with advanced-stage non-small-cell lung cancer, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score).",
    "Label": ""
  },
  {
    "id": "1859",
    "Sentence": "An open multicenter phase II trial of weekly docetaxel for <\\entity><\\entity> in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly docetaxel monotherapy in frail elderly patients with <\\entity><\\entity>, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score).",
    "Label": ""
  },
  {
    "id": "1861",
    "Sentence": "An open multicenter phase II trial of weekly <\\entity><\\entity> for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly <\\entity><\\entity> monotherapy in frail elderly patients with advanced-stage non-small-cell lung cancer, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score).",
    "Label": ""
  },
  {
    "id": "1862",
    "Sentence": "An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or <\\entity><\\entity>: The GFPC 02-02b study.CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly docetaxel monotherapy in frail elderly patients with advanced-stage non-small-cell lung cancer, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score).",
    "Label": ""
  },
  {
    "id": "1864",
    "Sentence": "An open multicenter phase II trial of weekly <\\entity><\\entity> for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly <\\entity><\\entity> monotherapy in frail elderly patients with advanced-stage non-small-cell lung cancer, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score).",
    "Label": ""
  },
  {
    "id": "1865",
    "Sentence": "An open multicenter phase II trial of weekly docetaxel for <\\entity><\\entity> in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly docetaxel monotherapy in frail elderly patients with <\\entity><\\entity>, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score).",
    "Label": ""
  },
  {
    "id": "1867",
    "Sentence": "An open multicenter phase II trial of weekly <\\entity><\\entity> for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly <\\entity><\\entity> monotherapy in frail elderly patients with advanced-stage non-small-cell lung cancer, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score).",
    "Label": ""
  },
  {
    "id": "1868",
    "Sentence": "An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly docetaxel monotherapy in frail elderly patients with advanced-stage non-small-cell lung cancer, selected on the basis of their precise age, general condition, and number of <\\entity><\\entity> (Charlson score).",
    "Label": ""
  },
  {
    "id": "1874",
    "Sentence": "Use of a novel and highly selective <\\entity><\\entity> to characterize uterine contractions in the rat.Spontaneous and induced uterine contractions in the rat were found to be inhibited by a novel and selective <\\entity><\\entity> GSK221149A (3R,6R)-3-Indan-2-yl-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1875",
    "Sentence": "Use of a novel and highly selective <\\entity><\\entity> to characterize uterine contractions in the rat.Spontaneous and induced uterine contractions in the rat were found to be inhibited by a novel and selective <\\entity><\\entity> GSK221149A (3R,6R)-3-Indan-2-yl-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1876",
    "Sentence": "Use of a novel and highly selective <\\entity><\\entity> to characterize uterine contractions in the rat.Spontaneous and induced uterine contractions in the rat were found to be inhibited by a novel and selective <\\entity><\\entity> GSK221149A (3R,6R)-3-Indan-2-yl-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1877",
    "Sentence": "Use of a novel and highly selective <\\entity><\\entity> to characterize uterine contractions in the rat.Spontaneous and induced uterine contractions in the rat were found to be inhibited by a novel and selective <\\entity><\\entity> GSK221149A (3R,6R)-3-Indan-2-yl-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1878",
    "Sentence": "Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.Spontaneous and induced uterine contractions in the rat were found to be inhibited by a novel and selective oxytocin receptor antagonist <\\entity><\\entity> (3R,6R)-3-Indan-2-yl-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1879",
    "Sentence": "Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.Spontaneous and induced uterine contractions in the rat were found to be inhibited by a novel and selective oxytocin receptor antagonist GSK221149A <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1880",
    "Sentence": "<\\entity><\\entity> displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant oxytocin receptors with >1,400-fold selectivity over human V1a, V1b, and V2 receptors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1881",
    "Sentence": "GSK221149A displayed nanomolar affinity (K(i) = 0.65 nM) for <\\entity><\\entity> with >1,400-fold selectivity over human V1a, V1b, and V2 receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1882",
    "Sentence": "GSK221149A displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant <\\entity><\\entity> receptors with >1,400-fold selectivity over human V1a, V1b, and V2 receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1883",
    "Sentence": "GSK221149A displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant oxytocin receptors with >1,400-fold selectivity over human <\\entity><\\entity>, V1b, and V2 receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1884",
    "Sentence": "GSK221149A displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant oxytocin receptors with >1,400-fold selectivity over human V1a, <\\entity><\\entity>, and V2 receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1885",
    "Sentence": "GSK221149A displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant oxytocin receptors with >1,400-fold selectivity over human V1a, V1b, and <\\entity><\\entity> receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1886",
    "Sentence": "<\\entity><\\entity> had similar affinity (K(i) = 4.1 nM) and selectivity for native oxytocin receptors from rat and produced a functional, competitive block of oxytocin-induced contractions in isolated rat myometrial strips with a pA(2) value of 8.18.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1887",
    "Sentence": "GSK221149A had similar affinity (K(i) = 4.1 nM) and selectivity for <\\entity><\\entity> and produced a functional, competitive block of oxytocin-induced contractions in isolated rat myometrial strips with a pA(2) value of 8.18.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1888",
    "Sentence": "GSK221149A had similar affinity (K(i) = 4.1 nM) and selectivity for native <\\entity><\\entity> receptors from rat and produced a functional, competitive block of <\\entity><\\entity>-induced contractions in isolated rat myometrial strips with a pA(2) value of 8.18.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1889",
    "Sentence": "GSK221149A had similar affinity (K(i) = 4.1 nM) and selectivity for native <\\entity><\\entity> receptors from rat and produced a functional, competitive block of <\\entity><\\entity>-induced contractions in isolated rat myometrial strips with a pA(2) value of 8.18.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1890",
    "Sentence": "Intravenous administration of <\\entity><\\entity> produced a dose-dependent decrease in oxytocin-induced uterine contractions in anesthetized rats with an ID(50) = 0.27 +/- 0.60 mg/kg (corresponding plasma concentrations were 88 ng/ml).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1891",
    "Sentence": "Intravenous administration of GSK221149A produced a dose-dependent decrease in <\\entity><\\entity>-induced uterine contractions in anesthetized rats with an ID(50) = 0.27 +/- 0.60 mg/kg (corresponding plasma concentrations were 88 ng/ml).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1892",
    "Sentence": "Oral administration of <\\entity><\\entity> (5 mg/kg) was effective in inhibiting oxytocin-induced uterine contractions after single and multiple (4-day) dosing.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1893",
    "Sentence": "Oral administration of GSK221149A (5 mg/kg) was effective in inhibiting <\\entity><\\entity>-induced uterine contractions after single and multiple (4-day) dosing.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1894",
    "Sentence": "Spontaneous uterine contractions in late-term pregnant rats (19-21 days gestation) were significantly reduced by intravenous administration of 0.3 mg/kg of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1895",
    "Sentence": "These results provide further evidence that selective <\\entity><\\entity> antagonism may offer an effective treatment for preterm labor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1896",
    "Sentence": "<\\entity><\\entity> displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant oxytocin receptors with >1,400-fold selectivity over human V1a, V1b, and V2 receptors.",
    "Label": ""
  },
  {
    "id": "1897",
    "Sentence": "GSK221149A displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant oxytocin receptors with >1,400-fold selectivity over human <\\entity><\\entity>, V1b, and V2 receptors.",
    "Label": ""
  },
  {
    "id": "1899",
    "Sentence": "<\\entity><\\entity> displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant oxytocin receptors with >1,400-fold selectivity over human V1a, V1b, and V2 receptors.",
    "Label": ""
  },
  {
    "id": "1900",
    "Sentence": "GSK221149A displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant oxytocin receptors with >1,400-fold selectivity over human V1a, <\\entity><\\entity>, and V2 receptors.",
    "Label": ""
  },
  {
    "id": "1902",
    "Sentence": "<\\entity><\\entity> displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant oxytocin receptors with >1,400-fold selectivity over human V1a, V1b, and V2 receptors.",
    "Label": ""
  },
  {
    "id": "1903",
    "Sentence": "GSK221149A displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant oxytocin receptors with >1,400-fold selectivity over human V1a, V1b, and <\\entity><\\entity> receptors.",
    "Label": ""
  },
  {
    "id": "1905",
    "Sentence": "<\\entity><\\entity> displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant oxytocin receptors with >1,400-fold selectivity over human V1a, V1b, and V2 receptors.",
    "Label": ""
  },
  {
    "id": "1906",
    "Sentence": "GSK221149A displayed nanomolar affinity (K(i) = 0.65 nM) for <\\entity><\\entity> with >1,400-fold selectivity over human V1a, V1b, and V2 receptors.",
    "Label": ""
  },
  {
    "id": "1908",
    "Sentence": "<\\entity><\\entity> had similar affinity (K(i) = 4.1 nM) and selectivity for native oxytocin receptors from rat and produced a functional, competitive block of oxytocin-induced contractions in isolated rat myometrial strips with a pA(2) value of 8.18.",
    "Label": ""
  },
  {
    "id": "1909",
    "Sentence": "GSK221149A had similar affinity (K(i) = 4.1 nM) and selectivity for native <\\entity><\\entity> receptors from rat and produced a functional, competitive block of <\\entity><\\entity>-induced contractions in isolated rat myometrial strips with a pA(2) value of 8.18.",
    "Label": ""
  },
  {
    "id": "1911",
    "Sentence": "<\\entity><\\entity> had similar affinity (K(i) = 4.1 nM) and selectivity for native oxytocin receptors from rat and produced a functional, competitive block of oxytocin-induced contractions in isolated rat myometrial strips with a pA(2) value of 8.18.",
    "Label": ""
  },
  {
    "id": "1912",
    "Sentence": "GSK221149A had similar affinity (K(i) = 4.1 nM) and selectivity for <\\entity><\\entity> and produced a functional, competitive block of oxytocin-induced contractions in isolated rat myometrial strips with a pA(2) value of 8.18.",
    "Label": ""
  },
  {
    "id": "1914",
    "Sentence": "Intravenous administration of <\\entity><\\entity> produced a dose-dependent decrease in oxytocin-induced uterine contractions in anesthetized rats with an ID(50) = 0.27 +/- 0.60 mg/kg (corresponding plasma concentrations were 88 ng/ml).",
    "Label": ""
  },
  {
    "id": "1915",
    "Sentence": "Intravenous administration of GSK221149A produced a dose-dependent decrease in <\\entity><\\entity>-induced uterine contractions in anesthetized rats with an ID(50) = 0.27 +/- 0.60 mg/kg (corresponding plasma concentrations were 88 ng/ml).",
    "Label": ""
  },
  {
    "id": "1917",
    "Sentence": "Oral administration of <\\entity><\\entity> (5 mg/kg) was effective in inhibiting oxytocin-induced uterine contractions after single and multiple (4-day) dosing.",
    "Label": ""
  },
  {
    "id": "1918",
    "Sentence": "Oral administration of GSK221149A (5 mg/kg) was effective in inhibiting <\\entity><\\entity>-induced uterine contractions after single and multiple (4-day) dosing.",
    "Label": ""
  },
  {
    "id": "1920",
    "Sentence": "Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.Spontaneous and induced uterine contractions in the rat were found to be inhibited by a novel and selective oxytocin receptor antagonist <\\entity><\\entity> (3R,6R)-3-Indan-2-yl-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione.",
    "Label": ""
  },
  {
    "id": "1921",
    "Sentence": "Use of a novel and highly selective <\\entity><\\entity> to characterize uterine contractions in the rat.Spontaneous and induced uterine contractions in the rat were found to be inhibited by a novel and selective <\\entity><\\entity> GSK221149A (3R,6R)-3-Indan-2-yl-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione.",
    "Label": ""
  },
  {
    "id": "1923",
    "Sentence": "<\\entity><\\entity> had similar affinity (K(i) = 4.1 nM) and selectivity for native oxytocin receptors from rat and produced a functional, competitive block of oxytocin-induced contractions in isolated rat myometrial strips with a pA(2) value of 8.18.",
    "Label": ""
  },
  {
    "id": "1924",
    "Sentence": "GSK221149A had similar affinity (K(i) = 4.1 nM) and selectivity for native <\\entity><\\entity> receptors from rat and produced a functional, competitive block of <\\entity><\\entity>-induced contractions in isolated rat myometrial strips with a pA(2) value of 8.18.",
    "Label": ""
  },
  {
    "id": "1926",
    "Sentence": "<\\entity><\\entity> displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant oxytocin receptors with >1,400-fold selectivity over human V1a, V1b, and V2 receptors.",
    "Label": ""
  },
  {
    "id": "1927",
    "Sentence": "GSK221149A displayed nanomolar affinity (K(i) = 0.65 nM) for human recombinant <\\entity><\\entity> receptors with >1,400-fold selectivity over human V1a, V1b, and V2 receptors.",
    "Label": ""
  },
  {
    "id": "1933",
    "Sentence": "<\\entity><\\entity>: in Crohn's disease.<\\entity><\\entity> is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1934",
    "Sentence": "<\\entity><\\entity>: in Crohn's disease.<\\entity><\\entity> is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1935",
    "Sentence": "Adalimumab: in Crohn's disease.Adalimumab is a <\\entity><\\entity> specific for human tumor necrosis factor (TNF).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1936",
    "Sentence": "Adalimumab: in Crohn's disease.Adalimumab is a subcutaneously administered, recombinant, human <\\entity><\\entity> monoclonal antibody specific for human tumor necrosis factor (TNF).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1937",
    "Sentence": "Adalimumab: in Crohn's disease.Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human <\\entity><\\entity> (TNF).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1938",
    "Sentence": "Adalimumab: in Crohn's disease.Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1939",
    "Sentence": "The clinical efficacy and safety of <\\entity><\\entity> in patients with moderate to severe Crohn's disease has been demonstrated in four pivotal, randomized, double-blind trials (CLASSIC-I, GAIN, CHARM, and CLASSIC-II) that included a total of >1400 patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1940",
    "Sentence": "In the CLASSIC-I trial, <\\entity><\\entity> was significantly more effective than placebo for induction of remission in patients who had not previously received anti-TNF therapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1941",
    "Sentence": "In the CLASSIC-I trial, adalimumab was significantly more effective than placebo for induction of remission in patients who had not previously received anti-<\\entity><\\entity> therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1942",
    "Sentence": "<\\entity><\\entity> was also more effective than placebo for induction of remission in the GAIN study in patients who had either lost responsiveness or developed intolerance to infliximab.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1943",
    "Sentence": "Adalimumab was also more effective than placebo for induction of remission in the GAIN study in patients who had either lost responsiveness or developed intolerance to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1944",
    "Sentence": "The CHARM trial showed that, among patients who responded to open-label <\\entity><\\entity> induction, maintenance therapy with <\\entity><\\entity> 40 mg weekly or every other week for up to 1 year was associated with significantly greater remission rates than placebo at weeks 26 and 56.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1945",
    "Sentence": "The CHARM trial showed that, among patients who responded to open-label <\\entity><\\entity> induction, maintenance therapy with <\\entity><\\entity> 40 mg weekly or every other week for up to 1 year was associated with significantly greater remission rates than placebo at weeks 26 and 56.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1946",
    "Sentence": "In addition, significantly more <\\entity><\\entity> than placebo recipients achieved corticosteroid-free remission and had complete fistula closure.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1947",
    "Sentence": "In addition, significantly more adalimumab than placebo recipients achieved <\\entity><\\entity>-free remission and had complete fistula closure.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1948",
    "Sentence": "In CLASSIC-II, an extension of the CLASSIC-I trial, patients who were in remission after a short course of <\\entity><\\entity> and were randomized to receive up to 1 year's treatment with <\\entity><\\entity> 40 mg weekly or every other week were significantly more likely to remain in remission than those randomized to receive placebo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1949",
    "Sentence": "In CLASSIC-II, an extension of the CLASSIC-I trial, patients who were in remission after a short course of <\\entity><\\entity> and were randomized to receive up to 1 year's treatment with <\\entity><\\entity> 40 mg weekly or every other week were significantly more likely to remain in remission than those randomized to receive placebo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1950",
    "Sentence": "In general, the tolerability profile of <\\entity><\\entity> in patients with Crohn's disease was similar to that in patients with rheumatoid arthritis or other approved indications.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "1951",
    "Sentence": "<\\entity><\\entity>: in Crohn's disease.<\\entity><\\entity> is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF).",
    "Label": ""
  },
  {
    "id": "1952",
    "Sentence": "Adalimumab: in Crohn's disease.Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "1954",
    "Sentence": "Adalimumab: in Crohn's disease.Adalimumab is a <\\entity><\\entity> specific for human tumor necrosis factor (TNF).",
    "Label": ""
  },
  {
    "id": "1955",
    "Sentence": "Adalimumab: in Crohn's disease.Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "1957",
    "Sentence": "<\\entity><\\entity>: in Crohn's disease.<\\entity><\\entity> is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF).",
    "Label": ""
  },
  {
    "id": "1958",
    "Sentence": "Adalimumab: in Crohn's disease.Adalimumab is a subcutaneously administered, recombinant, human <\\entity><\\entity> monoclonal antibody specific for human tumor necrosis factor (TNF).",
    "Label": ""
  },
  {
    "id": "1960",
    "Sentence": "<\\entity><\\entity>: in Crohn's disease.<\\entity><\\entity> is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF).",
    "Label": ""
  },
  {
    "id": "1961",
    "Sentence": "Adalimumab: in Crohn's disease.Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human <\\entity><\\entity> (TNF).",
    "Label": ""
  },
  {
    "id": "1963",
    "Sentence": "In the CLASSIC-I trial, <\\entity><\\entity> was significantly more effective than placebo for induction of remission in patients who had not previously received anti-TNF therapy.",
    "Label": ""
  },
  {
    "id": "1964",
    "Sentence": "In the CLASSIC-I trial, adalimumab was significantly more effective than placebo for induction of remission in patients who had not previously received anti-<\\entity><\\entity> therapy.",
    "Label": ""
  },
  {
    "id": "1970",
    "Sentence": "Characterization of <\\entity><\\entity> carried by atypical enteropathogenic Escherichia coli.Atypical enteropathogenic Escherichia coli (EPEC) comprise an important group of paediatric pathogens.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1971",
    "Sentence": "Characterization of tccP2 carried by atypical enteropathogenic <\\entity><\\entity> coli.Atypical enteropathogenic <\\entity><\\entity> coli (EPEC) comprise an important group of paediatric pathogens.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1972",
    "Sentence": "Characterization of tccP2 carried by atypical enteropathogenic <\\entity><\\entity> coli.Atypical enteropathogenic <\\entity><\\entity> coli (EPEC) comprise an important group of paediatric pathogens.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1973",
    "Sentence": "Characterization of tccP2 carried by atypical enteropathogenic Escherichia coli.Atypical enteropathogenic Escherichia coli (<\\entity><\\entity>) comprise an important group of paediatric pathogens.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1974",
    "Sentence": "Atypical <\\entity><\\entity> have reservoirs in farm and domestic animals where they can be either commensal or pathogenic; serogroup O26 is dominant in humans and animals.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1975",
    "Sentence": "Central to intestinal colonization by <\\entity><\\entity> is the translocation of the type III secretion system effector Tir into enterocytes, which following phosphorylation (Tir-Yp) recruits Nck to activate the N-WASP actin signalling cascade.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1976",
    "Sentence": "Central to intestinal colonization by EPEC is the <\\entity><\\entity> of the type III secretion system effector Tir into enterocytes, which following phosphorylation (Tir-Yp) recruits Nck to activate the N-WASP actin signalling cascade.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1977",
    "Sentence": "Central to intestinal colonization by EPEC is the translocation of the <\\entity><\\entity> Tir into enterocytes, which following phosphorylation (Tir-Yp) recruits Nck to activate the N-WASP actin signalling cascade.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1978",
    "Sentence": "Central to intestinal colonization by EPEC is the translocation of the type III secretion system effector <\\entity><\\entity> into enterocytes, which following phosphorylation (<\\entity><\\entity>-Yp) recruits Nck to activate the N-WASP actin signalling cascade.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1979",
    "Sentence": "Central to intestinal colonization by EPEC is the translocation of the type III secretion system effector Tir into enterocytes, which following phosphorylation (<\\entity><\\entity>) recruits Nck to activate the N-WASP actin signalling cascade.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1980",
    "Sentence": "Central to intestinal colonization by EPEC is the translocation of the type III secretion system effector Tir into enterocytes, which following phosphorylation (Tir-Yp) recruits <\\entity><\\entity> to activate the N-WASP actin signalling cascade.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1981",
    "Sentence": "Central to intestinal colonization by EPEC is the translocation of the type III secretion system effector Tir into enterocytes, which following phosphorylation (Tir-Yp) recruits Nck to activate the <\\entity><\\entity> signalling cascade.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1982",
    "Sentence": "The authors have recently shown that typical <\\entity><\\entity> strains, belonging to the <\\entity><\\entity>-2 lineage, carry a tir gene encoding Tir-Yp and can also use the alternative TccP2 actin-signalling cascade.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1983",
    "Sentence": "The authors have recently shown that typical EPEC <\\entity><\\entity>, belonging to the EPEC-2 lineage, carry a tir gene encoding Tir-Yp and can also use the alternative TccP2 actin-signalling cascade.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1984",
    "Sentence": "The authors have recently shown that typical <\\entity><\\entity> strains, belonging to the <\\entity><\\entity>-2 lineage, carry a tir gene encoding Tir-Yp and can also use the alternative TccP2 actin-signalling cascade.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1985",
    "Sentence": "The authors have recently shown that typical EPEC strains, belonging to the EPEC-2 lineage, carry a <\\entity><\\entity> gene encoding Tir-Yp and can also use the alternative TccP2 actin-signalling cascade.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1986",
    "Sentence": "The authors have recently shown that typical EPEC strains, belonging to the EPEC-2 lineage, carry a tir gene encoding <\\entity><\\entity> and can also use the alternative TccP2 actin-signalling cascade.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1987",
    "Sentence": "The authors have recently shown that typical EPEC strains, belonging to the EPEC-2 lineage, carry a tir gene encoding Tir-Yp and can also use the alternative <\\entity><\\entity>-signalling cascade.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1988",
    "Sentence": "The aim of this study was to determine if <\\entity><\\entity> is found in atypical EPEC isolated from human and farm animals.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1989",
    "Sentence": "The aim of this study was to determine if tccP2 is found in atypical <\\entity><\\entity> isolated from human and farm animals.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1990",
    "Sentence": "<\\entity><\\entity> was found at a frequency of 41% in non-O26 EPEC isolates and in 82.3% of the O26 strains.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1991",
    "Sentence": "tccP2 was found at a frequency of 41% in non-O26 <\\entity><\\entity> isolates and in 82.3% of the O26 strains.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1992",
    "Sentence": "tccP2 was found at a frequency of 41% in non-O26 EPEC isolates and in 82.3% of the O26 <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1993",
    "Sentence": "<\\entity><\\entity> of human and animal strains show high level of sequence identity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1994",
    "Sentence": "TccP2 of human and animal <\\entity><\\entity> show high level of sequence identity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1995",
    "Sentence": "It is shown that most <\\entity><\\entity> carry a tir gene encoding Tir-Yp.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "1996",
    "Sentence": "It is shown that most strains carry a <\\entity><\\entity> gene encoding Tir-Yp.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1997",
    "Sentence": "It is shown that most strains carry a tir gene encoding <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1998",
    "Sentence": "In addition the authors identified two new variants of <\\entity><\\entity> genes in EPEC O104:H12 and NT:H19 strains.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "1999",
    "Sentence": "In addition the authors identified two new variants of tir genes in <\\entity><\\entity> O104:H12 and NT:H19 strains.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2000",
    "Sentence": "In addition the authors identified two new variants of tir genes in EPEC <\\entity><\\entity> and NT:H19 strains.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2001",
    "Sentence": "In addition the authors identified two new variants of tir genes in EPEC <\\entity><\\entity> and NT:H19 strains.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2002",
    "Sentence": "In addition the authors identified two new variants of tir genes in EPEC O104:H12 and <\\entity><\\entity> strains.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2003",
    "Sentence": "In addition the authors identified two new variants of tir genes in EPEC O104:H12 and <\\entity><\\entity> strains.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2004",
    "Sentence": "In addition the authors identified two new variants of tir genes in EPEC O104:H12 and NT:H19 <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2005",
    "Sentence": "Central to intestinal colonization by EPEC is the translocation of the type III secretion system effector Tir into enterocytes, which following phosphorylation (Tir-Yp) recruits <\\entity><\\entity> to activate the N-WASP actin signalling cascade.",
    "Label": ""
  },
  {
    "id": "2006",
    "Sentence": "Central to intestinal colonization by EPEC is the <\\entity><\\entity> of the type III secretion system effector Tir into enterocytes, which following phosphorylation (Tir-Yp) recruits Nck to activate the N-WASP actin signalling cascade.",
    "Label": ""
  },
  {
    "id": "2008",
    "Sentence": "Central to intestinal colonization by EPEC is the translocation of the type III secretion system effector Tir into enterocytes, which following phosphorylation (Tir-Yp) recruits Nck to activate the <\\entity><\\entity> signalling cascade.",
    "Label": ""
  },
  {
    "id": "2009",
    "Sentence": "Central to intestinal colonization by EPEC is the <\\entity><\\entity> of the type III secretion system effector Tir into enterocytes, which following phosphorylation (Tir-Yp) recruits Nck to activate the N-WASP actin signalling cascade.",
    "Label": ""
  },
  {
    "id": "2011",
    "Sentence": "In addition the authors identified two new variants of tir genes in EPEC <\\entity><\\entity> and NT:H19 strains.",
    "Label": ""
  },
  {
    "id": "2012",
    "Sentence": "In addition the authors identified two new variants of tir genes in EPEC O104:H12 and NT:H19 <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2014",
    "Sentence": "In addition the authors identified two new variants of tir genes in EPEC O104:H12 and <\\entity><\\entity> strains.",
    "Label": ""
  },
  {
    "id": "2015",
    "Sentence": "In addition the authors identified two new variants of tir genes in EPEC O104:H12 and NT:H19 <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2017",
    "Sentence": "Central to intestinal colonization by EPEC is the translocation of the type III secretion system effector Tir into enterocytes, which following phosphorylation (Tir-Yp) recruits <\\entity><\\entity> to activate the N-WASP actin signalling cascade.",
    "Label": ""
  },
  {
    "id": "2018",
    "Sentence": "Central to intestinal colonization by <\\entity><\\entity> is the translocation of the type III secretion system effector Tir into enterocytes, which following phosphorylation (Tir-Yp) recruits Nck to activate the N-WASP actin signalling cascade.",
    "Label": ""
  },
  {
    "id": "2020",
    "Sentence": "Central to intestinal colonization by EPEC is the translocation of the type III secretion system effector Tir into enterocytes, which following phosphorylation (Tir-Yp) recruits Nck to activate the <\\entity><\\entity> signalling cascade.",
    "Label": ""
  },
  {
    "id": "2021",
    "Sentence": "Central to intestinal colonization by <\\entity><\\entity> is the translocation of the type III secretion system effector Tir into enterocytes, which following phosphorylation (Tir-Yp) recruits Nck to activate the N-WASP actin signalling cascade.",
    "Label": ""
  },
  {
    "id": "2023",
    "Sentence": "The authors have recently shown that typical EPEC strains, belonging to the EPEC-2 lineage, carry a tir gene encoding Tir-Yp and can also use the alternative <\\entity><\\entity>-signalling cascade.",
    "Label": ""
  },
  {
    "id": "2024",
    "Sentence": "The authors have recently shown that typical <\\entity><\\entity> strains, belonging to the <\\entity><\\entity>-2 lineage, carry a tir gene encoding Tir-Yp and can also use the alternative TccP2 actin-signalling cascade.",
    "Label": ""
  },
  {
    "id": "2026",
    "Sentence": "<\\entity><\\entity> was found at a frequency of 41% in non-O26 EPEC isolates and in 82.3% of the O26 strains.",
    "Label": ""
  },
  {
    "id": "2027",
    "Sentence": "tccP2 was found at a frequency of 41% in non-O26 <\\entity><\\entity> isolates and in 82.3% of the O26 strains.",
    "Label": ""
  },
  {
    "id": "2029",
    "Sentence": "In addition the authors identified two new variants of tir genes in EPEC <\\entity><\\entity> and NT:H19 strains.",
    "Label": ""
  },
  {
    "id": "2030",
    "Sentence": "In addition the authors identified two new variants of tir genes in <\\entity><\\entity> O104:H12 and NT:H19 strains.",
    "Label": ""
  },
  {
    "id": "2032",
    "Sentence": "In addition the authors identified two new variants of tir genes in EPEC O104:H12 and <\\entity><\\entity> strains.",
    "Label": ""
  },
  {
    "id": "2033",
    "Sentence": "In addition the authors identified two new variants of tir genes in <\\entity><\\entity> O104:H12 and NT:H19 strains.",
    "Label": ""
  },
  {
    "id": "2039",
    "Sentence": "<\\entity><\\entity> facilitates proliferation of colon cancer cells via induction of KrÃ¼ppel-like factor 5.Among the multiple cellular effects mediated by lysophosphatidic acid (LPA), the effect on cell proliferation has extensively been investigated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2040",
    "Sentence": "Lysophosphatidic acid facilitates proliferation of <\\entity><\\entity> cells via induction of KrÃ¼ppel-like factor 5.Among the multiple cellular effects mediated by lysophosphatidic acid (LPA), the effect on cell proliferation has extensively been investigated.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2041",
    "Sentence": "Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of <\\entity><\\entity>5.Among the multiple cellular effects mediated by lysophosphatidic acid (LPA), the effect on cell proliferation has extensively been investigated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2042",
    "Sentence": "Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of KrÃ¼ppel-like factor 5.Among the multiple cellular effects mediated by<\\entity><\\entity>d (LPA), the effect on cell proliferation has extensively been investigated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2043",
    "Sentence": "Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of KrÃ¼ppel-like factor 5.Among the multiple cellular effects mediated by lysophosphatidic acid <\\entity><\\entity>A), the effect on cell proliferation has extensively been investigated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2044",
    "Sentence": "A recent study showed that<\\entity><\\entity>A-mediated proliferation of colon cancer cells requires activation of beta-catenin.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2045",
    "Sentence": "A recent study showed that LPA-mediated proliferation of<\\entity><\\entity>r cells requires activation of beta-catenin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2046",
    "Sentence": "A recent study showed that LPA-mediated proliferation of colon cancer cells requires activation of<\\entity><\\entity>n.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2047",
    "Sentence": "However, the majority of<\\entity><\\entity>r cells have deregulation of the Wnt/beta-catenin pathway.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2048",
    "Sentence": "However, the majority of colon cancer cells have deregulation of the<\\entity><\\entity>t/beta-catenin pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2049",
    "Sentence": "However, the majority of colon cancer cells have deregulation of the Wnt<\\entity><\\entity>n pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2050",
    "Sentence": "This prompted us to hypothesize the presence of additional pathway(s) activated by<\\entity><\\entity>A resulting in an increase in the proliferation of colon cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2051",
    "Sentence": "This prompted us to hypothesize the presence of additional pathway(s) activated by LPA resulting in an increase in the proliferation of<\\entity><\\entity>r cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2052",
    "Sentence": "KrÃ¼ppel-like factor 5 (KLF5) is a transcriptional factor highly expressed in the crypt compartment of the intestinal epithelium.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2053",
    "Sentence": "KrÃ¼ppel-like factor 5<\\entity><\\entity>F5) is a transcriptional factor highly expressed in the crypt compartment of the intestinal epithelium.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2054",
    "Sentence": "In this work, we investigated a role o<\\entity><\\entity>F5 in LPA-mediated proliferation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2055",
    "Sentence": "In this work, we investigated a role of KLF5 i<\\entity><\\entity>PA-mediated proliferation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2056",
    "Sentence": "We show tha<\\entity><\\entity>PA stimulated the expression levels of KLF5 mRNA and protein in colon cancer cells and this stimulation was mediated by LPA(2) and LPA(3).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2057",
    "Sentence": "We show that LPA stimulated the expression levels o<\\entity><\\entity>F5 mRNA and protein in colon cancer cells and this stimulation was mediated by LPA(2) and LPA(3).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2058",
    "Sentence": "We show that LPA stimulated the expression levels of KLF5 mRNA and protein i<\\entity><\\entity>er cells and this stimulation was mediated by LPA(2) and LPA(3).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2059",
    "Sentence": "We show that LPA stimulated the expression levels of KLF5 mRNA and protein in colon cancer cells and this stimulation was mediated b<\\entity><\\entity>2) and LPA(3).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2060",
    "Sentence": "We show that LPA stimulated the expression levels of KLF5 mRNA and protein in colon cancer cells and this stimulation was mediated by LPA(2) an<\\entity><\\entity>3).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2062",
    "Sentence": "Silencing o<\\entity><\\entity>F5 expression by small interfering RNA significantly attenuated LPA-mediated proliferation of SW480 and HCT116 cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2063",
    "Sentence": "Silencing of KLF5 expression by small interfering RNA significantly attenuate<\\entity><\\entity>PA-mediated proliferation of SW480 and HCT116 cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2065",
    "Sentence": "LPA-mediate<\\entity><\\entity>F5 induction was partially blocked by inhibition of the mitogen-activated protein kinase kinase and protein kinase C-delta.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2066",
    "Sentence": "LPA-mediated KLF5 induction was partiall<\\entity><\\entity>ed by inhibition of the mitogen-activated protein kinase kinase and protein kinase C-delta.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2067",
    "Sentence": "LPA-mediated KLF5 induction was partially blocked by inhibition of the mitogen-activate<\\entity><\\entity>se and protein kinase C-delta.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2068",
    "Sentence": "LPA-mediated KLF5 induction was partially blocked by inhibition of the mitogen-activated protein kinase kinase an<\\entity><\\entity>ta.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2069",
    "Sentence": "Moreover, we observed tha<\\entity><\\entity>PA regulates KLF5 expression via eukaryotic elongation factor 2 kinase (eEF2k).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2070",
    "Sentence": "Moreover, we observed that LPA regulate<\\entity><\\entity>F5 expression via eukaryotic elongation factor 2 kinase (eEF2k).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2071",
    "Sentence": "Moreover, we observed that LPA regulates KLF5 expression via eukaryoti<\\entity><\\entity>se (eEF2k).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2072",
    "Sentence": "Moreover, we observed that LPA regulates KLF5 expression via eukaryotic elongation factor 2 kinase<\\entity><\\entity>2k).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2073",
    "Sentence": "Inhibition o<\\entity><\\entity>in or silencing of eEF2k blocked the stimulation in KLF5 expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2074",
    "Sentence": "Inhibition of calmodulin o<\\entity><\\entity>ng of eEF2k blocked the stimulation in KLF5 expression.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2075",
    "Sentence": "Inhibition of calmodulin or silencing o<\\entity><\\entity>2k blocked the stimulation in KLF5 expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2076",
    "Sentence": "Inhibition of calmodulin or silencing of eEF2<\\entity><\\entity>ed the stimulation in KLF5 expression.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2077",
    "Sentence": "Inhibition of calmodulin or silencing of eEF2k blocked the stimulation i<\\entity><\\entity>F5 expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2078",
    "Sentence": "Knockdown o<\\entity><\\entity>2k specifically inhibited KLF5 induction by LPA but not by fetal bovine serum or phorbol 12-myristate 13-acetate.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2079",
    "Sentence": "Knockdown of eEF2k specifically inhibite<\\entity><\\entity>F5 induction by LPA but not by fetal bovine serum or phorbol 12-myristate 13-acetate.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2080",
    "Sentence": "Knockdown of eEF2k specifically inhibited KLF5 induction b<\\entity><\\entity>PA but not by fetal bovine serum or phorbol 12-myristate 13-acetate.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2081",
    "Sentence": "Knockdown of eEF2k specifically inhibited KLF5 induction by LPA but not by fetal bovine serum o<\\entity><\\entity>te.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2082",
    "Sentence": "These results identif<\\entity><\\entity>F5 as a target of LPA-mediated signaling and suggest a role of KLF5 in promoting proliferation of intestinal epithelia in response to LPA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2083",
    "Sentence": "These results identify KLF5 as a target o<\\entity><\\entity>PA-mediated signaling and suggest a role of KLF5 in promoting proliferation of intestinal epithelia in response to LPA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2084",
    "Sentence": "These results identify KLF5 as a target of LPA-mediated signaling and suggest a role o<\\entity><\\entity>F5 in promoting proliferation of intestinal epithelia in response to LPA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2085",
    "Sentence": "These results identify KLF5 as a target of LPA-mediated signaling and suggest a role of KLF5 in promoting proliferation of intestinal epithelia in response t<\\entity><\\entity>PA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2086",
    "Sentence": "A recent study showed that<\\entity><\\entity>A-mediated proliferation of colon cancer cells requires activation of beta-catenin.",
    "Label": ""
  },
  {
    "id": "2087",
    "Sentence": "A recent study showed that LPA-mediated proliferation of<\\entity><\\entity>r cells requires activation of beta-catenin.",
    "Label": ""
  },
  {
    "id": "2089",
    "Sentence": "A recent study showed that LPA-mediated proliferation of colon cancer cells requires activation of<\\entity><\\entity>n.",
    "Label": ""
  },
  {
    "id": "2090",
    "Sentence": "A recent study showed that LPA-mediated proliferation of<\\entity><\\entity>r cells requires activation of beta-catenin.",
    "Label": ""
  },
  {
    "id": "2092",
    "Sentence": "However, the majority of colon cancer cells have deregulation of the Wnt<\\entity><\\entity>n pathway.",
    "Label": ""
  },
  {
    "id": "2093",
    "Sentence": "However, the majority of<\\entity><\\entity>r cells have deregulation of the Wnt/beta-catenin pathway.",
    "Label": ""
  },
  {
    "id": "2095",
    "Sentence": "This prompted us to hypothesize the presence of additional pathway(s) activated by<\\entity><\\entity>A resulting in an increase in the proliferation of colon cancer cells.",
    "Label": ""
  },
  {
    "id": "2096",
    "Sentence": "This prompted us to hypothesize the presence of additional pathway(s) activated by LPA resulting in an increase in the proliferation of<\\entity><\\entity>r cells.",
    "Label": ""
  },
  {
    "id": "2098",
    "Sentence": "We show tha<\\entity><\\entity>PA stimulated the expression levels of KLF5 mRNA and protein in colon cancer cells and this stimulation was mediated by LPA(2) and LPA(3).",
    "Label": ""
  },
  {
    "id": "2099",
    "Sentence": "We show that LPA stimulated the expression levels of KLF5 mRNA and protein i<\\entity><\\entity>er cells and this stimulation was mediated by LPA(2) and LPA(3).",
    "Label": ""
  },
  {
    "id": "2101",
    "Sentence": "We show that LPA stimulated the expression levels o<\\entity><\\entity>F5 mRNA and protein in colon cancer cells and this stimulation was mediated by LPA(2) and LPA(3).",
    "Label": ""
  },
  {
    "id": "2102",
    "Sentence": "We show that LPA stimulated the expression levels of KLF5 mRNA and protein i<\\entity><\\entity>er cells and this stimulation was mediated by LPA(2) and LPA(3).",
    "Label": ""
  },
  {
    "id": "2104",
    "Sentence": "Silencing of KLF5 expression by small interfering RNA significantly attenuate<\\entity><\\entity>PA-mediated proliferation of SW480 and HCT116 cells.",
    "Label": ""
  },
  {
    "id": "2107",
    "Sentence": "Silencing o<\\entity><\\entity>F5 expression by small interfering RNA significantly attenuated LPA-mediated proliferation of SW480 and HCT116 cells.",
    "Label": ""
  },
  {
    "id": "2111",
    "Sentence": "LPA-mediated KLF5 induction was partiall<\\entity><\\entity>ed by inhibition of the mitogen-activated protein kinase kinase and protein kinase C-delta.",
    "Label": ""
  },
  {
    "id": "2113",
    "Sentence": "LPA-mediate<\\entity><\\entity>F5 induction was partially blocked by inhibition of the mitogen-activated protein kinase kinase and protein kinase C-delta.",
    "Label": ""
  },
  {
    "id": "2114",
    "Sentence": "LPA-mediated KLF5 induction was partiall<\\entity><\\entity>ed by inhibition of the mitogen-activated protein kinase kinase and protein kinase C-delta.",
    "Label": ""
  },
  {
    "id": "2116",
    "Sentence": "Inhibition of calmodulin or silencing of eEF2k blocked the stimulation i<\\entity><\\entity>F5 expression.",
    "Label": ""
  },
  {
    "id": "2117",
    "Sentence": "Inhibition of calmodulin o<\\entity><\\entity>ng of eEF2k blocked the stimulation in KLF5 expression.",
    "Label": ""
  },
  {
    "id": "2119",
    "Sentence": "Inhibition of calmodulin or silencing of eEF2k blocked the stimulation i<\\entity><\\entity>F5 expression.",
    "Label": ""
  },
  {
    "id": "2120",
    "Sentence": "Inhibition of calmodulin or silencing of eEF2<\\entity><\\entity>ed the stimulation in KLF5 expression.",
    "Label": ""
  },
  {
    "id": "2122",
    "Sentence": "Inhibition of calmodulin or silencing o<\\entity><\\entity>2k blocked the stimulation in KLF5 expression.",
    "Label": ""
  },
  {
    "id": "2123",
    "Sentence": "Inhibition of calmodulin o<\\entity><\\entity>ng of eEF2k blocked the stimulation in KLF5 expression.",
    "Label": ""
  },
  {
    "id": "2125",
    "Sentence": "Inhibition of calmodulin or silencing o<\\entity><\\entity>2k blocked the stimulation in KLF5 expression.",
    "Label": ""
  },
  {
    "id": "2126",
    "Sentence": "Inhibition of calmodulin or silencing of eEF2<\\entity><\\entity>ed the stimulation in KLF5 expression.",
    "Label": ""
  },
  {
    "id": "2128",
    "Sentence": "Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of <\\entity><\\entity>5.Among the multiple cellular effects mediated by lysophosphatidic acid (LPA), the effect on cell proliferation has extensively been investigated.",
    "Label": ""
  },
  {
    "id": "2129",
    "Sentence": "Lysophosphatidic acid facilitates proliferation of <\\entity><\\entity> cells via induction of KrÃ¼ppel-like factor 5.Among the multiple cellular effects mediated by lysophosphatidic acid (LPA), the effect on cell proliferation has extensively been investigated.",
    "Label": ""
  },
  {
    "id": "2131",
    "Sentence": "However, the majority of colon cancer cells have deregulation of the<\\entity><\\entity>t/beta-catenin pathway.",
    "Label": ""
  },
  {
    "id": "2132",
    "Sentence": "However, the majority of<\\entity><\\entity>r cells have deregulation of the Wnt/beta-catenin pathway.",
    "Label": ""
  },
  {
    "id": "2134",
    "Sentence": "<\\entity><\\entity> facilitates proliferation of colon cancer cells via induction of KrÃ¼ppel-like factor 5.Among the multiple cellular effects mediated by lysophosphatidic acid (LPA), the effect on cell proliferation has extensively been investigated.",
    "Label": ""
  },
  {
    "id": "2135",
    "Sentence": "Lysophosphatidic acid facilitates proliferation of <\\entity><\\entity> cells via induction of KrÃ¼ppel-like factor 5.Among the multiple cellular effects mediated by lysophosphatidic acid (LPA), the effect on cell proliferation has extensively been investigated.",
    "Label": ""
  },
  {
    "id": "2141",
    "Sentence": "Allelic and non-allelic heterogeneities in <\\entity><\\entity> revealed by ALDH7A1 mutational analysis.Pyridoxine dependent seizure (PDS) is a disorder of neonates or infants with autosomal recessive inheritance characterized by seizures, which responds to pharmacological dose of pyridoxine.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2142",
    "Sentence": "Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by <\\entity><\\entity> mutational analysis.Pyridoxine dependent seizure (PDS) is a disorder of neonates or infants with autosomal recessive inheritance characterized by seizures, which responds to pharmacological dose of pyridoxine.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2143",
    "Sentence": "Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis.<\\entity><\\entity> (PDS) is a disorder of neonates or infants with autosomal recessive inheritance characterized by seizures, which responds to pharmacological dose of pyridoxine.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2144",
    "Sentence": "Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis.Pyridoxine dependent seizure (<\\entity><\\entity>) is a disorder of neonates or infants with autosomal recessive inheritance characterized by seizures, which responds to pharmacological dose of pyridoxine.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2145",
    "Sentence": "Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis.Pyridoxine dependent seizure (<\\entity><\\entity>) is a disorder of neonates or infants with autosomal recessive inheritance characterized by seizures, which responds to pharmacological dose of pyridoxine.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2146",
    "Sentence": "Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis.Pyridoxine dependent seizure (PDS) is a <\\entity><\\entity> of neonates or infants with autosomal recessive inheritance characterized by seizures, which responds to pharmacological dose of pyridoxine.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2147",
    "Sentence": "Allelic and non-allelic heterogeneities in pyridoxine dependent <\\entity><\\entity> revealed by ALDH7A1 mutational analysis.Pyridoxine dependent seizure (PDS) is a disorder of neonates or infants with autosomal recessive inheritance characterized by <\\entity><\\entity>, which responds to pharmacological dose of pyridoxine.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2148",
    "Sentence": "Recently, <\\entity><\\entity> have been identified in the ALDH7A1 gene in Caucasian families with PDS.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2149",
    "Sentence": "Recently, mutations have been identified in the <\\entity><\\entity> gene in Caucasian families with PDS.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2150",
    "Sentence": "Recently, mutations have been identified in the ALDH7A1 gene in Caucasian families with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2151",
    "Sentence": "Recently, mutations have been identified in the ALDH7A1 gene in Caucasian families with <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2152",
    "Sentence": "To elucidate further the genetic background of <\\entity><\\entity>, we screened for ALDH7A1 mutations in five <\\entity><\\entity> families (patients 1-5) that included four Orientals.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2153",
    "Sentence": "To elucidate further the genetic background of <\\entity><\\entity>, we screened for ALDH7A1 mutations in five <\\entity><\\entity> families (patients 1-5) that included four Orientals.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2154",
    "Sentence": "To elucidate further the genetic background of PDS, we screened for <\\entity><\\entity> in five PDS families (patients 1-5) that included four Orientals.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2155",
    "Sentence": "To elucidate further the genetic background of PDS, we screened for <\\entity><\\entity> in five PDS families (patients 1-5) that included four Orientals.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2156",
    "Sentence": "To elucidate further the genetic background of PDS, we screened for <\\entity><\\entity> in five PDS families (patients 1-5) that included four Orientals.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2157",
    "Sentence": "To elucidate further the genetic background of <\\entity><\\entity>, we screened for ALDH7A1 mutations in five <\\entity><\\entity> families (patients 1-5) that included four Orientals.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2158",
    "Sentence": "To elucidate further the genetic background of <\\entity><\\entity>, we screened for ALDH7A1 mutations in five <\\entity><\\entity> families (patients 1-5) that included four Orientals.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2159",
    "Sentence": "Diagnosis as having <\\entity><\\entity> was confirmed by pyridoxine-withdrawal test.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2160",
    "Sentence": "Diagnosis as having <\\entity><\\entity> was confirmed by pyridoxine-withdrawal test.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2161",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight <\\entity><\\entity> in compound heterozygous forms: five missense mutations, one nonsense mutation, one point mutation at the splicing donor site in intron 1, and a 1937-bp genomic deletion.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2162",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight <\\entity><\\entity> in compound heterozygous forms: five missense mutations, one nonsense mutation, one point mutation at the splicing donor site in intron 1, and a 1937-bp genomic deletion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2163",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight <\\entity><\\entity> in compound heterozygous forms: five missense mutations, one nonsense mutation, one point mutation at the splicing donor site in intron 1, and a 1937-bp genomic deletion.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2164",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight ALDH7A1 mutations in compound heterozygous forms: five <\\entity><\\entity>, one nonsense mutation, one point mutation at the splicing donor site in intron 1, and a 1937-bp genomic deletion.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2165",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight ALDH7A1 mutations in compound heterozygous forms: five missense mutations, one <\\entity><\\entity>, one point mutation at the splicing donor site in intron 1, and a 1937-bp genomic deletion.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2166",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight ALDH7A1 <\\entity><\\entity>s in compound heterozygous forms: five missense <\\entity><\\entity>s, one nonsense <\\entity><\\entity>, one point <\\entity><\\entity> at the splicing donor site in intron 1, and a 1937-bp genomic deletion.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2167",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight ALDH7A1 mutations in compound heterozygous forms: five missense mutations, one nonsense mutation, one point mutation at the splicing donor site in intron 1, and a 1937-bp genomic <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2168",
    "Sentence": "The <\\entity><\\entity> included the entire exon 17, which was flanked by two Alu elements in introns 16 and 17.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2169",
    "Sentence": "None of the <\\entity><\\entity> was found in 100 control chromosomes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2170",
    "Sentence": "In patient 5, no <\\entity><\\entity> was found by the exon sequencing analysis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2171",
    "Sentence": "Furthermore, expression level or nucleotide sequences of <\\entity><\\entity> mRNA in lymphoblasts were normal.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2172",
    "Sentence": "These observations suggest that <\\entity><\\entity> is unlikely to be responsible for patient 5.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2173",
    "Sentence": "These observations suggest that <\\entity><\\entity> is unlikely to be responsible for patient 5.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2174",
    "Sentence": "These observations suggest that <\\entity><\\entity> is unlikely to be responsible for patient 5.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2175",
    "Sentence": "Abnormal metabolism of <\\entity><\\entity> in brain has long been suggested as the underlying pathophysiology of PDS.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2176",
    "Sentence": "Abnormal metabolism of GABA/glutamate in brain has long been suggested as the underlying <\\entity><\\entity> of PDS.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2177",
    "Sentence": "Abnormal metabolism of GABA/glutamate in brain has long been suggested as the underlying pathophysiology of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2178",
    "Sentence": "Abnormal metabolism of GABA/glutamate in brain has long been suggested as the underlying pathophysiology of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2179",
    "Sentence": "<\\entity><\\entity> glutamate concentration was elevated during the off-pyridoxine period in patient 3, but not in patient 2 or 5.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2180",
    "Sentence": "CSF <\\entity><\\entity> concentration was elevated during the off-pyridoxine period in patient 3, but not in patient 2 or 5.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2181",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of <\\entity><\\entity>, and that the CSF glutamate elevation does not directly correlate with the presence of ALDH7A1 mutations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2182",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of <\\entity><\\entity>, and that the CSF glutamate elevation does not directly correlate with the presence of ALDH7A1 mutations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2183",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of PDS, and that the <\\entity><\\entity> glutamate elevation does not directly correlate with the presence of ALDH7A1 mutations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2184",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of PDS, and that the CSF <\\entity><\\entity> elevation does not directly correlate with the presence of ALDH7A1 mutations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2185",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of PDS, and that the CSF glutamate elevation does not directly correlate with the presence of <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2186",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of PDS, and that the CSF glutamate elevation does not directly correlate with the presence of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2187",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of PDS, and that the CSF glutamate elevation does not directly correlate with the presence of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2188",
    "Sentence": "Abnormal metabolism of <\\entity><\\entity> in brain has long been suggested as the underlying pathophysiology of PDS.",
    "Label": ""
  },
  {
    "id": "2189",
    "Sentence": "Abnormal metabolism of GABA/glutamate in brain has long been suggested as the underlying pathophysiology of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2191",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of PDS, and that the CSF glutamate elevation does not directly correlate with the presence of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2192",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of <\\entity><\\entity>, and that the CSF glutamate elevation does not directly correlate with the presence of ALDH7A1 mutations.",
    "Label": ""
  },
  {
    "id": "2194",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of PDS, and that the CSF <\\entity><\\entity> elevation does not directly correlate with the presence of ALDH7A1 mutations.",
    "Label": ""
  },
  {
    "id": "2195",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of <\\entity><\\entity>, and that the CSF glutamate elevation does not directly correlate with the presence of ALDH7A1 mutations.",
    "Label": ""
  },
  {
    "id": "2197",
    "Sentence": "Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by <\\entity><\\entity> mutational analysis.Pyridoxine dependent seizure (PDS) is a disorder of neonates or infants with autosomal recessive inheritance characterized by seizures, which responds to pharmacological dose of pyridoxine.",
    "Label": ""
  },
  {
    "id": "2198",
    "Sentence": "Allelic and non-allelic heterogeneities in <\\entity><\\entity> revealed by ALDH7A1 mutational analysis.Pyridoxine dependent seizure (PDS) is a disorder of neonates or infants with autosomal recessive inheritance characterized by seizures, which responds to pharmacological dose of pyridoxine.",
    "Label": ""
  },
  {
    "id": "2200",
    "Sentence": "Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis.Pyridoxine dependent seizure (<\\entity><\\entity>) is a disorder of neonates or infants with autosomal recessive inheritance characterized by seizures, which responds to pharmacological dose of pyridoxine.",
    "Label": ""
  },
  {
    "id": "2201",
    "Sentence": "Allelic and non-allelic heterogeneities in pyridoxine dependent <\\entity><\\entity> revealed by ALDH7A1 mutational analysis.Pyridoxine dependent seizure (PDS) is a disorder of neonates or infants with autosomal recessive inheritance characterized by <\\entity><\\entity>, which responds to pharmacological dose of pyridoxine.",
    "Label": ""
  },
  {
    "id": "2203",
    "Sentence": "Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis.Pyridoxine dependent seizure (<\\entity><\\entity>) is a disorder of neonates or infants with autosomal recessive inheritance characterized by seizures, which responds to pharmacological dose of pyridoxine.",
    "Label": ""
  },
  {
    "id": "2204",
    "Sentence": "Allelic and non-allelic heterogeneities in pyridoxine dependent seizures revealed by ALDH7A1 mutational analysis.Pyridoxine dependent seizure (PDS) is a <\\entity><\\entity> of neonates or infants with autosomal recessive inheritance characterized by seizures, which responds to pharmacological dose of pyridoxine.",
    "Label": ""
  },
  {
    "id": "2206",
    "Sentence": "Recently, mutations have been identified in the <\\entity><\\entity> gene in Caucasian families with PDS.",
    "Label": ""
  },
  {
    "id": "2207",
    "Sentence": "Recently, <\\entity><\\entity> have been identified in the ALDH7A1 gene in Caucasian families with PDS.",
    "Label": ""
  },
  {
    "id": "2209",
    "Sentence": "Recently, mutations have been identified in the ALDH7A1 gene in Caucasian families with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2210",
    "Sentence": "Recently, <\\entity><\\entity> have been identified in the ALDH7A1 gene in Caucasian families with PDS.",
    "Label": ""
  },
  {
    "id": "2212",
    "Sentence": "To elucidate further the genetic background of PDS, we screened for <\\entity><\\entity> in five PDS families (patients 1-5) that included four Orientals.",
    "Label": ""
  },
  {
    "id": "2213",
    "Sentence": "To elucidate further the genetic background of PDS, we screened for <\\entity><\\entity> in five PDS families (patients 1-5) that included four Orientals.",
    "Label": ""
  },
  {
    "id": "2215",
    "Sentence": "To elucidate further the genetic background of <\\entity><\\entity>, we screened for ALDH7A1 mutations in five <\\entity><\\entity> families (patients 1-5) that included four Orientals.",
    "Label": ""
  },
  {
    "id": "2216",
    "Sentence": "To elucidate further the genetic background of PDS, we screened for <\\entity><\\entity> in five PDS families (patients 1-5) that included four Orientals.",
    "Label": ""
  },
  {
    "id": "2218",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight <\\entity><\\entity> in compound heterozygous forms: five missense mutations, one nonsense mutation, one point mutation at the splicing donor site in intron 1, and a 1937-bp genomic deletion.",
    "Label": ""
  },
  {
    "id": "2219",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight ALDH7A1 <\\entity><\\entity>s in compound heterozygous forms: five missense <\\entity><\\entity>s, one nonsense <\\entity><\\entity>, one point <\\entity><\\entity> at the splicing donor site in intron 1, and a 1937-bp genomic deletion.",
    "Label": ""
  },
  {
    "id": "2221",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight <\\entity><\\entity> in compound heterozygous forms: five missense mutations, one nonsense mutation, one point mutation at the splicing donor site in intron 1, and a 1937-bp genomic deletion.",
    "Label": ""
  },
  {
    "id": "2222",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight ALDH7A1 mutations in compound heterozygous forms: five <\\entity><\\entity>, one nonsense mutation, one point mutation at the splicing donor site in intron 1, and a 1937-bp genomic deletion.",
    "Label": ""
  },
  {
    "id": "2224",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight <\\entity><\\entity> in compound heterozygous forms: five missense mutations, one nonsense mutation, one point mutation at the splicing donor site in intron 1, and a 1937-bp genomic deletion.",
    "Label": ""
  },
  {
    "id": "2225",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight ALDH7A1 mutations in compound heterozygous forms: five missense mutations, one <\\entity><\\entity>, one point mutation at the splicing donor site in intron 1, and a 1937-bp genomic deletion.",
    "Label": ""
  },
  {
    "id": "2227",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight <\\entity><\\entity> in compound heterozygous forms: five missense mutations, one nonsense mutation, one point mutation at the splicing donor site in intron 1, and a 1937-bp genomic deletion.",
    "Label": ""
  },
  {
    "id": "2228",
    "Sentence": "Exon sequencing analysis of patients 1-4 revealed eight ALDH7A1 mutations in compound heterozygous forms: five missense mutations, one nonsense mutation, one point mutation at the splicing donor site in intron 1, and a 1937-bp genomic <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2230",
    "Sentence": "These observations suggest that <\\entity><\\entity> is unlikely to be responsible for patient 5.",
    "Label": ""
  },
  {
    "id": "2231",
    "Sentence": "These observations suggest that <\\entity><\\entity> is unlikely to be responsible for patient 5.",
    "Label": ""
  },
  {
    "id": "2233",
    "Sentence": "Abnormal metabolism of GABA/glutamate in brain has long been suggested as the underlying pathophysiology of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2234",
    "Sentence": "Abnormal metabolism of GABA/glutamate in brain has long been suggested as the underlying <\\entity><\\entity> of PDS.",
    "Label": ""
  },
  {
    "id": "2236",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of PDS, and that the CSF glutamate elevation does not directly correlate with the presence of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2237",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of PDS, and that the CSF glutamate elevation does not directly correlate with the presence of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2239",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of <\\entity><\\entity>, and that the CSF glutamate elevation does not directly correlate with the presence of ALDH7A1 mutations.",
    "Label": ""
  },
  {
    "id": "2240",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of PDS, and that the CSF glutamate elevation does not directly correlate with the presence of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2242",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of PDS, and that the <\\entity><\\entity> glutamate elevation does not directly correlate with the presence of ALDH7A1 mutations.",
    "Label": ""
  },
  {
    "id": "2243",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of PDS, and that the CSF glutamate elevation does not directly correlate with the presence of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2245",
    "Sentence": "Recently, mutations have been identified in the <\\entity><\\entity> gene in Caucasian families with PDS.",
    "Label": ""
  },
  {
    "id": "2246",
    "Sentence": "Recently, mutations have been identified in the ALDH7A1 gene in Caucasian families with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2248",
    "Sentence": "To elucidate further the genetic background of PDS, we screened for <\\entity><\\entity> in five PDS families (patients 1-5) that included four Orientals.",
    "Label": ""
  },
  {
    "id": "2249",
    "Sentence": "To elucidate further the genetic background of <\\entity><\\entity>, we screened for ALDH7A1 mutations in five <\\entity><\\entity> families (patients 1-5) that included four Orientals.",
    "Label": ""
  },
  {
    "id": "2251",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of PDS, and that the CSF glutamate elevation does not directly correlate with the presence of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2252",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of <\\entity><\\entity>, and that the CSF glutamate elevation does not directly correlate with the presence of ALDH7A1 mutations.",
    "Label": ""
  },
  {
    "id": "2254",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of PDS, and that the CSF <\\entity><\\entity> elevation does not directly correlate with the presence of ALDH7A1 mutations.",
    "Label": ""
  },
  {
    "id": "2255",
    "Sentence": "These results suggest allelic and non-allelic heterogeneities of <\\entity><\\entity>, and that the CSF glutamate elevation does not directly correlate with the presence of ALDH7A1 mutations.",
    "Label": ""
  },
  {
    "id": "2261",
    "Sentence": "The development of human sera tests for <\\entity><\\entity>-bound serum PON1 and its lipolactonase activity.Serum paraoxonase (PON1) is a lipolactonase that associates with <\\entity><\\entity>-apolipoprotein A-I (<\\entity><\\entity>-apoA-I) and thereby plays a role in the prevention of atherosclerosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2262",
    "Sentence": "The development of human sera tests for HDL-bound <\\entity><\\entity> and its lipolactonase activity.Serum paraoxonase (PON1) is a lipolactonase that associates with HDL-apolipoprotein A-I (HDL-apoA-I) and thereby plays a role in the prevention of atherosclerosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2263",
    "Sentence": "The development of human sera tests for HDL-bound serum PON1 and its <\\entity><\\entity> activity.Serum paraoxonase (PON1) is a <\\entity><\\entity> that associates with HDL-apolipoprotein A-I (HDL-apoA-I) and thereby plays a role in the prevention of atherosclerosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2264",
    "Sentence": "The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity.<\\entity><\\entity> (PON1) is a lipolactonase that associates with HDL-apolipoprotein A-I (HDL-apoA-I) and thereby plays a role in the prevention of atherosclerosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2265",
    "Sentence": "The development of human sera tests for HDL-bound serum <\\entity><\\entity> and its lipolactonase activity.Serum paraoxonase (<\\entity><\\entity>) is a lipolactonase that associates with HDL-apolipoprotein A-I (HDL-apoA-I) and thereby plays a role in the prevention of atherosclerosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2266",
    "Sentence": "The development of human sera tests for HDL-bound serum PON1 and its <\\entity><\\entity> activity.Serum paraoxonase (PON1) is a <\\entity><\\entity> that associates with HDL-apolipoprotein A-I (HDL-apoA-I) and thereby plays a role in the prevention of atherosclerosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2267",
    "Sentence": "The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity.Serum paraoxonase (PON1) is a lipolactonase that associates with <\\entity><\\entity> (HDL-apoA-I) and thereby plays a role in the prevention of atherosclerosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2268",
    "Sentence": "The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity.Serum paraoxonase (PON1) is a lipolactonase that associates with HDL-apolipoprotein A-I (<\\entity><\\entity>) and thereby plays a role in the prevention of atherosclerosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2269",
    "Sentence": "Current sera tests make use of promiscuous substrates and provide no indications regarding <\\entity><\\entity> complex formation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2270",
    "Sentence": "We developed new enzymatic tests that detect total <\\entity><\\entity> levels, irrespective of HDL status and R/Q polymorphism, as well as the degree of catalytic stimulation and increased stability that follow <\\entity><\\entity>'s tight binding to HDL-apoA-I.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2271",
    "Sentence": "We developed new enzymatic tests that detect total PON1 levels, irrespective of <\\entity><\\entity> status and R/Q polymorphism, as well as the degree of catalytic stimulation and increased stability that follow PON1's tight binding to <\\entity><\\entity>-apoA-I.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2272",
    "Sentence": "We developed new enzymatic tests that detect total PON1 levels, irrespective of HDL status and <\\entity><\\entity>, as well as the degree of catalytic stimulation and increased stability that follow PON1's tight binding to HDL-apoA-I.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2273",
    "Sentence": "We developed new enzymatic tests that detect total <\\entity><\\entity> levels, irrespective of HDL status and R/Q polymorphism, as well as the degree of catalytic stimulation and increased stability that follow <\\entity><\\entity>'s tight binding to HDL-apoA-I.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2274",
    "Sentence": "We developed new enzymatic tests that detect total PON1 levels, irrespective of HDL status and R/Q polymorphism, as well as the degree of catalytic stimulation and increased stability that follow PON1's tight binding to <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2275",
    "Sentence": "The tests are based on measuring total <\\entity><\\entity> levels with a fluorogenic phosphotriester, measuring the lipolactonase activity with a chromogenic lactone, and assaying the enzyme's chelator-mediated inactivation rate.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2276",
    "Sentence": "The tests are based on measuring total PON1 levels with a <\\entity><\\entity>, measuring the lipolactonase activity with a chromogenic lactone, and assaying the enzyme's chelator-mediated inactivation rate.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2277",
    "Sentence": "The tests are based on measuring total PON1 levels with a fluorogenic phosphotriester, measuring the <\\entity><\\entity> activity with a chromogenic lactone, and assaying the enzyme's chelator-mediated inactivation rate.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2278",
    "Sentence": "The tests are based on measuring total PON1 levels with a fluorogenic phosphotriester, measuring the lipolactonase activity with a <\\entity><\\entity>, and assaying the enzyme's chelator-mediated inactivation rate.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2279",
    "Sentence": "The latter two are affected by tight <\\entity><\\entity> binding and thereby derive the levels of the serum PON1-<\\entity><\\entity> complex.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2280",
    "Sentence": "The latter two are affected by tight HDL binding and thereby derive the levels of the serum <\\entity><\\entity> complex.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2281",
    "Sentence": "We demonstrate these new tests with a group of healthy individuals (n=54) and show that the levels of <\\entity><\\entity> vary by a factor of 12.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2282",
    "Sentence": "Whereas the traditionally applied <\\entity><\\entity> and arylesterase tests weakly reflect PON1-HDL levels (R=0.64), the lipolactonase test provides better correlation (R=0.80).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2283",
    "Sentence": "Whereas the traditionally applied paraoxonase and <\\entity><\\entity> tests weakly reflect PON1-HDL levels (R=0.64), the lipolactonase test provides better correlation (R=0.80).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2284",
    "Sentence": "Whereas the traditionally applied paraoxonase and arylesterase tests weakly reflect <\\entity><\\entity> levels (R=0.64), the lipolactonase test provides better correlation (R=0.80).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2285",
    "Sentence": "Whereas the traditionally applied paraoxonase and arylesterase tests weakly reflect PON1-HDL levels (R=0.64), the <\\entity><\\entity> test provides better correlation (R=0.80).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2286",
    "Sentence": "These new tests indicate the levels and activity of <\\entity><\\entity> in a physiologically relevant context as well as the levels and quality of the HDL particles with which the enzyme is associated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2287",
    "Sentence": "These new tests indicate the levels and activity of PON1 in a physiologically relevant context as well as the levels and quality of the <\\entity><\\entity> particles with which the enzyme is associated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2288",
    "Sentence": "The tests are based on measuring total PON1 levels with a <\\entity><\\entity>, measuring the lipolactonase activity with a chromogenic lactone, and assaying the enzyme's chelator-mediated inactivation rate.",
    "Label": ""
  },
  {
    "id": "2289",
    "Sentence": "The tests are based on measuring total <\\entity><\\entity> levels with a fluorogenic phosphotriester, measuring the lipolactonase activity with a chromogenic lactone, and assaying the enzyme's chelator-mediated inactivation rate.",
    "Label": ""
  },
  {
    "id": "2291",
    "Sentence": "The tests are based on measuring total PON1 levels with a fluorogenic phosphotriester, measuring the lipolactonase activity with a <\\entity><\\entity>, and assaying the enzyme's chelator-mediated inactivation rate.",
    "Label": ""
  },
  {
    "id": "2292",
    "Sentence": "The tests are based on measuring total PON1 levels with a fluorogenic phosphotriester, measuring the <\\entity><\\entity> activity with a chromogenic lactone, and assaying the enzyme's chelator-mediated inactivation rate.",
    "Label": ""
  },
  {
    "id": "2298",
    "Sentence": "A <\\entity><\\entity> interacts with Munc18b and impacts on amylase secretion by pancreatic acini.We identified in a yeast two-hybrid screen the EF-hand Ca(2+)-binding protein Cab45 as an interaction partner of Munc18b.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2299",
    "Sentence": "A <\\entity><\\entity> interacts with Munc18b and impacts on amylase secretion by pancreatic acini.We identified in a yeast two-hybrid screen the EF-hand Ca(2+)-binding protein Cab45 as an interaction partner of Munc18b.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2300",
    "Sentence": "A cytosolic splice variant of Cab45 interacts with <\\entity><\\entity> and impacts on amylase secretion by pancreatic acini.We identified in a yeast two-hybrid screen the EF-hand Ca(2+)-binding protein Cab45 as an interaction partner of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2301",
    "Sentence": "A cytosolic splice variant of Cab45 interacts with Munc18b and impacts on <\\entity><\\entity> secretion by pancreatic acini.We identified in a yeast two-hybrid screen the EF-hand Ca(2+)-binding protein Cab45 as an interaction partner of Munc18b.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2302",
    "Sentence": "A cytosolic splice variant of Cab45 interacts with Munc18b and impacts on amylase secretion by pancreatic acini.We identified in a yeast two-hybrid screen the <\\entity><\\entity> Cab45 as an interaction partner of Munc18b.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2303",
    "Sentence": "A cytosolic splice variant of Cab45 interacts with Munc18b and impacts on amylase secretion by pancreatic acini.We identified in a yeast two-hybrid screen the EF-hand <\\entity><\\entity>-binding protein Cab45 as an interaction partner of Munc18b.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2304",
    "Sentence": "A cytosolic splice variant of <\\entity><\\entity> interacts with Munc18b and impacts on amylase secretion by pancreatic acini.We identified in a yeast two-hybrid screen the EF-hand Ca(2+)-binding protein <\\entity><\\entity> as an interaction partner of Munc18b.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2305",
    "Sentence": "A cytosolic splice variant of Cab45 interacts with <\\entity><\\entity> and impacts on amylase secretion by pancreatic acini.We identified in a yeast two-hybrid screen the EF-hand Ca(2+)-binding protein Cab45 as an interaction partner of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2306",
    "Sentence": "Although the full-length <\\entity><\\entity> resides in Golgi lumen, we characterize a cytosolic splice variant, <\\entity><\\entity>b, expressed in pancreatic acini.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2307",
    "Sentence": "Although the full-length Cab45 resides in Golgi <\\entity><\\entity>, we characterize a cytosolic splice variant, Cab45b, expressed in pancreatic acini.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2308",
    "Sentence": "Although the full-length Cab45 resides in Golgi lumen, we characterize a cytosolic splice variant, <\\entity><\\entity>, expressed in pancreatic acini.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2309",
    "Sentence": "Although the full-length Cab45 resides in Golgi lumen, we characterize a cytosolic splice variant, <\\entity><\\entity>, expressed in pancreatic acini.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2310",
    "Sentence": "<\\entity><\\entity> is shown to bind (45)Ca(2+), and, of its three EF-hand motifs, EF-hand 2 is demonstrated to be crucial for the ion binding.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2311",
    "Sentence": "<\\entity><\\entity> is shown to bind (45)Ca(2+), and, of its three EF-hand motifs, EF-hand 2 is demonstrated to be crucial for the ion binding.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2312",
    "Sentence": "Cab45b is shown to bind (45)<\\entity><\\entity>, and, of its three EF-hand motifs, EF-hand 2 is demonstrated to be crucial for the ion binding.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2313",
    "Sentence": "Cab45b is shown to bind (45)Ca(2+), and, of its three EF-hand motifs, <\\entity><\\entity> is demonstrated to be crucial for the ion binding.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2314",
    "Sentence": "<\\entity><\\entity> is shown to interact with Munc18b in an in vitro assay, and this interaction is enhanced in the presence of Ca(2+).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2315",
    "Sentence": "<\\entity><\\entity> is shown to interact with Munc18b in an in vitro assay, and this interaction is enhanced in the presence of Ca(2+).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2316",
    "Sentence": "Cab45b is shown to interact with <\\entity><\\entity> in an in vitro assay, and this interaction is enhanced in the presence of Ca(2+).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2317",
    "Sentence": "Cab45b is shown to interact with Munc18b in an in vitro assay, and this interaction is enhanced in the presence of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2318",
    "Sentence": "In this assay, <\\entity><\\entity> also binds the Munc18a isoform in a Ca(2+)-dependent manner.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2319",
    "Sentence": "In this assay, <\\entity><\\entity> also binds the Munc18a isoform in a Ca(2+)-dependent manner.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2320",
    "Sentence": "In this assay, Cab45b also binds the <\\entity><\\entity> isoform in a Ca(2+)-dependent manner.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2321",
    "Sentence": "In this assay, Cab45b also binds the Munc18a isoform in a <\\entity><\\entity>-dependent manner.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2322",
    "Sentence": "The endogenous <\\entity><\\entity> in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the Ca(2+)-triggered zymogen secretion.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2323",
    "Sentence": "The endogenous <\\entity><\\entity> in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the Ca(2+)-triggered zymogen secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2324",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with <\\entity><\\entity>, syntaxin 2, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the Ca(2+)-triggered zymogen secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2325",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, <\\entity><\\entity>, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the Ca(2+)-triggered zymogen secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2326",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and <\\entity><\\entity>, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the Ca(2+)-triggered zymogen secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2327",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, <\\entity><\\entity> with key roles in the Ca(2+)-triggered zymogen secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2328",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, soluble <\\entity><\\entity> attachment protein receptors with key roles in the Ca(2+)-triggered zymogen secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2329",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the <\\entity><\\entity>-triggered zymogen secretion.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2330",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the Ca(2+)-triggered <\\entity><\\entity> secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2331",
    "Sentence": "Furthermore, we show that <\\entity><\\entity> bound to syntaxin 3 recruits Cab45b onto the plasma membrane.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2332",
    "Sentence": "Furthermore, we show that Munc18b bound to <\\entity><\\entity> recruits Cab45b onto the plasma membrane.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2333",
    "Sentence": "Furthermore, we show that Munc18b bound to syntaxin 3 recruits <\\entity><\\entity> onto the plasma membrane.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2334",
    "Sentence": "Furthermore, we show that Munc18b bound to syntaxin 3 recruits <\\entity><\\entity> onto the plasma membrane.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2335",
    "Sentence": "Importantly, <\\entity><\\entity> are shown to inhibit in a specific and dose-dependent manner the Ca(2+)-induced amylase release from streptolysin-O-permeabilized acini.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2336",
    "Sentence": "Importantly, <\\entity><\\entity> are shown to inhibit in a specific and dose-dependent manner the Ca(2+)-induced amylase release from streptolysin-O-permeabilized acini.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2337",
    "Sentence": "Importantly, antibodies against Cab45b are shown to inhibit in a specific and dose-dependent manner the <\\entity><\\entity>-induced amylase release from streptolysin-O-permeabilized acini.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2338",
    "Sentence": "Importantly, antibodies against Cab45b are shown to inhibit in a specific and dose-dependent manner the Ca(2+)-induced <\\entity><\\entity> release from streptolysin-O-permeabilized acini.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2339",
    "Sentence": "Importantly, antibodies against Cab45b are shown to inhibit in a specific and dose-dependent manner the Ca(2+)-induced amylase release from <\\entity><\\entity>-permeabilized acini.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2340",
    "Sentence": "The present study identifies <\\entity><\\entity> as a novel protein factor involved in the exocytosis of zymogens by pancreatic acini.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2341",
    "Sentence": "The present study identifies <\\entity><\\entity> as a novel protein factor involved in the exocytosis of zymogens by pancreatic acini.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2342",
    "Sentence": "The present study identifies Cab45b as a novel protein factor involved in the exocytosis of <\\entity><\\entity> by pancreatic acini.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2343",
    "Sentence": "<\\entity><\\entity> is shown to bind (45)Ca(2+), and, of its three EF-hand motifs, EF-hand 2 is demonstrated to be crucial for the ion binding.",
    "Label": ""
  },
  {
    "id": "2344",
    "Sentence": "Cab45b is shown to bind (45)<\\entity><\\entity>, and, of its three EF-hand motifs, EF-hand 2 is demonstrated to be crucial for the ion binding.",
    "Label": ""
  },
  {
    "id": "2346",
    "Sentence": "Cab45b is shown to bind (45)<\\entity><\\entity>, and, of its three EF-hand motifs, EF-hand 2 is demonstrated to be crucial for the ion binding.",
    "Label": ""
  },
  {
    "id": "2347",
    "Sentence": "Cab45b is shown to bind (45)Ca(2+), and, of its three EF-hand motifs, <\\entity><\\entity> is demonstrated to be crucial for the ion binding.",
    "Label": ""
  },
  {
    "id": "2349",
    "Sentence": "<\\entity><\\entity> is shown to interact with Munc18b in an in vitro assay, and this interaction is enhanced in the presence of Ca(2+).",
    "Label": ""
  },
  {
    "id": "2350",
    "Sentence": "Cab45b is shown to interact with Munc18b in an in vitro assay, and this interaction is enhanced in the presence of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2352",
    "Sentence": "Cab45b is shown to interact with Munc18b in an in vitro assay, and this interaction is enhanced in the presence of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2353",
    "Sentence": "Cab45b is shown to interact with <\\entity><\\entity> in an in vitro assay, and this interaction is enhanced in the presence of Ca(2+).",
    "Label": ""
  },
  {
    "id": "2355",
    "Sentence": "In this assay, <\\entity><\\entity> also binds the Munc18a isoform in a Ca(2+)-dependent manner.",
    "Label": ""
  },
  {
    "id": "2356",
    "Sentence": "In this assay, Cab45b also binds the Munc18a isoform in a <\\entity><\\entity>-dependent manner.",
    "Label": ""
  },
  {
    "id": "2358",
    "Sentence": "In this assay, Cab45b also binds the Munc18a isoform in a <\\entity><\\entity>-dependent manner.",
    "Label": ""
  },
  {
    "id": "2359",
    "Sentence": "In this assay, Cab45b also binds the <\\entity><\\entity> isoform in a Ca(2+)-dependent manner.",
    "Label": ""
  },
  {
    "id": "2361",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the <\\entity><\\entity>-triggered zymogen secretion.",
    "Label": ""
  },
  {
    "id": "2362",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the Ca(2+)-triggered <\\entity><\\entity> secretion.",
    "Label": ""
  },
  {
    "id": "2364",
    "Sentence": "Importantly, antibodies against Cab45b are shown to inhibit in a specific and dose-dependent manner the <\\entity><\\entity>-induced amylase release from streptolysin-O-permeabilized acini.",
    "Label": ""
  },
  {
    "id": "2365",
    "Sentence": "Importantly, antibodies against Cab45b are shown to inhibit in a specific and dose-dependent manner the Ca(2+)-induced <\\entity><\\entity> release from streptolysin-O-permeabilized acini.",
    "Label": ""
  },
  {
    "id": "2367",
    "Sentence": "Importantly, <\\entity><\\entity> are shown to inhibit in a specific and dose-dependent manner the Ca(2+)-induced amylase release from streptolysin-O-permeabilized acini.",
    "Label": ""
  },
  {
    "id": "2368",
    "Sentence": "Importantly, antibodies against Cab45b are shown to inhibit in a specific and dose-dependent manner the Ca(2+)-induced <\\entity><\\entity> release from streptolysin-O-permeabilized acini.",
    "Label": ""
  },
  {
    "id": "2370",
    "Sentence": "Although the full-length Cab45 resides in Golgi <\\entity><\\entity>, we characterize a cytosolic splice variant, Cab45b, expressed in pancreatic acini.",
    "Label": ""
  },
  {
    "id": "2371",
    "Sentence": "Although the full-length <\\entity><\\entity> resides in Golgi lumen, we characterize a cytosolic splice variant, <\\entity><\\entity>b, expressed in pancreatic acini.",
    "Label": ""
  },
  {
    "id": "2373",
    "Sentence": "Importantly, antibodies against Cab45b are shown to inhibit in a specific and dose-dependent manner the Ca(2+)-induced amylase release from <\\entity><\\entity>-permeabilized acini.",
    "Label": ""
  },
  {
    "id": "2374",
    "Sentence": "Importantly, antibodies against Cab45b are shown to inhibit in a specific and dose-dependent manner the Ca(2+)-induced <\\entity><\\entity> release from streptolysin-O-permeabilized acini.",
    "Label": ""
  },
  {
    "id": "2376",
    "Sentence": "Importantly, antibodies against Cab45b are shown to inhibit in a specific and dose-dependent manner the Ca(2+)-induced amylase release from <\\entity><\\entity>-permeabilized acini.",
    "Label": ""
  },
  {
    "id": "2377",
    "Sentence": "Importantly, <\\entity><\\entity> are shown to inhibit in a specific and dose-dependent manner the Ca(2+)-induced amylase release from streptolysin-O-permeabilized acini.",
    "Label": ""
  },
  {
    "id": "2379",
    "Sentence": "A cytosolic splice variant of Cab45 interacts with Munc18b and impacts on amylase secretion by pancreatic acini.We identified in a yeast two-hybrid screen the EF-hand <\\entity><\\entity>-binding protein Cab45 as an interaction partner of Munc18b.",
    "Label": ""
  },
  {
    "id": "2380",
    "Sentence": "A cytosolic splice variant of <\\entity><\\entity> interacts with Munc18b and impacts on amylase secretion by pancreatic acini.We identified in a yeast two-hybrid screen the EF-hand Ca(2+)-binding protein <\\entity><\\entity> as an interaction partner of Munc18b.",
    "Label": ""
  },
  {
    "id": "2382",
    "Sentence": "A cytosolic splice variant of Cab45 interacts with Munc18b and impacts on amylase secretion by pancreatic acini.We identified in a yeast two-hybrid screen the EF-hand <\\entity><\\entity>-binding protein Cab45 as an interaction partner of Munc18b.",
    "Label": ""
  },
  {
    "id": "2383",
    "Sentence": "A cytosolic splice variant of Cab45 interacts with <\\entity><\\entity> and impacts on amylase secretion by pancreatic acini.We identified in a yeast two-hybrid screen the EF-hand Ca(2+)-binding protein Cab45 as an interaction partner of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2385",
    "Sentence": "Cab45b is shown to bind (45)<\\entity><\\entity>, and, of its three EF-hand motifs, EF-hand 2 is demonstrated to be crucial for the ion binding.",
    "Label": ""
  },
  {
    "id": "2386",
    "Sentence": "<\\entity><\\entity> is shown to bind (45)Ca(2+), and, of its three EF-hand motifs, EF-hand 2 is demonstrated to be crucial for the ion binding.",
    "Label": ""
  },
  {
    "id": "2388",
    "Sentence": "Cab45b is shown to interact with Munc18b in an in vitro assay, and this interaction is enhanced in the presence of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2389",
    "Sentence": "<\\entity><\\entity> is shown to interact with Munc18b in an in vitro assay, and this interaction is enhanced in the presence of Ca(2+).",
    "Label": ""
  },
  {
    "id": "2391",
    "Sentence": "In this assay, Cab45b also binds the Munc18a isoform in a <\\entity><\\entity>-dependent manner.",
    "Label": ""
  },
  {
    "id": "2392",
    "Sentence": "In this assay, <\\entity><\\entity> also binds the Munc18a isoform in a Ca(2+)-dependent manner.",
    "Label": ""
  },
  {
    "id": "2394",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the <\\entity><\\entity>-triggered zymogen secretion.",
    "Label": ""
  },
  {
    "id": "2395",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, <\\entity><\\entity>, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the Ca(2+)-triggered zymogen secretion.",
    "Label": ""
  },
  {
    "id": "2397",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the <\\entity><\\entity>-triggered zymogen secretion.",
    "Label": ""
  },
  {
    "id": "2398",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and <\\entity><\\entity>, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the Ca(2+)-triggered zymogen secretion.",
    "Label": ""
  },
  {
    "id": "2400",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the <\\entity><\\entity>-triggered zymogen secretion.",
    "Label": ""
  },
  {
    "id": "2401",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with <\\entity><\\entity>, syntaxin 2, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the Ca(2+)-triggered zymogen secretion.",
    "Label": ""
  },
  {
    "id": "2403",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the <\\entity><\\entity>-triggered zymogen secretion.",
    "Label": ""
  },
  {
    "id": "2404",
    "Sentence": "The endogenous <\\entity><\\entity> in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the Ca(2+)-triggered zymogen secretion.",
    "Label": ""
  },
  {
    "id": "2406",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, soluble N-ethylmaleimide-sensitive factor attachment protein receptors with key roles in the <\\entity><\\entity>-triggered zymogen secretion.",
    "Label": ""
  },
  {
    "id": "2407",
    "Sentence": "The endogenous Cab45b in rat acini coimmunoprecipitates with Munc18b, syntaxin 2, and syntaxin 3, <\\entity><\\entity> with key roles in the Ca(2+)-triggered zymogen secretion.",
    "Label": ""
  },
  {
    "id": "2409",
    "Sentence": "Importantly, antibodies against Cab45b are shown to inhibit in a specific and dose-dependent manner the <\\entity><\\entity>-induced amylase release from streptolysin-O-permeabilized acini.",
    "Label": ""
  },
  {
    "id": "2410",
    "Sentence": "Importantly, <\\entity><\\entity> are shown to inhibit in a specific and dose-dependent manner the Ca(2+)-induced amylase release from streptolysin-O-permeabilized acini.",
    "Label": ""
  },
  {
    "id": "2416",
    "Sentence": "<\\entity><\\entity> and aging.Mitochondria have been hypothesized to play a role in both aging and neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2417",
    "Sentence": "<\\entity><\\entity> and aging.Mitochondria have been hypothesized to play a role in both aging and neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2418",
    "Sentence": "<\\entity><\\entity> and aging.Mitochondria have been hypothesized to play a role in both aging and neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2419",
    "Sentence": "Mitochondrial DNA mutations and aging.Mitochondria have been hypothesized to play a role in both aging and <\\entity><\\entity>, such as Parkinson's disease (PD) and Alzheimer's disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2420",
    "Sentence": "Mitochondrial DNA mutations and aging.Mitochondria have been hypothesized to play a role in both aging and neurodegenerative diseases, such as <\\entity><\\entity> (PD) and Alzheimer's disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2421",
    "Sentence": "Mitochondrial DNA mutations and aging.Mitochondria have been hypothesized to play a role in both aging and neurodegenerative diseases, such as Parkinson's disease (<\\entity><\\entity>) and Alzheimer's disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2422",
    "Sentence": "Mitochondrial DNA mutations and aging.Mitochondria have been hypothesized to play a role in both aging and neurodegenerative diseases, such as Parkinson's disease (PD) and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2423",
    "Sentence": "Many studies have shown the accumulation of <\\entity><\\entity> (mtDNA) mutations in post-mitotic tissues and more recent data have shown this also to be a feature of aging mitotic tissues.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2424",
    "Sentence": "Many studies have shown the accumulation of mitochondrial DNA (<\\entity><\\entity> in post-mitotic tissues and more recent data have shown this also to be a feature of aging mitotic tissues.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2425",
    "Sentence": "Many studies have shown the accumulation of mitochondrial DNA (<\\entity><\\entity> in post-mitotic tissues and more recent data have shown this also to be a feature of aging mitotic tissues.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2426",
    "Sentence": "Many studies have shown the accumulation of mitochondrial DNA (<\\entity><\\entity> in post-mitotic tissues and more recent data have shown this also to be a feature of aging mitotic tissues.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2427",
    "Sentence": "Much of this data has been correlative, until recently with the development of <\\entity><\\entity> deficient mice which accumulate high levels of mtDNA mutations and show a premature aging phenotype, that a more causative role has been proposed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2428",
    "Sentence": "Much of this data has been correlative, until recently with the development of polymerase gamma deficient mice which accumulate high levels of <\\entity><\\entity> and show a premature aging phenotype, that a more causative role has been proposed.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2429",
    "Sentence": "Much of this data has been correlative, until recently with the development of polymerase gamma deficient mice which accumulate high levels of <\\entity><\\entity> and show a premature aging phenotype, that a more causative role has been proposed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2430",
    "Sentence": "Much of this data has been correlative, until recently with the development of polymerase gamma deficient mice which accumulate high levels of <\\entity><\\entity> and show a premature aging phenotype, that a more causative role has been proposed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2431",
    "Sentence": "Much of this data has been correlative, until recently with the development of polymerase gamma deficient mice which accumulate high levels of mtDNA mutations and show a <\\entity><\\entity> phenotype, that a more causative role has been proposed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2432",
    "Sentence": "This article focuses on recent developments in aging research into the role that <\\entity><\\entity> play in the aging process.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2433",
    "Sentence": "This article focuses on recent developments in aging research into the role that <\\entity><\\entity> play in the aging process.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2434",
    "Sentence": "This article focuses on recent developments in aging research into the role that <\\entity><\\entity> play in the aging process.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2435",
    "Sentence": "Much of this data has been correlative, until recently with the development of <\\entity><\\entity> deficient mice which accumulate high levels of mtDNA mutations and show a premature aging phenotype, that a more causative role has been proposed.",
    "Label": ""
  },
  {
    "id": "2436",
    "Sentence": "Much of this data has been correlative, until recently with the development of polymerase gamma deficient mice which accumulate high levels of <\\entity><\\entity> and show a premature aging phenotype, that a more causative role has been proposed.",
    "Label": ""
  },
  {
    "id": "2438",
    "Sentence": "Much of this data has been correlative, until recently with the development of <\\entity><\\entity> deficient mice which accumulate high levels of mtDNA mutations and show a premature aging phenotype, that a more causative role has been proposed.",
    "Label": ""
  },
  {
    "id": "2439",
    "Sentence": "Much of this data has been correlative, until recently with the development of polymerase gamma deficient mice which accumulate high levels of mtDNA mutations and show a <\\entity><\\entity> phenotype, that a more causative role has been proposed.",
    "Label": ""
  },
  {
    "id": "2441",
    "Sentence": "Much of this data has been correlative, until recently with the development of polymerase gamma deficient mice which accumulate high levels of <\\entity><\\entity> and show a premature aging phenotype, that a more causative role has been proposed.",
    "Label": ""
  },
  {
    "id": "2442",
    "Sentence": "Much of this data has been correlative, until recently with the development of polymerase gamma deficient mice which accumulate high levels of mtDNA mutations and show a <\\entity><\\entity> phenotype, that a more causative role has been proposed.",
    "Label": ""
  },
  {
    "id": "2448",
    "Sentence": "The effects of genetic liability for <\\entity><\\entity> and maternal smoking during pregnancy on obstetric complications.The purpose of this study was to determine whether a genetic vulnerability for <\\entity><\\entity> and/or health-risk behaviors among schizophrenic pregnant women were associated with an increased incidence of obstetric complications (OCs).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2449",
    "Sentence": "The effects of genetic liability for schizophrenia and maternal smoking during pregnancy on <\\entity><\\entity>.The purpose of this study was to determine whether a genetic vulnerability for schizophrenia and/or health-risk behaviors among schizophrenic pregnant women were associated with an increased incidence of <\\entity><\\entity> (OCs).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2450",
    "Sentence": "The effects of genetic liability for <\\entity><\\entity> and maternal smoking during pregnancy on obstetric complications.The purpose of this study was to determine whether a genetic vulnerability for <\\entity><\\entity> and/or health-risk behaviors among schizophrenic pregnant women were associated with an increased incidence of obstetric complications (OCs).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2451",
    "Sentence": "The effects of genetic liability for schizophrenia and maternal smoking during pregnancy on obstetric complications.The purpose of this study was to determine whether a genetic vulnerability for schizophrenia and/or health-risk behaviors among <\\entity><\\entity> pregnant women were associated with an increased incidence of obstetric complications (OCs).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2452",
    "Sentence": "The effects of genetic liability for schizophrenia and maternal smoking during pregnancy on <\\entity><\\entity>.The purpose of this study was to determine whether a genetic vulnerability for schizophrenia and/or health-risk behaviors among schizophrenic pregnant women were associated with an increased incidence of <\\entity><\\entity> (OCs).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2453",
    "Sentence": "The effects of genetic liability for schizophrenia and maternal smoking during pregnancy on obstetric complications.The purpose of this study was to determine whether a genetic vulnerability for schizophrenia and/or health-risk behaviors among schizophrenic pregnant women were associated with an increased incidence of obstetric complications (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2454",
    "Sentence": "METHOD: A high-risk birth cohort was formed by searching the Finnish Perinatal Register for all births from 1991-2000 with arterial cord pH values below 7.20, an indication of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2455",
    "Sentence": "Mothers were divided into 3 groups: women diagnosed with <\\entity><\\entity>/schizoaffective disorder (n=53), mothers with a first-degree relative with <\\entity><\\entity>/schizoaffective disorder (n=590) and healthy controls (n=36,895).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2456",
    "Sentence": "Mothers were divided into 3 groups: women diagnosed with schizophrenia/<\\entity><\\entity> (n=53), mothers with a first-degree relative with schizophrenia/<\\entity><\\entity> (n=590) and healthy controls (n=36,895).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2457",
    "Sentence": "Mothers were divided into 3 groups: women diagnosed with <\\entity><\\entity>/schizoaffective disorder (n=53), mothers with a first-degree relative with <\\entity><\\entity>/schizoaffective disorder (n=590) and healthy controls (n=36,895).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2458",
    "Sentence": "Mothers were divided into 3 groups: women diagnosed with schizophrenia/<\\entity><\\entity> (n=53), mothers with a first-degree relative with schizophrenia/<\\entity><\\entity> (n=590) and healthy controls (n=36,895).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2459",
    "Sentence": "RESULT: <\\entity><\\entity> women had significantly more OCs than mothers with a first-degree schizophrenic relative and controls.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2460",
    "Sentence": "RESULT: Schizophrenic women had significantly more <\\entity><\\entity> than mothers with a first-degree schizophrenic relative and controls.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2461",
    "Sentence": "RESULT: Schizophrenic women had significantly more OCs than mothers with a first-degree <\\entity><\\entity> relative and controls.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2462",
    "Sentence": "These women had significantly increased rates of <\\entity><\\entity>, premature delivery, prenatal hospitalizations, and marginally significant increases in high blood pressure.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2463",
    "Sentence": "These women had significantly increased rates of eclampsia, <\\entity><\\entity>, prenatal hospitalizations, and marginally significant increases in high blood pressure.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2464",
    "Sentence": "These women had significantly increased rates of eclampsia, premature delivery, <\\entity><\\entity>, and marginally significant increases in high blood pressure.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2465",
    "Sentence": "These women had significantly increased rates of eclampsia, premature delivery, prenatal hospitalizations, and marginally significant increases in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2466",
    "Sentence": "Offspring of <\\entity><\\entity> mothers had significantly decreased APGAR scores and birth weight and increased medical complications after birth.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2467",
    "Sentence": "Offspring of schizophrenic mothers had significantly decreased APGAR scores and birth weight and increased <\\entity><\\entity> after birth.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2468",
    "Sentence": "In contrast, women with a <\\entity><\\entity> first-degree relative had no significant increases in OCs compared to controls.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2469",
    "Sentence": "In contrast, women with a schizophrenic first-degree relative had no significant increases in <\\entity><\\entity> compared to controls.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2470",
    "Sentence": "<\\entity><\\entity> mothers also smoked more than the other groups and smoking was found to mediate the relationship between maternal schizophrenic status and decreased birth weight among offspring.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2471",
    "Sentence": "Schizophrenic mothers also smoked more than the other groups and smoking was found to mediate the relationship between maternal <\\entity><\\entity> status and decreased birth weight among offspring.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2472",
    "Sentence": "CONCLUSIONS: Maternal <\\entity><\\entity> during pregnancy leads to an increased risk of OCs, possibly due to engagement in health-risk behaviors during pregnancy, such as smoking, whereas genetic susceptibility to <\\entity><\\entity>, by itself, does not appear to be related to incidence of OCs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2473",
    "Sentence": "CONCLUSIONS: Maternal schizophrenia during pregnancy leads to an increased risk of <\\entity><\\entity>, possibly due to engagement in health-risk behaviors during pregnancy, such as smoking, whereas genetic susceptibility to schizophrenia, by itself, does not appear to be related to incidence of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2474",
    "Sentence": "CONCLUSIONS: Maternal <\\entity><\\entity> during pregnancy leads to an increased risk of OCs, possibly due to engagement in health-risk behaviors during pregnancy, such as smoking, whereas genetic susceptibility to <\\entity><\\entity>, by itself, does not appear to be related to incidence of OCs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2475",
    "Sentence": "CONCLUSIONS: Maternal schizophrenia during pregnancy leads to an increased risk of <\\entity><\\entity>, possibly due to engagement in health-risk behaviors during pregnancy, such as smoking, whereas genetic susceptibility to schizophrenia, by itself, does not appear to be related to incidence of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2480",
    "Sentence": "Quantification of circulating <\\entity><\\entity> DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral <\\entity><\\entity> (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2481",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of <\\entity><\\entity> ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2482",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with <\\entity><\\entity>.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with <\\entity><\\entity> (ACV).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2483",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with <\\entity><\\entity> (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2484",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (<\\entity><\\entity>) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2485",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed <\\entity><\\entity> (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2486",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (<\\entity><\\entity> following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2487",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with <\\entity><\\entity>.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with <\\entity><\\entity> (ACV).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2488",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (<\\entity><\\entity>).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2489",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2490",
    "Sentence": "A 24-year-old woman with <\\entity><\\entity> developed severe epigastric pain 168 days after CBSCT, followed by blistering eruptions 2 days later.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2491",
    "Sentence": "A 24-year-old woman with ALL developed <\\entity><\\entity> 168 days after CBSCT, followed by blistering eruptions 2 days later.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2492",
    "Sentence": "A 24-year-old woman with ALL developed severe epigastric pain 168 days after CBSCT, followed by <\\entity><\\entity> 2 days later.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2493",
    "Sentence": "A diagnosis of <\\entity><\\entity> was made, and early intravenous ACV therapy successfully alleviated the epigastric pain and skin lesions within 2 weeks.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2494",
    "Sentence": "A diagnosis of visceral varicella-zoster disease was made, and early <\\entity><\\entity> therapy successfully alleviated the epigastric pain and skin lesions within 2 weeks.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2495",
    "Sentence": "A diagnosis of visceral varicella-zoster disease was made, and early <\\entity><\\entity> therapy successfully alleviated the epigastric pain and skin lesions within 2 weeks.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2496",
    "Sentence": "A diagnosis of visceral varicella-zoster disease was made, and early intravenous ACV therapy successfully alleviated the <\\entity><\\entity> and skin lesions within 2 weeks.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2497",
    "Sentence": "A diagnosis of visceral varicella-zoster disease was made, and early intravenous ACV therapy successfully alleviated the epigastric pain and <\\entity><\\entity> within 2 weeks.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2498",
    "Sentence": "Polymerase chain reaction analysis of the serum showed dramatic decreases in the viral DNA copy number and revealed large viral concentrations prior to the <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2499",
    "Sentence": "Further treatment with <\\entity><\\entity> led to VZV DNA becoming undetectable in whole blood, a result not achieved with oral valacyclovir.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2500",
    "Sentence": "Further treatment with <\\entity><\\entity> led to VZV DNA becoming undetectable in whole blood, a result not achieved with oral valacyclovir.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2501",
    "Sentence": "Further treatment with intravenous ACV led to <\\entity><\\entity> DNA becoming undetectable in whole blood, a result not achieved with oral valacyclovir.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2502",
    "Sentence": "Further treatment with intravenous ACV led to VZV DNA becoming undetectable in whole blood, a result not achieved with <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2503",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with <\\entity><\\entity>.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with <\\entity><\\entity> (ACV).",
    "Label": ""
  },
  {
    "id": "2504",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of <\\entity><\\entity> ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).",
    "Label": ""
  },
  {
    "id": "2506",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "2507",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed <\\entity><\\entity> (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).",
    "Label": ""
  },
  {
    "id": "2509",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "2510",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (<\\entity><\\entity> following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).",
    "Label": ""
  },
  {
    "id": "2512",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with <\\entity><\\entity>.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with <\\entity><\\entity> (ACV).",
    "Label": ""
  },
  {
    "id": "2513",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed <\\entity><\\entity> (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).",
    "Label": ""
  },
  {
    "id": "2515",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with <\\entity><\\entity>.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with <\\entity><\\entity> (ACV).",
    "Label": ""
  },
  {
    "id": "2516",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (<\\entity><\\entity> following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).",
    "Label": ""
  },
  {
    "id": "2518",
    "Sentence": "A diagnosis of visceral varicella-zoster disease was made, and early <\\entity><\\entity> therapy successfully alleviated the epigastric pain and skin lesions within 2 weeks.",
    "Label": ""
  },
  {
    "id": "2519",
    "Sentence": "A diagnosis of visceral varicella-zoster disease was made, and early intravenous ACV therapy successfully alleviated the <\\entity><\\entity> and skin lesions within 2 weeks.",
    "Label": ""
  },
  {
    "id": "2521",
    "Sentence": "A diagnosis of visceral varicella-zoster disease was made, and early <\\entity><\\entity> therapy successfully alleviated the epigastric pain and skin lesions within 2 weeks.",
    "Label": ""
  },
  {
    "id": "2522",
    "Sentence": "A diagnosis of visceral varicella-zoster disease was made, and early intravenous ACV therapy successfully alleviated the epigastric pain and <\\entity><\\entity> within 2 weeks.",
    "Label": ""
  },
  {
    "id": "2524",
    "Sentence": "A diagnosis of visceral varicella-zoster disease was made, and early <\\entity><\\entity> therapy successfully alleviated the epigastric pain and skin lesions within 2 weeks.",
    "Label": ""
  },
  {
    "id": "2525",
    "Sentence": "A diagnosis of <\\entity><\\entity> was made, and early intravenous ACV therapy successfully alleviated the epigastric pain and skin lesions within 2 weeks.",
    "Label": ""
  },
  {
    "id": "2527",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with <\\entity><\\entity>.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with <\\entity><\\entity> (ACV).",
    "Label": ""
  },
  {
    "id": "2528",
    "Sentence": "Quantification of circulating <\\entity><\\entity> DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral <\\entity><\\entity> (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).",
    "Label": ""
  },
  {
    "id": "2530",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "2531",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with <\\entity><\\entity> (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).",
    "Label": ""
  },
  {
    "id": "2533",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "2534",
    "Sentence": "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir.We describe a patient with acute lymphocytic leukemia (<\\entity><\\entity>) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).",
    "Label": ""
  },
  {
    "id": "2536",
    "Sentence": "Further treatment with <\\entity><\\entity> led to VZV DNA becoming undetectable in whole blood, a result not achieved with oral valacyclovir.",
    "Label": ""
  },
  {
    "id": "2537",
    "Sentence": "Further treatment with intravenous ACV led to <\\entity><\\entity> DNA becoming undetectable in whole blood, a result not achieved with oral valacyclovir.",
    "Label": ""
  },
  {
    "id": "2539",
    "Sentence": "Further treatment with intravenous ACV led to VZV DNA becoming undetectable in whole blood, a result not achieved with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2540",
    "Sentence": "Further treatment with intravenous ACV led to <\\entity><\\entity> DNA becoming undetectable in whole blood, a result not achieved with oral valacyclovir.",
    "Label": ""
  },
  {
    "id": "2546",
    "Sentence": "Association between <\\entity><\\entity> exposure and levels of C-reactive protein in the Oslo II Study.It is well known that <\\entity><\\entity> exposure is related to the risk of developing cardiovascular diseases and events.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2547",
    "Sentence": "Association between <\\entity><\\entity> exposure and levels of C-reactive protein in the Oslo II Study.It is well known that <\\entity><\\entity> exposure is related to the risk of developing cardiovascular diseases and events.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2548",
    "Sentence": "Association between tobacco smoke exposure and levels of C-reactive protein in the Oslo II Study.It is well known that tobacco smoke exposure is related to the risk of developing <\\entity><\\entity> and events.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2549",
    "Sentence": "One mechanism could be that <\\entity><\\entity> acts on the cardiovascular system by altering the autonomic function and/or inducing inflammatory responses.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2550",
    "Sentence": "One mechanism could be that tobacco smoke acts on the cardiovascular system by altering the autonomic function and/or inducing <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2551",
    "Sentence": "We used data from 3 744 men aged 67-77 years from the city of Oslo that participated in the health screening for the Oslo II Health Study in 2000, to explore associations between C-reactive protein and environmental exposures including exposure to <\\entity><\\entity> products.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2552",
    "Sentence": "The risk of elevated C-reactive protein increased with both numbers of current cigarettes smoked per day and numbers of pack-years of <\\entity><\\entity>, when other factors were adjusted for (P < 0.001).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2553",
    "Sentence": "We found a positive dose-response relationship between amount of current cigarette <\\entity><\\entity> and elevated C-reactive protein levels.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2554",
    "Sentence": "These findings support the idea that the induction or exacerbation of <\\entity><\\entity> could be a mechanism by which smoking promotes atherosclerotic cardiovascular diseases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2555",
    "Sentence": "These findings support the idea that the induction or exacerbation of inflammation could be a mechanism by which <\\entity><\\entity> promotes atherosclerotic cardiovascular diseases.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2556",
    "Sentence": "These findings support the idea that the induction or exacerbation of inflammation could be a mechanism by which smoking promotes <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2557",
    "Sentence": "Association between <\\entity><\\entity> exposure and levels of C-reactive protein in the Oslo II Study.It is well known that <\\entity><\\entity> exposure is related to the risk of developing cardiovascular diseases and events.",
    "Label": ""
  },
  {
    "id": "2558",
    "Sentence": "Association between tobacco smoke exposure and levels of C-reactive protein in the Oslo II Study.It is well known that tobacco smoke exposure is related to the risk of developing <\\entity><\\entity> and events.",
    "Label": ""
  },
  {
    "id": "2560",
    "Sentence": "These findings support the idea that the induction or exacerbation of inflammation could be a mechanism by which <\\entity><\\entity> promotes atherosclerotic cardiovascular diseases.",
    "Label": ""
  },
  {
    "id": "2561",
    "Sentence": "These findings support the idea that the induction or exacerbation of <\\entity><\\entity> could be a mechanism by which smoking promotes atherosclerotic cardiovascular diseases.",
    "Label": ""
  },
  {
    "id": "2563",
    "Sentence": "These findings support the idea that the induction or exacerbation of inflammation could be a mechanism by which <\\entity><\\entity> promotes atherosclerotic cardiovascular diseases.",
    "Label": ""
  },
  {
    "id": "2564",
    "Sentence": "These findings support the idea that the induction or exacerbation of inflammation could be a mechanism by which smoking promotes <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2566",
    "Sentence": "One mechanism could be that <\\entity><\\entity> acts on the cardiovascular system by altering the autonomic function and/or inducing inflammatory responses.",
    "Label": ""
  },
  {
    "id": "2567",
    "Sentence": "One mechanism could be that tobacco smoke acts on the cardiovascular system by altering the autonomic function and/or inducing <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2573",
    "Sentence": "Pivotal advance: endogenous pathway to SIRS, sepsis, and related conditions.<\\entity><\\entity> are usually thought to recognize substances produced by microorganisms and thus, to initiate host defenses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2574",
    "Sentence": "Recognition of endogenous substances may explain the broader functions of <\\entity><\\entity> in physiology and disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2575",
    "Sentence": "Activation of <\\entity><\\entity> by endogenous substances necessitates vigorous control of the function of the receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2576",
    "Sentence": "This communication will summarize a line of research, which points to an endogenous agonist for <\\entity><\\entity> and a putative mechanism for controlling the function of that receptor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2581",
    "Sentence": "Effect of <\\entity><\\entity> chelation therapy on postural balance and gait outcomes in children with early exposure to environmental lead.This study investigated the influence of <\\entity><\\entity> chelation therapy in eliminating and/or minimizing lead-associated impairments of motor functions such as postural balance and locomotion or gait activities.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2582",
    "Sentence": "Effect of succimer chelation therapy on postural balance and gait outcomes in children with early exposure to environmental <\\entity><\\entity>.This study investigated the influence of succimer chelation therapy in eliminating and/or minimizing <\\entity><\\entity>-associated impairments of motor functions such as postural balance and locomotion or gait activities.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2583",
    "Sentence": "Effect of <\\entity><\\entity> chelation therapy on postural balance and gait outcomes in children with early exposure to environmental lead.This study investigated the influence of <\\entity><\\entity> chelation therapy in eliminating and/or minimizing lead-associated impairments of motor functions such as postural balance and locomotion or gait activities.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2584",
    "Sentence": "Effect of succimer chelation therapy on postural balance and gait outcomes in children with early exposure to environmental <\\entity><\\entity>.This study investigated the influence of succimer chelation therapy in eliminating and/or minimizing <\\entity><\\entity>-associated impairments of motor functions such as postural balance and locomotion or gait activities.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2585",
    "Sentence": "Effect of succimer chelation therapy on postural balance and gait outcomes in children with early exposure to environmental lead.This study investigated the influence of succimer chelation therapy in eliminating and/or minimizing lead-associated <\\entity><\\entity> such as postural balance and locomotion or gait activities.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2586",
    "Sentence": "In this study, postural balance and functional locomotion or gait were quantitated in 161 children in Cincinnati enrolled in a randomized, placebo-controlled, double <\\entity><\\entity> clinical trial.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2587",
    "Sentence": "In comparison to the placebo group, the <\\entity><\\entity> therapy group showed significantly decreased postural sway during dynamic task performance implying improved postural balance.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2588",
    "Sentence": "The results from locomotion tests demonstrated significant improvements in functional tasks of obstacle <\\entity><\\entity> and normal walking in the succimer treated group.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2589",
    "Sentence": "The results from locomotion tests demonstrated significant improvements in functional tasks of obstacle crossing and normal walking in the <\\entity><\\entity> treated group.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2590",
    "Sentence": "While some beneficial neuromotor effects of <\\entity><\\entity> therapy were observed in the present study there remains several unanswered questions such as how long these effects will persist and how <\\entity><\\entity> therapy modifies lead-associated cerebellar deficits manifesting as perturbations in vestibular and/or proprioception systems for postural balance and functional locomotion.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2591",
    "Sentence": "While some beneficial neuromotor effects of <\\entity><\\entity> therapy were observed in the present study there remains several unanswered questions such as how long these effects will persist and how <\\entity><\\entity> therapy modifies lead-associated cerebellar deficits manifesting as perturbations in vestibular and/or proprioception systems for postural balance and functional locomotion.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2592",
    "Sentence": "While some beneficial neuromotor effects of succimer therapy were observed in the present study there remains several unanswered questions such as how long these effects will persist and how succimer therapy modifies <\\entity><\\entity>-associated cerebellar deficits manifesting as perturbations in vestibular and/or proprioception systems for postural balance and functional locomotion.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2593",
    "Sentence": "While some beneficial neuromotor effects of succimer therapy were observed in the present study there remains several unanswered questions such as how long these effects will persist and how succimer therapy modifies lead-associated <\\entity><\\entity> manifesting as perturbations in vestibular and/or proprioception systems for postural balance and functional locomotion.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2594",
    "Sentence": "Effect of succimer chelation therapy on postural balance and gait outcomes in children with early exposure to environmental <\\entity><\\entity>.This study investigated the influence of succimer chelation therapy in eliminating and/or minimizing <\\entity><\\entity>-associated impairments of motor functions such as postural balance and locomotion or gait activities.",
    "Label": ""
  },
  {
    "id": "2595",
    "Sentence": "Effect of succimer chelation therapy on postural balance and gait outcomes in children with early exposure to environmental lead.This study investigated the influence of succimer chelation therapy in eliminating and/or minimizing lead-associated <\\entity><\\entity> such as postural balance and locomotion or gait activities.",
    "Label": ""
  },
  {
    "id": "2597",
    "Sentence": "While some beneficial neuromotor effects of <\\entity><\\entity> therapy were observed in the present study there remains several unanswered questions such as how long these effects will persist and how <\\entity><\\entity> therapy modifies lead-associated cerebellar deficits manifesting as perturbations in vestibular and/or proprioception systems for postural balance and functional locomotion.",
    "Label": ""
  },
  {
    "id": "2598",
    "Sentence": "While some beneficial neuromotor effects of succimer therapy were observed in the present study there remains several unanswered questions such as how long these effects will persist and how succimer therapy modifies lead-associated <\\entity><\\entity> manifesting as perturbations in vestibular and/or proprioception systems for postural balance and functional locomotion.",
    "Label": ""
  },
  {
    "id": "2600",
    "Sentence": "While some beneficial neuromotor effects of succimer therapy were observed in the present study there remains several unanswered questions such as how long these effects will persist and how succimer therapy modifies <\\entity><\\entity>-associated cerebellar deficits manifesting as perturbations in vestibular and/or proprioception systems for postural balance and functional locomotion.",
    "Label": ""
  },
  {
    "id": "2601",
    "Sentence": "While some beneficial neuromotor effects of succimer therapy were observed in the present study there remains several unanswered questions such as how long these effects will persist and how succimer therapy modifies lead-associated <\\entity><\\entity> manifesting as perturbations in vestibular and/or proprioception systems for postural balance and functional locomotion.",
    "Label": ""
  },
  {
    "id": "2603",
    "Sentence": "The results from locomotion tests demonstrated significant improvements in functional tasks of obstacle crossing and normal walking in the <\\entity><\\entity> treated group.",
    "Label": ""
  },
  {
    "id": "2604",
    "Sentence": "The results from locomotion tests demonstrated significant improvements in functional tasks of obstacle <\\entity><\\entity> and normal walking in the succimer treated group.",
    "Label": ""
  },
  {
    "id": "2610",
    "Sentence": "Pharmacokinetics of <\\entity><\\entity> and MP6-XT22 anti-murine TNF-alpha mAb in mice.Immunologic limitations make it difficult to study the pharmacokinetic effects of human tumor necrosis factor (TNF) blockers in murine models.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2611",
    "Sentence": "Pharmacokinetics of murine <\\entity><\\entity> fusion protein and MP6-XT22 anti-murine TNF-alpha mAb in mice.Immunologic limitations make it difficult to study the pharmacokinetic effects of human tumor necrosis factor (TNF) blockers in murine models.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2612",
    "Sentence": "Pharmacokinetics of murine <\\entity><\\entity> fusion protein and MP6-XT22 anti-murine TNF-alpha mAb in mice.Immunologic limitations make it difficult to study the pharmacokinetic effects of human tumor necrosis factor (TNF) blockers in murine models.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2613",
    "Sentence": "Pharmacokinetics of murine p75-Fc fusion protein and <\\entity><\\entity> in mice.Immunologic limitations make it difficult to study the pharmacokinetic effects of human tumor necrosis factor (TNF) blockers in murine models.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2614",
    "Sentence": "Pharmacokinetics of murine p75-Fc fusion protein and MP6-XT22 anti-murine <\\entity><\\entity> mAb in mice.Immunologic limitations make it difficult to study the pharmacokinetic effects of human tumor necrosis factor (TNF) blockers in murine models.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2615",
    "Sentence": "Pharmacokinetics of murine p75-Fc fusion protein and MP6-XT22 anti-murine TNF-alpha mAb in mice.Immunologic limitations make it difficult to study the pharmacokinetic effects of human <\\entity><\\entity> (TNF) blockers in murine models.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2616",
    "Sentence": "Pharmacokinetics of murine p75-Fc fusion protein and MP6-XT22 anti-murine TNF-alpha mAb in mice.Immunologic limitations make it difficult to study the pharmacokinetic effects of human <\\entity><\\entity> (TNF) blockers in murine models.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2617",
    "Sentence": "Pharmacokinetics of murine p75-Fc fusion protein and MP6-XT22 anti-murine <\\entity><\\entity>-alpha mAb in mice.Immunologic limitations make it difficult to study the pharmacokinetic effects of human tumor necrosis factor (<\\entity><\\entity>) blockers in murine models.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2618",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human <\\entity><\\entity> blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine <\\entity><\\entity> mAb (analogous to infliximab).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2619",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human <\\entity><\\entity> blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine <\\entity><\\entity> mAb (analogous to infliximab).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2620",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a <\\entity><\\entity> (analogous to etanercept), and the rat MP6-XT22 anti-murine TNF mAb (analogous to infliximab).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2621",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine <\\entity><\\entity> fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine TNF mAb (analogous to infliximab).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2622",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine <\\entity><\\entity> fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine TNF mAb (analogous to infliximab).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2623",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine p75-FC fusion protein (analogous to <\\entity><\\entity>), and the rat MP6-XT22 anti-murine TNF mAb (analogous to infliximab).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2624",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine p75-FC fusion protein (analogous to <\\entity><\\entity>), and the rat MP6-XT22 anti-murine TNF mAb (analogous to infliximab).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2625",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat <\\entity><\\entity> (analogous to infliximab).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2626",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human <\\entity><\\entity> blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine <\\entity><\\entity> mAb (analogous to infliximab).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2627",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine TNF mAb (analogous to <\\entity><\\entity>).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2628",
    "Sentence": "We analyzed the pharmacokinetics of the <\\entity><\\entity> and MP6-XT22 antibody in mice that were uninfected and in mice with disseminated candidiasis in order to confirm dosing strategies and interpret future studies evaluating the efficacy and tolerability of these agents in mice.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2629",
    "Sentence": "We analyzed the pharmacokinetics of the murine <\\entity><\\entity> protein and MP6-XT22 antibody in mice that were uninfected and in mice with disseminated candidiasis in order to confirm dosing strategies and interpret future studies evaluating the efficacy and tolerability of these agents in mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2630",
    "Sentence": "We analyzed the pharmacokinetics of the murine <\\entity><\\entity> protein and MP6-XT22 antibody in mice that were uninfected and in mice with disseminated candidiasis in order to confirm dosing strategies and interpret future studies evaluating the efficacy and tolerability of these agents in mice.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2631",
    "Sentence": "We analyzed the pharmacokinetics of the murine p75-Fc protein and <\\entity><\\entity> in mice that were uninfected and in mice with disseminated candidiasis in order to confirm dosing strategies and interpret future studies evaluating the efficacy and tolerability of these agents in mice.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2632",
    "Sentence": "We propose that, while conducting safety or efficacy studies in murine disease models, it is reasonable to administer the <\\entity><\\entity> to mice at <10 mg/kg every 4-5 days, and the MP6-XT22 antibody at 10-20 mg/kg every 4-5 days.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2633",
    "Sentence": "We propose that, while conducting safety or efficacy studies in murine disease models, it is reasonable to administer the murine <\\entity><\\entity> protein to mice at <10 mg/kg every 4-5 days, and the MP6-XT22 antibody at 10-20 mg/kg every 4-5 days.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2634",
    "Sentence": "We propose that, while conducting safety or efficacy studies in murine disease models, it is reasonable to administer the murine <\\entity><\\entity> protein to mice at <10 mg/kg every 4-5 days, and the MP6-XT22 antibody at 10-20 mg/kg every 4-5 days.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2635",
    "Sentence": "We propose that, while conducting safety or efficacy studies in murine disease models, it is reasonable to administer the murine p75-Fc protein to mice at <10 mg/kg every 4-5 days, and the <\\entity><\\entity> at 10-20 mg/kg every 4-5 days.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2636",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine p75-FC fusion protein (analogous to <\\entity><\\entity>), and the rat MP6-XT22 anti-murine TNF mAb (analogous to infliximab).",
    "Label": ""
  },
  {
    "id": "2637",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human <\\entity><\\entity> blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine <\\entity><\\entity> mAb (analogous to infliximab).",
    "Label": ""
  },
  {
    "id": "2639",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine TNF mAb (analogous to <\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "2640",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human <\\entity><\\entity> blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine <\\entity><\\entity> mAb (analogous to infliximab).",
    "Label": ""
  },
  {
    "id": "2642",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a <\\entity><\\entity> (analogous to etanercept), and the rat MP6-XT22 anti-murine TNF mAb (analogous to infliximab).",
    "Label": ""
  },
  {
    "id": "2643",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human <\\entity><\\entity> blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine <\\entity><\\entity> mAb (analogous to infliximab).",
    "Label": ""
  },
  {
    "id": "2645",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat <\\entity><\\entity> (analogous to infliximab).",
    "Label": ""
  },
  {
    "id": "2646",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human <\\entity><\\entity> blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine <\\entity><\\entity> mAb (analogous to infliximab).",
    "Label": ""
  },
  {
    "id": "2648",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine TNF mAb (analogous to <\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "2649",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine p75-FC fusion protein (analogous to <\\entity><\\entity>), and the rat MP6-XT22 anti-murine TNF mAb (analogous to infliximab).",
    "Label": ""
  },
  {
    "id": "2651",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine p75-FC fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine TNF mAb (analogous to <\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "2652",
    "Sentence": "To counter this, we have studied the pharmacokinetics in mice of two murine analogs of human TNF blockers, a murine <\\entity><\\entity> fusion protein (analogous to etanercept), and the rat MP6-XT22 anti-murine TNF mAb (analogous to infliximab).",
    "Label": ""
  },
  {
    "id": "2658",
    "Sentence": "Distinct involvement of <\\entity><\\entity>-, ERK1/2 and PKC signaling pathways in C5a-mediated priming of oxidative burst in phagocytic cells.C5a exerts various known harmful functions during experimental sepsis and blocking strategies demonstrated survival benefits in experimental sepsis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2659",
    "Sentence": "Distinct involvement of p38-, <\\entity><\\entity> and PKC signaling pathways in C5a-mediated priming of oxidative burst in phagocytic cells.C5a exerts various known harmful functions during experimental sepsis and blocking strategies demonstrated survival benefits in experimental sepsis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2660",
    "Sentence": "Distinct involvement of p38-, ERK1/2 and <\\entity><\\entity> signaling pathways in C5a-mediated priming of oxidative burst in phagocytic cells.C5a exerts various known harmful functions during experimental sepsis and blocking strategies demonstrated survival benefits in experimental sepsis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2661",
    "Sentence": "Distinct involvement of p38-, ERK1/2 and PKC signaling pathways in <\\entity><\\entity>-mediated priming of oxidative burst in phagocytic cells.<\\entity><\\entity> exerts various known harmful functions during experimental sepsis and blocking strategies demonstrated survival benefits in experimental sepsis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2662",
    "Sentence": "Distinct involvement of p38-, ERK1/2 and PKC signaling pathways in <\\entity><\\entity>-mediated priming of oxidative burst in phagocytic cells.<\\entity><\\entity> exerts various known harmful functions during experimental sepsis and blocking strategies demonstrated survival benefits in experimental sepsis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2663",
    "Sentence": "We here report that <\\entity><\\entity> induced priming of neutrophils and monocytes for Escherichia coli- and PMA-induced oxidative burst.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2664",
    "Sentence": "We here report that C5a induced priming of neutrophils and monocytes for Escherichia coli- and <\\entity><\\entity>-induced oxidative burst.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2665",
    "Sentence": "This effect was strongly dependent on intact <\\entity><\\entity> signaling.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2666",
    "Sentence": "<\\entity><\\entity> inhibition resulted in abrogation of C5a-induced priming only for E.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2667",
    "Sentence": "P38 inhibition resulted in abrogation of <\\entity><\\entity>-induced priming only for E.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2668",
    "Sentence": "coli-induced oxidative burst and <\\entity><\\entity> blockade had this effect only for PMA-induced burst.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2669",
    "Sentence": "coli-induced oxidative burst and PKC blockade had this effect only for <\\entity><\\entity>-induced burst.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2670",
    "Sentence": "<\\entity><\\entity> inhibition had no impact.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2671",
    "Sentence": "Our results demonstrate for the first time distinct involvement of <\\entity><\\entity>, p38 and PKC pathways for C5a-induced priming of oxidative burst in phagocytes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2672",
    "Sentence": "Our results demonstrate for the first time distinct involvement of ERK1/2, <\\entity><\\entity> and PKC pathways for C5a-induced priming of oxidative burst in phagocytes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2673",
    "Sentence": "Our results demonstrate for the first time distinct involvement of ERK1/2, p38 and <\\entity><\\entity> pathways for C5a-induced priming of oxidative burst in phagocytes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2674",
    "Sentence": "Our results demonstrate for the first time distinct involvement of ERK1/2, p38 and PKC pathways for <\\entity><\\entity>-induced priming of oxidative burst in phagocytes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2675",
    "Sentence": "We here report that C5a induced priming of neutrophils and monocytes for Escherichia coli- and <\\entity><\\entity>-induced oxidative burst.",
    "Label": ""
  },
  {
    "id": "2676",
    "Sentence": "We here report that <\\entity><\\entity> induced priming of neutrophils and monocytes for Escherichia coli- and PMA-induced oxidative burst.",
    "Label": ""
  },
  {
    "id": "2678",
    "Sentence": "coli-induced oxidative burst and PKC blockade had this effect only for <\\entity><\\entity>-induced burst.",
    "Label": ""
  },
  {
    "id": "2679",
    "Sentence": "coli-induced oxidative burst and <\\entity><\\entity> blockade had this effect only for PMA-induced burst.",
    "Label": ""
  },
  {
    "id": "2685",
    "Sentence": "Quantitative imaging of apoptosis commitment in colorectal tumor cells.We have studied <\\entity><\\entity> activation by combined DNA damage induction and EGFR kinase inhibition in order to identify potential EGFR-mediated survival signals conferring resistance to apoptosis in human colorectal tumor cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2686",
    "Sentence": "Quantitative imaging of apoptosis commitment in colorectal tumor cells.We have studied caspase-3 activation by combined DNA damage induction and <\\entity><\\entity> kinase inhibition in order to identify potential <\\entity><\\entity>-mediated survival signals conferring resistance to apoptosis in human colorectal tumor cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2687",
    "Sentence": "Quantitative imaging of apoptosis commitment in colorectal tumor cells.We have studied caspase-3 activation by combined DNA damage induction and <\\entity><\\entity> kinase inhibition in order to identify potential <\\entity><\\entity>-mediated survival signals conferring resistance to apoptosis in human colorectal tumor cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2688",
    "Sentence": "The onset of apoptosis was microscopically imaged with a newly developed <\\entity><\\entity> substrate sensor based on EGFP and tHcred1, enabling us to monitor <\\entity><\\entity> activation in cells by fluorescence lifetime imaging microscopy or fluorescence correlation spectroscopy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2689",
    "Sentence": "The onset of apoptosis was microscopically imaged with a newly developed caspase-3 substrate sensor based on <\\entity><\\entity> and tHcred1, enabling us to monitor caspase-3 activation in cells by fluorescence lifetime imaging microscopy or fluorescence correlation spectroscopy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2690",
    "Sentence": "The onset of apoptosis was microscopically imaged with a newly developed caspase-3 substrate sensor based on EGFP and <\\entity><\\entity>, enabling us to monitor caspase-3 activation in cells by fluorescence lifetime imaging microscopy or fluorescence correlation spectroscopy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2691",
    "Sentence": "The onset of apoptosis was microscopically imaged with a newly developed <\\entity><\\entity> substrate sensor based on EGFP and tHcred1, enabling us to monitor <\\entity><\\entity> activation in cells by fluorescence lifetime imaging microscopy or fluorescence correlation spectroscopy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2692",
    "Sentence": "Both optical approaches provide parameters quantitatively reporting the ratio between cleaved and uncleaved sensor, thereby facilitating the comparison of <\\entity><\\entity> activation between different cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2693",
    "Sentence": "Using these methods, we show that <\\entity><\\entity> sensitize colorectal SW-480 tumor cells for 5-fluorouracil-induced apoptosis, indicating that EGFR-mediated survival signaling contributes to apoptosis resistance via its intrinsic kinase activity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2694",
    "Sentence": "Using these methods, we show that <\\entity><\\entity> sensitize colorectal SW-480 tumor cells for 5-fluorouracil-induced apoptosis, indicating that EGFR-mediated survival signaling contributes to apoptosis resistance via its intrinsic kinase activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2695",
    "Sentence": "Using these methods, we show that EGFR kinase inhibitors sensitize colorectal SW-480 tumor cells for <\\entity><\\entity>-induced apoptosis, indicating that EGFR-mediated survival signaling contributes to apoptosis resistance via its intrinsic kinase activity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2696",
    "Sentence": "Using these methods, we show that <\\entity><\\entity> kinase inhibitors sensitize colorectal SW-480 tumor cells for 5-fluorouracil-induced apoptosis, indicating that <\\entity><\\entity>-mediated survival signaling contributes to apoptosis resistance via its intrinsic kinase activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2697",
    "Sentence": "Using these methods, we show that EGFR kinase inhibitors sensitize colorectal SW-480 tumor cells for <\\entity><\\entity>-induced apoptosis, indicating that EGFR-mediated survival signaling contributes to apoptosis resistance via its intrinsic kinase activity.",
    "Label": ""
  },
  {
    "id": "2698",
    "Sentence": "Using these methods, we show that <\\entity><\\entity> kinase inhibitors sensitize colorectal SW-480 tumor cells for 5-fluorouracil-induced apoptosis, indicating that <\\entity><\\entity>-mediated survival signaling contributes to apoptosis resistance via its intrinsic kinase activity.",
    "Label": ""
  },
  {
    "id": "2700",
    "Sentence": "Using these methods, we show that <\\entity><\\entity> sensitize colorectal SW-480 tumor cells for 5-fluorouracil-induced apoptosis, indicating that EGFR-mediated survival signaling contributes to apoptosis resistance via its intrinsic kinase activity.",
    "Label": ""
  },
  {
    "id": "2701",
    "Sentence": "Using these methods, we show that <\\entity><\\entity> kinase inhibitors sensitize colorectal SW-480 tumor cells for 5-fluorouracil-induced apoptosis, indicating that <\\entity><\\entity>-mediated survival signaling contributes to apoptosis resistance via its intrinsic kinase activity.",
    "Label": ""
  },
  {
    "id": "2707",
    "Sentence": "Apoptotic action of <\\entity><\\entity> activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation.Peroxisome proliferator-activated receptor (PPAR)-gamma ligands have been shown to inhibit human lung cancers by inducing apoptosis and differentiation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2708",
    "Sentence": "Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via <\\entity><\\entity>-induced reactive oxygen species formation.Peroxisome proliferator-activated receptor (PPAR)-gamma ligands have been shown to inhibit human lung cancers by inducing apoptosis and differentiation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2709",
    "Sentence": "Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced <\\entity><\\entity> formation.Peroxisome proliferator-activated receptor (PPAR)-gamma ligands have been shown to inhibit human lung cancers by inducing apoptosis and differentiation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2710",
    "Sentence": "Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced <\\entity><\\entity> formation.Peroxisome proliferator-activated receptor (PPAR)-gamma ligands have been shown to inhibit human lung cancers by inducing apoptosis and differentiation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2711",
    "Sentence": "Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation.<\\entity><\\entity> (PPAR)-gamma ligands have been shown to inhibit human lung cancers by inducing apoptosis and differentiation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2712",
    "Sentence": "Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation.<\\entity><\\entity> (PPAR)-gamma ligands have been shown to inhibit human lung cancers by inducing apoptosis and differentiation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2713",
    "Sentence": "Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation.Peroxisome proliferator-activated receptor (<\\entity><\\entity> have been shown to inhibit human lung cancers by inducing apoptosis and differentiation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2714",
    "Sentence": "Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation.Peroxisome proliferator-activated receptor (<\\entity><\\entity> have been shown to inhibit human lung cancers by inducing apoptosis and differentiation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2715",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of <\\entity><\\entity> activation in human lung cancers by using a novel <\\entity><\\entity> agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and rosiglitazone.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2716",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel <\\entity><\\entity>, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and rosiglitazone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2717",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel <\\entity><\\entity>, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and rosiglitazone.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2718",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel PPARgamma agonist, <\\entity><\\entity> (KR-62980), and rosiglitazone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2719",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel PPARgamma agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (<\\entity><\\entity>), and rosiglitazone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2720",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel PPARgamma agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2721",
    "Sentence": "<\\entity><\\entity> activation selectively inhibited cell viability of non-small-cell lung cancer with little effect on small-cell lung cancer and normal lung cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2722",
    "Sentence": "The cell death induced by <\\entity><\\entity> activation presented apoptotic features of oligonucleosomal DNA fragmentation in A549 human non-small-cell lung cancer cell line.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2723",
    "Sentence": "<\\entity><\\entity> (ROS) production was accompanied by increased expression of proline oxidase (POX), a redox enzyme expressed in mitochondria, upon incubation with the agonists.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2724",
    "Sentence": "<\\entity><\\entity> (ROS) production was accompanied by increased expression of proline oxidase (POX), a redox enzyme expressed in mitochondria, upon incubation with the agonists.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2725",
    "Sentence": "Reactive oxygen species (<\\entity><\\entity>) production was accompanied by increased expression of proline oxidase (POX), a redox enzyme expressed in mitochondria, upon incubation with the agonists.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2726",
    "Sentence": "Reactive oxygen species (<\\entity><\\entity>) production was accompanied by increased expression of proline oxidase (POX), a redox enzyme expressed in mitochondria, upon incubation with the agonists.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2727",
    "Sentence": "Reactive oxygen species (ROS) production was accompanied by increased expression of <\\entity><\\entity> (POX), a redox enzyme expressed in mitochondria, upon incubation with the agonists.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2728",
    "Sentence": "Reactive oxygen species (ROS) production was accompanied by increased expression of proline oxidase (<\\entity><\\entity>), a redox enzyme expressed in mitochondria, upon incubation with the agonists.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2729",
    "Sentence": "<\\entity><\\entity> RNA interference treatment blocked PPARgamma-induced ROS formation and cytotoxicity, suggesting that <\\entity><\\entity> plays a functional role in apoptosis through ROS formation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2730",
    "Sentence": "POX RNA interference treatment blocked <\\entity><\\entity>-induced ROS formation and cytotoxicity, suggesting that POX plays a functional role in apoptosis through ROS formation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2731",
    "Sentence": "POX RNA interference treatment blocked PPARgamma-induced <\\entity><\\entity> formation and cytotoxicity, suggesting that POX plays a functional role in apoptosis through <\\entity><\\entity> formation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2732",
    "Sentence": "POX RNA interference treatment blocked PPARgamma-induced <\\entity><\\entity> formation and cytotoxicity, suggesting that POX plays a functional role in apoptosis through <\\entity><\\entity> formation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2733",
    "Sentence": "<\\entity><\\entity> RNA interference treatment blocked PPARgamma-induced ROS formation and cytotoxicity, suggesting that <\\entity><\\entity> plays a functional role in apoptosis through ROS formation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2734",
    "Sentence": "POX RNA interference treatment blocked PPARgamma-induced <\\entity><\\entity> formation and cytotoxicity, suggesting that POX plays a functional role in apoptosis through <\\entity><\\entity> formation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2735",
    "Sentence": "POX RNA interference treatment blocked PPARgamma-induced <\\entity><\\entity> formation and cytotoxicity, suggesting that POX plays a functional role in apoptosis through <\\entity><\\entity> formation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2736",
    "Sentence": "The apoptotic effects by the agonists were antagonized by <\\entity><\\entity>, a PPARgamma antagonist, and by knockdown of PPARgamma expression, indicating the involvement of PPARgamma in these actions.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2737",
    "Sentence": "The apoptotic effects by the agonists were antagonized by bisphenol A diglycidyl ether, a <\\entity><\\entity>, and by knockdown of PPARgamma expression, indicating the involvement of PPARgamma in these actions.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2738",
    "Sentence": "The apoptotic effects by the agonists were antagonized by bisphenol A diglycidyl ether, a <\\entity><\\entity>, and by knockdown of PPARgamma expression, indicating the involvement of PPARgamma in these actions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2739",
    "Sentence": "The apoptotic effects by the agonists were antagonized by bisphenol A diglycidyl ether, a <\\entity><\\entity> antagonist, and by knockdown of <\\entity><\\entity> expression, indicating the involvement of <\\entity><\\entity> in these actions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2740",
    "Sentence": "The apoptotic effects by the agonists were antagonized by bisphenol A diglycidyl ether, a <\\entity><\\entity> antagonist, and by knockdown of <\\entity><\\entity> expression, indicating the involvement of <\\entity><\\entity> in these actions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2741",
    "Sentence": "The results of the present study suggest that <\\entity><\\entity> activation induces apoptotic cell death in non-small-cell lung carcinoma mainly through ROS formation via POX induction.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2742",
    "Sentence": "The results of the present study suggest that PPARgamma activation induces apoptotic cell death in non-small-cell lung carcinoma mainly through <\\entity><\\entity> formation via POX induction.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2743",
    "Sentence": "The results of the present study suggest that PPARgamma activation induces apoptotic cell death in non-small-cell lung carcinoma mainly through <\\entity><\\entity> formation via POX induction.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2744",
    "Sentence": "The results of the present study suggest that PPARgamma activation induces apoptotic cell death in non-small-cell lung carcinoma mainly through ROS formation via <\\entity><\\entity> induction.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2745",
    "Sentence": "Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced <\\entity><\\entity> formation.Peroxisome proliferator-activated receptor (PPAR)-gamma ligands have been shown to inhibit human lung cancers by inducing apoptosis and differentiation.",
    "Label": ""
  },
  {
    "id": "2746",
    "Sentence": "Apoptotic action of <\\entity><\\entity> activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation.Peroxisome proliferator-activated receptor (PPAR)-gamma ligands have been shown to inhibit human lung cancers by inducing apoptosis and differentiation.",
    "Label": ""
  },
  {
    "id": "2748",
    "Sentence": "Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced <\\entity><\\entity> formation.Peroxisome proliferator-activated receptor (PPAR)-gamma ligands have been shown to inhibit human lung cancers by inducing apoptosis and differentiation.",
    "Label": ""
  },
  {
    "id": "2749",
    "Sentence": "Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via <\\entity><\\entity>-induced reactive oxygen species formation.Peroxisome proliferator-activated receptor (PPAR)-gamma ligands have been shown to inhibit human lung cancers by inducing apoptosis and differentiation.",
    "Label": ""
  },
  {
    "id": "2751",
    "Sentence": "POX RNA interference treatment blocked PPARgamma-induced <\\entity><\\entity> formation and cytotoxicity, suggesting that POX plays a functional role in apoptosis through <\\entity><\\entity> formation.",
    "Label": ""
  },
  {
    "id": "2752",
    "Sentence": "POX RNA interference treatment blocked <\\entity><\\entity>-induced ROS formation and cytotoxicity, suggesting that POX plays a functional role in apoptosis through ROS formation.",
    "Label": ""
  },
  {
    "id": "2754",
    "Sentence": "POX RNA interference treatment blocked PPARgamma-induced <\\entity><\\entity> formation and cytotoxicity, suggesting that POX plays a functional role in apoptosis through <\\entity><\\entity> formation.",
    "Label": ""
  },
  {
    "id": "2755",
    "Sentence": "<\\entity><\\entity> RNA interference treatment blocked PPARgamma-induced ROS formation and cytotoxicity, suggesting that <\\entity><\\entity> plays a functional role in apoptosis through ROS formation.",
    "Label": ""
  },
  {
    "id": "2757",
    "Sentence": "The apoptotic effects by the agonists were antagonized by <\\entity><\\entity>, a PPARgamma antagonist, and by knockdown of PPARgamma expression, indicating the involvement of PPARgamma in these actions.",
    "Label": ""
  },
  {
    "id": "2758",
    "Sentence": "The apoptotic effects by the agonists were antagonized by bisphenol A diglycidyl ether, a <\\entity><\\entity> antagonist, and by knockdown of <\\entity><\\entity> expression, indicating the involvement of <\\entity><\\entity> in these actions.",
    "Label": ""
  },
  {
    "id": "2760",
    "Sentence": "The results of the present study suggest that PPARgamma activation induces apoptotic cell death in non-small-cell lung carcinoma mainly through <\\entity><\\entity> formation via POX induction.",
    "Label": ""
  },
  {
    "id": "2761",
    "Sentence": "The results of the present study suggest that <\\entity><\\entity> activation induces apoptotic cell death in non-small-cell lung carcinoma mainly through ROS formation via POX induction.",
    "Label": ""
  },
  {
    "id": "2763",
    "Sentence": "The results of the present study suggest that PPARgamma activation induces apoptotic cell death in non-small-cell lung carcinoma mainly through <\\entity><\\entity> formation via POX induction.",
    "Label": ""
  },
  {
    "id": "2764",
    "Sentence": "The results of the present study suggest that PPARgamma activation induces apoptotic cell death in non-small-cell lung carcinoma mainly through ROS formation via <\\entity><\\entity> induction.",
    "Label": ""
  },
  {
    "id": "2766",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel PPARgamma agonist, <\\entity><\\entity> (KR-62980), and rosiglitazone.",
    "Label": ""
  },
  {
    "id": "2767",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel <\\entity><\\entity>, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and rosiglitazone.",
    "Label": ""
  },
  {
    "id": "2769",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel PPARgamma agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (<\\entity><\\entity>), and rosiglitazone.",
    "Label": ""
  },
  {
    "id": "2770",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel <\\entity><\\entity>, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and rosiglitazone.",
    "Label": ""
  },
  {
    "id": "2772",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel PPARgamma agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2773",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel <\\entity><\\entity>, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and rosiglitazone.",
    "Label": ""
  },
  {
    "id": "2775",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel PPARgamma agonist, <\\entity><\\entity> (KR-62980), and rosiglitazone.",
    "Label": ""
  },
  {
    "id": "2776",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of <\\entity><\\entity> activation in human lung cancers by using a novel <\\entity><\\entity> agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and rosiglitazone.",
    "Label": ""
  },
  {
    "id": "2778",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel <\\entity><\\entity>, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and rosiglitazone.",
    "Label": ""
  },
  {
    "id": "2779",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of <\\entity><\\entity> activation in human lung cancers by using a novel <\\entity><\\entity> agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and rosiglitazone.",
    "Label": ""
  },
  {
    "id": "2781",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of PPARgamma activation in human lung cancers by using a novel PPARgamma agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2782",
    "Sentence": "In the present study, we elucidated the apoptotic mechanism of <\\entity><\\entity> activation in human lung cancers by using a novel <\\entity><\\entity> agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-(1H-indene-2-carboxylic acid ethyl ester (KR-62980), and rosiglitazone.",
    "Label": ""
  },
  {
    "id": "2784",
    "Sentence": "The apoptotic effects by the agonists were antagonized by bisphenol A diglycidyl ether, a <\\entity><\\entity>, and by knockdown of PPARgamma expression, indicating the involvement of PPARgamma in these actions.",
    "Label": ""
  },
  {
    "id": "2785",
    "Sentence": "The apoptotic effects by the agonists were antagonized by bisphenol A diglycidyl ether, a <\\entity><\\entity> antagonist, and by knockdown of <\\entity><\\entity> expression, indicating the involvement of <\\entity><\\entity> in these actions.",
    "Label": ""
  },
  {
    "id": "2791",
    "Sentence": "<\\entity><\\entity> outcome and tolerability: a practical clinical trial with plasma drug levels.INTRODUCTION: The aim of this study was to evaluate clinical outcomes and the tolerability of ziprasidone in relation to its plasma levels.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2792",
    "Sentence": "Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels.INTRODUCTION: The aim of this study was to evaluate clinical outcomes and the tolerability of <\\entity><\\entity> in relation to its plasma levels.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2793",
    "Sentence": "METHODS: Thirteen inpatients affected by <\\entity><\\entity> were included in the study after an acute exacerbation phase.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2794",
    "Sentence": "<\\entity><\\entity> monotherapy was administered for a period of eight weeks at a mean dose of 123.07+/-30.38 mg/day.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2795",
    "Sentence": "A significant clinical improvement was observed, especially in <\\entity><\\entity> ( P<0.05), and there was a significant improvement in extrapyramidal symptoms ( P<0.01).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2796",
    "Sentence": "A significant clinical improvement was observed, especially in negative symptoms ( P<0.05), and there was a significant improvement in <\\entity><\\entity> ( P<0.01).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2797",
    "Sentence": "Clinical laboratory tests, such as ECG and <\\entity><\\entity>, did not significantly change from baseline.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2798",
    "Sentence": "Plasma <\\entity><\\entity> levels ranged from 20 ng/mL to 160 ng/mL (mean: 75.8 ng/mL) and were significantly related to the improvement in negative symptoms.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2799",
    "Sentence": "Plasma ziprasidone levels ranged from 20 ng/mL to 160 ng/mL (mean: 75.8 ng/mL) and were significantly related to the improvement in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2800",
    "Sentence": "DISCUSSION: The study showed that <\\entity><\\entity> was effective and tolerable, that use of <\\entity><\\entity> was characterized by an absence of extrapyramidal symptoms and weight gain, and that no alterations in clinical laboratory tests occurred.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2801",
    "Sentence": "DISCUSSION: The study showed that <\\entity><\\entity> was effective and tolerable, that use of <\\entity><\\entity> was characterized by an absence of extrapyramidal symptoms and weight gain, and that no alterations in clinical laboratory tests occurred.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2802",
    "Sentence": "DISCUSSION: The study showed that ziprasidone was effective and tolerable, that use of ziprasidone was characterized by an <\\entity><\\entity> of extrapyramidal symptoms and weight gain, and that no alterations in clinical laboratory tests occurred.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2803",
    "Sentence": "DISCUSSION: The study showed that ziprasidone was effective and tolerable, that use of ziprasidone was characterized by an absence of <\\entity><\\entity> and weight gain, and that no alterations in clinical laboratory tests occurred.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2804",
    "Sentence": "DISCUSSION: The study showed that ziprasidone was effective and tolerable, that use of ziprasidone was characterized by an absence of extrapyramidal symptoms and <\\entity><\\entity>, and that no alterations in clinical laboratory tests occurred.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2805",
    "Sentence": "The findings suggest a relationship between plasma levels and the clinical response to <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2806",
    "Sentence": "The findings suggest a relationship between plasma levels and the clinical response to negative <\\entity><\\entity> of schizophrenia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2807",
    "Sentence": "Plasma <\\entity><\\entity> levels ranged from 20 ng/mL to 160 ng/mL (mean: 75.8 ng/mL) and were significantly related to the improvement in negative symptoms.",
    "Label": ""
  },
  {
    "id": "2808",
    "Sentence": "Plasma ziprasidone levels ranged from 20 ng/mL to 160 ng/mL (mean: 75.8 ng/mL) and were significantly related to the improvement in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2810",
    "Sentence": "DISCUSSION: The study showed that <\\entity><\\entity> was effective and tolerable, that use of <\\entity><\\entity> was characterized by an absence of extrapyramidal symptoms and weight gain, and that no alterations in clinical laboratory tests occurred.",
    "Label": ""
  },
  {
    "id": "2811",
    "Sentence": "DISCUSSION: The study showed that ziprasidone was effective and tolerable, that use of ziprasidone was characterized by an absence of <\\entity><\\entity> and weight gain, and that no alterations in clinical laboratory tests occurred.",
    "Label": ""
  },
  {
    "id": "2813",
    "Sentence": "DISCUSSION: The study showed that <\\entity><\\entity> was effective and tolerable, that use of <\\entity><\\entity> was characterized by an absence of extrapyramidal symptoms and weight gain, and that no alterations in clinical laboratory tests occurred.",
    "Label": ""
  },
  {
    "id": "2814",
    "Sentence": "DISCUSSION: The study showed that ziprasidone was effective and tolerable, that use of ziprasidone was characterized by an absence of <\\entity><\\entity> and weight gain, and that no alterations in clinical laboratory tests occurred.",
    "Label": ""
  },
  {
    "id": "2816",
    "Sentence": "DISCUSSION: The study showed that <\\entity><\\entity> was effective and tolerable, that use of <\\entity><\\entity> was characterized by an absence of extrapyramidal symptoms and weight gain, and that no alterations in clinical laboratory tests occurred.",
    "Label": ""
  },
  {
    "id": "2817",
    "Sentence": "DISCUSSION: The study showed that ziprasidone was effective and tolerable, that use of ziprasidone was characterized by an absence of extrapyramidal symptoms and <\\entity><\\entity>, and that no alterations in clinical laboratory tests occurred.",
    "Label": ""
  },
  {
    "id": "2823",
    "Sentence": "<\\entity><\\entity> in the management of hypertension.<\\entity><\\entity> have been maligned in recent years because of concerns regarding their cardiovascular and overall safety profile.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2824",
    "Sentence": "Dihydropyridine calcium channel antagonists in the management of <\\entity><\\entity>.Dihydropyridine calcium channel antagonists have been maligned in recent years because of concerns regarding their cardiovascular and overall safety profile.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2825",
    "Sentence": "<\\entity><\\entity> in the management of hypertension.<\\entity><\\entity> have been maligned in recent years because of concerns regarding their cardiovascular and overall safety profile.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2826",
    "Sentence": "Specifically, it was widely publicised in the mid-1990s that these agents might increase the risk of <\\entity><\\entity>, gastrointestinal bleeding and cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2827",
    "Sentence": "Specifically, it was widely publicised in the mid-1990s that these agents might increase the risk of myocardial infarction, <\\entity><\\entity> and cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2828",
    "Sentence": "Specifically, it was widely publicised in the mid-1990s that these agents might increase the risk of myocardial infarction, gastrointestinal bleeding and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2829",
    "Sentence": "Data linking these agents with increased cardiovascular risk were based on nonrandomised studies and implicated <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2830",
    "Sentence": "These results were inappropriately extrapolated to <\\entity><\\entity>, extended-release products, and to the non-dihydropyridine class.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2831",
    "Sentence": "These results were inappropriately extrapolated to longer-acting compounds, <\\entity><\\entity>, and to the non-dihydropyridine class.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2832",
    "Sentence": "These results were inappropriately extrapolated to longer-acting compounds, extended-release products, and to the <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2833",
    "Sentence": "Compared with both <\\entity><\\entity> and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2834",
    "Sentence": "Compared with both diuretics and <\\entity><\\entity>, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2835",
    "Sentence": "Compared with both diuretics and contemporary agents, <\\entity><\\entity> decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2836",
    "Sentence": "Compared with both diuretics and contemporary agents, amlodipine decreases <\\entity><\\entity> to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2837",
    "Sentence": "Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased <\\entity><\\entity>, gastrointestinal bleeding or cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2838",
    "Sentence": "Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, <\\entity><\\entity> or cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2839",
    "Sentence": "Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2840",
    "Sentence": "Despite these data, initial concerns have had lasting repercussions, as the use of <\\entity><\\entity> appears to lag behind what emerging data would support.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2841",
    "Sentence": "<\\entity><\\entity> have several noteworthy attributes that merit consideration in the management of hypertension.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2842",
    "Sentence": "Dihydropyridine calcium channel antagonists have several noteworthy attributes that merit consideration in the management of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2843",
    "Sentence": "The blood pressure response to this class of drugs is less contingent on patient factors such as age and race compared with other <\\entity><\\entity> (e.g.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2844",
    "Sentence": "<\\entity><\\entity>).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2845",
    "Sentence": "<\\entity><\\entity> may exert effects that protect against stroke that are independent of their blood pressure-lowering mechanism.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2846",
    "Sentence": "Dihydropyridine calcium channel antagonists may exert effects that protect against <\\entity><\\entity> that are independent of their blood pressure-lowering mechanism.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2847",
    "Sentence": "Unlike <\\entity><\\entity> and beta-adrenoceptor anatagonists (beta-blockers), dihydropyridine calcium channel antagonists are lipid neutral and do not disturb glucose homeostasis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2848",
    "Sentence": "Unlike diuretics and <\\entity><\\entity> (beta-blockers), dihydropyridine calcium channel antagonists are lipid neutral and do not disturb glucose homeostasis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2849",
    "Sentence": "Unlike diuretics and beta-adrenoceptor anatagonists (<\\entity><\\entity>), dihydropyridine calcium channel antagonists are lipid neutral and do not disturb glucose homeostasis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2850",
    "Sentence": "Unlike diuretics and beta-adrenoceptor anatagonists (beta-blockers), <\\entity><\\entity> are lipid neutral and do not disturb glucose homeostasis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2851",
    "Sentence": "Unlike diuretics and beta-adrenoceptor anatagonists (beta-blockers), dihydropyridine calcium channel antagonists are lipid neutral and do not disturb <\\entity><\\entity> homeostasis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2852",
    "Sentence": "<\\entity><\\entity> demonstrate a highly desirable profile when administered as part of combination therapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2853",
    "Sentence": "Combinations of <\\entity><\\entity> and ACE inhibitors or angiotensin receptor antagonists display additive efficacy and an enviable adverse-effect profile.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2854",
    "Sentence": "Combinations of dihydropyridine calcium channel antagonists and <\\entity><\\entity> or angiotensin receptor antagonists display additive efficacy and an enviable adverse-effect profile.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2855",
    "Sentence": "Combinations of dihydropyridine calcium channel antagonists and ACE inhibitors or <\\entity><\\entity> display additive efficacy and an enviable adverse-effect profile.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2856",
    "Sentence": "Combinations of dihydropyridine calcium channel antagonists and ACE inhibitors or angiotensin receptor antagonists display additive efficacy and an enviable <\\entity><\\entity> profile.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2857",
    "Sentence": "Collectively, the cardiovascular benefit, metabolic neutrality and homogeneous blood pressure response illuminated in recent studies, and reviewed here, represent a reaffirmation of the benefit of <\\entity><\\entity> and should serve to help reinforce the critical importance of these agents in the therapeutic armamentarium against cardiovascular disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2858",
    "Sentence": "Collectively, the cardiovascular benefit, metabolic neutrality and homogeneous blood pressure response illuminated in recent studies, and reviewed here, represent a reaffirmation of the benefit of long-acting dihydropyridine calcium channel antagonists and should serve to help reinforce the critical importance of these agents in the therapeutic armamentarium against <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2859",
    "Sentence": "Compared with both diuretics and contemporary agents, <\\entity><\\entity> decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.",
    "Label": ""
  },
  {
    "id": "2860",
    "Sentence": "Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2862",
    "Sentence": "Compared with both diuretics and contemporary agents, <\\entity><\\entity> decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.",
    "Label": ""
  },
  {
    "id": "2863",
    "Sentence": "Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased <\\entity><\\entity>, gastrointestinal bleeding or cancer.",
    "Label": ""
  },
  {
    "id": "2865",
    "Sentence": "Compared with both diuretics and contemporary agents, <\\entity><\\entity> decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.",
    "Label": ""
  },
  {
    "id": "2866",
    "Sentence": "Compared with both diuretics and contemporary agents, amlodipine decreases <\\entity><\\entity> to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.",
    "Label": ""
  },
  {
    "id": "2868",
    "Sentence": "Compared with both diuretics and contemporary agents, <\\entity><\\entity> decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.",
    "Label": ""
  },
  {
    "id": "2869",
    "Sentence": "Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, <\\entity><\\entity> or cancer.",
    "Label": ""
  },
  {
    "id": "2871",
    "Sentence": "<\\entity><\\entity> have several noteworthy attributes that merit consideration in the management of hypertension.",
    "Label": ""
  },
  {
    "id": "2872",
    "Sentence": "Dihydropyridine calcium channel antagonists have several noteworthy attributes that merit consideration in the management of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2874",
    "Sentence": "Collectively, the cardiovascular benefit, metabolic neutrality and homogeneous blood pressure response illuminated in recent studies, and reviewed here, represent a reaffirmation of the benefit of <\\entity><\\entity> and should serve to help reinforce the critical importance of these agents in the therapeutic armamentarium against cardiovascular disease.",
    "Label": ""
  },
  {
    "id": "2875",
    "Sentence": "Collectively, the cardiovascular benefit, metabolic neutrality and homogeneous blood pressure response illuminated in recent studies, and reviewed here, represent a reaffirmation of the benefit of long-acting dihydropyridine calcium channel antagonists and should serve to help reinforce the critical importance of these agents in the therapeutic armamentarium against <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2877",
    "Sentence": "Compared with both diuretics and contemporary agents, <\\entity><\\entity> decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.",
    "Label": ""
  },
  {
    "id": "2878",
    "Sentence": "Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, <\\entity><\\entity> or cancer.",
    "Label": ""
  },
  {
    "id": "2880",
    "Sentence": "Compared with both diuretics and contemporary agents, <\\entity><\\entity> decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.",
    "Label": ""
  },
  {
    "id": "2881",
    "Sentence": "Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2883",
    "Sentence": "Compared with both diuretics and contemporary agents, <\\entity><\\entity> decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.",
    "Label": ""
  },
  {
    "id": "2884",
    "Sentence": "Compared with both diuretics and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased <\\entity><\\entity>, gastrointestinal bleeding or cancer.",
    "Label": ""
  },
  {
    "id": "2886",
    "Sentence": "<\\entity><\\entity> may exert effects that protect against stroke that are independent of their blood pressure-lowering mechanism.",
    "Label": ""
  },
  {
    "id": "2887",
    "Sentence": "Dihydropyridine calcium channel antagonists may exert effects that protect against <\\entity><\\entity> that are independent of their blood pressure-lowering mechanism.",
    "Label": ""
  },
  {
    "id": "2889",
    "Sentence": "<\\entity><\\entity> in the management of hypertension.<\\entity><\\entity> have been maligned in recent years because of concerns regarding their cardiovascular and overall safety profile.",
    "Label": ""
  },
  {
    "id": "2890",
    "Sentence": "Dihydropyridine calcium channel antagonists in the management of <\\entity><\\entity>.Dihydropyridine calcium channel antagonists have been maligned in recent years because of concerns regarding their cardiovascular and overall safety profile.",
    "Label": ""
  },
  {
    "id": "2892",
    "Sentence": "Compared with both <\\entity><\\entity> and contemporary agents, amlodipine decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.",
    "Label": ""
  },
  {
    "id": "2893",
    "Sentence": "Compared with both diuretics and contemporary agents, amlodipine decreases <\\entity><\\entity> to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.",
    "Label": ""
  },
  {
    "id": "2899",
    "Sentence": "Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of <\\entity><\\entity> but protects against leprosy.TLRs constitute an essential family of pattern recognition molecules that, through direct recognition of conserved microbial components, initiate inflammatory responses following infection.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2900",
    "Sentence": "Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against <\\entity><\\entity>.TLRs constitute an essential family of pattern recognition molecules that, through direct recognition of conserved microbial components, initiate inflammatory responses following infection.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2901",
    "Sentence": "Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy.<\\entity><\\entity> constitute an essential family of pattern recognition molecules that, through direct recognition of conserved microbial components, initiate inflammatory responses following infection.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2902",
    "Sentence": "Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy.TLRs constitute an essential family of pattern recognition molecules that, through direct recognition of conserved microbial components, initiate <\\entity><\\entity> following infection.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2903",
    "Sentence": "Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy.TLRs constitute an essential family of pattern recognition molecules that, through direct recognition of conserved microbial components, initiate inflammatory responses following <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2904",
    "Sentence": "In this role, <\\entity><\\entity> enables host responses to a variety of bacteria, including pathogenic species of mycobacteria.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2905",
    "Sentence": "In this role, TLR1 enables host responses to a variety of bacteria, including pathogenic species of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2906",
    "Sentence": "In this study, we report that <\\entity><\\entity>, a common single nucleotide polymorphism within TLR1, is associated with aberrant trafficking of the receptor to the cell surface and diminished responses of blood monocytes to bacterial agonists.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2907",
    "Sentence": "In this study, we report that I602S, a common single nucleotide polymorphism within <\\entity><\\entity>, is associated with aberrant trafficking of the receptor to the cell surface and diminished responses of blood monocytes to bacterial agonists.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2908",
    "Sentence": "When expressed in heterologous systems, the <\\entity><\\entity> 602S variant, but not the <\\entity><\\entity> 602I variant, exhibits the expected deficiencies in trafficking and responsiveness.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2909",
    "Sentence": "When expressed in heterologous systems, the TLR1 <\\entity><\\entity> variant, but not the TLR1 602I variant, exhibits the expected deficiencies in trafficking and responsiveness.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2910",
    "Sentence": "When expressed in heterologous systems, the TLR1 602S variant, but not the <\\entity><\\entity> variant, exhibits the expected deficiencies in trafficking and responsiveness.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2911",
    "Sentence": "When expressed in heterologous systems, the TLR1 602S variant, but not the <\\entity><\\entity> variant, exhibits the expected deficiencies in trafficking and responsiveness.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2912",
    "Sentence": "When expressed in heterologous systems, the TLR1 602S variant, but not the TLR1 602I variant, exhibits the expected <\\entity><\\entity> in trafficking and responsiveness.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2913",
    "Sentence": "Among white Europeans, the <\\entity><\\entity> allele represents the most common single nucleotide polymorphism affecting TLR function identified to date.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2914",
    "Sentence": "Among white Europeans, the 602S allele represents the most common single nucleotide polymorphism affecting <\\entity><\\entity> function identified to date.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2915",
    "Sentence": "Surprisingly, the <\\entity><\\entity> allele is associated with a decreased incidence of leprosy, suggesting that Mycobacterium leprae subverts the TLR system as a mechanism of immune evasion.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "2916",
    "Sentence": "Surprisingly, the 602S allele is associated with a decreased incidence of <\\entity><\\entity>, suggesting that Mycobacterium leprae subverts the TLR system as a mechanism of immune evasion.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2917",
    "Sentence": "Surprisingly, the 602S allele is associated with a decreased incidence of leprosy, suggesting that <\\entity><\\entity> subverts the TLR system as a mechanism of immune evasion.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2918",
    "Sentence": "Surprisingly, the 602S allele is associated with a decreased incidence of leprosy, suggesting that Mycobacterium leprae subverts the <\\entity><\\entity> system as a mechanism of immune evasion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "2919",
    "Sentence": "Surprisingly, the <\\entity><\\entity> allele is associated with a decreased incidence of leprosy, suggesting that Mycobacterium leprae subverts the TLR system as a mechanism of immune evasion.",
    "Label": ""
  },
  {
    "id": "2920",
    "Sentence": "Surprisingly, the 602S allele is associated with a decreased incidence of <\\entity><\\entity>, suggesting that Mycobacterium leprae subverts the TLR system as a mechanism of immune evasion.",
    "Label": ""
  },
  {
    "id": "2922",
    "Sentence": "Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of <\\entity><\\entity> but protects against leprosy.TLRs constitute an essential family of pattern recognition molecules that, through direct recognition of conserved microbial components, initiate inflammatory responses following infection.",
    "Label": ""
  },
  {
    "id": "2923",
    "Sentence": "Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against <\\entity><\\entity>.TLRs constitute an essential family of pattern recognition molecules that, through direct recognition of conserved microbial components, initiate inflammatory responses following infection.",
    "Label": ""
  },
  {
    "id": "2925",
    "Sentence": "In this role, <\\entity><\\entity> enables host responses to a variety of bacteria, including pathogenic species of mycobacteria.",
    "Label": ""
  },
  {
    "id": "2926",
    "Sentence": "In this role, TLR1 enables host responses to a variety of bacteria, including pathogenic species of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "2928",
    "Sentence": "When expressed in heterologous systems, the <\\entity><\\entity> 602S variant, but not the <\\entity><\\entity> 602I variant, exhibits the expected deficiencies in trafficking and responsiveness.",
    "Label": ""
  },
  {
    "id": "2929",
    "Sentence": "When expressed in heterologous systems, the TLR1 602S variant, but not the TLR1 602I variant, exhibits the expected <\\entity><\\entity> in trafficking and responsiveness.",
    "Label": ""
  },
  {
    "id": "2931",
    "Sentence": "Surprisingly, the 602S allele is associated with a decreased incidence of leprosy, suggesting that Mycobacterium leprae subverts the <\\entity><\\entity> system as a mechanism of immune evasion.",
    "Label": ""
  },
  {
    "id": "2932",
    "Sentence": "Surprisingly, the 602S allele is associated with a decreased incidence of <\\entity><\\entity>, suggesting that Mycobacterium leprae subverts the TLR system as a mechanism of immune evasion.",
    "Label": ""
  },
  {
    "id": "2934",
    "Sentence": "Surprisingly, the <\\entity><\\entity> allele is associated with a decreased incidence of leprosy, suggesting that Mycobacterium leprae subverts the TLR system as a mechanism of immune evasion.",
    "Label": ""
  },
  {
    "id": "2935",
    "Sentence": "Surprisingly, the 602S allele is associated with a decreased incidence of leprosy, suggesting that <\\entity><\\entity> subverts the TLR system as a mechanism of immune evasion.",
    "Label": ""
  },
  {
    "id": "2937",
    "Sentence": "Surprisingly, the 602S allele is associated with a decreased incidence of leprosy, suggesting that Mycobacterium leprae subverts the <\\entity><\\entity> system as a mechanism of immune evasion.",
    "Label": ""
  },
  {
    "id": "2938",
    "Sentence": "Surprisingly, the 602S allele is associated with a decreased incidence of leprosy, suggesting that <\\entity><\\entity> subverts the TLR system as a mechanism of immune evasion.",
    "Label": ""
  },
  {
    "id": "2944",
    "Sentence": "Community-based trial of <\\entity><\\entity> and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose <\\entity><\\entity> (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2945",
    "Sentence": "Community-based trial of R-CHOP and maintenance <\\entity><\\entity> for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (<\\entity><\\entity>/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2946",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for <\\entity><\\entity>- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with <\\entity><\\entity>-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2947",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or <\\entity><\\entity> with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or <\\entity><\\entity> but might be difficult in older patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2948",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle <\\entity><\\entity> for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2949",
    "Sentence": "Community-based trial of <\\entity><\\entity> and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose <\\entity><\\entity> (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2950",
    "Sentence": "Community-based trial of R-CHOP and maintenance <\\entity><\\entity> for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (<\\entity><\\entity>/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2951",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/<\\entity><\\entity>/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2952",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/<\\entity><\\entity>/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2953",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/<\\entity><\\entity>/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2954",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/<\\entity><\\entity>) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2955",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) <\\entity><\\entity> is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2956",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for <\\entity><\\entity>- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with <\\entity><\\entity>-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2957",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or <\\entity><\\entity> with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or <\\entity><\\entity> but might be difficult in older patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2958",
    "Sentence": "PATIENTS AND METHODS: This community-based study was conducted to determine response, toxicity, and <\\entity><\\entity>-free survival in patients with intermediate-or high-grade non-Hodgkin lymphoma receiving R-CHOP with filgrastim.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2959",
    "Sentence": "PATIENTS AND METHODS: This community-based study was conducted to determine response, toxicity, and disease-free survival in patients with <\\entity><\\entity>-or high-grade non-Hodgkin lymphoma receiving R-CHOP with filgrastim.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2960",
    "Sentence": "PATIENTS AND METHODS: This community-based study was conducted to determine response, toxicity, and disease-free survival in patients with intermediate-or <\\entity><\\entity> receiving R-CHOP with filgrastim.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2961",
    "Sentence": "PATIENTS AND METHODS: This community-based study was conducted to determine response, toxicity, and disease-free survival in patients with intermediate-or high-grade non-Hodgkin lymphoma receiving <\\entity><\\entity> with filgrastim.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2962",
    "Sentence": "PATIENTS AND METHODS: This community-based study was conducted to determine response, toxicity, and disease-free survival in patients with intermediate-or high-grade non-Hodgkin lymphoma receiving R-CHOP with <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2963",
    "Sentence": "Patients received 6-8 cycles of <\\entity><\\entity> followed by 4 cycles of maintenance rituximab for responders.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2964",
    "Sentence": "Patients received 6-8 cycles of R-CHOP followed by 4 cycles of maintenance <\\entity><\\entity> for responders.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2965",
    "Sentence": "Patients aged > 60 years or with increased infection risk received <\\entity><\\entity> 5 microg/kg per day in all R-CHOP cycles; other patients received <\\entity><\\entity> after a neutropenic event (no planned administration for cycle 1).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2966",
    "Sentence": "Patients aged > 60 years or with increased infection risk received filgrastim 5 microg/kg per day in all <\\entity><\\entity> cycles; other patients received filgrastim after a neutropenic event (no planned administration for cycle 1).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2967",
    "Sentence": "Patients aged > 60 years or with increased infection risk received <\\entity><\\entity> 5 microg/kg per day in all R-CHOP cycles; other patients received <\\entity><\\entity> after a neutropenic event (no planned administration for cycle 1).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2968",
    "Sentence": "Patients aged > 60 years or with increased infection risk received filgrastim 5 microg/kg per day in all R-CHOP cycles; other patients received filgrastim after a <\\entity><\\entity> (no planned administration for cycle 1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2969",
    "Sentence": "RESULTS: Of 101 patients enrolled, 60 (59%) were aged > 60 years and received <\\entity><\\entity> in all cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2970",
    "Sentence": "Thirty-three patients aged <or= 60 years (80%) received <\\entity><\\entity>, 7 (17%) as primary use in cycle 1.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2971",
    "Sentence": "<\\entity><\\entity> average relative dose intensity was comparable between age groups (91% > 60 years vs.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2972",
    "Sentence": "<\\entity><\\entity> (fever >or= 38.3 degrees C with absolute neutrophil count < 500/mm) occurred in 17% of patients overall (22% > 60 years vs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "2973",
    "Sentence": "CONCLUSION: Patients aged > 60 years receiving <\\entity><\\entity> with filgrastim support in all cycles received comparable doses of chemotherapy and had similar overall response rates compared wtih those of younger patients receiving no preemptive cycle-1 filgrastim.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2974",
    "Sentence": "CONCLUSION: Patients aged > 60 years receiving R-CHOP with <\\entity><\\entity> support in all cycles received comparable doses of chemotherapy and had similar overall response rates compared wtih those of younger patients receiving no preemptive cycle-1 <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2975",
    "Sentence": "CONCLUSION: Patients aged > 60 years receiving R-CHOP with filgrastim support in all cycles received comparable doses of <\\entity><\\entity> and had similar overall response rates compared wtih those of younger patients receiving no preemptive cycle-1 filgrastim.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2976",
    "Sentence": "CONCLUSION: Patients aged > 60 years receiving R-CHOP with <\\entity><\\entity> support in all cycles received comparable doses of chemotherapy and had similar overall response rates compared wtih those of younger patients receiving no preemptive cycle-1 <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "2977",
    "Sentence": "Community-based trial of R-CHOP and maintenance <\\entity><\\entity> for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (<\\entity><\\entity>/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2978",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or <\\entity><\\entity> with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or <\\entity><\\entity> but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2980",
    "Sentence": "Community-based trial of R-CHOP and maintenance <\\entity><\\entity> for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (<\\entity><\\entity>/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2981",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for <\\entity><\\entity>- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with <\\entity><\\entity>-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2983",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/<\\entity><\\entity>/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2984",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or <\\entity><\\entity> with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or <\\entity><\\entity> but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2986",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/<\\entity><\\entity>/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2987",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for <\\entity><\\entity>- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with <\\entity><\\entity>-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2989",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/<\\entity><\\entity>/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2990",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or <\\entity><\\entity> with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or <\\entity><\\entity> but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2992",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/<\\entity><\\entity>/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2993",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for <\\entity><\\entity>- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with <\\entity><\\entity>-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2995",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/<\\entity><\\entity>/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2996",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or <\\entity><\\entity> with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or <\\entity><\\entity> but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2998",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/<\\entity><\\entity>/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "2999",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for <\\entity><\\entity>- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with <\\entity><\\entity>-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3001",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/<\\entity><\\entity>) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3002",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or <\\entity><\\entity> with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or <\\entity><\\entity> but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3004",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/<\\entity><\\entity>) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3005",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for <\\entity><\\entity>- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with <\\entity><\\entity>-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3007",
    "Sentence": "Community-based trial of <\\entity><\\entity> and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose <\\entity><\\entity> (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3008",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or <\\entity><\\entity> with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or <\\entity><\\entity> but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3010",
    "Sentence": "Community-based trial of <\\entity><\\entity> and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose <\\entity><\\entity> (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3011",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for <\\entity><\\entity>- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with <\\entity><\\entity>-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3013",
    "Sentence": "PATIENTS AND METHODS: This community-based study was conducted to determine response, toxicity, and disease-free survival in patients with intermediate-or high-grade non-Hodgkin lymphoma receiving R-CHOP with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3014",
    "Sentence": "PATIENTS AND METHODS: This community-based study was conducted to determine response, toxicity, and disease-free survival in patients with intermediate-or <\\entity><\\entity> receiving R-CHOP with filgrastim.",
    "Label": ""
  },
  {
    "id": "3016",
    "Sentence": "PATIENTS AND METHODS: This community-based study was conducted to determine response, toxicity, and disease-free survival in patients with intermediate-or high-grade non-Hodgkin lymphoma receiving R-CHOP with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3017",
    "Sentence": "PATIENTS AND METHODS: This community-based study was conducted to determine response, toxicity, and disease-free survival in patients with <\\entity><\\entity>-or high-grade non-Hodgkin lymphoma receiving R-CHOP with filgrastim.",
    "Label": ""
  },
  {
    "id": "3019",
    "Sentence": "PATIENTS AND METHODS: This community-based study was conducted to determine response, toxicity, and disease-free survival in patients with intermediate-or high-grade non-Hodgkin lymphoma receiving <\\entity><\\entity> with filgrastim.",
    "Label": ""
  },
  {
    "id": "3020",
    "Sentence": "PATIENTS AND METHODS: This community-based study was conducted to determine response, toxicity, and disease-free survival in patients with intermediate-or <\\entity><\\entity> receiving R-CHOP with filgrastim.",
    "Label": ""
  },
  {
    "id": "3022",
    "Sentence": "PATIENTS AND METHODS: This community-based study was conducted to determine response, toxicity, and disease-free survival in patients with intermediate-or high-grade non-Hodgkin lymphoma receiving <\\entity><\\entity> with filgrastim.",
    "Label": ""
  },
  {
    "id": "3023",
    "Sentence": "PATIENTS AND METHODS: This community-based study was conducted to determine response, toxicity, and disease-free survival in patients with <\\entity><\\entity>-or high-grade non-Hodgkin lymphoma receiving R-CHOP with filgrastim.",
    "Label": ""
  },
  {
    "id": "3025",
    "Sentence": "Patients aged > 60 years or with increased infection risk received <\\entity><\\entity> 5 microg/kg per day in all R-CHOP cycles; other patients received <\\entity><\\entity> after a neutropenic event (no planned administration for cycle 1).",
    "Label": ""
  },
  {
    "id": "3026",
    "Sentence": "Patients aged > 60 years or with increased infection risk received filgrastim 5 microg/kg per day in all R-CHOP cycles; other patients received filgrastim after a <\\entity><\\entity> (no planned administration for cycle 1).",
    "Label": ""
  },
  {
    "id": "3028",
    "Sentence": "Community-based trial of R-CHOP and maintenance <\\entity><\\entity> for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (<\\entity><\\entity>/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3029",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or <\\entity><\\entity> with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or <\\entity><\\entity> but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3031",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle <\\entity><\\entity> for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3032",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or <\\entity><\\entity> with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or <\\entity><\\entity> but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3034",
    "Sentence": "Community-based trial of <\\entity><\\entity> and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose <\\entity><\\entity> (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3035",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or <\\entity><\\entity> with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or <\\entity><\\entity> but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3037",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) <\\entity><\\entity> is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3038",
    "Sentence": "Community-based trial of R-CHOP and maintenance rituximab for intermediate- or <\\entity><\\entity> with first-cycle filgrastim for older patients.BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or <\\entity><\\entity> but might be difficult in older patients.",
    "Label": ""
  },
  {
    "id": "3044",
    "Sentence": "Molecular genetics study of <\\entity><\\entity> in Brazil: 8-year experience.Hereditary hearing loss is a complex disorder that involves a large number of genes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3045",
    "Sentence": "Molecular genetics study of deafness in Brazil: 8-year experience.Hereditary <\\entity><\\entity> is a complex disorder that involves a large number of genes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3046",
    "Sentence": "Molecular genetics study of deafness in Brazil: 8-year experience.Hereditary hearing loss is a complex <\\entity><\\entity> that involves a large number of genes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3047",
    "Sentence": "In developed countries, 1 in 1,000 children is born with <\\entity><\\entity> severe enough to require special education services, and about 60% of the cases of isolated <\\entity><\\entity> have a genetic origin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3048",
    "Sentence": "In developed countries, 1 in 1,000 children is born with deafness severe enough to require special education services, and about 60% of the cases of <\\entity><\\entity> have a genetic origin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3049",
    "Sentence": "Although more than 100 genes for <\\entity><\\entity> are known currently, only a few are routinely tested in the clinical practice.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3050",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the <\\entity><\\entity> and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3051",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and <\\entity><\\entity> genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3052",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, <\\entity><\\entity> and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3053",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(<\\entity><\\entity>) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3054",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and <\\entity><\\entity> deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3055",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(<\\entity><\\entity>) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3056",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) <\\entity><\\entity> gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3057",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) <\\entity><\\entity> gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3058",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) <\\entity><\\entity> gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3059",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, <\\entity><\\entity> mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3060",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, <\\entity><\\entity> mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3061",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X <\\entity><\\entity> in the otoferlin gene (OTOF) and, the A1,555G and A7,445G <\\entity><\\entity>s in the mitochondrial genome over an 8-year period.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3062",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the <\\entity><\\entity> gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3063",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (<\\entity><\\entity>) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3064",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the <\\entity><\\entity> and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3065",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and <\\entity><\\entity> mutations in the mitochondrial genome over an 8-year period.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3066",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G <\\entity><\\entity> in the mitochondrial genome over an 8-year period.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3067",
    "Sentence": "<\\entity><\\entity> analysis in the previously mentioned genes and mutations was performed on 645 unrelated Brazilian patients with hearing loss who fell into two different testing groups.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3068",
    "Sentence": "Mutations analysis in the previously mentioned genes and <\\entity><\\entity> was performed on 645 unrelated Brazilian patients with hearing loss who fell into two different testing groups.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3069",
    "Sentence": "Mutations analysis in the previously mentioned genes and mutations was performed on 645 unrelated Brazilian patients with <\\entity><\\entity> who fell into two different testing groups.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3070",
    "Sentence": "Different <\\entity><\\entity> gene were responsible for most of cases studied, but deletions in the GJB6 gene as well as mitochondrial mutations were also found.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3071",
    "Sentence": "Different <\\entity><\\entity> gene were responsible for most of cases studied, but deletions in the GJB6 gene as well as mitochondrial mutations were also found.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3072",
    "Sentence": "Different <\\entity><\\entity> gene were responsible for most of cases studied, but deletions in the GJB6 gene as well as mitochondrial mutations were also found.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3073",
    "Sentence": "Different mutations in the GJB2 gene were responsible for most of cases studied, but <\\entity><\\entity> gene as well as mitochondrial mutations were also found.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3074",
    "Sentence": "Different mutations in the GJB2 gene were responsible for most of cases studied, but <\\entity><\\entity> gene as well as mitochondrial mutations were also found.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3075",
    "Sentence": "Different mutations in the GJB2 gene were responsible for most of cases studied, but <\\entity><\\entity> gene as well as mitochondrial mutations were also found.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3076",
    "Sentence": "Different mutations in the GJB2 gene were responsible for most of cases studied, but deletions in the GJB6 gene as well as <\\entity><\\entity> were also found.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3077",
    "Sentence": "Different mutations in the GJB2 gene were responsible for most of cases studied, but deletions in the GJB6 gene as well as <\\entity><\\entity> were also found.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3078",
    "Sentence": "While most cases of <\\entity><\\entity> in this country are due to environmental factors, the genetic etiology of deafness will increasingly be determined as more genetic tests become available.CI - (c) 2007 Wiley-Liss, Inc",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3079",
    "Sentence": "While most cases of hearing loss in this country are due to environmental factors, the genetic etiology of <\\entity><\\entity> will increasingly be determined as more genetic tests become available.CI - (c) 2007 Wiley-Liss, Inc",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3080",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (<\\entity><\\entity>) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3081",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) <\\entity><\\entity> gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3083",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (<\\entity><\\entity>) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3084",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G <\\entity><\\entity> in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3086",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the <\\entity><\\entity> and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3087",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) <\\entity><\\entity> gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3089",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the <\\entity><\\entity> and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3090",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G <\\entity><\\entity> in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3092",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and <\\entity><\\entity> genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3093",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) <\\entity><\\entity> gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3095",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and <\\entity><\\entity> genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3096",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G <\\entity><\\entity> in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3098",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) <\\entity><\\entity> gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3099",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) <\\entity><\\entity> gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3101",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) <\\entity><\\entity> gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G mutations in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3102",
    "Sentence": "In this study, we present our findings from the molecular diagnostic screening of the GJB2 and GJB3 genes, del(GJB6-D13S1,830) and del(GJB6-D13S1,854) deletions in the GJB6 gene, Q829X mutation in the otoferlin gene (OTOF) and, the A1,555G and A7,445G <\\entity><\\entity> in the mitochondrial genome over an 8-year period.",
    "Label": ""
  },
  {
    "id": "3104",
    "Sentence": "Different <\\entity><\\entity> gene were responsible for most of cases studied, but deletions in the GJB6 gene as well as mitochondrial mutations were also found.",
    "Label": ""
  },
  {
    "id": "3105",
    "Sentence": "Different mutations in the GJB2 gene were responsible for most of cases studied, but <\\entity><\\entity> gene as well as mitochondrial mutations were also found.",
    "Label": ""
  },
  {
    "id": "3107",
    "Sentence": "Different <\\entity><\\entity> gene were responsible for most of cases studied, but deletions in the GJB6 gene as well as mitochondrial mutations were also found.",
    "Label": ""
  },
  {
    "id": "3108",
    "Sentence": "Different mutations in the GJB2 gene were responsible for most of cases studied, but deletions in the GJB6 gene as well as <\\entity><\\entity> were also found.",
    "Label": ""
  },
  {
    "id": "3110",
    "Sentence": "Different mutations in the GJB2 gene were responsible for most of cases studied, but <\\entity><\\entity> gene as well as mitochondrial mutations were also found.",
    "Label": ""
  },
  {
    "id": "3111",
    "Sentence": "Different mutations in the GJB2 gene were responsible for most of cases studied, but <\\entity><\\entity> gene as well as mitochondrial mutations were also found.",
    "Label": ""
  },
  {
    "id": "3113",
    "Sentence": "Different mutations in the GJB2 gene were responsible for most of cases studied, but <\\entity><\\entity> gene as well as mitochondrial mutations were also found.",
    "Label": ""
  },
  {
    "id": "3114",
    "Sentence": "Different mutations in the GJB2 gene were responsible for most of cases studied, but deletions in the GJB6 gene as well as <\\entity><\\entity> were also found.",
    "Label": ""
  },
  {
    "id": "3120",
    "Sentence": "Anti-<\\entity><\\entity> antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment.Amyloid beta protein (Abeta) levels are elevated in the brain of Alzheimer's disease patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3121",
    "Sentence": "Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of <\\entity><\\entity>: an age-related selective uptake with reversal of learning impairment.Amyloid beta protein (Abeta) levels are elevated in the brain of <\\entity><\\entity> patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3122",
    "Sentence": "Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of <\\entity><\\entity> impairment.Amyloid beta protein (Abeta) levels are elevated in the brain of Alzheimer's disease patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3123",
    "Sentence": "Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment.<\\entity><\\entity> (Abeta) levels are elevated in the brain of Alzheimer's disease patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3124",
    "Sentence": "Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment.<\\entity><\\entity> (Abeta) levels are elevated in the brain of Alzheimer's disease patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3125",
    "Sentence": "Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment.Amyloid beta protein (<\\entity><\\entity>) levels are elevated in the brain of Alzheimer's disease patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3126",
    "Sentence": "Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of <\\entity><\\entity>: an age-related selective uptake with reversal of learning impairment.Amyloid beta protein (Abeta) levels are elevated in the brain of <\\entity><\\entity> patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3127",
    "Sentence": "<\\entity><\\entity> can reverse the histologic and cognitive impairments in mice which overexpress Abeta.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3128",
    "Sentence": "Anti-<\\entity><\\entity> antibodies can reverse the histologic and cognitive impairments in mice which overexpress <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3129",
    "Sentence": "Anti-Abeta antibodies can reverse the <\\entity><\\entity> and cognitive impairments in mice which overexpress Abeta.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3130",
    "Sentence": "Anti-Abeta antibodies can reverse the histologic and <\\entity><\\entity> in mice which overexpress Abeta.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3131",
    "Sentence": "Anti-<\\entity><\\entity> antibodies can reverse the histologic and cognitive impairments in mice which overexpress <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3132",
    "Sentence": "Effective treatment will likely require antibody to <\\entity><\\entity> the blood-brain barrier (BBB).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3133",
    "Sentence": "Unfortunately, antibodies typically <\\entity><\\entity> the BBB very poorly and accumulate less well in brain than even albumin, a substance nearly totally excluded from the brain.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3134",
    "Sentence": "Unfortunately, antibodies typically cross the BBB very poorly and accumulate less well in brain than even <\\entity><\\entity>, a substance nearly totally excluded from the brain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3135",
    "Sentence": "We compared the ability of two <\\entity><\\entity>, L11.3 and HyL5, to cross the BBB of young CD-1 mice to that of young and aged SAMP8 mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3136",
    "Sentence": "We compared the ability of two anti-<\\entity><\\entity> human monoclonal IgM antibodies, L11.3 and HyL5, to cross the BBB of young CD-1 mice to that of young and aged SAMP8 mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3137",
    "Sentence": "We compared the ability of two anti-Abeta human monoclonal IgM antibodies, <\\entity><\\entity> and HyL5, to cross the BBB of young CD-1 mice to that of young and aged SAMP8 mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3138",
    "Sentence": "We compared the ability of two anti-Abeta human monoclonal IgM antibodies, L11.3 and <\\entity><\\entity>, to cross the BBB of young CD-1 mice to that of young and aged SAMP8 mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3139",
    "Sentence": "We compared the ability of two anti-Abeta human monoclonal IgM antibodies, L11.3 and HyL5, to <\\entity><\\entity> the BBB of young CD-1 mice to that of young and aged SAMP8 mice.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3140",
    "Sentence": "We compared the ability of two anti-Abeta human monoclonal IgM antibodies, L11.3 and HyL5, to cross the BBB of young <\\entity><\\entity> mice to that of young and aged SAMP8 mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3141",
    "Sentence": "The SAMP8 mouse has a spontaneous <\\entity><\\entity> that induces an age-related, Abeta-dependent cognitive deficit.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3142",
    "Sentence": "The SAMP8 mouse has a spontaneous mutation that induces an age-related, <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3143",
    "Sentence": "The SAMP8 mouse has a spontaneous mutation that induces an age-related, <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3144",
    "Sentence": "There was preferential uptake of intravenously administered <\\entity><\\entity> in comparison to HyL5, albumin, and a control human monoclonal IgM (RF), especially by hippocampus and olfactory bulb in aged SAMP8 mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3145",
    "Sentence": "There was preferential uptake of intravenously administered L11.3 in comparison to <\\entity><\\entity>, albumin, and a control human monoclonal IgM (RF), especially by hippocampus and olfactory bulb in aged SAMP8 mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3146",
    "Sentence": "There was preferential uptake of intravenously administered L11.3 in comparison to HyL5, <\\entity><\\entity>, and a control human monoclonal IgM (RF), especially by hippocampus and olfactory bulb in aged SAMP8 mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3147",
    "Sentence": "There was preferential uptake of intravenously administered L11.3 in comparison to HyL5, albumin, and a control human monoclonal <\\entity><\\entity> (RF), especially by hippocampus and olfactory bulb in aged SAMP8 mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3148",
    "Sentence": "Injection of <\\entity><\\entity> into the brains of aged SAMP8 mice reversed both learning and memory impairments in aged SAMP8 mice, whereas IgG and IgM controls were ineffective.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3149",
    "Sentence": "Injection of L11.3 into the brains of aged SAMP8 mice reversed both <\\entity><\\entity> and memory impairments in aged SAMP8 mice, whereas IgG and IgM controls were ineffective.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3150",
    "Sentence": "Injection of L11.3 into the brains of aged SAMP8 mice reversed both learning and <\\entity><\\entity> in aged SAMP8 mice, whereas IgG and IgM controls were ineffective.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3151",
    "Sentence": "Injection of L11.3 into the brains of aged SAMP8 mice reversed both learning and memory impairments in aged SAMP8 mice, whereas <\\entity><\\entity> and IgM controls were ineffective.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3152",
    "Sentence": "Injection of L11.3 into the brains of aged SAMP8 mice reversed both learning and memory impairments in aged SAMP8 mice, whereas IgG and <\\entity><\\entity> controls were ineffective.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3153",
    "Sentence": "Pharmacokinetic analysis predicted that an intravenous dose 1000 times higher than the brain injection dose would reverse <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3154",
    "Sentence": "This predicted intravenous dose reversed the <\\entity><\\entity>, but not memory, in aged SAMP8 mice.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3155",
    "Sentence": "This predicted intravenous dose reversed the impairment in learning, but not <\\entity><\\entity>, in aged SAMP8 mice.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3156",
    "Sentence": "In conclusion, an <\\entity><\\entity> was produced that crosses the BBB to reverse cognitive impairment in a murine model of Alzheimer's disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3157",
    "Sentence": "In conclusion, an IgM antibody was produced that <\\entity><\\entity> the BBB to reverse cognitive impairment in a murine model of Alzheimer's disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3158",
    "Sentence": "In conclusion, an IgM antibody was produced that crosses the BBB to reverse <\\entity><\\entity> in a murine model of Alzheimer's disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3159",
    "Sentence": "In conclusion, an IgM antibody was produced that crosses the BBB to reverse cognitive impairment in a murine model of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3160",
    "Sentence": "Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment.<\\entity><\\entity> (Abeta) levels are elevated in the brain of Alzheimer's disease patients.",
    "Label": ""
  },
  {
    "id": "3161",
    "Sentence": "Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of <\\entity><\\entity>: an age-related selective uptake with reversal of learning impairment.Amyloid beta protein (Abeta) levels are elevated in the brain of <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "3163",
    "Sentence": "Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment.Amyloid beta protein (<\\entity><\\entity>) levels are elevated in the brain of Alzheimer's disease patients.",
    "Label": ""
  },
  {
    "id": "3164",
    "Sentence": "Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of <\\entity><\\entity>: an age-related selective uptake with reversal of learning impairment.Amyloid beta protein (Abeta) levels are elevated in the brain of <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "3166",
    "Sentence": "<\\entity><\\entity> can reverse the histologic and cognitive impairments in mice which overexpress Abeta.",
    "Label": ""
  },
  {
    "id": "3167",
    "Sentence": "Anti-Abeta antibodies can reverse the histologic and <\\entity><\\entity> in mice which overexpress Abeta.",
    "Label": ""
  },
  {
    "id": "3169",
    "Sentence": "<\\entity><\\entity> can reverse the histologic and cognitive impairments in mice which overexpress Abeta.",
    "Label": ""
  },
  {
    "id": "3170",
    "Sentence": "Anti-Abeta antibodies can reverse the <\\entity><\\entity> and cognitive impairments in mice which overexpress Abeta.",
    "Label": ""
  },
  {
    "id": "3172",
    "Sentence": "Injection of <\\entity><\\entity> into the brains of aged SAMP8 mice reversed both learning and memory impairments in aged SAMP8 mice, whereas IgG and IgM controls were ineffective.",
    "Label": ""
  },
  {
    "id": "3173",
    "Sentence": "Injection of L11.3 into the brains of aged SAMP8 mice reversed both <\\entity><\\entity> and memory impairments in aged SAMP8 mice, whereas IgG and IgM controls were ineffective.",
    "Label": ""
  },
  {
    "id": "3175",
    "Sentence": "Injection of <\\entity><\\entity> into the brains of aged SAMP8 mice reversed both learning and memory impairments in aged SAMP8 mice, whereas IgG and IgM controls were ineffective.",
    "Label": ""
  },
  {
    "id": "3176",
    "Sentence": "Injection of L11.3 into the brains of aged SAMP8 mice reversed both learning and <\\entity><\\entity> in aged SAMP8 mice, whereas IgG and IgM controls were ineffective.",
    "Label": ""
  },
  {
    "id": "3178",
    "Sentence": "Injection of L11.3 into the brains of aged SAMP8 mice reversed both learning and memory impairments in aged SAMP8 mice, whereas <\\entity><\\entity> and IgM controls were ineffective.",
    "Label": ""
  },
  {
    "id": "3179",
    "Sentence": "Injection of L11.3 into the brains of aged SAMP8 mice reversed both <\\entity><\\entity> and memory impairments in aged SAMP8 mice, whereas IgG and IgM controls were ineffective.",
    "Label": ""
  },
  {
    "id": "3181",
    "Sentence": "Injection of L11.3 into the brains of aged SAMP8 mice reversed both learning and memory impairments in aged SAMP8 mice, whereas <\\entity><\\entity> and IgM controls were ineffective.",
    "Label": ""
  },
  {
    "id": "3182",
    "Sentence": "Injection of L11.3 into the brains of aged SAMP8 mice reversed both learning and <\\entity><\\entity> in aged SAMP8 mice, whereas IgG and IgM controls were ineffective.",
    "Label": ""
  },
  {
    "id": "3184",
    "Sentence": "Injection of L11.3 into the brains of aged SAMP8 mice reversed both learning and memory impairments in aged SAMP8 mice, whereas IgG and <\\entity><\\entity> controls were ineffective.",
    "Label": ""
  },
  {
    "id": "3185",
    "Sentence": "Injection of L11.3 into the brains of aged SAMP8 mice reversed both <\\entity><\\entity> and memory impairments in aged SAMP8 mice, whereas IgG and IgM controls were ineffective.",
    "Label": ""
  },
  {
    "id": "3187",
    "Sentence": "Injection of L11.3 into the brains of aged SAMP8 mice reversed both learning and memory impairments in aged SAMP8 mice, whereas IgG and <\\entity><\\entity> controls were ineffective.",
    "Label": ""
  },
  {
    "id": "3188",
    "Sentence": "Injection of L11.3 into the brains of aged SAMP8 mice reversed both learning and <\\entity><\\entity> in aged SAMP8 mice, whereas IgG and IgM controls were ineffective.",
    "Label": ""
  },
  {
    "id": "3190",
    "Sentence": "In conclusion, an <\\entity><\\entity> was produced that crosses the BBB to reverse cognitive impairment in a murine model of Alzheimer's disease.",
    "Label": ""
  },
  {
    "id": "3191",
    "Sentence": "In conclusion, an IgM antibody was produced that crosses the BBB to reverse cognitive impairment in a murine model of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3193",
    "Sentence": "In conclusion, an <\\entity><\\entity> was produced that crosses the BBB to reverse cognitive impairment in a murine model of Alzheimer's disease.",
    "Label": ""
  },
  {
    "id": "3194",
    "Sentence": "In conclusion, an IgM antibody was produced that crosses the BBB to reverse <\\entity><\\entity> in a murine model of Alzheimer's disease.",
    "Label": ""
  },
  {
    "id": "3196",
    "Sentence": "We compared the ability of two anti-Abeta human monoclonal IgM antibodies, L11.3 and HyL5, to cross the BBB of young <\\entity><\\entity> mice to that of young and aged SAMP8 mice.",
    "Label": ""
  },
  {
    "id": "3197",
    "Sentence": "We compared the ability of two anti-Abeta human monoclonal IgM antibodies, L11.3 and HyL5, to <\\entity><\\entity> the BBB of young CD-1 mice to that of young and aged SAMP8 mice.",
    "Label": ""
  },
  {
    "id": "3199",
    "Sentence": "Anti-<\\entity><\\entity> antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment.Amyloid beta protein (Abeta) levels are elevated in the brain of Alzheimer's disease patients.",
    "Label": ""
  },
  {
    "id": "3200",
    "Sentence": "Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of <\\entity><\\entity>: an age-related selective uptake with reversal of learning impairment.Amyloid beta protein (Abeta) levels are elevated in the brain of <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "3202",
    "Sentence": "Anti-<\\entity><\\entity> antibodies can reverse the histologic and cognitive impairments in mice which overexpress <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3203",
    "Sentence": "Anti-Abeta antibodies can reverse the histologic and <\\entity><\\entity> in mice which overexpress Abeta.",
    "Label": ""
  },
  {
    "id": "3205",
    "Sentence": "The SAMP8 mouse has a spontaneous mutation that induces an age-related, <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3206",
    "Sentence": "The SAMP8 mouse has a spontaneous mutation that induces an age-related, <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3208",
    "Sentence": "Anti-<\\entity><\\entity> antibodies can reverse the histologic and cognitive impairments in mice which overexpress <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3209",
    "Sentence": "Anti-Abeta antibodies can reverse the histologic and <\\entity><\\entity> in mice which overexpress Abeta.",
    "Label": ""
  },
  {
    "id": "3215",
    "Sentence": "<\\entity><\\entity> for the treatment of obesity.The melanocortin family of receptors (MC 1-5R) and their endogenous peptide ligands (alpha, beta, gamma- MSH and ACTH) have been implicated in the control of a wide variety of behavioral and physiological functions including the homeostatic control of food intake and body weight.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3216",
    "Sentence": "<\\entity><\\entity> for the treatment of obesity.The melanocortin family of receptors (MC 1-5R) and their endogenous peptide ligands (alpha, beta, gamma- MSH and ACTH) have been implicated in the control of a wide variety of behavioral and physiological functions including the homeostatic control of food intake and body weight.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3217",
    "Sentence": "Melanocortin-<\\entity><\\entity> agonists for the treatment of obesity.The melanocortin family of receptors (MC 1-5R) and their endogenous peptide ligands (alpha, beta, gamma- MSH and ACTH) have been implicated in the control of a wide variety of behavioral and physiological functions including the homeostatic control of food intake and body weight.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3218",
    "Sentence": "Melanocortin-4 receptor agonists for the treatment of obesity.The <\\entity><\\entity> family of receptors (MC 1-5R) and their endogenous peptide ligands (alpha, beta, gamma- MSH and ACTH) have been implicated in the control of a wide variety of behavioral and physiological functions including the homeostatic control of food intake and body weight.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3219",
    "Sentence": "Melanocortin-4 receptor agonists for the treatment of obesity.The melanocortin family of receptors (<\\entity><\\entity>) and their endogenous peptide ligands (alpha, beta, gamma- MSH and ACTH) have been implicated in the control of a wide variety of behavioral and physiological functions including the homeostatic control of food intake and body weight.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3220",
    "Sentence": "Melanocortin-4 receptor agonists for the treatment of obesity.The melanocortin family of receptors (MC 1-5R) and their endogenous peptide ligands (<\\entity><\\entity>, beta, gamma- MSH and ACTH) have been implicated in the control of a wide variety of behavioral and physiological functions including the homeostatic control of food intake and body weight.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3221",
    "Sentence": "Melanocortin-4 receptor agonists for the treatment of obesity.The melanocortin family of receptors (MC 1-5R) and their endogenous peptide ligands (alpha, <\\entity><\\entity>, gamma- MSH and ACTH) have been implicated in the control of a wide variety of behavioral and physiological functions including the homeostatic control of food intake and body weight.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3222",
    "Sentence": "Melanocortin-4 receptor agonists for the treatment of obesity.The melanocortin family of receptors (MC 1-5R) and their endogenous peptide ligands (alpha, beta, <\\entity><\\entity>- MSH and ACTH) have been implicated in the control of a wide variety of behavioral and physiological functions including the homeostatic control of food intake and body weight.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3223",
    "Sentence": "Melanocortin-4 receptor agonists for the treatment of obesity.The melanocortin family of receptors (MC 1-5R) and their endogenous peptide ligands (alpha, beta, gamma- <\\entity><\\entity> and ACTH) have been implicated in the control of a wide variety of behavioral and physiological functions including the homeostatic control of food intake and body weight.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3224",
    "Sentence": "Melanocortin-4 receptor agonists for the treatment of obesity.The melanocortin family of receptors (MC 1-5R) and their endogenous peptide ligands (alpha, beta, gamma- MSH and <\\entity><\\entity>) have been implicated in the control of a wide variety of behavioral and physiological functions including the homeostatic control of food intake and body weight.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3225",
    "Sentence": "Melanocortin-4 receptor agonists for the treatment of obesity.The melanocortin family of receptors (MC 1-5R) and their endogenous peptide ligands (alpha, beta, gamma- MSH and <\\entity><\\entity>) have been implicated in the control of a wide variety of behavioral and physiological functions including the homeostatic control of food intake and body weight.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3226",
    "Sentence": "In rodent models, <\\entity><\\entity> including the nonselective peptide MTII have been shown to decrease food intake and body weight while antagonists such as SHU9119 and AGRP have been shown to stimulate food intake and increase body weight.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3227",
    "Sentence": "In rodent models, <\\entity><\\entity> including the nonselective peptide MTII have been shown to decrease food intake and body weight while antagonists such as SHU9119 and AGRP have been shown to stimulate food intake and increase body weight.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3228",
    "Sentence": "In rodent models, melanocortin agonists including the nonselective peptide <\\entity><\\entity> have been shown to decrease food intake and body weight while antagonists such as SHU9119 and AGRP have been shown to stimulate food intake and increase body weight.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3229",
    "Sentence": "In rodent models, melanocortin agonists including the nonselective peptide MTII have been shown to decrease food intake and body weight while antagonists such as <\\entity><\\entity> and AGRP have been shown to stimulate food intake and increase body weight.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3230",
    "Sentence": "In rodent models, melanocortin agonists including the nonselective peptide MTII have been shown to decrease food intake and body weight while antagonists such as SHU9119 and <\\entity><\\entity> have been shown to stimulate food intake and increase body weight.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3231",
    "Sentence": "In rodent models, melanocortin agonists including the nonselective peptide MTII have been shown to decrease food intake and body weight while antagonists such as SHU9119 and <\\entity><\\entity> have been shown to stimulate food intake and increase body weight.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3232",
    "Sentence": "Deletion of either the <\\entity><\\entity> or MC4R in mice was found to be associated with obesity although hyperphagia was only observed in the MC4R deficient mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3233",
    "Sentence": "Deletion of either the MC3R or <\\entity><\\entity> in mice was found to be associated with obesity although hyperphagia was only observed in the <\\entity><\\entity> deficient mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3234",
    "Sentence": "Deletion of either the MC3R or <\\entity><\\entity> in mice was found to be associated with obesity although hyperphagia was only observed in the <\\entity><\\entity> deficient mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3235",
    "Sentence": "Similarly in humans, <\\entity><\\entity> have been found in as many as six percent of obese individuals.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3236",
    "Sentence": "Similarly in humans, <\\entity><\\entity> have been found in as many as six percent of obese individuals.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3237",
    "Sentence": "The suggestion from these findings that activation of <\\entity><\\entity> would have an anorectic effect in humans has resulted in efforts to produce selective agonists for the treatment of obesity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3238",
    "Sentence": "Over the past decade, efforts to develop <\\entity><\\entity> selective small molecule and peptide agonists have been met with fractional success.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3239",
    "Sentence": "Over the past decade, efforts to develop <\\entity><\\entity> selective small molecule and peptide agonists have been met with fractional success.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3240",
    "Sentence": "The subject of the current review is to examine the progress made to date on producing both small molecule and peptide <\\entity><\\entity> as potential therapeutics for obesity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3241",
    "Sentence": "The subject of the current review is to examine the progress made to date on producing both small molecule and peptide <\\entity><\\entity> as potential therapeutics for obesity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3242",
    "Sentence": "In rodent models, melanocortin agonists including the nonselective peptide <\\entity><\\entity> have been shown to decrease food intake and body weight while antagonists such as SHU9119 and AGRP have been shown to stimulate food intake and increase body weight.",
    "Label": ""
  },
  {
    "id": "3243",
    "Sentence": "In rodent models, <\\entity><\\entity> including the nonselective peptide MTII have been shown to decrease food intake and body weight while antagonists such as SHU9119 and AGRP have been shown to stimulate food intake and increase body weight.",
    "Label": ""
  },
  {
    "id": "3245",
    "Sentence": "In rodent models, melanocortin agonists including the nonselective peptide MTII have been shown to decrease food intake and body weight while antagonists such as <\\entity><\\entity> and AGRP have been shown to stimulate food intake and increase body weight.",
    "Label": ""
  },
  {
    "id": "3246",
    "Sentence": "In rodent models, <\\entity><\\entity> including the nonselective peptide MTII have been shown to decrease food intake and body weight while antagonists such as SHU9119 and AGRP have been shown to stimulate food intake and increase body weight.",
    "Label": ""
  },
  {
    "id": "3248",
    "Sentence": "In rodent models, melanocortin agonists including the nonselective peptide MTII have been shown to decrease food intake and body weight while antagonists such as SHU9119 and <\\entity><\\entity> have been shown to stimulate food intake and increase body weight.",
    "Label": ""
  },
  {
    "id": "3249",
    "Sentence": "In rodent models, <\\entity><\\entity> including the nonselective peptide MTII have been shown to decrease food intake and body weight while antagonists such as SHU9119 and AGRP have been shown to stimulate food intake and increase body weight.",
    "Label": ""
  },
  {
    "id": "3255",
    "Sentence": "Role of <\\entity><\\entity>, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding <\\entity><\\entity>s (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3256",
    "Sentence": "Role of matrix metalloproteinase, <\\entity><\\entity> and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3257",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and <\\entity><\\entity> in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3258",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and <\\entity><\\entity> in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3259",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in <\\entity><\\entity>.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of <\\entity><\\entity>s (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3260",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding <\\entity><\\entity> (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3261",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding <\\entity><\\entity> (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3262",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (<\\entity><\\entity>, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3263",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, <\\entity><\\entity>, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, <\\entity><\\entity> and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3264",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, <\\entity><\\entity>, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3265",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, <\\entity><\\entity>, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3266",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, <\\entity><\\entity> (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3267",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (<\\entity><\\entity>, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3268",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, <\\entity><\\entity>, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, <\\entity><\\entity> and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3269",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and <\\entity><\\entity>-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and <\\entity><\\entity> (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3270",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (<\\entity><\\entity> in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3271",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of <\\entity><\\entity> (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3272",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (<\\entity><\\entity>), that may enhance susceptibility and/or disease severity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3273",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel <\\entity><\\entity>.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel <\\entity><\\entity>s (IBD), that may enhance susceptibility and/or <\\entity><\\entity> severity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3274",
    "Sentence": "METHODS: Genomic DNA from 134 <\\entity><\\entity> (CD), 111 ulcerative colitis (UC) patients and 248 control subjects was isolated from resected intestinal tissue or blood.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3275",
    "Sentence": "METHODS: Genomic DNA from 134 Crohn' s disease (<\\entity><\\entity>), 111 ulcerative colitis (UC) patients and 248 control subjects was isolated from resected intestinal tissue or blood.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3276",
    "Sentence": "METHODS: Genomic DNA from 134 Crohn' s disease (CD), 111 <\\entity><\\entity> (UC) patients and 248 control subjects was isolated from resected intestinal tissue or blood.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3277",
    "Sentence": "METHODS: Genomic DNA from 134 Crohn' s disease (CD), 111 ulcerative colitis (<\\entity><\\entity>) patients and 248 control subjects was isolated from resected intestinal tissue or blood.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3278",
    "Sentence": "RESULTS: The <\\entity><\\entity> in women and T in men at SNP +372 T/C was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3279",
    "Sentence": "RESULTS: The <\\entity><\\entity> in women and T in men at SNP +372 T/C was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3280",
    "Sentence": "RESUL<\\entity><\\entity>S: <\\entity><\\entity>he <\\entity><\\entity>IMP-1 genotype <\\entity><\\entity><\\entity><\\entity> in women and <\\entity><\\entity> in men at SNP +372 <\\entity><\\entity>/C was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3281",
    "Sentence": "RESULTS: The TIMP-1 genotype TT in women and T in men at <\\entity><\\entity> was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3282",
    "Sentence": "RESULTS: The TIMP-1 genotype TT in women and T in men at SNP +372 T/C was found to increase <\\entity><\\entity> susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3283",
    "Sentence": "RESULTS: The TIMP-1 genotype TT in women and T in men at SNP +372 T/C was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of <\\entity><\\entity> during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3284",
    "Sentence": "Male <\\entity><\\entity> or CD patients carrying the TIMP-1 +372 T-allele expressed lower levels of TIMP-1 in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3285",
    "Sentence": "Male IBD or <\\entity><\\entity> patients carrying the TIMP-1 +372 T-allele expressed lower levels of TIMP-1 in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3286",
    "Sentence": "Male IBD or CD patients carrying the <\\entity><\\entity> expressed lower levels of TIMP-1 in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3287",
    "Sentence": "Male IBD or CD patients carrying the <\\entity><\\entity> expressed lower levels of TIMP-1 in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3288",
    "Sentence": "Male IBD or CD patients carrying the TIMP-1 <\\entity><\\entity>-allele expressed lower levels of TIMP-1 in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3289",
    "Sentence": "Male IBD or CD patients carrying the <\\entity><\\entity> +372 T-allele expressed lower levels of <\\entity><\\entity> in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3290",
    "Sentence": "The <\\entity><\\entity> increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3291",
    "Sentence": "The 5T5T genotype at <\\entity><\\entity> SNP -1613 5T/6T increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3292",
    "Sentence": "The 5T5T genotype at MMP-3 SNP -1613 5T/6T increased the chance of stenotic <\\entity><\\entity> in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3293",
    "Sentence": "The 5T5T genotype at MMP-3 SNP -1613 5T/6T increased the chance of stenotic complications in <\\entity><\\entity> during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3294",
    "Sentence": "The 5T5T genotype at MMP-3 SNP -1613 5T/6T increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against <\\entity><\\entity> of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3295",
    "Sentence": "The 5T5T genotype at MMP-3 SNP -1613 5T/6T increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this <\\entity><\\entity> at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3296",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for <\\entity><\\entity> and MMP-3 affect CD susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3297",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and <\\entity><\\entity> affect CD susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3298",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and MMP-3 affect <\\entity><\\entity> susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3299",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and MMP-3 affect CD susceptibility and/or phenotype, i.e., <\\entity><\\entity>, stricture pathogenesis and first disease localisation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3300",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and MMP-3 affect CD susceptibility and/or phenotype, i.e., fistulizing disease, <\\entity><\\entity> and first disease localisation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3301",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and MMP-3 affect CD susceptibility and/or phenotype, i.e., fistulizing <\\entity><\\entity>, stricture pathogenesis and first <\\entity><\\entity> localisation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3302",
    "Sentence": "These findings reinforce the important role of these proteins in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3303",
    "Sentence": "RESUL<\\entity><\\entity>S: <\\entity><\\entity>he <\\entity><\\entity>IMP-1 genotype <\\entity><\\entity><\\entity><\\entity> in women and <\\entity><\\entity> in men at SNP +372 <\\entity><\\entity>/C was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": ""
  },
  {
    "id": "3304",
    "Sentence": "RESULTS: The TIMP-1 genotype TT in women and T in men at SNP +372 T/C was found to increase <\\entity><\\entity> susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": ""
  },
  {
    "id": "3306",
    "Sentence": "RESULTS: The TIMP-1 genotype TT in women and T in men at <\\entity><\\entity> was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": ""
  },
  {
    "id": "3307",
    "Sentence": "RESULTS: The TIMP-1 genotype TT in women and T in men at SNP +372 T/C was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of <\\entity><\\entity> during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": ""
  },
  {
    "id": "3309",
    "Sentence": "RESULTS: The TIMP-1 genotype TT in women and T in men at <\\entity><\\entity> was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": ""
  },
  {
    "id": "3310",
    "Sentence": "RESULTS: The TIMP-1 genotype TT in women and T in men at SNP +372 T/C was found to increase <\\entity><\\entity> susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": ""
  },
  {
    "id": "3312",
    "Sentence": "RESULTS: The <\\entity><\\entity> in women and T in men at SNP +372 T/C was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": ""
  },
  {
    "id": "3313",
    "Sentence": "RESULTS: The TIMP-1 genotype TT in women and T in men at SNP +372 T/C was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of <\\entity><\\entity> during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": ""
  },
  {
    "id": "3315",
    "Sentence": "RESULTS: The <\\entity><\\entity> in women and T in men at SNP +372 T/C was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": ""
  },
  {
    "id": "3316",
    "Sentence": "RESULTS: The TIMP-1 genotype TT in women and T in men at SNP +372 T/C was found to increase <\\entity><\\entity> susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": ""
  },
  {
    "id": "3318",
    "Sentence": "Male IBD or CD patients carrying the <\\entity><\\entity> expressed lower levels of TIMP-1 in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01).",
    "Label": ""
  },
  {
    "id": "3319",
    "Sentence": "Male <\\entity><\\entity> or CD patients carrying the TIMP-1 +372 T-allele expressed lower levels of TIMP-1 in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01).",
    "Label": ""
  },
  {
    "id": "3321",
    "Sentence": "Male IBD or CD patients carrying the <\\entity><\\entity> expressed lower levels of TIMP-1 in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01).",
    "Label": ""
  },
  {
    "id": "3322",
    "Sentence": "Male IBD or <\\entity><\\entity> patients carrying the TIMP-1 +372 T-allele expressed lower levels of TIMP-1 in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01).",
    "Label": ""
  },
  {
    "id": "3324",
    "Sentence": "The <\\entity><\\entity> increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": ""
  },
  {
    "id": "3325",
    "Sentence": "The 5T5T genotype at MMP-3 SNP -1613 5T/6T increased the chance of stenotic complications in <\\entity><\\entity> during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": ""
  },
  {
    "id": "3327",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for <\\entity><\\entity> and MMP-3 affect CD susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation.",
    "Label": ""
  },
  {
    "id": "3328",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and MMP-3 affect <\\entity><\\entity> susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation.",
    "Label": ""
  },
  {
    "id": "3330",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and <\\entity><\\entity> affect CD susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation.",
    "Label": ""
  },
  {
    "id": "3331",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and MMP-3 affect <\\entity><\\entity> susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation.",
    "Label": ""
  },
  {
    "id": "3333",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and <\\entity><\\entity> in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3334",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in <\\entity><\\entity>.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of <\\entity><\\entity>s (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3336",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and <\\entity><\\entity>-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and <\\entity><\\entity> (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3337",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of <\\entity><\\entity> (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3339",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and <\\entity><\\entity>-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and <\\entity><\\entity> (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3340",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel <\\entity><\\entity>.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel <\\entity><\\entity>s (IBD), that may enhance susceptibility and/or <\\entity><\\entity> severity.",
    "Label": ""
  },
  {
    "id": "3342",
    "Sentence": "The 5T5T genotype at <\\entity><\\entity> SNP -1613 5T/6T increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": ""
  },
  {
    "id": "3343",
    "Sentence": "The 5T5T genotype at MMP-3 SNP -1613 5T/6T increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this <\\entity><\\entity> at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": ""
  },
  {
    "id": "3345",
    "Sentence": "The 5T5T genotype at <\\entity><\\entity> SNP -1613 5T/6T increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": ""
  },
  {
    "id": "3346",
    "Sentence": "The 5T5T genotype at MMP-3 SNP -1613 5T/6T increased the chance of stenotic <\\entity><\\entity> in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": ""
  },
  {
    "id": "3348",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for <\\entity><\\entity> and MMP-3 affect CD susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation.",
    "Label": ""
  },
  {
    "id": "3349",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and MMP-3 affect CD susceptibility and/or phenotype, i.e., fistulizing <\\entity><\\entity>, stricture pathogenesis and first <\\entity><\\entity> localisation.",
    "Label": ""
  },
  {
    "id": "3351",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for <\\entity><\\entity> and MMP-3 affect CD susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation.",
    "Label": ""
  },
  {
    "id": "3352",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and MMP-3 affect CD susceptibility and/or phenotype, i.e., fistulizing disease, <\\entity><\\entity> and first disease localisation.",
    "Label": ""
  },
  {
    "id": "3354",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and <\\entity><\\entity> affect CD susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation.",
    "Label": ""
  },
  {
    "id": "3355",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and MMP-3 affect CD susceptibility and/or phenotype, i.e., fistulizing <\\entity><\\entity>, stricture pathogenesis and first <\\entity><\\entity> localisation.",
    "Label": ""
  },
  {
    "id": "3357",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and <\\entity><\\entity> affect CD susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation.",
    "Label": ""
  },
  {
    "id": "3358",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and MMP-3 affect CD susceptibility and/or phenotype, i.e., fistulizing disease, <\\entity><\\entity> and first disease localisation.",
    "Label": ""
  },
  {
    "id": "3360",
    "Sentence": "Role of <\\entity><\\entity>, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding <\\entity><\\entity>s (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3361",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in <\\entity><\\entity>.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of <\\entity><\\entity>s (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3363",
    "Sentence": "Role of matrix metalloproteinase, <\\entity><\\entity> and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3364",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in <\\entity><\\entity>.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of <\\entity><\\entity>s (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3366",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and <\\entity><\\entity>-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and <\\entity><\\entity> (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3367",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (<\\entity><\\entity>), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3369",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding <\\entity><\\entity> (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3370",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of <\\entity><\\entity> (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3372",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding <\\entity><\\entity> (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3373",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (<\\entity><\\entity>), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3375",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (<\\entity><\\entity>, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3376",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of <\\entity><\\entity> (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3378",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (<\\entity><\\entity>, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3379",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (<\\entity><\\entity>), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3381",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, <\\entity><\\entity> (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3382",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of <\\entity><\\entity> (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3384",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, <\\entity><\\entity> (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3385",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (<\\entity><\\entity>), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3387",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (<\\entity><\\entity> in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3388",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of <\\entity><\\entity> (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3390",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (<\\entity><\\entity> in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3391",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (<\\entity><\\entity>), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3393",
    "Sentence": "RESULTS: The TIMP-1 genotype TT in women and T in men at <\\entity><\\entity> was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of fistulae during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": ""
  },
  {
    "id": "3394",
    "Sentence": "RESULTS: The TIMP-1 genotype TT in women and T in men at SNP +372 T/C was found to increase CD susceptibility (39% vs 23.8%, P = 0.018 and 67.9% vs 51.6%, P = 0.055, respectively), while women with this genotype were less prone to development of <\\entity><\\entity> during follow-up (41.4% vs 68.3%, P = 0.025).",
    "Label": ""
  },
  {
    "id": "3396",
    "Sentence": "The <\\entity><\\entity> increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": ""
  },
  {
    "id": "3397",
    "Sentence": "The 5T5T genotype at MMP-3 SNP -1613 5T/6T increased the chance of stenotic <\\entity><\\entity> in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": ""
  },
  {
    "id": "3399",
    "Sentence": "The 5T5T genotype at <\\entity><\\entity> SNP -1613 5T/6T increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": ""
  },
  {
    "id": "3400",
    "Sentence": "The 5T5T genotype at MMP-3 SNP -1613 5T/6T increased the chance of stenotic complications in <\\entity><\\entity> during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": ""
  },
  {
    "id": "3402",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for <\\entity><\\entity> and MMP-3 affect CD susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation.",
    "Label": ""
  },
  {
    "id": "3403",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and MMP-3 affect CD susceptibility and/or phenotype, i.e., <\\entity><\\entity>, stricture pathogenesis and first disease localisation.",
    "Label": ""
  },
  {
    "id": "3405",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and <\\entity><\\entity> affect CD susceptibility and/or phenotype, i.e., fistulizing disease, stricture pathogenesis and first disease localisation.",
    "Label": ""
  },
  {
    "id": "3406",
    "Sentence": "CONCLUSION: Allelic composition at the examined SNPs in genes coding for TIMP-1 and MMP-3 affect CD susceptibility and/or phenotype, i.e., <\\entity><\\entity>, stricture pathogenesis and first disease localisation.",
    "Label": ""
  },
  {
    "id": "3408",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (<\\entity><\\entity>, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3409",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of <\\entity><\\entity> (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3411",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (<\\entity><\\entity>, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (IBD), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3412",
    "Sentence": "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.AIM: To study the (functional) relevance of single nucleotide polymorphisms (SNPs) in genes encoding matrix metalloproteinases (MMP)-1, -2, -3, -9, tissue inhibitors of metalloproteinases (TIMP)-1, -2 and tumor necrosis factor (TNF)-alpha in the etiopathogenesis of inflammatory bowel diseases (<\\entity><\\entity>), that may enhance susceptibility and/or disease severity.",
    "Label": ""
  },
  {
    "id": "3414",
    "Sentence": "Male IBD or CD patients carrying the <\\entity><\\entity> +372 T-allele expressed lower levels of <\\entity><\\entity> in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01).",
    "Label": ""
  },
  {
    "id": "3415",
    "Sentence": "Male <\\entity><\\entity> or CD patients carrying the TIMP-1 +372 T-allele expressed lower levels of TIMP-1 in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01).",
    "Label": ""
  },
  {
    "id": "3417",
    "Sentence": "Male IBD or CD patients carrying the <\\entity><\\entity> +372 T-allele expressed lower levels of <\\entity><\\entity> in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01).",
    "Label": ""
  },
  {
    "id": "3418",
    "Sentence": "Male IBD or <\\entity><\\entity> patients carrying the TIMP-1 +372 T-allele expressed lower levels of TIMP-1 in surgically resected macroscopically inflamed tissue (0.065 < P < 0.01).",
    "Label": ""
  },
  {
    "id": "3420",
    "Sentence": "The 5T5T genotype at <\\entity><\\entity> SNP -1613 5T/6T increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": ""
  },
  {
    "id": "3421",
    "Sentence": "The 5T5T genotype at MMP-3 SNP -1613 5T/6T increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against <\\entity><\\entity> of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": ""
  },
  {
    "id": "3423",
    "Sentence": "The <\\entity><\\entity> increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against colonic involvement of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": ""
  },
  {
    "id": "3424",
    "Sentence": "The 5T5T genotype at MMP-3 SNP -1613 5T/6T increased the chance of stenotic complications in CD during follow-up (91.2% vs 71.8%, P = 0.022) but seemed to protect against <\\entity><\\entity> of this disease at first endoscopic/radiologic examination (35.3% vs 59.5%, P = 0.017).",
    "Label": ""
  },
  {
    "id": "3430",
    "Sentence": "Is <\\entity><\\entity>, an agent treating diabetes, a new hope for Alzheimer's disease?<\\entity><\\entity> (GLP-1) has been endorsed as a promising and attractive agent in the treatment of type 2 diabetes mellitus (T2DM).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3431",
    "Sentence": "Is <\\entity><\\entity>, an agent treating diabetes, a new hope for Alzheimer's disease?<\\entity><\\entity> (GLP-1) has been endorsed as a promising and attractive agent in the treatment of type 2 diabetes mellitus (T2DM).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3432",
    "Sentence": "Is <\\entity><\\entity>, an agent treating diabetes, a new hope for Alzheimer's disease?<\\entity><\\entity> (GLP-1) has been endorsed as a promising and attractive agent in the treatment of type 2 diabetes mellitus (T2DM).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3433",
    "Sentence": "Is <\\entity><\\entity>, an agent treating diabetes, a new hope for Alzheimer's disease?<\\entity><\\entity> (GLP-1) has been endorsed as a promising and attractive agent in the treatment of type 2 diabetes mellitus (T2DM).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3434",
    "Sentence": "Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?Glucagon-like peptide-1 (<\\entity><\\entity>) has been endorsed as a promising and attractive agent in the treatment of type 2 diabetes mellitus (T2DM).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3435",
    "Sentence": "Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?Glucagon-like peptide-1 (<\\entity><\\entity>) has been endorsed as a promising and attractive agent in the treatment of type 2 diabetes mellitus (T2DM).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3436",
    "Sentence": "Both Alzheimer's disease (AD) and T2DM share some common pathophysiologic hallmarks, such as <\\entity><\\entity> (Abeta), phosphoralation of tau protein, and glycogen synthase kinase-3.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3437",
    "Sentence": "Both Alzheimer's disease (AD) and T2DM share some common pathophysiologic hallmarks, such as amyloid beta (<\\entity><\\entity>), phosphoralation of tau protein, and glycogen synthase kinase-3.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3438",
    "Sentence": "Both Alzheimer's disease (AD) and T2DM share some common pathophysiologic hallmarks, such as amyloid beta (Abeta), phosphoralation of <\\entity><\\entity>, and glycogen synthase kinase-3.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3439",
    "Sentence": "Both Alzheimer's disease (AD) and T2DM share some common pathophysiologic hallmarks, such as amyloid beta (Abeta), phosphoralation of tau protein, and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3440",
    "Sentence": "<\\entity><\\entity> possesses neurotropic properties and can reduce amyloid protein levels in the brain.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3441",
    "Sentence": "<\\entity><\\entity> possesses neurotropic properties and can reduce amyloid protein levels in the brain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3442",
    "Sentence": "GLP-1 possesses neurotropic properties and can reduce <\\entity><\\entity> levels in the brain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3443",
    "Sentence": "Based on extensive studies during the past decades, the understanding on AD leads us to believe that the primary targets in AD are the <\\entity><\\entity> and tau protein.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3444",
    "Sentence": "Based on extensive studies during the past decades, the understanding on AD leads us to believe that the primary targets in AD are the Abeta and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3445",
    "Sentence": "Combine these findings, <\\entity><\\entity> is probably a promising agent in the therapy of AD.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3446",
    "Sentence": "Combine these findings, <\\entity><\\entity> is probably a promising agent in the therapy of AD.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3447",
    "Sentence": "This review was focused on the biochemistry and physiology of <\\entity><\\entity>, communities between T2DM and AD, new progresses of <\\entity><\\entity> in treating T2MD and improving some pathologic hallmarks of AD.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3448",
    "Sentence": "This review was focused on the biochemistry and physiology of <\\entity><\\entity>, communities between T2DM and AD, new progresses of <\\entity><\\entity> in treating T2MD and improving some pathologic hallmarks of AD.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3449",
    "Sentence": "This review was focused on the biochemistry and physiology of <\\entity><\\entity>, communities between T2DM and AD, new progresses of <\\entity><\\entity> in treating T2MD and improving some pathologic hallmarks of AD.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3450",
    "Sentence": "This review was focused on the biochemistry and physiology of <\\entity><\\entity>, communities between T2DM and AD, new progresses of <\\entity><\\entity> in treating T2MD and improving some pathologic hallmarks of AD.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3451",
    "Sentence": "<\\entity><\\entity> possesses neurotropic properties and can reduce amyloid protein levels in the brain.",
    "Label": ""
  },
  {
    "id": "3452",
    "Sentence": "GLP-1 possesses neurotropic properties and can reduce <\\entity><\\entity> levels in the brain.",
    "Label": ""
  },
  {
    "id": "3454",
    "Sentence": "Is <\\entity><\\entity>, an agent treating diabetes, a new hope for Alzheimer's disease?<\\entity><\\entity> (GLP-1) has been endorsed as a promising and attractive agent in the treatment of type 2 diabetes mellitus (T2DM).",
    "Label": ""
  },
  {
    "id": "3455",
    "Sentence": "Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?Glucagon-like peptide-1 (<\\entity><\\entity>) has been endorsed as a promising and attractive agent in the treatment of type 2 diabetes mellitus (T2DM).",
    "Label": ""
  },
  {
    "id": "3461",
    "Sentence": "<\\entity><\\entity> as molecular hotspots for congenital heart disease (CHD).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3462",
    "Sentence": "<\\entity><\\entity> as molecular hotspots for congenital heart disease (CHD).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3463",
    "Sentence": "<\\entity><\\entity> as molecular hotspots for congenital heart disease (CHD).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3464",
    "Sentence": "Mutations in the 3'-untranslated region of GATA4 as molecular hotspots for <\\entity><\\entity> (CHD).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3465",
    "Sentence": "Mutations in the 3'-untranslated region of GATA4 as molecular hotspots for congenital heart disease (<\\entity><\\entity>).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3466",
    "Sentence": "Mutations in the 3'-untranslated region of GATA4 as molecular hotspots for congenital heart disease (<\\entity><\\entity>).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3467",
    "Sentence": "Indeed, 3'-UTR <\\entity><\\entity> have been associated with disease, but frequently this region is not analyzed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3468",
    "Sentence": "Indeed, 3'-UTR <\\entity><\\entity> have been associated with disease, but frequently this region is not analyzed.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3469",
    "Sentence": "Indeed, 3'-UTR mutations have been associated with <\\entity><\\entity>, but frequently this region is not analyzed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3470",
    "Sentence": "To gain insights into <\\entity><\\entity> (CHD), we have been analyzing cardiac-specific transcription factor genes, including GATA4, which encodes a zinc finger transcription factor.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3471",
    "Sentence": "To gain insights into congenital heart disease (<\\entity><\\entity>), we have been analyzing cardiac-specific transcription factor genes, including GATA4, which encodes a zinc finger transcription factor.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3472",
    "Sentence": "To gain insights into congenital heart disease (<\\entity><\\entity>), we have been analyzing cardiac-specific transcription factor genes, including GATA4, which encodes a zinc finger transcription factor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3473",
    "Sentence": "To gain insights into congenital heart disease (CHD), we have been analyzing cardiac-specific transcription factor genes, including <\\entity><\\entity>, which encodes a zinc finger transcription factor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3474",
    "Sentence": "To gain insights into congenital heart disease (CHD), we have been analyzing cardiac-specific transcription factor genes, including GATA4, which encodes a <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3475",
    "Sentence": "<\\entity><\\entity> have been associated with septation defects of the human heart, but mutations are rather rare.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3476",
    "Sentence": "<\\entity><\\entity> have been associated with septation defects of the human heart, but mutations are rather rare.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3477",
    "Sentence": "<\\entity><\\entity> have been associated with septation defects of the human heart, but mutations are rather rare.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3478",
    "Sentence": "Germline mutations in the coding region of GATA4 have been associated with <\\entity><\\entity>, but mutations are rather rare.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3479",
    "Sentence": "Germline <\\entity><\\entity> in the coding region of GATA4 have been associated with septation defects of the human heart, but <\\entity><\\entity> are rather rare.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3480",
    "Sentence": "Previously, we identified 19 <\\entity><\\entity> in diseased tissues of malformed hearts.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3481",
    "Sentence": "Previously, we identified 19 <\\entity><\\entity> in diseased tissues of malformed hearts.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3482",
    "Sentence": "Previously, we identified 19 somatically-derived zinc finger mutations in diseased tissues of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3483",
    "Sentence": "We now continued our search in the 609 bp <\\entity><\\entity> to explore further molecular avenues leading to CHD.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3484",
    "Sentence": "We now continued our search in the 609 bp 3'-UTR region of GATA4 to explore further molecular avenues leading to <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3485",
    "Sentence": "We now continued our search in the 609 bp 3'-UTR region of GATA4 to explore further molecular avenues leading to <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3486",
    "Sentence": "METHODS: By direct sequencing, we analyzed the <\\entity><\\entity> in DNA isolated from 68 formalin-fixed explanted hearts with complex cardiac malformations encompassing ventricular, atrial, and atrioventricular septal defects.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3487",
    "Sentence": "METHODS: By direct sequencing, we analyzed the 3'-UTR of GATA4 in DNA isolated from 68 formalin-fixed explanted hearts with complex <\\entity><\\entity> encompassing ventricular, atrial, and atrioventricular septal defects.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3488",
    "Sentence": "METHODS: By direct sequencing, we analyzed the 3'-UTR of GATA4 in DNA isolated from 68 formalin-fixed explanted hearts with complex cardiac malformations encompassing <\\entity><\\entity>, atrial, and atrio<\\entity><\\entity> septal defects.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3489",
    "Sentence": "METHODS: By direct sequencing, we analyzed the 3'-UTR of GATA4 in DNA isolated from 68 formalin-fixed explanted hearts with complex cardiac malformations encompassing ventricular, <\\entity><\\entity>, and atrioventricular septal defects.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3490",
    "Sentence": "METHODS: By direct sequencing, we analyzed the 3'-UTR of GATA4 in DNA isolated from 68 formalin-fixed explanted hearts with complex cardiac malformations encompassing ventricular, atrial, and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3491",
    "Sentence": "We also analyzed blood samples of 12 patients with <\\entity><\\entity> and 100 unrelated healthy individuals.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3492",
    "Sentence": "We also analyzed blood samples of 12 patients with <\\entity><\\entity> and 100 unrelated healthy individuals.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3493",
    "Sentence": "RESULTS: We identified germline and <\\entity><\\entity> in the 3'-UTR of GATA4.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3494",
    "Sentence": "RESULTS: We identified germline and somatic mutations in the <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3495",
    "Sentence": "In the <\\entity><\\entity>, we found nine frequently occurring sequence alterations and six dbSNPs in the 3'-UTR region of GATA4.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3496",
    "Sentence": "In the malformed hearts, we found nine frequently occurring sequence alterations and six <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3497",
    "Sentence": "In the malformed hearts, we found nine frequently occurring sequence alterations and six <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3498",
    "Sentence": "Seven of these <\\entity><\\entity> are predicted to affect RNA folding.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3499",
    "Sentence": "We also found further five nonsynonymous <\\entity><\\entity> in exons 6 and 7 of GATA4.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3500",
    "Sentence": "We also found further five nonsynonymous mutations in exons 6 and 7 of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3501",
    "Sentence": "We also found further five nonsynonymous mutations in exons 6 and 7 of <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3502",
    "Sentence": "Except for the dbSNPs, analysis of tissue distal to the septation defect failed to detect sequence variations in the same donor, thus suggesting somatic origin and <\\entity><\\entity> of mutations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3503",
    "Sentence": "Except for the dbSNPs, analysis of tissue distal to the septation defect failed to detect sequence variations in the same donor, thus suggesting somatic origin and mosaicism of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3504",
    "Sentence": "In a family, we observed <\\entity><\\entity> associated with ASD type II.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3505",
    "Sentence": "In a family, we observed c.+119A > T in the 3'-UTR associated with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3506",
    "Sentence": "In a family, we observed c.+119A > T in the 3'-UTR associated with <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3507",
    "Sentence": "CONCLUSION: Our results suggest that <\\entity><\\entity> may provide an additional molecular rationale for CHD.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3508",
    "Sentence": "CONCLUSION: Our results suggest that somatic <\\entity><\\entity> mutations in the 3'-UTR may provide an additional molecular rationale for CHD.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3509",
    "Sentence": "CONCLUSION: Our results suggest that somatic GATA4 <\\entity><\\entity> in the 3'-UTR may provide an additional molecular rationale for CHD.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3510",
    "Sentence": "CONCLUSION: Our results suggest that somatic GATA4 mutations in the 3'-UTR may provide an additional molecular rationale for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3511",
    "Sentence": "CONCLUSION: Our results suggest that somatic GATA4 mutations in the 3'-UTR may provide an additional molecular rationale for <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3512",
    "Sentence": "Previously, we identified 19 <\\entity><\\entity> in diseased tissues of malformed hearts.",
    "Label": ""
  },
  {
    "id": "3513",
    "Sentence": "Previously, we identified 19 somatically-derived zinc finger mutations in diseased tissues of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3515",
    "Sentence": "In the malformed hearts, we found nine frequently occurring sequence alterations and six <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3516",
    "Sentence": "In the <\\entity><\\entity>, we found nine frequently occurring sequence alterations and six dbSNPs in the 3'-UTR region of GATA4.",
    "Label": ""
  },
  {
    "id": "3518",
    "Sentence": "In a family, we observed <\\entity><\\entity> associated with ASD type II.",
    "Label": ""
  },
  {
    "id": "3519",
    "Sentence": "In a family, we observed c.+119A > T in the 3'-UTR associated with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3521",
    "Sentence": "CONCLUSION: Our results suggest that <\\entity><\\entity> may provide an additional molecular rationale for CHD.",
    "Label": ""
  },
  {
    "id": "3522",
    "Sentence": "CONCLUSION: Our results suggest that somatic GATA4 mutations in the 3'-UTR may provide an additional molecular rationale for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3524",
    "Sentence": "Mutations in the 3'-untranslated region of GATA4 as molecular hotspots for congenital heart disease (<\\entity><\\entity>).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": ""
  },
  {
    "id": "3525",
    "Sentence": "<\\entity><\\entity> as molecular hotspots for congenital heart disease (CHD).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": ""
  },
  {
    "id": "3527",
    "Sentence": "Mutations in the 3'-untranslated region of GATA4 as molecular hotspots for congenital heart disease (<\\entity><\\entity>).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": ""
  },
  {
    "id": "3528",
    "Sentence": "Mutations in the 3'-untranslated region of GATA4 as molecular hotspots for <\\entity><\\entity> (CHD).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": ""
  },
  {
    "id": "3530",
    "Sentence": "<\\entity><\\entity> as molecular hotspots for congenital heart disease (CHD).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": ""
  },
  {
    "id": "3531",
    "Sentence": "<\\entity><\\entity> as molecular hotspots for congenital heart disease (CHD).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": ""
  },
  {
    "id": "3533",
    "Sentence": "<\\entity><\\entity> as molecular hotspots for congenital heart disease (CHD).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": ""
  },
  {
    "id": "3534",
    "Sentence": "Mutations in the 3'-untranslated region of GATA4 as molecular hotspots for <\\entity><\\entity> (CHD).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": ""
  },
  {
    "id": "3536",
    "Sentence": "To gain insights into congenital heart disease (<\\entity><\\entity>), we have been analyzing cardiac-specific transcription factor genes, including GATA4, which encodes a zinc finger transcription factor.",
    "Label": ""
  },
  {
    "id": "3537",
    "Sentence": "To gain insights into <\\entity><\\entity> (CHD), we have been analyzing cardiac-specific transcription factor genes, including GATA4, which encodes a zinc finger transcription factor.",
    "Label": ""
  },
  {
    "id": "3539",
    "Sentence": "To gain insights into congenital heart disease (CHD), we have been analyzing cardiac-specific transcription factor genes, including <\\entity><\\entity>, which encodes a zinc finger transcription factor.",
    "Label": ""
  },
  {
    "id": "3540",
    "Sentence": "To gain insights into <\\entity><\\entity> (CHD), we have been analyzing cardiac-specific transcription factor genes, including GATA4, which encodes a zinc finger transcription factor.",
    "Label": ""
  },
  {
    "id": "3542",
    "Sentence": "<\\entity><\\entity> have been associated with septation defects of the human heart, but mutations are rather rare.",
    "Label": ""
  },
  {
    "id": "3543",
    "Sentence": "Germline <\\entity><\\entity> in the coding region of GATA4 have been associated with septation defects of the human heart, but <\\entity><\\entity> are rather rare.",
    "Label": ""
  },
  {
    "id": "3545",
    "Sentence": "<\\entity><\\entity> have been associated with septation defects of the human heart, but mutations are rather rare.",
    "Label": ""
  },
  {
    "id": "3546",
    "Sentence": "<\\entity><\\entity> have been associated with septation defects of the human heart, but mutations are rather rare.",
    "Label": ""
  },
  {
    "id": "3548",
    "Sentence": "METHODS: By direct sequencing, we analyzed the <\\entity><\\entity> in DNA isolated from 68 formalin-fixed explanted hearts with complex cardiac malformations encompassing ventricular, atrial, and atrioventricular septal defects.",
    "Label": ""
  },
  {
    "id": "3549",
    "Sentence": "METHODS: By direct sequencing, we analyzed the 3'-UTR of GATA4 in DNA isolated from 68 formalin-fixed explanted hearts with complex <\\entity><\\entity> encompassing ventricular, atrial, and atrioventricular septal defects.",
    "Label": ""
  },
  {
    "id": "3551",
    "Sentence": "METHODS: By direct sequencing, we analyzed the <\\entity><\\entity> in DNA isolated from 68 formalin-fixed explanted hearts with complex cardiac malformations encompassing ventricular, atrial, and atrioventricular septal defects.",
    "Label": ""
  },
  {
    "id": "3552",
    "Sentence": "METHODS: By direct sequencing, we analyzed the 3'-UTR of GATA4 in DNA isolated from 68 formalin-fixed explanted hearts with complex cardiac malformations encompassing ventricular, atrial, and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3554",
    "Sentence": "RESULTS: We identified germline and somatic mutations in the <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3555",
    "Sentence": "RESULTS: We identified germline and <\\entity><\\entity> in the 3'-UTR of GATA4.",
    "Label": ""
  },
  {
    "id": "3557",
    "Sentence": "We also found further five nonsynonymous mutations in exons 6 and 7 of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3558",
    "Sentence": "We also found further five nonsynonymous <\\entity><\\entity> in exons 6 and 7 of GATA4.",
    "Label": ""
  },
  {
    "id": "3560",
    "Sentence": "CONCLUSION: Our results suggest that somatic GATA4 mutations in the 3'-UTR may provide an additional molecular rationale for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3561",
    "Sentence": "CONCLUSION: Our results suggest that somatic GATA4 <\\entity><\\entity> in the 3'-UTR may provide an additional molecular rationale for CHD.",
    "Label": ""
  },
  {
    "id": "3563",
    "Sentence": "CONCLUSION: Our results suggest that somatic <\\entity><\\entity> mutations in the 3'-UTR may provide an additional molecular rationale for CHD.",
    "Label": ""
  },
  {
    "id": "3564",
    "Sentence": "CONCLUSION: Our results suggest that somatic GATA4 <\\entity><\\entity> in the 3'-UTR may provide an additional molecular rationale for CHD.",
    "Label": ""
  },
  {
    "id": "3566",
    "Sentence": "<\\entity><\\entity> as molecular hotspots for congenital heart disease (CHD).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": ""
  },
  {
    "id": "3567",
    "Sentence": "Mutations in the 3'-untranslated region of GATA4 as molecular hotspots for congenital heart disease (<\\entity><\\entity>).BACKGROUND: The 3'-untranslated region (3'-UTR) of mRNA contains regulatory elements that are essential for the appropriate expression of many genes.",
    "Label": ""
  },
  {
    "id": "3569",
    "Sentence": "To gain insights into congenital heart disease (CHD), we have been analyzing cardiac-specific transcription factor genes, including <\\entity><\\entity>, which encodes a zinc finger transcription factor.",
    "Label": ""
  },
  {
    "id": "3570",
    "Sentence": "To gain insights into congenital heart disease (<\\entity><\\entity>), we have been analyzing cardiac-specific transcription factor genes, including GATA4, which encodes a zinc finger transcription factor.",
    "Label": ""
  },
  {
    "id": "3572",
    "Sentence": "<\\entity><\\entity> have been associated with septation defects of the human heart, but mutations are rather rare.",
    "Label": ""
  },
  {
    "id": "3573",
    "Sentence": "Germline mutations in the coding region of GATA4 have been associated with <\\entity><\\entity>, but mutations are rather rare.",
    "Label": ""
  },
  {
    "id": "3575",
    "Sentence": "We now continued our search in the 609 bp <\\entity><\\entity> to explore further molecular avenues leading to CHD.",
    "Label": ""
  },
  {
    "id": "3576",
    "Sentence": "We now continued our search in the 609 bp 3'-UTR region of GATA4 to explore further molecular avenues leading to <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3578",
    "Sentence": "CONCLUSION: Our results suggest that somatic <\\entity><\\entity> mutations in the 3'-UTR may provide an additional molecular rationale for CHD.",
    "Label": ""
  },
  {
    "id": "3579",
    "Sentence": "CONCLUSION: Our results suggest that somatic GATA4 mutations in the 3'-UTR may provide an additional molecular rationale for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3585",
    "Sentence": "<\\entity><\\entity> predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.Pharmacogenetic advances in cancer chemotherapy have the potential to predict clinical benefit to particular regimens.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3586",
    "Sentence": "<\\entity><\\entity> predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.Pharmacogenetic advances in cancer chemotherapy have the potential to predict clinical benefit to particular regimens.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3587",
    "Sentence": "Polymorphism of XRCC1 predicts overall survival of <\\entity><\\entity> patients receiving oxaliplatin-based chemotherapy in Chinese population.Pharmacogenetic advances in cancer chemotherapy have the potential to predict clinical benefit to particular regimens.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3588",
    "Sentence": "Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.Pharmacogenetic <\\entity><\\entity> chemotherapy have the potential to predict clinical benefit to particular regimens.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3589",
    "Sentence": "Platinum agents have shown to be effective in the treatment of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3590",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in <\\entity><\\entity> (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3591",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in <\\entity><\\entity> (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3592",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (<\\entity><\\entity>), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3593",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (<\\entity><\\entity>), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3594",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), <\\entity><\\entity> (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3595",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair <\\entity><\\entity> complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3596",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (<\\entity><\\entity>) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3597",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (XRCC1) and <\\entity><\\entity> (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3598",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (<\\entity><\\entity>) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3599",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in <\\entity><\\entity> patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3600",
    "Sentence": "<\\entity><\\entity>, XRCC1-399 and GSTP1-105 in 62 gastric cancer patients were evaluated using the TaqMan 5' nuclease assay.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3601",
    "Sentence": "SNPs of XPD-751, <\\entity><\\entity> and GSTP1-105 in 62 gastric cancer patients were evaluated using the TaqMan 5' nuclease assay.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3602",
    "Sentence": "SNPs of XPD-751, XRCC1-399 and <\\entity><\\entity> in 62 gastric cancer patients were evaluated using the TaqMan 5' nuclease assay.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3603",
    "Sentence": "SNPs of XPD-751, XRCC1-399 and GSTP1-105 in 62 <\\entity><\\entity> patients were evaluated using the TaqMan 5' nuclease assay.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3604",
    "Sentence": "The median survival times for patients with <\\entity><\\entity> or Arg/Gln genotypes of XRCC1 gene were significantly longer than others (P=0.03).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3605",
    "Sentence": "The median survival times for patients with Arg/Arg or <\\entity><\\entity> genotypes of XRCC1 gene were significantly longer than others (P=0.03).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3606",
    "Sentence": "The median survival times for patients with Arg/Arg or Arg/Gln genotypes of <\\entity><\\entity> gene were significantly longer than others (P=0.03).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3607",
    "Sentence": "Patients with <\\entity><\\entity> genotype demonstrated a significant worse survival.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3608",
    "Sentence": "No significant association was found between <\\entity><\\entity>, GSTP1-105 and survival (P=0.125, 0.475, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3609",
    "Sentence": "No significant association was found between SNPs of XPD-751, <\\entity><\\entity> and survival (P=0.125, 0.475, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3610",
    "Sentence": "<\\entity><\\entity> genotyping might make tailor chemotherapy possible for gastric cancer patients treated with oxaliplatin-based chemotherapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3611",
    "Sentence": "XRCC1 genotyping might make tailor chemotherapy possible for <\\entity><\\entity> patients treated with oxaliplatin-based chemotherapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3612",
    "Sentence": "<\\entity><\\entity> predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.Pharmacogenetic advances in cancer chemotherapy have the potential to predict clinical benefit to particular regimens.",
    "Label": ""
  },
  {
    "id": "3613",
    "Sentence": "Polymorphism of XRCC1 predicts overall survival of <\\entity><\\entity> patients receiving oxaliplatin-based chemotherapy in Chinese population.Pharmacogenetic advances in cancer chemotherapy have the potential to predict clinical benefit to particular regimens.",
    "Label": ""
  },
  {
    "id": "3615",
    "Sentence": "<\\entity><\\entity> genotyping might make tailor chemotherapy possible for gastric cancer patients treated with oxaliplatin-based chemotherapy.",
    "Label": ""
  },
  {
    "id": "3616",
    "Sentence": "XRCC1 genotyping might make tailor chemotherapy possible for <\\entity><\\entity> patients treated with oxaliplatin-based chemotherapy.",
    "Label": ""
  },
  {
    "id": "3618",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (<\\entity><\\entity>) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3619",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in <\\entity><\\entity> patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3621",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (<\\entity><\\entity>) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3622",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in <\\entity><\\entity> (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3624",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (<\\entity><\\entity>) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3625",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair <\\entity><\\entity> complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3627",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (<\\entity><\\entity>), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3628",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in <\\entity><\\entity> patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3630",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (<\\entity><\\entity>), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3631",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in <\\entity><\\entity> (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3633",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (<\\entity><\\entity>), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3634",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair <\\entity><\\entity> complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3636",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (<\\entity><\\entity>) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3637",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in <\\entity><\\entity> patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3639",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (<\\entity><\\entity>) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3640",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in <\\entity><\\entity> (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3642",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair cross complementing group 1 (XRCC1) and glutathione S-transferase P1 (<\\entity><\\entity>) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3643",
    "Sentence": "We assessed whether single nucleotide polymorphisms (SNPs) in xeroderma pigmentosum group D (XPD), X-ray repair <\\entity><\\entity> complementing group 1 (XRCC1) and glutathione S-transferase P1 (GSTP1) predicted overall survival in gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.",
    "Label": ""
  },
  {
    "id": "3645",
    "Sentence": "<\\entity><\\entity>, XRCC1-399 and GSTP1-105 in 62 gastric cancer patients were evaluated using the TaqMan 5' nuclease assay.",
    "Label": ""
  },
  {
    "id": "3646",
    "Sentence": "SNPs of XPD-751, XRCC1-399 and GSTP1-105 in 62 <\\entity><\\entity> patients were evaluated using the TaqMan 5' nuclease assay.",
    "Label": ""
  },
  {
    "id": "3648",
    "Sentence": "SNPs of XPD-751, <\\entity><\\entity> and GSTP1-105 in 62 gastric cancer patients were evaluated using the TaqMan 5' nuclease assay.",
    "Label": ""
  },
  {
    "id": "3649",
    "Sentence": "SNPs of XPD-751, XRCC1-399 and GSTP1-105 in 62 <\\entity><\\entity> patients were evaluated using the TaqMan 5' nuclease assay.",
    "Label": ""
  },
  {
    "id": "3651",
    "Sentence": "SNPs of XPD-751, XRCC1-399 and <\\entity><\\entity> in 62 gastric cancer patients were evaluated using the TaqMan 5' nuclease assay.",
    "Label": ""
  },
  {
    "id": "3652",
    "Sentence": "SNPs of XPD-751, XRCC1-399 and GSTP1-105 in 62 <\\entity><\\entity> patients were evaluated using the TaqMan 5' nuclease assay.",
    "Label": ""
  },
  {
    "id": "3658",
    "Sentence": "<\\entity><\\entity> and hypoxia inhibit aryl hydrocarbon receptor-mediated responses in breast cancer cells.The aryl hydrocarbon receptor (AhR) is expressed in estrogen receptor (ER)-positive ZR-75 breast cancer cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3659",
    "Sentence": "Cobaltous chloride and hypoxia inhibit <\\entity><\\entity>-mediated responses in breast cancer cells.The <\\entity><\\entity> (AhR) is expressed in estrogen receptor (ER)-positive ZR-75 breast cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3660",
    "Sentence": "Cobaltous chloride and hypoxia inhibit <\\entity><\\entity>-mediated responses in breast cancer cells.The <\\entity><\\entity> (AhR) is expressed in estrogen receptor (ER)-positive ZR-75 breast cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3661",
    "Sentence": "Cobaltous chloride and hypoxia inhibit aryl hydrocarbon receptor-mediated responses in breast cancer cells.The aryl hydrocarbon receptor (<\\entity><\\entity>) is expressed in estrogen receptor (ER)-positive ZR-75 breast cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3662",
    "Sentence": "Cobaltous chloride and hypoxia inhibit aryl hydrocarbon receptor-mediated responses in breast cancer cells.The aryl hydrocarbon receptor (AhR) is expressed in <\\entity><\\entity> (ER)-positive ZR-75 breast cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3663",
    "Sentence": "Cobaltous chloride and hypoxia inhibit aryl hydrocarbon receptor-mediated responses in breast cancer cells.The aryl hydrocarbon receptor (AhR) is expressed in estrogen receptor (<\\entity><\\entity>)-positive ZR-75 breast cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3664",
    "Sentence": "Treatment with <\\entity><\\entity> (TCDD) induces CYP1A1 protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3665",
    "Sentence": "Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (<\\entity><\\entity>) induces CYP1A1 protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3666",
    "Sentence": "Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces <\\entity><\\entity> protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3667",
    "Sentence": "Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces CYP1A1 protein and mRNA levels and also activates inhibitory <\\entity><\\entity> crosstalk associated with hormone-induced reporter gene expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3668",
    "Sentence": "In ZR-75 cells grown under hypoxia, induction of these <\\entity><\\entity>-mediated responses by TCDD was significantly inhibited.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3669",
    "Sentence": "In ZR-75 cells grown under hypoxia, induction of these AhR-mediated responses by <\\entity><\\entity> was significantly inhibited.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3670",
    "Sentence": "This was not accompanied by decreased nuclear <\\entity><\\entity> levels or decreased interaction of the <\\entity><\\entity> complex with the CYP1A1 gene promoter as determined in a chromatin immunoprecipitation assay.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3671",
    "Sentence": "This was not accompanied by decreased nuclear <\\entity><\\entity> levels or decreased interaction of the <\\entity><\\entity> complex with the CYP1A1 gene promoter as determined in a chromatin immunoprecipitation assay.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3672",
    "Sentence": "This was not accompanied by decreased nuclear AhR levels or decreased interaction of the AhR complex with the <\\entity><\\entity> gene promoter as determined in a chromatin immunoprecipitation assay.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3673",
    "Sentence": "This was not accompanied by decreased nuclear AhR levels or decreased interaction of the AhR complex with the CYP1A1 gene promoter as determined in a <\\entity><\\entity> immunoprecipitation assay.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3674",
    "Sentence": "Hypoxia-induced loss of Ah-responsiveness was not associated with induction of <\\entity><\\entity> or other factors that sequester the AhR nuclear translocation (Arnt) protein, and overexpression of Arnt under hypoxia did not restore Ah-responsiveness.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3675",
    "Sentence": "Hypoxia-induced loss of Ah-responsiveness was not associated with induction of hypoxia-inducible factor-1alpha or other factors that sequester the <\\entity><\\entity> (Arnt) protein, and overexpression of Arnt under hypoxia did not restore Ah-responsiveness.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3676",
    "Sentence": "Hypoxia-induced loss of Ah-responsiveness was not associated with induction of hypoxia-inducible factor-1alpha or other factors that sequester the AhR nuclear translocation (<\\entity><\\entity>, and overexpression of Arnt under hypoxia did not restore Ah-responsiveness.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3677",
    "Sentence": "Hypoxia-induced loss of Ah-responsiveness was not associated with induction of hypoxia-inducible factor-1alpha or other factors that sequester the AhR nuclear translocation (<\\entity><\\entity>) protein, and overexpression of <\\entity><\\entity> under hypoxia did not restore Ah-responsiveness.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3678",
    "Sentence": "The <\\entity><\\entity> subunit of NFkappaB which inhibits AhR-mediated transactivation was not induced by hypoxia and was primarily cytosolic in ZR-75 cells grown under hypoxic and normoxic conditions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3679",
    "Sentence": "The p65 subunit of <\\entity><\\entity> which inhibits AhR-mediated transactivation was not induced by hypoxia and was primarily cytosolic in ZR-75 cells grown under hypoxic and normoxic conditions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3680",
    "Sentence": "The p65 subunit of NFkappaB which inhibits <\\entity><\\entity>-mediated transactivation was not induced by hypoxia and was primarily cytosolic in ZR-75 cells grown under hypoxic and normoxic conditions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3681",
    "Sentence": "In ZR-75 cells maintained under hypoxic conditions for 24 h, <\\entity><\\entity> (an enhancer of AhR-mediated transactivation in breast cancer cells) was significantly decreased and this contributed to loss of Ah-responsiveness.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3682",
    "Sentence": "In ZR-75 cells maintained under hypoxic conditions for 24 h, BRCA1 (an enhancer of <\\entity><\\entity>-mediated transactivation in breast cancer cells) was significantly decreased and this contributed to loss of Ah-responsiveness.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3683",
    "Sentence": "In cells grown under hypoxia for 6 h, <\\entity><\\entity> was not decreased, but induction of CYP1A1 by TCDD was significantly decreased.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3684",
    "Sentence": "In cells grown under hypoxia for 6 h, BRCA1 was not decreased, but induction of <\\entity><\\entity> by TCDD was significantly decreased.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3685",
    "Sentence": "In cells grown under hypoxia for 6 h, BRCA1 was not decreased, but induction of CYP1A1 by <\\entity><\\entity> was significantly decreased.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3686",
    "Sentence": "Cotreatment of ZR-75 cells with <\\entity><\\entity> plus the protein synthesis inhibitor cycloheximide for 6 h enhanced CYP1A1 expression in cells grown under hypoxia and normoxia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3687",
    "Sentence": "Cotreatment of ZR-75 cells with TCDD plus the <\\entity><\\entity> cycloheximide for 6 h enhanced CYP1A1 expression in cells grown under hypoxia and normoxia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3688",
    "Sentence": "Cotreatment of ZR-75 cells with TCDD plus the protein synthesis inhibitor <\\entity><\\entity> for 6 h enhanced CYP1A1 expression in cells grown under hypoxia and normoxia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3689",
    "Sentence": "Cotreatment of ZR-75 cells with TCDD plus the protein synthesis inhibitor cycloheximide for 6 h enhanced <\\entity><\\entity> expression in cells grown under hypoxia and normoxia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3690",
    "Sentence": "These results suggest that hypoxia rapidly induces protein(s) that inhibit Ah-responsiveness and these may be similar to constitutively expressed inhibitors of Ah-responsiveness (under normoxia) that are also inhibited by <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3691",
    "Sentence": "<\\entity><\\entity> and hypoxia inhibit aryl hydrocarbon receptor-mediated responses in breast cancer cells.The aryl hydrocarbon receptor (AhR) is expressed in estrogen receptor (ER)-positive ZR-75 breast cancer cells.",
    "Label": ""
  },
  {
    "id": "3692",
    "Sentence": "Cobaltous chloride and hypoxia inhibit <\\entity><\\entity>-mediated responses in breast cancer cells.The <\\entity><\\entity> (AhR) is expressed in estrogen receptor (ER)-positive ZR-75 breast cancer cells.",
    "Label": ""
  },
  {
    "id": "3694",
    "Sentence": "Treatment with <\\entity><\\entity> (TCDD) induces CYP1A1 protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression.",
    "Label": ""
  },
  {
    "id": "3695",
    "Sentence": "Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces <\\entity><\\entity> protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression.",
    "Label": ""
  },
  {
    "id": "3697",
    "Sentence": "Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (<\\entity><\\entity>) induces CYP1A1 protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression.",
    "Label": ""
  },
  {
    "id": "3698",
    "Sentence": "Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces <\\entity><\\entity> protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression.",
    "Label": ""
  },
  {
    "id": "3700",
    "Sentence": "In ZR-75 cells grown under hypoxia, induction of these AhR-mediated responses by <\\entity><\\entity> was significantly inhibited.",
    "Label": ""
  },
  {
    "id": "3701",
    "Sentence": "In ZR-75 cells grown under hypoxia, induction of these <\\entity><\\entity>-mediated responses by TCDD was significantly inhibited.",
    "Label": ""
  },
  {
    "id": "3703",
    "Sentence": "In cells grown under hypoxia for 6 h, BRCA1 was not decreased, but induction of CYP1A1 by <\\entity><\\entity> was significantly decreased.",
    "Label": ""
  },
  {
    "id": "3704",
    "Sentence": "In cells grown under hypoxia for 6 h, BRCA1 was not decreased, but induction of <\\entity><\\entity> by TCDD was significantly decreased.",
    "Label": ""
  },
  {
    "id": "3706",
    "Sentence": "Cotreatment of ZR-75 cells with <\\entity><\\entity> plus the protein synthesis inhibitor cycloheximide for 6 h enhanced CYP1A1 expression in cells grown under hypoxia and normoxia.",
    "Label": ""
  },
  {
    "id": "3707",
    "Sentence": "Cotreatment of ZR-75 cells with TCDD plus the protein synthesis inhibitor cycloheximide for 6 h enhanced <\\entity><\\entity> expression in cells grown under hypoxia and normoxia.",
    "Label": ""
  },
  {
    "id": "3709",
    "Sentence": "Cotreatment of ZR-75 cells with TCDD plus the protein synthesis inhibitor <\\entity><\\entity> for 6 h enhanced CYP1A1 expression in cells grown under hypoxia and normoxia.",
    "Label": ""
  },
  {
    "id": "3710",
    "Sentence": "Cotreatment of ZR-75 cells with TCDD plus the protein synthesis inhibitor cycloheximide for 6 h enhanced <\\entity><\\entity> expression in cells grown under hypoxia and normoxia.",
    "Label": ""
  },
  {
    "id": "3712",
    "Sentence": "Cotreatment of ZR-75 cells with TCDD plus the <\\entity><\\entity> cycloheximide for 6 h enhanced CYP1A1 expression in cells grown under hypoxia and normoxia.",
    "Label": ""
  },
  {
    "id": "3713",
    "Sentence": "Cotreatment of ZR-75 cells with TCDD plus the protein synthesis inhibitor cycloheximide for 6 h enhanced <\\entity><\\entity> expression in cells grown under hypoxia and normoxia.",
    "Label": ""
  },
  {
    "id": "3715",
    "Sentence": "Treatment with <\\entity><\\entity> (TCDD) induces CYP1A1 protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression.",
    "Label": ""
  },
  {
    "id": "3716",
    "Sentence": "Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces CYP1A1 protein and mRNA levels and also activates inhibitory <\\entity><\\entity> crosstalk associated with hormone-induced reporter gene expression.",
    "Label": ""
  },
  {
    "id": "3718",
    "Sentence": "Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (<\\entity><\\entity>) induces CYP1A1 protein and mRNA levels and also activates inhibitory AhR-ERalpha crosstalk associated with hormone-induced reporter gene expression.",
    "Label": ""
  },
  {
    "id": "3719",
    "Sentence": "Treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces CYP1A1 protein and mRNA levels and also activates inhibitory <\\entity><\\entity> crosstalk associated with hormone-induced reporter gene expression.",
    "Label": ""
  },
  {
    "id": "3721",
    "Sentence": "In cells grown under hypoxia for 6 h, BRCA1 was not decreased, but induction of CYP1A1 by <\\entity><\\entity> was significantly decreased.",
    "Label": ""
  },
  {
    "id": "3722",
    "Sentence": "In cells grown under hypoxia for 6 h, <\\entity><\\entity> was not decreased, but induction of CYP1A1 by TCDD was significantly decreased.",
    "Label": ""
  },
  {
    "id": "3728",
    "Sentence": "Dynamic regulation of MTHFR mRNA expression and C677T genotype modulate <\\entity><\\entity> in coronary artery disease patients after revascularization.INTRODUCTION: A large body of evidence links plasma homocysteine (Hcy) concentrations and cardiovascular disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3729",
    "Sentence": "Dynamic regulation of MTHFR mRNA expression and C677T genotype modulate mortality in <\\entity><\\entity> patients after revascularization.INTRODUCTION: A large body of evidence links plasma homocysteine (Hcy) concentrations and cardiovascular disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3730",
    "Sentence": "Dynamic regulation of MTHFR mRNA expression and C677T genotype modulate mortality in coronary artery disease patients after revascularization.INTRODUCTION: A large body of evidence links plasma homocysteine (Hcy) concentrations and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3731",
    "Sentence": "A common MTHFR polymorphism (C677T) leads to a variant with <\\entity><\\entity> and associated with increased Hcy levels.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3732",
    "Sentence": "Coronary surgery precipitates a significant and sustained increase in the blood concentrations of Hcy and elevated levels of plasma Hcy have been associated to saphenous vein (<\\entity><\\entity> after CABG.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3733",
    "Sentence": "However, the effects of MTHFR genotypes in the incidence of <\\entity><\\entity> after CABG have not been investigated prospectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3734",
    "Sentence": "Here, we investigate whether MTHFR gene variants are associated with an increased <\\entity><\\entity> risk in individuals submitted to CABG.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3735",
    "Sentence": "METHODS: We performed MTHFR C677T genotypes in 558 patients with two or three vessel-disease and normal left ventricular function prospectively followed in the MASS II Trial, a randomized study to compare treatments for <\\entity><\\entity> and preserved left ventricle function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3736",
    "Sentence": "We assessed the relationship between baseline variables and the composite end-point of <\\entity><\\entity>, myocardial infarction and refractory angina using a Cox proportional hazards survival model.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3737",
    "Sentence": "We assessed the relationship between baseline variables and the composite end-point of death, <\\entity><\\entity> and refractory angina using a Cox proportional hazards survival model.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3738",
    "Sentence": "We assessed the relationship between baseline variables and the composite end-point of death, myocardial infarction and <\\entity><\\entity> using a Cox proportional hazards survival model.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3739",
    "Sentence": "A statistically significant association between the TT genotype, associated with increased serum levels of Hcy, and <\\entity><\\entity> mortality after 5 years was verified (p=0.007) in individuals submitted to CABG surgery.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3740",
    "Sentence": "A statistically significant association between the TT genotype, associated with increased serum levels of Hcy, and cardiovascular <\\entity><\\entity> after 5 years was verified (p=0.007) in individuals submitted to CABG surgery.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3741",
    "Sentence": "In addition, MTHFR TT genotype was <\\entity><\\entity> significantly associated with a 4.4 fold increased risk in cardiovascular outcomes (p=0.01) even after adjustment of a Cox multivariate model for age, sex, hypertension, diabetes, LDL, HDL, triglycerides, and number of diseased vessels in this population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3742",
    "Sentence": "In addition, MTHFR TT genotype was still significantly associated with a 4.4 fold increased risk in <\\entity><\\entity> outcomes (p=0.01) even after adjustment of a Cox multivariate model for age, sex, hypertension, diabetes, LDL, HDL, triglycerides, and number of diseased vessels in this population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3743",
    "Sentence": "In addition, MTHFR TT genotype was still significantly associated with a 4.4 fold increased risk in cardiovascular outcomes (p=0.01) even after adjustment of a Cox multivariate model for age, sex, <\\entity><\\entity>, diabetes, LDL, HDL, triglycerides, and number of diseased vessels in this population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3744",
    "Sentence": "In addition, MTHFR TT genotype was still significantly associated with a 4.4 fold increased risk in cardiovascular outcomes (p=0.01) even after adjustment of a Cox multivariate model for age, sex, hypertension, <\\entity><\\entity>, LDL, HDL, triglycerides, and number of diseased vessels in this population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3749",
    "Sentence": "Association of variants of the <\\entity><\\entity> gene with susceptibility to pediatric Crohn's disease.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the <\\entity><\\entity> (IL23R) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3750",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to <\\entity><\\entity>.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (IL23R) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3751",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), <\\entity><\\entity>, within the interleukin-23 receptor (IL23R) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3752",
    "Sentence": "Association of variants of the <\\entity><\\entity> gene with susceptibility to pediatric Crohn's disease.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the <\\entity><\\entity> (IL23R) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3753",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (<\\entity><\\entity>) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3754",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric <\\entity><\\entity>.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (IL23R) locus and <\\entity><\\entity> (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3755",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (IL23R) locus and Crohn's disease (<\\entity><\\entity>) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3756",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's <\\entity><\\entity>.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (IL23R) locus and Crohn's <\\entity><\\entity> (CD) as a consequence of a genome-wide association study of this <\\entity><\\entity> in adults.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3757",
    "Sentence": "We examined the effects of this and other previously reported SNPs at this locus with respect to <\\entity><\\entity> in children.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3758",
    "Sentence": "METHODS: By using data from our ongoing genome-wide association study in our cohort of 142 pediatric <\\entity><\\entity> patients and 281 matched controls, we investigated the association of the previously reported SNPs at the IL23R locus with the childhood form of this disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3759",
    "Sentence": "METHODS: By using data from our ongoing genome-wide association study in our cohort of 142 pediatric CD patients and 281 matched controls, we investigated the association of the previously reported SNPs at the <\\entity><\\entity> locus with the childhood form of this disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3760",
    "Sentence": "METHODS: By using data from our ongoing genome-wide association study in our cohort of 142 pediatric CD patients and 281 matched controls, we investigated the association of the previously reported SNPs at the IL23R locus with the childhood form of this <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3761",
    "Sentence": "RESULTS: By using the Fisher exact test, the <\\entity><\\entity> allele frequency of rs11209026 in the patients was 1.75%, whereas it was 6.61% in the controls, yielding a protective odds ratio (OR) of 0.25 (95% confidence interval, 0.10-0.65; 1-sided P = 9.2 x 10(-4)).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3762",
    "Sentence": "RESULTS: By using the Fisher exact test, the minor allele frequency of <\\entity><\\entity> in the patients was 1.75%, whereas it was 6.61% in the controls, yielding a protective odds ratio (OR) of 0.25 (95% confidence interval, 0.10-0.65; 1-sided P = 9.2 x 10(-4)).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3763",
    "Sentence": "Furthermore, of all the SNPs previously reported, <\\entity><\\entity> was associated the most strongly.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3764",
    "Sentence": "A subsequent family based association test (which is more resistant to population stratification) with 65 sets of trios derived from our initial patient cohort yielded significant association with <\\entity><\\entity> in a transmission disequilibrium test (1-sided P = .0017).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3765",
    "Sentence": "A subsequent family based association test (which is more resistant to population stratification) with 65 sets of trios derived from our initial patient cohort yielded significant association with rs11209026 in a <\\entity><\\entity> disequilibrium test (1-sided P = .0017).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3766",
    "Sentence": "In contrast, no association was detected to the <\\entity><\\entity> gene for the inflammatory bowel disease phenotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3767",
    "Sentence": "In contrast, no association was detected to the caspase-recruitment domain 15 gene for the <\\entity><\\entity> phenotype.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3768",
    "Sentence": "CONCLUSIONS: The OR of the <\\entity><\\entity> in our pediatric study is highly comparable with that reported previously in a non-Jewish adult inflammatory bowel disease case-control cohort (OR, 0.26).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3769",
    "Sentence": "CONCLUSIONS: The OR of the <\\entity><\\entity> in our pediatric study is highly comparable with that reported previously in a non-Jewish adult inflammatory bowel disease case-control cohort (OR, 0.26).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3770",
    "Sentence": "CONCLUSIONS: The OR of the IL23R variant in our pediatric study is highly comparable with that reported previously in a non-Jewish adult <\\entity><\\entity> case-control cohort (OR, 0.26).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3771",
    "Sentence": "As such, <\\entity><\\entity> gene confer a similar magnitude of risk of CD to children as for their adult counterparts.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3772",
    "Sentence": "As such, <\\entity><\\entity> gene confer a similar magnitude of risk of CD to children as for their adult counterparts.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3773",
    "Sentence": "As such, variants in the IL23R gene confer a similar magnitude of risk of <\\entity><\\entity> to children as for their adult counterparts.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3774",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), <\\entity><\\entity>, within the interleukin-23 receptor (IL23R) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": ""
  },
  {
    "id": "3775",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric <\\entity><\\entity>.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (IL23R) locus and <\\entity><\\entity> (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": ""
  },
  {
    "id": "3777",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), <\\entity><\\entity>, within the interleukin-23 receptor (IL23R) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": ""
  },
  {
    "id": "3778",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (IL23R) locus and Crohn's disease (<\\entity><\\entity>) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": ""
  },
  {
    "id": "3780",
    "Sentence": "METHODS: By using data from our ongoing genome-wide association study in our cohort of 142 pediatric CD patients and 281 matched controls, we investigated the association of the previously reported SNPs at the <\\entity><\\entity> locus with the childhood form of this disease.",
    "Label": ""
  },
  {
    "id": "3781",
    "Sentence": "METHODS: By using data from our ongoing genome-wide association study in our cohort of 142 pediatric <\\entity><\\entity> patients and 281 matched controls, we investigated the association of the previously reported SNPs at the IL23R locus with the childhood form of this disease.",
    "Label": ""
  },
  {
    "id": "3783",
    "Sentence": "In contrast, no association was detected to the <\\entity><\\entity> gene for the inflammatory bowel disease phenotype.",
    "Label": ""
  },
  {
    "id": "3784",
    "Sentence": "In contrast, no association was detected to the caspase-recruitment domain 15 gene for the <\\entity><\\entity> phenotype.",
    "Label": ""
  },
  {
    "id": "3786",
    "Sentence": "As such, <\\entity><\\entity> gene confer a similar magnitude of risk of CD to children as for their adult counterparts.",
    "Label": ""
  },
  {
    "id": "3787",
    "Sentence": "As such, variants in the IL23R gene confer a similar magnitude of risk of <\\entity><\\entity> to children as for their adult counterparts.",
    "Label": ""
  },
  {
    "id": "3789",
    "Sentence": "Association of variants of the <\\entity><\\entity> gene with susceptibility to pediatric Crohn's disease.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the <\\entity><\\entity> (IL23R) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": ""
  },
  {
    "id": "3790",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to <\\entity><\\entity>.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (IL23R) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": ""
  },
  {
    "id": "3792",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (<\\entity><\\entity>) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": ""
  },
  {
    "id": "3793",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric <\\entity><\\entity>.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (IL23R) locus and <\\entity><\\entity> (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": ""
  },
  {
    "id": "3795",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (<\\entity><\\entity>) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": ""
  },
  {
    "id": "3796",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's <\\entity><\\entity>.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (IL23R) locus and Crohn's <\\entity><\\entity> (CD) as a consequence of a genome-wide association study of this <\\entity><\\entity> in adults.",
    "Label": ""
  },
  {
    "id": "3798",
    "Sentence": "METHODS: By using data from our ongoing genome-wide association study in our cohort of 142 pediatric CD patients and 281 matched controls, we investigated the association of the previously reported SNPs at the <\\entity><\\entity> locus with the childhood form of this disease.",
    "Label": ""
  },
  {
    "id": "3799",
    "Sentence": "METHODS: By using data from our ongoing genome-wide association study in our cohort of 142 pediatric CD patients and 281 matched controls, we investigated the association of the previously reported SNPs at the IL23R locus with the childhood form of this <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3801",
    "Sentence": "CONCLUSIONS: The OR of the <\\entity><\\entity> in our pediatric study is highly comparable with that reported previously in a non-Jewish adult inflammatory bowel disease case-control cohort (OR, 0.26).",
    "Label": ""
  },
  {
    "id": "3802",
    "Sentence": "CONCLUSIONS: The OR of the IL23R variant in our pediatric study is highly comparable with that reported previously in a non-Jewish adult <\\entity><\\entity> case-control cohort (OR, 0.26).",
    "Label": ""
  },
  {
    "id": "3804",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (<\\entity><\\entity>) locus and Crohn's disease (CD) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": ""
  },
  {
    "id": "3805",
    "Sentence": "Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease.BACKGROUND & AIMS: Recently an association was shown between the single nucleotide polymorphism (SNP), rs11209026, within the interleukin-23 receptor (IL23R) locus and Crohn's disease (<\\entity><\\entity>) as a consequence of a genome-wide association study of this disease in adults.",
    "Label": ""
  },
  {
    "id": "3811",
    "Sentence": "Pharmacokinetic-pharmacodynamic correlation from mouse to human with <\\entity><\\entity>, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.With the development of targeted therapeutics, especially for small-molecule inhibitors, it is important to understand whether the observed in vivo efficacy correlates with the modulation of desired/intended target in vivo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3812",
    "Sentence": "Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a <\\entity><\\entity> with potent antitumor and antiangiogenic activity.With the development of targeted therapeutics, especially for small-molecule inhibitors, it is important to understand whether the observed in vivo efficacy correlates with the modulation of desired/intended target in vivo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3813",
    "Sentence": "We have developed a small-molecule inhibitor of all three <\\entity><\\entity> (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3814",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (<\\entity><\\entity> (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3815",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (<\\entity><\\entity>), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3816",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), <\\entity><\\entity>, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3817",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and <\\entity><\\entity>, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3818",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, <\\entity><\\entity> (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3819",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (<\\entity><\\entity>), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3820",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (<\\entity><\\entity>) receptors (<\\entity><\\entity>R), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits <\\entity><\\entity>-induced endothelial cell proliferation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3821",
    "Sentence": "Because bolus administration of the compound results in large differences in C(max) and C(trough), we investigated the effect of continuous infusion of a <\\entity><\\entity> on tumor growth and angiogenesis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3822",
    "Sentence": "Because bolus administration of the compound results in large differences in C(max) and C(trough), we investigated the effect of continuous infusion of a <\\entity><\\entity> on tumor growth and angiogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3823",
    "Sentence": "<\\entity><\\entity>, which has similar enzyme and cellular profiles to GW786034, was used for these studies due to higher solubility requirements for infusion studies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3824",
    "Sentence": "GW771806, which has similar enzyme and cellular profiles to <\\entity><\\entity>, was used for these studies due to higher solubility requirements for infusion studies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3825",
    "Sentence": "dosing and continuous infusion), we showed that the antitumor and antiangiogenic activity of <\\entity><\\entity> is dependent on steady-state concentration of the compound above a threshold.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3826",
    "Sentence": "dosing and continuous infusion), we showed that the antitumor and antiangiogenic activity of <\\entity><\\entity> is dependent on steady-state concentration of the compound above a threshold.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3827",
    "Sentence": "The steady-state concentration required for these effects is consistent with the concentration required for the inhibition of <\\entity><\\entity>-induced <\\entity><\\entity>R2 phosphorylation in mouse lungs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3828",
    "Sentence": "The steady-state concentration required for these effects is consistent with the concentration required for the inhibition of VEGF-induced <\\entity><\\entity> phosphorylation in mouse lungs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3829",
    "Sentence": "Furthermore, the steady-state concentration of <\\entity><\\entity> determined from preclinical activity showed a strong correlation with the pharmacodynamic effects and antitumor activity in the phase I clinical trial.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3830",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, <\\entity><\\entity> (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3831",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (<\\entity><\\entity>) receptors (<\\entity><\\entity>R), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits <\\entity><\\entity>-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3833",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, <\\entity><\\entity> (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3834",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (<\\entity><\\entity>), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3836",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, <\\entity><\\entity> (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3837",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (<\\entity><\\entity> (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3839",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, <\\entity><\\entity> (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3840",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), <\\entity><\\entity>, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3842",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, <\\entity><\\entity> (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3843",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and <\\entity><\\entity>, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3845",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (<\\entity><\\entity>), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3846",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (<\\entity><\\entity>) receptors (<\\entity><\\entity>R), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits <\\entity><\\entity>-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3848",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (<\\entity><\\entity>), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3849",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (<\\entity><\\entity>), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3851",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (<\\entity><\\entity>), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3852",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (<\\entity><\\entity> (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3854",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (<\\entity><\\entity>), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3855",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), <\\entity><\\entity>, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3857",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (<\\entity><\\entity>), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3858",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and <\\entity><\\entity>, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3860",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, <\\entity><\\entity> (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3861",
    "Sentence": "We have developed a small-molecule inhibitor of all three <\\entity><\\entity> (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3863",
    "Sentence": "We have developed a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (<\\entity><\\entity>), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3864",
    "Sentence": "We have developed a small-molecule inhibitor of all three <\\entity><\\entity> (VEGF) receptors (VEGFR), platelet-derived growth factor receptor, and c-Kit tyrosine kinases, pazopanib (GW786034), which selectively inhibits VEGF-induced endothelial cell proliferation.",
    "Label": ""
  },
  {
    "id": "3870",
    "Sentence": "Etiological and demographical characteristics of acute adult <\\entity><\\entity> in Adana, Turkey.The objective of this study is to define the etiological and demographical characteristics of the patients applying to the emergency department in Faculty of Medicine, Cukurova University because of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3871",
    "Sentence": "Etiological and demographical characteristics of acute adult <\\entity><\\entity> in Adana, Turkey.The objective of this study is to define the etiological and demographical characteristics of the patients applying to the emergency department in Faculty of Medicine, Cukurova University because of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3872",
    "Sentence": "This retrospective study was carried out by examining the records of 491 people who applied to the main emergency department in Faculty of Medicine, Cukurova University, with the complaint of <\\entity><\\entity> between January 1, 2004 and December 31, 2004.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3873",
    "Sentence": "It was determined that the reason why 491 of 20 817 persons (2.4%) applied during this term was because of <\\entity><\\entity>: 159 (32.4%) of such patients were male and 332 of them (67.6%) were female.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3874",
    "Sentence": "It was found that the average age of men was 27.1 +/- 10.5 years and that of women was 24.4 +/- 9.5 years (P = 0.005); 427 of <\\entity><\\entity> cases (87.0%) happened intentionally as suicide attempts and 64 of them (13.0%) were accidental.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3875",
    "Sentence": "It was found that the average age of men was 27.1 +/- 10.5 years and that of women was 24.4 +/- 9.5 years (P = 0.005); 427 of poisoning cases (87.0%) happened intentionally as <\\entity><\\entity> and 64 of them (13.0%) were accidental.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3876",
    "Sentence": "The rate of <\\entity><\\entity> was higher in women and the rate of unintentional poisoning was higher in men (P +/- 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3877",
    "Sentence": "The rate of suicide-purposed poisoning was higher in women and the rate of <\\entity><\\entity> was higher in men (P +/- 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3878",
    "Sentence": "The <\\entity><\\entity> were accountable for 71.1% of all poisoning cases and the pesticides were accountable for 18.9% of such cases.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3879",
    "Sentence": "The drugs were accountable for 71.1% of all <\\entity><\\entity> cases and the pesticides were accountable for 18.9% of such cases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3880",
    "Sentence": "The drugs were accountable for 71.1% of all poisoning cases and the <\\entity><\\entity> were accountable for 18.9% of such cases.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3881",
    "Sentence": "<\\entity><\\entity> increase during summers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3882",
    "Sentence": "The <\\entity><\\entity> rate in poisonings was found as 0.8%.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3883",
    "Sentence": "The mortality rate in <\\entity><\\entity> was found as 0.8%.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3884",
    "Sentence": "The <\\entity><\\entity> and pesticides in Ckurova region constitute 90.0% of all poisoning cases.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3885",
    "Sentence": "The drugs and <\\entity><\\entity> in Ckurova region constitute 90.0% of all poisoning cases.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3886",
    "Sentence": "The drugs and pesticides in Ckurova region constitute 90.0% of all <\\entity><\\entity> cases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3887",
    "Sentence": "The <\\entity><\\entity> rate in poisoning will be decreased by training the physicians employed in the emergency department about poisoning by drugs and pesticides.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3888",
    "Sentence": "The mortality rate in <\\entity><\\entity> will be decreased by training the physicians employed in the emergency department about <\\entity><\\entity> by drugs and pesticides.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3889",
    "Sentence": "The mortality rate in <\\entity><\\entity> will be decreased by training the physicians employed in the emergency department about <\\entity><\\entity> by drugs and pesticides.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3890",
    "Sentence": "The mortality rate in poisoning will be decreased by training the physicians employed in the emergency department about poisoning by <\\entity><\\entity> and pesticides.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3891",
    "Sentence": "The mortality rate in poisoning will be decreased by training the physicians employed in the emergency department about poisoning by drugs and <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3892",
    "Sentence": "The drugs were accountable for 71.1% of all poisoning cases and the <\\entity><\\entity> were accountable for 18.9% of such cases.",
    "Label": ""
  },
  {
    "id": "3893",
    "Sentence": "The drugs were accountable for 71.1% of all <\\entity><\\entity> cases and the pesticides were accountable for 18.9% of such cases.",
    "Label": ""
  },
  {
    "id": "3895",
    "Sentence": "The <\\entity><\\entity> were accountable for 71.1% of all poisoning cases and the pesticides were accountable for 18.9% of such cases.",
    "Label": ""
  },
  {
    "id": "3896",
    "Sentence": "The drugs were accountable for 71.1% of all <\\entity><\\entity> cases and the pesticides were accountable for 18.9% of such cases.",
    "Label": ""
  },
  {
    "id": "3898",
    "Sentence": "The drugs and <\\entity><\\entity> in Ckurova region constitute 90.0% of all poisoning cases.",
    "Label": ""
  },
  {
    "id": "3899",
    "Sentence": "The drugs and pesticides in Ckurova region constitute 90.0% of all <\\entity><\\entity> cases.",
    "Label": ""
  },
  {
    "id": "3901",
    "Sentence": "The <\\entity><\\entity> and pesticides in Ckurova region constitute 90.0% of all poisoning cases.",
    "Label": ""
  },
  {
    "id": "3902",
    "Sentence": "The drugs and pesticides in Ckurova region constitute 90.0% of all <\\entity><\\entity> cases.",
    "Label": ""
  },
  {
    "id": "3904",
    "Sentence": "The mortality rate in poisoning will be decreased by training the physicians employed in the emergency department about poisoning by drugs and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3905",
    "Sentence": "The mortality rate in <\\entity><\\entity> will be decreased by training the physicians employed in the emergency department about <\\entity><\\entity> by drugs and pesticides.",
    "Label": ""
  },
  {
    "id": "3907",
    "Sentence": "The mortality rate in poisoning will be decreased by training the physicians employed in the emergency department about poisoning by <\\entity><\\entity> and pesticides.",
    "Label": ""
  },
  {
    "id": "3908",
    "Sentence": "The mortality rate in <\\entity><\\entity> will be decreased by training the physicians employed in the emergency department about <\\entity><\\entity> by drugs and pesticides.",
    "Label": ""
  },
  {
    "id": "3910",
    "Sentence": "The mortality rate in poisoning will be decreased by training the physicians employed in the emergency department about poisoning by drugs and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "3911",
    "Sentence": "The <\\entity><\\entity> rate in poisoning will be decreased by training the physicians employed in the emergency department about poisoning by drugs and pesticides.",
    "Label": ""
  },
  {
    "id": "3917",
    "Sentence": "Nonthermal activation of <\\entity><\\entity> in abdominal viscera tonically inhibits autonomic cold-defense effectors.An involvement of the transient receptor potential vanilloid (TRPV) 1 channel in the regulation of body temperature (T(b)) has not been established decisively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3918",
    "Sentence": "Nonthermal activation of <\\entity><\\entity>-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors.An involvement of the <\\entity><\\entity> (TRPV) 1 channel in the regulation of body temperature (T(b)) has not been established decisively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3919",
    "Sentence": "Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors.An involvement of the transient receptor potential vanilloid (<\\entity><\\entity> in the regulation of body temperature (T(b)) has not been established decisively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3920",
    "Sentence": "We synthesized a new <\\entity><\\entity>, AMG0347 [(E)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)acrylamide], and characterized it in vitro.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3921",
    "Sentence": "We synthesized a new <\\entity><\\entity>, AMG0347 [(E)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)acrylamide], and characterized it in vitro.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3922",
    "Sentence": "We synthesized a new TRPV1 antagonist, <\\entity><\\entity> [(E)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)acrylamide], and characterized it in vitro.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3923",
    "Sentence": "We synthesized a new TRPV1 antagonist, AMG0347 [<\\entity><\\entity>], and characterized it in vitro.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3924",
    "Sentence": "We then found that this drug is the most potent <\\entity><\\entity> known to increase T(b) of rats and mice and showed (by using knock-out mice) that the entire hyperthermic effect of AMG0347 is TRPV1 dependent.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3925",
    "Sentence": "We then found that this drug is the most potent <\\entity><\\entity> known to increase T(b) of rats and mice and showed (by using knock-out mice) that the entire hyperthermic effect of AMG0347 is TRPV1 dependent.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3926",
    "Sentence": "We then found that this drug is the most potent TRPV1 antagonist known to increase T(b) of rats and mice and showed (by using knock-out mice) that the entire hyperthermic effect of <\\entity><\\entity> is TRPV1 dependent.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3927",
    "Sentence": "We then found that this drug is the most potent <\\entity><\\entity> antagonist known to increase T(b) of rats and mice and showed (by using knock-out mice) that the entire hyperthermic effect of AMG0347 is <\\entity><\\entity> dependent.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3928",
    "Sentence": "<\\entity><\\entity>-induced hyperthermia was brought about by one or both of the two major autonomic cold-defense effector mechanisms (tail-skin vasoconstriction and/or thermogenesis), but it did not involve warmth-seeking behavior.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3929",
    "Sentence": "The magnitude of the hyperthermic response depended on neither T(b) nor tail-skin temperature at the time of <\\entity><\\entity> administration, thus indicating that <\\entity><\\entity>-induced hyperthermia results from blockade of tonic TRPV1 activation by nonthermal factors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3930",
    "Sentence": "The magnitude of the hyperthermic response depended on neither T(b) nor tail-skin temperature at the time of <\\entity><\\entity> administration, thus indicating that <\\entity><\\entity>-induced hyperthermia results from blockade of tonic TRPV1 activation by nonthermal factors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3931",
    "Sentence": "The magnitude of the hyperthermic response depended on neither T(b) nor tail-skin temperature at the time of AMG0347 administration, thus indicating that AMG0347-induced hyperthermia results from blockade of tonic <\\entity><\\entity> activation by nonthermal factors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3932",
    "Sentence": "<\\entity><\\entity> was no more effective in causing hyperthermia when administered into the brain (intracerebroventricularly) or spinal cord (intrathecally) than when given systemically (intravenously), which indicates a peripheral site of action.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3933",
    "Sentence": "We then established that localized intra-abdominal desensitization of <\\entity><\\entity> with intraperitoneal resiniferatoxin blocks the T(b) response to systemic AMG0347; the extent of desensitization was determined by using a comprehensive battery of functional tests.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3934",
    "Sentence": "We then established that localized intra-abdominal desensitization of TRPV1 channels with <\\entity><\\entity> blocks the T(b) response to systemic AMG0347; the extent of desensitization was determined by using a comprehensive battery of functional tests.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3935",
    "Sentence": "We then established that localized intra-abdominal desensitization of TRPV1 channels with intraperitoneal resiniferatoxin blocks the T(b) response to systemic <\\entity><\\entity>; the extent of desensitization was determined by using a comprehensive battery of functional tests.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "3936",
    "Sentence": "We conclude that tonic activation of <\\entity><\\entity> in the abdominal viscera by yet unidentified nonthermal factors inhibits skin vasoconstriction and thermogenesis, thus having a suppressive effect on T(b).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3937",
    "Sentence": "We then found that this drug is the most potent <\\entity><\\entity> known to increase T(b) of rats and mice and showed (by using knock-out mice) that the entire hyperthermic effect of AMG0347 is TRPV1 dependent.",
    "Label": ""
  },
  {
    "id": "3938",
    "Sentence": "We then found that this drug is the most potent <\\entity><\\entity> antagonist known to increase T(b) of rats and mice and showed (by using knock-out mice) that the entire hyperthermic effect of AMG0347 is <\\entity><\\entity> dependent.",
    "Label": ""
  },
  {
    "id": "3940",
    "Sentence": "We then found that this drug is the most potent TRPV1 antagonist known to increase T(b) of rats and mice and showed (by using knock-out mice) that the entire hyperthermic effect of <\\entity><\\entity> is TRPV1 dependent.",
    "Label": ""
  },
  {
    "id": "3941",
    "Sentence": "We then found that this drug is the most potent <\\entity><\\entity> antagonist known to increase T(b) of rats and mice and showed (by using knock-out mice) that the entire hyperthermic effect of AMG0347 is <\\entity><\\entity> dependent.",
    "Label": ""
  },
  {
    "id": "3943",
    "Sentence": "The magnitude of the hyperthermic response depended on neither T(b) nor tail-skin temperature at the time of <\\entity><\\entity> administration, thus indicating that <\\entity><\\entity>-induced hyperthermia results from blockade of tonic TRPV1 activation by nonthermal factors.",
    "Label": ""
  },
  {
    "id": "3944",
    "Sentence": "The magnitude of the hyperthermic response depended on neither T(b) nor tail-skin temperature at the time of AMG0347 administration, thus indicating that AMG0347-induced hyperthermia results from blockade of tonic <\\entity><\\entity> activation by nonthermal factors.",
    "Label": ""
  },
  {
    "id": "3946",
    "Sentence": "We then established that localized intra-abdominal desensitization of TRPV1 channels with <\\entity><\\entity> blocks the T(b) response to systemic AMG0347; the extent of desensitization was determined by using a comprehensive battery of functional tests.",
    "Label": ""
  },
  {
    "id": "3947",
    "Sentence": "We then established that localized intra-abdominal desensitization of <\\entity><\\entity> with intraperitoneal resiniferatoxin blocks the T(b) response to systemic AMG0347; the extent of desensitization was determined by using a comprehensive battery of functional tests.",
    "Label": ""
  },
  {
    "id": "3949",
    "Sentence": "We synthesized a new TRPV1 antagonist, <\\entity><\\entity> [(E)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)acrylamide], and characterized it in vitro.",
    "Label": ""
  },
  {
    "id": "3950",
    "Sentence": "We synthesized a new <\\entity><\\entity>, AMG0347 [(E)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)acrylamide], and characterized it in vitro.",
    "Label": ""
  },
  {
    "id": "3952",
    "Sentence": "We synthesized a new TRPV1 antagonist, AMG0347 [<\\entity><\\entity>], and characterized it in vitro.",
    "Label": ""
  },
  {
    "id": "3953",
    "Sentence": "We synthesized a new <\\entity><\\entity>, AMG0347 [(E)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)acrylamide], and characterized it in vitro.",
    "Label": ""
  },
  {
    "id": "3955",
    "Sentence": "We then established that localized intra-abdominal desensitization of TRPV1 channels with intraperitoneal resiniferatoxin blocks the T(b) response to systemic <\\entity><\\entity>; the extent of desensitization was determined by using a comprehensive battery of functional tests.",
    "Label": ""
  },
  {
    "id": "3956",
    "Sentence": "We then established that localized intra-abdominal desensitization of <\\entity><\\entity> with intraperitoneal resiniferatoxin blocks the T(b) response to systemic AMG0347; the extent of desensitization was determined by using a comprehensive battery of functional tests.",
    "Label": ""
  },
  {
    "id": "3962",
    "Sentence": "Genetic polymorphisms in alcohol metabolism, alcohol intake and the risk of <\\entity><\\entity> in Warsaw, Poland.Genetic variations increasing blood levels of acetaldehyde, the first metabolite of alcohol, refrain their carriers from drinking alcohol but may also put them at increased risk of cancer because of the mutagenic and carcinogenic effect of acetaldehyde.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3963",
    "Sentence": "Genetic polymorphisms in alcohol metabolism, alcohol intake and the risk of stomach cancer in Warsaw, <\\entity><\\entity>.Genetic variations increasing blood levels of acetaldehyde, the first metabolite of alcohol, refrain their carriers from drinking alcohol but may also put them at increased risk of cancer because of the mutagenic and carcinogenic effect of acetaldehyde.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3964",
    "Sentence": "Genetic polymorphisms in alcohol metabolism, alcohol intake and the risk of stomach cancer in Warsaw, Poland.Genetic variations increasing blood levels of acetaldehyde, the first metabolite of alcohol, refrain their carriers from <\\entity><\\entity> alcohol but may also put them at increased risk of cancer because of the mutagenic and carcinogenic effect of acetaldehyde.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3965",
    "Sentence": "Genetic polymorphisms in alcohol metabolism, alcohol intake and the risk of stomach <\\entity><\\entity> in Warsaw, Poland.Genetic variations increasing blood levels of acetaldehyde, the first metabolite of alcohol, refrain their carriers from drinking alcohol but may also put them at increased risk of <\\entity><\\entity> because of the mutagenic and carcinogenic effect of acetaldehyde.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3966",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, <\\entity><\\entity>, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3967",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including <\\entity><\\entity> (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3968",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (<\\entity><\\entity>, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3969",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, <\\entity><\\entity>, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3970",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, <\\entity><\\entity> and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3971",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and <\\entity><\\entity>), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3972",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), <\\entity><\\entity> (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3973",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (<\\entity><\\entity> and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3974",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and <\\entity><\\entity>) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3975",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and <\\entity><\\entity> (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3976",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (<\\entity><\\entity>), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3977",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol <\\entity><\\entity> and susceptibility of stomach cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3978",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3979",
    "Sentence": "We found that among control subjects frequency of alcohol <\\entity><\\entity> varied by alcohol metabolizing genotype.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3980",
    "Sentence": "In particular, the weekly <\\entity><\\entity> of individuals carrying the AA, GA and GG genotypes of ALDH2 Ex1+82A>G polymorphism were 3.75, 2.26 and 1.53 drinks, respectively (p=0.04).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3981",
    "Sentence": "In particular, the weekly consumption of individuals carrying the <\\entity><\\entity>, GA and GG genotypes of ALDH2 Ex1+82A>G polymorphism were 3.75, 2.26 and 1.53 drinks, respectively (p=0.04).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3982",
    "Sentence": "In particular, the weekly consumption of individuals carrying the AA, <\\entity><\\entity> and GG genotypes of ALDH2 Ex1+82A>G polymorphism were 3.75, 2.26 and 1.53 drinks, respectively (p=0.04).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3983",
    "Sentence": "In particular, the weekly consumption of individuals carrying the AA, GA and <\\entity><\\entity> genotypes of ALDH2 Ex1+82A>G polymorphism were 3.75, 2.26 and 1.53 drinks, respectively (p=0.04).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3984",
    "Sentence": "In particular, the weekly consumption of individuals carrying the AA, GA and GG genotypes of <\\entity><\\entity> polymorphism were 3.75, 2.26 and 1.53 drinks, respectively (p=0.04).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3985",
    "Sentence": "In particular, the weekly consumption of individuals carrying the AA, GA and GG genotypes of <\\entity><\\entity> polymorphism were 3.75, 2.26 and 1.53 drinks, respectively (p=0.04).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3986",
    "Sentence": "In particular, the weekly consumption of individuals carrying the AA, GA and GG genotypes of ALDH2 Ex1+82A>G polymorphism were 3.75, 2.26 and 1.53 <\\entity><\\entity>, respectively (p=0.04).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3987",
    "Sentence": "However, none of the assessed polymorphisms in these 3 genes had a measurable effect on <\\entity><\\entity> risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3988",
    "Sentence": "When stratified by <\\entity><\\entity> polymorphism, alcohol-related increases in stomach cancer risk were restricted to individuals with the AG/GG genotypes, with a more than 2-fold risk among daily drinkers (OR=2.63, 95% CI=1.00-6.88) and 3-fold risk (OR=3.66, 95% CI=1.19-11.24) among those with 40 or more drink-years.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3989",
    "Sentence": "When stratified by <\\entity><\\entity> polymorphism, alcohol-related increases in stomach cancer risk were restricted to individuals with the AG/GG genotypes, with a more than 2-fold risk among daily drinkers (OR=2.63, 95% CI=1.00-6.88) and 3-fold risk (OR=3.66, 95% CI=1.19-11.24) among those with 40 or more drink-years.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3990",
    "Sentence": "When stratified by ALDH2 Ex1+82A>G polymorphism, alcohol-related increases in <\\entity><\\entity> risk were restricted to individuals with the AG/GG genotypes, with a more than 2-fold risk among daily drinkers (OR=2.63, 95% CI=1.00-6.88) and 3-fold risk (OR=3.66, 95% CI=1.19-11.24) among those with 40 or more drink-years.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3991",
    "Sentence": "When stratified by ALDH2 Ex1+82A>G polymorphism, alcohol-related increases in stomach cancer risk were restricted to individuals with the <\\entity><\\entity>/GG genotypes, with a more than 2-fold risk among daily drinkers (OR=2.63, 95% CI=1.00-6.88) and 3-fold risk (OR=3.66, 95% CI=1.19-11.24) among those with 40 or more drink-years.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3992",
    "Sentence": "When stratified by ALDH2 Ex1+82A>G polymorphism, alcohol-related increases in stomach cancer risk were restricted to individuals with the AG/<\\entity><\\entity> genotypes, with a more than 2-fold risk among daily drinkers (OR=2.63, 95% CI=1.00-6.88) and 3-fold risk (OR=3.66, 95% CI=1.19-11.24) among those with 40 or more drink-years.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3993",
    "Sentence": "In summary, our results suggested that the <\\entity><\\entity> allele may be functionally deficient in eliminating acetaldehyde and discourage alcohol drinking.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "3994",
    "Sentence": "In summary, our results suggested that the <\\entity><\\entity> allele may be functionally deficient in eliminating acetaldehyde and discourage alcohol drinking.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "3995",
    "Sentence": "In summary, our results suggested that the ALDH2 Ex1+82 G allele may be functionally deficient in eliminating acetaldehyde and discourage alcohol <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3996",
    "Sentence": "Furthermore, heavy drinkers of alcohol who were genetically prone to accumulate acetaldehyde may face an increased risk of <\\entity><\\entity>.CI - Copyright (c) 2007 Wiley-Liss, Inc.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "3997",
    "Sentence": "When stratified by ALDH2 Ex1+82A>G polymorphism, alcohol-related increases in stomach cancer risk were restricted to individuals with the AG/<\\entity><\\entity> genotypes, with a more than 2-fold risk among daily drinkers (OR=2.63, 95% CI=1.00-6.88) and 3-fold risk (OR=3.66, 95% CI=1.19-11.24) among those with 40 or more drink-years.",
    "Label": ""
  },
  {
    "id": "3998",
    "Sentence": "When stratified by ALDH2 Ex1+82A>G polymorphism, alcohol-related increases in <\\entity><\\entity> risk were restricted to individuals with the AG/GG genotypes, with a more than 2-fold risk among daily drinkers (OR=2.63, 95% CI=1.00-6.88) and 3-fold risk (OR=3.66, 95% CI=1.19-11.24) among those with 40 or more drink-years.",
    "Label": ""
  },
  {
    "id": "4000",
    "Sentence": "When stratified by ALDH2 Ex1+82A>G polymorphism, alcohol-related increases in stomach cancer risk were restricted to individuals with the <\\entity><\\entity>/GG genotypes, with a more than 2-fold risk among daily drinkers (OR=2.63, 95% CI=1.00-6.88) and 3-fold risk (OR=3.66, 95% CI=1.19-11.24) among those with 40 or more drink-years.",
    "Label": ""
  },
  {
    "id": "4001",
    "Sentence": "When stratified by ALDH2 Ex1+82A>G polymorphism, alcohol-related increases in <\\entity><\\entity> risk were restricted to individuals with the AG/GG genotypes, with a more than 2-fold risk among daily drinkers (OR=2.63, 95% CI=1.00-6.88) and 3-fold risk (OR=3.66, 95% CI=1.19-11.24) among those with 40 or more drink-years.",
    "Label": ""
  },
  {
    "id": "4003",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including <\\entity><\\entity> (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4004",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4006",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including <\\entity><\\entity> (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4007",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, <\\entity><\\entity>, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4009",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including <\\entity><\\entity> (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4010",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol <\\entity><\\entity> and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4012",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), <\\entity><\\entity> (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4013",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4015",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), <\\entity><\\entity> (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4016",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, <\\entity><\\entity>, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4018",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), <\\entity><\\entity> (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4019",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol <\\entity><\\entity> and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4021",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and <\\entity><\\entity> (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4022",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4024",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and <\\entity><\\entity> (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4025",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, <\\entity><\\entity>, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4027",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and <\\entity><\\entity> (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4028",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol <\\entity><\\entity> and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4030",
    "Sentence": "In particular, the weekly consumption of individuals carrying the AA, GA and GG genotypes of <\\entity><\\entity> polymorphism were 3.75, 2.26 and 1.53 drinks, respectively (p=0.04).",
    "Label": ""
  },
  {
    "id": "4031",
    "Sentence": "In particular, the weekly consumption of individuals carrying the AA, GA and GG genotypes of ALDH2 Ex1+82A>G polymorphism were 3.75, 2.26 and 1.53 <\\entity><\\entity>, respectively (p=0.04).",
    "Label": ""
  },
  {
    "id": "4033",
    "Sentence": "In particular, the weekly consumption of individuals carrying the AA, GA and GG genotypes of <\\entity><\\entity> polymorphism were 3.75, 2.26 and 1.53 drinks, respectively (p=0.04).",
    "Label": ""
  },
  {
    "id": "4034",
    "Sentence": "In particular, the weekly <\\entity><\\entity> of individuals carrying the AA, GA and GG genotypes of ALDH2 Ex1+82A>G polymorphism were 3.75, 2.26 and 1.53 drinks, respectively (p=0.04).",
    "Label": ""
  },
  {
    "id": "4036",
    "Sentence": "When stratified by <\\entity><\\entity> polymorphism, alcohol-related increases in stomach cancer risk were restricted to individuals with the AG/GG genotypes, with a more than 2-fold risk among daily drinkers (OR=2.63, 95% CI=1.00-6.88) and 3-fold risk (OR=3.66, 95% CI=1.19-11.24) among those with 40 or more drink-years.",
    "Label": ""
  },
  {
    "id": "4037",
    "Sentence": "When stratified by ALDH2 Ex1+82A>G polymorphism, alcohol-related increases in <\\entity><\\entity> risk were restricted to individuals with the AG/GG genotypes, with a more than 2-fold risk among daily drinkers (OR=2.63, 95% CI=1.00-6.88) and 3-fold risk (OR=3.66, 95% CI=1.19-11.24) among those with 40 or more drink-years.",
    "Label": ""
  },
  {
    "id": "4039",
    "Sentence": "In summary, our results suggested that the <\\entity><\\entity> allele may be functionally deficient in eliminating acetaldehyde and discourage alcohol drinking.",
    "Label": ""
  },
  {
    "id": "4040",
    "Sentence": "In summary, our results suggested that the ALDH2 Ex1+82 G allele may be functionally deficient in eliminating acetaldehyde and discourage alcohol <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4042",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (<\\entity><\\entity> and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4043",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4045",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and <\\entity><\\entity>) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4046",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4048",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (<\\entity><\\entity>), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4049",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4051",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (<\\entity><\\entity>, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4052",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4054",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, <\\entity><\\entity>, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4055",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4057",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, <\\entity><\\entity> and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4058",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4060",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and <\\entity><\\entity>), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of stomach cancer.",
    "Label": ""
  },
  {
    "id": "4061",
    "Sentence": "In a population-based study of 305 cases and 428 controls in Warsaw, Poland, we evaluated the effect of polymorphisms in alcohol metabolizing genes, including ADH1B (Ex9+5C>T, Ex3+23A>G, Ex3+58A>T and Ex9+77A>G), ADH1C (Ex8-56A>G and Ex6-14G>A) and ALDH2 (Ex1+82A>G), on levels of alcohol drinking and susceptibility of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4067",
    "Sentence": "<\\entity><\\entity> preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.BACKGROUND: Resistance to modern adjuvant treatment is in part due to the failure of programmed cell death.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4068",
    "Sentence": "The <\\entity><\\entity> has been found to be over-expressed in some types of malignant tumors, and, recently, small molecule ligands to the <\\entity><\\entity> were found to induce cancer cell apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4069",
    "Sentence": "The <\\entity><\\entity> has been found to be over-expressed in some types of malignant tumors, and, recently, small molecule ligands to the <\\entity><\\entity> were found to induce cancer cell apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4070",
    "Sentence": "The <\\entity><\\entity> has been found to be over-expressed in some types of malignant tumors, and, recently, small molecule ligands to the <\\entity><\\entity> were found to induce cancer cell apoptosis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4071",
    "Sentence": "RESULTS: The <\\entity><\\entity> was expressed at high levels in both human and murine pancreas cancer cell lines, with minimal or limited expression in normal tissues, including: brain, kidney, liver, lung, pancreas and spleen.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4072",
    "Sentence": "Micro-PET imaging was used to demonstrate that the <\\entity><\\entity> was preferentially expressed in tumor as opposed to normal tissues in pancreas tumor allograft-bearing mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4073",
    "Sentence": "Two structurally distinct <\\entity><\\entity>, SV119 and WC26, were found to induce apoptosis to mice and human pancreatic cancer cells in vitro and in vivo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4074",
    "Sentence": "Two structurally distinct <\\entity><\\entity>, SV119 and WC26, were found to induce apoptosis to mice and human pancreatic cancer cells in vitro and in vivo.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4075",
    "Sentence": "Two structurally distinct sigma-2 receptor ligands, <\\entity><\\entity> and WC26, were found to induce apoptosis to mice and human pancreatic cancer cells in vitro and in vivo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4076",
    "Sentence": "Two structurally distinct sigma-2 receptor ligands, SV119 and <\\entity><\\entity>, were found to induce apoptosis to mice and human pancreatic cancer cells in vitro and in vivo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4077",
    "Sentence": "<\\entity><\\entity> induced apoptosis in a dose dependent fashion in all pancreatic cell lines tested.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4078",
    "Sentence": "<\\entity><\\entity> induced apoptosis in a dose dependent fashion in all pancreatic cell lines tested.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4079",
    "Sentence": "At the highest dose tested (10 muM), all <\\entity><\\entity> induced 10-20% apoptosis in all pancreatic cancer cell lines tested (p < 0.05).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4080",
    "Sentence": "At the highest dose tested (10 muM), all <\\entity><\\entity> induced 10-20% apoptosis in all pancreatic cancer cell lines tested (p < 0.05).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4081",
    "Sentence": "In pancreas tumor allograft-bearing mice, a single bolus dose of <\\entity><\\entity> caused approximately 50% apoptosis in the tumor compared to no appreciable apoptosis in tumor-bearing, vehicle-injected control animals (p < 0.0001).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4082",
    "Sentence": "<\\entity><\\entity> significantly slowed tumor growth after a 5 day treatment compared to vehicle-injected control animals (p < 0.0001) and blood chemistry panels suggested that there is minimal peripheral toxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4083",
    "Sentence": "Two structurally distinct sigma-2 receptor ligands, <\\entity><\\entity> and WC26, were found to induce apoptosis to mice and human pancreatic cancer cells in vitro and in vivo.",
    "Label": ""
  },
  {
    "id": "4084",
    "Sentence": "Two structurally distinct <\\entity><\\entity>, SV119 and WC26, were found to induce apoptosis to mice and human pancreatic cancer cells in vitro and in vivo.",
    "Label": ""
  },
  {
    "id": "4086",
    "Sentence": "Two structurally distinct sigma-2 receptor ligands, SV119 and <\\entity><\\entity>, were found to induce apoptosis to mice and human pancreatic cancer cells in vitro and in vivo.",
    "Label": ""
  },
  {
    "id": "4087",
    "Sentence": "Two structurally distinct <\\entity><\\entity>, SV119 and WC26, were found to induce apoptosis to mice and human pancreatic cancer cells in vitro and in vivo.",
    "Label": ""
  },
  {
    "id": "4093",
    "Sentence": "Effect of <\\entity><\\entity> on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.PURPOSE: Tibolone is a selective tissue estrogenic activity regulator, approved for the treatment of vasomotor symptoms in postmenopausal women.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4094",
    "Sentence": "Effect of tibolone on <\\entity><\\entity> cell proliferation in postmenopausal ER+ patients: results from STEM trial.PURPOSE: Tibolone is a selective tissue estrogenic activity regulator, approved for the treatment of vasomotor symptoms in postmenopausal women.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4095",
    "Sentence": "Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.PURPOSE: <\\entity><\\entity> is a selective tissue estrogenic activity regulator, approved for the treatment of vasomotor symptoms in postmenopausal women.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4096",
    "Sentence": "Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.PURPOSE: Tibolone is a <\\entity><\\entity>, approved for the treatment of vasomotor symptoms in postmenopausal women.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4097",
    "Sentence": "Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.PURPOSE: Tibolone is a selective tissue estrogenic activity regulator, approved for the treatment of <\\entity><\\entity> in postmenopausal women.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4098",
    "Sentence": "We have done an exploratory, double-blind, randomized, placebo-controlled pilot trial to investigate the tissue-specific effects of 2.5 mg <\\entity><\\entity> on breast cancer in postmenopausal women, in particular on tissue proliferation (STEM, Study of Tibolone Effects on Mamma carcinoma tissue).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4099",
    "Sentence": "We have done an exploratory, double-blind, randomized, placebo-controlled pilot trial to investigate the tissue-specific effects of 2.5 mg tibolone on <\\entity><\\entity> in postmenopausal women, in particular on tissue proliferation (STEM, Study of Tibolone Effects on Mamma carcinoma tissue).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4100",
    "Sentence": "We have done an exploratory, double-blind, randomized, placebo-controlled pilot trial to investigate the tissue-specific effects of 2.5 mg tibolone on breast cancer in postmenopausal women, in particular on tissue proliferation (STEM, Study of <\\entity><\\entity> Effects on Mamma carcinoma tissue).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4101",
    "Sentence": "We have done an exploratory, double-blind, randomized, placebo-controlled pilot trial to investigate the tissue-specific effects of 2.5 mg tibolone on breast cancer in postmenopausal women, in particular on tissue proliferation (STEM, Study of Tibolone Effects on Mamma <\\entity><\\entity> tissue).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4102",
    "Sentence": "EXPERIMENTAL DESIGN: Postmenopausal women with initially stage I/II, <\\entity><\\entity>(ER+) primary breast cancer, were randomly assigned to 14 days of placebo or 2.5 mg/d tibolone.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4103",
    "Sentence": "EXPERIMENTAL DESIGN: Postmenopausal women with initially stage I/II, estrogen receptor-positive (<\\entity><\\entity>, were randomly assigned to 14 days of placebo or 2.5 mg/d tibolone.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4104",
    "Sentence": "EXPERIMENTAL DESIGN: Postmenopausal women with initially stage I/II, estrogen receptor-positive (ER+) primary breast cancer, were randomly assigned to 14 days of placebo or 2.5 mg/d <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4105",
    "Sentence": "Core biopsies of the <\\entity><\\entity> were obtained before and after treatment.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4106",
    "Sentence": "RESULTS: Of 102 enrolled patients, 95 had <\\entity><\\entity> data.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4107",
    "Sentence": "<\\entity><\\entity> cases are mainly invasive (99%), stage I or II (42% and 50% respectively), and ER+ (99%).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4108",
    "Sentence": "Median intratumoral Ki-67 expression at baseline was 13.0% in the <\\entity><\\entity> group and 17.8% in the placebo group, and decreased to 12.0% after 14 days of <\\entity><\\entity> while increasing to 19.0% in the placebo group.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4109",
    "Sentence": "Median intratumoral Ki-67 expression at baseline was 13.0% in the <\\entity><\\entity> group and 17.8% in the placebo group, and decreased to 12.0% after 14 days of <\\entity><\\entity> while increasing to 19.0% in the placebo group.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4110",
    "Sentence": "This change from baseline was not significantly different between <\\entity><\\entity> and placebo (Wilcoxon test; P=0.17).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4111",
    "Sentence": "A significant difference was observed between the treatment groups when the median change from baseline apoptosis index was compared between the treatment groups (<\\entity><\\entity>, 0.0%; placebo, +0.3%; Wilcoxon test; P=0.031).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4112",
    "Sentence": "The incidence of <\\entity><\\entity> was comparable.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4113",
    "Sentence": "CONCLUSIONS: In <\\entity><\\entity>, 2.5 mg/d tibolone given for 14 days has no significant effect on tumor cell proliferation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4114",
    "Sentence": "CONCLUSIONS: In ER+ breast tumors, 2.5 mg/d <\\entity><\\entity> given for 14 days has no significant effect on tumor cell proliferation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4115",
    "Sentence": "CONCLUSIONS: In ER+ breast <\\entity><\\entity>s, 2.5 mg/d tibolone given for 14 days has no significant effect on <\\entity><\\entity> cell proliferation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4116",
    "Sentence": "Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.PURPOSE: <\\entity><\\entity> is a selective tissue estrogenic activity regulator, approved for the treatment of vasomotor symptoms in postmenopausal women.",
    "Label": ""
  },
  {
    "id": "4117",
    "Sentence": "Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.PURPOSE: Tibolone is a selective tissue estrogenic activity regulator, approved for the treatment of <\\entity><\\entity> in postmenopausal women.",
    "Label": ""
  },
  {
    "id": "4119",
    "Sentence": "Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.PURPOSE: Tibolone is a <\\entity><\\entity>, approved for the treatment of vasomotor symptoms in postmenopausal women.",
    "Label": ""
  },
  {
    "id": "4120",
    "Sentence": "Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.PURPOSE: Tibolone is a selective tissue estrogenic activity regulator, approved for the treatment of <\\entity><\\entity> in postmenopausal women.",
    "Label": ""
  },
  {
    "id": "4122",
    "Sentence": "CONCLUSIONS: In ER+ breast tumors, 2.5 mg/d <\\entity><\\entity> given for 14 days has no significant effect on tumor cell proliferation.",
    "Label": ""
  },
  {
    "id": "4123",
    "Sentence": "CONCLUSIONS: In ER+ breast <\\entity><\\entity>s, 2.5 mg/d tibolone given for 14 days has no significant effect on <\\entity><\\entity> cell proliferation.",
    "Label": ""
  },
  {
    "id": "4125",
    "Sentence": "CONCLUSIONS: In ER+ breast tumors, 2.5 mg/d <\\entity><\\entity> given for 14 days has no significant effect on tumor cell proliferation.",
    "Label": ""
  },
  {
    "id": "4126",
    "Sentence": "CONCLUSIONS: In <\\entity><\\entity>, 2.5 mg/d tibolone given for 14 days has no significant effect on tumor cell proliferation.",
    "Label": ""
  },
  {
    "id": "4128",
    "Sentence": "EXPERIMENTAL DESIGN: Postmenopausal women with initially stage I/II, <\\entity><\\entity>(ER+) primary breast cancer, were randomly assigned to 14 days of placebo or 2.5 mg/d tibolone.",
    "Label": ""
  },
  {
    "id": "4129",
    "Sentence": "EXPERIMENTAL DESIGN: Postmenopausal women with initially stage I/II, estrogen receptor-positive (<\\entity><\\entity>, were randomly assigned to 14 days of placebo or 2.5 mg/d tibolone.",
    "Label": ""
  },
  {
    "id": "4131",
    "Sentence": "Median intratumoral Ki-67 expression at baseline was 13.0% in the <\\entity><\\entity> group and 17.8% in the placebo group, and decreased to 12.0% after 14 days of <\\entity><\\entity> while increasing to 19.0% in the placebo group.",
    "Label": ""
  },
  {
    "id": "4132",
    "Sentence": "Median intratumoral <\\entity><\\entity> expression at baseline was 13.0% in the tibolone group and 17.8% in the placebo group, and decreased to 12.0% after 14 days of tibolone while increasing to 19.0% in the placebo group.",
    "Label": ""
  },
  {
    "id": "4134",
    "Sentence": "CONCLUSIONS: In ER+ breast tumors, 2.5 mg/d <\\entity><\\entity> given for 14 days has no significant effect on tumor cell proliferation.",
    "Label": ""
  },
  {
    "id": "4135",
    "Sentence": "CONCLUSIONS: In <\\entity><\\entity>, 2.5 mg/d tibolone given for 14 days has no significant effect on tumor cell proliferation.",
    "Label": ""
  },
  {
    "id": "4137",
    "Sentence": "Effect of <\\entity><\\entity> on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.PURPOSE: Tibolone is a selective tissue estrogenic activity regulator, approved for the treatment of vasomotor symptoms in postmenopausal women.",
    "Label": ""
  },
  {
    "id": "4138",
    "Sentence": "Effect of tibolone on <\\entity><\\entity> cell proliferation in postmenopausal ER+ patients: results from STEM trial.PURPOSE: Tibolone is a selective tissue estrogenic activity regulator, approved for the treatment of vasomotor symptoms in postmenopausal women.",
    "Label": ""
  },
  {
    "id": "4140",
    "Sentence": "We have done an exploratory, double-blind, randomized, placebo-controlled pilot trial to investigate the tissue-specific effects of 2.5 mg tibolone on breast cancer in postmenopausal women, in particular on tissue proliferation (STEM, Study of <\\entity><\\entity> Effects on Mamma carcinoma tissue).",
    "Label": ""
  },
  {
    "id": "4141",
    "Sentence": "We have done an exploratory, double-blind, randomized, placebo-controlled pilot trial to investigate the tissue-specific effects of 2.5 mg tibolone on <\\entity><\\entity> in postmenopausal women, in particular on tissue proliferation (STEM, Study of Tibolone Effects on Mamma carcinoma tissue).",
    "Label": ""
  },
  {
    "id": "4143",
    "Sentence": "We have done an exploratory, double-blind, randomized, placebo-controlled pilot trial to investigate the tissue-specific effects of 2.5 mg tibolone on breast cancer in postmenopausal women, in particular on tissue proliferation (STEM, Study of <\\entity><\\entity> Effects on Mamma carcinoma tissue).",
    "Label": ""
  },
  {
    "id": "4144",
    "Sentence": "We have done an exploratory, double-blind, randomized, placebo-controlled pilot trial to investigate the tissue-specific effects of 2.5 mg tibolone on breast cancer in postmenopausal women, in particular on tissue proliferation (STEM, Study of Tibolone Effects on Mamma <\\entity><\\entity> tissue).",
    "Label": ""
  },
  {
    "id": "4146",
    "Sentence": "EXPERIMENTAL DESIGN: Postmenopausal women with initially stage I/II, estrogen receptor-positive (ER+) primary breast cancer, were randomly assigned to 14 days of placebo or 2.5 mg/d <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4147",
    "Sentence": "EXPERIMENTAL DESIGN: Postmenopausal women with initially stage I/II, estrogen receptor-positive (<\\entity><\\entity>, were randomly assigned to 14 days of placebo or 2.5 mg/d tibolone.",
    "Label": ""
  },
  {
    "id": "4149",
    "Sentence": "CONCLUSIONS: In ER+ breast tumors, 2.5 mg/d <\\entity><\\entity> given for 14 days has no significant effect on tumor cell proliferation.",
    "Label": ""
  },
  {
    "id": "4150",
    "Sentence": "CONCLUSIONS: In ER+ breast <\\entity><\\entity>s, 2.5 mg/d tibolone given for 14 days has no significant effect on <\\entity><\\entity> cell proliferation.",
    "Label": ""
  },
  {
    "id": "4156",
    "Sentence": "The histology of acute autochthonous <\\entity><\\entity> infection.AIM: To document the histological appearances of liver biopsies in autochthonous <\\entity><\\entity> (HEV) infection.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4157",
    "Sentence": "The histology of acute autochthonous <\\entity><\\entity> infection.AIM: To document the histological appearances of liver biopsies in autochthonous <\\entity><\\entity> (HEV) infection.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4158",
    "Sentence": "The histology of acute autochthonous hepatitis E virus infection.AIM: To document the histological appearances of liver biopsies in autochthonous hepatitis E virus (<\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4159",
    "Sentence": "METHODS AND RESULTS: Four patients were serologically positive for <\\entity><\\entity>; three had no traditional risk factors, the fourth had recently returned from China.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4160",
    "Sentence": "Moderate to severe interface <\\entity><\\entity> and cholangiolitis were present.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4161",
    "Sentence": "Moderate to severe interface hepatitis and <\\entity><\\entity> were present.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4162",
    "Sentence": "There was a <\\entity><\\entity> acinar mixed inflammatory infiltrate made up of polymorphs, lymphocytes and macrophages; frequent apoptotic hepatocytes, focal necrosis, cholestatic rosettes and zone 3 canalicular and cytoplasmic bilirubinostasis were noted.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4163",
    "Sentence": "There was a striking acinar mixed inflammatory infiltrate made up of polymorphs, lymphocytes and macrophages; frequent apoptotic hepatocytes, <\\entity><\\entity>, cholestatic rosettes and zone 3 canalicular and cytoplasmic bilirubinostasis were noted.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4164",
    "Sentence": "There was a striking acinar mixed inflammatory infiltrate made up of polymorphs, lymphocytes and macrophages; frequent apoptotic hepatocytes, focal necrosis, cholestatic rosettes and zone 3 canalicular and cytoplasmic <\\entity><\\entity> were noted.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4165",
    "Sentence": "Significant <\\entity><\\entity>, megamitochondria and Mallory bodies were not present.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4166",
    "Sentence": "There was no evidence of iron, copper or <\\entity><\\entity> accumulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4167",
    "Sentence": "By contrast, the histology of the imported case of <\\entity><\\entity> showed less intense portal and acinar inflammation, no cholangiolitis and no geographical distribution of the portal inflammatory infiltrate.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4168",
    "Sentence": "By contrast, the histology of the imported case of HEV infection showed less intense portal and acinar <\\entity><\\entity>, no cholangiolitis and no geographical distribution of the portal inflammatory infiltrate.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4169",
    "Sentence": "By contrast, the histology of the imported case of HEV infection showed less intense portal and acinar inflammation, no <\\entity><\\entity> and no geographical distribution of the portal inflammatory infiltrate.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4170",
    "Sentence": "CONCLUSION: The histological appearances of autochthonous <\\entity><\\entity> are sufficiently distinctive to consider the diagnosis in an acute setting and possibly to differentiate it from the endemic form of the disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4171",
    "Sentence": "CONCLUSION: The histological appearances of autochthonous HEV infection are sufficiently distinctive to consider the diagnosis in an acute setting and possibly to differentiate it from the endemic form of the <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4176",
    "Sentence": "Delivery of <\\entity><\\entity> to the vagina: difficulties reported with the use of three devices, adherence to use and preferences.PURPOSE: A crossover study was carried out in 405 couples to compare women's difficulties with three different devices that could be used to administer a microbicide and to evaluate adherence to use and preference for any one of the devices.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4177",
    "Sentence": "Delivery of <\\entity><\\entity>s to the vagina: difficulties reported with the use of three devices, adherence to use and preferences.PURPOSE: A crossover study was carried out in 405 couples to compare women's difficulties with three different devices that could be used to administer a <\\entity><\\entity> and to evaluate adherence to use and preference for any one of the devices.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4178",
    "Sentence": "CONCLUSION: The release of <\\entity><\\entity> from a vaginal ring is a lead worth pursuing.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4183",
    "Sentence": "<\\entity><\\entity> protein: a versatile matrix molecule induced by TGF-beta.<\\entity><\\entity> protein is an extracellular matrix molecule initially cloned from human adenocarcinoma cells treated with TGF-beta.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4184",
    "Sentence": "TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by <\\entity><\\entity>.TGFBIp/betaig-h3 protein is an extracellular matrix molecule initially cloned from human adenocarcinoma cells treated with <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4185",
    "Sentence": "<\\entity><\\entity> protein: a versatile matrix molecule induced by TGF-beta.<\\entity><\\entity> protein is an extracellular matrix molecule initially cloned from human adenocarcinoma cells treated with TGF-beta.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4186",
    "Sentence": "TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by TGF-beta.TGFBIp/betaig-h3 protein is an extracellular matrix molecule initially cloned from human <\\entity><\\entity> cells treated with TGF-beta.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4187",
    "Sentence": "TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by <\\entity><\\entity>.TGFBIp/betaig-h3 protein is an extracellular matrix molecule initially cloned from human adenocarcinoma cells treated with <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4188",
    "Sentence": "To date, the most extensively studied and reported action of <\\entity><\\entity> protein is in corneal dystrophy and several excellent reviews are available on this.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4189",
    "Sentence": "To date, the most extensively studied and reported action of TGFBIp/betaig-h3 protein is in <\\entity><\\entity> and several excellent reviews are available on this.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4190",
    "Sentence": "To date, the most extensively studied and reported action of TGFBIp/betaig-h3 protein is in <\\entity><\\entity> and several excellent reviews are available on this.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4191",
    "Sentence": "Here we review the current understanding on <\\entity><\\entity> protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4192",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in <\\entity><\\entity>, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4193",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, <\\entity><\\entity>, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4194",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, <\\entity><\\entity>/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4195",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, <\\entity><\\entity>, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4196",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, <\\entity><\\entity>, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4197",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, <\\entity><\\entity>, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4198",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, <\\entity><\\entity>, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4199",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, <\\entity><\\entity>, osteogenesis, wound healing and inflammation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4200",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, <\\entity><\\entity>, wound healing and inflammation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4201",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4202",
    "Sentence": "<\\entity><\\entity> protein: a versatile matrix molecule induced by TGF-beta.<\\entity><\\entity> protein is an extracellular matrix molecule initially cloned from human adenocarcinoma cells treated with TGF-beta.",
    "Label": ""
  },
  {
    "id": "4203",
    "Sentence": "TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by TGF-beta.TGFBIp/betaig-h3 protein is an extracellular matrix molecule initially cloned from human <\\entity><\\entity> cells treated with TGF-beta.",
    "Label": ""
  },
  {
    "id": "4205",
    "Sentence": "TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by <\\entity><\\entity>.TGFBIp/betaig-h3 protein is an extracellular matrix molecule initially cloned from human adenocarcinoma cells treated with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4206",
    "Sentence": "TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by TGF-beta.TGFBIp/betaig-h3 protein is an extracellular matrix molecule initially cloned from human <\\entity><\\entity> cells treated with TGF-beta.",
    "Label": ""
  },
  {
    "id": "4208",
    "Sentence": "To date, the most extensively studied and reported action of <\\entity><\\entity> protein is in corneal dystrophy and several excellent reviews are available on this.",
    "Label": ""
  },
  {
    "id": "4209",
    "Sentence": "To date, the most extensively studied and reported action of TGFBIp/betaig-h3 protein is in <\\entity><\\entity> and several excellent reviews are available on this.",
    "Label": ""
  },
  {
    "id": "4211",
    "Sentence": "Here we review the current understanding on <\\entity><\\entity> protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4212",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, <\\entity><\\entity>, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4214",
    "Sentence": "Here we review the current understanding on <\\entity><\\entity> protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4215",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, <\\entity><\\entity>, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4217",
    "Sentence": "Here we review the current understanding on <\\entity><\\entity> protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4218",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, <\\entity><\\entity>, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4220",
    "Sentence": "Here we review the current understanding on <\\entity><\\entity> protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4221",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4223",
    "Sentence": "Here we review the current understanding on <\\entity><\\entity> protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4224",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, <\\entity><\\entity>, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4226",
    "Sentence": "Here we review the current understanding on <\\entity><\\entity> protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4227",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, <\\entity><\\entity>, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4229",
    "Sentence": "Here we review the current understanding on <\\entity><\\entity> protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4230",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in <\\entity><\\entity>, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4232",
    "Sentence": "Here we review the current understanding on <\\entity><\\entity> protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4233",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, <\\entity><\\entity>, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4235",
    "Sentence": "Here we review the current understanding on <\\entity><\\entity> protein and its functions in morphogenesis, extracellular matrix interactions, adhesion/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4236",
    "Sentence": "Here we review the current understanding on TGFBIp/betaig-h3 protein and its functions in morphogenesis, extracellular matrix interactions, <\\entity><\\entity>/migration, corneal dystrophy, tumorigenesis, angiogenesis, nephropathies, osteogenesis, wound healing and inflammation.",
    "Label": ""
  },
  {
    "id": "4242",
    "Sentence": "<\\entity><\\entity> for the treatment of cystinosis: association with hepatotoxicity.Nephropathic cystinosis is a lysosomal storage disorder, which, if untreated, results in renal failure by age 10 years.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4243",
    "Sentence": "Intravenous delivery of cysteamine for the treatment of <\\entity><\\entity>: association with hepatotoxicity.Nephropathic <\\entity><\\entity> is a lysosomal storage disorder, which, if untreated, results in renal failure by age 10 years.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4244",
    "Sentence": "Intravenous delivery of cysteamine for the treatment of cystinosis: association with <\\entity><\\entity>.Nephropathic cystinosis is a lysosomal storage disorder, which, if untreated, results in renal failure by age 10 years.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4245",
    "Sentence": "Intravenous delivery of cysteamine for the treatment of cystinosis: association with hepatotoxicity.<\\entity><\\entity> is a lysosomal storage disorder, which, if untreated, results in renal failure by age 10 years.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4246",
    "Sentence": "Intravenous delivery of cysteamine for the treatment of cystinosis: association with hepatotoxicity.Nephropathic cystinosis is a <\\entity><\\entity>, which, if untreated, results in renal failure by age 10 years.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4247",
    "Sentence": "Intravenous delivery of cysteamine for the treatment of cystinosis: association with hepatotoxicity.Nephropathic cystinosis is a lysosomal storage disorder, which, if untreated, results in <\\entity><\\entity> by age 10 years.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4248",
    "Sentence": "<\\entity><\\entity> has been shown to preserve renal function in these patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4249",
    "Sentence": "In this study, a 2-year-old <\\entity><\\entity> with nephropathic cystinosis and severe gastrointestinal dysmotility was treated with intravenous (i.v.) administration of cysteamine hydrochloride (HCl).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4250",
    "Sentence": "In this study, a 2-year-old girl with <\\entity><\\entity> and severe gastrointestinal dysmotility was treated with intravenous (i.v.) administration of cysteamine hydrochloride (HCl).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4251",
    "Sentence": "In this study, a 2-year-old girl with nephropathic cystinosis and <\\entity><\\entity> was treated with intravenous (i.v.) administration of cysteamine hydrochloride (HCl).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4252",
    "Sentence": "In this study, a 2-year-old girl with nephropathic cystinosis and severe gastrointestinal dysmotility was treated with <\\entity><\\entity> (i.v.) administration of cysteamine hydrochloride (HCl).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4253",
    "Sentence": "In this study, a 2-year-old girl with nephropathic cystinosis and severe gastrointestinal dysmotility was treated with intravenous (<\\entity><\\entity> (HCl).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4254",
    "Sentence": "In this study, a 2-year-old girl with nephropathic cystinosis and severe gastrointestinal dysmotility was treated with intravenous (i.v.) administration of cysteamine hydrochloride (<\\entity><\\entity>).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4255",
    "Sentence": "This is only the second report of long-term i.v.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4256",
    "Sentence": "cysteamine therapy for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4257",
    "Sentence": "Unlike the treatment in the previous case, however, treatment in our patient was limited by <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4258",
    "Sentence": "<\\entity><\\entity> for the treatment of cystinosis: association with hepatotoxicity.Nephropathic cystinosis is a lysosomal storage disorder, which, if untreated, results in renal failure by age 10 years.",
    "Label": ""
  },
  {
    "id": "4259",
    "Sentence": "Intravenous delivery of cysteamine for the treatment of <\\entity><\\entity>: association with hepatotoxicity.Nephropathic <\\entity><\\entity> is a lysosomal storage disorder, which, if untreated, results in renal failure by age 10 years.",
    "Label": ""
  },
  {
    "id": "4261",
    "Sentence": "In this study, a 2-year-old girl with nephropathic cystinosis and severe gastrointestinal dysmotility was treated with <\\entity><\\entity> (i.v.) administration of cysteamine hydrochloride (HCl).",
    "Label": ""
  },
  {
    "id": "4262",
    "Sentence": "In this study, a 2-year-old girl with <\\entity><\\entity> and severe gastrointestinal dysmotility was treated with intravenous (i.v.) administration of cysteamine hydrochloride (HCl).",
    "Label": ""
  },
  {
    "id": "4264",
    "Sentence": "In this study, a 2-year-old girl with nephropathic cystinosis and severe gastrointestinal dysmotility was treated with <\\entity><\\entity> (i.v.) administration of cysteamine hydrochloride (HCl).",
    "Label": ""
  },
  {
    "id": "4265",
    "Sentence": "In this study, a 2-year-old girl with nephropathic cystinosis and <\\entity><\\entity> was treated with intravenous (i.v.) administration of cysteamine hydrochloride (HCl).",
    "Label": ""
  },
  {
    "id": "4267",
    "Sentence": "In this study, a 2-year-old girl with nephropathic cystinosis and severe gastrointestinal dysmotility was treated with intravenous (<\\entity><\\entity> (HCl).",
    "Label": ""
  },
  {
    "id": "4268",
    "Sentence": "In this study, a 2-year-old girl with <\\entity><\\entity> and severe gastrointestinal dysmotility was treated with intravenous (i.v.) administration of cysteamine hydrochloride (HCl).",
    "Label": ""
  },
  {
    "id": "4270",
    "Sentence": "In this study, a 2-year-old girl with nephropathic cystinosis and severe gastrointestinal dysmotility was treated with intravenous (<\\entity><\\entity> (HCl).",
    "Label": ""
  },
  {
    "id": "4271",
    "Sentence": "In this study, a 2-year-old girl with nephropathic cystinosis and <\\entity><\\entity> was treated with intravenous (i.v.) administration of cysteamine hydrochloride (HCl).",
    "Label": ""
  },
  {
    "id": "4273",
    "Sentence": "In this study, a 2-year-old girl with nephropathic cystinosis and severe gastrointestinal dysmotility was treated with intravenous (i.v.) administration of cysteamine hydrochloride (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "4274",
    "Sentence": "In this study, a 2-year-old girl with <\\entity><\\entity> and severe gastrointestinal dysmotility was treated with intravenous (i.v.) administration of cysteamine hydrochloride (HCl).",
    "Label": ""
  },
  {
    "id": "4276",
    "Sentence": "In this study, a 2-year-old girl with nephropathic cystinosis and severe gastrointestinal dysmotility was treated with intravenous (i.v.) administration of cysteamine hydrochloride (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "4277",
    "Sentence": "In this study, a 2-year-old girl with nephropathic cystinosis and <\\entity><\\entity> was treated with intravenous (i.v.) administration of cysteamine hydrochloride (HCl).",
    "Label": ""
  },
  {
    "id": "4279",
    "Sentence": "This is only the second report of long-term i.v.",
    "Label": ""
  },
  {
    "id": "4280",
    "Sentence": "cysteamine therapy for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4282",
    "Sentence": "In this study, a 2-year-old <\\entity><\\entity> with nephropathic cystinosis and severe gastrointestinal dysmotility was treated with intravenous (i.v.) administration of cysteamine hydrochloride (HCl).",
    "Label": ""
  },
  {
    "id": "4283",
    "Sentence": "In this study, a 2-year-old girl with <\\entity><\\entity> and severe gastrointestinal dysmotility was treated with intravenous (i.v.) administration of cysteamine hydrochloride (HCl).",
    "Label": ""
  },
  {
    "id": "4285",
    "Sentence": "<\\entity><\\entity> for the treatment of cystinosis: association with hepatotoxicity.Nephropathic cystinosis is a lysosomal storage disorder, which, if untreated, results in renal failure by age 10 years.",
    "Label": ""
  },
  {
    "id": "4286",
    "Sentence": "Intravenous delivery of cysteamine for the treatment of cystinosis: association with <\\entity><\\entity>.Nephropathic cystinosis is a lysosomal storage disorder, which, if untreated, results in renal failure by age 10 years.",
    "Label": ""
  },
  {
    "id": "4292",
    "Sentence": "Early intervention for the <\\entity><\\entity> and neurodevelopmental sequelae of Fetal Valproate Syndrome.The established teratogenicity of antiepileptic drugs raises important issues in women of child-bearing age.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4293",
    "Sentence": "Early intervention for the ocular and neurodevelopmental <\\entity><\\entity> of Fetal Valproate Syndrome.The established teratogenicity of antiepileptic drugs raises important issues in women of child-bearing age.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4294",
    "Sentence": "Early intervention for the ocular and neurodevelopmental sequelae of <\\entity><\\entity>.The established teratogenicity of antiepileptic drugs raises important issues in women of child-bearing age.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4295",
    "Sentence": "Early intervention for the ocular and neurodevelopmental sequelae of Fetal Valproate Syndrome.The established <\\entity><\\entity> of antiepileptic drugs raises important issues in women of child-bearing age.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4296",
    "Sentence": "Early intervention for the ocular and neurodevelopmental sequelae of Fetal Valproate Syndrome.The established teratogenicity of <\\entity><\\entity> raises important issues in women of child-bearing age.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4297",
    "Sentence": "While the association between <\\entity><\\entity> and antiepileptic drugs is well recognised, other congenital malformations are known to occur.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4298",
    "Sentence": "While the association between neural tube defects and <\\entity><\\entity> is well recognised, other congenital malformations are known to occur.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4299",
    "Sentence": "While the association between neural tube defects and antiepileptic drugs is well recognised, other <\\entity><\\entity> are known to occur.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4300",
    "Sentence": "We report two siblings with characteristic craniofacial features of <\\entity><\\entity> who also had associated ocular and neurodevelopmental problems which would benefit from early recognition and intervention.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4301",
    "Sentence": "We report two siblings with characteristic craniofacial features of Fetal Valproate Syndrome who also had associated <\\entity><\\entity> and neurodevelopmental problems which would benefit from early recognition and intervention.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4302",
    "Sentence": "We report two siblings with characteristic craniofacial features of Fetal Valproate Syndrome who also had associated <\\entity><\\entity> and neurodevelopmental problems which would benefit from early recognition and intervention.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4303",
    "Sentence": "We report two siblings with characteristic craniofacial features of Fetal Valproate Syndrome who also had associated ocular and <\\entity><\\entity> which would benefit from early recognition and intervention.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4304",
    "Sentence": "While the association between neural tube defects and <\\entity><\\entity> is well recognised, other congenital malformations are known to occur.",
    "Label": ""
  },
  {
    "id": "4305",
    "Sentence": "While the association between <\\entity><\\entity> and antiepileptic drugs is well recognised, other congenital malformations are known to occur.",
    "Label": ""
  },
  {
    "id": "4307",
    "Sentence": "While the association between neural tube defects and <\\entity><\\entity> is well recognised, other congenital malformations are known to occur.",
    "Label": ""
  },
  {
    "id": "4308",
    "Sentence": "While the association between neural tube defects and antiepileptic drugs is well recognised, other <\\entity><\\entity> are known to occur.",
    "Label": ""
  },
  {
    "id": "4310",
    "Sentence": "Early intervention for the ocular and neurodevelopmental sequelae of Fetal Valproate Syndrome.The established teratogenicity of <\\entity><\\entity> raises important issues in women of child-bearing age.",
    "Label": ""
  },
  {
    "id": "4311",
    "Sentence": "Early intervention for the ocular and neurodevelopmental sequelae of Fetal Valproate Syndrome.The established <\\entity><\\entity> of antiepileptic drugs raises important issues in women of child-bearing age.",
    "Label": ""
  },
  {
    "id": "4313",
    "Sentence": "We report two siblings with characteristic craniofacial features of Fetal Valproate Syndrome who also had associated <\\entity><\\entity> and neurodevelopmental problems which would benefit from early recognition and intervention.",
    "Label": ""
  },
  {
    "id": "4314",
    "Sentence": "We report two siblings with characteristic craniofacial features of <\\entity><\\entity> who also had associated ocular and neurodevelopmental problems which would benefit from early recognition and intervention.",
    "Label": ""
  },
  {
    "id": "4320",
    "Sentence": "Circulating <\\entity><\\entity> levels are not influenced by thyroid status in hypothyroid and euthyroid women.OBJECTIVES: Leptin regulates body weight by suppressing food intake and increasing energy expenditure.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4321",
    "Sentence": "Circulating leptin levels are not influenced by thyroid status in <\\entity><\\entity> and euthyroid women.OBJECTIVES: Leptin regulates body weight by suppressing food intake and increasing energy expenditure.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4322",
    "Sentence": "Circulating leptin levels are not influenced by thyroid status in hypothyroid and euthyroid women.OBJECTIVES: <\\entity><\\entity> regulates body weight by suppressing food intake and increasing energy expenditure.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4323",
    "Sentence": "Circulating leptin levels are not influenced by thyroid status in hypothyroid and euthyroid women.OBJECTIVES: Leptin regulates body <\\entity><\\entity> by suppressing food intake and increasing energy expenditure.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4324",
    "Sentence": "Alterations in thyroid hormone levels are also associated with changes in body <\\entity><\\entity> but the effect of thyroid hormone deficiency on serum leptin in humans is unclear.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4325",
    "Sentence": "Alterations in thyroid hormone levels are also associated with changes in body weight but the effect of <\\entity><\\entity> on serum leptin in humans is unclear.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4326",
    "Sentence": "Alterations in thyroid hormone levels are also associated with changes in body weight but the effect of thyroid hormone deficiency on serum <\\entity><\\entity> in humans is unclear.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4327",
    "Sentence": "DESIGN AND METHODS: The aim of this study was to measure <\\entity><\\entity> levels and to investigate their associations with thyroid hormones in 22 women with severe hypothyroidism after total thyroidectomy, and in a group of 22 healthy euthyroid control female subjects matched for age and body mass index (BMI).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4328",
    "Sentence": "DESIGN AND METHODS: The aim of this study was to measure leptin levels and to investigate their associations with thyroid hormones in 22 women with <\\entity><\\entity> after total thyroidectomy, and in a group of 22 healthy euthyroid control female subjects matched for age and body mass index (BMI).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4329",
    "Sentence": "Their plasma <\\entity><\\entity>, free thyroxine, triiodothyronine and TSH were measured.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4330",
    "Sentence": "Their plasma leptin, free <\\entity><\\entity>, triiodothyronine and TSH were measured.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4331",
    "Sentence": "Their plasma leptin, free thyroxine, <\\entity><\\entity> and TSH were measured.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4332",
    "Sentence": "Their plasma leptin, free thyroxine, triiodothyronine and <\\entity><\\entity> were measured.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4333",
    "Sentence": "RESULTS: <\\entity><\\entity> levels in subjects and controls were (pg/mL) 18761.64+/-16973.96 and 18729.19+/-18014.05, respectively, p=0.9; leptin did not correlate with free thyroxine, triiodothyroinine and TSH: r=0.1039 and p=0.6453, r=0.0113 and p=0.9602, and r=-0.0525 and p=0.8165 for leptin and FT4, leptin and FT3, and leptin and TSH, respectively in subjects; r=-0.00056 and p=0.9980, r=0.248727 and p=0.2643, and r=-0.046919 and p=0.8357 for leptin and FT4, leptin and FT3, and leptin and TSH, respectively in controls.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4334",
    "Sentence": "RESULTS: Leptin levels in subjects and controls were (pg/mL) 18761.64+/-16973.96 and 18729.19+/-18014.05, respectively, p=0.9; <\\entity><\\entity> did not correlate with free thyroxine, triiodothyroinine and TSH: r=0.1039 and p=0.6453, r=0.0113 and p=0.9602, and r=-0.0525 and p=0.8165 for <\\entity><\\entity> and FT4, <\\entity><\\entity> and FT3, and <\\entity><\\entity> and TSH, respectively in subjects; r=-0.00056 and p=0.9980, r=0.248727 and p=0.2643, and r=-0.046919 and p=0.8357 for <\\entity><\\entity> and FT4, <\\entity><\\entity> and FT3, and <\\entity><\\entity> and TSH, respectively in controls.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4335",
    "Sentence": "RESULTS: Leptin levels in subjects and controls were (pg/mL) 18761.64+/-16973.96 and 18729.19+/-18014.05, respectively, p=0.9; leptin did not correlate with free <\\entity><\\entity>, triiodothyroinine and TSH: r=0.1039 and p=0.6453, r=0.0113 and p=0.9602, and r=-0.0525 and p=0.8165 for leptin and FT4, leptin and FT3, and leptin and TSH, respectively in subjects; r=-0.00056 and p=0.9980, r=0.248727 and p=0.2643, and r=-0.046919 and p=0.8357 for leptin and FT4, leptin and FT3, and leptin and TSH, respectively in controls.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4336",
    "Sentence": "RESULTS: Leptin levels in subjects and controls were (pg/mL) 18761.64+/-16973.96 and 18729.19+/-18014.05, respectively, p=0.9; leptin did not correlate with free thyroxine, <\\entity><\\entity> and TSH: r=0.1039 and p=0.6453, r=0.0113 and p=0.9602, and r=-0.0525 and p=0.8165 for leptin and FT4, leptin and FT3, and leptin and TSH, respectively in subjects; r=-0.00056 and p=0.9980, r=0.248727 and p=0.2643, and r=-0.046919 and p=0.8357 for leptin and FT4, leptin and FT3, and leptin and TSH, respectively in controls.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4337",
    "Sentence": "RESULTS: Leptin levels in subjects and controls were (pg/mL) 18761.64+/-16973.96 and 18729.19+/-18014.05, respectively, p=0.9; leptin did not correlate with free thyroxine, triiodothyroinine and <\\entity><\\entity>: r=0.1039 and p=0.6453, r=0.0113 and p=0.9602, and r=-0.0525 and p=0.8165 for leptin and FT4, leptin and FT3, and leptin and <\\entity><\\entity>, respectively in subjects; r=-0.00056 and p=0.9980, r=0.248727 and p=0.2643, and r=-0.046919 and p=0.8357 for leptin and FT4, leptin and FT3, and leptin and <\\entity><\\entity>, respectively in controls.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4338",
    "Sentence": "RESULTS: Leptin levels in subjects and controls were (pg/mL) 18761.64+/-16973.96 and 18729.19+/-18014.05, respectively, p=0.9; <\\entity><\\entity> did not correlate with free thyroxine, triiodothyroinine and TSH: r=0.1039 and p=0.6453, r=0.0113 and p=0.9602, and r=-0.0525 and p=0.8165 for <\\entity><\\entity> and FT4, <\\entity><\\entity> and FT3, and <\\entity><\\entity> and TSH, respectively in subjects; r=-0.00056 and p=0.9980, r=0.248727 and p=0.2643, and r=-0.046919 and p=0.8357 for <\\entity><\\entity> and FT4, <\\entity><\\entity> and FT3, and <\\entity><\\entity> and TSH, respectively in controls.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4339",
    "Sentence": "RESULTS: Leptin levels in subjects and controls were (pg/mL) 18761.64+/-16973.96 and 18729.19+/-18014.05, respectively, p=0.9; <\\entity><\\entity> did not correlate with free thyroxine, triiodothyroinine and TSH: r=0.1039 and p=0.6453, r=0.0113 and p=0.9602, and r=-0.0525 and p=0.8165 for <\\entity><\\entity> and FT4, <\\entity><\\entity> and FT3, and <\\entity><\\entity> and TSH, respectively in subjects; r=-0.00056 and p=0.9980, r=0.248727 and p=0.2643, and r=-0.046919 and p=0.8357 for <\\entity><\\entity> and FT4, <\\entity><\\entity> and FT3, and <\\entity><\\entity> and TSH, respectively in controls.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4340",
    "Sentence": "RESULTS: Leptin levels in subjects and controls were (pg/mL) 18761.64+/-16973.96 and 18729.19+/-18014.05, respectively, p=0.9; <\\entity><\\entity> did not correlate with free thyroxine, triiodothyroinine and TSH: r=0.1039 and p=0.6453, r=0.0113 and p=0.9602, and r=-0.0525 and p=0.8165 for <\\entity><\\entity> and FT4, <\\entity><\\entity> and FT3, and <\\entity><\\entity> and TSH, respectively in subjects; r=-0.00056 and p=0.9980, r=0.248727 and p=0.2643, and r=-0.046919 and p=0.8357 for <\\entity><\\entity> and FT4, <\\entity><\\entity> and FT3, and <\\entity><\\entity> and TSH, respectively in controls.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4341",
    "Sentence": "RESULTS: Leptin levels in subjects and controls were (pg/mL) 18761.64+/-16973.96 and 18729.19+/-18014.05, respectively, p=0.9; leptin did not correlate with free thyroxine, triiodothyroinine and <\\entity><\\entity>: r=0.1039 and p=0.6453, r=0.0113 and p=0.9602, and r=-0.0525 and p=0.8165 for leptin and FT4, leptin and FT3, and leptin and <\\entity><\\entity>, respectively in subjects; r=-0.00056 and p=0.9980, r=0.248727 and p=0.2643, and r=-0.046919 and p=0.8357 for leptin and FT4, leptin and FT3, and leptin and <\\entity><\\entity>, respectively in controls.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4342",
    "Sentence": "RESULTS: Leptin levels in subjects and controls were (pg/mL) 18761.64+/-16973.96 and 18729.19+/-18014.05, respectively, p=0.9; <\\entity><\\entity> did not correlate with free thyroxine, triiodothyroinine and TSH: r=0.1039 and p=0.6453, r=0.0113 and p=0.9602, and r=-0.0525 and p=0.8165 for <\\entity><\\entity> and FT4, <\\entity><\\entity> and FT3, and <\\entity><\\entity> and TSH, respectively in subjects; r=-0.00056 and p=0.9980, r=0.248727 and p=0.2643, and r=-0.046919 and p=0.8357 for <\\entity><\\entity> and FT4, <\\entity><\\entity> and FT3, and <\\entity><\\entity> and TSH, respectively in controls.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4343",
    "Sentence": "RESULTS: Leptin levels in subjects and controls were (pg/mL) 18761.64+/-16973.96 and 18729.19+/-18014.05, respectively, p=0.9; <\\entity><\\entity> did not correlate with free thyroxine, triiodothyroinine and TSH: r=0.1039 and p=0.6453, r=0.0113 and p=0.9602, and r=-0.0525 and p=0.8165 for <\\entity><\\entity> and FT4, <\\entity><\\entity> and FT3, and <\\entity><\\entity> and TSH, respectively in subjects; r=-0.00056 and p=0.9980, r=0.248727 and p=0.2643, and r=-0.046919 and p=0.8357 for <\\entity><\\entity> and FT4, <\\entity><\\entity> and FT3, and <\\entity><\\entity> and TSH, respectively in controls.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4344",
    "Sentence": "RESULTS: Leptin levels in subjects and controls were (pg/mL) 18761.64+/-16973.96 and 18729.19+/-18014.05, respectively, p=0.9; <\\entity><\\entity> did not correlate with free thyroxine, triiodothyroinine and TSH: r=0.1039 and p=0.6453, r=0.0113 and p=0.9602, and r=-0.0525 and p=0.8165 for <\\entity><\\entity> and FT4, <\\entity><\\entity> and FT3, and <\\entity><\\entity> and TSH, respectively in subjects; r=-0.00056 and p=0.9980, r=0.248727 and p=0.2643, and r=-0.046919 and p=0.8357 for <\\entity><\\entity> and FT4, <\\entity><\\entity> and FT3, and <\\entity><\\entity> and TSH, respectively in controls.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4345",
    "Sentence": "RESULTS: Leptin levels in subjects and controls were (pg/mL) 18761.64+/-16973.96 and 18729.19+/-18014.05, respectively, p=0.9; leptin did not correlate with free thyroxine, triiodothyroinine and <\\entity><\\entity>: r=0.1039 and p=0.6453, r=0.0113 and p=0.9602, and r=-0.0525 and p=0.8165 for leptin and FT4, leptin and FT3, and leptin and <\\entity><\\entity>, respectively in subjects; r=-0.00056 and p=0.9980, r=0.248727 and p=0.2643, and r=-0.046919 and p=0.8357 for leptin and FT4, leptin and FT3, and leptin and <\\entity><\\entity>, respectively in controls.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4346",
    "Sentence": "<\\entity><\\entity> levels did not differ between subjects and controls and they did not correlate with thyroid hormones.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4347",
    "Sentence": "CONCLUSIONS: <\\entity><\\entity> levels are not influenced by hypothyroidism and do not correlate with thyroid hormones in euthyroid and hypothyroid women.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4348",
    "Sentence": "CONCLUSIONS: Leptin levels are not influenced by <\\entity><\\entity> and do not correlate with thyroid hormones in euthyroid and hypothyroid women.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4349",
    "Sentence": "CONCLUSIONS: Leptin levels are not influenced by <\\entity><\\entity>ism and do not correlate with thyroid hormones in euthyroid and <\\entity><\\entity> women.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4350",
    "Sentence": "CONCLUSIONS: <\\entity><\\entity> levels are not influenced by hypothyroidism and do not correlate with thyroid hormones in euthyroid and hypothyroid women.",
    "Label": ""
  },
  {
    "id": "4351",
    "Sentence": "CONCLUSIONS: Leptin levels are not influenced by <\\entity><\\entity> and do not correlate with thyroid hormones in euthyroid and hypothyroid women.",
    "Label": ""
  },
  {
    "id": "4353",
    "Sentence": "Circulating <\\entity><\\entity> levels are not influenced by thyroid status in hypothyroid and euthyroid women.OBJECTIVES: Leptin regulates body weight by suppressing food intake and increasing energy expenditure.",
    "Label": ""
  },
  {
    "id": "4354",
    "Sentence": "Circulating leptin levels are not influenced by thyroid status in <\\entity><\\entity> and euthyroid women.OBJECTIVES: Leptin regulates body weight by suppressing food intake and increasing energy expenditure.",
    "Label": ""
  },
  {
    "id": "4356",
    "Sentence": "Alterations in thyroid hormone levels are also associated with changes in body weight but the effect of thyroid hormone deficiency on serum <\\entity><\\entity> in humans is unclear.",
    "Label": ""
  },
  {
    "id": "4357",
    "Sentence": "Alterations in thyroid hormone levels are also associated with changes in body weight but the effect of <\\entity><\\entity> on serum leptin in humans is unclear.",
    "Label": ""
  },
  {
    "id": "4363",
    "Sentence": "Risk factors for <\\entity><\\entity> in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4364",
    "Sentence": "Risk factors for anaemia in <\\entity><\\entity> patients treated with interferon plus ribavirin.The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is anaemia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4365",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/<\\entity><\\entity> virus-coinfected patients treated with interferon plus ribavirin.The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is anaemia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4366",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with <\\entity><\\entity> plus ribavirin.The most frequent and the most troublesome adverse effect of <\\entity><\\entity> plus ribavirin-based therapy is anaemia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4367",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus <\\entity><\\entity>.The most frequent and the most troublesome adverse effect of interferon plus <\\entity><\\entity>-based therapy is anaemia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4368",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.The most frequent and the most troublesome <\\entity><\\entity> of interferon plus ribavirin-based therapy is anaemia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4369",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with <\\entity><\\entity> plus ribavirin.The most frequent and the most troublesome adverse effect of <\\entity><\\entity> plus ribavirin-based therapy is anaemia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4370",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus <\\entity><\\entity>.The most frequent and the most troublesome adverse effect of interferon plus <\\entity><\\entity>-based therapy is anaemia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4371",
    "Sentence": "Risk factors for <\\entity><\\entity> in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4372",
    "Sentence": "The aim of this analysis was to determine the incidence and risk factors of <\\entity><\\entity> (Hb < 10 g/dL) in human immunodeficiency virus/hepatitis C virus (HCV)-coinfected patients receiving anti-HCV therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4373",
    "Sentence": "The aim of this analysis was to determine the incidence and risk factors of anaemia (Hb < 10 g/dL) in <\\entity><\\entity> patients receiving anti-HCV therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4374",
    "Sentence": "The aim of this analysis was to determine the incidence and risk factors of anaemia (Hb < 10 g/dL) in human immunodeficiency virus/<\\entity><\\entity> virus (HCV)-coinfected patients receiving anti-HCV therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4375",
    "Sentence": "The aim of this analysis was to determine the incidence and risk factors of anaemia (Hb < 10 g/dL) in human immunodeficiency <\\entity><\\entity>/hepatitis C <\\entity><\\entity> (HCV)-coinfected patients receiving anti-HCV therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4376",
    "Sentence": "The aim of this analysis was to determine the incidence and risk factors of anaemia (Hb < 10 g/dL) in human immunodeficiency virus/hepatitis C virus (<\\entity><\\entity>)-coinfected patients receiving anti-<\\entity><\\entity> therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4377",
    "Sentence": "The aim of this analysis was to determine the incidence and risk factors of anaemia (Hb < 10 g/dL) in human immunodeficiency virus/hepatitis C virus (HCV)-coinfected patients receiving <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4378",
    "Sentence": "The aim of this analysis was to determine the incidence and risk factors of anaemia (Hb < 10 g/dL) in human immunodeficiency virus/hepatitis C virus (<\\entity><\\entity>)-coinfected patients receiving anti-<\\entity><\\entity> therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4379",
    "Sentence": "We reviewed all cases of <\\entity><\\entity> occurring among 416 patients participating in a randomized, controlled 48-week trial comparing peginterferon (peg-IFN) alpha 2b plus ribavirin with interferon alpha-2b plus ribavirin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4380",
    "Sentence": "We reviewed all cases of anaemia occurring among 416 patients participating in a randomized, controlled 48-week trial comparing <\\entity><\\entity> (peg-IFN) alpha 2b plus ribavirin with interferon alpha-2b plus ribavirin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4381",
    "Sentence": "We reviewed all cases of anaemia occurring among 416 patients participating in a randomized, controlled 48-week trial comparing peginterferon (<\\entity><\\entity> plus ribavirin with interferon alpha-2b plus ribavirin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4382",
    "Sentence": "We reviewed all cases of anaemia occurring among 416 patients participating in a randomized, controlled 48-week trial comparing peginterferon (peg-IFN) alpha 2b plus <\\entity><\\entity> with interferon alpha-2b plus <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4383",
    "Sentence": "We reviewed all cases of anaemia occurring among 416 patients participating in a randomized, controlled 48-week trial comparing peginterferon (peg-IFN) alpha 2b plus ribavirin with <\\entity><\\entity> plus ribavirin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4384",
    "Sentence": "We reviewed all cases of anaemia occurring among 416 patients participating in a randomized, controlled 48-week trial comparing peginterferon (peg-IFN) alpha 2b plus <\\entity><\\entity> with interferon alpha-2b plus <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4385",
    "Sentence": "Univariate and multivariate analyses were used to identify links with <\\entity><\\entity>, HCV therapy and clinical and laboratory findings.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4386",
    "Sentence": "Univariate and multivariate analyses were used to identify links with antiretroviral treatments, <\\entity><\\entity> therapy and clinical and laboratory findings.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4387",
    "Sentence": "Sixty-one (15.9%) of the 383 patients who received at least one dose of anti-<\\entity><\\entity> treatment developed anaemia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4388",
    "Sentence": "Sixty-one (15.9%) of the 383 patients who received at least one dose of anti-HCV treatment developed <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4389",
    "Sentence": "In multivariate analysis the risk of <\\entity><\\entity> was significantly associated with zidovudine (OR, 3.27 95% CI, 1.64-6.54, P = 0.0008) and peg-IFN (OR, 2.35; 95% CI, 1.16-4.57, P = 0.0179).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4390",
    "Sentence": "In multivariate analysis the risk of anaemia was significantly associated with <\\entity><\\entity> (OR, 3.27 95% CI, 1.64-6.54, P = 0.0008) and peg-IFN (OR, 2.35; 95% CI, 1.16-4.57, P = 0.0179).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4391",
    "Sentence": "In multivariate analysis the risk of anaemia was significantly associated with zidovudine (OR, 3.27 95% CI, 1.64-6.54, P = 0.0008) and <\\entity><\\entity> (OR, 2.35; 95% CI, 1.16-4.57, P = 0.0179).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4392",
    "Sentence": "The risk of <\\entity><\\entity> was lower in patients with higher baseline haemoglobin levels (OR, 0.35 95% CI, 0.26-0.49, P < 0.0001) and in patients receiving protease inhibitor-based antiretroviral therapy (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4393",
    "Sentence": "The risk of anaemia was lower in patients with higher baseline haemoglobin levels (OR, 0.35 95% CI, 0.26-0.49, P < 0.0001) and in patients receiving <\\entity><\\entity>-based antiretroviral therapy (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4394",
    "Sentence": "The risk of anaemia was lower in patients with higher baseline haemoglobin levels (OR, 0.35 95% CI, 0.26-0.49, P < 0.0001) and in patients receiving protease inhibitor-based <\\entity><\\entity> (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4395",
    "Sentence": "<\\entity><\\entity> discontinuation could help to avoid anaemia associated with anti-HCV therapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4396",
    "Sentence": "Zidovudine discontinuation could help to avoid <\\entity><\\entity> associated with anti-HCV therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4397",
    "Sentence": "Zidovudine discontinuation could help to avoid anaemia associated with <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4398",
    "Sentence": "Zidovudine discontinuation could help to avoid anaemia associated with anti-<\\entity><\\entity> therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4399",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with <\\entity><\\entity> plus ribavirin.The most frequent and the most troublesome adverse effect of <\\entity><\\entity> plus ribavirin-based therapy is anaemia.",
    "Label": ""
  },
  {
    "id": "4400",
    "Sentence": "Risk factors for anaemia in <\\entity><\\entity> patients treated with interferon plus ribavirin.The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is anaemia.",
    "Label": ""
  },
  {
    "id": "4402",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus <\\entity><\\entity>.The most frequent and the most troublesome adverse effect of interferon plus <\\entity><\\entity>-based therapy is anaemia.",
    "Label": ""
  },
  {
    "id": "4403",
    "Sentence": "Risk factors for anaemia in <\\entity><\\entity> patients treated with interferon plus ribavirin.The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is anaemia.",
    "Label": ""
  },
  {
    "id": "4405",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with <\\entity><\\entity> plus ribavirin.The most frequent and the most troublesome adverse effect of <\\entity><\\entity> plus ribavirin-based therapy is anaemia.",
    "Label": ""
  },
  {
    "id": "4406",
    "Sentence": "Risk factors for <\\entity><\\entity> in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4408",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus <\\entity><\\entity>.The most frequent and the most troublesome adverse effect of interferon plus <\\entity><\\entity>-based therapy is anaemia.",
    "Label": ""
  },
  {
    "id": "4409",
    "Sentence": "Risk factors for <\\entity><\\entity> in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4411",
    "Sentence": "In multivariate analysis the risk of anaemia was significantly associated with <\\entity><\\entity> (OR, 3.27 95% CI, 1.64-6.54, P = 0.0008) and peg-IFN (OR, 2.35; 95% CI, 1.16-4.57, P = 0.0179).",
    "Label": ""
  },
  {
    "id": "4412",
    "Sentence": "In multivariate analysis the risk of <\\entity><\\entity> was significantly associated with zidovudine (OR, 3.27 95% CI, 1.64-6.54, P = 0.0008) and peg-IFN (OR, 2.35; 95% CI, 1.16-4.57, P = 0.0179).",
    "Label": ""
  },
  {
    "id": "4414",
    "Sentence": "The risk of anaemia was lower in patients with higher baseline haemoglobin levels (OR, 0.35 95% CI, 0.26-0.49, P < 0.0001) and in patients receiving <\\entity><\\entity>-based antiretroviral therapy (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114).",
    "Label": ""
  },
  {
    "id": "4415",
    "Sentence": "The risk of <\\entity><\\entity> was lower in patients with higher baseline haemoglobin levels (OR, 0.35 95% CI, 0.26-0.49, P < 0.0001) and in patients receiving protease inhibitor-based antiretroviral therapy (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114).",
    "Label": ""
  },
  {
    "id": "4417",
    "Sentence": "<\\entity><\\entity> discontinuation could help to avoid anaemia associated with anti-HCV therapy.",
    "Label": ""
  },
  {
    "id": "4418",
    "Sentence": "Zidovudine discontinuation could help to avoid <\\entity><\\entity> associated with anti-HCV therapy.",
    "Label": ""
  },
  {
    "id": "4420",
    "Sentence": "In multivariate analysis the risk of anaemia was significantly associated with zidovudine (OR, 3.27 95% CI, 1.64-6.54, P = 0.0008) and <\\entity><\\entity> (OR, 2.35; 95% CI, 1.16-4.57, P = 0.0179).",
    "Label": ""
  },
  {
    "id": "4421",
    "Sentence": "In multivariate analysis the risk of <\\entity><\\entity> was significantly associated with zidovudine (OR, 3.27 95% CI, 1.64-6.54, P = 0.0008) and peg-IFN (OR, 2.35; 95% CI, 1.16-4.57, P = 0.0179).",
    "Label": ""
  },
  {
    "id": "4423",
    "Sentence": "Zidovudine discontinuation could help to avoid anaemia associated with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4424",
    "Sentence": "Zidovudine discontinuation could help to avoid <\\entity><\\entity> associated with anti-HCV therapy.",
    "Label": ""
  },
  {
    "id": "4426",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with <\\entity><\\entity> plus ribavirin.The most frequent and the most troublesome adverse effect of <\\entity><\\entity> plus ribavirin-based therapy is anaemia.",
    "Label": ""
  },
  {
    "id": "4427",
    "Sentence": "Risk factors for <\\entity><\\entity> in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4429",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with <\\entity><\\entity> plus ribavirin.The most frequent and the most troublesome adverse effect of <\\entity><\\entity> plus ribavirin-based therapy is anaemia.",
    "Label": ""
  },
  {
    "id": "4430",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/<\\entity><\\entity> virus-coinfected patients treated with interferon plus ribavirin.The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is anaemia.",
    "Label": ""
  },
  {
    "id": "4432",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus <\\entity><\\entity>.The most frequent and the most troublesome adverse effect of interferon plus <\\entity><\\entity>-based therapy is anaemia.",
    "Label": ""
  },
  {
    "id": "4433",
    "Sentence": "Risk factors for <\\entity><\\entity> in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4435",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus <\\entity><\\entity>.The most frequent and the most troublesome adverse effect of interferon plus <\\entity><\\entity>-based therapy is anaemia.",
    "Label": ""
  },
  {
    "id": "4436",
    "Sentence": "Risk factors for anaemia in human immunodeficiency virus/<\\entity><\\entity> virus-coinfected patients treated with interferon plus ribavirin.The most frequent and the most troublesome adverse effect of interferon plus ribavirin-based therapy is anaemia.",
    "Label": ""
  },
  {
    "id": "4438",
    "Sentence": "We reviewed all cases of anaemia occurring among 416 patients participating in a randomized, controlled 48-week trial comparing peginterferon (peg-IFN) alpha 2b plus ribavirin with <\\entity><\\entity> plus ribavirin.",
    "Label": ""
  },
  {
    "id": "4439",
    "Sentence": "We reviewed all cases of <\\entity><\\entity> occurring among 416 patients participating in a randomized, controlled 48-week trial comparing peginterferon (peg-IFN) alpha 2b plus ribavirin with interferon alpha-2b plus ribavirin.",
    "Label": ""
  },
  {
    "id": "4441",
    "Sentence": "We reviewed all cases of anaemia occurring among 416 patients participating in a randomized, controlled 48-week trial comparing peginterferon (peg-IFN) alpha 2b plus <\\entity><\\entity> with interferon alpha-2b plus <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4442",
    "Sentence": "We reviewed all cases of <\\entity><\\entity> occurring among 416 patients participating in a randomized, controlled 48-week trial comparing peginterferon (peg-IFN) alpha 2b plus ribavirin with interferon alpha-2b plus ribavirin.",
    "Label": ""
  },
  {
    "id": "4444",
    "Sentence": "We reviewed all cases of anaemia occurring among 416 patients participating in a randomized, controlled 48-week trial comparing peginterferon (<\\entity><\\entity> plus ribavirin with interferon alpha-2b plus ribavirin.",
    "Label": ""
  },
  {
    "id": "4445",
    "Sentence": "We reviewed all cases of <\\entity><\\entity> occurring among 416 patients participating in a randomized, controlled 48-week trial comparing peginterferon (peg-IFN) alpha 2b plus ribavirin with interferon alpha-2b plus ribavirin.",
    "Label": ""
  },
  {
    "id": "4447",
    "Sentence": "Univariate and multivariate analyses were used to identify links with <\\entity><\\entity>, HCV therapy and clinical and laboratory findings.",
    "Label": ""
  },
  {
    "id": "4448",
    "Sentence": "Univariate and multivariate analyses were used to identify links with antiretroviral treatments, <\\entity><\\entity> therapy and clinical and laboratory findings.",
    "Label": ""
  },
  {
    "id": "4450",
    "Sentence": "The risk of anaemia was lower in patients with higher baseline haemoglobin levels (OR, 0.35 95% CI, 0.26-0.49, P < 0.0001) and in patients receiving protease inhibitor-based <\\entity><\\entity> (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114).",
    "Label": ""
  },
  {
    "id": "4451",
    "Sentence": "The risk of <\\entity><\\entity> was lower in patients with higher baseline haemoglobin levels (OR, 0.35 95% CI, 0.26-0.49, P < 0.0001) and in patients receiving protease inhibitor-based antiretroviral therapy (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114).",
    "Label": ""
  },
  {
    "id": "4457",
    "Sentence": "The metabolism of the <\\entity><\\entity> ondansetron, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.The metabolism of the structurally related <\\entity><\\entity> ondansetron, alosetron and GR87442 in the rat, dog and human was determined in hepatocytes, liver microsomes and human recombinant microsomes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4458",
    "Sentence": "The metabolism of the 5HT3 antagonists <\\entity><\\entity>, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.The metabolism of the structurally related 5HT3 antagonists <\\entity><\\entity>, alosetron and GR87442 in the rat, dog and human was determined in hepatocytes, liver microsomes and human recombinant microsomes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4459",
    "Sentence": "The metabolism of the 5HT3 antagonists ondansetron, <\\entity><\\entity> and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.The metabolism of the structurally related 5HT3 antagonists ondansetron, <\\entity><\\entity> and GR87442 in the rat, dog and human was determined in hepatocytes, liver microsomes and human recombinant microsomes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4460",
    "Sentence": "The metabolism of the 5HT3 antagonists ondansetron, alosetron and <\\entity><\\entity> I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.The metabolism of the structurally related 5HT3 antagonists ondansetron, alosetron and <\\entity><\\entity> in the rat, dog and human was determined in hepatocytes, liver microsomes and human recombinant microsomes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4461",
    "Sentence": "The metabolism of the <\\entity><\\entity> ondansetron, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.The metabolism of the structurally related <\\entity><\\entity> ondansetron, alosetron and GR87442 in the rat, dog and human was determined in hepatocytes, liver microsomes and human recombinant microsomes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4462",
    "Sentence": "The metabolism of the 5HT3 antagonists <\\entity><\\entity>, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.The metabolism of the structurally related 5HT3 antagonists <\\entity><\\entity>, alosetron and GR87442 in the rat, dog and human was determined in hepatocytes, liver microsomes and human recombinant microsomes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4463",
    "Sentence": "The metabolism of the 5HT3 antagonists ondansetron, <\\entity><\\entity> and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.The metabolism of the structurally related 5HT3 antagonists ondansetron, <\\entity><\\entity> and GR87442 in the rat, dog and human was determined in hepatocytes, liver microsomes and human recombinant microsomes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4464",
    "Sentence": "The metabolism of the 5HT3 antagonists ondansetron, alosetron and <\\entity><\\entity> I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.The metabolism of the structurally related 5HT3 antagonists ondansetron, alosetron and <\\entity><\\entity> in the rat, dog and human was determined in hepatocytes, liver microsomes and human recombinant microsomes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4465",
    "Sentence": "The pharmacokinetics of the three <\\entity><\\entity> investigated were dominated by CYP3A4 (and/or 2C9) compared with CYP1A2 in man, possibly determined by enzyme capacity rather than relative enzyme affinity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4466",
    "Sentence": "The pharmacokinetics of the three 5HT3 antagonists investigated were dominated by <\\entity><\\entity> (and/or 2C9) compared with CYP1A2 in man, possibly determined by enzyme capacity rather than relative enzyme affinity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4467",
    "Sentence": "The pharmacokinetics of the three 5HT3 antagonists investigated were dominated by CYP3A4 (and/or <\\entity><\\entity>) compared with CYP1A2 in man, possibly determined by enzyme capacity rather than relative enzyme affinity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4468",
    "Sentence": "The pharmacokinetics of the three 5HT3 antagonists investigated were dominated by CYP3A4 (and/or 2C9) compared with <\\entity><\\entity> in man, possibly determined by enzyme capacity rather than relative enzyme affinity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4469",
    "Sentence": "These data support the use of rat, dog and human hepatocytes for the prediction of in vivo metabolites of <\\entity><\\entity>, alosetron and GR87442.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4470",
    "Sentence": "These data support the use of rat, dog and human hepatocytes for the prediction of in vivo metabolites of ondansetron, <\\entity><\\entity> and GR87442.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4471",
    "Sentence": "These data support the use of rat, dog and human hepatocytes for the prediction of in vivo metabolites of ondansetron, alosetron and <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4472",
    "Sentence": "The pharmacokinetics of the three <\\entity><\\entity> investigated were dominated by CYP3A4 (and/or 2C9) compared with CYP1A2 in man, possibly determined by enzyme capacity rather than relative enzyme affinity.",
    "Label": ""
  },
  {
    "id": "4473",
    "Sentence": "The pharmacokinetics of the three 5HT3 antagonists investigated were dominated by <\\entity><\\entity> (and/or 2C9) compared with CYP1A2 in man, possibly determined by enzyme capacity rather than relative enzyme affinity.",
    "Label": ""
  },
  {
    "id": "4475",
    "Sentence": "The pharmacokinetics of the three <\\entity><\\entity> investigated were dominated by CYP3A4 (and/or 2C9) compared with CYP1A2 in man, possibly determined by enzyme capacity rather than relative enzyme affinity.",
    "Label": ""
  },
  {
    "id": "4476",
    "Sentence": "The pharmacokinetics of the three 5HT3 antagonists investigated were dominated by CYP3A4 (and/or 2C9) compared with <\\entity><\\entity> in man, possibly determined by enzyme capacity rather than relative enzyme affinity.",
    "Label": ""
  },
  {
    "id": "4478",
    "Sentence": "The pharmacokinetics of the three <\\entity><\\entity> investigated were dominated by CYP3A4 (and/or 2C9) compared with CYP1A2 in man, possibly determined by enzyme capacity rather than relative enzyme affinity.",
    "Label": ""
  },
  {
    "id": "4479",
    "Sentence": "The pharmacokinetics of the three 5HT3 antagonists investigated were dominated by CYP3A4 (and/or <\\entity><\\entity>) compared with CYP1A2 in man, possibly determined by enzyme capacity rather than relative enzyme affinity.",
    "Label": ""
  },
  {
    "id": "4485",
    "Sentence": "Cytotoxic <\\entity><\\entity> and pregnane glycosides from Tribulus macropterus.The methanol extract of the whole parts of Tribulus macropterus Boiss.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4486",
    "Sentence": "Cytotoxic cholestane and <\\entity><\\entity> from Tribulus macropterus.The methanol extract of the whole parts of Tribulus macropterus Boiss.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4487",
    "Sentence": "Cytotoxic cholestane and pregnane glycosides from Tribulus macropterus.The <\\entity><\\entity> of the whole parts of Tribulus macropterus Boiss.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4488",
    "Sentence": "(family Zygophyllaceae) showed cytotoxic activity against a human <\\entity><\\entity> cell line (hepatocyte generation 2, HepG2) (IC50 = 2.9 microg/ml).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4489",
    "Sentence": "The <\\entity><\\entity> obtained from successive fractionation of the methanolic extract exhibited activity against HepG2 (IC50 = 2.6 microg/ml).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4490",
    "Sentence": "The n-butanolic fraction obtained from successive fractionation of the <\\entity><\\entity> exhibited activity against HepG2 (IC50 = 2.6 microg/ml).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4491",
    "Sentence": "Therefore, this fraction was subjected to <\\entity><\\entity> using different chromatographic techniques.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4492",
    "Sentence": "Five compounds, 1-5, were isolated and identified as: <\\entity><\\entity> (1), (22S,25S)-16beta,22,26-trihydroxy-cholest-4-en-3-one-16-O-beta-D-glucopyranosyl-(1-->3)-beta-D-glucopyranoside (2), sucrose (3), D-pinitol (4) and 3beta-hydroxy-5a-pregn-16(17)en-20-one-3-O-beta-D-xylopyranosyl-(1-->2)-[beta-D-xylopyranosyl-(1-->3)]-beta-D-glucopyranosyl-(1-->4)-[alpha-L-rhamnopyranosyl-(1-->2)]-beta-D-ga-lactopyranoside (5) on the basis of spectroscopic and chemical data.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4493",
    "Sentence": "Five compounds, 1-5, were isolated and identified as: (22S,25S)-16beta,22,26-trihydroxy-cholest-4-en-3-one-16-O-beta-D-glucopyranosyl-(1-->3)-beta-D-xylopyranoside (1), <\\entity><\\entity> (2), sucrose (3), D-pinitol (4) and 3beta-hydroxy-5a-pregn-16(17)en-20-one-3-O-beta-D-xylopyranosyl-(1-->2)-[beta-D-xylopyranosyl-(1-->3)]-beta-D-glucopyranosyl-(1-->4)-[alpha-L-rhamnopyranosyl-(1-->2)]-beta-D-ga-lactopyranoside (5) on the basis of spectroscopic and chemical data.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4494",
    "Sentence": "Five compounds, 1-5, were isolated and identified as: (22S,25S)-16beta,22,26-trihydroxy-cholest-4-en-3-one-16-O-beta-D-glucopyranosyl-(1-->3)-beta-D-xylopyranoside (1), (22S,25S)-16beta,22,26-trihydroxy-cholest-4-en-3-one-16-O-beta-D-glucopyranosyl-(1-->3)-beta-D-glucopyranoside (2), <\\entity><\\entity> (3), D-pinitol (4) and 3beta-hydroxy-5a-pregn-16(17)en-20-one-3-O-beta-D-xylopyranosyl-(1-->2)-[beta-D-xylopyranosyl-(1-->3)]-beta-D-glucopyranosyl-(1-->4)-[alpha-L-rhamnopyranosyl-(1-->2)]-beta-D-ga-lactopyranoside (5) on the basis of spectroscopic and chemical data.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4495",
    "Sentence": "Five compounds, 1-5, were isolated and identified as: (22S,25S)-16beta,22,26-trihydroxy-cholest-4-en-3-one-16-O-beta-D-glucopyranosyl-(1-->3)-beta-D-xylopyranoside (1), (22S,25S)-16beta,22,26-trihydroxy-cholest-4-en-3-one-16-O-beta-D-glucopyranosyl-(1-->3)-beta-D-glucopyranoside (2), sucrose (3), <\\entity><\\entity> (4) and 3beta-hydroxy-5a-pregn-16(17)en-20-one-3-O-beta-D-xylopyranosyl-(1-->2)-[beta-D-xylopyranosyl-(1-->3)]-beta-D-glucopyranosyl-(1-->4)-[alpha-L-rhamnopyranosyl-(1-->2)]-beta-D-ga-lactopyranoside (5) on the basis of spectroscopic and chemical data.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4496",
    "Sentence": "Five compounds, 1-5, were isolated and identified as: (22S,25S)-16beta,22,26-trihydroxy-cholest-4-en-3-one-16-O-beta-D-glucopyranosyl-(1-->3)-beta-D-xylopyranoside (1), (22S,25S)-16beta,22,26-trihydroxy-cholest-4-en-3-one-16-O-beta-D-glucopyranosyl-(1-->3)-beta-D-glucopyranoside (2), sucrose (3), D-pinitol (4) and <\\entity><\\entity> (5) on the basis of spectroscopic and chemical data.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4497",
    "Sentence": "The three <\\entity><\\entity> 1, 2 and 5 were also tested against the same cell line HepG2 and their IC50 values were 2.4, 2.2 and 1.1 microg/ml, respectively.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4498",
    "Sentence": "Cytotoxic cholestane and pregnane glycosides from Tribulus macropterus.The <\\entity><\\entity> of the whole parts of Tribulus macropterus Boiss.",
    "Label": ""
  },
  {
    "id": "4499",
    "Sentence": "(family Zygophyllaceae) showed cytotoxic activity against a human <\\entity><\\entity> cell line (hepatocyte generation 2, HepG2) (IC50 = 2.9 microg/ml).",
    "Label": ""
  },
  {
    "id": "4505",
    "Sentence": "<\\entity><\\entity> complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription.BACKGROUND: Enhanced removal of cisplatin-DNA adducts has been reported as one of main causes of cell resistance to cisplatin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4506",
    "Sentence": "Trans-platinum(II) complexes with <\\entity><\\entity> as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription.BACKGROUND: Enhanced removal of cisplatin-DNA adducts has been reported as one of main causes of cell resistance to cisplatin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4507",
    "Sentence": "Trans-platinum(II) complexes with cyclohexylamine as <\\entity><\\entity> induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription.BACKGROUND: Enhanced removal of cisplatin-DNA adducts has been reported as one of main causes of cell resistance to cisplatin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4508",
    "Sentence": "Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce <\\entity><\\entity> in tumour cells by inhibiting DNA synthesis and RNA transcription.BACKGROUND: Enhanced removal of cisplatin-DNA adducts has been reported as one of main causes of cell resistance to cisplatin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4509",
    "Sentence": "Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in <\\entity><\\entity> cells by inhibiting DNA synthesis and RNA transcription.BACKGROUND: Enhanced removal of cisplatin-DNA adducts has been reported as one of main causes of cell resistance to cisplatin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4510",
    "Sentence": "Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription.BACKGROUND: Enhanced removal of <\\entity><\\entity>-DNA adducts has been reported as one of main causes of cell resistance to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4511",
    "Sentence": "Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription.BACKGROUND: Enhanced removal of <\\entity><\\entity>-DNA adducts has been reported as one of main causes of cell resistance to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4512",
    "Sentence": "This particular resistance mechanism may be circumvented by <\\entity><\\entity> that bind differently to DNA.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4513",
    "Sentence": "One line of work is focussed on <\\entity><\\entity>, some of which exhibit antitumour activity similar to or even higher than that of their cis counterparts.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4514",
    "Sentence": "METHODS: We synthesised new <\\entity><\\entity>, trans-[PtCl2(cyclohexylamine)(dimethylamine)] and trans-[PtCl2(OH)2(cyclohexylamine)(dimethylamine)], previously evaluated as cytotoxic agents towards different cancer and normal cell lines.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4515",
    "Sentence": "METHODS: We synthesised new trans platinum complexes, <\\entity><\\entity> and trans-[PtCl2(OH)2(cyclohexylamine)(dimethylamine)], previously evaluated as cytotoxic agents towards different cancer and normal cell lines.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4516",
    "Sentence": "METHODS: We synthesised new trans platinum complexes, trans-[PtCl2(cyclohexylamine)(dimethylamine)] and <\\entity><\\entity>, previously evaluated as cytotoxic agents towards different cancer and normal cell lines.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4517",
    "Sentence": "METHODS: We synthesised new trans platinum complexes, trans-[PtCl2(cyclohexylamine)(dimethylamine)] and trans-[PtCl2(OH)2(cyclohexylamine)(dimethylamine)], previously evaluated as <\\entity><\\entity> towards different cancer and normal cell lines.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4518",
    "Sentence": "METHODS: We synthesised new trans platinum complexes, trans-[PtCl2(cyclohexylamine)(dimethylamine)] and trans-[PtCl2(OH)2(cyclohexylamine)(dimethylamine)], previously evaluated as cytotoxic agents towards different <\\entity><\\entity> and normal cell lines.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4519",
    "Sentence": "These <\\entity><\\entity> were highly effective against a panel of tumoral cell lines either sensitive to or with acquired resistance to cisplatin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4520",
    "Sentence": "These trans platinum compounds were highly effective against a panel of <\\entity><\\entity> either sensitive to or with acquired resistance to cisplatin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4521",
    "Sentence": "These trans platinum compounds were highly effective against a panel of tumoral cell lines either sensitive to or with acquired resistance to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4522",
    "Sentence": "RESULTS: In the present work we examined the mechanisms induced by these compounds to cause <\\entity><\\entity> cells toxicity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4523",
    "Sentence": "CONCLUSION: In contrast to other <\\entity><\\entity> agents, these compounds do not induce senescence-associated permanent arrest.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4524",
    "Sentence": "Furthermore, only a small percentage of these cells enter into apoptosis, with most of the population dying by a <\\entity><\\entity>-like mechanism.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4525",
    "Sentence": "These trans platinum compounds were highly effective against a panel of tumoral cell lines either sensitive to or with acquired resistance to <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4526",
    "Sentence": "These trans platinum compounds were highly effective against a panel of <\\entity><\\entity> either sensitive to or with acquired resistance to cisplatin.",
    "Label": ""
  },
  {
    "id": "4528",
    "Sentence": "These <\\entity><\\entity> were highly effective against a panel of tumoral cell lines either sensitive to or with acquired resistance to cisplatin.",
    "Label": ""
  },
  {
    "id": "4529",
    "Sentence": "These trans platinum compounds were highly effective against a panel of <\\entity><\\entity> either sensitive to or with acquired resistance to cisplatin.",
    "Label": ""
  },
  {
    "id": "4531",
    "Sentence": "<\\entity><\\entity> complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription.BACKGROUND: Enhanced removal of cisplatin-DNA adducts has been reported as one of main causes of cell resistance to cisplatin.",
    "Label": ""
  },
  {
    "id": "4532",
    "Sentence": "Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in <\\entity><\\entity> cells by inhibiting DNA synthesis and RNA transcription.BACKGROUND: Enhanced removal of cisplatin-DNA adducts has been reported as one of main causes of cell resistance to cisplatin.",
    "Label": ""
  },
  {
    "id": "4534",
    "Sentence": "Trans-platinum(II) complexes with cyclohexylamine as <\\entity><\\entity> induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription.BACKGROUND: Enhanced removal of cisplatin-DNA adducts has been reported as one of main causes of cell resistance to cisplatin.",
    "Label": ""
  },
  {
    "id": "4535",
    "Sentence": "Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in <\\entity><\\entity> cells by inhibiting DNA synthesis and RNA transcription.BACKGROUND: Enhanced removal of cisplatin-DNA adducts has been reported as one of main causes of cell resistance to cisplatin.",
    "Label": ""
  },
  {
    "id": "4537",
    "Sentence": "METHODS: We synthesised new <\\entity><\\entity>, trans-[PtCl2(cyclohexylamine)(dimethylamine)] and trans-[PtCl2(OH)2(cyclohexylamine)(dimethylamine)], previously evaluated as cytotoxic agents towards different cancer and normal cell lines.",
    "Label": ""
  },
  {
    "id": "4538",
    "Sentence": "METHODS: We synthesised new trans platinum complexes, trans-[PtCl2(cyclohexylamine)(dimethylamine)] and trans-[PtCl2(OH)2(cyclohexylamine)(dimethylamine)], previously evaluated as cytotoxic agents towards different <\\entity><\\entity> and normal cell lines.",
    "Label": ""
  },
  {
    "id": "4540",
    "Sentence": "METHODS: We synthesised new trans platinum complexes, <\\entity><\\entity> and trans-[PtCl2(OH)2(cyclohexylamine)(dimethylamine)], previously evaluated as cytotoxic agents towards different cancer and normal cell lines.",
    "Label": ""
  },
  {
    "id": "4541",
    "Sentence": "METHODS: We synthesised new trans platinum complexes, trans-[PtCl2(cyclohexylamine)(dimethylamine)] and trans-[PtCl2(OH)2(cyclohexylamine)(dimethylamine)], previously evaluated as cytotoxic agents towards different <\\entity><\\entity> and normal cell lines.",
    "Label": ""
  },
  {
    "id": "4543",
    "Sentence": "METHODS: We synthesised new trans platinum complexes, trans-[PtCl2(cyclohexylamine)(dimethylamine)] and <\\entity><\\entity>, previously evaluated as cytotoxic agents towards different cancer and normal cell lines.",
    "Label": ""
  },
  {
    "id": "4544",
    "Sentence": "METHODS: We synthesised new trans platinum complexes, trans-[PtCl2(cyclohexylamine)(dimethylamine)] and trans-[PtCl2(OH)2(cyclohexylamine)(dimethylamine)], previously evaluated as cytotoxic agents towards different <\\entity><\\entity> and normal cell lines.",
    "Label": ""
  },
  {
    "id": "4546",
    "Sentence": "METHODS: We synthesised new trans platinum complexes, trans-[PtCl2(cyclohexylamine)(dimethylamine)] and trans-[PtCl2(OH)2(cyclohexylamine)(dimethylamine)], previously evaluated as <\\entity><\\entity> towards different cancer and normal cell lines.",
    "Label": ""
  },
  {
    "id": "4547",
    "Sentence": "METHODS: We synthesised new trans platinum complexes, trans-[PtCl2(cyclohexylamine)(dimethylamine)] and trans-[PtCl2(OH)2(cyclohexylamine)(dimethylamine)], previously evaluated as cytotoxic agents towards different <\\entity><\\entity> and normal cell lines.",
    "Label": ""
  },
  {
    "id": "4553",
    "Sentence": "<\\entity><\\entity>: a rare cause of stomal hemorrhage.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4554",
    "Sentence": "Stomal varices: a rare cause of stomal <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4555",
    "Sentence": "A report of three cases.<\\entity><\\entity> are a rare but potentially fatal cause of hemorrhage.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4556",
    "Sentence": "A report of three cases.Stomal varices <\\entity><\\entity> to portal hypertension are a rare but potentially fatal cause of hemorrhage.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4557",
    "Sentence": "A report of three cases.Stomal varices secondary to portal hypertension are a rare but potentially fatal cause of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4558",
    "Sentence": "Management, determined by the site of the bleeding, centers on preventing additional bleeds and may include providing local pressure, applying <\\entity><\\entity>, injection sclerotherapy, suture ligation of the bleeding point, and/or the placement of transjugular intrahepatic portosystemic shunts and refashioning the stoma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4559",
    "Sentence": "Management, determined by the site of the bleeding, centers on preventing additional bleeds and may include providing local pressure, applying silver nitrate, injection <\\entity><\\entity>, suture ligation of the bleeding point, and/or the placement of transjugular intrahepatic portosystemic shunts and refashioning the stoma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4560",
    "Sentence": "Two patients (60- and 69-year-old women) had panproctocolectomy for <\\entity><\\entity> and presented at the authors' hospital with bleeding from the ileostomy 1 and 19 years, respectively, following the creation of their stomas.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4561",
    "Sentence": "A third patient (a 72-year-old man) <\\entity><\\entity> from an end colostomy following an abdominoperineal resection for Duke's C rectal adenocarcinoma performed 3 years previous.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4562",
    "Sentence": "A third patient (a 72-year-old man) bled from an end <\\entity><\\entity> following an abdominoperineal resection for Duke's C rectal adenocarcinoma performed 3 years previous.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4563",
    "Sentence": "A third patient (a 72-year-old man) bled from an end colostomy following an abdominoperineal resection for <\\entity><\\entity> performed 3 years previous.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4564",
    "Sentence": "All three patients had recurrent admissions for <\\entity><\\entity> and stomal varices secondary to portal hypertension and were initially treated with local measures (pressure, silver nitrate, and suture ligation).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4565",
    "Sentence": "All three patients had recurrent admissions for stomal bleeding and <\\entity><\\entity> and were initially treated with local measures (pressure, silver nitrate, and suture ligation).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4566",
    "Sentence": "All three patients had recurrent admissions for stomal bleeding and stomal varices <\\entity><\\entity> to portal hypertension and were initially treated with local measures (pressure, silver nitrate, and suture ligation).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4567",
    "Sentence": "All three patients had recurrent admissions for stomal bleeding and stomal varices secondary to portal hypertension and were initially treated with local measures (pressure, <\\entity><\\entity>, and suture ligation).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4568",
    "Sentence": "One patient responded to local treatment but later died due to <\\entity><\\entity>, one stopped bleeding after transjugular portosystemic shunt placement, and one died from metastatic cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4569",
    "Sentence": "One patient responded to local treatment but later died due to liver failure, one stopped bleeding after transjugular portosystemic shunt placement, and one died from <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4570",
    "Sentence": "Clinicians should maintain a high index of suspicion of <\\entity><\\entity> in patients with underlying liver disease who present with recurrent stomal bleeds and provide appropriate treatment to stop active bleeding and reduce portal venous pressure.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4571",
    "Sentence": "Clinicians should maintain a high index of suspicion of stomal varices in patients with underlying <\\entity><\\entity> who present with recurrent stomal bleeds and provide appropriate treatment to stop active bleeding and reduce portal venous pressure.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4572",
    "Sentence": "Clinicians should maintain a high index of suspicion of stomal varices in patients with underlying liver disease who present with recurrent <\\entity><\\entity> and provide appropriate treatment to stop active bleeding and reduce portal venous pressure.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4573",
    "Sentence": "All three patients had recurrent admissions for stomal bleeding and stomal varices secondary to portal hypertension and were initially treated with local measures (pressure, <\\entity><\\entity>, and suture ligation).",
    "Label": ""
  },
  {
    "id": "4574",
    "Sentence": "All three patients had recurrent admissions for <\\entity><\\entity> and stomal varices secondary to portal hypertension and were initially treated with local measures (pressure, silver nitrate, and suture ligation).",
    "Label": ""
  },
  {
    "id": "4576",
    "Sentence": "All three patients had recurrent admissions for stomal bleeding and stomal varices secondary to portal hypertension and were initially treated with local measures (pressure, <\\entity><\\entity>, and suture ligation).",
    "Label": ""
  },
  {
    "id": "4577",
    "Sentence": "All three patients had recurrent admissions for stomal bleeding and <\\entity><\\entity> and were initially treated with local measures (pressure, silver nitrate, and suture ligation).",
    "Label": ""
  },
  {
    "id": "4579",
    "Sentence": "All three patients had recurrent admissions for stomal bleeding and stomal varices secondary to portal hypertension and were initially treated with local measures (pressure, <\\entity><\\entity>, and suture ligation).",
    "Label": ""
  },
  {
    "id": "4580",
    "Sentence": "All three patients had recurrent admissions for stomal bleeding and stomal varices <\\entity><\\entity> to portal hypertension and were initially treated with local measures (pressure, silver nitrate, and suture ligation).",
    "Label": ""
  },
  {
    "id": "4586",
    "Sentence": "<\\entity><\\entity> and Bcl-2 mutually affect the expression of the other in T cells.The life and death of T cells is controlled to a large extent by the relative amounts of Bcl-2-related proteins they contain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4587",
    "Sentence": "Bim and <\\entity><\\entity> mutually affect the expression of the other in T cells.The life and death of T cells is controlled to a large extent by the relative amounts of <\\entity><\\entity>-related proteins they contain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4588",
    "Sentence": "Bim and Bcl-2 mutually affect the expression of the other in T cells.The life and death of T cells is controlled to a large extent by the relative amounts of <\\entity><\\entity> they contain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4589",
    "Sentence": "The <\\entity><\\entity> and the proapoptotic protein Bim are particularly important in this process with the amount of Bcl-2 per cell dropping by about one-half when T cells prepare to die.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4590",
    "Sentence": "The antiapoptotic protein Bcl-2 and the <\\entity><\\entity> are particularly important in this process with the amount of Bcl-2 per cell dropping by about one-half when T cells prepare to die.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4591",
    "Sentence": "The antiapoptotic protein <\\entity><\\entity> and the proapoptotic protein Bim are particularly important in this process with the amount of <\\entity><\\entity> per cell dropping by about one-half when T cells prepare to die.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4592",
    "Sentence": "In this study we show that <\\entity><\\entity> and Bim each control the expression of the other.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4593",
    "Sentence": "In this study we show that Bcl-2 and <\\entity><\\entity> each control the expression of the other.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4594",
    "Sentence": "Absence of <\\entity><\\entity> leads to a drop in the amount of intracellular Bcl-2 protein, while having no effect on the amounts of mRNA for Bcl-2.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4595",
    "Sentence": "Absence of Bim leads to a drop in the amount of intracellular <\\entity><\\entity> protein, while having no effect on the amounts of mRNA for <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4596",
    "Sentence": "Absence of Bim leads to a drop in the amount of intracellular <\\entity><\\entity> protein, while having no effect on the amounts of mRNA for <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4597",
    "Sentence": "Conversely, high amounts of <\\entity><\\entity> per cell allow high amounts of Bim, although in this case the effect involves increases in Bim mRNA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4598",
    "Sentence": "Conversely, high amounts of Bcl-2 per cell allow high amounts of <\\entity><\\entity>, although in this case the effect involves increases in <\\entity><\\entity> mRNA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4599",
    "Sentence": "Conversely, high amounts of Bcl-2 per cell allow high amounts of <\\entity><\\entity>, although in this case the effect involves increases in <\\entity><\\entity> mRNA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4600",
    "Sentence": "These mutual effects occur even if <\\entity><\\entity> is induced acutely.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4605",
    "Sentence": "Drug insight: effects mediated by <\\entity><\\entity> in CNS disorders.The finding that activation of <\\entity><\\entity> (PPARgamma) suppresses inflammation in peripheral macrophages and in models of human autoimmune disease instigated the evaluation of this salutary action for the treatment of CNS disorders with an inflammatory component.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4606",
    "Sentence": "Drug insight: effects mediated by <\\entity><\\entity> in CNS disorders.The finding that activation of <\\entity><\\entity> (PPARgamma) suppresses inflammation in peripheral macrophages and in models of human autoimmune disease instigated the evaluation of this salutary action for the treatment of CNS disorders with an inflammatory component.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4607",
    "Sentence": "Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders.The finding that activation of peroxisome proliferator-activated receptor-gamma (<\\entity><\\entity>) suppresses inflammation in peripheral macrophages and in models of human autoimmune disease instigated the evaluation of this salutary action for the treatment of CNS disorders with an inflammatory component.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4608",
    "Sentence": "The fact that <\\entity><\\entity> delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating PPARgamma, led to the hypothesis that one dimension of NSAID protection in AD is mediated by PPARgamma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4609",
    "Sentence": "The fact that NSAIDs delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating <\\entity><\\entity>, led to the hypothesis that one dimension of NSAID protection in AD is mediated by <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4610",
    "Sentence": "The fact that <\\entity><\\entity>s delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating PPARgamma, led to the hypothesis that one dimension of <\\entity><\\entity> protection in AD is mediated by PPARgamma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4611",
    "Sentence": "The fact that NSAIDs delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating <\\entity><\\entity>, led to the hypothesis that one dimension of NSAID protection in AD is mediated by <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4612",
    "Sentence": "The capacity of <\\entity><\\entity> to elicit anti-inflammatory, anti-amyloidogenic and insulin-sensitizing effects might account for their observed protective effects.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4613",
    "Sentence": "The capacity of <\\entity><\\entity> to elicit anti-inflammatory, anti-amyloidogenic and insulin-sensitizing effects might account for their observed protective effects.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4614",
    "Sentence": "The capacity of PPARgamma agonists to elicit anti-inflammatory, anti-amyloidogenic and <\\entity><\\entity>-sensitizing effects might account for their observed protective effects.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4615",
    "Sentence": "Several clinical trials employing <\\entity><\\entity> have yielded promising results, and further trials are in preparation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4616",
    "Sentence": "Several clinical trials employing <\\entity><\\entity> have yielded promising results, and further trials are in preparation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4617",
    "Sentence": "Positive outcomes following <\\entity><\\entity> administration have been obtained in animal models of other neurodegenerative diseases, including Parkinson's disease and amyotrophic lateral sclerosis, both of which are associated with a considerable degree of neuroinflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4618",
    "Sentence": "Finally, activation of <\\entity><\\entity> has been found to be protective in several models of multiple sclerosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4619",
    "Sentence": "The verification of these findings in human cells prompted the initiation of clinical studies evaluating <\\entity><\\entity> activation in patients with multiple sclerosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4620",
    "Sentence": "The fact that <\\entity><\\entity> delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating PPARgamma, led to the hypothesis that one dimension of NSAID protection in AD is mediated by PPARgamma.",
    "Label": ""
  },
  {
    "id": "4621",
    "Sentence": "The fact that NSAIDs delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating <\\entity><\\entity>, led to the hypothesis that one dimension of NSAID protection in AD is mediated by <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4623",
    "Sentence": "The fact that <\\entity><\\entity>s delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating PPARgamma, led to the hypothesis that one dimension of <\\entity><\\entity> protection in AD is mediated by PPARgamma.",
    "Label": ""
  },
  {
    "id": "4624",
    "Sentence": "The fact that NSAIDs delay the onset of and reduce the risk of developing Alzheimer's disease (AD), while also binding to and activating <\\entity><\\entity>, led to the hypothesis that one dimension of NSAID protection in AD is mediated by <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4630",
    "Sentence": "Identification of <\\entity><\\entity> as a novel Smad-binding modulator of BMP signaling expressed in cartilage.Bone morphogenetic proteins (BMP) play a prominent role in cartilage tissue homeostasis and perturbations of BMP signaling contribute to pathological processes like osteoarthritis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4631",
    "Sentence": "Identification of calponin 3 as a novel <\\entity><\\entity> of BMP signaling expressed in cartilage.Bone morphogenetic proteins (BMP) play a prominent role in cartilage tissue homeostasis and perturbations of BMP signaling contribute to pathological processes like osteoarthritis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4632",
    "Sentence": "Identification of calponin 3 as a novel Smad-binding modulator of <\\entity><\\entity> signaling expressed in cartilage.Bone morphogenetic proteins (<\\entity><\\entity>) play a prominent role in cartilage tissue homeostasis and perturbations of <\\entity><\\entity> signaling contribute to pathological processes like osteoarthritis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4633",
    "Sentence": "Identification of calponin 3 as a novel Smad-binding modulator of BMP signaling expressed in cartilage.<\\entity><\\entity> (BMP) play a prominent role in cartilage tissue homeostasis and perturbations of BMP signaling contribute to pathological processes like osteoarthritis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4634",
    "Sentence": "Identification of calponin 3 as a novel Smad-binding modulator of <\\entity><\\entity> signaling expressed in cartilage.Bone morphogenetic proteins (<\\entity><\\entity>) play a prominent role in cartilage tissue homeostasis and perturbations of <\\entity><\\entity> signaling contribute to pathological processes like osteoarthritis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4635",
    "Sentence": "Identification of calponin 3 as a novel Smad-binding modulator of <\\entity><\\entity> signaling expressed in cartilage.Bone morphogenetic proteins (<\\entity><\\entity>) play a prominent role in cartilage tissue homeostasis and perturbations of <\\entity><\\entity> signaling contribute to pathological processes like osteoarthritis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4636",
    "Sentence": "The response to <\\entity><\\entity> is determined by intracellular proteins interacting with the signal mediators Smads 1 and 5.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4637",
    "Sentence": "The response to BMP is determined by intracellular proteins interacting with the signal mediators <\\entity><\\entity> 1 and 5.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4638",
    "Sentence": "The response to BMP is determined by intracellular proteins interacting with the signal mediators Smads 1 and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4639",
    "Sentence": "Applying the yeast two-hybrid technique we could identify the <\\entity><\\entity> calponin 3 as a novel Smad-binding protein expressed in chondrocytes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4640",
    "Sentence": "Applying the yeast two-hybrid technique we could identify the actin-binding protein <\\entity><\\entity> as a novel Smad-binding protein expressed in chondrocytes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4641",
    "Sentence": "Applying the yeast two-hybrid technique we could identify the actin-binding protein calponin 3 as a novel <\\entity><\\entity> expressed in chondrocytes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4642",
    "Sentence": "It interacted with <\\entity><\\entity> 1 and 5 and overexpression led to an attenuation of BMP-dependent transcription.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4643",
    "Sentence": "It interacted with Smads 1 and <\\entity><\\entity> and overexpression led to an attenuation of BMP-dependent transcription.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4644",
    "Sentence": "It interacted with Smads 1 and 5 and overexpression led to an attenuation of <\\entity><\\entity>-dependent transcription.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4645",
    "Sentence": "<\\entity><\\entity> mRNA and protein were expressed in cartilage tissue and isolated chondrocytes and a slight, but statistically significant reduction of mRNA expression levels could be detected in osteoarthritic cartilage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4646",
    "Sentence": "Our results suggest a role of <\\entity><\\entity> in the regulation of BMP-dependent cellular responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4647",
    "Sentence": "Our results suggest a role of calponin 3 in the regulation of <\\entity><\\entity>-dependent cellular responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4648",
    "Sentence": "By interaction with the <\\entity><\\entity> and 5 and the inhibition of BMP-induced transcription, calponin 3 provides a negative regulatory mechanism for the BMP signaling pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4649",
    "Sentence": "By interaction with the Smad proteins 1 and <\\entity><\\entity> and the inhibition of BMP-induced transcription, calponin 3 provides a negative regulatory mechanism for the BMP signaling pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4650",
    "Sentence": "By interaction with the Smad proteins 1 and 5 and the inhibition of <\\entity><\\entity>-induced transcription, calponin 3 provides a negative regulatory mechanism for the <\\entity><\\entity> signaling pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4651",
    "Sentence": "By interaction with the Smad proteins 1 and 5 and the inhibition of BMP-induced transcription, <\\entity><\\entity> provides a negative regulatory mechanism for the BMP signaling pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4652",
    "Sentence": "By interaction with the Smad proteins 1 and 5 and the inhibition of <\\entity><\\entity>-induced transcription, calponin 3 provides a negative regulatory mechanism for the <\\entity><\\entity> signaling pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4653",
    "Sentence": "This inhibitory effect likely depends on a sequestration of the <\\entity><\\entity> to the cytoskeleton due to the actin-binding properties of calponin 3.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4654",
    "Sentence": "This inhibitory effect likely depends on a sequestration of the Smads to the cytoskeleton due to the <\\entity><\\entity>-binding properties of calponin 3.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4655",
    "Sentence": "This inhibitory effect likely depends on a sequestration of the Smads to the cytoskeleton due to the actin-binding properties of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4656",
    "Sentence": "The down-regulation of <\\entity><\\entity> expression in osteoarthritic joints could contribute to the increased responsiveness to BMPs described previously.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4657",
    "Sentence": "The down-regulation of calponin 3 expression in osteoarthritic joints could contribute to the increased responsiveness to <\\entity><\\entity> described previously.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4658",
    "Sentence": "Furthermore, our data provide a possible explanation for the effect of the related protein <\\entity><\\entity> on bone and cartilage development.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4663",
    "Sentence": "PET tracers for <\\entity><\\entity> receptors and uses thereof.The serotonin <\\entity><\\entity> receptor is implicated in the pathophysiology of major neuropsychiatric disorders, including depression, suicidal behavior, panic disorder, epilepsy, bulimia, schizophrenia, Parkinson's disease, and Alzheimer's disease and is, therefore, an important target for drug therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4664",
    "Sentence": "PET tracers for <\\entity><\\entity> receptors and uses thereof.The serotonin <\\entity><\\entity> receptor is implicated in the pathophysiology of major neuropsychiatric disorders, including depression, suicidal behavior, panic disorder, epilepsy, bulimia, schizophrenia, Parkinson's disease, and Alzheimer's disease and is, therefore, an important target for drug therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4665",
    "Sentence": "<\\entity><\\entity> receptors are expressed as somatodendritic autoreceptors in serotonin neurons of the raphÃ© nuclei (presynaptic) and as postsynaptic receptors in cortical and subcortical serotonin terminal fields in the brain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4666",
    "Sentence": "Here, we review the PET radioligands employed for imaging<\\entity><\\entity>) receptors in living brain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4671",
    "Sentence": "Extension of <\\entity><\\entity> through the luteal phase to improve the outcome of intracytoplasmic sperm injection.OBJECTIVE: To investigate the effect of continuous administration of gonadotropin-releasing hormone agonist (GnRHa) during the luteal phase in an intracytoplasmic sperm injection program.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4672",
    "Sentence": "Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection.OBJECTIVE: To investigate the effect of continuous administration of <\\entity><\\entity> (GnRHa) during the luteal phase in an intracytoplasmic sperm injection program.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4673",
    "Sentence": "Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection.OBJECTIVE: To investigate the effect of continuous administration of gonadotropin-releasing hormone agonist (<\\entity><\\entity>) during the luteal phase in an intracytoplasmic sperm injection program.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4674",
    "Sentence": "STUDY DESIGN: One hundred eighty-one women underwent a down-regulation protocol of <\\entity><\\entity> administered from the 21st day of the preceding cycle.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4675",
    "Sentence": "Group 1 patients (n = 90) were continuously administered <\\entity><\\entity> for 12 days after embryo transfer, while in group 2 patients <\\entity><\\entity> was stopped on the day of human chorionic gonadotropin administration.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4676",
    "Sentence": "Group 1 patients (n = 90) were continuously administered <\\entity><\\entity> for 12 days after embryo transfer, while in group 2 patients <\\entity><\\entity> was stopped on the day of human chorionic gonadotropin administration.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4677",
    "Sentence": "Group 1 patients (n = 90) were continuously administered GnRHa for 12 days after embryo transfer, while in group 2 patients GnRHa was stopped on the day of <\\entity><\\entity> administration.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4678",
    "Sentence": "CONCLUSION: Extending <\\entity><\\entity> treatment through the luteal phase appeared not to have a significant impact on pregnancy or implantation rates in intracytoplasmic sperm injection cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4683",
    "Sentence": "Development of a real-time PCR assay for the diagnosis of <\\entity><\\entity> cases in India and evidence of the prevalence of new genotype of O.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4684",
    "Sentence": "<\\entity><\\entity>.A qualitative syber green real-time PCR with primers designed for a truncated portion of the 56kDa major outer membrane antigen gene of Orientia <\\entity><\\entity> was used to diagnose scrub typhus from the blood or serum of suspected patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4685",
    "Sentence": "<\\entity><\\entity>.A qualitative syber green real-time PCR with primers designed for a truncated portion of the 56kDa major outer membrane antigen gene of Orientia <\\entity><\\entity> was used to diagnose scrub typhus from the blood or serum of suspected patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4686",
    "Sentence": "<\\entity><\\entity>.A qualitative syber green real-time PCR with primers designed for a truncated portion of the 56kDa major outer membrane antigen gene of Orientia <\\entity><\\entity> was used to diagnose scrub typhus from the blood or serum of suspected patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4687",
    "Sentence": "<\\entity><\\entity>.A qualitative syber green real-time PCR with primers designed for a truncated portion of the 56kDa major outer membrane antigen gene of Orientia <\\entity><\\entity> was used to diagnose scrub typhus from the blood or serum of suspected patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4688",
    "Sentence": "tsutsugamushi.A qualitative syber green real-time PCR with primers designed for a truncated portion of the 56kDa major outer membrane antigen gene of Orientia tsutsugamushi was used to diagnose <\\entity><\\entity> from the blood or serum of suspected patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4689",
    "Sentence": "Sixty-six blood and/or sera samples from fever cases, either with high index of suspicion for <\\entity><\\entity> and/or positive by Weil-Felix test (> or = 1:160), were tested with the PCR.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4690",
    "Sentence": "<\\entity><\\entity> was performed on to the samples.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4691",
    "Sentence": "<\\entity><\\entity> was performed on to the samples.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4692",
    "Sentence": "Serotype-specific PCR <\\entity><\\entity> of some of the positive samples was indicative of the Kuroki type whereas the rest were non-responsive to this test.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4693",
    "Sentence": "Serotype-specific PCR amplification of some of the positive samples was indicative of the <\\entity><\\entity> whereas the rest were non-responsive to this test.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4694",
    "Sentence": "<\\entity><\\entity> in this region.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4695",
    "Sentence": "<\\entity><\\entity> in this region.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4696",
    "Sentence": "This one-step real-time PCR can be used for the detection and confirmation of <\\entity><\\entity>, when used independently or in conjunction with, the Weil-Felix test, which is still the only available detection test for <\\entity><\\entity> in most parts of the developing world.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4697",
    "Sentence": "This one-step real-time PCR can be used for the detection and confirmation of scrub typhus, when used independently or in conjunction with, the Weil-Felix test, which is <\\entity><\\entity> the only available detection test for scrub typhus in most parts of the developing world.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4698",
    "Sentence": "This one-step real-time PCR can be used for the detection and confirmation of <\\entity><\\entity>, when used independently or in conjunction with, the Weil-Felix test, which is still the only available detection test for <\\entity><\\entity> in most parts of the developing world.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4699",
    "Sentence": "Elaborate studies need to be taken up to further evaluate its suitability as specific molecular tool for the diagnosis of <\\entity><\\entity> and to delineate the prevalent strain types in these regions for a clear epidemiological understanding of this emerging infectious disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4700",
    "Sentence": "Elaborate studies need to be taken up to further evaluate its suitability as specific molecular tool for the diagnosis of scrub typhus and to delineate the prevalent <\\entity><\\entity> types in these regions for a clear epidemiological understanding of this emerging infectious disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4701",
    "Sentence": "Elaborate studies need to be taken up to further evaluate its suitability as specific molecular tool for the diagnosis of scrub typhus and to delineate the prevalent strain types in these regions for a clear epidemiological understanding of this <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4702",
    "Sentence": "<\\entity><\\entity>.A qualitative syber green real-time PCR with primers designed for a truncated portion of the 56kDa major outer membrane antigen gene of Orientia <\\entity><\\entity> was used to diagnose scrub typhus from the blood or serum of suspected patients.",
    "Label": ""
  },
  {
    "id": "4703",
    "Sentence": "tsutsugamushi.A qualitative syber green real-time PCR with primers designed for a truncated portion of the 56kDa major outer membrane antigen gene of Orientia tsutsugamushi was used to diagnose <\\entity><\\entity> from the blood or serum of suspected patients.",
    "Label": ""
  },
  {
    "id": "4709",
    "Sentence": "<\\entity><\\entity> mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.Doxorubicin is among the most effective and widely used anticancer drugs in the clinic.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4710",
    "Sentence": "Topoisomerase IIbeta mediated DNA double-strand breaks: implications in <\\entity><\\entity> cardiotoxicity and prevention by dexrazoxane.Doxorubicin is among the most effective and widely used anticancer drugs in the clinic.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4711",
    "Sentence": "Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by <\\entity><\\entity>.Doxorubicin is among the most effective and widely used anticancer drugs in the clinic.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4712",
    "Sentence": "Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.<\\entity><\\entity> is among the most effective and widely used anticancer drugs in the clinic.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4713",
    "Sentence": "However, cardiotoxicity is one of the life-threatening side effects of <\\entity><\\entity>-based therapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4714",
    "Sentence": "<\\entity><\\entity> (Zinecard, also known as ICRF-187) has been used in the clinic as a cardioprotectant against doxorubicin cardiotoxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4715",
    "Sentence": "Dexrazoxane (<\\entity><\\entity>, also known as ICRF-187) has been used in the clinic as a cardioprotectant against doxorubicin cardiotoxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4716",
    "Sentence": "Dexrazoxane (Zinecard, also known as <\\entity><\\entity>) has been used in the clinic as a cardioprotectant against doxorubicin cardiotoxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4717",
    "Sentence": "Dexrazoxane (Zinecard, also known as ICRF-187) has been used in the clinic as a cardioprotectant against <\\entity><\\entity> cardiotoxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4718",
    "Sentence": "The molecular basis for <\\entity><\\entity> cardiotoxicity and the cardioprotective effect of dexrazoxane, however, is not fully understood.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4719",
    "Sentence": "The molecular basis for doxorubicin cardiotoxicity and the cardioprotective effect of <\\entity><\\entity>, however, is not fully understood.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4720",
    "Sentence": "In the present study, we showed that <\\entity><\\entity> specifically abolished the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4721",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal <\\entity><\\entity> induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4722",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal gamma-H2AX induced by <\\entity><\\entity>, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4723",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal gamma-H2AX induced by doxorubicin, but not <\\entity><\\entity> or hydrogen peroxide, in H9C2 cardiomyocytes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4724",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or <\\entity><\\entity>, in H9C2 cardiomyocytes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4725",
    "Sentence": "<\\entity><\\entity>-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4726",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the <\\entity><\\entity> bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4727",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors <\\entity><\\entity> and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4728",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and <\\entity><\\entity> and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4729",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in <\\entity><\\entity>(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4730",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (<\\entity><\\entity>) compared with TOP2beta(+/+) <\\entity><\\entity>s, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4731",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with <\\entity><\\entity>(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4732",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the <\\entity><\\entity> inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of <\\entity><\\entity> and DNA topoisomerase IIbeta (Top2beta).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4733",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA <\\entity><\\entity> (Top2beta).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4734",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4735",
    "Sentence": "Furthermore, in addition to antagonizing <\\entity><\\entity> cleavage complex formation, dexrazoxane also induced rapid degradation of <\\entity><\\entity>beta, which paralleled the reduction of doxorubicin-induced DNA damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4736",
    "Sentence": "Furthermore, in addition to antagonizing Top2 cleavage complex formation, <\\entity><\\entity> also induced rapid degradation of Top2beta, which paralleled the reduction of doxorubicin-induced DNA damage.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4737",
    "Sentence": "Furthermore, in addition to antagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of <\\entity><\\entity>, which paralleled the reduction of doxorubicin-induced DNA damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4738",
    "Sentence": "Furthermore, in addition to antagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of Top2beta, which paralleled the reduction of <\\entity><\\entity>-induced DNA damage.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4739",
    "Sentence": "Together, our results suggest that <\\entity><\\entity> antagonizes doxorubicin-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in doxorubicin cardiotoxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4740",
    "Sentence": "Together, our results suggest that dexrazoxane antagonizes <\\entity><\\entity>-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in <\\entity><\\entity> cardiotoxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4741",
    "Sentence": "Together, our results suggest that dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with <\\entity><\\entity>, which could implicate <\\entity><\\entity> in doxorubicin cardiotoxicity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4742",
    "Sentence": "Together, our results suggest that dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with <\\entity><\\entity>, which could implicate <\\entity><\\entity> in doxorubicin cardiotoxicity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4743",
    "Sentence": "Together, our results suggest that dexrazoxane antagonizes <\\entity><\\entity>-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in <\\entity><\\entity> cardiotoxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4744",
    "Sentence": "The specific involvement of <\\entity><\\entity> and Top2beta in doxorubicin-induced DNA damage is consistent with a model in which proteasomal processing of doxorubicin-induced Top2beta-DNA covalent complexes exposes the Top2beta-concealed DNA double-strand breaks.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4745",
    "Sentence": "The specific involvement of proteasome and <\\entity><\\entity> in doxorubicin-induced DNA damage is consistent with a model in which proteasomal processing of doxorubicin-induced <\\entity><\\entity>-DNA covalent complexes exposes the <\\entity><\\entity>-concealed DNA double-strand breaks.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4746",
    "Sentence": "The specific involvement of proteasome and Top2beta in <\\entity><\\entity>-induced DNA damage is consistent with a model in which proteasomal processing of <\\entity><\\entity>-induced Top2beta-DNA covalent complexes exposes the Top2beta-concealed DNA double-strand breaks.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4747",
    "Sentence": "The specific involvement of proteasome and Top2beta in <\\entity><\\entity>-induced DNA damage is consistent with a model in which proteasomal processing of <\\entity><\\entity>-induced Top2beta-DNA covalent complexes exposes the Top2beta-concealed DNA double-strand breaks.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4748",
    "Sentence": "The specific involvement of proteasome and <\\entity><\\entity> in doxorubicin-induced DNA damage is consistent with a model in which proteasomal processing of doxorubicin-induced <\\entity><\\entity>-DNA covalent complexes exposes the <\\entity><\\entity>-concealed DNA double-strand breaks.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4749",
    "Sentence": "The specific involvement of proteasome and <\\entity><\\entity> in doxorubicin-induced DNA damage is consistent with a model in which proteasomal processing of doxorubicin-induced <\\entity><\\entity>-DNA covalent complexes exposes the <\\entity><\\entity>-concealed DNA double-strand breaks.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4750",
    "Sentence": "Topoisomerase IIbeta mediated DNA double-strand breaks: implications in <\\entity><\\entity> cardiotoxicity and prevention by dexrazoxane.Doxorubicin is among the most effective and widely used anticancer drugs in the clinic.",
    "Label": ""
  },
  {
    "id": "4751",
    "Sentence": "<\\entity><\\entity> mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.Doxorubicin is among the most effective and widely used anticancer drugs in the clinic.",
    "Label": ""
  },
  {
    "id": "4753",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal gamma-H2AX induced by <\\entity><\\entity>, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes.",
    "Label": ""
  },
  {
    "id": "4754",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal <\\entity><\\entity> induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes.",
    "Label": ""
  },
  {
    "id": "4756",
    "Sentence": "In the present study, we showed that <\\entity><\\entity> specifically abolished the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes.",
    "Label": ""
  },
  {
    "id": "4757",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal <\\entity><\\entity> induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes.",
    "Label": ""
  },
  {
    "id": "4759",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or <\\entity><\\entity>, in H9C2 cardiomyocytes.",
    "Label": ""
  },
  {
    "id": "4760",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal <\\entity><\\entity> induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes.",
    "Label": ""
  },
  {
    "id": "4762",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal gamma-H2AX induced by doxorubicin, but not <\\entity><\\entity> or hydrogen peroxide, in H9C2 cardiomyocytes.",
    "Label": ""
  },
  {
    "id": "4763",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal <\\entity><\\entity> induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes.",
    "Label": ""
  },
  {
    "id": "4765",
    "Sentence": "Furthermore, in addition to antagonizing Top2 cleavage complex formation, <\\entity><\\entity> also induced rapid degradation of Top2beta, which paralleled the reduction of doxorubicin-induced DNA damage.",
    "Label": ""
  },
  {
    "id": "4766",
    "Sentence": "Furthermore, in addition to antagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of <\\entity><\\entity>, which paralleled the reduction of doxorubicin-induced DNA damage.",
    "Label": ""
  },
  {
    "id": "4768",
    "Sentence": "Together, our results suggest that dexrazoxane antagonizes <\\entity><\\entity>-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in <\\entity><\\entity> cardiotoxicity.",
    "Label": ""
  },
  {
    "id": "4769",
    "Sentence": "Together, our results suggest that dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with <\\entity><\\entity>, which could implicate <\\entity><\\entity> in doxorubicin cardiotoxicity.",
    "Label": ""
  },
  {
    "id": "4771",
    "Sentence": "Together, our results suggest that <\\entity><\\entity> antagonizes doxorubicin-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in doxorubicin cardiotoxicity.",
    "Label": ""
  },
  {
    "id": "4772",
    "Sentence": "Together, our results suggest that dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with <\\entity><\\entity>, which could implicate <\\entity><\\entity> in doxorubicin cardiotoxicity.",
    "Label": ""
  },
  {
    "id": "4774",
    "Sentence": "The specific involvement of proteasome and Top2beta in <\\entity><\\entity>-induced DNA damage is consistent with a model in which proteasomal processing of <\\entity><\\entity>-induced Top2beta-DNA covalent complexes exposes the Top2beta-concealed DNA double-strand breaks.",
    "Label": ""
  },
  {
    "id": "4775",
    "Sentence": "The specific involvement of proteasome and <\\entity><\\entity> in doxorubicin-induced DNA damage is consistent with a model in which proteasomal processing of doxorubicin-induced <\\entity><\\entity>-DNA covalent complexes exposes the <\\entity><\\entity>-concealed DNA double-strand breaks.",
    "Label": ""
  },
  {
    "id": "4777",
    "Sentence": "The specific involvement of proteasome and Top2beta in <\\entity><\\entity>-induced DNA damage is consistent with a model in which proteasomal processing of <\\entity><\\entity>-induced Top2beta-DNA covalent complexes exposes the Top2beta-concealed DNA double-strand breaks.",
    "Label": ""
  },
  {
    "id": "4778",
    "Sentence": "The specific involvement of <\\entity><\\entity> and Top2beta in doxorubicin-induced DNA damage is consistent with a model in which proteasomal processing of doxorubicin-induced Top2beta-DNA covalent complexes exposes the Top2beta-concealed DNA double-strand breaks.",
    "Label": ""
  },
  {
    "id": "4780",
    "Sentence": "<\\entity><\\entity>-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4781",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (<\\entity><\\entity>) compared with TOP2beta(+/+) <\\entity><\\entity>s, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4783",
    "Sentence": "<\\entity><\\entity>-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4784",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "4786",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors <\\entity><\\entity> and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4787",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (<\\entity><\\entity>) compared with TOP2beta(+/+) <\\entity><\\entity>s, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4789",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors <\\entity><\\entity> and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4790",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "4792",
    "Sentence": "Furthermore, in addition to antagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of Top2beta, which paralleled the reduction of <\\entity><\\entity>-induced DNA damage.",
    "Label": ""
  },
  {
    "id": "4793",
    "Sentence": "Furthermore, in addition to antagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of <\\entity><\\entity>, which paralleled the reduction of doxorubicin-induced DNA damage.",
    "Label": ""
  },
  {
    "id": "4795",
    "Sentence": "Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by <\\entity><\\entity>.Doxorubicin is among the most effective and widely used anticancer drugs in the clinic.",
    "Label": ""
  },
  {
    "id": "4796",
    "Sentence": "<\\entity><\\entity> mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.Doxorubicin is among the most effective and widely used anticancer drugs in the clinic.",
    "Label": ""
  },
  {
    "id": "4798",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or <\\entity><\\entity>, in H9C2 cardiomyocytes.",
    "Label": ""
  },
  {
    "id": "4799",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal <\\entity><\\entity> induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes.",
    "Label": ""
  },
  {
    "id": "4801",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal gamma-H2AX induced by doxorubicin, but not <\\entity><\\entity> or hydrogen peroxide, in H9C2 cardiomyocytes.",
    "Label": ""
  },
  {
    "id": "4802",
    "Sentence": "In the present study, we showed that dexrazoxane specifically abolished the DNA damage signal <\\entity><\\entity> induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes.",
    "Label": ""
  },
  {
    "id": "4804",
    "Sentence": "<\\entity><\\entity>-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4805",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA <\\entity><\\entity> (Top2beta).",
    "Label": ""
  },
  {
    "id": "4807",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors <\\entity><\\entity> and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4808",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA <\\entity><\\entity> (Top2beta).",
    "Label": ""
  },
  {
    "id": "4810",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and <\\entity><\\entity> and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4811",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with <\\entity><\\entity>(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4813",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and <\\entity><\\entity> and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4814",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA <\\entity><\\entity> (Top2beta).",
    "Label": ""
  },
  {
    "id": "4816",
    "Sentence": "<\\entity><\\entity>-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4817",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the <\\entity><\\entity> inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of <\\entity><\\entity> and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4819",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and <\\entity><\\entity> and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4820",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the <\\entity><\\entity> inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of <\\entity><\\entity> and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4822",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the <\\entity><\\entity> bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4823",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the <\\entity><\\entity> inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of <\\entity><\\entity> and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4825",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the <\\entity><\\entity> bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4826",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA <\\entity><\\entity> (Top2beta).",
    "Label": ""
  },
  {
    "id": "4828",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the <\\entity><\\entity> bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4829",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with <\\entity><\\entity>(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4831",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the proteasome inhibitors <\\entity><\\entity> and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of proteasome and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4832",
    "Sentence": "Doxorubicin-induced DNA damage was also specifically abolished by the <\\entity><\\entity> inhibitors bortezomib and MG132 and much reduced in top2beta(-/-) mouse embryonic fibroblasts (MEF) compared with TOP2beta(+/+) MEFs, suggesting the involvement of <\\entity><\\entity> and DNA topoisomerase IIbeta (Top2beta).",
    "Label": ""
  },
  {
    "id": "4834",
    "Sentence": "Furthermore, in addition to antagonizing Top2 cleavage complex formation, dexrazoxane also induced rapid degradation of Top2beta, which paralleled the reduction of <\\entity><\\entity>-induced DNA damage.",
    "Label": ""
  },
  {
    "id": "4835",
    "Sentence": "Furthermore, in addition to antagonizing <\\entity><\\entity> cleavage complex formation, dexrazoxane also induced rapid degradation of <\\entity><\\entity>beta, which paralleled the reduction of doxorubicin-induced DNA damage.",
    "Label": ""
  },
  {
    "id": "4837",
    "Sentence": "Furthermore, in addition to antagonizing Top2 cleavage complex formation, <\\entity><\\entity> also induced rapid degradation of Top2beta, which paralleled the reduction of doxorubicin-induced DNA damage.",
    "Label": ""
  },
  {
    "id": "4838",
    "Sentence": "Furthermore, in addition to antagonizing <\\entity><\\entity> cleavage complex formation, dexrazoxane also induced rapid degradation of <\\entity><\\entity>beta, which paralleled the reduction of doxorubicin-induced DNA damage.",
    "Label": ""
  },
  {
    "id": "4844",
    "Sentence": "Decreased plasma soluble <\\entity><\\entity> in patients with hypercholesterolemia: effects of statins.The receptor for advanced glycation endproducts (<\\entity><\\entity>) is overexpressed at sites of vascular pathology.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4845",
    "Sentence": "Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of <\\entity><\\entity>.The receptor for advanced glycation endproducts (RAGE) is overexpressed at sites of vascular pathology.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4846",
    "Sentence": "Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins.The <\\entity><\\entity> (RAGE) is overexpressed at sites of vascular pathology.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4847",
    "Sentence": "Decreased plasma soluble <\\entity><\\entity> in patients with hypercholesterolemia: effects of statins.The receptor for advanced glycation endproducts (<\\entity><\\entity>) is overexpressed at sites of vascular pathology.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4848",
    "Sentence": "A <\\entity><\\entity> (sRAGE) neutralizes the ligand-mediated damage by acting as a decoy.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "4849",
    "Sentence": "A <\\entity><\\entity> (sRAGE) neutralizes the ligand-mediated damage by acting as a decoy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4850",
    "Sentence": "A soluble <\\entity><\\entity> isoform (s<\\entity><\\entity>) neutralizes the ligand-mediated damage by acting as a decoy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4851",
    "Sentence": "A soluble RAGE isoform (<\\entity><\\entity>) neutralizes the ligand-mediated damage by acting as a decoy.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "4852",
    "Sentence": "A soluble RAGE isoform (<\\entity><\\entity>) neutralizes the ligand-mediated damage by acting as a decoy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4853",
    "Sentence": "We hypothesized that in hypercholesterolemia up-regulation of the ligand-<\\entity><\\entity> axis may bridge impairment of nitric oxide biosynthesis with oxidative stress.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4854",
    "Sentence": "We hypothesized that in hypercholesterolemia up-regulation of the ligand-RAGE axis may bridge impairment of <\\entity><\\entity> biosynthesis with oxidative stress.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4855",
    "Sentence": "We measured in 60 hypercholesterolemic patients and 20 controls plasma total <\\entity><\\entity> levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of asymmetric dimethylarginine (ADMA).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "4856",
    "Sentence": "We measured in 60 hypercholesterolemic patients and 20 controls plasma total <\\entity><\\entity> levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of asymmetric dimethylarginine (ADMA).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4857",
    "Sentence": "We measured in 60 hypercholesterolemic patients and 20 controls plasma total sRAGE levels, <\\entity><\\entity> excretion, and plasma levels of asymmetric dimethylarginine (ADMA).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4858",
    "Sentence": "We measured in 60 hypercholesterolemic patients and 20 controls plasma total sRAGE levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of <\\entity><\\entity> (ADMA).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4859",
    "Sentence": "We measured in 60 hypercholesterolemic patients and 20 controls plasma total sRAGE levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of <\\entity><\\entity> (ADMA).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4860",
    "Sentence": "We measured in 60 hypercholesterolemic patients and 20 controls plasma total sRAGE levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of asymmetric dimethylarginine (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4861",
    "Sentence": "We measured in 60 hypercholesterolemic patients and 20 controls plasma total sRAGE levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of asymmetric dimethylarginine (<\\entity><\\entity>).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4862",
    "Sentence": "The effects of two structurally different <\\entity><\\entity> (pravastatin and atorvastatin) on these parameters were analyzed in 20 hypercholesterolemic subjects free of vascular disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4863",
    "Sentence": "The effects of two structurally different statins (<\\entity><\\entity> and atorvastatin) on these parameters were analyzed in 20 hypercholesterolemic subjects free of vascular disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4864",
    "Sentence": "The effects of two structurally different statins (pravastatin and <\\entity><\\entity>) on these parameters were analyzed in 20 hypercholesterolemic subjects free of vascular disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4865",
    "Sentence": "Plasma <\\entity><\\entity> was significantly lower, ADMA and urinary 8-iso-PGF(2alpha) were higher, in hypercholesterolemic versus normocholesterolemic patients.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "4866",
    "Sentence": "Plasma <\\entity><\\entity> was significantly lower, ADMA and urinary 8-iso-PGF(2alpha) were higher, in hypercholesterolemic versus normocholesterolemic patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4867",
    "Sentence": "Plasma sRAGE was significantly lower, <\\entity><\\entity> and urinary 8-iso-PGF(2alpha) were higher, in hypercholesterolemic versus normocholesterolemic patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4868",
    "Sentence": "Plasma sRAGE was significantly lower, <\\entity><\\entity> and urinary 8-iso-PGF(2alpha) were higher, in hypercholesterolemic versus normocholesterolemic patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4869",
    "Sentence": "Plasma sRAGE was significantly lower, ADMA and <\\entity><\\entity> were higher, in hypercholesterolemic versus normocholesterolemic patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4870",
    "Sentence": "Plasma sRAGE was significantly lower, ADMA and urinary 8-iso-<\\entity><\\entity>) were higher, in hypercholesterolemic versus normocholesterolemic patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4871",
    "Sentence": "Patients on <\\entity><\\entity> treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher sRAGE, and unchanged ADMA levels compared to subjects free of vascular disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4872",
    "Sentence": "Patients on <\\entity><\\entity> treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher sRAGE, and unchanged ADMA levels compared to subjects free of vascular disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4873",
    "Sentence": "Patients on statin treatment with previous myocardial infarction had lower <\\entity><\\entity>, higher sRAGE, and unchanged ADMA levels compared to subjects free of vascular disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4874",
    "Sentence": "Patients on statin treatment with previous myocardial infarction had lower 8-iso-<\\entity><\\entity>), higher sRAGE, and unchanged ADMA levels compared to subjects free of vascular disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4875",
    "Sentence": "Patients on statin treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher <\\entity><\\entity>, and unchanged ADMA levels compared to subjects free of vascular disease.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "4876",
    "Sentence": "Patients on statin treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher <\\entity><\\entity>, and unchanged ADMA levels compared to subjects free of vascular disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4877",
    "Sentence": "Patients on statin treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher sRAGE, and unchanged <\\entity><\\entity> levels compared to subjects free of vascular disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4878",
    "Sentence": "Patients on statin treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher sRAGE, and unchanged <\\entity><\\entity> levels compared to subjects free of vascular disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4879",
    "Sentence": "On multivariate regression analysis only <\\entity><\\entity> and ADMA predicted sRAGE levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4880",
    "Sentence": "On multivariate regression analysis only 8-iso-<\\entity><\\entity>) and ADMA predicted sRAGE levels.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4881",
    "Sentence": "On multivariate regression analysis only 8-iso-PGF(2alpha) and <\\entity><\\entity> predicted sRAGE levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4882",
    "Sentence": "On multivariate regression analysis only 8-iso-PGF(2alpha) and <\\entity><\\entity> predicted sRAGE levels.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4883",
    "Sentence": "On multivariate regression analysis only 8-iso-PGF(2alpha) and ADMA predicted <\\entity><\\entity> levels.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "4884",
    "Sentence": "On multivariate regression analysis only 8-iso-PGF(2alpha) and ADMA predicted <\\entity><\\entity> levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4885",
    "Sentence": "An 8-week treatment with either <\\entity><\\entity> was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only atorva<\\entity><\\entity> raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4886",
    "Sentence": "An 8-week treatment with either <\\entity><\\entity> was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only atorva<\\entity><\\entity> raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4887",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in <\\entity><\\entity>, whereas only atorvastatin raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4888",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-<\\entity><\\entity>), whereas only atorvastatin raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4889",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only <\\entity><\\entity> raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4890",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only atorvastatin raised <\\entity><\\entity> levels near to normal values, with no change in ADMA levels.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "4891",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only atorvastatin raised <\\entity><\\entity> levels near to normal values, with no change in ADMA levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4892",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only atorvastatin raised sRAGE levels near to normal values, with no change in <\\entity><\\entity> levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4893",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only atorvastatin raised sRAGE levels near to normal values, with no change in <\\entity><\\entity> levels.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4894",
    "Sentence": "<\\entity><\\entity> might serve as an endogenous protecting factor for accelerated atherosclerosis mediated by oxidative stress and endothelial dysfunction in hypercholesterolemia.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "4895",
    "Sentence": "<\\entity><\\entity> might serve as an endogenous protecting factor for accelerated atherosclerosis mediated by oxidative stress and endothelial dysfunction in hypercholesterolemia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "4896",
    "Sentence": "Patients on <\\entity><\\entity> treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher sRAGE, and unchanged ADMA levels compared to subjects free of vascular disease.",
    "Label": ""
  },
  {
    "id": "4897",
    "Sentence": "Patients on statin treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher sRAGE, and unchanged <\\entity><\\entity> levels compared to subjects free of vascular disease.",
    "Label": ""
  },
  {
    "id": "4899",
    "Sentence": "Patients on <\\entity><\\entity> treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher sRAGE, and unchanged ADMA levels compared to subjects free of vascular disease.",
    "Label": ""
  },
  {
    "id": "4900",
    "Sentence": "Patients on statin treatment with previous myocardial infarction had lower <\\entity><\\entity>, higher sRAGE, and unchanged ADMA levels compared to subjects free of vascular disease.",
    "Label": ""
  },
  {
    "id": "4902",
    "Sentence": "Patients on statin treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher <\\entity><\\entity>, and unchanged ADMA levels compared to subjects free of vascular disease.",
    "Label": ""
  },
  {
    "id": "4903",
    "Sentence": "Patients on <\\entity><\\entity> treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher sRAGE, and unchanged ADMA levels compared to subjects free of vascular disease.",
    "Label": ""
  },
  {
    "id": "4905",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only <\\entity><\\entity> raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": ""
  },
  {
    "id": "4906",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only atorvastatin raised sRAGE levels near to normal values, with no change in <\\entity><\\entity> levels.",
    "Label": ""
  },
  {
    "id": "4908",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only <\\entity><\\entity> raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": ""
  },
  {
    "id": "4909",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in <\\entity><\\entity>, whereas only atorvastatin raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": ""
  },
  {
    "id": "4911",
    "Sentence": "An 8-week treatment with either <\\entity><\\entity> was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only atorva<\\entity><\\entity> raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": ""
  },
  {
    "id": "4912",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in <\\entity><\\entity>, whereas only atorvastatin raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": ""
  },
  {
    "id": "4914",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only atorvastatin raised <\\entity><\\entity> levels near to normal values, with no change in ADMA levels.",
    "Label": ""
  },
  {
    "id": "4915",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only <\\entity><\\entity> raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": ""
  },
  {
    "id": "4917",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only <\\entity><\\entity> raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": ""
  },
  {
    "id": "4918",
    "Sentence": "An 8-week treatment with either <\\entity><\\entity> was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only atorva<\\entity><\\entity> raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": ""
  },
  {
    "id": "4920",
    "Sentence": "Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of <\\entity><\\entity>.The receptor for advanced glycation endproducts (RAGE) is overexpressed at sites of vascular pathology.",
    "Label": ""
  },
  {
    "id": "4921",
    "Sentence": "Decreased plasma soluble <\\entity><\\entity> in patients with hypercholesterolemia: effects of statins.The receptor for advanced glycation endproducts (<\\entity><\\entity>) is overexpressed at sites of vascular pathology.",
    "Label": ""
  },
  {
    "id": "4923",
    "Sentence": "We measured in 60 hypercholesterolemic patients and 20 controls plasma total sRAGE levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of asymmetric dimethylarginine (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "4924",
    "Sentence": "We measured in 60 hypercholesterolemic patients and 20 controls plasma total <\\entity><\\entity> levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of asymmetric dimethylarginine (ADMA).",
    "Label": ""
  },
  {
    "id": "4926",
    "Sentence": "We measured in 60 hypercholesterolemic patients and 20 controls plasma total sRAGE levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of <\\entity><\\entity> (ADMA).",
    "Label": ""
  },
  {
    "id": "4927",
    "Sentence": "We measured in 60 hypercholesterolemic patients and 20 controls plasma total <\\entity><\\entity> levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of asymmetric dimethylarginine (ADMA).",
    "Label": ""
  },
  {
    "id": "4929",
    "Sentence": "Plasma sRAGE was significantly lower, ADMA and urinary 8-iso-<\\entity><\\entity>) were higher, in hypercholesterolemic versus normocholesterolemic patients.",
    "Label": ""
  },
  {
    "id": "4930",
    "Sentence": "Plasma <\\entity><\\entity> was significantly lower, ADMA and urinary 8-iso-PGF(2alpha) were higher, in hypercholesterolemic versus normocholesterolemic patients.",
    "Label": ""
  },
  {
    "id": "4932",
    "Sentence": "Plasma sRAGE was significantly lower, <\\entity><\\entity> and urinary 8-iso-PGF(2alpha) were higher, in hypercholesterolemic versus normocholesterolemic patients.",
    "Label": ""
  },
  {
    "id": "4933",
    "Sentence": "Plasma <\\entity><\\entity> was significantly lower, ADMA and urinary 8-iso-PGF(2alpha) were higher, in hypercholesterolemic versus normocholesterolemic patients.",
    "Label": ""
  },
  {
    "id": "4935",
    "Sentence": "Patients on <\\entity><\\entity> treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher sRAGE, and unchanged ADMA levels compared to subjects free of vascular disease.",
    "Label": ""
  },
  {
    "id": "4936",
    "Sentence": "Patients on statin treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher <\\entity><\\entity>, and unchanged ADMA levels compared to subjects free of vascular disease.",
    "Label": ""
  },
  {
    "id": "4938",
    "Sentence": "On multivariate regression analysis only 8-iso-<\\entity><\\entity>) and ADMA predicted sRAGE levels.",
    "Label": ""
  },
  {
    "id": "4939",
    "Sentence": "On multivariate regression analysis only 8-iso-PGF(2alpha) and ADMA predicted <\\entity><\\entity> levels.",
    "Label": ""
  },
  {
    "id": "4941",
    "Sentence": "On multivariate regression analysis only 8-iso-PGF(2alpha) and <\\entity><\\entity> predicted sRAGE levels.",
    "Label": ""
  },
  {
    "id": "4942",
    "Sentence": "On multivariate regression analysis only 8-iso-PGF(2alpha) and ADMA predicted <\\entity><\\entity> levels.",
    "Label": ""
  },
  {
    "id": "4944",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only <\\entity><\\entity> raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": ""
  },
  {
    "id": "4945",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only atorvastatin raised <\\entity><\\entity> levels near to normal values, with no change in ADMA levels.",
    "Label": ""
  },
  {
    "id": "4947",
    "Sentence": "Patients on <\\entity><\\entity> treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher sRAGE, and unchanged ADMA levels compared to subjects free of vascular disease.",
    "Label": ""
  },
  {
    "id": "4948",
    "Sentence": "Patients on statin treatment with previous myocardial infarction had lower 8-iso-PGF(2alpha), higher sRAGE, and unchanged <\\entity><\\entity> levels compared to subjects free of vascular disease.",
    "Label": ""
  },
  {
    "id": "4950",
    "Sentence": "An 8-week treatment with either <\\entity><\\entity> was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only atorva<\\entity><\\entity> raised sRAGE levels near to normal values, with no change in ADMA levels.",
    "Label": ""
  },
  {
    "id": "4951",
    "Sentence": "An 8-week treatment with either statin was associated with a significant reduction in urinary 8-iso-PGF(2alpha), whereas only atorvastatin raised sRAGE levels near to normal values, with no change in <\\entity><\\entity> levels.",
    "Label": ""
  },
  {
    "id": "4957",
    "Sentence": "Use of <\\entity><\\entity> and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4958",
    "Sentence": "Use of benzodiazepines and <\\entity><\\entity> during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4959",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: <\\entity><\\entity> and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4960",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and <\\entity><\\entity>.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some <\\entity><\\entity>, for example, orofacial clefts.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4961",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to <\\entity><\\entity> (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4962",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (<\\entity><\\entity>) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4963",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to <\\entity><\\entity> and some congenital malformations, for example, orofacial clefts.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4964",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and <\\entity><\\entity>.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some <\\entity><\\entity>, for example, orofacial clefts.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4965",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4966",
    "Sentence": "Here we aimed to study the <\\entity><\\entity> and congenital malformations in neonates whose mothers reported use of BZD and/or hypnotic benzodiazepine receptor agonists (HBRA) during pregnancy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4967",
    "Sentence": "Here we aimed to study the neonatal outcome and <\\entity><\\entity> in neonates whose mothers reported use of BZD and/or hypnotic benzodiazepine receptor agonists (HBRA) during pregnancy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4968",
    "Sentence": "Here we aimed to study the neonatal outcome and congenital malformations in neonates whose mothers reported use of <\\entity><\\entity> and/or hypnotic benzodiazepine receptor agonists (HBRA) during pregnancy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4969",
    "Sentence": "Here we aimed to study the neonatal outcome and congenital malformations in neonates whose mothers reported use of BZD and/or <\\entity><\\entity> (HBRA) during pregnancy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4970",
    "Sentence": "Here we aimed to study the neonatal outcome and congenital malformations in neonates whose mothers reported use of BZD and/or hypnotic benzodiazepine receptor agonists (<\\entity><\\entity>) during pregnancy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4971",
    "Sentence": "METHODS: In the Swedish Medical Birth Register we identified 1979 infants whose mothers (n = 1944) reported use of <\\entity><\\entity> and/or HBRA in early pregnancy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4972",
    "Sentence": "METHODS: In the Swedish Medical Birth Register we identified 1979 infants whose mothers (n = 1944) reported use of BZD and/or <\\entity><\\entity> in early pregnancy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4973",
    "Sentence": "An additional 401 infants were studied, born to 390 mothers who were prescribed such drugs during <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4974",
    "Sentence": "<\\entity><\\entity> including congenital malformations after exposure was compared with that of all births (n = 873 879).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4975",
    "Sentence": "Neonatal outcome including <\\entity><\\entity> after exposure was compared with that of all births (n = 873 879).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4976",
    "Sentence": "RESULTS: An increased risk for <\\entity><\\entity> and low birth weight was detected in the exposed population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4977",
    "Sentence": "RESULTS: An increased risk for preterm birth and <\\entity><\\entity> was detected in the exposed population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4978",
    "Sentence": "The rate of relatively major <\\entity><\\entity> was moderately increased among infants exposed in early pregnancy (adjusted OR = 1.24, 95%CI 1.00-1.55), not explained by known teratogenic maternal co-medication.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4979",
    "Sentence": "A higher than expected number of infants with <\\entity><\\entity> or alimentary tract atresia (especially small gut) was found.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4980",
    "Sentence": "A higher than expected number of infants with pylorostenosis or <\\entity><\\entity> (especially small gut) was found.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4981",
    "Sentence": "This was, however, based on only seven infants for each group of <\\entity><\\entity> without association to any specific BZD or HBRA.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4982",
    "Sentence": "This was, however, based on only seven infants for each group of malformation without association to any specific <\\entity><\\entity> or HBRA.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4983",
    "Sentence": "This was, however, based on only seven infants for each group of malformation without association to any specific BZD or <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4984",
    "Sentence": "The earlier proposed increased risk for <\\entity><\\entity> was not confirmed in our study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4985",
    "Sentence": "CONCLUSIONS: Maternal use of <\\entity><\\entity> and/or HBRA may increase the risk for preterm birth and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4986",
    "Sentence": "CONCLUSIONS: Maternal use of BZD and/or <\\entity><\\entity> may increase the risk for preterm birth and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "4987",
    "Sentence": "CONCLUSIONS: Maternal use of BZD and/or HBRA may increase the risk for <\\entity><\\entity> and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4988",
    "Sentence": "CONCLUSIONS: Maternal use of BZD and/or HBRA may increase the risk for preterm birth and <\\entity><\\entity> and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4989",
    "Sentence": "CONCLUSIONS: Maternal use of BZD and/or HBRA may increase the risk for preterm birth and low birth weight and cause neonatal <\\entity><\\entity>, but does not appear to have a strong teratogenic potential.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4990",
    "Sentence": "The tentative association with <\\entity><\\entity> and alimentary tract atresia needs confirmation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4991",
    "Sentence": "The tentative association with pylorostenosis and <\\entity><\\entity> needs confirmation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "4992",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to <\\entity><\\entity> (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "4993",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to <\\entity><\\entity> and some congenital malformations, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "4995",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to <\\entity><\\entity> (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "4996",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "4998",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to <\\entity><\\entity> (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "4999",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and <\\entity><\\entity>.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some <\\entity><\\entity>, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "5001",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (<\\entity><\\entity>) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "5002",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to <\\entity><\\entity> and some congenital malformations, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "5004",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (<\\entity><\\entity>) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "5005",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5007",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (<\\entity><\\entity>) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "5008",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and <\\entity><\\entity>.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some <\\entity><\\entity>, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "5010",
    "Sentence": "CONCLUSIONS: Maternal use of <\\entity><\\entity> and/or HBRA may increase the risk for preterm birth and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.",
    "Label": ""
  },
  {
    "id": "5011",
    "Sentence": "CONCLUSIONS: Maternal use of BZD and/or HBRA may increase the risk for <\\entity><\\entity> and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.",
    "Label": ""
  },
  {
    "id": "5013",
    "Sentence": "CONCLUSIONS: Maternal use of BZD and/or <\\entity><\\entity> may increase the risk for preterm birth and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.",
    "Label": ""
  },
  {
    "id": "5014",
    "Sentence": "CONCLUSIONS: Maternal use of BZD and/or HBRA may increase the risk for <\\entity><\\entity> and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.",
    "Label": ""
  },
  {
    "id": "5016",
    "Sentence": "CONCLUSIONS: Maternal use of <\\entity><\\entity> and/or HBRA may increase the risk for preterm birth and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.",
    "Label": ""
  },
  {
    "id": "5017",
    "Sentence": "CONCLUSIONS: Maternal use of BZD and/or HBRA may increase the risk for preterm birth and <\\entity><\\entity> and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.",
    "Label": ""
  },
  {
    "id": "5019",
    "Sentence": "Use of <\\entity><\\entity> and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "5020",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and <\\entity><\\entity>.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some <\\entity><\\entity>, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "5022",
    "Sentence": "Use of benzodiazepines and <\\entity><\\entity> during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "5023",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and <\\entity><\\entity>.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some <\\entity><\\entity>, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "5025",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.BACKGROUND: Exposure to Benzodiazepines (<\\entity><\\entity>) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "5026",
    "Sentence": "Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and <\\entity><\\entity>.BACKGROUND: Exposure to Benzodiazepines (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some <\\entity><\\entity>, for example, orofacial clefts.",
    "Label": ""
  },
  {
    "id": "5028",
    "Sentence": "Here we aimed to study the neonatal outcome and congenital malformations in neonates whose mothers reported use of <\\entity><\\entity> and/or hypnotic benzodiazepine receptor agonists (HBRA) during pregnancy.",
    "Label": ""
  },
  {
    "id": "5029",
    "Sentence": "Here we aimed to study the neonatal outcome and <\\entity><\\entity> in neonates whose mothers reported use of BZD and/or hypnotic benzodiazepine receptor agonists (HBRA) during pregnancy.",
    "Label": ""
  },
  {
    "id": "5031",
    "Sentence": "Here we aimed to study the neonatal outcome and congenital malformations in neonates whose mothers reported use of BZD and/or hypnotic benzodiazepine receptor agonists (<\\entity><\\entity>) during pregnancy.",
    "Label": ""
  },
  {
    "id": "5032",
    "Sentence": "Here we aimed to study the neonatal outcome and <\\entity><\\entity> in neonates whose mothers reported use of BZD and/or hypnotic benzodiazepine receptor agonists (HBRA) during pregnancy.",
    "Label": ""
  },
  {
    "id": "5034",
    "Sentence": "This was, however, based on only seven infants for each group of malformation without association to any specific <\\entity><\\entity> or HBRA.",
    "Label": ""
  },
  {
    "id": "5035",
    "Sentence": "This was, however, based on only seven infants for each group of <\\entity><\\entity> without association to any specific BZD or HBRA.",
    "Label": ""
  },
  {
    "id": "5037",
    "Sentence": "This was, however, based on only seven infants for each group of malformation without association to any specific BZD or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5038",
    "Sentence": "This was, however, based on only seven infants for each group of <\\entity><\\entity> without association to any specific BZD or HBRA.",
    "Label": ""
  },
  {
    "id": "5040",
    "Sentence": "CONCLUSIONS: Maternal use of <\\entity><\\entity> and/or HBRA may increase the risk for preterm birth and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.",
    "Label": ""
  },
  {
    "id": "5041",
    "Sentence": "CONCLUSIONS: Maternal use of BZD and/or HBRA may increase the risk for preterm birth and low birth weight and cause neonatal <\\entity><\\entity>, but does not appear to have a strong teratogenic potential.",
    "Label": ""
  },
  {
    "id": "5043",
    "Sentence": "CONCLUSIONS: Maternal use of BZD and/or <\\entity><\\entity> may increase the risk for preterm birth and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.",
    "Label": ""
  },
  {
    "id": "5044",
    "Sentence": "CONCLUSIONS: Maternal use of BZD and/or HBRA may increase the risk for preterm birth and <\\entity><\\entity> and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.",
    "Label": ""
  },
  {
    "id": "5046",
    "Sentence": "CONCLUSIONS: Maternal use of BZD and/or <\\entity><\\entity> may increase the risk for preterm birth and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.",
    "Label": ""
  },
  {
    "id": "5047",
    "Sentence": "CONCLUSIONS: Maternal use of BZD and/or HBRA may increase the risk for preterm birth and low birth weight and cause neonatal <\\entity><\\entity>, but does not appear to have a strong teratogenic potential.",
    "Label": ""
  },
  {
    "id": "5053",
    "Sentence": "Risk of <\\entity><\\entity>: obesity and its joint effect with oral contraceptive use and prothrombotic mutations.In the Multiple Environmental and Genetic Assessment of risk factors for <\\entity><\\entity> (MEGA study), body weight, height and body mass index (BMI) were evaluated as risk factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5054",
    "Sentence": "Risk of venous thrombosis: <\\entity><\\entity> and its joint effect with oral contraceptive use and prothrombotic mutations.In the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA study), body weight, height and body mass index (BMI) were evaluated as risk factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5055",
    "Sentence": "Risk of venous thrombosis: obesity and its joint effect with <\\entity><\\entity> use and prothrombotic mutations.In the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA study), body weight, height and body mass index (BMI) were evaluated as risk factors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5056",
    "Sentence": "Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic <\\entity><\\entity>.In the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA study), body weight, height and body mass index (BMI) were evaluated as risk factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5057",
    "Sentence": "Risk of <\\entity><\\entity>: obesity and its joint effect with oral contraceptive use and prothrombotic mutations.In the Multiple Environmental and Genetic Assessment of risk factors for <\\entity><\\entity> (MEGA study), body weight, height and body mass index (BMI) were evaluated as risk factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5058",
    "Sentence": "Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations.In the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA study), body <\\entity><\\entity>, height and body mass index (BMI) were evaluated as risk factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5059",
    "Sentence": "Additionally, the joint effect of <\\entity><\\entity> together with oral contraceptive use and prothrombotic mutations on the risk of venous thrombosis were analysed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5060",
    "Sentence": "Additionally, the joint effect of obesity together with <\\entity><\\entity> use and prothrombotic mutations on the risk of venous thrombosis were analysed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5061",
    "Sentence": "Additionally, the joint effect of obesity together with oral contraceptive use and prothrombotic <\\entity><\\entity> on the risk of venous thrombosis were analysed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5062",
    "Sentence": "Additionally, the joint effect of obesity together with oral contraceptive use and prothrombotic mutations on the risk of <\\entity><\\entity> were analysed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5063",
    "Sentence": "Three-thousand eight-hundred and thirty-four patients with a first <\\entity><\\entity> and 4683 control subjects were included, all non-pregnant and without active malignancies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5064",
    "Sentence": "Three-thousand eight-hundred and thirty-four patients with a first venous thrombosis and 4683 control subjects were included, all non-pregnant and without <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5065",
    "Sentence": "Relative to those with a normal BMI (<25 kg/m(2)), <\\entity><\\entity> (BMI > or = 25 and BMI < 30 kg/m(2)) increased the risk of venous thrombosis 1.7-fold [odds ratio (OR)(adj(age and sex)) 1.70, 95% confidence interval (CI) 1.55-1.87] and obesity (BMI > or = 30 kg/m(2)) 2.4-fold (OR(adj) 2.44, 95% CI 2.15-2.78).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5066",
    "Sentence": "Relative to those with a normal BMI (<25 kg/m(2)), overweight (BMI > or = 25 and BMI < 30 kg/m(2)) increased the risk of <\\entity><\\entity> 1.7-fold [odds ratio (OR)(adj(age and sex)) 1.70, 95% confidence interval (CI) 1.55-1.87] and obesity (BMI > or = 30 kg/m(2)) 2.4-fold (OR(adj) 2.44, 95% CI 2.15-2.78).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5067",
    "Sentence": "Relative to those with a normal BMI (<25 kg/m(2)), overweight (BMI > or = 25 and BMI < 30 kg/m(2)) increased the risk of venous thrombosis 1.7-fold [odds ratio (OR)(adj(age and sex)) 1.70, 95% confidence interval (CI) 1.55-1.87] and <\\entity><\\entity> (BMI > or = 30 kg/m(2)) 2.4-fold (OR(adj) 2.44, 95% CI 2.15-2.78).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5068",
    "Sentence": "An increase in body weight and body height also individually increased <\\entity><\\entity> risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5069",
    "Sentence": "<\\entity><\\entity> women who used oral contraceptives had a 24-fold higher thrombotic risk (OR(adj) 23.78, 95% CI 13.35-42.34) than women with a normal BMI who did not use oral contraceptives.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5070",
    "Sentence": "Obese women who used <\\entity><\\entity> had a 24-fold higher thrombotic risk (OR(adj) 23.78, 95% CI 13.35-42.34) than women with a normal BMI who did not use <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5071",
    "Sentence": "Obese women who used oral contraceptives had a 24-fold higher <\\entity><\\entity> risk (OR(adj) 23.78, 95% CI 13.35-42.34) than women with a normal BMI who did not use oral contraceptives.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5072",
    "Sentence": "Obese women who used <\\entity><\\entity> had a 24-fold higher thrombotic risk (OR(adj) 23.78, 95% CI 13.35-42.34) than women with a normal BMI who did not use <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5073",
    "Sentence": "Relative to non-carriers of normal BMI, the joint effect of factor V Leiden and <\\entity><\\entity> led to a 7.9-fold increased risk (OR(adj) 7.86, 95% CI 4.70-13.15); for prothrombin 20210A this was a 6.6-fold increased risk (OR(adj) 6.58, 95% CI 2.31-18.69).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5074",
    "Sentence": "Body height, <\\entity><\\entity> and obesity increase the risk of venous thrombosis, especially obesity in women using oral contraceptives.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5075",
    "Sentence": "Body height, weight and <\\entity><\\entity> increase the risk of venous thrombosis, especially <\\entity><\\entity> in women using oral contraceptives.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5076",
    "Sentence": "Body height, weight and obesity increase the risk of <\\entity><\\entity>, especially obesity in women using oral contraceptives.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5077",
    "Sentence": "Body height, weight and <\\entity><\\entity> increase the risk of venous thrombosis, especially <\\entity><\\entity> in women using oral contraceptives.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5078",
    "Sentence": "Body height, weight and obesity increase the risk of venous thrombosis, especially obesity in women using <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5079",
    "Sentence": "Obese women who used <\\entity><\\entity> had a 24-fold higher thrombotic risk (OR(adj) 23.78, 95% CI 13.35-42.34) than women with a normal BMI who did not use <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5080",
    "Sentence": "Obese women who used oral contraceptives had a 24-fold higher <\\entity><\\entity> risk (OR(adj) 23.78, 95% CI 13.35-42.34) than women with a normal BMI who did not use oral contraceptives.",
    "Label": ""
  },
  {
    "id": "5082",
    "Sentence": "Body height, weight and obesity increase the risk of venous thrombosis, especially obesity in women using <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5083",
    "Sentence": "Body height, weight and obesity increase the risk of <\\entity><\\entity>, especially obesity in women using oral contraceptives.",
    "Label": ""
  },
  {
    "id": "5085",
    "Sentence": "Obese women who used <\\entity><\\entity> had a 24-fold higher thrombotic risk (OR(adj) 23.78, 95% CI 13.35-42.34) than women with a normal BMI who did not use <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5086",
    "Sentence": "<\\entity><\\entity> women who used oral contraceptives had a 24-fold higher thrombotic risk (OR(adj) 23.78, 95% CI 13.35-42.34) than women with a normal BMI who did not use oral contraceptives.",
    "Label": ""
  },
  {
    "id": "5088",
    "Sentence": "Body height, weight and obesity increase the risk of venous thrombosis, especially obesity in women using <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5089",
    "Sentence": "Body height, weight and <\\entity><\\entity> increase the risk of venous thrombosis, especially <\\entity><\\entity> in women using oral contraceptives.",
    "Label": ""
  },
  {
    "id": "5095",
    "Sentence": "<\\entity><\\entity> result in anosmia caused by the selective loss of G proteins in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "5096",
    "Sentence": "<\\entity><\\entity> result in anosmia caused by the selective loss of G proteins in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5097",
    "Sentence": "Hypomorphic <\\entity><\\entity>/NPHP6 mutations result in anosmia caused by the selective loss of G proteins in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5098",
    "Sentence": "Hypomorphic CEP290/<\\entity><\\entity> mutations result in anosmia caused by the selective loss of G proteins in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5099",
    "Sentence": "Hypomorphic CEP290/NPHP6 mutations result in <\\entity><\\entity> caused by the selective loss of G proteins in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5100",
    "Sentence": "Hypomorphic CEP290/NPHP6 mutations result in anosmia caused by the selective loss of <\\entity><\\entity> in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5101",
    "Sentence": "The cilia of olfactory sensory neurons (OSNs) compartmentalize the signaling proteins necessary for odor detection; however, <\\entity><\\entity> is known regarding the mechanisms of protein sorting/entry into olfactory cilia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5102",
    "Sentence": "<\\entity><\\entity> are a family of ciliary proteins likely involved in cargo sorting during transport from the basal body to the ciliary axoneme.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5103",
    "Sentence": "Nephrocystins are a family of <\\entity><\\entity> likely involved in cargo sorting during transport from the basal body to the ciliary axoneme.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5104",
    "Sentence": "In humans, loss-of-function of the <\\entity><\\entity> CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5105",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein <\\entity><\\entity> is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5106",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with <\\entity><\\entity> and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5107",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and <\\entity><\\entity>, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5108",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas <\\entity><\\entity> result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "5109",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas <\\entity><\\entity> result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5110",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in <\\entity><\\entity> (LCA), a form of early-onset retinal dystrophy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5111",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in <\\entity><\\entity> (LCA), a form of early-onset retinal dystrophy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5112",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (<\\entity><\\entity>), a form of early-onset retinal dystrophy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5113",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (<\\entity><\\entity>), a form of early-onset retinal dystrophy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5114",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5115",
    "Sentence": "Here, we report that <\\entity><\\entity> exhibit severely abnormal olfactory function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5116",
    "Sentence": "Here, we report that <\\entity><\\entity> exhibit severely abnormal olfactory function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5117",
    "Sentence": "Here, we report that CEP290-<\\entity><\\entity> patients exhibit severely abnormal olfactory function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5118",
    "Sentence": "In a mouse model with hypomorphic <\\entity><\\entity> in CEP290 [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of CEP290-LCA patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5119",
    "Sentence": "In a mouse model with hypomorphic mutations in <\\entity><\\entity> [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of <\\entity><\\entity>-LCA patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5120",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [<\\entity><\\entity>-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of CEP290-LCA patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5121",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [retinal dystrophy-16 mice (<\\entity><\\entity>)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of CEP290-LCA patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5122",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an <\\entity><\\entity> phenotype analogous to that of CEP290-LCA patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5123",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5124",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5125",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of CEP290-<\\entity><\\entity> patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5126",
    "Sentence": "Despite the loss of olfactory function, cilia of OSNs remained intact in the <\\entity><\\entity> mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5127",
    "Sentence": "As in wild type, <\\entity><\\entity> localized to dendritic knobs of rd16 OSNs, where it was in complex with ciliary transport proteins and the olfactory G proteins G(olf) and Ggamma(13).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5128",
    "Sentence": "As in wild type, CEP290 localized to dendritic knobs of <\\entity><\\entity> OSNs, where it was in complex with ciliary transport proteins and the olfactory G proteins G(olf) and Ggamma(13).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5129",
    "Sentence": "As in wild type, CEP290 localized to dendritic knobs of rd16 OSNs, where it was in complex with <\\entity><\\entity> and the olfactory G proteins G(olf) and Ggamma(13).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5130",
    "Sentence": "As in wild type, CEP290 localized to dendritic knobs of rd16 OSNs, where it was in complex with ciliary transport proteins and the olfactory <\\entity><\\entity> G(olf) and Ggamma(13).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5131",
    "Sentence": "As in wild type, CEP290 localized to dendritic knobs of rd16 OSNs, where it was in complex with ciliary transport proteins and the olfactory G proteins <\\entity><\\entity> and Ggamma(13).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5132",
    "Sentence": "As in wild type, CEP290 localized to dendritic knobs of rd16 OSNs, where it was in complex with ciliary transport proteins and the olfactory G proteins G(olf) and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5133",
    "Sentence": "Interestingly, we observed defective ciliary localization of <\\entity><\\entity> and Ggamma(13) but not of G protein-coupled odorant receptors or other components of the odorant signaling pathway in the rd16 OSNs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5134",
    "Sentence": "Interestingly, we observed defective ciliary localization of G(olf) and <\\entity><\\entity> but not of G protein-coupled odorant receptors or other components of the odorant signaling pathway in the rd16 OSNs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5135",
    "Sentence": "Interestingly, we observed defective ciliary localization of G(olf) and Ggamma(13) but not of <\\entity><\\entity> or other components of the odorant signaling pathway in the rd16 OSNs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5136",
    "Sentence": "Interestingly, we observed defective ciliary localization of G(olf) and Ggamma(13) but not of G protein-coupled odorant receptors or other components of the odorant signaling pathway in the <\\entity><\\entity> OSNs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5137",
    "Sentence": "Our data implicate distinct mechanisms for ciliary transport of <\\entity><\\entity>, with CEP290 being a key mediator involved in G protein trafficking.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5138",
    "Sentence": "Our data implicate distinct mechanisms for ciliary transport of olfactory signaling proteins, with <\\entity><\\entity> being a key mediator involved in G protein trafficking.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5139",
    "Sentence": "Our data implicate distinct mechanisms for ciliary transport of olfactory signaling proteins, with CEP290 being a key mediator involved in <\\entity><\\entity> trafficking.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5140",
    "Sentence": "The assessment of olfactory function can, therefore, serve as a useful diagnostic tool for genetic screening of certain syndromic ciliary <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5141",
    "Sentence": "<\\entity><\\entity> result in anosmia caused by the selective loss of G proteins in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": ""
  },
  {
    "id": "5142",
    "Sentence": "Hypomorphic CEP290/NPHP6 mutations result in <\\entity><\\entity> caused by the selective loss of G proteins in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": ""
  },
  {
    "id": "5144",
    "Sentence": "Hypomorphic CEP290/NPHP6 mutations result in anosmia caused by the selective loss of <\\entity><\\entity> in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": ""
  },
  {
    "id": "5145",
    "Sentence": "Hypomorphic CEP290/NPHP6 mutations result in <\\entity><\\entity> caused by the selective loss of G proteins in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": ""
  },
  {
    "id": "5147",
    "Sentence": "In humans, loss-of-function of the <\\entity><\\entity> CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5148",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with <\\entity><\\entity> and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5150",
    "Sentence": "In humans, loss-of-function of the <\\entity><\\entity> CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5151",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and <\\entity><\\entity>, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5153",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas <\\entity><\\entity> result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5154",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (<\\entity><\\entity>), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5156",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas <\\entity><\\entity> result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5157",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in <\\entity><\\entity> (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5159",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein <\\entity><\\entity> is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5160",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with <\\entity><\\entity> and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5162",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein <\\entity><\\entity> is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5163",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and <\\entity><\\entity>, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5165",
    "Sentence": "In a mouse model with hypomorphic mutations in <\\entity><\\entity> [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of <\\entity><\\entity>-LCA patients.",
    "Label": ""
  },
  {
    "id": "5166",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an <\\entity><\\entity> phenotype analogous to that of CEP290-LCA patients.",
    "Label": ""
  },
  {
    "id": "5168",
    "Sentence": "In a mouse model with hypomorphic mutations in <\\entity><\\entity> [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of <\\entity><\\entity>-LCA patients.",
    "Label": ""
  },
  {
    "id": "5169",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5171",
    "Sentence": "Hypomorphic CEP290/<\\entity><\\entity> mutations result in anosmia caused by the selective loss of G proteins in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": ""
  },
  {
    "id": "5172",
    "Sentence": "<\\entity><\\entity> result in anosmia caused by the selective loss of G proteins in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": ""
  },
  {
    "id": "5174",
    "Sentence": "Hypomorphic CEP290/<\\entity><\\entity> mutations result in anosmia caused by the selective loss of G proteins in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": ""
  },
  {
    "id": "5175",
    "Sentence": "Hypomorphic CEP290/NPHP6 mutations result in <\\entity><\\entity> caused by the selective loss of G proteins in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": ""
  },
  {
    "id": "5177",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein <\\entity><\\entity> is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5178",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas <\\entity><\\entity> result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5180",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein <\\entity><\\entity> is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5181",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5183",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (<\\entity><\\entity>), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5184",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas <\\entity><\\entity> result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5186",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (<\\entity><\\entity>), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5187",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and <\\entity><\\entity>, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5189",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (<\\entity><\\entity>), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5190",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5192",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in <\\entity><\\entity> (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5193",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas <\\entity><\\entity> result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5195",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in <\\entity><\\entity> (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5196",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and <\\entity><\\entity>, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5198",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in <\\entity><\\entity> (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5199",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5201",
    "Sentence": "In a mouse model with hypomorphic mutations in <\\entity><\\entity> [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of <\\entity><\\entity>-LCA patients.",
    "Label": ""
  },
  {
    "id": "5202",
    "Sentence": "In a mouse model with hypomorphic <\\entity><\\entity> in CEP290 [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of CEP290-LCA patients.",
    "Label": ""
  },
  {
    "id": "5204",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [retinal dystrophy-16 mice (<\\entity><\\entity>)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of CEP290-LCA patients.",
    "Label": ""
  },
  {
    "id": "5205",
    "Sentence": "In a mouse model with hypomorphic <\\entity><\\entity> in CEP290 [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of CEP290-LCA patients.",
    "Label": ""
  },
  {
    "id": "5207",
    "Sentence": "Hypomorphic <\\entity><\\entity>/NPHP6 mutations result in anosmia caused by the selective loss of G proteins in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": ""
  },
  {
    "id": "5208",
    "Sentence": "Hypomorphic CEP290/NPHP6 mutations result in <\\entity><\\entity> caused by the selective loss of G proteins in cilia of olfactory sensory neurons.Cilia regulate diverse functions such as motility, fluid balance, and sensory perception.",
    "Label": ""
  },
  {
    "id": "5210",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein <\\entity><\\entity> is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5211",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (<\\entity><\\entity>), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5213",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein <\\entity><\\entity> is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in Leber congenital amaurosis (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5214",
    "Sentence": "In humans, loss-of-function of the cilia-centrosomal protein CEP290/NPHP6 is associated with Joubert and Meckel syndromes, whereas hypomorphic mutations result in <\\entity><\\entity> (LCA), a form of early-onset retinal dystrophy.",
    "Label": ""
  },
  {
    "id": "5216",
    "Sentence": "Here, we report that <\\entity><\\entity> exhibit severely abnormal olfactory function.",
    "Label": ""
  },
  {
    "id": "5217",
    "Sentence": "Here, we report that CEP290-<\\entity><\\entity> patients exhibit severely abnormal olfactory function.",
    "Label": ""
  },
  {
    "id": "5219",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5220",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of CEP290-<\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "5222",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5223",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [<\\entity><\\entity>-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of CEP290-LCA patients.",
    "Label": ""
  },
  {
    "id": "5225",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [retinal dystrophy-16 mice (<\\entity><\\entity>)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of CEP290-LCA patients.",
    "Label": ""
  },
  {
    "id": "5226",
    "Sentence": "In a mouse model with hypomorphic mutations in CEP290 [retinal dystrophy-16 mice (rd16)], electro-olfactogram recordings revealed an anosmic phenotype analogous to that of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5232",
    "Sentence": "<\\entity><\\entity> is associated with decreased expression of mucosal interleukin 22 receptor.INTRODUCTION: <\\entity><\\entity> (CRSwNP) is an inflammatory disorder of the sinonasal mucosa that is frequently associated with microbial colonization.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5233",
    "Sentence": "Chronic rhinosinusitis with nasal polyps is associated with decreased expression of mucosal <\\entity><\\entity>.INTRODUCTION: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disorder of the sinonasal mucosa that is frequently associated with microbial colonization.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5234",
    "Sentence": "<\\entity><\\entity> is associated with decreased expression of mucosal interleukin 22 receptor.INTRODUCTION: <\\entity><\\entity> (CRSwNP) is an inflammatory disorder of the sinonasal mucosa that is frequently associated with microbial colonization.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5235",
    "Sentence": "Chronic rhinosinusitis with nasal polyps is associated with decreased expression of mucosal interleukin 22 receptor.INTRODUCTION: Chronic rhinosinusitis with nasal polyps (<\\entity><\\entity>) is an inflammatory disorder of the sinonasal mucosa that is frequently associated with microbial colonization.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5236",
    "Sentence": "Chronic rhinosinusitis with nasal polyps is associated with decreased expression of mucosal interleukin 22 receptor.INTRODUCTION: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an <\\entity><\\entity> of the sinonasal mucosa that is frequently associated with microbial colonization.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5237",
    "Sentence": "Chronic rhinosinusitis with nasal polyps is associated with decreased expression of mucosal interleukin 22 receptor.INTRODUCTION: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disorder of the sinonasal mucosa that is frequently associated with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5238",
    "Sentence": "Recent studies of <\\entity><\\entity> and gastrointestinal tract inflammatory diseases have shown that stimulation of the interleukin-22 receptor (IL-22R1) nonspecifically increases innate immune responses.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5239",
    "Sentence": "Recent studies of skin and <\\entity><\\entity> have shown that stimulation of the interleukin-22 receptor (IL-22R1) nonspecifically increases innate immune responses.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5240",
    "Sentence": "Recent studies of skin and gastrointestinal tract inflammatory diseases have shown that stimulation of the <\\entity><\\entity> (IL-22R1) nonspecifically increases innate immune responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5241",
    "Sentence": "Recent studies of skin and gastrointestinal tract inflammatory diseases have shown that stimulation of the interleukin-22 receptor (<\\entity><\\entity>) nonspecifically increases innate immune responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5242",
    "Sentence": "Recent studies of skin and gastrointestinal tract inflammatory diseases have shown that stimulation of the interleukin-22 receptor (IL-22R1) nonspecifically increases <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5243",
    "Sentence": "The potential role of <\\entity><\\entity> in the pathogenesis of CRSwNP has never been explored.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5244",
    "Sentence": "The potential role of IL-22R1 in the <\\entity><\\entity> of CRSwNP has never been explored.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5245",
    "Sentence": "The potential role of IL-22R1 in the pathogenesis of <\\entity><\\entity> has never been explored.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5246",
    "Sentence": "METHODS: Nine controls and 19 subjects with <\\entity><\\entity> were prospectively enrolled prior to undergoing endoscopic sinus surgery.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5247",
    "Sentence": "METHODS: Nine controls and 19 subjects with <\\entity><\\entity> were prospectively enrolled prior to undergoing endoscopic sinus surgery.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5248",
    "Sentence": "METHODS: Nine controls and 19 subjects with CRS were prospectively enrolled prior to undergoing endoscopic <\\entity><\\entity> surgery.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5249",
    "Sentence": "Nasal epithelial cells were cultured from surgically obtained ethmoid mucosa and <\\entity><\\entity> protein expression was examined via flow cytometry.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5250",
    "Sentence": "RNA was extracted from whole mucosal samples and real-time polymerase chain reaction (PCR) was employed to determine expression of <\\entity><\\entity> and IL-22R1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5251",
    "Sentence": "RNA was extracted from whole mucosal samples and real-time polymerase chain reaction (PCR) was employed to determine expression of IL22 and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5252",
    "Sentence": "Subjects were followed for at least 6 months postoperative to assess for recurrence or persistence of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5253",
    "Sentence": "RESULTS: Flow cytometry demonstrated the expression of <\\entity><\\entity> protein on the surface of cultured nasal epithelial cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5254",
    "Sentence": "<\\entity><\\entity> mRNA was expressed in 100% of the controls and CRSsNP.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5255",
    "Sentence": "IL-22R1 mRNA was expressed in 100% of the controls and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5256",
    "Sentence": "However, <\\entity><\\entity> was only expressed in 55% of patients with recalcitrant CRSwNP.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5257",
    "Sentence": "However, IL-22R1 was only expressed in 55% of patients with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5258",
    "Sentence": "Additionally, levels of <\\entity><\\entity> were significantly lower in recalcitrant CRSwNP compared to controls and CRSsNP.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5259",
    "Sentence": "Additionally, levels of IL22R1 were significantly lower in <\\entity><\\entity> compared to controls and CRSsNP.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5260",
    "Sentence": "Additionally, levels of IL22R1 were significantly lower in recalcitrant CRSwNP compared to controls and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5261",
    "Sentence": "<\\entity><\\entity> levels did not reach statistical significance.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5262",
    "Sentence": "CONCLUSIONS: In this study, we demonstrate <\\entity><\\entity> mRNA and protein expression on nasal epithelial cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5263",
    "Sentence": "Failure of medical and surgical therapy in <\\entity><\\entity> is associated with significantly decreased expression of IL-22R1.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5264",
    "Sentence": "Failure of medical and surgical therapy in CRSwNP is associated with significantly decreased expression of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5265",
    "Sentence": "Further research is needed to determine the potential of <\\entity><\\entity> as a therapeutic target in CRSwNP.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5266",
    "Sentence": "Further research is needed to determine the potential of IL-22R1 as a therapeutic target in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5267",
    "Sentence": "Chronic rhinosinusitis with nasal polyps is associated with decreased expression of mucosal <\\entity><\\entity>.INTRODUCTION: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disorder of the sinonasal mucosa that is frequently associated with microbial colonization.",
    "Label": ""
  },
  {
    "id": "5268",
    "Sentence": "<\\entity><\\entity> is associated with decreased expression of mucosal interleukin 22 receptor.INTRODUCTION: <\\entity><\\entity> (CRSwNP) is an inflammatory disorder of the sinonasal mucosa that is frequently associated with microbial colonization.",
    "Label": ""
  },
  {
    "id": "5270",
    "Sentence": "<\\entity><\\entity> mRNA was expressed in 100% of the controls and CRSsNP.",
    "Label": ""
  },
  {
    "id": "5271",
    "Sentence": "IL-22R1 mRNA was expressed in 100% of the controls and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5273",
    "Sentence": "However, <\\entity><\\entity> was only expressed in 55% of patients with recalcitrant CRSwNP.",
    "Label": ""
  },
  {
    "id": "5274",
    "Sentence": "However, IL-22R1 was only expressed in 55% of patients with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5276",
    "Sentence": "Additionally, levels of <\\entity><\\entity> were significantly lower in recalcitrant CRSwNP compared to controls and CRSsNP.",
    "Label": ""
  },
  {
    "id": "5277",
    "Sentence": "Additionally, levels of IL22R1 were significantly lower in <\\entity><\\entity> compared to controls and CRSsNP.",
    "Label": ""
  },
  {
    "id": "5279",
    "Sentence": "Failure of medical and surgical therapy in CRSwNP is associated with significantly decreased expression of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5280",
    "Sentence": "Failure of medical and surgical therapy in <\\entity><\\entity> is associated with significantly decreased expression of IL-22R1.",
    "Label": ""
  },
  {
    "id": "5282",
    "Sentence": "Further research is needed to determine the potential of <\\entity><\\entity> as a therapeutic target in CRSwNP.",
    "Label": ""
  },
  {
    "id": "5283",
    "Sentence": "Further research is needed to determine the potential of IL-22R1 as a therapeutic target in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5285",
    "Sentence": "Recent studies of skin and gastrointestinal tract inflammatory diseases have shown that stimulation of the <\\entity><\\entity> (IL-22R1) nonspecifically increases innate immune responses.",
    "Label": ""
  },
  {
    "id": "5286",
    "Sentence": "Recent studies of skin and <\\entity><\\entity> have shown that stimulation of the interleukin-22 receptor (IL-22R1) nonspecifically increases innate immune responses.",
    "Label": ""
  },
  {
    "id": "5288",
    "Sentence": "Recent studies of skin and gastrointestinal tract inflammatory diseases have shown that stimulation of the <\\entity><\\entity> (IL-22R1) nonspecifically increases innate immune responses.",
    "Label": ""
  },
  {
    "id": "5289",
    "Sentence": "Recent studies of skin and gastrointestinal tract inflammatory diseases have shown that stimulation of the interleukin-22 receptor (IL-22R1) nonspecifically increases <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5291",
    "Sentence": "METHODS: Nine controls and 19 subjects with <\\entity><\\entity> were prospectively enrolled prior to undergoing endoscopic sinus surgery.",
    "Label": ""
  },
  {
    "id": "5292",
    "Sentence": "METHODS: Nine controls and 19 subjects with CRS were prospectively enrolled prior to undergoing endoscopic <\\entity><\\entity> surgery.",
    "Label": ""
  },
  {
    "id": "5294",
    "Sentence": "The potential role of <\\entity><\\entity> in the pathogenesis of CRSwNP has never been explored.",
    "Label": ""
  },
  {
    "id": "5295",
    "Sentence": "The potential role of IL-22R1 in the pathogenesis of <\\entity><\\entity> has never been explored.",
    "Label": ""
  },
  {
    "id": "5297",
    "Sentence": "Additionally, levels of <\\entity><\\entity> were significantly lower in recalcitrant CRSwNP compared to controls and CRSsNP.",
    "Label": ""
  },
  {
    "id": "5298",
    "Sentence": "Additionally, levels of IL22R1 were significantly lower in recalcitrant CRSwNP compared to controls and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5300",
    "Sentence": "Additionally, levels of <\\entity><\\entity> were significantly lower in recalcitrant CRSwNP compared to controls and CRSsNP.",
    "Label": ""
  },
  {
    "id": "5301",
    "Sentence": "Additionally, levels of IL22R1 were significantly lower in recalcitrant CRSwNP compared to controls and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5307",
    "Sentence": "HOpe for <\\entity><\\entity>.Contrast-induced nephropathy (CIN) is a common cause of acute kidney injury in hospitalized patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5308",
    "Sentence": "HOpe for <\\entity><\\entity>.Contrast-induced nephropathy (CIN) is a common cause of acute kidney injury in hospitalized patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5309",
    "Sentence": "HOpe for contrast-induced acute kidney injury.<\\entity><\\entity> (CIN) is a common cause of acute kidney injury in hospitalized patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5310",
    "Sentence": "HOpe for contrast-induced acute kidney injury.<\\entity><\\entity> (CIN) is a common cause of acute kidney injury in hospitalized patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5311",
    "Sentence": "HOpe for contrast-induced acute kidney injury.Contrast-induced nephropathy (<\\entity><\\entity>) is a common cause of acute kidney injury in hospitalized patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5312",
    "Sentence": "HOpe for contrast-induced <\\entity><\\entity>.Contrast-induced nephropathy (CIN) is a common cause of <\\entity><\\entity> in hospitalized patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5313",
    "Sentence": "The mechanisms involved in the <\\entity><\\entity> of CIN are incompletely understood.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5314",
    "Sentence": "The mechanisms involved in the pathogenesis of <\\entity><\\entity> are incompletely understood.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5315",
    "Sentence": "have demonstrated for the first time that heme oxygenase-1, a 32-kilodalton protein with antioxidant, antiapoptotic, anti-inflammatory effects, is induced in the kidney and, importantly, provides a beneficial effect in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5316",
    "Sentence": "HOpe for <\\entity><\\entity>.Contrast-induced nephropathy (CIN) is a common cause of acute kidney injury in hospitalized patients.",
    "Label": ""
  },
  {
    "id": "5317",
    "Sentence": "HOpe for <\\entity><\\entity>.Contrast-induced nephropathy (CIN) is a common cause of acute kidney injury in hospitalized patients.",
    "Label": ""
  },
  {
    "id": "5319",
    "Sentence": "HOpe for contrast-induced acute kidney injury.<\\entity><\\entity> (CIN) is a common cause of acute kidney injury in hospitalized patients.",
    "Label": ""
  },
  {
    "id": "5320",
    "Sentence": "HOpe for contrast-induced acute kidney injury.<\\entity><\\entity> (CIN) is a common cause of acute kidney injury in hospitalized patients.",
    "Label": ""
  },
  {
    "id": "5322",
    "Sentence": "HOpe for contrast-induced acute kidney injury.<\\entity><\\entity> (CIN) is a common cause of acute kidney injury in hospitalized patients.",
    "Label": ""
  },
  {
    "id": "5323",
    "Sentence": "HOpe for contrast-induced <\\entity><\\entity>.Contrast-induced nephropathy (CIN) is a common cause of <\\entity><\\entity> in hospitalized patients.",
    "Label": ""
  },
  {
    "id": "5325",
    "Sentence": "HOpe for contrast-induced acute kidney injury.<\\entity><\\entity> (CIN) is a common cause of acute kidney injury in hospitalized patients.",
    "Label": ""
  },
  {
    "id": "5326",
    "Sentence": "HOpe for contrast-induced acute kidney injury.Contrast-induced nephropathy (<\\entity><\\entity>) is a common cause of acute kidney injury in hospitalized patients.",
    "Label": ""
  },
  {
    "id": "5332",
    "Sentence": "Regulation of <\\entity><\\entity> function and cell surface expression by D3 dopamine receptors.D(3) dopamine receptors are expressed by dopamine neurons and are implicated in the modulation of presynaptic dopamine neurotransmission.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5333",
    "Sentence": "Regulation of <\\entity><\\entity> function and cell surface expression by D3 dopamine receptors.D(3) dopamine receptors are expressed by dopamine neurons and are implicated in the modulation of presynaptic dopamine neurotransmission.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5334",
    "Sentence": "Regulation of dopamine transporter function and cell surface expression by <\\entity><\\entity>.D(3) dopamine receptors are expressed by dopamine neurons and are implicated in the modulation of presynaptic dopamine neurotransmission.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5335",
    "Sentence": "Regulation of <\\entity><\\entity> transporter function and cell surface expression by D3 <\\entity><\\entity> receptors.D(3) <\\entity><\\entity> receptors are expressed by <\\entity><\\entity> neurons and are implicated in the modulation of presynaptic <\\entity><\\entity> neurotransmission.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5336",
    "Sentence": "Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors.<\\entity><\\entity> are expressed by dopamine neurons and are implicated in the modulation of presynaptic dopamine neurotransmission.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5337",
    "Sentence": "Regulation of <\\entity><\\entity> transporter function and cell surface expression by D3 <\\entity><\\entity> receptors.D(3) <\\entity><\\entity> receptors are expressed by <\\entity><\\entity> neurons and are implicated in the modulation of presynaptic <\\entity><\\entity> neurotransmission.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5338",
    "Sentence": "Regulation of <\\entity><\\entity> transporter function and cell surface expression by D3 <\\entity><\\entity> receptors.D(3) <\\entity><\\entity> receptors are expressed by <\\entity><\\entity> neurons and are implicated in the modulation of presynaptic <\\entity><\\entity> neurotransmission.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5339",
    "Sentence": "Regulation of <\\entity><\\entity> transporter function and cell surface expression by D3 <\\entity><\\entity> receptors.D(3) <\\entity><\\entity> receptors are expressed by <\\entity><\\entity> neurons and are implicated in the modulation of presynaptic <\\entity><\\entity> neurotransmission.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5340",
    "Sentence": "Regulation of <\\entity><\\entity> transporter function and cell surface expression by D3 <\\entity><\\entity> receptors.D(3) <\\entity><\\entity> receptors are expressed by <\\entity><\\entity> neurons and are implicated in the modulation of presynaptic <\\entity><\\entity> neurotransmission.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5341",
    "Sentence": "Regulation of <\\entity><\\entity> transporter function and cell surface expression by D3 <\\entity><\\entity> receptors.D(3) <\\entity><\\entity> receptors are expressed by <\\entity><\\entity> neurons and are implicated in the modulation of presynaptic <\\entity><\\entity> neurotransmission.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5342",
    "Sentence": "The <\\entity><\\entity>, which terminates dopamine transmission via reuptake of released neurotransmitter, is regulated by receptor- and second messenger-linked signaling pathways.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5343",
    "Sentence": "The <\\entity><\\entity>, which terminates dopamine transmission via reuptake of released neurotransmitter, is regulated by receptor- and second messenger-linked signaling pathways.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5344",
    "Sentence": "The <\\entity><\\entity> transporter, which terminates <\\entity><\\entity> transmission via reuptake of released neurotransmitter, is regulated by receptor- and second messenger-linked signaling pathways.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5345",
    "Sentence": "The <\\entity><\\entity> transporter, which terminates <\\entity><\\entity> transmission via reuptake of released neurotransmitter, is regulated by receptor- and second messenger-linked signaling pathways.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5346",
    "Sentence": "Whether <\\entity><\\entity> regulate dopamine transporter function is unknown.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5347",
    "Sentence": "Whether D3 receptors regulate <\\entity><\\entity> function is unknown.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5348",
    "Sentence": "Whether D3 receptors regulate <\\entity><\\entity> function is unknown.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5349",
    "Sentence": "We addressed this issue using a fluorescent imaging technique that permits real time quantification of <\\entity><\\entity> function in living single cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5350",
    "Sentence": "We addressed this issue using a fluorescent imaging technique that permits real time quantification of <\\entity><\\entity> function in living single cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5351",
    "Sentence": "Accumulation of the <\\entity><\\entity> trans-4-[4-(dimethylamino)styryl]-1-methylpyridinium (ASP(+)) in human embryonic kidney cells expressing human dopamine transporter was saturable and temperature-dependent.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5352",
    "Sentence": "Accumulation of the fluorescent <\\entity><\\entity> transporter substrate trans-4-[4-(dimethylamino)styryl]-1-methylpyridinium (ASP(+)) in human embryonic kidney cells expressing human <\\entity><\\entity> transporter was saturable and temperature-dependent.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5353",
    "Sentence": "Accumulation of the fluorescent <\\entity><\\entity> transporter substrate trans-4-[4-(dimethylamino)styryl]-1-methylpyridinium (ASP(+)) in human embryonic kidney cells expressing human <\\entity><\\entity> transporter was saturable and temperature-dependent.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5354",
    "Sentence": "Accumulation of the fluorescent dopamine transporter substrate <\\entity><\\entity> (ASP(+)) in human embryonic kidney cells expressing human dopamine transporter was saturable and temperature-dependent.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5355",
    "Sentence": "Accumulation of the fluorescent dopamine transporter substrate <\\entity><\\entity> (ASP(+)) in human embryonic kidney cells expressing human dopamine transporter was saturable and temperature-dependent.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5356",
    "Sentence": "Accumulation of the fluorescent dopamine transporter substrate trans-4-[4-(dimethylamino)styryl]-1-methylpyridinium (<\\entity><\\entity>) in human embryonic kidney cells expressing human dopamine transporter was saturable and temperature-dependent.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5357",
    "Sentence": "Accumulation of the fluorescent dopamine transporter substrate trans-4-[4-(dimethylamino)styryl]-1-methylpyridinium (<\\entity><\\entity>) in human embryonic kidney cells expressing human dopamine transporter was saturable and temperature-dependent.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5358",
    "Sentence": "Accumulation of the fluorescent <\\entity><\\entity> substrate trans-4-[4-(dimethylamino)styryl]-1-methylpyridinium (ASP(+)) in human embryonic kidney cells expressing human <\\entity><\\entity> was saturable and temperature-dependent.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5359",
    "Sentence": "Accumulation of the fluorescent <\\entity><\\entity> substrate trans-4-[4-(dimethylamino)styryl]-1-methylpyridinium (ASP(+)) in human embryonic kidney cells expressing human <\\entity><\\entity> was saturable and temperature-dependent.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5360",
    "Sentence": "In cells co-expressing <\\entity><\\entity> and D3 receptors, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of ASP(+) uptake.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5361",
    "Sentence": "In cells co-expressing <\\entity><\\entity> and D3 receptors, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of ASP(+) uptake.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5362",
    "Sentence": "In cells co-expressing dopamine transporter and <\\entity><\\entity>, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of ASP(+) uptake.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5363",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the <\\entity><\\entity> quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of ASP(+) uptake.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5364",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist <\\entity><\\entity> produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of ASP(+) uptake.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5365",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and <\\entity><\\entity> toxin-sensitive increase of ASP(+) uptake.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5366",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of <\\entity><\\entity> uptake.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5367",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of <\\entity><\\entity> uptake.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5368",
    "Sentence": "Similar agonist effects were observed in Neuro2A cells and replicated in human embryonic kidney cells using a radioligand uptake assay in which binding to and activation of <\\entity><\\entity> by [(3)H]dopamine was prevented.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5369",
    "Sentence": "Similar agonist effects were observed in Neuro2A cells and replicated in human embryonic kidney cells using a radioligand uptake assay in which binding to and activation of D3 receptors by <\\entity><\\entity> was prevented.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5370",
    "Sentence": "Similar agonist effects were observed in Neuro2A cells and replicated in human embryonic kidney cells using a radioligand uptake assay in which binding to and activation of D3 receptors by <\\entity><\\entity> was prevented.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5371",
    "Sentence": "<\\entity><\\entity> stimulation activated phosphoinositide 3-kinase and MAPK.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5372",
    "Sentence": "D3 receptor stimulation activated <\\entity><\\entity> and MAPK.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5373",
    "Sentence": "D3 receptor stimulation activated phosphoinositide 3-kinase and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5374",
    "Sentence": "Inhibition of either kinase prevented the <\\entity><\\entity>-induced increase in uptake.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5375",
    "Sentence": "<\\entity><\\entity> activation differentially affected dopamine transporter function and subcellular distribution depending on the duration of agonist exposure.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5376",
    "Sentence": "D3 receptor activation differentially affected <\\entity><\\entity> function and subcellular distribution depending on the duration of agonist exposure.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5377",
    "Sentence": "D3 receptor activation differentially affected <\\entity><\\entity> function and subcellular distribution depending on the duration of agonist exposure.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5378",
    "Sentence": "Biotinylation experiments revealed that the rapid increase of uptake was associated with increased cell surface and decreased intracellular expression and increased <\\entity><\\entity> exocytosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5379",
    "Sentence": "Biotinylation experiments revealed that the rapid increase of uptake was associated with increased cell surface and decreased intracellular expression and increased <\\entity><\\entity> exocytosis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5380",
    "Sentence": "These results demonstrate that <\\entity><\\entity> regulate dopamine transporter function and identify a novel mechanism by which <\\entity><\\entity> regulate extracellular dopamine concentrations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5381",
    "Sentence": "These results demonstrate that D3 receptors regulate <\\entity><\\entity> function and identify a novel mechanism by which D3 receptors regulate extracellular dopamine concentrations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5382",
    "Sentence": "These results demonstrate that D3 receptors regulate <\\entity><\\entity> function and identify a novel mechanism by which D3 receptors regulate extracellular dopamine concentrations.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5383",
    "Sentence": "These results demonstrate that <\\entity><\\entity> regulate dopamine transporter function and identify a novel mechanism by which <\\entity><\\entity> regulate extracellular dopamine concentrations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5384",
    "Sentence": "These results demonstrate that D3 receptors regulate <\\entity><\\entity> transporter function and identify a novel mechanism by which D3 receptors regulate extracellular <\\entity><\\entity> concentrations.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5385",
    "Sentence": "These results demonstrate that D3 receptors regulate <\\entity><\\entity> transporter function and identify a novel mechanism by which D3 receptors regulate extracellular <\\entity><\\entity> concentrations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5386",
    "Sentence": "Regulation of <\\entity><\\entity> transporter function and cell surface expression by D3 <\\entity><\\entity> receptors.D(3) <\\entity><\\entity> receptors are expressed by <\\entity><\\entity> neurons and are implicated in the modulation of presynaptic <\\entity><\\entity> neurotransmission.",
    "Label": ""
  },
  {
    "id": "5387",
    "Sentence": "Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors.<\\entity><\\entity> are expressed by dopamine neurons and are implicated in the modulation of presynaptic dopamine neurotransmission.",
    "Label": ""
  },
  {
    "id": "5389",
    "Sentence": "The <\\entity><\\entity> transporter, which terminates <\\entity><\\entity> transmission via reuptake of released neurotransmitter, is regulated by receptor- and second messenger-linked signaling pathways.",
    "Label": ""
  },
  {
    "id": "5390",
    "Sentence": "The <\\entity><\\entity>, which terminates dopamine transmission via reuptake of released neurotransmitter, is regulated by receptor- and second messenger-linked signaling pathways.",
    "Label": ""
  },
  {
    "id": "5392",
    "Sentence": "Similar agonist effects were observed in Neuro2A cells and replicated in human embryonic kidney cells using a radioligand uptake assay in which binding to and activation of D3 receptors by <\\entity><\\entity> was prevented.",
    "Label": ""
  },
  {
    "id": "5393",
    "Sentence": "Similar agonist effects were observed in Neuro2A cells and replicated in human embryonic kidney cells using a radioligand uptake assay in which binding to and activation of <\\entity><\\entity> by [(3)H]dopamine was prevented.",
    "Label": ""
  },
  {
    "id": "5395",
    "Sentence": "These results demonstrate that D3 receptors regulate <\\entity><\\entity> transporter function and identify a novel mechanism by which D3 receptors regulate extracellular <\\entity><\\entity> concentrations.",
    "Label": ""
  },
  {
    "id": "5396",
    "Sentence": "These results demonstrate that <\\entity><\\entity> regulate dopamine transporter function and identify a novel mechanism by which <\\entity><\\entity> regulate extracellular dopamine concentrations.",
    "Label": ""
  },
  {
    "id": "5398",
    "Sentence": "D3 receptor activation differentially affected <\\entity><\\entity> function and subcellular distribution depending on the duration of agonist exposure.",
    "Label": ""
  },
  {
    "id": "5399",
    "Sentence": "<\\entity><\\entity> activation differentially affected dopamine transporter function and subcellular distribution depending on the duration of agonist exposure.",
    "Label": ""
  },
  {
    "id": "5401",
    "Sentence": "Accumulation of the fluorescent dopamine transporter substrate trans-4-[4-(dimethylamino)styryl]-1-methylpyridinium (<\\entity><\\entity>) in human embryonic kidney cells expressing human dopamine transporter was saturable and temperature-dependent.",
    "Label": ""
  },
  {
    "id": "5402",
    "Sentence": "Accumulation of the fluorescent <\\entity><\\entity> transporter substrate trans-4-[4-(dimethylamino)styryl]-1-methylpyridinium (ASP(+)) in human embryonic kidney cells expressing human <\\entity><\\entity> transporter was saturable and temperature-dependent.",
    "Label": ""
  },
  {
    "id": "5404",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of <\\entity><\\entity> uptake.",
    "Label": ""
  },
  {
    "id": "5405",
    "Sentence": "In cells co-expressing dopamine transporter and <\\entity><\\entity>, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of ASP(+) uptake.",
    "Label": ""
  },
  {
    "id": "5407",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of <\\entity><\\entity> uptake.",
    "Label": ""
  },
  {
    "id": "5408",
    "Sentence": "In cells co-expressing <\\entity><\\entity> and D3 receptors, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of ASP(+) uptake.",
    "Label": ""
  },
  {
    "id": "5410",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist <\\entity><\\entity> produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of ASP(+) uptake.",
    "Label": ""
  },
  {
    "id": "5411",
    "Sentence": "In cells co-expressing dopamine transporter and <\\entity><\\entity>, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of ASP(+) uptake.",
    "Label": ""
  },
  {
    "id": "5413",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist <\\entity><\\entity> produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of ASP(+) uptake.",
    "Label": ""
  },
  {
    "id": "5414",
    "Sentence": "In cells co-expressing <\\entity><\\entity> and D3 receptors, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of ASP(+) uptake.",
    "Label": ""
  },
  {
    "id": "5416",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist <\\entity><\\entity> produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of ASP(+) uptake.",
    "Label": ""
  },
  {
    "id": "5417",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of <\\entity><\\entity> uptake.",
    "Label": ""
  },
  {
    "id": "5419",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the <\\entity><\\entity> quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of ASP(+) uptake.",
    "Label": ""
  },
  {
    "id": "5420",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of <\\entity><\\entity> uptake.",
    "Label": ""
  },
  {
    "id": "5422",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and <\\entity><\\entity> toxin-sensitive increase of ASP(+) uptake.",
    "Label": ""
  },
  {
    "id": "5423",
    "Sentence": "In cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist quinpirole produced a rapid, concentration-dependent, and pertussis toxin-sensitive increase of <\\entity><\\entity> uptake.",
    "Label": ""
  },
  {
    "id": "5429",
    "Sentence": "Discovery of <\\entity><\\entity> (mGluR1) antagonists for the treatment of chronic pain.Metabotropic glutamate receptor 1 (mGluR1) plays important roles in the neurotransmission and pathogenesis of several neurological disorders, including chronic pain.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5430",
    "Sentence": "Discovery of <\\entity><\\entity> (mGluR1) antagonists for the treatment of chronic pain.Metabotropic glutamate receptor 1 (mGluR1) plays important roles in the neurotransmission and pathogenesis of several neurological disorders, including chronic pain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5431",
    "Sentence": "Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (<\\entity><\\entity> for the treatment of chronic pain.Metabotropic glutamate receptor 1 (mGluR1) plays important roles in the neurotransmission and pathogenesis of several neurological disorders, including chronic pain.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5432",
    "Sentence": "Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (<\\entity><\\entity> for the treatment of chronic pain.Metabotropic glutamate receptor 1 (mGluR1) plays important roles in the neurotransmission and pathogenesis of several neurological disorders, including chronic pain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5433",
    "Sentence": "Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (mGluR1) antagonists for the treatment of chronic pain.<\\entity><\\entity> (mGluR1) plays important roles in the neurotransmission and pathogenesis of several neurological disorders, including chronic pain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5434",
    "Sentence": "Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (<\\entity><\\entity>) antagonists for the treatment of chronic pain.Metabotropic glutamate receptor 1 (<\\entity><\\entity>) plays important roles in the neurotransmission and pathogenesis of several neurological disorders, including chronic pain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5435",
    "Sentence": "<\\entity><\\entity> are suggested to be useful for the treatment of pain.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5436",
    "Sentence": "<\\entity><\\entity> are suggested to be useful for the treatment of pain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5437",
    "Sentence": "Herein, we report the discovery of a novel series of <\\entity><\\entity>, such as 23c and 23e, with oral efficacy of ED50 of 8 and 5.1 mg/kg, respectively, in rat spinal nerve ligation neuropathic pain model.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5438",
    "Sentence": "Herein, we report the discovery of a novel series of tetracyclic <\\entity><\\entity> antagonists, such as 23c and 23e, with oral efficacy of ED50 of 8 and 5.1 mg/kg, respectively, in rat spinal nerve ligation neuropathic pain model.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5439",
    "Sentence": "Herein, we report the discovery of a novel series of tetracyclic mGluR1 antagonists, such as <\\entity><\\entity> and 23e, with oral efficacy of ED50 of 8 and 5.1 mg/kg, respectively, in rat spinal nerve ligation neuropathic pain model.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5440",
    "Sentence": "Herein, we report the discovery of a novel series of tetracyclic mGluR1 antagonists, such as 23c and <\\entity><\\entity>, with oral efficacy of ED50 of 8 and 5.1 mg/kg, respectively, in rat spinal nerve ligation neuropathic pain model.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5441",
    "Sentence": "Herein, we report the discovery of a novel series of tetracyclic mGluR1 antagonists, such as <\\entity><\\entity> and 23e, with oral efficacy of ED50 of 8 and 5.1 mg/kg, respectively, in rat spinal nerve ligation neuropathic pain model.",
    "Label": ""
  },
  {
    "id": "5442",
    "Sentence": "Herein, we report the discovery of a novel series of tetracyclic <\\entity><\\entity> antagonists, such as 23c and 23e, with oral efficacy of ED50 of 8 and 5.1 mg/kg, respectively, in rat spinal nerve ligation neuropathic pain model.",
    "Label": ""
  },
  {
    "id": "5444",
    "Sentence": "Herein, we report the discovery of a novel series of tetracyclic mGluR1 antagonists, such as 23c and <\\entity><\\entity>, with oral efficacy of ED50 of 8 and 5.1 mg/kg, respectively, in rat spinal nerve ligation neuropathic pain model.",
    "Label": ""
  },
  {
    "id": "5445",
    "Sentence": "Herein, we report the discovery of a novel series of tetracyclic <\\entity><\\entity> antagonists, such as 23c and 23e, with oral efficacy of ED50 of 8 and 5.1 mg/kg, respectively, in rat spinal nerve ligation neuropathic pain model.",
    "Label": ""
  },
  {
    "id": "5451",
    "Sentence": "Trends in hospitalizations for <\\entity><\\entity>, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005.BACKGROUND: Recent investigations in developed countries have found marked increases in the prevalence of allergic conditions.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5452",
    "Sentence": "Trends in hospitalizations for anaphylaxis, <\\entity><\\entity>, and urticaria in Australia, 1993-1994 to 2004-2005.BACKGROUND: Recent investigations in developed countries have found marked increases in the prevalence of allergic conditions.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5453",
    "Sentence": "Trends in hospitalizations for anaphylaxis, angioedema, and <\\entity><\\entity> in Australia, 1993-1994 to 2004-2005.BACKGROUND: Recent investigations in developed countries have found marked increases in the prevalence of allergic conditions.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5454",
    "Sentence": "Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005.BACKGROUND: Recent investigations in developed countries have found marked increases in the prevalence of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5455",
    "Sentence": "OBJECTIVE: We sought to examine recent time trends in the prevalence of <\\entity><\\entity>, angioedema, and urticaria by describing trends and age and sex differentials in hospitalizations for these conditions in Australia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5456",
    "Sentence": "OBJECTIVE: We sought to examine recent time trends in the prevalence of anaphylaxis, <\\entity><\\entity>, and urticaria by describing trends and age and sex differentials in hospitalizations for these conditions in Australia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5457",
    "Sentence": "OBJECTIVE: We sought to examine recent time trends in the prevalence of anaphylaxis, angioedema, and <\\entity><\\entity> by describing trends and age and sex differentials in hospitalizations for these conditions in Australia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5458",
    "Sentence": "METHODS: Data on hospital admissions and deaths for <\\entity><\\entity>, angioedema, and urticaria were extracted for the periods 1993-1994 to 2004-2005 and 1997-2004, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5459",
    "Sentence": "METHODS: Data on hospital admissions and deaths for anaphylaxis, <\\entity><\\entity>, and urticaria were extracted for the periods 1993-1994 to 2004-2005 and 1997-2004, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5460",
    "Sentence": "METHODS: Data on hospital admissions and deaths for anaphylaxis, angioedema, and <\\entity><\\entity> were extracted for the periods 1993-1994 to 2004-2005 and 1997-2004, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5461",
    "Sentence": "RESULTS: During the study period, there was a continuous increase in the rate of hospital admissions for <\\entity><\\entity> (3.0% per year), urticaria (5.7% per year), and, most notably, anaphylaxis (8.8% per year).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5462",
    "Sentence": "RESULTS: During the study period, there was a continuous increase in the rate of hospital admissions for angioedema (3.0% per year), <\\entity><\\entity> (5.7% per year), and, most notably, anaphylaxis (8.8% per year).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5463",
    "Sentence": "RESULTS: During the study period, there was a continuous increase in the rate of hospital admissions for angioedema (3.0% per year), urticaria (5.7% per year), and, most notably, <\\entity><\\entity> (8.8% per year).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5464",
    "Sentence": "There was a particularly steep increase in the incidence of hospitalization for <\\entity><\\entity> among children aged less than 5 years.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5465",
    "Sentence": "Admissions for <\\entity><\\entity> occurred predominantly in adults, particularly those more than 35 years of age.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5466",
    "Sentence": "Over an 8-year period, there were 106 deaths associated with <\\entity><\\entity> or angioedema.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5467",
    "Sentence": "Over an 8-year period, there were 106 deaths associated with anaphylaxis or <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5468",
    "Sentence": "CONCLUSION: Hospitalization rates for <\\entity><\\entity> are on the increase, but the nature and causative factors differ between adults and children.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5469",
    "Sentence": "The relation of these changes to those in the prevalence of specific <\\entity><\\entity> sensitization in the community requires further investigation in population studies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5470",
    "Sentence": "CLINICAL IMPLICATIONS: Among older persons, <\\entity><\\entity> is becoming an increasing problem.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5471",
    "Sentence": "Among children, hospitalization because of <\\entity><\\entity> is a growing concern.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5476",
    "Sentence": "<\\entity><\\entity> inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5477",
    "Sentence": "Gefitinib inhibition of drug resistance to <\\entity><\\entity> by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of <\\entity><\\entity> hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5478",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating <\\entity><\\entity> in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein <\\entity><\\entity>/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5479",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the <\\entity><\\entity> by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5480",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating <\\entity><\\entity> in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein <\\entity><\\entity>/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5481",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/<\\entity><\\entity> drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5482",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by <\\entity><\\entity> (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5483",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (<\\entity><\\entity>) kinase activity, and to determine whether gefitinib, an <\\entity><\\entity> small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5484",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether <\\entity><\\entity>, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5485",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an <\\entity><\\entity>, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5486",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an <\\entity><\\entity>, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5487",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of <\\entity><\\entity> by inhibiting its extrusion from thyroid cancer cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5488",
    "Sentence": "DESIGN: Extrusion assays using flow cytometry analysis were used to determine the ability of thyroid cancer cells to extrude the chemotherapy drug, <\\entity><\\entity>, via the ABCG2 drug transporter in the presence or absence of gefitinib.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5489",
    "Sentence": "DESIGN: Extrusion assays using flow cytometry analysis were used to determine the ability of thyroid cancer cells to extrude the chemotherapy drug, doxorubicin, via the <\\entity><\\entity> in the presence or absence of gefitinib.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5490",
    "Sentence": "DESIGN: Extrusion assays using flow cytometry analysis were used to determine the ability of thyroid cancer cells to extrude the chemotherapy drug, doxorubicin, via the ABCG2 drug transporter in the presence or absence of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5491",
    "Sentence": "Immunofluorescence was employed to determine the cellular expression of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5492",
    "Sentence": "The <\\entity><\\entity> expression in ARO and WRO cell lines was analyzed by Western blot analysis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5493",
    "Sentence": "The ABCG2 expression in <\\entity><\\entity> and WRO cell lines was analyzed by Western blot analysis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5494",
    "Sentence": "Inactivation of <\\entity><\\entity> kinase by gefitinib was analyzed by Western blot analysis and immunofluorescence.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5495",
    "Sentence": "Inactivation of EGFR kinase by <\\entity><\\entity> was analyzed by Western blot analysis and immunofluorescence.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5496",
    "Sentence": "A terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay was performed to demonstrate <\\entity><\\entity>-mediated apoptosis in the presence of doxorubicin.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5497",
    "Sentence": "A terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay was performed to demonstrate ABCG2-mediated apoptosis in the presence of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5498",
    "Sentence": "Colony formation assays were performed to determine the effect of <\\entity><\\entity> on thyroid cancer cell survival in response to <\\entity><\\entity>, doxorubicin, or the combination of both drugs.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5499",
    "Sentence": "Colony formation assays were performed to determine the effect of <\\entity><\\entity> on thyroid cancer cell survival in response to <\\entity><\\entity>, doxorubicin, or the combination of both drugs.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5500",
    "Sentence": "Colony formation assays were performed to determine the effect of gefitinib on thyroid cancer cell survival in response to gefitinib, <\\entity><\\entity>, or the combination of both drugs.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5501",
    "Sentence": "RESULTS: Inhibition of <\\entity><\\entity> kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5502",
    "Sentence": "RESULTS: Inhibition of EGFR kinase activity by <\\entity><\\entity> causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5503",
    "Sentence": "RESULTS: Inhibition of EGFR kinase activity by gefitinib causes the translocation of the <\\entity><\\entity> away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5504",
    "Sentence": "RESULTS: Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in <\\entity><\\entity> extrusion in thyroid cancer cell lines.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5505",
    "Sentence": "Both <\\entity><\\entity> and WRO demonstrated differential ABCG2 expression, whereas both were sensitized to doxorubicin-induced apoptosis on ABCG2 knockdown with short interfering RNA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5506",
    "Sentence": "Both ARO and WRO demonstrated differential <\\entity><\\entity> expression, whereas both were sensitized to doxorubicin-induced apoptosis on <\\entity><\\entity> knockdown with short interfering RNA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5507",
    "Sentence": "Both ARO and WRO demonstrated differential ABCG2 expression, whereas both were sensitized to <\\entity><\\entity>-induced apoptosis on ABCG2 knockdown with short interfering RNA.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5508",
    "Sentence": "Both ARO and WRO demonstrated differential <\\entity><\\entity> expression, whereas both were sensitized to doxorubicin-induced apoptosis on <\\entity><\\entity> knockdown with short interfering RNA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5509",
    "Sentence": "The addition of <\\entity><\\entity> increases doxorubicin-induced cell death in thyroid cancer cells as measured by colony formation assay.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5510",
    "Sentence": "The addition of gefitinib increases <\\entity><\\entity>-induced cell death in thyroid cancer cells as measured by colony formation assay.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5511",
    "Sentence": "CONCLUSIONS: <\\entity><\\entity> regulates the function of the drug transporter ABCG2/BCRP1 and correlates with ABCG2 protein expression levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5512",
    "Sentence": "CONCLUSIONS: Epidermal growth factor receptor regulates the function of the drug transporter <\\entity><\\entity> and correlates with ABCG2 protein expression levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5513",
    "Sentence": "CONCLUSIONS: Epidermal growth factor receptor regulates the function of the drug transporter <\\entity><\\entity>/BCRP1 and correlates with <\\entity><\\entity> protein expression levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5514",
    "Sentence": "Inactivation of the <\\entity><\\entity> kinase by gefitinib potentiates the cytotoxic effect of doxorubicin in thyroid cancer, most likely by decreasing the ability of the cell to extrude doxorubicin.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5515",
    "Sentence": "Inactivation of the EGFR kinase by <\\entity><\\entity> potentiates the cytotoxic effect of doxorubicin in thyroid cancer, most likely by decreasing the ability of the cell to extrude doxorubicin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5516",
    "Sentence": "Inactivation of the EGFR kinase by gefitinib potentiates the cytotoxic effect of <\\entity><\\entity> in thyroid cancer, most likely by decreasing the ability of the cell to extrude <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5517",
    "Sentence": "Inactivation of the EGFR kinase by gefitinib potentiates the cytotoxic effect of <\\entity><\\entity> in thyroid cancer, most likely by decreasing the ability of the cell to extrude <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5518",
    "Sentence": "The expression of <\\entity><\\entity> may explain in part the ineffectiveness of doxorubicin as a single modality treatment for anaplastic thyroid cancer or for treatment of metastatic follicular thyroid cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5519",
    "Sentence": "The expression of ABCG2 may explain in part the ineffectiveness of <\\entity><\\entity> as a single modality treatment for anaplastic thyroid cancer or for treatment of metastatic follicular thyroid cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5520",
    "Sentence": "Use of this combination treatment of <\\entity><\\entity> and doxorubicin may be a promising therapy for anaplastic thyroid and metastatic follicular thyroid cancer and needs to be investigated further.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5521",
    "Sentence": "Use of this combination treatment of gefitinib and <\\entity><\\entity> may be a promising therapy for anaplastic thyroid and metastatic follicular thyroid cancer and needs to be investigated further.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5522",
    "Sentence": "DESIGN: Extrusion assays using flow cytometry analysis were used to determine the ability of thyroid cancer cells to extrude the chemotherapy drug, <\\entity><\\entity>, via the ABCG2 drug transporter in the presence or absence of gefitinib.",
    "Label": ""
  },
  {
    "id": "5523",
    "Sentence": "DESIGN: Extrusion assays using flow cytometry analysis were used to determine the ability of thyroid cancer cells to extrude the chemotherapy drug, doxorubicin, via the <\\entity><\\entity> in the presence or absence of gefitinib.",
    "Label": ""
  },
  {
    "id": "5525",
    "Sentence": "Inactivation of EGFR kinase by <\\entity><\\entity> was analyzed by Western blot analysis and immunofluorescence.",
    "Label": ""
  },
  {
    "id": "5526",
    "Sentence": "Inactivation of <\\entity><\\entity> kinase by gefitinib was analyzed by Western blot analysis and immunofluorescence.",
    "Label": ""
  },
  {
    "id": "5528",
    "Sentence": "RESULTS: Inhibition of EGFR kinase activity by <\\entity><\\entity> causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines.",
    "Label": ""
  },
  {
    "id": "5529",
    "Sentence": "RESULTS: Inhibition of <\\entity><\\entity> kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines.",
    "Label": ""
  },
  {
    "id": "5531",
    "Sentence": "RESULTS: Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in <\\entity><\\entity> extrusion in thyroid cancer cell lines.",
    "Label": ""
  },
  {
    "id": "5532",
    "Sentence": "RESULTS: Inhibition of EGFR kinase activity by gefitinib causes the translocation of the <\\entity><\\entity> away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines.",
    "Label": ""
  },
  {
    "id": "5534",
    "Sentence": "Inactivation of the EGFR kinase by <\\entity><\\entity> potentiates the cytotoxic effect of doxorubicin in thyroid cancer, most likely by decreasing the ability of the cell to extrude doxorubicin.",
    "Label": ""
  },
  {
    "id": "5535",
    "Sentence": "Inactivation of the <\\entity><\\entity> kinase by gefitinib potentiates the cytotoxic effect of doxorubicin in thyroid cancer, most likely by decreasing the ability of the cell to extrude doxorubicin.",
    "Label": ""
  },
  {
    "id": "5537",
    "Sentence": "Inactivation of the EGFR kinase by gefitinib potentiates the cytotoxic effect of <\\entity><\\entity> in thyroid cancer, most likely by decreasing the ability of the cell to extrude <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5538",
    "Sentence": "Inactivation of the <\\entity><\\entity> kinase by gefitinib potentiates the cytotoxic effect of doxorubicin in thyroid cancer, most likely by decreasing the ability of the cell to extrude doxorubicin.",
    "Label": ""
  },
  {
    "id": "5540",
    "Sentence": "The expression of ABCG2 may explain in part the ineffectiveness of <\\entity><\\entity> as a single modality treatment for anaplastic thyroid cancer or for treatment of metastatic follicular thyroid cancer.",
    "Label": ""
  },
  {
    "id": "5541",
    "Sentence": "The expression of <\\entity><\\entity> may explain in part the ineffectiveness of doxorubicin as a single modality treatment for anaplastic thyroid cancer or for treatment of metastatic follicular thyroid cancer.",
    "Label": ""
  },
  {
    "id": "5543",
    "Sentence": "<\\entity><\\entity> inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5544",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating <\\entity><\\entity> in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein <\\entity><\\entity>/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5546",
    "Sentence": "Gefitinib inhibition of drug resistance to <\\entity><\\entity> by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of <\\entity><\\entity> hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5547",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating <\\entity><\\entity> in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein <\\entity><\\entity>/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5549",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether <\\entity><\\entity>, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5550",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating <\\entity><\\entity> in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein <\\entity><\\entity>/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5552",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether <\\entity><\\entity>, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5553",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an <\\entity><\\entity>, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5555",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of <\\entity><\\entity> by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5556",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating <\\entity><\\entity> in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein <\\entity><\\entity>/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5558",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of <\\entity><\\entity> by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5559",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an <\\entity><\\entity>, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5561",
    "Sentence": "DESIGN: Extrusion assays using flow cytometry analysis were used to determine the ability of thyroid cancer cells to extrude the chemotherapy drug, doxorubicin, via the ABCG2 drug transporter in the presence or absence of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5562",
    "Sentence": "DESIGN: Extrusion assays using flow cytometry analysis were used to determine the ability of thyroid cancer cells to extrude the chemotherapy drug, doxorubicin, via the <\\entity><\\entity> in the presence or absence of gefitinib.",
    "Label": ""
  },
  {
    "id": "5564",
    "Sentence": "A terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay was performed to demonstrate ABCG2-mediated apoptosis in the presence of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5565",
    "Sentence": "A terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay was performed to demonstrate <\\entity><\\entity>-mediated apoptosis in the presence of doxorubicin.",
    "Label": ""
  },
  {
    "id": "5567",
    "Sentence": "RESULTS: Inhibition of EGFR kinase activity by <\\entity><\\entity> causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines.",
    "Label": ""
  },
  {
    "id": "5568",
    "Sentence": "RESULTS: Inhibition of EGFR kinase activity by gefitinib causes the translocation of the <\\entity><\\entity> away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines.",
    "Label": ""
  },
  {
    "id": "5570",
    "Sentence": "RESULTS: Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in <\\entity><\\entity> extrusion in thyroid cancer cell lines.",
    "Label": ""
  },
  {
    "id": "5571",
    "Sentence": "RESULTS: Inhibition of <\\entity><\\entity> kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in thyroid cancer cell lines.",
    "Label": ""
  },
  {
    "id": "5573",
    "Sentence": "Both ARO and WRO demonstrated differential ABCG2 expression, whereas both were sensitized to <\\entity><\\entity>-induced apoptosis on ABCG2 knockdown with short interfering RNA.",
    "Label": ""
  },
  {
    "id": "5574",
    "Sentence": "Both ARO and WRO demonstrated differential <\\entity><\\entity> expression, whereas both were sensitized to doxorubicin-induced apoptosis on <\\entity><\\entity> knockdown with short interfering RNA.",
    "Label": ""
  },
  {
    "id": "5576",
    "Sentence": "Both ARO and WRO demonstrated differential ABCG2 expression, whereas both were sensitized to <\\entity><\\entity>-induced apoptosis on ABCG2 knockdown with short interfering RNA.",
    "Label": ""
  },
  {
    "id": "5577",
    "Sentence": "Both <\\entity><\\entity> and WRO demonstrated differential ABCG2 expression, whereas both were sensitized to doxorubicin-induced apoptosis on ABCG2 knockdown with short interfering RNA.",
    "Label": ""
  },
  {
    "id": "5579",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether <\\entity><\\entity>, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5580",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the <\\entity><\\entity> by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5582",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the breast cancer resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of <\\entity><\\entity> by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5583",
    "Sentence": "Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.OBJECTIVE: To investigate the regulation of the <\\entity><\\entity> by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from thyroid cancer cells.",
    "Label": ""
  },
  {
    "id": "5589",
    "Sentence": "<\\entity><\\entity> in a child with spastic quadriparesis.Botulinum toxins are potent neurotoxins used in a variety of neurological disorders.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5590",
    "Sentence": "Iatrogenic botulism in a child with <\\entity><\\entity>.Botulinum toxins are potent neurotoxins used in a variety of neurological disorders.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5591",
    "Sentence": "Iatrogenic botulism in a child with spastic quadriparesis.<\\entity><\\entity> are potent neurotoxins used in a variety of neurological disorders.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5592",
    "Sentence": "Iatrogenic botulism in a child with spastic quadriparesis.Botulinum toxins are potent neurotoxins used in a variety of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5593",
    "Sentence": "Few pediatric reports have been published to date regarding the potential hazards of therapeutic use of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5594",
    "Sentence": "We describe the case of a 10-year-old boy who developed <\\entity><\\entity> following treatment of spasticity with botulinum toxin type B.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5595",
    "Sentence": "We describe the case of a 10-year-old boy who developed systemic weakness following treatment of <\\entity><\\entity> with botulinum toxin type B.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5596",
    "Sentence": "We describe the case of a 10-year-old boy who developed systemic weakness following treatment of spasticity with <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5597",
    "Sentence": "The patient developed <\\entity><\\entity> with ptosis, facial diplegia, neck flexor and extensor weakness, and profound hypopharyngeal laxity with respiratory compromise from which he eventually recovered.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5598",
    "Sentence": "The patient developed iatrogenic botulism with <\\entity><\\entity>, facial diplegia, neck flexor and extensor weakness, and profound hypopharyngeal laxity with respiratory compromise from which he eventually recovered.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5599",
    "Sentence": "The patient developed iatrogenic botulism with ptosis, <\\entity><\\entity>, neck flexor and extensor weakness, and profound hypopharyngeal laxity with respiratory compromise from which he eventually recovered.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5600",
    "Sentence": "The patient developed iatrogenic botulism with ptosis, facial diplegia, <\\entity><\\entity> and extensor weakness, and profound hypopharyngeal laxity with respiratory compromise from which he eventually recovered.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5601",
    "Sentence": "The patient developed iatrogenic botulism with ptosis, facial diplegia, neck flexor and <\\entity><\\entity>, and profound hypopharyngeal laxity with respiratory compromise from which he eventually recovered.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5602",
    "Sentence": "The patient developed iatrogenic botulism with ptosis, facial diplegia, neck flexor and extensor weakness, and <\\entity><\\entity> with respiratory compromise from which he eventually recovered.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5603",
    "Sentence": "Clinicians should be mindful of the risk for <\\entity><\\entity> when using local injections of the neurotoxin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5604",
    "Sentence": "Clinicians should be mindful of the risk for systemic botulism when using local injections of the <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5605",
    "Sentence": "Iatrogenic botulism in a child with spastic quadriparesis.<\\entity><\\entity> are potent neurotoxins used in a variety of neurological disorders.",
    "Label": ""
  },
  {
    "id": "5606",
    "Sentence": "Iatrogenic botulism in a child with spastic quadriparesis.Botulinum toxins are potent neurotoxins used in a variety of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5608",
    "Sentence": "We describe the case of a 10-year-old boy who developed systemic weakness following treatment of spasticity with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5609",
    "Sentence": "We describe the case of a 10-year-old boy who developed systemic weakness following treatment of <\\entity><\\entity> with botulinum toxin type B.",
    "Label": ""
  },
  {
    "id": "5611",
    "Sentence": "We describe the case of a 10-year-old boy who developed systemic weakness following treatment of spasticity with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5612",
    "Sentence": "We describe the case of a 10-year-old boy who developed <\\entity><\\entity> following treatment of spasticity with botulinum toxin type B.",
    "Label": ""
  },
  {
    "id": "5614",
    "Sentence": "Clinicians should be mindful of the risk for systemic botulism when using local injections of the <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5615",
    "Sentence": "Clinicians should be mindful of the risk for <\\entity><\\entity> when using local injections of the neurotoxin.",
    "Label": ""
  },
  {
    "id": "5621",
    "Sentence": "Activity of <\\entity><\\entity>, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.<\\entity><\\entity> sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5622",
    "Sentence": "Activity of SU11248, a <\\entity><\\entity> and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5623",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and <\\entity><\\entity>, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5624",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with <\\entity><\\entity> and various other solid tumors.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5625",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other <\\entity><\\entity>.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5626",
    "Sentence": "Activity of <\\entity><\\entity>, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.<\\entity><\\entity> sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5627",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 <\\entity><\\entity> sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5628",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 sunitinib malate <\\entity><\\entity> is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5629",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 sunitinib malate sutent is a selective <\\entity><\\entity> including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5630",
    "Sentence": "Its anti<\\entity><\\entity> activity may result from both inhibition of angiogenesis and direct antiproliferative effects on certain <\\entity><\\entity> types.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5631",
    "Sentence": "In several phase I/II/III studies, <\\entity><\\entity> was found to be effective as second and first line treatment in metastatic renal cell carcinoma (RCC).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5632",
    "Sentence": "In several phase I/II/III studies, sutent was found to be effective as second and first line treatment in <\\entity><\\entity> (RCC).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5633",
    "Sentence": "In several phase I/II/III studies, sutent was found to be effective as second and first line treatment in metastatic renal cell carcinoma (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5634",
    "Sentence": "In fact, with a 37% response rate and an additional 48% stable disease <\\entity><\\entity> became the drug of choice for first line treatment in RCC.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5635",
    "Sentence": "In fact, with a 37% response rate and an additional 48% stable disease sutent became the drug of choice for first line treatment in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5636",
    "Sentence": "<\\entity><\\entity> was also effective as second line treatment in patients with gastrointestinal stromal tumors (GIST) with 8% response rate, 70% stable disease and a 20-month median survival.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5637",
    "Sentence": "Sutent was also effective as second line treatment in patients with <\\entity><\\entity> (GIST) with 8% response rate, 70% stable disease and a 20-month median survival.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5638",
    "Sentence": "Sutent was also effective as second line treatment in patients with gastrointestinal stromal tumors (<\\entity><\\entity>) with 8% response rate, 70% stable disease and a 20-month median survival.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5639",
    "Sentence": "Prolonged stable disease was also documented in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5640",
    "Sentence": "In addition, a phase II study in multitreated women with <\\entity><\\entity>, sutent demonstrated a moderate activity with 16% clinical benefit.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5641",
    "Sentence": "In addition, a phase II study in multitreated women with breast cancer, <\\entity><\\entity> demonstrated a moderate activity with 16% clinical benefit.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5642",
    "Sentence": "Finally, in <\\entity><\\entity> (NSCLC) in patients' progressing on chemotherapy sutent was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for lung cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5643",
    "Sentence": "Finally, in non-small cell lung cancer (<\\entity><\\entity>) in patients' progressing on chemotherapy sutent was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for lung cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5644",
    "Sentence": "Finally, in non-small cell lung cancer (NSCLC) in patients' progressing on chemotherapy <\\entity><\\entity> was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for lung cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5645",
    "Sentence": "Finally, in non-small cell <\\entity><\\entity> (NSCLC) in patients' progressing on chemotherapy sutent was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5646",
    "Sentence": "The agent is being tested in other <\\entity><\\entity> with a modified schedule of dosage.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5647",
    "Sentence": "In several phase I/II/III studies, <\\entity><\\entity> was found to be effective as second and first line treatment in metastatic renal cell carcinoma (RCC).",
    "Label": ""
  },
  {
    "id": "5648",
    "Sentence": "In several phase I/II/III studies, sutent was found to be effective as second and first line treatment in <\\entity><\\entity> (RCC).",
    "Label": ""
  },
  {
    "id": "5650",
    "Sentence": "In several phase I/II/III studies, <\\entity><\\entity> was found to be effective as second and first line treatment in metastatic renal cell carcinoma (RCC).",
    "Label": ""
  },
  {
    "id": "5651",
    "Sentence": "In several phase I/II/III studies, sutent was found to be effective as second and first line treatment in metastatic renal cell carcinoma (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "5653",
    "Sentence": "In fact, with a 37% response rate and an additional 48% stable disease <\\entity><\\entity> became the drug of choice for first line treatment in RCC.",
    "Label": ""
  },
  {
    "id": "5654",
    "Sentence": "In fact, with a 37% response rate and an additional 48% stable disease sutent became the drug of choice for first line treatment in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5656",
    "Sentence": "<\\entity><\\entity> was also effective as second line treatment in patients with gastrointestinal stromal tumors (GIST) with 8% response rate, 70% stable disease and a 20-month median survival.",
    "Label": ""
  },
  {
    "id": "5657",
    "Sentence": "Sutent was also effective as second line treatment in patients with gastrointestinal stromal tumors (<\\entity><\\entity>) with 8% response rate, 70% stable disease and a 20-month median survival.",
    "Label": ""
  },
  {
    "id": "5659",
    "Sentence": "In addition, a phase II study in multitreated women with breast cancer, <\\entity><\\entity> demonstrated a moderate activity with 16% clinical benefit.",
    "Label": ""
  },
  {
    "id": "5660",
    "Sentence": "In addition, a phase II study in multitreated women with <\\entity><\\entity>, sutent demonstrated a moderate activity with 16% clinical benefit.",
    "Label": ""
  },
  {
    "id": "5662",
    "Sentence": "Finally, in non-small cell lung cancer (NSCLC) in patients' progressing on chemotherapy <\\entity><\\entity> was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for lung cancer.",
    "Label": ""
  },
  {
    "id": "5663",
    "Sentence": "Finally, in non-small cell lung cancer (<\\entity><\\entity>) in patients' progressing on chemotherapy sutent was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for lung cancer.",
    "Label": ""
  },
  {
    "id": "5665",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 sunitinib malate <\\entity><\\entity> is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5666",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including <\\entity><\\entity>-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5668",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 sunitinib malate <\\entity><\\entity> is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5669",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, <\\entity><\\entity>, and RET.",
    "Label": ""
  },
  {
    "id": "5671",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 sunitinib malate <\\entity><\\entity> is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5672",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5674",
    "Sentence": "Finally, in non-small cell lung cancer (NSCLC) in patients' progressing on chemotherapy <\\entity><\\entity> was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for lung cancer.",
    "Label": ""
  },
  {
    "id": "5675",
    "Sentence": "Finally, in non-small cell <\\entity><\\entity> (NSCLC) in patients' progressing on chemotherapy sutent was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5677",
    "Sentence": "Activity of <\\entity><\\entity>, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.<\\entity><\\entity> sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5678",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with <\\entity><\\entity> and various other solid tumors.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5680",
    "Sentence": "Activity of <\\entity><\\entity>, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.<\\entity><\\entity> sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5681",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other <\\entity><\\entity>.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5683",
    "Sentence": "Activity of SU11248, a <\\entity><\\entity> and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5684",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with <\\entity><\\entity> and various other solid tumors.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5686",
    "Sentence": "Activity of SU11248, a <\\entity><\\entity> and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5687",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other <\\entity><\\entity>.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5689",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and <\\entity><\\entity>, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5690",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with <\\entity><\\entity> and various other solid tumors.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5692",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and <\\entity><\\entity>, in patients with metastatic renal cell carcinoma and various other solid tumors.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5693",
    "Sentence": "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other <\\entity><\\entity>.SU11248 sunitinib malate sutent is a selective inhibitor of certain protein tyrosine kinases including VEGF-R types 1-3 PDGF-R-a and -b, c-kit, and RET.",
    "Label": ""
  },
  {
    "id": "5699",
    "Sentence": "<\\entity><\\entity> (Avastin) treatment of diffuse diabetic macular edema in an Indian population.BACKGROUND: To report the anatomic and visual acuity response after intravitreal bevacizumab (Avastin) in patients with diffuse diabetic macular edema.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5700",
    "Sentence": "Intravitreal bevacizumab (<\\entity><\\entity>) treatment of diffuse diabetic macular edema in an Indian population.BACKGROUND: To report the anatomic and visual acuity response after intravitreal bevacizumab (<\\entity><\\entity>) in patients with diffuse diabetic macular edema.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5701",
    "Sentence": "Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population.BACKGROUND: To report the anatomic and visual acuity response after <\\entity><\\entity> (Avastin) in patients with diffuse diabetic macular edema.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5702",
    "Sentence": "Intravitreal bevacizumab (<\\entity><\\entity>) treatment of diffuse diabetic macular edema in an Indian population.BACKGROUND: To report the anatomic and visual acuity response after intravitreal bevacizumab (<\\entity><\\entity>) in patients with diffuse diabetic macular edema.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5703",
    "Sentence": "MATERIALS AND METHODS: This study included 20 eyes of metabolically stable diabetes mellitus with diffuse diabetic macular edema with a mean age of 59 years who were treated with two intravitreal <\\entity><\\entity> 1.25 mg in 0.05 ml six weeks apart.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5704",
    "Sentence": "All the patients received two <\\entity><\\entity> at an interval of six weeks per eye.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5705",
    "Sentence": "The mean baseline acuity was 20/494 (log <\\entity><\\entity>=1.338+/-0.455) and the mean acuity at three months following the second intravitreal injection was 20/295 (log <\\entity><\\entity>=1.094+/-0.254), a difference that was highly significant ( P =0.008).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5706",
    "Sentence": "The mean baseline acuity was 20/494 (log <\\entity><\\entity>=1.338+/-0.455) and the mean acuity at three months following the second intravitreal injection was 20/295 (log <\\entity><\\entity>=1.094+/-0.254), a difference that was highly significant ( P =0.008).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5707",
    "Sentence": "<\\entity><\\entity> resulted in a significant decrease in macular thickness and improvement in visual acuity at three months but the effect was somewhat blunted, though still statistically significant at the end of six months.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5712",
    "Sentence": "<\\entity><\\entity> tissue of fetal origin in utero.Hysteroscopic examination in a woman with secondary infertility revealed calcified tissue in the uterine cavity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5713",
    "Sentence": "Calcified tissue of fetal origin in utero.Hysteroscopic examination in a woman with <\\entity><\\entity> revealed calcified tissue in the uterine cavity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5714",
    "Sentence": "Calcified tissue of fetal origin in utero.Hysteroscopic examination in a woman with secondary infertility revealed <\\entity><\\entity> tissue in the uterine cavity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5715",
    "Sentence": "Calcified tissue of fetal origin in utero.Hysteroscopic examination in a woman with secondary infertility revealed calcified tissue in the uterine <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5720",
    "Sentence": "In vitro <\\entity><\\entity> assays to predict the in vivo interactions of <\\entity><\\entity> with drugs in the central nervous system.Thirty-one structurally diverse marketed central nervous system (CNS)-active drugs, one active metabolite, and seven non-CNS-active compounds were tested in three <\\entity><\\entity> (P-gp) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse Mdr1a-MDCK cells, ATPase, and calcein AM inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5721",
    "Sentence": "In vitro <\\entity><\\entity> assays to predict the in vivo interactions of <\\entity><\\entity> with drugs in the central nervous system.Thirty-one structurally diverse marketed central nervous system (CNS)-active drugs, one active metabolite, and seven non-CNS-active compounds were tested in three <\\entity><\\entity> (P-gp) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse Mdr1a-MDCK cells, ATPase, and calcein AM inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5722",
    "Sentence": "In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the <\\entity><\\entity>.Thirty-one structurally diverse marketed <\\entity><\\entity> (CNS)-active drugs, one active metabolite, and seven non-CNS-active compounds were tested in three P-glycoprotein (P-gp) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse Mdr1a-MDCK cells, ATPase, and calcein AM inhibition.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5723",
    "Sentence": "In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the <\\entity><\\entity>.Thirty-one structurally diverse marketed <\\entity><\\entity> (CNS)-active drugs, one active metabolite, and seven non-CNS-active compounds were tested in three P-glycoprotein (P-gp) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse Mdr1a-MDCK cells, ATPase, and calcein AM inhibition.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5724",
    "Sentence": "In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.Thirty-one structurally diverse marketed central nervous system (<\\entity><\\entity>, one active metabolite, and seven non-CNS-active compounds were tested in three P-glycoprotein (P-gp) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse Mdr1a-MDCK cells, ATPase, and calcein AM inhibition.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5725",
    "Sentence": "In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.Thirty-one structurally diverse marketed central nervous system (CNS)-active drugs, one active metabolite, and seven <\\entity><\\entity> were tested in three P-glycoprotein (P-gp) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse Mdr1a-MDCK cells, ATPase, and calcein AM inhibition.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5726",
    "Sentence": "In vitro <\\entity><\\entity> assays to predict the in vivo interactions of <\\entity><\\entity> with drugs in the central nervous system.Thirty-one structurally diverse marketed central nervous system (CNS)-active drugs, one active metabolite, and seven non-CNS-active compounds were tested in three <\\entity><\\entity> (P-gp) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse Mdr1a-MDCK cells, ATPase, and calcein AM inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5727",
    "Sentence": "In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.Thirty-one structurally diverse marketed central nervous system (CNS)-active drugs, one active metabolite, and seven non-CNS-active compounds were tested in three P-glycoprotein (<\\entity><\\entity>) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse Mdr1a-MDCK cells, ATPase, and calcein AM inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5728",
    "Sentence": "In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.Thirty-one structurally diverse marketed central nervous system (CNS)-active drugs, one active metabolite, and seven non-CNS-active compounds were tested in three P-glycoprotein (P-gp) in vitro assays: transwell assays using MDCK, human <\\entity><\\entity>-MDCK, and mouse Mdr1a-MDCK cells, ATPase, and calcein AM inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5729",
    "Sentence": "In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.Thirty-one structurally diverse marketed central nervous system (CNS)-active drugs, one active metabolite, and seven non-CNS-active compounds were tested in three P-glycoprotein (P-gp) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse <\\entity><\\entity>-MDCK cells, ATPase, and calcein AM inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5730",
    "Sentence": "In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.Thirty-one structurally diverse marketed central nervous system (CNS)-active drugs, one active metabolite, and seven non-CNS-active compounds were tested in three P-glycoprotein (P-gp) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse Mdr1a-MDCK cells, <\\entity><\\entity>, and calcein AM inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5731",
    "Sentence": "In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.Thirty-one structurally diverse marketed central nervous system (CNS)-active drugs, one active metabolite, and seven non-CNS-active compounds were tested in three P-glycoprotein (P-gp) in vitro assays: transwell assays using MDCK, human MDR1-MDCK, and mouse Mdr1a-MDCK cells, ATPase, and <\\entity><\\entity> inhibition.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5732",
    "Sentence": "The exposure of the same set of compounds in brain and plasma was measured in <\\entity><\\entity> knockout (KO) and wild-type (WT) mice after subcutaneous administration.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5733",
    "Sentence": "One drug and its metabolite, <\\entity><\\entity> and 9-hydroxy<\\entity><\\entity>, of the 32 CNS compounds, and 6 of the 7 non-CNS drugs were determined to have positive efflux using ratio of ratios in MDR1-MDCK versus MDCK transwell assays.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5734",
    "Sentence": "One drug and its metabolite, risperidone and <\\entity><\\entity>, of the 32 CNS compounds, and 6 of the 7 non-CNS drugs were determined to have positive efflux using ratio of ratios in MDR1-MDCK versus MDCK transwell assays.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5735",
    "Sentence": "One drug and its metabolite, risperidone and 9-hydroxyrisperidone, of the 32 CNS compounds, and 6 of the 7 non-CNS drugs were determined to have positive efflux using ratio of ratios in <\\entity><\\entity>-MDCK versus MDCK transwell assays.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5736",
    "Sentence": "Data from transwell studies correlated well with the brain-to-plasma area under the curve ratios between <\\entity><\\entity> KO and WT mice for the 32 CNS compounds.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5737",
    "Sentence": "In addition, 3300 Pfizer compounds were tested in <\\entity><\\entity>-MDCK and Mdr1a-MDCK transwell assays, with a good correlation (R(2) = 0.92) between the efflux ratios in human <\\entity><\\entity>-MDCK and mouse Mdr1a-MDCK cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5738",
    "Sentence": "In addition, 3300 Pfizer compounds were tested in MDR1-MDCK and <\\entity><\\entity>-MDCK transwell assays, with a good correlation (R(2) = 0.92) between the efflux ratios in human MDR1-MDCK and mouse <\\entity><\\entity>-MDCK cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5739",
    "Sentence": "In addition, 3300 Pfizer compounds were tested in <\\entity><\\entity>-MDCK and Mdr1a-MDCK transwell assays, with a good correlation (R(2) = 0.92) between the efflux ratios in human <\\entity><\\entity>-MDCK and mouse Mdr1a-MDCK cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5740",
    "Sentence": "In addition, 3300 Pfizer compounds were tested in MDR1-MDCK and <\\entity><\\entity>-MDCK transwell assays, with a good correlation (R(2) = 0.92) between the efflux ratios in human MDR1-MDCK and mouse <\\entity><\\entity>-MDCK cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5741",
    "Sentence": "This work has demonstrated that in vitro transporter assays help in understanding the role of <\\entity><\\entity>-mediated efflux activity in determining the disposition of CNS drugs in vivo, and the transwell assay is a valuable in vitro assay to evaluate human <\\entity><\\entity> interaction with compounds for assessing brain penetration of new chemical entities to treat CNS disorders.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5742",
    "Sentence": "This work has demonstrated that in vitro transporter assays help in understanding the role of <\\entity><\\entity>-mediated efflux activity in determining the disposition of CNS drugs in vivo, and the transwell assay is a valuable in vitro assay to evaluate human <\\entity><\\entity> interaction with compounds for assessing brain penetration of new chemical entities to treat CNS disorders.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5743",
    "Sentence": "One drug and its metabolite, <\\entity><\\entity> and 9-hydroxy<\\entity><\\entity>, of the 32 CNS compounds, and 6 of the 7 non-CNS drugs were determined to have positive efflux using ratio of ratios in MDR1-MDCK versus MDCK transwell assays.",
    "Label": ""
  },
  {
    "id": "5744",
    "Sentence": "One drug and its metabolite, risperidone and 9-hydroxyrisperidone, of the 32 CNS compounds, and 6 of the 7 non-CNS drugs were determined to have positive efflux using ratio of ratios in <\\entity><\\entity>-MDCK versus MDCK transwell assays.",
    "Label": ""
  },
  {
    "id": "5746",
    "Sentence": "One drug and its metabolite, risperidone and <\\entity><\\entity>, of the 32 CNS compounds, and 6 of the 7 non-CNS drugs were determined to have positive efflux using ratio of ratios in MDR1-MDCK versus MDCK transwell assays.",
    "Label": ""
  },
  {
    "id": "5747",
    "Sentence": "One drug and its metabolite, risperidone and 9-hydroxyrisperidone, of the 32 CNS compounds, and 6 of the 7 non-CNS drugs were determined to have positive efflux using ratio of ratios in <\\entity><\\entity>-MDCK versus MDCK transwell assays.",
    "Label": ""
  },
  {
    "id": "5753",
    "Sentence": "<\\entity><\\entity> expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5754",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of <\\entity><\\entity> and estradiol from LDL and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5755",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of <\\entity><\\entity> and estradiol from LDL and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5756",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and <\\entity><\\entity> from LDL and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5757",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and <\\entity><\\entity> from LDL and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5758",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from <\\entity><\\entity> and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5759",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and <\\entity><\\entity>.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5760",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and HDL3.<\\entity><\\entity> transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5761",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and HDL3.Lipoproteins transport many <\\entity><\\entity> and hormones that have been shown to be necessary for bone formation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5762",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and HDL3.Lipoproteins transport many vitamins and <\\entity><\\entity> that have been shown to be necessary for bone formation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5763",
    "Sentence": "However, the metabolism of <\\entity><\\entity> and HDL3 by bone-forming osteoblastic cells remains unknown.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5764",
    "Sentence": "However, the metabolism of LDL and <\\entity><\\entity> by bone-forming osteoblastic cells remains unknown.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5765",
    "Sentence": "Here we report that osteoblastic cells express <\\entity><\\entity> of class B that are implicated in the uptake of cholesterol and estradiol from LDL and HDL3.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5766",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of <\\entity><\\entity> and estradiol from LDL and HDL3.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5767",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of <\\entity><\\entity> and estradiol from LDL and HDL3.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5768",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and <\\entity><\\entity> from LDL and HDL3.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5769",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and <\\entity><\\entity> from LDL and HDL3.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5770",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and estradiol from <\\entity><\\entity> and HDL3.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5771",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and estradiol from LDL and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5772",
    "Sentence": "Recent studies have reported the importance of <\\entity><\\entity> for the delivery of lipophilic vitamins necessary for normal bone metabolism.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5773",
    "Sentence": "Recent studies have reported the importance of <\\entity><\\entity> for the delivery of lipophilic vitamins necessary for normal bone metabolism.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5774",
    "Sentence": "Recent studies have reported the importance of triglyceride-rich lipoproteins for the delivery of <\\entity><\\entity> necessary for normal bone metabolism.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5775",
    "Sentence": "However, the ability of osteoblastic cells to process <\\entity><\\entity>- and high-density lipoproteins (LDL and HDL3) and the receptors involved remain unknown.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5776",
    "Sentence": "However, the ability of osteoblastic cells to process low- and <\\entity><\\entity> (LDL and HDL3) and the receptors involved remain unknown.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5777",
    "Sentence": "However, the ability of osteoblastic cells to process low- and high-density lipoproteins (<\\entity><\\entity> and HDL3) and the receptors involved remain unknown.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5778",
    "Sentence": "However, the ability of osteoblastic cells to process low- and high-density lipoproteins (LDL and <\\entity><\\entity>) and the receptors involved remain unknown.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5779",
    "Sentence": "MATERIALS AND METHODS: Binding, competition, degradation, and selective uptake assays with <\\entity><\\entity> and HDL3 radiolabeled in their protein and lipid moieties or with [3H]estradiol were conducted on human osteoblasts (MG-63 cell line and primary cultures of human osteoblasts [hOB cells]) and on mouse osteoblasts (MC3T3-E1 cell line and primary cultures of murine osteoblasts [mOB cells]).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5780",
    "Sentence": "MATERIALS AND METHODS: Binding, competition, degradation, and selective uptake assays with LDL and <\\entity><\\entity> radiolabeled in their protein and lipid moieties or with [3H]estradiol were conducted on human osteoblasts (MG-63 cell line and primary cultures of human osteoblasts [hOB cells]) and on mouse osteoblasts (MC3T3-E1 cell line and primary cultures of murine osteoblasts [mOB cells]).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5781",
    "Sentence": "MATERIALS AND METHODS: Binding, competition, degradation, and selective uptake assays with LDL and HDL3 radiolabeled in their protein and lipid moieties or with <\\entity><\\entity> were conducted on human osteoblasts (MG-63 cell line and primary cultures of human osteoblasts [hOB cells]) and on mouse osteoblasts (MC3T3-E1 cell line and primary cultures of murine osteoblasts [mOB cells]).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5782",
    "Sentence": "MATERIALS AND METHODS: Binding, competition, degradation, and selective uptake assays with LDL and HDL3 radiolabeled in their protein and lipid moieties or with <\\entity><\\entity> were conducted on human osteoblasts (MG-63 cell line and primary cultures of human osteoblasts [hOB cells]) and on mouse osteoblasts (MC3T3-E1 cell line and primary cultures of murine osteoblasts [mOB cells]).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5783",
    "Sentence": "The expression of <\\entity><\\entity> (SRs) by osteoblastic cells was determined by RT-PCR and Western immunoblotting, and cellular localization was assessed by sucrose gradient fractionation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5784",
    "Sentence": "The expression of scavenger receptors (<\\entity><\\entity>) by osteoblastic cells was determined by RT-PCR and Western immunoblotting, and cellular localization was assessed by sucrose gradient fractionation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5785",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade <\\entity><\\entity> and LDL and are capable of selectively taking up cholesteryl esters (CEs) from these lipoproteins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5786",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and <\\entity><\\entity> and are capable of selectively taking up cholesteryl esters (CEs) from these lipoproteins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5787",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and LDL and are capable of selectively taking up <\\entity><\\entity> (CEs) from these lipoproteins.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5788",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and LDL and are capable of selectively taking up <\\entity><\\entity> (CEs) from these lipoproteins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5789",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and LDL and are capable of selectively taking up cholesteryl esters (<\\entity><\\entity>) from these lipoproteins.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5790",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and LDL and are capable of selectively taking up cholesteryl esters (<\\entity><\\entity>) from these lipoproteins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5791",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and LDL and are capable of selectively taking up cholesteryl esters (CEs) from these <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5792",
    "Sentence": "Also, we provide evidence that osteoblastic cells express <\\entity><\\entity>, <\\entity><\\entity>I, and CD36 (SR-Bs receptors) and that these receptors are localized in membrane lipid rafts or caveolin-rich membranes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5793",
    "Sentence": "Also, we provide evidence that osteoblastic cells express SR-BI, <\\entity><\\entity>, and CD36 (SR-Bs receptors) and that these receptors are localized in membrane lipid rafts or caveolin-rich membranes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5794",
    "Sentence": "Also, we provide evidence that osteoblastic cells express SR-BI, SR-BII, and <\\entity><\\entity> (SR-Bs receptors) and that these receptors are localized in membrane lipid rafts or caveolin-rich membranes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5795",
    "Sentence": "Also, we provide evidence that osteoblastic cells express SR-BI, SR-BII, and CD36 (<\\entity><\\entity>) and that these receptors are localized in membrane lipid rafts or caveolin-rich membranes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5796",
    "Sentence": "Also, we provide evidence that osteoblastic cells express SR-BI, SR-BII, and CD36 (SR-Bs receptors) and that these receptors are localized in membrane lipid rafts or <\\entity><\\entity>-rich membranes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5797",
    "Sentence": "The selective uptake of <\\entity><\\entity> from LDL and HDL3 by osteoblastic cells was strongly inhibited by the known SR-B ligand oxidized LDL, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5798",
    "Sentence": "The selective uptake of <\\entity><\\entity> from LDL and HDL3 by osteoblastic cells was strongly inhibited by the known SR-B ligand oxidized LDL, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5799",
    "Sentence": "The selective uptake of CE from <\\entity><\\entity> and HDL3 by osteoblastic cells was strongly inhibited by the known SR-B ligand oxidized <\\entity><\\entity>, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5800",
    "Sentence": "The selective uptake of CE from LDL and <\\entity><\\entity> by osteoblastic cells was strongly inhibited by the known SR-B ligand oxidized LDL, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5801",
    "Sentence": "The selective uptake of CE from LDL and HDL3 by osteoblastic cells was strongly inhibited by the known <\\entity><\\entity>, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5802",
    "Sentence": "The selective uptake of CE from LDL and HDL3 by osteoblastic cells was strongly inhibited by the known <\\entity><\\entity>, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5803",
    "Sentence": "The selective uptake of CE from LDL and HDL3 by osteoblastic cells was strongly inhibited by the known SR-B ligand oxidized LDL, indicating that <\\entity><\\entity> are responsible for the selective uptake.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5804",
    "Sentence": "Finally, <\\entity><\\entity> carried by LDL and HDL3 was selectively transferred to the osteoblastic cells also through SR-B receptors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5805",
    "Sentence": "Finally, <\\entity><\\entity> carried by LDL and HDL3 was selectively transferred to the osteoblastic cells also through SR-B receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5806",
    "Sentence": "Finally, estradiol carried by <\\entity><\\entity> and HDL3 was selectively transferred to the osteoblastic cells also through SR-B receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5807",
    "Sentence": "Finally, estradiol carried by LDL and <\\entity><\\entity> was selectively transferred to the osteoblastic cells also through SR-B receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5808",
    "Sentence": "Finally, estradiol carried by LDL and HDL3 was selectively transferred to the osteoblastic cells also through <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5809",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of <\\entity><\\entity> and estradiol to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5810",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of <\\entity><\\entity> and estradiol to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5811",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of cholesterol and <\\entity><\\entity> to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5812",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of cholesterol and <\\entity><\\entity> to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5813",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of <\\entity><\\entity> and HDL3 by SR-B receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5814",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of LDL and <\\entity><\\entity> by SR-B receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5815",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of LDL and HDL3 by <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5816",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of <\\entity><\\entity> and estradiol from LDL and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": ""
  },
  {
    "id": "5817",
    "Sentence": "<\\entity><\\entity> expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": ""
  },
  {
    "id": "5819",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of <\\entity><\\entity> and estradiol from LDL and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": ""
  },
  {
    "id": "5820",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from <\\entity><\\entity> and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": ""
  },
  {
    "id": "5822",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of <\\entity><\\entity> and estradiol from LDL and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": ""
  },
  {
    "id": "5823",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and <\\entity><\\entity>.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": ""
  },
  {
    "id": "5825",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and <\\entity><\\entity> from LDL and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": ""
  },
  {
    "id": "5826",
    "Sentence": "<\\entity><\\entity> expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": ""
  },
  {
    "id": "5828",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and <\\entity><\\entity> from LDL and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": ""
  },
  {
    "id": "5829",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from <\\entity><\\entity> and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": ""
  },
  {
    "id": "5831",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and <\\entity><\\entity> from LDL and HDL3.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": ""
  },
  {
    "id": "5832",
    "Sentence": "Scavenger receptor of class B expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from LDL and <\\entity><\\entity>.Lipoproteins transport many vitamins and hormones that have been shown to be necessary for bone formation.",
    "Label": ""
  },
  {
    "id": "5834",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and <\\entity><\\entity> from LDL and HDL3.",
    "Label": ""
  },
  {
    "id": "5835",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and estradiol from <\\entity><\\entity> and HDL3.",
    "Label": ""
  },
  {
    "id": "5837",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and <\\entity><\\entity> from LDL and HDL3.",
    "Label": ""
  },
  {
    "id": "5838",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and estradiol from LDL and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5840",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and <\\entity><\\entity> from LDL and HDL3.",
    "Label": ""
  },
  {
    "id": "5841",
    "Sentence": "Here we report that osteoblastic cells express <\\entity><\\entity> of class B that are implicated in the uptake of cholesterol and estradiol from LDL and HDL3.",
    "Label": ""
  },
  {
    "id": "5843",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of <\\entity><\\entity> and estradiol from LDL and HDL3.",
    "Label": ""
  },
  {
    "id": "5844",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and estradiol from <\\entity><\\entity> and HDL3.",
    "Label": ""
  },
  {
    "id": "5846",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of <\\entity><\\entity> and estradiol from LDL and HDL3.",
    "Label": ""
  },
  {
    "id": "5847",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of cholesterol and estradiol from LDL and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5849",
    "Sentence": "Here we report that osteoblastic cells express scavenger receptors of class B that are implicated in the uptake of <\\entity><\\entity> and estradiol from LDL and HDL3.",
    "Label": ""
  },
  {
    "id": "5850",
    "Sentence": "Here we report that osteoblastic cells express <\\entity><\\entity> of class B that are implicated in the uptake of cholesterol and estradiol from LDL and HDL3.",
    "Label": ""
  },
  {
    "id": "5852",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and LDL and are capable of selectively taking up <\\entity><\\entity> (CEs) from these lipoproteins.",
    "Label": ""
  },
  {
    "id": "5853",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and <\\entity><\\entity> and are capable of selectively taking up cholesteryl esters (CEs) from these lipoproteins.",
    "Label": ""
  },
  {
    "id": "5855",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and LDL and are capable of selectively taking up <\\entity><\\entity> (CEs) from these lipoproteins.",
    "Label": ""
  },
  {
    "id": "5856",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade <\\entity><\\entity> and LDL and are capable of selectively taking up cholesteryl esters (CEs) from these lipoproteins.",
    "Label": ""
  },
  {
    "id": "5858",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and LDL and are capable of selectively taking up <\\entity><\\entity> (CEs) from these lipoproteins.",
    "Label": ""
  },
  {
    "id": "5859",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and LDL and are capable of selectively taking up cholesteryl esters (CEs) from these <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5861",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and LDL and are capable of selectively taking up cholesteryl esters (<\\entity><\\entity>) from these lipoproteins.",
    "Label": ""
  },
  {
    "id": "5862",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and <\\entity><\\entity> and are capable of selectively taking up cholesteryl esters (CEs) from these lipoproteins.",
    "Label": ""
  },
  {
    "id": "5864",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and LDL and are capable of selectively taking up cholesteryl esters (<\\entity><\\entity>) from these lipoproteins.",
    "Label": ""
  },
  {
    "id": "5865",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade <\\entity><\\entity> and LDL and are capable of selectively taking up cholesteryl esters (CEs) from these lipoproteins.",
    "Label": ""
  },
  {
    "id": "5867",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and LDL and are capable of selectively taking up cholesteryl esters (<\\entity><\\entity>) from these lipoproteins.",
    "Label": ""
  },
  {
    "id": "5868",
    "Sentence": "RESULTS: Osteoblastic cells were able to bind, internalize, and degrade HDL3 and LDL and are capable of selectively taking up cholesteryl esters (CEs) from these <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5870",
    "Sentence": "The selective uptake of <\\entity><\\entity> from LDL and HDL3 by osteoblastic cells was strongly inhibited by the known SR-B ligand oxidized LDL, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": ""
  },
  {
    "id": "5871",
    "Sentence": "The selective uptake of CE from <\\entity><\\entity> and HDL3 by osteoblastic cells was strongly inhibited by the known SR-B ligand oxidized <\\entity><\\entity>, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": ""
  },
  {
    "id": "5873",
    "Sentence": "The selective uptake of <\\entity><\\entity> from LDL and HDL3 by osteoblastic cells was strongly inhibited by the known SR-B ligand oxidized LDL, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": ""
  },
  {
    "id": "5874",
    "Sentence": "The selective uptake of CE from LDL and <\\entity><\\entity> by osteoblastic cells was strongly inhibited by the known SR-B ligand oxidized LDL, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": ""
  },
  {
    "id": "5876",
    "Sentence": "The selective uptake of <\\entity><\\entity> from LDL and HDL3 by osteoblastic cells was strongly inhibited by the known SR-B ligand oxidized LDL, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": ""
  },
  {
    "id": "5877",
    "Sentence": "The selective uptake of CE from LDL and HDL3 by osteoblastic cells was strongly inhibited by the known SR-B ligand oxidized LDL, indicating that <\\entity><\\entity> are responsible for the selective uptake.",
    "Label": ""
  },
  {
    "id": "5879",
    "Sentence": "The selective uptake of CE from LDL and HDL3 by osteoblastic cells was strongly inhibited by the known <\\entity><\\entity>, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": ""
  },
  {
    "id": "5880",
    "Sentence": "The selective uptake of CE from <\\entity><\\entity> and HDL3 by osteoblastic cells was strongly inhibited by the known SR-B ligand oxidized <\\entity><\\entity>, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": ""
  },
  {
    "id": "5882",
    "Sentence": "The selective uptake of CE from LDL and HDL3 by osteoblastic cells was strongly inhibited by the known <\\entity><\\entity>, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": ""
  },
  {
    "id": "5883",
    "Sentence": "The selective uptake of CE from LDL and <\\entity><\\entity> by osteoblastic cells was strongly inhibited by the known SR-B ligand oxidized LDL, indicating that SR-B receptors are responsible for the selective uptake.",
    "Label": ""
  },
  {
    "id": "5885",
    "Sentence": "Finally, <\\entity><\\entity> carried by LDL and HDL3 was selectively transferred to the osteoblastic cells also through SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5886",
    "Sentence": "Finally, estradiol carried by <\\entity><\\entity> and HDL3 was selectively transferred to the osteoblastic cells also through SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5888",
    "Sentence": "Finally, <\\entity><\\entity> carried by LDL and HDL3 was selectively transferred to the osteoblastic cells also through SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5889",
    "Sentence": "Finally, estradiol carried by LDL and <\\entity><\\entity> was selectively transferred to the osteoblastic cells also through SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5891",
    "Sentence": "Finally, <\\entity><\\entity> carried by LDL and HDL3 was selectively transferred to the osteoblastic cells also through SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5892",
    "Sentence": "Finally, estradiol carried by LDL and HDL3 was selectively transferred to the osteoblastic cells also through <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5894",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of cholesterol and <\\entity><\\entity> to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5895",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of <\\entity><\\entity> and HDL3 by SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5897",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of cholesterol and <\\entity><\\entity> to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5898",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of LDL and <\\entity><\\entity> by SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5900",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of cholesterol and <\\entity><\\entity> to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5901",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of LDL and HDL3 by <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5903",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of <\\entity><\\entity> and estradiol to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5904",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of <\\entity><\\entity> and HDL3 by SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5906",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of <\\entity><\\entity> and estradiol to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5907",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of LDL and <\\entity><\\entity> by SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5909",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of <\\entity><\\entity> and estradiol to osteoblasts involving the metabolism of LDL and HDL3 by SR-B receptors.",
    "Label": ""
  },
  {
    "id": "5910",
    "Sentence": "CONCLUSIONS: Overall, our results suggest a novel mechanism for the routing of cholesterol and estradiol to osteoblasts involving the metabolism of LDL and HDL3 by <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "5912",
    "Sentence": "Recent studies have reported the importance of <\\entity><\\entity> for the delivery of lipophilic vitamins necessary for normal bone metabolism.",
    "Label": ""
  },
  {
    "id": "5913",
    "Sentence": "Recent studies have reported the importance of <\\entity><\\entity> for the delivery of lipophilic vitamins necessary for normal bone metabolism.",
    "Label": ""
  },
  {
    "id": "5915",
    "Sentence": "MATERIALS AND METHODS: Binding, competition, degradation, and selective uptake assays with LDL and HDL3 radiolabeled in their protein and lipid moieties or with <\\entity><\\entity> were conducted on human osteoblasts (MG-63 cell line and primary cultures of human osteoblasts [hOB cells]) and on mouse osteoblasts (MC3T3-E1 cell line and primary cultures of murine osteoblasts [mOB cells]).",
    "Label": ""
  },
  {
    "id": "5916",
    "Sentence": "MATERIALS AND METHODS: Binding, competition, degradation, and selective uptake assays with <\\entity><\\entity> and HDL3 radiolabeled in their protein and lipid moieties or with [3H]estradiol were conducted on human osteoblasts (MG-63 cell line and primary cultures of human osteoblasts [hOB cells]) and on mouse osteoblasts (MC3T3-E1 cell line and primary cultures of murine osteoblasts [mOB cells]).",
    "Label": ""
  },
  {
    "id": "5918",
    "Sentence": "MATERIALS AND METHODS: Binding, competition, degradation, and selective uptake assays with LDL and HDL3 radiolabeled in their protein and lipid moieties or with <\\entity><\\entity> were conducted on human osteoblasts (MG-63 cell line and primary cultures of human osteoblasts [hOB cells]) and on mouse osteoblasts (MC3T3-E1 cell line and primary cultures of murine osteoblasts [mOB cells]).",
    "Label": ""
  },
  {
    "id": "5919",
    "Sentence": "MATERIALS AND METHODS: Binding, competition, degradation, and selective uptake assays with LDL and <\\entity><\\entity> radiolabeled in their protein and lipid moieties or with [3H]estradiol were conducted on human osteoblasts (MG-63 cell line and primary cultures of human osteoblasts [hOB cells]) and on mouse osteoblasts (MC3T3-E1 cell line and primary cultures of murine osteoblasts [mOB cells]).",
    "Label": ""
  },
  {
    "id": "5925",
    "Sentence": "<\\entity><\\entity>.Tumor necrosis-alpha (TNF-alpha) has been implicated in many forms of inflammation and is an end-stage product of the inflammatory cytokine cascade.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5926",
    "Sentence": "<\\entity><\\entity>.Tumor necrosis-alpha (TNF-alpha) has been implicated in many forms of inflammation and is an end-stage product of the inflammatory cytokine cascade.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5927",
    "Sentence": "TNF- alpha inhibitors.<\\entity><\\entity> (TNF-alpha) has been implicated in many forms of inflammation and is an end-stage product of the inflammatory cytokine cascade.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5928",
    "Sentence": "TNF- alpha inhibitors.Tumor necrosis-alpha (<\\entity><\\entity>) has been implicated in many forms of inflammation and is an end-stage product of the inflammatory cytokine cascade.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5929",
    "Sentence": "The development of agents that block the effects of <\\entity><\\entity> has aided in the treatment of many of these diseases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5930",
    "Sentence": "This article will briefly discuss the production, structure, and administration of the <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5931",
    "Sentence": "This article will briefly discuss the production, structure, and administration of the <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5932",
    "Sentence": "There will be a focus on the mechanism of action of each of the <\\entity><\\entity> as well as their benefit in their FDA approved and non FDA approved dermatologic conditions.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5933",
    "Sentence": "There will be a focus on the mechanism of action of each of the <\\entity><\\entity> as well as their benefit in their FDA approved and non FDA approved dermatologic conditions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5938",
    "Sentence": "Comprehensive biomarker and genomic analysis identifies <\\entity><\\entity> status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and remains incurable with conventional therapies.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5939",
    "Sentence": "Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to <\\entity><\\entity> in chronic lymphocytic leukemia.Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and remains incurable with conventional therapies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5940",
    "Sentence": "Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to <\\entity><\\entity> in chronic lymphocytic leukemia.Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and remains incurable with conventional therapies.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5941",
    "Sentence": "<\\entity><\\entity> have been developed and may have significant potential in the treatment of CLL.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5942",
    "Sentence": "<\\entity><\\entity> have been developed and may have significant potential in the treatment of CLL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5943",
    "Sentence": "To understand determinants of sensitivity or resistance to <\\entity><\\entity> therapy in CLL, we comprehensively analyzed a large cohort of CLL patient-derived samples for response to MDM2 inhibition and correlated these responses with clinically important biomarkers.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5944",
    "Sentence": "To understand determinants of sensitivity or resistance to <\\entity><\\entity> therapy in CLL, we comprehensively analyzed a large cohort of CLL patient-derived samples for response to MDM2 inhibition and correlated these responses with clinically important biomarkers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5945",
    "Sentence": "To understand determinants of sensitivity or resistance to <\\entity><\\entity> inhibitor therapy in CLL, we comprehensively analyzed a large cohort of CLL patient-derived samples for response to <\\entity><\\entity> inhibition and correlated these responses with clinically important biomarkers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5946",
    "Sentence": "Furthermore, we employed high-density single nucleotide polymorphism (SNP) arrays to analyze genomewide changes of copy number and allele status, including that of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5947",
    "Sentence": "The results of these studies conclusively demonstrate that <\\entity><\\entity> status is the major determinant of response to MDM2 inhibitors in CLL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5948",
    "Sentence": "The results of these studies conclusively demonstrate that p53 status is the major determinant of response to <\\entity><\\entity> in CLL.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5949",
    "Sentence": "The results of these studies conclusively demonstrate that p53 status is the major determinant of response to <\\entity><\\entity> in CLL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5950",
    "Sentence": "Additional defects in the <\\entity><\\entity> regulatory cascade do not appear operational in this leukemia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5951",
    "Sentence": "Further, we identify a novel subgroup of patients with CLL with early progressive disease that appears particularly sensitive to <\\entity><\\entity> treatment.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5952",
    "Sentence": "Further, we identify a novel subgroup of patients with CLL with early progressive disease that appears particularly sensitive to <\\entity><\\entity> treatment.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "5953",
    "Sentence": "Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to <\\entity><\\entity> in chronic lymphocytic leukemia.Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and remains incurable with conventional therapies.",
    "Label": ""
  },
  {
    "id": "5954",
    "Sentence": "Comprehensive biomarker and genomic analysis identifies <\\entity><\\entity> status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and remains incurable with conventional therapies.",
    "Label": ""
  },
  {
    "id": "5956",
    "Sentence": "To understand determinants of sensitivity or resistance to <\\entity><\\entity> therapy in CLL, we comprehensively analyzed a large cohort of CLL patient-derived samples for response to MDM2 inhibition and correlated these responses with clinically important biomarkers.",
    "Label": ""
  },
  {
    "id": "5957",
    "Sentence": "To understand determinants of sensitivity or resistance to <\\entity><\\entity> inhibitor therapy in CLL, we comprehensively analyzed a large cohort of CLL patient-derived samples for response to <\\entity><\\entity> inhibition and correlated these responses with clinically important biomarkers.",
    "Label": ""
  },
  {
    "id": "5959",
    "Sentence": "The results of these studies conclusively demonstrate that p53 status is the major determinant of response to <\\entity><\\entity> in CLL.",
    "Label": ""
  },
  {
    "id": "5960",
    "Sentence": "The results of these studies conclusively demonstrate that <\\entity><\\entity> status is the major determinant of response to MDM2 inhibitors in CLL.",
    "Label": ""
  },
  {
    "id": "5966",
    "Sentence": "<\\entity><\\entity> occurring within the red dye of a tattoo.<\\entity><\\entity> (KA) is a common keratinizing squamous cell neoplasm of unknown origin characterized by rapid growth and spontaneous involution.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5967",
    "Sentence": "Keratoacanthoma occurring within the <\\entity><\\entity>.Keratoacanthoma (KA) is a common keratinizing squamous cell neoplasm of unknown origin characterized by rapid growth and spontaneous involution.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5968",
    "Sentence": "Keratoacanthoma occurring within the <\\entity><\\entity>.Keratoacanthoma (KA) is a common keratinizing squamous cell neoplasm of unknown origin characterized by rapid growth and spontaneous involution.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5969",
    "Sentence": "<\\entity><\\entity> occurring within the red dye of a tattoo.<\\entity><\\entity> (KA) is a common keratinizing squamous cell neoplasm of unknown origin characterized by rapid growth and spontaneous involution.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5970",
    "Sentence": "Keratoacanthoma occurring within the red dye of a tattoo.Keratoacanthoma (<\\entity><\\entity>) is a common keratinizing squamous cell neoplasm of unknown origin characterized by rapid growth and spontaneous involution.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5971",
    "Sentence": "Keratoacanthoma occurring within the red dye of a tattoo.Keratoacanthoma (KA) is a common <\\entity><\\entity> of unknown origin characterized by rapid growth and spontaneous involution.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5972",
    "Sentence": "To our knowledge, reports of <\\entity><\\entity> arising at tattoo sites are scarce in the literature.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5973",
    "Sentence": "To our knowledge, reports of KA arising at <\\entity><\\entity> sites are scarce in the literature.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5974",
    "Sentence": "To our knowledge, reports of KA arising at <\\entity><\\entity> sites are scarce in the literature.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5975",
    "Sentence": "A 41-year-old woman with no medical history presented for a rapidly growing <\\entity><\\entity> confined to the red part of a tattoo located on the scapula.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5976",
    "Sentence": "A 41-year-old woman with no medical history presented for a rapidly growing nodule confined to the <\\entity><\\entity> located on the scapula.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5977",
    "Sentence": "A 41-year-old woman with no medical history presented for a rapidly growing nodule confined to the <\\entity><\\entity> located on the scapula.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5978",
    "Sentence": "Histology showed a keratin-filled cuplike crater with an <\\entity><\\entity> (hyperkeratosis, parakeratosis, no keratinocyte atypia).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5979",
    "Sentence": "Histology showed a keratin-filled cuplike crater with an epithelial proliferation (<\\entity><\\entity>, parakeratosis, no keratinocyte atypia).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5980",
    "Sentence": "Histology showed a keratin-filled cuplike crater with an epithelial proliferation (hyperkeratosis, <\\entity><\\entity>, no keratinocyte atypia).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5981",
    "Sentence": "Histology showed a keratin-filled cuplike crater with an epithelial proliferation (hyperkeratosis, parakeratosis, no <\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5982",
    "Sentence": "An inflammatory infiltrate in the dermis composed of lymphocytes and histiocytes intermixed with <\\entity><\\entity> was noted.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5983",
    "Sentence": "Lack of <\\entity><\\entity> and viral inclusions ruled out the diagnosis of viral wart, absence of granulomatous reaction ruled out deep fungal or mycobacterial infection and lack of cytological atypia and frank architectural abnormalities did not favour a squamous cell carcinoma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5984",
    "Sentence": "Lack of papillomatosis and viral inclusions ruled out the diagnosis of <\\entity><\\entity>, absence of granulomatous reaction ruled out deep fungal or mycobacterial infection and lack of cytological atypia and frank architectural abnormalities did not favour a squamous cell carcinoma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5985",
    "Sentence": "Lack of papillomatosis and viral inclusions ruled out the diagnosis of viral wart, <\\entity><\\entity> of granulomatous reaction ruled out deep fungal or mycobacterial infection and lack of cytological atypia and frank architectural abnormalities did not favour a squamous cell carcinoma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5986",
    "Sentence": "Lack of papillomatosis and viral inclusions ruled out the diagnosis of viral wart, absence of granulomatous reaction ruled out deep <\\entity><\\entity> or mycobacterial infection and lack of cytological atypia and frank architectural abnormalities did not favour a squamous cell carcinoma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5987",
    "Sentence": "Lack of papillomatosis and viral inclusions ruled out the diagnosis of viral wart, absence of granulomatous reaction ruled out deep fungal or <\\entity><\\entity> and lack of cytological atypia and frank architectural abnormalities did not favour a squamous cell carcinoma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5988",
    "Sentence": "Lack of papillomatosis and viral inclusions ruled out the diagnosis of viral wart, absence of granulomatous reaction ruled out deep fungal or mycobacterial infection and lack of <\\entity><\\entity> and frank architectural abnormalities did not favour a squamous cell carcinoma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5989",
    "Sentence": "Lack of papillomatosis and viral inclusions ruled out the diagnosis of viral wart, absence of granulomatous reaction ruled out deep fungal or mycobacterial infection and lack of cytological atypia and <\\entity><\\entity> did not favour a squamous cell carcinoma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5990",
    "Sentence": "Lack of papillomatosis and viral inclusions ruled out the diagnosis of viral wart, absence of granulomatous reaction ruled out deep fungal or mycobacterial infection and lack of cytological atypia and frank architectural abnormalities did not favour a <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5991",
    "Sentence": "<\\entity><\\entity> should be included in the list of cutaneous complications related to tattooing.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5992",
    "Sentence": "KA should be included in the list of cutaneous <\\entity><\\entity> related to tattooing.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5993",
    "Sentence": "KA should be included in the list of cutaneous complications related to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "5994",
    "Sentence": "KA should be included in the list of cutaneous complications related to <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5995",
    "Sentence": "Diagnosis can be challenging as differential diagnoses include <\\entity><\\entity> and squamous cell carcinoma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5996",
    "Sentence": "Diagnosis can be challenging as differential diagnoses include pseudoepitheliomatous hyperplasia and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "5997",
    "Sentence": "Keratoacanthoma occurring within the <\\entity><\\entity>.Keratoacanthoma (KA) is a common keratinizing squamous cell neoplasm of unknown origin characterized by rapid growth and spontaneous involution.",
    "Label": ""
  },
  {
    "id": "5998",
    "Sentence": "<\\entity><\\entity> occurring within the red dye of a tattoo.<\\entity><\\entity> (KA) is a common keratinizing squamous cell neoplasm of unknown origin characterized by rapid growth and spontaneous involution.",
    "Label": ""
  },
  {
    "id": "6000",
    "Sentence": "KA should be included in the list of cutaneous complications related to <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6001",
    "Sentence": "<\\entity><\\entity> should be included in the list of cutaneous complications related to tattooing.",
    "Label": ""
  },
  {
    "id": "6007",
    "Sentence": "<\\entity><\\entity> inhibition: a novel target for cancer therapy.During the last decade, sphingolipid deregulation, namely the balance between the pro-apoptotic molecule ceramide and the anti-apoptotic sphingolipid sphingosine-1-phosphate, has emerged as an important factor in cancer pathology and resistance to therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6008",
    "Sentence": "<\\entity><\\entity> inhibition: a novel target for cancer therapy.During the last decade, sphingolipid deregulation, namely the balance between the pro-apoptotic molecule ceramide and the anti-apoptotic sphingolipid sphingosine-1-phosphate, has emerged as an important factor in cancer pathology and resistance to therapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6009",
    "Sentence": "Acid ceramidase inhibition: a novel target for cancer therapy.During the last decade, <\\entity><\\entity> deregulation, namely the balance between the pro-apoptotic molecule ceramide and the anti-apoptotic <\\entity><\\entity> sphingosine-1-phosphate, has emerged as an important factor in cancer pathology and resistance to therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6010",
    "Sentence": "Acid ceramidase inhibition: a novel target for cancer therapy.During the last decade, <\\entity><\\entity> deregulation, namely the balance between the pro-apoptotic molecule ceramide and the anti-apoptotic <\\entity><\\entity> sphingosine-1-phosphate, has emerged as an important factor in cancer pathology and resistance to therapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6011",
    "Sentence": "Acid ceramidase inhibition: a novel target for cancer therapy.During the last decade, sphingolipid deregulation, namely the balance between the pro-apoptotic molecule <\\entity><\\entity> and the anti-apoptotic sphingolipid sphingosine-1-phosphate, has emerged as an important factor in cancer pathology and resistance to therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6012",
    "Sentence": "Acid ceramidase inhibition: a novel target for cancer therapy.During the last decade, sphingolipid deregulation, namely the balance between the pro-apoptotic molecule <\\entity><\\entity> and the anti-apoptotic sphingolipid sphingosine-1-phosphate, has emerged as an important factor in cancer pathology and resistance to therapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6013",
    "Sentence": "Acid ceramidase inhibition: a novel target for cancer therapy.During the last decade, <\\entity><\\entity> deregulation, namely the balance between the pro-apoptotic molecule ceramide and the anti-apoptotic <\\entity><\\entity> sphingosine-1-phosphate, has emerged as an important factor in cancer pathology and resistance to therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6014",
    "Sentence": "Acid ceramidase inhibition: a novel target for cancer therapy.During the last decade, <\\entity><\\entity> deregulation, namely the balance between the pro-apoptotic molecule ceramide and the anti-apoptotic <\\entity><\\entity> sphingosine-1-phosphate, has emerged as an important factor in cancer pathology and resistance to therapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6015",
    "Sentence": "Acid ceramidase inhibition: a novel target for cancer therapy.During the last decade, sphingolipid deregulation, namely the balance between the pro-apoptotic molecule ceramide and the anti-apoptotic sphingolipid <\\entity><\\entity>, has emerged as an important factor in cancer pathology and resistance to therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6016",
    "Sentence": "Acid ceramidase inhibition: a novel target for cancer therapy.During the last decade, sphingolipid deregulation, namely the balance between the pro-apoptotic molecule ceramide and the anti-apoptotic sphingolipid <\\entity><\\entity>, has emerged as an important factor in cancer pathology and resistance to therapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6017",
    "Sentence": "Thus, our research has been focused on developing drugs that are able to restore normal <\\entity><\\entity> balance, precisely through increasing the levels of ceramide and decreasing sphingosine-1-phosphate.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6018",
    "Sentence": "Thus, our research has been focused on developing drugs that are able to restore normal <\\entity><\\entity> balance, precisely through increasing the levels of ceramide and decreasing sphingosine-1-phosphate.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6019",
    "Sentence": "Thus, our research has been focused on developing drugs that are able to restore normal sphingolipid balance, precisely through increasing the levels of <\\entity><\\entity> and decreasing sphingosine-1-phosphate.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6020",
    "Sentence": "Thus, our research has been focused on developing drugs that are able to restore normal sphingolipid balance, precisely through increasing the levels of <\\entity><\\entity> and decreasing sphingosine-1-phosphate.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6021",
    "Sentence": "Thus, our research has been focused on developing drugs that are able to restore normal sphingolipid balance, precisely through increasing the levels of ceramide and decreasing <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6022",
    "Sentence": "Thus, our research has been focused on developing drugs that are able to restore normal sphingolipid balance, precisely through increasing the levels of ceramide and decreasing <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6023",
    "Sentence": "Particularly, inhibition of the <\\entity><\\entity> acid ceramidase, whose over-expression in cancer cells has been implicated in resistance to treatment, is proving to be an efficient and promising strategy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6024",
    "Sentence": "Particularly, inhibition of the <\\entity><\\entity> acid ceramidase, whose over-expression in cancer cells has been implicated in resistance to treatment, is proving to be an efficient and promising strategy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6025",
    "Sentence": "Particularly, inhibition of the ceramide metabolizing enzyme <\\entity><\\entity>, whose over-expression in cancer cells has been implicated in resistance to treatment, is proving to be an efficient and promising strategy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6026",
    "Sentence": "In this review, we consider our recent work with <\\entity><\\entity>, in combination with radiation or gene therapy as a sensitizer that enhance cancer therapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6027",
    "Sentence": "In this review, we consider our recent work with <\\entity><\\entity>, in combination with radiation or gene therapy as a sensitizer that enhance cancer therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6028",
    "Sentence": "Particularly, inhibition of the <\\entity><\\entity> acid ceramidase, whose over-expression in cancer cells has been implicated in resistance to treatment, is proving to be an efficient and promising strategy.",
    "Label": ""
  },
  {
    "id": "6029",
    "Sentence": "Particularly, inhibition of the ceramide metabolizing enzyme <\\entity><\\entity>, whose over-expression in cancer cells has been implicated in resistance to treatment, is proving to be an efficient and promising strategy.",
    "Label": ""
  },
  {
    "id": "6035",
    "Sentence": "<\\entity><\\entity> regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65.MAPK-p38 plays an important role in inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6036",
    "Sentence": "MAPK p38 regulates transcriptional activity of <\\entity><\\entity> in primary human astrocytes via acetylation of p65.MAPK-p38 plays an important role in inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6037",
    "Sentence": "MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of <\\entity><\\entity>.MAPK-p38 plays an important role in inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6038",
    "Sentence": "MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65.<\\entity><\\entity> plays an important role in inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6039",
    "Sentence": "Several studies have shown that blocking <\\entity><\\entity> activity attenuates the transcriptional activity of the proinflammatory transcription factor NF-kappaB without altering its DNA-binding activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6040",
    "Sentence": "Several studies have shown that blocking p38 activity attenuates the transcriptional activity of the proinflammatory transcription factor <\\entity><\\entity> without altering its DNA-binding activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6041",
    "Sentence": "We have also observed that blocking <\\entity><\\entity> in human primary astrocytes suppresses the transcriptional but not the DNA-binding activity of NF-kappaB and down-regulates the expression of an NF-kappaB-dependent gene, inducible NO synthase.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6042",
    "Sentence": "We have also observed that blocking p38 in human primary astrocytes suppresses the transcriptional but not the DNA-binding activity of <\\entity><\\entity> and down-regulates the expression of an <\\entity><\\entity>-dependent gene, inducible NO synthase.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6043",
    "Sentence": "We have also observed that blocking p38 in human primary astrocytes suppresses the transcriptional but not the DNA-binding activity of NF-kappaB and down-regulates the expression of an <\\entity><\\entity>, inducible NO synthase.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6044",
    "Sentence": "We have also observed that blocking p38 in human primary astrocytes suppresses the transcriptional but not the DNA-binding activity of NF-kappaB and down-regulates the expression of an NF-kappaB-dependent gene, <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6045",
    "Sentence": "However, the molecular mechanism of <\\entity><\\entity>-mediated regulation of NF-kappaB remains largely unknown.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6046",
    "Sentence": "However, the molecular mechanism of p38-mediated regulation of <\\entity><\\entity> remains largely unknown.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6047",
    "Sentence": "In this study, we delineate that <\\entity><\\entity> controls the transcriptional activity of NF-kappaB by regulating acetylation of p65, but not its phosphorylation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6048",
    "Sentence": "In this study, we delineate that p38 controls the transcriptional activity of <\\entity><\\entity> by regulating acetylation of p65, but not its phosphorylation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6049",
    "Sentence": "In this study, we delineate that p38 controls the transcriptional activity of NF-kappaB by regulating acetylation of <\\entity><\\entity>, but not its phosphorylation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6050",
    "Sentence": "The combination of <\\entity><\\entity> and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6051",
    "Sentence": "The combination of <\\entity><\\entity> and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6052",
    "Sentence": "The combination of IL-1beta and <\\entity><\\entity>, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6053",
    "Sentence": "The combination of IL-1beta and <\\entity><\\entity>, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6054",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce <\\entity><\\entity> in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6055",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced <\\entity><\\entity>-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6056",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of <\\entity><\\entity> coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6057",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator <\\entity><\\entity>, but not p65, and subsequent association of <\\entity><\\entity> with p65.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6058",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not <\\entity><\\entity>, and subsequent association of p300 with <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6059",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator <\\entity><\\entity>, but not p65, and subsequent association of <\\entity><\\entity> with p65.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6060",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not <\\entity><\\entity>, and subsequent association of p300 with <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6061",
    "Sentence": "Furthermore, immunocomplex-histone <\\entity><\\entity> assays demonstrated that cytokine-induced association of p65 with biologically active immunocomplex-histone <\\entity><\\entity> assay was dependent on p38.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6062",
    "Sentence": "Furthermore, immunocomplex-histone acetyltransferase assays demonstrated that cytokine-induced association of <\\entity><\\entity> with biologically active immunocomplex-histone acetyltransferase assay was dependent on p38.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6063",
    "Sentence": "Furthermore, immunocomplex-histone <\\entity><\\entity> assays demonstrated that cytokine-induced association of p65 with biologically active immunocomplex-histone <\\entity><\\entity> assay was dependent on p38.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6064",
    "Sentence": "Furthermore, immunocomplex-histone acetyltransferase assays demonstrated that cytokine-induced association of p65 with biologically active immunocomplex-histone acetyltransferase assay was dependent on <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6065",
    "Sentence": "It has been previously reported that acetylation of <\\entity><\\entity> at K310 residue is important for transcriptional activity of NF-kappaB.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6066",
    "Sentence": "It has been previously reported that acetylation of p65 at K310 residue is important for transcriptional activity of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6067",
    "Sentence": "Accordingly, we found that cytokine-induced association of <\\entity><\\entity> with p300 led to acetylation of <\\entity><\\entity> at K310.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6068",
    "Sentence": "Accordingly, we found that cytokine-induced association of p65 with <\\entity><\\entity> led to acetylation of p65 at K310.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6069",
    "Sentence": "Accordingly, we found that cytokine-induced association of <\\entity><\\entity> with p300 led to acetylation of <\\entity><\\entity> at K310.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6070",
    "Sentence": "Because <\\entity><\\entity> regulated the association between p65 and p300, blocking <\\entity><\\entity> activity also led to attenuation of p65-K310 acetylation in cytokine-stimulated astrocytes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6071",
    "Sentence": "Because p38 regulated the association between <\\entity><\\entity> and p300, blocking p38 activity also led to attenuation of <\\entity><\\entity>-K310 acetylation in cytokine-stimulated astrocytes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6072",
    "Sentence": "Because p38 regulated the association between p65 and <\\entity><\\entity>, blocking p38 activity also led to attenuation of p65-K310 acetylation in cytokine-stimulated astrocytes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6073",
    "Sentence": "Because <\\entity><\\entity> regulated the association between p65 and p300, blocking <\\entity><\\entity> activity also led to attenuation of p65-K310 acetylation in cytokine-stimulated astrocytes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6074",
    "Sentence": "Because p38 regulated the association between p65 and p300, blocking p38 activity also led to attenuation of <\\entity><\\entity> acetylation in cytokine-stimulated astrocytes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6075",
    "Sentence": "Taken together, this study illuminates a novel regulatory role of <\\entity><\\entity> during neuroinflammation where this MAP kinase controls acetylation of NF-kappaB p65 by regulating acetyltransferase activity of coactivator p300.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6076",
    "Sentence": "Taken together, this study illuminates a novel regulatory role of p38 during neuroinflammation where this <\\entity><\\entity> controls acetylation of NF-kappaB p65 by regulating acetyltransferase activity of coactivator p300.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6077",
    "Sentence": "Taken together, this study illuminates a novel regulatory role of p38 during neuroinflammation where this MAP kinase controls acetylation of <\\entity><\\entity> p65 by regulating acetyltransferase activity of coactivator p300.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6078",
    "Sentence": "Taken together, this study illuminates a novel regulatory role of p38 during neuroinflammation where this MAP kinase controls acetylation of NF-kappaB <\\entity><\\entity> by regulating acetyltransferase activity of coactivator p300.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6079",
    "Sentence": "Taken together, this study illuminates a novel regulatory role of p38 during neuroinflammation where this MAP kinase controls acetylation of NF-kappaB p65 by regulating <\\entity><\\entity> activity of coactivator p300.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6080",
    "Sentence": "Taken together, this study illuminates a novel regulatory role of p38 during neuroinflammation where this MAP kinase controls acetylation of NF-kappaB p65 by regulating acetyltransferase activity of coactivator <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6081",
    "Sentence": "The combination of <\\entity><\\entity> and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": ""
  },
  {
    "id": "6082",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced <\\entity><\\entity>-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": ""
  },
  {
    "id": "6084",
    "Sentence": "The combination of <\\entity><\\entity> and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": ""
  },
  {
    "id": "6085",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not <\\entity><\\entity>, and subsequent association of p300 with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6087",
    "Sentence": "The combination of <\\entity><\\entity> and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": ""
  },
  {
    "id": "6088",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce <\\entity><\\entity> in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": ""
  },
  {
    "id": "6090",
    "Sentence": "The combination of <\\entity><\\entity> and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": ""
  },
  {
    "id": "6091",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator <\\entity><\\entity>, but not p65, and subsequent association of <\\entity><\\entity> with p65.",
    "Label": ""
  },
  {
    "id": "6093",
    "Sentence": "The combination of IL-1beta and <\\entity><\\entity>, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": ""
  },
  {
    "id": "6094",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced <\\entity><\\entity>-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": ""
  },
  {
    "id": "6096",
    "Sentence": "The combination of IL-1beta and <\\entity><\\entity>, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": ""
  },
  {
    "id": "6097",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not <\\entity><\\entity>, and subsequent association of p300 with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6099",
    "Sentence": "The combination of IL-1beta and <\\entity><\\entity>, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": ""
  },
  {
    "id": "6100",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce <\\entity><\\entity> in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": ""
  },
  {
    "id": "6102",
    "Sentence": "The combination of IL-1beta and <\\entity><\\entity>, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator p300, but not p65, and subsequent association of p300 with p65.",
    "Label": ""
  },
  {
    "id": "6103",
    "Sentence": "The combination of IL-1beta and IFN-gamma, previously shown to strongly induce inducible NO synthase in human primary astrocytes, induced p38-dependent phosphorylation of acetyltransferase coactivator <\\entity><\\entity>, but not p65, and subsequent association of <\\entity><\\entity> with p65.",
    "Label": ""
  },
  {
    "id": "6109",
    "Sentence": "<\\entity><\\entity> (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (<\\entity><\\entity>) as first-line therapy for multiple myeloma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6110",
    "Sentence": "BiRD (<\\entity><\\entity> [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (<\\entity><\\entity>), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6111",
    "Sentence": "BiRD (Biaxin [<\\entity><\\entity>]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen <\\entity><\\entity> (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6112",
    "Sentence": "BiRD (Biaxin [clarithromycin]/<\\entity><\\entity> [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (<\\entity><\\entity>), and dexamethasone (BiRD) as first-line therapy for multiple myeloma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6113",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [<\\entity><\\entity>]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), <\\entity><\\entity> (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6114",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/<\\entity><\\entity>) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and <\\entity><\\entity> (BiRD) as first-line therapy for multiple myeloma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6115",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic <\\entity><\\entity>.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6116",
    "Sentence": "BiRD (Biaxin [<\\entity><\\entity>]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen <\\entity><\\entity> (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6117",
    "Sentence": "BiRD (<\\entity><\\entity> [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (<\\entity><\\entity>), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6118",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [<\\entity><\\entity>]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), <\\entity><\\entity> (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6119",
    "Sentence": "BiRD (Biaxin [clarithromycin]/<\\entity><\\entity> [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (<\\entity><\\entity>), and dexamethasone (BiRD) as first-line therapy for multiple myeloma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6120",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/<\\entity><\\entity>) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and <\\entity><\\entity> (BiRD) as first-line therapy for multiple myeloma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6121",
    "Sentence": "<\\entity><\\entity> (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (<\\entity><\\entity>) as first-line therapy for multiple myeloma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6122",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic <\\entity><\\entity>.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6123",
    "Sentence": "Patients received <\\entity><\\entity> in 28-day cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6124",
    "Sentence": "<\\entity><\\entity> (40 mg) was given orally once weekly, clarithromycin (500 mg) was given orally twice daily, and lenalidomide (25 mg) was given orally daily on days 1 to 21.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6125",
    "Sentence": "Dexamethasone (40 mg) was given orally once weekly, <\\entity><\\entity> (500 mg) was given orally twice daily, and lenalidomide (25 mg) was given orally daily on days 1 to 21.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6126",
    "Sentence": "Dexamethasone (40 mg) was given orally once weekly, clarithromycin (500 mg) was given orally twice daily, and <\\entity><\\entity> (25 mg) was given orally daily on days 1 to 21.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6127",
    "Sentence": "Objective response was defined by standard criteria (ie, decrease in serum <\\entity><\\entity> [M-protein] by at least 50%, and a decrease in urine M-protein by at least 90%).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6128",
    "Sentence": "Objective response was defined by standard criteria (ie, decrease in serum monoclonal protein [<\\entity><\\entity>] by at least 50%, and a decrease in urine <\\entity><\\entity> by at least 90%).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6129",
    "Sentence": "Objective response was defined by standard criteria (ie, decrease in serum monoclonal protein [<\\entity><\\entity>] by at least 50%, and a decrease in urine <\\entity><\\entity> by at least 90%).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6130",
    "Sentence": "A combined stringent and conventional complete response rate of 38.9% was achieved, and 73.6% of the patients achieved at least a 90% decrease in <\\entity><\\entity> levels.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6131",
    "Sentence": "The major adverse events were <\\entity><\\entity>, corticosteroid-related morbidity, and cytopenias.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6132",
    "Sentence": "The major adverse events were thromboembolic events, <\\entity><\\entity>, and cytopenias.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6133",
    "Sentence": "The major adverse events were thromboembolic events, <\\entity><\\entity>, and cytopenias.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6134",
    "Sentence": "The major adverse events were thromboembolic events, corticosteroid-related morbidity, and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6135",
    "Sentence": "<\\entity><\\entity> is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed multiple myeloma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6136",
    "Sentence": "BiRD is an effective regimen with manageable <\\entity><\\entity> of symptomatic, newly diagnosed multiple myeloma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6137",
    "Sentence": "BiRD is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6138",
    "Sentence": "BiRD (Biaxin [<\\entity><\\entity>]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen <\\entity><\\entity> (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma.",
    "Label": ""
  },
  {
    "id": "6139",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic <\\entity><\\entity>.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6141",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [<\\entity><\\entity>]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), <\\entity><\\entity> (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma.",
    "Label": ""
  },
  {
    "id": "6142",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic <\\entity><\\entity>.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6144",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/<\\entity><\\entity>) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and <\\entity><\\entity> (BiRD) as first-line therapy for multiple myeloma.",
    "Label": ""
  },
  {
    "id": "6145",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic <\\entity><\\entity>.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6147",
    "Sentence": "<\\entity><\\entity> (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (<\\entity><\\entity>) as first-line therapy for multiple myeloma.",
    "Label": ""
  },
  {
    "id": "6148",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic <\\entity><\\entity>.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6150",
    "Sentence": "BiRD (<\\entity><\\entity> [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (<\\entity><\\entity>), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma.",
    "Label": ""
  },
  {
    "id": "6151",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic <\\entity><\\entity>.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6153",
    "Sentence": "BiRD (Biaxin [clarithromycin]/<\\entity><\\entity> [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (<\\entity><\\entity>), and dexamethasone (BiRD) as first-line therapy for multiple myeloma.",
    "Label": ""
  },
  {
    "id": "6154",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic <\\entity><\\entity>.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6156",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/<\\entity><\\entity>) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and <\\entity><\\entity> (BiRD) as first-line therapy for multiple myeloma.",
    "Label": ""
  },
  {
    "id": "6157",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic <\\entity><\\entity>.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6159",
    "Sentence": "<\\entity><\\entity> (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (<\\entity><\\entity>) as first-line therapy for multiple myeloma.",
    "Label": ""
  },
  {
    "id": "6160",
    "Sentence": "BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic <\\entity><\\entity>.This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone (BiRD) as first-line therapy for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6162",
    "Sentence": "<\\entity><\\entity> is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed multiple myeloma.",
    "Label": ""
  },
  {
    "id": "6163",
    "Sentence": "BiRD is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6169",
    "Sentence": "<\\entity><\\entity> specifically suppresses early production of host interferon-gamma.<\\entity><\\entity> (PfEMP-1) is a variable antigen expressed by P.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6170",
    "Sentence": "Plasmodium falciparum erythrocyte membrane protein-1 specifically suppresses early production of host <\\entity><\\entity>.Plasmodium falciparum erythrocyte membrane protein-1 (PfEMP-1) is a variable antigen expressed by P.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6171",
    "Sentence": "Plasmodium falciparum erythrocyte membrane protein-1 specifically suppresses early production of host <\\entity><\\entity>.Plasmodium falciparum erythrocyte membrane protein-1 (PfEMP-1) is a variable antigen expressed by P.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6172",
    "Sentence": "<\\entity><\\entity> specifically suppresses early production of host interferon-gamma.<\\entity><\\entity> (PfEMP-1) is a variable antigen expressed by P.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6173",
    "Sentence": "Plasmodium falciparum erythrocyte membrane protein-1 specifically suppresses early production of host interferon-gamma.Plasmodium falciparum erythrocyte membrane protein-1 (<\\entity><\\entity>) is a variable antigen expressed by P.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6174",
    "Sentence": "<\\entity><\\entity>, present on the surface of infected host erythrocytes, mediates erythrocyte binding to vascular endothelium, enabling the parasite to avoid splenic clearance.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6175",
    "Sentence": "In addition, <\\entity><\\entity> is proposed to regulate host immune responses via interactions with the CD36 receptor on antigen-presenting cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6176",
    "Sentence": "In addition, PfEMP-1 is proposed to regulate host immune responses via interactions with the <\\entity><\\entity> on antigen-presenting cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6177",
    "Sentence": "We investigated the immunoregulatory function of <\\entity><\\entity> by comparing host cell responses to erythrocytes infected with either wild-type parasites or transgenic parasites lacking <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6178",
    "Sentence": "We investigated the immunoregulatory function of <\\entity><\\entity> by comparing host cell responses to erythrocytes infected with either wild-type parasites or transgenic parasites lacking <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6179",
    "Sentence": "We showed that <\\entity><\\entity> suppresses the production of the cytokine interferon-gamma by human peripheral blood mononuclear cells early after exposure to P.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6180",
    "Sentence": "We showed that PfEMP-1 suppresses the production of the cytokine <\\entity><\\entity> by human peripheral blood mononuclear cells early after exposure to P.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6181",
    "Sentence": "We showed that PfEMP-1 suppresses the production of the cytokine <\\entity><\\entity> by human peripheral blood mononuclear cells early after exposure to P.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6182",
    "Sentence": "Suppression of this rapid proinflammatory response was <\\entity><\\entity> independent and specific to interferon-gamma production by gammadelta-T, NK, and alphabeta-T cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6183",
    "Sentence": "Suppression of this rapid proinflammatory response was CD36 independent and specific to <\\entity><\\entity> production by gammadelta-T, NK, and alphabeta-T cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6184",
    "Sentence": "Suppression of this rapid proinflammatory response was CD36 independent and specific to <\\entity><\\entity> production by gammadelta-T, NK, and alphabeta-T cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6185",
    "Sentence": "These data demonstrate a parasite strategy for downregulating the proinflammatory <\\entity><\\entity> response and further establish transgenic parasites lacking PfEMP-1 as powerful tools for elucidating PfEMP-1 functions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6186",
    "Sentence": "These data demonstrate a parasite strategy for downregulating the proinflammatory <\\entity><\\entity> response and further establish transgenic parasites lacking PfEMP-1 as powerful tools for elucidating PfEMP-1 functions.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6187",
    "Sentence": "These data demonstrate a parasite strategy for downregulating the proinflammatory interferon-gamma response and further establish transgenic parasites lacking <\\entity><\\entity> as powerful tools for elucidating <\\entity><\\entity> functions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6188",
    "Sentence": "These data demonstrate a parasite strategy for downregulating the proinflammatory interferon-gamma response and further establish transgenic parasites lacking <\\entity><\\entity> as powerful tools for elucidating <\\entity><\\entity> functions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6193",
    "Sentence": "Can pregnancy rate be improved in <\\entity><\\entity> (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval?",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6194",
    "Sentence": "Can pregnancy rate be improved in gonadotropin-releasing hormone (<\\entity><\\entity> cycles by administering GnRH agonist before oocyte retrieval?",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6195",
    "Sentence": "Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering <\\entity><\\entity> before oocyte retrieval?",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6196",
    "Sentence": "A prospective, randomized study.OBJECTIVE: To examine whether the addition of one dose of <\\entity><\\entity> could improve implantation and pregnancy rates in GnRH antagonist IVF cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6197",
    "Sentence": "A prospective, randomized study.OBJECTIVE: To examine whether the addition of one dose of preovulatory GnRH agonist could improve implantation and pregnancy rates in <\\entity><\\entity> IVF cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6198",
    "Sentence": "PATIENT(S): Two hundred twenty-one patients intended for <\\entity><\\entity> protocol IVF.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6199",
    "Sentence": "The control group received <\\entity><\\entity> (5,000 U) 34 hours before oocyte aspiration, and the study group received triptorelin (0.2 mg SC) in addition to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6200",
    "Sentence": "The control group received <\\entity><\\entity> (5,000 U) 34 hours before oocyte aspiration, and the study group received triptorelin (0.2 mg SC) in addition to <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6201",
    "Sentence": "The control group received hCG (5,000 U) 34 hours before oocyte aspiration, and the study group received <\\entity><\\entity> (0.2 mg SC) in addition to hCG.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6202",
    "Sentence": "The control group received <\\entity><\\entity> (5,000 U) 34 hours before oocyte aspiration, and the study group received triptorelin (0.2 mg SC) in addition to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6203",
    "Sentence": "MAIN OUTCOME MEASURE(S): Oocyte pick-up day serum levels of <\\entity><\\entity>, P, LH, and FSH and implantation and pregnancy rates per started cycle and per completed cycle.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6204",
    "Sentence": "MAIN OUTCOME MEASURE(S): Oocyte pick-up day serum levels of <\\entity><\\entity>, P, LH, and FSH and implantation and pregnancy rates per started cycle and per completed cycle.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6205",
    "Sentence": "MAIN OUTCOME MEASURE(S): Oocyte pick-up day serum levels of E(2), <\\entity><\\entity>, LH, and FSH and implantation and pregnancy rates per started cycle and per completed cycle.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6206",
    "Sentence": "MAIN OUTCOME MEASURE(S): Oocyte pick-up day serum levels of E(2), P, <\\entity><\\entity>, and FSH and implantation and pregnancy rates per started cycle and per completed cycle.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6207",
    "Sentence": "MAIN OUTCOME MEASURE(S): Oocyte pick-up day serum levels of E(2), P, <\\entity><\\entity>, and FSH and implantation and pregnancy rates per started cycle and per completed cycle.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6208",
    "Sentence": "MAIN OUTCOME MEASURE(S): Oocyte pick-up day serum levels of E(2), P, LH, and <\\entity><\\entity> and implantation and pregnancy rates per started cycle and per completed cycle.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6209",
    "Sentence": "MAIN OUTCOME MEASURE(S): Oocyte pick-up day serum levels of E(2), P, LH, and <\\entity><\\entity> and implantation and pregnancy rates per started cycle and per completed cycle.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6210",
    "Sentence": "None of the cycle parameters of the study or control groups differed, excepting mean oocyte pick-up day <\\entity><\\entity> (11.26 IU/L [95% confidence interval (CI) 9.88-12.52] vs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6211",
    "Sentence": "None of the cycle parameters of the study or control groups differed, excepting mean oocyte pick-up day <\\entity><\\entity> (11.26 IU/L [95% confidence interval (CI) 9.88-12.52] vs.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6212",
    "Sentence": "6.27 IU/L [95% CI 5.76-8.77]) and <\\entity><\\entity> levels (5.19 IU/L [95% CI 4.47-5.9] vs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6213",
    "Sentence": "6.27 IU/L [95% CI 5.76-8.77]) and <\\entity><\\entity> levels (5.19 IU/L [95% CI 4.47-5.9] vs.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6214",
    "Sentence": "CONCLUSIONS: The administration of <\\entity><\\entity> (0.2 mg) at the time of hCG administration in GnRH antagonist IVF cycles significantly improved overall and ongoing pregnancy rates in completed cycles but not in all started cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6215",
    "Sentence": "CONCLUSIONS: The administration of triptorelin (0.2 mg) at the time of <\\entity><\\entity> administration in GnRH antagonist IVF cycles significantly improved overall and ongoing pregnancy rates in completed cycles but not in all started cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6216",
    "Sentence": "CONCLUSIONS: The administration of triptorelin (0.2 mg) at the time of hCG administration in <\\entity><\\entity> IVF cycles significantly improved overall and ongoing pregnancy rates in completed cycles but not in all started cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6217",
    "Sentence": "It is possible that this was achieved owing to an <\\entity><\\entity> effect, which should also be examined by direct endometrial studies.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6218",
    "Sentence": "The control group received hCG (5,000 U) 34 hours before oocyte aspiration, and the study group received <\\entity><\\entity> (0.2 mg SC) in addition to hCG.",
    "Label": ""
  },
  {
    "id": "6219",
    "Sentence": "The control group received <\\entity><\\entity> (5,000 U) 34 hours before oocyte aspiration, and the study group received triptorelin (0.2 mg SC) in addition to <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6225",
    "Sentence": "<\\entity><\\entity> and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.Ischaemia-reperfusion (I/R) is a pivotal mechanism of organ injury during stroke, myocardial infarction, organ transplantation and vascular surgeries.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6226",
    "Sentence": "Endocannabinoids and <\\entity><\\entity> in ischaemia-reperfusion injury and preconditioning.Ischaemia-reperfusion (I/R) is a pivotal mechanism of organ injury during stroke, myocardial infarction, organ transplantation and vascular surgeries.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6227",
    "Sentence": "On the one hand, <\\entity><\\entity> have been implicated in the protective effects of IPC through cannabinoid CB1/CB2 receptor-dependent and -independent mechanisms.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6228",
    "Sentence": "On the one hand, endocannabinoids have been implicated in the protective effects of IPC through cannabinoid <\\entity><\\entity>/CB2 receptor-dependent and -independent mechanisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6229",
    "Sentence": "On the one hand, endocannabinoids have been implicated in the protective effects of IPC through cannabinoid CB1/<\\entity><\\entity> receptor-dependent and -independent mechanisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6230",
    "Sentence": "However, there is evidence suggesting that <\\entity><\\entity> are overproduced during various forms of I/R, such as myocardial infarction or whole body I/R associated with circulatory shock, and may contribute to the cardiovascular depressive state associated with these pathologies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6231",
    "Sentence": "Previous studies using <\\entity><\\entity> or knockout mice demonstrated CB1 receptor-dependent protection against cerebral I/R injury in various animal models.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6232",
    "Sentence": "Previous studies using synthetic <\\entity><\\entity> receptor agonists or knockout mice demonstrated <\\entity><\\entity> receptor-dependent protection against cerebral I/R injury in various animal models.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6233",
    "Sentence": "Previous studies using synthetic <\\entity><\\entity> receptor agonists or knockout mice demonstrated <\\entity><\\entity> receptor-dependent protection against cerebral I/R injury in various animal models.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6234",
    "Sentence": "In contrast, several follow-up reports have shown protection afforded by <\\entity><\\entity>, but not agonists.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6235",
    "Sentence": "In contrast, several follow-up reports have shown protection afforded by <\\entity><\\entity>, but not agonists.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6236",
    "Sentence": "Excitedly, emerging studies using potent <\\entity><\\entity> and/or knockout mice have provided compelling evidence that CB2 receptor activation is protective against myocardial, cerebral and hepatic I/R injuries by decreasing the endothelial cell activation/inflammatory response (for example, expression of adhesion molecules, secretion of chemokines, and so on), and by attenuating the leukocyte chemotaxis, rolling, adhesion to endothelium, activation and transendothelial migration, and interrelated oxidative/nitrosative damage.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6237",
    "Sentence": "Excitedly, emerging studies using potent <\\entity><\\entity> and/or knockout mice have provided compelling evidence that CB2 receptor activation is protective against myocardial, cerebral and hepatic I/R injuries by decreasing the endothelial cell activation/inflammatory response (for example, expression of adhesion molecules, secretion of chemokines, and so on), and by attenuating the leukocyte chemotaxis, rolling, adhesion to endothelium, activation and transendothelial migration, and interrelated oxidative/nitrosative damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6238",
    "Sentence": "Excitedly, emerging studies using potent <\\entity><\\entity> receptor agonists and/or knockout mice have provided compelling evidence that <\\entity><\\entity> receptor activation is protective against myocardial, cerebral and hepatic I/R injuries by decreasing the endothelial cell activation/inflammatory response (for example, expression of adhesion molecules, secretion of chemokines, and so on), and by attenuating the leukocyte chemotaxis, rolling, adhesion to endothelium, activation and transendothelial migration, and interrelated oxidative/nitrosative damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6239",
    "Sentence": "Excitedly, emerging studies using potent CB2 receptor agonists and/or knockout mice have provided compelling evidence that CB2 receptor activation is protective against myocardial, cerebral and hepatic I/R injuries by decreasing the endothelial cell activation/inflammatory response (for example, expression of adhesion molecules, secretion of <\\entity><\\entity>, and so on), and by attenuating the leukocyte chemotaxis, rolling, adhesion to endothelium, activation and transendothelial migration, and interrelated oxidative/nitrosative damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6240",
    "Sentence": "This review is aimed to discuss the role of <\\entity><\\entity> and CB receptors in various forms of I/R injury (myocardial, cerebral, hepatic and circulatory shock) and preconditioning, and to delineate the evidence supporting the therapeutic utility of selective CB2 receptor agonists, which are devoid of psychoactive effects, as a promising new approach to limit I/R-induced tissue damage.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6241",
    "Sentence": "This review is aimed to discuss the role of endocannabinoids and <\\entity><\\entity> in various forms of I/R injury (myocardial, cerebral, hepatic and circulatory shock) and preconditioning, and to delineate the evidence supporting the therapeutic utility of selective CB2 receptor agonists, which are devoid of psychoactive effects, as a promising new approach to limit I/R-induced tissue damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6242",
    "Sentence": "This review is aimed to discuss the role of endocannabinoids and CB receptors in various forms of I/R injury (myocardial, cerebral, hepatic and circulatory shock) and preconditioning, and to delineate the evidence supporting the therapeutic utility of selective <\\entity><\\entity>, which are devoid of psychoactive effects, as a promising new approach to limit I/R-induced tissue damage.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6243",
    "Sentence": "This review is aimed to discuss the role of endocannabinoids and CB receptors in various forms of I/R injury (myocardial, cerebral, hepatic and circulatory shock) and preconditioning, and to delineate the evidence supporting the therapeutic utility of selective <\\entity><\\entity>, which are devoid of psychoactive effects, as a promising new approach to limit I/R-induced tissue damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6244",
    "Sentence": "On the one hand, <\\entity><\\entity> have been implicated in the protective effects of IPC through cannabinoid CB1/CB2 receptor-dependent and -independent mechanisms.",
    "Label": ""
  },
  {
    "id": "6245",
    "Sentence": "On the one hand, endocannabinoids have been implicated in the protective effects of IPC through cannabinoid <\\entity><\\entity>/CB2 receptor-dependent and -independent mechanisms.",
    "Label": ""
  },
  {
    "id": "6247",
    "Sentence": "On the one hand, <\\entity><\\entity> have been implicated in the protective effects of IPC through cannabinoid CB1/CB2 receptor-dependent and -independent mechanisms.",
    "Label": ""
  },
  {
    "id": "6248",
    "Sentence": "On the one hand, endocannabinoids have been implicated in the protective effects of IPC through cannabinoid CB1/<\\entity><\\entity> receptor-dependent and -independent mechanisms.",
    "Label": ""
  },
  {
    "id": "6250",
    "Sentence": "Previous studies using <\\entity><\\entity> or knockout mice demonstrated CB1 receptor-dependent protection against cerebral I/R injury in various animal models.",
    "Label": ""
  },
  {
    "id": "6251",
    "Sentence": "Previous studies using synthetic <\\entity><\\entity> receptor agonists or knockout mice demonstrated <\\entity><\\entity> receptor-dependent protection against cerebral I/R injury in various animal models.",
    "Label": ""
  },
  {
    "id": "6253",
    "Sentence": "Excitedly, emerging studies using potent <\\entity><\\entity> and/or knockout mice have provided compelling evidence that CB2 receptor activation is protective against myocardial, cerebral and hepatic I/R injuries by decreasing the endothelial cell activation/inflammatory response (for example, expression of adhesion molecules, secretion of chemokines, and so on), and by attenuating the leukocyte chemotaxis, rolling, adhesion to endothelium, activation and transendothelial migration, and interrelated oxidative/nitrosative damage.",
    "Label": ""
  },
  {
    "id": "6254",
    "Sentence": "Excitedly, emerging studies using potent <\\entity><\\entity> receptor agonists and/or knockout mice have provided compelling evidence that <\\entity><\\entity> receptor activation is protective against myocardial, cerebral and hepatic I/R injuries by decreasing the endothelial cell activation/inflammatory response (for example, expression of adhesion molecules, secretion of chemokines, and so on), and by attenuating the leukocyte chemotaxis, rolling, adhesion to endothelium, activation and transendothelial migration, and interrelated oxidative/nitrosative damage.",
    "Label": ""
  },
  {
    "id": "6256",
    "Sentence": "Excitedly, emerging studies using potent <\\entity><\\entity> and/or knockout mice have provided compelling evidence that CB2 receptor activation is protective against myocardial, cerebral and hepatic I/R injuries by decreasing the endothelial cell activation/inflammatory response (for example, expression of adhesion molecules, secretion of chemokines, and so on), and by attenuating the leukocyte chemotaxis, rolling, adhesion to endothelium, activation and transendothelial migration, and interrelated oxidative/nitrosative damage.",
    "Label": ""
  },
  {
    "id": "6257",
    "Sentence": "Excitedly, emerging studies using potent CB2 receptor agonists and/or knockout mice have provided compelling evidence that CB2 receptor activation is protective against myocardial, cerebral and hepatic I/R injuries by decreasing the endothelial cell activation/inflammatory response (for example, expression of adhesion molecules, secretion of <\\entity><\\entity>, and so on), and by attenuating the leukocyte chemotaxis, rolling, adhesion to endothelium, activation and transendothelial migration, and interrelated oxidative/nitrosative damage.",
    "Label": ""
  },
  {
    "id": "6259",
    "Sentence": "This review is aimed to discuss the role of <\\entity><\\entity> and CB receptors in various forms of I/R injury (myocardial, cerebral, hepatic and circulatory shock) and preconditioning, and to delineate the evidence supporting the therapeutic utility of selective CB2 receptor agonists, which are devoid of psychoactive effects, as a promising new approach to limit I/R-induced tissue damage.",
    "Label": ""
  },
  {
    "id": "6260",
    "Sentence": "This review is aimed to discuss the role of endocannabinoids and <\\entity><\\entity> in various forms of I/R injury (myocardial, cerebral, hepatic and circulatory shock) and preconditioning, and to delineate the evidence supporting the therapeutic utility of selective CB2 receptor agonists, which are devoid of psychoactive effects, as a promising new approach to limit I/R-induced tissue damage.",
    "Label": ""
  },
  {
    "id": "6262",
    "Sentence": "This review is aimed to discuss the role of endocannabinoids and CB receptors in various forms of I/R injury (myocardial, cerebral, hepatic and circulatory shock) and preconditioning, and to delineate the evidence supporting the therapeutic utility of selective <\\entity><\\entity>, which are devoid of psychoactive effects, as a promising new approach to limit I/R-induced tissue damage.",
    "Label": ""
  },
  {
    "id": "6263",
    "Sentence": "This review is aimed to discuss the role of endocannabinoids and <\\entity><\\entity> in various forms of I/R injury (myocardial, cerebral, hepatic and circulatory shock) and preconditioning, and to delineate the evidence supporting the therapeutic utility of selective CB2 receptor agonists, which are devoid of psychoactive effects, as a promising new approach to limit I/R-induced tissue damage.",
    "Label": ""
  },
  {
    "id": "6269",
    "Sentence": "In vivo gene delivery for development of mammalian models for <\\entity><\\entity>.During the last decade, identification of the genes involved in familial forms of <\\entity><\\entity> (PD) has advanced our understanding of the mechanisms underlying the development of different aspects of PD.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6270",
    "Sentence": "In vivo gene delivery for development of mammalian models for <\\entity><\\entity>.During the last decade, identification of the genes involved in familial forms of <\\entity><\\entity> (PD) has advanced our understanding of the mechanisms underlying the development of different aspects of PD.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6271",
    "Sentence": "In vivo gene delivery for development of mammalian models for Parkinson's disease.During the last decade, identification of the genes involved in familial forms of Parkinson's disease (<\\entity><\\entity>) has advanced our understanding of the mechanisms underlying the development of different aspects of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6272",
    "Sentence": "In vivo gene delivery for development of mammalian models for Parkinson's disease.During the last decade, identification of the genes involved in familial forms of Parkinson's disease (<\\entity><\\entity>) has advanced our understanding of the mechanisms underlying the development of different aspects of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6273",
    "Sentence": "However the available animal models <\\entity><\\entity> remain as the main limiting factor for the development of neuroprotective therapies that can halt the progression of the disease, through which we wish to provide a better quality of life for the PD patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6274",
    "Sentence": "However the available animal models still remain as the main limiting factor for the development of neuroprotective therapies that can halt the progression of the <\\entity><\\entity>, through which we wish to provide a better quality of life for the PD patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6275",
    "Sentence": "However the available animal models still remain as the main limiting factor for the development of neuroprotective therapies that can halt the progression of the disease, through which we wish to provide a better quality of life for the <\\entity><\\entity> patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6276",
    "Sentence": "Here, we review the recently developed animal models based on overexpression of <\\entity><\\entity> using recombinant viral vectors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6277",
    "Sentence": "Here, we review the recently developed animal models based on overexpression of <\\entity><\\entity> using recombinant viral vectors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6278",
    "Sentence": "<\\entity><\\entity>, in particular, have been very useful in targeting the nigral dopamine neurons both in the rodent and the primate brain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6279",
    "Sentence": "Recombinant adeno-associated viral vectors, in particular, have been very useful in targeting the nigral <\\entity><\\entity> neurons both in the rodent and the primate brain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6284",
    "Sentence": "Design and synthesis of <\\entity><\\entity>: A novel class of PPARalpha agonists.A series of aminoindane derivatives were synthesized and shown to be potent PPARalpha agonists.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6285",
    "Sentence": "Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of <\\entity><\\entity>.A series of aminoindane derivatives were synthesized and shown to be potent <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6286",
    "Sentence": "Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of <\\entity><\\entity>.A series of aminoindane derivatives were synthesized and shown to be potent <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6287",
    "Sentence": "Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.A series of <\\entity><\\entity> were synthesized and shown to be potent PPARalpha agonists.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6288",
    "Sentence": "Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of <\\entity><\\entity>.A series of aminoindane derivatives were synthesized and shown to be potent <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6289",
    "Sentence": "Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of <\\entity><\\entity>.A series of aminoindane derivatives were synthesized and shown to be potent <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6290",
    "Sentence": "The compounds were obtained as racemates in 12 steps, and tested for <\\entity><\\entity> activation and <\\entity><\\entity> mediated induction of the HD gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6291",
    "Sentence": "The compounds were obtained as racemates in 12 steps, and tested for <\\entity><\\entity> activation and <\\entity><\\entity> mediated induction of the HD gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6292",
    "Sentence": "The compounds were obtained as racemates in 12 steps, and tested for PPARalpha activation and PPARalpha mediated induction of the <\\entity><\\entity> gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6293",
    "Sentence": "<\\entity><\\entity> was developed by variation to the core structure as shown within.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6294",
    "Sentence": "Oral bioavailability was demonstrated in a Sprague-Dawley rat, while efficacy to reduce plasma <\\entity><\\entity> and plasma glucose was demonstrated in db/db mice.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6295",
    "Sentence": "Oral bioavailability was demonstrated in a Sprague-Dawley rat, while efficacy to reduce plasma <\\entity><\\entity> and plasma glucose was demonstrated in db/db mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6296",
    "Sentence": "Oral bioavailability was demonstrated in a Sprague-Dawley rat, while efficacy to reduce plasma triglycerides and plasma <\\entity><\\entity> was demonstrated in db/db mice.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6297",
    "Sentence": "Oral bioavailability was demonstrated in a Sprague-Dawley rat, while efficacy to reduce plasma triglycerides and plasma <\\entity><\\entity> was demonstrated in db/db mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6298",
    "Sentence": "Design and synthesis of <\\entity><\\entity>: A novel class of PPARalpha agonists.A series of aminoindane derivatives were synthesized and shown to be potent PPARalpha agonists.",
    "Label": ""
  },
  {
    "id": "6299",
    "Sentence": "Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of <\\entity><\\entity>.A series of aminoindane derivatives were synthesized and shown to be potent <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6305",
    "Sentence": "Retained <\\entity><\\entity> as a cause of dacryocystorhinostomy failure.Silicone sleeves are 1 method of stabilizing bicanalicular silicone intubation near the ostia during dacryocystorhinostomy surgery to prevent tube prolapse.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6306",
    "Sentence": "Retained silicone sleeve as a cause of <\\entity><\\entity>.Silicone sleeves are 1 method of stabilizing bicanalicular silicone intubation near the ostia during dacryocystorhinostomy surgery to prevent tube prolapse.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6307",
    "Sentence": "Retained silicone sleeve as a cause of dacryocystorhinostomy failure.<\\entity><\\entity> sleeves are 1 method of stabilizing bicanalicular silicone intubation near the ostia during dacryocystorhinostomy surgery to prevent tube prolapse.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6308",
    "Sentence": "Retained <\\entity><\\entity> sleeve as a cause of dacryocystorhinostomy failure.Silicone sleeves are 1 method of stabilizing bicanalicular <\\entity><\\entity> intubation near the ostia during dacryocystorhinostomy surgery to prevent tube prolapse.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6309",
    "Sentence": "Retained silicone sleeve as a cause of dacryocystorhinostomy failure.Silicone sleeves are 1 method of stabilizing bicanalicular silicone intubation near the ostia during dacryocystorhinostomy surgery to prevent <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6310",
    "Sentence": "Retained <\\entity><\\entity> following dacryocystorhinostomy is a rare and previously unreported complication that can occur despite endoscopic visualization during tube removal, particularly in narrow nasal passages.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6311",
    "Sentence": "Retained silicone sleeve following dacryocystorhinostomy is a rare and previously unreported <\\entity><\\entity> that can occur despite endoscopic visualization during tube removal, particularly in narrow nasal passages.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6312",
    "Sentence": "It is an easily reversible cause of <\\entity><\\entity> if identified.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6313",
    "Sentence": "Retained <\\entity><\\entity> sleeve as a cause of dacryocystorhinostomy failure.Silicone sleeves are 1 method of stabilizing bicanalicular <\\entity><\\entity> intubation near the ostia during dacryocystorhinostomy surgery to prevent tube prolapse.",
    "Label": ""
  },
  {
    "id": "6314",
    "Sentence": "Retained silicone sleeve as a cause of dacryocystorhinostomy failure.Silicone sleeves are 1 method of stabilizing bicanalicular silicone intubation near the ostia during dacryocystorhinostomy surgery to prevent <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6320",
    "Sentence": "<\\entity><\\entity>' two-edged sword: when immunity meets apoptosis.<\\entity><\\entity> (TLR) have emerged as key players in the detection of pathogens and the induction of anti-microbial immune response.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6321",
    "Sentence": "<\\entity><\\entity>' two-edged sword: when immunity meets apoptosis.<\\entity><\\entity> (TLR) have emerged as key players in the detection of pathogens and the induction of anti-microbial immune response.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6322",
    "Sentence": "Toll-like receptors' two-edged sword: when immunity meets apoptosis.Toll-like receptors (<\\entity><\\entity>) have emerged as key players in the detection of pathogens and the induction of anti-microbial immune response.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6323",
    "Sentence": "<\\entity><\\entity> recognize pathogen-associated molecular patterns, and trigger anti-microbial innate immune responses ranging from the secretion of pro-inflammatory mediators to the increase of natural killer cell cytotoxicity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6324",
    "Sentence": "TLR recognize pathogen-associated molecular patterns, and <\\entity><\\entity> anti-microbial innate immune responses ranging from the secretion of pro-inflammatory mediators to the increase of natural killer cell cytotoxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6325",
    "Sentence": "TLR recognize pathogen-associated molecular patterns, and trigger anti-microbial innate immune responses ranging from the secretion of <\\entity><\\entity> to the increase of natural killer cell cytotoxicity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6326",
    "Sentence": "TLR recognize pathogen-associated molecular patterns, and trigger anti-microbial innate immune responses ranging from the secretion of pro-inflammatory mediators to the increase of natural <\\entity><\\entity> cell cytotoxicity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6327",
    "Sentence": "Besides activating the innate immune response, <\\entity><\\entity> engagement also shapes the adaptive immune response.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6328",
    "Sentence": "Indeed, the broad diversity of signaling pathways initiated by <\\entity><\\entity> is progressively unraveled.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6329",
    "Sentence": "Recent reports suggested that among the anti-microbial defenses they initiate, members of the <\\entity><\\entity> family can induce apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6330",
    "Sentence": "This review focuses on this newly described function of <\\entity><\\entity>, and emphasizes the similarities and differences between the different apoptosis-signaling pathways described downstream of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6331",
    "Sentence": "This review focuses on this newly described function of <\\entity><\\entity>, and emphasizes the similarities and differences between the different apoptosis-signaling pathways described downstream of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6332",
    "Sentence": "The functional relevance of <\\entity><\\entity>-triggered apoptosis is also discussed, as therapeutic applications are likely to ensue in the near future.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6333",
    "Sentence": "TLR recognize pathogen-associated molecular patterns, and <\\entity><\\entity> anti-microbial innate immune responses ranging from the secretion of pro-inflammatory mediators to the increase of natural killer cell cytotoxicity.",
    "Label": ""
  },
  {
    "id": "6334",
    "Sentence": "TLR recognize pathogen-associated molecular patterns, and trigger anti-microbial innate immune responses ranging from the secretion of pro-inflammatory mediators to the increase of natural <\\entity><\\entity> cell cytotoxicity.",
    "Label": ""
  },
  {
    "id": "6340",
    "Sentence": "Postoperative beneficial effects of <\\entity><\\entity> in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, <\\entity><\\entity> was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6341",
    "Sentence": "Postoperative beneficial effects of esmolol in treated <\\entity><\\entity> patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6342",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease <\\entity><\\entity> and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6343",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative <\\entity><\\entity> such as nausea, vomiting, and pain, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6344",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as <\\entity><\\entity>, vomiting, and pain, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6345",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, <\\entity><\\entity>, and pain, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6346",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and <\\entity><\\entity>, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6347",
    "Sentence": "Postoperative beneficial effects of <\\entity><\\entity> in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, <\\entity><\\entity> was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6348",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine <\\entity><\\entity> infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6349",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine alfentanil infusion of patients with treated <\\entity><\\entity> undergoing laparoscopic cholecystectomy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6350",
    "Sentence": "METHODS: Forty consecutive <\\entity><\\entity> class II patients with controlled hypertension about to undergo laparoscopic cholecystectomy were randomized into two groups: an esmolol group (Group E, n=20) was given a 1 mg kg(-1) bolus of esmolol and a placebo group (Group P, n=20) was given an identical volume of Ringer's lactate.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6351",
    "Sentence": "METHODS: Forty consecutive ASA class II patients with controlled <\\entity><\\entity> about to undergo laparoscopic cholecystectomy were randomized into two groups: an esmolol group (Group E, n=20) was given a 1 mg kg(-1) bolus of esmolol and a placebo group (Group P, n=20) was given an identical volume of Ringer's lactate.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6352",
    "Sentence": "METHODS: Forty consecutive ASA class II patients with controlled hypertension about to undergo laparoscopic cholecystectomy were randomized into two groups: an <\\entity><\\entity> group (Group E, n=20) was given a 1 mg kg(-1) bolus of <\\entity><\\entity> and a placebo group (Group P, n=20) was given an identical volume of Ringer's lactate.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6353",
    "Sentence": "METHODS: Forty consecutive ASA class II patients with controlled hypertension about to undergo laparoscopic cholecystectomy were randomized into two groups: an <\\entity><\\entity> group (Group E, n=20) was given a 1 mg kg(-1) bolus of <\\entity><\\entity> and a placebo group (Group P, n=20) was given an identical volume of Ringer's lactate.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6354",
    "Sentence": "METHODS: Forty consecutive ASA class II patients with controlled hypertension about to undergo laparoscopic cholecystectomy were randomized into two groups: an esmolol group (Group E, n=20) was given a 1 mg kg(-1) bolus of esmolol and a placebo group (Group P, n=20) was given an identical volume of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6355",
    "Sentence": "The rate of <\\entity><\\entity> infusion was adjusted to keep the heart rate between 65 and 75 beats min(-1) and was 5-10 microg kg(-1) min(-1) throughout the procedure.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6356",
    "Sentence": "After operation, patients reported their <\\entity><\\entity> using a four-point scale.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6357",
    "Sentence": "RESULTS: <\\entity><\\entity> had an opioid-sparing effect intraoperatively (P=0.001).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6358",
    "Sentence": "Postoperative requirements for <\\entity><\\entity> were significantly less in the esmolol group, with no <\\entity><\\entity> given to eight patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6359",
    "Sentence": "Postoperative requirements for antiemetics were significantly less in the <\\entity><\\entity> group, with no antiemetics given to eight patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6360",
    "Sentence": "Postoperative requirements for <\\entity><\\entity> were significantly less in the esmolol group, with no <\\entity><\\entity> given to eight patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6361",
    "Sentence": "In the placebo group, however, all patients required at least one dose of <\\entity><\\entity> (P=0.007).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6362",
    "Sentence": "The frequency of <\\entity><\\entity> did not correlate to the amounts of alfentanil, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of <\\entity><\\entity> or motion sickness.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6363",
    "Sentence": "The frequency of PONV did not correlate to the amounts of <\\entity><\\entity>, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or motion sickness.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6364",
    "Sentence": "The frequency of PONV did not correlate to the amounts of alfentanil, <\\entity><\\entity>, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or motion sickness.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6365",
    "Sentence": "The frequency of PONV did not correlate to the amounts of alfentanil, propofol, postoperative <\\entity><\\entity> consumed, or to female gender, non-smoking status, and history of PONV or motion sickness.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6366",
    "Sentence": "The frequency of <\\entity><\\entity> did not correlate to the amounts of alfentanil, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of <\\entity><\\entity> or motion sickness.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6367",
    "Sentence": "The frequency of PONV did not correlate to the amounts of alfentanil, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6368",
    "Sentence": "Postoperative analgesic <\\entity><\\entity> in Group E was significantly lower than in Group P (P=0.012).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6369",
    "Sentence": "CONCLUSIONS: <\\entity><\\entity> had an opioid-sparing effect in the intraoperative and immediate postoperative period in hypertensive patients undergoing laparoscopy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6370",
    "Sentence": "CONCLUSIONS: Esmolol had an opioid-sparing effect in the intraoperative and immediate postoperative period in <\\entity><\\entity> patients undergoing laparoscopy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6371",
    "Sentence": "When combined with <\\entity><\\entity>, it was more effective than placebo in decreasing early PONV.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6372",
    "Sentence": "When combined with alfentanil, it was more effective than placebo in decreasing early <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6373",
    "Sentence": "CONCLUSIONS: <\\entity><\\entity> had an opioid-sparing effect in the intraoperative and immediate postoperative period in hypertensive patients undergoing laparoscopy.",
    "Label": ""
  },
  {
    "id": "6374",
    "Sentence": "CONCLUSIONS: Esmolol had an opioid-sparing effect in the intraoperative and immediate postoperative period in <\\entity><\\entity> patients undergoing laparoscopy.",
    "Label": ""
  },
  {
    "id": "6376",
    "Sentence": "When combined with <\\entity><\\entity>, it was more effective than placebo in decreasing early PONV.",
    "Label": ""
  },
  {
    "id": "6377",
    "Sentence": "When combined with alfentanil, it was more effective than placebo in decreasing early <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6379",
    "Sentence": "The frequency of PONV did not correlate to the amounts of <\\entity><\\entity>, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or motion sickness.",
    "Label": ""
  },
  {
    "id": "6380",
    "Sentence": "The frequency of PONV did not correlate to the amounts of alfentanil, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6382",
    "Sentence": "The frequency of PONV did not correlate to the amounts of alfentanil, <\\entity><\\entity>, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or motion sickness.",
    "Label": ""
  },
  {
    "id": "6383",
    "Sentence": "The frequency of PONV did not correlate to the amounts of alfentanil, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6385",
    "Sentence": "Postoperative beneficial effects of <\\entity><\\entity> in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, <\\entity><\\entity> was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6386",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease <\\entity><\\entity> and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6388",
    "Sentence": "Postoperative beneficial effects of <\\entity><\\entity> in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, <\\entity><\\entity> was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6389",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative <\\entity><\\entity> such as nausea, vomiting, and pain, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6391",
    "Sentence": "Postoperative beneficial effects of <\\entity><\\entity> in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, <\\entity><\\entity> was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6392",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as <\\entity><\\entity>, vomiting, and pain, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6394",
    "Sentence": "Postoperative beneficial effects of <\\entity><\\entity> in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, <\\entity><\\entity> was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6395",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, <\\entity><\\entity>, and pain, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6397",
    "Sentence": "Postoperative beneficial effects of <\\entity><\\entity> in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, <\\entity><\\entity> was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6398",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and <\\entity><\\entity>, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6400",
    "Sentence": "Postoperative beneficial effects of <\\entity><\\entity> in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, <\\entity><\\entity> was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6401",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine alfentanil infusion of patients with treated <\\entity><\\entity> undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6403",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine <\\entity><\\entity> infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6404",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease <\\entity><\\entity> and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6406",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine <\\entity><\\entity> infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6407",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative <\\entity><\\entity> such as nausea, vomiting, and pain, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6409",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine <\\entity><\\entity> infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6410",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as <\\entity><\\entity>, vomiting, and pain, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6412",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine <\\entity><\\entity> infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6413",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, <\\entity><\\entity>, and pain, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6415",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine <\\entity><\\entity> infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6416",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and <\\entity><\\entity>, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6418",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine <\\entity><\\entity> infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6419",
    "Sentence": "Postoperative beneficial effects of esmolol in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine alfentanil infusion of patients with treated <\\entity><\\entity> undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6421",
    "Sentence": "METHODS: Forty consecutive ASA class II patients with controlled hypertension about to undergo laparoscopic cholecystectomy were randomized into two groups: an <\\entity><\\entity> group (Group E, n=20) was given a 1 mg kg(-1) bolus of <\\entity><\\entity> and a placebo group (Group P, n=20) was given an identical volume of Ringer's lactate.",
    "Label": ""
  },
  {
    "id": "6422",
    "Sentence": "METHODS: Forty consecutive ASA class II patients with controlled <\\entity><\\entity> about to undergo laparoscopic cholecystectomy were randomized into two groups: an esmolol group (Group E, n=20) was given a 1 mg kg(-1) bolus of esmolol and a placebo group (Group P, n=20) was given an identical volume of Ringer's lactate.",
    "Label": ""
  },
  {
    "id": "6424",
    "Sentence": "METHODS: Forty consecutive <\\entity><\\entity> class II patients with controlled hypertension about to undergo laparoscopic cholecystectomy were randomized into two groups: an esmolol group (Group E, n=20) was given a 1 mg kg(-1) bolus of esmolol and a placebo group (Group P, n=20) was given an identical volume of Ringer's lactate.",
    "Label": ""
  },
  {
    "id": "6425",
    "Sentence": "METHODS: Forty consecutive ASA class II patients with controlled <\\entity><\\entity> about to undergo laparoscopic cholecystectomy were randomized into two groups: an esmolol group (Group E, n=20) was given a 1 mg kg(-1) bolus of esmolol and a placebo group (Group P, n=20) was given an identical volume of Ringer's lactate.",
    "Label": ""
  },
  {
    "id": "6427",
    "Sentence": "The frequency of PONV did not correlate to the amounts of <\\entity><\\entity>, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or motion sickness.",
    "Label": ""
  },
  {
    "id": "6428",
    "Sentence": "The frequency of <\\entity><\\entity> did not correlate to the amounts of alfentanil, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of <\\entity><\\entity> or motion sickness.",
    "Label": ""
  },
  {
    "id": "6430",
    "Sentence": "The frequency of PONV did not correlate to the amounts of <\\entity><\\entity>, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or motion sickness.",
    "Label": ""
  },
  {
    "id": "6431",
    "Sentence": "The frequency of PONV did not correlate to the amounts of alfentanil, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6433",
    "Sentence": "The frequency of PONV did not correlate to the amounts of alfentanil, <\\entity><\\entity>, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or motion sickness.",
    "Label": ""
  },
  {
    "id": "6434",
    "Sentence": "The frequency of <\\entity><\\entity> did not correlate to the amounts of alfentanil, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of <\\entity><\\entity> or motion sickness.",
    "Label": ""
  },
  {
    "id": "6436",
    "Sentence": "The frequency of PONV did not correlate to the amounts of alfentanil, <\\entity><\\entity>, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or motion sickness.",
    "Label": ""
  },
  {
    "id": "6437",
    "Sentence": "The frequency of PONV did not correlate to the amounts of alfentanil, propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6439",
    "Sentence": "Postoperative beneficial effects of <\\entity><\\entity> in treated hypertensive patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, <\\entity><\\entity> was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6440",
    "Sentence": "Postoperative beneficial effects of esmolol in treated <\\entity><\\entity> patients undergoing laparoscopic cholecystectomy.BACKGROUND: In an attempt to decrease haemodynamic instability and early postoperative complications such as nausea, vomiting, and pain, esmolol was added to the routine alfentanil infusion of patients with treated hypertension undergoing laparoscopic cholecystectomy.",
    "Label": ""
  },
  {
    "id": "6446",
    "Sentence": "<\\entity><\\entity> update 2007.The use of photodynamic therapy (PDT) in the US has shown record growth in 2007 with more clinicians utilizing PDT for more clinical entities than ever before.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6447",
    "Sentence": "Photodynamic therapy update 2007.The use of <\\entity><\\entity> (PDT) in the US has shown record growth in 2007 with more clinicians utilizing PDT for more clinical entities than ever before.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6448",
    "Sentence": "Photodynamic therapy update 2007.The use of photodynamic therapy (<\\entity><\\entity>) in the US has shown record growth in 2007 with more clinicians utilizing <\\entity><\\entity> for more clinical entities than ever before.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6449",
    "Sentence": "Photodynamic therapy update 2007.The use of photodynamic therapy (<\\entity><\\entity>) in the US has shown record growth in 2007 with more clinicians utilizing <\\entity><\\entity> for more clinical entities than ever before.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6450",
    "Sentence": "Research endeavors utilizing <\\entity><\\entity> in published clinical manuscripts have been slow in 2007 and yet the use continues to rise significantly.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6451",
    "Sentence": "This manuscript will highlight the state of <\\entity><\\entity> in the US as 2007 comes to a close and focus on the future of <\\entity><\\entity> as we move toward 2008.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6452",
    "Sentence": "This manuscript will highlight the state of <\\entity><\\entity> in the US as 2007 comes to a close and focus on the future of <\\entity><\\entity> as we move toward 2008.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6457",
    "Sentence": "<\\entity><\\entity> associated with coxofemoral arthrodesis.The discovery of biomaterials led to their use in the manufacture of implants for biomedical applications.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6458",
    "Sentence": "Malignant fibrous histiocytoma associated with coxofemoral <\\entity><\\entity>.The discovery of biomaterials led to their use in the manufacture of implants for biomedical applications.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6459",
    "Sentence": "However, few reports have discussed the potential development of <\\entity><\\entity> associated with prosthetic structures in humans.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6460",
    "Sentence": "However, few reports have discussed the potential development of malignant tumors associated with <\\entity><\\entity> in humans.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6461",
    "Sentence": "The present study documents a case of <\\entity><\\entity> that developed in the vicinity of a metallic prosthesis 43 months after a coxofemoral arthrodesis with metallic pins and screws.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6462",
    "Sentence": "The present study documents a case of intraosseous sarcoma that developed in the vicinity of a <\\entity><\\entity> 43 months after a coxofemoral arthrodesis with metallic pins and screws.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6463",
    "Sentence": "The present study documents a case of intraosseous sarcoma that developed in the vicinity of a metallic prosthesis 43 months after a coxofemoral <\\entity><\\entity> with metallic pins and screws.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6464",
    "Sentence": "With this report the authors seek to contribute to the understanding of the potential toxicity and risks of using <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6465",
    "Sentence": "Since <\\entity><\\entity> employed in the rehabilitation of osteo-muscular-articular disorders usually remain in the organism for long periods of time, the need to monitor the metallic structures and the adjacent tissues is extremely relevant.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6466",
    "Sentence": "Since metallic implants employed in the rehabilitation of <\\entity><\\entity> usually remain in the organism for long periods of time, the need to monitor the metallic structures and the adjacent tissues is extremely relevant.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6467",
    "Sentence": "However, few reports have discussed the potential development of malignant tumors associated with <\\entity><\\entity> in humans.",
    "Label": ""
  },
  {
    "id": "6468",
    "Sentence": "However, few reports have discussed the potential development of <\\entity><\\entity> associated with prosthetic structures in humans.",
    "Label": ""
  },
  {
    "id": "6470",
    "Sentence": "The present study documents a case of intraosseous sarcoma that developed in the vicinity of a <\\entity><\\entity> 43 months after a coxofemoral arthrodesis with metallic pins and screws.",
    "Label": ""
  },
  {
    "id": "6471",
    "Sentence": "The present study documents a case of <\\entity><\\entity> that developed in the vicinity of a metallic prosthesis 43 months after a coxofemoral arthrodesis with metallic pins and screws.",
    "Label": ""
  },
  {
    "id": "6473",
    "Sentence": "Since <\\entity><\\entity> employed in the rehabilitation of osteo-muscular-articular disorders usually remain in the organism for long periods of time, the need to monitor the metallic structures and the adjacent tissues is extremely relevant.",
    "Label": ""
  },
  {
    "id": "6474",
    "Sentence": "Since metallic implants employed in the rehabilitation of <\\entity><\\entity> usually remain in the organism for long periods of time, the need to monitor the metallic structures and the adjacent tissues is extremely relevant.",
    "Label": ""
  },
  {
    "id": "6480",
    "Sentence": "<\\entity><\\entity> associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6481",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with <\\entity><\\entity>-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and <\\entity><\\entity> [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6482",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and <\\entity><\\entity>.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6483",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased <\\entity><\\entity> (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6484",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (<\\entity><\\entity> from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6485",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from <\\entity><\\entity> (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6486",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (<\\entity><\\entity>, both nonselective [NS]-<\\entity><\\entity> and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6487",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective <\\entity><\\entity> and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6488",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with <\\entity><\\entity>-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and <\\entity><\\entity> [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6489",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase <\\entity><\\entity>) have prevented their use despite numerous benefits.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6490",
    "Sentence": "METHODS: In this descriptive review, we critically examine the randomized, active- and placebo-controlled studies, observational trials, and meta-analyses evaluating the <\\entity><\\entity> associated with long-term and short-term use of COX-2 selective inhibitors and NS-NSAIDs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6491",
    "Sentence": "METHODS: In this descriptive review, we critically examine the randomized, active- and placebo-controlled studies, observational trials, and meta-analyses evaluating the CV adverse effects associated with long-term and short-term use of <\\entity><\\entity> and NS-NSAIDs.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6492",
    "Sentence": "METHODS: In this descriptive review, we critically examine the randomized, active- and placebo-controlled studies, observational trials, and meta-analyses evaluating the CV adverse effects associated with long-term and short-term use of COX-2 selective inhibitors and <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6493",
    "Sentence": "The potential mechanisms for these <\\entity><\\entity> are also presented.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6494",
    "Sentence": "RESULTS: Although the studies evaluating the CV risks have limitations, there appears to be an increased CV risk with both <\\entity><\\entity> and NS-NSAIDs, particularly in high-risk patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6495",
    "Sentence": "RESULTS: Although the studies evaluating the CV risks have limitations, there appears to be an increased CV risk with both COX-2 selective inhibitors and <\\entity><\\entity>, particularly in high-risk patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6496",
    "Sentence": "Therefore, the United States Food and Drug Administration has given a similar \"boxed\" warning highlighting the potential for increased risk of <\\entity><\\entity> associated with their use.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6497",
    "Sentence": "Nevertheless, there are differences in the CV risks between <\\entity><\\entity> (e.g., higher CV risk with rofecoxib than celecoxib) as well as differences in the CV risks between individual NS-NSAIDs (e.g., higher CV risks with diclofenac than naproxen).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6498",
    "Sentence": "Nevertheless, there are differences in the CV risks between COX-2 selective inhibitors (e.g., higher CV risk with <\\entity><\\entity> than celecoxib) as well as differences in the CV risks between individual NS-NSAIDs (e.g., higher CV risks with diclofenac than naproxen).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6499",
    "Sentence": "Nevertheless, there are differences in the CV risks between COX-2 selective inhibitors (e.g., higher CV risk with rofecoxib than <\\entity><\\entity>) as well as differences in the CV risks between individual NS-NSAIDs (e.g., higher CV risks with diclofenac than naproxen).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6500",
    "Sentence": "Nevertheless, there are differences in the CV risks between COX-2 selective inhibitors (e.g., higher CV risk with rofecoxib than celecoxib) as well as differences in the CV risks between individual <\\entity><\\entity> (e.g., higher CV risks with diclofenac than naproxen).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6501",
    "Sentence": "Nevertheless, there are differences in the CV risks between COX-2 selective inhibitors (e.g., higher CV risk with rofecoxib than celecoxib) as well as differences in the CV risks between individual NS-NSAIDs (e.g., higher CV risks with <\\entity><\\entity> than naproxen).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6502",
    "Sentence": "Nevertheless, there are differences in the CV risks between COX-2 selective inhibitors (e.g., higher CV risk with rofecoxib than celecoxib) as well as differences in the CV risks between individual NS-NSAIDs (e.g., higher CV risks with diclofenac than <\\entity><\\entity>).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6503",
    "Sentence": "CONCLUSIONS: Until long-term, prospective, randomized, adequately powered, clinical studies in relevant patient populations have been completed, the CV risks associated with the use of <\\entity><\\entity>, especially in high-risk patients, will likely continue to be controversial.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6504",
    "Sentence": "Nevertheless, the benefits of their short-term (e.g., perioperative) use in patients without CV risks probably outweigh their potential <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6505",
    "Sentence": "Finally, careful risk/benefit assessment should be undertaken and both <\\entity><\\entity> and NS-NSAIDs should be used with caution in patients with CV risk factors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6506",
    "Sentence": "Finally, careful risk/benefit assessment should be undertaken and both COX-2 selective inhibitors and <\\entity><\\entity> should be used with caution in patients with CV risk factors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6507",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and <\\entity><\\entity>.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": ""
  },
  {
    "id": "6508",
    "Sentence": "<\\entity><\\entity> associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": ""
  },
  {
    "id": "6510",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with <\\entity><\\entity>-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and <\\entity><\\entity> [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": ""
  },
  {
    "id": "6511",
    "Sentence": "<\\entity><\\entity> associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": ""
  },
  {
    "id": "6513",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from <\\entity><\\entity> (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": ""
  },
  {
    "id": "6514",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased <\\entity><\\entity> (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": ""
  },
  {
    "id": "6516",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (<\\entity><\\entity>, both nonselective [NS]-<\\entity><\\entity> and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": ""
  },
  {
    "id": "6517",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased <\\entity><\\entity> (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": ""
  },
  {
    "id": "6519",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective <\\entity><\\entity> and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": ""
  },
  {
    "id": "6520",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased <\\entity><\\entity> (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": ""
  },
  {
    "id": "6522",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with <\\entity><\\entity>-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased cardiovascular (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and <\\entity><\\entity> [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": ""
  },
  {
    "id": "6523",
    "Sentence": "Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.BACKGROUND: Concerns of increased <\\entity><\\entity> (CV) thromboembolic adverse effects from nonsteroidal antiinflammatory drugs (NSAIDs, both nonselective [NS]-NSAIDs and cyclooxygenase [COX]-2 selective inhibitors) have prevented their use despite numerous benefits.",
    "Label": ""
  },
  {
    "id": "6529",
    "Sentence": "<\\entity><\\entity> in female populations occupationally exposed to ionizing radiation.OBJECTIVE: Exposure to radioisotopes of metals and halogen elements occurring in medical practice may cause spontaneous abortions.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6530",
    "Sentence": "Spontaneous abortions in female populations occupationally exposed to <\\entity><\\entity>.OBJECTIVE: Exposure to radioisotopes of metals and halogen elements occurring in medical practice may cause spontaneous abortions.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6531",
    "Sentence": "Spontaneous abortions in female populations occupationally exposed to ionizing radiation.OBJECTIVE: Exposure to <\\entity><\\entity> occurring in medical practice may cause spontaneous abortions.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6532",
    "Sentence": "Spontaneous abortions in female populations occupationally exposed to ionizing radiation.OBJECTIVE: Exposure to radioisotopes of metals and halogen elements occurring in medical practice may cause <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6533",
    "Sentence": "The potential role of occupational exposure to <\\entity><\\entity> and internal radioisotopes on pregnancy outcome in childbearing age women employed in hospital departments were analyzed in order to estimate miscarriage risk.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6534",
    "Sentence": "The potential role of occupational exposure to X-rays and internal <\\entity><\\entity> on pregnancy outcome in childbearing age women employed in hospital departments were analyzed in order to estimate miscarriage risk.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6535",
    "Sentence": "The potential role of occupational exposure to X-rays and internal radioisotopes on pregnancy outcome in childbearing age women employed in hospital departments were analyzed in order to estimate <\\entity><\\entity> risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6536",
    "Sentence": "METHODS: Over a period of 16 years, the occurrence of <\\entity><\\entity> in 61 women exposed to radioisotopes was compared to that reported in 170 X-ray exposed women.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6537",
    "Sentence": "METHODS: Over a period of 16 years, the occurrence of miscarriages in 61 women exposed to <\\entity><\\entity> was compared to that reported in 170 X-ray exposed women.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6538",
    "Sentence": "METHODS: Over a period of 16 years, the occurrence of miscarriages in 61 women exposed to radioisotopes was compared to that reported in 170 <\\entity><\\entity> exposed women.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6539",
    "Sentence": "<\\entity><\\entity> (CA) were measured in both radiation-exposed groups and in 53 non-exposed women.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6540",
    "Sentence": "Chromosomal aberrations (<\\entity><\\entity>) were measured in both radiation-exposed groups and in 53 non-exposed women.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6541",
    "Sentence": "RESULTS: Women exposed to <\\entity><\\entity> experienced at least a threefold higher rate of spontaneous abortions than those exposed to X-ray (OR = 3.68, 95% CI = 1.39-9.74, P < 0.01).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6542",
    "Sentence": "RESULTS: Women exposed to radioisotopes experienced at least a threefold higher rate of <\\entity><\\entity> than those exposed to X-ray (OR = 3.68, 95% CI = 1.39-9.74, P < 0.01).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6543",
    "Sentence": "RESULTS: Women exposed to radioisotopes experienced at least a threefold higher rate of spontaneous abortions than those exposed to <\\entity><\\entity> (OR = 3.68, 95% CI = 1.39-9.74, P < 0.01).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6544",
    "Sentence": "Although <\\entity><\\entity> and radioisotopes exposed women had significantly higher levels of chromosome type frequency (0.51 +/- 0.82, and 0.63 +/- 0.99, respectively) than referents (0.17 +/- 0.34), there was no clear difference between radiation-exposed women.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6545",
    "Sentence": "Although X-ray and <\\entity><\\entity> exposed women had significantly higher levels of chromosome type frequency (0.51 +/- 0.82, and 0.63 +/- 0.99, respectively) than referents (0.17 +/- 0.34), there was no clear difference between radiation-exposed women.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6546",
    "Sentence": "CONCLUSIONS: For exposure levels within standard recommended guidelines, <\\entity><\\entity> are far more likely to play a role in the occurrence of spontaneous abortions than X-rays.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6547",
    "Sentence": "CONCLUSIONS: For exposure levels within standard recommended guidelines, radioisotopes are far more likely to play a role in the occurrence of <\\entity><\\entity> than X-rays.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6548",
    "Sentence": "CONCLUSIONS: For exposure levels within standard recommended guidelines, radioisotopes are far more likely to play a role in the occurrence of spontaneous abortions than <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6549",
    "Sentence": "Such biological effect is not detectable by deviations in <\\entity><\\entity> frequency.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6550",
    "Sentence": "Spontaneous abortions in female populations occupationally exposed to ionizing radiation.OBJECTIVE: Exposure to <\\entity><\\entity> occurring in medical practice may cause spontaneous abortions.",
    "Label": ""
  },
  {
    "id": "6551",
    "Sentence": "Spontaneous abortions in female populations occupationally exposed to ionizing radiation.OBJECTIVE: Exposure to radioisotopes of metals and halogen elements occurring in medical practice may cause <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6553",
    "Sentence": "RESULTS: Women exposed to <\\entity><\\entity> experienced at least a threefold higher rate of spontaneous abortions than those exposed to X-ray (OR = 3.68, 95% CI = 1.39-9.74, P < 0.01).",
    "Label": ""
  },
  {
    "id": "6554",
    "Sentence": "RESULTS: Women exposed to radioisotopes experienced at least a threefold higher rate of <\\entity><\\entity> than those exposed to X-ray (OR = 3.68, 95% CI = 1.39-9.74, P < 0.01).",
    "Label": ""
  },
  {
    "id": "6556",
    "Sentence": "CONCLUSIONS: For exposure levels within standard recommended guidelines, <\\entity><\\entity> are far more likely to play a role in the occurrence of spontaneous abortions than X-rays.",
    "Label": ""
  },
  {
    "id": "6557",
    "Sentence": "CONCLUSIONS: For exposure levels within standard recommended guidelines, radioisotopes are far more likely to play a role in the occurrence of <\\entity><\\entity> than X-rays.",
    "Label": ""
  },
  {
    "id": "6559",
    "Sentence": "The potential role of occupational exposure to <\\entity><\\entity> and internal radioisotopes on pregnancy outcome in childbearing age women employed in hospital departments were analyzed in order to estimate miscarriage risk.",
    "Label": ""
  },
  {
    "id": "6560",
    "Sentence": "The potential role of occupational exposure to X-rays and internal radioisotopes on pregnancy outcome in childbearing age women employed in hospital departments were analyzed in order to estimate <\\entity><\\entity> risk.",
    "Label": ""
  },
  {
    "id": "6562",
    "Sentence": "The potential role of occupational exposure to X-rays and internal <\\entity><\\entity> on pregnancy outcome in childbearing age women employed in hospital departments were analyzed in order to estimate miscarriage risk.",
    "Label": ""
  },
  {
    "id": "6563",
    "Sentence": "The potential role of occupational exposure to X-rays and internal radioisotopes on pregnancy outcome in childbearing age women employed in hospital departments were analyzed in order to estimate <\\entity><\\entity> risk.",
    "Label": ""
  },
  {
    "id": "6565",
    "Sentence": "METHODS: Over a period of 16 years, the occurrence of miscarriages in 61 women exposed to <\\entity><\\entity> was compared to that reported in 170 X-ray exposed women.",
    "Label": ""
  },
  {
    "id": "6566",
    "Sentence": "METHODS: Over a period of 16 years, the occurrence of <\\entity><\\entity> in 61 women exposed to radioisotopes was compared to that reported in 170 X-ray exposed women.",
    "Label": ""
  },
  {
    "id": "6568",
    "Sentence": "METHODS: Over a period of 16 years, the occurrence of miscarriages in 61 women exposed to radioisotopes was compared to that reported in 170 <\\entity><\\entity> exposed women.",
    "Label": ""
  },
  {
    "id": "6569",
    "Sentence": "METHODS: Over a period of 16 years, the occurrence of <\\entity><\\entity> in 61 women exposed to radioisotopes was compared to that reported in 170 X-ray exposed women.",
    "Label": ""
  },
  {
    "id": "6571",
    "Sentence": "RESULTS: Women exposed to radioisotopes experienced at least a threefold higher rate of spontaneous abortions than those exposed to <\\entity><\\entity> (OR = 3.68, 95% CI = 1.39-9.74, P < 0.01).",
    "Label": ""
  },
  {
    "id": "6572",
    "Sentence": "RESULTS: Women exposed to radioisotopes experienced at least a threefold higher rate of <\\entity><\\entity> than those exposed to X-ray (OR = 3.68, 95% CI = 1.39-9.74, P < 0.01).",
    "Label": ""
  },
  {
    "id": "6574",
    "Sentence": "CONCLUSIONS: For exposure levels within standard recommended guidelines, radioisotopes are far more likely to play a role in the occurrence of spontaneous abortions than <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6575",
    "Sentence": "CONCLUSIONS: For exposure levels within standard recommended guidelines, radioisotopes are far more likely to play a role in the occurrence of <\\entity><\\entity> than X-rays.",
    "Label": ""
  },
  {
    "id": "6581",
    "Sentence": "Regulation of <\\entity><\\entity> secretion by fibroblasts in patients with acute lung injury.The mechanisms of pulmonary repair in acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) are poorly known.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6582",
    "Sentence": "<\\entity><\\entity> (HGF) and keratinocyte growth factor (KGF) are key factors involved in alveolar epithelial repair, present in the bronchoalveolar lavage fluid (BALF) from patients with ALI/ARDS.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6583",
    "Sentence": "Hepatocyte growth factor (<\\entity><\\entity>) and keratinocyte growth factor (KGF) are key factors involved in alveolar epithelial repair, present in the bronchoalveolar lavage fluid (BALF) from patients with ALI/ARDS.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6584",
    "Sentence": "Hepatocyte growth factor (HGF) and <\\entity><\\entity> (KGF) are key factors involved in alveolar epithelial repair, present in the bronchoalveolar lavage fluid (BALF) from patients with ALI/ARDS.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6585",
    "Sentence": "Hepatocyte growth factor (HGF) and keratinocyte growth factor (<\\entity><\\entity>) are key factors involved in alveolar epithelial repair, present in the bronchoalveolar lavage fluid (BALF) from patients with ALI/ARDS.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6586",
    "Sentence": "The role of <\\entity><\\entity> in their production remains to be determined.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6587",
    "Sentence": "We evaluated the overall effect of BALF from 52 patients (27 ventilated patients with ALI/ARDS, 10 ventilated patients without ALI, and 15 nonventilated control patients) on <\\entity><\\entity> and KGF synthesis by lung fibroblasts.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6588",
    "Sentence": "We evaluated the overall effect of BALF from 52 patients (27 ventilated patients with ALI/ARDS, 10 ventilated patients without ALI, and 15 nonventilated control patients) on HGF and <\\entity><\\entity> synthesis by lung fibroblasts.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6589",
    "Sentence": "<\\entity><\\entity> and KGF protein secretion was measured using ELISA, and mRNA expression was evaluated using quantitative real-time RT-PCR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6590",
    "Sentence": "HGF and <\\entity><\\entity> protein secretion was measured using ELISA, and mRNA expression was evaluated using quantitative real-time RT-PCR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6591",
    "Sentence": "Only BALF from ALI/ARDS patients upregulated both <\\entity><\\entity> and KGF mRNA expression and protein synthesis (+271 and +146% for <\\entity><\\entity> and KGF, respectively).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6592",
    "Sentence": "Only BALF from ALI/ARDS patients upregulated both HGF and <\\entity><\\entity> mRNA expression and protein synthesis (+271 and +146% for HGF and <\\entity><\\entity>, respectively).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6593",
    "Sentence": "Only BALF from ALI/ARDS patients upregulated both <\\entity><\\entity> and KGF mRNA expression and protein synthesis (+271 and +146% for <\\entity><\\entity> and KGF, respectively).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6594",
    "Sentence": "Only BALF from ALI/ARDS patients upregulated both HGF and <\\entity><\\entity> mRNA expression and protein synthesis (+271 and +146% for HGF and <\\entity><\\entity>, respectively).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6595",
    "Sentence": "BALF-induced <\\entity><\\entity> synthesis from ALI/ARDS patients was higher than that from ventilated patients without ALI (P < 0.05).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6596",
    "Sentence": "<\\entity><\\entity> secretion was correlated with BALF IL-1beta levels (rho = 0.62, P < 0.001) and BALF IL-1beta/IL-1 receptor antagonist ratio (rho = 0.54, P < 0.007) in the ALI/ARDS group.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6597",
    "Sentence": "HGF secretion was correlated with BALF <\\entity><\\entity> levels (rho = 0.62, P < 0.001) and BALF <\\entity><\\entity>/IL-1 receptor antagonist ratio (rho = 0.54, P < 0.007) in the ALI/ARDS group.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6598",
    "Sentence": "HGF secretion was correlated with BALF <\\entity><\\entity> levels (rho = 0.62, P < 0.001) and BALF <\\entity><\\entity>/IL-1 receptor antagonist ratio (rho = 0.54, P < 0.007) in the ALI/ARDS group.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6599",
    "Sentence": "HGF secretion was correlated with BALF IL-1beta levels (rho = 0.62, P < 0.001) and BALF IL-1beta/<\\entity><\\entity> ratio (rho = 0.54, P < 0.007) in the ALI/ARDS group.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6600",
    "Sentence": "HGF secretion was correlated with BALF IL-1beta levels (rho = 0.62, P < 0.001) and BALF IL-1beta/<\\entity><\\entity> ratio (rho = 0.54, P < 0.007) in the ALI/ARDS group.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6601",
    "Sentence": "An <\\entity><\\entity> partially (>50%) inhibited the BALF-induced HGF and PGE(2) secretion, whereas NS-398, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6602",
    "Sentence": "An <\\entity><\\entity> partially (>50%) inhibited the BALF-induced HGF and PGE(2) secretion, whereas NS-398, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6603",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced <\\entity><\\entity> and PGE(2) secretion, whereas NS-398, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6604",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and <\\entity><\\entity> secretion, whereas NS-398, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6605",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and <\\entity><\\entity> secretion, whereas NS-398, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6606",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and PGE(2) secretion, whereas <\\entity><\\entity>, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6607",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and PGE(2) secretion, whereas <\\entity><\\entity>, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6608",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and PGE(2) secretion, whereas NS-398, a specific <\\entity><\\entity> (COX-2) inhibitor, completely inhibited it.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6609",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and PGE(2) secretion, whereas NS-398, a specific cyclooxygenase-2 (<\\entity><\\entity>, completely inhibited it.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6610",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and PGE(2) secretion, whereas NS-398, a specific cyclooxygenase-2 (<\\entity><\\entity>, completely inhibited it.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6611",
    "Sentence": "<\\entity><\\entity> as well as NS-398 reversed the COX-2 upregulation induced by BALF.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6612",
    "Sentence": "<\\entity><\\entity> as well as NS-398 reversed the COX-2 upregulation induced by BALF.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6613",
    "Sentence": "Anti-IL-1beta antibodies as well as <\\entity><\\entity> reversed the COX-2 upregulation induced by BALF.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6614",
    "Sentence": "Anti-IL-1beta antibodies as well as <\\entity><\\entity> reversed the COX-2 upregulation induced by BALF.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6615",
    "Sentence": "Anti-IL-1beta antibodies as well as NS-398 reversed the <\\entity><\\entity> upregulation induced by BALF.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6616",
    "Sentence": "Therefore, <\\entity><\\entity> is a main BALF mediator involved in HGF secretion, which is mediated through a PGE(2)/COX-2-dependent mechanism.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6617",
    "Sentence": "Therefore, IL-1beta is a main <\\entity><\\entity> involved in HGF secretion, which is mediated through a PGE(2)/COX-2-dependent mechanism.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6618",
    "Sentence": "Therefore, IL-1beta is a main BALF mediator involved in <\\entity><\\entity> secretion, which is mediated through a PGE(2)/COX-2-dependent mechanism.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6619",
    "Sentence": "Therefore, IL-1beta is a main BALF mediator involved in HGF secretion, which is mediated through a <\\entity><\\entity>/COX-2-dependent mechanism.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6620",
    "Sentence": "Therefore, IL-1beta is a main BALF mediator involved in HGF secretion, which is mediated through a <\\entity><\\entity>/COX-2-dependent mechanism.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6621",
    "Sentence": "Therefore, IL-1beta is a main BALF mediator involved in HGF secretion, which is mediated through a PGE(2)/<\\entity><\\entity>-dependent mechanism.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6622",
    "Sentence": "<\\entity><\\entity> may participate in vivo in the production of HGF and KGF by lung fibroblasts during ALI/ARDS.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6623",
    "Sentence": "BALF mediators may participate in vivo in the production of <\\entity><\\entity> and KGF by lung fibroblasts during ALI/ARDS.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6624",
    "Sentence": "BALF mediators may participate in vivo in the production of HGF and <\\entity><\\entity> by lung fibroblasts during ALI/ARDS.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6625",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and PGE(2) secretion, whereas <\\entity><\\entity>, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": ""
  },
  {
    "id": "6626",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced <\\entity><\\entity> and PGE(2) secretion, whereas NS-398, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": ""
  },
  {
    "id": "6628",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and PGE(2) secretion, whereas <\\entity><\\entity>, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": ""
  },
  {
    "id": "6629",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and PGE(2) secretion, whereas NS-398, a specific <\\entity><\\entity> (COX-2) inhibitor, completely inhibited it.",
    "Label": ""
  },
  {
    "id": "6631",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and PGE(2) secretion, whereas <\\entity><\\entity>, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": ""
  },
  {
    "id": "6632",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and <\\entity><\\entity> secretion, whereas NS-398, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": ""
  },
  {
    "id": "6634",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and PGE(2) secretion, whereas NS-398, a specific cyclooxygenase-2 (<\\entity><\\entity>, completely inhibited it.",
    "Label": ""
  },
  {
    "id": "6635",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced <\\entity><\\entity> and PGE(2) secretion, whereas NS-398, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": ""
  },
  {
    "id": "6637",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and PGE(2) secretion, whereas NS-398, a specific cyclooxygenase-2 (<\\entity><\\entity>, completely inhibited it.",
    "Label": ""
  },
  {
    "id": "6638",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced HGF and <\\entity><\\entity> secretion, whereas NS-398, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": ""
  },
  {
    "id": "6640",
    "Sentence": "Anti-IL-1beta antibodies as well as <\\entity><\\entity> reversed the COX-2 upregulation induced by BALF.",
    "Label": ""
  },
  {
    "id": "6641",
    "Sentence": "Anti-IL-1beta antibodies as well as NS-398 reversed the <\\entity><\\entity> upregulation induced by BALF.",
    "Label": ""
  },
  {
    "id": "6643",
    "Sentence": "An <\\entity><\\entity> partially (>50%) inhibited the BALF-induced HGF and PGE(2) secretion, whereas NS-398, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": ""
  },
  {
    "id": "6644",
    "Sentence": "An anti-IL-1beta antibody partially (>50%) inhibited the BALF-induced <\\entity><\\entity> and PGE(2) secretion, whereas NS-398, a specific cyclooxygenase-2 (COX-2) inhibitor, completely inhibited it.",
    "Label": ""
  },
  {
    "id": "6646",
    "Sentence": "<\\entity><\\entity> as well as NS-398 reversed the COX-2 upregulation induced by BALF.",
    "Label": ""
  },
  {
    "id": "6647",
    "Sentence": "Anti-IL-1beta antibodies as well as NS-398 reversed the <\\entity><\\entity> upregulation induced by BALF.",
    "Label": ""
  },
  {
    "id": "6649",
    "Sentence": "Therefore, IL-1beta is a main BALF mediator involved in HGF secretion, which is mediated through a <\\entity><\\entity>/COX-2-dependent mechanism.",
    "Label": ""
  },
  {
    "id": "6650",
    "Sentence": "Therefore, IL-1beta is a main BALF mediator involved in <\\entity><\\entity> secretion, which is mediated through a PGE(2)/COX-2-dependent mechanism.",
    "Label": ""
  },
  {
    "id": "6652",
    "Sentence": "Therefore, IL-1beta is a main BALF mediator involved in HGF secretion, which is mediated through a <\\entity><\\entity>/COX-2-dependent mechanism.",
    "Label": ""
  },
  {
    "id": "6653",
    "Sentence": "Therefore, <\\entity><\\entity> is a main BALF mediator involved in HGF secretion, which is mediated through a PGE(2)/COX-2-dependent mechanism.",
    "Label": ""
  },
  {
    "id": "6655",
    "Sentence": "Therefore, IL-1beta is a main BALF mediator involved in HGF secretion, which is mediated through a <\\entity><\\entity>/COX-2-dependent mechanism.",
    "Label": ""
  },
  {
    "id": "6656",
    "Sentence": "Therefore, IL-1beta is a main BALF mediator involved in HGF secretion, which is mediated through a PGE(2)/<\\entity><\\entity>-dependent mechanism.",
    "Label": ""
  },
  {
    "id": "6658",
    "Sentence": "Therefore, IL-1beta is a main <\\entity><\\entity> involved in HGF secretion, which is mediated through a PGE(2)/COX-2-dependent mechanism.",
    "Label": ""
  },
  {
    "id": "6659",
    "Sentence": "Therefore, IL-1beta is a main BALF mediator involved in <\\entity><\\entity> secretion, which is mediated through a PGE(2)/COX-2-dependent mechanism.",
    "Label": ""
  },
  {
    "id": "6661",
    "Sentence": "Therefore, IL-1beta is a main <\\entity><\\entity> involved in HGF secretion, which is mediated through a PGE(2)/COX-2-dependent mechanism.",
    "Label": ""
  },
  {
    "id": "6662",
    "Sentence": "Therefore, <\\entity><\\entity> is a main BALF mediator involved in HGF secretion, which is mediated through a PGE(2)/COX-2-dependent mechanism.",
    "Label": ""
  },
  {
    "id": "6664",
    "Sentence": "Therefore, IL-1beta is a main <\\entity><\\entity> involved in HGF secretion, which is mediated through a PGE(2)/COX-2-dependent mechanism.",
    "Label": ""
  },
  {
    "id": "6665",
    "Sentence": "Therefore, IL-1beta is a main BALF mediator involved in HGF secretion, which is mediated through a PGE(2)/<\\entity><\\entity>-dependent mechanism.",
    "Label": ""
  },
  {
    "id": "6667",
    "Sentence": "Therefore, IL-1beta is a main <\\entity><\\entity> involved in HGF secretion, which is mediated through a PGE(2)/COX-2-dependent mechanism.",
    "Label": ""
  },
  {
    "id": "6668",
    "Sentence": "Therefore, IL-1beta is a main BALF mediator involved in HGF secretion, which is mediated through a <\\entity><\\entity>/COX-2-dependent mechanism.",
    "Label": ""
  },
  {
    "id": "6670",
    "Sentence": "<\\entity><\\entity> may participate in vivo in the production of HGF and KGF by lung fibroblasts during ALI/ARDS.",
    "Label": ""
  },
  {
    "id": "6671",
    "Sentence": "BALF mediators may participate in vivo in the production of <\\entity><\\entity> and KGF by lung fibroblasts during ALI/ARDS.",
    "Label": ""
  },
  {
    "id": "6673",
    "Sentence": "<\\entity><\\entity> may participate in vivo in the production of HGF and KGF by lung fibroblasts during ALI/ARDS.",
    "Label": ""
  },
  {
    "id": "6674",
    "Sentence": "BALF mediators may participate in vivo in the production of HGF and <\\entity><\\entity> by lung fibroblasts during ALI/ARDS.",
    "Label": ""
  },
  {
    "id": "6680",
    "Sentence": "<\\entity><\\entity> clinically mimicking Lemierre's syndrome.Lemierre's syndrome is an oropharyngeal infection which leads to severe septic thrombophlebitis of the internal jugular vein and metastatic abscesses of the lungs and other organs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6681",
    "Sentence": "Infection by Panton-Valentine leukocidin-producing Staphylococcus aureus clinically mimicking <\\entity><\\entity>.<\\entity><\\entity> is an oropharyngeal infection which leads to severe septic thrombophlebitis of the internal jugular vein and metastatic abscesses of the lungs and other organs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6682",
    "Sentence": "Infection by Panton-Valentine leukocidin-producing Staphylococcus aureus clinically mimicking <\\entity><\\entity>.<\\entity><\\entity> is an oropharyngeal infection which leads to severe septic thrombophlebitis of the internal jugular vein and metastatic abscesses of the lungs and other organs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6683",
    "Sentence": "Infection by Panton-Valentine leukocidin-producing Staphylococcus aureus clinically mimicking Lemierre's syndrome.Lemierre's syndrome is an <\\entity><\\entity> which leads to severe septic thrombophlebitis of the internal jugular vein and metastatic abscesses of the lungs and other organs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6684",
    "Sentence": "Infection by Panton-Valentine leukocidin-producing Staphylococcus aureus clinically mimicking Lemierre's syndrome.Lemierre's syndrome is an oropharyngeal infection which leads to severe <\\entity><\\entity> of the internal jugular vein and metastatic abscesses of the lungs and other organs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6685",
    "Sentence": "Infection by Panton-Valentine leukocidin-producing Staphylococcus aureus clinically mimicking Lemierre's syndrome.Lemierre's syndrome is an oropharyngeal infection which leads to severe septic thrombophlebitis of the internal jugular vein and <\\entity><\\entity> and other organs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6686",
    "Sentence": "An unusual case of Panton-Valentine leukocidin (<\\entity><\\entity> masquerading as Lemierre's syndrome is reported here.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6687",
    "Sentence": "An unusual case of Panton-Valentine leukocidin (PVL)-producing Staphylococcus aureus infection masquerading as <\\entity><\\entity> is reported here.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6688",
    "Sentence": "A 32-year-old <\\entity><\\entity> and otherwise healthy male presented on Christmas morning with a boil on his left cheek for 2 days and generalized rash for 3 h.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6689",
    "Sentence": "A 32-year-old fit and otherwise healthy male presented on Christmas morning with a <\\entity><\\entity> on his left cheek for 2 days and generalized rash for 3 h.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6690",
    "Sentence": "His general condition began to worsen, he developed <\\entity><\\entity> and loss of vision in the left eye and was transferred to the intensive care unit.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6691",
    "Sentence": "His general condition began to worsen, he developed facial swelling and <\\entity><\\entity> and was transferred to the intensive care unit.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6692",
    "Sentence": "His treatment was taken over by team of specialists and further investigations revealed <\\entity><\\entity> of the left internal jugular vein and cavernous sinus thrombosis with multiple brain infarcts and lung abscesses.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6693",
    "Sentence": "His treatment was taken over by team of specialists and further investigations revealed thrombophlebitis of the left internal jugular vein and <\\entity><\\entity> with multiple brain infarcts and lung abscesses.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6694",
    "Sentence": "His treatment was taken over by team of specialists and further investigations revealed thrombophlebitis of the left internal jugular vein and cavernous sinus thrombosis with multiple <\\entity><\\entity> and lung abscesses.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6695",
    "Sentence": "His treatment was taken over by team of specialists and further investigations revealed thrombophlebitis of the left internal jugular vein and cavernous sinus thrombosis with multiple brain infarcts and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6696",
    "Sentence": "His condition remained critical with multiple cranial nerve involvement despite being on broad-spectrum <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6697",
    "Sentence": "Although a rare entity, it is important to consider <\\entity><\\entity> in septic patients who present with rapidly worsening symptoms.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6698",
    "Sentence": "Although a rare entity, it is important to consider Lemierre's syndrome in <\\entity><\\entity> patients who present with rapidly worsening symptoms.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6699",
    "Sentence": "Although a rare entity, it is important to consider Lemierre's syndrome in septic patients who present with rapidly worsening <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6704",
    "Sentence": "Relationship between pathogenicity for humans and <\\entity><\\entity> genotype in Shiga toxin-producing Escherichia coli serotype O157.To examine the reason why people infected with Shiga toxin (Stx) producing Escherichia coli (STEC) O157 strains develop varying clinical manifestations, 65 STEC O157 isolates originating from 64 different occurrences of infection in Miyazaki Prefecture in 2001-2003 and their 79 infected individuals were analyzed by <\\entity><\\entity> genotyping, quantitative analysis of reversed passive latex agglutination (RPLA), genomic DNA analysis using pulsed-field gel electrophoresis (PFGE), and clinical manifestations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6705",
    "Sentence": "Relationship between pathogenicity for humans and stx genotype in <\\entity><\\entity> toxin-producing Escherichia coli serotype O157.To examine the reason why people infected with <\\entity><\\entity> toxin (Stx) producing Escherichia coli (STEC) O157 strains develop varying clinical manifestations, 65 STEC O157 isolates originating from 64 different occurrences of infection in Miyazaki Prefecture in 2001-2003 and their 79 infected individuals were analyzed by stx genotyping, quantitative analysis of reversed passive latex agglutination (RPLA), genomic DNA analysis using pulsed-field gel electrophoresis (PFGE), and clinical manifestations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6706",
    "Sentence": "Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing <\\entity><\\entity> coli serotype O157.To examine the reason why people infected with Shiga toxin (Stx) producing <\\entity><\\entity> coli (STEC) O157 strains develop varying clinical manifestations, 65 STEC O157 isolates originating from 64 different occurrences of infection in Miyazaki Prefecture in 2001-2003 and their 79 infected individuals were analyzed by stx genotyping, quantitative analysis of reversed passive latex agglutination (RPLA), genomic DNA analysis using pulsed-field gel electrophoresis (PFGE), and clinical manifestations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6707",
    "Sentence": "Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing <\\entity><\\entity> coli serotype O157.To examine the reason why people infected with Shiga toxin (Stx) producing <\\entity><\\entity> coli (STEC) O157 strains develop varying clinical manifestations, 65 STEC O157 isolates originating from 64 different occurrences of infection in Miyazaki Prefecture in 2001-2003 and their 79 infected individuals were analyzed by stx genotyping, quantitative analysis of reversed passive latex agglutination (RPLA), genomic DNA analysis using pulsed-field gel electrophoresis (PFGE), and clinical manifestations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6708",
    "Sentence": "Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing Escherichia coli serotype O157.To examine the reason why people <\\entity><\\entity> strains develop varying clinical manifestations, 65 STEC O157 isolates originating from 64 different occurrences of infection in Miyazaki Prefecture in 2001-2003 and their 79 infected individuals were analyzed by stx genotyping, quantitative analysis of reversed passive latex agglutination (RPLA), genomic DNA analysis using pulsed-field gel electrophoresis (PFGE), and clinical manifestations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6709",
    "Sentence": "Relationship between pathogenicity for humans and stx genotype in <\\entity><\\entity> toxin-producing Escherichia coli serotype O157.To examine the reason why people infected with <\\entity><\\entity> toxin (Stx) producing Escherichia coli (STEC) O157 strains develop varying clinical manifestations, 65 STEC O157 isolates originating from 64 different occurrences of infection in Miyazaki Prefecture in 2001-2003 and their 79 infected individuals were analyzed by stx genotyping, quantitative analysis of reversed passive latex agglutination (RPLA), genomic DNA analysis using pulsed-field gel electrophoresis (PFGE), and clinical manifestations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6710",
    "Sentence": "Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing <\\entity><\\entity> coli serotype O157.To examine the reason why people infected with Shiga toxin (Stx) producing <\\entity><\\entity> coli (STEC) O157 strains develop varying clinical manifestations, 65 STEC O157 isolates originating from 64 different occurrences of infection in Miyazaki Prefecture in 2001-2003 and their 79 infected individuals were analyzed by stx genotyping, quantitative analysis of reversed passive latex agglutination (RPLA), genomic DNA analysis using pulsed-field gel electrophoresis (PFGE), and clinical manifestations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6711",
    "Sentence": "Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing Escherichia coli serotype O157.To examine the reason why people infected with Shiga toxin (Stx) producing Escherichia coli (STEC) O157 <\\entity><\\entity> develop varying clinical manifestations, 65 STEC O157 isolates originating from 64 different occurrences of infection in Miyazaki Prefecture in 2001-2003 and their 79 infected individuals were analyzed by stx genotyping, quantitative analysis of reversed passive latex agglutination (RPLA), genomic DNA analysis using pulsed-field gel electrophoresis (PFGE), and clinical manifestations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6712",
    "Sentence": "Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing Escherichia coli serotype O157.To examine the reason why people infected with Shiga toxin (Stx) producing Escherichia coli (STEC) O157 strains develop varying clinical manifestations, 65 STEC O157 isolates originating from 64 different occurrences of <\\entity><\\entity> in Miyazaki Prefecture in 2001-2003 and their 79 infected individuals were analyzed by stx genotyping, quantitative analysis of reversed passive latex agglutination (RPLA), genomic DNA analysis using pulsed-field gel electrophoresis (PFGE), and clinical manifestations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6713",
    "Sentence": "Relationship between pathogenicity for humans and <\\entity><\\entity> genotype in Shiga toxin-producing Escherichia coli serotype O157.To examine the reason why people infected with Shiga toxin (Stx) producing Escherichia coli (STEC) O157 strains develop varying clinical manifestations, 65 STEC O157 isolates originating from 64 different occurrences of infection in Miyazaki Prefecture in 2001-2003 and their 79 infected individuals were analyzed by <\\entity><\\entity> genotyping, quantitative analysis of reversed passive latex agglutination (RPLA), genomic DNA analysis using pulsed-field gel electrophoresis (PFGE), and clinical manifestations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6714",
    "Sentence": "The isolates were found to carry the following <\\entity><\\entity> genes: <\\entity><\\entity>2vha alone (60.0%), <\\entity><\\entity>1/<\\entity><\\entity>2 (27.7%), <\\entity><\\entity>1/<\\entity><\\entity>2vha (6.1%), <\\entity><\\entity>2 alone (3.1%), and <\\entity><\\entity>2/<\\entity><\\entity>2vha (3.1%).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6715",
    "Sentence": "The isolates were found to carry the following stx genes: <\\entity><\\entity> alone (60.0%), stx1/stx2 (27.7%), stx1/<\\entity><\\entity> (6.1%), stx2 alone (3.1%), and stx2/<\\entity><\\entity> (3.1%).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6716",
    "Sentence": "The isolates were found to carry the following stx genes: stx2vha alone (60.0%), <\\entity><\\entity> (27.7%), <\\entity><\\entity>vha (6.1%), stx2 alone (3.1%), and stx2/stx2vha (3.1%).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6717",
    "Sentence": "The isolates were found to carry the following stx genes: stx2vha alone (60.0%), stx1/stx2 (27.7%), <\\entity><\\entity> (6.1%), stx2 alone (3.1%), and stx2/stx2vha (3.1%).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6718",
    "Sentence": "The isolates were found to carry the following stx genes: <\\entity><\\entity>vha alone (60.0%), stx1/<\\entity><\\entity> (27.7%), stx1/<\\entity><\\entity>vha (6.1%), <\\entity><\\entity> alone (3.1%), and <\\entity><\\entity>/<\\entity><\\entity>vha (3.1%).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6719",
    "Sentence": "The isolates were found to carry the following stx genes: stx2vha alone (60.0%), stx1/stx2 (27.7%), stx1/stx2vha (6.1%), stx2 alone (3.1%), and <\\entity><\\entity> (3.1%).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6720",
    "Sentence": "No <\\entity><\\entity> carried the stx1 gene alone.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6721",
    "Sentence": "No strain carried the <\\entity><\\entity> gene alone.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6722",
    "Sentence": "STEC <\\entity><\\entity> carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying stx2vha.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6723",
    "Sentence": "STEC strains carrying <\\entity><\\entity> were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying <\\entity><\\entity>vha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6724",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of <\\entity><\\entity> (HUS) or bloody diarrhea than those carrying stx2vha.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6725",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (<\\entity><\\entity>) or bloody diarrhea than those carrying stx2vha.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6726",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (<\\entity><\\entity>) or bloody diarrhea than those carrying stx2vha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6727",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or <\\entity><\\entity> than those carrying stx2vha.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6728",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6729",
    "Sentence": "Clusters of PFGE banding patterns were correlated well with the <\\entity><\\entity> genotypes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6730",
    "Sentence": "We conclude that <\\entity><\\entity> genotype is one of the important factors of clinical outcome of STEC O157 infection and that pathogenicity for humans was higher in the <\\entity><\\entity>2 genotype strains than in the <\\entity><\\entity>2vha genotype strains, as reported previously by other researchers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6731",
    "Sentence": "We conclude that stx genotype is one of the important factors of clinical outcome of <\\entity><\\entity> and that pathogenicity for humans was higher in the stx2 genotype strains than in the stx2vha genotype strains, as reported previously by other researchers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6732",
    "Sentence": "We conclude that stx genotype is one of the important factors of clinical outcome of STEC O157 infection and that pathogenicity for humans was higher in the <\\entity><\\entity> genotype strains than in the <\\entity><\\entity>vha genotype strains, as reported previously by other researchers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6733",
    "Sentence": "We conclude that stx genotype is one of the important factors of clinical outcome of STEC O157 infection and that pathogenicity for humans was higher in the stx2 genotype <\\entity><\\entity> than in the stx2vha genotype <\\entity><\\entity>, as reported previously by other researchers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6734",
    "Sentence": "We conclude that stx genotype is one of the important factors of clinical outcome of STEC O157 infection and that pathogenicity for humans was higher in the stx2 genotype strains than in the <\\entity><\\entity> genotype strains, as reported previously by other researchers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6735",
    "Sentence": "We conclude that stx genotype is one of the important factors of clinical outcome of STEC O157 infection and that pathogenicity for humans was higher in the stx2 genotype <\\entity><\\entity> than in the stx2vha genotype <\\entity><\\entity>, as reported previously by other researchers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6736",
    "Sentence": "Further, we newly found that four clusters identified by PFGE using restriction enzyme <\\entity><\\entity>, stx genotypes and clinical manifestations were well correlated with each other.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6737",
    "Sentence": "Further, we newly found that four clusters identified by PFGE using restriction enzyme XbaI, <\\entity><\\entity> genotypes and clinical manifestations were well correlated with each other.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6738",
    "Sentence": "STEC strains carrying <\\entity><\\entity> were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying <\\entity><\\entity>vha.",
    "Label": ""
  },
  {
    "id": "6739",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (<\\entity><\\entity>) or bloody diarrhea than those carrying stx2vha.",
    "Label": ""
  },
  {
    "id": "6741",
    "Sentence": "STEC strains carrying <\\entity><\\entity> were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying <\\entity><\\entity>vha.",
    "Label": ""
  },
  {
    "id": "6742",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of <\\entity><\\entity> (HUS) or bloody diarrhea than those carrying stx2vha.",
    "Label": ""
  },
  {
    "id": "6744",
    "Sentence": "STEC strains carrying <\\entity><\\entity> were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying <\\entity><\\entity>vha.",
    "Label": ""
  },
  {
    "id": "6745",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or <\\entity><\\entity> than those carrying stx2vha.",
    "Label": ""
  },
  {
    "id": "6747",
    "Sentence": "We conclude that stx genotype is one of the important factors of clinical outcome of STEC O157 infection and that pathogenicity for humans was higher in the <\\entity><\\entity> genotype strains than in the <\\entity><\\entity>vha genotype strains, as reported previously by other researchers.",
    "Label": ""
  },
  {
    "id": "6748",
    "Sentence": "We conclude that stx genotype is one of the important factors of clinical outcome of <\\entity><\\entity> and that pathogenicity for humans was higher in the stx2 genotype strains than in the stx2vha genotype strains, as reported previously by other researchers.",
    "Label": ""
  },
  {
    "id": "6750",
    "Sentence": "No strain carried the <\\entity><\\entity> gene alone.",
    "Label": ""
  },
  {
    "id": "6751",
    "Sentence": "No <\\entity><\\entity> carried the stx1 gene alone.",
    "Label": ""
  },
  {
    "id": "6753",
    "Sentence": "STEC strains carrying <\\entity><\\entity> were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying <\\entity><\\entity>vha.",
    "Label": ""
  },
  {
    "id": "6754",
    "Sentence": "STEC <\\entity><\\entity> carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying stx2vha.",
    "Label": ""
  },
  {
    "id": "6756",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (<\\entity><\\entity>) or bloody diarrhea than those carrying stx2vha.",
    "Label": ""
  },
  {
    "id": "6757",
    "Sentence": "STEC <\\entity><\\entity> carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying stx2vha.",
    "Label": ""
  },
  {
    "id": "6759",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (<\\entity><\\entity>) or bloody diarrhea than those carrying stx2vha.",
    "Label": ""
  },
  {
    "id": "6760",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of <\\entity><\\entity> (HUS) or bloody diarrhea than those carrying stx2vha.",
    "Label": ""
  },
  {
    "id": "6762",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (<\\entity><\\entity>) or bloody diarrhea than those carrying stx2vha.",
    "Label": ""
  },
  {
    "id": "6763",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or <\\entity><\\entity> than those carrying stx2vha.",
    "Label": ""
  },
  {
    "id": "6765",
    "Sentence": "We conclude that stx genotype is one of the important factors of clinical outcome of STEC O157 infection and that pathogenicity for humans was higher in the <\\entity><\\entity> genotype strains than in the <\\entity><\\entity>vha genotype strains, as reported previously by other researchers.",
    "Label": ""
  },
  {
    "id": "6766",
    "Sentence": "We conclude that stx genotype is one of the important factors of clinical outcome of STEC O157 infection and that pathogenicity for humans was higher in the stx2 genotype <\\entity><\\entity> than in the stx2vha genotype <\\entity><\\entity>, as reported previously by other researchers.",
    "Label": ""
  },
  {
    "id": "6768",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6769",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (<\\entity><\\entity>) or bloody diarrhea than those carrying stx2vha.",
    "Label": ""
  },
  {
    "id": "6771",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6772",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of <\\entity><\\entity> (HUS) or bloody diarrhea than those carrying stx2vha.",
    "Label": ""
  },
  {
    "id": "6774",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or bloody diarrhea than those carrying <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6775",
    "Sentence": "STEC strains carrying stx2 were more frequently associated with clinical manifestations of hemolytic-uremic syndrome (HUS) or <\\entity><\\entity> than those carrying stx2vha.",
    "Label": ""
  },
  {
    "id": "6777",
    "Sentence": "We conclude that stx genotype is one of the important factors of clinical outcome of STEC O157 infection and that pathogenicity for humans was higher in the stx2 genotype strains than in the <\\entity><\\entity> genotype strains, as reported previously by other researchers.",
    "Label": ""
  },
  {
    "id": "6778",
    "Sentence": "We conclude that stx genotype is one of the important factors of clinical outcome of <\\entity><\\entity> and that pathogenicity for humans was higher in the stx2 genotype strains than in the stx2vha genotype strains, as reported previously by other researchers.",
    "Label": ""
  },
  {
    "id": "6780",
    "Sentence": "Relationship between pathogenicity for humans and <\\entity><\\entity> genotype in Shiga toxin-producing Escherichia coli serotype O157.To examine the reason why people infected with Shiga toxin (Stx) producing Escherichia coli (STEC) O157 strains develop varying clinical manifestations, 65 STEC O157 isolates originating from 64 different occurrences of infection in Miyazaki Prefecture in 2001-2003 and their 79 infected individuals were analyzed by <\\entity><\\entity> genotyping, quantitative analysis of reversed passive latex agglutination (RPLA), genomic DNA analysis using pulsed-field gel electrophoresis (PFGE), and clinical manifestations.",
    "Label": ""
  },
  {
    "id": "6781",
    "Sentence": "Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing Escherichia coli serotype O157.To examine the reason why people <\\entity><\\entity> strains develop varying clinical manifestations, 65 STEC O157 isolates originating from 64 different occurrences of infection in Miyazaki Prefecture in 2001-2003 and their 79 infected individuals were analyzed by stx genotyping, quantitative analysis of reversed passive latex agglutination (RPLA), genomic DNA analysis using pulsed-field gel electrophoresis (PFGE), and clinical manifestations.",
    "Label": ""
  },
  {
    "id": "6783",
    "Sentence": "We conclude that <\\entity><\\entity> genotype is one of the important factors of clinical outcome of STEC O157 infection and that pathogenicity for humans was higher in the <\\entity><\\entity>2 genotype strains than in the <\\entity><\\entity>2vha genotype strains, as reported previously by other researchers.",
    "Label": ""
  },
  {
    "id": "6784",
    "Sentence": "We conclude that stx genotype is one of the important factors of clinical outcome of <\\entity><\\entity> and that pathogenicity for humans was higher in the stx2 genotype strains than in the stx2vha genotype strains, as reported previously by other researchers.",
    "Label": ""
  },
  {
    "id": "6790",
    "Sentence": "Long-term exposure to <\\entity><\\entity> therapy associates with hypertension in patients with rheumatoid arthritis.OBJECTIVE: Rheumatoid arthritis (RA) associates with increased cardiovascular morbidity and mortality that is due to both traditional and novel cardiovascular risk factors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6791",
    "Sentence": "Long-term exposure to medium-dose glucocorticoid therapy associates with <\\entity><\\entity> in patients with rheumatoid arthritis.OBJECTIVE: Rheumatoid arthritis (RA) associates with increased cardiovascular morbidity and mortality that is due to both traditional and novel cardiovascular risk factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6792",
    "Sentence": "Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with <\\entity><\\entity>.OBJECTIVE: Rheumatoid arthritis (RA) associates with increased cardiovascular morbidity and mortality that is due to both traditional and novel cardiovascular risk factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6793",
    "Sentence": "Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis.OBJECTIVE: <\\entity><\\entity> (RA) associates with increased cardiovascular morbidity and mortality that is due to both traditional and novel cardiovascular risk factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6794",
    "Sentence": "Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis.OBJECTIVE: Rheumatoid arthritis (<\\entity><\\entity>) associates with increased cardiovascular morbidity and mortality that is due to both traditional and novel cardiovascular risk factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6795",
    "Sentence": "Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis.OBJECTIVE: Rheumatoid arthritis (RA) associates with increased <\\entity><\\entity> and mortality that is due to both traditional and novel cardiovascular risk factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6796",
    "Sentence": "Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis.OBJECTIVE: Rheumatoid arthritis (RA) associates with increased cardiovascular morbidity and <\\entity><\\entity> that is due to both traditional and novel cardiovascular risk factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6797",
    "Sentence": "Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis.OBJECTIVE: Rheumatoid arthritis (RA) associates with increased cardiovascular morbidity and mortality that is due to both traditional and novel <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6798",
    "Sentence": "<\\entity><\\entity> (HT), one of the most common risk factors for cardiovascular disease, is highly prevalent in RA.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6799",
    "Sentence": "Hypertension (<\\entity><\\entity>), one of the most common risk factors for cardiovascular disease, is highly prevalent in RA.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6800",
    "Sentence": "Hypertension (HT), one of the most common risk factors for <\\entity><\\entity>, is highly prevalent in RA.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6801",
    "Sentence": "Hypertension (HT), one of the most common risk factors for cardiovascular disease, is highly prevalent in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6802",
    "Sentence": "The effects of long-term <\\entity><\\entity> (GC) therapy on blood pressure have not been established yet.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6803",
    "Sentence": "The effects of long-term glucocorticoid (<\\entity><\\entity>) therapy on blood pressure have not been established yet.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6804",
    "Sentence": "This study examined whether <\\entity><\\entity> exposure associates with HT in patients with RA.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6805",
    "Sentence": "This study examined whether GC exposure associates with <\\entity><\\entity> in patients with RA.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6806",
    "Sentence": "This study examined whether GC exposure associates with HT in patients with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6807",
    "Sentence": "METHODS: Four hundred consecutive <\\entity><\\entity> patients with detailed clinical and laboratory assessments were categorized into three groups according to GC exposure: no or limited exposure (N/L-E); a low-dose (< 7.5 mg) long-term exposure (LD/LT-E); and medium-dose (> or = 7.5 mg) long-term exposure (MD/LT-E).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6808",
    "Sentence": "METHODS: Four hundred consecutive RA patients with detailed clinical and laboratory assessments were categorized into three groups according to <\\entity><\\entity> exposure: no or limited exposure (N/L-E); a low-dose (< 7.5 mg) long-term exposure (LD/LT-E); and medium-dose (> or = 7.5 mg) long-term exposure (MD/LT-E).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6809",
    "Sentence": "METHODS: Four hundred consecutive RA patients with detailed clinical and laboratory assessments were categorized into three groups according to GC exposure: no or limited exposure (N/L-E); a low-dose (< 7.5 mg) long-term exposure (LD/LT-E); and medium-dose (> or = 7.5 mg) long-term exposure (<\\entity><\\entity>/LT-E).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6810",
    "Sentence": "The association of <\\entity><\\entity> exposure with HT was evaluated using logistic regression analysis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6811",
    "Sentence": "The association of GC exposure with <\\entity><\\entity> was evaluated using logistic regression analysis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6812",
    "Sentence": "The association of GC exposure with HT was evaluated using logistic <\\entity><\\entity> analysis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6813",
    "Sentence": "RESULTS: <\\entity><\\entity> was more prevalent in the MD/LT-E group (84.7%) than the LD/LT-E or N/L-E groups (70.7 and 67.3%, respectively, P = 0.028).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6814",
    "Sentence": "RESULTS: HT was more prevalent in the <\\entity><\\entity>/LT-E group (84.7%) than the LD/LT-E or N/L-E groups (70.7 and 67.3%, respectively, P = 0.028).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6815",
    "Sentence": "Logistic <\\entity><\\entity> revealed increased odds for HT when comparing MD/LT-E with N/L-E, after adjustment for HT risk factors [odds ratio (OR) = 2.57, 95% CI 1.01-6.56, P = 0.049] and RA disease characteristics (OR = 3.64, 95% CI: 1.36-9.77, P = 0.01).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6816",
    "Sentence": "Logistic regression revealed increased odds for <\\entity><\\entity> when comparing MD/LT-E with N/L-E, after adjustment for <\\entity><\\entity> risk factors [odds ratio (OR) = 2.57, 95% CI 1.01-6.56, P = 0.049] and RA disease characteristics (OR = 3.64, 95% CI: 1.36-9.77, P = 0.01).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6817",
    "Sentence": "Logistic regression revealed increased odds for HT when comparing <\\entity><\\entity>/LT-E with N/L-E, after adjustment for HT risk factors [odds ratio (OR) = 2.57, 95% CI 1.01-6.56, P = 0.049] and RA disease characteristics (OR = 3.64, 95% CI: 1.36-9.77, P = 0.01).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6818",
    "Sentence": "Logistic regression revealed increased odds for <\\entity><\\entity> when comparing MD/LT-E with N/L-E, after adjustment for <\\entity><\\entity> risk factors [odds ratio (OR) = 2.57, 95% CI 1.01-6.56, P = 0.049] and RA disease characteristics (OR = 3.64, 95% CI: 1.36-9.77, P = 0.01).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6819",
    "Sentence": "Logistic regression revealed increased odds for HT when comparing MD/LT-E with N/L-E, after adjustment for HT risk factors [odds ratio (OR) = 2.57, 95% CI 1.01-6.56, P = 0.049] and <\\entity><\\entity> disease characteristics (OR = 3.64, 95% CI: 1.36-9.77, P = 0.01).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6820",
    "Sentence": "Logistic regression revealed increased odds for HT when comparing MD/LT-E with N/L-E, after adjustment for HT risk factors [odds ratio (OR) = 2.57, 95% CI 1.01-6.56, P = 0.049] and RA <\\entity><\\entity> (OR = 3.64, 95% CI: 1.36-9.77, P = 0.01).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6821",
    "Sentence": "CONCLUSIONS: <\\entity><\\entity> exposure associates with a very high prevalence of HT.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6822",
    "Sentence": "CONCLUSIONS: MD/LT GC exposure associates with a very high prevalence of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6823",
    "Sentence": "This appears to be independent of other risk factors for <\\entity><\\entity> or of channelling bias due to disease severity, even though the latter cannot be excluded given the cross-sectional nature of our study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6824",
    "Sentence": "This appears to be independent of other risk factors for HT or of channelling bias due to <\\entity><\\entity> severity, even though the latter cannot be excluded given the cross-sectional nature of our study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6825",
    "Sentence": "<\\entity><\\entity> patients in this GC exposure group should be particularly targeted for early identification and aggressive management of HT.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6826",
    "Sentence": "RA patients in this <\\entity><\\entity> exposure group should be particularly targeted for early identification and aggressive management of HT.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6827",
    "Sentence": "RA patients in this GC exposure group should be particularly targeted for early identification and <\\entity><\\entity> management of HT.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6828",
    "Sentence": "RA patients in this GC exposure group should be particularly targeted for early identification and aggressive management of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6829",
    "Sentence": "Long-term exposure to <\\entity><\\entity> therapy associates with hypertension in patients with rheumatoid arthritis.OBJECTIVE: Rheumatoid arthritis (RA) associates with increased cardiovascular morbidity and mortality that is due to both traditional and novel cardiovascular risk factors.",
    "Label": ""
  },
  {
    "id": "6830",
    "Sentence": "Long-term exposure to medium-dose glucocorticoid therapy associates with <\\entity><\\entity> in patients with rheumatoid arthritis.OBJECTIVE: Rheumatoid arthritis (RA) associates with increased cardiovascular morbidity and mortality that is due to both traditional and novel cardiovascular risk factors.",
    "Label": ""
  },
  {
    "id": "6832",
    "Sentence": "This study examined whether <\\entity><\\entity> exposure associates with HT in patients with RA.",
    "Label": ""
  },
  {
    "id": "6833",
    "Sentence": "This study examined whether GC exposure associates with <\\entity><\\entity> in patients with RA.",
    "Label": ""
  },
  {
    "id": "6835",
    "Sentence": "The association of <\\entity><\\entity> exposure with HT was evaluated using logistic regression analysis.",
    "Label": ""
  },
  {
    "id": "6836",
    "Sentence": "The association of GC exposure with <\\entity><\\entity> was evaluated using logistic regression analysis.",
    "Label": ""
  },
  {
    "id": "6838",
    "Sentence": "CONCLUSIONS: <\\entity><\\entity> exposure associates with a very high prevalence of HT.",
    "Label": ""
  },
  {
    "id": "6839",
    "Sentence": "CONCLUSIONS: MD/LT GC exposure associates with a very high prevalence of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6841",
    "Sentence": "RA patients in this <\\entity><\\entity> exposure group should be particularly targeted for early identification and aggressive management of HT.",
    "Label": ""
  },
  {
    "id": "6842",
    "Sentence": "RA patients in this GC exposure group should be particularly targeted for early identification and aggressive management of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6844",
    "Sentence": "Long-term exposure to <\\entity><\\entity> therapy associates with hypertension in patients with rheumatoid arthritis.OBJECTIVE: Rheumatoid arthritis (RA) associates with increased cardiovascular morbidity and mortality that is due to both traditional and novel cardiovascular risk factors.",
    "Label": ""
  },
  {
    "id": "6845",
    "Sentence": "Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with <\\entity><\\entity>.OBJECTIVE: Rheumatoid arthritis (RA) associates with increased cardiovascular morbidity and mortality that is due to both traditional and novel cardiovascular risk factors.",
    "Label": ""
  },
  {
    "id": "6847",
    "Sentence": "Logistic regression revealed increased odds for HT when comparing <\\entity><\\entity>/LT-E with N/L-E, after adjustment for HT risk factors [odds ratio (OR) = 2.57, 95% CI 1.01-6.56, P = 0.049] and RA disease characteristics (OR = 3.64, 95% CI: 1.36-9.77, P = 0.01).",
    "Label": ""
  },
  {
    "id": "6848",
    "Sentence": "Logistic <\\entity><\\entity> revealed increased odds for HT when comparing MD/LT-E with N/L-E, after adjustment for HT risk factors [odds ratio (OR) = 2.57, 95% CI 1.01-6.56, P = 0.049] and RA disease characteristics (OR = 3.64, 95% CI: 1.36-9.77, P = 0.01).",
    "Label": ""
  },
  {
    "id": "6850",
    "Sentence": "Logistic regression revealed increased odds for HT when comparing <\\entity><\\entity>/LT-E with N/L-E, after adjustment for HT risk factors [odds ratio (OR) = 2.57, 95% CI 1.01-6.56, P = 0.049] and RA disease characteristics (OR = 3.64, 95% CI: 1.36-9.77, P = 0.01).",
    "Label": ""
  },
  {
    "id": "6851",
    "Sentence": "Logistic regression revealed increased odds for HT when comparing MD/LT-E with N/L-E, after adjustment for HT risk factors [odds ratio (OR) = 2.57, 95% CI 1.01-6.56, P = 0.049] and RA <\\entity><\\entity> (OR = 3.64, 95% CI: 1.36-9.77, P = 0.01).",
    "Label": ""
  },
  {
    "id": "6853",
    "Sentence": "This study examined whether <\\entity><\\entity> exposure associates with HT in patients with RA.",
    "Label": ""
  },
  {
    "id": "6854",
    "Sentence": "This study examined whether GC exposure associates with HT in patients with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6856",
    "Sentence": "RA patients in this <\\entity><\\entity> exposure group should be particularly targeted for early identification and aggressive management of HT.",
    "Label": ""
  },
  {
    "id": "6857",
    "Sentence": "<\\entity><\\entity> patients in this GC exposure group should be particularly targeted for early identification and aggressive management of HT.",
    "Label": ""
  },
  {
    "id": "6863",
    "Sentence": "<\\entity><\\entity>-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing.Tandem PHD and bromodomains are often found in chromatin-associated proteins and have been shown to cooperate in gene silencing.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6864",
    "Sentence": "PHD domain-mediated <\\entity><\\entity> activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing.Tandem PHD and bromodomains are often found in chromatin-associated proteins and have been shown to cooperate in gene silencing.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6865",
    "Sentence": "PHD domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent <\\entity><\\entity> required for gene silencing.Tandem PHD and <\\entity><\\entity>s are often found in chromatin-associated proteins and have been shown to cooperate in gene silencing.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6866",
    "Sentence": "<\\entity><\\entity> domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing.Tandem <\\entity><\\entity> and bromodomains are often found in chromatin-associated proteins and have been shown to cooperate in gene silencing.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6867",
    "Sentence": "PHD domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing.Tandem PHD and <\\entity><\\entity> are often found in chromatin-associated proteins and have been shown to cooperate in gene silencing.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6868",
    "Sentence": "PHD domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing.Tandem PHD and bromodomains are often found in <\\entity><\\entity> and have been shown to cooperate in gene silencing.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6869",
    "Sentence": "Each domain can bind specifically modified <\\entity><\\entity>: the mechanisms of cooperation between these domains are unknown.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6870",
    "Sentence": "We show that the <\\entity><\\entity> of the KAP1 corepressor functions as an intramolecular E3 ligase for sumoylation of the adjacent bromodomain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6871",
    "Sentence": "We show that the PHD domain of the <\\entity><\\entity> corepressor functions as an intramolecular E3 ligase for sumoylation of the adjacent bromodomain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6872",
    "Sentence": "We show that the PHD domain of the KAP1 corepressor functions as an intramolecular <\\entity><\\entity> for sumoylation of the adjacent bromodomain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6873",
    "Sentence": "We show that the PHD domain of the KAP1 corepressor functions as an intramolecular E3 ligase for sumoylation of the adjacent <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6874",
    "Sentence": "The RING finger-like structure of the <\\entity><\\entity> is required for both Ubc9 binding and sumoylation and directs modification to specific lysine residues in the bromodomain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6875",
    "Sentence": "The RING finger-like structure of the PHD domain is required for both <\\entity><\\entity> binding and sumoylation and directs modification to specific lysine residues in the bromodomain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6876",
    "Sentence": "The RING finger-like structure of the PHD domain is required for both Ubc9 binding and sumoylation and directs modification to specific <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6877",
    "Sentence": "The RING finger-like structure of the PHD domain is required for both Ubc9 binding and sumoylation and directs modification to specific <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6878",
    "Sentence": "Sumoylation is required for <\\entity><\\entity>-mediated gene silencing and functions by directly recruiting the SETDB1 histone methyltransferase and the CHD3/Mi2 component of the NuRD complex via SUMO-interacting motifs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6879",
    "Sentence": "Sumoylation is required for KAP1-mediated gene silencing and functions by directly recruiting the <\\entity><\\entity> and the CHD3/Mi2 component of the NuRD complex via SUMO-interacting motifs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6880",
    "Sentence": "Sumoylation is required for KAP1-mediated gene silencing and functions by directly recruiting the SETDB1 histone methyltransferase and the <\\entity><\\entity> component of the NuRD complex via SUMO-interacting motifs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6881",
    "Sentence": "Sumoylation is required for KAP1-mediated gene silencing and functions by directly recruiting the SETDB1 histone methyltransferase and the CHD3/Mi2 component of the <\\entity><\\entity> complex via SUMO-interacting motifs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6882",
    "Sentence": "Sumoylation is required for KAP1-mediated gene silencing and functions by directly recruiting the SETDB1 histone methyltransferase and the CHD3/Mi2 component of the NuRD complex via <\\entity><\\entity>-interacting motifs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6883",
    "Sentence": "Sumoylated <\\entity><\\entity> stimulates the histone methyltransferase activity of SETDB1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6884",
    "Sentence": "Sumoylated KAP1 stimulates the <\\entity><\\entity> activity of SETDB1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6885",
    "Sentence": "Sumoylated KAP1 stimulates the histone methyltransferase activity of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6886",
    "Sentence": "These data provide a mechanistic explanation for the cooperation of <\\entity><\\entity> and bromodomains in gene regulation and describe a function of the <\\entity><\\entity> domain as an intramolecular E3 SUMO ligase.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6887",
    "Sentence": "These data provide a mechanistic explanation for the cooperation of PHD and <\\entity><\\entity> in gene regulation and describe a function of the PHD domain as an intramolecular E3 SUMO ligase.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6888",
    "Sentence": "These data provide a mechanistic explanation for the cooperation of PHD and bromodomains in gene regulation and describe a function of the <\\entity><\\entity> as an intramolecular E3 SUMO ligase.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6889",
    "Sentence": "These data provide a mechanistic explanation for the cooperation of PHD and bromodomains in gene regulation and describe a function of the PHD domain as an intramolecular E3 <\\entity><\\entity> ligase.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6890",
    "Sentence": "The RING finger-like structure of the PHD domain is required for both Ubc9 binding and sumoylation and directs modification to specific <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6891",
    "Sentence": "The RING finger-like structure of the <\\entity><\\entity> is required for both Ubc9 binding and sumoylation and directs modification to specific lysine residues in the bromodomain.",
    "Label": ""
  },
  {
    "id": "6893",
    "Sentence": "The RING finger-like structure of the PHD domain is required for both Ubc9 binding and sumoylation and directs modification to specific <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6894",
    "Sentence": "The RING finger-like structure of the PHD domain is required for both <\\entity><\\entity> binding and sumoylation and directs modification to specific lysine residues in the bromodomain.",
    "Label": ""
  },
  {
    "id": "6900",
    "Sentence": "A double-blind placebo controlled trial of <\\entity><\\entity> in patients with giant cell arteritis and corticosteroid side effects.OBJECTIVE: Open label studies have suggested that tumour necrosis factor (TNF) antagonists led to sustained improvement and corticosteroid sparing effect in patients with giant cell arteritis (GCA).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6901",
    "Sentence": "A double-blind placebo controlled trial of <\\entity><\\entity> in patients with giant cell arteritis and corticosteroid side effects.OBJECTIVE: Open label studies have suggested that tumour necrosis factor (TNF) antagonists led to sustained improvement and corticosteroid sparing effect in patients with giant cell arteritis (GCA).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6902",
    "Sentence": "A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and <\\entity><\\entity> side effects.OBJECTIVE: Open label studies have suggested that tumour necrosis factor (TNF) antagonists led to sustained improvement and <\\entity><\\entity> sparing effect in patients with giant cell arteritis (GCA).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6903",
    "Sentence": "A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.OBJECTIVE: Open <\\entity><\\entity> studies have suggested that tumour necrosis factor (TNF) antagonists led to sustained improvement and corticosteroid sparing effect in patients with giant cell arteritis (GCA).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6904",
    "Sentence": "A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.OBJECTIVE: Open label studies have suggested that <\\entity><\\entity> (TNF) antagonists led to sustained improvement and corticosteroid sparing effect in patients with giant cell arteritis (GCA).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6905",
    "Sentence": "A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.OBJECTIVE: Open label studies have suggested that <\\entity><\\entity> (TNF) antagonists led to sustained improvement and corticosteroid sparing effect in patients with giant cell arteritis (GCA).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6906",
    "Sentence": "A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.OBJECTIVE: Open label studies have suggested that tumour necrosis factor (<\\entity><\\entity> led to sustained improvement and corticosteroid sparing effect in patients with giant cell arteritis (GCA).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6907",
    "Sentence": "A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.OBJECTIVE: Open label studies have suggested that tumour necrosis factor (<\\entity><\\entity> led to sustained improvement and corticosteroid sparing effect in patients with giant cell arteritis (GCA).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6908",
    "Sentence": "A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and <\\entity><\\entity> side effects.OBJECTIVE: Open label studies have suggested that tumour necrosis factor (TNF) antagonists led to sustained improvement and <\\entity><\\entity> sparing effect in patients with giant cell arteritis (GCA).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6909",
    "Sentence": "A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.OBJECTIVE: Open label studies have suggested that tumour necrosis factor (TNF) antagonists led to sustained improvement and corticosteroid sparing effect in patients with giant cell arteritis (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6910",
    "Sentence": "To confirm these observations, we conducted a randomised, double-blind, placebo controlled trial with <\\entity><\\entity> in patients with biopsy-proven GCA with side effects secondary to corticosteroids.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6911",
    "Sentence": "To confirm these observations, we conducted a randomised, double-blind, placebo controlled trial with <\\entity><\\entity> in patients with biopsy-proven GCA with side effects secondary to corticosteroids.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6912",
    "Sentence": "To confirm these observations, we conducted a randomised, double-blind, placebo controlled trial with etanercept in patients with biopsy-proven <\\entity><\\entity> with side effects secondary to corticosteroids.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6913",
    "Sentence": "To confirm these observations, we conducted a randomised, double-blind, placebo controlled trial with etanercept in patients with biopsy-proven GCA with side effects secondary to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6914",
    "Sentence": "METHODS: We randomly assigned patients with <\\entity><\\entity> to receive etanercept (n = 8) or placebo (n = 9) over 1 year together with corticosteroids that were reduced according to a predefined schedule.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6915",
    "Sentence": "METHODS: We randomly assigned patients with GCA to receive <\\entity><\\entity> (n = 8) or placebo (n = 9) over 1 year together with corticosteroids that were reduced according to a predefined schedule.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6916",
    "Sentence": "METHODS: We randomly assigned patients with GCA to receive <\\entity><\\entity> (n = 8) or placebo (n = 9) over 1 year together with corticosteroids that were reduced according to a predefined schedule.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6917",
    "Sentence": "METHODS: We randomly assigned patients with GCA to receive etanercept (n = 8) or placebo (n = 9) over 1 year together with <\\entity><\\entity> that were reduced according to a predefined schedule.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6918",
    "Sentence": "The primary outcome was the ability to withdraw the <\\entity><\\entity> therapy and control the disease activity at 12 months.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6919",
    "Sentence": "RESULTS: Baseline characteristics were similar in the two groups, although patients in the <\\entity><\\entity> group showed higher levels of basal glycaemia (p = 0.02) and a higher erythrocyte sedimentation rate (ESR) (p = 0.01).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6920",
    "Sentence": "RESULTS: Baseline characteristics were similar in the two groups, although patients in the <\\entity><\\entity> group showed higher levels of basal glycaemia (p = 0.02) and a higher erythrocyte sedimentation rate (ESR) (p = 0.01).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6921",
    "Sentence": "RESULTS: Baseline characteristics were similar in the two groups, although patients in the etanercept group showed higher levels of basal glycaemia (p = 0.02) and a higher erythrocyte sedimentation rate (<\\entity><\\entity>) (p = 0.01).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6922",
    "Sentence": "After 12 months, 50% of the patients in the <\\entity><\\entity> group and 22.2% in the placebo group were able to control the disease without corticosteroid therapy (p value not significant).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6923",
    "Sentence": "After 12 months, 50% of the patients in the <\\entity><\\entity> group and 22.2% in the placebo group were able to control the disease without corticosteroid therapy (p value not significant).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6924",
    "Sentence": "After 12 months, 50% of the patients in the etanercept group and 22.2% in the placebo group were able to control the disease without <\\entity><\\entity> therapy (p value not significant).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6925",
    "Sentence": "Patients in the <\\entity><\\entity> group had a significant lower dose of accumulated prednisone during the first year of treatment (p = 0.03).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6926",
    "Sentence": "Patients in the <\\entity><\\entity> group had a significant lower dose of accumulated prednisone during the first year of treatment (p = 0.03).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6927",
    "Sentence": "Patients in the etanercept group had a significant lower dose of accumulated <\\entity><\\entity> during the first year of treatment (p = 0.03).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6928",
    "Sentence": "<\\entity><\\entity> therapy was well tolerated in this aged population.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6929",
    "Sentence": "<\\entity><\\entity> therapy was well tolerated in this aged population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6930",
    "Sentence": "The therapeutic role of <\\entity><\\entity> in patients with GCA should be evaluated in studies with a larger number of patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6931",
    "Sentence": "The therapeutic role of <\\entity><\\entity> in patients with GCA should be evaluated in studies with a larger number of patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6932",
    "Sentence": "The therapeutic role of etanercept in patients with <\\entity><\\entity> should be evaluated in studies with a larger number of patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6933",
    "Sentence": "A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.OBJECTIVE: Open <\\entity><\\entity> studies have suggested that tumour necrosis factor (TNF) antagonists led to sustained improvement and corticosteroid sparing effect in patients with giant cell arteritis (GCA).",
    "Label": ""
  },
  {
    "id": "6934",
    "Sentence": "A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.OBJECTIVE: Open label studies have suggested that tumour necrosis factor (<\\entity><\\entity> led to sustained improvement and corticosteroid sparing effect in patients with giant cell arteritis (GCA).",
    "Label": ""
  },
  {
    "id": "6936",
    "Sentence": "A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.OBJECTIVE: Open <\\entity><\\entity> studies have suggested that tumour necrosis factor (TNF) antagonists led to sustained improvement and corticosteroid sparing effect in patients with giant cell arteritis (GCA).",
    "Label": ""
  },
  {
    "id": "6937",
    "Sentence": "A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.OBJECTIVE: Open label studies have suggested that tumour necrosis factor (TNF) antagonists led to sustained improvement and corticosteroid sparing effect in patients with giant cell arteritis (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "6939",
    "Sentence": "Patients in the etanercept group had a significant lower dose of accumulated <\\entity><\\entity> during the first year of treatment (p = 0.03).",
    "Label": ""
  },
  {
    "id": "6940",
    "Sentence": "Patients in the <\\entity><\\entity> group had a significant lower dose of accumulated prednisone during the first year of treatment (p = 0.03).",
    "Label": ""
  },
  {
    "id": "6946",
    "Sentence": "Clinical presentation and pathophysiology of <\\entity><\\entity> dermatologic toxicities.This review summarizes the pathophysiology and clinical presentation of the cutaneous toxicities associated with EGFR inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6947",
    "Sentence": "Clinical presentation and pathophysiology of <\\entity><\\entity> dermatologic toxicities.This review summarizes the pathophysiology and clinical presentation of the cutaneous toxicities associated with EGFR inhibition.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6948",
    "Sentence": "Clinical presentation and pathophysiology of <\\entity><\\entity>I dermatologic toxicities.This review summarizes the pathophysiology and clinical presentation of the cutaneous toxicities associated with <\\entity><\\entity> inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6953",
    "Sentence": "<\\entity><\\entity> pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors.OBJECTIVE: To test the hypothesis that 5,10-methylenetetrahydroreductase (MTHFR) polymorphisms can partially explain the individual variation in developing attention-deficit/hyperactivity disorder (ADHD) after acute lymphoblastic leukemia (ALL) therapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6954",
    "Sentence": "Folate pathway genetic polymorphisms are related to <\\entity><\\entity> in childhood leukemia survivors.OBJECTIVE: To test the hypothesis that 5,10-methylenetetrahydroreductase (MTHFR) polymorphisms can partially explain the individual variation in developing attention-deficit/hyperactivity disorder (ADHD) after acute lymphoblastic leukemia (ALL) therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6955",
    "Sentence": "Folate pathway genetic polymorphisms are related to attention disorders in <\\entity><\\entity> survivors.OBJECTIVE: To test the hypothesis that 5,10-methylenetetrahydroreductase (MTHFR) polymorphisms can partially explain the individual variation in developing attention-deficit/hyperactivity disorder (ADHD) after acute lymphoblastic leukemia (ALL) therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6956",
    "Sentence": "Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors.OBJECTIVE: To test the hypothesis that 5,10-methylenetetrahydroreductase (MTHFR) polymorphisms can partially explain the individual variation in developing <\\entity><\\entity> (ADHD) after acute lymphoblastic leukemia (ALL) therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6957",
    "Sentence": "Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors.OBJECTIVE: To test the hypothesis that 5,10-methylenetetrahydroreductase (MTHFR) polymorphisms can partially explain the individual variation in developing attention-deficit/hyperactivity disorder (<\\entity><\\entity>) after acute lymphoblastic leukemia (ALL) therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6958",
    "Sentence": "Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors.OBJECTIVE: To test the hypothesis that 5,10-methylenetetrahydroreductase (MTHFR) polymorphisms can partially explain the individual variation in developing attention-deficit/hyperactivity disorder (ADHD) after <\\entity><\\entity> (ALL) therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6959",
    "Sentence": "Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors.OBJECTIVE: To test the hypothesis that 5,10-methylenetetrahydroreductase (MTHFR) polymorphisms can partially explain the individual variation in developing attention-deficit/hyperactivity disorder (ADHD) after acute lymphoblastic leukemia (<\\entity><\\entity>) therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6960",
    "Sentence": "STUDY DESIGN: Parents of 48 survivors of <\\entity><\\entity> ALL completed a clinical diagnostic process to identify subtypes of ADHD.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6961",
    "Sentence": "STUDY DESIGN: Parents of 48 survivors of childhood <\\entity><\\entity> completed a clinical diagnostic process to identify subtypes of ADHD.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6962",
    "Sentence": "STUDY DESIGN: Parents of 48 survivors of childhood ALL completed a clinical diagnostic process to identify subtypes of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6963",
    "Sentence": "RESULTS: <\\entity><\\entity> of the 48 patients (22.9%) had scores consistent with the inattentive symptoms of ADHD.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6964",
    "Sentence": "RESULTS: Eleven of the 48 patients (22.9%) had scores consistent with the inattentive <\\entity><\\entity> of ADHD.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6965",
    "Sentence": "RESULTS: Eleven of the 48 patients (22.9%) had scores consistent with the inattentive symptoms of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6966",
    "Sentence": "Patients with genotypes related to lower <\\entity><\\entity> levels (11 out of 39; 39.2%) were more likely to have ADHD.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6967",
    "Sentence": "Patients with genotypes related to lower folate levels (11 out of 39; 39.2%) were more likely to have <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6968",
    "Sentence": "The A1298C genotype appeared to be the predominant linkage to the inattentive <\\entity><\\entity>, leading to a 7.4-fold increase in diagnosis, compared with a 1.3-fold increase for the C677T genotype.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6969",
    "Sentence": "Age at diagnosis and sex were not associated with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6970",
    "Sentence": "CONCLUSIONS: Preliminary data imply a strong relationship between MTHFR polymorphisms and the inattentive <\\entity><\\entity> of ADHD in survivors of childhood ALL.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6971",
    "Sentence": "CONCLUSIONS: Preliminary data imply a strong relationship between MTHFR polymorphisms and the inattentive symptoms of <\\entity><\\entity> in survivors of childhood ALL.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6972",
    "Sentence": "CONCLUSIONS: Preliminary data imply a strong relationship between MTHFR polymorphisms and the inattentive symptoms of ADHD in survivors of <\\entity><\\entity> ALL.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6973",
    "Sentence": "CONCLUSIONS: Preliminary data imply a strong relationship between MTHFR polymorphisms and the inattentive symptoms of ADHD in survivors of childhood <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "6974",
    "Sentence": "<\\entity><\\entity> pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors.OBJECTIVE: To test the hypothesis that 5,10-methylenetetrahydroreductase (MTHFR) polymorphisms can partially explain the individual variation in developing attention-deficit/hyperactivity disorder (ADHD) after acute lymphoblastic leukemia (ALL) therapy.",
    "Label": ""
  },
  {
    "id": "6975",
    "Sentence": "Folate pathway genetic polymorphisms are related to <\\entity><\\entity> in childhood leukemia survivors.OBJECTIVE: To test the hypothesis that 5,10-methylenetetrahydroreductase (MTHFR) polymorphisms can partially explain the individual variation in developing attention-deficit/hyperactivity disorder (ADHD) after acute lymphoblastic leukemia (ALL) therapy.",
    "Label": ""
  },
  {
    "id": "6977",
    "Sentence": "<\\entity><\\entity> pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors.OBJECTIVE: To test the hypothesis that 5,10-methylenetetrahydroreductase (MTHFR) polymorphisms can partially explain the individual variation in developing attention-deficit/hyperactivity disorder (ADHD) after acute lymphoblastic leukemia (ALL) therapy.",
    "Label": ""
  },
  {
    "id": "6978",
    "Sentence": "Folate pathway genetic polymorphisms are related to attention disorders in <\\entity><\\entity> survivors.OBJECTIVE: To test the hypothesis that 5,10-methylenetetrahydroreductase (MTHFR) polymorphisms can partially explain the individual variation in developing attention-deficit/hyperactivity disorder (ADHD) after acute lymphoblastic leukemia (ALL) therapy.",
    "Label": ""
  },
  {
    "id": "6980",
    "Sentence": "RESULTS: <\\entity><\\entity> of the 48 patients (22.9%) had scores consistent with the inattentive symptoms of ADHD.",
    "Label": ""
  },
  {
    "id": "6981",
    "Sentence": "RESULTS: Eleven of the 48 patients (22.9%) had scores consistent with the inattentive symptoms of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6983",
    "Sentence": "RESULTS: <\\entity><\\entity> of the 48 patients (22.9%) had scores consistent with the inattentive symptoms of ADHD.",
    "Label": ""
  },
  {
    "id": "6984",
    "Sentence": "RESULTS: Eleven of the 48 patients (22.9%) had scores consistent with the inattentive <\\entity><\\entity> of ADHD.",
    "Label": ""
  },
  {
    "id": "6986",
    "Sentence": "Patients with genotypes related to lower <\\entity><\\entity> levels (11 out of 39; 39.2%) were more likely to have ADHD.",
    "Label": ""
  },
  {
    "id": "6987",
    "Sentence": "Patients with genotypes related to lower folate levels (11 out of 39; 39.2%) were more likely to have <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "6993",
    "Sentence": "<\\entity><\\entity>-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets.We explored the in vitro effects of Rosiglitazone (RZG), a <\\entity><\\entity> agonist, on human pancreatic islet dysfunctions induced by chronic free fatty acid exposure.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6994",
    "Sentence": "PPARgamma-dependent and -independent effects of <\\entity><\\entity> on lipotoxic human pancreatic islets.We explored the in vitro effects of Rosiglitazone (RZG), a PPARgamma agonist, on human pancreatic islet dysfunctions induced by chronic free fatty acid exposure.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6995",
    "Sentence": "PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets.We explored the in vitro effects of <\\entity><\\entity> (RZG), a PPARgamma agonist, on human pancreatic islet dysfunctions induced by chronic free fatty acid exposure.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6996",
    "Sentence": "PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets.We explored the in vitro effects of Rosiglitazone (<\\entity><\\entity>), a PPARgamma agonist, on human pancreatic islet dysfunctions induced by chronic free fatty acid exposure.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6997",
    "Sentence": "PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets.We explored the in vitro effects of Rosiglitazone (RZG), a <\\entity><\\entity>, on human pancreatic islet dysfunctions induced by chronic free fatty acid exposure.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "6998",
    "Sentence": "PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets.We explored the in vitro effects of Rosiglitazone (RZG), a <\\entity><\\entity>, on human pancreatic islet dysfunctions induced by chronic free fatty acid exposure.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "6999",
    "Sentence": "We demonstrated that <\\entity><\\entity> beneficial effects on insulin secretion and apoptosis did not imply PDX-1 or insulin gene modulation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7000",
    "Sentence": "We demonstrated that RZG beneficial effects on <\\entity><\\entity> secretion and apoptosis did not imply PDX-1 or <\\entity><\\entity> gene modulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7001",
    "Sentence": "We demonstrated that RZG beneficial effects on insulin secretion and apoptosis did not imply <\\entity><\\entity> or insulin gene modulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7002",
    "Sentence": "We demonstrated that RZG beneficial effects on <\\entity><\\entity> secretion and apoptosis did not imply PDX-1 or <\\entity><\\entity> gene modulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7003",
    "Sentence": "It rather involved, through a <\\entity><\\entity>-dependent mechanism, a reduction of iNOS overexpressed in lipotoxic islets.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7004",
    "Sentence": "It rather involved, through a PPARgamma-dependent mechanism, a reduction of <\\entity><\\entity> overexpressed in lipotoxic islets.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7005",
    "Sentence": "This reduction likely led to the restoration of <\\entity><\\entity> level and insulin secretion as well as the decrease in apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7006",
    "Sentence": "This reduction likely led to the restoration of <\\entity><\\entity> level and insulin secretion as well as the decrease in apoptosis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7007",
    "Sentence": "This reduction likely led to the restoration of ATP level and <\\entity><\\entity> secretion as well as the decrease in apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7008",
    "Sentence": "More interestingly, we also demonstrated that <\\entity><\\entity> beneficial effects involved PPARgamma-independent mechanisms.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7009",
    "Sentence": "More interestingly, we also demonstrated that RZG beneficial effects involved <\\entity><\\entity>-independent mechanisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7010",
    "Sentence": "<\\entity><\\entity> treatment led to a limitation of oxidative stress exemplified by an increase of GPx and SOD expression.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7011",
    "Sentence": "RZG treatment led to a limitation of oxidative stress exemplified by an increase of <\\entity><\\entity> and SOD expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7012",
    "Sentence": "RZG treatment led to a limitation of oxidative stress exemplified by an increase of GPx and <\\entity><\\entity> expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7013",
    "Sentence": "It also increased <\\entity><\\entity> expression that seemed to display antioxidant action in this model.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7014",
    "Sentence": "Thus, <\\entity><\\entity> did not appear to exert a direct action on insulin expression but rather an indirect action on insulin secretion and apoptosis, through PPARgamma-dependent and -independent mechanisms, via regulation of nitrogen and oxygen reactive species injury.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7015",
    "Sentence": "Thus, RZG did not appear to exert a direct action on <\\entity><\\entity> expression but rather an indirect action on <\\entity><\\entity> secretion and apoptosis, through PPARgamma-dependent and -independent mechanisms, via regulation of nitrogen and oxygen reactive species injury.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7016",
    "Sentence": "Thus, RZG did not appear to exert a direct action on <\\entity><\\entity> expression but rather an indirect action on <\\entity><\\entity> secretion and apoptosis, through PPARgamma-dependent and -independent mechanisms, via regulation of nitrogen and oxygen reactive species injury.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7017",
    "Sentence": "Thus, RZG did not appear to exert a direct action on insulin expression but rather an indirect action on insulin secretion and apoptosis, through <\\entity><\\entity>-dependent and -independent mechanisms, via regulation of nitrogen and oxygen reactive species injury.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7018",
    "Sentence": "We demonstrated that <\\entity><\\entity> beneficial effects on insulin secretion and apoptosis did not imply PDX-1 or insulin gene modulation.",
    "Label": ""
  },
  {
    "id": "7019",
    "Sentence": "We demonstrated that RZG beneficial effects on insulin secretion and apoptosis did not imply <\\entity><\\entity> or insulin gene modulation.",
    "Label": ""
  },
  {
    "id": "7021",
    "Sentence": "We demonstrated that <\\entity><\\entity> beneficial effects on insulin secretion and apoptosis did not imply PDX-1 or insulin gene modulation.",
    "Label": ""
  },
  {
    "id": "7022",
    "Sentence": "We demonstrated that RZG beneficial effects on <\\entity><\\entity> secretion and apoptosis did not imply PDX-1 or <\\entity><\\entity> gene modulation.",
    "Label": ""
  },
  {
    "id": "7024",
    "Sentence": "<\\entity><\\entity> treatment led to a limitation of oxidative stress exemplified by an increase of GPx and SOD expression.",
    "Label": ""
  },
  {
    "id": "7025",
    "Sentence": "RZG treatment led to a limitation of oxidative stress exemplified by an increase of <\\entity><\\entity> and SOD expression.",
    "Label": ""
  },
  {
    "id": "7027",
    "Sentence": "<\\entity><\\entity> treatment led to a limitation of oxidative stress exemplified by an increase of GPx and SOD expression.",
    "Label": ""
  },
  {
    "id": "7028",
    "Sentence": "RZG treatment led to a limitation of oxidative stress exemplified by an increase of GPx and <\\entity><\\entity> expression.",
    "Label": ""
  },
  {
    "id": "7030",
    "Sentence": "Thus, <\\entity><\\entity> did not appear to exert a direct action on insulin expression but rather an indirect action on insulin secretion and apoptosis, through PPARgamma-dependent and -independent mechanisms, via regulation of nitrogen and oxygen reactive species injury.",
    "Label": ""
  },
  {
    "id": "7031",
    "Sentence": "Thus, RZG did not appear to exert a direct action on <\\entity><\\entity> expression but rather an indirect action on <\\entity><\\entity> secretion and apoptosis, through PPARgamma-dependent and -independent mechanisms, via regulation of nitrogen and oxygen reactive species injury.",
    "Label": ""
  },
  {
    "id": "7033",
    "Sentence": "PPARgamma-dependent and -independent effects of <\\entity><\\entity> on lipotoxic human pancreatic islets.We explored the in vitro effects of Rosiglitazone (RZG), a PPARgamma agonist, on human pancreatic islet dysfunctions induced by chronic free fatty acid exposure.",
    "Label": ""
  },
  {
    "id": "7034",
    "Sentence": "<\\entity><\\entity>-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets.We explored the in vitro effects of Rosiglitazone (RZG), a <\\entity><\\entity> agonist, on human pancreatic islet dysfunctions induced by chronic free fatty acid exposure.",
    "Label": ""
  },
  {
    "id": "7036",
    "Sentence": "PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets.We explored the in vitro effects of <\\entity><\\entity> (RZG), a PPARgamma agonist, on human pancreatic islet dysfunctions induced by chronic free fatty acid exposure.",
    "Label": ""
  },
  {
    "id": "7037",
    "Sentence": "PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets.We explored the in vitro effects of Rosiglitazone (RZG), a <\\entity><\\entity>, on human pancreatic islet dysfunctions induced by chronic free fatty acid exposure.",
    "Label": ""
  },
  {
    "id": "7039",
    "Sentence": "PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets.We explored the in vitro effects of Rosiglitazone (<\\entity><\\entity>), a PPARgamma agonist, on human pancreatic islet dysfunctions induced by chronic free fatty acid exposure.",
    "Label": ""
  },
  {
    "id": "7040",
    "Sentence": "PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets.We explored the in vitro effects of Rosiglitazone (RZG), a <\\entity><\\entity>, on human pancreatic islet dysfunctions induced by chronic free fatty acid exposure.",
    "Label": ""
  },
  {
    "id": "7042",
    "Sentence": "We demonstrated that <\\entity><\\entity> beneficial effects on insulin secretion and apoptosis did not imply PDX-1 or insulin gene modulation.",
    "Label": ""
  },
  {
    "id": "7043",
    "Sentence": "We demonstrated that RZG beneficial effects on <\\entity><\\entity> secretion and apoptosis did not imply PDX-1 or <\\entity><\\entity> gene modulation.",
    "Label": ""
  },
  {
    "id": "7045",
    "Sentence": "More interestingly, we also demonstrated that <\\entity><\\entity> beneficial effects involved PPARgamma-independent mechanisms.",
    "Label": ""
  },
  {
    "id": "7046",
    "Sentence": "More interestingly, we also demonstrated that RZG beneficial effects involved <\\entity><\\entity>-independent mechanisms.",
    "Label": ""
  },
  {
    "id": "7048",
    "Sentence": "Thus, <\\entity><\\entity> did not appear to exert a direct action on insulin expression but rather an indirect action on insulin secretion and apoptosis, through PPARgamma-dependent and -independent mechanisms, via regulation of nitrogen and oxygen reactive species injury.",
    "Label": ""
  },
  {
    "id": "7049",
    "Sentence": "Thus, RZG did not appear to exert a direct action on insulin expression but rather an indirect action on insulin secretion and apoptosis, through <\\entity><\\entity>-dependent and -independent mechanisms, via regulation of nitrogen and oxygen reactive species injury.",
    "Label": ""
  },
  {
    "id": "7055",
    "Sentence": "Do <\\entity><\\entity> decrease cardiovascular disease at the expense of increasing cancer?A recent report of an inverse relationship between achieved low-density lipoprotein (LDL) cholesterol levels and cancer incidence has refueled the debate on cholesterol lowering and cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7056",
    "Sentence": "Do statins decrease <\\entity><\\entity> at the expense of increasing cancer?A recent report of an inverse relationship between achieved low-density lipoprotein (LDL) cholesterol levels and cancer incidence has refueled the debate on cholesterol lowering and cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7057",
    "Sentence": "Do statins decrease cardiovascular disease at the expense of increasing <\\entity><\\entity>?A recent report of an inverse relationship between achieved low-density lipoprotein (LDL) cholesterol levels and <\\entity><\\entity> incidence has refueled the debate on cholesterol lowering and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7058",
    "Sentence": "Do statins decrease cardiovascular disease at the expense of increasing <\\entity><\\entity>?A recent report of an inverse relationship between achieved low-density lipoprotein (LDL) cholesterol levels and <\\entity><\\entity> incidence has refueled the debate on cholesterol lowering and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7059",
    "Sentence": "Do statins decrease cardiovascular disease at the expense of increasing <\\entity><\\entity>?A recent report of an inverse relationship between achieved low-density lipoprotein (LDL) cholesterol levels and <\\entity><\\entity> incidence has refueled the debate on cholesterol lowering and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7060",
    "Sentence": "This is timely, since <\\entity><\\entity> cholesterol lowering with statins is the trend.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7061",
    "Sentence": "This is timely, since aggressive cholesterol lowering with <\\entity><\\entity> is the trend.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7062",
    "Sentence": "There are data suggesting that cholesterol lowering increases <\\entity><\\entity> at the expense of decreasing cardiovascular disease in certain populations, such as the elderly and those treated with immunotherapy for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7063",
    "Sentence": "There are data suggesting that cholesterol lowering increases cancer at the expense of decreasing <\\entity><\\entity> in certain populations, such as the elderly and those treated with immunotherapy for cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7064",
    "Sentence": "There are data suggesting that cholesterol lowering increases cancer at the expense of decreasing cardiovascular disease in certain populations, such as the elderly and those treated with <\\entity><\\entity> for cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7065",
    "Sentence": "There are data suggesting that cholesterol lowering increases <\\entity><\\entity> at the expense of decreasing cardiovascular disease in certain populations, such as the elderly and those treated with immunotherapy for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7066",
    "Sentence": "Furthermore, there may be a relationship between <\\entity><\\entity> dose and cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7067",
    "Sentence": "Furthermore, there may be a relationship between statin dose and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7068",
    "Sentence": "Future <\\entity><\\entity> trials should accurately tract the incidence of new cancers over extended time periods.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7069",
    "Sentence": "Future statin trials should accurately tract the incidence of new <\\entity><\\entity> over extended time periods.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7070",
    "Sentence": "Do <\\entity><\\entity> decrease cardiovascular disease at the expense of increasing cancer?A recent report of an inverse relationship between achieved low-density lipoprotein (LDL) cholesterol levels and cancer incidence has refueled the debate on cholesterol lowering and cancer.",
    "Label": ""
  },
  {
    "id": "7071",
    "Sentence": "Do statins decrease <\\entity><\\entity> at the expense of increasing cancer?A recent report of an inverse relationship between achieved low-density lipoprotein (LDL) cholesterol levels and cancer incidence has refueled the debate on cholesterol lowering and cancer.",
    "Label": ""
  },
  {
    "id": "7073",
    "Sentence": "Do <\\entity><\\entity> decrease cardiovascular disease at the expense of increasing cancer?A recent report of an inverse relationship between achieved low-density lipoprotein (LDL) cholesterol levels and cancer incidence has refueled the debate on cholesterol lowering and cancer.",
    "Label": ""
  },
  {
    "id": "7074",
    "Sentence": "Do statins decrease cardiovascular disease at the expense of increasing <\\entity><\\entity>?A recent report of an inverse relationship between achieved low-density lipoprotein (LDL) cholesterol levels and <\\entity><\\entity> incidence has refueled the debate on cholesterol lowering and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7076",
    "Sentence": "Furthermore, there may be a relationship between <\\entity><\\entity> dose and cancer.",
    "Label": ""
  },
  {
    "id": "7077",
    "Sentence": "Furthermore, there may be a relationship between statin dose and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7079",
    "Sentence": "Future <\\entity><\\entity> trials should accurately tract the incidence of new cancers over extended time periods.",
    "Label": ""
  },
  {
    "id": "7080",
    "Sentence": "Future statin trials should accurately tract the incidence of new <\\entity><\\entity> over extended time periods.",
    "Label": ""
  },
  {
    "id": "7082",
    "Sentence": "There are data suggesting that cholesterol lowering increases cancer at the expense of decreasing cardiovascular disease in certain populations, such as the elderly and those treated with <\\entity><\\entity> for cancer.",
    "Label": ""
  },
  {
    "id": "7083",
    "Sentence": "There are data suggesting that cholesterol lowering increases cancer at the expense of decreasing <\\entity><\\entity> in certain populations, such as the elderly and those treated with immunotherapy for cancer.",
    "Label": ""
  },
  {
    "id": "7085",
    "Sentence": "There are data suggesting that cholesterol lowering increases cancer at the expense of decreasing cardiovascular disease in certain populations, such as the elderly and those treated with <\\entity><\\entity> for cancer.",
    "Label": ""
  },
  {
    "id": "7086",
    "Sentence": "There are data suggesting that cholesterol lowering increases <\\entity><\\entity> at the expense of decreasing cardiovascular disease in certain populations, such as the elderly and those treated with immunotherapy for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7092",
    "Sentence": "The effect of a long term <\\entity><\\entity> on CYP2D6 activity.BACKGROUND: Ropivacaine and one of its metabolites, pipecoloxylidide, inhibit CYP2D6 in.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7093",
    "Sentence": "The effect of a long term epidural infusion of ropivacaine on <\\entity><\\entity> activity.BACKGROUND: Ropivacaine and one of its metabolites, pipecoloxylidide, inhibit <\\entity><\\entity> in.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7094",
    "Sentence": "The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity.BACKGROUND: <\\entity><\\entity> and one of its metabolites, pipecoloxylidide, inhibit CYP2D6 in.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7095",
    "Sentence": "The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity.BACKGROUND: Ropivacaine and one of its metabolites, <\\entity><\\entity>, inhibit CYP2D6 in.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7096",
    "Sentence": "The effect of a long term epidural infusion of ropivacaine on <\\entity><\\entity> activity.BACKGROUND: Ropivacaine and one of its metabolites, pipecoloxylidide, inhibit <\\entity><\\entity> in.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7097",
    "Sentence": "We investigated the effect of a 50 h continuous <\\entity><\\entity> 2 mg/mL at a rate of 14 mL/h on CYP2D6 activity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7098",
    "Sentence": "We investigated the effect of a 50 h continuous epidural infusion of ropivacaine 2 mg/mL at a rate of 14 mL/h on <\\entity><\\entity> activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7099",
    "Sentence": "METHODS: Nineteen patients (41-85 yr) undergoing hip or knee replacement, all extensive metabolizers with respect to <\\entity><\\entity> activity, were included.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7100",
    "Sentence": "Medications known to inhibit or be metabolized by <\\entity><\\entity>, or known to be strong inhibitors/inducers of CYP1A2 or CYP3A4 were not allowed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7101",
    "Sentence": "Medications known to inhibit or be metabolized by <\\entity><\\entity>, or known to be strong inhibitors/inducers of CYP1A2 or CYP3A4 were not allowed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7102",
    "Sentence": "Medications known to inhibit or be metabolized by CYP2D6, or known to be strong inhibitors/inducers of <\\entity><\\entity> or CYP3A4 were not allowed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7103",
    "Sentence": "Medications known to inhibit or be metabolized by CYP2D6, or known to be strong inhibitors/inducers of <\\entity><\\entity> or CYP3A4 were not allowed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7104",
    "Sentence": "Medications known to inhibit or be metabolized by CYP2D6, or known to be strong inhibitors/inducers of CYP1A2 or <\\entity><\\entity> were not allowed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7105",
    "Sentence": "Patients received 10 mg <\\entity><\\entity> (a marker for CYP2D6 activity) before surgery and after 40 h epidural infusion.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7106",
    "Sentence": "Patients received 10 mg debrisoquine (a marker for <\\entity><\\entity> activity) before surgery and after 40 h epidural infusion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7107",
    "Sentence": "The metabolic ratio (MR) for <\\entity><\\entity> hydroxylation was calculated as the amount of <\\entity><\\entity>/amount of 4-OH-<\\entity><\\entity> excreted in 0-10 h urine.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7108",
    "Sentence": "The metabolic ratio (MR) for <\\entity><\\entity> hydroxylation was calculated as the amount of <\\entity><\\entity>/amount of 4-OH-<\\entity><\\entity> excreted in 0-10 h urine.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7109",
    "Sentence": "The metabolic ratio (MR) for debrisoquine hydroxylation was calculated as the amount of debrisoquine/amount of <\\entity><\\entity> excreted in 0-10 h urine.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7110",
    "Sentence": "RESULTS: The median (range) of MR before and after <\\entity><\\entity> were 0.54 (0.1-3.4) and 1.79 (0.3-6.7), respectively.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7111",
    "Sentence": "The Hodges Lehman estimate of the ratio MR after/MR before <\\entity><\\entity> was 2.2 with a 95% confidence interval 1.9-2.7 (P < 0.001).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7112",
    "Sentence": "CONCLUSION: A continuous <\\entity><\\entity> inhibits CYP2D6 activity in patients who are extensive metabolizers resulting in a twofold increase in the MR for debrisoquine hydroxylation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7113",
    "Sentence": "CONCLUSION: A continuous epidural infusion of ropivacaine inhibits <\\entity><\\entity> activity in patients who are extensive metabolizers resulting in a twofold increase in the MR for debrisoquine hydroxylation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7114",
    "Sentence": "CONCLUSION: A continuous epidural infusion of ropivacaine inhibits CYP2D6 activity in patients who are extensive metabolizers resulting in a twofold increase in the MR for <\\entity><\\entity> hydroxylation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7115",
    "Sentence": "However, since none of the patients was converted into a functional poor metabolizer (MR >12.6), the effect on the metabolism of other drugs metabolized by <\\entity><\\entity> is unlikely to be of major clinical importance.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7116",
    "Sentence": "The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity.BACKGROUND: <\\entity><\\entity> and one of its metabolites, pipecoloxylidide, inhibit CYP2D6 in.",
    "Label": ""
  },
  {
    "id": "7117",
    "Sentence": "The effect of a long term epidural infusion of ropivacaine on <\\entity><\\entity> activity.BACKGROUND: Ropivacaine and one of its metabolites, pipecoloxylidide, inhibit <\\entity><\\entity> in.",
    "Label": ""
  },
  {
    "id": "7119",
    "Sentence": "The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity.BACKGROUND: Ropivacaine and one of its metabolites, <\\entity><\\entity>, inhibit CYP2D6 in.",
    "Label": ""
  },
  {
    "id": "7120",
    "Sentence": "The effect of a long term epidural infusion of ropivacaine on <\\entity><\\entity> activity.BACKGROUND: Ropivacaine and one of its metabolites, pipecoloxylidide, inhibit <\\entity><\\entity> in.",
    "Label": ""
  },
  {
    "id": "7122",
    "Sentence": "CONCLUSION: A continuous <\\entity><\\entity> inhibits CYP2D6 activity in patients who are extensive metabolizers resulting in a twofold increase in the MR for debrisoquine hydroxylation.",
    "Label": ""
  },
  {
    "id": "7123",
    "Sentence": "CONCLUSION: A continuous epidural infusion of ropivacaine inhibits <\\entity><\\entity> activity in patients who are extensive metabolizers resulting in a twofold increase in the MR for debrisoquine hydroxylation.",
    "Label": ""
  },
  {
    "id": "7125",
    "Sentence": "The effect of a long term <\\entity><\\entity> on CYP2D6 activity.BACKGROUND: Ropivacaine and one of its metabolites, pipecoloxylidide, inhibit CYP2D6 in.",
    "Label": ""
  },
  {
    "id": "7126",
    "Sentence": "The effect of a long term epidural infusion of ropivacaine on <\\entity><\\entity> activity.BACKGROUND: Ropivacaine and one of its metabolites, pipecoloxylidide, inhibit <\\entity><\\entity> in.",
    "Label": ""
  },
  {
    "id": "7128",
    "Sentence": "We investigated the effect of a 50 h continuous <\\entity><\\entity> 2 mg/mL at a rate of 14 mL/h on CYP2D6 activity.",
    "Label": ""
  },
  {
    "id": "7129",
    "Sentence": "We investigated the effect of a 50 h continuous epidural infusion of ropivacaine 2 mg/mL at a rate of 14 mL/h on <\\entity><\\entity> activity.",
    "Label": ""
  },
  {
    "id": "7131",
    "Sentence": "Patients received 10 mg <\\entity><\\entity> (a marker for CYP2D6 activity) before surgery and after 40 h epidural infusion.",
    "Label": ""
  },
  {
    "id": "7132",
    "Sentence": "Patients received 10 mg debrisoquine (a marker for <\\entity><\\entity> activity) before surgery and after 40 h epidural infusion.",
    "Label": ""
  },
  {
    "id": "7134",
    "Sentence": "CONCLUSION: A continuous epidural infusion of ropivacaine inhibits CYP2D6 activity in patients who are extensive metabolizers resulting in a twofold increase in the MR for <\\entity><\\entity> hydroxylation.",
    "Label": ""
  },
  {
    "id": "7135",
    "Sentence": "CONCLUSION: A continuous epidural infusion of ropivacaine inhibits <\\entity><\\entity> activity in patients who are extensive metabolizers resulting in a twofold increase in the MR for debrisoquine hydroxylation.",
    "Label": ""
  },
  {
    "id": "7141",
    "Sentence": "Is there a role for routine abdominal imaging in predicting <\\entity><\\entity> formation after appendectomy for pediatric ruptured appendix?To determine if there is a role for routine abdominal imaging in predicting <\\entity><\\entity> after appendectomy for the pediatric ruptured appendix.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7142",
    "Sentence": "Is there a role for routine abdominal imaging in predicting <\\entity><\\entity> formation after appendectomy for pediatric ruptured appendix?To determine if there is a role for routine abdominal imaging in predicting <\\entity><\\entity> after appendectomy for the pediatric ruptured appendix.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7143",
    "Sentence": "From January 2000 to December 2003 inclusive, 44 consecutive pediatric patients with a ruptured appendix had an open appendectomy and were treated for a minimum of 5 days with <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7144",
    "Sentence": "On postoperative day 5, each patient was evaluated for <\\entity><\\entity> (fever, abdominal pain, gastrointestinal dysfunction) and radiological evidence of an intraabdominal fluid collection.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7145",
    "Sentence": "On postoperative day 5, each patient was evaluated for symptoms (<\\entity><\\entity>, abdominal pain, gastrointestinal dysfunction) and radiological evidence of an intraabdominal fluid collection.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7146",
    "Sentence": "On postoperative day 5, each patient was evaluated for symptoms (fever, <\\entity><\\entity>, gastrointestinal dysfunction) and radiological evidence of an intraabdominal fluid collection.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7147",
    "Sentence": "On postoperative day 5, each patient was evaluated for symptoms (fever, abdominal pain, <\\entity><\\entity>) and radiological evidence of an intraabdominal fluid collection.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7148",
    "Sentence": "Further treatment was determined by the clinical evidence of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7149",
    "Sentence": "Two of these 36 patients (6%) returned within a week, symptomatic and with a larger collection suspicious for an <\\entity><\\entity> and requiring further treatment.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7150",
    "Sentence": "The other 8 (18%) were symptomatic, and had an <\\entity><\\entity> more than 5 cm on imaging.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7151",
    "Sentence": "The use of routine abdominal imaging on postoperative day 5, (compared with clinical evaluation), did not improve the ability to predict the development of an <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7156",
    "Sentence": "<\\entity><\\entity> (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: <\\entity><\\entity> (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7157",
    "Sentence": "<\\entity><\\entity> (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: <\\entity><\\entity> (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7158",
    "Sentence": "Lysine-specific <\\entity><\\entity> 1 (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: Lysine-specific <\\entity><\\entity> 1 (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7159",
    "Sentence": "Lysine-specific demethylase 1 (<\\entity><\\entity>) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: Lysine-specific demethylase 1 (<\\entity><\\entity>), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7160",
    "Sentence": "Lysine-specific demethylase 1 (LSD1) Is required for the transcriptional repression of the <\\entity><\\entity> reverse transcriptase (hTERT) gene.BACKGROUND: Lysine-specific demethylase 1 (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7161",
    "Sentence": "Lysine-specific demethylase 1 (LSD1) Is required for the transcriptional repression of the telomerase <\\entity><\\entity> (hTERT) gene.BACKGROUND: Lysine-specific demethylase 1 (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7162",
    "Sentence": "Lysine-specific demethylase 1 (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (<\\entity><\\entity>) gene.BACKGROUND: Lysine-specific demethylase 1 (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7163",
    "Sentence": "<\\entity><\\entity> (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: <\\entity><\\entity> (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7164",
    "Sentence": "<\\entity><\\entity> (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: <\\entity><\\entity> (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7165",
    "Sentence": "Lysine-specific <\\entity><\\entity> 1 (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: Lysine-specific <\\entity><\\entity> 1 (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7166",
    "Sentence": "Lysine-specific demethylase 1 (<\\entity><\\entity>) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: Lysine-specific demethylase 1 (<\\entity><\\entity>), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7167",
    "Sentence": "Lysine-specific demethylase 1 (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: Lysine-specific demethylase 1 (LSD1), catalysing demethylation of mono- and di-methylated histone <\\entity><\\entity> or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7168",
    "Sentence": "Lysine-specific demethylase 1 (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: Lysine-specific demethylase 1 (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or <\\entity><\\entity>, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7169",
    "Sentence": "Lysine-specific demethylase 1 (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: Lysine-specific demethylase 1 (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating <\\entity><\\entity> reconfiguration.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7170",
    "Sentence": "The <\\entity><\\entity> reverse transcriptase (hTERT) gene, encoding an essential component for <\\entity><\\entity> activity that is involved in cellular immortalization and transformation, is silent in most normal human cells while activated in up to 90% of human cancers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7171",
    "Sentence": "The telomerase <\\entity><\\entity> (hTERT) gene, encoding an essential component for telomerase activity that is involved in cellular immortalization and transformation, is silent in most normal human cells while activated in up to 90% of human cancers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7172",
    "Sentence": "The telomerase reverse transcriptase (<\\entity><\\entity>) gene, encoding an essential component for telomerase activity that is involved in cellular immortalization and transformation, is silent in most normal human cells while activated in up to 90% of human cancers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7173",
    "Sentence": "The <\\entity><\\entity> reverse transcriptase (hTERT) gene, encoding an essential component for <\\entity><\\entity> activity that is involved in cellular immortalization and transformation, is silent in most normal human cells while activated in up to 90% of human cancers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7174",
    "Sentence": "It remains to be defined how exactly the transcriptional activation of the <\\entity><\\entity> gene occurs during the oncogenic process.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7175",
    "Sentence": "METHODOLOGY/PRINCIPAL FINDINGS: In the present study, we determined the effect of <\\entity><\\entity> on hTERT transcription.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7176",
    "Sentence": "METHODOLOGY/PRINCIPAL FINDINGS: In the present study, we determined the effect of LSD1 on <\\entity><\\entity> transcription.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7177",
    "Sentence": "In normal human fibroblasts with a tight <\\entity><\\entity> repression, a pharmacological inhibition of LSD1 led to a weak <\\entity><\\entity> expression, and a robust induction of <\\entity><\\entity> mRNA was observed when LSD1 and histone deacetylases (HDACs) were both inhibited.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7178",
    "Sentence": "In normal human fibroblasts with a tight hTERT repression, a pharmacological inhibition of <\\entity><\\entity> led to a weak hTERT expression, and a robust induction of hTERT mRNA was observed when <\\entity><\\entity> and histone deacetylases (HDACs) were both inhibited.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7179",
    "Sentence": "In normal human fibroblasts with a tight hTERT repression, a pharmacological inhibition of <\\entity><\\entity> led to a weak hTERT expression, and a robust induction of hTERT mRNA was observed when <\\entity><\\entity> and histone deacetylases (HDACs) were both inhibited.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7180",
    "Sentence": "In normal human fibroblasts with a tight <\\entity><\\entity> repression, a pharmacological inhibition of LSD1 led to a weak <\\entity><\\entity> expression, and a robust induction of <\\entity><\\entity> mRNA was observed when LSD1 and histone deacetylases (HDACs) were both inhibited.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7181",
    "Sentence": "In normal human fibroblasts with a tight <\\entity><\\entity> repression, a pharmacological inhibition of LSD1 led to a weak <\\entity><\\entity> expression, and a robust induction of <\\entity><\\entity> mRNA was observed when LSD1 and histone deacetylases (HDACs) were both inhibited.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7182",
    "Sentence": "In normal human fibroblasts with a tight hTERT repression, a pharmacological inhibition of <\\entity><\\entity> led to a weak hTERT expression, and a robust induction of hTERT mRNA was observed when <\\entity><\\entity> and histone deacetylases (HDACs) were both inhibited.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7183",
    "Sentence": "In normal human fibroblasts with a tight hTERT repression, a pharmacological inhibition of LSD1 led to a weak hTERT expression, and a robust induction of hTERT mRNA was observed when LSD1 and <\\entity><\\entity> (HDACs) were both inhibited.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7184",
    "Sentence": "In normal human fibroblasts with a tight hTERT repression, a pharmacological inhibition of LSD1 led to a weak hTERT expression, and a robust induction of hTERT mRNA was observed when LSD1 and histone deacetylases (<\\entity><\\entity>) were both inhibited.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7185",
    "Sentence": "Small interference RNA-mediated depletion of both <\\entity><\\entity> and CoREST, a co-repressor in HDAC-containing complexes, synergistically activated hTERT transcription.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7186",
    "Sentence": "Small interference RNA-mediated depletion of both LSD1 and <\\entity><\\entity>, a co-repressor in HDAC-containing complexes, synergistically activated hTERT transcription.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7187",
    "Sentence": "Small interference RNA-mediated depletion of both LSD1 and CoREST, a co-repressor in <\\entity><\\entity>-containing complexes, synergistically activated hTERT transcription.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7188",
    "Sentence": "Small interference RNA-mediated depletion of both LSD1 and CoREST, a co-repressor in HDAC-containing complexes, synergistically activated <\\entity><\\entity> transcription.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7189",
    "Sentence": "In cancer cells, inhibition of <\\entity><\\entity> activity or knocking-down of its expression led to significant increases in levels of hTERT mRNA and telomerase activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7190",
    "Sentence": "In cancer cells, inhibition of LSD1 activity or knocking-down of its expression led to significant increases in levels of <\\entity><\\entity> mRNA and telomerase activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7191",
    "Sentence": "In cancer cells, inhibition of LSD1 activity or knocking-down of its expression led to significant increases in levels of hTERT mRNA and <\\entity><\\entity> activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7192",
    "Sentence": "<\\entity><\\entity> immunoprecipitation assay showed that LSD1 occupied the hTERT proximal promoter, and its depletion resulted in elevated di-methylation of histone H3-K4 accompanied by increased H3 acetylation locally in cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7193",
    "Sentence": "Chromatin immunoprecipitation assay showed that <\\entity><\\entity> occupied the hTERT proximal promoter, and its depletion resulted in elevated di-methylation of histone H3-K4 accompanied by increased H3 acetylation locally in cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7194",
    "Sentence": "Chromatin immunoprecipitation assay showed that LSD1 occupied the <\\entity><\\entity> proximal promoter, and its depletion resulted in elevated di-methylation of histone H3-K4 accompanied by increased H3 acetylation locally in cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7195",
    "Sentence": "Chromatin immunoprecipitation assay showed that LSD1 occupied the hTERT proximal promoter, and its depletion resulted in elevated di-methylation of histone <\\entity><\\entity> accompanied by increased H3 acetylation locally in cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7196",
    "Sentence": "Chromatin immunoprecipitation assay showed that LSD1 occupied the hTERT proximal promoter, and its depletion resulted in elevated di-methylation of histone <\\entity><\\entity>-K4 accompanied by increased <\\entity><\\entity> acetylation locally in cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7197",
    "Sentence": "Moreover, during the differentiation of leukemic HL60 cells, the decreased <\\entity><\\entity> expression was accompanied by the LSD1 recruitment to the <\\entity><\\entity> promoter.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7198",
    "Sentence": "Moreover, during the differentiation of leukemic HL60 cells, the decreased hTERT expression was accompanied by the <\\entity><\\entity> recruitment to the hTERT promoter.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7199",
    "Sentence": "Moreover, during the differentiation of leukemic HL60 cells, the decreased <\\entity><\\entity> expression was accompanied by the LSD1 recruitment to the <\\entity><\\entity> promoter.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7200",
    "Sentence": "CONCLUSIONS/SIGNIFICANCE: <\\entity><\\entity> represses hTERT transcription via demethylating H3-K4 in normal and cancerous cells, and together with HDACs, participates in the establishment of a stable repression state of the hTERT gene in normal or differentiated malignant cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7201",
    "Sentence": "CONCLUSIONS/SIGNIFICANCE: LSD1 represses <\\entity><\\entity> transcription via demethylating H3-K4 in normal and cancerous cells, and together with HDACs, participates in the establishment of a stable repression state of the <\\entity><\\entity> gene in normal or differentiated malignant cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7202",
    "Sentence": "CONCLUSIONS/SIGNIFICANCE: LSD1 represses hTERT transcription via demethylating <\\entity><\\entity> in normal and cancerous cells, and together with HDACs, participates in the establishment of a stable repression state of the hTERT gene in normal or differentiated malignant cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7203",
    "Sentence": "CONCLUSIONS/SIGNIFICANCE: LSD1 represses hTERT transcription via demethylating H3-K4 in normal and cancerous cells, and together with <\\entity><\\entity>, participates in the establishment of a stable repression state of the hTERT gene in normal or differentiated malignant cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7204",
    "Sentence": "CONCLUSIONS/SIGNIFICANCE: LSD1 represses <\\entity><\\entity> transcription via demethylating H3-K4 in normal and cancerous cells, and together with HDACs, participates in the establishment of a stable repression state of the <\\entity><\\entity> gene in normal or differentiated malignant cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7205",
    "Sentence": "The findings contribute to better understandings of <\\entity><\\entity>/telomerase regulation, which may be implicated in the development of therapeutic strategies for telomerase dysregulation-associated human diseases including cancers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7206",
    "Sentence": "The findings contribute to better understandings of hTERT/<\\entity><\\entity> regulation, which may be implicated in the development of therapeutic strategies for <\\entity><\\entity> dysregulation-associated human diseases including cancers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7207",
    "Sentence": "The findings contribute to better understandings of hTERT/<\\entity><\\entity> regulation, which may be implicated in the development of therapeutic strategies for <\\entity><\\entity> dysregulation-associated human diseases including cancers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7208",
    "Sentence": "<\\entity><\\entity> (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: <\\entity><\\entity> (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": ""
  },
  {
    "id": "7209",
    "Sentence": "Lysine-specific demethylase 1 (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (<\\entity><\\entity>) gene.BACKGROUND: Lysine-specific demethylase 1 (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": ""
  },
  {
    "id": "7211",
    "Sentence": "<\\entity><\\entity> (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: <\\entity><\\entity> (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": ""
  },
  {
    "id": "7212",
    "Sentence": "Lysine-specific <\\entity><\\entity> 1 (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: Lysine-specific <\\entity><\\entity> 1 (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": ""
  },
  {
    "id": "7214",
    "Sentence": "<\\entity><\\entity> (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: <\\entity><\\entity> (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": ""
  },
  {
    "id": "7215",
    "Sentence": "Lysine-specific demethylase 1 (<\\entity><\\entity>) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: Lysine-specific demethylase 1 (<\\entity><\\entity>), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": ""
  },
  {
    "id": "7217",
    "Sentence": "<\\entity><\\entity> (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: <\\entity><\\entity> (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": ""
  },
  {
    "id": "7218",
    "Sentence": "Lysine-specific <\\entity><\\entity> 1 (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: Lysine-specific <\\entity><\\entity> 1 (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": ""
  },
  {
    "id": "7220",
    "Sentence": "<\\entity><\\entity> (LSD1) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: <\\entity><\\entity> (LSD1), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": ""
  },
  {
    "id": "7221",
    "Sentence": "Lysine-specific demethylase 1 (<\\entity><\\entity>) Is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene.BACKGROUND: Lysine-specific demethylase 1 (<\\entity><\\entity>), catalysing demethylation of mono- and di-methylated histone H3-K4 or K9, exhibits diverse transcriptional activities by mediating chromatin reconfiguration.",
    "Label": ""
  },
  {
    "id": "7223",
    "Sentence": "In normal human fibroblasts with a tight hTERT repression, a pharmacological inhibition of <\\entity><\\entity> led to a weak hTERT expression, and a robust induction of hTERT mRNA was observed when <\\entity><\\entity> and histone deacetylases (HDACs) were both inhibited.",
    "Label": ""
  },
  {
    "id": "7224",
    "Sentence": "In normal human fibroblasts with a tight <\\entity><\\entity> repression, a pharmacological inhibition of LSD1 led to a weak <\\entity><\\entity> expression, and a robust induction of <\\entity><\\entity> mRNA was observed when LSD1 and histone deacetylases (HDACs) were both inhibited.",
    "Label": ""
  },
  {
    "id": "7226",
    "Sentence": "In normal human fibroblasts with a tight hTERT repression, a pharmacological inhibition of <\\entity><\\entity> led to a weak hTERT expression, and a robust induction of hTERT mRNA was observed when <\\entity><\\entity> and histone deacetylases (HDACs) were both inhibited.",
    "Label": ""
  },
  {
    "id": "7227",
    "Sentence": "In normal human fibroblasts with a tight <\\entity><\\entity> repression, a pharmacological inhibition of LSD1 led to a weak <\\entity><\\entity> expression, and a robust induction of <\\entity><\\entity> mRNA was observed when LSD1 and histone deacetylases (HDACs) were both inhibited.",
    "Label": ""
  },
  {
    "id": "7233",
    "Sentence": "A novel role for <\\entity><\\entity> in intestinal epithelial cell survival and homeostasis.Apoptosis is a key regulator for the normal turnover of the intestinal mucosa, and abnormalities associated with this function have been linked to inflammatory bowel disease and colorectal cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7234",
    "Sentence": "A novel role for villin in intestinal epithelial cell survival and homeostasis.Apoptosis is a key regulator for the normal turnover of the intestinal mucosa, and <\\entity><\\entity> associated with this function have been linked to inflammatory bowel disease and colorectal cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7235",
    "Sentence": "A novel role for villin in intestinal epithelial cell survival and homeostasis.Apoptosis is a key regulator for the normal turnover of the intestinal mucosa, and abnormalities associated with this function have been linked to <\\entity><\\entity> and colorectal cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7236",
    "Sentence": "A novel role for villin in intestinal epithelial cell survival and homeostasis.Apoptosis is a key regulator for the normal turnover of the intestinal mucosa, and abnormalities associated with this function have been linked to inflammatory bowel disease and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7237",
    "Sentence": "Despite this, <\\entity><\\entity> is known about the mechanism(s) mediating intestinal epithelial cell apoptosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7238",
    "Sentence": "<\\entity><\\entity> is an actin regulatory protein that is expressed in every cell of the intestinal epithelium as well as in exocrine glands associated with the gastrointestinal tract.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7239",
    "Sentence": "In this study we demonstrate for the first time that <\\entity><\\entity> is an epithelial cell-specific anti-apoptotic protein.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7240",
    "Sentence": "<\\entity><\\entity> of villin predisposes mice to dextran sodium sulfate-induced colitis by promoting apoptosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7241",
    "Sentence": "Absence of <\\entity><\\entity> predisposes mice to dextran sodium sulfate-induced colitis by promoting apoptosis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7242",
    "Sentence": "Absence of villin predisposes mice to <\\entity><\\entity>-induced colitis by promoting apoptosis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7243",
    "Sentence": "Absence of villin predisposes mice to dextran sodium sulfate-induced <\\entity><\\entity> by promoting apoptosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7244",
    "Sentence": "To better understand the cellular and molecular mechanisms of the anti-apoptotic function of <\\entity><\\entity>, we overexpressed <\\entity><\\entity> in the Madin-Darby canine kidney Tet-Off epithelial cell line to demonstrate that expression of <\\entity><\\entity> protects cells from apoptosis by maintaining mitochondrial integrity thus inhibiting the activation of caspase-9 and caspase-3.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7245",
    "Sentence": "To better understand the cellular and molecular mechanisms of the anti-apoptotic function of <\\entity><\\entity>, we overexpressed <\\entity><\\entity> in the Madin-Darby canine kidney Tet-Off epithelial cell line to demonstrate that expression of <\\entity><\\entity> protects cells from apoptosis by maintaining mitochondrial integrity thus inhibiting the activation of caspase-9 and caspase-3.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7246",
    "Sentence": "To better understand the cellular and molecular mechanisms of the anti-apoptotic function of <\\entity><\\entity>, we overexpressed <\\entity><\\entity> in the Madin-Darby canine kidney Tet-Off epithelial cell line to demonstrate that expression of <\\entity><\\entity> protects cells from apoptosis by maintaining mitochondrial integrity thus inhibiting the activation of caspase-9 and caspase-3.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7247",
    "Sentence": "Furthermore, we report that the anti-apoptotic response of <\\entity><\\entity> depends on activation of the pro-survival proteins, phosphatidylinositol 3-kinase and phosphorylated Akt.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7248",
    "Sentence": "The results of our studies shed new light on the previously unrecognized function of <\\entity><\\entity> in the regulation of apoptosis in the gastrointestinal epithelium.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7249",
    "Sentence": "Absence of villin predisposes mice to <\\entity><\\entity>-induced colitis by promoting apoptosis.",
    "Label": ""
  },
  {
    "id": "7250",
    "Sentence": "Absence of villin predisposes mice to dextran sodium sulfate-induced <\\entity><\\entity> by promoting apoptosis.",
    "Label": ""
  },
  {
    "id": "7252",
    "Sentence": "Absence of <\\entity><\\entity> predisposes mice to dextran sodium sulfate-induced colitis by promoting apoptosis.",
    "Label": ""
  },
  {
    "id": "7253",
    "Sentence": "Absence of villin predisposes mice to dextran sodium sulfate-induced <\\entity><\\entity> by promoting apoptosis.",
    "Label": ""
  },
  {
    "id": "7259",
    "Sentence": "Multiple regulatory inputs converge on <\\entity><\\entity> to control invadopodia biogenesis and extracellular matrix degradation.Invadopodia are proteolytically active protrusions formed by invasive tumoral cells when grown on an extracellular matrix (ECM) substratum.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7260",
    "Sentence": "Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation.Invadopodia are proteolytically active protrusions formed by invasive tumoral cells when grown on an extracellular matrix (<\\entity><\\entity>) substratum.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7261",
    "Sentence": "Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation.Invadopodia are proteolytically active protrusions formed by invasive tumoral cells when grown on an extracellular matrix (<\\entity><\\entity>) substratum.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7262",
    "Sentence": "The multidomain protein <\\entity><\\entity>, which is involved in the regulation of actin polymerisation, is one such component, but how <\\entity><\\entity> is modulated to control the formation of invadopodia has not been elucidated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7263",
    "Sentence": "The multidomain protein cort<\\entity><\\entity>, which is involved in the regulation of <\\entity><\\entity> polymerisation, is one such component, but how cort<\\entity><\\entity> is modulated to control the formation of invadopodia has not been elucidated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7264",
    "Sentence": "The multidomain protein <\\entity><\\entity>, which is involved in the regulation of actin polymerisation, is one such component, but how <\\entity><\\entity> is modulated to control the formation of invadopodia has not been elucidated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7265",
    "Sentence": "Here, a new invadopodia synchronization protocol is used to show that the <\\entity><\\entity> and SH3 domains, involved in Arp2/3 complex and N-WASP binding and activation, respectively, are both required for invadopodia biogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7266",
    "Sentence": "Here, a new invadopodia synchronization protocol is used to show that the cortactin N-terminal acidic and <\\entity><\\entity>, involved in Arp2/3 complex and N-WASP binding and activation, respectively, are both required for invadopodia biogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7267",
    "Sentence": "Here, a new invadopodia synchronization protocol is used to show that the cortactin N-terminal acidic and SH3 domains, involved in <\\entity><\\entity> complex and N-WASP binding and activation, respectively, are both required for invadopodia biogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7268",
    "Sentence": "Here, a new invadopodia synchronization protocol is used to show that the cortactin N-terminal acidic and SH3 domains, involved in Arp2/3 complex and <\\entity><\\entity> binding and activation, respectively, are both required for invadopodia biogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7269",
    "Sentence": "In addition, through a combination of RNA interference and a wide array of <\\entity><\\entity>, we were able to show that three convergent regulatory inputs based on the regulation of cortactin phosphorylation by Src-family kinases, Erk1/Erk2 and PAK are necessary for invadopodia formation and extracellular matrix degradation.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "7270",
    "Sentence": "In addition, through a combination of RNA interference and a wide array of <\\entity><\\entity>, we were able to show that three convergent regulatory inputs based on the regulation of cortactin phosphorylation by Src-family kinases, Erk1/Erk2 and PAK are necessary for invadopodia formation and extracellular matrix degradation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7271",
    "Sentence": "In addition, through a combination of RNA interference and a wide array of <\\entity><\\entity> phosphorylation mutants, we were able to show that three convergent regulatory inputs based on the regulation of <\\entity><\\entity> phosphorylation by Src-family kinases, Erk1/Erk2 and PAK are necessary for invadopodia formation and extracellular matrix degradation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7272",
    "Sentence": "In addition, through a combination of RNA interference and a wide array of cortactin phosphorylation mutants, we were able to show that three convergent regulatory inputs based on the regulation of cortactin phosphorylation by <\\entity><\\entity>, Erk1/Erk2 and PAK are necessary for invadopodia formation and extracellular matrix degradation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7273",
    "Sentence": "In addition, through a combination of RNA interference and a wide array of cortactin phosphorylation mutants, we were able to show that three convergent regulatory inputs based on the regulation of cortactin phosphorylation by Src-family kinases, <\\entity><\\entity>/Erk2 and PAK are necessary for invadopodia formation and extracellular matrix degradation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7274",
    "Sentence": "In addition, through a combination of RNA interference and a wide array of cortactin phosphorylation mutants, we were able to show that three convergent regulatory inputs based on the regulation of cortactin phosphorylation by Src-family kinases, Erk1/<\\entity><\\entity> and PAK are necessary for invadopodia formation and extracellular matrix degradation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7275",
    "Sentence": "In addition, through a combination of RNA interference and a wide array of cortactin phosphorylation mutants, we were able to show that three convergent regulatory inputs based on the regulation of cortactin phosphorylation by Src-family kinases, Erk1/Erk2 and <\\entity><\\entity> are necessary for invadopodia formation and extracellular matrix degradation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7276",
    "Sentence": "These findings suggest that <\\entity><\\entity> is a scaffold protein bringing together the different components necessary for the formation of the invadopodia, and that a fine balance between different phosphorylation events induces subtle changes in structure to calibrate <\\entity><\\entity> function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7277",
    "Sentence": "These findings suggest that <\\entity><\\entity> is a scaffold protein bringing together the different components necessary for the formation of the invadopodia, and that a fine balance between different phosphorylation events induces subtle changes in structure to calibrate <\\entity><\\entity> function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7282",
    "Sentence": "<\\entity><\\entity> up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.Chronic myelogenous leukemia (CML) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of CML cells to bone marrow stroma.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7283",
    "Sentence": "CXCR4 up-regulation by <\\entity><\\entity> induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.Chronic myelogenous leukemia (CML) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of CML cells to bone marrow stroma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7284",
    "Sentence": "CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (<\\entity><\\entity>) cell migration to bone marrow stroma and promotes survival of quiescent <\\entity><\\entity> cells.Chronic myelogenous leukemia (<\\entity><\\entity>) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of <\\entity><\\entity> cells to bone marrow stroma.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7285",
    "Sentence": "CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (<\\entity><\\entity>) cell migration to bone marrow stroma and promotes survival of quiescent <\\entity><\\entity> cells.Chronic myelogenous leukemia (<\\entity><\\entity>) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of <\\entity><\\entity> cells to bone marrow stroma.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7286",
    "Sentence": "CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (<\\entity><\\entity>) cell migration to bone marrow stroma and promotes survival of quiescent <\\entity><\\entity> cells.Chronic myelogenous leukemia (<\\entity><\\entity>) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of <\\entity><\\entity> cells to bone marrow stroma.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7287",
    "Sentence": "CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.Chronic myelogenous leukemia (CML) is driven by constitutively activated <\\entity><\\entity>, which causes the defective adhesion of CML cells to bone marrow stroma.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7288",
    "Sentence": "CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (<\\entity><\\entity>) cell migration to bone marrow stroma and promotes survival of quiescent <\\entity><\\entity> cells.Chronic myelogenous leukemia (<\\entity><\\entity>) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of <\\entity><\\entity> cells to bone marrow stroma.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7289",
    "Sentence": "The overexpression of <\\entity><\\entity> was reported to down-regulate CXCR4 expression, and this is associated with the cell migration defects in CML.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7290",
    "Sentence": "The overexpression of p210Bcr-Abl was reported to down-regulate <\\entity><\\entity> expression, and this is associated with the cell migration defects in CML.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7291",
    "Sentence": "The overexpression of p210Bcr-Abl was reported to down-regulate CXCR4 expression, and this is associated with the cell migration defects in <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7292",
    "Sentence": "We proposed that <\\entity><\\entity>, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7293",
    "Sentence": "We proposed that tyrosine kinase inhibitors, <\\entity><\\entity> or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7294",
    "Sentence": "We proposed that tyrosine kinase inhibitors, imatinib or <\\entity><\\entity>, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7295",
    "Sentence": "We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore <\\entity><\\entity> expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7296",
    "Sentence": "We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of <\\entity><\\entity> cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of <\\entity><\\entity> progenitor cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7297",
    "Sentence": "We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of <\\entity><\\entity> cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of <\\entity><\\entity> progenitor cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7298",
    "Sentence": "In KBM5 and K562 cells, <\\entity><\\entity>, INNO-406, or IFN-alpha increased CXCR4 expression and migration.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7299",
    "Sentence": "In KBM5 and K562 cells, imatinib, <\\entity><\\entity>, or IFN-alpha increased CXCR4 expression and migration.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7300",
    "Sentence": "In KBM5 and K562 cells, imatinib, INNO-406, or <\\entity><\\entity> increased CXCR4 expression and migration.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7301",
    "Sentence": "In KBM5 and K562 cells, imatinib, INNO-406, or IFN-alpha increased <\\entity><\\entity> expression and migration.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7302",
    "Sentence": "This increase in <\\entity><\\entity> levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or IFN-alpha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7303",
    "Sentence": "This increase in CXCR4 levels on <\\entity><\\entity> progenitor cells was likewise found in samples from <\\entity><\\entity> patients treated with imatinib or IFN-alpha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7304",
    "Sentence": "This increase in CXCR4 levels on <\\entity><\\entity> progenitor cells was likewise found in samples from <\\entity><\\entity> patients treated with imatinib or IFN-alpha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7305",
    "Sentence": "This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with <\\entity><\\entity> or IFN-alpha.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7306",
    "Sentence": "This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7307",
    "Sentence": "<\\entity><\\entity> induced G0-G1 cell cycle block in CML cells, which was further enhanced in a mesenchymal stem cell (MSC) coculture system.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7308",
    "Sentence": "Imatinib induced G0-G1 cell cycle block in <\\entity><\\entity> cells, which was further enhanced in a mesenchymal stem cell (MSC) coculture system.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7309",
    "Sentence": "Imatinib induced G0-G1 cell cycle block in CML cells, which was further enhanced in a mesenchymal stem cell (<\\entity><\\entity>) coculture system.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7310",
    "Sentence": "<\\entity><\\entity> coculture protected KBM-5 cells from imatinib-induced cell death.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7311",
    "Sentence": "MSC coculture protected KBM-5 cells from <\\entity><\\entity>-induced cell death.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7312",
    "Sentence": "These antiapoptotic effects were abrogated by the <\\entity><\\entity> AMD3465 or by inhibitor of integrin-linked kinase QLT0267.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7313",
    "Sentence": "These antiapoptotic effects were abrogated by the <\\entity><\\entity> AMD3465 or by inhibitor of integrin-linked kinase QLT0267.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7314",
    "Sentence": "These antiapoptotic effects were abrogated by the CXCR4 antagonist <\\entity><\\entity> or by inhibitor of integrin-linked kinase QLT0267.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7315",
    "Sentence": "These antiapoptotic effects were abrogated by the CXCR4 antagonist AMD3465 or by <\\entity><\\entity> QLT0267.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7316",
    "Sentence": "These antiapoptotic effects were abrogated by the CXCR4 antagonist AMD3465 or by <\\entity><\\entity> QLT0267.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7317",
    "Sentence": "These antiapoptotic effects were abrogated by the CXCR4 antagonist AMD3465 or by inhibitor of integrin-linked kinase <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7318",
    "Sentence": "Altogether, these findings suggest that the up-regulation of <\\entity><\\entity> by imatinib promotes migration of CML cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7319",
    "Sentence": "Altogether, these findings suggest that the up-regulation of CXCR4 by <\\entity><\\entity> promotes migration of CML cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7320",
    "Sentence": "Altogether, these findings suggest that the up-regulation of CXCR4 by imatinib promotes migration of <\\entity><\\entity> cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent <\\entity><\\entity> progenitor cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7321",
    "Sentence": "Altogether, these findings suggest that the up-regulation of CXCR4 by imatinib promotes migration of <\\entity><\\entity> cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent <\\entity><\\entity> progenitor cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7322",
    "Sentence": "CXCR4 up-regulation by <\\entity><\\entity> induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.Chronic myelogenous leukemia (CML) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of CML cells to bone marrow stroma.",
    "Label": ""
  },
  {
    "id": "7323",
    "Sentence": "<\\entity><\\entity> up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.Chronic myelogenous leukemia (CML) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of CML cells to bone marrow stroma.",
    "Label": ""
  },
  {
    "id": "7325",
    "Sentence": "We proposed that tyrosine kinase inhibitors, <\\entity><\\entity> or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells.",
    "Label": ""
  },
  {
    "id": "7326",
    "Sentence": "We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore <\\entity><\\entity> expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells.",
    "Label": ""
  },
  {
    "id": "7328",
    "Sentence": "We proposed that <\\entity><\\entity>, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells.",
    "Label": ""
  },
  {
    "id": "7329",
    "Sentence": "We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore <\\entity><\\entity> expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells.",
    "Label": ""
  },
  {
    "id": "7331",
    "Sentence": "We proposed that tyrosine kinase inhibitors, imatinib or <\\entity><\\entity>, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells.",
    "Label": ""
  },
  {
    "id": "7332",
    "Sentence": "We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore <\\entity><\\entity> expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells.",
    "Label": ""
  },
  {
    "id": "7334",
    "Sentence": "In KBM5 and K562 cells, <\\entity><\\entity>, INNO-406, or IFN-alpha increased CXCR4 expression and migration.",
    "Label": ""
  },
  {
    "id": "7335",
    "Sentence": "In KBM5 and K562 cells, imatinib, INNO-406, or IFN-alpha increased <\\entity><\\entity> expression and migration.",
    "Label": ""
  },
  {
    "id": "7337",
    "Sentence": "In KBM5 and K562 cells, imatinib, <\\entity><\\entity>, or IFN-alpha increased CXCR4 expression and migration.",
    "Label": ""
  },
  {
    "id": "7338",
    "Sentence": "In KBM5 and K562 cells, imatinib, INNO-406, or IFN-alpha increased <\\entity><\\entity> expression and migration.",
    "Label": ""
  },
  {
    "id": "7340",
    "Sentence": "In KBM5 and K562 cells, imatinib, INNO-406, or <\\entity><\\entity> increased CXCR4 expression and migration.",
    "Label": ""
  },
  {
    "id": "7341",
    "Sentence": "In KBM5 and K562 cells, imatinib, INNO-406, or IFN-alpha increased <\\entity><\\entity> expression and migration.",
    "Label": ""
  },
  {
    "id": "7343",
    "Sentence": "Altogether, these findings suggest that the up-regulation of CXCR4 by <\\entity><\\entity> promotes migration of CML cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells.",
    "Label": ""
  },
  {
    "id": "7344",
    "Sentence": "Altogether, these findings suggest that the up-regulation of <\\entity><\\entity> by imatinib promotes migration of CML cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells.",
    "Label": ""
  },
  {
    "id": "7346",
    "Sentence": "CXCR4 up-regulation by <\\entity><\\entity> induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.Chronic myelogenous leukemia (CML) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of CML cells to bone marrow stroma.",
    "Label": ""
  },
  {
    "id": "7347",
    "Sentence": "CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (<\\entity><\\entity>) cell migration to bone marrow stroma and promotes survival of quiescent <\\entity><\\entity> cells.Chronic myelogenous leukemia (<\\entity><\\entity>) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of <\\entity><\\entity> cells to bone marrow stroma.",
    "Label": ""
  },
  {
    "id": "7349",
    "Sentence": "We proposed that tyrosine kinase inhibitors, <\\entity><\\entity> or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells.",
    "Label": ""
  },
  {
    "id": "7350",
    "Sentence": "We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of <\\entity><\\entity> cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of <\\entity><\\entity> progenitor cells.",
    "Label": ""
  },
  {
    "id": "7352",
    "Sentence": "This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with <\\entity><\\entity> or IFN-alpha.",
    "Label": ""
  },
  {
    "id": "7353",
    "Sentence": "This increase in CXCR4 levels on <\\entity><\\entity> progenitor cells was likewise found in samples from <\\entity><\\entity> patients treated with imatinib or IFN-alpha.",
    "Label": ""
  },
  {
    "id": "7355",
    "Sentence": "This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with <\\entity><\\entity> or IFN-alpha.",
    "Label": ""
  },
  {
    "id": "7356",
    "Sentence": "This increase in <\\entity><\\entity> levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or IFN-alpha.",
    "Label": ""
  },
  {
    "id": "7358",
    "Sentence": "<\\entity><\\entity> induced G0-G1 cell cycle block in CML cells, which was further enhanced in a mesenchymal stem cell (MSC) coculture system.",
    "Label": ""
  },
  {
    "id": "7359",
    "Sentence": "Imatinib induced G0-G1 cell cycle block in <\\entity><\\entity> cells, which was further enhanced in a mesenchymal stem cell (MSC) coculture system.",
    "Label": ""
  },
  {
    "id": "7361",
    "Sentence": "<\\entity><\\entity> induced G0-G1 cell cycle block in CML cells, which was further enhanced in a mesenchymal stem cell (MSC) coculture system.",
    "Label": ""
  },
  {
    "id": "7362",
    "Sentence": "Imatinib induced G0-G1 cell cycle block in CML cells, which was further enhanced in a mesenchymal stem cell (<\\entity><\\entity>) coculture system.",
    "Label": ""
  },
  {
    "id": "7364",
    "Sentence": "MSC coculture protected KBM-5 cells from <\\entity><\\entity>-induced cell death.",
    "Label": ""
  },
  {
    "id": "7365",
    "Sentence": "<\\entity><\\entity> coculture protected KBM-5 cells from imatinib-induced cell death.",
    "Label": ""
  },
  {
    "id": "7367",
    "Sentence": "Altogether, these findings suggest that the up-regulation of CXCR4 by <\\entity><\\entity> promotes migration of CML cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent CML progenitor cells.",
    "Label": ""
  },
  {
    "id": "7368",
    "Sentence": "Altogether, these findings suggest that the up-regulation of CXCR4 by imatinib promotes migration of <\\entity><\\entity> cells to bone marrow stroma, causing the G0-G1 cell cycle arrest and hence ensuring the survival of quiescent <\\entity><\\entity> progenitor cells.",
    "Label": ""
  },
  {
    "id": "7370",
    "Sentence": "This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7371",
    "Sentence": "This increase in <\\entity><\\entity> levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or IFN-alpha.",
    "Label": ""
  },
  {
    "id": "7373",
    "Sentence": "These antiapoptotic effects were abrogated by the CXCR4 antagonist <\\entity><\\entity> or by inhibitor of integrin-linked kinase QLT0267.",
    "Label": ""
  },
  {
    "id": "7374",
    "Sentence": "These antiapoptotic effects were abrogated by the <\\entity><\\entity> AMD3465 or by inhibitor of integrin-linked kinase QLT0267.",
    "Label": ""
  },
  {
    "id": "7376",
    "Sentence": "These antiapoptotic effects were abrogated by the CXCR4 antagonist <\\entity><\\entity> or by inhibitor of integrin-linked kinase QLT0267.",
    "Label": ""
  },
  {
    "id": "7377",
    "Sentence": "These antiapoptotic effects were abrogated by the CXCR4 antagonist AMD3465 or by <\\entity><\\entity> QLT0267.",
    "Label": ""
  },
  {
    "id": "7379",
    "Sentence": "These antiapoptotic effects were abrogated by the CXCR4 antagonist AMD3465 or by inhibitor of integrin-linked kinase <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7380",
    "Sentence": "These antiapoptotic effects were abrogated by the <\\entity><\\entity> AMD3465 or by inhibitor of integrin-linked kinase QLT0267.",
    "Label": ""
  },
  {
    "id": "7382",
    "Sentence": "These antiapoptotic effects were abrogated by the CXCR4 antagonist AMD3465 or by inhibitor of integrin-linked kinase <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7383",
    "Sentence": "These antiapoptotic effects were abrogated by the CXCR4 antagonist AMD3465 or by <\\entity><\\entity> QLT0267.",
    "Label": ""
  },
  {
    "id": "7389",
    "Sentence": "Differential effects of selective <\\entity><\\entity> inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.Cyclooxygenase-2 (COX-2), an enzyme that catalyzes the synthesis of prostaglandins, is made inducible by various stimuli such as inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7390",
    "Sentence": "Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in <\\entity><\\entity>.Cyclooxygenase-2 (COX-2), an enzyme that catalyzes the synthesis of prostaglandins, is made inducible by various stimuli such as inflammation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7391",
    "Sentence": "Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.<\\entity><\\entity> (COX-2), an enzyme that catalyzes the synthesis of prostaglandins, is made inducible by various stimuli such as inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7392",
    "Sentence": "Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.Cyclooxygenase-2 (<\\entity><\\entity>), an enzyme that catalyzes the synthesis of prostaglandins, is made inducible by various stimuli such as inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7393",
    "Sentence": "Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.Cyclooxygenase-2 (COX-2), an enzyme that catalyzes the synthesis of <\\entity><\\entity>, is made inducible by various stimuli such as inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7394",
    "Sentence": "Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.Cyclooxygenase-2 (COX-2), an enzyme that catalyzes the synthesis of prostaglandins, is made inducible by various stimuli such as <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7395",
    "Sentence": "Although <\\entity><\\entity> is commonly overexpressed in a variety of premalignant and malignant conditions including oral leukoplakia and squamous cell carcinoma, relatively little research has compared the effects of various <\\entity><\\entity> inhibitors (celecoxib, NS-398, nimesulide and meloxicam).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7396",
    "Sentence": "Although COX-2 is commonly overexpressed in a variety of premalignant and malignant conditions including <\\entity><\\entity> and squamous cell carcinoma, relatively little research has compared the effects of various COX-2 inhibitors (celecoxib, NS-398, nimesulide and meloxicam).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7397",
    "Sentence": "Although COX-2 is commonly overexpressed in a variety of premalignant and malignant conditions including oral leukoplakia and <\\entity><\\entity>, relatively little research has compared the effects of various COX-2 inhibitors (celecoxib, NS-398, nimesulide and meloxicam).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7398",
    "Sentence": "Although COX-2 is commonly overexpressed in a variety of premalignant and malignant conditions including oral leukoplakia and squamous cell carcinoma, relatively <\\entity><\\entity> research has compared the effects of various COX-2 inhibitors (celecoxib, NS-398, nimesulide and meloxicam).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7399",
    "Sentence": "Although <\\entity><\\entity> is commonly overexpressed in a variety of premalignant and malignant conditions including oral leukoplakia and squamous cell carcinoma, relatively little research has compared the effects of various <\\entity><\\entity> inhibitors (celecoxib, NS-398, nimesulide and meloxicam).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7400",
    "Sentence": "Therefore, we investigated the effects of four different selective <\\entity><\\entity> inhibitors on the growth of KB cells, derived from oral squamous cell carcinoma (OSCC) and its mechanisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7401",
    "Sentence": "Therefore, we investigated the effects of four different selective COX-2 inhibitors on the growth of KB cells, derived from <\\entity><\\entity> (OSCC) and its mechanisms.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7402",
    "Sentence": "Therefore, we investigated the effects of four different selective COX-2 inhibitors on the growth of KB cells, derived from oral squamous cell carcinoma (<\\entity><\\entity>) and its mechanisms.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7403",
    "Sentence": "Only celecoxib induced apoptosis of the KB cells, as detected on the basis of DNA <\\entity><\\entity>, caspase-3/7 activation and cleaved poly(ADP-ribose) polymerase (PARP) <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7404",
    "Sentence": "Only celecoxib induced apoptosis of the KB cells, as detected on the basis of DNA fragmentation, <\\entity><\\entity> activation and cleaved poly(ADP-ribose) polymerase (PARP) fragmentation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7405",
    "Sentence": "Only celecoxib induced apoptosis of the KB cells, as detected on the basis of DNA fragmentation, caspase-3/7 activation and cleaved <\\entity><\\entity> (PARP) fragmentation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7406",
    "Sentence": "Only celecoxib induced apoptosis of the KB cells, as detected on the basis of DNA fragmentation, caspase-3/7 activation and cleaved poly(ADP-ribose) polymerase (<\\entity><\\entity>) fragmentation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7407",
    "Sentence": "Only celecoxib induced apoptosis of the KB cells, as detected on the basis of DNA <\\entity><\\entity>, caspase-3/7 activation and cleaved poly(ADP-ribose) polymerase (PARP) <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7408",
    "Sentence": "All four <\\entity><\\entity> inhibitors increased <\\entity><\\entity> protein expression but suppressed prostaglandin (PG) E2 production in the KB cells, suggesting that the pro-apoptotic effect of celecoxib was unrelated to the inhibition of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7409",
    "Sentence": "All four <\\entity><\\entity> inhibitors increased <\\entity><\\entity> protein expression but suppressed prostaglandin (PG) E2 production in the KB cells, suggesting that the pro-apoptotic effect of celecoxib was unrelated to the inhibition of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7410",
    "Sentence": "All four COX-2 inhibitors increased COX-2 protein expression but suppressed <\\entity><\\entity> (PG) E2 production in the KB cells, suggesting that the pro-apoptotic effect of celecoxib was unrelated to the inhibition of COX-2.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7411",
    "Sentence": "All four COX-2 inhibitors increased COX-2 protein expression but suppressed prostaglandin (<\\entity><\\entity> production in the KB cells, suggesting that the pro-apoptotic effect of celecoxib was unrelated to the inhibition of COX-2.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7412",
    "Sentence": "All four <\\entity><\\entity> inhibitors increased <\\entity><\\entity> protein expression but suppressed prostaglandin (PG) E2 production in the KB cells, suggesting that the pro-apoptotic effect of celecoxib was unrelated to the inhibition of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7413",
    "Sentence": "Mechanistically, a high level of <\\entity><\\entity> protein and a low level of multidrug-resistant protein 1 (MRP1) and breast cancer resistant protein (BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7414",
    "Sentence": "Mechanistically, a high level of p53 protein and a low level of <\\entity><\\entity> (MRP1) and breast cancer resistant protein (BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7415",
    "Sentence": "Mechanistically, a high level of p53 protein and a low level of multidrug-resistant protein 1 (<\\entity><\\entity>) and breast cancer resistant protein (BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7416",
    "Sentence": "Mechanistically, a high level of p53 protein and a low level of multidrug-resistant protein 1 (MRP1) and <\\entity><\\entity>(BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7417",
    "Sentence": "Mechanistically, a high level of p53 protein and a low level of multidrug-resistant protein 1 (MRP1) and <\\entity><\\entity>(BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7418",
    "Sentence": "Mechanistically, a high level of p53 protein and a low level of multidrug-resistant protein 1 (MRP1) and breast cancer resistant protein (<\\entity><\\entity>) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7419",
    "Sentence": "Mechanistically, a high level of p53 protein and a low level of multidrug-resistant protein 1 (MRP1) and breast cancer resistant protein (BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective <\\entity><\\entity> inhibitors in KB cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7420",
    "Sentence": "Taken together, celecoxib is a good therapeutic candidate for treating <\\entity><\\entity> through the suppression of cell proliferation and the induction of apoptosis in a COX-2 independent manner.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7421",
    "Sentence": "Taken together, celecoxib is a good therapeutic candidate for treating OSCC through the <\\entity><\\entity> of cell proliferation and the induction of apoptosis in a COX-2 independent manner.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7422",
    "Sentence": "Taken together, celecoxib is a good therapeutic candidate for treating OSCC through the suppression of cell proliferation and the induction of apoptosis in a <\\entity><\\entity> independent manner.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7423",
    "Sentence": "Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.Cyclooxygenase-2 (<\\entity><\\entity>), an enzyme that catalyzes the synthesis of prostaglandins, is made inducible by various stimuli such as inflammation.",
    "Label": ""
  },
  {
    "id": "7424",
    "Sentence": "Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.Cyclooxygenase-2 (COX-2), an enzyme that catalyzes the synthesis of prostaglandins, is made inducible by various stimuli such as <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7426",
    "Sentence": "Although <\\entity><\\entity> is commonly overexpressed in a variety of premalignant and malignant conditions including oral leukoplakia and squamous cell carcinoma, relatively little research has compared the effects of various <\\entity><\\entity> inhibitors (celecoxib, NS-398, nimesulide and meloxicam).",
    "Label": ""
  },
  {
    "id": "7427",
    "Sentence": "Although COX-2 is commonly overexpressed in a variety of premalignant and malignant conditions including oral leukoplakia and <\\entity><\\entity>, relatively little research has compared the effects of various COX-2 inhibitors (celecoxib, NS-398, nimesulide and meloxicam).",
    "Label": ""
  },
  {
    "id": "7429",
    "Sentence": "Although <\\entity><\\entity> is commonly overexpressed in a variety of premalignant and malignant conditions including oral leukoplakia and squamous cell carcinoma, relatively little research has compared the effects of various <\\entity><\\entity> inhibitors (celecoxib, NS-398, nimesulide and meloxicam).",
    "Label": ""
  },
  {
    "id": "7430",
    "Sentence": "Although COX-2 is commonly overexpressed in a variety of premalignant and malignant conditions including <\\entity><\\entity> and squamous cell carcinoma, relatively little research has compared the effects of various COX-2 inhibitors (celecoxib, NS-398, nimesulide and meloxicam).",
    "Label": ""
  },
  {
    "id": "7432",
    "Sentence": "Differential effects of selective <\\entity><\\entity> inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma.Cyclooxygenase-2 (COX-2), an enzyme that catalyzes the synthesis of prostaglandins, is made inducible by various stimuli such as inflammation.",
    "Label": ""
  },
  {
    "id": "7433",
    "Sentence": "Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in <\\entity><\\entity>.Cyclooxygenase-2 (COX-2), an enzyme that catalyzes the synthesis of prostaglandins, is made inducible by various stimuli such as inflammation.",
    "Label": ""
  },
  {
    "id": "7435",
    "Sentence": "Although <\\entity><\\entity> is commonly overexpressed in a variety of premalignant and malignant conditions including oral leukoplakia and squamous cell carcinoma, relatively little research has compared the effects of various <\\entity><\\entity> inhibitors (celecoxib, NS-398, nimesulide and meloxicam).",
    "Label": ""
  },
  {
    "id": "7436",
    "Sentence": "Although COX-2 is commonly overexpressed in a variety of premalignant and malignant conditions including oral leukoplakia and squamous cell carcinoma, relatively <\\entity><\\entity> research has compared the effects of various COX-2 inhibitors (celecoxib, NS-398, nimesulide and meloxicam).",
    "Label": ""
  },
  {
    "id": "7438",
    "Sentence": "Therefore, we investigated the effects of four different selective <\\entity><\\entity> inhibitors on the growth of KB cells, derived from oral squamous cell carcinoma (OSCC) and its mechanisms.",
    "Label": ""
  },
  {
    "id": "7439",
    "Sentence": "Therefore, we investigated the effects of four different selective COX-2 inhibitors on the growth of KB cells, derived from <\\entity><\\entity> (OSCC) and its mechanisms.",
    "Label": ""
  },
  {
    "id": "7441",
    "Sentence": "Only celecoxib induced apoptosis of the KB cells, as detected on the basis of DNA fragmentation, caspase-3/7 activation and cleaved poly(ADP-ribose) polymerase (<\\entity><\\entity>) fragmentation.",
    "Label": ""
  },
  {
    "id": "7442",
    "Sentence": "Only celecoxib induced apoptosis of the KB cells, as detected on the basis of DNA <\\entity><\\entity>, caspase-3/7 activation and cleaved poly(ADP-ribose) polymerase (PARP) <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7444",
    "Sentence": "Only celecoxib induced apoptosis of the KB cells, as detected on the basis of DNA fragmentation, <\\entity><\\entity> activation and cleaved poly(ADP-ribose) polymerase (PARP) fragmentation.",
    "Label": ""
  },
  {
    "id": "7445",
    "Sentence": "Only celecoxib induced apoptosis of the KB cells, as detected on the basis of DNA <\\entity><\\entity>, caspase-3/7 activation and cleaved poly(ADP-ribose) polymerase (PARP) <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7447",
    "Sentence": "Mechanistically, a high level of p53 protein and a low level of multidrug-resistant protein 1 (MRP1) and breast cancer resistant protein (BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective <\\entity><\\entity> inhibitors in KB cells.",
    "Label": ""
  },
  {
    "id": "7448",
    "Sentence": "Mechanistically, a high level of p53 protein and a low level of multidrug-resistant protein 1 (MRP1) and <\\entity><\\entity>(BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells.",
    "Label": ""
  },
  {
    "id": "7450",
    "Sentence": "Mechanistically, a high level of p53 protein and a low level of multidrug-resistant protein 1 (MRP1) and breast cancer resistant protein (<\\entity><\\entity>) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells.",
    "Label": ""
  },
  {
    "id": "7451",
    "Sentence": "Mechanistically, a high level of p53 protein and a low level of multidrug-resistant protein 1 (MRP1) and <\\entity><\\entity>(BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells.",
    "Label": ""
  },
  {
    "id": "7453",
    "Sentence": "Mechanistically, a high level of <\\entity><\\entity> protein and a low level of multidrug-resistant protein 1 (MRP1) and breast cancer resistant protein (BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells.",
    "Label": ""
  },
  {
    "id": "7454",
    "Sentence": "Mechanistically, a high level of p53 protein and a low level of multidrug-resistant protein 1 (MRP1) and <\\entity><\\entity>(BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells.",
    "Label": ""
  },
  {
    "id": "7456",
    "Sentence": "Mechanistically, a high level of p53 protein and a low level of multidrug-resistant protein 1 (<\\entity><\\entity>) and breast cancer resistant protein (BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells.",
    "Label": ""
  },
  {
    "id": "7457",
    "Sentence": "Mechanistically, a high level of p53 protein and a low level of multidrug-resistant protein 1 (MRP1) and <\\entity><\\entity>(BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells.",
    "Label": ""
  },
  {
    "id": "7459",
    "Sentence": "Taken together, celecoxib is a good therapeutic candidate for treating OSCC through the suppression of cell proliferation and the induction of apoptosis in a <\\entity><\\entity> independent manner.",
    "Label": ""
  },
  {
    "id": "7460",
    "Sentence": "Taken together, celecoxib is a good therapeutic candidate for treating OSCC through the <\\entity><\\entity> of cell proliferation and the induction of apoptosis in a COX-2 independent manner.",
    "Label": ""
  },
  {
    "id": "7462",
    "Sentence": "Therefore, we investigated the effects of four different selective <\\entity><\\entity> inhibitors on the growth of KB cells, derived from oral squamous cell carcinoma (OSCC) and its mechanisms.",
    "Label": ""
  },
  {
    "id": "7463",
    "Sentence": "Therefore, we investigated the effects of four different selective COX-2 inhibitors on the growth of KB cells, derived from oral squamous cell carcinoma (<\\entity><\\entity>) and its mechanisms.",
    "Label": ""
  },
  {
    "id": "7465",
    "Sentence": "Taken together, celecoxib is a good therapeutic candidate for treating OSCC through the suppression of cell proliferation and the induction of apoptosis in a <\\entity><\\entity> independent manner.",
    "Label": ""
  },
  {
    "id": "7466",
    "Sentence": "Taken together, celecoxib is a good therapeutic candidate for treating <\\entity><\\entity> through the suppression of cell proliferation and the induction of apoptosis in a COX-2 independent manner.",
    "Label": ""
  },
  {
    "id": "7468",
    "Sentence": "Taken together, celecoxib is a good therapeutic candidate for treating OSCC through the suppression of cell proliferation and the induction of apoptosis in a <\\entity><\\entity> independent manner.",
    "Label": ""
  },
  {
    "id": "7469",
    "Sentence": "Taken together, celecoxib is a good therapeutic candidate for treating <\\entity><\\entity> through the suppression of cell proliferation and the induction of apoptosis in a COX-2 independent manner.",
    "Label": ""
  },
  {
    "id": "7475",
    "Sentence": "Rotational thrombelastometry for the bedside monitoring of <\\entity><\\entity>.BACKGROUND: Recombinant hirudin is used as an alternative anticoagulant, particularly in patients with heparin-induced thrombocytopenia type II.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7476",
    "Sentence": "Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.BACKGROUND: <\\entity><\\entity> is used as an alternative anticoagulant, particularly in patients with heparin-induced thrombocytopenia type II.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7477",
    "Sentence": "Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.BACKGROUND: Recombinant hirudin is used as an alternative <\\entity><\\entity>, particularly in patients with heparin-induced thrombocytopenia type II.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7478",
    "Sentence": "Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.BACKGROUND: Recombinant hirudin is used as an alternative anticoagulant, particularly in patients with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7479",
    "Sentence": "However, bedside monitoring for <\\entity><\\entity> is not available.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7480",
    "Sentence": "The present study aims to evaluate rotational thrombelastometry regarding its suitability to detect the effects of <\\entity><\\entity> on whole blood coagulation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7481",
    "Sentence": "<\\entity><\\entity> was added to whole blood samples from healthy donors (n=5) and thrombelastometry variables resulting from activation of samples with tissue factor, ellagic acid, and ecarin were determined.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7482",
    "Sentence": "Hirudin was added to whole blood samples from healthy donors (n=5) and thrombelastometry variables resulting from activation of samples with <\\entity><\\entity>, ellagic acid, and ecarin were determined.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7483",
    "Sentence": "Hirudin was added to whole blood samples from healthy donors (n=5) and thrombelastometry variables resulting from activation of samples with tissue factor, <\\entity><\\entity>, and ecarin were determined.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7484",
    "Sentence": "Hirudin was added to whole blood samples from healthy donors (n=5) and thrombelastometry variables resulting from activation of samples with tissue factor, ellagic acid, and <\\entity><\\entity> were determined.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7485",
    "Sentence": "METHODS: <\\entity><\\entity> (0.1-10 microg/ml) was added to citrated blood.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7486",
    "Sentence": "Thereafter, rotational thrombelastometry was performed by initiating coagulation via recalcification and addition of <\\entity><\\entity>, ellagic acid, and ecarin, respectively, using the commercially available assays.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7487",
    "Sentence": "Thereafter, rotational thrombelastometry was performed by initiating coagulation via recalcification and addition of tissue factor, <\\entity><\\entity>, and ecarin, respectively, using the commercially available assays.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7488",
    "Sentence": "Thereafter, rotational thrombelastometry was performed by initiating coagulation via recalcification and addition of tissue factor, ellagic acid, and <\\entity><\\entity>, respectively, using the commercially available assays.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7489",
    "Sentence": "RESULTS: In the <\\entity><\\entity> of hirudin, clotting times (CT) induced by ellagic acid, tissue factor, and ecarin, respectively, were 141.7+/-18.0, 54.0+/-7.6, and 64.5+/-4.1 s.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7490",
    "Sentence": "RESULTS: In the absence of <\\entity><\\entity>, clotting times (CT) induced by ellagic acid, tissue factor, and ecarin, respectively, were 141.7+/-18.0, 54.0+/-7.6, and 64.5+/-4.1 s.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7491",
    "Sentence": "RESULTS: In the absence of hirudin, <\\entity><\\entity> times (CT) induced by ellagic acid, tissue factor, and ecarin, respectively, were 141.7+/-18.0, 54.0+/-7.6, and 64.5+/-4.1 s.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7492",
    "Sentence": "RESULTS: In the absence of hirudin, clotting times (<\\entity><\\entity>) induced by ellagic acid, tissue factor, and ecarin, respectively, were 141.7+/-18.0, 54.0+/-7.6, and 64.5+/-4.1 s.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7493",
    "Sentence": "RESULTS: In the absence of hirudin, clotting times (CT) induced by <\\entity><\\entity>, tissue factor, and ecarin, respectively, were 141.7+/-18.0, 54.0+/-7.6, and 64.5+/-4.1 s.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7494",
    "Sentence": "RESULTS: In the absence of hirudin, clotting times (CT) induced by ellagic acid, <\\entity><\\entity>, and ecarin, respectively, were 141.7+/-18.0, 54.0+/-7.6, and 64.5+/-4.1 s.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7495",
    "Sentence": "RESULTS: In the absence of hirudin, clotting times (CT) induced by ellagic acid, tissue factor, and <\\entity><\\entity>, respectively, were 141.7+/-18.0, 54.0+/-7.6, and 64.5+/-4.1 s.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7496",
    "Sentence": "Increasing concentrations of <\\entity><\\entity> led to dose-dependent prolongation of the clotting time with the three activators.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7497",
    "Sentence": "Increasing concentrations of hirudin led to dose-dependent prolongation of the <\\entity><\\entity> time with the three activators.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7498",
    "Sentence": "All assays were capable to detect <\\entity><\\entity> concentrations in the range of 0.5-5 microg/ml.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7499",
    "Sentence": "At a final <\\entity><\\entity> concentration of 1 microg/ml, clotting time increased to 268.0+/-25.1, 84.0+/-9.3, and 107.5+/-9.9 s, respectively, with the above-mentioned activators.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7500",
    "Sentence": "The other thrombelastographic variables, including <\\entity><\\entity> formation time, angle alpha, and maximum <\\entity><\\entity> firmness, were not altered by hirudin at concentrations up to 5 microg/ml.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7501",
    "Sentence": "The other thrombelastographic variables, including <\\entity><\\entity> formation time, angle alpha, and maximum <\\entity><\\entity> firmness, were not altered by hirudin at concentrations up to 5 microg/ml.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7502",
    "Sentence": "The other thrombelastographic variables, including clot formation time, angle alpha, and maximum clot firmness, were not altered by <\\entity><\\entity> at concentrations up to 5 microg/ml.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7503",
    "Sentence": "CONCLUSIONS: Our study demonstrates the suitability of rotational thrombelastometry to detect <\\entity><\\entity> effects of recombinant hirudin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7504",
    "Sentence": "CONCLUSIONS: Our study demonstrates the suitability of rotational thrombelastometry to detect anticoagulant effects of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7505",
    "Sentence": "Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.BACKGROUND: Recombinant hirudin is used as an alternative <\\entity><\\entity>, particularly in patients with heparin-induced thrombocytopenia type II.",
    "Label": ""
  },
  {
    "id": "7506",
    "Sentence": "Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.BACKGROUND: Recombinant hirudin is used as an alternative anticoagulant, particularly in patients with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7508",
    "Sentence": "Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.BACKGROUND: <\\entity><\\entity> is used as an alternative anticoagulant, particularly in patients with heparin-induced thrombocytopenia type II.",
    "Label": ""
  },
  {
    "id": "7509",
    "Sentence": "Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.BACKGROUND: Recombinant hirudin is used as an alternative anticoagulant, particularly in patients with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7515",
    "Sentence": "Cognitive performance in recreational <\\entity><\\entity> polydrug users: a two-year follow-up study.There is important preclinical evidence of long lasting neurotoxic and selective effects of <\\entity><\\entity> MDMA on serotonin systems in non-human primates.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7516",
    "Sentence": "Cognitive performance in recreational <\\entity><\\entity> polydrug users: a two-year follow-up study.There is important preclinical evidence of long lasting neurotoxic and selective effects of <\\entity><\\entity> MDMA on serotonin systems in non-human primates.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7517",
    "Sentence": "Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.There is important preclinical evidence of long lasting neurotoxic and selective effects of ecstasy <\\entity><\\entity> on serotonin systems in non-human primates.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7518",
    "Sentence": "In humans long-term recreational use of <\\entity><\\entity> has been mainly associated with learning and memory impairments.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7519",
    "Sentence": "In humans long-term recreational use of ecstasy has been mainly associated with <\\entity><\\entity> and memory impairments.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7520",
    "Sentence": "In humans long-term recreational use of ecstasy has been mainly associated with learning and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7521",
    "Sentence": "The aim of the present study was to investigate the neuropsychological profile associated with <\\entity><\\entity> use within recreational polydrug users, and describe the cognitive changes related to maintained or variable <\\entity><\\entity> use along a two years period.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7522",
    "Sentence": "The aim of the present study was to investigate the neuropsychological profile associated with ecstasy use within recreational polydrug users, and describe the <\\entity><\\entity> related to maintained or variable ecstasy use along a two years period.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7523",
    "Sentence": "The aim of the present study was to investigate the neuropsychological profile associated with <\\entity><\\entity> use within recreational polydrug users, and describe the cognitive changes related to maintained or variable <\\entity><\\entity> use along a two years period.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7524",
    "Sentence": "We administered cognitive measures of attention, executive functions, memory and <\\entity><\\entity> to three groups of participants: 37 current polydrug users with regular consumption of ecstasy and cannabis, 23 current cannabis users and 34 non-users free of illicit drugs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7525",
    "Sentence": "We administered cognitive measures of attention, executive functions, memory and learning to three groups of participants: 37 current polydrug users with regular <\\entity><\\entity> of ecstasy and cannabis, 23 current cannabis users and 34 non-users free of illicit drugs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7526",
    "Sentence": "We administered cognitive measures of attention, executive functions, memory and learning to three groups of participants: 37 current polydrug users with regular consumption of <\\entity><\\entity> and cannabis, 23 current cannabis users and 34 non-users free of illicit drugs.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7527",
    "Sentence": "We administered cognitive measures of attention, executive functions, memory and learning to three groups of participants: 37 current polydrug users with regular consumption of ecstasy and <\\entity><\\entity>, 23 current <\\entity><\\entity> users and 34 non-users free of illicit drugs.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7528",
    "Sentence": "We administered cognitive measures of attention, executive functions, memory and learning to three groups of participants: 37 current polydrug users with regular consumption of ecstasy and <\\entity><\\entity>, 23 current <\\entity><\\entity> users and 34 non-users free of illicit drugs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7529",
    "Sentence": "We administered cognitive measures of attention, executive functions, memory and learning to three groups of participants: 37 current polydrug users with regular consumption of ecstasy and <\\entity><\\entity>, 23 current <\\entity><\\entity> users and 34 non-users free of illicit drugs.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7530",
    "Sentence": "We administered cognitive measures of attention, executive functions, memory and learning to three groups of participants: 37 current polydrug users with regular consumption of ecstasy and <\\entity><\\entity>, 23 current <\\entity><\\entity> users and 34 non-users free of illicit drugs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7531",
    "Sentence": "At baseline, <\\entity><\\entity> polydrug users showed significantly poorer performance than cannabis users and non-drug using controls in a measure of semantic word fluency.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7532",
    "Sentence": "At baseline, ecstasy polydrug users showed significantly poorer performance than <\\entity><\\entity> users and non-drug using controls in a measure of semantic word fluency.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7533",
    "Sentence": "At baseline, ecstasy polydrug users showed significantly poorer performance than <\\entity><\\entity> users and non-drug using controls in a measure of semantic word fluency.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7534",
    "Sentence": "When <\\entity><\\entity> users were classified according to lifetime use of <\\entity><\\entity>, the more severe users (more than 100 tablets) showed additional deficits on episodic memory.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7535",
    "Sentence": "When <\\entity><\\entity> users were classified according to lifetime use of <\\entity><\\entity>, the more severe users (more than 100 tablets) showed additional deficits on episodic memory.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7536",
    "Sentence": "When ecstasy users were classified according to lifetime use of ecstasy, the more severe users (more than 100 tablets) showed additional <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7537",
    "Sentence": "After two years <\\entity><\\entity> users showed persistent deficits on verbal fluency, working memory and processing speed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7538",
    "Sentence": "After two years ecstasy users showed persistent <\\entity><\\entity>, working memory and processing speed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7539",
    "Sentence": "After two years ecstasy users showed persistent deficits on verbal fluency, <\\entity><\\entity> and processing speed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7540",
    "Sentence": "After two years ecstasy users showed persistent deficits on verbal fluency, working memory and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7541",
    "Sentence": "Our findings support that <\\entity><\\entity> use, or <\\entity><\\entity>/cannabis synergic effects, are responsible for the sub-clinical deficits observed in <\\entity><\\entity> polydrug users, and provides additional evidence for long-term cognitive impairment owing to <\\entity><\\entity> consumption in the context of polydrug use.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7542",
    "Sentence": "Our findings support that ecstasy use, or <\\entity><\\entity> synergic effects, are responsible for the sub-clinical deficits observed in ecstasy polydrug users, and provides additional evidence for long-term cognitive impairment owing to ecstasy consumption in the context of polydrug use.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7543",
    "Sentence": "Our findings support that ecstasy use, or <\\entity><\\entity> synergic effects, are responsible for the sub-clinical deficits observed in ecstasy polydrug users, and provides additional evidence for long-term cognitive impairment owing to ecstasy consumption in the context of polydrug use.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7544",
    "Sentence": "Our findings support that ecstasy use, or ecstasy/cannabis synergic effects, are responsible for the sub-clinical <\\entity><\\entity> observed in ecstasy polydrug users, and provides additional evidence for long-term cognitive impairment owing to ecstasy consumption in the context of polydrug use.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7545",
    "Sentence": "Our findings support that <\\entity><\\entity> use, or <\\entity><\\entity>/cannabis synergic effects, are responsible for the sub-clinical deficits observed in <\\entity><\\entity> polydrug users, and provides additional evidence for long-term cognitive impairment owing to <\\entity><\\entity> consumption in the context of polydrug use.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7546",
    "Sentence": "Our findings support that ecstasy use, or ecstasy/cannabis synergic effects, are responsible for the sub-clinical deficits observed in ecstasy polydrug users, and provides additional evidence for <\\entity><\\entity> owing to ecstasy consumption in the context of polydrug use.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7547",
    "Sentence": "Our findings support that <\\entity><\\entity> use, or <\\entity><\\entity>/cannabis synergic effects, are responsible for the sub-clinical deficits observed in <\\entity><\\entity> polydrug users, and provides additional evidence for long-term cognitive impairment owing to <\\entity><\\entity> consumption in the context of polydrug use.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7548",
    "Sentence": "Our findings support that ecstasy use, or ecstasy/cannabis synergic effects, are responsible for the sub-clinical deficits observed in ecstasy polydrug users, and provides additional evidence for long-term cognitive impairment owing to ecstasy <\\entity><\\entity> in the context of polydrug use.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7549",
    "Sentence": "Our findings support that ecstasy use, or ecstasy/cannabis synergic effects, are responsible for the sub-clinical deficits observed in ecstasy <\\entity><\\entity>rs, and provides additional evidence for long-term cognitive impairment owing to ecstasy consumption in the context of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7550",
    "Sentence": "In humans long-term recreational use of <\\entity><\\entity> has been mainly associated with learning and memory impairments.",
    "Label": ""
  },
  {
    "id": "7551",
    "Sentence": "In humans long-term recreational use of ecstasy has been mainly associated with learning and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7553",
    "Sentence": "In humans long-term recreational use of <\\entity><\\entity> has been mainly associated with learning and memory impairments.",
    "Label": ""
  },
  {
    "id": "7554",
    "Sentence": "In humans long-term recreational use of ecstasy has been mainly associated with <\\entity><\\entity> and memory impairments.",
    "Label": ""
  },
  {
    "id": "7556",
    "Sentence": "When <\\entity><\\entity> users were classified according to lifetime use of <\\entity><\\entity>, the more severe users (more than 100 tablets) showed additional deficits on episodic memory.",
    "Label": ""
  },
  {
    "id": "7557",
    "Sentence": "When ecstasy users were classified according to lifetime use of ecstasy, the more severe users (more than 100 tablets) showed additional <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7559",
    "Sentence": "After two years <\\entity><\\entity> users showed persistent deficits on verbal fluency, working memory and processing speed.",
    "Label": ""
  },
  {
    "id": "7560",
    "Sentence": "After two years ecstasy users showed persistent <\\entity><\\entity>, working memory and processing speed.",
    "Label": ""
  },
  {
    "id": "7562",
    "Sentence": "After two years <\\entity><\\entity> users showed persistent deficits on verbal fluency, working memory and processing speed.",
    "Label": ""
  },
  {
    "id": "7563",
    "Sentence": "After two years ecstasy users showed persistent deficits on verbal fluency, <\\entity><\\entity> and processing speed.",
    "Label": ""
  },
  {
    "id": "7565",
    "Sentence": "After two years <\\entity><\\entity> users showed persistent deficits on verbal fluency, working memory and processing speed.",
    "Label": ""
  },
  {
    "id": "7566",
    "Sentence": "After two years ecstasy users showed persistent deficits on verbal fluency, working memory and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7568",
    "Sentence": "Our findings support that <\\entity><\\entity> use, or <\\entity><\\entity>/cannabis synergic effects, are responsible for the sub-clinical deficits observed in <\\entity><\\entity> polydrug users, and provides additional evidence for long-term cognitive impairment owing to <\\entity><\\entity> consumption in the context of polydrug use.",
    "Label": ""
  },
  {
    "id": "7569",
    "Sentence": "Our findings support that ecstasy use, or ecstasy/cannabis synergic effects, are responsible for the sub-clinical deficits observed in ecstasy polydrug users, and provides additional evidence for <\\entity><\\entity> owing to ecstasy consumption in the context of polydrug use.",
    "Label": ""
  },
  {
    "id": "7571",
    "Sentence": "Our findings support that ecstasy use, or <\\entity><\\entity> synergic effects, are responsible for the sub-clinical deficits observed in ecstasy polydrug users, and provides additional evidence for long-term cognitive impairment owing to ecstasy consumption in the context of polydrug use.",
    "Label": ""
  },
  {
    "id": "7572",
    "Sentence": "Our findings support that ecstasy use, or ecstasy/cannabis synergic effects, are responsible for the sub-clinical deficits observed in ecstasy polydrug users, and provides additional evidence for <\\entity><\\entity> owing to ecstasy consumption in the context of polydrug use.",
    "Label": ""
  },
  {
    "id": "7574",
    "Sentence": "Our findings support that ecstasy use, or <\\entity><\\entity> synergic effects, are responsible for the sub-clinical deficits observed in ecstasy polydrug users, and provides additional evidence for long-term cognitive impairment owing to ecstasy consumption in the context of polydrug use.",
    "Label": ""
  },
  {
    "id": "7575",
    "Sentence": "Our findings support that ecstasy use, or ecstasy/cannabis synergic effects, are responsible for the sub-clinical <\\entity><\\entity> observed in ecstasy polydrug users, and provides additional evidence for long-term cognitive impairment owing to ecstasy consumption in the context of polydrug use.",
    "Label": ""
  },
  {
    "id": "7581",
    "Sentence": "Dose-response relationships between occupational exposure to <\\entity><\\entity>, diesel exhaust and nitrogen oxides and lung function: cross-sectional and longitudinal study in two salt mines.OBJECTIVE: Several studies have shown that underground salt miners may have an increased incidence of chest symptoms and sometimes decreased lung function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7582",
    "Sentence": "Dose-response relationships between occupational exposure to potash, <\\entity><\\entity> and nitrogen oxides and lung function: cross-sectional and longitudinal study in two salt mines.OBJECTIVE: Several studies have shown that underground salt miners may have an increased incidence of chest symptoms and sometimes decreased lung function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7583",
    "Sentence": "Dose-response relationships between occupational exposure to potash, <\\entity><\\entity> and nitrogen oxides and lung function: cross-sectional and longitudinal study in two salt mines.OBJECTIVE: Several studies have shown that underground salt miners may have an increased incidence of chest symptoms and sometimes decreased lung function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7584",
    "Sentence": "Dose-response relationships between occupational exposure to potash, diesel exhaust and <\\entity><\\entity> and lung function: cross-sectional and longitudinal study in two salt mines.OBJECTIVE: Several studies have shown that underground salt miners may have an increased incidence of chest symptoms and sometimes decreased lung function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7585",
    "Sentence": "Dose-response relationships between occupational exposure to potash, diesel exhaust and nitrogen oxides and lung function: cross-sectional and longitudinal study in two <\\entity><\\entity> mines.OBJECTIVE: Several studies have shown that underground <\\entity><\\entity> miners may have an increased incidence of chest symptoms and sometimes decreased lung function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7586",
    "Sentence": "Dose-response relationships between occupational exposure to potash, diesel exhaust and nitrogen oxides and lung function: cross-sectional and longitudinal study in two <\\entity><\\entity> mines.OBJECTIVE: Several studies have shown that underground <\\entity><\\entity> miners may have an increased incidence of chest symptoms and sometimes decreased lung function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7587",
    "Sentence": "Dose-response relationships between occupational exposure to potash, diesel exhaust and nitrogen oxides and lung function: cross-sectional and longitudinal study in two salt mines.OBJECTIVE: Several studies have shown that underground salt miners may have an increased incidence of <\\entity><\\entity> and sometimes decreased lung function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7588",
    "Sentence": "Dose-response relationships between occupational exposure to potash, diesel exhaust and nitrogen oxides and lung function: cross-sectional and longitudinal study in two salt mines.OBJECTIVE: Several studies have shown that underground salt miners may have an increased incidence of chest symptoms and sometimes <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7589",
    "Sentence": "Miners of two <\\entity><\\entity> mines were investigated to evaluate relationships between the lung function and the workplace exposure.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7590",
    "Sentence": "The effect of <\\entity><\\entity> (NO) and nitrogen dioxide (NO(2)) was investigated in view of the recent debate on European occupational exposure limits.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7591",
    "Sentence": "The effect of nitrogen monoxide (<\\entity><\\entity>) and nitrogen dioxide (<\\entity><\\entity>(2)) was investigated in view of the recent debate on European occupational exposure limits.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7592",
    "Sentence": "The effect of nitrogen monoxide (NO) and <\\entity><\\entity> (NO(2)) was investigated in view of the recent debate on European occupational exposure limits.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7593",
    "Sentence": "The effect of nitrogen monoxide (NO) and nitrogen dioxide (<\\entity><\\entity>) was investigated in view of the recent debate on European occupational exposure limits.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7594",
    "Sentence": "Personal lifetime exposure doses of <\\entity><\\entity>, diesel exhaust, NO(2) and NO were calculated for all miners.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7595",
    "Sentence": "Personal lifetime exposure doses of salt dust, <\\entity><\\entity>, NO(2) and NO were calculated for all miners.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7596",
    "Sentence": "Personal lifetime exposure doses of salt dust, <\\entity><\\entity>, NO(2) and NO were calculated for all miners.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7597",
    "Sentence": "Personal lifetime exposure doses of salt dust, diesel exhaust, <\\entity><\\entity> and NO were calculated for all miners.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7598",
    "Sentence": "Personal lifetime exposure doses of salt dust, diesel exhaust, <\\entity><\\entity>(2) and <\\entity><\\entity> were calculated for all miners.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7599",
    "Sentence": "Dose-response relationships were calculated by multiple <\\entity><\\entity> analysis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7600",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) <\\entity><\\entity>, 2.4/0.8 mg/m(3) respirable dust, 0.09/0.09 mg/m(3) diesel exhaust, 0.4/0.5 ppm NO(2) and 1.7/1.4 ppm NO (mine A/B).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7601",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) <\\entity><\\entity>, 2.4/0.8 mg/m(3) respirable dust, 0.09/0.09 mg/m(3) diesel exhaust, 0.4/0.5 ppm NO(2) and 1.7/1.4 ppm NO (mine A/B).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7602",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) inhalable dust, 2.4/0.8 mg/m(3) <\\entity><\\entity>, 0.09/0.09 mg/m(3) diesel exhaust, 0.4/0.5 ppm NO(2) and 1.7/1.4 ppm NO (mine A/B).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7603",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) inhalable dust, 2.4/0.8 mg/m(3) respirable dust, 0.09/0.09 mg/m(3) <\\entity><\\entity>, 0.4/0.5 ppm NO(2) and 1.7/1.4 ppm NO (mine A/B).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7604",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) inhalable dust, 2.4/0.8 mg/m(3) respirable dust, 0.09/0.09 mg/m(3) <\\entity><\\entity>, 0.4/0.5 ppm NO(2) and 1.7/1.4 ppm NO (mine A/B).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7605",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) inhalable dust, 2.4/0.8 mg/m(3) respirable dust, 0.09/0.09 mg/m(3) diesel exhaust, 0.4/0.5 ppm <\\entity><\\entity> and 1.7/1.4 ppm NO (mine A/B).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7606",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) inhalable dust, 2.4/0.8 mg/m(3) respirable dust, 0.09/0.09 mg/m(3) diesel exhaust, 0.4/0.5 ppm <\\entity><\\entity>(2) and 1.7/1.4 ppm <\\entity><\\entity> (mine A/B).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7607",
    "Sentence": "Exposure was related to <\\entity><\\entity> of chronic bronchitis only in mine B.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7608",
    "Sentence": "Exposure was related to symptoms of <\\entity><\\entity> only in mine B.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7609",
    "Sentence": "CONCLUSION: The effects found in both mines indicate that the mixed exposure can cause <\\entity><\\entity> in salt miners exposed over a long time.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7610",
    "Sentence": "CONCLUSION: The effects found in both mines indicate that the mixed exposure can cause lung function disorders in <\\entity><\\entity> miners exposed over a long time.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7611",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) <\\entity><\\entity>, 2.4/0.8 mg/m(3) respirable dust, 0.09/0.09 mg/m(3) diesel exhaust, 0.4/0.5 ppm NO(2) and 1.7/1.4 ppm NO (mine A/B).",
    "Label": ""
  },
  {
    "id": "7612",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) inhalable dust, 2.4/0.8 mg/m(3) respirable dust, 0.09/0.09 mg/m(3) <\\entity><\\entity>, 0.4/0.5 ppm NO(2) and 1.7/1.4 ppm NO (mine A/B).",
    "Label": ""
  },
  {
    "id": "7614",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) inhalable dust, 2.4/0.8 mg/m(3) respirable dust, 0.09/0.09 mg/m(3) diesel exhaust, 0.4/0.5 ppm <\\entity><\\entity>(2) and 1.7/1.4 ppm <\\entity><\\entity> (mine A/B).",
    "Label": ""
  },
  {
    "id": "7615",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) <\\entity><\\entity>, 2.4/0.8 mg/m(3) respirable dust, 0.09/0.09 mg/m(3) diesel exhaust, 0.4/0.5 ppm NO(2) and 1.7/1.4 ppm NO (mine A/B).",
    "Label": ""
  },
  {
    "id": "7617",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) inhalable dust, 2.4/0.8 mg/m(3) respirable dust, 0.09/0.09 mg/m(3) <\\entity><\\entity>, 0.4/0.5 ppm NO(2) and 1.7/1.4 ppm NO (mine A/B).",
    "Label": ""
  },
  {
    "id": "7618",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) <\\entity><\\entity>, 2.4/0.8 mg/m(3) respirable dust, 0.09/0.09 mg/m(3) diesel exhaust, 0.4/0.5 ppm NO(2) and 1.7/1.4 ppm NO (mine A/B).",
    "Label": ""
  },
  {
    "id": "7620",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) inhalable dust, 2.4/0.8 mg/m(3) <\\entity><\\entity>, 0.09/0.09 mg/m(3) diesel exhaust, 0.4/0.5 ppm NO(2) and 1.7/1.4 ppm NO (mine A/B).",
    "Label": ""
  },
  {
    "id": "7621",
    "Sentence": "The personal concentrations related to this effect were 12.6/7.1 mg/m(3) <\\entity><\\entity>, 2.4/0.8 mg/m(3) respirable dust, 0.09/0.09 mg/m(3) diesel exhaust, 0.4/0.5 ppm NO(2) and 1.7/1.4 ppm NO (mine A/B).",
    "Label": ""
  },
  {
    "id": "7627",
    "Sentence": "Analysis of preincisional and postincisional treatment with <\\entity><\\entity> clonidine regarding analgesic consumption and hemodynamic stability in surgical patients.Preemptive analgesia aims to prevent the sensitization of central nervous system, hence the development of pathologic pain after tissular injury.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7628",
    "Sentence": "Analysis of preincisional and postincisional treatment with <\\entity><\\entity> clonidine regarding analgesic consumption and hemodynamic stability in surgical patients.Preemptive analgesia aims to prevent the sensitization of central nervous system, hence the development of pathologic pain after tissular injury.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7629",
    "Sentence": "Analysis of preincisional and postincisional treatment with alpha2-adrenoreceptor agonist <\\entity><\\entity> regarding analgesic consumption and hemodynamic stability in surgical patients.Preemptive analgesia aims to prevent the sensitization of central nervous system, hence the development of pathologic pain after tissular injury.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7630",
    "Sentence": "The aim of the study was to assess the effect of preincisional <\\entity><\\entity> treatment on analgesic consumption and hemodynamic stability compared to <\\entity><\\entity> administered at the end of the operation and control group.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7631",
    "Sentence": "The aim of the study was to assess the effect of preincisional <\\entity><\\entity> treatment on analgesic consumption and hemodynamic stability compared to <\\entity><\\entity> administered at the end of the operation and control group.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7632",
    "Sentence": "Ninety-one patients undergoing elective colorectal surgery were randomly assigned to four groups: <\\entity><\\entity> before operation, epidural clonidine before operation, epidural clonidine at the end of operation, and epidural saline before operation as a control group.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7633",
    "Sentence": "Ninety-one patients undergoing elective colorectal surgery were randomly assigned to four groups: peroral clonidine before operation, <\\entity><\\entity> before operation, <\\entity><\\entity> at the end of operation, and epidural saline before operation as a control group.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7634",
    "Sentence": "Ninety-one patients undergoing elective colorectal surgery were randomly assigned to four groups: peroral clonidine before operation, <\\entity><\\entity> before operation, <\\entity><\\entity> at the end of operation, and epidural saline before operation as a control group.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7635",
    "Sentence": "Ninety-one patients undergoing elective colorectal surgery were randomly assigned to four groups: peroral clonidine before operation, epidural clonidine before operation, epidural clonidine at the end of operation, and <\\entity><\\entity> before operation as a control group.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7636",
    "Sentence": "After the operation, patient-controlled analgesia with <\\entity><\\entity> was instituted.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7637",
    "Sentence": "Significant differences (p < 0.05) in postoperative systolic blood pressure, with highest hemodynamic stability was observed at 1 h and 6 h in the group of patients administered <\\entity><\\entity> before operation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7638",
    "Sentence": "The cumulative consumption of analgesics assessed at the end of the study period was significantly reduced (p < 0.05) in the group of patients administered <\\entity><\\entity> before operation (8.40 +/- 3.74, respectively) as compared with the peroral clonidine before operation (16.79 +/- 5.75, respectively), <\\entity><\\entity> at the end of the operation (11.11 +/- 4.24, respectively) and control group of patients (18.00 +/- 6.45, respectively).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7639",
    "Sentence": "The cumulative consumption of analgesics assessed at the end of the study period was significantly reduced (p < 0.05) in the group of patients administered epidural clonidine before operation (8.40 +/- 3.74, respectively) as compared with the <\\entity><\\entity> before operation (16.79 +/- 5.75, respectively), epidural clonidine at the end of the operation (11.11 +/- 4.24, respectively) and control group of patients (18.00 +/- 6.45, respectively).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7640",
    "Sentence": "The cumulative consumption of analgesics assessed at the end of the study period was significantly reduced (p < 0.05) in the group of patients administered <\\entity><\\entity> before operation (8.40 +/- 3.74, respectively) as compared with the peroral clonidine before operation (16.79 +/- 5.75, respectively), <\\entity><\\entity> at the end of the operation (11.11 +/- 4.24, respectively) and control group of patients (18.00 +/- 6.45, respectively).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7641",
    "Sentence": "Preincisional administration of <\\entity><\\entity> was associated with a significantly lower analgesic use, lower cumulative analgesic consumption and greater hemodynamic stability, in comparison with other groups.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7642",
    "Sentence": "Analysis of preincisional and postincisional treatment with alpha2-adrenoreceptor agonist <\\entity><\\entity> regarding analgesic consumption and hemodynamic stability in surgical patients.Preemptive analgesia aims to prevent the sensitization of central nervous system, hence the development of pathologic pain after tissular injury.",
    "Label": ""
  },
  {
    "id": "7643",
    "Sentence": "Analysis of preincisional and postincisional treatment with <\\entity><\\entity> clonidine regarding analgesic consumption and hemodynamic stability in surgical patients.Preemptive analgesia aims to prevent the sensitization of central nervous system, hence the development of pathologic pain after tissular injury.",
    "Label": ""
  },
  {
    "id": "7649",
    "Sentence": "<\\entity><\\entity> use in children and adolescents.BACKGROUND: Although the role of clozapine is well established for treatment-resistant schizophrenia, it is rarely used in pediatric populations, mainly due to its potentially serious adverse effects.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7650",
    "Sentence": "Clozapine use in children and adolescents.BACKGROUND: Although the role of <\\entity><\\entity> is well established for treatment-resistant schizophrenia, it is rarely used in pediatric populations, mainly due to its potentially serious adverse effects.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7651",
    "Sentence": "Clozapine use in children and adolescents.BACKGROUND: Although the role of clozapine is well established for <\\entity><\\entity>, it is rarely used in pediatric populations, mainly due to its potentially serious adverse effects.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7652",
    "Sentence": "Clozapine use in children and adolescents.BACKGROUND: Although the role of clozapine is well established for treatment-resistant schizophrenia, it is rarely used in pediatric populations, mainly due to its potentially serious <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7653",
    "Sentence": "OBJECTIVE: To summarize practical aspects of use of <\\entity><\\entity> in treating children with schizophrenia and management of associated adverse effects.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7654",
    "Sentence": "OBJECTIVE: To summarize practical aspects of use of clozapine in treating children with <\\entity><\\entity> and management of associated adverse effects.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7655",
    "Sentence": "OBJECTIVE: To summarize practical aspects of use of clozapine in treating children with schizophrenia and management of associated <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7656",
    "Sentence": "METHODS: Available studies in the literature using <\\entity><\\entity> in the pediatric population are summarized and the NIMH experience in treating refractory childhood-onset schizophrenia cases with <\\entity><\\entity> is discussed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7657",
    "Sentence": "METHODS: Available studies in the literature using clozapine in the pediatric population are summarized and the NIMH experience in treating <\\entity><\\entity> cases with clozapine is discussed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7658",
    "Sentence": "METHODS: Available studies in the literature using <\\entity><\\entity> in the pediatric population are summarized and the NIMH experience in treating refractory childhood-onset schizophrenia cases with <\\entity><\\entity> is discussed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7659",
    "Sentence": "CONCLUSION: Despite a higher incidence of <\\entity><\\entity> in children, clozapine appears to be a uniquely beneficial second-line agent for treating children with refractory schizophrenia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7660",
    "Sentence": "CONCLUSION: Despite a higher incidence of adverse effects in children, <\\entity><\\entity> appears to be a uniquely beneficial second-line agent for treating children with refractory schizophrenia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7661",
    "Sentence": "CONCLUSION: Despite a higher incidence of adverse effects in children, clozapine appears to be a uniquely beneficial second-line agent for treating children with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7662",
    "Sentence": "Clozapine use in children and adolescents.BACKGROUND: Although the role of <\\entity><\\entity> is well established for treatment-resistant schizophrenia, it is rarely used in pediatric populations, mainly due to its potentially serious adverse effects.",
    "Label": ""
  },
  {
    "id": "7663",
    "Sentence": "Clozapine use in children and adolescents.BACKGROUND: Although the role of clozapine is well established for <\\entity><\\entity>, it is rarely used in pediatric populations, mainly due to its potentially serious adverse effects.",
    "Label": ""
  },
  {
    "id": "7665",
    "Sentence": "OBJECTIVE: To summarize practical aspects of use of <\\entity><\\entity> in treating children with schizophrenia and management of associated adverse effects.",
    "Label": ""
  },
  {
    "id": "7666",
    "Sentence": "OBJECTIVE: To summarize practical aspects of use of clozapine in treating children with <\\entity><\\entity> and management of associated adverse effects.",
    "Label": ""
  },
  {
    "id": "7668",
    "Sentence": "METHODS: Available studies in the literature using <\\entity><\\entity> in the pediatric population are summarized and the NIMH experience in treating refractory childhood-onset schizophrenia cases with <\\entity><\\entity> is discussed.",
    "Label": ""
  },
  {
    "id": "7669",
    "Sentence": "METHODS: Available studies in the literature using clozapine in the pediatric population are summarized and the NIMH experience in treating <\\entity><\\entity> cases with clozapine is discussed.",
    "Label": ""
  },
  {
    "id": "7671",
    "Sentence": "CONCLUSION: Despite a higher incidence of adverse effects in children, <\\entity><\\entity> appears to be a uniquely beneficial second-line agent for treating children with refractory schizophrenia.",
    "Label": ""
  },
  {
    "id": "7672",
    "Sentence": "CONCLUSION: Despite a higher incidence of adverse effects in children, clozapine appears to be a uniquely beneficial second-line agent for treating children with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "7678",
    "Sentence": "<\\entity><\\entity>: a new promising agent in the treatment of infections due to Gram-positive pathogens.Nosocomial and community-acquired infections caused by Gram-positive pathogens continue to be a challenge, mainly due to the increasing rates of resistance among Staphylococcus spp.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7679",
    "Sentence": "Oritavancin: a new promising agent in the treatment of <\\entity><\\entity>.Nosocomial and community-acquired infections caused by Gram-positive pathogens continue to be a challenge, mainly due to the increasing rates of resistance among Staphylococcus spp.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7680",
    "Sentence": "Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.<\\entity><\\entity> and community-acquired infections caused by Gram-positive pathogens continue to be a challenge, mainly due to the increasing rates of resistance among Staphylococcus spp.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7681",
    "Sentence": "Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Nosocomial and <\\entity><\\entity> continue to be a challenge, mainly due to the increasing rates of resistance among Staphylococcus spp.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7682",
    "Sentence": "Oritavancin: a new promising agent in the treatment of <\\entity><\\entity> due to Gram-positive pathogens.Nosocomial and community-acquired <\\entity><\\entity> caused by Gram-positive pathogens continue to be a challenge, mainly due to the increasing rates of resistance among Staphylococcus spp.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7683",
    "Sentence": "Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Nosocomial and community-acquired infections caused by Gram-positive pathogens continue to be a challenge, mainly due to the increasing rates of resistance among <\\entity><\\entity> spp.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7684",
    "Sentence": "Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Nosocomial and community-acquired infections caused by Gram-positive pathogens continue to be a challenge, mainly due to the increasing rates of resistance among Staphylococcus <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7685",
    "Sentence": "and Enterococcus <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7686",
    "Sentence": "<\\entity><\\entity>, a new parenteral semisynthetic glycopeptide, possessing rapid bactericidal action and an antimicrobial spectrum containing all Gram-positive pathogens (streptococci, staphylococci, enterococci--vancomycin-resistant enterococci included--and Clostridia spp.) irrespective of their resistance status to the precursor molecule of vancomycin, is expected to file a new drug application by the first trimester of 2008.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7687",
    "Sentence": "Oritavancin, a new <\\entity><\\entity>, possessing rapid bactericidal action and an antimicrobial spectrum containing all Gram-positive pathogens (streptococci, staphylococci, enterococci--vancomycin-resistant enterococci included--and Clostridia spp.) irrespective of their resistance status to the precursor molecule of vancomycin, is expected to file a new drug application by the first trimester of 2008.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7688",
    "Sentence": "Oritavancin, a new parenteral semisynthetic glycopeptide, <\\entity><\\entity> rapid bactericidal action and an antimicrobial spectrum containing all Gram-positive pathogens (streptococci, staphylococci, enterococci--vancomycin-resistant enterococci included--and Clostridia spp.) irrespective of their resistance status to the precursor molecule of vancomycin, is expected to file a new drug application by the first trimester of 2008.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7689",
    "Sentence": "Oritavancin, a new parenteral semisynthetic glycopeptide, possessing rapid bactericidal action and an antimicrobial spectrum containing all Gram-positive pathogens (streptococci, <\\entity><\\entity>, enterococci--vancomycin-resistant enterococci included--and Clostridia spp.) irrespective of their resistance status to the precursor molecule of vancomycin, is expected to file a new drug application by the first trimester of 2008.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7690",
    "Sentence": "Oritavancin, a new parenteral semisynthetic glycopeptide, possessing rapid bactericidal action and an antimicrobial spectrum containing all Gram-positive pathogens (streptococci, staphylococci, enterococci--vancomycin-resistant enterococci included--and Clostridia <\\entity><\\entity>.) irrespective of their resistance status to the precursor molecule of vancomycin, is expected to file a new drug application by the first trimester of 2008.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7691",
    "Sentence": "Oritavancin, a new parenteral semisynthetic glycopeptide, possessing rapid bactericidal action and an antimicrobial spectrum containing all Gram-positive pathogens (streptococci, staphylococci, enterococci--<\\entity><\\entity>-resistant enterococci included--and Clostridia spp.) irrespective of their resistance status to the precursor molecule of <\\entity><\\entity>, is expected to file a new drug application by the first trimester of 2008.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7692",
    "Sentence": "Once-daily dosing, good penetration into macrophages, in vitro activity against bacteria embedded in biofilms and low adverse reaction potential are further considered as <\\entity><\\entity>'s advantages over existing drugs.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7693",
    "Sentence": "<\\entity><\\entity>: a new promising agent in the treatment of infections due to Gram-positive pathogens.Nosocomial and community-acquired infections caused by Gram-positive pathogens continue to be a challenge, mainly due to the increasing rates of resistance among Staphylococcus spp.",
    "Label": ""
  },
  {
    "id": "7694",
    "Sentence": "Oritavancin: a new promising agent in the treatment of <\\entity><\\entity>.Nosocomial and community-acquired infections caused by Gram-positive pathogens continue to be a challenge, mainly due to the increasing rates of resistance among Staphylococcus spp.",
    "Label": ""
  },
  {
    "id": "7696",
    "Sentence": "Oritavancin, a new parenteral semisynthetic glycopeptide, possessing rapid bactericidal action and an antimicrobial spectrum containing all Gram-positive pathogens (streptococci, staphylococci, enterococci--<\\entity><\\entity>-resistant enterococci included--and Clostridia spp.) irrespective of their resistance status to the precursor molecule of <\\entity><\\entity>, is expected to file a new drug application by the first trimester of 2008.",
    "Label": ""
  },
  {
    "id": "7697",
    "Sentence": "Oritavancin, a new parenteral semisynthetic glycopeptide, possessing rapid bactericidal action and an antimicrobial spectrum containing all Gram-positive pathogens (streptococci, <\\entity><\\entity>, enterococci--vancomycin-resistant enterococci included--and Clostridia spp.) irrespective of their resistance status to the precursor molecule of vancomycin, is expected to file a new drug application by the first trimester of 2008.",
    "Label": ""
  },
  {
    "id": "7699",
    "Sentence": "Oritavancin, a new parenteral semisynthetic glycopeptide, possessing rapid bactericidal action and an antimicrobial spectrum containing all Gram-positive pathogens (streptococci, staphylococci, enterococci--<\\entity><\\entity>-resistant enterococci included--and Clostridia spp.) irrespective of their resistance status to the precursor molecule of <\\entity><\\entity>, is expected to file a new drug application by the first trimester of 2008.",
    "Label": ""
  },
  {
    "id": "7700",
    "Sentence": "Oritavancin, a new parenteral semisynthetic glycopeptide, <\\entity><\\entity> rapid bactericidal action and an antimicrobial spectrum containing all Gram-positive pathogens (streptococci, staphylococci, enterococci--vancomycin-resistant enterococci included--and Clostridia spp.) irrespective of their resistance status to the precursor molecule of vancomycin, is expected to file a new drug application by the first trimester of 2008.",
    "Label": ""
  },
  {
    "id": "7706",
    "Sentence": "Inhibition of <\\entity><\\entity> (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as <\\entity><\\entity> (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7707",
    "Sentence": "Inhibition of P-glycoprotein (<\\entity><\\entity>)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7708",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and <\\entity><\\entity> 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), <\\entity><\\entity> (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7709",
    "Sentence": "Inhibition of P-glycoprotein (ABCB<\\entity><\\entity>)- and multidrug resistance-associated protein <\\entity><\\entity> (ABCC<\\entity><\\entity>)-mediated transport by the orally administered inhibitor, CBT-<\\entity><\\entity>((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP<\\entity><\\entity>), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7710",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (<\\entity><\\entity>)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7711",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, <\\entity><\\entity>.Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7712",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of <\\entity><\\entity>-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7713",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (<\\entity><\\entity>, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7714",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (<\\entity><\\entity>, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7715",
    "Sentence": "Inhibition of <\\entity><\\entity> (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as <\\entity><\\entity> (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7716",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (<\\entity><\\entity>), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7717",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and <\\entity><\\entity> 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), <\\entity><\\entity> (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7718",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (<\\entity><\\entity>), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7719",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or <\\entity><\\entity>, is known to confer a drug-resistant phenotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7720",
    "Sentence": "<\\entity><\\entity> is a bisbenzylisoquinoline plant alkyloid currently in development as a Pgp inhibitor.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7721",
    "Sentence": "<\\entity><\\entity> is a bisbenzylisoquinoline plant alkyloid currently in development as a Pgp inhibitor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7722",
    "Sentence": "CBT-1 is a <\\entity><\\entity> currently in development as a Pgp inhibitor.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7723",
    "Sentence": "CBT-1 is a bisbenzylisoquinoline plant alkyloid currently in development as a <\\entity><\\entity> inhibitor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7724",
    "Sentence": "CBT-1 is a bisbenzylisoquinoline plant alkyloid currently in development as a <\\entity><\\entity> inhibitor.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7725",
    "Sentence": "We characterized its interactions with the three major <\\entity><\\entity> associated with drug resistance - Pgp, MRP1 and ABCG2 - and compared it to other known inhibitors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7726",
    "Sentence": "We characterized its interactions with the three major <\\entity><\\entity> associated with drug resistance - Pgp, MRP1 and ABCG2 - and compared it to other known inhibitors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7727",
    "Sentence": "We characterized its interactions with the three major ABC transporters associated with drug resistance - <\\entity><\\entity>, MRP1 and ABCG2 - and compared it to other known inhibitors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7728",
    "Sentence": "We characterized its interactions with the three major ABC transporters associated with drug resistance - Pgp, <\\entity><\\entity> and ABCG2 - and compared it to other known inhibitors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7729",
    "Sentence": "We characterized its interactions with the three major ABC transporters associated with drug resistance - Pgp, MRP1 and <\\entity><\\entity> - and compared it to other known inhibitors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7730",
    "Sentence": "<\\entity><\\entity> completely inhibited rhodamine 123 transport from Pgp-overexpressing cells at a concentration of 1muM.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7731",
    "Sentence": "<\\entity><\\entity> completely inhibited rhodamine 123 transport from Pgp-overexpressing cells at a concentration of 1muM.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7732",
    "Sentence": "CBT-1 completely inhibited <\\entity><\\entity> transport from Pgp-overexpressing cells at a concentration of 1muM.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7733",
    "Sentence": "CBT-1 completely inhibited <\\entity><\\entity> transport from Pgp-overexpressing cells at a concentration of 1muM.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7734",
    "Sentence": "CBT-1 completely inhibited rhodamine 123 transport from <\\entity><\\entity>-overexpressing cells at a concentration of 1muM.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7735",
    "Sentence": "Additionally, 1 microM completely reversed <\\entity><\\entity>-mediated resistance to vinblastine, paclitaxel and depsipeptide in SW620 Ad20 cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7736",
    "Sentence": "Additionally, 1 microM completely reversed Pgp-mediated resistance to <\\entity><\\entity>, paclitaxel and depsipeptide in SW620 Ad20 cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7737",
    "Sentence": "Additionally, 1 microM completely reversed Pgp-mediated resistance to vinblastine, <\\entity><\\entity> and depsipeptide in SW620 Ad20 cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7738",
    "Sentence": "Additionally, 1 microM completely reversed Pgp-mediated resistance to vinblastine, paclitaxel and <\\entity><\\entity> in SW620 Ad20 cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7739",
    "Sentence": "<\\entity><\\entity> was found to compete [(125)I]-IAAP labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of <\\entity><\\entity> (<1 microM) stimulated Pgp-mediated ATP hydrolysis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7740",
    "Sentence": "<\\entity><\\entity> was found to compete [(125)I]-IAAP labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of <\\entity><\\entity> (<1 microM) stimulated Pgp-mediated ATP hydrolysis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7741",
    "Sentence": "CBT-1 was found to compete <\\entity><\\entity> labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (<1 microM) stimulated Pgp-mediated ATP hydrolysis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7742",
    "Sentence": "CBT-1 was found to compete [(125)I]-IAAP labeling of <\\entity><\\entity> with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (<1 microM) stimulated <\\entity><\\entity>-mediated ATP hydrolysis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7743",
    "Sentence": "<\\entity><\\entity> was found to compete [(125)I]-IAAP labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of <\\entity><\\entity> (<1 microM) stimulated Pgp-mediated ATP hydrolysis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7744",
    "Sentence": "<\\entity><\\entity> was found to compete [(125)I]-IAAP labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of <\\entity><\\entity> (<1 microM) stimulated Pgp-mediated ATP hydrolysis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7745",
    "Sentence": "CBT-1 was found to compete [(125)I]-IAAP labeling of <\\entity><\\entity> with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (<1 microM) stimulated <\\entity><\\entity>-mediated ATP hydrolysis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7746",
    "Sentence": "CBT-1 was found to compete [(125)I]-IAAP labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (<1 microM) stimulated Pgp-mediated <\\entity><\\entity> hydrolysis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7747",
    "Sentence": "CBT-1 was found to compete [(125)I]-IAAP labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (<1 microM) stimulated Pgp-mediated <\\entity><\\entity> hydrolysis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7748",
    "Sentence": "In <\\entity><\\entity>-overexpressing cells, 10 microM CBT-1 was found to completely inhibit <\\entity><\\entity>-mediated calcein transport.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7749",
    "Sentence": "In MRP1-overexpressing cells, 10 microM <\\entity><\\entity> was found to completely inhibit MRP1-mediated calcein transport.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7750",
    "Sentence": "In MRP1-overexpressing cells, 10 microM <\\entity><\\entity> was found to completely inhibit MRP1-mediated calcein transport.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7751",
    "Sentence": "In <\\entity><\\entity>-overexpressing cells, 10 microM CBT-1 was found to completely inhibit <\\entity><\\entity>-mediated calcein transport.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7752",
    "Sentence": "In MRP1-overexpressing cells, 10 microM CBT-1 was found to completely inhibit MRP1-mediated <\\entity><\\entity> transport.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7753",
    "Sentence": "In MRP1-overexpressing cells, 10 microM CBT-1 was found to completely inhibit MRP1-mediated <\\entity><\\entity> transport.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7754",
    "Sentence": "<\\entity><\\entity> at 25 microM did not have a significant effect on ABCG2-mediated pheophorbide a transport.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7755",
    "Sentence": "<\\entity><\\entity> at 25 microM did not have a significant effect on ABCG2-mediated pheophorbide a transport.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7756",
    "Sentence": "CBT-1 at 25 microM did not have a significant effect on <\\entity><\\entity>-mediated pheophorbide a transport.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7757",
    "Sentence": "CBT-1 at 25 microM did not have a significant effect on ABCG2-mediated <\\entity><\\entity> a transport.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7758",
    "Sentence": "CBT-1 at 25 microM did not have a significant effect on ABCG2-mediated <\\entity><\\entity> a transport.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7759",
    "Sentence": "Serum levels of <\\entity><\\entity> in samples obtained from eight patients receiving <\\entity><\\entity> increased intracellular rhodamine 123 levels in CD56+ cells 2.1- to 5.7-fold in an ex vivo assay.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7760",
    "Sentence": "Serum levels of <\\entity><\\entity> in samples obtained from eight patients receiving <\\entity><\\entity> increased intracellular rhodamine 123 levels in CD56+ cells 2.1- to 5.7-fold in an ex vivo assay.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7761",
    "Sentence": "Serum levels of <\\entity><\\entity> in samples obtained from eight patients receiving <\\entity><\\entity> increased intracellular rhodamine 123 levels in CD56+ cells 2.1- to 5.7-fold in an ex vivo assay.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7762",
    "Sentence": "Serum levels of <\\entity><\\entity> in samples obtained from eight patients receiving <\\entity><\\entity> increased intracellular rhodamine 123 levels in CD56+ cells 2.1- to 5.7-fold in an ex vivo assay.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7763",
    "Sentence": "Serum levels of CBT-1 in samples obtained from eight patients receiving CBT-1 increased intracellular <\\entity><\\entity> levels in CD56+ cells 2.1- to 5.7-fold in an ex vivo assay.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7764",
    "Sentence": "Serum levels of CBT-1 in samples obtained from eight patients receiving CBT-1 increased intracellular <\\entity><\\entity> levels in CD56+ cells 2.1- to 5.7-fold in an ex vivo assay.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7765",
    "Sentence": "Serum levels of CBT-1 in samples obtained from eight patients receiving CBT-1 increased intracellular rhodamine 123 levels in <\\entity><\\entity>+ cells 2.1- to 5.7-fold in an ex vivo assay.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7766",
    "Sentence": "<\\entity><\\entity> is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7767",
    "Sentence": "<\\entity><\\entity> is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7768",
    "Sentence": "CBT-1 is able to inhibit the <\\entity><\\entity> Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7769",
    "Sentence": "CBT-1 is able to inhibit the <\\entity><\\entity> Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7770",
    "Sentence": "CBT-1 is able to inhibit the ABC transporters <\\entity><\\entity> and MRP1, making it an attractive candidate for clinical trials in cancers where <\\entity><\\entity> and/or MRP1 might be overexpressed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7771",
    "Sentence": "CBT-1 is able to inhibit the ABC transporters Pgp and <\\entity><\\entity>, making it an attractive candidate for clinical trials in cancers where Pgp and/or <\\entity><\\entity> might be overexpressed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7772",
    "Sentence": "CBT-1 is able to inhibit the ABC transporters <\\entity><\\entity> and MRP1, making it an attractive candidate for clinical trials in cancers where <\\entity><\\entity> and/or MRP1 might be overexpressed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7773",
    "Sentence": "CBT-1 is able to inhibit the ABC transporters Pgp and <\\entity><\\entity>, making it an attractive candidate for clinical trials in cancers where Pgp and/or <\\entity><\\entity> might be overexpressed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7774",
    "Sentence": "Further clinical studies with <\\entity><\\entity> are warranted.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7775",
    "Sentence": "Further clinical studies with <\\entity><\\entity> are warranted.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7776",
    "Sentence": "<\\entity><\\entity> is a bisbenzylisoquinoline plant alkyloid currently in development as a Pgp inhibitor.",
    "Label": ""
  },
  {
    "id": "7777",
    "Sentence": "CBT-1 is a bisbenzylisoquinoline plant alkyloid currently in development as a <\\entity><\\entity> inhibitor.",
    "Label": ""
  },
  {
    "id": "7779",
    "Sentence": "CBT-1 is a <\\entity><\\entity> currently in development as a Pgp inhibitor.",
    "Label": ""
  },
  {
    "id": "7780",
    "Sentence": "CBT-1 is a bisbenzylisoquinoline plant alkyloid currently in development as a <\\entity><\\entity> inhibitor.",
    "Label": ""
  },
  {
    "id": "7782",
    "Sentence": "<\\entity><\\entity> completely inhibited rhodamine 123 transport from Pgp-overexpressing cells at a concentration of 1muM.",
    "Label": ""
  },
  {
    "id": "7783",
    "Sentence": "CBT-1 completely inhibited <\\entity><\\entity> transport from Pgp-overexpressing cells at a concentration of 1muM.",
    "Label": ""
  },
  {
    "id": "7785",
    "Sentence": "Additionally, 1 microM completely reversed Pgp-mediated resistance to <\\entity><\\entity>, paclitaxel and depsipeptide in SW620 Ad20 cells.",
    "Label": ""
  },
  {
    "id": "7786",
    "Sentence": "Additionally, 1 microM completely reversed <\\entity><\\entity>-mediated resistance to vinblastine, paclitaxel and depsipeptide in SW620 Ad20 cells.",
    "Label": ""
  },
  {
    "id": "7788",
    "Sentence": "Additionally, 1 microM completely reversed Pgp-mediated resistance to vinblastine, <\\entity><\\entity> and depsipeptide in SW620 Ad20 cells.",
    "Label": ""
  },
  {
    "id": "7789",
    "Sentence": "Additionally, 1 microM completely reversed <\\entity><\\entity>-mediated resistance to vinblastine, paclitaxel and depsipeptide in SW620 Ad20 cells.",
    "Label": ""
  },
  {
    "id": "7791",
    "Sentence": "Additionally, 1 microM completely reversed Pgp-mediated resistance to vinblastine, paclitaxel and <\\entity><\\entity> in SW620 Ad20 cells.",
    "Label": ""
  },
  {
    "id": "7792",
    "Sentence": "Additionally, 1 microM completely reversed <\\entity><\\entity>-mediated resistance to vinblastine, paclitaxel and depsipeptide in SW620 Ad20 cells.",
    "Label": ""
  },
  {
    "id": "7794",
    "Sentence": "<\\entity><\\entity> was found to compete [(125)I]-IAAP labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of <\\entity><\\entity> (<1 microM) stimulated Pgp-mediated ATP hydrolysis.",
    "Label": ""
  },
  {
    "id": "7795",
    "Sentence": "CBT-1 was found to compete [(125)I]-IAAP labeling of <\\entity><\\entity> with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (<1 microM) stimulated <\\entity><\\entity>-mediated ATP hydrolysis.",
    "Label": ""
  },
  {
    "id": "7797",
    "Sentence": "<\\entity><\\entity> was found to compete [(125)I]-IAAP labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of <\\entity><\\entity> (<1 microM) stimulated Pgp-mediated ATP hydrolysis.",
    "Label": ""
  },
  {
    "id": "7798",
    "Sentence": "CBT-1 was found to compete [(125)I]-IAAP labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (<1 microM) stimulated Pgp-mediated <\\entity><\\entity> hydrolysis.",
    "Label": ""
  },
  {
    "id": "7800",
    "Sentence": "CBT-1 was found to compete <\\entity><\\entity> labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (<1 microM) stimulated Pgp-mediated ATP hydrolysis.",
    "Label": ""
  },
  {
    "id": "7801",
    "Sentence": "CBT-1 was found to compete [(125)I]-IAAP labeling of <\\entity><\\entity> with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (<1 microM) stimulated <\\entity><\\entity>-mediated ATP hydrolysis.",
    "Label": ""
  },
  {
    "id": "7803",
    "Sentence": "In MRP1-overexpressing cells, 10 microM <\\entity><\\entity> was found to completely inhibit MRP1-mediated calcein transport.",
    "Label": ""
  },
  {
    "id": "7804",
    "Sentence": "In <\\entity><\\entity>-overexpressing cells, 10 microM CBT-1 was found to completely inhibit <\\entity><\\entity>-mediated calcein transport.",
    "Label": ""
  },
  {
    "id": "7806",
    "Sentence": "In MRP1-overexpressing cells, 10 microM <\\entity><\\entity> was found to completely inhibit MRP1-mediated calcein transport.",
    "Label": ""
  },
  {
    "id": "7807",
    "Sentence": "In MRP1-overexpressing cells, 10 microM CBT-1 was found to completely inhibit MRP1-mediated <\\entity><\\entity> transport.",
    "Label": ""
  },
  {
    "id": "7809",
    "Sentence": "<\\entity><\\entity> at 25 microM did not have a significant effect on ABCG2-mediated pheophorbide a transport.",
    "Label": ""
  },
  {
    "id": "7810",
    "Sentence": "CBT-1 at 25 microM did not have a significant effect on <\\entity><\\entity>-mediated pheophorbide a transport.",
    "Label": ""
  },
  {
    "id": "7812",
    "Sentence": "<\\entity><\\entity> at 25 microM did not have a significant effect on ABCG2-mediated pheophorbide a transport.",
    "Label": ""
  },
  {
    "id": "7813",
    "Sentence": "CBT-1 at 25 microM did not have a significant effect on ABCG2-mediated <\\entity><\\entity> a transport.",
    "Label": ""
  },
  {
    "id": "7815",
    "Sentence": "Serum levels of <\\entity><\\entity> in samples obtained from eight patients receiving <\\entity><\\entity> increased intracellular rhodamine 123 levels in CD56+ cells 2.1- to 5.7-fold in an ex vivo assay.",
    "Label": ""
  },
  {
    "id": "7816",
    "Sentence": "Serum levels of CBT-1 in samples obtained from eight patients receiving CBT-1 increased intracellular <\\entity><\\entity> levels in CD56+ cells 2.1- to 5.7-fold in an ex vivo assay.",
    "Label": ""
  },
  {
    "id": "7818",
    "Sentence": "<\\entity><\\entity> is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed.",
    "Label": ""
  },
  {
    "id": "7819",
    "Sentence": "CBT-1 is able to inhibit the ABC transporters Pgp and <\\entity><\\entity>, making it an attractive candidate for clinical trials in cancers where Pgp and/or <\\entity><\\entity> might be overexpressed.",
    "Label": ""
  },
  {
    "id": "7821",
    "Sentence": "<\\entity><\\entity> is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed.",
    "Label": ""
  },
  {
    "id": "7822",
    "Sentence": "CBT-1 is able to inhibit the ABC transporters <\\entity><\\entity> and MRP1, making it an attractive candidate for clinical trials in cancers where <\\entity><\\entity> and/or MRP1 might be overexpressed.",
    "Label": ""
  },
  {
    "id": "7824",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (<\\entity><\\entity>, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7825",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (<\\entity><\\entity>), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7827",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (<\\entity><\\entity>, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7828",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (<\\entity><\\entity>), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7830",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (<\\entity><\\entity>, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7831",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or <\\entity><\\entity>, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7833",
    "Sentence": "We characterized its interactions with the three major <\\entity><\\entity> associated with drug resistance - Pgp, MRP1 and ABCG2 - and compared it to other known inhibitors.",
    "Label": ""
  },
  {
    "id": "7834",
    "Sentence": "We characterized its interactions with the three major ABC transporters associated with drug resistance - Pgp, <\\entity><\\entity> and ABCG2 - and compared it to other known inhibitors.",
    "Label": ""
  },
  {
    "id": "7836",
    "Sentence": "We characterized its interactions with the three major <\\entity><\\entity> associated with drug resistance - Pgp, MRP1 and ABCG2 - and compared it to other known inhibitors.",
    "Label": ""
  },
  {
    "id": "7837",
    "Sentence": "We characterized its interactions with the three major ABC transporters associated with drug resistance - <\\entity><\\entity>, MRP1 and ABCG2 - and compared it to other known inhibitors.",
    "Label": ""
  },
  {
    "id": "7839",
    "Sentence": "We characterized its interactions with the three major <\\entity><\\entity> associated with drug resistance - Pgp, MRP1 and ABCG2 - and compared it to other known inhibitors.",
    "Label": ""
  },
  {
    "id": "7840",
    "Sentence": "We characterized its interactions with the three major ABC transporters associated with drug resistance - Pgp, MRP1 and <\\entity><\\entity> - and compared it to other known inhibitors.",
    "Label": ""
  },
  {
    "id": "7842",
    "Sentence": "CBT-1 is able to inhibit the <\\entity><\\entity> Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed.",
    "Label": ""
  },
  {
    "id": "7843",
    "Sentence": "CBT-1 is able to inhibit the ABC transporters Pgp and <\\entity><\\entity>, making it an attractive candidate for clinical trials in cancers where Pgp and/or <\\entity><\\entity> might be overexpressed.",
    "Label": ""
  },
  {
    "id": "7845",
    "Sentence": "CBT-1 is able to inhibit the <\\entity><\\entity> Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed.",
    "Label": ""
  },
  {
    "id": "7846",
    "Sentence": "CBT-1 is able to inhibit the ABC transporters <\\entity><\\entity> and MRP1, making it an attractive candidate for clinical trials in cancers where <\\entity><\\entity> and/or MRP1 might be overexpressed.",
    "Label": ""
  },
  {
    "id": "7848",
    "Sentence": "CBT-1 is able to inhibit the <\\entity><\\entity> Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed.",
    "Label": ""
  },
  {
    "id": "7849",
    "Sentence": "<\\entity><\\entity> is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed.",
    "Label": ""
  },
  {
    "id": "7851",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, <\\entity><\\entity>.Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7852",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (<\\entity><\\entity>)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7854",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, <\\entity><\\entity>.Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7855",
    "Sentence": "Inhibition of P-glycoprotein (<\\entity><\\entity>)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7857",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, <\\entity><\\entity>.Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7858",
    "Sentence": "Inhibition of <\\entity><\\entity> (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as <\\entity><\\entity> (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7860",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, <\\entity><\\entity>.Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7861",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and <\\entity><\\entity> 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), <\\entity><\\entity> (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7863",
    "Sentence": "<\\entity><\\entity> completely inhibited rhodamine 123 transport from Pgp-overexpressing cells at a concentration of 1muM.",
    "Label": ""
  },
  {
    "id": "7864",
    "Sentence": "CBT-1 completely inhibited rhodamine 123 transport from <\\entity><\\entity>-overexpressing cells at a concentration of 1muM.",
    "Label": ""
  },
  {
    "id": "7866",
    "Sentence": "CBT-1 completely inhibited <\\entity><\\entity> transport from Pgp-overexpressing cells at a concentration of 1muM.",
    "Label": ""
  },
  {
    "id": "7867",
    "Sentence": "CBT-1 completely inhibited rhodamine 123 transport from <\\entity><\\entity>-overexpressing cells at a concentration of 1muM.",
    "Label": ""
  },
  {
    "id": "7869",
    "Sentence": "CBT-1 was found to compete [(125)I]-IAAP labeling of Pgp with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (<1 microM) stimulated Pgp-mediated <\\entity><\\entity> hydrolysis.",
    "Label": ""
  },
  {
    "id": "7870",
    "Sentence": "CBT-1 was found to compete [(125)I]-IAAP labeling of <\\entity><\\entity> with an IC(50) of 0.14 microM, and low concentrations of CBT-1 (<1 microM) stimulated <\\entity><\\entity>-mediated ATP hydrolysis.",
    "Label": ""
  },
  {
    "id": "7872",
    "Sentence": "In MRP1-overexpressing cells, 10 microM CBT-1 was found to completely inhibit MRP1-mediated <\\entity><\\entity> transport.",
    "Label": ""
  },
  {
    "id": "7873",
    "Sentence": "In <\\entity><\\entity>-overexpressing cells, 10 microM CBT-1 was found to completely inhibit <\\entity><\\entity>-mediated calcein transport.",
    "Label": ""
  },
  {
    "id": "7875",
    "Sentence": "CBT-1 at 25 microM did not have a significant effect on ABCG2-mediated <\\entity><\\entity> a transport.",
    "Label": ""
  },
  {
    "id": "7876",
    "Sentence": "CBT-1 at 25 microM did not have a significant effect on <\\entity><\\entity>-mediated pheophorbide a transport.",
    "Label": ""
  },
  {
    "id": "7878",
    "Sentence": "Serum levels of <\\entity><\\entity> in samples obtained from eight patients receiving <\\entity><\\entity> increased intracellular rhodamine 123 levels in CD56+ cells 2.1- to 5.7-fold in an ex vivo assay.",
    "Label": ""
  },
  {
    "id": "7879",
    "Sentence": "Serum levels of CBT-1 in samples obtained from eight patients receiving CBT-1 increased intracellular rhodamine 123 levels in <\\entity><\\entity>+ cells 2.1- to 5.7-fold in an ex vivo assay.",
    "Label": ""
  },
  {
    "id": "7881",
    "Sentence": "Serum levels of CBT-1 in samples obtained from eight patients receiving CBT-1 increased intracellular <\\entity><\\entity> levels in CD56+ cells 2.1- to 5.7-fold in an ex vivo assay.",
    "Label": ""
  },
  {
    "id": "7882",
    "Sentence": "Serum levels of CBT-1 in samples obtained from eight patients receiving CBT-1 increased intracellular rhodamine 123 levels in <\\entity><\\entity>+ cells 2.1- to 5.7-fold in an ex vivo assay.",
    "Label": ""
  },
  {
    "id": "7884",
    "Sentence": "<\\entity><\\entity> is able to inhibit the ABC transporters Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed.",
    "Label": ""
  },
  {
    "id": "7885",
    "Sentence": "CBT-1 is able to inhibit the <\\entity><\\entity> Pgp and MRP1, making it an attractive candidate for clinical trials in cancers where Pgp and/or MRP1 might be overexpressed.",
    "Label": ""
  },
  {
    "id": "7887",
    "Sentence": "Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, <\\entity><\\entity>.Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7888",
    "Sentence": "Inhibition of P-glycoprotein (ABCB<\\entity><\\entity>)- and multidrug resistance-associated protein <\\entity><\\entity> (ABCC<\\entity><\\entity>)-mediated transport by the orally administered inhibitor, CBT-<\\entity><\\entity>((R)).Cellular expression of ATP-binding cassette (ABC) transport proteins, such as P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP<\\entity><\\entity>), or ABCG2, is known to confer a drug-resistant phenotype.",
    "Label": ""
  },
  {
    "id": "7894",
    "Sentence": "Is serum <\\entity><\\entity> a reliable marker of nutritional status in patients with end-stage renal disease?OBJECTIVE: To test the value of serum <\\entity><\\entity> (TTR) concentration as a nutritional marker in renal patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7895",
    "Sentence": "Is serum transthyretin a reliable marker of nutritional status in patients with <\\entity><\\entity>?OBJECTIVE: To test the value of serum transthyretin (TTR) concentration as a nutritional marker in renal patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7896",
    "Sentence": "Is serum <\\entity><\\entity> a reliable marker of nutritional status in patients with end-stage renal disease?OBJECTIVE: To test the value of serum <\\entity><\\entity> (TTR) concentration as a nutritional marker in renal patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7897",
    "Sentence": "Is serum transthyretin a reliable marker of nutritional status in patients with end-stage renal disease?OBJECTIVE: To test the value of serum transthyretin (<\\entity><\\entity>) concentration as a nutritional marker in renal patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7898",
    "Sentence": "Is serum transthyretin a reliable marker of nutritional status in patients with end-stage renal disease?OBJECTIVE: To test the value of serum transthyretin (TTR) concentration as a nutritional marker in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7899",
    "Sentence": "METHODS: The study included 115 <\\entity><\\entity>, out of which 35 are on conservative treatment, 50 on hemodialysis and 30 renal transplant recipients, and 31 healthy control subjects.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7900",
    "Sentence": "Serum <\\entity><\\entity>, albumin, transferrin, C-reactive protein (CRP) and alpha1 anti trypsine (AAT) were assessed by immunoturbidimetry, and vitamin A by HPLC.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7901",
    "Sentence": "Serum TTR, <\\entity><\\entity>, transferrin, C-reactive protein (CRP) and alpha1 anti trypsine (AAT) were assessed by immunoturbidimetry, and vitamin A by HPLC.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7902",
    "Sentence": "Serum TTR, albumin, transferrin, C-reactive protein (CRP) and alpha1 anti trypsine (AAT) were assessed by immunoturbidimetry, and <\\entity><\\entity> by HPLC.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7903",
    "Sentence": "Linear <\\entity><\\entity> models were applied to test the association between serum TTR and body mass index (BMI).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7904",
    "Sentence": "Linear regression models were applied to test the association between serum <\\entity><\\entity> and body mass index (BMI).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7905",
    "Sentence": "RESULTS: Serum <\\entity><\\entity> concentrations were normal, but serum vitamin A, CRP and AAT concentrations were significantly higher in patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7906",
    "Sentence": "RESULTS: Serum TTR concentrations were normal, but serum <\\entity><\\entity>, CRP and AAT concentrations were significantly higher in patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7907",
    "Sentence": "In <\\entity><\\entity>, serum TTR was positively and independently related to BMI and was significantly lower in malnourished than well-nourished patients (367+/-91 vs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7908",
    "Sentence": "In renal patients, serum <\\entity><\\entity> was positively and independently related to BMI and was significantly lower in malnourished than well-nourished patients (367+/-91 vs.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7909",
    "Sentence": "In renal patients, serum TTR was positively and independently related to BMI and was significantly lower in <\\entity><\\entity> than well-nourished patients (367+/-91 vs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7910",
    "Sentence": "The risk of serum <\\entity><\\entity><300 mg/L was higher in malnourished patients [OR, 4.82 (1.78-13.2); p=0.001].",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7911",
    "Sentence": "The risk of serum TTR<300 mg/L was higher in <\\entity><\\entity> patients [OR, 4.82 (1.78-13.2); p=0.001].",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7912",
    "Sentence": "CONCLUSION: Serum <\\entity><\\entity> concentrations were at normal range in renal patients despite evidence of malnutrition and inflammation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7913",
    "Sentence": "CONCLUSION: Serum TTR concentrations were at normal range in <\\entity><\\entity> despite evidence of malnutrition and inflammation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7914",
    "Sentence": "CONCLUSION: Serum TTR concentrations were at normal range in renal patients despite evidence of <\\entity><\\entity> and inflammation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7915",
    "Sentence": "CONCLUSION: Serum TTR concentrations were at normal range in renal patients despite evidence of malnutrition and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7916",
    "Sentence": "However, they were related to BMI and were significantly lowered in <\\entity><\\entity> patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7917",
    "Sentence": "Thus, serum <\\entity><\\entity> would reflect nutritional status in renal patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7918",
    "Sentence": "Thus, serum TTR would reflect nutritional status in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7919",
    "Sentence": "However, the cutoff of <\\entity><\\entity> should be raised to 300 mg/L.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7924",
    "Sentence": "Docking study yields four novel <\\entity><\\entity>.To supplement the hits from a high throughput screen, docking was performed against Pim-1 kinase.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7925",
    "Sentence": "Docking study yields four novel <\\entity><\\entity>.To supplement the hits from a high throughput screen, docking was performed against Pim-1 kinase.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7926",
    "Sentence": "Docking study yields four novel inhibitors of the protooncogene <\\entity><\\entity> kinase.To supplement the hits from a high throughput screen, docking was performed against <\\entity><\\entity> kinase.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7927",
    "Sentence": "Docking study yields four novel inhibitors of the protooncogene <\\entity><\\entity>.To supplement the hits from a high throughput screen, docking was performed against <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7928",
    "Sentence": "<\\entity><\\entity> docking was augmented with a filter to require traditional or aromatic CH..O hydrogen bonds to the kinase hinge.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7929",
    "Sentence": "This gives a 14-fold enrichment over the earlier <\\entity><\\entity> run, and the two crystal structures solved confirmed the binding modes predicted by docking.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7934",
    "Sentence": "<\\entity><\\entity>.Food allergies affect approximately 3.5-4.0% of the worldwide population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7935",
    "Sentence": "Molluscan shellfish allergy.<\\entity><\\entity> affect approximately 3.5-4.0% of the worldwide population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7936",
    "Sentence": "Immediate-type <\\entity><\\entity> are mediated by the production of IgE antibodies to specific proteins that occur naturally in allergenic foods.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7937",
    "Sentence": "<\\entity><\\entity> are individually variable ranging from mild rashes and hives to life-threatening anaphylactic shock.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7938",
    "Sentence": "Symptoms are individually variable ranging from <\\entity><\\entity> and hives to life-threatening anaphylactic shock.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7939",
    "Sentence": "Symptoms are individually variable ranging from mild rashes and <\\entity><\\entity> to life-threatening anaphylactic shock.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7940",
    "Sentence": "Symptoms are individually variable ranging from mild rashes and hives to life-threatening <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7941",
    "Sentence": "<\\entity><\\entity> are among the most common types of food allergies on a worldwide basis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7942",
    "Sentence": "Sea<\\entity><\\entity> are among the most common types of <\\entity><\\entity> on a worldwide basis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7943",
    "Sentence": "<\\entity><\\entity> and crustacean shellfish are very common.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7944",
    "Sentence": "Allergies to fish and <\\entity><\\entity> are very common.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7945",
    "Sentence": "<\\entity><\\entity> are well known but do not appear to occur as frequently.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7946",
    "Sentence": "<\\entity><\\entity> have been documented to all classes of mollusks including gastropods (e.g., limpet, abalone), bivalves (e.g., clams, oysters, mussels), and cephalopods (e.g., squid, octopus).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7947",
    "Sentence": "<\\entity><\\entity>, a major muscle protein, is the only well-recognized allergen in molluscan shellfish.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7948",
    "Sentence": "Tropomyosin, a major muscle protein, is the only well-recognized <\\entity><\\entity> in molluscan shellfish.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7949",
    "Sentence": "The <\\entity><\\entity> in oyster (Cra g 1), abalone (Hal m 1), and squid (Tod p 1) have been identified as tropomyosin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7950",
    "Sentence": "The allergens in oyster (Cra g 1), abalone (Hal <\\entity><\\entity> 1), and squid (Tod p 1) have been identified as tropo<\\entity><\\entity>yosin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7951",
    "Sentence": "The allergens in oyster (Cra g 1), abalone (Hal m 1), and squid (Tod p 1) have been identified as <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7952",
    "Sentence": "Cross-reactivity to <\\entity><\\entity> from other molluscan shellfish species has been observed with sera from patients allergic to oysters, suggesting that individuals with allergies to molluscan shellfish should avoid eating all species of molluscan shellfish.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7953",
    "Sentence": "Cross-reactivity to tropomyosin from other molluscan shellfish species has been observed with sera from patients allergic to oysters, suggesting that individuals with <\\entity><\\entity> to molluscan shellfish should avoid eating all species of molluscan shellfish.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7954",
    "Sentence": "Cross-reactions with the related <\\entity><\\entity> in crustacean shellfish may also occur but this is less clearly defined.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7955",
    "Sentence": "Cross-reactions with the related tropomyosin allergens in <\\entity><\\entity> may also occur but this is less clearly defined.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7956",
    "Sentence": "Occupational <\\entity><\\entity> have also been described in workers exposed to molluscan shellfish products by the respiratory and/or cutaneous routes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7957",
    "Sentence": "With <\\entity><\\entity>, one man's food may truly be another man's poison.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7958",
    "Sentence": "Individuals with <\\entity><\\entity> react adversely to the ingestion of foods and food ingredients that most consumers can safely ingest (Taylor and Hefle, 2001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7959",
    "Sentence": "The <\\entity><\\entity> that provoke adverse reactions in susceptible individuals are naturally occurring proteins in the specific foods (Bush and Hefle, 1996).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7960",
    "Sentence": "Molluscan shellfish, like virtually all foods that contain protein, can provoke <\\entity><\\entity> in some individuals.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7961",
    "Sentence": "Cross-reactivity to <\\entity><\\entity> from other molluscan shellfish species has been observed with sera from patients allergic to oysters, suggesting that individuals with allergies to molluscan shellfish should avoid eating all species of molluscan shellfish.",
    "Label": ""
  },
  {
    "id": "7962",
    "Sentence": "Cross-reactivity to tropomyosin from other molluscan shellfish species has been observed with sera from patients allergic to oysters, suggesting that individuals with <\\entity><\\entity> to molluscan shellfish should avoid eating all species of molluscan shellfish.",
    "Label": ""
  },
  {
    "id": "7964",
    "Sentence": "Cross-reactions with the related <\\entity><\\entity> in crustacean shellfish may also occur but this is less clearly defined.",
    "Label": ""
  },
  {
    "id": "7965",
    "Sentence": "Cross-reactions with the related tropomyosin allergens in <\\entity><\\entity> may also occur but this is less clearly defined.",
    "Label": ""
  },
  {
    "id": "7971",
    "Sentence": "<\\entity><\\entity> during fluoroscopically guided cervical interlaminar steroid injection at C6-7: a case report.We report 4 cases of intravascular venous uptake of contrast material during fluoroscopically guided cervical interlaminar epidural steroid injection at the C6-7 level.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7972",
    "Sentence": "Intravascular uptake during <\\entity><\\entity>: a case report.We report 4 cases of intravascular venous uptake of contrast material during fluoroscopically guided cervical interlaminar epidural steroid injection at the C6-7 level.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7973",
    "Sentence": "Intravascular uptake during fluoroscopically guided cervical interlaminar <\\entity><\\entity> injection at C6-7: a case report.We report 4 cases of intravascular venous uptake of contrast material during fluoroscopically guided cervical interlaminar epidural <\\entity><\\entity> injection at the C6-7 level.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7974",
    "Sentence": "Intravascular uptake during fluoroscopically guided cervical interlaminar steroid injection at C6-7: a case report.We report 4 cases of <\\entity><\\entity> of contrast material during fluoroscopically guided cervical interlaminar epidural steroid injection at the C6-7 level.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7975",
    "Sentence": "Intravascular uptake during fluoroscopically guided cervical interlaminar steroid injection at C6-7: a case report.We report 4 cases of intravascular venous uptake of <\\entity><\\entity> during fluoroscopically guided cervical interlaminar epidural steroid injection at the C6-7 level.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7976",
    "Sentence": "Intravascular uptake during fluoroscopically guided cervical interlaminar steroid injection at C6-7: a case report.We report 4 cases of intravascular venous uptake of contrast material during <\\entity><\\entity> level.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7977",
    "Sentence": "Intravascular uptake during fluoroscopically guided cervical interlaminar <\\entity><\\entity> injection at C6-7: a case report.We report 4 cases of intravascular venous uptake of contrast material during fluoroscopically guided cervical interlaminar epidural <\\entity><\\entity> injection at the C6-7 level.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7978",
    "Sentence": "The blood vessel probably involved is the <\\entity><\\entity> internal vertebral venous plexus, which drains the interlaminar space and returns blood to the right atrium through the paired vertebral veins and right and left brachiocephalic veins.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7979",
    "Sentence": "In all 4 cases, <\\entity><\\entity> occurred despite negative aspiration of blood before the contrast material was injected.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7980",
    "Sentence": "In all 4 cases, intravascular uptake occurred despite negative <\\entity><\\entity> of blood before the contrast material was injected.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7981",
    "Sentence": "In all 4 cases, intravascular uptake occurred despite negative aspiration of blood before the <\\entity><\\entity> was injected.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7982",
    "Sentence": "Potential <\\entity><\\entity> of intravascular venous uptake of contrast material and steroid solution are discussed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7983",
    "Sentence": "Potential complications of <\\entity><\\entity> of contrast material and steroid solution are discussed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7984",
    "Sentence": "Potential complications of intravascular venous uptake of <\\entity><\\entity> and steroid solution are discussed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7985",
    "Sentence": "Potential complications of intravascular venous uptake of contrast material and <\\entity><\\entity> solution are discussed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "7986",
    "Sentence": "Intravascular uptake during fluoroscopically guided cervical interlaminar <\\entity><\\entity> injection at C6-7: a case report.We report 4 cases of intravascular venous uptake of contrast material during fluoroscopically guided cervical interlaminar epidural <\\entity><\\entity> injection at the C6-7 level.",
    "Label": ""
  },
  {
    "id": "7987",
    "Sentence": "Intravascular uptake during fluoroscopically guided cervical interlaminar steroid injection at C6-7: a case report.We report 4 cases of <\\entity><\\entity> of contrast material during fluoroscopically guided cervical interlaminar epidural steroid injection at the C6-7 level.",
    "Label": ""
  },
  {
    "id": "7989",
    "Sentence": "Potential complications of intravascular venous uptake of contrast material and <\\entity><\\entity> solution are discussed.",
    "Label": ""
  },
  {
    "id": "7990",
    "Sentence": "Potential complications of <\\entity><\\entity> of contrast material and steroid solution are discussed.",
    "Label": ""
  },
  {
    "id": "7996",
    "Sentence": "Association of <\\entity><\\entity> with prevalent hypertension in 1406 older adults: the BambuÃ­ Health Aging Study (BHAS).Apolipoprotein E (ApoE) polymorphism influences lipid metabolism, but its association with arterial hypertension is controversial.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "7997",
    "Sentence": "Association of <\\entity><\\entity> with prevalent hypertension in 1406 older adults: the BambuÃ­ Health Aging Study (BHAS).Apolipoprotein E (ApoE) polymorphism influences lipid metabolism, but its association with arterial hypertension is controversial.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "7998",
    "Sentence": "Association of ApoE polymorphisms with <\\entity><\\entity> in 1406 older adults: the BambuÃ­ Health Aging Study (BHAS).Apolipoprotein E (ApoE) polymorphism influences lipid metabolism, but its association with arterial hypertension is controversial.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "7999",
    "Sentence": "Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the BambuÃ­ Health Aging Study (BHAS).Apolipoprotein E (ApoE) polymorphism influences lipid metabolism, but its association with arterial hypertension is controversial.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8000",
    "Sentence": "Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the BambuÃ­ Health Aging Study (BHAS).Apolipoprotein E <\\entity><\\entity>m influences lipid metabolism, but its association with arterial hypertension is controversial.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8001",
    "Sentence": "Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the BambuÃ­ Health Aging Study (BHAS).Apolipoprotein E <\\entity><\\entity>m influences lipid metabolism, but its association with arterial hypertension is controversial.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8002",
    "Sentence": "Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the BambuÃ­ Health Aging Study (BHAS).Apolipoprotein E (ApoE) polymorphism influences lipid metabolism, but its association with<\\entity><\\entity>n is controversial.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8003",
    "Sentence": "The objective of this study was to examine the association between<\\entity><\\entity>m and prevalent hypertension in a large unselected population of older adults.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8004",
    "Sentence": "The objective of this study was to examine the association between<\\entity><\\entity>m and prevalent hypertension in a large unselected population of older adults.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8005",
    "Sentence": "The objective of this study was to examine the association between ApoE polymorphism and<\\entity><\\entity>n in a large unselected population of older adults.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8006",
    "Sentence": "Participants from the baseline of the BambuÃ­ Health Aging Study whos<\\entity><\\entity>oE genes had been genotyped were selected for this study (N = 1406, aged 60-95 years).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8007",
    "Sentence": "These subjects represented 80.7% of the total elderly residents in BambuÃ­ city, MG, Brazil.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8008",
    "Sentence": "The exposure variable was t<\\entity><\\entity>poE genotype as follows: epsilon3 carriers, epsilon3epsilon3; epsilon2 carriers, epsilon2epsilon2 or epsilon2epsilon3, and epsilon4 carriers, epsilon3epsilon4 or epsilon4epsilon4.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8009",
    "Sentence": "The exposure variable was the ApoE genotype as follow<\\entity><\\entity>on3 carriers, epsilon3epsilon3; epsilon2 carriers, epsilon2epsilon2 or epsilon2epsilon3, and epsilon4 carriers, epsilon3epsilon4 or epsilon4epsilon4.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8010",
    "Sentence": "The exposure variable was the ApoE genotype as follows: epsilon3 carrier<\\entity><\\entity>on3; epsilon2 carriers, epsilon2epsilon2 or epsilon2epsilon3, and epsilon4 carrier<\\entity><\\entity>on4 or epsilon4epsilon4.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8011",
    "Sentence": "The exposure variable was the ApoE genotype as follows: epsilon3 carriers, epsilon3epsilon<\\entity><\\entity>on2 carriers, epsilon2epsilon2 or epsilon2epsilon3, and epsilon4 carriers, epsilon3epsilon4 or epsilon4epsilon4.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8012",
    "Sentence": "The exposure variable was the ApoE genotype as follows: epsilon3 carriers, epsilon3epsilon3; epsilon2 carrier<\\entity><\\entity>on2 or epsilon2epsilon3, and epsilon4 carriers, epsilon3epsilon4 or epsilon4epsilon4.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8013",
    "Sentence": "The exposure variable was the ApoE genotype as follows: epsilon3 carriers, epsilon3epsilon3; epsilon2 carriers, epsilon2epsilon2 <\\entity><\\entity>on3, and epsilon4 carriers, epsilon3epsilon4 or epsilon4epsilon4.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8014",
    "Sentence": "The exposure variable was the ApoE genotype as follows: epsilon3 carriers, epsilon3epsilon3; epsilon2 carriers, epsilon2epsilon2 or epsilon2epsilon3, a<\\entity><\\entity>on4 carriers, epsilon3epsilon4 or epsilon4epsilon4.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8015",
    "Sentence": "The exposure variable was the ApoE genotype as follows: epsilon3 carrier<\\entity><\\entity>on3; epsilon2 carriers, epsilon2epsilon2 or epsilon2epsilon3, and epsilon4 carrier<\\entity><\\entity>on4 or epsilon4epsilon4.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8016",
    "Sentence": "The exposure variable was the ApoE genotype as follows: epsilon3 carriers, epsilon3epsilon3; epsilon2 carriers, epsilon2epsilon2 or epsilon2epsilon3, and epsilon4 carriers, epsilon3epsilon4 <\\entity><\\entity>on4.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8017",
    "Sentence": "Potential confounding variables were age, gender, tradition<\\entity><\\entity>ors, uric acid, and creatinine levels.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8018",
    "Sentence": "The prevalence <\\entity><\\entity>ion was 61.3%.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8019",
    "Sentence": "Compared with t<\\entity><\\entity>on3 homozygotes, neither t<\\entity><\\entity>on2 nor t<\\entity><\\entity>on4 carrier status was associated with hypertension (adjusted prevalence ratios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8020",
    "Sentence": "Compared with t<\\entity><\\entity>on3 homozygotes, neither t<\\entity><\\entity>on2 nor t<\\entity><\\entity>on4 carrier status was associated with hypertension (adjusted prevalence ratios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8021",
    "Sentence": "Compared with t<\\entity><\\entity>on3 homozygotes, neither t<\\entity><\\entity>on2 nor t<\\entity><\\entity>on4 carrier status was associated with hypertension (adjusted prevalence ratios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8022",
    "Sentence": "Compared with the epsilon3 homozygotes, neither the epsilon2 nor the epsilon4 carrier status was associated wi<\\entity><\\entity>ion (adjusted prevalence ratios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8023",
    "Sentence": "On the other hand, t<\\entity><\\entity>on2 allele carriers had lower LDL cholesterol levels (P < 0.001) and t<\\entity><\\entity>on4 carriers had higher LDL cholesterol levels (P = 0.036).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8024",
    "Sentence": "On the other hand, the epsilon2 allele carriers had low<\\entity><\\entity>rol levels (P < 0.001) and the epsilon4 carriers had high<\\entity><\\entity>rol levels (P = 0.036).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8025",
    "Sentence": "On the other hand, t<\\entity><\\entity>on2 allele carriers had lower LDL cholesterol levels (P < 0.001) and t<\\entity><\\entity>on4 carriers had higher LDL cholesterol levels (P = 0.036).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8026",
    "Sentence": "On the other hand, the epsilon2 allele carriers had low<\\entity><\\entity>rol levels (P < 0.001) and the epsilon4 carriers had high<\\entity><\\entity>rol levels (P = 0.036).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8027",
    "Sentence": "This study provides epidemiologic evidence that t<\\entity><\\entity>poE genotype is not associated with prevalent hypertension in old age.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8028",
    "Sentence": "This study provides epidemiologic evidence that the ApoE genotype is not associated wi<\\entity><\\entity>ion in old age.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8029",
    "Sentence": "Association of <\\entity><\\entity> with prevalent hypertension in 1406 older adults: the BambuÃ­ Health Aging Study (BHAS).Apolipoprotein E (ApoE) polymorphism influences lipid metabolism, but its association with arterial hypertension is controversial.",
    "Label": ""
  },
  {
    "id": "8030",
    "Sentence": "Association of ApoE polymorphisms with <\\entity><\\entity> in 1406 older adults: the BambuÃ­ Health Aging Study (BHAS).Apolipoprotein E (ApoE) polymorphism influences lipid metabolism, but its association with arterial hypertension is controversial.",
    "Label": ""
  },
  {
    "id": "8032",
    "Sentence": "Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the BambuÃ­ Health Aging Study (BHAS).Apolipoprotein E <\\entity><\\entity>m influences lipid metabolism, but its association with arterial hypertension is controversial.",
    "Label": ""
  },
  {
    "id": "8033",
    "Sentence": "Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the BambuÃ­ Health Aging Study (BHAS).Apolipoprotein E (ApoE) polymorphism influences lipid metabolism, but its association with<\\entity><\\entity>n is controversial.",
    "Label": ""
  },
  {
    "id": "8035",
    "Sentence": "The objective of this study was to examine the association between<\\entity><\\entity>m and prevalent hypertension in a large unselected population of older adults.",
    "Label": ""
  },
  {
    "id": "8036",
    "Sentence": "The objective of this study was to examine the association between ApoE polymorphism and<\\entity><\\entity>n in a large unselected population of older adults.",
    "Label": ""
  },
  {
    "id": "8038",
    "Sentence": "Compared with t<\\entity><\\entity>on3 homozygotes, neither t<\\entity><\\entity>on2 nor t<\\entity><\\entity>on4 carrier status was associated with hypertension (adjusted prevalence ratios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07, respectively).",
    "Label": ""
  },
  {
    "id": "8039",
    "Sentence": "Compared with the epsilon3 homozygotes, neither the epsilon2 nor the epsilon4 carrier status was associated wi<\\entity><\\entity>ion (adjusted prevalence ratios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07, respectively).",
    "Label": ""
  },
  {
    "id": "8041",
    "Sentence": "Compared with t<\\entity><\\entity>on3 homozygotes, neither t<\\entity><\\entity>on2 nor t<\\entity><\\entity>on4 carrier status was associated with hypertension (adjusted prevalence ratios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07, respectively).",
    "Label": ""
  },
  {
    "id": "8042",
    "Sentence": "Compared with the epsilon3 homozygotes, neither the epsilon2 nor the epsilon4 carrier status was associated wi<\\entity><\\entity>ion (adjusted prevalence ratios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07, respectively).",
    "Label": ""
  },
  {
    "id": "8044",
    "Sentence": "This study provides epidemiologic evidence that t<\\entity><\\entity>poE genotype is not associated with prevalent hypertension in old age.",
    "Label": ""
  },
  {
    "id": "8045",
    "Sentence": "This study provides epidemiologic evidence that the ApoE genotype is not associated wi<\\entity><\\entity>ion in old age.",
    "Label": ""
  },
  {
    "id": "8047",
    "Sentence": "Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the BambuÃ­ Health Aging Study (BHAS).Apolipoprotein E (ApoE) polymorphism influences lipid metabolism, but its association with arterial hypertension is controversial.",
    "Label": ""
  },
  {
    "id": "8048",
    "Sentence": "Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the BambuÃ­ Health Aging Study (BHAS).Apolipoprotein E (ApoE) polymorphism influences lipid metabolism, but its association with<\\entity><\\entity>n is controversial.",
    "Label": ""
  },
  {
    "id": "8050",
    "Sentence": "Compared with t<\\entity><\\entity>on3 homozygotes, neither t<\\entity><\\entity>on2 nor t<\\entity><\\entity>on4 carrier status was associated with hypertension (adjusted prevalence ratios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07, respectively).",
    "Label": ""
  },
  {
    "id": "8051",
    "Sentence": "Compared with the epsilon3 homozygotes, neither the epsilon2 nor the epsilon4 carrier status was associated wi<\\entity><\\entity>ion (adjusted prevalence ratios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07, respectively).",
    "Label": ""
  },
  {
    "id": "8057",
    "Sentence": "Intracameral <\\entity><\\entity>: questions for the United States based on prospective studies.Recent prospective studies from Europe suggest the use of intracameral <\\entity><\\entity> for prophylaxis of endophthalmitis, although the studies did not make a comparison with the most common United States prophylaxis techniques.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8058",
    "Sentence": "Intracameral <\\entity><\\entity>: questions for the United States based on prospective studies.Recent prospective studies from Europe suggest the use of intracameral <\\entity><\\entity> for prophylaxis of endophthalmitis, although the studies did not make a comparison with the most common United States prophylaxis techniques.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8059",
    "Sentence": "Intracameral antibiotics: questions for the United States based on prospective studies.Recent prospective studies from Europe suggest the use of intracameral antibiotics for prophylaxis of <\\entity><\\entity>, although the studies did not make a comparison with the most common United States prophylaxis techniques.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8060",
    "Sentence": "There is no worldwide-established approach to prophylaxis of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8061",
    "Sentence": "In the <\\entity><\\entity> of a strong evidence-based approach most surgeons use surrogate studies to support their techniques and mold their opinions based on their interpretation of the literature and when they believe organisms causing endophthalmitis enter the eye.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8062",
    "Sentence": "In the absence of a strong evidence-based approach most surgeons use surrogate studies to support their techniques and mold their opinions based on their interpretation of the literature and when they believe organisms causing <\\entity><\\entity> enter the eye.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8063",
    "Sentence": "The review showed that preoperative topical <\\entity><\\entity> limit the number of bacteria on the ocular surface at surgery and postoperative topical <\\entity><\\entity> are most appropriate to address postoperative inoculation until the wound is sealed (with no tapering).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8064",
    "Sentence": "The review showed that preoperative topical <\\entity><\\entity> limit the number of bacteria on the ocular surface at surgery and postoperative topical <\\entity><\\entity> are most appropriate to address postoperative inoculation until the wound is sealed (with no tapering).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8065",
    "Sentence": "The review showed that preoperative topical antibiotics limit the number of bacteria on the ocular surface at surgery and postoperative topical antibiotics are most appropriate to address postoperative inoculation until the <\\entity><\\entity> is sealed (with no tapering).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8066",
    "Sentence": "Whereas <\\entity><\\entity> may be an appropriate route of administration to address inoculation occurring at the time of surgery, more research on safety and effectiveness is needed before we expose the millions of eyes having cataract surgery each year.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8067",
    "Sentence": "Whereas intracameral antibiotic injection may be an appropriate route of administration to address inoculation occurring at the time of surgery, more research on safety and effectiveness is needed before we expose the millions of eyes having <\\entity><\\entity> surgery each year.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8068",
    "Sentence": "A multipronged approach to limit <\\entity><\\entity> risk is also needed, with antibiotics as only part of the strategy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8069",
    "Sentence": "A multipronged approach to limit endophthalmitis risk is also needed, with <\\entity><\\entity> as only part of the strategy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8070",
    "Sentence": "Intracameral <\\entity><\\entity>: questions for the United States based on prospective studies.Recent prospective studies from Europe suggest the use of intracameral <\\entity><\\entity> for prophylaxis of endophthalmitis, although the studies did not make a comparison with the most common United States prophylaxis techniques.",
    "Label": ""
  },
  {
    "id": "8071",
    "Sentence": "Intracameral antibiotics: questions for the United States based on prospective studies.Recent prospective studies from Europe suggest the use of intracameral antibiotics for prophylaxis of <\\entity><\\entity>, although the studies did not make a comparison with the most common United States prophylaxis techniques.",
    "Label": ""
  },
  {
    "id": "8073",
    "Sentence": "The review showed that preoperative topical <\\entity><\\entity> limit the number of bacteria on the ocular surface at surgery and postoperative topical <\\entity><\\entity> are most appropriate to address postoperative inoculation until the wound is sealed (with no tapering).",
    "Label": ""
  },
  {
    "id": "8074",
    "Sentence": "The review showed that preoperative topical antibiotics limit the number of bacteria on the ocular surface at surgery and postoperative topical antibiotics are most appropriate to address postoperative inoculation until the <\\entity><\\entity> is sealed (with no tapering).",
    "Label": ""
  },
  {
    "id": "8076",
    "Sentence": "Whereas <\\entity><\\entity> may be an appropriate route of administration to address inoculation occurring at the time of surgery, more research on safety and effectiveness is needed before we expose the millions of eyes having cataract surgery each year.",
    "Label": ""
  },
  {
    "id": "8077",
    "Sentence": "Whereas intracameral antibiotic injection may be an appropriate route of administration to address inoculation occurring at the time of surgery, more research on safety and effectiveness is needed before we expose the millions of eyes having <\\entity><\\entity> surgery each year.",
    "Label": ""
  },
  {
    "id": "8079",
    "Sentence": "A multipronged approach to limit endophthalmitis risk is also needed, with <\\entity><\\entity> as only part of the strategy.",
    "Label": ""
  },
  {
    "id": "8080",
    "Sentence": "A multipronged approach to limit <\\entity><\\entity> risk is also needed, with antibiotics as only part of the strategy.",
    "Label": ""
  },
  {
    "id": "8086",
    "Sentence": "Methods for identifying long-term <\\entity><\\entity> of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.PURPOSE: To evaluate potential epidemiologic methods for studying long-term effects of immunosuppression on the risk of mortality and fatal malignancy, and present the methodological details of the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8087",
    "Sentence": "Methods for identifying long-term adverse effects of treatment in patients with <\\entity><\\entity>: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.PURPOSE: To evaluate potential epidemiologic methods for studying long-term effects of immunosuppression on the risk of mortality and fatal malignancy, and present the methodological details of the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8088",
    "Sentence": "Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the <\\entity><\\entity> for Eye Diseases (SITE) Cohort Study.PURPOSE: To evaluate potential epidemiologic methods for studying long-term effects of immunosuppression on the risk of mortality and fatal malignancy, and present the methodological details of the <\\entity><\\entity> for Eye Diseases (SITE) Cohort Study.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8089",
    "Sentence": "Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for <\\entity><\\entity> (SITE) Cohort Study.PURPOSE: To evaluate potential epidemiologic methods for studying long-term effects of immunosuppression on the risk of mortality and fatal malignancy, and present the methodological details of the Systemic Immunosuppressive Therapy for <\\entity><\\entity> (SITE) Cohort Study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8090",
    "Sentence": "Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.PURPOSE: To evaluate potential epidemiologic methods for studying long-term effects of <\\entity><\\entity> on the risk of mortality and fatal malignancy, and present the methodological details of the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8091",
    "Sentence": "Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.PURPOSE: To evaluate potential epidemiologic methods for studying long-term effects of immunosuppression on the risk of <\\entity><\\entity> and fatal malignancy, and present the methodological details of the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8092",
    "Sentence": "Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.PURPOSE: To evaluate potential epidemiologic methods for studying long-term effects of immunosuppression on the risk of mortality and <\\entity><\\entity>, and present the methodological details of the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8093",
    "Sentence": "Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the <\\entity><\\entity> for Eye Diseases (SITE) Cohort Study.PURPOSE: To evaluate potential epidemiologic methods for studying long-term effects of immunosuppression on the risk of mortality and fatal malignancy, and present the methodological details of the <\\entity><\\entity> for Eye Diseases (SITE) Cohort Study.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8094",
    "Sentence": "Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for <\\entity><\\entity> (SITE) Cohort Study.PURPOSE: To evaluate potential epidemiologic methods for studying long-term effects of immunosuppression on the risk of mortality and fatal malignancy, and present the methodological details of the Systemic Immunosuppressive Therapy for <\\entity><\\entity> (SITE) Cohort Study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8095",
    "Sentence": "Case-control methods require extremely large sample sizes to evaluate risk associated with rare exposures, and recall bias is problematic when studying <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8096",
    "Sentence": "Past use of <\\entity><\\entity>, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8097",
    "Sentence": "Past use of antimetabolites, <\\entity><\\entity>, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8098",
    "Sentence": "Past use of antimetabolites, T-cell inhibitors, <\\entity><\\entity>, and other immunosuppressives is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8099",
    "Sentence": "Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other <\\entity><\\entity> is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8100",
    "Sentence": "Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 <\\entity><\\entity> patients at five tertiary centers over up to 30 years.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8101",
    "Sentence": "<\\entity><\\entity> and cause-specific mortality outcomes over approximately 100,000 person-years are ascertained using the National Death Index.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8102",
    "Sentence": "Mortality and cause-specific <\\entity><\\entity> outcomes over approximately 100,000 person-years are ascertained using the National Death Index.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8103",
    "Sentence": "Immunosuppressed and non-immunosuppressed groups of patients are compared with each other and general population <\\entity><\\entity> rates from US vital statistics.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8104",
    "Sentence": "Calculated detectable differences for <\\entity><\\entity>/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8105",
    "Sentence": "Calculated detectable differences for mortality/<\\entity><\\entity> with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8106",
    "Sentence": "Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for <\\entity><\\entity>, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8107",
    "Sentence": "Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for <\\entity><\\entity>, and 36%/81% for alkylating agents.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8108",
    "Sentence": "Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8109",
    "Sentence": "CONCLUSIONS: Information from the SITE Cohort Study should clarify whether use of these <\\entity><\\entity> for ocular inflammation increases the risk of mortality and fatal cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8110",
    "Sentence": "CONCLUSIONS: Information from the SITE Cohort Study should clarify whether use of these immunosuppressive drugs for <\\entity><\\entity> increases the risk of mortality and fatal cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8111",
    "Sentence": "CONCLUSIONS: Information from the SITE Cohort Study should clarify whether use of these immunosuppressive drugs for ocular inflammation increases the risk of <\\entity><\\entity> and fatal cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8112",
    "Sentence": "CONCLUSIONS: Information from the SITE Cohort Study should clarify whether use of these immunosuppressive drugs for ocular inflammation increases the risk of mortality and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8113",
    "Sentence": "This epidemiologic approach may be useful for evaluating long-term risks of systemic therapies for other ocular <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8114",
    "Sentence": "Past use of <\\entity><\\entity>, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years.",
    "Label": ""
  },
  {
    "id": "8115",
    "Sentence": "Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 <\\entity><\\entity> patients at five tertiary centers over up to 30 years.",
    "Label": ""
  },
  {
    "id": "8117",
    "Sentence": "Past use of antimetabolites, <\\entity><\\entity>, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years.",
    "Label": ""
  },
  {
    "id": "8118",
    "Sentence": "Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 <\\entity><\\entity> patients at five tertiary centers over up to 30 years.",
    "Label": ""
  },
  {
    "id": "8120",
    "Sentence": "Past use of antimetabolites, T-cell inhibitors, <\\entity><\\entity>, and other immunosuppressives is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years.",
    "Label": ""
  },
  {
    "id": "8121",
    "Sentence": "Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 <\\entity><\\entity> patients at five tertiary centers over up to 30 years.",
    "Label": ""
  },
  {
    "id": "8123",
    "Sentence": "Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other <\\entity><\\entity> is ascertained from medical records of approximately 9,250 ocular inflammation patients at five tertiary centers over up to 30 years.",
    "Label": ""
  },
  {
    "id": "8124",
    "Sentence": "Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 <\\entity><\\entity> patients at five tertiary centers over up to 30 years.",
    "Label": ""
  },
  {
    "id": "8126",
    "Sentence": "Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for <\\entity><\\entity>, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents.",
    "Label": ""
  },
  {
    "id": "8127",
    "Sentence": "Calculated detectable differences for mortality/<\\entity><\\entity> with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents.",
    "Label": ""
  },
  {
    "id": "8129",
    "Sentence": "Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for <\\entity><\\entity>, and 36%/81% for alkylating agents.",
    "Label": ""
  },
  {
    "id": "8130",
    "Sentence": "Calculated detectable differences for mortality/<\\entity><\\entity> with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents.",
    "Label": ""
  },
  {
    "id": "8132",
    "Sentence": "Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8133",
    "Sentence": "Calculated detectable differences for mortality/<\\entity><\\entity> with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents.",
    "Label": ""
  },
  {
    "id": "8135",
    "Sentence": "CONCLUSIONS: Information from the SITE Cohort Study should clarify whether use of these <\\entity><\\entity> for ocular inflammation increases the risk of mortality and fatal cancer.",
    "Label": ""
  },
  {
    "id": "8136",
    "Sentence": "CONCLUSIONS: Information from the SITE Cohort Study should clarify whether use of these immunosuppressive drugs for <\\entity><\\entity> increases the risk of mortality and fatal cancer.",
    "Label": ""
  },
  {
    "id": "8138",
    "Sentence": "CONCLUSIONS: Information from the SITE Cohort Study should clarify whether use of these <\\entity><\\entity> for ocular inflammation increases the risk of mortality and fatal cancer.",
    "Label": ""
  },
  {
    "id": "8139",
    "Sentence": "CONCLUSIONS: Information from the SITE Cohort Study should clarify whether use of these immunosuppressive drugs for ocular inflammation increases the risk of mortality and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8141",
    "Sentence": "Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8142",
    "Sentence": "Calculated detectable differences for <\\entity><\\entity>/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents.",
    "Label": ""
  },
  {
    "id": "8144",
    "Sentence": "Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for <\\entity><\\entity>, and 36%/81% for alkylating agents.",
    "Label": ""
  },
  {
    "id": "8145",
    "Sentence": "Calculated detectable differences for <\\entity><\\entity>/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents.",
    "Label": ""
  },
  {
    "id": "8147",
    "Sentence": "Calculated detectable differences for mortality/fatal malignancy with respect to the general population are 22%/49% for <\\entity><\\entity>, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents.",
    "Label": ""
  },
  {
    "id": "8148",
    "Sentence": "Calculated detectable differences for <\\entity><\\entity>/fatal malignancy with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents.",
    "Label": ""
  },
  {
    "id": "8150",
    "Sentence": "CONCLUSIONS: Information from the SITE Cohort Study should clarify whether use of these <\\entity><\\entity> for ocular inflammation increases the risk of mortality and fatal cancer.",
    "Label": ""
  },
  {
    "id": "8151",
    "Sentence": "CONCLUSIONS: Information from the SITE Cohort Study should clarify whether use of these immunosuppressive drugs for ocular inflammation increases the risk of <\\entity><\\entity> and fatal cancer.",
    "Label": ""
  },
  {
    "id": "8157",
    "Sentence": "<\\entity><\\entity> (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.AIM: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young patients with peripheral T-cell lymphoma (PTCL).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8158",
    "Sentence": "Intensive chemotherapy (<\\entity><\\entity>/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.AIM: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young patients with peripheral T-cell lymphoma (PTCL).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8159",
    "Sentence": "Intensive chemotherapy (high-dose CHOP/<\\entity><\\entity> regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.AIM: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young patients with peripheral T-cell lymphoma (PTCL).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8160",
    "Sentence": "Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with <\\entity><\\entity>.AIM: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young patients with <\\entity><\\entity> (PTCL).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8161",
    "Sentence": "Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.AIM: To analyze toxicity, response and outcome of a phase II trial with <\\entity><\\entity> plus autologous stem-cell transplantation (ASCT) for young patients with peripheral T-cell lymphoma (PTCL).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8162",
    "Sentence": "Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with <\\entity><\\entity>.AIM: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young patients with <\\entity><\\entity> (PTCL).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8163",
    "Sentence": "Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.AIM: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young patients with peripheral T-cell lymphoma (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8164",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with <\\entity><\\entity> received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8165",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of <\\entity><\\entity> 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8166",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, <\\entity><\\entity> 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8167",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, <\\entity><\\entity> and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8168",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and <\\entity><\\entity> alternating with three courses of etoposide, cisplatin, cytarabine and <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8169",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of <\\entity><\\entity>, cisplatin, cytarabine and prednisone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8170",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, <\\entity><\\entity>, cytarabine and prednisone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8171",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, <\\entity><\\entity> and prednisone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8172",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and <\\entity><\\entity> alternating with three courses of etoposide, cisplatin, cytarabine and <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8173",
    "Sentence": "ASCT was carried out in 17 of 24 candidates due to lack of mobilization (three cases), toxicity (two), early <\\entity><\\entity> and patient decision (one each).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8174",
    "Sentence": "With a median follow-up of 3.2 years, 5 of 21 CR patients <\\entity><\\entity> and 2 died in CR due to secondary neoplasms.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8175",
    "Sentence": "With a median follow-up of 3.2 years, 5 of 21 CR patients relapsed and 2 died in CR due to <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8176",
    "Sentence": "CONCLUSION: This <\\entity><\\entity> resulted in moderate CR rate, with manageable toxicity in PTCL.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8177",
    "Sentence": "CONCLUSION: This intensive regimen resulted in moderate CR rate, with manageable toxicity in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8178",
    "Sentence": "The contribution of ASCT in preventing <\\entity><\\entity> is debatable.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8179",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, <\\entity><\\entity> 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.",
    "Label": ""
  },
  {
    "id": "8180",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with <\\entity><\\entity> received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.",
    "Label": ""
  },
  {
    "id": "8182",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, <\\entity><\\entity> and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.",
    "Label": ""
  },
  {
    "id": "8183",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with <\\entity><\\entity> received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.",
    "Label": ""
  },
  {
    "id": "8185",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and <\\entity><\\entity> alternating with three courses of etoposide, cisplatin, cytarabine and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8186",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with <\\entity><\\entity> received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.",
    "Label": ""
  },
  {
    "id": "8188",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of <\\entity><\\entity>, cisplatin, cytarabine and prednisone.",
    "Label": ""
  },
  {
    "id": "8189",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with <\\entity><\\entity> received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.",
    "Label": ""
  },
  {
    "id": "8191",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, <\\entity><\\entity>, cytarabine and prednisone.",
    "Label": ""
  },
  {
    "id": "8192",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with <\\entity><\\entity> received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.",
    "Label": ""
  },
  {
    "id": "8194",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, <\\entity><\\entity> and prednisone.",
    "Label": ""
  },
  {
    "id": "8195",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with <\\entity><\\entity> received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.",
    "Label": ""
  },
  {
    "id": "8197",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of <\\entity><\\entity> 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.",
    "Label": ""
  },
  {
    "id": "8198",
    "Sentence": "PATIENTS AND METHODS: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with <\\entity><\\entity> received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.",
    "Label": ""
  },
  {
    "id": "8200",
    "Sentence": "CONCLUSION: This <\\entity><\\entity> resulted in moderate CR rate, with manageable toxicity in PTCL.",
    "Label": ""
  },
  {
    "id": "8201",
    "Sentence": "CONCLUSION: This intensive regimen resulted in moderate CR rate, with manageable toxicity in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8203",
    "Sentence": "<\\entity><\\entity> (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.AIM: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young patients with peripheral T-cell lymphoma (PTCL).",
    "Label": ""
  },
  {
    "id": "8204",
    "Sentence": "Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with <\\entity><\\entity>.AIM: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young patients with <\\entity><\\entity> (PTCL).",
    "Label": ""
  },
  {
    "id": "8206",
    "Sentence": "Intensive chemotherapy (<\\entity><\\entity>/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.AIM: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young patients with peripheral T-cell lymphoma (PTCL).",
    "Label": ""
  },
  {
    "id": "8207",
    "Sentence": "Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with <\\entity><\\entity>.AIM: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young patients with <\\entity><\\entity> (PTCL).",
    "Label": ""
  },
  {
    "id": "8209",
    "Sentence": "Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.AIM: To analyze toxicity, response and outcome of a phase II trial with <\\entity><\\entity> plus autologous stem-cell transplantation (ASCT) for young patients with peripheral T-cell lymphoma (PTCL).",
    "Label": ""
  },
  {
    "id": "8210",
    "Sentence": "Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.AIM: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young patients with peripheral T-cell lymphoma (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "8216",
    "Sentence": "<\\entity><\\entity>, <\\entity><\\entity>R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis.Different research groups have extensively studied the associations of cytokine gene polymorphisms in different diseases.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8217",
    "Sentence": "<\\entity><\\entity>, <\\entity><\\entity>R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis.Different research groups have extensively studied the associations of cytokine gene polymorphisms in different diseases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8218",
    "Sentence": "IL-1, <\\entity><\\entity> and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis.Different research groups have extensively studied the associations of cytokine gene polymorphisms in different diseases.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8219",
    "Sentence": "IL-1, <\\entity><\\entity> and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis.Different research groups have extensively studied the associations of cytokine gene polymorphisms in different diseases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8220",
    "Sentence": "IL-1, IL-1R and <\\entity><\\entity> in Iranian patients with multiple sclerosis.Different research groups have extensively studied the associations of cytokine gene polymorphisms in different diseases.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8221",
    "Sentence": "IL-1, IL-1R and <\\entity><\\entity> in Iranian patients with multiple sclerosis.Different research groups have extensively studied the associations of cytokine gene polymorphisms in different diseases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8222",
    "Sentence": "IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with <\\entity><\\entity>.Different research groups have extensively studied the associations of cytokine gene polymorphisms in different diseases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8223",
    "Sentence": "IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis.Different research groups have extensively studied the associations of <\\entity><\\entity> in different diseases.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8224",
    "Sentence": "IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis.Different research groups have extensively studied the associations of <\\entity><\\entity> in different diseases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8225",
    "Sentence": "IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis.Different research groups have extensively studied the associations of cytokine gene polymorphisms in different <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8226",
    "Sentence": "The role of <\\entity><\\entity> in multiple sclerosis (MS), as a chronic Immune-mediated neurodegenerative disease, has been previously reported in the various populations.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8227",
    "Sentence": "The role of cytokines gene polymorphisms in <\\entity><\\entity> (MS), as a chronic Immune-mediated neurodegenerative disease, has been previously reported in the various populations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8228",
    "Sentence": "The role of cytokines gene polymorphisms in multiple sclerosis (<\\entity><\\entity>), as a chronic Immune-mediated neurodegenerative disease, has been previously reported in the various populations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8229",
    "Sentence": "The role of cytokines gene polymorphisms in multiple sclerosis (MS), as a <\\entity><\\entity>, has been previously reported in the various populations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8230",
    "Sentence": "For determining pro-inflammatory <\\entity><\\entity>, 100 relapsing remitting multiple sclerosis (RRMS) Iranian patients and 140 normal individuals as control enrolled in this study.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8231",
    "Sentence": "For determining pro-inflammatory <\\entity><\\entity>, 100 relapsing remitting multiple sclerosis (RRMS) Iranian patients and 140 normal individuals as control enrolled in this study.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8232",
    "Sentence": "For determining pro-inflammatory cytokine gene polymorphisms, 100 <\\entity><\\entity> (RRMS) Iranian patients and 140 normal individuals as control enrolled in this study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8233",
    "Sentence": "For determining pro-inflammatory cytokine gene polymorphisms, 100 relapsing remitting multiple sclerosis (<\\entity><\\entity>) Iranian patients and 140 normal individuals as control enrolled in this study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8234",
    "Sentence": "<\\entity><\\entity> single gene nucleotide polymorphisms including IL-1alpha -889, IL-1beta (-511 and +3962), IL-1R pst1 1970, IL-1RA mspal 11100, and TNF-alpha (-308 and -238) were determined by using the PCR-SSP method.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8235",
    "Sentence": "Cytokine single gene nucleotide polymorphisms including <\\entity><\\entity>, IL-1beta (-511 and +3962), IL-1R pst1 1970, IL-1RA mspal 11100, and TNF-alpha (-308 and -238) were determined by using the PCR-SSP method.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8236",
    "Sentence": "Cytokine single gene nucleotide polymorphisms including <\\entity><\\entity>, IL-1beta (-511 and +3962), IL-1R pst1 1970, IL-1RA mspal 11100, and TNF-alpha (-308 and -238) were determined by using the PCR-SSP method.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8237",
    "Sentence": "Cytokine single gene nucleotide polymorphisms including IL-1alpha -889, <\\entity><\\entity> and +3962), IL-1R pst1 1970, IL-1RA mspal 11100, and TNF-alpha (-308 and -238) were determined by using the PCR-SSP method.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8238",
    "Sentence": "Cytokine single gene nucleotide polymorphisms including IL-1alpha -889, <\\entity><\\entity> and +3962), IL-1R pst1 1970, IL-1RA mspal 11100, and TNF-alpha (-308 and -238) were determined by using the PCR-SSP method.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8239",
    "Sentence": "Cytokine single gene nucleotide polymorphisms including IL-1alpha -889, IL-1beta (-511 and <\\entity><\\entity>), IL-1R pst1 1970, IL-1RA mspal 11100, and TNF-alpha (-308 and -238) were determined by using the PCR-SSP method.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8240",
    "Sentence": "Cytokine single gene nucleotide polymorphisms including IL-1alpha -889, IL-1beta (-511 and +3962), <\\entity><\\entity>, IL-1RA mspal 11100, and TNF-alpha (-308 and -238) were determined by using the PCR-SSP method.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8241",
    "Sentence": "Cytokine single gene nucleotide polymorphisms including IL-1alpha -889, IL-1beta (-511 and +3962), <\\entity><\\entity>, IL-1RA mspal 11100, and TNF-alpha (-308 and -238) were determined by using the PCR-SSP method.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8242",
    "Sentence": "Cytokine single gene nucleotide polymorphisms including IL-1alpha -889, IL-1beta (-511 and +3962), IL-1R <\\entity><\\entity> 1970, IL-1RA mspal 11100, and TNF-alpha (-308 and -238) were determined by using the PCR-SSP method.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8243",
    "Sentence": "Cytokine single gene nucleotide polymorphisms including IL-1alpha -889, IL-1beta (-511 and +3962), IL-1R <\\entity><\\entity> 1970, IL-1RA mspal 11100, and TNF-alpha (-308 and -238) were determined by using the PCR-SSP method.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8244",
    "Sentence": "Cytokine single gene nucleotide polymorphisms including IL-1alpha -889, IL-1beta (-511 and +3962), IL-1R pst1 1970, <\\entity><\\entity>, and TNF-alpha (-308 and -238) were determined by using the PCR-SSP method.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8245",
    "Sentence": "Cytokine single gene nucleotide polymorphisms including IL-1alpha -889, IL-1beta (-511 and +3962), IL-1R pst1 1970, <\\entity><\\entity>, and TNF-alpha (-308 and -238) were determined by using the PCR-SSP method.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8246",
    "Sentence": "Cytokine single gene nucleotide polymorphisms including IL-1alpha -889, IL-1beta (-511 and +3962), IL-1R pst1 1970, IL-1RA mspal 11100, and <\\entity><\\entity> and -238) were determined by using the PCR-SSP method.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8247",
    "Sentence": "Cytokine single gene nucleotide polymorphisms including IL-1alpha -889, IL-1beta (-511 and +3962), IL-1R pst1 1970, IL-1RA mspal 11100, and <\\entity><\\entity> and -238) were determined by using the PCR-SSP method.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8248",
    "Sentence": "Cytokine single gene nucleotide polymorphisms including IL-1alpha -889, IL-1beta (-511 and +3962), IL-1R pst1 1970, IL-1RA mspal 11100, and TNF-alpha (-308 and <\\entity><\\entity>) were determined by using the PCR-SSP method.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8249",
    "Sentence": "The results of our data indicate the decrease in frequency of <\\entity><\\entity> genotype (p=0.002), IL-1beta TC +3962 genotype (p=0.004), IL-1R T pst1 1970 allele (p= 0.0001), IL-1 RA TC Mspa1 11100 genotype (p=0.009), TNF-alpha A-308 allele (p=0.0002) and AG genotype (p=0.00001) in the patients group versus normal subjects.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8250",
    "Sentence": "The results of our data indicate the decrease in frequency of <\\entity><\\entity> genotype (p=0.002), IL-1beta TC +3962 genotype (p=0.004), IL-1R T pst1 1970 allele (p= 0.0001), IL-1 RA TC Mspa1 11100 genotype (p=0.009), TNF-alpha A-308 allele (p=0.0002) and AG genotype (p=0.00001) in the patients group versus normal subjects.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8251",
    "Sentence": "The results of our data indicate the decrease in frequency of IL-1alpha TC-889 genotype (p=0.002), <\\entity><\\entity> genotype (p=0.004), IL-1R T pst1 1970 allele (p= 0.0001), IL-1 RA TC Mspa1 11100 genotype (p=0.009), TNF-alpha A-308 allele (p=0.0002) and AG genotype (p=0.00001) in the patients group versus normal subjects.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8252",
    "Sentence": "The results of our data indicate the decrease in frequency of IL-1alpha TC-889 genotype (p=0.002), <\\entity><\\entity> genotype (p=0.004), IL-1R T pst1 1970 allele (p= 0.0001), IL-1 RA TC Mspa1 11100 genotype (p=0.009), TNF-alpha A-308 allele (p=0.0002) and AG genotype (p=0.00001) in the patients group versus normal subjects.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8253",
    "Sentence": "The results of our data indicate the decrease in frequency of IL-1alpha TC-889 genotype (p=0.002), IL-1beta TC +3962 genotype (p=0.004), <\\entity><\\entity> (p= 0.0001), IL-1 RA TC Mspa1 11100 genotype (p=0.009), TNF-alpha A-308 allele (p=0.0002) and AG genotype (p=0.00001) in the patients group versus normal subjects.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8254",
    "Sentence": "The results of our data indicate the decrease in frequency of IL-1alpha TC-889 genotype (p=0.002), IL-1beta TC +3962 genotype (p=0.004), <\\entity><\\entity> (p= 0.0001), IL-1 RA TC Mspa1 11100 genotype (p=0.009), TNF-alpha A-308 allele (p=0.0002) and AG genotype (p=0.00001) in the patients group versus normal subjects.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8255",
    "Sentence": "The results of our data indicate the decrease in frequency of IL-1alpha TC-889 genotype (p=0.002), IL-1beta TC +3962 genotype (p=0.004), IL-1R T <\\entity><\\entity> 1970 allele (p= 0.0001), IL-1 RA TC Mspa1 11100 genotype (p=0.009), TNF-alpha A-308 allele (p=0.0002) and AG genotype (p=0.00001) in the patients group versus normal subjects.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8256",
    "Sentence": "The results of our data indicate the decrease in frequency of IL-1alpha TC-889 genotype (p=0.002), IL-1beta TC +3962 genotype (p=0.004), IL-1R T <\\entity><\\entity> 1970 allele (p= 0.0001), IL-1 RA TC Mspa1 11100 genotype (p=0.009), TNF-alpha A-308 allele (p=0.0002) and AG genotype (p=0.00001) in the patients group versus normal subjects.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8257",
    "Sentence": "The results of our data indicate the decrease in frequency of IL-1alpha TC-889 genotype (p=0.002), IL-1beta TC +3962 genotype (p=0.004), IL-1R T pst1 1970 allele (p= 0.0001), <\\entity><\\entity> genotype (p=0.009), TNF-alpha A-308 allele (p=0.0002) and AG genotype (p=0.00001) in the patients group versus normal subjects.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8258",
    "Sentence": "The results of our data indicate the decrease in frequency of IL-1alpha TC-889 genotype (p=0.002), IL-1beta TC +3962 genotype (p=0.004), IL-1R T pst1 1970 allele (p= 0.0001), <\\entity><\\entity> genotype (p=0.009), TNF-alpha A-308 allele (p=0.0002) and AG genotype (p=0.00001) in the patients group versus normal subjects.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8259",
    "Sentence": "The results of our data indicate the decrease in frequency of IL-1alpha TC-889 genotype (p=0.002), IL-1beta TC +3962 genotype (p=0.004), IL-1R T pst1 1970 allele (p= 0.0001), IL-1 RA TC Mspa1 11100 genotype (p=0.009), <\\entity><\\entity> (p=0.0002) and AG genotype (p=0.00001) in the patients group versus normal subjects.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8260",
    "Sentence": "The results of our data indicate the decrease in frequency of IL-1alpha TC-889 genotype (p=0.002), IL-1beta TC +3962 genotype (p=0.004), IL-1R T pst1 1970 allele (p= 0.0001), IL-1 RA TC Mspa1 11100 genotype (p=0.009), <\\entity><\\entity> (p=0.0002) and AG genotype (p=0.00001) in the patients group versus normal subjects.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8261",
    "Sentence": "The results of our data indicate the decrease in frequency of IL-1alpha TC-889 genotype (p=0.002), IL-1beta TC +3962 genotype (p=0.004), IL-1R T pst1 1970 allele (p= 0.0001), IL-1 RA TC Mspa1 11100 genotype (p=0.009), TNF-alpha <\\entity><\\entity> allele (p=0.0002) and AG genotype (p=0.00001) in the patients group versus normal subjects.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8262",
    "Sentence": "The results of our data indicate the decrease in frequency of IL-1alpha TC-889 genotype (p=0.002), IL-1beta TC +3962 genotype (p=0.004), IL-1R T pst1 1970 allele (p= 0.0001), IL-1 RA TC Mspa1 11100 genotype (p=0.009), TNF-alpha A-308 allele (p=0.0002) and <\\entity><\\entity> genotype (p=0.00001) in the patients group versus normal subjects.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8263",
    "Sentence": "On the other hand the frequency of <\\entity><\\entity> genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8264",
    "Sentence": "On the other hand the frequency of <\\entity><\\entity> genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8265",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), <\\entity><\\entity> (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8266",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), <\\entity><\\entity> (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8267",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C <\\entity><\\entity> 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8268",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C <\\entity><\\entity> 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8269",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and <\\entity><\\entity> genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8270",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), <\\entity><\\entity> (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8271",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), <\\entity><\\entity> (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8272",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha <\\entity><\\entity> allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8273",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and <\\entity><\\entity> genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8274",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these <\\entity><\\entity> may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8275",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian <\\entity><\\entity> patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8276",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these <\\entity><\\entity> may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": ""
  },
  {
    "id": "8277",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "8279",
    "Sentence": "<\\entity><\\entity>, <\\entity><\\entity>R and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis.Different research groups have extensively studied the associations of cytokine gene polymorphisms in different diseases.",
    "Label": ""
  },
  {
    "id": "8280",
    "Sentence": "IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with <\\entity><\\entity>.Different research groups have extensively studied the associations of cytokine gene polymorphisms in different diseases.",
    "Label": ""
  },
  {
    "id": "8282",
    "Sentence": "IL-1, IL-1R and <\\entity><\\entity> in Iranian patients with multiple sclerosis.Different research groups have extensively studied the associations of cytokine gene polymorphisms in different diseases.",
    "Label": ""
  },
  {
    "id": "8283",
    "Sentence": "IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with <\\entity><\\entity>.Different research groups have extensively studied the associations of cytokine gene polymorphisms in different diseases.",
    "Label": ""
  },
  {
    "id": "8285",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), <\\entity><\\entity> (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": ""
  },
  {
    "id": "8286",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "8288",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C <\\entity><\\entity> 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": ""
  },
  {
    "id": "8289",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "8291",
    "Sentence": "IL-1, <\\entity><\\entity> and TNFalpha gene polymorphisms in Iranian patients with multiple sclerosis.Different research groups have extensively studied the associations of cytokine gene polymorphisms in different diseases.",
    "Label": ""
  },
  {
    "id": "8292",
    "Sentence": "IL-1, IL-1R and TNFalpha gene polymorphisms in Iranian patients with <\\entity><\\entity>.Different research groups have extensively studied the associations of cytokine gene polymorphisms in different diseases.",
    "Label": ""
  },
  {
    "id": "8294",
    "Sentence": "For determining pro-inflammatory <\\entity><\\entity>, 100 relapsing remitting multiple sclerosis (RRMS) Iranian patients and 140 normal individuals as control enrolled in this study.",
    "Label": ""
  },
  {
    "id": "8295",
    "Sentence": "For determining pro-inflammatory cytokine gene polymorphisms, 100 <\\entity><\\entity> (RRMS) Iranian patients and 140 normal individuals as control enrolled in this study.",
    "Label": ""
  },
  {
    "id": "8297",
    "Sentence": "For determining pro-inflammatory <\\entity><\\entity>, 100 relapsing remitting multiple sclerosis (RRMS) Iranian patients and 140 normal individuals as control enrolled in this study.",
    "Label": ""
  },
  {
    "id": "8298",
    "Sentence": "For determining pro-inflammatory cytokine gene polymorphisms, 100 relapsing remitting multiple sclerosis (<\\entity><\\entity>) Iranian patients and 140 normal individuals as control enrolled in this study.",
    "Label": ""
  },
  {
    "id": "8300",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), <\\entity><\\entity> (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": ""
  },
  {
    "id": "8301",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "8303",
    "Sentence": "On the other hand the frequency of <\\entity><\\entity> genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": ""
  },
  {
    "id": "8304",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "8306",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha <\\entity><\\entity> allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": ""
  },
  {
    "id": "8307",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "8309",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and <\\entity><\\entity> genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian multiple sclerosis patients.",
    "Label": ""
  },
  {
    "id": "8310",
    "Sentence": "On the other hand the frequency of IL-1alpha TT -889 genotype (p=0.028), IL-1R C pst1 1970 allele (p=0.0001) and CC genotype (p=0.00006), TNFalpha G -308 allele (p=0.0002) and GG genotype (p=0.000001) decreased significantly in the patients versus normal subjects.These results suggest that polymorphic variations of these pro-inflammatory cytokines may play an important role in susceptibility of Iranian <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "8316",
    "Sentence": "Synthesis and pharmacological in vitro and in vivo profile of <\\entity><\\entity> (SHA 68), a selective antagonist of the neuropeptide S receptor.Neuropeptide S (NPS) has been shown to modulate arousal, sleep wakefulness, anxiety-like behavior, and feeding after central administration of the peptide agonist to mice or rats.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8317",
    "Sentence": "Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (<\\entity><\\entity>), a selective antagonist of the neuropeptide S receptor.Neuropeptide S (NPS) has been shown to modulate arousal, sleep wakefulness, anxiety-like behavior, and feeding after central administration of the peptide agonist to mice or rats.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8318",
    "Sentence": "Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the <\\entity><\\entity>.Neuropeptide S (NPS) has been shown to modulate arousal, sleep wakefulness, anxiety-like behavior, and feeding after central administration of the peptide agonist to mice or rats.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8319",
    "Sentence": "Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor.<\\entity><\\entity> (NPS) has been shown to modulate arousal, sleep wakefulness, anxiety-like behavior, and feeding after central administration of the peptide agonist to mice or rats.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8320",
    "Sentence": "Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor.Neuropeptide S (<\\entity><\\entity>) has been shown to modulate arousal, sleep wakefulness, anxiety-like behavior, and feeding after central administration of the peptide agonist to mice or rats.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8321",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of <\\entity><\\entity> (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8322",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (<\\entity><\\entity>) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8323",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and <\\entity><\\entity> (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8324",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (<\\entity><\\entity>), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8325",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the <\\entity><\\entity> (NPSR).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8326",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8327",
    "Sentence": "The compounds block <\\entity><\\entity>-induced Ca2+ mobilization, and SHA 68 shows displaceable binding to <\\entity><\\entity>R in the nanomolar range.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8328",
    "Sentence": "The compounds block NPS-induced Ca2+ mobilization, and <\\entity><\\entity> shows displaceable binding to NPSR in the nanomolar range.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8329",
    "Sentence": "The compounds block NPS-induced Ca2+ mobilization, and SHA 68 shows displaceable binding to <\\entity><\\entity> in the nanomolar range.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8330",
    "Sentence": "The antagonistic activity of <\\entity><\\entity> seems to be specific because it does not affect signaling at 14 unrelated G protein-coupled receptors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8331",
    "Sentence": "The antagonistic activity of SHA 68 seems to be specific because it does not affect signaling at 14 unrelated <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8332",
    "Sentence": "Analysis of pharmacokinetic parameters of <\\entity><\\entity> demonstrates that the compound reaches pharmacologically relevant levels in plasma and brain after i.p.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8333",
    "Sentence": "Furthermore, peripheral administration of <\\entity><\\entity> in mice (50 mg/kg i.p.) is able to antagonize NPS-induced horizontal and vertical activity as well as stereotypic behavior.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8334",
    "Sentence": "Furthermore, peripheral administration of SHA 68 in mice (50 mg/kg i.p.) is able to antagonize <\\entity><\\entity>-induced horizontal and vertical activity as well as stereotypic behavior.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8335",
    "Sentence": "Therefore, <\\entity><\\entity> could be a useful tool to characterize physiological functions and pharmacological parameters of the NPS system in vitro and in vivo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8336",
    "Sentence": "Therefore, SHA 68 could be a useful tool to characterize physiological functions and pharmacological parameters of the <\\entity><\\entity> system in vitro and in vivo.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8337",
    "Sentence": "Synthesis and pharmacological in vitro and in vivo profile of <\\entity><\\entity> (SHA 68), a selective antagonist of the neuropeptide S receptor.Neuropeptide S (NPS) has been shown to modulate arousal, sleep wakefulness, anxiety-like behavior, and feeding after central administration of the peptide agonist to mice or rats.",
    "Label": ""
  },
  {
    "id": "8338",
    "Sentence": "Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the <\\entity><\\entity>.Neuropeptide S (NPS) has been shown to modulate arousal, sleep wakefulness, anxiety-like behavior, and feeding after central administration of the peptide agonist to mice or rats.",
    "Label": ""
  },
  {
    "id": "8340",
    "Sentence": "Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (<\\entity><\\entity>), a selective antagonist of the neuropeptide S receptor.Neuropeptide S (NPS) has been shown to modulate arousal, sleep wakefulness, anxiety-like behavior, and feeding after central administration of the peptide agonist to mice or rats.",
    "Label": ""
  },
  {
    "id": "8341",
    "Sentence": "Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the <\\entity><\\entity>.Neuropeptide S (NPS) has been shown to modulate arousal, sleep wakefulness, anxiety-like behavior, and feeding after central administration of the peptide agonist to mice or rats.",
    "Label": ""
  },
  {
    "id": "8343",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (<\\entity><\\entity>), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR).",
    "Label": ""
  },
  {
    "id": "8344",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "8346",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (<\\entity><\\entity>), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR).",
    "Label": ""
  },
  {
    "id": "8347",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the <\\entity><\\entity> (NPSR).",
    "Label": ""
  },
  {
    "id": "8349",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of <\\entity><\\entity> (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR).",
    "Label": ""
  },
  {
    "id": "8350",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "8352",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of <\\entity><\\entity> (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR).",
    "Label": ""
  },
  {
    "id": "8353",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the <\\entity><\\entity> (NPSR).",
    "Label": ""
  },
  {
    "id": "8355",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (<\\entity><\\entity>) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR).",
    "Label": ""
  },
  {
    "id": "8356",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "8358",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (<\\entity><\\entity>) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR).",
    "Label": ""
  },
  {
    "id": "8359",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the <\\entity><\\entity> (NPSR).",
    "Label": ""
  },
  {
    "id": "8361",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and <\\entity><\\entity> (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR).",
    "Label": ""
  },
  {
    "id": "8362",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "8364",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and <\\entity><\\entity> (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the NPS receptor (NPSR).",
    "Label": ""
  },
  {
    "id": "8365",
    "Sentence": "We report here the chemical synthesis and pharmacological characterization of SHA 66 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid benzylamide) and SHA 68 (3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide), two closely related bicyclic piperazines with antagonistic properties at the <\\entity><\\entity> (NPSR).",
    "Label": ""
  },
  {
    "id": "8367",
    "Sentence": "The compounds block NPS-induced Ca2+ mobilization, and <\\entity><\\entity> shows displaceable binding to NPSR in the nanomolar range.",
    "Label": ""
  },
  {
    "id": "8368",
    "Sentence": "The compounds block NPS-induced Ca2+ mobilization, and SHA 68 shows displaceable binding to <\\entity><\\entity> in the nanomolar range.",
    "Label": ""
  },
  {
    "id": "8370",
    "Sentence": "Furthermore, peripheral administration of <\\entity><\\entity> in mice (50 mg/kg i.p.) is able to antagonize NPS-induced horizontal and vertical activity as well as stereotypic behavior.",
    "Label": ""
  },
  {
    "id": "8371",
    "Sentence": "Furthermore, peripheral administration of SHA 68 in mice (50 mg/kg i.p.) is able to antagonize <\\entity><\\entity>-induced horizontal and vertical activity as well as stereotypic behavior.",
    "Label": ""
  },
  {
    "id": "8373",
    "Sentence": "Therefore, <\\entity><\\entity> could be a useful tool to characterize physiological functions and pharmacological parameters of the NPS system in vitro and in vivo.",
    "Label": ""
  },
  {
    "id": "8374",
    "Sentence": "Therefore, SHA 68 could be a useful tool to characterize physiological functions and pharmacological parameters of the <\\entity><\\entity> system in vitro and in vivo.",
    "Label": ""
  },
  {
    "id": "8376",
    "Sentence": "The compounds block NPS-induced Ca2+ mobilization, and <\\entity><\\entity> shows displaceable binding to NPSR in the nanomolar range.",
    "Label": ""
  },
  {
    "id": "8377",
    "Sentence": "The compounds block <\\entity><\\entity>-induced Ca2+ mobilization, and SHA 68 shows displaceable binding to <\\entity><\\entity>R in the nanomolar range.",
    "Label": ""
  },
  {
    "id": "8379",
    "Sentence": "The antagonistic activity of <\\entity><\\entity> seems to be specific because it does not affect signaling at 14 unrelated G protein-coupled receptors.",
    "Label": ""
  },
  {
    "id": "8380",
    "Sentence": "The antagonistic activity of SHA 68 seems to be specific because it does not affect signaling at 14 unrelated <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8386",
    "Sentence": "Acute myeloid leukaemia <\\entity><\\entity> cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8387",
    "Sentence": "Acute myeloid leukaemia blast cells with a <\\entity><\\entity> are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8388",
    "Sentence": "Acute myeloid leukaemia blast cells with a <\\entity><\\entity> are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8389",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to <\\entity><\\entity> than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8390",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a <\\entity><\\entity>.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike <\\entity><\\entity>s (FLT3/ITDs) that have a poor prognosis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8391",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a <\\entity><\\entity>.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike <\\entity><\\entity>s (FLT3/ITDs) that have a poor prognosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8392",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.<\\entity><\\entity> (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8393",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.<\\entity><\\entity> (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8394",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (<\\entity><\\entity>) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8395",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (<\\entity><\\entity>) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8396",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike <\\entity><\\entity> (FLT3/ITDs) that have a poor prognosis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8397",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike <\\entity><\\entity> (FLT3/ITDs) that have a poor prognosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8398",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (<\\entity><\\entity>) that have a poor prognosis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8399",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (<\\entity><\\entity>) that have a poor prognosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8400",
    "Sentence": "Whilst <\\entity><\\entity> cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8401",
    "Sentence": "Whilst <\\entity><\\entity> cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8402",
    "Sentence": "Whilst FLT3/<\\entity><\\entity>+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8403",
    "Sentence": "Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of <\\entity><\\entity> than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8404",
    "Sentence": "Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of <\\entity><\\entity> than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8405",
    "Sentence": "Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (<\\entity><\\entity>) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8406",
    "Sentence": "Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (WT) cells, the sensitivity of <\\entity><\\entity> cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8407",
    "Sentence": "Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (WT) cells, the sensitivity of <\\entity><\\entity> cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8408",
    "Sentence": "We therefore studied the effect of <\\entity><\\entity> and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8409",
    "Sentence": "We therefore studied the effect of cytarabine and the <\\entity><\\entity> lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8410",
    "Sentence": "We therefore studied the effect of cytarabine and the <\\entity><\\entity> lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8411",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor <\\entity><\\entity>, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8412",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of <\\entity><\\entity> cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8413",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 <\\entity><\\entity>, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8414",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 <\\entity><\\entity>, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8415",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 <\\entity><\\entity> and 11 FLT3/TKD+).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8416",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 <\\entity><\\entity> and 11 FLT3/TKD+).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8417",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/<\\entity><\\entity>+ and 11 FLT3/TKD+).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8418",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 <\\entity><\\entity>).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8419",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 <\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8420",
    "Sentence": "All three groups showed similar sensitivity to the cytotoxic effects of <\\entity><\\entity> but FLT3/ITD mutant level was inversely correlated with <\\entity><\\entity> cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8421",
    "Sentence": "All three groups showed similar sensitivity to the cytotoxic effects of cytarabine but <\\entity><\\entity> mutant level was inversely correlated with cytarabine cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8422",
    "Sentence": "All three groups showed similar sensitivity to the cytotoxic effects of cytarabine but <\\entity><\\entity> mutant level was inversely correlated with cytarabine cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8423",
    "Sentence": "All three groups showed similar sensitivity to the cytotoxic effects of <\\entity><\\entity> but FLT3/ITD mutant level was inversely correlated with <\\entity><\\entity> cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8424",
    "Sentence": "All three groups showed similar sensitivity to the cytotoxic effects of cytarabine but FLT3/ITD mutant level was inversely correlated with cytarabine cytotoxicity (P = 0.04) whereas <\\entity><\\entity> mutant level had no impact.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8425",
    "Sentence": "All three groups showed similar sensitivity to the cytotoxic effects of cytarabine but FLT3/ITD mutant level was inversely correlated with cytarabine cytotoxicity (P = 0.04) whereas <\\entity><\\entity> mutant level had no impact.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8426",
    "Sentence": "<\\entity><\\entity> cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8427",
    "Sentence": "<\\entity><\\entity> cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8428",
    "Sentence": "FLT3/TKD+ cells showed a similar response to <\\entity><\\entity> as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8429",
    "Sentence": "FLT3/TKD+ cells showed a similar response to lestaurtinib as <\\entity><\\entity> cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8430",
    "Sentence": "FLT3/TKD+ cells showed a similar response to lestaurtinib as <\\entity><\\entity> cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8431",
    "Sentence": "FLT3/TKD+ cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas <\\entity><\\entity> cells were more sensitive (P = 0.004).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8432",
    "Sentence": "FLT3/TKD+ cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas <\\entity><\\entity> cells were more sensitive (P = 0.004).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8433",
    "Sentence": "FLT3/TKD+ cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas FLT3/<\\entity><\\entity>+ cells were more sensitive (P = 0.004).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8434",
    "Sentence": "There was no correlation between mutant level and <\\entity><\\entity> sensitivity for either FLT3/ITD+ or FLT3/TKD+ cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8435",
    "Sentence": "There was no correlation between mutant level and lestaurtinib sensitivity for either <\\entity><\\entity> or FLT3/TKD+ cells.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8436",
    "Sentence": "There was no correlation between mutant level and lestaurtinib sensitivity for either <\\entity><\\entity> or FLT3/TKD+ cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8437",
    "Sentence": "There was no correlation between mutant level and lestaurtinib sensitivity for either FLT3/<\\entity><\\entity>+ or FLT3/TKD+ cells.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8438",
    "Sentence": "There was no correlation between mutant level and lestaurtinib sensitivity for either FLT3/ITD+ or <\\entity><\\entity> cells.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8439",
    "Sentence": "There was no correlation between mutant level and lestaurtinib sensitivity for either FLT3/ITD+ or <\\entity><\\entity> cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8440",
    "Sentence": "Synergistic cytotoxicity of <\\entity><\\entity> plus cytarabine was demonstrated in all three groups.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8441",
    "Sentence": "Synergistic cytotoxicity of lestaurtinib plus <\\entity><\\entity> was demonstrated in all three groups.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8442",
    "Sentence": "These results suggest that <\\entity><\\entity> and FLT3/WT cases should not be differentiated when considering patients for treatment with FLT3 inhibitors.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8443",
    "Sentence": "These results suggest that <\\entity><\\entity> and FLT3/WT cases should not be differentiated when considering patients for treatment with FLT3 inhibitors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8444",
    "Sentence": "These results suggest that FLT3/TKD+ and <\\entity><\\entity> cases should not be differentiated when considering patients for treatment with FLT3 inhibitors.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8445",
    "Sentence": "These results suggest that FLT3/TKD+ and <\\entity><\\entity> cases should not be differentiated when considering patients for treatment with FLT3 inhibitors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8446",
    "Sentence": "These results suggest that FLT3/TKD+ and FLT3/WT cases should not be differentiated when considering patients for treatment with <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8447",
    "Sentence": "These results suggest that FLT3/TKD+ and FLT3/WT cases should not be differentiated when considering patients for treatment with <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8448",
    "Sentence": "Acute myeloid leukaemia blast cells with a <\\entity><\\entity> are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis.",
    "Label": ""
  },
  {
    "id": "8449",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to <\\entity><\\entity> than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis.",
    "Label": ""
  },
  {
    "id": "8451",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a <\\entity><\\entity>.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike <\\entity><\\entity>s (FLT3/ITDs) that have a poor prognosis.",
    "Label": ""
  },
  {
    "id": "8452",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to <\\entity><\\entity> than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis.",
    "Label": ""
  },
  {
    "id": "8454",
    "Sentence": "Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (<\\entity><\\entity>) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": ""
  },
  {
    "id": "8455",
    "Sentence": "Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of <\\entity><\\entity> than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": ""
  },
  {
    "id": "8457",
    "Sentence": "Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (WT) cells, the sensitivity of <\\entity><\\entity> cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": ""
  },
  {
    "id": "8458",
    "Sentence": "Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of <\\entity><\\entity> than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": ""
  },
  {
    "id": "8460",
    "Sentence": "Whilst <\\entity><\\entity> cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": ""
  },
  {
    "id": "8461",
    "Sentence": "Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of <\\entity><\\entity> than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": ""
  },
  {
    "id": "8463",
    "Sentence": "All three groups showed similar sensitivity to the cytotoxic effects of cytarabine but <\\entity><\\entity> mutant level was inversely correlated with cytarabine cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact.",
    "Label": ""
  },
  {
    "id": "8464",
    "Sentence": "All three groups showed similar sensitivity to the cytotoxic effects of <\\entity><\\entity> but FLT3/ITD mutant level was inversely correlated with <\\entity><\\entity> cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact.",
    "Label": ""
  },
  {
    "id": "8466",
    "Sentence": "All three groups showed similar sensitivity to the cytotoxic effects of cytarabine but FLT3/ITD mutant level was inversely correlated with cytarabine cytotoxicity (P = 0.04) whereas <\\entity><\\entity> mutant level had no impact.",
    "Label": ""
  },
  {
    "id": "8467",
    "Sentence": "All three groups showed similar sensitivity to the cytotoxic effects of <\\entity><\\entity> but FLT3/ITD mutant level was inversely correlated with <\\entity><\\entity> cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact.",
    "Label": ""
  },
  {
    "id": "8469",
    "Sentence": "FLT3/TKD+ cells showed a similar response to lestaurtinib as <\\entity><\\entity> cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004).",
    "Label": ""
  },
  {
    "id": "8470",
    "Sentence": "FLT3/TKD+ cells showed a similar response to <\\entity><\\entity> as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004).",
    "Label": ""
  },
  {
    "id": "8472",
    "Sentence": "<\\entity><\\entity> cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004).",
    "Label": ""
  },
  {
    "id": "8473",
    "Sentence": "FLT3/TKD+ cells showed a similar response to <\\entity><\\entity> as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004).",
    "Label": ""
  },
  {
    "id": "8475",
    "Sentence": "FLT3/TKD+ cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas <\\entity><\\entity> cells were more sensitive (P = 0.004).",
    "Label": ""
  },
  {
    "id": "8476",
    "Sentence": "FLT3/TKD+ cells showed a similar response to <\\entity><\\entity> as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004).",
    "Label": ""
  },
  {
    "id": "8478",
    "Sentence": "There was no correlation between mutant level and lestaurtinib sensitivity for either FLT3/ITD+ or <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "8479",
    "Sentence": "There was no correlation between mutant level and <\\entity><\\entity> sensitivity for either FLT3/ITD+ or FLT3/TKD+ cells.",
    "Label": ""
  },
  {
    "id": "8481",
    "Sentence": "There was no correlation between mutant level and lestaurtinib sensitivity for either <\\entity><\\entity> or FLT3/TKD+ cells.",
    "Label": ""
  },
  {
    "id": "8482",
    "Sentence": "There was no correlation between mutant level and <\\entity><\\entity> sensitivity for either FLT3/ITD+ or FLT3/TKD+ cells.",
    "Label": ""
  },
  {
    "id": "8484",
    "Sentence": "Acute myeloid leukaemia <\\entity><\\entity> cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis.",
    "Label": ""
  },
  {
    "id": "8485",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a <\\entity><\\entity>.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike <\\entity><\\entity>s (FLT3/ITDs) that have a poor prognosis.",
    "Label": ""
  },
  {
    "id": "8487",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of <\\entity><\\entity> cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8488",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 <\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "8490",
    "Sentence": "We therefore studied the effect of <\\entity><\\entity> and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8491",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 <\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "8493",
    "Sentence": "All three groups showed similar sensitivity to the cytotoxic effects of <\\entity><\\entity> but FLT3/ITD mutant level was inversely correlated with <\\entity><\\entity> cytotoxicity (P = 0.04) whereas FLT3/TKD mutant level had no impact.",
    "Label": ""
  },
  {
    "id": "8494",
    "Sentence": "All three groups showed similar sensitivity to the cytotoxic effects of cytarabine but FLT3/ITD mutant level was inversely correlated with cytarabine cytotoxicity (P = 0.04) whereas <\\entity><\\entity> mutant level had no impact.",
    "Label": ""
  },
  {
    "id": "8496",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to <\\entity><\\entity> than those with a FLT3 internal tandem duplication.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike FLT3 internal tandem duplications (FLT3/ITDs) that have a poor prognosis.",
    "Label": ""
  },
  {
    "id": "8497",
    "Sentence": "Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a <\\entity><\\entity>.FLT3 tyrosine kinase domain mutations (FLT3/TKDs) are associated with a favourable prognosis in acute myeloid leukaemia (AML), unlike <\\entity><\\entity>s (FLT3/ITDs) that have a poor prognosis.",
    "Label": ""
  },
  {
    "id": "8499",
    "Sentence": "We therefore studied the effect of <\\entity><\\entity> and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8500",
    "Sentence": "We therefore studied the effect of cytarabine and the <\\entity><\\entity> lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8502",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor <\\entity><\\entity>, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8503",
    "Sentence": "We therefore studied the effect of cytarabine and the <\\entity><\\entity> lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8505",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 <\\entity><\\entity>, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8506",
    "Sentence": "We therefore studied the effect of <\\entity><\\entity> and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8508",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 <\\entity><\\entity>, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8509",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor <\\entity><\\entity>, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8511",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 <\\entity><\\entity> and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8512",
    "Sentence": "We therefore studied the effect of <\\entity><\\entity> and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8514",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 <\\entity><\\entity> and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8515",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor <\\entity><\\entity>, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8517",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 <\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "8518",
    "Sentence": "We therefore studied the effect of <\\entity><\\entity> and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8520",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor lestaurtinib, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 <\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "8521",
    "Sentence": "We therefore studied the effect of cytarabine and the FLT3 inhibitor <\\entity><\\entity>, either alone or in combination, on in vitro survival of blast cells from 36 cases of AML (14 FLT3/WT, 11 FLT3/ITD+ and 11 FLT3/TKD+).",
    "Label": ""
  },
  {
    "id": "8523",
    "Sentence": "These results suggest that FLT3/TKD+ and <\\entity><\\entity> cases should not be differentiated when considering patients for treatment with FLT3 inhibitors.",
    "Label": ""
  },
  {
    "id": "8524",
    "Sentence": "These results suggest that FLT3/TKD+ and FLT3/WT cases should not be differentiated when considering patients for treatment with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8526",
    "Sentence": "These results suggest that <\\entity><\\entity> and FLT3/WT cases should not be differentiated when considering patients for treatment with FLT3 inhibitors.",
    "Label": ""
  },
  {
    "id": "8527",
    "Sentence": "These results suggest that FLT3/TKD+ and FLT3/WT cases should not be differentiated when considering patients for treatment with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8529",
    "Sentence": "Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of <\\entity><\\entity> than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": ""
  },
  {
    "id": "8530",
    "Sentence": "Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (WT) cells, the sensitivity of <\\entity><\\entity> cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": ""
  },
  {
    "id": "8532",
    "Sentence": "Whilst FLT3/<\\entity><\\entity>+ cells are more susceptible to the cytotoxic effects of FLT3 inhibitors than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": ""
  },
  {
    "id": "8533",
    "Sentence": "Whilst FLT3/ITD+ cells are more susceptible to the cytotoxic effects of <\\entity><\\entity> than wild type (WT) cells, the sensitivity of FLT3/TKD+ cells to therapeutic agents is unclear, as is the importance of the mutant level.",
    "Label": ""
  },
  {
    "id": "8535",
    "Sentence": "FLT3/TKD+ cells showed a similar response to lestaurtinib as FLT3/WT cells, whereas FLT3/<\\entity><\\entity>+ cells were more sensitive (P = 0.004).",
    "Label": ""
  },
  {
    "id": "8536",
    "Sentence": "FLT3/TKD+ cells showed a similar response to <\\entity><\\entity> as FLT3/WT cells, whereas FLT3/ITD+ cells were more sensitive (P = 0.004).",
    "Label": ""
  },
  {
    "id": "8538",
    "Sentence": "These results suggest that FLT3/TKD+ and FLT3/WT cases should not be differentiated when considering patients for treatment with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8539",
    "Sentence": "These results suggest that FLT3/TKD+ and <\\entity><\\entity> cases should not be differentiated when considering patients for treatment with FLT3 inhibitors.",
    "Label": ""
  },
  {
    "id": "8541",
    "Sentence": "These results suggest that <\\entity><\\entity> and FLT3/WT cases should not be differentiated when considering patients for treatment with FLT3 inhibitors.",
    "Label": ""
  },
  {
    "id": "8542",
    "Sentence": "These results suggest that FLT3/TKD+ and FLT3/WT cases should not be differentiated when considering patients for treatment with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8544",
    "Sentence": "These results suggest that FLT3/TKD+ and <\\entity><\\entity> cases should not be differentiated when considering patients for treatment with FLT3 inhibitors.",
    "Label": ""
  },
  {
    "id": "8545",
    "Sentence": "These results suggest that FLT3/TKD+ and FLT3/WT cases should not be differentiated when considering patients for treatment with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8551",
    "Sentence": "<\\entity><\\entity> during pregnancy: a review of methodologic issues.BACKGROUND: There is evidence in the literature that inhaled corticosteroids (ICSs) are safe for pregnant women with asthma and their infants.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8552",
    "Sentence": "Inhaled corticosteroids during pregnancy: a review of methodologic issues.BACKGROUND: There is evidence in the literature that <\\entity><\\entity> (ICSs) are safe for pregnant women with asthma and their infants.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8553",
    "Sentence": "Inhaled corticosteroids during pregnancy: a review of methodologic issues.BACKGROUND: There is evidence in the literature that inhaled corticosteroids (<\\entity><\\entity>) are safe for pregnant women with asthma and their infants.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8554",
    "Sentence": "Inhaled corticosteroids during pregnancy: a review of methodologic issues.BACKGROUND: There is evidence in the literature that inhaled corticosteroids (<\\entity><\\entity>) are safe for pregnant women with asthma and their infants.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8555",
    "Sentence": "Inhaled corticosteroids during pregnancy: a review of methodologic issues.BACKGROUND: There is evidence in the literature that inhaled corticosteroids (ICSs) are safe for pregnant women with <\\entity><\\entity> and their infants.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8556",
    "Sentence": "Although this is useful information about <\\entity><\\entity> use during pregnancy, some articles must be viewed cautiously because of lack of power and adjustment for potentially important confounding variables.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8557",
    "Sentence": "Although this is useful information about <\\entity><\\entity> use during pregnancy, some articles must be viewed cautiously because of lack of power and adjustment for potentially important confounding variables.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8558",
    "Sentence": "OBJECTIVE: To summarize evidence on the potential effects of <\\entity><\\entity> to treat asthma in pregnant mothers and their children with particular focus on study power.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8559",
    "Sentence": "OBJECTIVE: To summarize evidence on the potential effects of <\\entity><\\entity> to treat asthma in pregnant mothers and their children with particular focus on study power.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8560",
    "Sentence": "OBJECTIVE: To summarize evidence on the potential effects of ICSs to treat <\\entity><\\entity> in pregnant mothers and their children with particular focus on study power.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8561",
    "Sentence": "METHODS: Studies published before September 1, 2007, and focusing mainly on <\\entity><\\entity> use for asthma treatment during pregnancy were researched in Pubmed and the Cochrane Library.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8562",
    "Sentence": "METHODS: Studies published before September 1, 2007, and focusing mainly on <\\entity><\\entity> use for asthma treatment during pregnancy were researched in Pubmed and the Cochrane Library.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8563",
    "Sentence": "METHODS: Studies published before September 1, 2007, and focusing mainly on ICS use for <\\entity><\\entity> treatment during pregnancy were researched in Pubmed and the Cochrane Library.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8564",
    "Sentence": "RESULTS: Twenty-three studies that evaluated the associations between <\\entity><\\entity> use during pregnancy and maternal and/or perinatal outcomes were retained.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8565",
    "Sentence": "RESULTS: Twenty-three studies that evaluated the associations between <\\entity><\\entity> use during pregnancy and maternal and/or perinatal outcomes were retained.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8566",
    "Sentence": "RESULTS: Twenty-three studies that evaluated the associations between ICS use during pregnancy and maternal and/or <\\entity><\\entity> were retained.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8567",
    "Sentence": "Only six studies on the association between <\\entity><\\entity> use and maternal outcomes reported significant results; five studies found significant associations between <\\entity><\\entity> use and perinatal outcomes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8568",
    "Sentence": "Only six studies on the association between <\\entity><\\entity> use and maternal outcomes reported significant results; five studies found significant associations between <\\entity><\\entity> use and perinatal outcomes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8569",
    "Sentence": "Only six studies on the association between ICS use and <\\entity><\\entity> reported significant results; five studies found significant associations between ICS use and perinatal outcomes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8570",
    "Sentence": "Only six studies on the association between <\\entity><\\entity> use and maternal outcomes reported significant results; five studies found significant associations between <\\entity><\\entity> use and perinatal outcomes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8571",
    "Sentence": "Only six studies on the association between <\\entity><\\entity> use and maternal outcomes reported significant results; five studies found significant associations between <\\entity><\\entity> use and perinatal outcomes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8572",
    "Sentence": "Only six studies on the association between ICS use and maternal outcomes reported significant results; five studies found significant associations between ICS use and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8573",
    "Sentence": "Regarding non-significant results, two studies on <\\entity><\\entity> and seven studies on perinatal outcomes had a power higher than 80% to detect a relative risk of 1.5 or a mean birth weight difference of 500 g.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8574",
    "Sentence": "Regarding non-significant results, two studies on maternal outcomes and seven studies on <\\entity><\\entity> had a power higher than 80% to detect a relative risk of 1.5 or a mean birth weight difference of 500 g.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8575",
    "Sentence": "CONCLUSION: While there currently is some degree of evidence to support the safety of <\\entity><\\entity> use during pregnancy, this review highlights the limited statistical power of several studies published in this area.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8576",
    "Sentence": "CONCLUSION: While there currently is some degree of evidence to support the safety of <\\entity><\\entity> use during pregnancy, this review highlights the limited statistical power of several studies published in this area.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8577",
    "Sentence": "Inhaled corticosteroids during pregnancy: a review of methodologic issues.BACKGROUND: There is evidence in the literature that inhaled corticosteroids (<\\entity><\\entity>) are safe for pregnant women with asthma and their infants.",
    "Label": ""
  },
  {
    "id": "8578",
    "Sentence": "Inhaled corticosteroids during pregnancy: a review of methodologic issues.BACKGROUND: There is evidence in the literature that inhaled corticosteroids (ICSs) are safe for pregnant women with <\\entity><\\entity> and their infants.",
    "Label": ""
  },
  {
    "id": "8580",
    "Sentence": "Inhaled corticosteroids during pregnancy: a review of methodologic issues.BACKGROUND: There is evidence in the literature that <\\entity><\\entity> (ICSs) are safe for pregnant women with asthma and their infants.",
    "Label": ""
  },
  {
    "id": "8581",
    "Sentence": "Inhaled corticosteroids during pregnancy: a review of methodologic issues.BACKGROUND: There is evidence in the literature that inhaled corticosteroids (ICSs) are safe for pregnant women with <\\entity><\\entity> and their infants.",
    "Label": ""
  },
  {
    "id": "8583",
    "Sentence": "OBJECTIVE: To summarize evidence on the potential effects of <\\entity><\\entity> to treat asthma in pregnant mothers and their children with particular focus on study power.",
    "Label": ""
  },
  {
    "id": "8584",
    "Sentence": "OBJECTIVE: To summarize evidence on the potential effects of ICSs to treat <\\entity><\\entity> in pregnant mothers and their children with particular focus on study power.",
    "Label": ""
  },
  {
    "id": "8586",
    "Sentence": "METHODS: Studies published before September 1, 2007, and focusing mainly on <\\entity><\\entity> use for asthma treatment during pregnancy were researched in Pubmed and the Cochrane Library.",
    "Label": ""
  },
  {
    "id": "8587",
    "Sentence": "METHODS: Studies published before September 1, 2007, and focusing mainly on ICS use for <\\entity><\\entity> treatment during pregnancy were researched in Pubmed and the Cochrane Library.",
    "Label": ""
  },
  {
    "id": "8589",
    "Sentence": "RESULTS: Twenty-three studies that evaluated the associations between <\\entity><\\entity> use during pregnancy and maternal and/or perinatal outcomes were retained.",
    "Label": ""
  },
  {
    "id": "8590",
    "Sentence": "RESULTS: Twenty-three studies that evaluated the associations between ICS use during pregnancy and maternal and/or <\\entity><\\entity> were retained.",
    "Label": ""
  },
  {
    "id": "8596",
    "Sentence": "Overall and <\\entity><\\entity>-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene.PURPOSE: In previous studies, we have shown that the T allele of a specific single-nucleotide polymorphism (SNP) in the Galphas gene (T393C) correlates with increased Galphas expression and hence apoptosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8597",
    "Sentence": "Overall and relapse-free survival in <\\entity><\\entity> and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene.PURPOSE: In previous studies, we have shown that the T allele of a specific single-nucleotide polymorphism (SNP) in the Galphas gene (T393C) correlates with increased Galphas expression and hence apoptosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8598",
    "Sentence": "Overall and relapse-free survival in oropharyngeal and <\\entity><\\entity> are associated with genotypes of T393C polymorphism of the GNAS1 gene.PURPOSE: In previous studies, we have shown that the T allele of a specific single-nucleotide polymorphism (SNP) in the Galphas gene (T393C) correlates with increased Galphas expression and hence apoptosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8599",
    "Sentence": "Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of <\\entity><\\entity> gene.PURPOSE: In previous studies, we have shown that the T allele of a specific single-nucleotide polymorphism (SNP) in the Galphas gene (T393C) correlates with increased Galphas expression and hence apoptosis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8600",
    "Sentence": "Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of <\\entity><\\entity> gene.PURPOSE: In previous studies, we have shown that the T allele of a specific single-nucleotide polymorphism (SNP) in the Galphas gene (T393C) correlates with increased Galphas expression and hence apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8601",
    "Sentence": "Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene.PURPOSE: In previous studies, we have shown that the <\\entity><\\entity> of a specific single-nucleotide polymorphism (SNP) in the Galphas gene (T393C) correlates with increased Galphas expression and hence apoptosis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8602",
    "Sentence": "Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene.PURPOSE: In previous studies, we have shown that the T allele of a specific single-nucleotide polymorphism (SNP) in the <\\entity><\\entity> gene (T393C) correlates with increased <\\entity><\\entity> expression and hence apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8603",
    "Sentence": "Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of <\\entity><\\entity> polymorphism of the GNAS1 gene.PURPOSE: In previous studies, we have shown that the T allele of a specific single-nucleotide polymorphism (SNP) in the Galphas gene (<\\entity><\\entity>) correlates with increased Galphas expression and hence apoptosis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8604",
    "Sentence": "Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene.PURPOSE: In previous studies, we have shown that the T allele of a specific single-nucleotide polymorphism (SNP) in the <\\entity><\\entity> gene (T393C) correlates with increased <\\entity><\\entity> expression and hence apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8605",
    "Sentence": "The <\\entity><\\entity> was associated with a favorable outcome in a variety of human cancers, e.g., carcinoma of the urinary bladder, kidney, and colorectum.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8606",
    "Sentence": "The T allele was associated with a favorable outcome in a variety of human <\\entity><\\entity>, e.g., carcinoma of the urinary bladder, kidney, and colorectum.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8607",
    "Sentence": "The T allele was associated with a favorable outcome in a variety of human cancers, e.g., <\\entity><\\entity>, kidney, and colorectum.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8608",
    "Sentence": "The T allele was associated with a favorable outcome in a variety of human cancers, e.g., carcinoma of the urinary bladder, <\\entity><\\entity>, and colorectum.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8609",
    "Sentence": "The T allele was associated with a favorable outcome in a variety of human cancers, e.g., carcinoma of the urinary bladder, kidney, and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8610",
    "Sentence": "EXPERIMENTAL DESIGN: The prognostic value of the <\\entity><\\entity> SNP was evaluated in an unselected series of patients treated with curative intent for oropharyngeal and hypopharyngeal squamous cell carcinomas, including all tumor stages with different therapeutic regimens.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8611",
    "Sentence": "EXPERIMENTAL DESIGN: The prognostic value of the T393C SNP was evaluated in an unselected series of patients treated with curative intent for <\\entity><\\entity> and hypopharyngeal squamous cell carcinomas, including all tumor stages with different therapeutic regimens.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8612",
    "Sentence": "EXPERIMENTAL DESIGN: The prognostic value of the T393C SNP was evaluated in an unselected series of patients treated with curative intent for oropharyngeal and <\\entity><\\entity>, including all tumor stages with different therapeutic regimens.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8613",
    "Sentence": "EXPERIMENTAL DESIGN: The prognostic value of the T393C SNP was evaluated in an unselected series of patients treated with curative intent for oropharyngeal and hypopharyngeal squamous cell carcinomas, including all <\\entity><\\entity> stages with different therapeutic regimens.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8614",
    "Sentence": "The various genotypes were correlated with <\\entity><\\entity>-free and overall survival.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8615",
    "Sentence": "RESULTS: <\\entity><\\entity> patients displayed a higher risk for disease progression than T393 homozygous patients (hazard ratio CC versus TT, 1.9; 95% confidence interval, 1.1-3.2; P = 0.019).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8616",
    "Sentence": "RESULTS: <\\entity><\\entity> patients displayed a higher risk for disease progression than T393 homozygous patients (hazard ratio CC versus TT, 1.9; 95% confidence interval, 1.1-3.2; P = 0.019).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8617",
    "Sentence": "RESULTS: GNAS1 <\\entity><\\entity> homozygous patients displayed a higher risk for disease progression than T393 homozygous patients (hazard ratio CC versus TT, 1.9; 95% confidence interval, 1.1-3.2; P = 0.019).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8618",
    "Sentence": "RESULTS: GNAS1 393C homozygous patients displayed a higher risk for <\\entity><\\entity> than T393 homozygous patients (hazard ratio CC versus TT, 1.9; 95% confidence interval, 1.1-3.2; P = 0.019).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8619",
    "Sentence": "RESULTS: GNAS1 393C homozygous patients displayed a higher risk for disease progression than <\\entity><\\entity> patients (hazard ratio CC versus TT, 1.9; 95% confidence interval, 1.1-3.2; P = 0.019).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8620",
    "Sentence": "RESULTS: GNAS1 393C homozygous patients displayed a higher risk for disease progression than T393 homozygous patients (hazard ratio <\\entity><\\entity> versus TT, 1.9; 95% confidence interval, 1.1-3.2; P = 0.019).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8621",
    "Sentence": "RESULTS: GNAS1 393C homozygous patients displayed a higher risk for disease progression than T393 homozygous patients (hazard ratio CC versus <\\entity><\\entity>, 1.9; 95% confidence interval, 1.1-3.2; P = 0.019).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8622",
    "Sentence": "The same genotype effect was observed for overall survival with <\\entity><\\entity> genotypes at higher risk for death compared with TT genotypes (hazard ratio, 1.7; 95% confidence interval, 1.1-2.9; P = 0.015).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8623",
    "Sentence": "The same genotype effect was observed for overall survival with CC genotypes at higher risk for <\\entity><\\entity> compared with TT genotypes (hazard ratio, 1.7; 95% confidence interval, 1.1-2.9; P = 0.015).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8624",
    "Sentence": "The same genotype effect was observed for overall survival with CC genotypes at higher risk for death compared with <\\entity><\\entity> genotypes (hazard ratio, 1.7; 95% confidence interval, 1.1-2.9; P = 0.015).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8625",
    "Sentence": "Multivariate analysis showed that, besides American Joint Committee on <\\entity><\\entity> stage, tumor localization, and gender, the T393C polymorphism was an independent prognostic factor for disease progression and death.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8626",
    "Sentence": "Multivariate analysis showed that, besides American Joint Committee on Cancer stage, <\\entity><\\entity> localization, and gender, the T393C polymorphism was an independent prognostic factor for disease progression and death.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8627",
    "Sentence": "Multivariate analysis showed that, besides American Joint Committee on Cancer stage, tumor localization, and gender, the <\\entity><\\entity> polymorphism was an independent prognostic factor for disease progression and death.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8628",
    "Sentence": "Multivariate analysis showed that, besides American Joint Committee on Cancer stage, tumor localization, and gender, the T393C polymorphism was an independent prognostic factor for <\\entity><\\entity> and death.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8629",
    "Sentence": "Multivariate analysis showed that, besides American Joint Committee on Cancer stage, tumor localization, and gender, the T393C polymorphism was an independent prognostic factor for disease progression and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8630",
    "Sentence": "CONCLUSION: The <\\entity><\\entity> SNP could be considered as a genetic marker to predict the clinical course of patients suffering from oropharyngeal and hypopharyngeal cancer.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8631",
    "Sentence": "CONCLUSION: The T393C SNP could be considered as a genetic marker to predict the clinical course of patients <\\entity><\\entity> from oropharyngeal and hypopharyngeal cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8632",
    "Sentence": "CONCLUSION: The T393C SNP could be considered as a genetic marker to predict the clinical course of patients suffering from <\\entity><\\entity> and hypopharyngeal cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8633",
    "Sentence": "CONCLUSION: The T393C SNP could be considered as a genetic marker to predict the clinical course of patients suffering from oropharyngeal and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8634",
    "Sentence": "Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of <\\entity><\\entity> gene.PURPOSE: In previous studies, we have shown that the T allele of a specific single-nucleotide polymorphism (SNP) in the Galphas gene (T393C) correlates with increased Galphas expression and hence apoptosis.",
    "Label": ""
  },
  {
    "id": "8635",
    "Sentence": "Overall and relapse-free survival in oropharyngeal and <\\entity><\\entity> are associated with genotypes of T393C polymorphism of the GNAS1 gene.PURPOSE: In previous studies, we have shown that the T allele of a specific single-nucleotide polymorphism (SNP) in the Galphas gene (T393C) correlates with increased Galphas expression and hence apoptosis.",
    "Label": ""
  },
  {
    "id": "8637",
    "Sentence": "Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of <\\entity><\\entity> gene.PURPOSE: In previous studies, we have shown that the T allele of a specific single-nucleotide polymorphism (SNP) in the Galphas gene (T393C) correlates with increased Galphas expression and hence apoptosis.",
    "Label": ""
  },
  {
    "id": "8638",
    "Sentence": "Overall and relapse-free survival in <\\entity><\\entity> and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene.PURPOSE: In previous studies, we have shown that the T allele of a specific single-nucleotide polymorphism (SNP) in the Galphas gene (T393C) correlates with increased Galphas expression and hence apoptosis.",
    "Label": ""
  },
  {
    "id": "8640",
    "Sentence": "The <\\entity><\\entity> was associated with a favorable outcome in a variety of human cancers, e.g., carcinoma of the urinary bladder, kidney, and colorectum.",
    "Label": ""
  },
  {
    "id": "8641",
    "Sentence": "The T allele was associated with a favorable outcome in a variety of human cancers, e.g., <\\entity><\\entity>, kidney, and colorectum.",
    "Label": ""
  },
  {
    "id": "8643",
    "Sentence": "The <\\entity><\\entity> was associated with a favorable outcome in a variety of human cancers, e.g., carcinoma of the urinary bladder, kidney, and colorectum.",
    "Label": ""
  },
  {
    "id": "8644",
    "Sentence": "The T allele was associated with a favorable outcome in a variety of human cancers, e.g., carcinoma of the urinary bladder, <\\entity><\\entity>, and colorectum.",
    "Label": ""
  },
  {
    "id": "8646",
    "Sentence": "The <\\entity><\\entity> was associated with a favorable outcome in a variety of human cancers, e.g., carcinoma of the urinary bladder, kidney, and colorectum.",
    "Label": ""
  },
  {
    "id": "8647",
    "Sentence": "The T allele was associated with a favorable outcome in a variety of human cancers, e.g., carcinoma of the urinary bladder, kidney, and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8649",
    "Sentence": "The <\\entity><\\entity> was associated with a favorable outcome in a variety of human cancers, e.g., carcinoma of the urinary bladder, kidney, and colorectum.",
    "Label": ""
  },
  {
    "id": "8650",
    "Sentence": "The T allele was associated with a favorable outcome in a variety of human <\\entity><\\entity>, e.g., carcinoma of the urinary bladder, kidney, and colorectum.",
    "Label": ""
  },
  {
    "id": "8652",
    "Sentence": "The same genotype effect was observed for overall survival with <\\entity><\\entity> genotypes at higher risk for death compared with TT genotypes (hazard ratio, 1.7; 95% confidence interval, 1.1-2.9; P = 0.015).",
    "Label": ""
  },
  {
    "id": "8653",
    "Sentence": "The same genotype effect was observed for overall survival with CC genotypes at higher risk for <\\entity><\\entity> compared with TT genotypes (hazard ratio, 1.7; 95% confidence interval, 1.1-2.9; P = 0.015).",
    "Label": ""
  },
  {
    "id": "8655",
    "Sentence": "The same genotype effect was observed for overall survival with CC genotypes at higher risk for death compared with <\\entity><\\entity> genotypes (hazard ratio, 1.7; 95% confidence interval, 1.1-2.9; P = 0.015).",
    "Label": ""
  },
  {
    "id": "8656",
    "Sentence": "The same genotype effect was observed for overall survival with CC genotypes at higher risk for <\\entity><\\entity> compared with TT genotypes (hazard ratio, 1.7; 95% confidence interval, 1.1-2.9; P = 0.015).",
    "Label": ""
  },
  {
    "id": "8658",
    "Sentence": "Multivariate analysis showed that, besides American Joint Committee on Cancer stage, tumor localization, and gender, the <\\entity><\\entity> polymorphism was an independent prognostic factor for disease progression and death.",
    "Label": ""
  },
  {
    "id": "8659",
    "Sentence": "Multivariate analysis showed that, besides American Joint Committee on Cancer stage, tumor localization, and gender, the T393C polymorphism was an independent prognostic factor for disease progression and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8661",
    "Sentence": "CONCLUSION: The <\\entity><\\entity> SNP could be considered as a genetic marker to predict the clinical course of patients suffering from oropharyngeal and hypopharyngeal cancer.",
    "Label": ""
  },
  {
    "id": "8662",
    "Sentence": "CONCLUSION: The T393C SNP could be considered as a genetic marker to predict the clinical course of patients suffering from oropharyngeal and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8664",
    "Sentence": "CONCLUSION: The <\\entity><\\entity> SNP could be considered as a genetic marker to predict the clinical course of patients suffering from oropharyngeal and hypopharyngeal cancer.",
    "Label": ""
  },
  {
    "id": "8665",
    "Sentence": "CONCLUSION: The T393C SNP could be considered as a genetic marker to predict the clinical course of patients suffering from <\\entity><\\entity> and hypopharyngeal cancer.",
    "Label": ""
  },
  {
    "id": "8667",
    "Sentence": "Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of <\\entity><\\entity> gene.PURPOSE: In previous studies, we have shown that the T allele of a specific single-nucleotide polymorphism (SNP) in the Galphas gene (T393C) correlates with increased Galphas expression and hence apoptosis.",
    "Label": ""
  },
  {
    "id": "8668",
    "Sentence": "Overall and <\\entity><\\entity>-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene.PURPOSE: In previous studies, we have shown that the T allele of a specific single-nucleotide polymorphism (SNP) in the Galphas gene (T393C) correlates with increased Galphas expression and hence apoptosis.",
    "Label": ""
  },
  {
    "id": "8670",
    "Sentence": "RESULTS: <\\entity><\\entity> patients displayed a higher risk for disease progression than T393 homozygous patients (hazard ratio CC versus TT, 1.9; 95% confidence interval, 1.1-3.2; P = 0.019).",
    "Label": ""
  },
  {
    "id": "8671",
    "Sentence": "RESULTS: GNAS1 393C homozygous patients displayed a higher risk for <\\entity><\\entity> than T393 homozygous patients (hazard ratio CC versus TT, 1.9; 95% confidence interval, 1.1-3.2; P = 0.019).",
    "Label": ""
  },
  {
    "id": "8673",
    "Sentence": "EXPERIMENTAL DESIGN: The prognostic value of the <\\entity><\\entity> SNP was evaluated in an unselected series of patients treated with curative intent for oropharyngeal and hypopharyngeal squamous cell carcinomas, including all tumor stages with different therapeutic regimens.",
    "Label": ""
  },
  {
    "id": "8674",
    "Sentence": "EXPERIMENTAL DESIGN: The prognostic value of the T393C SNP was evaluated in an unselected series of patients treated with curative intent for <\\entity><\\entity> and hypopharyngeal squamous cell carcinomas, including all tumor stages with different therapeutic regimens.",
    "Label": ""
  },
  {
    "id": "8680",
    "Sentence": "Surface expression of <\\entity><\\entity> in response to proteasome inhibition in human colon cells.<\\entity><\\entity> was expressed on the surface of HT-29 and CRL-1809 but not SW-480 human colon cell lines in response to proteasome inhibition as detected using flow cytometry.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8681",
    "Sentence": "Surface expression of Hsp70B' in response to <\\entity><\\entity> inhibition in human colon cells.Hsp70B' was expressed on the surface of HT-29 and CRL-1809 but not SW-480 human colon cell lines in response to <\\entity><\\entity> inhibition as detected using flow cytometry.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8682",
    "Sentence": "Surface expression of <\\entity><\\entity> in response to proteasome inhibition in human colon cells.<\\entity><\\entity> was expressed on the surface of HT-29 and CRL-1809 but not SW-480 human colon cell lines in response to proteasome inhibition as detected using flow cytometry.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8683",
    "Sentence": "Surface expression of Hsp70B' in response to <\\entity><\\entity> inhibition in human colon cells.Hsp70B' was expressed on the surface of HT-29 and CRL-1809 but not SW-480 human colon cell lines in response to <\\entity><\\entity> inhibition as detected using flow cytometry.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8684",
    "Sentence": "Phylogenetic analysis indicated that the <\\entity><\\entity> protein sequence was most closely related to another major inducible human Hsp70, Hsp72.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8685",
    "Sentence": "Phylogenetic analysis indicated that the <\\entity><\\entity>B' protein sequence was most closely related to another major inducible human <\\entity><\\entity>, Hsp72.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8686",
    "Sentence": "Phylogenetic analysis indicated that the Hsp70B' protein sequence was most closely related to another major inducible human Hsp70, <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8687",
    "Sentence": "<\\entity><\\entity> appeared to be recently diverged, as homologs for <\\entity><\\entity> have not been found in rodents.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8688",
    "Sentence": "<\\entity><\\entity> appeared to be recently diverged, as homologs for <\\entity><\\entity> have not been found in rodents.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8689",
    "Sentence": "<\\entity><\\entity> and Hsp70B' shared 100% amino acid sequence identity in their predicted peptide-binding regions suggesting that they bind the same peptide substrates, perhaps in extracellular antigen presentation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8690",
    "Sentence": "Hsp72 and <\\entity><\\entity> shared 100% amino acid sequence identity in their predicted peptide-binding regions suggesting that they bind the same peptide substrates, perhaps in extracellular antigen presentation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8691",
    "Sentence": "Amino acid sequence differences were concentrated in the lid regions and the C-terminal domains raising the possibility that <\\entity><\\entity> and Hsp70B' bind different co-chaperones or cell surface receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8692",
    "Sentence": "Amino acid sequence differences were concentrated in the lid regions and the C-terminal domains raising the possibility that Hsp72 and <\\entity><\\entity> bind different co-chaperones or cell surface receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8697",
    "Sentence": "Metabolic changes during <\\entity><\\entity> therapy for prostate cancer: differences from the classic metabolic syndrome.BACKGROUND: In men with prostate cancer, gonadotropin-releasing hormone (GnRH) agonists increase fat mass, decrease insulin sensitivity, and increase triglycerides, features that are shared with metabolic syndrome.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8698",
    "Sentence": "Metabolic changes during <\\entity><\\entity> agonist therapy for prostate cancer: differences from the classic metabolic syndrome.BACKGROUND: In men with prostate cancer, <\\entity><\\entity> (GnRH) agonists increase fat mass, decrease insulin sensitivity, and increase triglycerides, features that are shared with metabolic syndrome.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8699",
    "Sentence": "Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.BACKGROUND: In men with prostate cancer, gonadotropin-releasing hormone (<\\entity><\\entity> increase fat mass, decrease insulin sensitivity, and increase triglycerides, features that are shared with metabolic syndrome.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8700",
    "Sentence": "Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.BACKGROUND: In men with prostate cancer, gonadotropin-releasing hormone (GnRH) agonists increase fat mass, decrease <\\entity><\\entity> sensitivity, and increase triglycerides, features that are shared with metabolic syndrome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8701",
    "Sentence": "To the authors' knowledge, however, less is known regarding the effects of <\\entity><\\entity> on other attributes of the metabolic syndrome.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8702",
    "Sentence": "METHODS: In an open-label prospective study, 26 men with recurrent or locally advanced prostate cancer were treated with <\\entity><\\entity> for 12 months.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8703",
    "Sentence": "Outcomes included changes in blood pressure, body composition, <\\entity><\\entity>, adipocytokines, and C-reactive protein.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8704",
    "Sentence": "Outcomes included changes in blood pressure, body composition, lipids, <\\entity><\\entity>, and C-reactive protein.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8705",
    "Sentence": "Outcomes included changes in blood pressure, body composition, lipids, adipocytokines, and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8706",
    "Sentence": "Serum <\\entity><\\entity> (HDL) cholesterol concentrations increased significantly (P = .002).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8707",
    "Sentence": "Serum high-density lipoprotein (<\\entity><\\entity> concentrations increased significantly (P = .002).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8708",
    "Sentence": "Serum <\\entity><\\entity> levels increased by 36.4 +/- 5.9% from baseline to Month 3 and remained significantly elevated through Month 12 (P < .001).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8709",
    "Sentence": "<\\entity><\\entity> and C-reactive protein levels did not change significantly.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8710",
    "Sentence": "Resistin and <\\entity><\\entity> levels did not change significantly.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8711",
    "Sentence": "CONCLUSIONS: The term metabolic syndrome does not appear to adequately describe the effects of <\\entity><\\entity> in men with prostate cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8712",
    "Sentence": "In contrast to the metabolic syndrome, <\\entity><\\entity> increase subcutaneous fat mass, HDL cholesterol, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level.CI - (c) 2008 American Cancer Society.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8713",
    "Sentence": "In contrast to the metabolic syndrome, GnRH agonists increase subcutaneous fat mass, <\\entity><\\entity>, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level.CI - (c) 2008 American Cancer Society.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8714",
    "Sentence": "In contrast to the metabolic syndrome, GnRH agonists increase subcutaneous fat mass, HDL cholesterol, and <\\entity><\\entity>, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level.CI - (c) 2008 American Cancer Society.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8715",
    "Sentence": "In contrast to the metabolic syndrome, GnRH agonists increase subcutaneous fat mass, HDL cholesterol, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or <\\entity><\\entity> level.CI - (c) 2008 American Cancer Society.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8716",
    "Sentence": "Metabolic changes during <\\entity><\\entity> agonist therapy for prostate cancer: differences from the classic metabolic syndrome.BACKGROUND: In men with prostate cancer, <\\entity><\\entity> (GnRH) agonists increase fat mass, decrease insulin sensitivity, and increase triglycerides, features that are shared with metabolic syndrome.",
    "Label": ""
  },
  {
    "id": "8717",
    "Sentence": "Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.BACKGROUND: In men with prostate cancer, gonadotropin-releasing hormone (GnRH) agonists increase fat mass, decrease <\\entity><\\entity> sensitivity, and increase triglycerides, features that are shared with metabolic syndrome.",
    "Label": ""
  },
  {
    "id": "8719",
    "Sentence": "Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.BACKGROUND: In men with prostate cancer, gonadotropin-releasing hormone (<\\entity><\\entity> increase fat mass, decrease insulin sensitivity, and increase triglycerides, features that are shared with metabolic syndrome.",
    "Label": ""
  },
  {
    "id": "8720",
    "Sentence": "Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.BACKGROUND: In men with prostate cancer, gonadotropin-releasing hormone (GnRH) agonists increase fat mass, decrease <\\entity><\\entity> sensitivity, and increase triglycerides, features that are shared with metabolic syndrome.",
    "Label": ""
  },
  {
    "id": "8722",
    "Sentence": "In contrast to the metabolic syndrome, <\\entity><\\entity> increase subcutaneous fat mass, HDL cholesterol, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level.CI - (c) 2008 American Cancer Society.",
    "Label": ""
  },
  {
    "id": "8723",
    "Sentence": "In contrast to the metabolic syndrome, GnRH agonists increase subcutaneous fat mass, HDL cholesterol, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or <\\entity><\\entity> level.CI - (c) 2008 American Cancer Society.",
    "Label": ""
  },
  {
    "id": "8725",
    "Sentence": "In contrast to the metabolic syndrome, <\\entity><\\entity> increase subcutaneous fat mass, HDL cholesterol, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level.CI - (c) 2008 American Cancer Society.",
    "Label": ""
  },
  {
    "id": "8726",
    "Sentence": "In contrast to the metabolic syndrome, GnRH agonists increase subcutaneous fat mass, HDL cholesterol, and <\\entity><\\entity>, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level.CI - (c) 2008 American Cancer Society.",
    "Label": ""
  },
  {
    "id": "8728",
    "Sentence": "In contrast to the metabolic syndrome, <\\entity><\\entity> increase subcutaneous fat mass, HDL cholesterol, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level.CI - (c) 2008 American Cancer Society.",
    "Label": ""
  },
  {
    "id": "8729",
    "Sentence": "In contrast to the metabolic syndrome, GnRH agonists increase subcutaneous fat mass, <\\entity><\\entity>, and adiponectin, and do not alter the waist-to-hip ratio, blood pressure, or C-reactive protein level.CI - (c) 2008 American Cancer Society.",
    "Label": ""
  },
  {
    "id": "8735",
    "Sentence": "Postoperative <\\entity><\\entity> and quality of life after primary hip arthroplasty in patients over 65 years old.BACKGROUND: It is uncertain whether <\\entity><\\entity> in elderly patients after primary hip arthroplasty has an effect on their quality of life.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8736",
    "Sentence": "Postoperative <\\entity><\\entity> and quality of life after primary hip arthroplasty in patients over 65 years old.BACKGROUND: It is uncertain whether <\\entity><\\entity> in elderly patients after primary hip arthroplasty has an effect on their quality of life.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8737",
    "Sentence": "METHODS: We conducted a prospective observational study over 3 <\\entity><\\entity> to investigate the association between discharge he<\\entity><\\entity>globin levels and subjective experience of quality of life at 2 <\\entity><\\entity> postoperatively in patients aged over 65 yr who were scheduled for primary hip arthroplasty.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8738",
    "Sentence": "METHODS: We conducted a prospective observational study over 3 mo to investigate the association between discharge hemoglobin levels and <\\entity><\\entity> experience of quality of life at 2 mo postoperatively in patients aged over 65 yr who were scheduled for primary hip arthroplasty.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8739",
    "Sentence": "METHODS: We conducted a prospective observational study over 3 <\\entity><\\entity> to investigate the association between discharge he<\\entity><\\entity>globin levels and subjective experience of quality of life at 2 <\\entity><\\entity> postoperatively in patients aged over 65 yr who were scheduled for primary hip arthroplasty.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8740",
    "Sentence": "Quality of life was measured preoperatively and at 2 <\\entity><\\entity> postoperatively using the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and the Functional Assessment of Cancer Therapy Anemia (FACT-Anemia) subscale.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8741",
    "Sentence": "Quality of life was measured preoperatively and at 2 mo postoperatively using the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and the Functional Assessment of <\\entity><\\entity> Therapy Anemia (FACT-Anemia) subscale.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8742",
    "Sentence": "Quality of life was measured preoperatively and at 2 mo postoperatively using the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and the Functional Assessment of Cancer Therapy <\\entity><\\entity> (FACT-<\\entity><\\entity>) subscale.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8743",
    "Sentence": "Quality of life was measured preoperatively and at 2 mo postoperatively using the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and the Functional Assessment of Cancer Therapy <\\entity><\\entity> (FACT-<\\entity><\\entity>) subscale.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8744",
    "Sentence": "Pearson correlation coefficients between change in SF-36 and FACT-<\\entity><\\entity> subscale scores (from preoperatively to 2 mo postoperatively) and hemoglobin on Day 8 were calculated.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8745",
    "Sentence": "Pearson correlation coefficients between change in SF-36 and FACT-Anemia subscale scores (from preoperatively to 2 <\\entity><\\entity> postoperatively) and he<\\entity><\\entity>globin on Day 8 were calculated.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8746",
    "Sentence": "Data were available at 2 <\\entity><\\entity> postoperatively from 79 of these patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8747",
    "Sentence": "The correlation between Day 8 postoperative hemoglobin and change in SF-36 was 0.49 (P < 0.0005) and change in FACT-<\\entity><\\entity> subscale score was 0.46 (P = < 0.0005).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8748",
    "Sentence": "The correlation was not significantly changed after adjusting for advancing age, presence of significant <\\entity><\\entity>, or whether the patient was transfused.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8749",
    "Sentence": "CONCLUSIONS: We found a positive correlation between he<\\entity><\\entity>globin levels on discharge and change in quality of life scores from preoperatively to 2 <\\entity><\\entity> postoperatively in patients over 65 yr old after primary hip arthroplasty.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8754",
    "Sentence": "Hypofractionated accelerated <\\entity><\\entity> using concomitant intensity-modulated <\\entity><\\entity> boost technique for localized high-risk prostate cancer: acute toxicity results.PURPOSE: To evaluate the acute toxicities of hypofractionated accelerated <\\entity><\\entity> (RT) using a concomitant intensity-modulated RT boost in conjunction with elective pelvic nodal irradiation for high-risk prostate cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8755",
    "Sentence": "Hypofractionated accelerated <\\entity><\\entity> using concomitant intensity-modulated <\\entity><\\entity> boost technique for localized high-risk prostate cancer: acute toxicity results.PURPOSE: To evaluate the acute toxicities of hypofractionated accelerated <\\entity><\\entity> (RT) using a concomitant intensity-modulated RT boost in conjunction with elective pelvic nodal irradiation for high-risk prostate cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8756",
    "Sentence": "Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized <\\entity><\\entity>: acute toxicity results.PURPOSE: To evaluate the acute toxicities of hypofractionated accelerated radiotherapy (RT) using a concomitant intensity-modulated RT boost in conjunction with elective pelvic nodal irradiation for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8757",
    "Sentence": "Hypofractionated accelerated <\\entity><\\entity> using concomitant intensity-modulated <\\entity><\\entity> boost technique for localized high-risk prostate cancer: acute toxicity results.PURPOSE: To evaluate the acute toxicities of hypofractionated accelerated <\\entity><\\entity> (RT) using a concomitant intensity-modulated RT boost in conjunction with elective pelvic nodal irradiation for high-risk prostate cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8758",
    "Sentence": "Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.PURPOSE: To evaluate the acute toxicities of hypofractionated accelerated radiotherapy (<\\entity><\\entity>) using a concomitant intensity-modulated <\\entity><\\entity> boost in conjunction with elective pelvic nodal irradiation for high-risk prostate cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8759",
    "Sentence": "Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.PURPOSE: To evaluate the acute toxicities of hypofractionated accelerated radiotherapy (<\\entity><\\entity>) using a concomitant intensity-modulated <\\entity><\\entity> boost in conjunction with elective pelvic nodal irradiation for high-risk prostate cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8760",
    "Sentence": "Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized <\\entity><\\entity>: acute toxicity results.PURPOSE: To evaluate the acute toxicities of hypofractionated accelerated radiotherapy (RT) using a concomitant intensity-modulated RT boost in conjunction with elective pelvic nodal irradiation for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8761",
    "Sentence": "The eligible patients had clinically localized <\\entity><\\entity> with at least one of the following high-risk features (Stage T3, Gleason score >or=8, or prostate-specific antigen level >20 ng/mL).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8762",
    "Sentence": "The eligible patients had clinically localized prostate cancer with at least one of the following high-risk features (Stage <\\entity><\\entity>, Gleason score >or=8, or prostate-specific antigen level >20 ng/mL).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8763",
    "Sentence": "A concomitant intensity-modulated <\\entity><\\entity> boost of 22.5 Gy in 25 fractions was delivered to the prostate.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8764",
    "Sentence": "Acute toxicities were assessed using the Common Terminology Criteria for Adverse Events, version 3.0, weekly during treatment and at 3 months after <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8765",
    "Sentence": "Grade 1-2 <\\entity><\\entity> were common during RT but most had settled at 3 months after treatment.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8766",
    "Sentence": "Grade 1-2 genitourinary and gastrointestinal toxicities were common during <\\entity><\\entity> but most had settled at 3 months after treatment.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8767",
    "Sentence": "Only 5 patients had acute Grade 3 <\\entity><\\entity>, in the form of urinary incontinence (n = 1), urinary frequency/urgency (n = 3), and urinary retention (n = 1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8768",
    "Sentence": "Only 5 patients had acute Grade 3 genitourinary toxicity, in the form of <\\entity><\\entity> (n = 1), urinary frequency/urgency (n = 3), and urinary retention (n = 1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8769",
    "Sentence": "Only 5 patients had acute Grade 3 genitourinary toxicity, in the form of urinary incontinence (n = 1), <\\entity><\\entity> (n = 3), and urinary retention (n = 1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8770",
    "Sentence": "Only 5 patients had acute Grade 3 genitourinary toxicity, in the form of urinary incontinence (n = 1), urinary frequency/urgency (n = 3), and <\\entity><\\entity> (n = 1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8771",
    "Sentence": "None of the patients developed Grade 3 or greater gastrointestinal or Grade 4 or greater <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8772",
    "Sentence": "CONCLUSION: The results of the present study have indicated that hypofractionated accelerated <\\entity><\\entity> with a concomitant intensity-modulated <\\entity><\\entity> boost and pelvic nodal irradiation is feasible with acceptable acute toxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8773",
    "Sentence": "CONCLUSION: The results of the present study have indicated that hypofractionated accelerated <\\entity><\\entity> with a concomitant intensity-modulated <\\entity><\\entity> boost and pelvic nodal irradiation is feasible with acceptable acute toxicity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8774",
    "Sentence": "Hypofractionated accelerated <\\entity><\\entity> using concomitant intensity-modulated <\\entity><\\entity> boost technique for localized high-risk prostate cancer: acute toxicity results.PURPOSE: To evaluate the acute toxicities of hypofractionated accelerated <\\entity><\\entity> (RT) using a concomitant intensity-modulated RT boost in conjunction with elective pelvic nodal irradiation for high-risk prostate cancer.",
    "Label": ""
  },
  {
    "id": "8775",
    "Sentence": "Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized <\\entity><\\entity>: acute toxicity results.PURPOSE: To evaluate the acute toxicities of hypofractionated accelerated radiotherapy (RT) using a concomitant intensity-modulated RT boost in conjunction with elective pelvic nodal irradiation for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8777",
    "Sentence": "The eligible patients had clinically localized prostate cancer with at least one of the following high-risk features (Stage <\\entity><\\entity>, Gleason score >or=8, or prostate-specific antigen level >20 ng/mL).",
    "Label": ""
  },
  {
    "id": "8778",
    "Sentence": "The eligible patients had clinically localized <\\entity><\\entity> with at least one of the following high-risk features (Stage T3, Gleason score >or=8, or prostate-specific antigen level >20 ng/mL).",
    "Label": ""
  },
  {
    "id": "8784",
    "Sentence": "Case-control study of the role of the <\\entity><\\entity> in essential hypertension.BACKGROUND: Gitelman's syndrome is an inherited tubular disorder characterized by sodium wasting, low blood pressure, secondary hyperaldosteronism, metabolic alkalosis, hypokalemia, hypomagnesemia of renal origin, and hypocalciuria.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8785",
    "Sentence": "Case-control study of the role of the <\\entity><\\entity> in essential hypertension.BACKGROUND: Gitelman's syndrome is an inherited tubular disorder characterized by sodium wasting, low blood pressure, secondary hyperaldosteronism, metabolic alkalosis, hypokalemia, hypomagnesemia of renal origin, and hypocalciuria.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8786",
    "Sentence": "Case-control study of the role of the Gitelman's syndrome gene in <\\entity><\\entity>.BACKGROUND: Gitelman's syndrome is an inherited tubular disorder characterized by sodium wasting, low blood pressure, secondary hyperaldosteronism, metabolic alkalosis, hypokalemia, hypomagnesemia of renal origin, and hypocalciuria.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8787",
    "Sentence": "Case-control study of the role of the <\\entity><\\entity> gene in essential hypertension.BACKGROUND: <\\entity><\\entity> is an inherited tubular disorder characterized by sodium wasting, low blood pressure, secondary hyperaldosteronism, metabolic alkalosis, hypokalemia, hypomagnesemia of renal origin, and hypocalciuria.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8788",
    "Sentence": "Case-control study of the role of the Gitelman's syndrome gene in essential hypertension.BACKGROUND: Gitelman's syndrome is an inherited tubular <\\entity><\\entity> characterized by sodium wasting, low blood pressure, secondary hyperaldosteronism, metabolic alkalosis, hypokalemia, hypomagnesemia of renal origin, and hypocalciuria.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8789",
    "Sentence": "Case-control study of the role of the Gitelman's syndrome gene in essential hypertension.BACKGROUND: Gitelman's syndrome is an inherited tubular disorder characterized by sodium <\\entity><\\entity>, low blood pressure, secondary hyperaldosteronism, metabolic alkalosis, hypokalemia, hypomagnesemia of renal origin, and hypocalciuria.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8790",
    "Sentence": "Case-control study of the role of the Gitelman's syndrome gene in essential hypertension.BACKGROUND: Gitelman's syndrome is an inherited tubular disorder characterized by sodium wasting, low blood pressure, <\\entity><\\entity>, metabolic alkalosis, hypokalemia, hypomagnesemia of renal origin, and hypocalciuria.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8791",
    "Sentence": "Case-control study of the role of the Gitelman's syndrome gene in essential hypertension.BACKGROUND: Gitelman's syndrome is an inherited tubular disorder characterized by sodium wasting, low blood pressure, secondary hyperaldosteronism, <\\entity><\\entity>, hypokalemia, hypomagnesemia of renal origin, and hypocalciuria.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8792",
    "Sentence": "Case-control study of the role of the Gitelman's syndrome gene in essential hypertension.BACKGROUND: Gitelman's syndrome is an inherited tubular disorder characterized by sodium wasting, low blood pressure, secondary hyperaldosteronism, metabolic alkalosis, <\\entity><\\entity>, hypomagnesemia of renal origin, and hypocalciuria.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8793",
    "Sentence": "Case-control study of the role of the Gitelman's syndrome gene in essential hypertension.BACKGROUND: Gitelman's syndrome is an inherited tubular disorder characterized by sodium wasting, low blood pressure, secondary hyperaldosteronism, metabolic alkalosis, hypokalemia, <\\entity><\\entity>, and hypocalciuria.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8794",
    "Sentence": "Case-control study of the role of the Gitelman's syndrome gene in essential hypertension.BACKGROUND: Gitelman's syndrome is an inherited tubular disorder characterized by sodium wasting, low blood pressure, secondary hyperaldosteronism, metabolic alkalosis, hypokalemia, hypomagnesemia of renal origin, and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8795",
    "Sentence": "The majority of patients with this <\\entity><\\entity> carry inactivating mutations in the SLC12A3 gene encoding the thiazide-sensitive Na (+)-Cl (-) cotransporter (NCC) located in the distal convoluted tubule, which is involved in renal sodium reabsorption.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8796",
    "Sentence": "The majority of patients with this syndrome carry inactivating <\\entity><\\entity> gene encoding the thiazide-sensitive Na (+)-Cl (-) cotransporter (NCC) located in the distal convoluted tubule, which is involved in renal sodium reabsorption.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8797",
    "Sentence": "The majority of patients with this syndrome carry inactivating <\\entity><\\entity> gene encoding the thiazide-sensitive Na (+)-Cl (-) cotransporter (NCC) located in the distal convoluted tubule, which is involved in renal sodium reabsorption.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8798",
    "Sentence": "The majority of patients with this syndrome carry inactivating <\\entity><\\entity> gene encoding the thiazide-sensitive Na (+)-Cl (-) cotransporter (NCC) located in the distal convoluted tubule, which is involved in renal sodium reabsorption.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8799",
    "Sentence": "The majority of patients with this syndrome carry inactivating mutations in the SLC12A3 gene encoding the <\\entity><\\entity> (NCC) located in the distal convoluted tubule, which is involved in renal sodium reabsorption.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8800",
    "Sentence": "The majority of patients with this syndrome carry inactivating mutations in the SLC12A3 gene encoding the thiazide-sensitive Na (+)-Cl (-) cotransporter (<\\entity><\\entity>) located in the distal convoluted tubule, which is involved in renal sodium reabsorption.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8801",
    "Sentence": "This suggests that the <\\entity><\\entity> gene is involved in mediation of blood pressure levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8802",
    "Sentence": "The aim of the present study was to investigate relationships between single nucleotide polymorphisms (<\\entity><\\entity> gene and essential hypertension (EH) in Japanese.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8803",
    "Sentence": "The aim of the present study was to investigate relationships between single nucleotide polymorphisms (<\\entity><\\entity> gene and essential hypertension (EH) in Japanese.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8804",
    "Sentence": "The aim of the present study was to investigate relationships between single nucleotide polymorphisms (SNPs) in the human SLC12A3 gene and <\\entity><\\entity> (EH) in Japanese.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8805",
    "Sentence": "The aim of the present study was to investigate relationships between single nucleotide polymorphisms (SNPs) in the human SLC12A3 gene and essential hypertension (<\\entity><\\entity>) in Japanese.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8806",
    "Sentence": "METHOD: We selected 3 SNPs in the human <\\entity><\\entity> gene (T180K, A569V, L849H), and performed a case-control study of 315 EH patients and 305 normotensive (NT) individuals.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8807",
    "Sentence": "METHOD: We selected 3 SNPs in the human SLC12A3 gene (<\\entity><\\entity>, A569V, L849H), and performed a case-control study of 315 EH patients and 305 normotensive (NT) individuals.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8808",
    "Sentence": "METHOD: We selected 3 SNPs in the human SLC12A3 gene (T180K, <\\entity><\\entity>, L849H), and performed a case-control study of 315 EH patients and 305 normotensive (NT) individuals.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8809",
    "Sentence": "METHOD: We selected 3 SNPs in the human SLC12A3 gene (T180K, A569V, <\\entity><\\entity>), and performed a case-control study of 315 EH patients and 305 normotensive (NT) individuals.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8810",
    "Sentence": "METHOD: We selected 3 SNPs in the human SLC12A3 gene (T180K, A569V, L849H), and performed a case-control study of 315 <\\entity><\\entity> patients and 305 normotensive (NT) individuals.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8811",
    "Sentence": "RESULTS: There was no significant difference in overall distribution of genotypes or alleles of any of the SNPs between the <\\entity><\\entity> and NT groups.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8812",
    "Sentence": "CONCLUSION: We conclude that the causal gene of <\\entity><\\entity> is not involved in determining blood pressure levels.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8813",
    "Sentence": "The majority of patients with this syndrome carry inactivating mutations in the SLC12A3 gene encoding the thiazide-sensitive Na (+)-Cl (-) cotransporter (<\\entity><\\entity>) located in the distal convoluted tubule, which is involved in renal sodium reabsorption.",
    "Label": ""
  },
  {
    "id": "8814",
    "Sentence": "The majority of patients with this <\\entity><\\entity> carry inactivating mutations in the SLC12A3 gene encoding the thiazide-sensitive Na (+)-Cl (-) cotransporter (NCC) located in the distal convoluted tubule, which is involved in renal sodium reabsorption.",
    "Label": ""
  },
  {
    "id": "8816",
    "Sentence": "The majority of patients with this syndrome carry inactivating mutations in the SLC12A3 gene encoding the thiazide-sensitive Na (+)-Cl (-) cotransporter (<\\entity><\\entity>) located in the distal convoluted tubule, which is involved in renal sodium reabsorption.",
    "Label": ""
  },
  {
    "id": "8817",
    "Sentence": "The majority of patients with this syndrome carry inactivating <\\entity><\\entity> gene encoding the thiazide-sensitive Na (+)-Cl (-) cotransporter (NCC) located in the distal convoluted tubule, which is involved in renal sodium reabsorption.",
    "Label": ""
  },
  {
    "id": "8819",
    "Sentence": "The aim of the present study was to investigate relationships between single nucleotide polymorphisms (<\\entity><\\entity> gene and essential hypertension (EH) in Japanese.",
    "Label": ""
  },
  {
    "id": "8820",
    "Sentence": "The aim of the present study was to investigate relationships between single nucleotide polymorphisms (SNPs) in the human SLC12A3 gene and <\\entity><\\entity> (EH) in Japanese.",
    "Label": ""
  },
  {
    "id": "8822",
    "Sentence": "The aim of the present study was to investigate relationships between single nucleotide polymorphisms (<\\entity><\\entity> gene and essential hypertension (EH) in Japanese.",
    "Label": ""
  },
  {
    "id": "8823",
    "Sentence": "The aim of the present study was to investigate relationships between single nucleotide polymorphisms (SNPs) in the human SLC12A3 gene and essential hypertension (<\\entity><\\entity>) in Japanese.",
    "Label": ""
  },
  {
    "id": "8825",
    "Sentence": "METHOD: We selected 3 SNPs in the human <\\entity><\\entity> gene (T180K, A569V, L849H), and performed a case-control study of 315 EH patients and 305 normotensive (NT) individuals.",
    "Label": ""
  },
  {
    "id": "8826",
    "Sentence": "METHOD: We selected 3 SNPs in the human SLC12A3 gene (T180K, A569V, L849H), and performed a case-control study of 315 <\\entity><\\entity> patients and 305 normotensive (NT) individuals.",
    "Label": ""
  },
  {
    "id": "8828",
    "Sentence": "METHOD: We selected 3 SNPs in the human SLC12A3 gene (<\\entity><\\entity>, A569V, L849H), and performed a case-control study of 315 EH patients and 305 normotensive (NT) individuals.",
    "Label": ""
  },
  {
    "id": "8829",
    "Sentence": "METHOD: We selected 3 SNPs in the human SLC12A3 gene (T180K, A569V, L849H), and performed a case-control study of 315 <\\entity><\\entity> patients and 305 normotensive (NT) individuals.",
    "Label": ""
  },
  {
    "id": "8831",
    "Sentence": "METHOD: We selected 3 SNPs in the human SLC12A3 gene (T180K, <\\entity><\\entity>, L849H), and performed a case-control study of 315 EH patients and 305 normotensive (NT) individuals.",
    "Label": ""
  },
  {
    "id": "8832",
    "Sentence": "METHOD: We selected 3 SNPs in the human SLC12A3 gene (T180K, A569V, L849H), and performed a case-control study of 315 <\\entity><\\entity> patients and 305 normotensive (NT) individuals.",
    "Label": ""
  },
  {
    "id": "8834",
    "Sentence": "METHOD: We selected 3 SNPs in the human SLC12A3 gene (T180K, A569V, <\\entity><\\entity>), and performed a case-control study of 315 EH patients and 305 normotensive (NT) individuals.",
    "Label": ""
  },
  {
    "id": "8835",
    "Sentence": "METHOD: We selected 3 SNPs in the human SLC12A3 gene (T180K, A569V, L849H), and performed a case-control study of 315 <\\entity><\\entity> patients and 305 normotensive (NT) individuals.",
    "Label": ""
  },
  {
    "id": "8841",
    "Sentence": "Selective <\\entity><\\entity> of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cell lines: an in vitro study.Gliomas are the most common and devastating tumors of the central nervous system.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8842",
    "Sentence": "Selective cytotoxicity of <\\entity><\\entity> and <\\entity><\\entity> ethyl ester-loaded nanocapsules against glioma cell lines: an in vitro study.Gliomas are the most common and devastating tumors of the central nervous system.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8843",
    "Sentence": "Selective cytotoxicity of indomethacin and <\\entity><\\entity> against glioma cell lines: an in vitro study.Gliomas are the most common and devastating tumors of the central nervous system.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8844",
    "Sentence": "Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against <\\entity><\\entity> cell lines: an in vitro study.Gliomas are the most common and devastating tumors of the central nervous system.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8845",
    "Sentence": "Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cell lines: an in vitro study.<\\entity><\\entity> are the most common and devastating tumors of the central nervous system.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8846",
    "Sentence": "Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cell lines: an in vitro study.Gliomas are the most common and devastating <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8847",
    "Sentence": "Several studies have suggested that <\\entity><\\entity> (NSAIDs) are promising anticancer agents.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8848",
    "Sentence": "Several studies have suggested that nonsteroidal anti-inflammatory drugs (<\\entity><\\entity>) are promising anticancer agents.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8849",
    "Sentence": "Several studies have suggested that nonsteroidal anti-inflammatory drugs (NSAIDs) are promising <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8850",
    "Sentence": "The aim of this study was to evaluate the effects of <\\entity><\\entity> and indomethacin ethyl ester-loaded nanocapsules on glioma cell lines.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8851",
    "Sentence": "The aim of this study was to evaluate the effects of indomethacin-loaded nanocapsules and <\\entity><\\entity> on glioma cell lines.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8852",
    "Sentence": "The aim of this study was to evaluate the effects of indomethacin-loaded nanocapsules and indomethacin ethyl ester-loaded nanocapsules on <\\entity><\\entity> cell lines.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8853",
    "Sentence": "In order to investigate this, <\\entity><\\entity> cell lines (U138-MG and C6) and hippocampal organotypic cultures were used.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8854",
    "Sentence": "The main finding of the present study is that <\\entity><\\entity> formulation was more potent than a solution of indomethacin in decreasing the viability and cell proliferation of glioma lines.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8855",
    "Sentence": "The main finding of the present study is that indomethacin-loaded nanocapsules formulation was more potent than a <\\entity><\\entity> in decreasing the viability and cell proliferation of glioma lines.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8856",
    "Sentence": "The main finding of the present study is that indomethacin-loaded nanocapsules formulation was more potent than a solution of indomethacin in decreasing the viability and cell proliferation of <\\entity><\\entity> lines.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8857",
    "Sentence": "<\\entity><\\entity> and indomethacin ethyl ester associated together in the same nanocapsule formulation caused a synergic effect decreasing glioma cell proliferation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8858",
    "Sentence": "Indomethacin and <\\entity><\\entity> associated together in the same nanocapsule formulation caused a synergic effect decreasing glioma cell proliferation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8859",
    "Sentence": "Indomethacin and indomethacin ethyl ester associated together in the same nanocapsule formulation caused a synergic effect decreasing <\\entity><\\entity> cell proliferation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8860",
    "Sentence": "In addition, when the <\\entity><\\entity> cells were exposed to 25 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, a necrotic cell death was observed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8861",
    "Sentence": "In addition, when the glioma cells were exposed to 25 microM of <\\entity><\\entity> or indomethacin ethyl ester-loaded nanocapsules, a necrotic cell death was observed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8862",
    "Sentence": "In addition, when the glioma cells were exposed to 25 microM of indomethacin-loaded nanocapsules or <\\entity><\\entity>, a necrotic cell death was observed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8863",
    "Sentence": "In addition, when the glioma cells were exposed to 25 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, a <\\entity><\\entity> cell death was observed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8864",
    "Sentence": "Interestingly, 5 microM of <\\entity><\\entity> was able to cause an antiproliferative effect without promoting necrosis in glioma cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8865",
    "Sentence": "Interestingly, 5 microM of indomethacin-loaded nanocapsules was able to cause an antiproliferative effect without promoting <\\entity><\\entity> in glioma cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8866",
    "Sentence": "Interestingly, 5 microM of indomethacin-loaded nanocapsules was able to cause an antiproliferative effect without promoting necrosis in <\\entity><\\entity> cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8867",
    "Sentence": "Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of <\\entity><\\entity> or indomethacin ethyl ester-loaded nanocapsules, in glioma cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8868",
    "Sentence": "Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of indomethacin-loaded nanocapsules or <\\entity><\\entity>, in glioma cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8869",
    "Sentence": "Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, in <\\entity><\\entity> cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8870",
    "Sentence": "Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, in glioma cells was not observed in the organotypic cultures, indicating selective <\\entity><\\entity> of those formulations for tumoral cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8871",
    "Sentence": "Further investigations using in vivo <\\entity><\\entity> model should be helpful to confirm the distinct effects of indomethacin-loaded nanocapsules and indomethacin ethyl ester-loaded nanocapsules, in normal versus tumoral cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8872",
    "Sentence": "Further investigations using in vivo glioma model should be helpful to confirm the distinct effects of <\\entity><\\entity> and indomethacin ethyl ester-loaded nanocapsules, in normal versus tumoral cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8873",
    "Sentence": "Further investigations using in vivo glioma model should be helpful to confirm the distinct effects of indomethacin-loaded nanocapsules and <\\entity><\\entity>, in normal versus tumoral cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8874",
    "Sentence": "Selective cytotoxicity of <\\entity><\\entity> and <\\entity><\\entity> ethyl ester-loaded nanocapsules against glioma cell lines: an in vitro study.Gliomas are the most common and devastating tumors of the central nervous system.",
    "Label": ""
  },
  {
    "id": "8875",
    "Sentence": "Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against <\\entity><\\entity> cell lines: an in vitro study.Gliomas are the most common and devastating tumors of the central nervous system.",
    "Label": ""
  },
  {
    "id": "8877",
    "Sentence": "Selective cytotoxicity of indomethacin and <\\entity><\\entity> against glioma cell lines: an in vitro study.Gliomas are the most common and devastating tumors of the central nervous system.",
    "Label": ""
  },
  {
    "id": "8878",
    "Sentence": "Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against <\\entity><\\entity> cell lines: an in vitro study.Gliomas are the most common and devastating tumors of the central nervous system.",
    "Label": ""
  },
  {
    "id": "8880",
    "Sentence": "The aim of this study was to evaluate the effects of indomethacin-loaded nanocapsules and <\\entity><\\entity> on glioma cell lines.",
    "Label": ""
  },
  {
    "id": "8881",
    "Sentence": "The aim of this study was to evaluate the effects of indomethacin-loaded nanocapsules and indomethacin ethyl ester-loaded nanocapsules on <\\entity><\\entity> cell lines.",
    "Label": ""
  },
  {
    "id": "8883",
    "Sentence": "The aim of this study was to evaluate the effects of <\\entity><\\entity> and indomethacin ethyl ester-loaded nanocapsules on glioma cell lines.",
    "Label": ""
  },
  {
    "id": "8884",
    "Sentence": "The aim of this study was to evaluate the effects of indomethacin-loaded nanocapsules and indomethacin ethyl ester-loaded nanocapsules on <\\entity><\\entity> cell lines.",
    "Label": ""
  },
  {
    "id": "8886",
    "Sentence": "The main finding of the present study is that <\\entity><\\entity> formulation was more potent than a solution of indomethacin in decreasing the viability and cell proliferation of glioma lines.",
    "Label": ""
  },
  {
    "id": "8887",
    "Sentence": "The main finding of the present study is that indomethacin-loaded nanocapsules formulation was more potent than a solution of indomethacin in decreasing the viability and cell proliferation of <\\entity><\\entity> lines.",
    "Label": ""
  },
  {
    "id": "8889",
    "Sentence": "The main finding of the present study is that indomethacin-loaded nanocapsules formulation was more potent than a <\\entity><\\entity> in decreasing the viability and cell proliferation of glioma lines.",
    "Label": ""
  },
  {
    "id": "8890",
    "Sentence": "The main finding of the present study is that indomethacin-loaded nanocapsules formulation was more potent than a solution of indomethacin in decreasing the viability and cell proliferation of <\\entity><\\entity> lines.",
    "Label": ""
  },
  {
    "id": "8892",
    "Sentence": "<\\entity><\\entity> and indomethacin ethyl ester associated together in the same nanocapsule formulation caused a synergic effect decreasing glioma cell proliferation.",
    "Label": ""
  },
  {
    "id": "8893",
    "Sentence": "Indomethacin and indomethacin ethyl ester associated together in the same nanocapsule formulation caused a synergic effect decreasing <\\entity><\\entity> cell proliferation.",
    "Label": ""
  },
  {
    "id": "8895",
    "Sentence": "Indomethacin and <\\entity><\\entity> associated together in the same nanocapsule formulation caused a synergic effect decreasing glioma cell proliferation.",
    "Label": ""
  },
  {
    "id": "8896",
    "Sentence": "Indomethacin and indomethacin ethyl ester associated together in the same nanocapsule formulation caused a synergic effect decreasing <\\entity><\\entity> cell proliferation.",
    "Label": ""
  },
  {
    "id": "8898",
    "Sentence": "In addition, when the glioma cells were exposed to 25 microM of indomethacin-loaded nanocapsules or <\\entity><\\entity>, a necrotic cell death was observed.",
    "Label": ""
  },
  {
    "id": "8899",
    "Sentence": "In addition, when the <\\entity><\\entity> cells were exposed to 25 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, a necrotic cell death was observed.",
    "Label": ""
  },
  {
    "id": "8901",
    "Sentence": "In addition, when the glioma cells were exposed to 25 microM of <\\entity><\\entity> or indomethacin ethyl ester-loaded nanocapsules, a necrotic cell death was observed.",
    "Label": ""
  },
  {
    "id": "8902",
    "Sentence": "In addition, when the <\\entity><\\entity> cells were exposed to 25 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, a necrotic cell death was observed.",
    "Label": ""
  },
  {
    "id": "8904",
    "Sentence": "Interestingly, 5 microM of <\\entity><\\entity> was able to cause an antiproliferative effect without promoting necrosis in glioma cells.",
    "Label": ""
  },
  {
    "id": "8905",
    "Sentence": "Interestingly, 5 microM of indomethacin-loaded nanocapsules was able to cause an antiproliferative effect without promoting necrosis in <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "8907",
    "Sentence": "Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of indomethacin-loaded nanocapsules or <\\entity><\\entity>, in glioma cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells.",
    "Label": ""
  },
  {
    "id": "8908",
    "Sentence": "Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, in <\\entity><\\entity> cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells.",
    "Label": ""
  },
  {
    "id": "8910",
    "Sentence": "Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of <\\entity><\\entity> or indomethacin ethyl ester-loaded nanocapsules, in glioma cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells.",
    "Label": ""
  },
  {
    "id": "8911",
    "Sentence": "Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, in <\\entity><\\entity> cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells.",
    "Label": ""
  },
  {
    "id": "8913",
    "Sentence": "Further investigations using in vivo glioma model should be helpful to confirm the distinct effects of indomethacin-loaded nanocapsules and <\\entity><\\entity>, in normal versus tumoral cells.",
    "Label": ""
  },
  {
    "id": "8914",
    "Sentence": "Further investigations using in vivo <\\entity><\\entity> model should be helpful to confirm the distinct effects of indomethacin-loaded nanocapsules and indomethacin ethyl ester-loaded nanocapsules, in normal versus tumoral cells.",
    "Label": ""
  },
  {
    "id": "8916",
    "Sentence": "Further investigations using in vivo glioma model should be helpful to confirm the distinct effects of <\\entity><\\entity> and indomethacin ethyl ester-loaded nanocapsules, in normal versus tumoral cells.",
    "Label": ""
  },
  {
    "id": "8917",
    "Sentence": "Further investigations using in vivo <\\entity><\\entity> model should be helpful to confirm the distinct effects of indomethacin-loaded nanocapsules and indomethacin ethyl ester-loaded nanocapsules, in normal versus tumoral cells.",
    "Label": ""
  },
  {
    "id": "8919",
    "Sentence": "Selective cytotoxicity of indomethacin and <\\entity><\\entity> against glioma cell lines: an in vitro study.Gliomas are the most common and devastating tumors of the central nervous system.",
    "Label": ""
  },
  {
    "id": "8920",
    "Sentence": "Selective <\\entity><\\entity> of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cell lines: an in vitro study.Gliomas are the most common and devastating tumors of the central nervous system.",
    "Label": ""
  },
  {
    "id": "8922",
    "Sentence": "In addition, when the glioma cells were exposed to 25 microM of indomethacin-loaded nanocapsules or <\\entity><\\entity>, a necrotic cell death was observed.",
    "Label": ""
  },
  {
    "id": "8923",
    "Sentence": "In addition, when the glioma cells were exposed to 25 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, a <\\entity><\\entity> cell death was observed.",
    "Label": ""
  },
  {
    "id": "8925",
    "Sentence": "Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of indomethacin-loaded nanocapsules or <\\entity><\\entity>, in glioma cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells.",
    "Label": ""
  },
  {
    "id": "8926",
    "Sentence": "Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of indomethacin-loaded nanocapsules or indomethacin ethyl ester-loaded nanocapsules, in glioma cells was not observed in the organotypic cultures, indicating selective <\\entity><\\entity> of those formulations for tumoral cells.",
    "Label": ""
  },
  {
    "id": "8932",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in <\\entity><\\entity> patients influence pouchitis development after ileal pouch-anal anastomosis.BACKGROUND & AIMS: Acute pouchitis (AP) and chronic pouchitis (CP) are common after ileal pouch-anal anastomosis (IPAA) for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8933",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence <\\entity><\\entity> development after ileal pouch-anal anastomosis.BACKGROUND & AIMS: Acute <\\entity><\\entity> (AP) and chronic <\\entity><\\entity> (CP) are common after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8934",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after <\\entity><\\entity>.BACKGROUND & AIMS: Acute pouchitis (AP) and chronic pouchitis (CP) are common after <\\entity><\\entity> (IPAA) for ulcerative colitis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8935",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis.BACKGROUND & AIMS: <\\entity><\\entity> (AP) and chronic pouchitis (CP) are common after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8936",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis.BACKGROUND & AIMS: Acute pouchitis (<\\entity><\\entity>) and chronic pouchitis (CP) are common after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8937",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis.BACKGROUND & AIMS: Acute pouchitis (AP) and <\\entity><\\entity> (CP) are common after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8938",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis.BACKGROUND & AIMS: Acute pouchitis (AP) and chronic pouchitis (<\\entity><\\entity>) are common after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8939",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis.BACKGROUND & AIMS: Acute pouchitis (AP) and chronic pouchitis (<\\entity><\\entity>) are common after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8940",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after <\\entity><\\entity>.BACKGROUND & AIMS: Acute pouchitis (AP) and chronic pouchitis (CP) are common after <\\entity><\\entity> (IPAA) for ulcerative colitis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8941",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis.BACKGROUND & AIMS: Acute pouchitis (AP) and chronic pouchitis (CP) are common after ileal pouch-anal anastomosis (<\\entity><\\entity>) for ulcerative colitis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8942",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in <\\entity><\\entity> patients influence pouchitis development after ileal pouch-anal anastomosis.BACKGROUND & AIMS: Acute pouchitis (AP) and chronic pouchitis (CP) are common after ileal pouch-anal anastomosis (IPAA) for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8943",
    "Sentence": "The aim of this study was to assess associations of preoperative perinuclear antineutrophil cytoplasmic antibody (pANCA) and anti-CBir1 flagellin on <\\entity><\\entity> or CP development.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8944",
    "Sentence": "The aim of this study was to assess associations of preoperative perinuclear antineutrophil cytoplasmic antibody (pANCA) and anti-CBir1 flagellin on AP or <\\entity><\\entity> development.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8945",
    "Sentence": "The aim of this study was to assess associations of preoperative perinuclear antineutrophil cytoplasmic antibody (pANCA) and anti-CBir1 flagellin on AP or <\\entity><\\entity> development.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8946",
    "Sentence": "METHODS: Patients were assessed prospectively for clinically and endoscopically proven <\\entity><\\entity> (antibiotic responsive) or CP (antibiotic-dependent or refractory to antibiotic therapy).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8947",
    "Sentence": "METHODS: Patients were assessed prospectively for clinically and endoscopically proven AP (<\\entity><\\entity> responsive) or CP (<\\entity><\\entity>-dependent or refractory to <\\entity><\\entity> therapy).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8948",
    "Sentence": "METHODS: Patients were assessed prospectively for clinically and endoscopically proven AP (antibiotic responsive) or <\\entity><\\entity> (antibiotic-dependent or refractory to antibiotic therapy).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8949",
    "Sentence": "METHODS: Patients were assessed prospectively for clinically and endoscopically proven AP (antibiotic responsive) or <\\entity><\\entity> (antibiotic-dependent or refractory to antibiotic therapy).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8950",
    "Sentence": "METHODS: Patients were assessed prospectively for clinically and endoscopically proven AP (<\\entity><\\entity> responsive) or CP (<\\entity><\\entity>-dependent or refractory to <\\entity><\\entity> therapy).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8951",
    "Sentence": "METHODS: Patients were assessed prospectively for clinically and endoscopically proven AP (<\\entity><\\entity> responsive) or CP (<\\entity><\\entity>-dependent or refractory to <\\entity><\\entity> therapy).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8952",
    "Sentence": "RESULTS: After a median follow-up period of 47 months, 72 patients (30%) developed <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8953",
    "Sentence": "<\\entity><\\entity> developed in 36% of pANCA(+) patients versus 16% of pANCA(-) patients (P = .005), 46% of anti-CBir1(+) patients versus 26% of anti-CBir1(-) patients (P = .02), and 54% of 35 pANCA(+)/anti-CBir1(+) patients versus 31% of 136 pANCA(+)/anti-CBir1(-) patients (P = .02).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8954",
    "Sentence": "<\\entity><\\entity> developed in 37 pANCA(+) patients (22%) versus 6 pANCA(-) patients (9%) (P = .02), and 12 anti-CBir1(+) patients (26%) versus 31 anti-CBir1(-) patients (16%) (P = .1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8955",
    "Sentence": "Although <\\entity><\\entity> was not influenced by pANCA level, <\\entity><\\entity> was seen in 38% of low-level pANCA(+)/anti-CBir1(+) patients versus 18% low-level pANCA(+)/anti-CBir1(-) patients (P = .03).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8956",
    "Sentence": "Although <\\entity><\\entity> was not influenced by pANCA level, <\\entity><\\entity> was seen in 38% of low-level pANCA(+)/anti-CBir1(+) patients versus 18% low-level pANCA(+)/anti-CBir1(-) patients (P = .03).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8957",
    "Sentence": "<\\entity><\\entity> was seen in 29% of high-level pANCA(+) patients versus 11% of low-level pANCA(+) patients (P = .03).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8958",
    "Sentence": "<\\entity><\\entity> was seen in 29% of high-level pANCA(+) patients versus 11% of low-level pANCA(+) patients (P = .03).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8959",
    "Sentence": "CONCLUSIONS: Both pANCA and anti-CBir1 expression are associated with <\\entity><\\entity> after IPAA.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8960",
    "Sentence": "CONCLUSIONS: Both pANCA and anti-CBir1 expression are associated with pouchitis after <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8961",
    "Sentence": "Anti-CBir1 increases the incidence of <\\entity><\\entity> only in patients who have low-level pANCA expression, and increases the incidence of CP only in patients who have high-level pANCA expression.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8962",
    "Sentence": "Anti-CBir1 increases the incidence of AP only in patients who have low-level pANCA expression, and increases the incidence of <\\entity><\\entity> only in patients who have high-level pANCA expression.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8963",
    "Sentence": "Anti-CBir1 increases the incidence of AP only in patients who have low-level pANCA expression, and increases the incidence of <\\entity><\\entity> only in patients who have high-level pANCA expression.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "8964",
    "Sentence": "Diverse patterns of reactivity to microbial antigens may manifest as different forms of <\\entity><\\entity> after IPAA.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8965",
    "Sentence": "Diverse patterns of reactivity to microbial antigens may manifest as different forms of pouchitis after <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8966",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis.BACKGROUND & AIMS: Acute pouchitis (AP) and chronic pouchitis (<\\entity><\\entity>) are common after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "8967",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in <\\entity><\\entity> patients influence pouchitis development after ileal pouch-anal anastomosis.BACKGROUND & AIMS: Acute pouchitis (AP) and chronic pouchitis (CP) are common after ileal pouch-anal anastomosis (IPAA) for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "8969",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis.BACKGROUND & AIMS: Acute pouchitis (AP) and chronic pouchitis (<\\entity><\\entity>) are common after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "8970",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis.BACKGROUND & AIMS: Acute pouchitis (AP) and <\\entity><\\entity> (CP) are common after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "8972",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis.BACKGROUND & AIMS: Acute pouchitis (AP) and chronic pouchitis (<\\entity><\\entity>) are common after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "8973",
    "Sentence": "Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after <\\entity><\\entity>.BACKGROUND & AIMS: Acute pouchitis (AP) and chronic pouchitis (CP) are common after <\\entity><\\entity> (IPAA) for ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "8979",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of <\\entity><\\entity> poisons by suppressing Rad51 expression in a p53-dependent manner.The results of a phase I clinical trial of the <\\entity><\\entity> (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid tumors indicate that patients whose tumors were wild-type, but not mutant, for p53 obtained the most clinical benefit from this combination therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8980",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing <\\entity><\\entity> expression in a p53-dependent manner.The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid tumors indicate that patients whose tumors were wild-type, but not mutant, for p53 obtained the most clinical benefit from this combination therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8981",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a <\\entity><\\entity>-dependent manner.The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid tumors indicate that patients whose tumors were wild-type, but not mutant, for <\\entity><\\entity> obtained the most clinical benefit from this combination therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8982",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of <\\entity><\\entity> poisons by suppressing Rad51 expression in a p53-dependent manner.The results of a phase I clinical trial of the <\\entity><\\entity> (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid tumors indicate that patients whose tumors were wild-type, but not mutant, for p53 obtained the most clinical benefit from this combination therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8983",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.The results of a phase I clinical trial of the topoisomerase I (<\\entity><\\entity>) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid tumors indicate that patients whose tumors were wild-type, but not mutant, for p53 obtained the most clinical benefit from this combination therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8984",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced <\\entity><\\entity> indicate that patients whose tumors were wild-type, but not mutant, for p53 obtained the most clinical benefit from this combination therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8985",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid <\\entity><\\entity> indicate that patients whose <\\entity><\\entity> were wild-type, but not mutant, for p53 obtained the most clinical benefit from this combination therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8986",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid tumors indicate that patients whose tumors were wild-type, but not <\\entity><\\entity>, for p53 obtained the most clinical benefit from this combination therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8987",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a <\\entity><\\entity>-dependent manner.The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid tumors indicate that patients whose tumors were wild-type, but not mutant, for <\\entity><\\entity> obtained the most clinical benefit from this combination therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8988",
    "Sentence": "We elected to elucidate the mechanistic basis for this effect in isogenic-paired HCT116 <\\entity><\\entity> cells that were either wild-type (+/+) or null (-/-) for p53.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "8989",
    "Sentence": "We elected to elucidate the mechanistic basis for this effect in isogenic-paired HCT116 colon cancer cells that were either <\\entity><\\entity> or null (-/-) for p53.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8990",
    "Sentence": "We elected to elucidate the mechanistic basis for this effect in isogenic-paired HCT116 colon cancer cells that were either wild-type (+/+) or <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8991",
    "Sentence": "We elected to elucidate the mechanistic basis for this effect in isogenic-paired HCT116 colon cancer cells that were either wild-type (+/+) or <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8992",
    "Sentence": "With the combination therapy of SN-38 (the active metabolite of CPT-11) followed by flavopiridol, the induction of apoptosis was 5-fold greater in the <\\entity><\\entity> cells compared with the p53-/- cells.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8993",
    "Sentence": "With the combination therapy of SN-38 (the active metabolite of CPT-11) followed by flavopiridol, the induction of apoptosis was 5-fold greater in the <\\entity><\\entity> cells compared with the p53-/- cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8994",
    "Sentence": "With the combination therapy of SN-38 (the active metabolite of CPT-11) followed by flavopiridol, the induction of apoptosis was 5-fold greater in the p53+/+ cells compared with the <\\entity><\\entity> cells.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "8995",
    "Sentence": "With the combination therapy of SN-38 (the active metabolite of CPT-11) followed by flavopiridol, the induction of apoptosis was 5-fold greater in the p53+/+ cells compared with the <\\entity><\\entity> cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8996",
    "Sentence": "This sequential treatment induced phosphorylation of <\\entity><\\entity> at Ser(15), which interacted with Rad51, a DNA repair protein involved in homologous recombination.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8997",
    "Sentence": "This sequential treatment induced phosphorylation of p53 at Ser(15), which interacted with <\\entity><\\entity>, a DNA repair protein involved in homologous recombination.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8998",
    "Sentence": "This sequential treatment induced phosphorylation of p53 at Ser(15), which interacted with Rad51, a <\\entity><\\entity> involved in homologous recombination.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "8999",
    "Sentence": "<\\entity><\\entity> bound to p53-Ser(15) within the first 5 hours of combination therapy, and then was transcriptionally suppressed at 24 hours by flavopiridol only in p53+/+ cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9000",
    "Sentence": "Rad51 bound to <\\entity><\\entity> within the first 5 hours of combination therapy, and then was transcriptionally suppressed at 24 hours by flavopiridol only in p53+/+ cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9001",
    "Sentence": "Rad51 bound to p53-Ser(15) within the first 5 hours of combination therapy, and then was transcriptionally suppressed at 24 hours by flavopiridol only in <\\entity><\\entity> cells.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9002",
    "Sentence": "Rad51 bound to p53-Ser(15) within the first 5 hours of combination therapy, and then was transcriptionally suppressed at 24 hours by flavopiridol only in <\\entity><\\entity> cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9003",
    "Sentence": "Microarray analysis also revealed <\\entity><\\entity> of Rad51 in a p53-dependent manner.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9004",
    "Sentence": "Microarray analysis also revealed suppression of <\\entity><\\entity> in a p53-dependent manner.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9005",
    "Sentence": "Microarray analysis also revealed suppression of Rad51 in a <\\entity><\\entity>-dependent manner.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9006",
    "Sentence": "Depletion of <\\entity><\\entity> by small interfering RNA (siRNA) sensitized both p53+/+ and p53-/- cells to SN-38-induced apoptosis with increase of gamma H2AX, a marker of DNA damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9007",
    "Sentence": "Depletion of Rad51 by small interfering RNA (siRNA) sensitized both <\\entity><\\entity> and p53-/- cells to SN-38-induced apoptosis with increase of gamma H2AX, a marker of DNA damage.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9008",
    "Sentence": "Depletion of Rad51 by small interfering RNA (siRNA) sensitized both <\\entity><\\entity> and p53-/- cells to SN-38-induced apoptosis with increase of gamma H2AX, a marker of DNA damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9009",
    "Sentence": "Depletion of Rad51 by small interfering RNA (siRNA) sensitized both p53+/+ and <\\entity><\\entity> cells to SN-38-induced apoptosis with increase of gamma H2AX, a marker of DNA damage.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9010",
    "Sentence": "Depletion of Rad51 by small interfering RNA (siRNA) sensitized both p53+/+ and <\\entity><\\entity> cells to SN-38-induced apoptosis with increase of gamma H2AX, a marker of DNA damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9011",
    "Sentence": "Depletion of Rad51 by small interfering RNA (siRNA) sensitized both p53+/+ and p53-/- cells to SN-38-induced apoptosis with increase of gamma <\\entity><\\entity>, a marker of DNA damage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9012",
    "Sentence": "Depletion of Rad51 by small interfering RNA (siRNA) sensitized both p53+/+ and p53-/- cells to SN-38-induced apoptosis with increase of gamma H2AX, a marker of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9013",
    "Sentence": "Conversely, overexpression of <\\entity><\\entity> rescued p53+/+ cells from SN-->F-induced apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9014",
    "Sentence": "Conversely, overexpression of Rad51 rescued <\\entity><\\entity> cells from SN-->F-induced apoptosis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9015",
    "Sentence": "Conversely, overexpression of Rad51 rescued <\\entity><\\entity> cells from SN-->F-induced apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9016",
    "Sentence": "Because flavopiridol inhibits <\\entity><\\entity>, we found that inhibition of <\\entity><\\entity> by DRB or by siRNA could recapitulate the flavopiridol effects, with suppression of Rad51 and induction of apoptosis only in p53+/+ cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9017",
    "Sentence": "Because flavopiridol inhibits <\\entity><\\entity>, we found that inhibition of <\\entity><\\entity> by DRB or by siRNA could recapitulate the flavopiridol effects, with suppression of Rad51 and induction of apoptosis only in p53+/+ cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9018",
    "Sentence": "Because flavopiridol inhibits Cdk9, we found that inhibition of Cdk9 by DRB or by siRNA could recapitulate the flavopiridol effects, with <\\entity><\\entity> of Rad51 and induction of apoptosis only in p53+/+ cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9019",
    "Sentence": "Because flavopiridol inhibits Cdk9, we found that inhibition of Cdk9 by DRB or by siRNA could recapitulate the flavopiridol effects, with suppression of <\\entity><\\entity> and induction of apoptosis only in p53+/+ cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9020",
    "Sentence": "Because flavopiridol inhibits Cdk9, we found that inhibition of Cdk9 by DRB or by siRNA could recapitulate the flavopiridol effects, with suppression of Rad51 and induction of apoptosis only in <\\entity><\\entity> cells.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9021",
    "Sentence": "Because flavopiridol inhibits Cdk9, we found that inhibition of Cdk9 by DRB or by siRNA could recapitulate the flavopiridol effects, with suppression of Rad51 and induction of apoptosis only in <\\entity><\\entity> cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9022",
    "Sentence": "In conclusion, after <\\entity><\\entity> by Topo I poisons, flavopiridol targets homologous recombination through a p53-dependent down-regulation of Rad51, resulting in enhancement of apoptosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9023",
    "Sentence": "In conclusion, after DNA damage by <\\entity><\\entity> poisons, flavopiridol targets homologous recombination through a p53-dependent down-regulation of Rad51, resulting in enhancement of apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9024",
    "Sentence": "In conclusion, after DNA damage by Topo I poisons, flavopiridol targets homologous recombination through a <\\entity><\\entity>-dependent down-regulation of Rad51, resulting in enhancement of apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9025",
    "Sentence": "In conclusion, after DNA damage by Topo I poisons, flavopiridol targets homologous recombination through a p53-dependent down-regulation of <\\entity><\\entity>, resulting in enhancement of apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9026",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a <\\entity><\\entity>-dependent manner.The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid tumors indicate that patients whose tumors were wild-type, but not mutant, for <\\entity><\\entity> obtained the most clinical benefit from this combination therapy.",
    "Label": ""
  },
  {
    "id": "9027",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced <\\entity><\\entity> indicate that patients whose tumors were wild-type, but not mutant, for p53 obtained the most clinical benefit from this combination therapy.",
    "Label": ""
  },
  {
    "id": "9029",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a <\\entity><\\entity>-dependent manner.The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid tumors indicate that patients whose tumors were wild-type, but not mutant, for <\\entity><\\entity> obtained the most clinical benefit from this combination therapy.",
    "Label": ""
  },
  {
    "id": "9030",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid <\\entity><\\entity> indicate that patients whose <\\entity><\\entity> were wild-type, but not mutant, for p53 obtained the most clinical benefit from this combination therapy.",
    "Label": ""
  },
  {
    "id": "9032",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a <\\entity><\\entity>-dependent manner.The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid tumors indicate that patients whose tumors were wild-type, but not mutant, for <\\entity><\\entity> obtained the most clinical benefit from this combination therapy.",
    "Label": ""
  },
  {
    "id": "9033",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid tumors indicate that patients whose tumors were wild-type, but not <\\entity><\\entity>, for p53 obtained the most clinical benefit from this combination therapy.",
    "Label": ""
  },
  {
    "id": "9035",
    "Sentence": "We elected to elucidate the mechanistic basis for this effect in isogenic-paired HCT116 colon cancer cells that were either wild-type (+/+) or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9036",
    "Sentence": "We elected to elucidate the mechanistic basis for this effect in isogenic-paired HCT116 <\\entity><\\entity> cells that were either wild-type (+/+) or null (-/-) for p53.",
    "Label": ""
  },
  {
    "id": "9038",
    "Sentence": "Microarray analysis also revealed suppression of <\\entity><\\entity> in a p53-dependent manner.",
    "Label": ""
  },
  {
    "id": "9039",
    "Sentence": "Microarray analysis also revealed <\\entity><\\entity> of Rad51 in a p53-dependent manner.",
    "Label": ""
  },
  {
    "id": "9041",
    "Sentence": "Microarray analysis also revealed suppression of Rad51 in a <\\entity><\\entity>-dependent manner.",
    "Label": ""
  },
  {
    "id": "9042",
    "Sentence": "Microarray analysis also revealed <\\entity><\\entity> of Rad51 in a p53-dependent manner.",
    "Label": ""
  },
  {
    "id": "9044",
    "Sentence": "Depletion of <\\entity><\\entity> by small interfering RNA (siRNA) sensitized both p53+/+ and p53-/- cells to SN-38-induced apoptosis with increase of gamma H2AX, a marker of DNA damage.",
    "Label": ""
  },
  {
    "id": "9045",
    "Sentence": "Depletion of Rad51 by small interfering RNA (siRNA) sensitized both p53+/+ and p53-/- cells to SN-38-induced apoptosis with increase of gamma H2AX, a marker of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9047",
    "Sentence": "Depletion of Rad51 by small interfering RNA (siRNA) sensitized both p53+/+ and p53-/- cells to SN-38-induced apoptosis with increase of gamma <\\entity><\\entity>, a marker of DNA damage.",
    "Label": ""
  },
  {
    "id": "9048",
    "Sentence": "Depletion of Rad51 by small interfering RNA (siRNA) sensitized both p53+/+ and p53-/- cells to SN-38-induced apoptosis with increase of gamma H2AX, a marker of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9050",
    "Sentence": "Because flavopiridol inhibits Cdk9, we found that inhibition of Cdk9 by DRB or by siRNA could recapitulate the flavopiridol effects, with suppression of <\\entity><\\entity> and induction of apoptosis only in p53+/+ cells.",
    "Label": ""
  },
  {
    "id": "9051",
    "Sentence": "Because flavopiridol inhibits Cdk9, we found that inhibition of Cdk9 by DRB or by siRNA could recapitulate the flavopiridol effects, with <\\entity><\\entity> of Rad51 and induction of apoptosis only in p53+/+ cells.",
    "Label": ""
  },
  {
    "id": "9053",
    "Sentence": "Because flavopiridol inhibits <\\entity><\\entity>, we found that inhibition of <\\entity><\\entity> by DRB or by siRNA could recapitulate the flavopiridol effects, with suppression of Rad51 and induction of apoptosis only in p53+/+ cells.",
    "Label": ""
  },
  {
    "id": "9054",
    "Sentence": "Because flavopiridol inhibits Cdk9, we found that inhibition of Cdk9 by DRB or by siRNA could recapitulate the flavopiridol effects, with <\\entity><\\entity> of Rad51 and induction of apoptosis only in p53+/+ cells.",
    "Label": ""
  },
  {
    "id": "9056",
    "Sentence": "In conclusion, after DNA damage by Topo I poisons, flavopiridol targets homologous recombination through a p53-dependent down-regulation of <\\entity><\\entity>, resulting in enhancement of apoptosis.",
    "Label": ""
  },
  {
    "id": "9057",
    "Sentence": "In conclusion, after <\\entity><\\entity> by Topo I poisons, flavopiridol targets homologous recombination through a p53-dependent down-regulation of Rad51, resulting in enhancement of apoptosis.",
    "Label": ""
  },
  {
    "id": "9059",
    "Sentence": "In conclusion, after DNA damage by Topo I poisons, flavopiridol targets homologous recombination through a <\\entity><\\entity>-dependent down-regulation of Rad51, resulting in enhancement of apoptosis.",
    "Label": ""
  },
  {
    "id": "9060",
    "Sentence": "In conclusion, after <\\entity><\\entity> by Topo I poisons, flavopiridol targets homologous recombination through a p53-dependent down-regulation of Rad51, resulting in enhancement of apoptosis.",
    "Label": ""
  },
  {
    "id": "9062",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of <\\entity><\\entity> poisons by suppressing Rad51 expression in a p53-dependent manner.The results of a phase I clinical trial of the <\\entity><\\entity> (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid tumors indicate that patients whose tumors were wild-type, but not mutant, for p53 obtained the most clinical benefit from this combination therapy.",
    "Label": ""
  },
  {
    "id": "9063",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced <\\entity><\\entity> indicate that patients whose tumors were wild-type, but not mutant, for p53 obtained the most clinical benefit from this combination therapy.",
    "Label": ""
  },
  {
    "id": "9065",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.The results of a phase I clinical trial of the topoisomerase I (<\\entity><\\entity>) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced solid tumors indicate that patients whose tumors were wild-type, but not mutant, for p53 obtained the most clinical benefit from this combination therapy.",
    "Label": ""
  },
  {
    "id": "9066",
    "Sentence": "The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.The results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the cyclin-dependent kinase inhibitor flavopiridol in patients with advanced <\\entity><\\entity> indicate that patients whose tumors were wild-type, but not mutant, for p53 obtained the most clinical benefit from this combination therapy.",
    "Label": ""
  },
  {
    "id": "9072",
    "Sentence": "Oral surgery in a child with a prosthetic aortic valve and pulmonary <\\entity><\\entity> stent at risk for thromboembolism.Children with prosthetic cardiac valves and other invasive mechanical devices that direct blood flow require anticoagulant medication for prevention of thrombosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9073",
    "Sentence": "Oral surgery in a child with a prosthetic aortic valve and pulmonary artery stent at risk for <\\entity><\\entity>.Children with prosthetic cardiac valves and other invasive mechanical devices that direct blood flow require anticoagulant medication for prevention of thrombosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9074",
    "Sentence": "Oral surgery in a child with a prosthetic aortic valve and pulmonary artery stent at risk for thromboembolism.Children with prosthetic cardiac valves and other invasive mechanical devices that direct blood flow require <\\entity><\\entity> medication for prevention of thrombosis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9075",
    "Sentence": "Oral surgery in a child with a prosthetic aortic valve and pulmonary artery stent at risk for thromboembolism.Children with prosthetic cardiac valves and other invasive mechanical devices that direct blood flow require anticoagulant medication for prevention of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9076",
    "Sentence": "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral <\\entity><\\entity> and instituting heparin therapy prior to the planned dental procedure, which can result in thromboembolism and increased morbidity and mortality.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9077",
    "Sentence": "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting <\\entity><\\entity> therapy prior to the planned dental procedure, which can result in thromboembolism and increased morbidity and mortality.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9078",
    "Sentence": "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting heparin therapy prior to the planned dental procedure, which can result in <\\entity><\\entity> and increased morbidity and mortality.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9079",
    "Sentence": "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting heparin therapy prior to the planned dental procedure, which can result in thromboembolism and increased morbidity and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9080",
    "Sentence": "This case report demonstrates that <\\entity><\\entity> need not be decreased or discontinued prior to extraction of multiple carious primary teeth in a child at risk for thromboembolism.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9081",
    "Sentence": "This case report demonstrates that oral anticoagulation need not be decreased or discontinued prior to extraction of multiple carious primary teeth in a child at risk for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9082",
    "Sentence": "Oral surgery in a child with a prosthetic aortic valve and pulmonary artery stent at risk for thromboembolism.Children with prosthetic cardiac valves and other invasive mechanical devices that direct blood flow require <\\entity><\\entity> medication for prevention of thrombosis.",
    "Label": ""
  },
  {
    "id": "9083",
    "Sentence": "Oral surgery in a child with a prosthetic aortic valve and pulmonary artery stent at risk for thromboembolism.Children with prosthetic cardiac valves and other invasive mechanical devices that direct blood flow require anticoagulant medication for prevention of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9085",
    "Sentence": "This case report demonstrates that <\\entity><\\entity> need not be decreased or discontinued prior to extraction of multiple carious primary teeth in a child at risk for thromboembolism.",
    "Label": ""
  },
  {
    "id": "9086",
    "Sentence": "This case report demonstrates that oral anticoagulation need not be decreased or discontinued prior to extraction of multiple carious primary teeth in a child at risk for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9088",
    "Sentence": "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting <\\entity><\\entity> therapy prior to the planned dental procedure, which can result in thromboembolism and increased morbidity and mortality.",
    "Label": ""
  },
  {
    "id": "9089",
    "Sentence": "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting heparin therapy prior to the planned dental procedure, which can result in <\\entity><\\entity> and increased morbidity and mortality.",
    "Label": ""
  },
  {
    "id": "9091",
    "Sentence": "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral <\\entity><\\entity> and instituting heparin therapy prior to the planned dental procedure, which can result in thromboembolism and increased morbidity and mortality.",
    "Label": ""
  },
  {
    "id": "9092",
    "Sentence": "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting heparin therapy prior to the planned dental procedure, which can result in <\\entity><\\entity> and increased morbidity and mortality.",
    "Label": ""
  },
  {
    "id": "9094",
    "Sentence": "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting <\\entity><\\entity> therapy prior to the planned dental procedure, which can result in thromboembolism and increased morbidity and mortality.",
    "Label": ""
  },
  {
    "id": "9095",
    "Sentence": "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting heparin therapy prior to the planned dental procedure, which can result in thromboembolism and increased morbidity and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9097",
    "Sentence": "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral <\\entity><\\entity> and instituting heparin therapy prior to the planned dental procedure, which can result in thromboembolism and increased morbidity and mortality.",
    "Label": ""
  },
  {
    "id": "9098",
    "Sentence": "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting heparin therapy prior to the planned dental procedure, which can result in thromboembolism and increased morbidity and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9100",
    "Sentence": "This case report demonstrates that <\\entity><\\entity> need not be decreased or discontinued prior to extraction of multiple carious primary teeth in a child at risk for thromboembolism.",
    "Label": ""
  },
  {
    "id": "9101",
    "Sentence": "This case report demonstrates that oral anticoagulation need not be decreased or discontinued prior to extraction of multiple carious primary teeth in a child at risk for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9107",
    "Sentence": "Adherence to the <\\entity><\\entity> for multiple sclerosis: contrasting factors affect stopping drug and missing doses.BACKGROUND: Long-term immunomodulatory drug (IMD) treatment is now common in multiple sclerosis (MS).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9108",
    "Sentence": "Adherence to the immunomodulatory drugs for <\\entity><\\entity>: contrasting factors affect stopping drug and missing doses.BACKGROUND: Long-term immunomodulatory drug (IMD) treatment is now common in <\\entity><\\entity> (MS).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9109",
    "Sentence": "Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses.BACKGROUND: <\\entity><\\entity> (IMD) treatment is now common in multiple sclerosis (MS).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9110",
    "Sentence": "Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses.BACKGROUND: Long-term immunomodulatory drug (<\\entity><\\entity>) treatment is now common in multiple sclerosis (MS).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9111",
    "Sentence": "Adherence to the immunomodulatory drugs for <\\entity><\\entity>: contrasting factors affect stopping drug and missing doses.BACKGROUND: Long-term immunomodulatory drug (IMD) treatment is now common in <\\entity><\\entity> (MS).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9112",
    "Sentence": "Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses.BACKGROUND: Long-term immunomodulatory drug (IMD) treatment is now common in multiple sclerosis (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9113",
    "Sentence": "We examined both levels of non-adherence-stopping <\\entity><\\entity> and missing doses.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9114",
    "Sentence": "METHODS: This longitudinal prospective study followed a population-based cohort (n = 199) of definite <\\entity><\\entity> patients in Southern Tasmania (January 2002 to April 2005, source population 226 559) every 6 months.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9115",
    "Sentence": "Baseline factors (demographic, clinical, psychological and cognitive) affecting adherence were examined by logistic <\\entity><\\entity> and a longitudinal analysis (generalized estimating equation (GEE)).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9116",
    "Sentence": "RESULTS: Of the 97 patients taking an <\\entity><\\entity> (mean follow-up = 2.4 years), 73% (71/97) missed doses, with 1 in 10 missing > 10 doses in any 6-month period.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9117",
    "Sentence": "Missed doses were positively associated with <\\entity><\\entity> amount consumed per session (p = 0.008).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9118",
    "Sentence": "Over one-quarter (27/97) stopped their current <\\entity><\\entity>, which was associated with lower education levels (p = 0.032) and previous relapses (p = 0.05).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9119",
    "Sentence": "Over one-quarter (27/97) stopped their current IMD, which was associated with lower education levels (p = 0.032) and previous <\\entity><\\entity> (p = 0.05).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9120",
    "Sentence": "CONCLUSIONS: There were few strong predictors of missed doses, although people with <\\entity><\\entity> consuming more alcoholic drinks per session are at a higher risk of missing doses.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9121",
    "Sentence": "CONCLUSIONS: There were few strong predictors of missed doses, although people with MS consuming more alcoholic <\\entity><\\entity> per session are at a higher risk of missing doses.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9122",
    "Sentence": "Divergent factors influenced the two levels of non-adherence indicating the need for a multifaceted approach to improving <\\entity><\\entity> adherence.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9123",
    "Sentence": "Adherence to the <\\entity><\\entity> for multiple sclerosis: contrasting factors affect stopping drug and missing doses.BACKGROUND: Long-term immunomodulatory drug (IMD) treatment is now common in multiple sclerosis (MS).",
    "Label": ""
  },
  {
    "id": "9124",
    "Sentence": "Adherence to the immunomodulatory drugs for <\\entity><\\entity>: contrasting factors affect stopping drug and missing doses.BACKGROUND: Long-term immunomodulatory drug (IMD) treatment is now common in <\\entity><\\entity> (MS).",
    "Label": ""
  },
  {
    "id": "9126",
    "Sentence": "Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses.BACKGROUND: <\\entity><\\entity> (IMD) treatment is now common in multiple sclerosis (MS).",
    "Label": ""
  },
  {
    "id": "9127",
    "Sentence": "Adherence to the immunomodulatory drugs for <\\entity><\\entity>: contrasting factors affect stopping drug and missing doses.BACKGROUND: Long-term immunomodulatory drug (IMD) treatment is now common in <\\entity><\\entity> (MS).",
    "Label": ""
  },
  {
    "id": "9129",
    "Sentence": "Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses.BACKGROUND: <\\entity><\\entity> (IMD) treatment is now common in multiple sclerosis (MS).",
    "Label": ""
  },
  {
    "id": "9130",
    "Sentence": "Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses.BACKGROUND: Long-term immunomodulatory drug (IMD) treatment is now common in multiple sclerosis (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "9132",
    "Sentence": "Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses.BACKGROUND: Long-term immunomodulatory drug (<\\entity><\\entity>) treatment is now common in multiple sclerosis (MS).",
    "Label": ""
  },
  {
    "id": "9133",
    "Sentence": "Adherence to the immunomodulatory drugs for <\\entity><\\entity>: contrasting factors affect stopping drug and missing doses.BACKGROUND: Long-term immunomodulatory drug (IMD) treatment is now common in <\\entity><\\entity> (MS).",
    "Label": ""
  },
  {
    "id": "9135",
    "Sentence": "Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses.BACKGROUND: Long-term immunomodulatory drug (<\\entity><\\entity>) treatment is now common in multiple sclerosis (MS).",
    "Label": ""
  },
  {
    "id": "9136",
    "Sentence": "Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses.BACKGROUND: Long-term immunomodulatory drug (IMD) treatment is now common in multiple sclerosis (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "9142",
    "Sentence": "Intensified neoadjuvant <\\entity><\\entity> in early-responding breast cancer: phase III randomized GeparTrio study.BACKGROUND: Patients with an early response to neoadjuvant <\\entity><\\entity> have chemosensitive tumors and a high probability for a pathological complete response at surgery.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9143",
    "Sentence": "Intensified neoadjuvant chemotherapy in early-responding <\\entity><\\entity>: phase III randomized GeparTrio study.BACKGROUND: Patients with an early response to neoadjuvant chemotherapy have chemosensitive tumors and a high probability for a pathological complete response at surgery.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9144",
    "Sentence": "Intensified neoadjuvant <\\entity><\\entity> in early-responding breast cancer: phase III randomized GeparTrio study.BACKGROUND: Patients with an early response to neoadjuvant <\\entity><\\entity> have chemosensitive tumors and a high probability for a pathological complete response at surgery.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9145",
    "Sentence": "Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.BACKGROUND: Patients with an early response to neoadjuvant chemotherapy have chemosensitive <\\entity><\\entity> and a high probability for a pathological complete response at surgery.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9146",
    "Sentence": "The relationship between extended <\\entity><\\entity> and pathological complete response at surgery was investigated in a clinical trial.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9147",
    "Sentence": "METHODS: Untreated <\\entity><\\entity> patients received two 3-week cycles of docetaxel at 75 mg/m(2), doxorubicin at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) (TAC).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9148",
    "Sentence": "METHODS: Untreated breast cancer patients received two 3-week cycles of <\\entity><\\entity> at 75 mg/m(2), doxorubicin at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) (TAC).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9149",
    "Sentence": "METHODS: Untreated breast cancer patients received two 3-week cycles of docetaxel at 75 mg/m(2), <\\entity><\\entity> at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) (TAC).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9150",
    "Sentence": "METHODS: Untreated breast cancer patients received two 3-week cycles of docetaxel at 75 mg/m(2), doxorubicin at 50 mg/m(2), and <\\entity><\\entity> at 500 mg/m(2) (TAC).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9151",
    "Sentence": "METHODS: Untreated breast cancer patients received two 3-week cycles of docetaxel at 75 mg/m(2), doxorubicin at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) (<\\entity><\\entity>).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9152",
    "Sentence": "Those whose <\\entity><\\entity> size decreased by 50% or more by sonographic measurement (ie, reduction in the product of the two largest perpendicular diameters by at least 50%) were classified as responders and randomly assigned to receive four or six more cycles of TAC, for a total of six or eight TAC cycles.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9153",
    "Sentence": "Those whose tumor size decreased by 50% or more by sonographic measurement (ie, reduction in the product of the two largest perpendicular diameters by at least 50%) were classified as responders and randomly assigned to receive four or six more cycles of <\\entity><\\entity>, for a total of six or eight <\\entity><\\entity> cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9154",
    "Sentence": "Those whose tumor size decreased by 50% or more by sonographic measurement (ie, reduction in the product of the two largest perpendicular diameters by at least 50%) were classified as responders and randomly assigned to receive four or six more cycles of <\\entity><\\entity>, for a total of six or eight <\\entity><\\entity> cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9155",
    "Sentence": "The primary aim was to increase the rate of a pathological complete response (defined as no invasive or in situ <\\entity><\\entity> in the breast and lymph nodes) from 20% to 26%.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9156",
    "Sentence": "The primary aim was to increase the rate of a pathological complete response (defined as no invasive or in situ residual <\\entity><\\entity> masses in the breast and lymph nodes) from 20% to 26%.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9157",
    "Sentence": "Sonographic response rates and rates of breast-conserving surgery and <\\entity><\\entity> were also assessed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9158",
    "Sentence": "RESULTS: Of the 2090 patients in the GeparTrio trial, 1390 (66.5%) were randomly assigned as responders after two initial <\\entity><\\entity> cycles to receive an additional four (n = 704) or six (n = 686) <\\entity><\\entity> cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9159",
    "Sentence": "RESULTS: Of the 2090 patients in the GeparTrio trial, 1390 (66.5%) were randomly assigned as responders after two initial <\\entity><\\entity> cycles to receive an additional four (n = 704) or six (n = 686) <\\entity><\\entity> cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9160",
    "Sentence": "Rates of pathological complete response were not statistically significantly different between the arms (21.0% with six <\\entity><\\entity> cycles and 23.5% with eight <\\entity><\\entity> cycles; difference = 2.5%, 95% confidence interval [CI] = -1.8% to 6.8%; P = .27).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9161",
    "Sentence": "Rates of pathological complete response were not statistically significantly different between the arms (21.0% with six <\\entity><\\entity> cycles and 23.5% with eight <\\entity><\\entity> cycles; difference = 2.5%, 95% confidence interval [CI] = -1.8% to 6.8%; P = .27).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9162",
    "Sentence": "More clinical (48.2% vs 52.9%, difference = 4.7%; 95% CI = -0.55% to 9.95%; P = .08) and sonographic (22.6% vs 27.6%, difference = 5%; 95% CI = 0.45% to 9.55%; P = .033) complete responses at surgery were observed with eight <\\entity><\\entity> cycles than with six <\\entity><\\entity> cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9163",
    "Sentence": "More clinical (48.2% vs 52.9%, difference = 4.7%; 95% CI = -0.55% to 9.95%; P = .08) and sonographic (22.6% vs 27.6%, difference = 5%; 95% CI = 0.45% to 9.55%; P = .033) complete responses at surgery were observed with eight <\\entity><\\entity> cycles than with six <\\entity><\\entity> cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9164",
    "Sentence": "<\\entity><\\entity> or 4 leukopenia and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight TAC cycles than in those receiving six cycles.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9165",
    "Sentence": "Grade 3 or <\\entity><\\entity> and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight TAC cycles than in those receiving six cycles.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9166",
    "Sentence": "Grade 3 or 4 leukopenia and <\\entity><\\entity> and various grade 1 or 2 adverse events were more frequent in patients receiving eight TAC cycles than in those receiving six cycles.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9167",
    "Sentence": "Grade 3 or 4 leukopenia and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight <\\entity><\\entity> cycles than in those receiving six cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9168",
    "Sentence": "CONCLUSION: Patients receiving eight <\\entity><\\entity> cycles had statistically significantly higher sonographic response rates but not pathological complete response rates than those receiving six <\\entity><\\entity> cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9169",
    "Sentence": "CONCLUSION: Patients receiving eight <\\entity><\\entity> cycles had statistically significantly higher sonographic response rates but not pathological complete response rates than those receiving six <\\entity><\\entity> cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9170",
    "Sentence": "So far, eight cycles of <\\entity><\\entity> cannot be recommended for the whole group of patients responding to two initial cycles of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9171",
    "Sentence": "So far, eight cycles of <\\entity><\\entity> cannot be recommended for the whole group of patients responding to two initial cycles of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9172",
    "Sentence": "Grade 3 or 4 leukopenia and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight <\\entity><\\entity> cycles than in those receiving six cycles.",
    "Label": ""
  },
  {
    "id": "9173",
    "Sentence": "Grade 3 or 4 leukopenia and <\\entity><\\entity> and various grade 1 or 2 adverse events were more frequent in patients receiving eight TAC cycles than in those receiving six cycles.",
    "Label": ""
  },
  {
    "id": "9175",
    "Sentence": "Grade 3 or 4 leukopenia and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight <\\entity><\\entity> cycles than in those receiving six cycles.",
    "Label": ""
  },
  {
    "id": "9176",
    "Sentence": "<\\entity><\\entity> or 4 leukopenia and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight TAC cycles than in those receiving six cycles.",
    "Label": ""
  },
  {
    "id": "9178",
    "Sentence": "Grade 3 or 4 leukopenia and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight <\\entity><\\entity> cycles than in those receiving six cycles.",
    "Label": ""
  },
  {
    "id": "9179",
    "Sentence": "Grade 3 or <\\entity><\\entity> and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight TAC cycles than in those receiving six cycles.",
    "Label": ""
  },
  {
    "id": "9181",
    "Sentence": "METHODS: Untreated breast cancer patients received two 3-week cycles of docetaxel at 75 mg/m(2), doxorubicin at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "9182",
    "Sentence": "METHODS: Untreated <\\entity><\\entity> patients received two 3-week cycles of docetaxel at 75 mg/m(2), doxorubicin at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) (TAC).",
    "Label": ""
  },
  {
    "id": "9184",
    "Sentence": "METHODS: Untreated breast cancer patients received two 3-week cycles of <\\entity><\\entity> at 75 mg/m(2), doxorubicin at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) (TAC).",
    "Label": ""
  },
  {
    "id": "9185",
    "Sentence": "METHODS: Untreated <\\entity><\\entity> patients received two 3-week cycles of docetaxel at 75 mg/m(2), doxorubicin at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) (TAC).",
    "Label": ""
  },
  {
    "id": "9187",
    "Sentence": "METHODS: Untreated breast cancer patients received two 3-week cycles of docetaxel at 75 mg/m(2), <\\entity><\\entity> at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) (TAC).",
    "Label": ""
  },
  {
    "id": "9188",
    "Sentence": "METHODS: Untreated <\\entity><\\entity> patients received two 3-week cycles of docetaxel at 75 mg/m(2), doxorubicin at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) (TAC).",
    "Label": ""
  },
  {
    "id": "9190",
    "Sentence": "METHODS: Untreated breast cancer patients received two 3-week cycles of docetaxel at 75 mg/m(2), doxorubicin at 50 mg/m(2), and <\\entity><\\entity> at 500 mg/m(2) (TAC).",
    "Label": ""
  },
  {
    "id": "9191",
    "Sentence": "METHODS: Untreated <\\entity><\\entity> patients received two 3-week cycles of docetaxel at 75 mg/m(2), doxorubicin at 50 mg/m(2), and cyclophosphamide at 500 mg/m(2) (TAC).",
    "Label": ""
  },
  {
    "id": "9193",
    "Sentence": "Those whose tumor size decreased by 50% or more by sonographic measurement (ie, reduction in the product of the two largest perpendicular diameters by at least 50%) were classified as responders and randomly assigned to receive four or six more cycles of <\\entity><\\entity>, for a total of six or eight <\\entity><\\entity> cycles.",
    "Label": ""
  },
  {
    "id": "9194",
    "Sentence": "Those whose <\\entity><\\entity> size decreased by 50% or more by sonographic measurement (ie, reduction in the product of the two largest perpendicular diameters by at least 50%) were classified as responders and randomly assigned to receive four or six more cycles of TAC, for a total of six or eight TAC cycles.",
    "Label": ""
  },
  {
    "id": "9196",
    "Sentence": "Intensified neoadjuvant <\\entity><\\entity> in early-responding breast cancer: phase III randomized GeparTrio study.BACKGROUND: Patients with an early response to neoadjuvant <\\entity><\\entity> have chemosensitive tumors and a high probability for a pathological complete response at surgery.",
    "Label": ""
  },
  {
    "id": "9197",
    "Sentence": "Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.BACKGROUND: Patients with an early response to neoadjuvant chemotherapy have chemosensitive <\\entity><\\entity> and a high probability for a pathological complete response at surgery.",
    "Label": ""
  },
  {
    "id": "9203",
    "Sentence": "<\\entity><\\entity> virus genotypes: clinical relevance and therapeutic implications.The incidence of hepatitis C virus (HCV) -related hepatocellular carcinoma (HCC) has been increasing in several countries including Taiwan.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9204",
    "Sentence": "<\\entity><\\entity> virus genotypes: clinical relevance and therapeutic implications.The incidence of hepatitis C virus (HCV) -related hepatocellular carcinoma (HCC) has been increasing in several countries including Taiwan.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9205",
    "Sentence": "Hepatitis C <\\entity><\\entity> genotypes: clinical relevance and therapeutic implications.The incidence of hepatitis C <\\entity><\\entity> (HCV) -related hepatocellular carcinoma (HCC) has been increasing in several countries including Taiwan.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9206",
    "Sentence": "Hepatitis C virus genotypes: clinical relevance and therapeutic implications.The incidence of <\\entity><\\entity> virus (HCV) -related hepatocellular carcinoma (HCC) has been increasing in several countries including Taiwan.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9207",
    "Sentence": "Hepatitis C <\\entity><\\entity> genotypes: clinical relevance and therapeutic implications.The incidence of hepatitis C <\\entity><\\entity> (HCV) -related hepatocellular carcinoma (HCC) has been increasing in several countries including Taiwan.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9208",
    "Sentence": "Hepatitis C virus genotypes: clinical relevance and therapeutic implications.The incidence of hepatitis C virus (<\\entity><\\entity>) -related hepatocellular carcinoma (HCC) has been increasing in several countries including Taiwan.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9209",
    "Sentence": "Hepatitis C virus genotypes: clinical relevance and therapeutic implications.The incidence of hepatitis C virus (HCV) -related <\\entity><\\entity> (HCC) has been increasing in several countries including Taiwan.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9210",
    "Sentence": "Hepatitis C virus genotypes: clinical relevance and therapeutic implications.The incidence of hepatitis C virus (HCV) -related hepatocellular carcinoma (<\\entity><\\entity>) has been increasing in several countries including Taiwan.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9211",
    "Sentence": "Hepatitis C virus genotypes: clinical relevance and therapeutic implications.The incidence of hepatitis C virus (HCV) -related hepatocellular carcinoma (<\\entity><\\entity>) has been increasing in several countries including Taiwan.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9212",
    "Sentence": "<\\entity><\\entity> may play a role in the development of HCC, although some studies have argued against this.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9213",
    "Sentence": "HCV genotype 1 may play a role in the development of <\\entity><\\entity>, although some studies have argued against this.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9214",
    "Sentence": "HCV genotype 1 may play a role in the development of <\\entity><\\entity>, although some studies have argued against this.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9215",
    "Sentence": "A sustained virological response <\\entity><\\entity> to interferon monotherapy or interferon/ribavirin combination therapy may reduce the risk of HCC and improve survival in chronic hepatitis C patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9216",
    "Sentence": "A sustained virological response secondary to interferon monotherapy or interferon/ribavirin combination therapy may reduce the risk of <\\entity><\\entity> and improve survival in chronic hepatitis C patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9217",
    "Sentence": "A sustained virological response secondary to interferon monotherapy or interferon/ribavirin combination therapy may reduce the risk of <\\entity><\\entity> and improve survival in chronic hepatitis C patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9218",
    "Sentence": "A sustained virological response secondary to interferon monotherapy or interferon/ribavirin combination therapy may reduce the risk of HCC and improve survival in <\\entity><\\entity> patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9219",
    "Sentence": "The <\\entity><\\entity> are associated with therapeutic response.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9220",
    "Sentence": "Newly developed bio-techniques (microarray, proteomes, bioinformatics), drugs, and treatment strategies may elucidate the <\\entity><\\entity> and improve the therapeutic response in HCV infection.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9221",
    "Sentence": "Newly developed bio-techniques (microarray, proteomes, bioinformatics), drugs, and treatment strategies may elucidate the pathogenesis and improve the therapeutic response in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9222",
    "Sentence": "Hepatitis C virus genotypes: clinical relevance and therapeutic implications.The incidence of hepatitis C virus (HCV) -related hepatocellular carcinoma (<\\entity><\\entity>) has been increasing in several countries including Taiwan.",
    "Label": ""
  },
  {
    "id": "9223",
    "Sentence": "Hepatitis C virus genotypes: clinical relevance and therapeutic implications.The incidence of <\\entity><\\entity> virus (HCV) -related hepatocellular carcinoma (HCC) has been increasing in several countries including Taiwan.",
    "Label": ""
  },
  {
    "id": "9225",
    "Sentence": "Hepatitis C virus genotypes: clinical relevance and therapeutic implications.The incidence of hepatitis C virus (HCV) -related hepatocellular carcinoma (<\\entity><\\entity>) has been increasing in several countries including Taiwan.",
    "Label": ""
  },
  {
    "id": "9226",
    "Sentence": "Hepatitis C <\\entity><\\entity> genotypes: clinical relevance and therapeutic implications.The incidence of hepatitis C <\\entity><\\entity> (HCV) -related hepatocellular carcinoma (HCC) has been increasing in several countries including Taiwan.",
    "Label": ""
  },
  {
    "id": "9228",
    "Sentence": "Hepatitis C virus genotypes: clinical relevance and therapeutic implications.The incidence of hepatitis C virus (HCV) -related hepatocellular carcinoma (<\\entity><\\entity>) has been increasing in several countries including Taiwan.",
    "Label": ""
  },
  {
    "id": "9229",
    "Sentence": "Hepatitis C virus genotypes: clinical relevance and therapeutic implications.The incidence of hepatitis C virus (HCV) -related <\\entity><\\entity> (HCC) has been increasing in several countries including Taiwan.",
    "Label": ""
  },
  {
    "id": "9231",
    "Sentence": "A sustained virological response secondary to interferon monotherapy or interferon/ribavirin combination therapy may reduce the risk of <\\entity><\\entity> and improve survival in chronic hepatitis C patients.",
    "Label": ""
  },
  {
    "id": "9232",
    "Sentence": "A sustained virological response secondary to interferon monotherapy or interferon/ribavirin combination therapy may reduce the risk of HCC and improve survival in <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "9234",
    "Sentence": "A sustained virological response secondary to interferon monotherapy or interferon/ribavirin combination therapy may reduce the risk of <\\entity><\\entity> and improve survival in chronic hepatitis C patients.",
    "Label": ""
  },
  {
    "id": "9235",
    "Sentence": "A sustained virological response <\\entity><\\entity> to interferon monotherapy or interferon/ribavirin combination therapy may reduce the risk of HCC and improve survival in chronic hepatitis C patients.",
    "Label": ""
  },
  {
    "id": "9237",
    "Sentence": "<\\entity><\\entity> may play a role in the development of HCC, although some studies have argued against this.",
    "Label": ""
  },
  {
    "id": "9238",
    "Sentence": "HCV genotype 1 may play a role in the development of <\\entity><\\entity>, although some studies have argued against this.",
    "Label": ""
  },
  {
    "id": "9244",
    "Sentence": "Changing patterns in <\\entity><\\entity> after availability of tenofovir.Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of tenofovir use.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9245",
    "Sentence": "Changing patterns in <\\entity><\\entity> after availability of tenofovir.Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of tenofovir use.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9246",
    "Sentence": "Changing patterns in HIV reverse transcriptase resistance mutations after availability of <\\entity><\\entity>.Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of <\\entity><\\entity> use.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9247",
    "Sentence": "Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the <\\entity><\\entity>, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of tenofovir use.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9248",
    "Sentence": "Changing patterns in HIV reverse transcriptase resistance mutations after availability of <\\entity><\\entity>.Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of <\\entity><\\entity> use.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9249",
    "Sentence": "A reduction in the rate of coadministration of <\\entity><\\entity> (from 41.6% of patients in 2004 to 0.8% of patients in 2006; P < .001) largely explained this observation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9250",
    "Sentence": "Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the <\\entity><\\entity>, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of tenofovir use.",
    "Label": ""
  },
  {
    "id": "9251",
    "Sentence": "Changing patterns in HIV reverse transcriptase resistance mutations after availability of <\\entity><\\entity>.Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of <\\entity><\\entity> use.",
    "Label": ""
  },
  {
    "id": "9253",
    "Sentence": "Changing patterns in HIV reverse transcriptase resistance mutations after availability of <\\entity><\\entity>.Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of <\\entity><\\entity> use.",
    "Label": ""
  },
  {
    "id": "9254",
    "Sentence": "Changing patterns in <\\entity><\\entity> after availability of tenofovir.Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of tenofovir use.",
    "Label": ""
  },
  {
    "id": "9260",
    "Sentence": "<\\entity><\\entity> versus intravenous meperidine/diazepam in anterior shoulder dislocation: a randomised clinical trial.BACKGROUND: Anterior shoulder dislocation is one of the most common complaints of patients referred to emergency departments.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9261",
    "Sentence": "Intra-articular lidocaine versus <\\entity><\\entity>/diazepam in anterior shoulder dislocation: a randomised clinical trial.BACKGROUND: Anterior shoulder dislocation is one of the most common complaints of patients referred to emergency departments.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9262",
    "Sentence": "Intra-articular lidocaine versus intravenous meperidine/<\\entity><\\entity> in anterior shoulder dislocation: a randomised clinical trial.BACKGROUND: Anterior shoulder dislocation is one of the most common complaints of patients referred to emergency departments.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9263",
    "Sentence": "Intra-articular lidocaine versus intravenous meperidine/diazepam in <\\entity><\\entity>: a randomised clinical trial.BACKGROUND: Anterior shoulder dislocation is one of the most common complaints of patients referred to emergency departments.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9264",
    "Sentence": "Intra-articular lidocaine versus intravenous meperidine/diazepam in anterior shoulder dislocation: a randomised clinical trial.BACKGROUND: <\\entity><\\entity> is one of the most common complaints of patients referred to emergency departments.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9265",
    "Sentence": "<\\entity><\\entity> and benzodiazepines are traditionally prescribed in order to relieve the pain in this group of patients; however, complications always pose a problem.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9266",
    "Sentence": "<\\entity><\\entity> and benzodiazepines are traditionally prescribed in order to relieve the pain in this group of patients; however, complications always pose a problem.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9267",
    "Sentence": "Intravenous opiates and <\\entity><\\entity> are traditionally prescribed in order to relieve the pain in this group of patients; however, complications always pose a problem.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9268",
    "Sentence": "Intravenous opiates and benzodiazepines are traditionally prescribed in order to relieve the <\\entity><\\entity> in this group of patients; however, complications always pose a problem.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9269",
    "Sentence": "Intravenous opiates and benzodiazepines are traditionally prescribed in order to relieve the pain in this group of patients; however, <\\entity><\\entity> always pose a problem.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9270",
    "Sentence": "OBJECTIVE: To compare the <\\entity><\\entity> relief and complications following intra-articular lidocaine and intravenous meperidine/diazepam in patients with anterior shoulder dislocation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9271",
    "Sentence": "OBJECTIVE: To compare the pain relief and <\\entity><\\entity> following intra-articular lidocaine and intravenous meperidine/diazepam in patients with anterior shoulder dislocation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9272",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following <\\entity><\\entity> and intravenous meperidine/diazepam in patients with anterior shoulder dislocation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9273",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following intra-articular lidocaine and <\\entity><\\entity>/diazepam in patients with anterior shoulder dislocation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9274",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following intra-articular lidocaine and intravenous meperidine/<\\entity><\\entity> in patients with anterior shoulder dislocation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9275",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following intra-articular lidocaine and intravenous meperidine/diazepam in patients with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9276",
    "Sentence": "METHODS: 48 patients with <\\entity><\\entity> admitted to Imam Khomeini hospital emergency department were enrolled in this randomised clinical trial.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9277",
    "Sentence": "METHODS: 48 patients with non-habitual traumatic anterior <\\entity><\\entity> of the glenohumoral joint admitted to Imam Khomeini hospital emergency department were enrolled in this randomised clinical trial.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9278",
    "Sentence": "They were divided into two groups: one group of patients received <\\entity><\\entity> 1%, while the other received intravenous meperidine and diazepam.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9279",
    "Sentence": "They were divided into two groups: one group of patients received intra-articular lidocaine 1%, while the other received <\\entity><\\entity> and diazepam.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9280",
    "Sentence": "They were divided into two groups: one group of patients received intra-articular lidocaine 1%, while the other received intravenous meperidine and <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9281",
    "Sentence": "Utilising a 100 mm visual analogue scale, each patient's <\\entity><\\entity> was recorded before injection, before reduction, and after reduction.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9282",
    "Sentence": "RESULTS: Mean <\\entity><\\entity> (mm) recorded before injection, before reduction, and after reduction in the intra-articular lidocaine group was 84.3 (95% confidence interval (CI) 79.8 to 88.8), 52.6 (95% CI 45.2 to 60.1), and 27.3 (95% CI 19.9 to 34.7), respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9283",
    "Sentence": "RESULTS: Mean pain (mm) recorded before injection, before reduction, and after reduction in the <\\entity><\\entity> group was 84.3 (95% confidence interval (CI) 79.8 to 88.8), 52.6 (95% CI 45.2 to 60.1), and 27.3 (95% CI 19.9 to 34.7), respectively.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9284",
    "Sentence": "The corresponding rates in the <\\entity><\\entity>/diazepam group were 83.2 (95% CI 79.2 to 87.2), 57.9 (95% CI 53.8 to 62.0), and 23.9 (95% CI 18.9 to 28.8), respectively.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9285",
    "Sentence": "The corresponding rates in the intravenous meperidine/<\\entity><\\entity> group were 83.2 (95% CI 79.2 to 87.2), 57.9 (95% CI 53.8 to 62.0), and 23.9 (95% CI 18.9 to 28.8), respectively.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9286",
    "Sentence": "Both groups demonstrated a similar significant decline in <\\entity><\\entity> after injection (p<0.005).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9287",
    "Sentence": "<\\entity><\\entity> severe complications were reported in either of the groups.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9288",
    "Sentence": "No severe <\\entity><\\entity> were reported in either of the groups.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9289",
    "Sentence": "CONCLUSION: <\\entity><\\entity> before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9290",
    "Sentence": "CONCLUSION: Intra-articular injection of lidocaine before closed reduction of <\\entity><\\entity> produces the same pain relief as intravenous meperidine and diazepam.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9291",
    "Sentence": "CONCLUSION: Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same <\\entity><\\entity> relief as intravenous meperidine and diazepam.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9292",
    "Sentence": "CONCLUSION: Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as <\\entity><\\entity> and diazepam.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9293",
    "Sentence": "CONCLUSION: Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9294",
    "Sentence": "CONCLUSION: Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as <\\entity><\\entity> and diazepam.",
    "Label": ""
  },
  {
    "id": "9295",
    "Sentence": "CONCLUSION: Intra-articular injection of lidocaine before closed reduction of <\\entity><\\entity> produces the same pain relief as intravenous meperidine and diazepam.",
    "Label": ""
  },
  {
    "id": "9297",
    "Sentence": "CONCLUSION: Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9298",
    "Sentence": "CONCLUSION: Intra-articular injection of lidocaine before closed reduction of <\\entity><\\entity> produces the same pain relief as intravenous meperidine and diazepam.",
    "Label": ""
  },
  {
    "id": "9300",
    "Sentence": "CONCLUSION: <\\entity><\\entity> before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam.",
    "Label": ""
  },
  {
    "id": "9301",
    "Sentence": "CONCLUSION: Intra-articular injection of lidocaine before closed reduction of <\\entity><\\entity> produces the same pain relief as intravenous meperidine and diazepam.",
    "Label": ""
  },
  {
    "id": "9303",
    "Sentence": "RESULTS: Mean pain (mm) recorded before injection, before reduction, and after reduction in the <\\entity><\\entity> group was 84.3 (95% confidence interval (CI) 79.8 to 88.8), 52.6 (95% CI 45.2 to 60.1), and 27.3 (95% CI 19.9 to 34.7), respectively.",
    "Label": ""
  },
  {
    "id": "9304",
    "Sentence": "RESULTS: Mean <\\entity><\\entity> (mm) recorded before injection, before reduction, and after reduction in the intra-articular lidocaine group was 84.3 (95% confidence interval (CI) 79.8 to 88.8), 52.6 (95% CI 45.2 to 60.1), and 27.3 (95% CI 19.9 to 34.7), respectively.",
    "Label": ""
  },
  {
    "id": "9306",
    "Sentence": "CONCLUSION: <\\entity><\\entity> before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and diazepam.",
    "Label": ""
  },
  {
    "id": "9307",
    "Sentence": "CONCLUSION: Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same <\\entity><\\entity> relief as intravenous meperidine and diazepam.",
    "Label": ""
  },
  {
    "id": "9309",
    "Sentence": "CONCLUSION: Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as <\\entity><\\entity> and diazepam.",
    "Label": ""
  },
  {
    "id": "9310",
    "Sentence": "CONCLUSION: Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same <\\entity><\\entity> relief as intravenous meperidine and diazepam.",
    "Label": ""
  },
  {
    "id": "9312",
    "Sentence": "CONCLUSION: Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same pain relief as intravenous meperidine and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9313",
    "Sentence": "CONCLUSION: Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same <\\entity><\\entity> relief as intravenous meperidine and diazepam.",
    "Label": ""
  },
  {
    "id": "9315",
    "Sentence": "<\\entity><\\entity> versus intravenous meperidine/diazepam in anterior shoulder dislocation: a randomised clinical trial.BACKGROUND: Anterior shoulder dislocation is one of the most common complaints of patients referred to emergency departments.",
    "Label": ""
  },
  {
    "id": "9316",
    "Sentence": "Intra-articular lidocaine versus intravenous meperidine/diazepam in <\\entity><\\entity>: a randomised clinical trial.BACKGROUND: Anterior shoulder dislocation is one of the most common complaints of patients referred to emergency departments.",
    "Label": ""
  },
  {
    "id": "9318",
    "Sentence": "Intra-articular lidocaine versus <\\entity><\\entity>/diazepam in anterior shoulder dislocation: a randomised clinical trial.BACKGROUND: Anterior shoulder dislocation is one of the most common complaints of patients referred to emergency departments.",
    "Label": ""
  },
  {
    "id": "9319",
    "Sentence": "Intra-articular lidocaine versus intravenous meperidine/diazepam in <\\entity><\\entity>: a randomised clinical trial.BACKGROUND: Anterior shoulder dislocation is one of the most common complaints of patients referred to emergency departments.",
    "Label": ""
  },
  {
    "id": "9321",
    "Sentence": "Intra-articular lidocaine versus intravenous meperidine/<\\entity><\\entity> in anterior shoulder dislocation: a randomised clinical trial.BACKGROUND: Anterior shoulder dislocation is one of the most common complaints of patients referred to emergency departments.",
    "Label": ""
  },
  {
    "id": "9322",
    "Sentence": "Intra-articular lidocaine versus intravenous meperidine/diazepam in <\\entity><\\entity>: a randomised clinical trial.BACKGROUND: Anterior shoulder dislocation is one of the most common complaints of patients referred to emergency departments.",
    "Label": ""
  },
  {
    "id": "9324",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following <\\entity><\\entity> and intravenous meperidine/diazepam in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9325",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following intra-articular lidocaine and intravenous meperidine/diazepam in patients with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9327",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following <\\entity><\\entity> and intravenous meperidine/diazepam in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9328",
    "Sentence": "OBJECTIVE: To compare the <\\entity><\\entity> relief and complications following intra-articular lidocaine and intravenous meperidine/diazepam in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9330",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following <\\entity><\\entity> and intravenous meperidine/diazepam in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9331",
    "Sentence": "OBJECTIVE: To compare the pain relief and <\\entity><\\entity> following intra-articular lidocaine and intravenous meperidine/diazepam in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9333",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following intra-articular lidocaine and <\\entity><\\entity>/diazepam in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9334",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following intra-articular lidocaine and intravenous meperidine/diazepam in patients with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9336",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following intra-articular lidocaine and <\\entity><\\entity>/diazepam in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9337",
    "Sentence": "OBJECTIVE: To compare the <\\entity><\\entity> relief and complications following intra-articular lidocaine and intravenous meperidine/diazepam in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9339",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following intra-articular lidocaine and <\\entity><\\entity>/diazepam in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9340",
    "Sentence": "OBJECTIVE: To compare the pain relief and <\\entity><\\entity> following intra-articular lidocaine and intravenous meperidine/diazepam in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9342",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following intra-articular lidocaine and intravenous meperidine/<\\entity><\\entity> in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9343",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following intra-articular lidocaine and intravenous meperidine/diazepam in patients with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9345",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following intra-articular lidocaine and intravenous meperidine/<\\entity><\\entity> in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9346",
    "Sentence": "OBJECTIVE: To compare the <\\entity><\\entity> relief and complications following intra-articular lidocaine and intravenous meperidine/diazepam in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9348",
    "Sentence": "OBJECTIVE: To compare the pain relief and complications following intra-articular lidocaine and intravenous meperidine/<\\entity><\\entity> in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9349",
    "Sentence": "OBJECTIVE: To compare the pain relief and <\\entity><\\entity> following intra-articular lidocaine and intravenous meperidine/diazepam in patients with anterior shoulder dislocation.",
    "Label": ""
  },
  {
    "id": "9351",
    "Sentence": "<\\entity><\\entity> and benzodiazepines are traditionally prescribed in order to relieve the pain in this group of patients; however, complications always pose a problem.",
    "Label": ""
  },
  {
    "id": "9352",
    "Sentence": "Intravenous opiates and benzodiazepines are traditionally prescribed in order to relieve the <\\entity><\\entity> in this group of patients; however, complications always pose a problem.",
    "Label": ""
  },
  {
    "id": "9354",
    "Sentence": "Intravenous opiates and <\\entity><\\entity> are traditionally prescribed in order to relieve the pain in this group of patients; however, complications always pose a problem.",
    "Label": ""
  },
  {
    "id": "9355",
    "Sentence": "Intravenous opiates and benzodiazepines are traditionally prescribed in order to relieve the <\\entity><\\entity> in this group of patients; however, complications always pose a problem.",
    "Label": ""
  },
  {
    "id": "9361",
    "Sentence": "<\\entity><\\entity> inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.The hallmark of acute promyelocytic leukaemia (APL) is the reciprocal translocation t(15;17), which leads to the expression of the promyelocytic leukaemia/retinoic acid receptor alpha (PML/RARalpha) fusion protein and a cell differentiation blockade at the promyelocytic stage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9362",
    "Sentence": "MEK inhibition induces <\\entity><\\entity> activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.The hallmark of acute promyelocytic leukaemia (APL) is the reciprocal translocation t(15;17), which leads to the expression of the promyelocytic leukaemia/retinoic acid receptor alpha (PML/RARalpha) fusion protein and a cell differentiation blockade at the promyelocytic stage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9363",
    "Sentence": "MEK inhibition induces caspases activation, differentiation blockade and <\\entity><\\entity> degradation in acute promyelocytic leukaemia.The hallmark of acute promyelocytic leukaemia (APL) is the reciprocal translocation t(15;17), which leads to the expression of the promyelocytic leukaemia/retinoic acid receptor alpha (<\\entity><\\entity>) fusion protein and a cell differentiation blockade at the promyelocytic stage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9364",
    "Sentence": "MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.The hallmark of acute promyelocytic leukaemia (<\\entity><\\entity>) is the reciprocal translocation t(15;17), which leads to the expression of the promyelocytic leukaemia/retinoic acid receptor alpha (PML/RARalpha) fusion protein and a cell differentiation blockade at the promyelocytic stage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9365",
    "Sentence": "MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.The hallmark of acute promyelocytic leukaemia (APL) is the <\\entity><\\entity>, which leads to the expression of the promyelocytic leukaemia/retinoic acid receptor alpha (PML/RARalpha) fusion protein and a cell differentiation blockade at the promyelocytic stage.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9366",
    "Sentence": "MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.The hallmark of acute promyelocytic leukaemia (APL) is the reciprocal translocation t(15;17), which leads to the expression of the <\\entity><\\entity> (PML/RARalpha) fusion protein and a cell differentiation blockade at the promyelocytic stage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9367",
    "Sentence": "MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.The hallmark of acute promyelocytic leukaemia (APL) is the reciprocal translocation t(15;17), which leads to the expression of the promyelocytic leukaemia/retinoic acid receptor alpha <\\entity><\\entity> and a cell differentiation blockade at the promyelocytic stage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9368",
    "Sentence": "MEK inhibition induces caspases activation, differentiation blockade and <\\entity><\\entity>/RARalpha degradation in acute promyelocytic leukaemia.The hallmark of acute promyelocytic leukaemia (APL) is the reciprocal translocation t(15;17), which leads to the expression of the promyelocytic leukaemia/retinoic acid receptor alpha (<\\entity><\\entity>/RARalpha) fusion protein and a cell differentiation blockade at the promyelocytic stage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9369",
    "Sentence": "<\\entity><\\entity> is directly targeted by all-trans-retinoic acid (ATRA), which degrades the oncoprotein and induces complete remission of malignancies.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9370",
    "Sentence": "PML/RARalpha is directly targeted by <\\entity><\\entity> (ATRA), which degrades the oncoprotein and induces complete remission of malignancies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9371",
    "Sentence": "PML/RARalpha is directly targeted by all-trans-retinoic acid (<\\entity><\\entity>), which degrades the oncoprotein and induces complete remission of malignancies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9372",
    "Sentence": "The aberrant function of <\\entity><\\entity>, together with the constitutive activation of the mitogen-activated protein/extracellular signal-regulated kinase (MEK/ERK) signalling pathway, regulates the ability of haematopoietic cells to proliferate, differentiate, and escape from apoptotic episodes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9373",
    "Sentence": "The aberrant function of PML/RARalpha, together with the constitutive activation of the <\\entity><\\entity> (MEK/ERK) signalling pathway, regulates the ability of haematopoietic cells to proliferate, differentiate, and escape from apoptotic episodes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9374",
    "Sentence": "The aberrant function of PML/RARalpha, together with the constitutive activation of the mitogen-activated protein/extracellular signal-regulated kinase (<\\entity><\\entity>) signalling pathway, regulates the ability of haematopoietic cells to proliferate, differentiate, and escape from apoptotic episodes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9375",
    "Sentence": "The aberrant function of PML/RARalpha, together with the constitutive activation of the mitogen-activated protein/extracellular signal-regulated kinase (<\\entity><\\entity>) signalling pathway, regulates the ability of haematopoietic cells to proliferate, differentiate, and escape from apoptotic episodes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9376",
    "Sentence": "The role of the <\\entity><\\entity> pathway in PML/RARalpha expression, differentiation, proliferation and apoptosis in APL cells was analysed using specific MEK inhibitors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9377",
    "Sentence": "The role of the <\\entity><\\entity> pathway in PML/RARalpha expression, differentiation, proliferation and apoptosis in APL cells was analysed using specific MEK inhibitors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9378",
    "Sentence": "The role of the MEK/ERK pathway in <\\entity><\\entity> expression, differentiation, proliferation and apoptosis in APL cells was analysed using specific MEK inhibitors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9379",
    "Sentence": "The role of the MEK/ERK pathway in PML/RARalpha expression, differentiation, proliferation and apoptosis in <\\entity><\\entity> cells was analysed using specific MEK inhibitors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9380",
    "Sentence": "The role of the MEK/ERK pathway in PML/RARalpha expression, differentiation, proliferation and apoptosis in APL cells was analysed using specific <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9381",
    "Sentence": "The role of the MEK/ERK pathway in PML/RARalpha expression, differentiation, proliferation and apoptosis in APL cells was analysed using specific <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9382",
    "Sentence": "The blockade of <\\entity><\\entity> pathway resulted in caspase-dependent degradation of PML/RARalpha, and attenuation of the cell differentiation induction.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9383",
    "Sentence": "The blockade of <\\entity><\\entity> pathway resulted in caspase-dependent degradation of PML/RARalpha, and attenuation of the cell differentiation induction.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9384",
    "Sentence": "The blockade of MEK/ERK pathway resulted in <\\entity><\\entity>-dependent degradation of PML/RARalpha, and attenuation of the cell differentiation induction.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9385",
    "Sentence": "The blockade of MEK/ERK pathway resulted in caspase-dependent degradation of <\\entity><\\entity>, and attenuation of the cell differentiation induction.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9386",
    "Sentence": "To our knowledge, this is the first report to show that <\\entity><\\entity> was suppressed by MEK/ERK inhibition, through a mechanism dependent on caspase activation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9387",
    "Sentence": "To our knowledge, this is the first report to show that PML/RARalpha was suppressed by <\\entity><\\entity> inhibition, through a mechanism dependent on caspase activation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9388",
    "Sentence": "To our knowledge, this is the first report to show that PML/RARalpha was suppressed by <\\entity><\\entity> inhibition, through a mechanism dependent on caspase activation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9389",
    "Sentence": "To our knowledge, this is the first report to show that PML/RARalpha was suppressed by MEK/ERK inhibition, through a mechanism dependent on <\\entity><\\entity> activation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9390",
    "Sentence": "<\\entity><\\entity> co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with MEK inhibitors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9391",
    "Sentence": "ATRA co-operated with <\\entity><\\entity> to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with <\\entity><\\entity>s.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9392",
    "Sentence": "ATRA co-operated with <\\entity><\\entity> to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with <\\entity><\\entity>s.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9393",
    "Sentence": "ATRA co-operated with MEK inhibitor to increase degradation of <\\entity><\\entity> and exhibited a convergence point in caspase activation with MEK inhibitors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9394",
    "Sentence": "ATRA co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in <\\entity><\\entity> activation with MEK inhibitors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9395",
    "Sentence": "ATRA co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9396",
    "Sentence": "ATRA co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9397",
    "Sentence": "Taken together, our data suggest a new role of <\\entity><\\entity> pathway in the pathogenesis of APL, thus supporting the use of <\\entity><\\entity> inhibitors as an efficient therapeutic strategy for this haematological malignancy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9398",
    "Sentence": "Taken together, our data suggest a new role of <\\entity><\\entity> pathway in the pathogenesis of APL, thus supporting the use of <\\entity><\\entity> inhibitors as an efficient therapeutic strategy for this haematological malignancy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9399",
    "Sentence": "Taken together, our data suggest a new role of MEK/ERK pathway in the pathogenesis of <\\entity><\\entity>, thus supporting the use of MEK/ERK inhibitors as an efficient therapeutic strategy for this haematological malignancy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9400",
    "Sentence": "Taken together, our data suggest a new role of MEK/ERK pathway in the pathogenesis of APL, thus supporting the use of <\\entity><\\entity> as an efficient therapeutic strategy for this haematological malignancy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9401",
    "Sentence": "Taken together, our data suggest a new role of MEK/ERK pathway in the pathogenesis of APL, thus supporting the use of <\\entity><\\entity> as an efficient therapeutic strategy for this haematological malignancy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9402",
    "Sentence": "PML/RARalpha is directly targeted by all-trans-retinoic acid (<\\entity><\\entity>), which degrades the oncoprotein and induces complete remission of malignancies.",
    "Label": ""
  },
  {
    "id": "9403",
    "Sentence": "<\\entity><\\entity> is directly targeted by all-trans-retinoic acid (ATRA), which degrades the oncoprotein and induces complete remission of malignancies.",
    "Label": ""
  },
  {
    "id": "9405",
    "Sentence": "<\\entity><\\entity> co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with MEK inhibitors.",
    "Label": ""
  },
  {
    "id": "9406",
    "Sentence": "ATRA co-operated with MEK inhibitor to increase degradation of <\\entity><\\entity> and exhibited a convergence point in caspase activation with MEK inhibitors.",
    "Label": ""
  },
  {
    "id": "9408",
    "Sentence": "<\\entity><\\entity> co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with MEK inhibitors.",
    "Label": ""
  },
  {
    "id": "9409",
    "Sentence": "ATRA co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in <\\entity><\\entity> activation with MEK inhibitors.",
    "Label": ""
  },
  {
    "id": "9411",
    "Sentence": "ATRA co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9412",
    "Sentence": "ATRA co-operated with MEK inhibitor to increase degradation of <\\entity><\\entity> and exhibited a convergence point in caspase activation with MEK inhibitors.",
    "Label": ""
  },
  {
    "id": "9414",
    "Sentence": "ATRA co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9415",
    "Sentence": "ATRA co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in <\\entity><\\entity> activation with MEK inhibitors.",
    "Label": ""
  },
  {
    "id": "9417",
    "Sentence": "ATRA co-operated with <\\entity><\\entity> to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with <\\entity><\\entity>s.",
    "Label": ""
  },
  {
    "id": "9418",
    "Sentence": "ATRA co-operated with MEK inhibitor to increase degradation of <\\entity><\\entity> and exhibited a convergence point in caspase activation with MEK inhibitors.",
    "Label": ""
  },
  {
    "id": "9420",
    "Sentence": "ATRA co-operated with <\\entity><\\entity> to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with <\\entity><\\entity>s.",
    "Label": ""
  },
  {
    "id": "9421",
    "Sentence": "ATRA co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in <\\entity><\\entity> activation with MEK inhibitors.",
    "Label": ""
  },
  {
    "id": "9423",
    "Sentence": "Taken together, our data suggest a new role of MEK/ERK pathway in the pathogenesis of APL, thus supporting the use of <\\entity><\\entity> as an efficient therapeutic strategy for this haematological malignancy.",
    "Label": ""
  },
  {
    "id": "9424",
    "Sentence": "Taken together, our data suggest a new role of <\\entity><\\entity> pathway in the pathogenesis of APL, thus supporting the use of <\\entity><\\entity> inhibitors as an efficient therapeutic strategy for this haematological malignancy.",
    "Label": ""
  },
  {
    "id": "9426",
    "Sentence": "<\\entity><\\entity> co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with MEK inhibitors.",
    "Label": ""
  },
  {
    "id": "9427",
    "Sentence": "ATRA co-operated with MEK inhibitor to increase degradation of PML/RARalpha and exhibited a convergence point in caspase activation with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9429",
    "Sentence": "The blockade of <\\entity><\\entity> pathway resulted in caspase-dependent degradation of PML/RARalpha, and attenuation of the cell differentiation induction.",
    "Label": ""
  },
  {
    "id": "9430",
    "Sentence": "The blockade of MEK/ERK pathway resulted in caspase-dependent degradation of <\\entity><\\entity>, and attenuation of the cell differentiation induction.",
    "Label": ""
  },
  {
    "id": "9432",
    "Sentence": "To our knowledge, this is the first report to show that PML/RARalpha was suppressed by <\\entity><\\entity> inhibition, through a mechanism dependent on caspase activation.",
    "Label": ""
  },
  {
    "id": "9433",
    "Sentence": "To our knowledge, this is the first report to show that <\\entity><\\entity> was suppressed by MEK/ERK inhibition, through a mechanism dependent on caspase activation.",
    "Label": ""
  },
  {
    "id": "9439",
    "Sentence": "Proteomic analysis of differential proteins in pancreatic carcinomas: Effects of <\\entity><\\entity> knock-down by stable RNA interference.BACKGROUND: Methyl-CpG binding domain protein 1 (<\\entity><\\entity>), a suppressor of gene transcription, may be involved in inactivation of tumor suppressor genes during tumorigenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9440",
    "Sentence": "Proteomic analysis of differential proteins in pancreatic carcinomas: Effects of MBD1 knock-down by stable RNA interference.BACKGROUND: <\\entity><\\entity> (MBD1), a suppressor of gene transcription, may be involved in inactivation of tumor suppressor genes during tumorigenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9441",
    "Sentence": "Proteomic analysis of differential proteins in pancreatic carcinomas: Effects of <\\entity><\\entity> knock-down by stable RNA interference.BACKGROUND: Methyl-CpG binding domain protein 1 (<\\entity><\\entity>), a suppressor of gene transcription, may be involved in inactivation of tumor suppressor genes during tumorigenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9442",
    "Sentence": "Proteomic analysis of differential proteins in pancreatic carcinomas: Effects of MBD1 knock-down by stable RNA interference.BACKGROUND: Methyl-CpG binding domain protein 1 (MBD1), a suppressor of gene transcription, may be involved in inactivation of <\\entity><\\entity> suppressor genes during <\\entity><\\entity>igenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9443",
    "Sentence": "Over-expression of <\\entity><\\entity> has been reported in human pancreatic carcinomas.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9444",
    "Sentence": "METHODS: In this study, we established a <\\entity><\\entity>-knock-down pancreatic cancer cell line (BxPC-3) using stable RNA interference, to compare the proteomic changes between control and <\\entity><\\entity>-knock-down cells using two-dimensional gel electrophoresis and mass spectrometry.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9445",
    "Sentence": "METHODS: In this study, we established a MBD1-knock-down <\\entity><\\entity> cell line (BxPC-3) using stable RNA interference, to compare the proteomic changes between control and MBD1-knock-down cells using two-dimensional gel electrophoresis and mass spectrometry.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9446",
    "Sentence": "METHODS: In this study, we established a MBD1-knock-down pancreatic cancer cell line (<\\entity><\\entity>) using stable RNA interference, to compare the proteomic changes between control and MBD1-knock-down cells using two-dimensional gel electrophoresis and mass spectrometry.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9447",
    "Sentence": "METHODS: In this study, we established a <\\entity><\\entity>-knock-down pancreatic cancer cell line (BxPC-3) using stable RNA interference, to compare the proteomic changes between control and <\\entity><\\entity>-knock-down cells using two-dimensional gel electrophoresis and mass spectrometry.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9448",
    "Sentence": "CONCLUSION: Our data suggest that these differential proteins may be associated with the function of <\\entity><\\entity>, and provide some insight into the functional mechanism of <\\entity><\\entity> in the development of pancreatic cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9449",
    "Sentence": "CONCLUSION: Our data suggest that these differential proteins may be associated with the function of <\\entity><\\entity>, and provide some insight into the functional mechanism of <\\entity><\\entity> in the development of pancreatic cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9454",
    "Sentence": "<\\entity><\\entity> is a colon-selective store-operated calcium channel promoting malignant cell processes.Using a data mining approach for the discovery of new targets for antibody therapy of colon cancer, we identified <\\entity><\\entity>, a sequence homologue of CD20.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9455",
    "Sentence": "MS4A12 is a colon-selective store-operated <\\entity><\\entity> channel promoting malignant cell processes.Using a data mining approach for the discovery of new targets for antibody therapy of colon cancer, we identified MS4A12, a sequence homologue of CD20.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9456",
    "Sentence": "<\\entity><\\entity> is a colon-selective store-operated calcium channel promoting malignant cell processes.Using a data mining approach for the discovery of new targets for antibody therapy of colon cancer, we identified <\\entity><\\entity>, a sequence homologue of CD20.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9457",
    "Sentence": "MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes.Using a data mining approach for the discovery of new targets for antibody therapy of colon cancer, we identified MS4A12, a sequence homologue of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9458",
    "Sentence": "We show that <\\entity><\\entity> is a cell surface protein.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9459",
    "Sentence": "Expression analysis and immunohistochemistry revealed <\\entity><\\entity> to be a colonic epithelial cell lineage gene confined to the apical membrane of colonocytes with strict transcriptional repression in all other normal tissue types.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9460",
    "Sentence": "<\\entity><\\entity> flux analyses disclosed that MS4A12 is a novel component of store-operated <\\entity><\\entity> entry in intestinal cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9461",
    "Sentence": "Ca(2+) flux analyses disclosed that <\\entity><\\entity> is a novel component of store-operated Ca(2+) entry in intestinal cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9462",
    "Sentence": "<\\entity><\\entity> flux analyses disclosed that MS4A12 is a novel component of store-operated <\\entity><\\entity> entry in intestinal cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9463",
    "Sentence": "Using RNAi-mediated gene silencing, we show that loss of <\\entity><\\entity> in LoVo colon cancer cells attenuates epidermal growth factor receptor-mediated effects.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9464",
    "Sentence": "Using RNAi-mediated gene silencing, we show that loss of MS4A12 in LoVo colon cancer cells attenuates <\\entity><\\entity>-mediated effects.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9465",
    "Sentence": "Cancer cells expressing <\\entity><\\entity>, in contrast, are sensitized and respond to lower concentrations of epidermal growth factor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9466",
    "Sentence": "Cancer cells expressing MS4A12, in contrast, are sensitized and respond to lower concentrations of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9467",
    "Sentence": "MS4A12 is a colon-selective store-operated <\\entity><\\entity> channel promoting malignant cell processes.Using a data mining approach for the discovery of new targets for antibody therapy of colon cancer, we identified MS4A12, a sequence homologue of CD20.",
    "Label": ""
  },
  {
    "id": "9468",
    "Sentence": "<\\entity><\\entity> is a colon-selective store-operated calcium channel promoting malignant cell processes.Using a data mining approach for the discovery of new targets for antibody therapy of colon cancer, we identified <\\entity><\\entity>, a sequence homologue of CD20.",
    "Label": ""
  },
  {
    "id": "9470",
    "Sentence": "<\\entity><\\entity> flux analyses disclosed that MS4A12 is a novel component of store-operated <\\entity><\\entity> entry in intestinal cells.",
    "Label": ""
  },
  {
    "id": "9471",
    "Sentence": "Ca(2+) flux analyses disclosed that <\\entity><\\entity> is a novel component of store-operated Ca(2+) entry in intestinal cells.",
    "Label": ""
  },
  {
    "id": "9473",
    "Sentence": "<\\entity><\\entity> is a colon-selective store-operated calcium channel promoting malignant cell processes.Using a data mining approach for the discovery of new targets for antibody therapy of colon cancer, we identified <\\entity><\\entity>, a sequence homologue of CD20.",
    "Label": ""
  },
  {
    "id": "9474",
    "Sentence": "MS4A12 is a colon-selective store-operated calcium channel promoting <\\entity><\\entity> cell processes.Using a data mining approach for the discovery of new targets for antibody therapy of colon cancer, we identified MS4A12, a sequence homologue of CD20.",
    "Label": ""
  },
  {
    "id": "9476",
    "Sentence": "<\\entity><\\entity> is a colon-selective store-operated calcium channel promoting malignant cell processes.Using a data mining approach for the discovery of new targets for antibody therapy of colon cancer, we identified <\\entity><\\entity>, a sequence homologue of CD20.",
    "Label": ""
  },
  {
    "id": "9477",
    "Sentence": "MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes.Using a data mining approach for the discovery of new targets for antibody therapy of <\\entity><\\entity>, we identified MS4A12, a sequence homologue of CD20.",
    "Label": ""
  },
  {
    "id": "9479",
    "Sentence": "MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes.Using a data mining approach for the discovery of new targets for antibody therapy of colon cancer, we identified MS4A12, a sequence homologue of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9480",
    "Sentence": "MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes.Using a data mining approach for the discovery of new targets for antibody therapy of <\\entity><\\entity>, we identified MS4A12, a sequence homologue of CD20.",
    "Label": ""
  },
  {
    "id": "9482",
    "Sentence": "Using RNAi-mediated gene silencing, we show that loss of <\\entity><\\entity> in LoVo colon cancer cells attenuates epidermal growth factor receptor-mediated effects.",
    "Label": ""
  },
  {
    "id": "9483",
    "Sentence": "Using RNAi-mediated gene silencing, we show that loss of MS4A12 in LoVo <\\entity><\\entity> cells attenuates epidermal growth factor receptor-mediated effects.",
    "Label": ""
  },
  {
    "id": "9485",
    "Sentence": "Using RNAi-mediated gene silencing, we show that loss of MS4A12 in LoVo colon cancer cells attenuates <\\entity><\\entity>-mediated effects.",
    "Label": ""
  },
  {
    "id": "9486",
    "Sentence": "Using RNAi-mediated gene silencing, we show that loss of MS4A12 in LoVo <\\entity><\\entity> cells attenuates epidermal growth factor receptor-mediated effects.",
    "Label": ""
  },
  {
    "id": "9488",
    "Sentence": "Cancer cells expressing <\\entity><\\entity>, in contrast, are sensitized and respond to lower concentrations of epidermal growth factor.",
    "Label": ""
  },
  {
    "id": "9489",
    "Sentence": "<\\entity><\\entity> cells expressing MS4A12, in contrast, are sensitized and respond to lower concentrations of epidermal growth factor.",
    "Label": ""
  },
  {
    "id": "9491",
    "Sentence": "Cancer cells expressing MS4A12, in contrast, are sensitized and respond to lower concentrations of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9492",
    "Sentence": "<\\entity><\\entity> cells expressing MS4A12, in contrast, are sensitized and respond to lower concentrations of epidermal growth factor.",
    "Label": ""
  },
  {
    "id": "9498",
    "Sentence": "<\\entity><\\entity> inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.BACKGROUND: The impact of the antiinflammatory agent <\\entity><\\entity> (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9499",
    "Sentence": "5-aminosalicylic acid inhibits <\\entity><\\entity> in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9500",
    "Sentence": "5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of <\\entity><\\entity>/dextran sulfate sodium-induced colitis.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9501",
    "Sentence": "5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/<\\entity><\\entity>-induced colitis.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9502",
    "Sentence": "5-aminosalicylic acid inhibits <\\entity><\\entity>-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced <\\entity><\\entity>.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for <\\entity><\\entity>-associated colorectal cancer remains controversial.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9503",
    "Sentence": "<\\entity><\\entity> inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.BACKGROUND: The impact of the antiinflammatory agent <\\entity><\\entity> (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9504",
    "Sentence": "5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (<\\entity><\\entity>) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9505",
    "Sentence": "5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for <\\entity><\\entity> remains controversial.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9506",
    "Sentence": "The chemopreventive activity of <\\entity><\\entity> was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9507",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of <\\entity><\\entity> (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9508",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (<\\entity><\\entity>)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9509",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (<\\entity><\\entity>)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9510",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/<\\entity><\\entity> (DSS)-induced colitis-associated neoplasia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9511",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (<\\entity><\\entity>)-induced colitis-associated neoplasia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9512",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (<\\entity><\\entity>)-induced colitis-associated neoplasia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9513",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9514",
    "Sentence": "METHODS: Mice were injected with <\\entity><\\entity> (7.4 mg/kg i.p.) and randomized to receive either vehicle or 5-ASA (75, 150, and 225 mg/kg) for the remainder of the study.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9515",
    "Sentence": "METHODS: Mice were injected with <\\entity><\\entity> (7.4 mg/kg i.p.) and randomized to receive either vehicle or 5-ASA (75, 150, and 225 mg/kg) for the remainder of the study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9516",
    "Sentence": "METHODS: Mice were injected with AOM (7.4 mg/kg i.p.) and randomized to receive either vehicle or <\\entity><\\entity> (75, 150, and 225 mg/kg) for the remainder of the study.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9517",
    "Sentence": "<\\entity><\\entity> treatment began at 9 weeks of age and continued for 3 cycles.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9518",
    "Sentence": "<\\entity><\\entity> treatment began at 9 weeks of age and continued for 3 cycles.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9519",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of <\\entity><\\entity> in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9520",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg <\\entity><\\entity> exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9521",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic <\\entity><\\entity> in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of <\\entity><\\entity> of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9522",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the <\\entity><\\entity>/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9523",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the <\\entity><\\entity>/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9524",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/<\\entity><\\entity> controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9525",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/<\\entity><\\entity> controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9526",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- <\\entity><\\entity>: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9527",
    "Sentence": "Administration of 75 mg/kg <\\entity><\\entity> decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9528",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of <\\entity><\\entity> (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9529",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for <\\entity><\\entity>/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for <\\entity><\\entity>/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9530",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for <\\entity><\\entity>/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for <\\entity><\\entity>/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9531",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/<\\entity><\\entity> control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/<\\entity><\\entity> controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9532",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/<\\entity><\\entity> control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/<\\entity><\\entity> controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9533",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of <\\entity><\\entity> (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9534",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (<\\entity><\\entity> burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9535",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for <\\entity><\\entity>/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for <\\entity><\\entity>/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9536",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for <\\entity><\\entity>/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for <\\entity><\\entity>/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9537",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/<\\entity><\\entity> control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/<\\entity><\\entity> controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9538",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/<\\entity><\\entity> control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/<\\entity><\\entity> controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9539",
    "Sentence": "<\\entity><\\entity> was least severe in the 75 mg/kg group, which exhibited the fewest number of colorectal tumors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9540",
    "Sentence": "Inflammation was least severe in the 75 mg/kg group, which exhibited the fewest number of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9541",
    "Sentence": "CONCLUSIONS: These data suggest that <\\entity><\\entity> may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with ulcerative colitis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9542",
    "Sentence": "CONCLUSIONS: These data suggest that low-dose 5-ASA may be efficacious in preventing <\\entity><\\entity> and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with ulcerative colitis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9543",
    "Sentence": "CONCLUSIONS: These data suggest that low-dose 5-ASA may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of <\\entity><\\entity> in patients with ulcerative colitis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9544",
    "Sentence": "CONCLUSIONS: These data suggest that low-dose 5-ASA may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9545",
    "Sentence": "<\\entity><\\entity> inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.BACKGROUND: The impact of the antiinflammatory agent <\\entity><\\entity> (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": ""
  },
  {
    "id": "9546",
    "Sentence": "5-aminosalicylic acid inhibits <\\entity><\\entity> in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": ""
  },
  {
    "id": "9548",
    "Sentence": "5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of <\\entity><\\entity>/dextran sulfate sodium-induced colitis.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": ""
  },
  {
    "id": "9549",
    "Sentence": "5-aminosalicylic acid inhibits <\\entity><\\entity>-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced <\\entity><\\entity>.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for <\\entity><\\entity>-associated colorectal cancer remains controversial.",
    "Label": ""
  },
  {
    "id": "9551",
    "Sentence": "5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/<\\entity><\\entity>-induced colitis.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": ""
  },
  {
    "id": "9552",
    "Sentence": "5-aminosalicylic acid inhibits <\\entity><\\entity>-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced <\\entity><\\entity>.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for <\\entity><\\entity>-associated colorectal cancer remains controversial.",
    "Label": ""
  },
  {
    "id": "9554",
    "Sentence": "5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (<\\entity><\\entity>) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": ""
  },
  {
    "id": "9555",
    "Sentence": "5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for <\\entity><\\entity> remains controversial.",
    "Label": ""
  },
  {
    "id": "9557",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of <\\entity><\\entity> (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia.",
    "Label": ""
  },
  {
    "id": "9558",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9560",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (<\\entity><\\entity>)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia.",
    "Label": ""
  },
  {
    "id": "9561",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9563",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/<\\entity><\\entity> (DSS)-induced colitis-associated neoplasia.",
    "Label": ""
  },
  {
    "id": "9564",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9566",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (<\\entity><\\entity>)-induced colitis-associated neoplasia.",
    "Label": ""
  },
  {
    "id": "9567",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9569",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg <\\entity><\\entity> exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9570",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of <\\entity><\\entity> in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9572",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg <\\entity><\\entity> exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9573",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic <\\entity><\\entity> in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of <\\entity><\\entity> of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9575",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the <\\entity><\\entity>/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9576",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of <\\entity><\\entity> in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9578",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the <\\entity><\\entity>/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9579",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic <\\entity><\\entity> in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of <\\entity><\\entity> of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9581",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/<\\entity><\\entity> controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9582",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of <\\entity><\\entity> in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9584",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/<\\entity><\\entity> controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9585",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic <\\entity><\\entity> in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of <\\entity><\\entity> of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9587",
    "Sentence": "Administration of 75 mg/kg <\\entity><\\entity> decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9588",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (<\\entity><\\entity> burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9590",
    "Sentence": "Administration of 75 mg/kg <\\entity><\\entity> decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9591",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of <\\entity><\\entity> (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9593",
    "Sentence": "Administration of 75 mg/kg <\\entity><\\entity> decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9594",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of <\\entity><\\entity> (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9596",
    "Sentence": "CONCLUSIONS: These data suggest that <\\entity><\\entity> may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "9597",
    "Sentence": "CONCLUSIONS: These data suggest that low-dose 5-ASA may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of <\\entity><\\entity> in patients with ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "9599",
    "Sentence": "CONCLUSIONS: These data suggest that <\\entity><\\entity> may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "9600",
    "Sentence": "CONCLUSIONS: These data suggest that low-dose 5-ASA may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9602",
    "Sentence": "CONCLUSIONS: These data suggest that <\\entity><\\entity> may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "9603",
    "Sentence": "CONCLUSIONS: These data suggest that low-dose 5-ASA may be efficacious in preventing <\\entity><\\entity> and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "9605",
    "Sentence": "5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/<\\entity><\\entity>-induced colitis.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": ""
  },
  {
    "id": "9606",
    "Sentence": "5-aminosalicylic acid inhibits <\\entity><\\entity> in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": ""
  },
  {
    "id": "9608",
    "Sentence": "The chemopreventive activity of <\\entity><\\entity> was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia.",
    "Label": ""
  },
  {
    "id": "9609",
    "Sentence": "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9611",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg <\\entity><\\entity> exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9612",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- <\\entity><\\entity>: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9614",
    "Sentence": "5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of <\\entity><\\entity>/dextran sulfate sodium-induced colitis.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": ""
  },
  {
    "id": "9615",
    "Sentence": "5-aminosalicylic acid inhibits <\\entity><\\entity> in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.BACKGROUND: The impact of the antiinflammatory agent 5-aminosalicylic acid (5-ASA) on the risk for colitis-associated colorectal cancer remains controversial.",
    "Label": ""
  },
  {
    "id": "9617",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the <\\entity><\\entity>/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9618",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- <\\entity><\\entity>: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9620",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/<\\entity><\\entity> controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9621",
    "Sentence": "RESULTS: An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- <\\entity><\\entity>: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).",
    "Label": ""
  },
  {
    "id": "9623",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for <\\entity><\\entity>/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for <\\entity><\\entity>/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9624",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (<\\entity><\\entity> burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9626",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for <\\entity><\\entity>/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for <\\entity><\\entity>/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9627",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of <\\entity><\\entity> (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9629",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for <\\entity><\\entity>/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for <\\entity><\\entity>/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9630",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of <\\entity><\\entity> (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9632",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/<\\entity><\\entity> control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/<\\entity><\\entity> controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9633",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (<\\entity><\\entity> burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9635",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/<\\entity><\\entity> control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/<\\entity><\\entity> controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9636",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of <\\entity><\\entity> (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9638",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/<\\entity><\\entity> control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/<\\entity><\\entity> controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9639",
    "Sentence": "Administration of 75 mg/kg 5-ASA decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of <\\entity><\\entity> (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).",
    "Label": ""
  },
  {
    "id": "9645",
    "Sentence": "<\\entity><\\entity> provide a large population attributable risk for Crohn's disease.BACKGROUND: The IL-23 pathway plays a pivotal role in the development of chronic mucosal inflammation seen in the inflammatory bowel diseases.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9646",
    "Sentence": "<\\entity><\\entity> provide a large population attributable risk for Crohn's disease.BACKGROUND: The IL-23 pathway plays a pivotal role in the development of chronic mucosal inflammation seen in the inflammatory bowel diseases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9647",
    "Sentence": "IL23R haplotypes provide a large population attributable risk for <\\entity><\\entity>.BACKGROUND: The IL-23 pathway plays a pivotal role in the development of chronic mucosal inflammation seen in the inflammatory bowel diseases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9648",
    "Sentence": "IL23R haplotypes provide a large population attributable risk for Crohn's disease.BACKGROUND: The <\\entity><\\entity> pathway plays a pivotal role in the development of chronic mucosal inflammation seen in the inflammatory bowel diseases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9649",
    "Sentence": "IL23R haplotypes provide a large population attributable risk for Crohn's disease.BACKGROUND: The IL-23 pathway plays a pivotal role in the development of <\\entity><\\entity> seen in the inflammatory bowel diseases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9650",
    "Sentence": "IL23R haplotypes provide a large population attributable risk for Crohn's disease.BACKGROUND: The IL-23 pathway plays a pivotal role in the development of chronic mucosal inflammation seen in the <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9651",
    "Sentence": "Multiple studies have now established the contribution of the <\\entity><\\entity> gene (IL23R) to Crohn's disease (CD) risk in general and of the IL23R R381Q variant in particular.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9652",
    "Sentence": "Multiple studies have now established the contribution of the interleukin 23 receptor gene (<\\entity><\\entity>) to Crohn's disease (CD) risk in general and of the <\\entity><\\entity> R381Q variant in particular.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9653",
    "Sentence": "Multiple studies have now established the contribution of the interleukin 23 receptor gene (IL23R) to <\\entity><\\entity> (CD) risk in general and of the IL23R R381Q variant in particular.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9654",
    "Sentence": "Multiple studies have now established the contribution of the interleukin 23 receptor gene (IL23R) to Crohn's disease (<\\entity><\\entity>) risk in general and of the IL23R R381Q variant in particular.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9655",
    "Sentence": "Multiple studies have now established the contribution of the interleukin 23 receptor gene (IL23R) to Crohn's disease (CD) risk in general and of the <\\entity><\\entity> variant in particular.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9656",
    "Sentence": "Multiple studies have now established the contribution of the interleukin 23 receptor gene (IL23R) to Crohn's disease (CD) risk in general and of the <\\entity><\\entity> variant in particular.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9657",
    "Sentence": "The aim of this work was to estimate the total contribution of this gene to <\\entity><\\entity> risk test using a haplotype approach.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9658",
    "Sentence": "METHODS: In all, 763 <\\entity><\\entity> subjects and 254 controls were genotyped for single nucleotide polymorphisms in the IL23R gene using Illumina and ABI methods.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9659",
    "Sentence": "METHODS: In all, 763 CD subjects and 254 controls were genotyped for single nucleotide polymorphisms in the <\\entity><\\entity> gene using Illumina and ABI methods.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9660",
    "Sentence": "Haplotypes were assigned using PHASEv2 and tested for association with <\\entity><\\entity> by chi-square and permutation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9661",
    "Sentence": "RESULTS: Haplotypes with both increased and decreased risk for <\\entity><\\entity> were observed in 2 of the 4 observed blocks (Block 2 H1: 55.4% control, 64% <\\entity><\\entity>, P = 0.019; H2: 64.5% control, 54.4% <\\entity><\\entity>, P = 0.006; Block 3 H1: 55.8% control, 64.4% <\\entity><\\entity>, P = 0.013; H2: 47.0% control, 36.6% <\\entity><\\entity>, P = 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9662",
    "Sentence": "RESULTS: Haplotypes with both increased and decreased risk for CD were observed in 2 of the 4 observed <\\entity><\\entity> (Block 2 H1: 55.4% control, 64% CD, P = 0.019; H2: 64.5% control, 54.4% CD, P = 0.006; Block 3 H1: 55.8% control, 64.4% CD, P = 0.013; H2: 47.0% control, 36.6% CD, P = 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9663",
    "Sentence": "RESULTS: Haplotypes with both increased and decreased risk for CD were observed in 2 of the 4 observed blocks (<\\entity><\\entity> 2 H1: 55.4% control, 64% CD, P = 0.019; H2: 64.5% control, 54.4% CD, P = 0.006; <\\entity><\\entity> 3 H1: 55.8% control, 64.4% CD, P = 0.013; H2: 47.0% control, 36.6% CD, P = 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9664",
    "Sentence": "RESULTS: Haplotypes with both increased and decreased risk for <\\entity><\\entity> were observed in 2 of the 4 observed blocks (Block 2 H1: 55.4% control, 64% <\\entity><\\entity>, P = 0.019; H2: 64.5% control, 54.4% <\\entity><\\entity>, P = 0.006; Block 3 H1: 55.8% control, 64.4% <\\entity><\\entity>, P = 0.013; H2: 47.0% control, 36.6% <\\entity><\\entity>, P = 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9665",
    "Sentence": "RESULTS: Haplotypes with both increased and decreased risk for <\\entity><\\entity> were observed in 2 of the 4 observed blocks (Block 2 H1: 55.4% control, 64% <\\entity><\\entity>, P = 0.019; H2: 64.5% control, 54.4% <\\entity><\\entity>, P = 0.006; Block 3 H1: 55.8% control, 64.4% <\\entity><\\entity>, P = 0.013; H2: 47.0% control, 36.6% <\\entity><\\entity>, P = 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9666",
    "Sentence": "RESULTS: Haplotypes with both increased and decreased risk for CD were observed in 2 of the 4 observed blocks (<\\entity><\\entity> 2 H1: 55.4% control, 64% CD, P = 0.019; H2: 64.5% control, 54.4% CD, P = 0.006; <\\entity><\\entity> 3 H1: 55.8% control, 64.4% CD, P = 0.013; H2: 47.0% control, 36.6% CD, P = 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9667",
    "Sentence": "RESULTS: Haplotypes with both increased and decreased risk for <\\entity><\\entity> were observed in 2 of the 4 observed blocks (Block 2 H1: 55.4% control, 64% <\\entity><\\entity>, P = 0.019; H2: 64.5% control, 54.4% <\\entity><\\entity>, P = 0.006; Block 3 H1: 55.8% control, 64.4% <\\entity><\\entity>, P = 0.013; H2: 47.0% control, 36.6% <\\entity><\\entity>, P = 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9668",
    "Sentence": "RESULTS: Haplotypes with both increased and decreased risk for <\\entity><\\entity> were observed in 2 of the 4 observed blocks (Block 2 H1: 55.4% control, 64% <\\entity><\\entity>, P = 0.019; H2: 64.5% control, 54.4% <\\entity><\\entity>, P = 0.006; Block 3 H1: 55.8% control, 64.4% <\\entity><\\entity>, P = 0.013; H2: 47.0% control, 36.6% <\\entity><\\entity>, P = 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9669",
    "Sentence": "The population attributable risk for these haplotypes was substantially larger than that estimated for the <\\entity><\\entity> variant (Block 2 H1 and block 3 H1 approximately 20%, compared with approximately 4% for Block 3 H6, containing the variant).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9670",
    "Sentence": "The population attributable risk for these haplotypes was substantially larger than that estimated for the <\\entity><\\entity> variant (Block 2 H1 and block 3 H1 approximately 20%, compared with approximately 4% for Block 3 H6, containing the variant).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9671",
    "Sentence": "The population attributable risk for these haplotypes was substantially larger than that estimated for the IL23R R381Q variant (<\\entity><\\entity> 2 H1 and block 3 H1 approximately 20%, compared with approximately 4% for <\\entity><\\entity> 3 H6, containing the variant).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9672",
    "Sentence": "The population attributable risk for these haplotypes was substantially larger than that estimated for the IL23R R381Q variant (Block 2 H1 and <\\entity><\\entity> 3 H1 approximately 20%, compared with approximately 4% for Block 3 H6, containing the variant).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9673",
    "Sentence": "The population attributable risk for these haplotypes was substantially larger than that estimated for the IL23R R381Q variant (<\\entity><\\entity> 2 H1 and block 3 H1 approximately 20%, compared with approximately 4% for <\\entity><\\entity> 3 H6, containing the variant).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9674",
    "Sentence": "CONCLUSIONS: These observations suggest that <\\entity><\\entity> makes a substantial contribution to CD susceptibility, larger than that estimated from the population frequency of the R381Q variant.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9675",
    "Sentence": "CONCLUSIONS: These observations suggest that IL23R makes a substantial contribution to <\\entity><\\entity> susceptibility, larger than that estimated from the population frequency of the R381Q variant.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9676",
    "Sentence": "CONCLUSIONS: These observations suggest that IL23R makes a substantial contribution to CD susceptibility, larger than that estimated from the population frequency of the <\\entity><\\entity> variant.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9677",
    "Sentence": "These observations also support the expectation that finding \"hits\" from genomewide association studies will be but an important chapter in the story of unraveling the genetic contribution to <\\entity><\\entity>, rather than the final chapter that brings clarity to all the plot twists of a complicated story.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9678",
    "Sentence": "These observations also support the expectation that finding \"hits\" from genomewide association studies will be but an important chapter in the story of unraveling the genetic contribution to CD, rather than the final chapter that brings clarity to all the plot <\\entity><\\entity> of a complicated story.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9679",
    "Sentence": "<\\entity><\\entity> provide a large population attributable risk for Crohn's disease.BACKGROUND: The IL-23 pathway plays a pivotal role in the development of chronic mucosal inflammation seen in the inflammatory bowel diseases.",
    "Label": ""
  },
  {
    "id": "9680",
    "Sentence": "IL23R haplotypes provide a large population attributable risk for <\\entity><\\entity>.BACKGROUND: The IL-23 pathway plays a pivotal role in the development of chronic mucosal inflammation seen in the inflammatory bowel diseases.",
    "Label": ""
  },
  {
    "id": "9682",
    "Sentence": "IL23R haplotypes provide a large population attributable risk for Crohn's disease.BACKGROUND: The <\\entity><\\entity> pathway plays a pivotal role in the development of chronic mucosal inflammation seen in the inflammatory bowel diseases.",
    "Label": ""
  },
  {
    "id": "9683",
    "Sentence": "IL23R haplotypes provide a large population attributable risk for Crohn's disease.BACKGROUND: The IL-23 pathway plays a pivotal role in the development of <\\entity><\\entity> seen in the inflammatory bowel diseases.",
    "Label": ""
  },
  {
    "id": "9685",
    "Sentence": "Multiple studies have now established the contribution of the interleukin 23 receptor gene (<\\entity><\\entity>) to Crohn's disease (CD) risk in general and of the <\\entity><\\entity> R381Q variant in particular.",
    "Label": ""
  },
  {
    "id": "9686",
    "Sentence": "Multiple studies have now established the contribution of the interleukin 23 receptor gene (IL23R) to <\\entity><\\entity> (CD) risk in general and of the IL23R R381Q variant in particular.",
    "Label": ""
  },
  {
    "id": "9688",
    "Sentence": "Multiple studies have now established the contribution of the interleukin 23 receptor gene (<\\entity><\\entity>) to Crohn's disease (CD) risk in general and of the <\\entity><\\entity> R381Q variant in particular.",
    "Label": ""
  },
  {
    "id": "9689",
    "Sentence": "Multiple studies have now established the contribution of the interleukin 23 receptor gene (IL23R) to Crohn's disease (<\\entity><\\entity>) risk in general and of the IL23R R381Q variant in particular.",
    "Label": ""
  },
  {
    "id": "9691",
    "Sentence": "Multiple studies have now established the contribution of the interleukin 23 receptor gene (IL23R) to Crohn's disease (CD) risk in general and of the <\\entity><\\entity> variant in particular.",
    "Label": ""
  },
  {
    "id": "9692",
    "Sentence": "Multiple studies have now established the contribution of the interleukin 23 receptor gene (IL23R) to <\\entity><\\entity> (CD) risk in general and of the IL23R R381Q variant in particular.",
    "Label": ""
  },
  {
    "id": "9694",
    "Sentence": "Multiple studies have now established the contribution of the interleukin 23 receptor gene (IL23R) to Crohn's disease (CD) risk in general and of the <\\entity><\\entity> variant in particular.",
    "Label": ""
  },
  {
    "id": "9695",
    "Sentence": "Multiple studies have now established the contribution of the interleukin 23 receptor gene (IL23R) to Crohn's disease (<\\entity><\\entity>) risk in general and of the IL23R R381Q variant in particular.",
    "Label": ""
  },
  {
    "id": "9697",
    "Sentence": "METHODS: In all, 763 CD subjects and 254 controls were genotyped for single nucleotide polymorphisms in the <\\entity><\\entity> gene using Illumina and ABI methods.",
    "Label": ""
  },
  {
    "id": "9698",
    "Sentence": "METHODS: In all, 763 <\\entity><\\entity> subjects and 254 controls were genotyped for single nucleotide polymorphisms in the IL23R gene using Illumina and ABI methods.",
    "Label": ""
  },
  {
    "id": "9700",
    "Sentence": "CONCLUSIONS: These observations suggest that <\\entity><\\entity> makes a substantial contribution to CD susceptibility, larger than that estimated from the population frequency of the R381Q variant.",
    "Label": ""
  },
  {
    "id": "9701",
    "Sentence": "CONCLUSIONS: These observations suggest that IL23R makes a substantial contribution to <\\entity><\\entity> susceptibility, larger than that estimated from the population frequency of the R381Q variant.",
    "Label": ""
  },
  {
    "id": "9703",
    "Sentence": "CONCLUSIONS: These observations suggest that IL23R makes a substantial contribution to CD susceptibility, larger than that estimated from the population frequency of the <\\entity><\\entity> variant.",
    "Label": ""
  },
  {
    "id": "9704",
    "Sentence": "CONCLUSIONS: These observations suggest that IL23R makes a substantial contribution to <\\entity><\\entity> susceptibility, larger than that estimated from the population frequency of the R381Q variant.",
    "Label": ""
  },
  {
    "id": "9706",
    "Sentence": "IL23R haplotypes provide a large population attributable risk for Crohn's disease.BACKGROUND: The <\\entity><\\entity> pathway plays a pivotal role in the development of chronic mucosal inflammation seen in the inflammatory bowel diseases.",
    "Label": ""
  },
  {
    "id": "9707",
    "Sentence": "IL23R haplotypes provide a large population attributable risk for Crohn's disease.BACKGROUND: The IL-23 pathway plays a pivotal role in the development of chronic mucosal inflammation seen in the <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9709",
    "Sentence": "The population attributable risk for these haplotypes was substantially larger than that estimated for the <\\entity><\\entity> variant (Block 2 H1 and block 3 H1 approximately 20%, compared with approximately 4% for Block 3 H6, containing the variant).",
    "Label": ""
  },
  {
    "id": "9710",
    "Sentence": "The population attributable risk for these haplotypes was substantially larger than that estimated for the IL23R R381Q variant (<\\entity><\\entity> 2 H1 and block 3 H1 approximately 20%, compared with approximately 4% for <\\entity><\\entity> 3 H6, containing the variant).",
    "Label": ""
  },
  {
    "id": "9716",
    "Sentence": "Three new <\\entity><\\entity> associated with Bloom syndrome.Bloom's syndrome (BS) is a rare autosomal recessive disease predisposing patients to all types of cancers affecting the general population.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9717",
    "Sentence": "Three new <\\entity><\\entity> associated with Bloom syndrome.Bloom's syndrome (BS) is a rare autosomal recessive disease predisposing patients to all types of cancers affecting the general population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9718",
    "Sentence": "Three new <\\entity><\\entity> associated with Bloom syndrome.Bloom's syndrome (BS) is a rare autosomal recessive disease predisposing patients to all types of cancers affecting the general population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9719",
    "Sentence": "Three new BLM gene mutations associated with <\\entity><\\entity>.Bloom's syndrome (BS) is a rare autosomal recessive disease predisposing patients to all types of cancers affecting the general population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9720",
    "Sentence": "Three new BLM gene mutations associated with <\\entity><\\entity>.Bloom's syndrome (BS) is a rare autosomal recessive disease predisposing patients to all types of cancers affecting the general population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9721",
    "Sentence": "Three new BLM gene mutations associated with Bloom syndrome.<\\entity><\\entity> (BS) is a rare autosomal recessive disease predisposing patients to all types of cancers affecting the general population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9722",
    "Sentence": "Three new BLM gene mutations associated with Bloom syndrome.Bloom's syndrome (<\\entity><\\entity>) is a rare autosomal recessive disease predisposing patients to all types of cancers affecting the general population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9723",
    "Sentence": "Three new BLM gene mutations associated with Bloom syndrome.Bloom's syndrome (BS) is a rare autosomal recessive <\\entity><\\entity> predisposing patients to all types of cancers affecting the general population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9724",
    "Sentence": "Three new BLM gene mutations associated with Bloom syndrome.Bloom's syndrome (BS) is a rare autosomal recessive disease predisposing patients to all types of <\\entity><\\entity> affecting the general population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9725",
    "Sentence": "<\\entity><\\entity> cells display a high level of genetic instability, including a 10-fold increase in the rate of sister chromatid exchanges, currently the only objective criterion for <\\entity><\\entity> diagnosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9726",
    "Sentence": "BS cells display a high level of genetic instability, including a 10-fold increase in the rate of <\\entity><\\entity>, currently the only objective criterion for BS diagnosis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9727",
    "Sentence": "<\\entity><\\entity> cells display a high level of genetic instability, including a 10-fold increase in the rate of sister chromatid exchanges, currently the only objective criterion for <\\entity><\\entity> diagnosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9728",
    "Sentence": "We have developed a method for screening the <\\entity><\\entity> gene for mutations based on direct genomic DNA sequencing.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9729",
    "Sentence": "We have developed a method for screening the <\\entity><\\entity> gene for mutations based on direct genomic DNA sequencing.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9730",
    "Sentence": "We have developed a method for screening the BLM gene for <\\entity><\\entity> based on direct genomic DNA sequencing.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9731",
    "Sentence": "A questionnaire based on clinical information, cytogenetic features, and family history was addressed to physicians prescribing <\\entity><\\entity> genetic screening, with the aim of confirming or guiding diagnosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9732",
    "Sentence": "We report here four <\\entity><\\entity>, three of which have not been described before.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9733",
    "Sentence": "We report here four <\\entity><\\entity>, three of which have not been described before.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9734",
    "Sentence": "We report here four <\\entity><\\entity>, three of which have not been described before.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9735",
    "Sentence": "Three of the <\\entity><\\entity> are frameshift <\\entity><\\entity>, and the fourth is a nonsense mutation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9736",
    "Sentence": "Three of the mutations are <\\entity><\\entity>, and the fourth is a nonsense mutation.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9737",
    "Sentence": "Three of the mutations are <\\entity><\\entity>, and the fourth is a nonsense mutation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9738",
    "Sentence": "Three of the mutations are frameshift mutations, and the fourth is a <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9739",
    "Sentence": "Three of the mutations are frameshift mutations, and the fourth is a <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9740",
    "Sentence": "All these <\\entity><\\entity> introduce a stop codon, and may therefore be considered to have deleterious biological effect.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9741",
    "Sentence": "This approach should make it possible to identify new <\\entity><\\entity> and to correlate them with clinical information.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9742",
    "Sentence": "Three new <\\entity><\\entity> associated with Bloom syndrome.Bloom's syndrome (BS) is a rare autosomal recessive disease predisposing patients to all types of cancers affecting the general population.",
    "Label": ""
  },
  {
    "id": "9743",
    "Sentence": "Three new BLM gene mutations associated with <\\entity><\\entity>.Bloom's syndrome (BS) is a rare autosomal recessive disease predisposing patients to all types of cancers affecting the general population.",
    "Label": ""
  },
  {
    "id": "9745",
    "Sentence": "BS cells display a high level of genetic instability, including a 10-fold increase in the rate of <\\entity><\\entity>, currently the only objective criterion for BS diagnosis.",
    "Label": ""
  },
  {
    "id": "9746",
    "Sentence": "<\\entity><\\entity> cells display a high level of genetic instability, including a 10-fold increase in the rate of sister chromatid exchanges, currently the only objective criterion for <\\entity><\\entity> diagnosis.",
    "Label": ""
  },
  {
    "id": "9748",
    "Sentence": "Three new BLM gene mutations associated with <\\entity><\\entity>.Bloom's syndrome (BS) is a rare autosomal recessive disease predisposing patients to all types of cancers affecting the general population.",
    "Label": ""
  },
  {
    "id": "9749",
    "Sentence": "Three new <\\entity><\\entity> associated with Bloom syndrome.Bloom's syndrome (BS) is a rare autosomal recessive disease predisposing patients to all types of cancers affecting the general population.",
    "Label": ""
  },
  {
    "id": "9751",
    "Sentence": "We have developed a method for screening the <\\entity><\\entity> gene for mutations based on direct genomic DNA sequencing.",
    "Label": ""
  },
  {
    "id": "9752",
    "Sentence": "We have developed a method for screening the BLM gene for <\\entity><\\entity> based on direct genomic DNA sequencing.",
    "Label": ""
  },
  {
    "id": "9754",
    "Sentence": "We report here four <\\entity><\\entity>, three of which have not been described before.",
    "Label": ""
  },
  {
    "id": "9755",
    "Sentence": "We report here four <\\entity><\\entity>, three of which have not been described before.",
    "Label": ""
  },
  {
    "id": "9761",
    "Sentence": "<\\entity><\\entity> counteracts<\\entity><\\entity>, the gastrointestinal glutathione peroxidase, is a selenoprotein predominantly expressed in the intestine.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9762",
    "Sentence": "<\\entity><\\entity> counteracts<\\entity><\\entity>, the gastrointestinal glutathione peroxidase, is a selenoprotein predominantly expressed in the intestine.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9763",
    "Sentence": "GPx2 counteractsGPx2, the gastrointestinal gl<\\entity><\\entity>ione peroxidase, is a selenoprotein predominantly expressed in the intestine.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9764",
    "Sentence": "GPx2 counteractsGPx2, the gastrointestinal glutathione <\\entity><\\entity>ase, is a selenoprotein predominantly expressed in the intestine.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9765",
    "Sentence": "GPx2 counteractsGPx2, the gastrointestinal glutathione peroxidase, is a selenoprote<\\entity><\\entity>ntly expressed in the intestine.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9766",
    "Sentence": "GPx2 counteractsGPx2, the gastrointestinal glutathione peroxidase, is a selenoprotein predominantly exp<\\entity><\\entity>ed in the intestine.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9767",
    "Sentence": "GPx2 counteractsGPx2, the gastrointestinal glutathione peroxidase, is a selenoprotein predominantly expressed in the intestine.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9768",
    "Sentence": "An anti-inflammatory and antica<\\entity><\\entity>tential has been inferred from the development of colitis and intestinal cancer in GPx1 and GPx2 double knockout mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9769",
    "Sentence": "Further, induction<\\entity><\\entity>2 activators classifies GPx2 as a protective enzyme.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9770",
    "Sentence": "Further, induction by Nrf2 act<\\entity><\\entity>s GPx2 as a protective enzyme.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9771",
    "Sentence": "Further, induction by Nrf2 activators classifies GP<\\entity><\\entity>s a protective enzyme.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9772",
    "Sentence": "Further, induction by Nrf2 activators classifies GPx2 as a p<\\entity><\\entity>ctive enzyme.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9773",
    "Sentence": "In contrast, enhanced COX-2 exp<\\entity><\\entity>ion is consistently associated with inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9774",
    "Sentence": "In contrast, enhanced COX-2 expression is consistently ass<\\entity><\\entity>ted with inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9775",
    "Sentence": "The antagonistic roles a<\\entity><\\entity> intriguing co-localization of GPx2 and COX-2 prompted us to investigate their possible mutual regulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9776",
    "Sentence": "The antagonistic roles and an intriguing co-localization of GPx2 and COX-<\\entity><\\entity>s to investigate their possible mutual regulation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9777",
    "Sentence": "Both enzyme<\\entity><\\entity>re upregulated in tissues of patients with colorectal cancer and colitis, and co-localized in the endoplasmic reticulum.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9778",
    "Sentence": "Both enzymes were up<\\entity><\\entity>ated in tissues of patients with colorectal cancer and colitis, and co-localized in the endoplasmic reticulum.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9779",
    "Sentence": "A stable <\\entity><\\entity> in HT-29 cells by siRNA resulted in a high basal and IL-1-induced expression of COX-2 and mPGES-1, enzymes required for the production of the pro-inflammatory PGE(2).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9780",
    "Sentence": "A stable knockdown of GPx2 in H<\\entity><\\entity>lls by siRNA resulted in a high basal and IL-1-induced expression of COX-2 and mPGES-1, enzymes required for the production of the pro-inflammatory PGE(2).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9781",
    "Sentence": "A stable knockdown of GPx2 in HT-29 cells by siRNA resulted in a high basal and IL-1-induced expression of CO<\\entity><\\entity>and mPGES-1, enzymes required for the production of the pro-inflammatory PGE(2).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9782",
    "Sentence": "A stable knockdown of GPx2 in HT-29 cells by siRNA resulted in a high basal and IL-1-induced expression of COX-2 and mPGES-1, enzymes required for th<\\entity><\\entity>oduction of th<\\entity><\\entity>o-inflammatory PGE(2).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9783",
    "Sentence": "<\\entity><\\entity>dingly, si-GPx2 cells released high concentrations of PGE(2).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9784",
    "Sentence": "Accordingl<\\entity><\\entity>Px2 cells released high concentrations of PGE(2).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9785",
    "Sentence": "Observed eff<\\entity><\\entity>ere specific for GPx2, since COX-2 and mPGES-1 expression was not affected by selenium-deprivation which resulted in the disappearance of GPx1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9786",
    "Sentence": "Observed effects were specific for G<\\entity><\\entity> since COX-2 and mPGES-1 expression was not affected by selenium-deprivation which resulted in the disappearance of GPx1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9787",
    "Sentence": "Observed effects were specific for GPx2, since COX-2 and mPGES-1 expression was<\\entity><\\entity>ffected by selenium-deprivation which resulted in the disappearance of GPx1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9788",
    "Sentence": "Observed effects were specific for GPx2, since COX-2 and mPGES-1 expression was not affected by selenium-deprivation which<\\entity><\\entity>ulted in the disappearance of GPx1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9789",
    "Sentence": "Observed effects were specific for GPx2, since COX-2 and mPGES-1 expression was not affected by selenium-deprivation which resulted in<\\entity><\\entity>disappearance of GPx1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9790",
    "Sentence": "Observed effects were specific for GPx2, since COX-2 and mPGES-1 expression was not affected by selenium-deprivation which resulted in the disap<\\entity><\\entity>e of GPx1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9791",
    "Sentence": "It is concluded that GPx2 by compartmentalized removal of hydroperoxides silences<\\entity><\\entity>-2 activity and suppresses PGE(2)-dependent<\\entity><\\entity>-2 expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9792",
    "Sentence": "It is concluded that GPx2 by compartmentalized removal of hydroperoxides silences COX-2 activity and suppres<\\entity><\\entity>PGE(2)-dependent COX-2 expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9793",
    "Sentence": "Thus, GPx2 ma<\\entity><\\entity>t undue responses to inflammatory stimuli and, in consequence, inflammation-driven initiation of carcinogenesis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9794",
    "Sentence": "Thus, GPx2 may prevent<\\entity><\\entity>e responses to inflammatory stimuli and, in consequence, inflammation-driven initiation of carcinogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9795",
    "Sentence": "Thus, GPx2 may prevent undue responses to inflammato<\\entity><\\entity>muli and, in consequence, inflammation-driven initiation of carcinogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9796",
    "Sentence": "Thus, GPx2 may prevent undue responses to inflammatory stimuli and, i<\\entity><\\entity>sequence, inflammation-driven initiation of carcinogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9797",
    "Sentence": "Thus, GPx2 may prevent undue responses to inflammatory stimuli and, in consequence, inflammat<\\entity><\\entity>driven initiation of carcinogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9799",
    "Sentence": "Further, induction by Nrf2 activators classifies GPx2 as a p<\\entity><\\entity>ctive enzyme.",
    "Label": ""
  },
  {
    "id": "9800",
    "Sentence": "Further, induction<\\entity><\\entity>2 activators classifies GPx2 as a protective enzyme.",
    "Label": ""
  },
  {
    "id": "9802",
    "Sentence": "Further, induction by Nrf2 activators classifies GPx2 as a p<\\entity><\\entity>ctive enzyme.",
    "Label": ""
  },
  {
    "id": "9803",
    "Sentence": "Further, induction by Nrf2 act<\\entity><\\entity>s GPx2 as a protective enzyme.",
    "Label": ""
  },
  {
    "id": "9805",
    "Sentence": "Further, induction by Nrf2 activators classifies GP<\\entity><\\entity>s a protective enzyme.",
    "Label": ""
  },
  {
    "id": "9806",
    "Sentence": "Further, induction<\\entity><\\entity>2 activators classifies GPx2 as a protective enzyme.",
    "Label": ""
  },
  {
    "id": "9808",
    "Sentence": "Further, induction by Nrf2 activators classifies GP<\\entity><\\entity>s a protective enzyme.",
    "Label": ""
  },
  {
    "id": "9809",
    "Sentence": "Further, induction by Nrf2 act<\\entity><\\entity>s GPx2 as a protective enzyme.",
    "Label": ""
  },
  {
    "id": "9811",
    "Sentence": "The antagonistic roles a<\\entity><\\entity> intriguing co-localization of GPx2 and COX-2 prompted us to investigate their possible mutual regulation.",
    "Label": ""
  },
  {
    "id": "9812",
    "Sentence": "The antagonistic roles and an intriguing co-localization of GPx2 and COX-<\\entity><\\entity>s to investigate their possible mutual regulation.",
    "Label": ""
  },
  {
    "id": "9814",
    "Sentence": "Thus, GPx2 may prevent undue responses to inflammatory stimuli and, in consequence, inflammat<\\entity><\\entity>driven initiation of carcinogenesis.",
    "Label": ""
  },
  {
    "id": "9817",
    "Sentence": "<\\entity><\\entity> counteracts<\\entity><\\entity>, the gastrointestinal glutathione peroxidase, is a selenoprotein predominantly expressed in the intestine.",
    "Label": ""
  },
  {
    "id": "9818",
    "Sentence": "GPx2 counteractsGPx2, the gastrointestinal glutathione peroxidase, is a selenoprote<\\entity><\\entity>ntly expressed in the intestine.",
    "Label": ""
  },
  {
    "id": "9820",
    "Sentence": "<\\entity><\\entity> counteracts<\\entity><\\entity>, the gastrointestinal glutathione peroxidase, is a selenoprotein predominantly expressed in the intestine.",
    "Label": ""
  },
  {
    "id": "9821",
    "Sentence": "GPx2 counteractsGPx2, the gastrointestinal glutathione peroxidase, is a selenoprote<\\entity><\\entity>ntly expressed in the intestine.",
    "Label": ""
  },
  {
    "id": "9823",
    "Sentence": "GPx2 counteractsGPx2, the gastrointestinal gl<\\entity><\\entity>ione peroxidase, is a selenoprotein predominantly expressed in the intestine.",
    "Label": ""
  },
  {
    "id": "9824",
    "Sentence": "GPx2 counteractsGPx2, the gastrointestinal glutathione peroxidase, is a selenoprote<\\entity><\\entity>ntly expressed in the intestine.",
    "Label": ""
  },
  {
    "id": "9826",
    "Sentence": "GPx2 counteractsGPx2, the gastrointestinal glutathione <\\entity><\\entity>ase, is a selenoprotein predominantly expressed in the intestine.",
    "Label": ""
  },
  {
    "id": "9827",
    "Sentence": "GPx2 counteractsGPx2, the gastrointestinal glutathione peroxidase, is a selenoprote<\\entity><\\entity>ntly expressed in the intestine.",
    "Label": ""
  },
  {
    "id": "9829",
    "Sentence": "It is concluded that GPx2 by compartmentalized removal of hydroperoxides silences COX-2 activity and suppres<\\entity><\\entity>PGE(2)-dependent COX-2 expression.",
    "Label": ""
  },
  {
    "id": "9830",
    "Sentence": "Thus, GPx2 ma<\\entity><\\entity>t undue responses to inflammatory stimuli and, in consequence, inflammation-driven initiation of carcinogenesis.",
    "Label": ""
  },
  {
    "id": "9832",
    "Sentence": "Thus, GPx2 may prevent undue responses to inflammatory stimuli and, i<\\entity><\\entity>sequence, inflammation-driven initiation of carcinogenesis.",
    "Label": ""
  },
  {
    "id": "9833",
    "Sentence": "Thus, GPx2 ma<\\entity><\\entity>t undue responses to inflammatory stimuli and, in consequence, inflammation-driven initiation of carcinogenesis.",
    "Label": ""
  },
  {
    "id": "9839",
    "Sentence": "Role of <\\entity><\\entity> in suppressing anti-tumor immunity.Recent evidence suggests that what sustains a tumor's survival and proliferation can also subvert the immune system from its defense role.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9840",
    "Sentence": "As a point of convergence for numerous oncogenic signaling pathways, <\\entity><\\entity> is constitutively activated in diverse human cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9841",
    "Sentence": "Activated <\\entity><\\entity> not only upregulates genes crucial for survival, proliferation, angiogenesis, and metastasis but also promotes expression of immune suppressive factors while inhibiting Th1 immunostimulatory molecules.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9842",
    "Sentence": "Activated Stat3 not only upregulates genes crucial for survival, proliferation, angiogenesis, and metastasis but also promotes expression of immune suppressive factors while inhibiting <\\entity><\\entity> immunostimulatory molecules.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9843",
    "Sentence": "By virtue of its ability to promote expression of many factors that activate <\\entity><\\entity> in diverse cells, <\\entity><\\entity> allows malignant and immune cells resonate, forming close partnership for tumor immune evasion, tumor progression, and resistance to therapies.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9844",
    "Sentence": "By virtue of its ability to promote expression of many factors that activate <\\entity><\\entity> in diverse cells, <\\entity><\\entity> allows malignant and immune cells resonate, forming close partnership for tumor immune evasion, tumor progression, and resistance to therapies.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9849",
    "Sentence": "<\\entity><\\entity>, an oral direct factor Xa inhibitor.<\\entity><\\entity> is a small molecule, direct Factor Xa inhibitor and may be a potentially attractive alternative to vitamin K antagonists.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9850",
    "Sentence": "Rivaroxaban, an oral <\\entity><\\entity>.Rivaroxaban is a small molecule, direct Factor Xa inhibitor and may be a potentially attractive alternative to vitamin K antagonists.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9851",
    "Sentence": "Rivaroxaban, an oral direct <\\entity><\\entity> inhibitor.Rivaroxaban is a small molecule, direct Factor Xa inhibitor and may be a potentially attractive alternative to vitamin K antagonists.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9852",
    "Sentence": "<\\entity><\\entity>, an oral direct factor Xa inhibitor.<\\entity><\\entity> is a small molecule, direct Factor Xa inhibitor and may be a potentially attractive alternative to vitamin K antagonists.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9853",
    "Sentence": "Rivaroxaban, an oral direct factor Xa inhibitor.Rivaroxaban is a small molecule, <\\entity><\\entity> and may be a potentially attractive alternative to vitamin K antagonists.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9854",
    "Sentence": "Rivaroxaban, an oral direct factor Xa inhibitor.Rivaroxaban is a small molecule, direct <\\entity><\\entity> inhibitor and may be a potentially attractive alternative to vitamin K antagonists.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9855",
    "Sentence": "Rivaroxaban, an oral direct factor Xa inhibitor.Rivaroxaban is a small molecule, direct Factor Xa inhibitor and may be a potentially attractive alternative to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9856",
    "Sentence": "<\\entity><\\entity> is being investigated for the prevention and treatment of venous and arterial thrombosis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9857",
    "Sentence": "This review addresses the findings of this systematic search, including the need for new <\\entity><\\entity>, the development and pharmacology of rivaroxaban, and the results of completed as well as ongoing trials with rivaroxaban.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9858",
    "Sentence": "This review addresses the findings of this systematic search, including the need for new oral anticoagulants, the development and pharmacology of <\\entity><\\entity>, and the results of completed as well as ongoing trials with <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9859",
    "Sentence": "This review addresses the findings of this systematic search, including the need for new oral anticoagulants, the development and pharmacology of <\\entity><\\entity>, and the results of completed as well as ongoing trials with <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9860",
    "Sentence": "At present, the safety and efficacy of <\\entity><\\entity> for the prophylaxis and treatment of venous thromboembolism has been evaluated in Phase II and Phase III trials involving over 24,000 patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9861",
    "Sentence": "Additionally, <\\entity><\\entity> is being evaluated for the treatment of pulmonary embolism, secondary prevention after acute coronary syndromes and the prevention of stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9862",
    "Sentence": "The drug may have its greatest impact in providing a much-needed and attractive alternative to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9863",
    "Sentence": "<\\entity><\\entity>, an oral direct factor Xa inhibitor.<\\entity><\\entity> is a small molecule, direct Factor Xa inhibitor and may be a potentially attractive alternative to vitamin K antagonists.",
    "Label": ""
  },
  {
    "id": "9864",
    "Sentence": "Rivaroxaban, an oral direct <\\entity><\\entity> inhibitor.Rivaroxaban is a small molecule, direct Factor Xa inhibitor and may be a potentially attractive alternative to vitamin K antagonists.",
    "Label": ""
  },
  {
    "id": "9866",
    "Sentence": "Rivaroxaban, an oral direct factor Xa inhibitor.Rivaroxaban is a small molecule, direct Factor Xa inhibitor and may be a potentially attractive alternative to <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9867",
    "Sentence": "Rivaroxaban, an oral direct factor Xa inhibitor.Rivaroxaban is a small molecule, direct <\\entity><\\entity> inhibitor and may be a potentially attractive alternative to vitamin K antagonists.",
    "Label": ""
  },
  {
    "id": "9869",
    "Sentence": "<\\entity><\\entity>, an oral direct factor Xa inhibitor.<\\entity><\\entity> is a small molecule, direct Factor Xa inhibitor and may be a potentially attractive alternative to vitamin K antagonists.",
    "Label": ""
  },
  {
    "id": "9870",
    "Sentence": "Rivaroxaban, an oral direct factor Xa inhibitor.Rivaroxaban is a small molecule, direct <\\entity><\\entity> inhibitor and may be a potentially attractive alternative to vitamin K antagonists.",
    "Label": ""
  },
  {
    "id": "9872",
    "Sentence": "<\\entity><\\entity> is being investigated for the prevention and treatment of venous and arterial thrombosis.",
    "Label": ""
  },
  {
    "id": "9873",
    "Sentence": "Rivaroxaban is being investigated for the prevention and treatment of venous and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9875",
    "Sentence": "At present, the safety and efficacy of <\\entity><\\entity> for the prophylaxis and treatment of venous thromboembolism has been evaluated in Phase II and Phase III trials involving over 24,000 patients.",
    "Label": ""
  },
  {
    "id": "9876",
    "Sentence": "At present, the safety and efficacy of rivaroxaban for the prophylaxis and treatment of <\\entity><\\entity> has been evaluated in Phase II and Phase III trials involving over 24,000 patients.",
    "Label": ""
  },
  {
    "id": "9878",
    "Sentence": "Additionally, <\\entity><\\entity> is being evaluated for the treatment of pulmonary embolism, secondary prevention after acute coronary syndromes and the prevention of stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation.",
    "Label": ""
  },
  {
    "id": "9879",
    "Sentence": "Additionally, rivaroxaban is being evaluated for the treatment of <\\entity><\\entity>, secondary prevention after acute coronary syndromes and the prevention of stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation.",
    "Label": ""
  },
  {
    "id": "9881",
    "Sentence": "Additionally, <\\entity><\\entity> is being evaluated for the treatment of pulmonary embolism, secondary prevention after acute coronary syndromes and the prevention of stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation.",
    "Label": ""
  },
  {
    "id": "9882",
    "Sentence": "Additionally, rivaroxaban is being evaluated for the treatment of pulmonary embolism, secondary prevention after <\\entity><\\entity> and the prevention of stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation.",
    "Label": ""
  },
  {
    "id": "9884",
    "Sentence": "Additionally, <\\entity><\\entity> is being evaluated for the treatment of pulmonary embolism, secondary prevention after acute coronary syndromes and the prevention of stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation.",
    "Label": ""
  },
  {
    "id": "9885",
    "Sentence": "Additionally, rivaroxaban is being evaluated for the treatment of pulmonary embolism, secondary prevention after acute coronary syndromes and the prevention of <\\entity><\\entity> and non-central nervous system embolism in patients with non-valvular atrial fibrillation.",
    "Label": ""
  },
  {
    "id": "9887",
    "Sentence": "Additionally, <\\entity><\\entity> is being evaluated for the treatment of pulmonary embolism, secondary prevention after acute coronary syndromes and the prevention of stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation.",
    "Label": ""
  },
  {
    "id": "9888",
    "Sentence": "Additionally, rivaroxaban is being evaluated for the treatment of pulmonary embolism, secondary prevention after acute coronary syndromes and the prevention of stroke and non-central nervous system embolism in patients with non-valvular <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9890",
    "Sentence": "Additionally, <\\entity><\\entity> is being evaluated for the treatment of pulmonary embolism, secondary prevention after acute coronary syndromes and the prevention of stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation.",
    "Label": ""
  },
  {
    "id": "9891",
    "Sentence": "Additionally, rivaroxaban is being evaluated for the treatment of pulmonary <\\entity><\\entity>, secondary prevention after acute coronary syndromes and the prevention of stroke and non-central nervous system <\\entity><\\entity> in patients with non-valvular atrial fibrillation.",
    "Label": ""
  },
  {
    "id": "9897",
    "Sentence": "The impact of ovarian stimulation with <\\entity><\\entity> in combination with GnRH antagonist on the endometrial transcriptome in the window of implantation.The aim of this prospective paired cohort study is to elucidate the impact of ovarian stimulation with recombinant follicle-stimulating hormone in combination with gonadotropin-releasing hormone antagonist on the endometrial transcriptome.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9898",
    "Sentence": "The impact of ovarian stimulation with recombinant FSH in combination with <\\entity><\\entity> on the endometrial transcriptome in the window of implantation.The aim of this prospective paired cohort study is to elucidate the impact of ovarian stimulation with recombinant follicle-stimulating hormone in combination with gonadotropin-releasing hormone antagonist on the endometrial transcriptome.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9899",
    "Sentence": "The impact of ovarian stimulation with recombinant FSH in combination with GnRH antagonist on the <\\entity><\\entity> in the window of implantation.The aim of this prospective paired cohort study is to elucidate the impact of ovarian stimulation with recombinant follicle-stimulating hormone in combination with gonadotropin-releasing hormone antagonist on the <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9900",
    "Sentence": "The impact of ovarian stimulation with recombinant FSH in combination with GnRH antagonist on the endometrial transcriptome in the window of implantation.The aim of this prospective paired cohort study is to elucidate the impact of ovarian stimulation with <\\entity><\\entity> in combination with gonadotropin-releasing hormone antagonist on the endometrial transcriptome.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9901",
    "Sentence": "The impact of ovarian stimulation with recombinant FSH in combination with GnRH antagonist on the endometrial transcriptome in the window of implantation.The aim of this prospective paired cohort study is to elucidate the impact of ovarian stimulation with recombinant follicle-stimulating hormone in combination with <\\entity><\\entity> on the endometrial transcriptome.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9902",
    "Sentence": "The impact of ovarian stimulation with recombinant FSH in combination with GnRH antagonist on the <\\entity><\\entity> in the window of implantation.The aim of this prospective paired cohort study is to elucidate the impact of ovarian stimulation with recombinant follicle-stimulating hormone in combination with gonadotropin-releasing hormone antagonist on the <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9903",
    "Sentence": "Oocyte donors underwent endometrial biopsy during the implantation window of the nonstimulated cycle and following ovarian stimulation with <\\entity><\\entity> and gonadotropin-releasing hormone antagonist but no luteal progesterone supplementation (n = 4).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9904",
    "Sentence": "Oocyte donors underwent endometrial biopsy during the implantation window of the nonstimulated cycle and following ovarian stimulation with recombinant follicle-stimulating hormone and <\\entity><\\entity> but no luteal progesterone supplementation (n = 4).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9905",
    "Sentence": "Oocyte donors underwent endometrial biopsy during the implantation window of the nonstimulated cycle and following ovarian stimulation with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonist but no <\\entity><\\entity> supplementation (n = 4).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9906",
    "Sentence": "Significantly upregulated genes included those sequencing for the <\\entity><\\entity> CXCL 13, the Dickkopf homolog, steroidogenic acute regulatory protein, and homeobox C6.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9907",
    "Sentence": "Significantly upregulated genes included those sequencing for the chemokine ligand <\\entity><\\entity>, the Dickkopf homolog, steroidogenic acute regulatory protein, and homeobox C6.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9908",
    "Sentence": "Significantly upregulated genes included those sequencing for the chemokine ligand <\\entity><\\entity>, the Dickkopf homolog, steroidogenic acute regulatory protein, and homeobox C6.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9909",
    "Sentence": "Significantly upregulated genes included those sequencing for the chemokine ligand CXCL 13, the <\\entity><\\entity>, and homeobox C6.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9910",
    "Sentence": "Significantly upregulated genes included those sequencing for the chemokine ligand CXCL 13, the Dickkopf homolog, steroidogenic acute regulatory protein, and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9911",
    "Sentence": "Also upregulated were genes inhibited by <\\entity><\\entity>, such as insulin-like growth factor binding protein 5.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9912",
    "Sentence": "Also upregulated were genes inhibited by progesterone, such as <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9913",
    "Sentence": "In conclusion, ovarian stimulation with <\\entity><\\entity> and gonadotropin-releasing hormone antagonist dysregulates the expression of many genes involved in cell adhesion, T-cell receptor signaling, and regulation of signal transduction.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9914",
    "Sentence": "In conclusion, ovarian stimulation with follicle-stimulating hormone and <\\entity><\\entity> dysregulates the expression of many genes involved in cell adhesion, T-cell receptor signaling, and regulation of signal transduction.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "9915",
    "Sentence": "These data suggest that dysregulation of the <\\entity><\\entity> in the stimulated cycle is not fully attributable to supraphysiological sex steroid levels at the folliculo-luteal transition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9916",
    "Sentence": "These data suggest that dysregulation of the endometrial transcriptome in the stimulated cycle is not fully attributable to supraphysiological <\\entity><\\entity> levels at the folliculo-luteal transition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9917",
    "Sentence": "Significantly upregulated genes included those sequencing for the chemokine ligand <\\entity><\\entity>, the Dickkopf homolog, steroidogenic acute regulatory protein, and homeobox C6.",
    "Label": ""
  },
  {
    "id": "9918",
    "Sentence": "Significantly upregulated genes included those sequencing for the chemokine ligand CXCL 13, the Dickkopf homolog, steroidogenic acute regulatory protein, and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9920",
    "Sentence": "Significantly upregulated genes included those sequencing for the chemokine ligand <\\entity><\\entity>, the Dickkopf homolog, steroidogenic acute regulatory protein, and homeobox C6.",
    "Label": ""
  },
  {
    "id": "9921",
    "Sentence": "Significantly upregulated genes included those sequencing for the chemokine ligand CXCL 13, the <\\entity><\\entity>, and homeobox C6.",
    "Label": ""
  },
  {
    "id": "9923",
    "Sentence": "Significantly upregulated genes included those sequencing for the <\\entity><\\entity> CXCL 13, the Dickkopf homolog, steroidogenic acute regulatory protein, and homeobox C6.",
    "Label": ""
  },
  {
    "id": "9924",
    "Sentence": "Significantly upregulated genes included those sequencing for the chemokine ligand CXCL 13, the Dickkopf homolog, steroidogenic acute regulatory protein, and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9926",
    "Sentence": "Significantly upregulated genes included those sequencing for the <\\entity><\\entity> CXCL 13, the Dickkopf homolog, steroidogenic acute regulatory protein, and homeobox C6.",
    "Label": ""
  },
  {
    "id": "9927",
    "Sentence": "Significantly upregulated genes included those sequencing for the chemokine ligand CXCL 13, the <\\entity><\\entity>, and homeobox C6.",
    "Label": ""
  },
  {
    "id": "9929",
    "Sentence": "Also upregulated were genes inhibited by <\\entity><\\entity>, such as insulin-like growth factor binding protein 5.",
    "Label": ""
  },
  {
    "id": "9930",
    "Sentence": "Also upregulated were genes inhibited by progesterone, such as <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "9936",
    "Sentence": "Genome-wide analysis of <\\entity><\\entity> changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.BACKGROUND: We undertook a genome wide single nucleotide polymorphism analysis of a spectrum of patients with myelodysplastic syndrome del(5q) in order to investigate whether additional genomic abnormalities occur.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9937",
    "Sentence": "Genome-wide analysis of copy number changes and <\\entity><\\entity> in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.BACKGROUND: We undertook a genome wide single nucleotide polymorphism analysis of a spectrum of patients with myelodysplastic syndrome del(5q) in order to investigate whether additional genomic abnormalities occur.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9938",
    "Sentence": "Genome-wide analysis of copy number changes and loss of heterozygosity in <\\entity><\\entity> with del(5q) using high-density single nucleotide polymorphism arrays.BACKGROUND: We undertook a genome wide single nucleotide polymorphism analysis of a spectrum of patients with <\\entity><\\entity> del(5q) in order to investigate whether additional genomic abnormalities occur.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9939",
    "Sentence": "Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with <\\entity><\\entity> using high-density single nucleotide polymorphism arrays.BACKGROUND: We undertook a genome wide single nucleotide polymorphism analysis of a spectrum of patients with myelodysplastic syndrome <\\entity><\\entity> in order to investigate whether additional genomic abnormalities occur.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9940",
    "Sentence": "Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with <\\entity><\\entity> using high-density single nucleotide polymorphism arrays.BACKGROUND: We undertook a genome wide single nucleotide polymorphism analysis of a spectrum of patients with myelodysplastic syndrome <\\entity><\\entity> in order to investigate whether additional genomic abnormalities occur.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9941",
    "Sentence": "Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with <\\entity><\\entity> using high-density single nucleotide polymorphism arrays.BACKGROUND: We undertook a genome wide single nucleotide polymorphism analysis of a spectrum of patients with myelodysplastic syndrome <\\entity><\\entity> in order to investigate whether additional genomic abnormalities occur.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9942",
    "Sentence": "Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.BACKGROUND: We undertook a genome wide single nucleotide polymorphism analysis of a spectrum of patients with <\\entity><\\entity> in order to investigate whether additional genomic abnormalities occur.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9943",
    "Sentence": "Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with <\\entity><\\entity>) using high-density single nucleotide polymorphism arrays.BACKGROUND: We undertook a genome wide single nucleotide polymorphism analysis of a spectrum of patients with myelodysplastic syndrome <\\entity><\\entity>) in order to investigate whether additional genomic abnormalities occur.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9944",
    "Sentence": "Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.BACKGROUND: We undertook a genome wide single nucleotide polymorphism analysis of a spectrum of patients with myelodysplastic syndrome del(5q) in order to investigate whether additional genomic <\\entity><\\entity> occur.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9945",
    "Sentence": "Single nucleotide polymorphism array analysis has been shown to detect not only <\\entity><\\entity> but also regions of uniparental disomy that can pinpoint particular regions for mutation analysis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9946",
    "Sentence": "Single nucleotide polymorphism array analysis has been shown to detect not only gene deletions but also regions of <\\entity><\\entity> that can pinpoint particular regions for mutation analysis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9947",
    "Sentence": "Single nucleotide polymorphism array analysis has been shown to detect not only gene deletions but also regions of <\\entity><\\entity> that can pinpoint particular regions for mutation analysis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9948",
    "Sentence": "Single nucleotide polymorphism array analysis has been shown to detect not only gene deletions but also regions of uniparental disomy that can pinpoint particular regions for <\\entity><\\entity> analysis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9949",
    "Sentence": "DESIGN AND METHODS: We studied 42 cases of <\\entity><\\entity> with del(5q), comprising 21 patients with 5q- syndrome and 21 with del(5q) (not 5q- syndrome), and 45 healthy controls by genome wide single nucleotide polymorphism analysis with the 50K Affymetrix single nucleotide polymorphism arrays.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9950",
    "Sentence": "DESIGN AND METHODS: We studied 42 cases of myelodysplastic syndrome with <\\entity><\\entity>, comprising 21 patients with 5q- syndrome and 21 with <\\entity><\\entity> (not 5q- syndrome), and 45 healthy controls by genome wide single nucleotide polymorphism analysis with the 50K Affymetrix single nucleotide polymorphism arrays.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9951",
    "Sentence": "DESIGN AND METHODS: We studied 42 cases of myelodysplastic syndrome with <\\entity><\\entity>, comprising 21 patients with 5q- syndrome and 21 with <\\entity><\\entity> (not 5q- syndrome), and 45 healthy controls by genome wide single nucleotide polymorphism analysis with the 50K Affymetrix single nucleotide polymorphism arrays.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9952",
    "Sentence": "DESIGN AND METHODS: We studied 42 cases of myelodysplastic syndrome with <\\entity><\\entity>, comprising 21 patients with 5q- syndrome and 21 with <\\entity><\\entity> (not 5q- syndrome), and 45 healthy controls by genome wide single nucleotide polymorphism analysis with the 50K Affymetrix single nucleotide polymorphism arrays.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9953",
    "Sentence": "DESIGN AND METHODS: We studied 42 cases of myelodysplastic syndrome with del(5q), comprising 21 patients with <\\entity><\\entity> and 21 with del(5q) (not <\\entity><\\entity>), and 45 healthy controls by genome wide single nucleotide polymorphism analysis with the 50K Affymetrix single nucleotide polymorphism arrays.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9954",
    "Sentence": "DESIGN AND METHODS: We studied 42 cases of myelodysplastic syndrome with <\\entity><\\entity>, comprising 21 patients with 5q- syndrome and 21 with <\\entity><\\entity> (not 5q- syndrome), and 45 healthy controls by genome wide single nucleotide polymorphism analysis with the 50K Affymetrix single nucleotide polymorphism arrays.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9955",
    "Sentence": "DESIGN AND METHODS: We studied 42 cases of myelodysplastic syndrome with <\\entity><\\entity>, comprising 21 patients with 5q- syndrome and 21 with <\\entity><\\entity> (not 5q- syndrome), and 45 healthy controls by genome wide single nucleotide polymorphism analysis with the 50K Affymetrix single nucleotide polymorphism arrays.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9956",
    "Sentence": "DESIGN AND METHODS: We studied 42 cases of myelodysplastic syndrome with <\\entity><\\entity>, comprising 21 patients with 5q- syndrome and 21 with <\\entity><\\entity> (not 5q- syndrome), and 45 healthy controls by genome wide single nucleotide polymorphism analysis with the 50K Affymetrix single nucleotide polymorphism arrays.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9957",
    "Sentence": "DESIGN AND METHODS: We studied 42 cases of myelodysplastic syndrome with del(5q), comprising 21 patients with <\\entity><\\entity> and 21 with del(5q) (not <\\entity><\\entity>), and 45 healthy controls by genome wide single nucleotide polymorphism analysis with the 50K Affymetrix single nucleotide polymorphism arrays.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9958",
    "Sentence": "RESULTS: The <\\entity><\\entity> was characterized in all cases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9959",
    "Sentence": "RESULTS: The <\\entity><\\entity> was characterized in all cases.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9960",
    "Sentence": "RESULTS: The <\\entity><\\entity> was characterized in all cases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9961",
    "Sentence": "The commonly deleted region of the <\\entity><\\entity> extends between the genes SH3TC2 (proximal boundary) and GLRA1 (distal boundary) and measures 2.9 Mb.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9962",
    "Sentence": "The commonly deleted region of the 5q- syndrome extends between the genes <\\entity><\\entity> (proximal boundary) and GLRA1 (distal boundary) and measures 2.9 Mb.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9963",
    "Sentence": "The commonly deleted region of the 5q- syndrome extends between the genes SH3TC2 (proximal boundary) and <\\entity><\\entity> (distal boundary) and measures 2.9 Mb.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9964",
    "Sentence": "<\\entity><\\entity> changes in addition to the del(5q) were observed in 10 of 21 patients with del(5q) myelodysplastic syndrome but in none of the patients with the 5q- syndrome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9965",
    "Sentence": "Copy number changes in addition to the <\\entity><\\entity> were observed in 10 of 21 patients with <\\entity><\\entity> myelodysplastic syndrome but in none of the patients with the 5q- syndrome.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9966",
    "Sentence": "Copy number changes in addition to the <\\entity><\\entity> were observed in 10 of 21 patients with <\\entity><\\entity> myelodysplastic syndrome but in none of the patients with the 5q- syndrome.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9967",
    "Sentence": "Copy number changes in addition to the <\\entity><\\entity> were observed in 10 of 21 patients with <\\entity><\\entity> myelodysplastic syndrome but in none of the patients with the 5q- syndrome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9968",
    "Sentence": "Copy number changes in addition to the del(5q) were observed in 10 of 21 patients with <\\entity><\\entity> but in none of the patients with the 5q- syndrome.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9969",
    "Sentence": "Copy number changes in addition to the del(5q) were observed in 10 of 21 patients with <\\entity><\\entity> but in none of the patients with the 5q- syndrome.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9970",
    "Sentence": "Copy number changes in addition to the del(5q) were observed in 10 of 21 patients with del(5q) myelodysplastic syndrome but in none of the patients with the <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9971",
    "Sentence": "A total of 63 regions of <\\entity><\\entity> greater than 2 Mb were detected in 40 of 42 patients, dispersed on 18/23 chromosomes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9972",
    "Sentence": "A total of 63 regions of <\\entity><\\entity> greater than 2 Mb were detected in 40 of 42 patients, dispersed on 18/23 chromosomes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9973",
    "Sentence": "In the <\\entity><\\entity> group 31 regions of uniparental disomy were identified in 19 of 21 patients, the largest one being 7.6 Mb.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9974",
    "Sentence": "In the 5q- syndrome group 31 regions of <\\entity><\\entity> were identified in 19 of 21 patients, the largest one being 7.6 Mb.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9975",
    "Sentence": "In the 5q- syndrome group 31 regions of <\\entity><\\entity> were identified in 19 of 21 patients, the largest one being 7.6 Mb.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9976",
    "Sentence": "All 21 patients with <\\entity><\\entity> had uniparental disomy; in total 32 regions of uniparental disomy were identified in the 21 patients, including six regions of uniparental disomy > 10 Mb.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9977",
    "Sentence": "All 21 patients with <\\entity><\\entity> had uniparental disomy; in total 32 regions of uniparental disomy were identified in the 21 patients, including six regions of uniparental disomy > 10 Mb.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9978",
    "Sentence": "All 21 patients with del(5q) myelodysplastic syndrome had <\\entity><\\entity>; in total 32 regions of <\\entity><\\entity> were identified in the 21 patients, including six regions of <\\entity><\\entity> > 10 Mb.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9979",
    "Sentence": "All 21 patients with del(5q) myelodysplastic syndrome had <\\entity><\\entity>; in total 32 regions of <\\entity><\\entity> were identified in the 21 patients, including six regions of <\\entity><\\entity> > 10 Mb.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9980",
    "Sentence": "All 21 patients with del(5q) myelodysplastic syndrome had <\\entity><\\entity>; in total 32 regions of <\\entity><\\entity> were identified in the 21 patients, including six regions of <\\entity><\\entity> > 10 Mb.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9981",
    "Sentence": "All 21 patients with del(5q) myelodysplastic syndrome had <\\entity><\\entity>; in total 32 regions of <\\entity><\\entity> were identified in the 21 patients, including six regions of <\\entity><\\entity> > 10 Mb.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9982",
    "Sentence": "All 21 patients with del(5q) myelodysplastic syndrome had <\\entity><\\entity>; in total 32 regions of <\\entity><\\entity> were identified in the 21 patients, including six regions of <\\entity><\\entity> > 10 Mb.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9983",
    "Sentence": "All 21 patients with del(5q) myelodysplastic syndrome had <\\entity><\\entity>; in total 32 regions of <\\entity><\\entity> were identified in the 21 patients, including six regions of <\\entity><\\entity> > 10 Mb.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9984",
    "Sentence": "Eight recurrent regions of <\\entity><\\entity> were observed among the 42 patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9985",
    "Sentence": "Eight recurrent regions of <\\entity><\\entity> were observed among the 42 patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9986",
    "Sentence": "For eight patients we had T-cell DNA as a germline control and four recurrent regions of <\\entity><\\entity> were identified that were present only in the neutrophil and not T-cell DNA.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9987",
    "Sentence": "For eight patients we had T-cell DNA as a germline control and four recurrent regions of <\\entity><\\entity> were identified that were present only in the neutrophil and not T-cell DNA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9988",
    "Sentence": "One small region of <\\entity><\\entity> at 10p12.31-p12.2 was observed in four patients with the 5q- syndrome.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9989",
    "Sentence": "One small region of <\\entity><\\entity> at 10p12.31-p12.2 was observed in four patients with the 5q- syndrome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9990",
    "Sentence": "One small region of uniparental disomy at <\\entity><\\entity> was observed in four patients with the 5q- syndrome.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9991",
    "Sentence": "One small region of uniparental disomy at 10p12.31-p12.2 was observed in four patients with the <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9992",
    "Sentence": "CONCLUSIONS: This study shows that regions of <\\entity><\\entity> greater than 2 Mb are found in the 5q-syndrome and del(5q) myelodysplastic syndrome, although large regions of <\\entity><\\entity> (>10 Mb) are only found in the latter group.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9993",
    "Sentence": "CONCLUSIONS: This study shows that regions of <\\entity><\\entity> greater than 2 Mb are found in the 5q-syndrome and del(5q) myelodysplastic syndrome, although large regions of <\\entity><\\entity> (>10 Mb) are only found in the latter group.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9994",
    "Sentence": "CONCLUSIONS: This study shows that regions of uniparental disomy greater than 2 Mb are found in the <\\entity><\\entity> and del(5q) myelodysplastic syndrome, although large regions of uniparental disomy (>10 Mb) are only found in the latter group.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9995",
    "Sentence": "CONCLUSIONS: This study shows that regions of uniparental disomy greater than 2 Mb are found in the 5q-syndrome and <\\entity><\\entity>, although large regions of uniparental disomy (>10 Mb) are only found in the latter group.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9996",
    "Sentence": "CONCLUSIONS: This study shows that regions of uniparental disomy greater than 2 Mb are found in the 5q-syndrome and <\\entity><\\entity>, although large regions of uniparental disomy (>10 Mb) are only found in the latter group.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "9997",
    "Sentence": "CONCLUSIONS: This study shows that regions of <\\entity><\\entity> greater than 2 Mb are found in the 5q-syndrome and del(5q) myelodysplastic syndrome, although large regions of <\\entity><\\entity> (>10 Mb) are only found in the latter group.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "9998",
    "Sentence": "CONCLUSIONS: This study shows that regions of <\\entity><\\entity> greater than 2 Mb are found in the 5q-syndrome and del(5q) myelodysplastic syndrome, although large regions of <\\entity><\\entity> (>10 Mb) are only found in the latter group.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "9999",
    "Sentence": "The recurrent regions of <\\entity><\\entity> may indicate the position of novel leukemia-associated genes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10000",
    "Sentence": "The recurrent regions of <\\entity><\\entity> may indicate the position of novel leukemia-associated genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10001",
    "Sentence": "The recurrent regions of uniparental disomy may indicate the position of novel <\\entity><\\entity>-associated genes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10002",
    "Sentence": "The commonly deleted region of the 5q- syndrome extends between the genes <\\entity><\\entity> (proximal boundary) and GLRA1 (distal boundary) and measures 2.9 Mb.",
    "Label": ""
  },
  {
    "id": "10003",
    "Sentence": "The commonly deleted region of the <\\entity><\\entity> extends between the genes SH3TC2 (proximal boundary) and GLRA1 (distal boundary) and measures 2.9 Mb.",
    "Label": ""
  },
  {
    "id": "10005",
    "Sentence": "The commonly deleted region of the 5q- syndrome extends between the genes SH3TC2 (proximal boundary) and <\\entity><\\entity> (distal boundary) and measures 2.9 Mb.",
    "Label": ""
  },
  {
    "id": "10006",
    "Sentence": "The commonly deleted region of the <\\entity><\\entity> extends between the genes SH3TC2 (proximal boundary) and GLRA1 (distal boundary) and measures 2.9 Mb.",
    "Label": ""
  },
  {
    "id": "10008",
    "Sentence": "Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with <\\entity><\\entity> using high-density single nucleotide polymorphism arrays.BACKGROUND: We undertook a genome wide single nucleotide polymorphism analysis of a spectrum of patients with myelodysplastic syndrome <\\entity><\\entity> in order to investigate whether additional genomic abnormalities occur.",
    "Label": ""
  },
  {
    "id": "10009",
    "Sentence": "Genome-wide analysis of copy number changes and loss of heterozygosity in <\\entity><\\entity> with del(5q) using high-density single nucleotide polymorphism arrays.BACKGROUND: We undertook a genome wide single nucleotide polymorphism analysis of a spectrum of patients with <\\entity><\\entity> del(5q) in order to investigate whether additional genomic abnormalities occur.",
    "Label": ""
  },
  {
    "id": "10011",
    "Sentence": "Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with <\\entity><\\entity>) using high-density single nucleotide polymorphism arrays.BACKGROUND: We undertook a genome wide single nucleotide polymorphism analysis of a spectrum of patients with myelodysplastic syndrome <\\entity><\\entity>) in order to investigate whether additional genomic abnormalities occur.",
    "Label": ""
  },
  {
    "id": "10012",
    "Sentence": "Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.BACKGROUND: We undertook a genome wide single nucleotide polymorphism analysis of a spectrum of patients with <\\entity><\\entity> in order to investigate whether additional genomic abnormalities occur.",
    "Label": ""
  },
  {
    "id": "10014",
    "Sentence": "DESIGN AND METHODS: We studied 42 cases of myelodysplastic syndrome with <\\entity><\\entity>, comprising 21 patients with 5q- syndrome and 21 with <\\entity><\\entity> (not 5q- syndrome), and 45 healthy controls by genome wide single nucleotide polymorphism analysis with the 50K Affymetrix single nucleotide polymorphism arrays.",
    "Label": ""
  },
  {
    "id": "10015",
    "Sentence": "DESIGN AND METHODS: We studied 42 cases of myelodysplastic syndrome with del(5q), comprising 21 patients with <\\entity><\\entity> and 21 with del(5q) (not <\\entity><\\entity>), and 45 healthy controls by genome wide single nucleotide polymorphism analysis with the 50K Affymetrix single nucleotide polymorphism arrays.",
    "Label": ""
  },
  {
    "id": "10017",
    "Sentence": "DESIGN AND METHODS: We studied 42 cases of myelodysplastic syndrome with <\\entity><\\entity>, comprising 21 patients with 5q- syndrome and 21 with <\\entity><\\entity> (not 5q- syndrome), and 45 healthy controls by genome wide single nucleotide polymorphism analysis with the 50K Affymetrix single nucleotide polymorphism arrays.",
    "Label": ""
  },
  {
    "id": "10018",
    "Sentence": "DESIGN AND METHODS: We studied 42 cases of <\\entity><\\entity> with del(5q), comprising 21 patients with 5q- syndrome and 21 with del(5q) (not 5q- syndrome), and 45 healthy controls by genome wide single nucleotide polymorphism analysis with the 50K Affymetrix single nucleotide polymorphism arrays.",
    "Label": ""
  },
  {
    "id": "10020",
    "Sentence": "Copy number changes in addition to the del(5q) were observed in 10 of 21 patients with <\\entity><\\entity> but in none of the patients with the 5q- syndrome.",
    "Label": ""
  },
  {
    "id": "10021",
    "Sentence": "Copy number changes in addition to the del(5q) were observed in 10 of 21 patients with del(5q) myelodysplastic syndrome but in none of the patients with the <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10023",
    "Sentence": "Copy number changes in addition to the del(5q) were observed in 10 of 21 patients with <\\entity><\\entity> but in none of the patients with the 5q- syndrome.",
    "Label": ""
  },
  {
    "id": "10024",
    "Sentence": "Copy number changes in addition to the del(5q) were observed in 10 of 21 patients with <\\entity><\\entity> but in none of the patients with the 5q- syndrome.",
    "Label": ""
  },
  {
    "id": "10026",
    "Sentence": "All 21 patients with <\\entity><\\entity> had uniparental disomy; in total 32 regions of uniparental disomy were identified in the 21 patients, including six regions of uniparental disomy > 10 Mb.",
    "Label": ""
  },
  {
    "id": "10027",
    "Sentence": "All 21 patients with <\\entity><\\entity> had uniparental disomy; in total 32 regions of uniparental disomy were identified in the 21 patients, including six regions of uniparental disomy > 10 Mb.",
    "Label": ""
  },
  {
    "id": "10029",
    "Sentence": "One small region of uniparental disomy at <\\entity><\\entity> was observed in four patients with the 5q- syndrome.",
    "Label": ""
  },
  {
    "id": "10030",
    "Sentence": "One small region of uniparental disomy at 10p12.31-p12.2 was observed in four patients with the <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10032",
    "Sentence": "CONCLUSIONS: This study shows that regions of uniparental disomy greater than 2 Mb are found in the 5q-syndrome and <\\entity><\\entity>, although large regions of uniparental disomy (>10 Mb) are only found in the latter group.",
    "Label": ""
  },
  {
    "id": "10033",
    "Sentence": "CONCLUSIONS: This study shows that regions of uniparental disomy greater than 2 Mb are found in the <\\entity><\\entity> and del(5q) myelodysplastic syndrome, although large regions of uniparental disomy (>10 Mb) are only found in the latter group.",
    "Label": ""
  },
  {
    "id": "10035",
    "Sentence": "CONCLUSIONS: This study shows that regions of uniparental disomy greater than 2 Mb are found in the 5q-syndrome and <\\entity><\\entity>, although large regions of uniparental disomy (>10 Mb) are only found in the latter group.",
    "Label": ""
  },
  {
    "id": "10036",
    "Sentence": "CONCLUSIONS: This study shows that regions of uniparental disomy greater than 2 Mb are found in the 5q-syndrome and <\\entity><\\entity>, although large regions of uniparental disomy (>10 Mb) are only found in the latter group.",
    "Label": ""
  },
  {
    "id": "10038",
    "Sentence": "<\\entity><\\entity> changes in addition to the del(5q) were observed in 10 of 21 patients with del(5q) myelodysplastic syndrome but in none of the patients with the 5q- syndrome.",
    "Label": ""
  },
  {
    "id": "10039",
    "Sentence": "Copy number changes in addition to the del(5q) were observed in 10 of 21 patients with del(5q) myelodysplastic syndrome but in none of the patients with the <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10041",
    "Sentence": "<\\entity><\\entity> changes in addition to the del(5q) were observed in 10 of 21 patients with del(5q) myelodysplastic syndrome but in none of the patients with the 5q- syndrome.",
    "Label": ""
  },
  {
    "id": "10042",
    "Sentence": "Copy number changes in addition to the del(5q) were observed in 10 of 21 patients with <\\entity><\\entity> but in none of the patients with the 5q- syndrome.",
    "Label": ""
  },
  {
    "id": "10044",
    "Sentence": "Copy number changes in addition to the <\\entity><\\entity> were observed in 10 of 21 patients with <\\entity><\\entity> myelodysplastic syndrome but in none of the patients with the 5q- syndrome.",
    "Label": ""
  },
  {
    "id": "10045",
    "Sentence": "Copy number changes in addition to the del(5q) were observed in 10 of 21 patients with del(5q) myelodysplastic syndrome but in none of the patients with the <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10047",
    "Sentence": "Copy number changes in addition to the <\\entity><\\entity> were observed in 10 of 21 patients with <\\entity><\\entity> myelodysplastic syndrome but in none of the patients with the 5q- syndrome.",
    "Label": ""
  },
  {
    "id": "10048",
    "Sentence": "Copy number changes in addition to the del(5q) were observed in 10 of 21 patients with <\\entity><\\entity> but in none of the patients with the 5q- syndrome.",
    "Label": ""
  },
  {
    "id": "10050",
    "Sentence": "In the 5q- syndrome group 31 regions of <\\entity><\\entity> were identified in 19 of 21 patients, the largest one being 7.6 Mb.",
    "Label": ""
  },
  {
    "id": "10051",
    "Sentence": "In the <\\entity><\\entity> group 31 regions of uniparental disomy were identified in 19 of 21 patients, the largest one being 7.6 Mb.",
    "Label": ""
  },
  {
    "id": "10053",
    "Sentence": "All 21 patients with del(5q) myelodysplastic syndrome had <\\entity><\\entity>; in total 32 regions of <\\entity><\\entity> were identified in the 21 patients, including six regions of <\\entity><\\entity> > 10 Mb.",
    "Label": ""
  },
  {
    "id": "10054",
    "Sentence": "All 21 patients with <\\entity><\\entity> had uniparental disomy; in total 32 regions of uniparental disomy were identified in the 21 patients, including six regions of uniparental disomy > 10 Mb.",
    "Label": ""
  },
  {
    "id": "10056",
    "Sentence": "One small region of <\\entity><\\entity> at 10p12.31-p12.2 was observed in four patients with the 5q- syndrome.",
    "Label": ""
  },
  {
    "id": "10057",
    "Sentence": "One small region of uniparental disomy at 10p12.31-p12.2 was observed in four patients with the <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10059",
    "Sentence": "CONCLUSIONS: This study shows that regions of <\\entity><\\entity> greater than 2 Mb are found in the 5q-syndrome and del(5q) myelodysplastic syndrome, although large regions of <\\entity><\\entity> (>10 Mb) are only found in the latter group.",
    "Label": ""
  },
  {
    "id": "10060",
    "Sentence": "CONCLUSIONS: This study shows that regions of uniparental disomy greater than 2 Mb are found in the <\\entity><\\entity> and del(5q) myelodysplastic syndrome, although large regions of uniparental disomy (>10 Mb) are only found in the latter group.",
    "Label": ""
  },
  {
    "id": "10062",
    "Sentence": "CONCLUSIONS: This study shows that regions of <\\entity><\\entity> greater than 2 Mb are found in the 5q-syndrome and del(5q) myelodysplastic syndrome, although large regions of <\\entity><\\entity> (>10 Mb) are only found in the latter group.",
    "Label": ""
  },
  {
    "id": "10063",
    "Sentence": "CONCLUSIONS: This study shows that regions of uniparental disomy greater than 2 Mb are found in the 5q-syndrome and <\\entity><\\entity>, although large regions of uniparental disomy (>10 Mb) are only found in the latter group.",
    "Label": ""
  },
  {
    "id": "10065",
    "Sentence": "The recurrent regions of <\\entity><\\entity> may indicate the position of novel leukemia-associated genes.",
    "Label": ""
  },
  {
    "id": "10066",
    "Sentence": "The recurrent regions of uniparental disomy may indicate the position of novel <\\entity><\\entity>-associated genes.",
    "Label": ""
  },
  {
    "id": "10072",
    "Sentence": "Incidence of <\\entity><\\entity> and other malignancies among rheumatoid arthritis patients treated with methotrexate.OBJECTIVE: To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with methotrexate in community practice.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10073",
    "Sentence": "Incidence of melanoma and other <\\entity><\\entity> among rheumatoid arthritis patients treated with methotrexate.OBJECTIVE: To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with methotrexate in community practice.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10074",
    "Sentence": "Incidence of melanoma and other malignancies among <\\entity><\\entity> patients treated with methotrexate.OBJECTIVE: To determine cancer risk in a cohort of 459 <\\entity><\\entity> (RA) patients treated with methotrexate in community practice.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10075",
    "Sentence": "Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with <\\entity><\\entity>.OBJECTIVE: To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with <\\entity><\\entity> in community practice.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10076",
    "Sentence": "Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate.OBJECTIVE: To determine <\\entity><\\entity> risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with methotrexate in community practice.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10077",
    "Sentence": "Incidence of melanoma and other malignancies among <\\entity><\\entity> patients treated with methotrexate.OBJECTIVE: To determine cancer risk in a cohort of 459 <\\entity><\\entity> (RA) patients treated with methotrexate in community practice.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10078",
    "Sentence": "Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate.OBJECTIVE: To determine cancer risk in a cohort of 459 rheumatoid arthritis (<\\entity><\\entity>) patients treated with methotrexate in community practice.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10079",
    "Sentence": "Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with <\\entity><\\entity>.OBJECTIVE: To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with <\\entity><\\entity> in community practice.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10080",
    "Sentence": "METHODS: All <\\entity><\\entity> patients who started methotrexate prior to June 1986 and were attending 1 of 6 rheumatologists were studied.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10081",
    "Sentence": "METHODS: All RA patients who started <\\entity><\\entity> prior to June 1986 and were attending 1 of 6 rheumatologists were studied.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10082",
    "Sentence": "Demographic data were matched to the State <\\entity><\\entity> Registry to identify all malignancies (except nonmelanoma skin cancer) for 1983-1998, and to the National Death Index to identify all deaths to the end of 1999.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10083",
    "Sentence": "Demographic data were matched to the State Cancer Registry to identify all <\\entity><\\entity> (except nonmelanoma skin cancer) for 1983-1998, and to the National Death Index to identify all deaths to the end of 1999.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10084",
    "Sentence": "Demographic data were matched to the State Cancer Registry to identify all malignancies (except <\\entity><\\entity>) for 1983-1998, and to the National Death Index to identify all deaths to the end of 1999.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10085",
    "Sentence": "Demographic data were matched to the State Cancer Registry to identify all malignancies (except nonmelanoma skin cancer) for 1983-1998, and to the National Death Index to identify all <\\entity><\\entity> to the end of 1999.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10086",
    "Sentence": "Followup started on the date when <\\entity><\\entity> was started and ended either on the last confirmed date on which the patient was seen by the rheumatologist or at death.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10087",
    "Sentence": "Standardized incidence ratios (SIRs) were calculated using state population <\\entity><\\entity> rates stratified by sex, age (in 5-year groups), and calendar year.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10088",
    "Sentence": "Eighty-seven <\\entity><\\entity> were identified (14 before, 64 during, and 9 after the followup period).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10089",
    "Sentence": "There was an estimated 50% excess risk of <\\entity><\\entity> among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10090",
    "Sentence": "There was an estimated 50% excess risk of malignancy among <\\entity><\\entity>-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10091",
    "Sentence": "There was an estimated 50% excess risk of malignancy among methotrexate-exposed <\\entity><\\entity> patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10092",
    "Sentence": "There was an estimated 50% excess risk of malignancy among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in <\\entity><\\entity> (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10093",
    "Sentence": "There was an estimated 50% excess risk of malignancy among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in <\\entity><\\entity> (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10094",
    "Sentence": "There was an estimated 50% excess risk of malignancy among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in <\\entity><\\entity> (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10095",
    "Sentence": "CONCLUSION: Compared with the general population, <\\entity><\\entity>-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and lung cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10096",
    "Sentence": "CONCLUSION: Compared with the general population, methotrexate-treated <\\entity><\\entity> patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and lung cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10097",
    "Sentence": "CONCLUSION: Compared with the general population, methotrexate-treated RA patients have an increased incidence of <\\entity><\\entity>, non-Hodgkin's lymphoma, and lung cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10098",
    "Sentence": "CONCLUSION: Compared with the general population, methotrexate-treated RA patients have an increased incidence of melanoma, <\\entity><\\entity>, and lung cancer.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10099",
    "Sentence": "CONCLUSION: Compared with the general population, methotrexate-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10100",
    "Sentence": "There may be a role for regular <\\entity><\\entity> screening for all RA patients, particularly those receiving immunosuppressive therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10101",
    "Sentence": "There may be a role for regular skin cancer screening for all <\\entity><\\entity> patients, particularly those receiving immunosuppressive therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10102",
    "Sentence": "There may be a role for regular skin cancer screening for all RA patients, particularly those receiving <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10103",
    "Sentence": "Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with <\\entity><\\entity>.OBJECTIVE: To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with <\\entity><\\entity> in community practice.",
    "Label": ""
  },
  {
    "id": "10104",
    "Sentence": "Incidence of <\\entity><\\entity> and other malignancies among rheumatoid arthritis patients treated with methotrexate.OBJECTIVE: To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with methotrexate in community practice.",
    "Label": ""
  },
  {
    "id": "10106",
    "Sentence": "Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with <\\entity><\\entity>.OBJECTIVE: To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with <\\entity><\\entity> in community practice.",
    "Label": ""
  },
  {
    "id": "10107",
    "Sentence": "Incidence of melanoma and other <\\entity><\\entity> among rheumatoid arthritis patients treated with methotrexate.OBJECTIVE: To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with methotrexate in community practice.",
    "Label": ""
  },
  {
    "id": "10109",
    "Sentence": "Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with <\\entity><\\entity>.OBJECTIVE: To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with <\\entity><\\entity> in community practice.",
    "Label": ""
  },
  {
    "id": "10110",
    "Sentence": "Incidence of melanoma and other malignancies among <\\entity><\\entity> patients treated with methotrexate.OBJECTIVE: To determine cancer risk in a cohort of 459 <\\entity><\\entity> (RA) patients treated with methotrexate in community practice.",
    "Label": ""
  },
  {
    "id": "10112",
    "Sentence": "Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with <\\entity><\\entity>.OBJECTIVE: To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with <\\entity><\\entity> in community practice.",
    "Label": ""
  },
  {
    "id": "10113",
    "Sentence": "Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate.OBJECTIVE: To determine <\\entity><\\entity> risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with methotrexate in community practice.",
    "Label": ""
  },
  {
    "id": "10115",
    "Sentence": "Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with <\\entity><\\entity>.OBJECTIVE: To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with <\\entity><\\entity> in community practice.",
    "Label": ""
  },
  {
    "id": "10116",
    "Sentence": "Incidence of melanoma and other malignancies among <\\entity><\\entity> patients treated with methotrexate.OBJECTIVE: To determine cancer risk in a cohort of 459 <\\entity><\\entity> (RA) patients treated with methotrexate in community practice.",
    "Label": ""
  },
  {
    "id": "10118",
    "Sentence": "Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with <\\entity><\\entity>.OBJECTIVE: To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with <\\entity><\\entity> in community practice.",
    "Label": ""
  },
  {
    "id": "10119",
    "Sentence": "Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate.OBJECTIVE: To determine cancer risk in a cohort of 459 rheumatoid arthritis (<\\entity><\\entity>) patients treated with methotrexate in community practice.",
    "Label": ""
  },
  {
    "id": "10121",
    "Sentence": "METHODS: All RA patients who started <\\entity><\\entity> prior to June 1986 and were attending 1 of 6 rheumatologists were studied.",
    "Label": ""
  },
  {
    "id": "10122",
    "Sentence": "METHODS: All <\\entity><\\entity> patients who started methotrexate prior to June 1986 and were attending 1 of 6 rheumatologists were studied.",
    "Label": ""
  },
  {
    "id": "10124",
    "Sentence": "There was an estimated 50% excess risk of malignancy among <\\entity><\\entity>-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": ""
  },
  {
    "id": "10125",
    "Sentence": "There was an estimated 50% excess risk of malignancy among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in <\\entity><\\entity> (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": ""
  },
  {
    "id": "10127",
    "Sentence": "There was an estimated 50% excess risk of malignancy among <\\entity><\\entity>-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": ""
  },
  {
    "id": "10128",
    "Sentence": "There was an estimated 50% excess risk of <\\entity><\\entity> among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": ""
  },
  {
    "id": "10130",
    "Sentence": "There was an estimated 50% excess risk of malignancy among <\\entity><\\entity>-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": ""
  },
  {
    "id": "10131",
    "Sentence": "There was an estimated 50% excess risk of malignancy among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in <\\entity><\\entity> (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": ""
  },
  {
    "id": "10133",
    "Sentence": "There was an estimated 50% excess risk of malignancy among <\\entity><\\entity>-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": ""
  },
  {
    "id": "10134",
    "Sentence": "There was an estimated 50% excess risk of malignancy among methotrexate-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in <\\entity><\\entity> (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": ""
  },
  {
    "id": "10136",
    "Sentence": "There was an estimated 50% excess risk of malignancy among <\\entity><\\entity>-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": ""
  },
  {
    "id": "10137",
    "Sentence": "There was an estimated 50% excess risk of malignancy among methotrexate-exposed <\\entity><\\entity> patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).",
    "Label": ""
  },
  {
    "id": "10139",
    "Sentence": "CONCLUSION: Compared with the general population, <\\entity><\\entity>-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and lung cancer.",
    "Label": ""
  },
  {
    "id": "10140",
    "Sentence": "CONCLUSION: Compared with the general population, methotrexate-treated RA patients have an increased incidence of <\\entity><\\entity>, non-Hodgkin's lymphoma, and lung cancer.",
    "Label": ""
  },
  {
    "id": "10142",
    "Sentence": "CONCLUSION: Compared with the general population, <\\entity><\\entity>-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and lung cancer.",
    "Label": ""
  },
  {
    "id": "10143",
    "Sentence": "CONCLUSION: Compared with the general population, methotrexate-treated RA patients have an increased incidence of melanoma, <\\entity><\\entity>, and lung cancer.",
    "Label": ""
  },
  {
    "id": "10145",
    "Sentence": "CONCLUSION: Compared with the general population, <\\entity><\\entity>-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and lung cancer.",
    "Label": ""
  },
  {
    "id": "10146",
    "Sentence": "CONCLUSION: Compared with the general population, methotrexate-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10148",
    "Sentence": "CONCLUSION: Compared with the general population, <\\entity><\\entity>-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and lung cancer.",
    "Label": ""
  },
  {
    "id": "10149",
    "Sentence": "CONCLUSION: Compared with the general population, methotrexate-treated <\\entity><\\entity> patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and lung cancer.",
    "Label": ""
  },
  {
    "id": "10151",
    "Sentence": "There may be a role for regular skin cancer screening for all RA patients, particularly those receiving <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10152",
    "Sentence": "There may be a role for regular <\\entity><\\entity> screening for all RA patients, particularly those receiving immunosuppressive therapy.",
    "Label": ""
  },
  {
    "id": "10154",
    "Sentence": "There may be a role for regular skin cancer screening for all RA patients, particularly those receiving <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10155",
    "Sentence": "There may be a role for regular skin cancer screening for all <\\entity><\\entity> patients, particularly those receiving immunosuppressive therapy.",
    "Label": ""
  },
  {
    "id": "10161",
    "Sentence": "Detection and surveillance of waterborne protozoan parasites.The majority of the world's population <\\entity><\\entity> live without access to healthy water and the contamination of drinking water with protozoan pathogens poses a serious threat to millions of people in the developing world.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10162",
    "Sentence": "Detection and surveillance of waterborne protozoan parasites.The majority of the world's population still live without access to healthy water and the contamination of <\\entity><\\entity> water with protozoan pathogens poses a serious threat to millions of people in the developing world.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10163",
    "Sentence": "Even in the developed world periodic outbreaks of <\\entity><\\entity> are caused by the protozoan parasites Cryptosporidium sp., Giardia duodenalis and Entamoeba histolytica.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10164",
    "Sentence": "Even in the developed world periodic outbreaks of diarrhoeal diseases are caused by the protozoan parasites <\\entity><\\entity>., Giardia duodenalis and Entamoeba histolytica.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10165",
    "Sentence": "Even in the developed world periodic outbreaks of diarrhoeal diseases are caused by the protozoan parasites Cryptosporidium sp., <\\entity><\\entity> and Entamoeba histolytica.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10166",
    "Sentence": "Even in the developed world periodic outbreaks of diarrhoeal diseases are caused by the protozoan parasites Cryptosporidium sp., Giardia duodenalis and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10167",
    "Sentence": "Thus, surveillance of <\\entity><\\entity> water is imperative to minimize such contaminations and ensure continuous supplies of healthy water world-wide.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10168",
    "Sentence": "Even in the developed world periodic outbreaks of diarrhoeal diseases are caused by the protozoan parasites <\\entity><\\entity>., Giardia duodenalis and Entamoeba histolytica.",
    "Label": ""
  },
  {
    "id": "10169",
    "Sentence": "Even in the developed world periodic outbreaks of <\\entity><\\entity> are caused by the protozoan parasites Cryptosporidium sp., Giardia duodenalis and Entamoeba histolytica.",
    "Label": ""
  },
  {
    "id": "10171",
    "Sentence": "Even in the developed world periodic outbreaks of diarrhoeal diseases are caused by the protozoan parasites Cryptosporidium sp., <\\entity><\\entity> and Entamoeba histolytica.",
    "Label": ""
  },
  {
    "id": "10172",
    "Sentence": "Even in the developed world periodic outbreaks of <\\entity><\\entity> are caused by the protozoan parasites Cryptosporidium sp., Giardia duodenalis and Entamoeba histolytica.",
    "Label": ""
  },
  {
    "id": "10174",
    "Sentence": "Even in the developed world periodic outbreaks of diarrhoeal diseases are caused by the protozoan parasites Cryptosporidium sp., Giardia duodenalis and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10175",
    "Sentence": "Even in the developed world periodic outbreaks of <\\entity><\\entity> are caused by the protozoan parasites Cryptosporidium sp., Giardia duodenalis and Entamoeba histolytica.",
    "Label": ""
  },
  {
    "id": "10181",
    "Sentence": "Targeting of <\\entity><\\entity> signaling: a potential strategy to improve therapy for mantle cell lymphoma.Mantle cell lymphoma (MCL) has one of the worst clinical outcomes among the B-cell lymphomas, with a median survival of only 3 to 4 years.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10182",
    "Sentence": "Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma.Mantle cell lymphoma (<\\entity><\\entity>) has one of the worst clinical outcomes among the B-cell lymphomas, with a median survival of only 3 to 4 years.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10183",
    "Sentence": "Therefore, a better understanding of the underlying mechanisms that regulate <\\entity><\\entity> proliferation/survival is needed to develop an effective therapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10184",
    "Sentence": "Because <\\entity><\\entity> (Shh)-GLI signaling has been shown to be important in the proliferation and survival of several cancers, and no such information is available for MCL, this study was undertaken.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10185",
    "Sentence": "Because sonic hedgehog (<\\entity><\\entity> signaling has been shown to be important in the proliferation and survival of several cancers, and no such information is available for MCL, this study was undertaken.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10186",
    "Sentence": "Because sonic hedgehog (Shh)-GLI signaling has been shown to be important in the proliferation and survival of several cancers, and no such information is available for <\\entity><\\entity>, this study was undertaken.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10187",
    "Sentence": "Our results show that the molecules associated with <\\entity><\\entity> signaling, such as PTCH and SMO receptors, and GLI1 and GLI2 target transcription factors were expressed in the human MCL cell lines and primary MCL cells from patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10188",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as <\\entity><\\entity> and SMO receptors, and GLI1 and GLI2 target transcription factors were expressed in the human MCL cell lines and primary MCL cells from patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10189",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and <\\entity><\\entity> receptors, and GLI1 and GLI2 target transcription factors were expressed in the human MCL cell lines and primary MCL cells from patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10190",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and SMO receptors, and <\\entity><\\entity> and GLI2 target transcription factors were expressed in the human MCL cell lines and primary MCL cells from patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10191",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and SMO receptors, and GLI1 and <\\entity><\\entity> target transcription factors were expressed in the human MCL cell lines and primary MCL cells from patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10192",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and SMO receptors, and GLI1 and GLI2 target transcription factors were expressed in the human <\\entity><\\entity> cell lines and primary <\\entity><\\entity> cells from patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10193",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and SMO receptors, and GLI1 and GLI2 target transcription factors were expressed in the human <\\entity><\\entity> cell lines and primary <\\entity><\\entity> cells from patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10194",
    "Sentence": "Perturbation of this signaling in the presence of exogenous <\\entity><\\entity> significantly (P < 0.001) influenced the proliferation of JVM2 MCL cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10195",
    "Sentence": "Perturbation of this signaling in the presence of exogenous <\\entity><\\entity> significantly (P < 0.001) influenced the proliferation of JVM2 MCL cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10196",
    "Sentence": "Perturbation of this signaling in the presence of exogenous Shh/cyclopamine significantly (P < 0.001) influenced the proliferation of JVM2 <\\entity><\\entity> cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10197",
    "Sentence": "Furthermore, down-regulation of <\\entity><\\entity> transcription factors using antisense oligonucleotides not only resulted in significantly (P < 0.001) decreased proliferation of the MCL cells but also significantly (P < 0.05) increased their susceptibility to chemotherapeutic drug, doxorubicin.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10198",
    "Sentence": "Furthermore, down-regulation of GLI transcription factors using <\\entity><\\entity> not only resulted in significantly (P < 0.001) decreased proliferation of the MCL cells but also significantly (P < 0.05) increased their susceptibility to chemotherapeutic drug, doxorubicin.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10199",
    "Sentence": "Furthermore, down-regulation of GLI transcription factors using antisense oligonucleotides not only resulted in significantly (P < 0.001) decreased proliferation of the <\\entity><\\entity> cells but also significantly (P < 0.05) increased their susceptibility to chemotherapeutic drug, doxorubicin.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10200",
    "Sentence": "Furthermore, down-regulation of GLI transcription factors using antisense oligonucleotides not only resulted in significantly (P < 0.001) decreased proliferation of the MCL cells but also significantly (P < 0.05) increased their susceptibility to chemotherapeutic drug, <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10201",
    "Sentence": "Also, down-regulation of <\\entity><\\entity> decreased cyclin D1 and BCL2 transcript levels, which suggests that these key molecules might be regulated by <\\entity><\\entity> in MCL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10202",
    "Sentence": "Also, down-regulation of GLI decreased <\\entity><\\entity> and BCL2 transcript levels, which suggests that these key molecules might be regulated by GLI in MCL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10203",
    "Sentence": "Also, down-regulation of GLI decreased cyclin D1 and <\\entity><\\entity> transcript levels, which suggests that these key molecules might be regulated by GLI in MCL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10204",
    "Sentence": "Also, down-regulation of <\\entity><\\entity> decreased cyclin D1 and BCL2 transcript levels, which suggests that these key molecules might be regulated by <\\entity><\\entity> in MCL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10205",
    "Sentence": "Also, down-regulation of GLI decreased cyclin D1 and BCL2 transcript levels, which suggests that these key molecules might be regulated by GLI in <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10206",
    "Sentence": "Thus, our results indicate a significant role for <\\entity><\\entity> signaling in the proliferation of MCL, and molecular targeting of GLI is a potential therapeutic approach to improve the treatment for MCL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10207",
    "Sentence": "Thus, our results indicate a significant role for Shh-GLI signaling in the proliferation of <\\entity><\\entity>, and molecular targeting of GLI is a potential therapeutic approach to improve the treatment for <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10208",
    "Sentence": "Thus, our results indicate a significant role for Shh-<\\entity><\\entity> signaling in the proliferation of MCL, and molecular targeting of <\\entity><\\entity> is a potential therapeutic approach to improve the treatment for MCL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10209",
    "Sentence": "Thus, our results indicate a significant role for Shh-GLI signaling in the proliferation of <\\entity><\\entity>, and molecular targeting of GLI is a potential therapeutic approach to improve the treatment for <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10210",
    "Sentence": "Furthermore, down-regulation of GLI transcription factors using antisense oligonucleotides not only resulted in significantly (P < 0.001) decreased proliferation of the MCL cells but also significantly (P < 0.05) increased their susceptibility to chemotherapeutic drug, <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10211",
    "Sentence": "Furthermore, down-regulation of <\\entity><\\entity> transcription factors using antisense oligonucleotides not only resulted in significantly (P < 0.001) decreased proliferation of the MCL cells but also significantly (P < 0.05) increased their susceptibility to chemotherapeutic drug, doxorubicin.",
    "Label": ""
  },
  {
    "id": "10213",
    "Sentence": "Furthermore, down-regulation of GLI transcription factors using antisense oligonucleotides not only resulted in significantly (P < 0.001) decreased proliferation of the MCL cells but also significantly (P < 0.05) increased their susceptibility to chemotherapeutic drug, <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10214",
    "Sentence": "Furthermore, down-regulation of GLI transcription factors using antisense oligonucleotides not only resulted in significantly (P < 0.001) decreased proliferation of the <\\entity><\\entity> cells but also significantly (P < 0.05) increased their susceptibility to chemotherapeutic drug, doxorubicin.",
    "Label": ""
  },
  {
    "id": "10216",
    "Sentence": "Targeting of <\\entity><\\entity> signaling: a potential strategy to improve therapy for mantle cell lymphoma.Mantle cell lymphoma (MCL) has one of the worst clinical outcomes among the B-cell lymphomas, with a median survival of only 3 to 4 years.",
    "Label": ""
  },
  {
    "id": "10217",
    "Sentence": "Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for <\\entity><\\entity>.Mantle cell lymphoma (MCL) has one of the worst clinical outcomes among the B-cell lymphomas, with a median survival of only 3 to 4 years.",
    "Label": ""
  },
  {
    "id": "10219",
    "Sentence": "Because sonic hedgehog (<\\entity><\\entity> signaling has been shown to be important in the proliferation and survival of several cancers, and no such information is available for MCL, this study was undertaken.",
    "Label": ""
  },
  {
    "id": "10220",
    "Sentence": "Because sonic hedgehog (Shh)-GLI signaling has been shown to be important in the proliferation and survival of several <\\entity><\\entity>, and no such information is available for MCL, this study was undertaken.",
    "Label": ""
  },
  {
    "id": "10222",
    "Sentence": "Because sonic hedgehog (<\\entity><\\entity> signaling has been shown to be important in the proliferation and survival of several cancers, and no such information is available for MCL, this study was undertaken.",
    "Label": ""
  },
  {
    "id": "10223",
    "Sentence": "Because sonic hedgehog (Shh)-GLI signaling has been shown to be important in the proliferation and survival of several cancers, and no such information is available for <\\entity><\\entity>, this study was undertaken.",
    "Label": ""
  },
  {
    "id": "10225",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and SMO receptors, and <\\entity><\\entity> and GLI2 target transcription factors were expressed in the human MCL cell lines and primary MCL cells from patients.",
    "Label": ""
  },
  {
    "id": "10226",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and SMO receptors, and GLI1 and GLI2 target transcription factors were expressed in the human <\\entity><\\entity> cell lines and primary <\\entity><\\entity> cells from patients.",
    "Label": ""
  },
  {
    "id": "10228",
    "Sentence": "Our results show that the molecules associated with <\\entity><\\entity> signaling, such as PTCH and SMO receptors, and GLI1 and GLI2 target transcription factors were expressed in the human MCL cell lines and primary MCL cells from patients.",
    "Label": ""
  },
  {
    "id": "10229",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and SMO receptors, and GLI1 and GLI2 target transcription factors were expressed in the human <\\entity><\\entity> cell lines and primary <\\entity><\\entity> cells from patients.",
    "Label": ""
  },
  {
    "id": "10231",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as <\\entity><\\entity> and SMO receptors, and GLI1 and GLI2 target transcription factors were expressed in the human MCL cell lines and primary MCL cells from patients.",
    "Label": ""
  },
  {
    "id": "10232",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and SMO receptors, and GLI1 and GLI2 target transcription factors were expressed in the human <\\entity><\\entity> cell lines and primary <\\entity><\\entity> cells from patients.",
    "Label": ""
  },
  {
    "id": "10234",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and <\\entity><\\entity> receptors, and GLI1 and GLI2 target transcription factors were expressed in the human MCL cell lines and primary MCL cells from patients.",
    "Label": ""
  },
  {
    "id": "10235",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and SMO receptors, and GLI1 and GLI2 target transcription factors were expressed in the human <\\entity><\\entity> cell lines and primary <\\entity><\\entity> cells from patients.",
    "Label": ""
  },
  {
    "id": "10237",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and SMO receptors, and GLI1 and <\\entity><\\entity> target transcription factors were expressed in the human MCL cell lines and primary MCL cells from patients.",
    "Label": ""
  },
  {
    "id": "10238",
    "Sentence": "Our results show that the molecules associated with Shh-GLI signaling, such as PTCH and SMO receptors, and GLI1 and GLI2 target transcription factors were expressed in the human <\\entity><\\entity> cell lines and primary <\\entity><\\entity> cells from patients.",
    "Label": ""
  },
  {
    "id": "10240",
    "Sentence": "Perturbation of this signaling in the presence of exogenous <\\entity><\\entity> significantly (P < 0.001) influenced the proliferation of JVM2 MCL cells.",
    "Label": ""
  },
  {
    "id": "10241",
    "Sentence": "Perturbation of this signaling in the presence of exogenous Shh/cyclopamine significantly (P < 0.001) influenced the proliferation of JVM2 <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "10243",
    "Sentence": "Furthermore, down-regulation of <\\entity><\\entity> transcription factors using antisense oligonucleotides not only resulted in significantly (P < 0.001) decreased proliferation of the MCL cells but also significantly (P < 0.05) increased their susceptibility to chemotherapeutic drug, doxorubicin.",
    "Label": ""
  },
  {
    "id": "10244",
    "Sentence": "Furthermore, down-regulation of GLI transcription factors using antisense oligonucleotides not only resulted in significantly (P < 0.001) decreased proliferation of the <\\entity><\\entity> cells but also significantly (P < 0.05) increased their susceptibility to chemotherapeutic drug, doxorubicin.",
    "Label": ""
  },
  {
    "id": "10246",
    "Sentence": "Also, down-regulation of <\\entity><\\entity> decreased cyclin D1 and BCL2 transcript levels, which suggests that these key molecules might be regulated by <\\entity><\\entity> in MCL.",
    "Label": ""
  },
  {
    "id": "10247",
    "Sentence": "Also, down-regulation of GLI decreased cyclin D1 and BCL2 transcript levels, which suggests that these key molecules might be regulated by GLI in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10249",
    "Sentence": "Also, down-regulation of GLI decreased <\\entity><\\entity> and BCL2 transcript levels, which suggests that these key molecules might be regulated by GLI in MCL.",
    "Label": ""
  },
  {
    "id": "10250",
    "Sentence": "Also, down-regulation of GLI decreased cyclin D1 and BCL2 transcript levels, which suggests that these key molecules might be regulated by GLI in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10252",
    "Sentence": "Also, down-regulation of GLI decreased cyclin D1 and <\\entity><\\entity> transcript levels, which suggests that these key molecules might be regulated by GLI in MCL.",
    "Label": ""
  },
  {
    "id": "10253",
    "Sentence": "Also, down-regulation of GLI decreased cyclin D1 and BCL2 transcript levels, which suggests that these key molecules might be regulated by GLI in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10255",
    "Sentence": "Thus, our results indicate a significant role for Shh-<\\entity><\\entity> signaling in the proliferation of MCL, and molecular targeting of <\\entity><\\entity> is a potential therapeutic approach to improve the treatment for MCL.",
    "Label": ""
  },
  {
    "id": "10256",
    "Sentence": "Thus, our results indicate a significant role for Shh-GLI signaling in the proliferation of <\\entity><\\entity>, and molecular targeting of GLI is a potential therapeutic approach to improve the treatment for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10258",
    "Sentence": "Thus, our results indicate a significant role for <\\entity><\\entity> signaling in the proliferation of MCL, and molecular targeting of GLI is a potential therapeutic approach to improve the treatment for MCL.",
    "Label": ""
  },
  {
    "id": "10259",
    "Sentence": "Thus, our results indicate a significant role for Shh-GLI signaling in the proliferation of <\\entity><\\entity>, and molecular targeting of GLI is a potential therapeutic approach to improve the treatment for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10261",
    "Sentence": "Furthermore, down-regulation of GLI transcription factors using antisense oligonucleotides not only resulted in significantly (P < 0.001) decreased proliferation of the MCL cells but also significantly (P < 0.05) increased their susceptibility to chemotherapeutic drug, <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10262",
    "Sentence": "Furthermore, down-regulation of GLI transcription factors using <\\entity><\\entity> not only resulted in significantly (P < 0.001) decreased proliferation of the MCL cells but also significantly (P < 0.05) increased their susceptibility to chemotherapeutic drug, doxorubicin.",
    "Label": ""
  },
  {
    "id": "10268",
    "Sentence": "Multiple <\\entity><\\entity> of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism.Constitutively activating thyrotropin receptor (TSHR) germline mutations have been identified as a molecular cause of congenital hyperthyroidism.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10269",
    "Sentence": "Multiple relapses of <\\entity><\\entity> after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune <\\entity><\\entity>.Constitutively activating thyrotropin receptor (TSHR) germline mutations have been identified as a molecular cause of congenital <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10270",
    "Sentence": "Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of <\\entity><\\entity>.Constitutively activating thyrotropin receptor (TSHR) germline mutations have been identified as a molecular cause of congenital hyperthyroidism.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10271",
    "Sentence": "Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism.Constitutively activating <\\entity><\\entity> (TSHR) germline mutations have been identified as a molecular cause of congenital hyperthyroidism.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10272",
    "Sentence": "Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism.Constitutively activating <\\entity><\\entity> (TSHR) germline mutations have been identified as a molecular cause of congenital hyperthyroidism.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "10273",
    "Sentence": "Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism.Constitutively activating thyrotropin receptor (<\\entity><\\entity> have been identified as a molecular cause of congenital hyperthyroidism.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "10274",
    "Sentence": "Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism.Constitutively activating thyrotropin receptor (<\\entity><\\entity> have been identified as a molecular cause of congenital hyperthyroidism.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10275",
    "Sentence": "Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism.Constitutively activating thyrotropin receptor (<\\entity><\\entity> have been identified as a molecular cause of congenital hyperthyroidism.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10276",
    "Sentence": "Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism.Constitutively activating thyrotropin receptor (TSHR) germline mutations have been identified as a molecular cause of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10277",
    "Sentence": "Patients with <\\entity><\\entity> hyperthyroidism were previously treated with surgery and radioiodine.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10278",
    "Sentence": "Patients with relapsing <\\entity><\\entity> were previously treated with surgery and radioiodine.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10279",
    "Sentence": "We report on a 22-year-old male patient who was treated for his multiple <\\entity><\\entity> of hyperthyroidism by repeated subtotal thyroidectomies (STE).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10280",
    "Sentence": "We report on a 22-year-old male patient who was treated for his multiple relapses of <\\entity><\\entity> by repeated subtotal thyroidectomies (STE).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10281",
    "Sentence": "We report on a 22-year-old male patient who was treated for his multiple relapses of hyperthyroidism by repeated subtotal thyroidectomies (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10282",
    "Sentence": "During the 22 years of follow-up, the patient developed several <\\entity><\\entity> of hyperthyroidism, four of them after thyroid surgeries.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10283",
    "Sentence": "During the 22 years of follow-up, the patient developed several relapses of <\\entity><\\entity>, four of them after thyroid surgeries.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10284",
    "Sentence": "Sequencing of the <\\entity><\\entity> gene revealed a gain-of-function mutation with an amino acid exchange of aspartate to tyrosine in codon 633 which is located in the sixth transmembrane domain of the TSH receptor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10285",
    "Sentence": "Sequencing of the TSHR gene revealed a gain-of-function <\\entity><\\entity> with an amino acid exchange of aspartate to tyrosine in codon 633 which is located in the sixth transmembrane domain of the TSH receptor.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10286",
    "Sentence": "Sequencing of the TSHR gene revealed a gain-of-function mutation with an amino acid <\\entity><\\entity> which is located in the sixth transmembrane domain of the TSH receptor.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "10287",
    "Sentence": "Sequencing of the <\\entity><\\entity>R gene revealed a gain-of-function mutation with an amino acid exchange of aspartate to tyrosine in codon 633 which is located in the sixth transmembrane domain of the <\\entity><\\entity> receptor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10288",
    "Sentence": "The <\\entity><\\entity> of the mutation in all other family members identifies the patient's TSHR mutation as a sporadic germline mutation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10289",
    "Sentence": "The absence of the <\\entity><\\entity> in all other family members identifies the patient's TSHR <\\entity><\\entity> as a sporadic germline <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10290",
    "Sentence": "The absence of the mutation in all other family members identifies the patient's <\\entity><\\entity> mutation as a sporadic germline mutation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10291",
    "Sentence": "The absence of the mutation in all other family members identifies the patient's <\\entity><\\entity> mutation as a sporadic germline mutation.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "10292",
    "Sentence": "The absence of the <\\entity><\\entity> in all other family members identifies the patient's TSHR <\\entity><\\entity> as a sporadic germline <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10293",
    "Sentence": "The absence of the mutation in all other family members identifies the patient's TSHR mutation as a sporadic <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "10294",
    "Sentence": "The absence of the mutation in all other family members identifies the patient's TSHR mutation as a sporadic <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10295",
    "Sentence": "In this patient, thyroid tissue growth and <\\entity><\\entity> could repeatedly be controlled only for limited periods by near total thyroidectomy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10296",
    "Sentence": "Therefore, this case confirms that early combined treatment with near-total thyroidectomy plus radioiodine therapy seems to be the treatment of choice for patients with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10297",
    "Sentence": "Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism.Constitutively activating thyrotropin receptor (<\\entity><\\entity> have been identified as a molecular cause of congenital hyperthyroidism.",
    "Label": ""
  },
  {
    "id": "10298",
    "Sentence": "Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism.Constitutively activating thyrotropin receptor (TSHR) germline mutations have been identified as a molecular cause of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10300",
    "Sentence": "Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism.Constitutively activating thyrotropin receptor (<\\entity><\\entity> have been identified as a molecular cause of congenital hyperthyroidism.",
    "Label": ""
  },
  {
    "id": "10301",
    "Sentence": "Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism.Constitutively activating thyrotropin receptor (<\\entity><\\entity> have been identified as a molecular cause of congenital hyperthyroidism.",
    "Label": ""
  },
  {
    "id": "10303",
    "Sentence": "We report on a 22-year-old male patient who was treated for his multiple relapses of hyperthyroidism by repeated subtotal thyroidectomies (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "10304",
    "Sentence": "We report on a 22-year-old male patient who was treated for his multiple <\\entity><\\entity> of hyperthyroidism by repeated subtotal thyroidectomies (STE).",
    "Label": ""
  },
  {
    "id": "10306",
    "Sentence": "We report on a 22-year-old male patient who was treated for his multiple relapses of hyperthyroidism by repeated subtotal thyroidectomies (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "10307",
    "Sentence": "We report on a 22-year-old male patient who was treated for his multiple relapses of <\\entity><\\entity> by repeated subtotal thyroidectomies (STE).",
    "Label": ""
  },
  {
    "id": "10309",
    "Sentence": "Sequencing of the <\\entity><\\entity> gene revealed a gain-of-function mutation with an amino acid exchange of aspartate to tyrosine in codon 633 which is located in the sixth transmembrane domain of the TSH receptor.",
    "Label": ""
  },
  {
    "id": "10310",
    "Sentence": "Sequencing of the TSHR gene revealed a gain-of-function <\\entity><\\entity> with an amino acid exchange of aspartate to tyrosine in codon 633 which is located in the sixth transmembrane domain of the TSH receptor.",
    "Label": ""
  },
  {
    "id": "10312",
    "Sentence": "The absence of the mutation in all other family members identifies the patient's <\\entity><\\entity> mutation as a sporadic germline mutation.",
    "Label": ""
  },
  {
    "id": "10313",
    "Sentence": "The absence of the mutation in all other family members identifies the patient's TSHR mutation as a sporadic <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10315",
    "Sentence": "The absence of the mutation in all other family members identifies the patient's <\\entity><\\entity> mutation as a sporadic germline mutation.",
    "Label": ""
  },
  {
    "id": "10316",
    "Sentence": "The absence of the <\\entity><\\entity> in all other family members identifies the patient's TSHR <\\entity><\\entity> as a sporadic germline <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10318",
    "Sentence": "Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism.Constitutively activating <\\entity><\\entity> (TSHR) germline mutations have been identified as a molecular cause of congenital hyperthyroidism.",
    "Label": ""
  },
  {
    "id": "10319",
    "Sentence": "Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism.Constitutively activating thyrotropin receptor (TSHR) germline mutations have been identified as a molecular cause of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10325",
    "Sentence": "<\\entity><\\entity> once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.<\\entity><\\entity> effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and lymphoid malignancies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10326",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with <\\entity><\\entity>-induced anemia.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic <\\entity><\\entity>-induced anemia with a range of solid tumors and lymphoid malignancies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10327",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced <\\entity><\\entity>.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced <\\entity><\\entity> with a range of solid tumors and lymphoid malignancies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10328",
    "Sentence": "<\\entity><\\entity> once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.<\\entity><\\entity> effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and lymphoid malignancies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10329",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with <\\entity><\\entity>-induced anemia.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic <\\entity><\\entity>-induced anemia with a range of solid tumors and lymphoid malignancies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10330",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced <\\entity><\\entity>.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced <\\entity><\\entity> with a range of solid tumors and lymphoid malignancies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10331",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of <\\entity><\\entity> and lymphoid malignancies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10332",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10333",
    "Sentence": "Recent evidence-based guidelines recommend the once weekly administration of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10334",
    "Sentence": "This once-weekly regimen is generally well tolerated, and studies to date have reported that <\\entity><\\entity> has a neutral effect on survival of patients with cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10335",
    "Sentence": "This once-weekly regimen is generally well tolerated, and studies to date have reported that epoetin beta has a neutral effect on survival of patients with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10336",
    "Sentence": "<\\entity><\\entity> once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.<\\entity><\\entity> effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and lymphoid malignancies.",
    "Label": ""
  },
  {
    "id": "10337",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced <\\entity><\\entity>.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced <\\entity><\\entity> with a range of solid tumors and lymphoid malignancies.",
    "Label": ""
  },
  {
    "id": "10339",
    "Sentence": "<\\entity><\\entity> once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.<\\entity><\\entity> effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and lymphoid malignancies.",
    "Label": ""
  },
  {
    "id": "10340",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced <\\entity><\\entity>.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced <\\entity><\\entity> with a range of solid tumors and lymphoid malignancies.",
    "Label": ""
  },
  {
    "id": "10342",
    "Sentence": "This once-weekly regimen is generally well tolerated, and studies to date have reported that <\\entity><\\entity> has a neutral effect on survival of patients with cancer.",
    "Label": ""
  },
  {
    "id": "10343",
    "Sentence": "This once-weekly regimen is generally well tolerated, and studies to date have reported that epoetin beta has a neutral effect on survival of patients with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10345",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with <\\entity><\\entity>-induced anemia.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic <\\entity><\\entity>-induced anemia with a range of solid tumors and lymphoid malignancies.",
    "Label": ""
  },
  {
    "id": "10346",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced <\\entity><\\entity>.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced <\\entity><\\entity> with a range of solid tumors and lymphoid malignancies.",
    "Label": ""
  },
  {
    "id": "10348",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with <\\entity><\\entity>-induced anemia.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic <\\entity><\\entity>-induced anemia with a range of solid tumors and lymphoid malignancies.",
    "Label": ""
  },
  {
    "id": "10349",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced <\\entity><\\entity>.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced <\\entity><\\entity> with a range of solid tumors and lymphoid malignancies.",
    "Label": ""
  },
  {
    "id": "10351",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with <\\entity><\\entity>-induced anemia.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic <\\entity><\\entity>-induced anemia with a range of solid tumors and lymphoid malignancies.",
    "Label": ""
  },
  {
    "id": "10352",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of <\\entity><\\entity> and lymphoid malignancies.",
    "Label": ""
  },
  {
    "id": "10354",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with <\\entity><\\entity>-induced anemia.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic <\\entity><\\entity>-induced anemia with a range of solid tumors and lymphoid malignancies.",
    "Label": ""
  },
  {
    "id": "10355",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10357",
    "Sentence": "<\\entity><\\entity> once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.<\\entity><\\entity> effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and lymphoid malignancies.",
    "Label": ""
  },
  {
    "id": "10358",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of <\\entity><\\entity> and lymphoid malignancies.",
    "Label": ""
  },
  {
    "id": "10360",
    "Sentence": "<\\entity><\\entity> once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.<\\entity><\\entity> effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and lymphoid malignancies.",
    "Label": ""
  },
  {
    "id": "10361",
    "Sentence": "Epoetin beta once weekly: review of its efficacy and safety in patients with chemotherapy-induced anemia.Epoetin beta effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced anemia with a range of solid tumors and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10367",
    "Sentence": "Update on novel therapeutic agents for cervical cancer.Effective <\\entity><\\entity> treatment options for advanced cervical cancer are exceedingly limited.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10368",
    "Sentence": "<\\entity><\\entity>-based combination chemotherapy, the most commonly used cytotoxic therapy, has produced response rates ranging from 20% to 30% and overall survival of less than 10 months.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10369",
    "Sentence": "Cisplatin-based combination chemotherapy, the most commonly used <\\entity><\\entity> therapy, has produced response rates ranging from 20% to 30% and overall survival of less than 10 months.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10370",
    "Sentence": "Because of the minimal degree of success with <\\entity><\\entity> therapies and the poor prognosis of patients with this disease, interest has increased in targeted therapeutics for the treatment of cervical cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10371",
    "Sentence": "Two of these promising targets are <\\entity><\\entity> (EGFR) and the vascular endothelial growth factor (VEGF) signaling pathway, which play critical roles in tumor growth and angiogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10372",
    "Sentence": "Two of these promising targets are epidermal growth factor receptor (<\\entity><\\entity>) and the vascular endothelial growth factor (VEGF) signaling pathway, which play critical roles in tumor growth and angiogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10373",
    "Sentence": "Two of these promising targets are epidermal growth factor receptor (EGFR) and the <\\entity><\\entity> (VEGF) signaling pathway, which play critical roles in tumor growth and angiogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10374",
    "Sentence": "Two of these promising targets are epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (<\\entity><\\entity>) signaling pathway, which play critical roles in tumor growth and angiogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10375",
    "Sentence": "Two monoclonal antibodies, <\\entity><\\entity>, which targets EGFR, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10376",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets <\\entity><\\entity>, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10377",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets EGFR, and <\\entity><\\entity>, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10378",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets EGFR, and bevacizumab, which target the <\\entity><\\entity> signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10379",
    "Sentence": "In addition, <\\entity><\\entity>, such as sorafenib and pazopanib, are being studied in phase I/II clinical trials.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10380",
    "Sentence": "In addition, <\\entity><\\entity>, such as sorafenib and pazopanib, are being studied in phase I/II clinical trials.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10381",
    "Sentence": "In addition, VEGF receptor tyrosine kinase inhibitors, such as <\\entity><\\entity> and pazopanib, are being studied in phase I/II clinical trials.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10382",
    "Sentence": "In addition, VEGF receptor tyrosine kinase inhibitors, such as sorafenib and <\\entity><\\entity>, are being studied in phase I/II clinical trials.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10383",
    "Sentence": "Two monoclonal antibodies, <\\entity><\\entity>, which targets EGFR, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": ""
  },
  {
    "id": "10384",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets <\\entity><\\entity>, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": ""
  },
  {
    "id": "10386",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets EGFR, and <\\entity><\\entity>, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": ""
  },
  {
    "id": "10387",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets EGFR, and bevacizumab, which target the <\\entity><\\entity> signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": ""
  },
  {
    "id": "10389",
    "Sentence": "Two monoclonal antibodies, <\\entity><\\entity>, which targets EGFR, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": ""
  },
  {
    "id": "10390",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets EGFR, and bevacizumab, which target the <\\entity><\\entity> signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": ""
  },
  {
    "id": "10392",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets EGFR, and <\\entity><\\entity>, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": ""
  },
  {
    "id": "10393",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets <\\entity><\\entity>, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": ""
  },
  {
    "id": "10395",
    "Sentence": "In addition, VEGF receptor tyrosine kinase inhibitors, such as <\\entity><\\entity> and pazopanib, are being studied in phase I/II clinical trials.",
    "Label": ""
  },
  {
    "id": "10396",
    "Sentence": "In addition, <\\entity><\\entity>, such as sorafenib and pazopanib, are being studied in phase I/II clinical trials.",
    "Label": ""
  },
  {
    "id": "10398",
    "Sentence": "Two of these promising targets are epidermal growth factor receptor (<\\entity><\\entity>) and the vascular endothelial growth factor (VEGF) signaling pathway, which play critical roles in tumor growth and angiogenesis.",
    "Label": ""
  },
  {
    "id": "10399",
    "Sentence": "Two of these promising targets are epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) signaling pathway, which play critical roles in <\\entity><\\entity> and angiogenesis.",
    "Label": ""
  },
  {
    "id": "10401",
    "Sentence": "Two of these promising targets are epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (<\\entity><\\entity>) signaling pathway, which play critical roles in tumor growth and angiogenesis.",
    "Label": ""
  },
  {
    "id": "10402",
    "Sentence": "Two of these promising targets are epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) signaling pathway, which play critical roles in <\\entity><\\entity> and angiogenesis.",
    "Label": ""
  },
  {
    "id": "10404",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets <\\entity><\\entity>, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": ""
  },
  {
    "id": "10405",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets EGFR, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10407",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets EGFR, and bevacizumab, which target the <\\entity><\\entity> signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": ""
  },
  {
    "id": "10408",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets EGFR, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10410",
    "Sentence": "Two monoclonal antibodies, <\\entity><\\entity>, which targets EGFR, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": ""
  },
  {
    "id": "10411",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets EGFR, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10413",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets EGFR, and <\\entity><\\entity>, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of cervical cancer.",
    "Label": ""
  },
  {
    "id": "10414",
    "Sentence": "Two monoclonal antibodies, cetuximab, which targets EGFR, and bevacizumab, which target the VEGF signaling pathway, are being evaluated as monotherapy and in combination with other agents and/or radiotherapy for the treatment of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10416",
    "Sentence": "In addition, VEGF receptor tyrosine kinase inhibitors, such as sorafenib and <\\entity><\\entity>, are being studied in phase I/II clinical trials.",
    "Label": ""
  },
  {
    "id": "10417",
    "Sentence": "In addition, <\\entity><\\entity>, such as sorafenib and pazopanib, are being studied in phase I/II clinical trials.",
    "Label": ""
  },
  {
    "id": "10423",
    "Sentence": "Improvement of <\\entity><\\entity>-like photosensitizer selectivity with folate-based targeted delivery.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10424",
    "Sentence": "Improvement of meta-<\\entity><\\entity>(hydroxyphenyl)chlorin-like photosensitizer selectivity with folate-based targeted delivery.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10425",
    "Sentence": "Improvement of meta-tetra(hydroxyphenyl)chlorin-like <\\entity><\\entity> selectivity with folate-based targeted delivery.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10426",
    "Sentence": "Improvement of meta-tetra(hydroxyphenyl)chlorin-like photosensitizer selectivity with <\\entity><\\entity>-based targeted delivery.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10427",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane <\\entity><\\entity> (FR) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (PDT).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10428",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane <\\entity><\\entity> (FR) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (PDT).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10429",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (<\\entity><\\entity>) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (PDT).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10430",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (FR) is a molecular target for tumor-selective drug delivery, including delivery of <\\entity><\\entity> for anticancer photodynamic therapy (PDT).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10431",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (FR) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for <\\entity><\\entity> (PDT).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10432",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (FR) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (<\\entity><\\entity>).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10433",
    "Sentence": "Tumor selectivity of <\\entity><\\entity> ( m-THPC), a photosensitizer used in PDT clinical trials, demonstrates a low tumor-to-normal epithelial uptake ratio.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10434",
    "Sentence": "Tumor selectivity of meta-<\\entity><\\entity>(hydroxyphenyl)chlorin ( m-THPC), a photosensitizer used in PDT clinical trials, demonstrates a low tumor-to-normal epithelial uptake ratio.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10435",
    "Sentence": "Tumor selectivity of meta-tetra(hydroxyphenyl)chlorin ( <\\entity><\\entity>), a photosensitizer used in PDT clinical trials, demonstrates a low tumor-to-normal epithelial uptake ratio.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10436",
    "Sentence": "Tumor selectivity of meta-tetra(hydroxyphenyl)chlorin ( m-THPC), a <\\entity><\\entity> used in PDT clinical trials, demonstrates a low tumor-to-normal epithelial uptake ratio.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10437",
    "Sentence": "Tumor selectivity of meta-tetra(hydroxyphenyl)chlorin ( m-THPC), a photosensitizer used in <\\entity><\\entity> clinical trials, demonstrates a low tumor-to-normal epithelial uptake ratio.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10438",
    "Sentence": "We report on the synthesis and on the photophysical properties of a <\\entity><\\entity>-like photosensitizer 1 conjugated to folic acid (compound 8).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10439",
    "Sentence": "We report on the synthesis and on the photophysical properties of a m-THPC-like photosensitizer <\\entity><\\entity> conjugated to folic acid (compound 8).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10440",
    "Sentence": "We report on the synthesis and on the photophysical properties of a m-THPC-like photosensitizer 1 conjugated to <\\entity><\\entity> (compound 8).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10441",
    "Sentence": "We report on the synthesis and on the photophysical properties of a m-THPC-like photosensitizer 1 conjugated to folic acid (compound <\\entity><\\entity>).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10442",
    "Sentence": "A comparative study of the accumulation of <\\entity><\\entity> 1 and 8 is described.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10443",
    "Sentence": "A comparative study of the accumulation of photosensitizers <\\entity><\\entity> and 8 is described.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10444",
    "Sentence": "A comparative study of the accumulation of photosensitizers 1 and <\\entity><\\entity> is described.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10445",
    "Sentence": "Nude mice were xenografted with <\\entity><\\entity>-positive KB or HT-29 cells lacking <\\entity><\\entity> as a negative control.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10446",
    "Sentence": "Nude mice were xenografted with FR-alpha-positive KB or <\\entity><\\entity> cells lacking FR-alpha as a negative control.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10447",
    "Sentence": "Nude mice were xenografted with <\\entity><\\entity>-positive KB or HT-29 cells lacking <\\entity><\\entity> as a negative control.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10448",
    "Sentence": "Using optical fiber fluorimetry, we demonstrated that conjugate <\\entity><\\entity> exhibited enhanced accumulation in KB tumors compared to 1 4 h after injection.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10449",
    "Sentence": "Using optical fiber fluorimetry, we demonstrated that conjugate 8 exhibited enhanced accumulation in <\\entity><\\entity> tumors compared to 1 4 h after injection.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10450",
    "Sentence": "Using optical fiber fluorimetry, we demonstrated that conjugate 8 exhibited enhanced accumulation in KB tumors compared to <\\entity><\\entity> 4 h after injection.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10451",
    "Sentence": "No significant difference between <\\entity><\\entity> and HT-29 tumors was observed in case of compound 1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10452",
    "Sentence": "No significant difference between KB and <\\entity><\\entity> tumors was observed in case of compound 1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10453",
    "Sentence": "No significant difference between KB and HT-29 tumors was observed in case of compound <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10454",
    "Sentence": "Tumor-to-normal tissue ratio exhibited a very interesting selectivity for conjugate <\\entity><\\entity> (5:1) in KB tumors 4 h postinjection.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10455",
    "Sentence": "Tumor-to-normal tissue ratio exhibited a very interesting selectivity for conjugate 8 (5:<\\entity><\\entity>) in KB tumors 4 h postinjection.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10456",
    "Sentence": "Tumor-to-normal tissue ratio exhibited a very interesting selectivity for conjugate 8 (5:1) in <\\entity><\\entity> tumors 4 h postinjection.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10457",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (FR) is a molecular target for tumor-selective drug delivery, including delivery of <\\entity><\\entity> for anticancer photodynamic therapy (PDT).",
    "Label": ""
  },
  {
    "id": "10458",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane <\\entity><\\entity> (FR) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (PDT).",
    "Label": ""
  },
  {
    "id": "10460",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (FR) is a molecular target for tumor-selective drug delivery, including delivery of <\\entity><\\entity> for anticancer photodynamic therapy (PDT).",
    "Label": ""
  },
  {
    "id": "10461",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (<\\entity><\\entity>) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (PDT).",
    "Label": ""
  },
  {
    "id": "10463",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane <\\entity><\\entity> (FR) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (PDT).",
    "Label": ""
  },
  {
    "id": "10464",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (FR) is a molecular target for <\\entity><\\entity>-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (PDT).",
    "Label": ""
  },
  {
    "id": "10466",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (<\\entity><\\entity>) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (PDT).",
    "Label": ""
  },
  {
    "id": "10467",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (FR) is a molecular target for <\\entity><\\entity>-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (PDT).",
    "Label": ""
  },
  {
    "id": "10469",
    "Sentence": "Tumor selectivity of meta-tetra(hydroxyphenyl)chlorin ( <\\entity><\\entity>), a photosensitizer used in PDT clinical trials, demonstrates a low tumor-to-normal epithelial uptake ratio.",
    "Label": ""
  },
  {
    "id": "10470",
    "Sentence": "Tumor selectivity of meta-tetra(hydroxyphenyl)chlorin ( m-THPC), a photosensitizer used in PDT clinical trials, demonstrates a low <\\entity><\\entity>-to-normal epithelial uptake ratio.",
    "Label": ""
  },
  {
    "id": "10472",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (FR) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "10473",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane <\\entity><\\entity> (FR) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (PDT).",
    "Label": ""
  },
  {
    "id": "10475",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (FR) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "10476",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (<\\entity><\\entity>) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (PDT).",
    "Label": ""
  },
  {
    "id": "10478",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (FR) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for <\\entity><\\entity> (PDT).",
    "Label": ""
  },
  {
    "id": "10479",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane <\\entity><\\entity> (FR) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (PDT).",
    "Label": ""
  },
  {
    "id": "10481",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (FR) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for <\\entity><\\entity> (PDT).",
    "Label": ""
  },
  {
    "id": "10482",
    "Sentence": "synthesis and in vivo delivery studies.The cell membrane folate receptor (<\\entity><\\entity>) is a molecular target for tumor-selective drug delivery, including delivery of photosensitizers for anticancer photodynamic therapy (PDT).",
    "Label": ""
  },
  {
    "id": "10488",
    "Sentence": "<\\entity><\\entity> in an adult on immunosuppressive therapy.'<\\entity><\\entity>' is a rare presentation of celiac disease with manifestations that include severe diarrhea, and severe metabolic and electrolyte abnormalities.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10489",
    "Sentence": "Celiac crisis in an adult on <\\entity><\\entity>.'Celiac crisis' is a rare presentation of celiac disease with manifestations that include severe diarrhea, and severe metabolic and electrolyte abnormalities.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10490",
    "Sentence": "<\\entity><\\entity> in an adult on immunosuppressive therapy.'<\\entity><\\entity>' is a rare presentation of celiac disease with manifestations that include severe diarrhea, and severe metabolic and electrolyte abnormalities.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10491",
    "Sentence": "Celiac crisis in an adult on immunosuppressive therapy.'Celiac crisis' is a rare presentation of <\\entity><\\entity> with manifestations that include severe diarrhea, and severe metabolic and electrolyte abnormalities.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10492",
    "Sentence": "Celiac crisis in an adult on immunosuppressive therapy.'Celiac crisis' is a rare presentation of celiac disease with manifestations that include <\\entity><\\entity>, and severe metabolic and electrolyte abnormalities.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10493",
    "Sentence": "Celiac crisis in an adult on immunosuppressive therapy.'Celiac crisis' is a rare presentation of celiac disease with manifestations that include severe diarrhea, and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10494",
    "Sentence": "A case of a 50-year-old woman who presented with <\\entity><\\entity>, severe dehydration, hypokalemia and metabolic acidosis is described.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10495",
    "Sentence": "A case of a 50-year-old woman who presented with diarrhea, <\\entity><\\entity>, hypokalemia and metabolic acidosis is described.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10496",
    "Sentence": "A case of a 50-year-old woman who presented with diarrhea, severe dehydration, <\\entity><\\entity> and metabolic acidosis is described.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10497",
    "Sentence": "A case of a 50-year-old woman who presented with diarrhea, severe dehydration, hypokalemia and <\\entity><\\entity> is described.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10498",
    "Sentence": "Based on positive serology and small bowel biopsy, she was diagnosed with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10499",
    "Sentence": "She also had histological evidence of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10500",
    "Sentence": "<\\entity><\\entity> has not previously been described in association with celiac crisis, but it may have contributed to the presentation of celiac crisis in the current case.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10501",
    "Sentence": "Microscopic colitis has not previously been described in association with <\\entity><\\entity>, but it may have contributed to the presentation of <\\entity><\\entity> in the current case.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10502",
    "Sentence": "Microscopic colitis has not previously been described in association with <\\entity><\\entity>, but it may have contributed to the presentation of <\\entity><\\entity> in the current case.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10503",
    "Sentence": "The patient was on <\\entity><\\entity> and azathioprine for autoimmune hepatitis at the time of her presentation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10504",
    "Sentence": "The patient was on corticosteroids and <\\entity><\\entity> for autoimmune hepatitis at the time of her presentation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10505",
    "Sentence": "The patient was on corticosteroids and azathioprine for <\\entity><\\entity> at the time of her presentation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10506",
    "Sentence": "The patient was on corticosteroids and azathioprine for autoimmune hepatitis at the time of <\\entity><\\entity> presentation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10507",
    "Sentence": "The current case demonstrates that modest <\\entity><\\entity> does not prevent a celiac crisis, although previous reports have shown that patients may respond rapidly to high-dose corticosteroids.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10508",
    "Sentence": "The current case demonstrates that modest immunosuppression does not prevent a <\\entity><\\entity>, although previous reports have shown that patients may respond rapidly to high-dose corticosteroids.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10509",
    "Sentence": "The current case demonstrates that modest immunosuppression does not prevent a celiac crisis, although previous reports have shown that patients may respond rapidly to high-dose <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10510",
    "Sentence": "The patient was on corticosteroids and <\\entity><\\entity> for autoimmune hepatitis at the time of her presentation.",
    "Label": ""
  },
  {
    "id": "10511",
    "Sentence": "The patient was on corticosteroids and azathioprine for <\\entity><\\entity> at the time of her presentation.",
    "Label": ""
  },
  {
    "id": "10513",
    "Sentence": "The patient was on <\\entity><\\entity> and azathioprine for autoimmune hepatitis at the time of her presentation.",
    "Label": ""
  },
  {
    "id": "10514",
    "Sentence": "The patient was on corticosteroids and azathioprine for <\\entity><\\entity> at the time of her presentation.",
    "Label": ""
  },
  {
    "id": "10516",
    "Sentence": "The current case demonstrates that modest immunosuppression does not prevent a celiac crisis, although previous reports have shown that patients may respond rapidly to high-dose <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10517",
    "Sentence": "The current case demonstrates that modest immunosuppression does not prevent a <\\entity><\\entity>, although previous reports have shown that patients may respond rapidly to high-dose corticosteroids.",
    "Label": ""
  },
  {
    "id": "10519",
    "Sentence": "The patient was on corticosteroids and <\\entity><\\entity> for autoimmune hepatitis at the time of her presentation.",
    "Label": ""
  },
  {
    "id": "10520",
    "Sentence": "The patient was on corticosteroids and azathioprine for <\\entity><\\entity> at the time of her presentation.",
    "Label": ""
  },
  {
    "id": "10522",
    "Sentence": "The patient was on corticosteroids and azathioprine for autoimmune hepatitis at the time of <\\entity><\\entity> presentation.",
    "Label": ""
  },
  {
    "id": "10523",
    "Sentence": "The patient was on corticosteroids and azathioprine for <\\entity><\\entity> at the time of her presentation.",
    "Label": ""
  },
  {
    "id": "10525",
    "Sentence": "Celiac crisis in an adult on <\\entity><\\entity>.'Celiac crisis' is a rare presentation of celiac disease with manifestations that include severe diarrhea, and severe metabolic and electrolyte abnormalities.",
    "Label": ""
  },
  {
    "id": "10526",
    "Sentence": "<\\entity><\\entity> in an adult on immunosuppressive therapy.'<\\entity><\\entity>' is a rare presentation of celiac disease with manifestations that include severe diarrhea, and severe metabolic and electrolyte abnormalities.",
    "Label": ""
  },
  {
    "id": "10528",
    "Sentence": "The current case demonstrates that modest immunosuppression does not prevent a celiac crisis, although previous reports have shown that patients may respond rapidly to high-dose <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10529",
    "Sentence": "The current case demonstrates that modest immunosuppression does not prevent a <\\entity><\\entity>, although previous reports have shown that patients may respond rapidly to high-dose corticosteroids.",
    "Label": ""
  },
  {
    "id": "10531",
    "Sentence": "The current case demonstrates that modest immunosuppression does not prevent a celiac crisis, although previous reports have shown that patients may respond rapidly to high-dose <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10532",
    "Sentence": "The current case demonstrates that modest <\\entity><\\entity> does not prevent a celiac crisis, although previous reports have shown that patients may respond rapidly to high-dose corticosteroids.",
    "Label": ""
  },
  {
    "id": "10538",
    "Sentence": "Preoperative periumbilical <\\entity><\\entity> (PUGSI) as a tool in predicting obliterating subumbilical adhesions in laparoscopy.OBJECTIVE: To report the novel technique of periumbilical <\\entity><\\entity> (PUGSI).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10539",
    "Sentence": "Preoperative periumbilical ultrasound-guided saline infusion (<\\entity><\\entity>) as a tool in predicting obliterating subumbilical adhesions in laparoscopy.OBJECTIVE: To report the novel technique of periumbilical ultrasound-guided saline infusion (<\\entity><\\entity>).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10540",
    "Sentence": "Preoperative periumbilical ultrasound-guided saline infusion (PUGSI) as a tool in predicting <\\entity><\\entity> in laparoscopy.OBJECTIVE: To report the novel technique of periumbilical ultrasound-guided saline infusion (PUGSI).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10541",
    "Sentence": "Preoperative periumbilical <\\entity><\\entity> (PUGSI) as a tool in predicting obliterating subumbilical adhesions in laparoscopy.OBJECTIVE: To report the novel technique of periumbilical <\\entity><\\entity> (PUGSI).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10542",
    "Sentence": "Preoperative periumbilical ultrasound-guided saline infusion (<\\entity><\\entity>) as a tool in predicting obliterating subumbilical adhesions in laparoscopy.OBJECTIVE: To report the novel technique of periumbilical ultrasound-guided saline infusion (<\\entity><\\entity>).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10543",
    "Sentence": "DESIGN: Prospective study of two noninvasive diagnostic tests to detect <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10544",
    "Sentence": "Patients without risk factors for <\\entity><\\entity> were used as a control group (n = 38), whereas the study group had risk factors for intra-abdominal <\\entity><\\entity> (n = 112).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10545",
    "Sentence": "Patients without risk factors for adhesions were used as a control group (n = 38), whereas the study group had risk factors for <\\entity><\\entity> (n = 112).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10546",
    "Sentence": "INTERVENTION(S): Preoperative examination with the visceral slide and the <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10547",
    "Sentence": "MAIN OUTCOME MEASURE(S): The presence of <\\entity><\\entity> in the high-risk patient and the ability of the PUGSI to detect them preoperatively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10548",
    "Sentence": "MAIN OUTCOME MEASURE(S): The presence of obliterating subumbilical adhesions in the high-risk patient and the ability of the <\\entity><\\entity> to detect them preoperatively.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10549",
    "Sentence": "RESULT(S): There were no <\\entity><\\entity> in the control group.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10550",
    "Sentence": "The prevalence of <\\entity><\\entity> in the risk group was 3.6%.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10551",
    "Sentence": "The <\\entity><\\entity> test was able to detect all cases of obliterating subumbilical adhesions, demonstrating sensitivity and specificity of 100%.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10552",
    "Sentence": "The PUGSI test was able to detect all cases of <\\entity><\\entity>, demonstrating sensitivity and specificity of 100%.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10553",
    "Sentence": "CONCLUSION(S): The <\\entity><\\entity> test has excellent negative and positive predictive values and is useful in determining patients who have obliterating subumbilical adhesions.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10554",
    "Sentence": "CONCLUSION(S): The PUGSI test has excellent negative and positive predictive values and is useful in determining patients who have <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10555",
    "Sentence": "Use of both tests preoperatively appears to be helpful in identifying patients at risk for <\\entity><\\entity> during laparoscopic surgery.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10556",
    "Sentence": "The <\\entity><\\entity> test was able to detect all cases of obliterating subumbilical adhesions, demonstrating sensitivity and specificity of 100%.",
    "Label": ""
  },
  {
    "id": "10557",
    "Sentence": "The PUGSI test was able to detect all cases of <\\entity><\\entity>, demonstrating sensitivity and specificity of 100%.",
    "Label": ""
  },
  {
    "id": "10559",
    "Sentence": "CONCLUSION(S): The <\\entity><\\entity> test has excellent negative and positive predictive values and is useful in determining patients who have obliterating subumbilical adhesions.",
    "Label": ""
  },
  {
    "id": "10560",
    "Sentence": "CONCLUSION(S): The PUGSI test has excellent negative and positive predictive values and is useful in determining patients who have <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10562",
    "Sentence": "Preoperative periumbilical ultrasound-guided saline infusion (<\\entity><\\entity>) as a tool in predicting obliterating subumbilical adhesions in laparoscopy.OBJECTIVE: To report the novel technique of periumbilical ultrasound-guided saline infusion (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "10563",
    "Sentence": "Preoperative periumbilical ultrasound-guided saline infusion (PUGSI) as a tool in predicting <\\entity><\\entity> in laparoscopy.OBJECTIVE: To report the novel technique of periumbilical ultrasound-guided saline infusion (PUGSI).",
    "Label": ""
  },
  {
    "id": "10565",
    "Sentence": "MAIN OUTCOME MEASURE(S): The presence of obliterating subumbilical adhesions in the high-risk patient and the ability of the <\\entity><\\entity> to detect them preoperatively.",
    "Label": ""
  },
  {
    "id": "10566",
    "Sentence": "MAIN OUTCOME MEASURE(S): The presence of <\\entity><\\entity> in the high-risk patient and the ability of the PUGSI to detect them preoperatively.",
    "Label": ""
  },
  {
    "id": "10572",
    "Sentence": "<\\entity><\\entity> regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells.In the endometrium, hormonal effects on epithelial cells are often elicited through stromal hormone receptors via unknown paracrine mechanisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10573",
    "Sentence": "Secreted frizzled-related protein 4 regulates two <\\entity><\\entity> signaling pathways and inhibits proliferation in endometrial cancer cells.In the endometrium, hormonal effects on epithelial cells are often elicited through stromal hormone receptors via unknown paracrine mechanisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10574",
    "Sentence": "Several lines of evidence support the hypothesis that <\\entity><\\entity> participate in stromal-epithelial cell communication.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10575",
    "Sentence": "<\\entity><\\entity> is expressed in the luminal epithelium, whereas the extracellular modulator of Wnt signaling, secreted frizzled-related protein 4 (SFRP4), is localized to the stroma.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10576",
    "Sentence": "Wnt7a is expressed in the <\\entity><\\entity> epithelium, whereas the extracellular modulator of Wnt signaling, secreted frizzled-related protein 4 (SFRP4), is localized to the stroma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10577",
    "Sentence": "<\\entity><\\entity>7a is expressed in the luminal epithelium, whereas the extracellular modulator of <\\entity><\\entity> signaling, secreted frizzled-related protein 4 (SFRP4), is localized to the stroma.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10578",
    "Sentence": "Wnt7a is expressed in the luminal epithelium, whereas the extracellular modulator of Wnt signaling, <\\entity><\\entity> (SFRP4), is localized to the stroma.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10579",
    "Sentence": "Wnt7a is expressed in the luminal epithelium, whereas the extracellular modulator of Wnt signaling, secreted frizzled-related protein 4 (<\\entity><\\entity>), is localized to the stroma.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10580",
    "Sentence": "Studies have reported that <\\entity><\\entity> expression is significantly decreased in endometrial carcinoma and that both <\\entity><\\entity> and Wnt7a genes are differentially regulated in response to estrogenic stimuli.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10581",
    "Sentence": "Studies have reported that <\\entity><\\entity> expression is significantly decreased in endometrial carcinoma and that both <\\entity><\\entity> and Wnt7a genes are differentially regulated in response to estrogenic stimuli.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10582",
    "Sentence": "Studies have reported that SFRP4 expression is significantly decreased in endometrial carcinoma and that both SFRP4 and <\\entity><\\entity> genes are differentially regulated in response to estrogenic stimuli.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10583",
    "Sentence": "Aberrant <\\entity><\\entity> signaling irrevocably causes organ defects and infertility and contributes to the onset of disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10584",
    "Sentence": "However, <\\entity><\\entity> (Fzd) that bind Wnt7a and the particular signal transduction pathway each Wnt7a-Fzd pair activates have not been identified.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10585",
    "Sentence": "However, specific frizzled receptors (<\\entity><\\entity>) that bind Wnt7a and the particular signal transduction pathway each Wnt7a-<\\entity><\\entity> pair activates have not been identified.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10586",
    "Sentence": "However, specific frizzled receptors (Fzd) that bind <\\entity><\\entity> and the particular signal transduction pathway each <\\entity><\\entity>-Fzd pair activates have not been identified.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10587",
    "Sentence": "However, specific frizzled receptors (Fzd) that bind Wnt7a and the particular signal transduction pathway each <\\entity><\\entity> pair activates have not been identified.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10588",
    "Sentence": "Additionally, the function of <\\entity><\\entity> in the endometrium has not been addressed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10589",
    "Sentence": "We show here that <\\entity><\\entity> coimmunoprecipitates with Fzd5, Fzd10, and SFRP4 in Ishikawa cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10590",
    "Sentence": "We show here that Wnt7a coimmunoprecipitates with <\\entity><\\entity>, Fzd10, and SFRP4 in Ishikawa cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10591",
    "Sentence": "We show here that Wnt7a coimmunoprecipitates with Fzd5, <\\entity><\\entity>, and SFRP4 in Ishikawa cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10592",
    "Sentence": "We show here that Wnt7a coimmunoprecipitates with Fzd5, Fzd10, and <\\entity><\\entity> in Ishikawa cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10593",
    "Sentence": "We show here that Wnt7a coimmunoprecipitates with Fzd5, Fzd10, and SFRP4 in <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10594",
    "Sentence": "<\\entity><\\entity> binding to Fzd5 was shown to activate beta-catenin/canonical Wnt signaling and increase cellular proliferation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10595",
    "Sentence": "Wnt7a binding to <\\entity><\\entity> was shown to activate beta-catenin/canonical Wnt signaling and increase cellular proliferation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10596",
    "Sentence": "Wnt7a binding to Fzd5 was shown to activate <\\entity><\\entity>/canonical Wnt signaling and increase cellular proliferation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10597",
    "Sentence": "<\\entity><\\entity>7a binding to Fzd5 was shown to activate beta-catenin/canonical <\\entity><\\entity> signaling and increase cellular proliferation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10598",
    "Sentence": "Conversely, <\\entity><\\entity> signaling mediated by Fzd10 induced a noncanonical c-Jun NH2-terminal kinase-responsive pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10599",
    "Sentence": "Conversely, Wnt7a signaling mediated by <\\entity><\\entity> induced a noncanonical c-Jun NH2-terminal kinase-responsive pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10600",
    "Sentence": "Conversely, Wnt7a signaling mediated by Fzd10 induced a noncanonical <\\entity><\\entity> NH2-terminal kinase-responsive pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10601",
    "Sentence": "<\\entity><\\entity> suppresses activation of Wnt7a signaling in both an autocrine and paracrine manner.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10602",
    "Sentence": "SFRP4 suppresses activation of <\\entity><\\entity> signaling in both an autocrine and paracrine manner.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10603",
    "Sentence": "Stable overexpression of <\\entity><\\entity> and treatment with recombinant <\\entity><\\entity> protein inhibited endometrial cancer cell growth in vitro.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10604",
    "Sentence": "Stable overexpression of <\\entity><\\entity> and treatment with recombinant <\\entity><\\entity> protein inhibited endometrial cancer cell growth in vitro.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10605",
    "Sentence": "These findings support a mechanism by which the nature of the <\\entity><\\entity> signal in the endometrium is dependent on the Fzd repertoire of the cell and can be regulated by SFRP4.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10606",
    "Sentence": "These findings support a mechanism by which the nature of the Wnt7a signal in the endometrium is dependent on the <\\entity><\\entity> repertoire of the cell and can be regulated by SFRP4.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10607",
    "Sentence": "These findings support a mechanism by which the nature of the Wnt7a signal in the endometrium is dependent on the Fzd repertoire of the cell and can be regulated by <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10608",
    "Sentence": "Wnt7a is expressed in the <\\entity><\\entity> epithelium, whereas the extracellular modulator of Wnt signaling, secreted frizzled-related protein 4 (SFRP4), is localized to the stroma.",
    "Label": ""
  },
  {
    "id": "10609",
    "Sentence": "Wnt7a is expressed in the luminal epithelium, whereas the extracellular modulator of Wnt signaling, secreted frizzled-related protein 4 (<\\entity><\\entity>), is localized to the stroma.",
    "Label": ""
  },
  {
    "id": "10611",
    "Sentence": "Wnt7a is expressed in the <\\entity><\\entity> epithelium, whereas the extracellular modulator of Wnt signaling, secreted frizzled-related protein 4 (SFRP4), is localized to the stroma.",
    "Label": ""
  },
  {
    "id": "10612",
    "Sentence": "<\\entity><\\entity> is expressed in the luminal epithelium, whereas the extracellular modulator of Wnt signaling, secreted frizzled-related protein 4 (SFRP4), is localized to the stroma.",
    "Label": ""
  },
  {
    "id": "10614",
    "Sentence": "<\\entity><\\entity> regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells.In the endometrium, hormonal effects on epithelial cells are often elicited through stromal hormone receptors via unknown paracrine mechanisms.",
    "Label": ""
  },
  {
    "id": "10615",
    "Sentence": "Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in <\\entity><\\entity> cells.In the endometrium, hormonal effects on epithelial cells are often elicited through stromal hormone receptors via unknown paracrine mechanisms.",
    "Label": ""
  },
  {
    "id": "10617",
    "Sentence": "Secreted frizzled-related protein 4 regulates two <\\entity><\\entity> signaling pathways and inhibits proliferation in endometrial cancer cells.In the endometrium, hormonal effects on epithelial cells are often elicited through stromal hormone receptors via unknown paracrine mechanisms.",
    "Label": ""
  },
  {
    "id": "10618",
    "Sentence": "Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in <\\entity><\\entity> cells.In the endometrium, hormonal effects on epithelial cells are often elicited through stromal hormone receptors via unknown paracrine mechanisms.",
    "Label": ""
  },
  {
    "id": "10620",
    "Sentence": "Studies have reported that <\\entity><\\entity> expression is significantly decreased in endometrial carcinoma and that both <\\entity><\\entity> and Wnt7a genes are differentially regulated in response to estrogenic stimuli.",
    "Label": ""
  },
  {
    "id": "10621",
    "Sentence": "Studies have reported that SFRP4 expression is significantly decreased in <\\entity><\\entity> and that both SFRP4 and Wnt7a genes are differentially regulated in response to estrogenic stimuli.",
    "Label": ""
  },
  {
    "id": "10623",
    "Sentence": "Studies have reported that SFRP4 expression is significantly decreased in endometrial carcinoma and that both SFRP4 and <\\entity><\\entity> genes are differentially regulated in response to estrogenic stimuli.",
    "Label": ""
  },
  {
    "id": "10624",
    "Sentence": "Studies have reported that SFRP4 expression is significantly decreased in <\\entity><\\entity> and that both SFRP4 and Wnt7a genes are differentially regulated in response to estrogenic stimuli.",
    "Label": ""
  },
  {
    "id": "10626",
    "Sentence": "Aberrant <\\entity><\\entity> signaling irrevocably causes organ defects and infertility and contributes to the onset of disease.",
    "Label": ""
  },
  {
    "id": "10627",
    "Sentence": "Aberrant Wnt7a signaling irrevocably causes organ defects and <\\entity><\\entity> and contributes to the onset of disease.",
    "Label": ""
  },
  {
    "id": "10629",
    "Sentence": "Aberrant <\\entity><\\entity> signaling irrevocably causes organ defects and infertility and contributes to the onset of disease.",
    "Label": ""
  },
  {
    "id": "10630",
    "Sentence": "Aberrant Wnt7a signaling irrevocably causes <\\entity><\\entity> and infertility and contributes to the onset of disease.",
    "Label": ""
  },
  {
    "id": "10632",
    "Sentence": "<\\entity><\\entity> binding to Fzd5 was shown to activate beta-catenin/canonical Wnt signaling and increase cellular proliferation.",
    "Label": ""
  },
  {
    "id": "10633",
    "Sentence": "Wnt7a binding to Fzd5 was shown to activate beta-catenin/canonical Wnt signaling and increase <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10635",
    "Sentence": "Wnt7a binding to <\\entity><\\entity> was shown to activate beta-catenin/canonical Wnt signaling and increase cellular proliferation.",
    "Label": ""
  },
  {
    "id": "10636",
    "Sentence": "Wnt7a binding to Fzd5 was shown to activate beta-catenin/canonical Wnt signaling and increase <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10638",
    "Sentence": "Wnt7a binding to Fzd5 was shown to activate <\\entity><\\entity>/canonical Wnt signaling and increase cellular proliferation.",
    "Label": ""
  },
  {
    "id": "10639",
    "Sentence": "Wnt7a binding to Fzd5 was shown to activate beta-catenin/canonical Wnt signaling and increase <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10641",
    "Sentence": "Stable overexpression of <\\entity><\\entity> and treatment with recombinant <\\entity><\\entity> protein inhibited endometrial cancer cell growth in vitro.",
    "Label": ""
  },
  {
    "id": "10642",
    "Sentence": "Stable overexpression of SFRP4 and treatment with recombinant SFRP4 protein inhibited endometrial <\\entity><\\entity> in vitro.",
    "Label": ""
  },
  {
    "id": "10648",
    "Sentence": "Novel <\\entity><\\entity> compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10649",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits <\\entity><\\entity> activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10650",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting <\\entity><\\entity> kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10651",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating <\\entity><\\entity> expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10652",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in <\\entity><\\entity>-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10653",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in <\\entity><\\entity>-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10654",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.<\\entity><\\entity> have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10655",
    "Sentence": "We postulated that the derivatives could mediate some of their pharmacological actions by modulating <\\entity><\\entity> (NF)-kappaB activation, which is closely linked to the inflammatory and immune disorders.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10656",
    "Sentence": "We postulated that the derivatives could mediate some of their pharmacological actions by modulating nuclear factor (<\\entity><\\entity> activation, which is closely linked to the inflammatory and immune disorders.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10657",
    "Sentence": "In this study, a novel <\\entity><\\entity> LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10658",
    "Sentence": "In this study, a novel iminobenzoxathiolone <\\entity><\\entity> of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10659",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of <\\entity><\\entity> has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10660",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of <\\entity><\\entity> (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10661",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (<\\entity><\\entity> (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10662",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (<\\entity><\\entity>), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10663",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for <\\entity><\\entity> activation, with an IC(50) value of 7 microM.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10664",
    "Sentence": "<\\entity><\\entity> inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10665",
    "Sentence": "LYR-71 inhibited <\\entity><\\entity>-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10666",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic <\\entity><\\entity> in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing <\\entity><\\entity> degradation as well as transcriptional activation of NF-kappaB.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10667",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in <\\entity><\\entity> (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10668",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (<\\entity><\\entity>)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10669",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (<\\entity><\\entity>)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10670",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic <\\entity><\\entity> in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing <\\entity><\\entity> degradation as well as transcriptional activation of NF-kappaB.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10671",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10672",
    "Sentence": "Furthermore, <\\entity><\\entity> down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10673",
    "Sentence": "Furthermore, LYR-71 down-regulated <\\entity><\\entity>-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10674",
    "Sentence": "Furthermore, LYR-71 down-regulated <\\entity><\\entity>-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10675",
    "Sentence": "Furthermore, LYR-71 down-regulated LPS-induced transcription of <\\entity><\\entity> (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10676",
    "Sentence": "Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (<\\entity><\\entity> or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10677",
    "Sentence": "Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other <\\entity><\\entity> in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10678",
    "Sentence": "Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector <\\entity><\\entity>-elicited IL-1beta promoter activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10679",
    "Sentence": "Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited <\\entity><\\entity> promoter activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10680",
    "Sentence": "Taken together, <\\entity><\\entity> was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10681",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of <\\entity><\\entity>, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10682",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing <\\entity><\\entity> activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10683",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on <\\entity><\\entity>-induced expression of inflammatory cytokines at the transcription level.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10684",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on <\\entity><\\entity>-induced expression of inflammatory cytokines at the transcription level.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10685",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of <\\entity><\\entity> at the transcription level.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10686",
    "Sentence": "Novel <\\entity><\\entity> compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10687",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting <\\entity><\\entity> kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10689",
    "Sentence": "In this study, a novel iminobenzoxathiolone <\\entity><\\entity> of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10690",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for <\\entity><\\entity> activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10692",
    "Sentence": "In this study, a novel iminobenzoxathiolone <\\entity><\\entity> of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10693",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (<\\entity><\\entity>), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10695",
    "Sentence": "In this study, a novel iminobenzoxathiolone <\\entity><\\entity> of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10696",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of <\\entity><\\entity> (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10698",
    "Sentence": "In this study, a novel iminobenzoxathiolone <\\entity><\\entity> of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10699",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (<\\entity><\\entity> (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10701",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of <\\entity><\\entity> has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10702",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for <\\entity><\\entity> activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10704",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of <\\entity><\\entity> has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10705",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (<\\entity><\\entity>), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10707",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of <\\entity><\\entity> has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10708",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of <\\entity><\\entity> (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10710",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of <\\entity><\\entity> has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10711",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (<\\entity><\\entity> (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10713",
    "Sentence": "<\\entity><\\entity> inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10714",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10716",
    "Sentence": "<\\entity><\\entity> inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10717",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic <\\entity><\\entity> in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing <\\entity><\\entity> degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10719",
    "Sentence": "<\\entity><\\entity> inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10720",
    "Sentence": "LYR-71 inhibited <\\entity><\\entity>-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10722",
    "Sentence": "Furthermore, <\\entity><\\entity> down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": ""
  },
  {
    "id": "10723",
    "Sentence": "Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited <\\entity><\\entity> promoter activity.",
    "Label": ""
  },
  {
    "id": "10725",
    "Sentence": "Furthermore, <\\entity><\\entity> down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": ""
  },
  {
    "id": "10726",
    "Sentence": "Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector <\\entity><\\entity>-elicited IL-1beta promoter activity.",
    "Label": ""
  },
  {
    "id": "10728",
    "Sentence": "Taken together, <\\entity><\\entity> was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level.",
    "Label": ""
  },
  {
    "id": "10729",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing <\\entity><\\entity> activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level.",
    "Label": ""
  },
  {
    "id": "10731",
    "Sentence": "Taken together, <\\entity><\\entity> was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level.",
    "Label": ""
  },
  {
    "id": "10732",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of <\\entity><\\entity>, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level.",
    "Label": ""
  },
  {
    "id": "10734",
    "Sentence": "Taken together, <\\entity><\\entity> was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level.",
    "Label": ""
  },
  {
    "id": "10735",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of <\\entity><\\entity> at the transcription level.",
    "Label": ""
  },
  {
    "id": "10737",
    "Sentence": "Novel <\\entity><\\entity> compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10738",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits <\\entity><\\entity> activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10740",
    "Sentence": "Novel <\\entity><\\entity> compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10741",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating <\\entity><\\entity> expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10743",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in <\\entity><\\entity>-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10744",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits <\\entity><\\entity> activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10746",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in <\\entity><\\entity>-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10747",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting <\\entity><\\entity> kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10749",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in <\\entity><\\entity>-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10750",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating <\\entity><\\entity> expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10752",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.<\\entity><\\entity> have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10753",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the <\\entity><\\entity> and acne.",
    "Label": ""
  },
  {
    "id": "10755",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.<\\entity><\\entity> have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10756",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10758",
    "Sentence": "We postulated that the derivatives could mediate some of their pharmacological actions by modulating nuclear factor (<\\entity><\\entity> activation, which is closely linked to the inflammatory and immune disorders.",
    "Label": ""
  },
  {
    "id": "10759",
    "Sentence": "We postulated that the derivatives could mediate some of their pharmacological actions by modulating nuclear factor (NF)-kappaB activation, which is closely linked to the inflammatory and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10761",
    "Sentence": "In this study, a novel <\\entity><\\entity> LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10762",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for <\\entity><\\entity> activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10764",
    "Sentence": "In this study, a novel <\\entity><\\entity> LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10765",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (<\\entity><\\entity> (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10767",
    "Sentence": "In this study, a novel <\\entity><\\entity> LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10768",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (<\\entity><\\entity>), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10770",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in <\\entity><\\entity> (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10771",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10773",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in <\\entity><\\entity> (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10774",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic <\\entity><\\entity> in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing <\\entity><\\entity> degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10776",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in <\\entity><\\entity> (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10777",
    "Sentence": "LYR-71 inhibited <\\entity><\\entity>-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10779",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (<\\entity><\\entity>)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10780",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10782",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (<\\entity><\\entity>)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10783",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic <\\entity><\\entity> in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing <\\entity><\\entity> degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10785",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (<\\entity><\\entity>)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10786",
    "Sentence": "LYR-71 inhibited <\\entity><\\entity>-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10788",
    "Sentence": "Furthermore, <\\entity><\\entity> down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": ""
  },
  {
    "id": "10789",
    "Sentence": "Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other <\\entity><\\entity> in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": ""
  },
  {
    "id": "10791",
    "Sentence": "Furthermore, LYR-71 down-regulated <\\entity><\\entity>-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": ""
  },
  {
    "id": "10792",
    "Sentence": "Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited <\\entity><\\entity> promoter activity.",
    "Label": ""
  },
  {
    "id": "10794",
    "Sentence": "Furthermore, LYR-71 down-regulated <\\entity><\\entity>-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": ""
  },
  {
    "id": "10795",
    "Sentence": "Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector <\\entity><\\entity>-elicited IL-1beta promoter activity.",
    "Label": ""
  },
  {
    "id": "10797",
    "Sentence": "Furthermore, LYR-71 down-regulated <\\entity><\\entity>-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": ""
  },
  {
    "id": "10798",
    "Sentence": "Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (IL)-1beta or other <\\entity><\\entity> in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": ""
  },
  {
    "id": "10800",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on <\\entity><\\entity>-induced expression of inflammatory cytokines at the transcription level.",
    "Label": ""
  },
  {
    "id": "10801",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing <\\entity><\\entity> activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level.",
    "Label": ""
  },
  {
    "id": "10803",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on <\\entity><\\entity>-induced expression of inflammatory cytokines at the transcription level.",
    "Label": ""
  },
  {
    "id": "10804",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of <\\entity><\\entity>, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level.",
    "Label": ""
  },
  {
    "id": "10806",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on <\\entity><\\entity>-induced expression of inflammatory cytokines at the transcription level.",
    "Label": ""
  },
  {
    "id": "10807",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of <\\entity><\\entity> at the transcription level.",
    "Label": ""
  },
  {
    "id": "10809",
    "Sentence": "Novel <\\entity><\\entity> compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in lipopolysaccharide-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10810",
    "Sentence": "Novel iminobenzoxathiolone compound inhibits nuclear factor-kappaB activation targeting inhibitory kappaB kinase beta and down-regulating interleukin-1beta expression in <\\entity><\\entity>-activated macrophages.Benzoxathiolone derivatives have been reported to show pharmacological potentials in the psoriasis and acne.",
    "Label": ""
  },
  {
    "id": "10812",
    "Sentence": "In this study, a novel <\\entity><\\entity> LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of inhibitory kappaB (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10813",
    "Sentence": "In this study, a novel iminobenzoxathiolone LYR-71 of 6-methyl-2-propylimino-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one has been demonstrated to inhibit in vitro catalytic activity of <\\entity><\\entity> (IkappaB) kinase beta (IKKbeta), a key enzyme required for NF-kappaB activation, with an IC(50) value of 7 microM.",
    "Label": ""
  },
  {
    "id": "10815",
    "Sentence": "<\\entity><\\entity> inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (LPS)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10816",
    "Sentence": "LYR-71 inhibited IKKbeta-mediated phosphorylation of cytoplasmic IkappaBalpha in lipopolysaccharide (<\\entity><\\entity>)-activated macrophages, and sequentially preventing IkappaBalpha degradation as well as transcriptional activation of NF-kappaB.",
    "Label": ""
  },
  {
    "id": "10818",
    "Sentence": "Furthermore, <\\entity><\\entity> down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": ""
  },
  {
    "id": "10819",
    "Sentence": "Furthermore, LYR-71 down-regulated LPS-induced transcription of interleukin (<\\entity><\\entity> or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": ""
  },
  {
    "id": "10821",
    "Sentence": "Furthermore, <\\entity><\\entity> down-regulated LPS-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": ""
  },
  {
    "id": "10822",
    "Sentence": "Furthermore, LYR-71 down-regulated <\\entity><\\entity>-induced transcription of interleukin (IL)-1beta or other cytokines in the cells, and inhibited expression vector IKKbeta-elicited IL-1beta promoter activity.",
    "Label": ""
  },
  {
    "id": "10824",
    "Sentence": "Taken together, <\\entity><\\entity> was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on LPS-induced expression of inflammatory cytokines at the transcription level.",
    "Label": ""
  },
  {
    "id": "10825",
    "Sentence": "Taken together, LYR-71 was an efficient inhibitor of IKKbeta, preventing NF-kappaB activation in macrophages, and this mechanism of action could contribute its down-regulatory effect on <\\entity><\\entity>-induced expression of inflammatory cytokines at the transcription level.",
    "Label": ""
  },
  {
    "id": "10831",
    "Sentence": "A comparative intervention trial on <\\entity><\\entity> fortified with NaFe-EDTA and FeSO4+citrate in iron deficiency anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of iron deficiency and anemia in the context of a monotonous diet.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10832",
    "Sentence": "A comparative intervention trial on fish sauce fortified with <\\entity><\\entity> and FeSO4+citrate in iron deficiency anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of iron deficiency and anemia in the context of a monotonous diet.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10833",
    "Sentence": "A comparative intervention trial on fish sauce fortified with NaFe-EDTA and <\\entity><\\entity>+citrate in iron deficiency anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of iron deficiency and anemia in the context of a monotonous diet.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10834",
    "Sentence": "A comparative intervention trial on fish sauce fortified with NaFe-EDTA and FeSO4+<\\entity><\\entity> in iron deficiency anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of iron deficiency and anemia in the context of a monotonous diet.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10835",
    "Sentence": "A comparative intervention trial on fish sauce fortified with NaFe-EDTA and FeSO4+citrate in <\\entity><\\entity> anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of <\\entity><\\entity> and anemia in the context of a monotonous diet.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10836",
    "Sentence": "A comparative intervention trial on fish sauce fortified with NaFe-EDTA and FeSO4+citrate in iron deficiency <\\entity><\\entity> school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of iron deficiency and anemia in the context of a monotonous diet.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10837",
    "Sentence": "A comparative intervention trial on fish sauce fortified with NaFe-EDTA and FeSO4+citrate in iron deficiency anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia <\\entity><\\entity> from high prevalences of iron deficiency and anemia in the context of a monotonous diet.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10838",
    "Sentence": "A comparative intervention trial on fish sauce fortified with NaFe-EDTA and FeSO4+citrate in <\\entity><\\entity> anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of <\\entity><\\entity> and anemia in the context of a monotonous diet.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10839",
    "Sentence": "A comparative intervention trial on fish sauce fortified with NaFe-EDTA and FeSO4+citrate in iron deficiency anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of iron deficiency and <\\entity><\\entity> in the context of a monotonous diet.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10840",
    "Sentence": "OBJECTIVE: To compare the efficacy and safety of placebo Khmer <\\entity><\\entity> to that of 10 mL of <\\entity><\\entity> containing 10 mg of iron, added to daily school meals either as NaFe-EDTA or as FeSO4+ citrate.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10841",
    "Sentence": "OBJECTIVE: To compare the efficacy and safety of placebo Khmer <\\entity><\\entity> to that of 10 mL of <\\entity><\\entity> containing 10 mg of iron, added to daily school meals either as NaFe-EDTA or as FeSO4+ citrate.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10842",
    "Sentence": "OBJECTIVE: To compare the efficacy and safety of placebo Khmer fish sauce to that of 10 mL of fish sauce containing 10 mg of iron, added to daily school meals either as <\\entity><\\entity> or as FeSO4+ citrate.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10843",
    "Sentence": "OBJECTIVE: To compare the efficacy and safety of placebo Khmer fish sauce to that of 10 mL of fish sauce containing 10 mg of iron, added to daily school meals either as NaFe-EDTA or as <\\entity><\\entity>+ citrate.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10844",
    "Sentence": "OBJECTIVE: To compare the efficacy and safety of placebo Khmer fish sauce to that of 10 mL of fish sauce containing 10 mg of iron, added to daily school meals either as NaFe-EDTA or as FeSO4+ <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10845",
    "Sentence": "They were randomly allocated to one of three treatment groups, and followed for 21 weeks during which 114 school meals seasoned with 10 mL of <\\entity><\\entity> were consumed by each participant.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10846",
    "Sentence": "Changes in the concentrations of hemoglobin (hb), serum ferritin (SF), and C-reactive protein (CRP) and in body <\\entity><\\entity> and standing height were determined.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10847",
    "Sentence": "Prevalences of <\\entity><\\entity>, diarrhea, and acute respiratory infections were monitored weekly.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10848",
    "Sentence": "Prevalences of vomiting, <\\entity><\\entity>, and acute respiratory infections were monitored weekly.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10849",
    "Sentence": "Prevalences of vomiting, diarrhea, and <\\entity><\\entity> were monitored weekly.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10850",
    "Sentence": "RESULTS: Both <\\entity><\\entity> increased hb and SF concentrations significantly as compared to placebo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10851",
    "Sentence": "No significant differences were observed between <\\entity><\\entity>+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10852",
    "Sentence": "No significant differences were observed between FeSO4+<\\entity><\\entity> and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10853",
    "Sentence": "No significant differences were observed between FeSO4+citrate and <\\entity><\\entity> fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10854",
    "Sentence": "No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of <\\entity><\\entity> (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10855",
    "Sentence": "No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (<\\entity><\\entity>) or regarding CRP, growth, infections, or side-effects.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10856",
    "Sentence": "No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (<\\entity><\\entity>) or regarding CRP, growth, infections, or side-effects.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10857",
    "Sentence": "No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, <\\entity><\\entity>, or side-effects.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10858",
    "Sentence": "No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10859",
    "Sentence": "CONCLUSIONS: Iron-fortified Khmer <\\entity><\\entity> added to Khmer food is a suitable vehicle for iron fortification in children and adolescents.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10860",
    "Sentence": "<\\entity><\\entity>+citrate and NaFe-EDTA show equivalent efficacy and safety.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10861",
    "Sentence": "FeSO4+<\\entity><\\entity> and NaFe-EDTA show equivalent efficacy and safety.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10862",
    "Sentence": "FeSO4+citrate and <\\entity><\\entity> show equivalent efficacy and safety.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10863",
    "Sentence": "No significant differences were observed between <\\entity><\\entity>+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": ""
  },
  {
    "id": "10864",
    "Sentence": "No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, <\\entity><\\entity>, or side-effects.",
    "Label": ""
  },
  {
    "id": "10866",
    "Sentence": "No significant differences were observed between <\\entity><\\entity>+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": ""
  },
  {
    "id": "10867",
    "Sentence": "No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of <\\entity><\\entity> (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": ""
  },
  {
    "id": "10869",
    "Sentence": "No significant differences were observed between FeSO4+citrate and <\\entity><\\entity> fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": ""
  },
  {
    "id": "10870",
    "Sentence": "No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, <\\entity><\\entity>, or side-effects.",
    "Label": ""
  },
  {
    "id": "10872",
    "Sentence": "No significant differences were observed between FeSO4+citrate and <\\entity><\\entity> fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": ""
  },
  {
    "id": "10873",
    "Sentence": "No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of <\\entity><\\entity> (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": ""
  },
  {
    "id": "10875",
    "Sentence": "No significant differences were observed between FeSO4+<\\entity><\\entity> and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": ""
  },
  {
    "id": "10876",
    "Sentence": "No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, <\\entity><\\entity>, or side-effects.",
    "Label": ""
  },
  {
    "id": "10878",
    "Sentence": "No significant differences were observed between FeSO4+<\\entity><\\entity> and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": ""
  },
  {
    "id": "10879",
    "Sentence": "No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of <\\entity><\\entity> (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": ""
  },
  {
    "id": "10881",
    "Sentence": "A comparative intervention trial on <\\entity><\\entity> fortified with NaFe-EDTA and FeSO4+citrate in iron deficiency anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of iron deficiency and anemia in the context of a monotonous diet.",
    "Label": ""
  },
  {
    "id": "10882",
    "Sentence": "A comparative intervention trial on fish sauce fortified with NaFe-EDTA and FeSO4+citrate in <\\entity><\\entity> anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of <\\entity><\\entity> and anemia in the context of a monotonous diet.",
    "Label": ""
  },
  {
    "id": "10884",
    "Sentence": "A comparative intervention trial on fish sauce fortified with <\\entity><\\entity> and FeSO4+citrate in iron deficiency anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of iron deficiency and anemia in the context of a monotonous diet.",
    "Label": ""
  },
  {
    "id": "10885",
    "Sentence": "A comparative intervention trial on fish sauce fortified with NaFe-EDTA and FeSO4+citrate in iron deficiency <\\entity><\\entity> school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of iron deficiency and anemia in the context of a monotonous diet.",
    "Label": ""
  },
  {
    "id": "10887",
    "Sentence": "A comparative intervention trial on fish sauce fortified with <\\entity><\\entity> and FeSO4+citrate in iron deficiency anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of iron deficiency and anemia in the context of a monotonous diet.",
    "Label": ""
  },
  {
    "id": "10888",
    "Sentence": "A comparative intervention trial on fish sauce fortified with NaFe-EDTA and FeSO4+citrate in <\\entity><\\entity> anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of <\\entity><\\entity> and anemia in the context of a monotonous diet.",
    "Label": ""
  },
  {
    "id": "10890",
    "Sentence": "A comparative intervention trial on fish sauce fortified with NaFe-EDTA and <\\entity><\\entity>+citrate in iron deficiency anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of iron deficiency and anemia in the context of a monotonous diet.",
    "Label": ""
  },
  {
    "id": "10891",
    "Sentence": "A comparative intervention trial on fish sauce fortified with NaFe-EDTA and FeSO4+citrate in iron deficiency <\\entity><\\entity> school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of iron deficiency and anemia in the context of a monotonous diet.",
    "Label": ""
  },
  {
    "id": "10893",
    "Sentence": "A comparative intervention trial on fish sauce fortified with NaFe-EDTA and <\\entity><\\entity>+citrate in iron deficiency anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of iron deficiency and anemia in the context of a monotonous diet.",
    "Label": ""
  },
  {
    "id": "10894",
    "Sentence": "A comparative intervention trial on fish sauce fortified with NaFe-EDTA and FeSO4+citrate in <\\entity><\\entity> anemic school children in Kampot, Cambodia.BACKGROUND: Inhabitants of agrarian villages of rural Cambodia suffer from high prevalences of <\\entity><\\entity> and anemia in the context of a monotonous diet.",
    "Label": ""
  },
  {
    "id": "10896",
    "Sentence": "No significant differences were observed between FeSO4+citrate and <\\entity><\\entity> fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": ""
  },
  {
    "id": "10897",
    "Sentence": "No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (<\\entity><\\entity>) or regarding CRP, growth, infections, or side-effects.",
    "Label": ""
  },
  {
    "id": "10899",
    "Sentence": "No significant differences were observed between <\\entity><\\entity>+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, infections, or side-effects.",
    "Label": ""
  },
  {
    "id": "10900",
    "Sentence": "No significant differences were observed between FeSO4+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (<\\entity><\\entity>) or regarding CRP, growth, infections, or side-effects.",
    "Label": ""
  },
  {
    "id": "10906",
    "Sentence": "Inhibition of apoptosome formation by suppression of <\\entity><\\entity> phosphorylation in tyrosine kinase-induced leukemias.Constitutively active tyrosine kinases promote leukemogenesis by increasing cell proliferation and inhibiting apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10907",
    "Sentence": "Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias.Constitutively active <\\entity><\\entity> promote leukemogenesis by increasing cell proliferation and inhibiting apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10908",
    "Sentence": "In many settings, apoptosis occurs by <\\entity><\\entity> release, which nucleates the Apaf-1/caspase-9 apoptosome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10909",
    "Sentence": "In many settings, apoptosis occurs by mitochondrial cytochrome c release, which nucleates the <\\entity><\\entity> apoptosome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10910",
    "Sentence": "Here we report that the leukemogenic kinases, <\\entity><\\entity>, FLT3/D835Y, and Tel-PDGFRbeta, all can inhibit apoptosome function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10911",
    "Sentence": "Here we report that the leukemogenic kinases, Bcr-Abl, <\\entity><\\entity>, and Tel-PDGFRbeta, all can inhibit apoptosome function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10912",
    "Sentence": "Here we report that the leukemogenic kinases, Bcr-Abl, <\\entity><\\entity>, and Tel-PDGFRbeta, all can inhibit apoptosome function.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "10913",
    "Sentence": "Here we report that the leukemogenic kinases, Bcr-Abl, FLT3/D835Y, and <\\entity><\\entity>, all can inhibit apoptosome function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10914",
    "Sentence": "In cells expressing these kinases, the previously reported apoptosome inhibitor, <\\entity><\\entity>, bound strongly to Apaf-1, preventing cytochrome c-induced Apaf-1 oligomerization and caspase-9 recruitment.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10915",
    "Sentence": "In cells expressing these kinases, the previously reported apoptosome inhibitor, Hsp90beta, bound strongly to <\\entity><\\entity>, preventing cytochrome c-induced <\\entity><\\entity> oligomerization and caspase-9 recruitment.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10916",
    "Sentence": "In cells expressing these kinases, the previously reported apoptosome inhibitor, Hsp90beta, bound strongly to Apaf-1, preventing <\\entity><\\entity>-induced Apaf-1 oligomerization and caspase-9 recruitment.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10917",
    "Sentence": "In cells expressing these kinases, the previously reported apoptosome inhibitor, Hsp90beta, bound strongly to <\\entity><\\entity>, preventing cytochrome c-induced <\\entity><\\entity> oligomerization and caspase-9 recruitment.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10918",
    "Sentence": "In cells expressing these kinases, the previously reported apoptosome inhibitor, Hsp90beta, bound strongly to Apaf-1, preventing cytochrome c-induced Apaf-1 oligomerization and <\\entity><\\entity> recruitment.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10919",
    "Sentence": "<\\entity><\\entity> interacted weakly with the apoptosome in untransformed cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10920",
    "Sentence": "While <\\entity><\\entity> was phosphorylated at Ser 226/Ser 255 in untransformed cells, phosphorylation was absent in leukemic cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10921",
    "Sentence": "While Hsp90beta was phosphorylated at <\\entity><\\entity> in untransformed cells, phosphorylation was absent in leukemic cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10922",
    "Sentence": "Expression of <\\entity><\\entity> Hsp90beta (S226A/S255A), which mimics the hypophosphorylated form in leukemic cells, conferred resistance to cytochrome c-induced apoptosome activation in normal cells, reflecting enhanced binding of nonphosphorylatable Hsp90beta to Apaf-1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10923",
    "Sentence": "Expression of mutant <\\entity><\\entity>, which mimics the hypophosphorylated form in leukemic cells, conferred resistance to cytochrome c-induced apoptosome activation in normal cells, reflecting enhanced binding of nonphosphorylatable Hsp90beta to Apaf-1.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "10924",
    "Sentence": "Expression of mutant <\\entity><\\entity>, which mimics the hypophosphorylated form in leukemic cells, conferred resistance to cytochrome c-induced apoptosome activation in normal cells, reflecting enhanced binding of nonphosphorylatable Hsp90beta to Apaf-1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10925",
    "Sentence": "Expression of mutant Hsp90beta (<\\entity><\\entity>), which mimics the hypophosphorylated form in leukemic cells, conferred resistance to cytochrome c-induced apoptosome activation in normal cells, reflecting enhanced binding of nonphosphorylatable Hsp90beta to Apaf-1.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "10926",
    "Sentence": "Expression of mutant Hsp90beta (<\\entity><\\entity>), which mimics the hypophosphorylated form in leukemic cells, conferred resistance to cytochrome c-induced apoptosome activation in normal cells, reflecting enhanced binding of nonphosphorylatable Hsp90beta to Apaf-1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10927",
    "Sentence": "Expression of mutant Hsp90beta (S226A/S255A), which mimics the hypophosphorylated form in leukemic cells, conferred resistance to <\\entity><\\entity>-induced apoptosome activation in normal cells, reflecting enhanced binding of nonphosphorylatable Hsp90beta to Apaf-1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10928",
    "Sentence": "Expression of mutant <\\entity><\\entity> (S226A/S255A), which mimics the hypophosphorylated form in leukemic cells, conferred resistance to cytochrome c-induced apoptosome activation in normal cells, reflecting enhanced binding of nonphosphorylatable <\\entity><\\entity> to Apaf-1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10929",
    "Sentence": "Expression of mutant Hsp90beta (S226A/S255A), which mimics the hypophosphorylated form in leukemic cells, conferred resistance to cytochrome c-induced apoptosome activation in normal cells, reflecting enhanced binding of nonphosphorylatable Hsp90beta to <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10930",
    "Sentence": "In <\\entity><\\entity>-positive mouse bone marrow cells, nonphosphorylatable Hsp90beta expression conferred imatinib (Gleevec) resistance.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10931",
    "Sentence": "In Bcr-Abl-positive mouse bone marrow cells, nonphosphorylatable <\\entity><\\entity> expression conferred imatinib (Gleevec) resistance.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10932",
    "Sentence": "In Bcr-Abl-positive mouse bone marrow cells, nonphosphorylatable Hsp90beta expression conferred <\\entity><\\entity> (Gleevec) resistance.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10933",
    "Sentence": "In Bcr-Abl-positive mouse bone marrow cells, nonphosphorylatable Hsp90beta expression conferred imatinib (<\\entity><\\entity>) resistance.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10934",
    "Sentence": "These data provide an explanation for apoptosome inhibition by activated leukemogenic <\\entity><\\entity> and suggest that alterations in Hsp90beta-apoptosome interactions may contribute to chemoresistance in leukemias.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10935",
    "Sentence": "These data provide an explanation for apoptosome inhibition by activated leukemogenic tyrosine kinases and suggest that alterations in <\\entity><\\entity>-apoptosome interactions may contribute to chemoresistance in leukemias.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10936",
    "Sentence": "In Bcr-Abl-positive mouse bone marrow cells, nonphosphorylatable Hsp90beta expression conferred imatinib (<\\entity><\\entity>) resistance.",
    "Label": ""
  },
  {
    "id": "10937",
    "Sentence": "In <\\entity><\\entity>-positive mouse bone marrow cells, nonphosphorylatable Hsp90beta expression conferred imatinib (Gleevec) resistance.",
    "Label": ""
  },
  {
    "id": "10939",
    "Sentence": "In Bcr-Abl-positive mouse bone marrow cells, nonphosphorylatable Hsp90beta expression conferred imatinib (<\\entity><\\entity>) resistance.",
    "Label": ""
  },
  {
    "id": "10940",
    "Sentence": "In Bcr-Abl-positive mouse bone marrow cells, nonphosphorylatable <\\entity><\\entity> expression conferred imatinib (Gleevec) resistance.",
    "Label": ""
  },
  {
    "id": "10942",
    "Sentence": "Inhibition of apoptosome formation by suppression of <\\entity><\\entity> phosphorylation in tyrosine kinase-induced leukemias.Constitutively active tyrosine kinases promote leukemogenesis by increasing cell proliferation and inhibiting apoptosis.",
    "Label": ""
  },
  {
    "id": "10943",
    "Sentence": "Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced <\\entity><\\entity>.Constitutively active tyrosine kinases promote leukemogenesis by increasing cell proliferation and inhibiting apoptosis.",
    "Label": ""
  },
  {
    "id": "10945",
    "Sentence": "These data provide an explanation for apoptosome inhibition by activated leukemogenic tyrosine kinases and suggest that alterations in <\\entity><\\entity>-apoptosome interactions may contribute to chemoresistance in leukemias.",
    "Label": ""
  },
  {
    "id": "10946",
    "Sentence": "These data provide an explanation for apoptosome inhibition by activated leukemogenic tyrosine kinases and suggest that alterations in Hsp90beta-apoptosome interactions may contribute to chemoresistance in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10948",
    "Sentence": "In Bcr-Abl-positive mouse bone marrow cells, nonphosphorylatable Hsp90beta expression conferred <\\entity><\\entity> (Gleevec) resistance.",
    "Label": ""
  },
  {
    "id": "10949",
    "Sentence": "In Bcr-Abl-positive mouse bone marrow cells, nonphosphorylatable <\\entity><\\entity> expression conferred imatinib (Gleevec) resistance.",
    "Label": ""
  },
  {
    "id": "10955",
    "Sentence": "<\\entity><\\entity>: a proposal for treatment protocol with surgery and adjuvant chemotherapy.The case of a 4-month-old male infant treated with combined surgery and chemotherapy for an aggressive recurrent melanotic neuroectodermal tumor of infancy (MNTI) on the top of the alveolar process of the mandible with a long-term follow-up is presented.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10956",
    "Sentence": "Recurrent melanotic neuroectodermal tumor of infancy: a proposal for treatment protocol with surgery and adjuvant chemotherapy.The case of a 4-month-old male infant treated with combined surgery and chemotherapy for an <\\entity><\\entity> recurrent melanotic neuroectodermal tumor of infancy (MNTI) on the top of the alveolar process of the mandible with a long-term follow-up is presented.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10957",
    "Sentence": "Recurrent melanotic neuroectodermal tumor of infancy: a proposal for treatment protocol with surgery and adjuvant chemotherapy.The case of a 4-month-old male infant treated with combined surgery and chemotherapy for an aggressive <\\entity><\\entity> (MNTI) on the top of the alveolar process of the mandible with a long-term follow-up is presented.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10958",
    "Sentence": "Recurrent melanotic neuroectodermal tumor of infancy: a proposal for treatment protocol with surgery and adjuvant chemotherapy.The case of a 4-month-old male infant treated with combined surgery and chemotherapy for an aggressive recurrent melanotic neuroectodermal tumor of infancy (<\\entity><\\entity>) on the top of the alveolar process of the mandible with a long-term follow-up is presented.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10959",
    "Sentence": "After several local recurrences and because radical surgical excision would give gross functional and aesthetic mutilation, finally complete, long-lasting remission was achieved with adjuvant chemotherapy, according to a <\\entity><\\entity> protocol (10-year follow-up).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10960",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this <\\entity><\\entity> showed loss of heterozygosity of chromosome 1p and gain of chromosome 7q analogue to neuroblastomas.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10961",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this tumor showed <\\entity><\\entity> and gain of chromosome 7q analogue to neuroblastomas.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "10962",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this tumor showed <\\entity><\\entity> and gain of chromosome 7q analogue to neuroblastomas.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10963",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this tumor showed loss of heterozygosity of chromosome 1p and <\\entity><\\entity> analogue to neuroblastomas.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "10964",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this tumor showed loss of heterozygosity of chromosome 1p and <\\entity><\\entity> analogue to neuroblastomas.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10965",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this tumor showed loss of heterozygosity of chromosome 1p and <\\entity><\\entity> analogue to neuroblastomas.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10966",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this tumor showed loss of heterozygosity of chromosome 1p and gain of chromosome 7q analogue to <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10967",
    "Sentence": "A combination of surgery and chemotherapy should be the preferred treatment in case of a recurrence <\\entity><\\entity> because optimal functional and aesthetic outcome.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "10968",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this tumor showed loss of heterozygosity of chromosome 1p and <\\entity><\\entity> analogue to neuroblastomas.",
    "Label": ""
  },
  {
    "id": "10969",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this tumor showed loss of heterozygosity of chromosome 1p and gain of chromosome 7q analogue to <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10971",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this tumor showed loss of heterozygosity of chromosome 1p and <\\entity><\\entity> analogue to neuroblastomas.",
    "Label": ""
  },
  {
    "id": "10972",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this <\\entity><\\entity> showed loss of heterozygosity of chromosome 1p and gain of chromosome 7q analogue to neuroblastomas.",
    "Label": ""
  },
  {
    "id": "10974",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this tumor showed <\\entity><\\entity> and gain of chromosome 7q analogue to neuroblastomas.",
    "Label": ""
  },
  {
    "id": "10975",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this tumor showed loss of heterozygosity of chromosome 1p and gain of chromosome 7q analogue to <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "10977",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this tumor showed <\\entity><\\entity> and gain of chromosome 7q analogue to neuroblastomas.",
    "Label": ""
  },
  {
    "id": "10978",
    "Sentence": "The reason for this protocol was because molecular genetic studies of this <\\entity><\\entity> showed loss of heterozygosity of chromosome 1p and gain of chromosome 7q analogue to neuroblastomas.",
    "Label": ""
  },
  {
    "id": "10984",
    "Sentence": "<\\entity><\\entity> ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.ATP-sensitive P2X7 receptors are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10985",
    "Sentence": "[3H]A-804598 (<\\entity><\\entity>) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.ATP-sensitive P2X7 receptors are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10986",
    "Sentence": "[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for <\\entity><\\entity>.ATP-sensitive <\\entity><\\entity> are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10987",
    "Sentence": "[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.<\\entity><\\entity> are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10988",
    "Sentence": "[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.<\\entity><\\entity> are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10989",
    "Sentence": "[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for <\\entity><\\entity> receptors.ATP-sensitive <\\entity><\\entity> receptors are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10990",
    "Sentence": "Activation of <\\entity><\\entity> leads to rapid changes in intracellular calcium concentrations, release of the pro-inflammatory cytokine IL-1beta, and following prolonged agonist exposure, the formation of cytolytic pores in plasma membranes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10991",
    "Sentence": "Activation of P2X7 receptors leads to rapid changes in intracellular <\\entity><\\entity> concentrations, release of the pro-inflammatory cytokine IL-1beta, and following prolonged agonist exposure, the formation of cytolytic pores in plasma membranes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10992",
    "Sentence": "Activation of P2X7 receptors leads to rapid changes in intracellular calcium concentrations, release of the pro-inflammatory cytokine <\\entity><\\entity>, and following prolonged agonist exposure, the formation of cytolytic pores in plasma membranes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10993",
    "Sentence": "Data from gene knockout studies and recently described selective antagonists indicate a role for <\\entity><\\entity> activation in inflammation and pain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10994",
    "Sentence": "While several species <\\entity><\\entity> exist, A-804598 represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10995",
    "Sentence": "While several species selective <\\entity><\\entity> antagonists exist, A-804598 represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) <\\entity><\\entity> receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10996",
    "Sentence": "While several species selective P2X7 antagonists exist, <\\entity><\\entity> represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10997",
    "Sentence": "While several species selective P2X7 antagonists exist, A-804598 represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "10998",
    "Sentence": "<\\entity><\\entity> also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "10999",
    "Sentence": "A-804598 also potently blocked agonist stimulated release of <\\entity><\\entity> and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11000",
    "Sentence": "A-804598 also potently blocked agonist stimulated release of IL-1beta and <\\entity><\\entity> uptake from differentiated THP-1 cells that natively express human P2X7 receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11001",
    "Sentence": "A-804598 also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated <\\entity><\\entity> that natively express human P2X7 receptors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11002",
    "Sentence": "A-804598 also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11003",
    "Sentence": "<\\entity><\\entity> was tritiated ([3H]<\\entity><\\entity>; 8.1Ci/mmol) and utilized to study recombinant rat P2X7 receptors expressed in 1321N1 cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11004",
    "Sentence": "A-804598 was tritiated (<\\entity><\\entity>; 8.1Ci/mmol) and utilized to study recombinant rat P2X7 receptors expressed in 1321N1 cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11005",
    "Sentence": "A-804598 was tritiated ([3H]A-804598; 8.1Ci/mmol) and utilized to study recombinant rat <\\entity><\\entity> expressed in 1321N1 cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11006",
    "Sentence": "<\\entity><\\entity> labeled a single class of high affinity binding sites (Kd=2.4 nM and apparent Bmax=0.56 pmol/mg).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11007",
    "Sentence": "<\\entity><\\entity> specific binding was observed in untransfected 1321N1 cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11008",
    "Sentence": "The pharmacological profile for <\\entity><\\entity> to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P<0.05).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11009",
    "Sentence": "The pharmacological profile for <\\entity><\\entity> to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P<0.05).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11010",
    "Sentence": "The pharmacological profile for P2X antagonists to inhibit <\\entity><\\entity> binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P<0.05).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11011",
    "Sentence": "The pharmacological profile for P2X antagonists to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of <\\entity><\\entity> (r=0.95, P<0.05).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11012",
    "Sentence": "These data demonstrate that <\\entity><\\entity> is one of the most potent and selective antagonists for mammalian P2X7 receptors described to date and [3H]<\\entity><\\entity> is a high affinity antagonist radioligand that specifically labels rat P2X7 receptors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11013",
    "Sentence": "These data demonstrate that A-804598 is one of the most potent and selective antagonists for mammalian <\\entity><\\entity> described to date and [3H]A-804598 is a high affinity antagonist radioligand that specifically labels rat <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11014",
    "Sentence": "These data demonstrate that A-804598 is one of the most potent and selective antagonists for mammalian P2X7 receptors described to date and <\\entity><\\entity> is a high affinity antagonist radioligand that specifically labels rat P2X7 receptors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11015",
    "Sentence": "These data demonstrate that A-804598 is one of the most potent and selective antagonists for mammalian <\\entity><\\entity> described to date and [3H]A-804598 is a high affinity antagonist radioligand that specifically labels rat <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11016",
    "Sentence": "<\\entity><\\entity> ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.ATP-sensitive P2X7 receptors are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.",
    "Label": ""
  },
  {
    "id": "11017",
    "Sentence": "[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for <\\entity><\\entity>.ATP-sensitive <\\entity><\\entity> are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.",
    "Label": ""
  },
  {
    "id": "11019",
    "Sentence": "[3H]A-804598 (<\\entity><\\entity>) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.ATP-sensitive P2X7 receptors are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.",
    "Label": ""
  },
  {
    "id": "11020",
    "Sentence": "[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for <\\entity><\\entity>.ATP-sensitive <\\entity><\\entity> are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.",
    "Label": ""
  },
  {
    "id": "11022",
    "Sentence": "Activation of P2X7 receptors leads to rapid changes in intracellular <\\entity><\\entity> concentrations, release of the pro-inflammatory cytokine IL-1beta, and following prolonged agonist exposure, the formation of cytolytic pores in plasma membranes.",
    "Label": ""
  },
  {
    "id": "11023",
    "Sentence": "Activation of <\\entity><\\entity> leads to rapid changes in intracellular calcium concentrations, release of the pro-inflammatory cytokine IL-1beta, and following prolonged agonist exposure, the formation of cytolytic pores in plasma membranes.",
    "Label": ""
  },
  {
    "id": "11025",
    "Sentence": "While several species selective P2X7 antagonists exist, <\\entity><\\entity> represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors.",
    "Label": ""
  },
  {
    "id": "11026",
    "Sentence": "While several species selective P2X7 antagonists exist, A-804598 represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11028",
    "Sentence": "<\\entity><\\entity> also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors.",
    "Label": ""
  },
  {
    "id": "11029",
    "Sentence": "A-804598 also potently blocked agonist stimulated release of <\\entity><\\entity> and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors.",
    "Label": ""
  },
  {
    "id": "11031",
    "Sentence": "<\\entity><\\entity> also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors.",
    "Label": ""
  },
  {
    "id": "11032",
    "Sentence": "A-804598 also potently blocked agonist stimulated release of IL-1beta and <\\entity><\\entity> uptake from differentiated THP-1 cells that natively express human P2X7 receptors.",
    "Label": ""
  },
  {
    "id": "11034",
    "Sentence": "The pharmacological profile for <\\entity><\\entity> to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P<0.05).",
    "Label": ""
  },
  {
    "id": "11035",
    "Sentence": "The pharmacological profile for P2X antagonists to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of <\\entity><\\entity> (r=0.95, P<0.05).",
    "Label": ""
  },
  {
    "id": "11037",
    "Sentence": "These data demonstrate that <\\entity><\\entity> is one of the most potent and selective antagonists for mammalian P2X7 receptors described to date and [3H]<\\entity><\\entity> is a high affinity antagonist radioligand that specifically labels rat P2X7 receptors.",
    "Label": ""
  },
  {
    "id": "11038",
    "Sentence": "These data demonstrate that A-804598 is one of the most potent and selective antagonists for mammalian <\\entity><\\entity> described to date and [3H]A-804598 is a high affinity antagonist radioligand that specifically labels rat <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11040",
    "Sentence": "These data demonstrate that A-804598 is one of the most potent and selective antagonists for mammalian P2X7 receptors described to date and <\\entity><\\entity> is a high affinity antagonist radioligand that specifically labels rat P2X7 receptors.",
    "Label": ""
  },
  {
    "id": "11041",
    "Sentence": "These data demonstrate that A-804598 is one of the most potent and selective antagonists for mammalian <\\entity><\\entity> described to date and [3H]A-804598 is a high affinity antagonist radioligand that specifically labels rat <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11043",
    "Sentence": "[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.<\\entity><\\entity> are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.",
    "Label": ""
  },
  {
    "id": "11044",
    "Sentence": "[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors.<\\entity><\\entity> are localized on cells of immunological origin including peripheral macrophages and glial cells in the CNS.",
    "Label": ""
  },
  {
    "id": "11046",
    "Sentence": "Activation of P2X7 receptors leads to rapid changes in intracellular <\\entity><\\entity> concentrations, release of the pro-inflammatory cytokine IL-1beta, and following prolonged agonist exposure, the formation of cytolytic pores in plasma membranes.",
    "Label": ""
  },
  {
    "id": "11047",
    "Sentence": "Activation of P2X7 receptors leads to rapid changes in intracellular calcium concentrations, release of the pro-inflammatory cytokine <\\entity><\\entity>, and following prolonged agonist exposure, the formation of cytolytic pores in plasma membranes.",
    "Label": ""
  },
  {
    "id": "11049",
    "Sentence": "Data from gene knockout studies and recently described selective antagonists indicate a role for <\\entity><\\entity> activation in inflammation and pain.",
    "Label": ""
  },
  {
    "id": "11050",
    "Sentence": "Data from gene knockout studies and recently described selective antagonists indicate a role for P2X7 receptor activation in <\\entity><\\entity> and pain.",
    "Label": ""
  },
  {
    "id": "11052",
    "Sentence": "Data from gene knockout studies and recently described selective antagonists indicate a role for <\\entity><\\entity> activation in inflammation and pain.",
    "Label": ""
  },
  {
    "id": "11053",
    "Sentence": "Data from gene knockout studies and recently described selective antagonists indicate a role for P2X7 receptor activation in inflammation and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11055",
    "Sentence": "<\\entity><\\entity> also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors.",
    "Label": ""
  },
  {
    "id": "11056",
    "Sentence": "A-804598 also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11058",
    "Sentence": "<\\entity><\\entity> labeled a single class of high affinity binding sites (Kd=2.4 nM and apparent Bmax=0.56 pmol/mg).",
    "Label": ""
  },
  {
    "id": "11059",
    "Sentence": "A-804598 was tritiated ([3H]A-804598; 8.1Ci/mmol) and utilized to study recombinant rat <\\entity><\\entity> expressed in 1321N1 cells.",
    "Label": ""
  },
  {
    "id": "11061",
    "Sentence": "The pharmacological profile for P2X antagonists to inhibit <\\entity><\\entity> binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P<0.05).",
    "Label": ""
  },
  {
    "id": "11062",
    "Sentence": "The pharmacological profile for P2X antagonists to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of <\\entity><\\entity> (r=0.95, P<0.05).",
    "Label": ""
  },
  {
    "id": "11064",
    "Sentence": "The pharmacological profile for P2X antagonists to inhibit <\\entity><\\entity> binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P<0.05).",
    "Label": ""
  },
  {
    "id": "11065",
    "Sentence": "The pharmacological profile for <\\entity><\\entity> to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P<0.05).",
    "Label": ""
  },
  {
    "id": "11067",
    "Sentence": "While several species selective P2X7 antagonists exist, <\\entity><\\entity> represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) P2X7 receptors.",
    "Label": ""
  },
  {
    "id": "11068",
    "Sentence": "While several species selective <\\entity><\\entity> antagonists exist, A-804598 represents a structurally novel, competitive, and selective antagonist that has equivalent high affinity at rat (IC50 = 10 nM), mouse (IC50 = 9 nM) and human (IC50 = 11 nM) <\\entity><\\entity> receptors.",
    "Label": ""
  },
  {
    "id": "11070",
    "Sentence": "<\\entity><\\entity> also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated THP-1 cells that natively express human P2X7 receptors.",
    "Label": ""
  },
  {
    "id": "11071",
    "Sentence": "A-804598 also potently blocked agonist stimulated release of IL-1beta and Yo-Pro uptake from differentiated <\\entity><\\entity> that natively express human P2X7 receptors.",
    "Label": ""
  },
  {
    "id": "11077",
    "Sentence": "<\\entity><\\entity> in Wegener's granulomatosis.OBJECTIVE: Current developments in the management of Wegener's granulomatosis (WG) focus on adoption of therapeutic strategies to avoid complications of both the disease and its therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11078",
    "Sentence": "Hypogonadism in <\\entity><\\entity>.OBJECTIVE: Current developments in the management of <\\entity><\\entity> (WG) focus on adoption of therapeutic strategies to avoid complications of both the disease and its therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11079",
    "Sentence": "Hypogonadism in <\\entity><\\entity>.OBJECTIVE: Current developments in the management of <\\entity><\\entity> (WG) focus on adoption of therapeutic strategies to avoid complications of both the disease and its therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11080",
    "Sentence": "Hypogonadism in Wegener's granulomatosis.OBJECTIVE: Current developments in the management of Wegener's granulomatosis (<\\entity><\\entity>) focus on adoption of therapeutic strategies to avoid complications of both the disease and its therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11081",
    "Sentence": "Hypogonadism in Wegener's granulomatosis.OBJECTIVE: Current developments in the management of Wegener's granulomatosis (WG) focus on adoption of therapeutic strategies to avoid <\\entity><\\entity> of both the disease and its therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11082",
    "Sentence": "Hypogonadism in Wegener's granulomatosis.OBJECTIVE: Current developments in the management of Wegener's granulomatosis (WG) focus on adoption of therapeutic strategies to avoid complications of both the <\\entity><\\entity> and its therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11083",
    "Sentence": "Systematic analyses with respect to the reproductive system in <\\entity><\\entity> are missing.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11084",
    "Sentence": "METHODS: Data of a cross-sectional study of <\\entity><\\entity> in 19 male WG patients were analysed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11085",
    "Sentence": "METHODS: Data of a cross-sectional study of sexual hormones in 19 male <\\entity><\\entity> patients were analysed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11086",
    "Sentence": "<\\entity><\\entity> extension was classified according to the ears, nose, and throat (E), lungs (L), and kidneys (K) classification (ELK classification) and to the disease extent index (DEI).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11087",
    "Sentence": "Disease extension was classified according to the ears, nose, and throat (E), lungs (L), and kidneys (K) classification (ELK classification) and to the <\\entity><\\entity> extent index (DEI).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11088",
    "Sentence": "Laboratory investigation included measurement of <\\entity><\\entity>, oestradiol, and total serum testosterone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11089",
    "Sentence": "Laboratory investigation included measurement of gonadotrophins, <\\entity><\\entity>, and total serum testosterone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11090",
    "Sentence": "Laboratory investigation included measurement of gonadotrophins, oestradiol, and total serum <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11091",
    "Sentence": "<\\entity><\\entity> was defined by an increase in follicle-stimulating hormone (FSH) beyond twice the upper reference range in the presence of low serum testosterone.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11092",
    "Sentence": "Hypogonadism was defined by an increase in follicle-stimulating hormone (<\\entity><\\entity>) beyond twice the upper reference range in the presence of low serum testosterone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11093",
    "Sentence": "Hypogonadism was defined by an increase in follicle-stimulating hormone (FSH) beyond twice the upper reference range in the presence of low serum <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11094",
    "Sentence": "RESULTS: <\\entity><\\entity> was found in 52.6% of the patients but was not detectable in any of the controls (p<0.0001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11095",
    "Sentence": "No significant correlation to any clinical factor of <\\entity><\\entity>, current or past medication was detected.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11096",
    "Sentence": "In particular, <\\entity><\\entity> or FSH levels were not correlated with current or cumulative use of cyclophosphamide or corticosteroids (p = 0.417, p = 0.293; p = 0.893, p = 0.317).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11097",
    "Sentence": "In particular, testosterone or <\\entity><\\entity> levels were not correlated with current or cumulative use of cyclophosphamide or corticosteroids (p = 0.417, p = 0.293; p = 0.893, p = 0.317).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11098",
    "Sentence": "In particular, testosterone or FSH levels were not correlated with current or cumulative use of <\\entity><\\entity> or corticosteroids (p = 0.417, p = 0.293; p = 0.893, p = 0.317).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11099",
    "Sentence": "In particular, testosterone or FSH levels were not correlated with current or cumulative use of cyclophosphamide or <\\entity><\\entity> (p = 0.417, p = 0.293; p = 0.893, p = 0.317).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11100",
    "Sentence": "CONCLUSION: Data of our study revealed an unexpected high rate of <\\entity><\\entity> irrespective of cyclophosphamide use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11101",
    "Sentence": "CONCLUSION: Data of our study revealed an unexpected high rate of hypogonadism irrespective of <\\entity><\\entity> use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11102",
    "Sentence": "CONCLUSION: Data of our study revealed an unexpected high rate of hypogonadism irrespective of cyclophosphamide use, and subclinical involvement of the <\\entity><\\entity> by the vasculitis itself might be an alternative explanation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11103",
    "Sentence": "CONCLUSION: Data of our study revealed an unexpected high rate of hypogonadism irrespective of cyclophosphamide use, and subclinical involvement of the testes by the <\\entity><\\entity> itself might be an alternative explanation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11104",
    "Sentence": "Screening during the course of the <\\entity><\\entity> is reasonable as hypogonadism might severely affect patients' quality of life.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11105",
    "Sentence": "Screening during the course of the disease is reasonable as <\\entity><\\entity> might severely affect patients' quality of life.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11106",
    "Sentence": "CONCLUSION: Data of our study revealed an unexpected high rate of hypogonadism irrespective of <\\entity><\\entity> use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation.",
    "Label": ""
  },
  {
    "id": "11107",
    "Sentence": "CONCLUSION: Data of our study revealed an unexpected high rate of <\\entity><\\entity> irrespective of cyclophosphamide use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation.",
    "Label": ""
  },
  {
    "id": "11109",
    "Sentence": "CONCLUSION: Data of our study revealed an unexpected high rate of hypogonadism irrespective of <\\entity><\\entity> use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation.",
    "Label": ""
  },
  {
    "id": "11110",
    "Sentence": "CONCLUSION: Data of our study revealed an unexpected high rate of hypogonadism irrespective of cyclophosphamide use, and subclinical involvement of the <\\entity><\\entity> by the vasculitis itself might be an alternative explanation.",
    "Label": ""
  },
  {
    "id": "11112",
    "Sentence": "CONCLUSION: Data of our study revealed an unexpected high rate of hypogonadism irrespective of <\\entity><\\entity> use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation.",
    "Label": ""
  },
  {
    "id": "11113",
    "Sentence": "CONCLUSION: Data of our study revealed an unexpected high rate of hypogonadism irrespective of cyclophosphamide use, and subclinical involvement of the testes by the <\\entity><\\entity> itself might be an alternative explanation.",
    "Label": ""
  },
  {
    "id": "11115",
    "Sentence": "Hypogonadism was defined by an increase in follicle-stimulating hormone (FSH) beyond twice the upper reference range in the presence of low serum <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11116",
    "Sentence": "<\\entity><\\entity> was defined by an increase in follicle-stimulating hormone (FSH) beyond twice the upper reference range in the presence of low serum testosterone.",
    "Label": ""
  },
  {
    "id": "11118",
    "Sentence": "CONCLUSION: Data of our study revealed an unexpected high rate of hypogonadism irrespective of <\\entity><\\entity> use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation.",
    "Label": ""
  },
  {
    "id": "11119",
    "Sentence": "CONCLUSION: Data of our study revealed an unexpected high rate of <\\entity><\\entity> irrespective of cyclophosphamide use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation.",
    "Label": ""
  },
  {
    "id": "11121",
    "Sentence": "CONCLUSION: Data of our study revealed an unexpected high rate of hypogonadism irrespective of <\\entity><\\entity> use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation.",
    "Label": ""
  },
  {
    "id": "11122",
    "Sentence": "CONCLUSION: Data of our study revealed an unexpected high rate of hypogonadism irrespective of cyclophosphamide use, and subclinical involvement of the <\\entity><\\entity> by the vasculitis itself might be an alternative explanation.",
    "Label": ""
  },
  {
    "id": "11124",
    "Sentence": "Hypogonadism was defined by an increase in follicle-stimulating hormone (<\\entity><\\entity>) beyond twice the upper reference range in the presence of low serum testosterone.",
    "Label": ""
  },
  {
    "id": "11125",
    "Sentence": "<\\entity><\\entity> was defined by an increase in follicle-stimulating hormone (FSH) beyond twice the upper reference range in the presence of low serum testosterone.",
    "Label": ""
  },
  {
    "id": "11131",
    "Sentence": "Role of transporter genes in <\\entity><\\entity> resistance.The 50% inhibitory concentration (IC50) values for <\\entity><\\entity> from 60 cell lines of the National Cancer Institute (NCI), USA, were correlated with the microarray-based mRNA expression levels of 55 transporter genes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11132",
    "Sentence": "Role of transporter genes in <\\entity><\\entity> resistance.The 50% inhibitory concentration (IC50) values for <\\entity><\\entity> from 60 cell lines of the National Cancer Institute (NCI), USA, were correlated with the microarray-based mRNA expression levels of 55 transporter genes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11133",
    "Sentence": "<\\entity><\\entity> transporting ATPases, Cu2+ transporting ATPases, glutamate transporters of the solute carrier family 31, copper transporters of the solute carrier family 31, and ATP-binding cassette (ABC) transporter genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11134",
    "Sentence": "lysosomal H+ <\\entity><\\entity>, Cu2+ <\\entity><\\entity>, glutamate transporters of the solute carrier family 31, copper transporters of the solute carrier family 31, and ATP-binding cassette (ABC) transporter genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11135",
    "Sentence": "lysosomal H+ transporting ATPases, <\\entity><\\entity> transporting ATPases, glutamate transporters of the solute carrier family 31, copper transporters of the solute carrier family 31, and ATP-binding cassette (ABC) transporter genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11136",
    "Sentence": "lysosomal H+ <\\entity><\\entity>, Cu2+ <\\entity><\\entity>, glutamate transporters of the solute carrier family 31, copper transporters of the solute carrier family 31, and ATP-binding cassette (ABC) transporter genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11137",
    "Sentence": "lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, <\\entity><\\entity>, copper transporters of the solute carrier family 31, and ATP-binding cassette (ABC) transporter genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11138",
    "Sentence": "lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, glutamate transporters of the <\\entity><\\entity> family 31, copper transporters of the <\\entity><\\entity> family 31, and ATP-binding cassette (ABC) transporter genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11139",
    "Sentence": "lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, glutamate transporters of the solute carrier family 31, <\\entity><\\entity>, and ATP-binding cassette (ABC) transporter genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11140",
    "Sentence": "lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, glutamate transporters of the <\\entity><\\entity> family 31, copper transporters of the <\\entity><\\entity> family 31, and ATP-binding cassette (ABC) transporter genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11141",
    "Sentence": "lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, glutamate transporters of the solute carrier family 31, copper transporters of the solute carrier family 31, and <\\entity><\\entity> (ABC) transporter genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11142",
    "Sentence": "lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, glutamate transporters of the solute carrier family 31, copper transporters of the solute carrier family 31, and ATP-binding cassette (<\\entity><\\entity> genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11143",
    "Sentence": "lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, glutamate transporters of the solute carrier family 31, copper transporters of the solute carrier family 31, and ATP-binding cassette (<\\entity><\\entity> genes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11144",
    "Sentence": "The expression levels of 17 genes represented by 21 clones correlated significantly with the IC50 values for <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11145",
    "Sentence": "Hierarchical cluster analysis further enabled the prediction of the sensitivity or resistance of these cell lines to <\\entity><\\entity> with respect to the mRNA expression of these set of transporter genes under study.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11146",
    "Sentence": "One among the 17 genes studied is <\\entity><\\entity> which is involved in the transport of copper ions across the cell membrane into the cell.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11147",
    "Sentence": "One among the 17 genes studied is ATP7B which is involved in the transport of <\\entity><\\entity> across the cell membrane into the cell.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11148",
    "Sentence": "We conclude that our microarray-based approach is a feasible and effective tool in identifying prognostic markers for drug resistance in <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11149",
    "Sentence": "One among the 17 genes studied is ATP7B which is involved in the transport of <\\entity><\\entity> across the cell membrane into the cell.",
    "Label": ""
  },
  {
    "id": "11150",
    "Sentence": "One among the 17 genes studied is <\\entity><\\entity> which is involved in the transport of copper ions across the cell membrane into the cell.",
    "Label": ""
  },
  {
    "id": "11152",
    "Sentence": "lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, glutamate transporters of the solute carrier family 31, copper transporters of the solute carrier family 31, and ATP-binding cassette (<\\entity><\\entity> genes.",
    "Label": ""
  },
  {
    "id": "11153",
    "Sentence": "lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, glutamate transporters of the <\\entity><\\entity> family 31, copper transporters of the <\\entity><\\entity> family 31, and ATP-binding cassette (ABC) transporter genes.",
    "Label": ""
  },
  {
    "id": "11155",
    "Sentence": "lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, <\\entity><\\entity>, copper transporters of the solute carrier family 31, and ATP-binding cassette (ABC) transporter genes.",
    "Label": ""
  },
  {
    "id": "11156",
    "Sentence": "The transporters are known to be involved in multiple <\\entity><\\entity> resistance and belong to different classes, e.g.",
    "Label": ""
  },
  {
    "id": "11158",
    "Sentence": "lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, glutamate transporters of the solute carrier family 31, <\\entity><\\entity>, and ATP-binding cassette (ABC) transporter genes.",
    "Label": ""
  },
  {
    "id": "11159",
    "Sentence": "The transporters are known to be involved in multiple <\\entity><\\entity> resistance and belong to different classes, e.g.",
    "Label": ""
  },
  {
    "id": "11161",
    "Sentence": "lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, glutamate transporters of the solute carrier family 31, copper transporters of the solute carrier family 31, and <\\entity><\\entity> (ABC) transporter genes.",
    "Label": ""
  },
  {
    "id": "11162",
    "Sentence": "The transporters are known to be involved in multiple <\\entity><\\entity> resistance and belong to different classes, e.g.",
    "Label": ""
  },
  {
    "id": "11164",
    "Sentence": "lysosomal H+ transporting ATPases, Cu2+ transporting ATPases, glutamate transporters of the solute carrier family 31, copper transporters of the solute carrier family 31, and ATP-binding cassette (<\\entity><\\entity> genes.",
    "Label": ""
  },
  {
    "id": "11165",
    "Sentence": "The transporters are known to be involved in multiple <\\entity><\\entity> resistance and belong to different classes, e.g.",
    "Label": ""
  },
  {
    "id": "11167",
    "Sentence": "lysosomal H+ <\\entity><\\entity>, Cu2+ <\\entity><\\entity>, glutamate transporters of the solute carrier family 31, copper transporters of the solute carrier family 31, and ATP-binding cassette (ABC) transporter genes.",
    "Label": ""
  },
  {
    "id": "11168",
    "Sentence": "The transporters are known to be involved in multiple <\\entity><\\entity> resistance and belong to different classes, e.g.",
    "Label": ""
  },
  {
    "id": "11174",
    "Sentence": "Discriminatory accuracy from single-nucleotide polymorphisms in models to predict <\\entity><\\entity> risk.One purpose for seeking common alleles that are associated with disease is to use them to improve models for projecting individualized disease risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11175",
    "Sentence": "Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk.One purpose for seeking common alleles that are associated with <\\entity><\\entity> is to use them to improve models for projecting individualized <\\entity><\\entity> risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11176",
    "Sentence": "Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk.One purpose for seeking common alleles that are associated with <\\entity><\\entity> is to use them to improve models for projecting individualized <\\entity><\\entity> risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11177",
    "Sentence": "Two genome-wide association studies and a study of candidate genes recently identified seven common single-nucleotide polymorphisms (SNPs) that were associated with <\\entity><\\entity> risk in independent samples.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11178",
    "Sentence": "These seven SNPs were located in <\\entity><\\entity>, TNRC9 (now known as TOX3), MAP3K1, LSP1, CASP8, chromosomal region 8q, and chromosomal region 2q35.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11179",
    "Sentence": "These seven SNPs were located in FGFR2, <\\entity><\\entity> (now known as TOX3), MAP3K1, LSP1, CASP8, chromosomal region 8q, and chromosomal region 2q35.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11180",
    "Sentence": "These seven SNPs were located in FGFR2, TNRC9 (now known as <\\entity><\\entity>), MAP3K1, LSP1, CASP8, chromosomal region 8q, and chromosomal region 2q35.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11181",
    "Sentence": "These seven SNPs were located in FGFR2, TNRC9 (now known as TOX3), <\\entity><\\entity>, LSP1, CASP8, chromosomal region 8q, and chromosomal region 2q35.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11182",
    "Sentence": "These seven SNPs were located in FGFR2, TNRC9 (now known as TOX3), MAP3K1, <\\entity><\\entity>, CASP8, chromosomal region 8q, and chromosomal region 2q35.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11183",
    "Sentence": "These seven SNPs were located in FGFR2, TNRC9 (now known as TOX3), MAP3K1, LSP1, <\\entity><\\entity>, chromosomal region 8q, and chromosomal region 2q35.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11184",
    "Sentence": "These seven SNPs were located in FGFR2, TNRC9 (now known as TOX3), MAP3K1, LSP1, CASP8, chromosomal region <\\entity><\\entity>, and chromosomal region 2q35.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11185",
    "Sentence": "These seven SNPs were located in FGFR2, TNRC9 (now known as TOX3), MAP3K1, LSP1, CASP8, chromosomal region 8q, and chromosomal region <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11186",
    "Sentence": "A model with these seven SNPs (AUC = 0.574) and a hypothetical model with 14 such SNPs (AUC = 0.604) have less discriminatory accuracy than a model, the National <\\entity><\\entity> Institute's Breast <\\entity><\\entity> Risk Assessment Tool (BCRAT), that is based on ages at menarche and at first live birth, family history of breast cancer, and history of breast biopsy examinations (AUC = 0.607).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11187",
    "Sentence": "A model with these seven SNPs (AUC = 0.574) and a hypothetical model with 14 such SNPs (AUC = 0.604) have less discriminatory accuracy than a model, the National Cancer Institute's <\\entity><\\entity> Risk Assessment Tool (BCRAT), that is based on ages at menarche and at first live birth, family history of breast cancer, and history of breast biopsy examinations (AUC = 0.607).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11188",
    "Sentence": "A model with these seven SNPs (AUC = 0.574) and a hypothetical model with 14 such SNPs (AUC = 0.604) have less discriminatory accuracy than a model, the National Cancer Institute's Breast Cancer Risk Assessment Tool (BCRAT), that is based on ages at menarche and at first live birth, family history of <\\entity><\\entity>, and history of breast biopsy examinations (AUC = 0.607).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11189",
    "Sentence": "Experience to date and quantitative arguments indicate that a huge increase in the numbers of case patients with <\\entity><\\entity> and control subjects would be required in genome-wide association studies to find enough SNPs to achieve high discriminatory accuracy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11194",
    "Sentence": "Molecular determinants for the interaction of <\\entity><\\entity> with its propeptide.Human neutrophil alpha-defensins (HNPs) are cationic antimicrobial peptides that are synthesized in vivo as inactive precursors (proHNPs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11195",
    "Sentence": "Molecular determinants for the interaction of human neutrophil alpha <\\entity><\\entity> 1 with its propeptide.Human neutrophil alpha-<\\entity><\\entity>s (HNPs) are cationic antimicrobial peptides that are synthesized in vivo as inactive precursors (proHNPs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11196",
    "Sentence": "Molecular determinants for the interaction of human neutrophil alpha defensin 1 with its propeptide.<\\entity><\\entity> (HNPs) are cationic antimicrobial peptides that are synthesized in vivo as inactive precursors (proHNPs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11197",
    "Sentence": "Molecular determinants for the interaction of human neutrophil alpha defensin 1 with its propeptide.Human neutrophil alpha-defensins (<\\entity><\\entity>) are cationic antimicrobial peptides that are synthesized in vivo as inactive precursors (pro<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11198",
    "Sentence": "Molecular determinants for the interaction of human neutrophil alpha defensin 1 with its propeptide.Human neutrophil alpha-defensins (HNPs) are <\\entity><\\entity> that are synthesized in vivo as inactive precursors (proHNPs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11199",
    "Sentence": "Molecular determinants for the interaction of human neutrophil alpha defensin 1 with its propeptide.Human neutrophil alpha-defensins (HNPs) are cationic antimicrobial peptides that are synthesized in vivo as inactive precursors (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11200",
    "Sentence": "Activation requires proteolytic excision of their <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11201",
    "Sentence": "The pro peptide of <\\entity><\\entity> also interacts specifically with and inhibits the antimicrobial activity of HNP1 inter-molecularly.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11202",
    "Sentence": "The pro peptide of pro<\\entity><\\entity> also interacts specifically with and inhibits the antimicrobial activity of <\\entity><\\entity> inter-molecularly.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11203",
    "Sentence": "In the light of the opposite <\\entity><\\entity> charges segregated in proHNP1, functional inhibition of the C-terminal defensin domain by its propeptide is generally thought to be of electrostatic nature.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11204",
    "Sentence": "In the light of the opposite net charges segregated in <\\entity><\\entity>, functional inhibition of the C-terminal defensin domain by its propeptide is generally thought to be of electrostatic nature.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11205",
    "Sentence": "In the light of the opposite net charges segregated in proHNP1, functional inhibition of the <\\entity><\\entity> by its propeptide is generally thought to be of electrostatic nature.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11206",
    "Sentence": "Using a battery of analogs of the propeptide and of <\\entity><\\entity>, we identified residues in the propeptide region important for HNP1 binding and inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11207",
    "Sentence": "Using a battery of analogs of the propeptide and of pro<\\entity><\\entity>, we identified residues in the propeptide region important for <\\entity><\\entity> binding and inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11208",
    "Sentence": "Only three anionic residues in the propeptide, <\\entity><\\entity>, Asp(20) and Glu(23), were modestly important for interactions with HNP1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11209",
    "Sentence": "Only three anionic residues in the propeptide, Glu(15), <\\entity><\\entity> and Glu(23), were modestly important for interactions with HNP1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11210",
    "Sentence": "Only three anionic residues in the propeptide, Glu(15), <\\entity><\\entity> and Glu(23), were modestly important for interactions with HNP1.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11211",
    "Sentence": "Only three anionic residues in the propeptide, Glu(15), Asp(20) and <\\entity><\\entity>, were modestly important for interactions with HNP1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11212",
    "Sentence": "Only three anionic residues in the propeptide, Glu(15), Asp(20) and Glu(23), were modestly important for interactions with <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11213",
    "Sentence": "By contrast, the hydrophobic residues in the central part of the propeptide, and the conserved hydrophobic motif <\\entity><\\entity> in particular, were critical for HNP1 binding and inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11214",
    "Sentence": "By contrast, the hydrophobic residues in the central part of the propeptide, and the conserved hydrophobic motif <\\entity><\\entity>(24)<\\entity><\\entity>(25)<\\entity><\\entity>(26)Leu(28) in particular, were critical for HNP1 binding and inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11215",
    "Sentence": "By contrast, the hydrophobic residues in the central part of the propeptide, and the conserved hydrophobic motif <\\entity><\\entity>(24)<\\entity><\\entity>(25)<\\entity><\\entity>(26)Leu(28) in particular, were critical for HNP1 binding and inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11216",
    "Sentence": "By contrast, the hydrophobic residues in the central part of the propeptide, and the conserved hydrophobic motif Val(24)Val(25)Val(26)<\\entity><\\entity>(28) in particular, were critical for HNP1 binding and inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11217",
    "Sentence": "By contrast, the hydrophobic residues in the central part of the propeptide, and the conserved hydrophobic motif Val(24)Val(25)Val(26)Leu(28) in particular, were critical for <\\entity><\\entity> binding and inhibition.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11218",
    "Sentence": "Neutralization of all negative charges in the propeptide only partially activated the bactericidal activity of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11219",
    "Sentence": "Our data indicate that hydrophobic forces have a dominant role in mediating the interactions between <\\entity><\\entity> and its propeptide--a finding largely contrasting the commonly held view that the interactions are of an electrostatic nature.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11224",
    "Sentence": "Non-organ-specific autoantibodies in renal transplant recipients: relation to <\\entity><\\entity>.Polyomavirus BK reactivation is common in renal transplant recipients and may cause nephropathy with significant graft dysfunction.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11225",
    "Sentence": "Non-organ-specific autoantibodies in renal transplant recipients: relation to BK virus infection.<\\entity><\\entity> is common in renal transplant recipients and may cause nephropathy with significant graft dysfunction.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11226",
    "Sentence": "Non-organ-specific autoantibodies in renal transplant recipients: relation to BK virus infection.Polyomavirus BK reactivation is common in renal transplant recipients and may cause <\\entity><\\entity> with significant graft dysfunction.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11227",
    "Sentence": "Non-organ-specific autoantibodies in renal transplant recipients: relation to BK virus infection.Polyomavirus BK reactivation is common in renal transplant recipients and may cause nephropathy with significant <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11228",
    "Sentence": "The induction of anti-double stranded DNA (anti-dsDNA) antibodies by <\\entity><\\entity> has been described in experimental animals and during primary infection, and has been implicated in the pathogenesis of systemic lupus erythematosus.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11229",
    "Sentence": "The induction of anti-double stranded DNA (anti-dsDNA) antibodies by BKV has been described in experimental animals and during <\\entity><\\entity>, and has been implicated in the pathogenesis of systemic lupus erythematosus.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11230",
    "Sentence": "The induction of anti-double stranded DNA (anti-dsDNA) antibodies by BKV has been described in experimental animals and during primary infection, and has been implicated in the <\\entity><\\entity> of systemic lupus erythematosus.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11231",
    "Sentence": "The induction of anti-double stranded DNA (anti-dsDNA) antibodies by BKV has been described in experimental animals and during primary infection, and has been implicated in the pathogenesis of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11232",
    "Sentence": "This study evaluated the occurrence of anti-dsDNA antibodies and non-organ-specific autoantibodies (NOSA) by indirect immunofluorescence before transplantation and at 3 and 6 months post-transplantation in 90 renal transplant recipients and the association with <\\entity><\\entity> reactivation, demographic and clinical features.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11233",
    "Sentence": "Moreover, the relation to <\\entity><\\entity>, as detected by pp65-antigenemia, was also evaluated.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11234",
    "Sentence": "<\\entity><\\entity> was detected in at least one serum sample in 22 patients: 9 anti-dsDNA antibody-positive vs 13 negative (p<0.01).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11235",
    "Sentence": "Although a relation seems to exist between <\\entity><\\entity> and the occurrence of anti-dsDNA antibodies in renal transplant patients, the lack of correlation with other epidemiological and clinical features does not allow any conclusion.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11236",
    "Sentence": "The role of <\\entity><\\entity> in this context and the relation with other patient-related factors and infectious agents should be further investigated.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11237",
    "Sentence": "The role of autoimmune response in this context and the relation with other patient-related factors and <\\entity><\\entity> agents should be further investigated.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11238",
    "Sentence": "The role of autoimmune response in this context and the relation with other patient-related factors and <\\entity><\\entity> agents should be further investigated.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11239",
    "Sentence": "The role of autoimmune response in this context and the relation with other patient-related factors and infectious <\\entity><\\entity> should be further investigated.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11244",
    "Sentence": "Expression of <\\entity><\\entity> (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as <\\entity><\\entity> (Flt-1) expressed on tumour cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11245",
    "Sentence": "Expression of VEGFR-1 (<\\entity><\\entity>) in breast cancer is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (<\\entity><\\entity>) expressed on tumour cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11246",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in <\\entity><\\entity> is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes <\\entity><\\entity> progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11247",
    "Sentence": "Expression of <\\entity><\\entity>R-1 (Flt-1) in breast cancer is associated with <\\entity><\\entity> expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (<\\entity><\\entity>) promotes breast cancer progression by inducing angiogenesis via <\\entity><\\entity> receptors on endothelial cells but also signals directly through receptors such as <\\entity><\\entity>R-1 (Flt-1) expressed on tumour cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11248",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with <\\entity><\\entity>.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11249",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative <\\entity><\\entity> stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on <\\entity><\\entity> cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11250",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: <\\entity><\\entity> (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11251",
    "Sentence": "Expression of <\\entity><\\entity>R-1 (Flt-1) in breast cancer is associated with <\\entity><\\entity> expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (<\\entity><\\entity>) promotes breast cancer progression by inducing angiogenesis via <\\entity><\\entity> receptors on endothelial cells but also signals directly through receptors such as <\\entity><\\entity>R-1 (Flt-1) expressed on tumour cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11252",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in <\\entity><\\entity> is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes <\\entity><\\entity> progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11253",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via <\\entity><\\entity> on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11254",
    "Sentence": "Expression of <\\entity><\\entity> (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as <\\entity><\\entity> (Flt-1) expressed on tumour cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11255",
    "Sentence": "Expression of VEGFR-1 (<\\entity><\\entity>) in breast cancer is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (<\\entity><\\entity>) expressed on tumour cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11256",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative <\\entity><\\entity> stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on <\\entity><\\entity> cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11257",
    "Sentence": "The impact of autocrine signalling loops on treatment with <\\entity><\\entity> inhibitors is still unclear.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11258",
    "Sentence": "The impact of autocrine signalling loops on treatment with VEGF inhibitors is <\\entity><\\entity> unclear.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11259",
    "Sentence": "MATERIALS AND METHODS: Six <\\entity><\\entity> cell lines were tested for expression of VEGFR-1 by RT-PCR and Western blot.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11260",
    "Sentence": "MATERIALS AND METHODS: Six breast cancer cell lines were tested for expression of <\\entity><\\entity> by RT-PCR and Western blot.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11261",
    "Sentence": "To assess clinical significance, 93 <\\entity><\\entity> lesions were evaluated for expression of VEGF and VEGFR-1 by immunohistochemistry.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11262",
    "Sentence": "To assess clinical significance, 93 breast cancer lesions were evaluated for expression of <\\entity><\\entity> and <\\entity><\\entity>R-1 by immunohistochemistry.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11263",
    "Sentence": "To assess clinical significance, 93 breast cancer lesions were evaluated for expression of VEGF and <\\entity><\\entity> by immunohistochemistry.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11264",
    "Sentence": "RESULTS: <\\entity><\\entity> mRNA was found in all 6 cell lines, while protein expression was found in 5 cell lines.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11265",
    "Sentence": "<\\entity><\\entity> was expressed in 60% and <\\entity><\\entity>R-1 in 39% of breast cancer specimens.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11266",
    "Sentence": "VEGF was expressed in 60% and <\\entity><\\entity> in 39% of breast cancer specimens.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11267",
    "Sentence": "VEGF was expressed in 60% and VEGFR-1 in 39% of <\\entity><\\entity> specimens.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11268",
    "Sentence": "<\\entity><\\entity> expression was associated with VEGF expression and with node-negative tumour stage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11269",
    "Sentence": "<\\entity><\\entity>R-1 expression was associated with <\\entity><\\entity> expression and with node-negative tumour stage.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11270",
    "Sentence": "VEGFR-1 expression was associated with VEGF expression and with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11271",
    "Sentence": "VEGFR-1 expression was associated with VEGF expression and with node-negative <\\entity><\\entity> stage.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11272",
    "Sentence": "CONCLUSION: Our data suggest that analysis of <\\entity><\\entity>/<\\entity><\\entity>R-1 expression might be relevant in identifying patients with different response rates upon treatment with antiangiogenic agents.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11273",
    "Sentence": "CONCLUSION: Our data suggest that analysis of VEGF/<\\entity><\\entity> expression might be relevant in identifying patients with different response rates upon treatment with antiangiogenic agents.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11274",
    "Sentence": "Expression of VEGFR-1 (<\\entity><\\entity>) in breast cancer is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (<\\entity><\\entity>) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11275",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with <\\entity><\\entity>.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11277",
    "Sentence": "Expression of <\\entity><\\entity>R-1 (Flt-1) in breast cancer is associated with <\\entity><\\entity> expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (<\\entity><\\entity>) promotes breast cancer progression by inducing angiogenesis via <\\entity><\\entity> receptors on endothelial cells but also signals directly through receptors such as <\\entity><\\entity>R-1 (Flt-1) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11278",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in <\\entity><\\entity> is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes <\\entity><\\entity> progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11280",
    "Sentence": "<\\entity><\\entity> was expressed in 60% and <\\entity><\\entity>R-1 in 39% of breast cancer specimens.",
    "Label": ""
  },
  {
    "id": "11281",
    "Sentence": "VEGF was expressed in 60% and VEGFR-1 in 39% of <\\entity><\\entity> specimens.",
    "Label": ""
  },
  {
    "id": "11283",
    "Sentence": "VEGF was expressed in 60% and <\\entity><\\entity> in 39% of breast cancer specimens.",
    "Label": ""
  },
  {
    "id": "11284",
    "Sentence": "VEGF was expressed in 60% and VEGFR-1 in 39% of <\\entity><\\entity> specimens.",
    "Label": ""
  },
  {
    "id": "11286",
    "Sentence": "<\\entity><\\entity> expression was associated with VEGF expression and with node-negative tumour stage.",
    "Label": ""
  },
  {
    "id": "11287",
    "Sentence": "VEGFR-1 expression was associated with VEGF expression and with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11289",
    "Sentence": "Expression of <\\entity><\\entity>R-1 (Flt-1) in breast cancer is associated with <\\entity><\\entity> expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (<\\entity><\\entity>) promotes breast cancer progression by inducing angiogenesis via <\\entity><\\entity> receptors on endothelial cells but also signals directly through receptors such as <\\entity><\\entity>R-1 (Flt-1) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11290",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in <\\entity><\\entity> is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes <\\entity><\\entity> progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11292",
    "Sentence": "Expression of <\\entity><\\entity>R-1 (Flt-1) in breast cancer is associated with <\\entity><\\entity> expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (<\\entity><\\entity>) promotes breast cancer progression by inducing angiogenesis via <\\entity><\\entity> receptors on endothelial cells but also signals directly through receptors such as <\\entity><\\entity>R-1 (Flt-1) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11293",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative <\\entity><\\entity> stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "11295",
    "Sentence": "Expression of VEGFR-1 (<\\entity><\\entity>) in breast cancer is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (<\\entity><\\entity>) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11296",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in <\\entity><\\entity> is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes <\\entity><\\entity> progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11298",
    "Sentence": "Expression of VEGFR-1 (<\\entity><\\entity>) in breast cancer is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (<\\entity><\\entity>) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11299",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative <\\entity><\\entity> stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "11301",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via <\\entity><\\entity> on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11302",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative <\\entity><\\entity> stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "11304",
    "Sentence": "Expression of VEGFR-1 (<\\entity><\\entity>) in breast cancer is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (<\\entity><\\entity>) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11305",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in <\\entity><\\entity> is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes <\\entity><\\entity> progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11307",
    "Sentence": "Expression of VEGFR-1 (<\\entity><\\entity>) in breast cancer is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (<\\entity><\\entity>) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11308",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative <\\entity><\\entity> stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "11310",
    "Sentence": "The impact of autocrine signalling loops on treatment with <\\entity><\\entity> inhibitors is still unclear.",
    "Label": ""
  },
  {
    "id": "11311",
    "Sentence": "The impact of autocrine signalling loops on treatment with VEGF inhibitors is <\\entity><\\entity> unclear.",
    "Label": ""
  },
  {
    "id": "11313",
    "Sentence": "MATERIALS AND METHODS: Six breast cancer cell lines were tested for expression of <\\entity><\\entity> by RT-PCR and Western blot.",
    "Label": ""
  },
  {
    "id": "11314",
    "Sentence": "MATERIALS AND METHODS: Six <\\entity><\\entity> cell lines were tested for expression of VEGFR-1 by RT-PCR and Western blot.",
    "Label": ""
  },
  {
    "id": "11316",
    "Sentence": "To assess clinical significance, 93 breast cancer lesions were evaluated for expression of <\\entity><\\entity> and <\\entity><\\entity>R-1 by immunohistochemistry.",
    "Label": ""
  },
  {
    "id": "11317",
    "Sentence": "To assess clinical significance, 93 <\\entity><\\entity> lesions were evaluated for expression of VEGF and VEGFR-1 by immunohistochemistry.",
    "Label": ""
  },
  {
    "id": "11319",
    "Sentence": "To assess clinical significance, 93 breast cancer lesions were evaluated for expression of VEGF and <\\entity><\\entity> by immunohistochemistry.",
    "Label": ""
  },
  {
    "id": "11320",
    "Sentence": "To assess clinical significance, 93 <\\entity><\\entity> lesions were evaluated for expression of VEGF and VEGFR-1 by immunohistochemistry.",
    "Label": ""
  },
  {
    "id": "11322",
    "Sentence": "<\\entity><\\entity>R-1 expression was associated with <\\entity><\\entity> expression and with node-negative tumour stage.",
    "Label": ""
  },
  {
    "id": "11323",
    "Sentence": "VEGFR-1 expression was associated with VEGF expression and with node-negative <\\entity><\\entity> stage.",
    "Label": ""
  },
  {
    "id": "11325",
    "Sentence": "<\\entity><\\entity> expression was associated with VEGF expression and with node-negative tumour stage.",
    "Label": ""
  },
  {
    "id": "11326",
    "Sentence": "VEGFR-1 expression was associated with VEGF expression and with node-negative <\\entity><\\entity> stage.",
    "Label": ""
  },
  {
    "id": "11328",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: <\\entity><\\entity> (VEGF) promotes breast cancer progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11329",
    "Sentence": "Expression of VEGFR-1 (Flt-1) in <\\entity><\\entity> is associated with VEGF expression and with node-negative tumour stage.BACKGROUND: Vascular endothelial growth factor (VEGF) promotes <\\entity><\\entity> progression by inducing angiogenesis via VEGF receptors on endothelial cells but also signals directly through receptors such as VEGFR-1 (Flt-1) expressed on tumour cells.",
    "Label": ""
  },
  {
    "id": "11335",
    "Sentence": "Epigenetic mapping and functional analysis in a <\\entity><\\entity> model using whole-genome promoter tiling microarrays.INTRODUCTION: Breast cancer metastasis is a complex, multi-step biological process.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11336",
    "Sentence": "Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays.INTRODUCTION: <\\entity><\\entity> is a complex, multi-step biological process.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11337",
    "Sentence": "Genetic <\\entity><\\entity> along with epigenetic alterations in the form of DNA methylation patterns and histone modifications contribute to metastasis-related gene expression changes and genomic instability.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11338",
    "Sentence": "Genetic mutations along with epigenetic alterations in the form of DNA methylation patterns and <\\entity><\\entity> modifications contribute to metastasis-related gene expression changes and genomic instability.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11339",
    "Sentence": "Genetic mutations along with epigenetic alterations in the form of DNA methylation patterns and histone modifications contribute to <\\entity><\\entity>-related gene expression changes and genomic instability.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11340",
    "Sentence": "Genetic mutations along with epigenetic alterations in the form of DNA methylation patterns and histone modifications contribute to metastasis-related gene expression changes and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11341",
    "Sentence": "So far, these epigenetic contributions to <\\entity><\\entity> have not been well characterized, and there is only a limited understanding of the functional mechanisms affected by such epigenetic alterations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11342",
    "Sentence": "Furthermore, no genome-wide assessments have been undertaken to identify altered DNA methylation patterns in the context of <\\entity><\\entity> and their effects on specific functional pathways or gene networks.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11343",
    "Sentence": "METHODS: We have used a human gene promoter tiling microarray platform to analyze a cell line model of <\\entity><\\entity> composed of a poorly metastatic MDA-MB-468GFP human breast adenocarcinoma cell line and its highly metastatic variant (468LN).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11344",
    "Sentence": "METHODS: We have used a human gene promoter tiling microarray platform to analyze a cell line model of metastasis to lymph nodes composed of a poorly metastatic MDA-MB-468GFP human <\\entity><\\entity> cell line and its highly metastatic variant (468LN).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11345",
    "Sentence": "Gene networks and pathways associated with <\\entity><\\entity> were identified, and target genes associated with epithelial-mesenchymal transition were validated with respect to DNA methylation effects on gene expression.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11346",
    "Sentence": "Gene networks and pathways associated with metastasis were identified, and target genes associated with epithelial-mesenchymal <\\entity><\\entity> were validated with respect to DNA methylation effects on gene expression.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11347",
    "Sentence": "RESULTS: We integrated data from the tiling microarrays with targets identified by Ingenuity Pathways Analysis software and observed epigenetic variations in genes implicated in epithelial-mesenchymal <\\entity><\\entity> and with tumor cell migration.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11348",
    "Sentence": "RESULTS: We integrated data from the tiling microarrays with targets identified by Ingenuity Pathways Analysis software and observed epigenetic variations in genes implicated in epithelial-mesenchymal transition and with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11349",
    "Sentence": "We identified widespread genomic hypermethylation and hypomethylation events in these cells and we confirmed functional associations between methylation status and expression of the <\\entity><\\entity>, CST6, EGFR, SNAI2 and ZEB2 genes by quantitative real-time PCR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11350",
    "Sentence": "We identified widespread genomic hypermethylation and hypomethylation events in these cells and we confirmed functional associations between methylation status and expression of the CDH1, <\\entity><\\entity>, EGFR, SNAI2 and ZEB2 genes by quantitative real-time PCR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11351",
    "Sentence": "We identified widespread genomic hypermethylation and hypomethylation events in these cells and we confirmed functional associations between methylation status and expression of the CDH1, CST6, <\\entity><\\entity>, SNAI2 and ZEB2 genes by quantitative real-time PCR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11352",
    "Sentence": "We identified widespread genomic hypermethylation and hypomethylation events in these cells and we confirmed functional associations between methylation status and expression of the CDH1, CST6, EGFR, <\\entity><\\entity> and ZEB2 genes by quantitative real-time PCR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11353",
    "Sentence": "We identified widespread genomic hypermethylation and hypomethylation events in these cells and we confirmed functional associations between methylation status and expression of the CDH1, CST6, EGFR, SNAI2 and <\\entity><\\entity> genes by quantitative real-time PCR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11354",
    "Sentence": "Our data also suggest that the complex genomic reorganization present in <\\entity><\\entity> cells may be superimposed over promoter-specific methylation events that are responsible for gene-specific expression changes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11355",
    "Sentence": "CONCLUSION: This is the first whole-genome approach to identify genome-wide and gene-specific epigenetic alterations, and the functional consequences of these changes, in the context of <\\entity><\\entity> to lymph nodes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11356",
    "Sentence": "This approach allows the development of epigenetic signatures of <\\entity><\\entity> to be used concurrently with genomic signatures to improve mapping of the evolving molecular landscape of <\\entity><\\entity> and to permit translational approaches to target epigenetically regulated molecular pathways related to metastatic progression.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11357",
    "Sentence": "This approach allows the development of epigenetic signatures of <\\entity><\\entity> to be used concurrently with genomic signatures to improve mapping of the evolving molecular landscape of <\\entity><\\entity> and to permit translational approaches to target epigenetically regulated molecular pathways related to metastatic progression.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11362",
    "Sentence": "Review of recent results of <\\entity><\\entity> use as a monotherapy in children with mild asthma.BACKGROUND: Asthma is a chronic disease with a heterogeneous phenotype that is often associated with allergic sensitization in childhood.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11363",
    "Sentence": "Review of recent results of montelukast use as a monotherapy in children with <\\entity><\\entity>.BACKGROUND: Asthma is a chronic disease with a heterogeneous phenotype that is often associated with allergic sensitization in childhood.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11364",
    "Sentence": "Review of recent results of montelukast use as a monotherapy in children with mild asthma.BACKGROUND: <\\entity><\\entity> is a chronic disease with a heterogeneous phenotype that is often associated with allergic sensitization in childhood.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11365",
    "Sentence": "Review of recent results of montelukast use as a monotherapy in children with mild asthma.BACKGROUND: Asthma is a <\\entity><\\entity> with a heterogeneous phenotype that is often associated with allergic sensitization in childhood.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11366",
    "Sentence": "The earliest definable form of <\\entity><\\entity> is mild (intermittent or persistent), a severity level that may be characteristic of a majority of children with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11367",
    "Sentence": "The earliest definable form of <\\entity><\\entity> is mild (intermittent or persistent), a severity level that may be characteristic of a majority of children with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11368",
    "Sentence": "Several <\\entity><\\entity> controllers are indicated for use in children.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11369",
    "Sentence": "International guidelines recommend the use of <\\entity><\\entity> as the preferred controller therapy in mild persistent asthma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11370",
    "Sentence": "International guidelines recommend the use of <\\entity><\\entity> as the preferred controller therapy in mild persistent asthma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11371",
    "Sentence": "International guidelines recommend the use of inhaled corticosteroids as the preferred controller therapy in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11372",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with <\\entity><\\entity> treated with montelukast, a leukotriene receptor antagonist that is approved for the treatment of asthma and allergic rhinitis in children and adults.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11373",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with <\\entity><\\entity>, a leukotriene receptor antagonist that is approved for the treatment of asthma and allergic rhinitis in children and adults.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11374",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with montelukast, a <\\entity><\\entity> that is approved for the treatment of asthma and allergic rhinitis in children and adults.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11375",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with mild <\\entity><\\entity> treated with montelukast, a leukotriene receptor antagonist that is approved for the treatment of <\\entity><\\entity> and allergic rhinitis in children and adults.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11376",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with montelukast, a leukotriene receptor antagonist that is approved for the treatment of asthma and <\\entity><\\entity> in children and adults.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11377",
    "Sentence": "METHODS: A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, <\\entity><\\entity>, leukotriene receptor antagonist, pediatric asthma, mild asthma, exercise-induced asthma, and bronchoconstriction.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11378",
    "Sentence": "METHODS: A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, montelukast, <\\entity><\\entity>, pediatric asthma, mild asthma, exercise-induced asthma, and bronchoconstriction.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11379",
    "Sentence": "METHODS: A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, montelukast, leukotriene receptor antagonist, <\\entity><\\entity>, mild asthma, exercise-induced asthma, and bronchoconstriction.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11380",
    "Sentence": "METHODS: A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, montelukast, leukotriene receptor antagonist, pediatric asthma, <\\entity><\\entity>, exercise-induced asthma, and bronchoconstriction.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11381",
    "Sentence": "METHODS: A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, montelukast, leukotriene receptor antagonist, pediatric asthma, mild asthma, <\\entity><\\entity>, and bronchoconstriction.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11382",
    "Sentence": "METHODS: A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, montelukast, leukotriene receptor antagonist, pediatric asthma, mild asthma, exercise-induced asthma, and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11383",
    "Sentence": "Recent articles (since 1998) that described the use of <\\entity><\\entity> as a monotherapy were chosen for this review.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11384",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old <\\entity><\\entity> (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent asthmatics (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old asthmatics; a 12-month study comparing montelukast with fluticasone in 6- to 14-year-old mild persistent asthmatics (N = 949); and 3 placebo-controlled studies in children with exercise-induced asthma (N = 123).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11385",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent <\\entity><\\entity> (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent <\\entity><\\entity> (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old <\\entity><\\entity>; a 12-month study comparing montelukast with fluticasone in 6- to 14-year-old mild persistent <\\entity><\\entity> (N = 949); and 3 placebo-controlled studies in children with exercise-induced asthma (N = 123).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11386",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent asthmatics (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old <\\entity><\\entity>s (N = 689); an analysis of a <\\entity><\\entity> cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old asthmatics; a 12-month study comparing montelukast with fluticasone in 6- to 14-year-old <\\entity><\\entity>s (N = 949); and 3 placebo-controlled studies in children with exercise-induced asthma (N = 123).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11387",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent <\\entity><\\entity> (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent <\\entity><\\entity> (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old <\\entity><\\entity>; a 12-month study comparing montelukast with fluticasone in 6- to 14-year-old mild persistent <\\entity><\\entity> (N = 949); and 3 placebo-controlled studies in children with exercise-induced asthma (N = 123).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11388",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent asthmatics (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent asthmatics (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old asthmatics; a 12-month study comparing <\\entity><\\entity> with fluticasone in 6- to 14-year-old mild persistent asthmatics (N = 949); and 3 placebo-controlled studies in children with exercise-induced asthma (N = 123).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11389",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent asthmatics (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent asthmatics (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old asthmatics; a 12-month study comparing montelukast with <\\entity><\\entity> in 6- to 14-year-old mild persistent asthmatics (N = 949); and 3 placebo-controlled studies in children with exercise-induced asthma (N = 123).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11390",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent <\\entity><\\entity> (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent <\\entity><\\entity> (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old <\\entity><\\entity>; a 12-month study comparing montelukast with fluticasone in 6- to 14-year-old mild persistent <\\entity><\\entity> (N = 949); and 3 placebo-controlled studies in children with exercise-induced asthma (N = 123).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11391",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent asthmatics (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent asthmatics (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old asthmatics; a 12-month study comparing montelukast with fluticasone in 6- to 14-year-old mild persistent asthmatics (N = 949); and 3 placebo-controlled studies in children with <\\entity><\\entity> (N = 123).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11392",
    "Sentence": "The results from these studies, encompassing end points measuring lung function and <\\entity><\\entity>, found that montelukast provided effective and beneficial asthma control to children aged 2 to 14 years with mild asthma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11393",
    "Sentence": "The results from these studies, encompassing end points measuring lung function and symptoms, found that <\\entity><\\entity> provided effective and beneficial asthma control to children aged 2 to 14 years with mild asthma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11394",
    "Sentence": "The results from these studies, encompassing end points measuring lung function and symptoms, found that montelukast provided effective and beneficial <\\entity><\\entity> control to children aged 2 to 14 years with mild <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11395",
    "Sentence": "The results from these studies, encompassing end points measuring lung function and symptoms, found that montelukast provided effective and beneficial asthma control to children aged 2 to 14 years with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11396",
    "Sentence": "CONCLUSION: The evidence suggests that <\\entity><\\entity> is an effective monotherapy controller in children with mild asthma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11397",
    "Sentence": "CONCLUSION: The evidence suggests that montelukast is an effective monotherapy controller in children with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11398",
    "Sentence": "Review of recent results of <\\entity><\\entity> use as a monotherapy in children with mild asthma.BACKGROUND: Asthma is a chronic disease with a heterogeneous phenotype that is often associated with allergic sensitization in childhood.",
    "Label": ""
  },
  {
    "id": "11399",
    "Sentence": "Review of recent results of montelukast use as a monotherapy in children with <\\entity><\\entity>.BACKGROUND: Asthma is a chronic disease with a heterogeneous phenotype that is often associated with allergic sensitization in childhood.",
    "Label": ""
  },
  {
    "id": "11401",
    "Sentence": "International guidelines recommend the use of <\\entity><\\entity> as the preferred controller therapy in mild persistent asthma.",
    "Label": ""
  },
  {
    "id": "11402",
    "Sentence": "International guidelines recommend the use of inhaled corticosteroids as the preferred controller therapy in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11404",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with <\\entity><\\entity>, a leukotriene receptor antagonist that is approved for the treatment of asthma and allergic rhinitis in children and adults.",
    "Label": ""
  },
  {
    "id": "11405",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with mild <\\entity><\\entity> treated with montelukast, a leukotriene receptor antagonist that is approved for the treatment of <\\entity><\\entity> and allergic rhinitis in children and adults.",
    "Label": ""
  },
  {
    "id": "11407",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with <\\entity><\\entity>, a leukotriene receptor antagonist that is approved for the treatment of asthma and allergic rhinitis in children and adults.",
    "Label": ""
  },
  {
    "id": "11408",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with montelukast, a leukotriene receptor antagonist that is approved for the treatment of asthma and <\\entity><\\entity> in children and adults.",
    "Label": ""
  },
  {
    "id": "11410",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with <\\entity><\\entity>, a leukotriene receptor antagonist that is approved for the treatment of asthma and allergic rhinitis in children and adults.",
    "Label": ""
  },
  {
    "id": "11411",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with <\\entity><\\entity> treated with montelukast, a leukotriene receptor antagonist that is approved for the treatment of asthma and allergic rhinitis in children and adults.",
    "Label": ""
  },
  {
    "id": "11413",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with montelukast, a <\\entity><\\entity> that is approved for the treatment of asthma and allergic rhinitis in children and adults.",
    "Label": ""
  },
  {
    "id": "11414",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with mild <\\entity><\\entity> treated with montelukast, a leukotriene receptor antagonist that is approved for the treatment of <\\entity><\\entity> and allergic rhinitis in children and adults.",
    "Label": ""
  },
  {
    "id": "11416",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with montelukast, a <\\entity><\\entity> that is approved for the treatment of asthma and allergic rhinitis in children and adults.",
    "Label": ""
  },
  {
    "id": "11417",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with montelukast, a leukotriene receptor antagonist that is approved for the treatment of asthma and <\\entity><\\entity> in children and adults.",
    "Label": ""
  },
  {
    "id": "11419",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with montelukast, a <\\entity><\\entity> that is approved for the treatment of asthma and allergic rhinitis in children and adults.",
    "Label": ""
  },
  {
    "id": "11420",
    "Sentence": "OBJECTIVE: This article reviewed recent results from randomized, double-blind studies of children with <\\entity><\\entity> treated with montelukast, a leukotriene receptor antagonist that is approved for the treatment of asthma and allergic rhinitis in children and adults.",
    "Label": ""
  },
  {
    "id": "11422",
    "Sentence": "METHODS: A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, <\\entity><\\entity>, leukotriene receptor antagonist, pediatric asthma, mild asthma, exercise-induced asthma, and bronchoconstriction.",
    "Label": ""
  },
  {
    "id": "11423",
    "Sentence": "METHODS: A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, montelukast, leukotriene receptor antagonist, pediatric asthma, <\\entity><\\entity>, exercise-induced asthma, and bronchoconstriction.",
    "Label": ""
  },
  {
    "id": "11425",
    "Sentence": "The results from these studies, encompassing end points measuring lung function and symptoms, found that <\\entity><\\entity> provided effective and beneficial asthma control to children aged 2 to 14 years with mild asthma.",
    "Label": ""
  },
  {
    "id": "11426",
    "Sentence": "The results from these studies, encompassing end points measuring lung function and symptoms, found that montelukast provided effective and beneficial <\\entity><\\entity> control to children aged 2 to 14 years with mild <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11428",
    "Sentence": "The results from these studies, encompassing end points measuring lung function and symptoms, found that <\\entity><\\entity> provided effective and beneficial asthma control to children aged 2 to 14 years with mild asthma.",
    "Label": ""
  },
  {
    "id": "11429",
    "Sentence": "The results from these studies, encompassing end points measuring lung function and symptoms, found that montelukast provided effective and beneficial asthma control to children aged 2 to 14 years with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11431",
    "Sentence": "CONCLUSION: The evidence suggests that <\\entity><\\entity> is an effective monotherapy controller in children with mild asthma.",
    "Label": ""
  },
  {
    "id": "11432",
    "Sentence": "CONCLUSION: The evidence suggests that montelukast is an effective monotherapy controller in children with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11434",
    "Sentence": "METHODS: A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, <\\entity><\\entity>, leukotriene receptor antagonist, pediatric asthma, mild asthma, exercise-induced asthma, and bronchoconstriction.",
    "Label": ""
  },
  {
    "id": "11435",
    "Sentence": "METHODS: A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, montelukast, leukotriene receptor antagonist, pediatric asthma, mild asthma, <\\entity><\\entity>, and bronchoconstriction.",
    "Label": ""
  },
  {
    "id": "11437",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent asthmatics (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent asthmatics (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old asthmatics; a 12-month study comparing <\\entity><\\entity> with fluticasone in 6- to 14-year-old mild persistent asthmatics (N = 949); and 3 placebo-controlled studies in children with exercise-induced asthma (N = 123).",
    "Label": ""
  },
  {
    "id": "11438",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent <\\entity><\\entity> (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent <\\entity><\\entity> (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old <\\entity><\\entity>; a 12-month study comparing montelukast with fluticasone in 6- to 14-year-old mild persistent <\\entity><\\entity> (N = 949); and 3 placebo-controlled studies in children with exercise-induced asthma (N = 123).",
    "Label": ""
  },
  {
    "id": "11440",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent asthmatics (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent asthmatics (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old asthmatics; a 12-month study comparing <\\entity><\\entity> with fluticasone in 6- to 14-year-old mild persistent asthmatics (N = 949); and 3 placebo-controlled studies in children with exercise-induced asthma (N = 123).",
    "Label": ""
  },
  {
    "id": "11441",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent asthmatics (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent asthmatics (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old asthmatics; a 12-month study comparing montelukast with fluticasone in 6- to 14-year-old mild persistent asthmatics (N = 949); and 3 placebo-controlled studies in children with <\\entity><\\entity> (N = 123).",
    "Label": ""
  },
  {
    "id": "11443",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent asthmatics (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent asthmatics (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old asthmatics; a 12-month study comparing montelukast with <\\entity><\\entity> in 6- to 14-year-old mild persistent asthmatics (N = 949); and 3 placebo-controlled studies in children with exercise-induced asthma (N = 123).",
    "Label": ""
  },
  {
    "id": "11444",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent <\\entity><\\entity> (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent <\\entity><\\entity> (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old <\\entity><\\entity>; a 12-month study comparing montelukast with fluticasone in 6- to 14-year-old mild persistent <\\entity><\\entity> (N = 949); and 3 placebo-controlled studies in children with exercise-induced asthma (N = 123).",
    "Label": ""
  },
  {
    "id": "11446",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent asthmatics (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent asthmatics (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old asthmatics; a 12-month study comparing montelukast with <\\entity><\\entity> in 6- to 14-year-old mild persistent asthmatics (N = 949); and 3 placebo-controlled studies in children with exercise-induced asthma (N = 123).",
    "Label": ""
  },
  {
    "id": "11447",
    "Sentence": "RESULTS: Relevant studies included a 48-week, placebo-controlled study of 2- to 5-year-old mild intermittent asthmatics (N = 549); a 12-week, placebo-controlled study of 2- to 5-year-old mild persistent asthmatics (N = 689); an analysis of a mild persistent asthmatic cohort (N = 138) from an 8-week, placebo-controlled study of 6- to 14-year-old asthmatics; a 12-month study comparing montelukast with fluticasone in 6- to 14-year-old mild persistent asthmatics (N = 949); and 3 placebo-controlled studies in children with <\\entity><\\entity> (N = 123).",
    "Label": ""
  },
  {
    "id": "11449",
    "Sentence": "The results from these studies, encompassing end points measuring lung function and symptoms, found that <\\entity><\\entity> provided effective and beneficial asthma control to children aged 2 to 14 years with mild asthma.",
    "Label": ""
  },
  {
    "id": "11450",
    "Sentence": "The results from these studies, encompassing end points measuring lung function and <\\entity><\\entity>, found that montelukast provided effective and beneficial asthma control to children aged 2 to 14 years with mild asthma.",
    "Label": ""
  },
  {
    "id": "11452",
    "Sentence": "METHODS: A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, <\\entity><\\entity>, leukotriene receptor antagonist, pediatric asthma, mild asthma, exercise-induced asthma, and bronchoconstriction.",
    "Label": ""
  },
  {
    "id": "11453",
    "Sentence": "METHODS: A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, montelukast, leukotriene receptor antagonist, pediatric asthma, mild asthma, exercise-induced asthma, and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11455",
    "Sentence": "METHODS: A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, montelukast, <\\entity><\\entity>, pediatric asthma, mild asthma, exercise-induced asthma, and bronchoconstriction.",
    "Label": ""
  },
  {
    "id": "11456",
    "Sentence": "METHODS: A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, montelukast, leukotriene receptor antagonist, pediatric asthma, mild asthma, exercise-induced asthma, and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11462",
    "Sentence": "An audit of <\\entity><\\entity> prescribing and plasma electrolyte monitoring; a comparison with guidelines from the National Patient Safety Agency.OBJECTIVES: To audit past practice of intravenous (i.v.) fluid prescribing and electrolyte monitoring, prior to the publication of guidelines by the National Patient Safety Agency (NPSA, Ref.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11463",
    "Sentence": "An audit of intravenous fluid prescribing and plasma electrolyte monitoring; a comparison with guidelines from the National Patient Safety Agency.OBJECTIVES: To audit past practice of <\\entity><\\entity> prescribing and electrolyte monitoring, prior to the publication of guidelines by the National Patient Safety Agency (NPSA, Ref.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11464",
    "Sentence": "METHODS: We performed a retrospective case note review of 100 appendectomy patients between February 2004 and March 2007, recording; fluid type and volumes given as maintenance therapy, resuscitation boluses and nasogastric replacement; the frequency and timing of plasma electrolyte measurement; the relationship between plasma <\\entity><\\entity> [Na] concentration and i.v.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11465",
    "Sentence": "METHODS: We performed a retrospective case note review of 100 appendectomy patients between February 2004 and March 2007, recording; fluid type and volumes given as maintenance therapy, resuscitation boluses and nasogastric replacement; the frequency and timing of plasma electrolyte measurement; the relationship between plasma sodium [<\\entity><\\entity>] concentration and i.v.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11466",
    "Sentence": "METHODS: We performed a retrospective case note review of 100 appendectomy patients between February 2004 and March 2007, recording; fluid type and volumes given as maintenance therapy, resuscitation boluses and nasogastric replacement; the frequency and timing of plasma electrolyte measurement; the relationship between plasma sodium [Na] concentration and i.v.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11467",
    "Sentence": "fluid prescribed; and patient <\\entity><\\entity> recordings.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11468",
    "Sentence": "Before surgery, <\\entity><\\entity> was prescribed for 94% patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11469",
    "Sentence": "Before surgery, <\\entity><\\entity> was prescribed for 94% patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11470",
    "Sentence": "During surgery, <\\entity><\\entity> was predominantly isotonic.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11471",
    "Sentence": "After surgery, <\\entity><\\entity> was prescribed for 92% patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11472",
    "Sentence": "After surgery, <\\entity><\\entity> was prescribed for 92% patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11473",
    "Sentence": "All <\\entity><\\entity> volumes were appropriately calculated according to weight using the Holliday and Segar formula (Paediatrics, 19, 1957, 823).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11474",
    "Sentence": "All maintenance fluid volumes were appropriately calculated according to <\\entity><\\entity> using the Holliday and Segar formula (Paediatrics, 19, 1957, 823).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11475",
    "Sentence": "Fluid boluses were isotonic on 128/129 occasions and all accurately calculated according to <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11476",
    "Sentence": "Nasogastric losses were replaced with 0.9% <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11477",
    "Sentence": "No patient had daily plasma electrolyte measurements whilst administered i.v.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11478",
    "Sentence": "Twenty-seven patients had recorded <\\entity><\\entity> ([Na] <135 mmol x l(-1); 21 at presentation, six subsequently after admission).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11479",
    "Sentence": "Twenty-seven patients had recorded hyponatremia ([<\\entity><\\entity>] <135 mmol x l(-1); 21 at presentation, six subsequently after admission).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11480",
    "Sentence": "<\\entity><\\entity> was continued in 26/27 patients with hyponatremia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11481",
    "Sentence": "<\\entity><\\entity> was continued in 26/27 patients with hyponatremia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11482",
    "Sentence": "Hypotonic maintenance fluid was continued in 26/27 patients with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11483",
    "Sentence": "CONCLUSIONS: Our practice of i.v.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11484",
    "Sentence": "Twenty-seven patients had recorded hyponatremia ([<\\entity><\\entity>] <135 mmol x l(-1); 21 at presentation, six subsequently after admission).",
    "Label": ""
  },
  {
    "id": "11485",
    "Sentence": "Twenty-seven patients had recorded <\\entity><\\entity> ([Na] <135 mmol x l(-1); 21 at presentation, six subsequently after admission).",
    "Label": ""
  },
  {
    "id": "11487",
    "Sentence": "<\\entity><\\entity> was continued in 26/27 patients with hyponatremia.",
    "Label": ""
  },
  {
    "id": "11488",
    "Sentence": "Hypotonic maintenance fluid was continued in 26/27 patients with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11494",
    "Sentence": "Randomized, double-blind, placebo-controlled study of postoperative nightly <\\entity><\\entity> for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy.Four weeks after bilateral nerve-sparing radical retropubic prostatectomy, men with normal erectile function before surgery were randomized to double-blind sildenafil (50 or 100 mg) or placebo nightly for 36 weeks, followed by an 8-week drug-free period before assessment of erectile function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11495",
    "Sentence": "Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of <\\entity><\\entity> after bilateral nerve-sparing radical prostatectomy.Four weeks after bilateral nerve-sparing radical retropubic prostatectomy, men with normal erectile function before surgery were randomized to double-blind sildenafil (50 or 100 mg) or placebo nightly for 36 weeks, followed by an 8-week drug-free period before assessment of erectile function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11496",
    "Sentence": "Randomized, double-blind, placebo-controlled study of postoperative nightly <\\entity><\\entity> citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy.Four weeks after bilateral nerve-sparing radical retropubic prostatectomy, men with normal erectile function before surgery were randomized to double-blind <\\entity><\\entity> (50 or 100 mg) or placebo nightly for 36 weeks, followed by an 8-week drug-free period before assessment of erectile function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11497",
    "Sentence": "Enrollment was prematurely ceased and only 76 men completed because, assuming a placebo response rate similar to the published literature (for example, 34% in meta-analysis), the 25% response at <\\entity><\\entity> interim review suggested a lack of treatment effect.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11498",
    "Sentence": "On the contrary, spontaneous erectile function (a combined score of >or=8 for questions 3 and 4 of the International Index of Erectile Function and a positive response to 'Were erections good enough for satisfactory sexual activity?') occurred in only 4% of the placebo group (n=1 of 25) versus 27% (n=14 of 51, P=0.0156, Fisher's exact test) of the <\\entity><\\entity> group.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11499",
    "Sentence": "Nightly <\\entity><\\entity> administration for 36 weeks after surgery markedly increased the return of normal spontaneous erections.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11500",
    "Sentence": "Randomized, double-blind, placebo-controlled study of postoperative nightly <\\entity><\\entity> for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy.Four weeks after bilateral nerve-sparing radical retropubic prostatectomy, men with normal erectile function before surgery were randomized to double-blind sildenafil (50 or 100 mg) or placebo nightly for 36 weeks, followed by an 8-week drug-free period before assessment of erectile function.",
    "Label": ""
  },
  {
    "id": "11501",
    "Sentence": "Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of <\\entity><\\entity> after bilateral nerve-sparing radical prostatectomy.Four weeks after bilateral nerve-sparing radical retropubic prostatectomy, men with normal erectile function before surgery were randomized to double-blind sildenafil (50 or 100 mg) or placebo nightly for 36 weeks, followed by an 8-week drug-free period before assessment of erectile function.",
    "Label": ""
  },
  {
    "id": "11507",
    "Sentence": "<\\entity><\\entity> delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway.Apoptosis of human neutrophils is a crucial mechanism for the resolution of inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11508",
    "Sentence": "Insulin-like growth factor-1 delays <\\entity><\\entity>-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway.Apoptosis of human neutrophils is a crucial mechanism for the resolution of inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11509",
    "Sentence": "Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the <\\entity><\\entity> pathway.Apoptosis of human neutrophils is a crucial mechanism for the resolution of inflammation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11510",
    "Sentence": "We previously showed that <\\entity><\\entity> (IGF1) delays spontaneous neutrophil apoptosis without influencing the secretion of cytokines by these cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11511",
    "Sentence": "We previously showed that insulin-like growth factor-1 (<\\entity><\\entity>) delays spontaneous neutrophil apoptosis without influencing the secretion of cytokines by these cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11512",
    "Sentence": "We previously showed that insulin-like growth factor-1 (IGF1) delays spontaneous neutrophil apoptosis without influencing the secretion of <\\entity><\\entity> by these cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11513",
    "Sentence": "In the present study, we further addressed the role of <\\entity><\\entity> in regulating neutrophil survival in the presence of other factors present during inflammation, and the mechanism involved in delaying apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11514",
    "Sentence": "We show that <\\entity><\\entity> delays neutrophil apoptosis triggered by the agonistic anti-Fas antibody CH11 and that the effect of <\\entity><\\entity> is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines interferon-gamma (IFNG) and granulocyte-macrophage colony-stimulating factor (GM-CSF; now known as CSF2).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11515",
    "Sentence": "We show that IGF1 delays neutrophil apoptosis triggered by the agonistic <\\entity><\\entity> antibody CH11 and that the effect of IGF1 is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines interferon-gamma (IFNG) and granulocyte-macrophage colony-stimulating factor (GM-CSF; now known as CSF2).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11516",
    "Sentence": "We show that IGF1 delays neutrophil apoptosis triggered by the agonistic <\\entity><\\entity> antibody CH11 and that the effect of IGF1 is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines interferon-gamma (IFNG) and granulocyte-macrophage colony-stimulating factor (GM-CSF; now known as CSF2).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11517",
    "Sentence": "We show that IGF1 delays neutrophil apoptosis triggered by the agonistic anti-Fas antibody <\\entity><\\entity> and that the effect of IGF1 is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines interferon-gamma (IFNG) and granulocyte-macrophage colony-stimulating factor (GM-CSF; now known as CSF2).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11518",
    "Sentence": "We show that <\\entity><\\entity> delays neutrophil apoptosis triggered by the agonistic anti-Fas antibody CH11 and that the effect of <\\entity><\\entity> is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines interferon-gamma (IFNG) and granulocyte-macrophage colony-stimulating factor (GM-CSF; now known as CSF2).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11519",
    "Sentence": "We show that IGF1 delays neutrophil apoptosis triggered by the agonistic anti-Fas antibody CH11 and that the effect of IGF1 is comparable in magnitude to that of the acknowledged anti-apoptotic <\\entity><\\entity> interferon-gamma (IFNG) and granulocyte-macrophage colony-stimulating factor (GM-CSF; now known as CSF2).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11520",
    "Sentence": "We show that IGF1 delays neutrophil apoptosis triggered by the agonistic anti-Fas antibody CH11 and that the effect of IGF1 is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines <\\entity><\\entity> (IFNG) and granulocyte-macrophage colony-stimulating factor (GM-CSF; now known as CSF2).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11521",
    "Sentence": "We show that IGF1 delays neutrophil apoptosis triggered by the agonistic anti-Fas antibody CH11 and that the effect of IGF1 is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines <\\entity><\\entity> (IFNG) and granulocyte-macrophage colony-stimulating factor (GM-CSF; now known as CSF2).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11522",
    "Sentence": "We show that IGF1 delays neutrophil apoptosis triggered by the agonistic anti-Fas antibody CH11 and that the effect of IGF1 is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines interferon-gamma (<\\entity><\\entity>) and granulocyte-macrophage colony-stimulating factor (GM-CSF; now known as CSF2).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11523",
    "Sentence": "We show that IGF1 delays neutrophil apoptosis triggered by the agonistic anti-Fas antibody CH11 and that the effect of IGF1 is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines interferon-gamma (IFNG) and <\\entity><\\entity> (GM-CSF; now known as CSF2).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11524",
    "Sentence": "We show that IGF1 delays neutrophil apoptosis triggered by the agonistic anti-Fas antibody CH11 and that the effect of IGF1 is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines interferon-gamma (IFNG) and <\\entity><\\entity> (GM-CSF; now known as CSF2).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11525",
    "Sentence": "We show that IGF1 delays neutrophil apoptosis triggered by the agonistic anti-Fas antibody CH11 and that the effect of IGF1 is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines interferon-gamma (IFNG) and granulocyte-macrophage colony-stimulating factor (<\\entity><\\entity>; now known as CSF2).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11526",
    "Sentence": "We show that IGF1 delays neutrophil apoptosis triggered by the agonistic anti-Fas antibody CH11 and that the effect of IGF1 is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines interferon-gamma (IFNG) and granulocyte-macrophage colony-stimulating factor (<\\entity><\\entity>; now known as CSF2).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11527",
    "Sentence": "We show that IGF1 delays neutrophil apoptosis triggered by the agonistic anti-Fas antibody CH11 and that the effect of IGF1 is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines interferon-gamma (IFNG) and granulocyte-macrophage colony-stimulating factor (GM-CSF; now known as <\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11528",
    "Sentence": "Furthermore, <\\entity><\\entity> exerted additional effects on cell survival in the presence of these cytokines.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11529",
    "Sentence": "Furthermore, IGF1 exerted additional effects on cell survival in the presence of these <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11530",
    "Sentence": "<\\entity><\\entity> did not affect Fas expression or activation by anti-Fas of caspase-8, but inhibited the depolarization of the mitochondrial membrane.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11531",
    "Sentence": "IGF1 did not affect <\\entity><\\entity> expression or activation by anti-<\\entity><\\entity> of caspase-8, but inhibited the depolarization of the mitochondrial membrane.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11532",
    "Sentence": "IGF1 did not affect Fas expression or activation by <\\entity><\\entity> of caspase-8, but inhibited the depolarization of the mitochondrial membrane.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11533",
    "Sentence": "IGF1 did not affect Fas expression or activation by <\\entity><\\entity> of caspase-8, but inhibited the depolarization of the mitochondrial membrane.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11534",
    "Sentence": "IGF1 did not affect Fas expression or activation by anti-Fas of <\\entity><\\entity>, but inhibited the depolarization of the mitochondrial membrane.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11535",
    "Sentence": "Inhibitor studies indicate that the <\\entity><\\entity> (PI3K) pathway, but not the MEK-ERK pathway, mediates the effects of IGF1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11536",
    "Sentence": "Inhibitor studies indicate that the phosphatidylinositol-3 kinase (<\\entity><\\entity>) pathway, but not the MEK-ERK pathway, mediates the effects of IGF1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11537",
    "Sentence": "Inhibitor studies indicate that the phosphatidylinositol-3 kinase (PI3K) pathway, but not the <\\entity><\\entity> pathway, mediates the effects of IGF1.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11538",
    "Sentence": "Inhibitor studies indicate that the phosphatidylinositol-3 kinase (PI3K) pathway, but not the MEK-ERK pathway, mediates the effects of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11539",
    "Sentence": "However, in contrast to <\\entity><\\entity>, IGF1 did not induce phosphorylation and translocation to the membrane of AKT, the canonical downstream target of PI3K.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11540",
    "Sentence": "However, in contrast to CSF2, <\\entity><\\entity> did not induce phosphorylation and translocation to the membrane of AKT, the canonical downstream target of PI3K.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11541",
    "Sentence": "However, in contrast to CSF2, IGF1 did not induce phosphorylation and translocation to the membrane of <\\entity><\\entity>, the canonical downstream target of PI3K.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11542",
    "Sentence": "However, in contrast to CSF2, IGF1 did not induce phosphorylation and translocation to the membrane of AKT, the canonical downstream target of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11543",
    "Sentence": "We therefore speculate that other downstream targets of <\\entity><\\entity> are involved in the delay of neutrophil apoptosis by IGF1, possibly through stabilization of the mitochondrial membrane.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11544",
    "Sentence": "We therefore speculate that other downstream targets of PI3K are involved in the delay of neutrophil apoptosis by <\\entity><\\entity>, possibly through stabilization of the mitochondrial membrane.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11545",
    "Sentence": "In the present study, we further addressed the role of <\\entity><\\entity> in regulating neutrophil survival in the presence of other factors present during inflammation, and the mechanism involved in delaying apoptosis.",
    "Label": ""
  },
  {
    "id": "11546",
    "Sentence": "In the present study, we further addressed the role of IGF1 in regulating neutrophil survival in the presence of other factors present during <\\entity><\\entity>, and the mechanism involved in delaying apoptosis.",
    "Label": ""
  },
  {
    "id": "11548",
    "Sentence": "We show that IGF1 delays neutrophil apoptosis triggered by the agonistic <\\entity><\\entity> antibody CH11 and that the effect of IGF1 is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines interferon-gamma (IFNG) and granulocyte-macrophage colony-stimulating factor (GM-CSF; now known as CSF2).",
    "Label": ""
  },
  {
    "id": "11549",
    "Sentence": "We show that <\\entity><\\entity> delays neutrophil apoptosis triggered by the agonistic anti-Fas antibody CH11 and that the effect of <\\entity><\\entity> is comparable in magnitude to that of the acknowledged anti-apoptotic cytokines interferon-gamma (IFNG) and granulocyte-macrophage colony-stimulating factor (GM-CSF; now known as CSF2).",
    "Label": ""
  },
  {
    "id": "11555",
    "Sentence": "Management and risk factors for <\\entity><\\entity> with the ketogenic diet.A prospective study was performed of all children started on the ketogenic diet at our institution for intractable epilepsy from January 2003 to March 2007 (n = 137), examining for baseline and follow-up total cholesterol and triglyceride levels.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11556",
    "Sentence": "Management and risk factors for dyslipidemia with the <\\entity><\\entity>.A prospective study was performed of all children started on the <\\entity><\\entity> at our institution for intractable epilepsy from January 2003 to March 2007 (n = 137), examining for baseline and follow-up total cholesterol and triglyceride levels.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11557",
    "Sentence": "Management and risk factors for dyslipidemia with the <\\entity><\\entity>.A prospective study was performed of all children started on the <\\entity><\\entity> at our institution for intractable epilepsy from January 2003 to March 2007 (n = 137), examining for baseline and follow-up total cholesterol and triglyceride levels.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11558",
    "Sentence": "Management and risk factors for dyslipidemia with the ketogenic diet.A prospective study was performed of all children started on the ketogenic diet at our institution for <\\entity><\\entity> from January 2003 to March 2007 (n = 137), examining for baseline and follow-up total cholesterol and triglyceride levels.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11559",
    "Sentence": "Interventions for <\\entity><\\entity> were analyzed for their effectiveness.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11560",
    "Sentence": "At baseline, 25% of children had <\\entity><\\entity> (>200 mg/dL), which increased to 60% for those receiving the ketogenic diet.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11561",
    "Sentence": "At baseline, 25% of children had hypercholesterolemia (>200 mg/dL), which increased to 60% for those receiving the <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11562",
    "Sentence": "Children receiving a solely formula-based <\\entity><\\entity> were less likely to have hypercholesterolemia than those eating solid food after adjusting for age and initial ketogenic ratio (P < .001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11563",
    "Sentence": "Children receiving a solely formula-based ketogenic diet were less likely to have <\\entity><\\entity> than those eating solid food after adjusting for age and initial ketogenic ratio (P < .001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11564",
    "Sentence": "<\\entity><\\entity> occurs in most children receiving a solid food based ketogenic diet but improved in approximately half, even without interventions.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11565",
    "Sentence": "Hypercholesterolemia occurs in most children receiving a solid food based <\\entity><\\entity> but improved in approximately half, even without interventions.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11570",
    "Sentence": "<\\entity><\\entity> maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.PURPOSE: The aims of this study were to investigate telomere function in normal and Barrett's esophageal adenocarcinoma (BEAC) cells purified by laser capture microdissection and to evaluate the effect of telomerase inhibition in cancer cells in vitro and in vivo.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11571",
    "Sentence": "Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of <\\entity><\\entity> inhibition in vivo.PURPOSE: The aims of this study were to investigate telomere function in normal and Barrett's esophageal adenocarcinoma (BEAC) cells purified by laser capture microdissection and to evaluate the effect of <\\entity><\\entity> inhibition in cancer cells in vitro and in vivo.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11572",
    "Sentence": "Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.PURPOSE: The aims of this study were to investigate <\\entity><\\entity> function in normal and Barrett's esophageal adenocarcinoma (BEAC) cells purified by laser capture microdissection and to evaluate the effect of telomerase inhibition in cancer cells in vitro and in vivo.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11573",
    "Sentence": "Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of <\\entity><\\entity> inhibition in vivo.PURPOSE: The aims of this study were to investigate telomere function in normal and Barrett's esophageal adenocarcinoma (BEAC) cells purified by laser capture microdissection and to evaluate the effect of <\\entity><\\entity> inhibition in cancer cells in vitro and in vivo.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11574",
    "Sentence": "<\\entity><\\entity> activity was measured by modified telomeric repeat amplification protocol and telomere length was determined by real-time PCR assay.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11575",
    "Sentence": "Telomerase activity was measured by modified telomeric repeat amplification protocol and <\\entity><\\entity> length was determined by real-time PCR assay.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11576",
    "Sentence": "To evaluate the effect of <\\entity><\\entity> inhibition, adenocarcinoma cell lines were continuously treated with a specific <\\entity><\\entity> inhibitor (GRN163L) and live cell number was determined weekly.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11577",
    "Sentence": "To evaluate the effect of telomerase inhibition, adenocarcinoma cell lines were continuously treated with a specific <\\entity><\\entity> (GRN163L) and live cell number was determined weekly.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11578",
    "Sentence": "To evaluate the effect of telomerase inhibition, adenocarcinoma cell lines were continuously treated with a specific <\\entity><\\entity> (GRN163L) and live cell number was determined weekly.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11579",
    "Sentence": "To evaluate the effect of telomerase inhibition, adenocarcinoma cell lines were continuously treated with a specific telomerase inhibitor (<\\entity><\\entity>) and live cell number was determined weekly.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11580",
    "Sentence": "Apoptosis was evaluated by <\\entity><\\entity> labeling and senescence by beta-galactosidase staining.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11581",
    "Sentence": "Apoptosis was evaluated by Annexin labeling and senescence by <\\entity><\\entity> staining.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11582",
    "Sentence": "with saline or <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11583",
    "Sentence": "RESULTS: <\\entity><\\entity> activity was significantly elevated whereas telomeres were shorter in BEAC cells relative to normal esophageal epithelial cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11584",
    "Sentence": "The treatment of adenocarcinoma cells with <\\entity><\\entity>, GRN163L, led to loss of telomerase activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11585",
    "Sentence": "The treatment of adenocarcinoma cells with <\\entity><\\entity>, GRN163L, led to loss of telomerase activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11586",
    "Sentence": "The treatment of adenocarcinoma cells with telomerase inhibitor, <\\entity><\\entity>, led to loss of telomerase activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11587",
    "Sentence": "The treatment of adenocarcinoma cells with <\\entity><\\entity> inhibitor, GRN163L, led to loss of <\\entity><\\entity> activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11588",
    "Sentence": "The treatment of adenocarcinoma cells with telomerase inhibitor, GRN163L, led to loss of telomerase activity, reduction in <\\entity><\\entity> length, and growth arrest through induction of both the senescence and apoptosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11589",
    "Sentence": "<\\entity><\\entity>-induced cell death could also be expedited by addition of the chemotherapeutic agents doxorubicin and ritonavir.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11590",
    "Sentence": "GRN163L-induced cell death could also be expedited by addition of the chemotherapeutic agents <\\entity><\\entity> and ritonavir.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11591",
    "Sentence": "GRN163L-induced cell death could also be expedited by addition of the chemotherapeutic agents doxorubicin and <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11592",
    "Sentence": "Finally, the treatment with <\\entity><\\entity> led to a significant reduction in tumor volume in a subcutaneous tumor model.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11593",
    "Sentence": "CONCLUSIONS: We show that <\\entity><\\entity> activity is significantly elevated whereas telomeres are shorter in BEAC and suppression of <\\entity><\\entity> inhibits proliferation of adenocarcinoma cells both in vitro and in vivo.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11594",
    "Sentence": "CONCLUSIONS: We show that <\\entity><\\entity> activity is significantly elevated whereas telomeres are shorter in BEAC and suppression of <\\entity><\\entity> inhibits proliferation of adenocarcinoma cells both in vitro and in vivo.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11595",
    "Sentence": "The treatment of adenocarcinoma cells with <\\entity><\\entity>, GRN163L, led to loss of telomerase activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis.",
    "Label": ""
  },
  {
    "id": "11596",
    "Sentence": "The treatment of adenocarcinoma cells with <\\entity><\\entity> inhibitor, GRN163L, led to loss of <\\entity><\\entity> activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis.",
    "Label": ""
  },
  {
    "id": "11598",
    "Sentence": "The treatment of adenocarcinoma cells with <\\entity><\\entity>, GRN163L, led to loss of telomerase activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis.",
    "Label": ""
  },
  {
    "id": "11599",
    "Sentence": "The treatment of adenocarcinoma cells with telomerase inhibitor, GRN163L, led to loss of telomerase activity, reduction in <\\entity><\\entity> length, and growth arrest through induction of both the senescence and apoptosis.",
    "Label": ""
  },
  {
    "id": "11601",
    "Sentence": "The treatment of adenocarcinoma cells with telomerase inhibitor, <\\entity><\\entity>, led to loss of telomerase activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis.",
    "Label": ""
  },
  {
    "id": "11602",
    "Sentence": "The treatment of adenocarcinoma cells with <\\entity><\\entity> inhibitor, GRN163L, led to loss of <\\entity><\\entity> activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis.",
    "Label": ""
  },
  {
    "id": "11604",
    "Sentence": "The treatment of adenocarcinoma cells with telomerase inhibitor, <\\entity><\\entity>, led to loss of telomerase activity, reduction in telomere length, and growth arrest through induction of both the senescence and apoptosis.",
    "Label": ""
  },
  {
    "id": "11605",
    "Sentence": "The treatment of adenocarcinoma cells with telomerase inhibitor, GRN163L, led to loss of telomerase activity, reduction in <\\entity><\\entity> length, and growth arrest through induction of both the senescence and apoptosis.",
    "Label": ""
  },
  {
    "id": "11607",
    "Sentence": "To evaluate the effect of telomerase inhibition, adenocarcinoma cell lines were continuously treated with a specific telomerase inhibitor (<\\entity><\\entity>) and live cell number was determined weekly.",
    "Label": ""
  },
  {
    "id": "11608",
    "Sentence": "To evaluate the effect of telomerase inhibition, adenocarcinoma cell lines were continuously treated with a specific <\\entity><\\entity> (GRN163L) and live cell number was determined weekly.",
    "Label": ""
  },
  {
    "id": "11614",
    "Sentence": "Clinicopathological evaluation of immunohistochemical <\\entity><\\entity> and endothelial nitric oxide synthase expression in intracranial ependymoma.PURPOSE: To analyze the association between <\\entity><\\entity> and eNOS expression with the pathological grades of patients with intracranial ependymomas, and to determine its value in distinguishing the progression of the disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11615",
    "Sentence": "Clinicopathological evaluation of immunohistochemical <\\entity><\\entity> and endothelial nitric oxide synthase expression in intracranial ependymoma.PURPOSE: To analyze the association between <\\entity><\\entity> and eNOS expression with the pathological grades of patients with intracranial ependymomas, and to determine its value in distinguishing the progression of the disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11616",
    "Sentence": "Clinicopathological evaluation of immunohistochemical Ki-67 and <\\entity><\\entity> expression in intracranial ependymoma.PURPOSE: To analyze the association between Ki-67 and eNOS expression with the pathological grades of patients with intracranial ependymomas, and to determine its value in distinguishing the progression of the disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11617",
    "Sentence": "Clinicopathological evaluation of immunohistochemical <\\entity><\\entity> and endothelial nitric oxide synthase expression in intracranial ependymoma.PURPOSE: To analyze the association between <\\entity><\\entity> and eNOS expression with the pathological grades of patients with intracranial ependymomas, and to determine its value in distinguishing the progression of the disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11618",
    "Sentence": "Clinicopathological evaluation of immunohistochemical <\\entity><\\entity> and endothelial nitric oxide synthase expression in intracranial ependymoma.PURPOSE: To analyze the association between <\\entity><\\entity> and eNOS expression with the pathological grades of patients with intracranial ependymomas, and to determine its value in distinguishing the progression of the disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11619",
    "Sentence": "Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial ependymoma.PURPOSE: To analyze the association between Ki-67 and <\\entity><\\entity> expression with the pathological grades of patients with intracranial ependymomas, and to determine its value in distinguishing the progression of the disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11620",
    "Sentence": "Immuno-histochemical staining was performed to analyze the association between <\\entity><\\entity> and eNOS expression with various tumour grades.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11621",
    "Sentence": "Immuno-histochemical staining was performed to analyze the association between <\\entity><\\entity> and eNOS expression with various tumour grades.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11622",
    "Sentence": "Immuno-histochemical staining was performed to analyze the association between Ki-67 and <\\entity><\\entity> expression with various tumour grades.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11623",
    "Sentence": "The cell proliferating marker <\\entity><\\entity> was assessed by positive cell count.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11624",
    "Sentence": "The cell proliferating marker <\\entity><\\entity> was assessed by positive cell count.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11625",
    "Sentence": "The levels of <\\entity><\\entity> positive expression were evaluated as slight, moderate and intense.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11626",
    "Sentence": "RESULTS: 48 of 82 cases (58.54%) expressed <\\entity><\\entity> protein.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11627",
    "Sentence": "RESULTS: 48 of 82 cases (58.54%) expressed <\\entity><\\entity> protein.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11628",
    "Sentence": "Expression of <\\entity><\\entity> and eNOS was negative in all control samples.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11629",
    "Sentence": "Expression of <\\entity><\\entity> and eNOS was negative in all control samples.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11630",
    "Sentence": "Expression of Ki-67 and <\\entity><\\entity> was negative in all control samples.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11631",
    "Sentence": "In low-grade ependymomas there were 8 and 12 cases that expressed <\\entity><\\entity> slightly or moderately.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11632",
    "Sentence": "In the mid-grade ependymoma group <\\entity><\\entity> was expressed moderately in 10 cases and intensely in 15.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11633",
    "Sentence": "In the high-grade group 20 cases showed intense positive expression of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11634",
    "Sentence": "The <\\entity><\\entity> positive cell counts for slight, moderate and intense eNOS expression were 2.20, 6.07 and 22.25, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11635",
    "Sentence": "The <\\entity><\\entity> positive cell counts for slight, moderate and intense eNOS expression were 2.20, 6.07 and 22.25, respectively.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11636",
    "Sentence": "The Ki-67 positive cell counts for slight, moderate and intense <\\entity><\\entity> expression were 2.20, 6.07 and 22.25, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11637",
    "Sentence": "CONCLUSION: <\\entity><\\entity> and eNOS expression in intracranial ependymoma tissue was associated with the histopathological grade and malignant degree.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11638",
    "Sentence": "CONCLUSION: <\\entity><\\entity> and eNOS expression in intracranial ependymoma tissue was associated with the histopathological grade and malignant degree.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11639",
    "Sentence": "CONCLUSION: Ki-67 and <\\entity><\\entity> expression in intracranial ependymoma tissue was associated with the histopathological grade and malignant degree.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11640",
    "Sentence": "Clinicopathological evaluation of immunohistochemical Ki-67 and <\\entity><\\entity> expression in intracranial ependymoma.PURPOSE: To analyze the association between Ki-67 and eNOS expression with the pathological grades of patients with intracranial ependymomas, and to determine its value in distinguishing the progression of the disease.",
    "Label": ""
  },
  {
    "id": "11641",
    "Sentence": "Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial <\\entity><\\entity>.PURPOSE: To analyze the association between Ki-67 and eNOS expression with the pathological grades of patients with intracranial <\\entity><\\entity>s, and to determine its value in distinguishing the progression of the disease.",
    "Label": ""
  },
  {
    "id": "11643",
    "Sentence": "Clinicopathological evaluation of immunohistochemical <\\entity><\\entity> and endothelial nitric oxide synthase expression in intracranial ependymoma.PURPOSE: To analyze the association between <\\entity><\\entity> and eNOS expression with the pathological grades of patients with intracranial ependymomas, and to determine its value in distinguishing the progression of the disease.",
    "Label": ""
  },
  {
    "id": "11644",
    "Sentence": "Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial <\\entity><\\entity>.PURPOSE: To analyze the association between Ki-67 and eNOS expression with the pathological grades of patients with intracranial <\\entity><\\entity>s, and to determine its value in distinguishing the progression of the disease.",
    "Label": ""
  },
  {
    "id": "11646",
    "Sentence": "Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial ependymoma.PURPOSE: To analyze the association between Ki-67 and <\\entity><\\entity> expression with the pathological grades of patients with intracranial ependymomas, and to determine its value in distinguishing the progression of the disease.",
    "Label": ""
  },
  {
    "id": "11647",
    "Sentence": "Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial ependymoma.PURPOSE: To analyze the association between Ki-67 and eNOS expression with the pathological grades of patients with intracranial <\\entity><\\entity>, and to determine its value in distinguishing the progression of the disease.",
    "Label": ""
  },
  {
    "id": "11649",
    "Sentence": "Clinicopathological evaluation of immunohistochemical <\\entity><\\entity> and endothelial nitric oxide synthase expression in intracranial ependymoma.PURPOSE: To analyze the association between <\\entity><\\entity> and eNOS expression with the pathological grades of patients with intracranial ependymomas, and to determine its value in distinguishing the progression of the disease.",
    "Label": ""
  },
  {
    "id": "11650",
    "Sentence": "Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial ependymoma.PURPOSE: To analyze the association between Ki-67 and eNOS expression with the pathological grades of patients with intracranial <\\entity><\\entity>, and to determine its value in distinguishing the progression of the disease.",
    "Label": ""
  },
  {
    "id": "11652",
    "Sentence": "Immuno-histochemical staining was performed to analyze the association between Ki-67 and <\\entity><\\entity> expression with various tumour grades.",
    "Label": ""
  },
  {
    "id": "11653",
    "Sentence": "Immuno-histochemical staining was performed to analyze the association between Ki-67 and eNOS expression with various <\\entity><\\entity> grades.",
    "Label": ""
  },
  {
    "id": "11655",
    "Sentence": "Immuno-histochemical staining was performed to analyze the association between <\\entity><\\entity> and eNOS expression with various tumour grades.",
    "Label": ""
  },
  {
    "id": "11656",
    "Sentence": "Immuno-histochemical staining was performed to analyze the association between Ki-67 and eNOS expression with various <\\entity><\\entity> grades.",
    "Label": ""
  },
  {
    "id": "11658",
    "Sentence": "In low-grade ependymomas there were 8 and 12 cases that expressed <\\entity><\\entity> slightly or moderately.",
    "Label": ""
  },
  {
    "id": "11659",
    "Sentence": "In low-grade <\\entity><\\entity> there were 8 and 12 cases that expressed eNOS slightly or moderately.",
    "Label": ""
  },
  {
    "id": "11661",
    "Sentence": "In the mid-grade ependymoma group <\\entity><\\entity> was expressed moderately in 10 cases and intensely in 15.",
    "Label": ""
  },
  {
    "id": "11662",
    "Sentence": "In the mid-grade <\\entity><\\entity> group eNOS was expressed moderately in 10 cases and intensely in 15.",
    "Label": ""
  },
  {
    "id": "11664",
    "Sentence": "CONCLUSION: Ki-67 and <\\entity><\\entity> expression in intracranial ependymoma tissue was associated with the histopathological grade and malignant degree.",
    "Label": ""
  },
  {
    "id": "11665",
    "Sentence": "CONCLUSION: Ki-67 and eNOS expression in intracranial <\\entity><\\entity> tissue was associated with the histopathological grade and malignant degree.",
    "Label": ""
  },
  {
    "id": "11667",
    "Sentence": "CONCLUSION: <\\entity><\\entity> and eNOS expression in intracranial ependymoma tissue was associated with the histopathological grade and malignant degree.",
    "Label": ""
  },
  {
    "id": "11668",
    "Sentence": "CONCLUSION: Ki-67 and eNOS expression in intracranial <\\entity><\\entity> tissue was associated with the histopathological grade and malignant degree.",
    "Label": ""
  },
  {
    "id": "11670",
    "Sentence": "Clinicopathological evaluation of immunohistochemical <\\entity><\\entity> and endothelial nitric oxide synthase expression in intracranial ependymoma.PURPOSE: To analyze the association between <\\entity><\\entity> and eNOS expression with the pathological grades of patients with intracranial ependymomas, and to determine its value in distinguishing the progression of the disease.",
    "Label": ""
  },
  {
    "id": "11671",
    "Sentence": "Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial ependymoma.PURPOSE: To analyze the association between Ki-67 and <\\entity><\\entity> expression with the pathological grades of patients with intracranial ependymomas, and to determine its value in distinguishing the progression of the disease.",
    "Label": ""
  },
  {
    "id": "11673",
    "Sentence": "Immuno-histochemical staining was performed to analyze the association between <\\entity><\\entity> and eNOS expression with various tumour grades.",
    "Label": ""
  },
  {
    "id": "11674",
    "Sentence": "Immuno-histochemical staining was performed to analyze the association between Ki-67 and <\\entity><\\entity> expression with various tumour grades.",
    "Label": ""
  },
  {
    "id": "11676",
    "Sentence": "The <\\entity><\\entity> positive cell counts for slight, moderate and intense eNOS expression were 2.20, 6.07 and 22.25, respectively.",
    "Label": ""
  },
  {
    "id": "11677",
    "Sentence": "The Ki-67 positive cell counts for slight, moderate and intense <\\entity><\\entity> expression were 2.20, 6.07 and 22.25, respectively.",
    "Label": ""
  },
  {
    "id": "11683",
    "Sentence": "Evidence-based recommendations for <\\entity><\\entity>.The experience of patients living with cancer and being treated with chemotherapy often includes the symptoms of nausea and vomiting.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11684",
    "Sentence": "Evidence-based recommendations for cancer <\\entity><\\entity> and vomiting.The experience of patients living with cancer and being treated with chemotherapy often includes the symptoms of <\\entity><\\entity> and vomiting.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11685",
    "Sentence": "Evidence-based recommendations for <\\entity><\\entity> nausea and vomiting.The experience of patients living with <\\entity><\\entity> and being treated with chemotherapy often includes the symptoms of nausea and vomiting.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11686",
    "Sentence": "Evidence-based recommendations for cancer nausea and vomiting.The experience of patients living with cancer and being treated with <\\entity><\\entity> often includes the symptoms of nausea and vomiting.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11687",
    "Sentence": "Evidence-based recommendations for cancer nausea and vomiting.The experience of patients living with cancer and being treated with chemotherapy often includes the <\\entity><\\entity> of nausea and vomiting.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11688",
    "Sentence": "Evidence-based recommendations for cancer <\\entity><\\entity>.The experience of patients living with cancer and being treated with chemotherapy often includes the symptoms of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11689",
    "Sentence": "To provide a framework for high-quality management of these <\\entity><\\entity>, we developed a set of key targeted evidence-based standards through an iterative process of targeted systematic review, development, and refinement of topic areas and standards and consensus ratings by a multidisciplinary expert panel as part of the RAND Cancer Quality-Assessing Symptoms Side Effects and Indicators of Supportive Treatment Project.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11690",
    "Sentence": "To provide a framework for high-quality management of these symptoms, we developed a set of key targeted evidence-based standards through an iterative process of targeted systematic review, development, and refinement of topic areas and standards and consensus ratings by a multidisciplinary expert panel as part of the RAND <\\entity><\\entity> Quality-Assessing Symptoms Side Effects and Indicators of Supportive Treatment Project.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11691",
    "Sentence": "To provide a framework for high-quality management of these symptoms, we developed a set of key targeted evidence-based standards through an iterative process of targeted systematic review, development, and refinement of topic areas and standards and consensus ratings by a multidisciplinary expert panel as part of the RAND Cancer Quality-Assessing <\\entity><\\entity> Side Effects and Indicators of Supportive Treatment Project.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11692",
    "Sentence": "To provide a framework for high-quality management of these symptoms, we developed a set of key targeted evidence-based standards through an iterative process of targeted systematic review, development, and refinement of topic areas and standards and consensus ratings by a multidisciplinary expert panel as part of the RAND Cancer Quality-Assessing Symptoms <\\entity><\\entity> and Indicators of Supportive Treatment Project.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11693",
    "Sentence": "For <\\entity><\\entity>, key clinical standards included screening at the initial outpatient and inpatient visit, prophylaxis for acute and delayed emesis in patients receiving moderate to highly emetic chemotherapy, and follow-up after treatment for <\\entity><\\entity> symptoms.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11694",
    "Sentence": "For nausea and vomiting, key clinical standards included screening at the initial outpatient and inpatient visit, prophylaxis for acute and delayed <\\entity><\\entity> in patients receiving moderate to highly emetic chemotherapy, and follow-up after treatment for nausea and vomiting symptoms.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11695",
    "Sentence": "For nausea and vomiting, key clinical standards included screening at the initial outpatient and inpatient visit, prophylaxis for acute and delayed emesis in patients receiving moderate to highly emetic <\\entity><\\entity>, and follow-up after treatment for nausea and vomiting symptoms.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11696",
    "Sentence": "For <\\entity><\\entity>, key clinical standards included screening at the initial outpatient and inpatient visit, prophylaxis for acute and delayed emesis in patients receiving moderate to highly emetic chemotherapy, and follow-up after treatment for <\\entity><\\entity> symptoms.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11697",
    "Sentence": "In addition, patients with <\\entity><\\entity> and small bowel obstruction were examined as a special subset of patients who present with nausea and vomiting.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11698",
    "Sentence": "In addition, patients with cancer and <\\entity><\\entity> were examined as a special subset of patients who present with nausea and vomiting.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11699",
    "Sentence": "In addition, patients with cancer and small bowel obstruction were examined as a special subset of patients who present with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11700",
    "Sentence": "The standards presented here for preventing and managing <\\entity><\\entity> in cancer care should be incorporated into care pathways and should become the expectation rather than the exception.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11701",
    "Sentence": "The standards presented here for preventing and managing nausea and vomiting in <\\entity><\\entity> care should be incorporated into care pathways and should become the expectation rather than the exception.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11702",
    "Sentence": "Evidence-based recommendations for cancer nausea and vomiting.The experience of patients living with cancer and being treated with <\\entity><\\entity> often includes the symptoms of nausea and vomiting.",
    "Label": ""
  },
  {
    "id": "11703",
    "Sentence": "Evidence-based recommendations for <\\entity><\\entity> nausea and vomiting.The experience of patients living with <\\entity><\\entity> and being treated with chemotherapy often includes the symptoms of nausea and vomiting.",
    "Label": ""
  },
  {
    "id": "11705",
    "Sentence": "Evidence-based recommendations for cancer nausea and vomiting.The experience of patients living with cancer and being treated with <\\entity><\\entity> often includes the symptoms of nausea and vomiting.",
    "Label": ""
  },
  {
    "id": "11706",
    "Sentence": "Evidence-based recommendations for cancer <\\entity><\\entity>.The experience of patients living with cancer and being treated with chemotherapy often includes the symptoms of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11708",
    "Sentence": "For nausea and vomiting, key clinical standards included screening at the initial outpatient and inpatient visit, prophylaxis for acute and delayed emesis in patients receiving moderate to highly emetic <\\entity><\\entity>, and follow-up after treatment for nausea and vomiting symptoms.",
    "Label": ""
  },
  {
    "id": "11709",
    "Sentence": "For nausea and vomiting, key clinical standards included screening at the initial outpatient and inpatient visit, prophylaxis for acute and delayed <\\entity><\\entity> in patients receiving moderate to highly emetic chemotherapy, and follow-up after treatment for nausea and vomiting symptoms.",
    "Label": ""
  },
  {
    "id": "11711",
    "Sentence": "For nausea and vomiting, key clinical standards included screening at the initial outpatient and inpatient visit, prophylaxis for acute and delayed emesis in patients receiving moderate to highly emetic <\\entity><\\entity>, and follow-up after treatment for nausea and vomiting symptoms.",
    "Label": ""
  },
  {
    "id": "11712",
    "Sentence": "For <\\entity><\\entity>, key clinical standards included screening at the initial outpatient and inpatient visit, prophylaxis for acute and delayed emesis in patients receiving moderate to highly emetic chemotherapy, and follow-up after treatment for <\\entity><\\entity> symptoms.",
    "Label": ""
  },
  {
    "id": "11718",
    "Sentence": "The <\\entity><\\entity> intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11719",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome <\\entity><\\entity> is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11720",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling <\\entity><\\entity> level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11721",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling <\\entity><\\entity> level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11722",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of <\\entity><\\entity>.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11723",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: <\\entity><\\entity> (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11724",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: <\\entity><\\entity> (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11725",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (<\\entity><\\entity>) level modifies the clinical severity of HBB disorders.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11726",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11727",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11728",
    "Sentence": "Intergenic variants of <\\entity><\\entity> on chromosome 6q23 have recently been shown to be a major quantitative trait locus (QTL) influencing HbF levels in normal Caucasian adults.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11729",
    "Sentence": "Intergenic variants of HBS1L-MYB on chromosome <\\entity><\\entity> have recently been shown to be a major quantitative trait locus (QTL) influencing HbF levels in normal Caucasian adults.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11730",
    "Sentence": "Intergenic variants of HBS1L-MYB on chromosome 6q23 have recently been shown to be a major quantitative trait locus (QTL) influencing <\\entity><\\entity> levels in normal Caucasian adults.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11731",
    "Sentence": "METHODS: A unique and well-characterised cohort of 238 Chinese subjects with <\\entity><\\entity> trait was used to conduct a single-nucleotide polymorphism (SNP) association study for HbF level.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11732",
    "Sentence": "METHODS: A unique and well-characterised cohort of 238 Chinese subjects with beta-thalassaemia trait was used to conduct a single-nucleotide polymorphism (SNP) association study for <\\entity><\\entity> level.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11733",
    "Sentence": "They were divided into five linkage disequilibrium (LD) <\\entity><\\entity> in the Chinese participants.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11734",
    "Sentence": "CONCLUSIONS: The data independently validate for the first time the significance of the <\\entity><\\entity> intergenic region in regulating HbF expression in a separate ethnic group that has a high prevalence of beta-thalassaemia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11735",
    "Sentence": "CONCLUSIONS: The data independently validate for the first time the significance of the HBS1L-MYB intergenic region in regulating <\\entity><\\entity> expression in a separate ethnic group that has a high prevalence of beta-thalassaemia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11736",
    "Sentence": "CONCLUSIONS: The data independently validate for the first time the significance of the HBS1L-MYB intergenic region in regulating <\\entity><\\entity> expression in a separate ethnic group that has a high prevalence of beta-thalassaemia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11737",
    "Sentence": "CONCLUSIONS: The data independently validate for the first time the significance of the HBS1L-MYB intergenic region in regulating HbF expression in a separate ethnic group that has a high prevalence of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11738",
    "Sentence": "Functional studies to unravel the biological significance of this region in regulating <\\entity><\\entity> production is clearly indicated, which may lead to new strategies to modify the disease course of severe HBB disorders.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11739",
    "Sentence": "Functional studies to unravel the biological significance of this region in regulating HbF production is clearly indicated, which may lead to new strategies to modify the <\\entity><\\entity> of severe HBB disorders.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11740",
    "Sentence": "Functional studies to unravel the biological significance of this region in regulating HbF production is clearly indicated, which may lead to new strategies to modify the disease course of severe <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11741",
    "Sentence": "Functional studies to unravel the biological significance of this region in regulating HbF production is clearly indicated, which may lead to new strategies to modify the disease course of severe <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11742",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: <\\entity><\\entity> (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": ""
  },
  {
    "id": "11743",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11745",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (<\\entity><\\entity>) level modifies the clinical severity of HBB disorders.",
    "Label": ""
  },
  {
    "id": "11746",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11748",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11749",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: <\\entity><\\entity> (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": ""
  },
  {
    "id": "11751",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11752",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11754",
    "Sentence": "Functional studies to unravel the biological significance of this region in regulating HbF production is clearly indicated, which may lead to new strategies to modify the disease course of severe <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11755",
    "Sentence": "Functional studies to unravel the biological significance of this region in regulating HbF production is clearly indicated, which may lead to new strategies to modify the disease course of severe <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11757",
    "Sentence": "Functional studies to unravel the biological significance of this region in regulating HbF production is clearly indicated, which may lead to new strategies to modify the disease course of severe <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11758",
    "Sentence": "Functional studies to unravel the biological significance of this region in regulating HbF production is clearly indicated, which may lead to new strategies to modify the <\\entity><\\entity> of severe HBB disorders.",
    "Label": ""
  },
  {
    "id": "11760",
    "Sentence": "The <\\entity><\\entity> intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": ""
  },
  {
    "id": "11761",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of <\\entity><\\entity>.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": ""
  },
  {
    "id": "11763",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome <\\entity><\\entity> is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": ""
  },
  {
    "id": "11764",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of <\\entity><\\entity>.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": ""
  },
  {
    "id": "11766",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling <\\entity><\\entity> level in carriers of beta-thalassaemia.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": ""
  },
  {
    "id": "11767",
    "Sentence": "The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of <\\entity><\\entity>.BACKGROUND: Fetal haemoglobin (HbF) level modifies the clinical severity of HBB disorders.",
    "Label": ""
  },
  {
    "id": "11769",
    "Sentence": "METHODS: A unique and well-characterised cohort of 238 Chinese subjects with beta-thalassaemia trait was used to conduct a single-nucleotide polymorphism (SNP) association study for <\\entity><\\entity> level.",
    "Label": ""
  },
  {
    "id": "11770",
    "Sentence": "METHODS: A unique and well-characterised cohort of 238 Chinese subjects with <\\entity><\\entity> trait was used to conduct a single-nucleotide polymorphism (SNP) association study for HbF level.",
    "Label": ""
  },
  {
    "id": "11772",
    "Sentence": "CONCLUSIONS: The data independently validate for the first time the significance of the <\\entity><\\entity> intergenic region in regulating HbF expression in a separate ethnic group that has a high prevalence of beta-thalassaemia.",
    "Label": ""
  },
  {
    "id": "11773",
    "Sentence": "CONCLUSIONS: The data independently validate for the first time the significance of the HBS1L-MYB intergenic region in regulating HbF expression in a separate ethnic group that has a high prevalence of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11775",
    "Sentence": "CONCLUSIONS: The data independently validate for the first time the significance of the HBS1L-MYB intergenic region in regulating <\\entity><\\entity> expression in a separate ethnic group that has a high prevalence of beta-thalassaemia.",
    "Label": ""
  },
  {
    "id": "11776",
    "Sentence": "CONCLUSIONS: The data independently validate for the first time the significance of the HBS1L-MYB intergenic region in regulating HbF expression in a separate ethnic group that has a high prevalence of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11778",
    "Sentence": "Functional studies to unravel the biological significance of this region in regulating <\\entity><\\entity> production is clearly indicated, which may lead to new strategies to modify the disease course of severe HBB disorders.",
    "Label": ""
  },
  {
    "id": "11779",
    "Sentence": "Functional studies to unravel the biological significance of this region in regulating HbF production is clearly indicated, which may lead to new strategies to modify the disease course of severe <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11781",
    "Sentence": "CONCLUSIONS: The data independently validate for the first time the significance of the <\\entity><\\entity> intergenic region in regulating HbF expression in a separate ethnic group that has a high prevalence of beta-thalassaemia.",
    "Label": ""
  },
  {
    "id": "11782",
    "Sentence": "CONCLUSIONS: The data independently validate for the first time the significance of the HBS1L-MYB intergenic region in regulating <\\entity><\\entity> expression in a separate ethnic group that has a high prevalence of beta-thalassaemia.",
    "Label": ""
  },
  {
    "id": "11788",
    "Sentence": "Could iron deposits in hepatocytes serve as a prognostic marker of <\\entity><\\entity>?BACKGROUND/AIMS: The diagnosis of hereditary hemochromatosis (HH) is based on qualitative measurement of tissue iron concentration and genetic tests.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11789",
    "Sentence": "Could iron deposits in hepatocytes serve as a prognostic marker of <\\entity><\\entity>?BACKGROUND/AIMS: The diagnosis of hereditary hemochromatosis (HH) is based on qualitative measurement of tissue iron concentration and genetic tests.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11790",
    "Sentence": "Could iron deposits in hepatocytes serve as a prognostic marker of <\\entity><\\entity>?BACKGROUND/AIMS: The diagnosis of hereditary hemochromatosis (HH) is based on qualitative measurement of tissue iron concentration and genetic tests.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11791",
    "Sentence": "Could iron deposits in hepatocytes serve as a prognostic marker of HFE gene mutations?BACKGROUND/AIMS: The diagnosis of <\\entity><\\entity> (HH) is based on qualitative measurement of tissue iron concentration and genetic tests.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11792",
    "Sentence": "Could iron deposits in hepatocytes serve as a prognostic marker of HFE gene mutations?BACKGROUND/AIMS: The diagnosis of hereditary hemochromatosis (<\\entity><\\entity>) is based on qualitative measurement of tissue iron concentration and genetic tests.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11793",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the <\\entity><\\entity> in patients with chronic liver diseases (CLD).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11794",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the <\\entity><\\entity> in patients with chronic liver diseases (CLD).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11795",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the <\\entity><\\entity> in patients with chronic liver diseases (CLD).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11796",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the HFE gene mutations in patients with <\\entity><\\entity> (CLD).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11797",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the HFE gene mutations in patients with chronic liver diseases (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11798",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the HFE gene mutations in patients with chronic liver diseases (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11799",
    "Sentence": "METHODOLOGY: The 182 patients, age range 18-71 years, were hospitalized in Gdansk because of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11800",
    "Sentence": "METHODOLOGY: The 182 patients, age range 18-71 years, were hospitalized in Gdansk because of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11801",
    "Sentence": "The <\\entity><\\entity>, H63D and S65C HFE mutations were screened by PCR-RFLP analysis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11802",
    "Sentence": "The C282Y, <\\entity><\\entity> and S65C HFE mutations were screened by PCR-RFLP analysis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11803",
    "Sentence": "The C282Y, H63D and <\\entity><\\entity> HFE mutations were screened by PCR-RFLP analysis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11804",
    "Sentence": "The C282Y, H63D and S65C <\\entity><\\entity> were screened by PCR-RFLP analysis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11805",
    "Sentence": "The C282Y, H63D and S65C <\\entity><\\entity> were screened by PCR-RFLP analysis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11806",
    "Sentence": "The C282Y, H63D and S65C <\\entity><\\entity> were screened by PCR-RFLP analysis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11807",
    "Sentence": "Liver function tests, serological examinations for <\\entity><\\entity>, serum iron and ferritin concentration and semiquantitative assessment of liver iron were done in all subjects.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11808",
    "Sentence": "Patients were divided into Group A without iron deposits in the liver, and <\\entity><\\entity> with deposits.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11809",
    "Sentence": "The most frequent etiology of <\\entity><\\entity> was chronic hepatitis C.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11810",
    "Sentence": "The most frequent etiology of <\\entity><\\entity> was chronic hepatitis C.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11811",
    "Sentence": "The most frequent etiology of CLD was <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11812",
    "Sentence": "RESULTS: Biochemical parameters indicating iron storage and <\\entity><\\entity> activity were significantly higher in Group B.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11813",
    "Sentence": "RESULTS: Biochemical parameters indicating iron storage and ALT activity were significantly higher in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11814",
    "Sentence": "Either typical for diagnosis <\\entity><\\entity> homozygotes C282Y/C282Y and combined heterozygotes C282Y/H63D or carriers of other HFE gene mutations were found significantly more frequently in Group B.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11815",
    "Sentence": "Either typical for diagnosis HH homozygotes <\\entity><\\entity> and combined heterozygotes C282Y/H63D or carriers of other HFE gene mutations were found significantly more frequently in Group B.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11816",
    "Sentence": "Either typical for diagnosis HH homozygotes C282Y/C282Y and combined heterozygotes <\\entity><\\entity> or carriers of other HFE gene mutations were found significantly more frequently in Group B.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11817",
    "Sentence": "Either typical for diagnosis HH homozygotes C282Y/C282Y and combined heterozygotes C282Y/H63D or carriers of other <\\entity><\\entity> were found significantly more frequently in Group B.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11818",
    "Sentence": "Either typical for diagnosis HH homozygotes C282Y/C282Y and combined heterozygotes C282Y/H63D or carriers of other <\\entity><\\entity> were found significantly more frequently in Group B.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11819",
    "Sentence": "Either typical for diagnosis HH homozygotes C282Y/C282Y and combined heterozygotes C282Y/H63D or carriers of other <\\entity><\\entity> were found significantly more frequently in Group B.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11820",
    "Sentence": "Either typical for diagnosis HH homozygotes C282Y/C282Y and combined heterozygotes C282Y/H63D or carriers of other HFE gene mutations were found significantly more frequently in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11821",
    "Sentence": "CONCLUSIONS: The finding of iron deposits in routinely obtained liver specimen correlates with occurrence of the different <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11822",
    "Sentence": "CONCLUSIONS: The finding of iron deposits in routinely obtained liver specimen correlates with occurrence of the different <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11823",
    "Sentence": "CONCLUSIONS: The finding of iron deposits in routinely obtained liver specimen correlates with occurrence of the different <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11824",
    "Sentence": "Could iron deposits in hepatocytes serve as a prognostic marker of <\\entity><\\entity>?BACKGROUND/AIMS: The diagnosis of hereditary hemochromatosis (HH) is based on qualitative measurement of tissue iron concentration and genetic tests.",
    "Label": ""
  },
  {
    "id": "11825",
    "Sentence": "Could iron deposits in hepatocytes serve as a prognostic marker of <\\entity><\\entity>?BACKGROUND/AIMS: The diagnosis of hereditary hemochromatosis (HH) is based on qualitative measurement of tissue iron concentration and genetic tests.",
    "Label": ""
  },
  {
    "id": "11827",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the <\\entity><\\entity> in patients with chronic liver diseases (CLD).",
    "Label": ""
  },
  {
    "id": "11828",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the <\\entity><\\entity> in patients with chronic liver diseases (CLD).",
    "Label": ""
  },
  {
    "id": "11830",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the <\\entity><\\entity> in patients with chronic liver diseases (CLD).",
    "Label": ""
  },
  {
    "id": "11831",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the HFE gene mutations in patients with <\\entity><\\entity> (CLD).",
    "Label": ""
  },
  {
    "id": "11833",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the HFE gene mutations in patients with chronic liver diseases (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "11834",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the <\\entity><\\entity> in patients with chronic liver diseases (CLD).",
    "Label": ""
  },
  {
    "id": "11836",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the HFE gene mutations in patients with chronic liver diseases (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "11837",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the HFE gene mutations in patients with <\\entity><\\entity> (CLD).",
    "Label": ""
  },
  {
    "id": "11839",
    "Sentence": "The C282Y, H63D and S65C <\\entity><\\entity> were screened by PCR-RFLP analysis.",
    "Label": ""
  },
  {
    "id": "11840",
    "Sentence": "The C282Y, H63D and S65C <\\entity><\\entity> were screened by PCR-RFLP analysis.",
    "Label": ""
  },
  {
    "id": "11842",
    "Sentence": "The most frequent etiology of <\\entity><\\entity> was chronic hepatitis C.",
    "Label": ""
  },
  {
    "id": "11843",
    "Sentence": "The most frequent etiology of CLD was <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11845",
    "Sentence": "RESULTS: Biochemical parameters indicating iron storage and <\\entity><\\entity> activity were significantly higher in Group B.",
    "Label": ""
  },
  {
    "id": "11846",
    "Sentence": "RESULTS: Biochemical parameters indicating iron storage and ALT activity were significantly higher in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11848",
    "Sentence": "Either typical for diagnosis HH homozygotes C282Y/C282Y and combined heterozygotes C282Y/H63D or carriers of other <\\entity><\\entity> were found significantly more frequently in Group B.",
    "Label": ""
  },
  {
    "id": "11849",
    "Sentence": "Either typical for diagnosis HH homozygotes C282Y/C282Y and combined heterozygotes C282Y/H63D or carriers of other <\\entity><\\entity> were found significantly more frequently in Group B.",
    "Label": ""
  },
  {
    "id": "11851",
    "Sentence": "Either typical for diagnosis HH homozygotes C282Y/C282Y and combined heterozygotes C282Y/H63D or carriers of other <\\entity><\\entity> were found significantly more frequently in Group B.",
    "Label": ""
  },
  {
    "id": "11852",
    "Sentence": "Either typical for diagnosis HH homozygotes C282Y/C282Y and combined heterozygotes C282Y/H63D or carriers of other HFE gene mutations were found significantly more frequently in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11854",
    "Sentence": "CONCLUSIONS: The finding of iron deposits in routinely obtained liver specimen correlates with occurrence of the different <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11855",
    "Sentence": "CONCLUSIONS: The finding of iron deposits in routinely obtained liver specimen correlates with occurrence of the different <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11857",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the <\\entity><\\entity> in patients with chronic liver diseases (CLD).",
    "Label": ""
  },
  {
    "id": "11858",
    "Sentence": "The aim of this study was to evaluate the correlation between the presence of iron deposits in the liver and the HFE gene mutations in patients with chronic liver diseases (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "11860",
    "Sentence": "Either typical for diagnosis HH homozygotes C282Y/C282Y and combined heterozygotes C282Y/H63D or carriers of other <\\entity><\\entity> were found significantly more frequently in Group B.",
    "Label": ""
  },
  {
    "id": "11861",
    "Sentence": "Either typical for diagnosis <\\entity><\\entity> homozygotes C282Y/C282Y and combined heterozygotes C282Y/H63D or carriers of other HFE gene mutations were found significantly more frequently in Group B.",
    "Label": ""
  },
  {
    "id": "11863",
    "Sentence": "Either typical for diagnosis HH homozygotes C282Y/C282Y and combined heterozygotes <\\entity><\\entity> or carriers of other HFE gene mutations were found significantly more frequently in Group B.",
    "Label": ""
  },
  {
    "id": "11864",
    "Sentence": "Either typical for diagnosis <\\entity><\\entity> homozygotes C282Y/C282Y and combined heterozygotes C282Y/H63D or carriers of other HFE gene mutations were found significantly more frequently in Group B.",
    "Label": ""
  },
  {
    "id": "11870",
    "Sentence": "<\\entity><\\entity> genetic variations and susceptibility to schizophrenia in a Chinese population.BACKGROUND: The study investigated the possible association of NRG3 gene and schizophrenia in a Han Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11871",
    "Sentence": "Neuregulin 3 genetic variations and susceptibility to <\\entity><\\entity> in a Chinese population.BACKGROUND: The study investigated the possible association of NRG3 gene and <\\entity><\\entity> in a Han Chinese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11872",
    "Sentence": "Neuregulin 3 genetic variations and susceptibility to schizophrenia in a Chinese population.BACKGROUND: The study investigated the possible association of <\\entity><\\entity> gene and schizophrenia in a Han Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11873",
    "Sentence": "Neuregulin 3 genetic variations and susceptibility to <\\entity><\\entity> in a Chinese population.BACKGROUND: The study investigated the possible association of NRG3 gene and <\\entity><\\entity> in a Han Chinese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11874",
    "Sentence": "METHODS: Of a total of 1345, 270 unrelated <\\entity><\\entity> inpatients, 235 normal control subjects, and 280 nuclear families (trios) with <\\entity><\\entity> probands were studied.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11875",
    "Sentence": "METHODS: Of a total of 1345, 270 unrelated <\\entity><\\entity> inpatients, 235 normal control subjects, and 280 nuclear families (trios) with <\\entity><\\entity> probands were studied.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11876",
    "Sentence": "Nine single nucleotide polymorphisms (SNPs) spanning intron 1 to exon 9 of the <\\entity><\\entity> gene were analyzed, starting with the case-control samples.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11877",
    "Sentence": "The SNPs showing significant association with <\\entity><\\entity> in the case-control samples were subsequently studied in the independent trio samples with family-based association analysis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11878",
    "Sentence": "The SNPs showing significant association with schizophrenia in the case-control samples were subsequently studied in the independent <\\entity><\\entity> samples with family-based association analysis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11879",
    "Sentence": "RESULTS: In case-control samples, two SNPs (<\\entity><\\entity> and rs677221) showed significant genotypic and allelic association with schizophrenia (all p < .05) with rs677221-C being the risk allele for schizophrenia (uncorrected p = .001, odds ratio = 1.439, 95% confidence interval = 1.115-1.858).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11880",
    "Sentence": "RESULTS: In case-control samples, two SNPs (rs1937970 and <\\entity><\\entity>) showed significant genotypic and allelic association with schizophrenia (all p < .05) with <\\entity><\\entity>-C being the risk allele for schizophrenia (uncorrected p = .001, odds ratio = 1.439, 95% confidence interval = 1.115-1.858).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11881",
    "Sentence": "RESULTS: In case-control samples, two SNPs (rs1937970 and rs677221) showed significant genotypic and allelic association with <\\entity><\\entity> (all p < .05) with rs677221-C being the risk allele for <\\entity><\\entity> (uncorrected p = .001, odds ratio = 1.439, 95% confidence interval = 1.115-1.858).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11882",
    "Sentence": "RESULTS: In case-control samples, two SNPs (rs1937970 and rs677221) showed significant genotypic and allelic association with schizophrenia (all p < .05) with <\\entity><\\entity> being the risk allele for schizophrenia (uncorrected p = .001, odds ratio = 1.439, 95% confidence interval = 1.115-1.858).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11883",
    "Sentence": "RESULTS: In case-control samples, two SNPs (rs1937970 and rs677221) showed significant genotypic and allelic association with <\\entity><\\entity> (all p < .05) with rs677221-C being the risk allele for <\\entity><\\entity> (uncorrected p = .001, odds ratio = 1.439, 95% confidence interval = 1.115-1.858).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11884",
    "Sentence": "<\\entity><\\entity> constructed by the two SNPs was also significantly associated with schizophrenia (permutation p value = .0047).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11885",
    "Sentence": "Haplotypes GC constructed by the two SNPs was also significantly associated with <\\entity><\\entity> (permutation p value = .0047).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11886",
    "Sentence": "In the independent <\\entity><\\entity> samples, rs1937970-A and rs677221-G consistently showed significant under-transmission to schizophrenic offspring (unadjusted p = .003 and p = .004, respectively).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11887",
    "Sentence": "In the independent trio samples, <\\entity><\\entity> and rs677221-G consistently showed significant under-transmission to schizophrenic offspring (unadjusted p = .003 and p = .004, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11888",
    "Sentence": "In the independent trio samples, rs1937970-A and <\\entity><\\entity> consistently showed significant under-transmission to schizophrenic offspring (unadjusted p = .003 and p = .004, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11889",
    "Sentence": "In the independent trio samples, rs1937970-A and rs677221-G consistently showed significant under-transmission to <\\entity><\\entity> offspring (unadjusted p = .003 and p = .004, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11890",
    "Sentence": "In the haplotype-transmission disequilibrium test (<\\entity><\\entity>) for allelic combination of rs1937970-rs677221, significant under-transmission for haplotype AG (uncorrected p = .006) and over-transmission for haplotype GC (uncorrected p = .004) to the affected schizophrenia offspring were observed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11891",
    "Sentence": "In the haplotype-transmission disequilibrium test (TDT) for allelic combination of <\\entity><\\entity>, significant under-transmission for haplotype AG (uncorrected p = .006) and over-transmission for haplotype GC (uncorrected p = .004) to the affected schizophrenia offspring were observed.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11892",
    "Sentence": "In the haplotype-transmission disequilibrium test (TDT) for allelic combination of rs1937970-rs677221, significant under-transmission for <\\entity><\\entity> (uncorrected p = .006) and over-transmission for haplotype GC (uncorrected p = .004) to the affected schizophrenia offspring were observed.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11893",
    "Sentence": "In the haplotype-transmission disequilibrium test (TDT) for allelic combination of rs1937970-rs677221, significant under-transmission for haplotype AG (uncorrected p = .006) and over-transmission for <\\entity><\\entity> (uncorrected p = .004) to the affected schizophrenia offspring were observed.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "11894",
    "Sentence": "In the haplotype-transmission disequilibrium test (TDT) for allelic combination of rs1937970-rs677221, significant under-transmission for haplotype AG (uncorrected p = .006) and over-transmission for haplotype GC (uncorrected p = .004) to the affected <\\entity><\\entity> offspring were observed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11895",
    "Sentence": "CONCLUSIONS: The result supports that the <\\entity><\\entity> gene is a susceptibility gene for schizophrenia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "11896",
    "Sentence": "CONCLUSIONS: The result supports that the NRG3 gene is a susceptibility gene for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11897",
    "Sentence": "Neuregulin 3 genetic variations and susceptibility to schizophrenia in a Chinese population.BACKGROUND: The study investigated the possible association of <\\entity><\\entity> gene and schizophrenia in a Han Chinese population.",
    "Label": ""
  },
  {
    "id": "11898",
    "Sentence": "Neuregulin 3 genetic variations and susceptibility to <\\entity><\\entity> in a Chinese population.BACKGROUND: The study investigated the possible association of NRG3 gene and <\\entity><\\entity> in a Han Chinese population.",
    "Label": ""
  },
  {
    "id": "11900",
    "Sentence": "RESULTS: In case-control samples, two SNPs (<\\entity><\\entity> and rs677221) showed significant genotypic and allelic association with schizophrenia (all p < .05) with rs677221-C being the risk allele for schizophrenia (uncorrected p = .001, odds ratio = 1.439, 95% confidence interval = 1.115-1.858).",
    "Label": ""
  },
  {
    "id": "11901",
    "Sentence": "RESULTS: In case-control samples, two SNPs (rs1937970 and rs677221) showed significant genotypic and allelic association with <\\entity><\\entity> (all p < .05) with rs677221-C being the risk allele for <\\entity><\\entity> (uncorrected p = .001, odds ratio = 1.439, 95% confidence interval = 1.115-1.858).",
    "Label": ""
  },
  {
    "id": "11903",
    "Sentence": "RESULTS: In case-control samples, two SNPs (rs1937970 and <\\entity><\\entity>) showed significant genotypic and allelic association with schizophrenia (all p < .05) with <\\entity><\\entity>-C being the risk allele for schizophrenia (uncorrected p = .001, odds ratio = 1.439, 95% confidence interval = 1.115-1.858).",
    "Label": ""
  },
  {
    "id": "11904",
    "Sentence": "RESULTS: In case-control samples, two SNPs (rs1937970 and rs677221) showed significant genotypic and allelic association with <\\entity><\\entity> (all p < .05) with rs677221-C being the risk allele for <\\entity><\\entity> (uncorrected p = .001, odds ratio = 1.439, 95% confidence interval = 1.115-1.858).",
    "Label": ""
  },
  {
    "id": "11906",
    "Sentence": "RESULTS: In case-control samples, two SNPs (rs1937970 and rs677221) showed significant genotypic and allelic association with schizophrenia (all p < .05) with <\\entity><\\entity> being the risk allele for schizophrenia (uncorrected p = .001, odds ratio = 1.439, 95% confidence interval = 1.115-1.858).",
    "Label": ""
  },
  {
    "id": "11907",
    "Sentence": "RESULTS: In case-control samples, two SNPs (rs1937970 and rs677221) showed significant genotypic and allelic association with <\\entity><\\entity> (all p < .05) with rs677221-C being the risk allele for <\\entity><\\entity> (uncorrected p = .001, odds ratio = 1.439, 95% confidence interval = 1.115-1.858).",
    "Label": ""
  },
  {
    "id": "11909",
    "Sentence": "<\\entity><\\entity> constructed by the two SNPs was also significantly associated with schizophrenia (permutation p value = .0047).",
    "Label": ""
  },
  {
    "id": "11910",
    "Sentence": "Haplotypes GC constructed by the two SNPs was also significantly associated with <\\entity><\\entity> (permutation p value = .0047).",
    "Label": ""
  },
  {
    "id": "11912",
    "Sentence": "In the independent trio samples, <\\entity><\\entity> and rs677221-G consistently showed significant under-transmission to schizophrenic offspring (unadjusted p = .003 and p = .004, respectively).",
    "Label": ""
  },
  {
    "id": "11913",
    "Sentence": "In the independent trio samples, rs1937970-A and rs677221-G consistently showed significant under-transmission to <\\entity><\\entity> offspring (unadjusted p = .003 and p = .004, respectively).",
    "Label": ""
  },
  {
    "id": "11915",
    "Sentence": "In the independent trio samples, rs1937970-A and <\\entity><\\entity> consistently showed significant under-transmission to schizophrenic offspring (unadjusted p = .003 and p = .004, respectively).",
    "Label": ""
  },
  {
    "id": "11916",
    "Sentence": "In the independent trio samples, rs1937970-A and rs677221-G consistently showed significant under-transmission to <\\entity><\\entity> offspring (unadjusted p = .003 and p = .004, respectively).",
    "Label": ""
  },
  {
    "id": "11918",
    "Sentence": "In the haplotype-transmission disequilibrium test (TDT) for allelic combination of <\\entity><\\entity>, significant under-transmission for haplotype AG (uncorrected p = .006) and over-transmission for haplotype GC (uncorrected p = .004) to the affected schizophrenia offspring were observed.",
    "Label": ""
  },
  {
    "id": "11919",
    "Sentence": "In the haplotype-transmission disequilibrium test (TDT) for allelic combination of rs1937970-rs677221, significant under-transmission for haplotype AG (uncorrected p = .006) and over-transmission for haplotype GC (uncorrected p = .004) to the affected <\\entity><\\entity> offspring were observed.",
    "Label": ""
  },
  {
    "id": "11921",
    "Sentence": "In the haplotype-transmission disequilibrium test (TDT) for allelic combination of rs1937970-rs677221, significant under-transmission for <\\entity><\\entity> (uncorrected p = .006) and over-transmission for haplotype GC (uncorrected p = .004) to the affected schizophrenia offspring were observed.",
    "Label": ""
  },
  {
    "id": "11922",
    "Sentence": "In the haplotype-transmission disequilibrium test (TDT) for allelic combination of rs1937970-rs677221, significant under-transmission for haplotype AG (uncorrected p = .006) and over-transmission for haplotype GC (uncorrected p = .004) to the affected <\\entity><\\entity> offspring were observed.",
    "Label": ""
  },
  {
    "id": "11924",
    "Sentence": "In the haplotype-transmission disequilibrium test (TDT) for allelic combination of rs1937970-rs677221, significant under-transmission for haplotype AG (uncorrected p = .006) and over-transmission for <\\entity><\\entity> (uncorrected p = .004) to the affected schizophrenia offspring were observed.",
    "Label": ""
  },
  {
    "id": "11925",
    "Sentence": "In the haplotype-transmission disequilibrium test (TDT) for allelic combination of rs1937970-rs677221, significant under-transmission for haplotype AG (uncorrected p = .006) and over-transmission for haplotype GC (uncorrected p = .004) to the affected <\\entity><\\entity> offspring were observed.",
    "Label": ""
  },
  {
    "id": "11927",
    "Sentence": "CONCLUSIONS: The result supports that the <\\entity><\\entity> gene is a susceptibility gene for schizophrenia.",
    "Label": ""
  },
  {
    "id": "11928",
    "Sentence": "CONCLUSIONS: The result supports that the NRG3 gene is a susceptibility gene for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11930",
    "Sentence": "<\\entity><\\entity> genetic variations and susceptibility to schizophrenia in a Chinese population.BACKGROUND: The study investigated the possible association of NRG3 gene and schizophrenia in a Han Chinese population.",
    "Label": ""
  },
  {
    "id": "11931",
    "Sentence": "Neuregulin 3 genetic variations and susceptibility to <\\entity><\\entity> in a Chinese population.BACKGROUND: The study investigated the possible association of NRG3 gene and <\\entity><\\entity> in a Han Chinese population.",
    "Label": ""
  },
  {
    "id": "11933",
    "Sentence": "The SNPs showing significant association with schizophrenia in the case-control samples were subsequently studied in the independent <\\entity><\\entity> samples with family-based association analysis.",
    "Label": ""
  },
  {
    "id": "11934",
    "Sentence": "The SNPs showing significant association with <\\entity><\\entity> in the case-control samples were subsequently studied in the independent trio samples with family-based association analysis.",
    "Label": ""
  },
  {
    "id": "11936",
    "Sentence": "In the haplotype-transmission disequilibrium test (<\\entity><\\entity>) for allelic combination of rs1937970-rs677221, significant under-transmission for haplotype AG (uncorrected p = .006) and over-transmission for haplotype GC (uncorrected p = .004) to the affected schizophrenia offspring were observed.",
    "Label": ""
  },
  {
    "id": "11937",
    "Sentence": "In the haplotype-transmission disequilibrium test (TDT) for allelic combination of rs1937970-rs677221, significant under-transmission for haplotype AG (uncorrected p = .006) and over-transmission for haplotype GC (uncorrected p = .004) to the affected <\\entity><\\entity> offspring were observed.",
    "Label": ""
  },
  {
    "id": "11943",
    "Sentence": "A double-blind, randomized trial of low-dose <\\entity><\\entity> vs propranolol in migraine prophylaxis.OBJECTIVE: To assess the efficacy and safety of low-dose <\\entity><\\entity> in migraine prophylaxis vs propranolol.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11944",
    "Sentence": "A double-blind, randomized trial of low-dose topiramate vs <\\entity><\\entity> in migraine prophylaxis.OBJECTIVE: To assess the efficacy and safety of low-dose topiramate in migraine prophylaxis vs <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11945",
    "Sentence": "A double-blind, randomized trial of low-dose topiramate vs propranolol in <\\entity><\\entity> prophylaxis.OBJECTIVE: To assess the efficacy and safety of low-dose topiramate in <\\entity><\\entity> prophylaxis vs propranolol.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11946",
    "Sentence": "A double-blind, randomized trial of low-dose <\\entity><\\entity> vs propranolol in migraine prophylaxis.OBJECTIVE: To assess the efficacy and safety of low-dose <\\entity><\\entity> in migraine prophylaxis vs propranolol.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11947",
    "Sentence": "A double-blind, randomized trial of low-dose topiramate vs propranolol in <\\entity><\\entity> prophylaxis.OBJECTIVE: To assess the efficacy and safety of low-dose topiramate in <\\entity><\\entity> prophylaxis vs propranolol.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11948",
    "Sentence": "A double-blind, randomized trial of low-dose topiramate vs <\\entity><\\entity> in migraine prophylaxis.OBJECTIVE: To assess the efficacy and safety of low-dose topiramate in migraine prophylaxis vs <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11949",
    "Sentence": "PATIENTS AND METHODS: A randomized, double-blind, clinical trial including 62 patients with frequent <\\entity><\\entity> (> or = 3 attacks per month) was performed for a period of 8 weeks.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11950",
    "Sentence": "The patients were randomly divided into two treatment groups - treated by <\\entity><\\entity> 50 mg/day and propranolol 80 mg/day, respectively.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11951",
    "Sentence": "The patients were randomly divided into two treatment groups - treated by topiramate 50 mg/day and <\\entity><\\entity> 80 mg/day, respectively.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11952",
    "Sentence": "Results - The <\\entity><\\entity> group showed a reduction in the mean (+/-SD) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, headache intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11953",
    "Sentence": "Results - The topiramate group showed a reduction in the mean (+/-SD) of monthly <\\entity><\\entity> frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, headache intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11954",
    "Sentence": "Results - The topiramate group showed a reduction in the mean (+/-SD) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, <\\entity><\\entity> intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and <\\entity><\\entity> duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11955",
    "Sentence": "Results - The topiramate group showed a reduction in the mean (+/-SD) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, <\\entity><\\entity> intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and <\\entity><\\entity> duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11956",
    "Sentence": "In the patients treated with <\\entity><\\entity>, the mean (+/-SD) of monthly headache frequency declined from 5.83 (+/-1.98) to 2.2 (+/-1.67) per month, headache intensity lessened from 6.43 (+/-1.6) to 4.13 (+/-1.94) and headache duration decreased from 15.10 (+/-6.84) to 7.27 (+/-6.46) h (P < 0.001).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11957",
    "Sentence": "In the patients treated with propranolol, the mean (+/-SD) of monthly <\\entity><\\entity> frequency declined from 5.83 (+/-1.98) to 2.2 (+/-1.67) per month, <\\entity><\\entity> intensity lessened from 6.43 (+/-1.6) to 4.13 (+/-1.94) and <\\entity><\\entity> duration decreased from 15.10 (+/-6.84) to 7.27 (+/-6.46) h (P < 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11958",
    "Sentence": "In the patients treated with propranolol, the mean (+/-SD) of monthly <\\entity><\\entity> frequency declined from 5.83 (+/-1.98) to 2.2 (+/-1.67) per month, <\\entity><\\entity> intensity lessened from 6.43 (+/-1.6) to 4.13 (+/-1.94) and <\\entity><\\entity> duration decreased from 15.10 (+/-6.84) to 7.27 (+/-6.46) h (P < 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11959",
    "Sentence": "In the patients treated with propranolol, the mean (+/-SD) of monthly <\\entity><\\entity> frequency declined from 5.83 (+/-1.98) to 2.2 (+/-1.67) per month, <\\entity><\\entity> intensity lessened from 6.43 (+/-1.6) to 4.13 (+/-1.94) and <\\entity><\\entity> duration decreased from 15.10 (+/-6.84) to 7.27 (+/-6.46) h (P < 0.001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11960",
    "Sentence": "CONCLUSION: This study demonstrated that both low-dose <\\entity><\\entity> and propranolol could significantly reduce migraine headache frequency, intensity, and duration.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11961",
    "Sentence": "CONCLUSION: This study demonstrated that both low-dose topiramate and <\\entity><\\entity> could significantly reduce migraine headache frequency, intensity, and duration.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11962",
    "Sentence": "CONCLUSION: This study demonstrated that both low-dose topiramate and propranolol could significantly reduce <\\entity><\\entity> frequency, intensity, and duration.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "11963",
    "Sentence": "However, compared with <\\entity><\\entity>, low-dose topiramate showed better results.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11964",
    "Sentence": "However, compared with propranolol, low-dose <\\entity><\\entity> showed better results.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "11965",
    "Sentence": "Results - The <\\entity><\\entity> group showed a reduction in the mean (+/-SD) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, headache intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001).",
    "Label": ""
  },
  {
    "id": "11966",
    "Sentence": "Results - The topiramate group showed a reduction in the mean (+/-SD) of monthly <\\entity><\\entity> frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, headache intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001).",
    "Label": ""
  },
  {
    "id": "11968",
    "Sentence": "Results - The <\\entity><\\entity> group showed a reduction in the mean (+/-SD) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, headache intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001).",
    "Label": ""
  },
  {
    "id": "11969",
    "Sentence": "Results - The topiramate group showed a reduction in the mean (+/-SD) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, <\\entity><\\entity> intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and <\\entity><\\entity> duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001).",
    "Label": ""
  },
  {
    "id": "11971",
    "Sentence": "In the patients treated with <\\entity><\\entity>, the mean (+/-SD) of monthly headache frequency declined from 5.83 (+/-1.98) to 2.2 (+/-1.67) per month, headache intensity lessened from 6.43 (+/-1.6) to 4.13 (+/-1.94) and headache duration decreased from 15.10 (+/-6.84) to 7.27 (+/-6.46) h (P < 0.001).",
    "Label": ""
  },
  {
    "id": "11972",
    "Sentence": "In the patients treated with propranolol, the mean (+/-SD) of monthly <\\entity><\\entity> frequency declined from 5.83 (+/-1.98) to 2.2 (+/-1.67) per month, <\\entity><\\entity> intensity lessened from 6.43 (+/-1.6) to 4.13 (+/-1.94) and <\\entity><\\entity> duration decreased from 15.10 (+/-6.84) to 7.27 (+/-6.46) h (P < 0.001).",
    "Label": ""
  },
  {
    "id": "11974",
    "Sentence": "CONCLUSION: This study demonstrated that both low-dose <\\entity><\\entity> and propranolol could significantly reduce migraine headache frequency, intensity, and duration.",
    "Label": ""
  },
  {
    "id": "11975",
    "Sentence": "CONCLUSION: This study demonstrated that both low-dose topiramate and propranolol could significantly reduce <\\entity><\\entity> frequency, intensity, and duration.",
    "Label": ""
  },
  {
    "id": "11977",
    "Sentence": "CONCLUSION: This study demonstrated that both low-dose topiramate and <\\entity><\\entity> could significantly reduce migraine headache frequency, intensity, and duration.",
    "Label": ""
  },
  {
    "id": "11978",
    "Sentence": "CONCLUSION: This study demonstrated that both low-dose topiramate and propranolol could significantly reduce <\\entity><\\entity> frequency, intensity, and duration.",
    "Label": ""
  },
  {
    "id": "11980",
    "Sentence": "Results - The <\\entity><\\entity> group showed a reduction in the mean (+/-SD) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, headache intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001).",
    "Label": ""
  },
  {
    "id": "11981",
    "Sentence": "Results - The topiramate group showed a reduction in the mean (+/-SD) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, <\\entity><\\entity> intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and <\\entity><\\entity> duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001).",
    "Label": ""
  },
  {
    "id": "11983",
    "Sentence": "In the patients treated with <\\entity><\\entity>, the mean (+/-SD) of monthly headache frequency declined from 5.83 (+/-1.98) to 2.2 (+/-1.67) per month, headache intensity lessened from 6.43 (+/-1.6) to 4.13 (+/-1.94) and headache duration decreased from 15.10 (+/-6.84) to 7.27 (+/-6.46) h (P < 0.001).",
    "Label": ""
  },
  {
    "id": "11984",
    "Sentence": "In the patients treated with propranolol, the mean (+/-SD) of monthly <\\entity><\\entity> frequency declined from 5.83 (+/-1.98) to 2.2 (+/-1.67) per month, <\\entity><\\entity> intensity lessened from 6.43 (+/-1.6) to 4.13 (+/-1.94) and <\\entity><\\entity> duration decreased from 15.10 (+/-6.84) to 7.27 (+/-6.46) h (P < 0.001).",
    "Label": ""
  },
  {
    "id": "11986",
    "Sentence": "A double-blind, randomized trial of low-dose <\\entity><\\entity> vs propranolol in migraine prophylaxis.OBJECTIVE: To assess the efficacy and safety of low-dose <\\entity><\\entity> in migraine prophylaxis vs propranolol.",
    "Label": ""
  },
  {
    "id": "11987",
    "Sentence": "A double-blind, randomized trial of low-dose topiramate vs propranolol in <\\entity><\\entity> prophylaxis.OBJECTIVE: To assess the efficacy and safety of low-dose topiramate in <\\entity><\\entity> prophylaxis vs propranolol.",
    "Label": ""
  },
  {
    "id": "11989",
    "Sentence": "A double-blind, randomized trial of low-dose topiramate vs <\\entity><\\entity> in migraine prophylaxis.OBJECTIVE: To assess the efficacy and safety of low-dose topiramate in migraine prophylaxis vs <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11990",
    "Sentence": "A double-blind, randomized trial of low-dose topiramate vs propranolol in <\\entity><\\entity> prophylaxis.OBJECTIVE: To assess the efficacy and safety of low-dose topiramate in <\\entity><\\entity> prophylaxis vs propranolol.",
    "Label": ""
  },
  {
    "id": "11992",
    "Sentence": "A double-blind, randomized trial of low-dose <\\entity><\\entity> vs propranolol in migraine prophylaxis.OBJECTIVE: To assess the efficacy and safety of low-dose <\\entity><\\entity> in migraine prophylaxis vs propranolol.",
    "Label": ""
  },
  {
    "id": "11993",
    "Sentence": "A double-blind, randomized trial of low-dose topiramate vs propranolol in <\\entity><\\entity> prophylaxis.OBJECTIVE: To assess the efficacy and safety of low-dose topiramate in <\\entity><\\entity> prophylaxis vs propranolol.",
    "Label": ""
  },
  {
    "id": "11995",
    "Sentence": "A double-blind, randomized trial of low-dose topiramate vs <\\entity><\\entity> in migraine prophylaxis.OBJECTIVE: To assess the efficacy and safety of low-dose topiramate in migraine prophylaxis vs <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "11996",
    "Sentence": "A double-blind, randomized trial of low-dose topiramate vs propranolol in <\\entity><\\entity> prophylaxis.OBJECTIVE: To assess the efficacy and safety of low-dose topiramate in <\\entity><\\entity> prophylaxis vs propranolol.",
    "Label": ""
  },
  {
    "id": "11998",
    "Sentence": "In the patients treated with <\\entity><\\entity>, the mean (+/-SD) of monthly headache frequency declined from 5.83 (+/-1.98) to 2.2 (+/-1.67) per month, headache intensity lessened from 6.43 (+/-1.6) to 4.13 (+/-1.94) and headache duration decreased from 15.10 (+/-6.84) to 7.27 (+/-6.46) h (P < 0.001).",
    "Label": ""
  },
  {
    "id": "11999",
    "Sentence": "In the patients treated with propranolol, the mean (+/-SD) of monthly <\\entity><\\entity> frequency declined from 5.83 (+/-1.98) to 2.2 (+/-1.67) per month, <\\entity><\\entity> intensity lessened from 6.43 (+/-1.6) to 4.13 (+/-1.94) and <\\entity><\\entity> duration decreased from 15.10 (+/-6.84) to 7.27 (+/-6.46) h (P < 0.001).",
    "Label": ""
  },
  {
    "id": "12005",
    "Sentence": "<\\entity><\\entity>: an oral triazole with an extended spectrum of activity.OBJECTIVE: To summarize the published clinical data on posaconazole, critically review the New Drug Application data submitted to the Food and Drug Administration, and provide information critical for evaluation and formulary positioning.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12006",
    "Sentence": "Posaconazole: an <\\entity><\\entity> with an extended spectrum of activity.OBJECTIVE: To summarize the published clinical data on posaconazole, critically review the New Drug Application data submitted to the Food and Drug Administration, and provide information critical for evaluation and formulary positioning.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12007",
    "Sentence": "Posaconazole: an oral triazole with an extended spectrum of activity.OBJECTIVE: To summarize the published clinical data on <\\entity><\\entity>, critically review the New Drug Application data submitted to the Food and Drug Administration, and provide information critical for evaluation and formulary positioning.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12008",
    "Sentence": "All available in vitro, animal, clinical, and human studies describing the pharmacology, pharmacokinetics, pharmacodynamics, efficacy, safety, and adverse events of <\\entity><\\entity> were reviewed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12009",
    "Sentence": "DATA SYNTHESIS: <\\entity><\\entity> is an oral broad-spectrum triazole with activity against many yeasts and molds.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12010",
    "Sentence": "DATA SYNTHESIS: Posaconazole is an <\\entity><\\entity> with activity against many yeasts and molds.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12011",
    "Sentence": "Resistance to <\\entity><\\entity> has been reported, but has been rare to date.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12012",
    "Sentence": "<\\entity><\\entity>, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12013",
    "Sentence": "Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough <\\entity><\\entity> (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12014",
    "Sentence": "Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and <\\entity><\\entity> incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12015",
    "Sentence": "Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12016",
    "Sentence": "Similarly, the same regimen of <\\entity><\\entity> reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12017",
    "Sentence": "Similarly, the same regimen of posaconazole reduced <\\entity><\\entity> (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12018",
    "Sentence": "Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and <\\entity><\\entity> (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12019",
    "Sentence": "Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with <\\entity><\\entity> and itraconazole in neutropenic patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12020",
    "Sentence": "Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and <\\entity><\\entity> in neutropenic patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12021",
    "Sentence": "<\\entity><\\entity> is noninferior to fluconazole for treatment of oropharyngeal candidiasis (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12022",
    "Sentence": "Posaconazole is noninferior to <\\entity><\\entity> for treatment of oropharyngeal candidiasis (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12023",
    "Sentence": "Posaconazole is noninferior to fluconazole for treatment of <\\entity><\\entity> (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12024",
    "Sentence": "Smaller investigations have analyzed use of <\\entity><\\entity> for patients requiring salvage or alternative treatment for zygomycosis, fusariosis, cryptococcal meningitis, coccidioidomycosis, and histoplasmosis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12025",
    "Sentence": "Smaller investigations have analyzed use of posaconazole for patients requiring salvage or alternative treatment for <\\entity><\\entity>, fusariosis, cryptococcal meningitis, coccidioidomycosis, and histoplasmosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12026",
    "Sentence": "Smaller investigations have analyzed use of posaconazole for patients requiring salvage or alternative treatment for zygomycosis, <\\entity><\\entity>, cryptococcal meningitis, coccidioidomycosis, and histoplasmosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12027",
    "Sentence": "Smaller investigations have analyzed use of posaconazole for patients requiring salvage or alternative treatment for zygomycosis, fusariosis, <\\entity><\\entity>, coccidioidomycosis, and histoplasmosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12028",
    "Sentence": "Smaller investigations have analyzed use of posaconazole for patients requiring salvage or alternative treatment for zygomycosis, fusariosis, cryptococcal meningitis, <\\entity><\\entity>, and histoplasmosis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12029",
    "Sentence": "Smaller investigations have analyzed use of posaconazole for patients requiring salvage or alternative treatment for zygomycosis, fusariosis, cryptococcal meningitis, coccidioidomycosis, and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12030",
    "Sentence": "The most common <\\entity><\\entity> associated with the use of posaconazole include headache, fever, nausea, vomiting, and diarrhea.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12031",
    "Sentence": "The most common adverse effects associated with the use of <\\entity><\\entity> include headache, fever, nausea, vomiting, and diarrhea.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12032",
    "Sentence": "The most common adverse effects associated with the use of posaconazole include <\\entity><\\entity>, fever, nausea, vomiting, and diarrhea.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12033",
    "Sentence": "The most common adverse effects associated with the use of posaconazole include headache, fever, <\\entity><\\entity>, vomiting, and diarrhea.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12034",
    "Sentence": "The most common adverse effects associated with the use of posaconazole include headache, fever, nausea, <\\entity><\\entity>, and diarrhea.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12035",
    "Sentence": "The most common adverse effects associated with the use of posaconazole include headache, fever, nausea, vomiting, and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12036",
    "Sentence": "CONCLUSIONS: <\\entity><\\entity> appears to be a valuable and promising addition to the antifungal armamentarium for prophylaxis and treatment of various fungal processes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12037",
    "Sentence": "CONCLUSIONS: Posaconazole appears to be a valuable and promising addition to the <\\entity><\\entity> armamentarium for prophylaxis and treatment of various fungal processes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12038",
    "Sentence": "At this time, <\\entity><\\entity> should probably be reserved for prophylaxis in patients at high risk for invasive fungal infection, as salvage therapy in refractory or resistant infections, or for patients with intolerance to other therapies.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12039",
    "Sentence": "At this time, posaconazole should probably be reserved for prophylaxis in patients at high risk for <\\entity><\\entity>, as salvage therapy in refractory or resistant infections, or for patients with intolerance to other therapies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12040",
    "Sentence": "At this time, posaconazole should probably be reserved for prophylaxis in patients at high risk for invasive fungal infection, as salvage therapy in refractory or <\\entity><\\entity>, or for patients with intolerance to other therapies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12041",
    "Sentence": "<\\entity><\\entity>, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole.",
    "Label": ""
  },
  {
    "id": "12042",
    "Sentence": "Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and <\\entity><\\entity> incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole.",
    "Label": ""
  },
  {
    "id": "12044",
    "Sentence": "<\\entity><\\entity>, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole.",
    "Label": ""
  },
  {
    "id": "12045",
    "Sentence": "Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough <\\entity><\\entity> (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole.",
    "Label": ""
  },
  {
    "id": "12047",
    "Sentence": "Similarly, the same regimen of <\\entity><\\entity> reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.",
    "Label": ""
  },
  {
    "id": "12048",
    "Sentence": "Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and <\\entity><\\entity> (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.",
    "Label": ""
  },
  {
    "id": "12050",
    "Sentence": "Similarly, the same regimen of <\\entity><\\entity> reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.",
    "Label": ""
  },
  {
    "id": "12051",
    "Sentence": "Similarly, the same regimen of posaconazole reduced <\\entity><\\entity> (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.",
    "Label": ""
  },
  {
    "id": "12053",
    "Sentence": "<\\entity><\\entity> is noninferior to fluconazole for treatment of oropharyngeal candidiasis (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist.",
    "Label": ""
  },
  {
    "id": "12054",
    "Sentence": "Posaconazole is noninferior to fluconazole for treatment of <\\entity><\\entity> (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist.",
    "Label": ""
  },
  {
    "id": "12056",
    "Sentence": "Posaconazole is noninferior to <\\entity><\\entity> for treatment of oropharyngeal candidiasis (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist.",
    "Label": ""
  },
  {
    "id": "12057",
    "Sentence": "Posaconazole is noninferior to fluconazole for treatment of <\\entity><\\entity> (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist.",
    "Label": ""
  },
  {
    "id": "12059",
    "Sentence": "The most common adverse effects associated with the use of <\\entity><\\entity> include headache, fever, nausea, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "12060",
    "Sentence": "The most common adverse effects associated with the use of posaconazole include <\\entity><\\entity>, fever, nausea, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "12062",
    "Sentence": "The most common adverse effects associated with the use of <\\entity><\\entity> include headache, fever, nausea, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "12063",
    "Sentence": "The most common adverse effects associated with the use of posaconazole include headache, fever, <\\entity><\\entity>, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "12065",
    "Sentence": "The most common adverse effects associated with the use of <\\entity><\\entity> include headache, fever, nausea, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "12066",
    "Sentence": "The most common adverse effects associated with the use of posaconazole include headache, fever, nausea, <\\entity><\\entity>, and diarrhea.",
    "Label": ""
  },
  {
    "id": "12068",
    "Sentence": "The most common adverse effects associated with the use of <\\entity><\\entity> include headache, fever, nausea, vomiting, and diarrhea.",
    "Label": ""
  },
  {
    "id": "12069",
    "Sentence": "The most common adverse effects associated with the use of posaconazole include headache, fever, nausea, vomiting, and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12071",
    "Sentence": "At this time, <\\entity><\\entity> should probably be reserved for prophylaxis in patients at high risk for invasive fungal infection, as salvage therapy in refractory or resistant infections, or for patients with intolerance to other therapies.",
    "Label": ""
  },
  {
    "id": "12072",
    "Sentence": "At this time, posaconazole should probably be reserved for prophylaxis in patients at high risk for invasive fungal infection, as salvage therapy in refractory or <\\entity><\\entity>, or for patients with intolerance to other therapies.",
    "Label": ""
  },
  {
    "id": "12074",
    "Sentence": "At this time, <\\entity><\\entity> should probably be reserved for prophylaxis in patients at high risk for invasive fungal infection, as salvage therapy in refractory or resistant infections, or for patients with intolerance to other therapies.",
    "Label": ""
  },
  {
    "id": "12075",
    "Sentence": "At this time, posaconazole should probably be reserved for prophylaxis in patients at high risk for <\\entity><\\entity>, as salvage therapy in refractory or resistant infections, or for patients with intolerance to other therapies.",
    "Label": ""
  },
  {
    "id": "12077",
    "Sentence": "Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12078",
    "Sentence": "Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough <\\entity><\\entity> (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole.",
    "Label": ""
  },
  {
    "id": "12080",
    "Sentence": "Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12081",
    "Sentence": "Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and <\\entity><\\entity> incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole.",
    "Label": ""
  },
  {
    "id": "12083",
    "Sentence": "Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with <\\entity><\\entity> and itraconazole in neutropenic patients.",
    "Label": ""
  },
  {
    "id": "12084",
    "Sentence": "Similarly, the same regimen of posaconazole reduced <\\entity><\\entity> (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.",
    "Label": ""
  },
  {
    "id": "12086",
    "Sentence": "Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with <\\entity><\\entity> and itraconazole in neutropenic patients.",
    "Label": ""
  },
  {
    "id": "12087",
    "Sentence": "Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and <\\entity><\\entity> (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.",
    "Label": ""
  },
  {
    "id": "12089",
    "Sentence": "Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and <\\entity><\\entity> in neutropenic patients.",
    "Label": ""
  },
  {
    "id": "12090",
    "Sentence": "Similarly, the same regimen of posaconazole reduced <\\entity><\\entity> (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.",
    "Label": ""
  },
  {
    "id": "12092",
    "Sentence": "Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and <\\entity><\\entity> in neutropenic patients.",
    "Label": ""
  },
  {
    "id": "12093",
    "Sentence": "Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and <\\entity><\\entity> (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.",
    "Label": ""
  },
  {
    "id": "12095",
    "Sentence": "Smaller investigations have analyzed use of <\\entity><\\entity> for patients requiring salvage or alternative treatment for zygomycosis, fusariosis, cryptococcal meningitis, coccidioidomycosis, and histoplasmosis.",
    "Label": ""
  },
  {
    "id": "12096",
    "Sentence": "Smaller investigations have analyzed use of posaconazole for patients requiring salvage or alternative treatment for <\\entity><\\entity>, fusariosis, cryptococcal meningitis, coccidioidomycosis, and histoplasmosis.",
    "Label": ""
  },
  {
    "id": "12098",
    "Sentence": "Smaller investigations have analyzed use of <\\entity><\\entity> for patients requiring salvage or alternative treatment for zygomycosis, fusariosis, cryptococcal meningitis, coccidioidomycosis, and histoplasmosis.",
    "Label": ""
  },
  {
    "id": "12099",
    "Sentence": "Smaller investigations have analyzed use of posaconazole for patients requiring salvage or alternative treatment for zygomycosis, fusariosis, <\\entity><\\entity>, coccidioidomycosis, and histoplasmosis.",
    "Label": ""
  },
  {
    "id": "12101",
    "Sentence": "Smaller investigations have analyzed use of <\\entity><\\entity> for patients requiring salvage or alternative treatment for zygomycosis, fusariosis, cryptococcal meningitis, coccidioidomycosis, and histoplasmosis.",
    "Label": ""
  },
  {
    "id": "12102",
    "Sentence": "Smaller investigations have analyzed use of posaconazole for patients requiring salvage or alternative treatment for zygomycosis, fusariosis, cryptococcal meningitis, <\\entity><\\entity>, and histoplasmosis.",
    "Label": ""
  },
  {
    "id": "12104",
    "Sentence": "Smaller investigations have analyzed use of <\\entity><\\entity> for patients requiring salvage or alternative treatment for zygomycosis, fusariosis, cryptococcal meningitis, coccidioidomycosis, and histoplasmosis.",
    "Label": ""
  },
  {
    "id": "12105",
    "Sentence": "Smaller investigations have analyzed use of posaconazole for patients requiring salvage or alternative treatment for zygomycosis, fusariosis, cryptococcal meningitis, coccidioidomycosis, and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12107",
    "Sentence": "Smaller investigations have analyzed use of <\\entity><\\entity> for patients requiring salvage or alternative treatment for zygomycosis, fusariosis, cryptococcal meningitis, coccidioidomycosis, and histoplasmosis.",
    "Label": ""
  },
  {
    "id": "12108",
    "Sentence": "Smaller investigations have analyzed use of posaconazole for patients requiring salvage or alternative treatment for zygomycosis, <\\entity><\\entity>, cryptococcal meningitis, coccidioidomycosis, and histoplasmosis.",
    "Label": ""
  },
  {
    "id": "12114",
    "Sentence": "The importance of preoperative hemoglobin evaluation in large volume liposuction: lessons learned from our 15-year experience.Liposuction of >5 L of total <\\entity><\\entity> at one setting is defined as large volume liposuction (LVL).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12115",
    "Sentence": "The mean volume of total <\\entity><\\entity> was 8 L (5.0-11.7 L).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12116",
    "Sentence": "There were a total of 6 patients who had <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12117",
    "Sentence": "These included <\\entity><\\entity> requiring blood transfusions on postoperative day 1 (n = 5), and an expanding hematoma requiring operative evacuation without transfusion (n = 1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12118",
    "Sentence": "These included symptomatic postoperative anemia requiring blood transfusions on postoperative day 1 (n = 5), and an <\\entity><\\entity> requiring operative evacuation without transfusion (n = 1).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12123",
    "Sentence": "During the induction phase, <\\entity><\\entity> or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for immunosuppression.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12124",
    "Sentence": "During the induction phase, tacrolimus or <\\entity><\\entity>, mycophenolate mofetil, and methylprednisolone were used for immunosuppression.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12125",
    "Sentence": "During the induction phase, tacrolimus or cyclosporine, <\\entity><\\entity>, and methylprednisolone were used for immunosuppression.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12126",
    "Sentence": "During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and <\\entity><\\entity> were used for immunosuppression.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12127",
    "Sentence": "During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12128",
    "Sentence": "<\\entity><\\entity> was administered on postoperative days 0 and 4.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12129",
    "Sentence": "Among G2, one patient died with a functioning graft due to a <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12130",
    "Sentence": "The incidence of <\\entity><\\entity> was 33.3% and 25.0% in G1 and G2, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12131",
    "Sentence": "No patient experienced a <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12132",
    "Sentence": "No patient experienced a lethal <\\entity><\\entity> complication.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12133",
    "Sentence": "During the induction phase, <\\entity><\\entity> or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for immunosuppression.",
    "Label": ""
  },
  {
    "id": "12134",
    "Sentence": "During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12136",
    "Sentence": "During the induction phase, tacrolimus or <\\entity><\\entity>, mycophenolate mofetil, and methylprednisolone were used for immunosuppression.",
    "Label": ""
  },
  {
    "id": "12137",
    "Sentence": "During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12139",
    "Sentence": "During the induction phase, tacrolimus or cyclosporine, <\\entity><\\entity>, and methylprednisolone were used for immunosuppression.",
    "Label": ""
  },
  {
    "id": "12140",
    "Sentence": "During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12142",
    "Sentence": "During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and <\\entity><\\entity> were used for immunosuppression.",
    "Label": ""
  },
  {
    "id": "12143",
    "Sentence": "During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12149",
    "Sentence": "Administration of <\\entity><\\entity> with atelocollagen prevents the growth of liver metastases of lung cancer.Liver metastasis is one of the most important prognostic factors in lung cancer patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12150",
    "Sentence": "Administration of <\\entity><\\entity> with atelocollagen prevents the growth of liver metastases of lung cancer.Liver metastasis is one of the most important prognostic factors in lung cancer patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12151",
    "Sentence": "Administration of PLK-1 small interfering RNA with <\\entity><\\entity> prevents the growth of liver metastases of lung cancer.Liver metastasis is one of the most important prognostic factors in lung cancer patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12152",
    "Sentence": "Herein, we investigated the in vitro effects of <\\entity><\\entity> (siRNA) on human lung cancer cell lines and the in vivo usage of PLK-1 siRNA with atelocollagen as a drug delivery system in a murine liver metastasis model of lung cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12153",
    "Sentence": "Herein, we investigated the in vitro effects of <\\entity><\\entity> (siRNA) on human lung cancer cell lines and the in vivo usage of PLK-1 siRNA with atelocollagen as a drug delivery system in a murine liver metastasis model of lung cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12154",
    "Sentence": "Herein, we investigated the in vitro effects of PLK-1 small interfering RNA (<\\entity><\\entity>) on human lung cancer cell lines and the in vivo usage of PLK-1 <\\entity><\\entity> with atelocollagen as a drug delivery system in a murine liver metastasis model of lung cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12155",
    "Sentence": "Herein, we investigated the in vitro effects of PLK-1 small interfering RNA (siRNA) on human lung cancer cell lines and the in vivo usage of <\\entity><\\entity> as a drug delivery system in a murine liver metastasis model of lung cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12156",
    "Sentence": "Herein, we investigated the in vitro effects of PLK-1 small interfering RNA (siRNA) on human lung cancer cell lines and the in vivo usage of <\\entity><\\entity> as a drug delivery system in a murine liver metastasis model of lung cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12157",
    "Sentence": "Herein, we investigated the in vitro effects of PLK-1 small interfering RNA (<\\entity><\\entity>) on human lung cancer cell lines and the in vivo usage of PLK-1 <\\entity><\\entity> with atelocollagen as a drug delivery system in a murine liver metastasis model of lung cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12158",
    "Sentence": "<\\entity><\\entity> was overexpressed in cell lines and in cancerous tissues from lung cancer patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12159",
    "Sentence": "<\\entity><\\entity> treatment inhibited growth and induced apoptosis in a concentration-dependent manner.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12160",
    "Sentence": "<\\entity><\\entity> treatment inhibited growth and induced apoptosis in a concentration-dependent manner.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12161",
    "Sentence": "To verify in vivo efficacy, we confirmed that <\\entity><\\entity> was a useful drug delivery system in our model of implanted luciferase-labeled A549LUC cells by detecting reduced bioluminescence after an i.v.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12162",
    "Sentence": "To verify in vivo efficacy, we confirmed that atelocollagen was a useful drug delivery system in our model of implanted <\\entity><\\entity> by detecting reduced bioluminescence after an i.v.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12163",
    "Sentence": "injection of luciferase <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12164",
    "Sentence": "injection of luciferase <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12165",
    "Sentence": "<\\entity><\\entity> was also successfully transfected into cells and inhibited the progression of metastases.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12166",
    "Sentence": "<\\entity><\\entity> was also successfully transfected into cells and inhibited the progression of metastases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12167",
    "Sentence": "PLK-1 <\\entity><\\entity>/atelocollagen was also successfully transfected into cells and inhibited the progression of metastases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12168",
    "Sentence": "administration of <\\entity><\\entity> for liver metastases of lung cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12169",
    "Sentence": "administration of <\\entity><\\entity> for liver metastases of lung cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12170",
    "Sentence": "administration of PLK-1 <\\entity><\\entity>/atelocollagen for liver metastases of lung cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12171",
    "Sentence": "We believe <\\entity><\\entity> therapy will be a powerful and promising strategy against advanced lung cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12172",
    "Sentence": "We believe <\\entity><\\entity> therapy will be a powerful and promising strategy against advanced lung cancer.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12173",
    "Sentence": "Administration of PLK-1 small interfering RNA with <\\entity><\\entity> prevents the growth of liver metastases of lung cancer.Liver metastasis is one of the most important prognostic factors in lung cancer patients.",
    "Label": ""
  },
  {
    "id": "12174",
    "Sentence": "Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of <\\entity><\\entity> of lung cancer.Liver metastasis is one of the most important prognostic factors in lung cancer patients.",
    "Label": ""
  },
  {
    "id": "12176",
    "Sentence": "Administration of PLK-1 small interfering RNA with <\\entity><\\entity> prevents the growth of liver metastases of lung cancer.Liver metastasis is one of the most important prognostic factors in lung cancer patients.",
    "Label": ""
  },
  {
    "id": "12177",
    "Sentence": "Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of <\\entity><\\entity>.Liver metastasis is one of the most important prognostic factors in <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "12179",
    "Sentence": "Administration of <\\entity><\\entity> with atelocollagen prevents the growth of liver metastases of lung cancer.Liver metastasis is one of the most important prognostic factors in lung cancer patients.",
    "Label": ""
  },
  {
    "id": "12180",
    "Sentence": "Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of <\\entity><\\entity> of lung cancer.Liver metastasis is one of the most important prognostic factors in lung cancer patients.",
    "Label": ""
  },
  {
    "id": "12182",
    "Sentence": "Administration of <\\entity><\\entity> with atelocollagen prevents the growth of liver metastases of lung cancer.Liver metastasis is one of the most important prognostic factors in lung cancer patients.",
    "Label": ""
  },
  {
    "id": "12183",
    "Sentence": "Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of <\\entity><\\entity>.Liver metastasis is one of the most important prognostic factors in <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "12185",
    "Sentence": "Herein, we investigated the in vitro effects of PLK-1 small interfering RNA (siRNA) on human lung cancer cell lines and the in vivo usage of <\\entity><\\entity> as a drug delivery system in a murine liver metastasis model of lung cancer.",
    "Label": ""
  },
  {
    "id": "12186",
    "Sentence": "Herein, we investigated the in vitro effects of PLK-1 small interfering RNA (siRNA) on human lung cancer cell lines and the in vivo usage of PLK-1 siRNA with atelocollagen as a drug delivery system in a murine <\\entity><\\entity> model of lung cancer.",
    "Label": ""
  },
  {
    "id": "12188",
    "Sentence": "Herein, we investigated the in vitro effects of PLK-1 small interfering RNA (siRNA) on human lung cancer cell lines and the in vivo usage of <\\entity><\\entity> as a drug delivery system in a murine liver metastasis model of lung cancer.",
    "Label": ""
  },
  {
    "id": "12189",
    "Sentence": "Herein, we investigated the in vitro effects of PLK-1 small interfering RNA (siRNA) on human <\\entity><\\entity> cell lines and the in vivo usage of PLK-1 siRNA with atelocollagen as a drug delivery system in a murine liver metastasis model of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12191",
    "Sentence": "Herein, we investigated the in vitro effects of <\\entity><\\entity> (siRNA) on human lung cancer cell lines and the in vivo usage of PLK-1 siRNA with atelocollagen as a drug delivery system in a murine liver metastasis model of lung cancer.",
    "Label": ""
  },
  {
    "id": "12192",
    "Sentence": "Herein, we investigated the in vitro effects of PLK-1 small interfering RNA (siRNA) on human lung cancer cell lines and the in vivo usage of PLK-1 siRNA with atelocollagen as a drug delivery system in a murine <\\entity><\\entity> model of lung cancer.",
    "Label": ""
  },
  {
    "id": "12194",
    "Sentence": "Herein, we investigated the in vitro effects of <\\entity><\\entity> (siRNA) on human lung cancer cell lines and the in vivo usage of PLK-1 siRNA with atelocollagen as a drug delivery system in a murine liver metastasis model of lung cancer.",
    "Label": ""
  },
  {
    "id": "12195",
    "Sentence": "Herein, we investigated the in vitro effects of PLK-1 small interfering RNA (siRNA) on human <\\entity><\\entity> cell lines and the in vivo usage of PLK-1 siRNA with atelocollagen as a drug delivery system in a murine liver metastasis model of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12197",
    "Sentence": "<\\entity><\\entity> was overexpressed in cell lines and in cancerous tissues from lung cancer patients.",
    "Label": ""
  },
  {
    "id": "12198",
    "Sentence": "PLK-1 was overexpressed in cell lines and in cancerous tissues from <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "12200",
    "Sentence": "<\\entity><\\entity> was also successfully transfected into cells and inhibited the progression of metastases.",
    "Label": ""
  },
  {
    "id": "12201",
    "Sentence": "PLK-1 siRNA/atelocollagen was also successfully transfected into cells and inhibited the progression of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12203",
    "Sentence": "administration of <\\entity><\\entity> for liver metastases of lung cancer.",
    "Label": ""
  },
  {
    "id": "12204",
    "Sentence": "administration of PLK-1 siRNA/atelocollagen for <\\entity><\\entity> of lung cancer.",
    "Label": ""
  },
  {
    "id": "12206",
    "Sentence": "administration of <\\entity><\\entity> for liver metastases of lung cancer.",
    "Label": ""
  },
  {
    "id": "12207",
    "Sentence": "administration of PLK-1 siRNA/atelocollagen for liver metastases of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12209",
    "Sentence": "injection of luciferase <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12210",
    "Sentence": "To verify in vivo efficacy, we confirmed that atelocollagen was a useful drug delivery system in our model of implanted <\\entity><\\entity> by detecting reduced bioluminescence after an i.v.",
    "Label": ""
  },
  {
    "id": "12216",
    "Sentence": "<\\entity><\\entity>.This article reviews the incidence, causes, risk factors, diagnosis, treatment, complications, and prevention of deep vein thrombosis (DVT).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12217",
    "Sentence": "Deep vein thrombosis.This article reviews the incidence, causes, risk factors, diagnosis, treatment, <\\entity><\\entity>, and prevention of deep vein thrombosis (DVT).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12218",
    "Sentence": "Deep vein thrombosis.This article reviews the incidence, causes, risk factors, diagnosis, treatment, complications, and prevention of <\\entity><\\entity> (DVT).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12219",
    "Sentence": "Deep vein thrombosis.This article reviews the incidence, causes, risk factors, diagnosis, treatment, complications, and prevention of deep vein thrombosis (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12220",
    "Sentence": "Various employees, including long-distance drivers or travelers, sedentary office workers, females taking <\\entity><\\entity>, those who are obese, those who have cancer, and those who are hospitalized, may be at risk for developing this condition.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12221",
    "Sentence": "Various employees, including long-distance drivers or travelers, sedentary office workers, females taking estrogen, those who are <\\entity><\\entity>, those who have cancer, and those who are hospitalized, may be at risk for developing this condition.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12222",
    "Sentence": "Various employees, including long-distance drivers or travelers, sedentary office workers, females taking estrogen, those who are obese, those who have <\\entity><\\entity>, and those who are hospitalized, may be at risk for developing this condition.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12223",
    "Sentence": "Genetic testing can determine some inherited factors predisposing workers to <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12224",
    "Sentence": "<\\entity><\\entity> can be used to manage DVT on an outpatient basis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12225",
    "Sentence": "Low-molecular <\\entity><\\entity> heparins can be used to manage DVT on an outpatient basis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12226",
    "Sentence": "Low-molecular weight heparins can be used to manage <\\entity><\\entity> on an outpatient basis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12227",
    "Sentence": "<\\entity><\\entity> can be used to manage DVT on an outpatient basis.",
    "Label": ""
  },
  {
    "id": "12228",
    "Sentence": "Low-molecular weight heparins can be used to manage <\\entity><\\entity> on an outpatient basis.",
    "Label": ""
  },
  {
    "id": "12230",
    "Sentence": "<\\entity><\\entity> can be used to manage DVT on an outpatient basis.",
    "Label": ""
  },
  {
    "id": "12231",
    "Sentence": "Low-molecular weight heparins can be used to manage <\\entity><\\entity> on an outpatient basis.",
    "Label": ""
  },
  {
    "id": "12233",
    "Sentence": "Various employees, including long-distance drivers or travelers, sedentary office workers, females taking <\\entity><\\entity>, those who are obese, those who have cancer, and those who are hospitalized, may be at risk for developing this condition.",
    "Label": ""
  },
  {
    "id": "12234",
    "Sentence": "Various employees, including long-distance drivers or travelers, sedentary office workers, females taking estrogen, those who are <\\entity><\\entity>, those who have cancer, and those who are hospitalized, may be at risk for developing this condition.",
    "Label": ""
  },
  {
    "id": "12236",
    "Sentence": "Various employees, including long-distance drivers or travelers, sedentary office workers, females taking <\\entity><\\entity>, those who are obese, those who have cancer, and those who are hospitalized, may be at risk for developing this condition.",
    "Label": ""
  },
  {
    "id": "12237",
    "Sentence": "Various employees, including long-distance drivers or travelers, sedentary office workers, females taking estrogen, those who are obese, those who have <\\entity><\\entity>, and those who are hospitalized, may be at risk for developing this condition.",
    "Label": ""
  },
  {
    "id": "12243",
    "Sentence": "The signaling hubs at the crossroad of longevity and age-related <\\entity><\\entity> networks.The established human age-related <\\entity><\\entity> proteins (ARDPs) and longevity-associated proteins (LAPs) together with their first-order interacting partners form scale-free networks which significantly overlap.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12244",
    "Sentence": "The signaling hubs at the crossroad of longevity and age-related disease networks.The established human <\\entity><\\entity> (ARDPs) and longevity-associated proteins (LAPs) together with their first-order interacting partners form scale-free networks which significantly overlap.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12245",
    "Sentence": "The signaling hubs at the crossroad of longevity and age-related disease networks.The established human <\\entity><\\entity> (ARDPs) and longevity-associated proteins (LAPs) together with their first-order interacting partners form scale-free networks which significantly overlap.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12246",
    "Sentence": "The signaling hubs at the crossroad of longevity and age-related disease networks.The established human age-related disease proteins (<\\entity><\\entity>) and longevity-associated proteins (LAPs) together with their first-order interacting partners form scale-free networks which significantly overlap.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12247",
    "Sentence": "The signaling hubs at the crossroad of longevity and age-related disease networks.The established human age-related disease proteins (ARDPs) and <\\entity><\\entity> (LAPs) together with their first-order interacting partners form scale-free networks which significantly overlap.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12248",
    "Sentence": "The signaling hubs at the crossroad of longevity and age-related disease networks.The established human age-related disease proteins (ARDPs) and longevity-associated proteins (<\\entity><\\entity>) together with their first-order interacting partners form scale-free networks which significantly overlap.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12249",
    "Sentence": "The signaling hubs at the crossroad of longevity and age-related disease networks.The established human age-related disease proteins (ARDPs) and longevity-associated proteins (<\\entity><\\entity>) together with their first-order interacting partners form scale-free networks which significantly overlap.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12250",
    "Sentence": "Along with the <\\entity><\\entity> pathway, the common signaling network is remarkably enriched with the focal adhesion and adherens junction proteins whose relation to the control of lifespan is yet to be fully addressed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12251",
    "Sentence": "Along with the insulin pathway, the common signaling network is remarkably enriched with the focal <\\entity><\\entity> and adherens junction proteins whose relation to the control of lifespan is yet to be fully addressed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12252",
    "Sentence": "Along with the insulin pathway, the common signaling network is remarkably enriched with the focal adhesion and adherens junction proteins whose relation to the control of <\\entity><\\entity> is yet to be fully addressed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12253",
    "Sentence": "The examples of such candidate proteins include several hubs, focal <\\entity><\\entity> kinase PTK2 and the extracellular proteins fibronectin FN1, paxillin PXN, and vinculin VCL.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12254",
    "Sentence": "The examples of such candidate proteins include several hubs, focal adhesion kinase <\\entity><\\entity> and the extracellular proteins fibronectin FN1, paxillin PXN, and vinculin VCL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12255",
    "Sentence": "The examples of such candidate proteins include several hubs, focal adhesion kinase PTK2 and the extracellular proteins <\\entity><\\entity> FN1, paxillin PXN, and vinculin VCL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12256",
    "Sentence": "The examples of such candidate proteins include several hubs, focal adhesion kinase PTK2 and the extracellular proteins fibronectin <\\entity><\\entity>, paxillin PXN, and vinculin VCL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12257",
    "Sentence": "The examples of such candidate proteins include several hubs, focal adhesion kinase PTK2 and the extracellular proteins fibronectin FN1, <\\entity><\\entity> PXN, and vinculin VCL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12258",
    "Sentence": "The examples of such candidate proteins include several hubs, focal adhesion kinase PTK2 and the extracellular proteins fibronectin FN1, paxillin <\\entity><\\entity>, and vinculin VCL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12259",
    "Sentence": "The examples of such candidate proteins include several hubs, focal adhesion kinase PTK2 and the extracellular proteins fibronectin FN1, paxillin PXN, and <\\entity><\\entity> VCL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12260",
    "Sentence": "The examples of such candidate proteins include several hubs, focal adhesion kinase PTK2 and the extracellular proteins fibronectin FN1, paxillin PXN, and vinculin <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12261",
    "Sentence": "The results of the network-based analysis highlight the potential importance of these pathways, especially hubs, in linking the human longevity and age-related <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12262",
    "Sentence": "The examples of such candidate proteins include several hubs, focal adhesion kinase PTK2 and the extracellular proteins fibronectin FN1, paxillin <\\entity><\\entity>, and vinculin VCL.",
    "Label": ""
  },
  {
    "id": "12263",
    "Sentence": "The examples of such candidate proteins include several hubs, focal <\\entity><\\entity> kinase PTK2 and the extracellular proteins fibronectin FN1, paxillin PXN, and vinculin VCL.",
    "Label": ""
  },
  {
    "id": "12265",
    "Sentence": "The examples of such candidate proteins include several hubs, focal adhesion kinase PTK2 and the extracellular proteins fibronectin FN1, paxillin PXN, and vinculin <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12266",
    "Sentence": "The examples of such candidate proteins include several hubs, focal <\\entity><\\entity> kinase PTK2 and the extracellular proteins fibronectin FN1, paxillin PXN, and vinculin VCL.",
    "Label": ""
  },
  {
    "id": "12268",
    "Sentence": "The examples of such candidate proteins include several hubs, focal adhesion kinase <\\entity><\\entity> and the extracellular proteins fibronectin FN1, paxillin PXN, and vinculin VCL.",
    "Label": ""
  },
  {
    "id": "12269",
    "Sentence": "The examples of such candidate proteins include several hubs, focal <\\entity><\\entity> kinase PTK2 and the extracellular proteins fibronectin FN1, paxillin PXN, and vinculin VCL.",
    "Label": ""
  },
  {
    "id": "12271",
    "Sentence": "The examples of such candidate proteins include several hubs, focal adhesion kinase PTK2 and the extracellular proteins fibronectin <\\entity><\\entity>, paxillin PXN, and vinculin VCL.",
    "Label": ""
  },
  {
    "id": "12272",
    "Sentence": "The examples of such candidate proteins include several hubs, focal <\\entity><\\entity> kinase PTK2 and the extracellular proteins fibronectin FN1, paxillin PXN, and vinculin VCL.",
    "Label": ""
  },
  {
    "id": "12278",
    "Sentence": "<\\entity><\\entity> of the upper urinary tract: clinical outcome and molecular characterization.<\\entity><\\entity> (carcinosarcoma) of the upper urinary collecting system is a rare aggressive malignancy composed of malignant epithelial and stromal components.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12279",
    "Sentence": "<\\entity><\\entity> of the upper urinary tract: clinical outcome and molecular characterization.<\\entity><\\entity> (carcinosarcoma) of the upper urinary collecting system is a rare aggressive malignancy composed of malignant epithelial and stromal components.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12280",
    "Sentence": "Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization.Sarcomatoid carcinoma (<\\entity><\\entity>) of the upper urinary collecting system is a rare aggressive malignancy composed of malignant epithelial and stromal components.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12281",
    "Sentence": "Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization.Sarcomatoid carcinoma (carcinosarcoma) of the upper urinary collecting system is a rare <\\entity><\\entity> malignancy composed of malignant epithelial and stromal components.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12282",
    "Sentence": "Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization.Sarcomatoid carcinoma (carcinosarcoma) of the upper urinary collecting system is a rare aggressive <\\entity><\\entity> composed of malignant epithelial and stromal components.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12283",
    "Sentence": "Because of the paucity of reported cases, the clinical behavior, molecular alterations, and potential therapies for this <\\entity><\\entity> are not well understood.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12284",
    "Sentence": "Eight cases of <\\entity><\\entity> involving the upper urinary tract were studied.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12285",
    "Sentence": "Immunohistochemical expression of <\\entity><\\entity> (EGFR), human <\\entity><\\entity> 2 (HER2)/neu, c-kit, and p53 was analyzed in each case.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12286",
    "Sentence": "Immunohistochemical expression of epidermal growth factor receptor (<\\entity><\\entity>), human epidermal growth factor receptor 2 (HER2)/neu, c-kit, and p53 was analyzed in each case.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12287",
    "Sentence": "Immunohistochemical expression of epidermal growth factor receptor (EGFR), <\\entity><\\entity> (HER2)/neu, c-kit, and p53 was analyzed in each case.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12288",
    "Sentence": "Immunohistochemical expression of <\\entity><\\entity> (EGFR), human <\\entity><\\entity> 2 (HER2)/neu, c-kit, and p53 was analyzed in each case.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12289",
    "Sentence": "Immunohistochemical expression of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (<\\entity><\\entity>)/neu, c-kit, and p53 was analyzed in each case.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12290",
    "Sentence": "Immunohistochemical expression of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2)/<\\entity><\\entity>, c-kit, and p53 was analyzed in each case.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12291",
    "Sentence": "Immunohistochemical expression of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2)/neu, <\\entity><\\entity>, and p53 was analyzed in each case.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12292",
    "Sentence": "Immunohistochemical expression of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2)/neu, c-kit, and <\\entity><\\entity> was analyzed in each case.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12293",
    "Sentence": "Evaluation for <\\entity><\\entity> of EGFR and HER2 genes was performed by interphase fluorescence in situ hybridization (FISH).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12294",
    "Sentence": "Evaluation for amplification of <\\entity><\\entity> and HER2 genes was performed by interphase fluorescence in situ hybridization (FISH).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12295",
    "Sentence": "Evaluation for amplification of EGFR and <\\entity><\\entity> genes was performed by interphase fluorescence in situ hybridization (FISH).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12296",
    "Sentence": "Evaluation for amplification of EGFR and HER2 genes was performed by interphase fluorescence in situ hybridization (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12297",
    "Sentence": "Each <\\entity><\\entity> was also examined for gains of chromosomes 3, 7, and 17 and for loss of chromosome 9p21 by UroVysion FISH (Vysis, Downers Grove, IL).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12298",
    "Sentence": "Each tumor was also examined for <\\entity><\\entity> and for loss of chromosome 9p21 by UroVysion FISH (Vysis, Downers Grove, IL).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12299",
    "Sentence": "Each tumor was also examined for <\\entity><\\entity> and for loss of chromosome 9p21 by UroVysion FISH (Vysis, Downers Grove, IL).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12300",
    "Sentence": "Each tumor was also examined for <\\entity><\\entity> and for loss of chromosome 9p21 by UroVysion FISH (Vysis, Downers Grove, IL).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12301",
    "Sentence": "Each tumor was also examined for gains of chromosomes 3, <\\entity><\\entity>, and 1<\\entity><\\entity> and for loss of chromosome 9p21 by UroVysion FISH (Vysis, Downers Grove, IL).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12302",
    "Sentence": "Each tumor was also examined for gains of chromosomes 3, 7, and 17 and for <\\entity><\\entity> by UroVysion FISH (Vysis, Downers Grove, IL).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12303",
    "Sentence": "Each tumor was also examined for gains of chromosomes 3, 7, and 17 and for <\\entity><\\entity> by UroVysion FISH (Vysis, Downers Grove, IL).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12304",
    "Sentence": "Each tumor was also examined for gains of chromosomes 3, 7, and 17 and for loss of chromosome 9p21 by UroVysion <\\entity><\\entity> (Vysis, Downers Grove, IL).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12305",
    "Sentence": "Presenting <\\entity><\\entity> included gross hematuria, flank mass, urinary obstruction, fever, or sepsis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12306",
    "Sentence": "Presenting symptoms included <\\entity><\\entity>, flank mass, urinary obstruction, fever, or sepsis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12307",
    "Sentence": "Presenting symptoms included gross hematuria, <\\entity><\\entity>, urinary obstruction, fever, or sepsis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12308",
    "Sentence": "Presenting symptoms included gross hematuria, flank mass, <\\entity><\\entity>, fever, or sepsis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12309",
    "Sentence": "Presenting symptoms included gross hematuria, flank mass, urinary obstruction, <\\entity><\\entity>, or sepsis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12310",
    "Sentence": "Presenting symptoms included gross hematuria, flank mass, urinary obstruction, fever, or <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12311",
    "Sentence": "<\\entity><\\entity> size ranged from 2 to 13 cm.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12312",
    "Sentence": "Coexisting <\\entity><\\entity> was present in all 8 cases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12313",
    "Sentence": "<\\entity><\\entity> was identified in 2 cases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12314",
    "Sentence": "Pathologic stage was pT4 in 5 cases and <\\entity><\\entity> in 3 cases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12315",
    "Sentence": "<\\entity><\\entity> were present in 5 patients at the time of surgery.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12316",
    "Sentence": "Of 8 patients, <\\entity><\\entity> died within 2 years after surgery.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12317",
    "Sentence": "Of 8 patients, <\\entity><\\entity> died within 2 years after surgery.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12318",
    "Sentence": "<\\entity><\\entity> immunostaining had moderately to strongly positive results in 6 of 8 cases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12319",
    "Sentence": "Both <\\entity><\\entity>/neu and c-kit immunostaining had negative results in all cases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12320",
    "Sentence": "Both HER2/<\\entity><\\entity> and c-kit immunostaining had negative results in all cases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12321",
    "Sentence": "Both HER2/neu and <\\entity><\\entity> immunostaining had negative results in all cases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12322",
    "Sentence": "<\\entity><\\entity> immunostaining had positive results in 5 of 8 cases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12323",
    "Sentence": "The <\\entity><\\entity> was demonstrated in 7 of 8 cases.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12324",
    "Sentence": "The <\\entity><\\entity> was demonstrated in 7 of 8 cases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12325",
    "Sentence": "The <\\entity><\\entity> was demonstrated in 7 of 8 cases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12326",
    "Sentence": "The EGFR polysomy was demonstrated in <\\entity><\\entity> of 8 cases.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12327",
    "Sentence": "The EGFR polysomy was demonstrated in <\\entity><\\entity> of 8 cases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12328",
    "Sentence": "No <\\entity><\\entity> of HER2/neu was present in any case.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12329",
    "Sentence": "No amplification of <\\entity><\\entity>/neu was present in any case.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12330",
    "Sentence": "No amplification of HER2/<\\entity><\\entity> was present in any case.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12331",
    "Sentence": "UroVysion <\\entity><\\entity> showed abnormalities typical of urothelial carcinoma in all 8 cases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12332",
    "Sentence": "UroVysion FISH showed <\\entity><\\entity> typical of urothelial carcinoma in all 8 cases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12333",
    "Sentence": "UroVysion FISH showed abnormalities typical of <\\entity><\\entity> in all 8 cases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12334",
    "Sentence": "In conclusion, the prognosis of <\\entity><\\entity> of the upper urinary tract is extremely poor, most patients died within 2 years (7/8 patients).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12335",
    "Sentence": "In conclusion, the prognosis of sarcomatoid carcinoma of the upper urinary tract is extremely poor, most patients died within 2 years (<\\entity><\\entity>/8 patients).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12336",
    "Sentence": "In conclusion, the prognosis of sarcomatoid carcinoma of the upper urinary tract is extremely poor, most patients died within 2 years (<\\entity><\\entity>/8 patients).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12337",
    "Sentence": "<\\entity><\\entity> and loss of chromosome 9p21 were commonly observed in these tumors.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12338",
    "Sentence": "<\\entity><\\entity> and loss of chromosome 9p21 were commonly observed in these tumors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12339",
    "Sentence": "<\\entity><\\entity> and loss of chromosome 9p21 were commonly observed in these tumors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12340",
    "Sentence": "Gains of chromosome 3, <\\entity><\\entity>, and 1<\\entity><\\entity> and loss of chromosome 9p21 were commonly observed in these tumors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12341",
    "Sentence": "Gains of chromosome 3, 7, and 17 and <\\entity><\\entity> were commonly observed in these tumors.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12342",
    "Sentence": "Gains of chromosome 3, 7, and 17 and <\\entity><\\entity> were commonly observed in these tumors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12343",
    "Sentence": "Gains of chromosome 3, 7, and 17 and loss of chromosome 9p21 were commonly observed in these <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12344",
    "Sentence": "Gains of chromosome 3, 7, and 17 and <\\entity><\\entity> were commonly observed in these tumors.",
    "Label": ""
  },
  {
    "id": "12345",
    "Sentence": "Gains of chromosome 3, 7, and 17 and loss of chromosome 9p21 were commonly observed in these <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12347",
    "Sentence": "<\\entity><\\entity> and loss of chromosome 9p21 were commonly observed in these tumors.",
    "Label": ""
  },
  {
    "id": "12348",
    "Sentence": "Gains of chromosome 3, 7, and 17 and loss of chromosome 9p21 were commonly observed in these <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12350",
    "Sentence": "Evaluation for amplification of <\\entity><\\entity> and HER2 genes was performed by interphase fluorescence in situ hybridization (FISH).",
    "Label": ""
  },
  {
    "id": "12351",
    "Sentence": "Evaluation for <\\entity><\\entity> of EGFR and HER2 genes was performed by interphase fluorescence in situ hybridization (FISH).",
    "Label": ""
  },
  {
    "id": "12353",
    "Sentence": "Evaluation for amplification of EGFR and <\\entity><\\entity> genes was performed by interphase fluorescence in situ hybridization (FISH).",
    "Label": ""
  },
  {
    "id": "12354",
    "Sentence": "Evaluation for <\\entity><\\entity> of EGFR and HER2 genes was performed by interphase fluorescence in situ hybridization (FISH).",
    "Label": ""
  },
  {
    "id": "12356",
    "Sentence": "Evaluation for amplification of EGFR and HER2 genes was performed by interphase fluorescence in situ hybridization (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "12357",
    "Sentence": "Evaluation for <\\entity><\\entity> of EGFR and HER2 genes was performed by interphase fluorescence in situ hybridization (FISH).",
    "Label": ""
  },
  {
    "id": "12359",
    "Sentence": "Each tumor was also examined for gains of chromosomes 3, 7, and 17 and for loss of chromosome 9p21 by UroVysion <\\entity><\\entity> (Vysis, Downers Grove, IL).",
    "Label": ""
  },
  {
    "id": "12360",
    "Sentence": "Each <\\entity><\\entity> was also examined for gains of chromosomes 3, 7, and 17 and for loss of chromosome 9p21 by UroVysion FISH (Vysis, Downers Grove, IL).",
    "Label": ""
  },
  {
    "id": "12362",
    "Sentence": "Each tumor was also examined for gains of chromosomes 3, 7, and 17 and for loss of chromosome 9p21 by UroVysion <\\entity><\\entity> (Vysis, Downers Grove, IL).",
    "Label": ""
  },
  {
    "id": "12363",
    "Sentence": "Each tumor was also examined for <\\entity><\\entity> and for loss of chromosome 9p21 by UroVysion FISH (Vysis, Downers Grove, IL).",
    "Label": ""
  },
  {
    "id": "12365",
    "Sentence": "The <\\entity><\\entity> was demonstrated in 7 of 8 cases.",
    "Label": ""
  },
  {
    "id": "12366",
    "Sentence": "The <\\entity><\\entity> was demonstrated in 7 of 8 cases.",
    "Label": ""
  },
  {
    "id": "12368",
    "Sentence": "No amplification of HER2/<\\entity><\\entity> was present in any case.",
    "Label": ""
  },
  {
    "id": "12369",
    "Sentence": "No <\\entity><\\entity> of HER2/neu was present in any case.",
    "Label": ""
  },
  {
    "id": "12371",
    "Sentence": "UroVysion <\\entity><\\entity> showed abnormalities typical of urothelial carcinoma in all 8 cases.",
    "Label": ""
  },
  {
    "id": "12372",
    "Sentence": "UroVysion FISH showed abnormalities typical of <\\entity><\\entity> in all 8 cases.",
    "Label": ""
  },
  {
    "id": "12374",
    "Sentence": "UroVysion <\\entity><\\entity> showed abnormalities typical of urothelial carcinoma in all 8 cases.",
    "Label": ""
  },
  {
    "id": "12375",
    "Sentence": "UroVysion FISH showed <\\entity><\\entity> typical of urothelial carcinoma in all 8 cases.",
    "Label": ""
  },
  {
    "id": "12381",
    "Sentence": "Association of genetic profiles to <\\entity><\\entity> by linear combinations of single nucleotide polymorphisms.MOTIVATIONS: A large number of single nucleotide polymorphisms (SNPs) are supposed to be involved in onset, differentiation and development of complex diseases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12382",
    "Sentence": "Association of genetic profiles to Crohn's disease by linear combinations of single nucleotide polymorphisms.MOTIVATIONS: A large number of single nucleotide polymorphisms (SNPs) are supposed to be involved in onset, differentiation and development of complex <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12383",
    "Sentence": "Univariate analysis is limited in studying complex <\\entity><\\entity> since does not take into account gene-gene interaction, and the correlation of multiple SNPs with a specific phenotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12384",
    "Sentence": "Moreover it might underestimate gene variants with <\\entity><\\entity> genetic contribution.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12385",
    "Sentence": "Therefore more sophisticated techniques should be adopted when investigating the role of a panel of genetic markers in <\\entity><\\entity> predisposition.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12386",
    "Sentence": "METHODS: In this paper we describe a general method to simultaneously investigate the association between SNPs profile and <\\entity><\\entity> (CD), by evaluating the susceptibility or protective role of single or groups of markers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12387",
    "Sentence": "METHODS: In this paper we describe a general method to simultaneously investigate the association between SNPs profile and Crohn's disease (<\\entity><\\entity>), by evaluating the susceptibility or protective role of single or groups of markers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12388",
    "Sentence": "As an association measure we adopted a <\\entity><\\entity> linear combination of SNPs in which suitable weighting vectors belonged to predefined and over-complete vocabularies of vectors (frames), or were determined by the data.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12389",
    "Sentence": "As an association measure we adopted a weighted linear combination of SNPs in which suitable <\\entity><\\entity> vectors belonged to predefined and over-complete vocabularies of vectors (frames), or were determined by the data.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12390",
    "Sentence": "RESULTS: The proposed method found a <\\entity><\\entity> linear combination of SNPs statistically associated to CD (p=3.81 x 10(-10)) describing the role of the markers in the pathology.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12391",
    "Sentence": "RESULTS: The proposed method found a weighted linear combination of SNPs statistically associated to <\\entity><\\entity> (p=3.81 x 10(-10)) describing the role of the markers in the pathology.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12392",
    "Sentence": "In particular, <\\entity><\\entity> gave the major contribution as protective locus, similarly to TNF-alpha-C857T, DLG5 rs124869, PTPN22 C1858T variants.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12393",
    "Sentence": "In particular, <\\entity><\\entity> gave the major contribution as protective locus, similarly to TNF-alpha-C857T, DLG5 rs124869, PTPN22 C1858T variants.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12394",
    "Sentence": "In particular, MCP1-A2518G gave the major contribution as protective locus, similarly to <\\entity><\\entity>, DLG5 rs124869, PTPN22 C1858T variants.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12395",
    "Sentence": "In particular, MCP1-A2518G gave the major contribution as protective locus, similarly to <\\entity><\\entity>, DLG5 rs124869, PTPN22 C1858T variants.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12396",
    "Sentence": "In particular, MCP1-A2518G gave the major contribution as protective locus, similarly to TNF-alpha-C857T, <\\entity><\\entity>, PTPN22 C1858T variants.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12397",
    "Sentence": "In particular, MCP1-A2518G gave the major contribution as protective locus, similarly to TNF-alpha-C857T, <\\entity><\\entity>, PTPN22 C1858T variants.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12398",
    "Sentence": "In particular, MCP1-A2518G gave the major contribution as protective locus, similarly to TNF-alpha-C857T, DLG5 rs124869, <\\entity><\\entity> variants.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12399",
    "Sentence": "In particular, MCP1-A2518G gave the major contribution as protective locus, similarly to TNF-alpha-C857T, DLG5 rs124869, <\\entity><\\entity> variants.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12400",
    "Sentence": "The <\\entity><\\entity> variants was found to be irrelevant for CD.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12401",
    "Sentence": "The <\\entity><\\entity> variants was found to be irrelevant for CD.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12402",
    "Sentence": "The NF kappaB -94ATTG variants was found to be irrelevant for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12403",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on <\\entity><\\entity> gene, in particular G908R and L1007fsinsC, are involved with CD to the same extent as FcGIIIA G559T and TNF-alpha-G308A.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12404",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular <\\entity><\\entity> and L1007fsinsC, are involved with CD to the same extent as FcGIIIA G559T and TNF-alpha-G308A.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12405",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and <\\entity><\\entity>, are involved with CD to the same extent as FcGIIIA G559T and TNF-alpha-G308A.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12406",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with <\\entity><\\entity> to the same extent as FcGIIIA G559T and TNF-alpha-G308A.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12407",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with CD to the same extent as <\\entity><\\entity> and TNF-alpha-G308A.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12408",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with CD to the same extent as <\\entity><\\entity> and TNF-alpha-G308A.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12409",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with CD to the same extent as FcGIIIA G559T and <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12410",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with CD to the same extent as FcGIIIA G559T and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12411",
    "Sentence": "Moreover, an odds ratio of 3.99(p<1.0 x 10(-4)) was assigned to this combination which is greater than the <\\entity><\\entity> odds ratio found in the single SNP analysis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12412",
    "Sentence": "Therefore this approach could be suitable for a population screening program with simultaneous evaluation of a large <\\entity><\\entity> polymorphism.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12413",
    "Sentence": "The <\\entity><\\entity> variants was found to be irrelevant for CD.",
    "Label": ""
  },
  {
    "id": "12414",
    "Sentence": "The NF kappaB -94ATTG variants was found to be irrelevant for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12416",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular <\\entity><\\entity> and L1007fsinsC, are involved with CD to the same extent as FcGIIIA G559T and TNF-alpha-G308A.",
    "Label": ""
  },
  {
    "id": "12417",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with <\\entity><\\entity> to the same extent as FcGIIIA G559T and TNF-alpha-G308A.",
    "Label": ""
  },
  {
    "id": "12419",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and <\\entity><\\entity>, are involved with CD to the same extent as FcGIIIA G559T and TNF-alpha-G308A.",
    "Label": ""
  },
  {
    "id": "12420",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with <\\entity><\\entity> to the same extent as FcGIIIA G559T and TNF-alpha-G308A.",
    "Label": ""
  },
  {
    "id": "12422",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with CD to the same extent as <\\entity><\\entity> and TNF-alpha-G308A.",
    "Label": ""
  },
  {
    "id": "12423",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with <\\entity><\\entity> to the same extent as FcGIIIA G559T and TNF-alpha-G308A.",
    "Label": ""
  },
  {
    "id": "12425",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with CD to the same extent as FcGIIIA G559T and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12426",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with <\\entity><\\entity> to the same extent as FcGIIIA G559T and TNF-alpha-G308A.",
    "Label": ""
  },
  {
    "id": "12428",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on <\\entity><\\entity> gene, in particular G908R and L1007fsinsC, are involved with CD to the same extent as FcGIIIA G559T and TNF-alpha-G308A.",
    "Label": ""
  },
  {
    "id": "12429",
    "Sentence": "For the remaining markers, a susceptibility role was attributed also confirming that markers on CARD15 gene, in particular G908R and L1007fsinsC, are involved with <\\entity><\\entity> to the same extent as FcGIIIA G559T and TNF-alpha-G308A.",
    "Label": ""
  },
  {
    "id": "12435",
    "Sentence": "Use of self-closing U-clips for dural repair in mini-invasive surgery for <\\entity><\\entity>.OBJECT: The feasibility of a new technique of dural repair (self-closing U-clips) in mini-invasive surgery for herniated disk is demonstrated in this case report.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12436",
    "Sentence": "Use of self-closing U-clips for dural repair in mini-invasive surgery for herniated disc.OBJECT: The feasibility of a new technique of dural repair (self-closing U-clips) in mini-invasive surgery for <\\entity><\\entity> is demonstrated in this case report.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12437",
    "Sentence": "RESULTS: After the intervention the patient no more presented <\\entity><\\entity> or symptoms due to the unintended durotomy, and the postoperative course was uneventful.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12438",
    "Sentence": "RESULTS: After the intervention the patient no more presented signs or <\\entity><\\entity> due to the unintended durotomy, and the postoperative course was uneventful.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12439",
    "Sentence": "CONCLUSION: Self-closing nitinol U-clips (Medtronic, Inc., Minneapolis) can be used for closing a <\\entity><\\entity> through a mini-invasive approach that could make a conventional microsuturing technique very difficult.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12444",
    "Sentence": "Identification and replication of three novel <\\entity><\\entity> common susceptibility gene loci on chromosome 3q26 using linkage and linkage disequilibrium mapping.Refractive error is a highly heritable quantitative trait responsible for considerable morbidity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12445",
    "Sentence": "Identification and replication of three novel myopia common susceptibility gene loci on chromosome <\\entity><\\entity> using linkage and linkage disequilibrium mapping.Refractive error is a highly heritable quantitative trait responsible for considerable morbidity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12446",
    "Sentence": "Identification and replication of three novel myopia common susceptibility gene loci on chromosome 3q26 using linkage and linkage disequilibrium mapping.<\\entity><\\entity> is a highly heritable quantitative trait responsible for considerable morbidity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12447",
    "Sentence": "Following an initial genome-wide linkage study using microsatellite markers, we confirmed evidence for linkage to chromosome <\\entity><\\entity> and then conducted fine-scale association mapping using high-resolution linkage disequilibrium unit (LDU) maps.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12448",
    "Sentence": "We used a preliminary discovery marker set across the 30-Mb region with an average SNP density of 1 SNP/15 kb (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12449",
    "Sentence": "<\\entity><\\entity> was divided into 51 LDU windows and additional SNPs were genotyped for six regions (Map 2) that showed preliminary evidence of multi-marker association using composite likelihood.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12450",
    "Sentence": "Map 1 was divided into 51 LDU windows and additional SNPs were genotyped for six regions (<\\entity><\\entity>) that showed preliminary evidence of multi-marker association using composite likelihood.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12451",
    "Sentence": "Malecot model estimates indicate three loci with putative common functional variants centred on <\\entity><\\entity> (180,566 kb; 95% confidence interval 180,505-180, 655 kb), approximately 156 kb upstream from alternate-splicing SOX2OT (182,595 kb; 95% CI 182,533-182,688 kb) and PSARL (184,386 kb; 95% CI 184,356-184,411 kb), with the loci showing modest to strong evidence of association for the Map 2 discovery samples (p<10(-7), p<10(-10), and p = 0.01, respectively).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12452",
    "Sentence": "Malecot model estimates indicate three loci with putative common functional variants centred on MFN1 (180,566 kb; 95% confidence interval 180,505-180, 655 kb), approximately 156 kb upstream from alternate-splicing <\\entity><\\entity> (182,595 kb; 95% CI 182,533-182,688 kb) and PSARL (184,386 kb; 95% CI 184,356-184,411 kb), with the loci showing modest to strong evidence of association for the Map 2 discovery samples (p<10(-7), p<10(-10), and p = 0.01, respectively).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12453",
    "Sentence": "Malecot model estimates indicate three loci with putative common functional variants centred on MFN1 (180,566 kb; 95% confidence interval 180,505-180, 655 kb), approximately 156 kb upstream from alternate-splicing SOX2OT (182,595 kb; 95% CI 182,533-182,688 kb) and <\\entity><\\entity> (184,386 kb; 95% CI 184,356-184,411 kb), with the loci showing modest to strong evidence of association for the Map 2 discovery samples (p<10(-7), p<10(-10), and p = 0.01, respectively).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12454",
    "Sentence": "Malecot model estimates indicate three loci with putative common functional variants centred on MFN1 (180,566 kb; 95% confidence interval 180,505-180, 655 kb), approximately 156 kb upstream from alternate-splicing SOX2OT (182,595 kb; 95% CI 182,533-182,688 kb) and PSARL (184,386 kb; 95% CI 184,356-184,411 kb), with the loci showing modest to strong evidence of association for the <\\entity><\\entity> discovery samples (p<10(-7), p<10(-10), and p = 0.01, respectively).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12455",
    "Sentence": "Using an unselected independent sample of 1,430 individuals, results replicated for the <\\entity><\\entity> (p = 0.006), SOX2OT (p = 0.0002), and PSARL (p = 0.0005) gene regions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12456",
    "Sentence": "Using an unselected independent sample of 1,430 individuals, results replicated for the MFN1 (p = 0.006), <\\entity><\\entity> (p = 0.0002), and PSARL (p = 0.0005) gene regions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12457",
    "Sentence": "Using an unselected independent sample of 1,430 individuals, results replicated for the MFN1 (p = 0.006), SOX2OT (p = 0.0002), and <\\entity><\\entity> (p = 0.0005) gene regions.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12458",
    "Sentence": "<\\entity><\\entity> and PSARL both interact with OPA1 to regulate mitochondrial fusion and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12459",
    "Sentence": "MFN1 and <\\entity><\\entity> both interact with OPA1 to regulate mitochondrial fusion and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12460",
    "Sentence": "MFN1 and PSARL both interact with <\\entity><\\entity> to regulate mitochondrial fusion and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12461",
    "Sentence": "MFN1 and PSARL both interact with <\\entity><\\entity> to regulate mitochondrial fusion and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12462",
    "Sentence": "MFN1 and PSARL both interact with OPA1 to regulate <\\entity><\\entity> and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12463",
    "Sentence": "MFN1 and PSARL both interact with OPA1 to regulate mitochondrial fusion and the <\\entity><\\entity>, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12464",
    "Sentence": "That two mitochondrial regulatory processes in the retina are implicated in the aetiology of <\\entity><\\entity> is surprising and is likely to provide novel insight into the molecular genetic basis of common <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12465",
    "Sentence": "That two mitochondrial regulatory processes in the retina are implicated in the aetiology of <\\entity><\\entity> is surprising and is likely to provide novel insight into the molecular genetic basis of common <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12466",
    "Sentence": "Identification and replication of three novel myopia common susceptibility gene loci on chromosome <\\entity><\\entity> using linkage and linkage disequilibrium mapping.Refractive error is a highly heritable quantitative trait responsible for considerable morbidity.",
    "Label": ""
  },
  {
    "id": "12467",
    "Sentence": "Identification and replication of three novel <\\entity><\\entity> common susceptibility gene loci on chromosome 3q26 using linkage and linkage disequilibrium mapping.Refractive error is a highly heritable quantitative trait responsible for considerable morbidity.",
    "Label": ""
  },
  {
    "id": "12469",
    "Sentence": "MFN1 and <\\entity><\\entity> both interact with OPA1 to regulate mitochondrial fusion and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": ""
  },
  {
    "id": "12470",
    "Sentence": "MFN1 and PSARL both interact with <\\entity><\\entity> to regulate mitochondrial fusion and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": ""
  },
  {
    "id": "12472",
    "Sentence": "<\\entity><\\entity> and PSARL both interact with OPA1 to regulate mitochondrial fusion and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": ""
  },
  {
    "id": "12473",
    "Sentence": "MFN1 and PSARL both interact with <\\entity><\\entity> to regulate mitochondrial fusion and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": ""
  },
  {
    "id": "12475",
    "Sentence": "MFN1 and <\\entity><\\entity> both interact with OPA1 to regulate mitochondrial fusion and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": ""
  },
  {
    "id": "12476",
    "Sentence": "MFN1 and PSARL both interact with OPA1 to regulate mitochondrial fusion and the <\\entity><\\entity>, respectively.",
    "Label": ""
  },
  {
    "id": "12478",
    "Sentence": "<\\entity><\\entity> and PSARL both interact with OPA1 to regulate mitochondrial fusion and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": ""
  },
  {
    "id": "12479",
    "Sentence": "MFN1 and PSARL both interact with OPA1 to regulate <\\entity><\\entity> and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": ""
  },
  {
    "id": "12481",
    "Sentence": "MFN1 and PSARL both interact with <\\entity><\\entity> to regulate mitochondrial fusion and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": ""
  },
  {
    "id": "12482",
    "Sentence": "MFN1 and PSARL both interact with OPA1 to regulate mitochondrial fusion and the <\\entity><\\entity>, respectively.",
    "Label": ""
  },
  {
    "id": "12484",
    "Sentence": "MFN1 and PSARL both interact with <\\entity><\\entity> to regulate mitochondrial fusion and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": ""
  },
  {
    "id": "12485",
    "Sentence": "MFN1 and PSARL both interact with OPA1 to regulate <\\entity><\\entity> and the inhibition of mitochondrial-led apoptosis, respectively.",
    "Label": ""
  },
  {
    "id": "12491",
    "Sentence": "Activated <\\entity><\\entity> impairs cell invasiveness through p190RhoGAP-mediated inhibition of RhoA activity.The GTPase RhoA is a downstream target of heterotrimeric G(13) proteins and plays key roles in cell migration and invasion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12492",
    "Sentence": "Activated G(alpha)13 impairs cell invasiveness through <\\entity><\\entity>-mediated inhibition of RhoA activity.The GTPase RhoA is a downstream target of heterotrimeric G(13) proteins and plays key roles in cell migration and invasion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12493",
    "Sentence": "Activated G(alpha)13 impairs cell invasiveness through p190RhoGAP-mediated inhibition of <\\entity><\\entity> activity.The GTPase <\\entity><\\entity> is a downstream target of heterotrimeric G(13) proteins and plays key roles in cell migration and invasion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12494",
    "Sentence": "Activated G(alpha)13 impairs cell invasiveness through p190RhoGAP-mediated inhibition of RhoA activity.The <\\entity><\\entity> is a downstream target of heterotrimeric G(13) proteins and plays key roles in cell migration and invasion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12495",
    "Sentence": "Activated G(alpha)13 impairs cell invasiveness through p190RhoGAP-mediated inhibition of RhoA activity.The GTPase RhoA is a downstream target of heterotrimeric <\\entity><\\entity> proteins and plays key roles in cell migration and invasion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12496",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, <\\entity><\\entity> (G(alpha)(13)QL) or lysophosphatidylcholine (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12497",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient <\\entity><\\entity> form (G(alpha)(13)QL) or lysophosphatidylcholine (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12498",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (<\\entity><\\entity>) or lysophosphatidylcholine (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12499",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or <\\entity><\\entity> (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12500",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or <\\entity><\\entity> (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12501",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or lysophosphatidylcholine (<\\entity><\\entity>)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12502",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or lysophosphatidylcholine (<\\entity><\\entity>)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12503",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (<\\entity><\\entity>QL) or lysophosphatidylcholine (LPC)-promoted signaling through <\\entity><\\entity>-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12504",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or lysophosphatidylcholine (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of <\\entity><\\entity>-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12505",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or lysophosphatidylcholine (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated <\\entity><\\entity> activation and cell invasion that was rescued by active <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12506",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or lysophosphatidylcholine (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated <\\entity><\\entity> activation and cell invasion that was rescued by active <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12507",
    "Sentence": "Melanoma cells expressing <\\entity><\\entity> or cells stimulated with LPC displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12508",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with <\\entity><\\entity> displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12509",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with <\\entity><\\entity> displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12510",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with LPC displayed an increase in <\\entity><\\entity> activation, and defects in RhoA activation and invasion were recovered by knocking down <\\entity><\\entity> expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12511",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with LPC displayed an increase in p190RhoGAP activation, and defects in <\\entity><\\entity> activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12512",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with LPC displayed an increase in <\\entity><\\entity> activation, and defects in RhoA activation and invasion were recovered by knocking down <\\entity><\\entity> expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12513",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with LPC displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this <\\entity><\\entity> (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12514",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with LPC displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (<\\entity><\\entity> as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12515",
    "Sentence": "Melanoma cells expressing <\\entity><\\entity>QL or cells stimulated with LPC displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream <\\entity><\\entity> target that is responsible for these inhibitory responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12516",
    "Sentence": "In addition, defective stress fiber assembly and reduced migration speed underlay inefficient invasion of <\\entity><\\entity> melanoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12517",
    "Sentence": "Importantly, <\\entity><\\entity> expression in melanoma cells led to impairment in lung metastasis associated with prolonged survival in SCID mice.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12518",
    "Sentence": "The data indicate that <\\entity><\\entity>-dependent downstream effects on RhoA activation and invasion tightly depend on cell type-specific GAP activities and that <\\entity><\\entity>-p190RhoGAP signaling might represent a potential target for intervention in melanoma metastasis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12519",
    "Sentence": "The data indicate that G(alpha)(13)-dependent downstream effects on <\\entity><\\entity> activation and invasion tightly depend on cell type-specific GAP activities and that G(alpha)(13)-p190RhoGAP signaling might represent a potential target for intervention in melanoma metastasis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12520",
    "Sentence": "The data indicate that G(alpha)(13)-dependent downstream effects on RhoA activation and invasion tightly depend on cell type-specific <\\entity><\\entity> activities and that G(alpha)(13)-p190Rho<\\entity><\\entity> signaling might represent a potential target for intervention in melanoma metastasis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12521",
    "Sentence": "The data indicate that G(alpha)(13)-dependent downstream effects on RhoA activation and invasion tightly depend on cell type-specific GAP activities and that <\\entity><\\entity> signaling might represent a potential target for intervention in melanoma metastasis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12522",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or <\\entity><\\entity> (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": ""
  },
  {
    "id": "12523",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or lysophosphatidylcholine (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated <\\entity><\\entity> activation and cell invasion that was rescued by active <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12525",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or <\\entity><\\entity> (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": ""
  },
  {
    "id": "12526",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient <\\entity><\\entity> form (G(alpha)(13)QL) or lysophosphatidylcholine (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": ""
  },
  {
    "id": "12528",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or <\\entity><\\entity> (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": ""
  },
  {
    "id": "12529",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (<\\entity><\\entity>QL) or lysophosphatidylcholine (LPC)-promoted signaling through <\\entity><\\entity>-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": ""
  },
  {
    "id": "12531",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or lysophosphatidylcholine (<\\entity><\\entity>)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": ""
  },
  {
    "id": "12532",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or lysophosphatidylcholine (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated <\\entity><\\entity> activation and cell invasion that was rescued by active <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12534",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or lysophosphatidylcholine (<\\entity><\\entity>)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": ""
  },
  {
    "id": "12535",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient <\\entity><\\entity> form (G(alpha)(13)QL) or lysophosphatidylcholine (LPC)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": ""
  },
  {
    "id": "12537",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (G(alpha)(13)QL) or lysophosphatidylcholine (<\\entity><\\entity>)-promoted signaling through G(alpha)(13)-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": ""
  },
  {
    "id": "12538",
    "Sentence": "Here, we show that expression in human melanoma cells of a constitutively active, GTPase-deficient Galpha(13) form (<\\entity><\\entity>QL) or lysophosphatidylcholine (LPC)-promoted signaling through <\\entity><\\entity>-coupled receptors led to a blockade of chemokine-stimulated RhoA activation and cell invasion that was rescued by active RhoA.",
    "Label": ""
  },
  {
    "id": "12540",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with <\\entity><\\entity> displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": ""
  },
  {
    "id": "12541",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with LPC displayed an increase in p190RhoGAP activation, and defects in <\\entity><\\entity> activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": ""
  },
  {
    "id": "12543",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with <\\entity><\\entity> displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": ""
  },
  {
    "id": "12544",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with LPC displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (<\\entity><\\entity> as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": ""
  },
  {
    "id": "12546",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with <\\entity><\\entity> displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": ""
  },
  {
    "id": "12547",
    "Sentence": "Melanoma cells expressing <\\entity><\\entity>QL or cells stimulated with LPC displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream <\\entity><\\entity> target that is responsible for these inhibitory responses.",
    "Label": ""
  },
  {
    "id": "12549",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with <\\entity><\\entity> displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": ""
  },
  {
    "id": "12550",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with LPC displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this <\\entity><\\entity> (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": ""
  },
  {
    "id": "12552",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with <\\entity><\\entity> displayed an increase in p190RhoGAP activation, and defects in RhoA activation and invasion were recovered by knocking down p190RhoGAP expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": ""
  },
  {
    "id": "12553",
    "Sentence": "Melanoma cells expressing G(alpha)(13)QL or cells stimulated with LPC displayed an increase in <\\entity><\\entity> activation, and defects in RhoA activation and invasion were recovered by knocking down <\\entity><\\entity> expression, thus identifying this GTPase-activating protein (GAP) protein as a downstream G(alpha)(13) target that is responsible for these inhibitory responses.",
    "Label": ""
  },
  {
    "id": "12559",
    "Sentence": "Pupillary changes among Nigerian adults following the instillation of <\\entity><\\entity>: multicentric studies.BACKGROUND: A multi-centre, open, within-patient controlled study was performed on 106 adult volunteers to investigate the effects of Garcinia kolanut extracts on the pupillary sizes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12560",
    "Sentence": "Pupillary changes among Nigerian adults following the instillation of Garcinia kola nut extracts: multicentric studies.BACKGROUND: A multi-centre, open, within-patient controlled study was performed on 106 adult volunteers to investigate the effects of <\\entity><\\entity> on the pupillary sizes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12561",
    "Sentence": "STUDY DESIGN: 106 participants in three Nigerian Ophthalmic Centres with no <\\entity><\\entity> and associated ocular or systemic co-morbidities had their pupillary diameters measured at 0, 15, 30 and 45 minutes respectively with a pupillometer (Neuroptics model # 586009).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12562",
    "Sentence": "Using the left eyes as control, <\\entity><\\entity> was instilled into the right eyes at 15 minutes intervals.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12563",
    "Sentence": "Average pupillary diameter measured among participants was 4.1 - 8.4 mm with the mean value of 6.0 mm prior to <\\entity><\\entity> instillation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12564",
    "Sentence": "There was a <\\entity><\\entity> reduction in the baseline pupillary size with age in years at 0.2mm per decade without garcinia extract instillation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12565",
    "Sentence": "There was a gradual reduction in the baseline pupillary size with age in years at 0.2mm per decade without <\\entity><\\entity> instillation.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12566",
    "Sentence": "There were consistent significant <\\entity><\\entity> in the right eyes with instilled Garcinia kola nut extract compared to the left eyes at 15, 30 and 45 minutes (p=0.0000).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12567",
    "Sentence": "There were consistent significant miosis in the right eyes with instilled <\\entity><\\entity> compared to the left eyes at 15, 30 and 45 minutes (p=0.0000).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12568",
    "Sentence": "CONCLUSION: 4% <\\entity><\\entity> drop has a transient miotic effect on human pupils not sustainable for more than 45 minutes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12569",
    "Sentence": "CONCLUSION: 4% Garcinia kola nut extract drop has a transient <\\entity><\\entity> effect on human pupils not sustainable for more than 45 minutes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12570",
    "Sentence": "There were consistent significant miosis in the right eyes with instilled <\\entity><\\entity> compared to the left eyes at 15, 30 and 45 minutes (p=0.0000).",
    "Label": ""
  },
  {
    "id": "12571",
    "Sentence": "There were consistent significant <\\entity><\\entity> in the right eyes with instilled Garcinia kola nut extract compared to the left eyes at 15, 30 and 45 minutes (p=0.0000).",
    "Label": ""
  },
  {
    "id": "12573",
    "Sentence": "CONCLUSION: 4% <\\entity><\\entity> drop has a transient miotic effect on human pupils not sustainable for more than 45 minutes.",
    "Label": ""
  },
  {
    "id": "12574",
    "Sentence": "CONCLUSION: 4% Garcinia kola nut extract drop has a transient <\\entity><\\entity> effect on human pupils not sustainable for more than 45 minutes.",
    "Label": ""
  },
  {
    "id": "12580",
    "Sentence": "A novel <\\entity><\\entity> is efficacious in a murine model of colitis.Ulcerative colitis is an autoimmune-inflammatory disease characterized by increased proliferation of colonic epithelial cells, dysregulation of signal transduction pathways, elevated mucosal T cell activation, increased production of proinflammatory cytokines, and enhanced leukocyte infiltration into colonic interstitium.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12581",
    "Sentence": "A novel <\\entity><\\entity> is efficacious in a murine model of colitis.Ulcerative colitis is an autoimmune-inflammatory disease characterized by increased proliferation of colonic epithelial cells, dysregulation of signal transduction pathways, elevated mucosal T cell activation, increased production of proinflammatory cytokines, and enhanced leukocyte infiltration into colonic interstitium.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12582",
    "Sentence": "A novel mTOR inhibitor is efficacious in a murine model of colitis.Ulcerative colitis is an autoimmune-inflammatory disease characterized by increased proliferation of colonic epithelial cells, dysregulation of signal transduction pathways, elevated mucosal <\\entity><\\entity> activation, increased production of proinflammatory cytokines, and enhanced leukocyte infiltration into colonic interstitium.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12583",
    "Sentence": "A novel mTOR inhibitor is efficacious in a murine model of colitis.Ulcerative colitis is an autoimmune-inflammatory disease characterized by increased proliferation of colonic epithelial cells, dysregulation of signal transduction pathways, elevated mucosal T cell activation, increased production of <\\entity><\\entity>, and enhanced leukocyte infiltration into colonic interstitium.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12584",
    "Sentence": "Several compounds that possess antiproliferative properties and/or inhibit <\\entity><\\entity> production exhibit a therapeutic effect in murine models of colitis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12585",
    "Sentence": "<\\entity><\\entity> (mTOR), a protein kinase regulating cell proliferation, is implicated in colon carcinogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12586",
    "Sentence": "Mammalian target of rapamycin (<\\entity><\\entity>), a protein kinase regulating cell proliferation, is implicated in colon carcinogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12587",
    "Sentence": "In this study, we report that a novel <\\entity><\\entity> (P2281) is a mTOR inhibitor and is efficacious in a murine model of human colitis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12588",
    "Sentence": "In this study, we report that a novel haloacyl aminopyridine-based molecule (<\\entity><\\entity>) is a mTOR inhibitor and is efficacious in a murine model of human colitis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12589",
    "Sentence": "In this study, we report that a novel haloacyl aminopyridine-based molecule (P2281) is a <\\entity><\\entity> and is efficacious in a murine model of human colitis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12590",
    "Sentence": "In this study, we report that a novel haloacyl aminopyridine-based molecule (P2281) is a <\\entity><\\entity> and is efficacious in a murine model of human colitis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12591",
    "Sentence": "In vitro studies using Western blot analysis and cell-based ELISA assays showed that <\\entity><\\entity> inhibits mTOR activity in colon cancer cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12592",
    "Sentence": "In vitro studies using Western blot analysis and cell-based ELISA assays showed that P2281 inhibits <\\entity><\\entity> activity in colon cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12593",
    "Sentence": "In vitro and in vivo assays of <\\entity><\\entity> production revealed that P2281 diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of P2281 on T cell function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12594",
    "Sentence": "In vitro and in vivo assays of proinflammatory cytokine production revealed that <\\entity><\\entity> diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of <\\entity><\\entity> on T cell function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12595",
    "Sentence": "In vitro and in vivo assays of proinflammatory cytokine production revealed that P2281 diminishes induced <\\entity><\\entity> production but not TNF-alpha production, indicating preferential inhibitory effects of P2281 on T cell function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12596",
    "Sentence": "In vitro and in vivo assays of proinflammatory cytokine production revealed that P2281 diminishes induced IFN-gamma production but not <\\entity><\\entity> production, indicating preferential inhibitory effects of P2281 on T cell function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12597",
    "Sentence": "In vitro and in vivo assays of proinflammatory cytokine production revealed that <\\entity><\\entity> diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of <\\entity><\\entity> on T cell function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12598",
    "Sentence": "In vitro and in vivo assays of proinflammatory cytokine production revealed that P2281 diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of P2281 on <\\entity><\\entity> function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12599",
    "Sentence": "In the <\\entity><\\entity> (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12600",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12601",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12602",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that <\\entity><\\entity> significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that <\\entity><\\entity> distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that <\\entity><\\entity> blocks DSS-induced activation of mTOR.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12603",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12604",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12605",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12606",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12607",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that <\\entity><\\entity> significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that <\\entity><\\entity> distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that <\\entity><\\entity> blocks DSS-induced activation of mTOR.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12608",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12609",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12610",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12611",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12612",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that <\\entity><\\entity> significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that <\\entity><\\entity> distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that <\\entity><\\entity> blocks DSS-induced activation of mTOR.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12613",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12614",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12615",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12616",
    "Sentence": "Collectively, these results provide direct evidence that <\\entity><\\entity>, a novel mTOR inhibitor, suppresses DSS-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12617",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel <\\entity><\\entity>, suppresses DSS-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12618",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel <\\entity><\\entity>, suppresses DSS-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12619",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses <\\entity><\\entity>-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12620",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses <\\entity><\\entity>-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12621",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses DSS-induced colitis by inhibiting <\\entity><\\entity> function and is a potential therapeutic for colitis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12622",
    "Sentence": "In vitro studies using Western blot analysis and cell-based ELISA assays showed that <\\entity><\\entity> inhibits mTOR activity in colon cancer cells.",
    "Label": ""
  },
  {
    "id": "12623",
    "Sentence": "In vitro studies using Western blot analysis and cell-based ELISA assays showed that P2281 inhibits <\\entity><\\entity> activity in colon cancer cells.",
    "Label": ""
  },
  {
    "id": "12625",
    "Sentence": "In vitro and in vivo assays of proinflammatory cytokine production revealed that <\\entity><\\entity> diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of <\\entity><\\entity> on T cell function.",
    "Label": ""
  },
  {
    "id": "12626",
    "Sentence": "In vitro and in vivo assays of proinflammatory cytokine production revealed that P2281 diminishes induced <\\entity><\\entity> production but not TNF-alpha production, indicating preferential inhibitory effects of P2281 on T cell function.",
    "Label": ""
  },
  {
    "id": "12628",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12629",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12631",
    "Sentence": "In the <\\entity><\\entity> (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12632",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12634",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that <\\entity><\\entity> significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that <\\entity><\\entity> distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that <\\entity><\\entity> blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12635",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12637",
    "Sentence": "In the <\\entity><\\entity> (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12638",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12640",
    "Sentence": "A novel <\\entity><\\entity> is efficacious in a murine model of colitis.Ulcerative colitis is an autoimmune-inflammatory disease characterized by increased proliferation of colonic epithelial cells, dysregulation of signal transduction pathways, elevated mucosal T cell activation, increased production of proinflammatory cytokines, and enhanced leukocyte infiltration into colonic interstitium.",
    "Label": ""
  },
  {
    "id": "12641",
    "Sentence": "A novel mTOR inhibitor is efficacious in a murine model of <\\entity><\\entity>.Ulcerative <\\entity><\\entity> is an autoimmune-inflammatory disease characterized by increased proliferation of colonic epithelial cells, dysregulation of signal transduction pathways, elevated mucosal T cell activation, increased production of proinflammatory cytokines, and enhanced leukocyte infiltration into colonic interstitium.",
    "Label": ""
  },
  {
    "id": "12643",
    "Sentence": "Several compounds that possess antiproliferative properties and/or inhibit <\\entity><\\entity> production exhibit a therapeutic effect in murine models of colitis.",
    "Label": ""
  },
  {
    "id": "12644",
    "Sentence": "Several compounds that possess antiproliferative properties and/or inhibit cytokine production exhibit a therapeutic effect in murine models of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12646",
    "Sentence": "Mammalian target of rapamycin (<\\entity><\\entity>), a protein kinase regulating cell proliferation, is implicated in colon carcinogenesis.",
    "Label": ""
  },
  {
    "id": "12647",
    "Sentence": "Mammalian target of rapamycin (mTOR), a protein kinase regulating cell proliferation, is implicated in colon <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12649",
    "Sentence": "In this study, we report that a novel haloacyl aminopyridine-based molecule (P2281) is a <\\entity><\\entity> and is efficacious in a murine model of human colitis.",
    "Label": ""
  },
  {
    "id": "12650",
    "Sentence": "In this study, we report that a novel haloacyl aminopyridine-based molecule (P2281) is a mTOR inhibitor and is efficacious in a murine model of human <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12652",
    "Sentence": "In this study, we report that a novel haloacyl aminopyridine-based molecule (<\\entity><\\entity>) is a mTOR inhibitor and is efficacious in a murine model of human colitis.",
    "Label": ""
  },
  {
    "id": "12653",
    "Sentence": "In this study, we report that a novel haloacyl aminopyridine-based molecule (P2281) is a <\\entity><\\entity> and is efficacious in a murine model of human colitis.",
    "Label": ""
  },
  {
    "id": "12655",
    "Sentence": "In this study, we report that a novel haloacyl aminopyridine-based molecule (<\\entity><\\entity>) is a mTOR inhibitor and is efficacious in a murine model of human colitis.",
    "Label": ""
  },
  {
    "id": "12656",
    "Sentence": "In this study, we report that a novel haloacyl aminopyridine-based molecule (P2281) is a mTOR inhibitor and is efficacious in a murine model of human <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12658",
    "Sentence": "In vitro studies using Western blot analysis and cell-based ELISA assays showed that P2281 inhibits <\\entity><\\entity> activity in colon cancer cells.",
    "Label": ""
  },
  {
    "id": "12659",
    "Sentence": "In vitro studies using Western blot analysis and cell-based ELISA assays showed that P2281 inhibits mTOR activity in <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "12661",
    "Sentence": "In vitro and in vivo assays of proinflammatory cytokine production revealed that <\\entity><\\entity> diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of <\\entity><\\entity> on T cell function.",
    "Label": ""
  },
  {
    "id": "12662",
    "Sentence": "In vitro and in vivo assays of proinflammatory cytokine production revealed that P2281 diminishes induced IFN-gamma production but not <\\entity><\\entity> production, indicating preferential inhibitory effects of P2281 on T cell function.",
    "Label": ""
  },
  {
    "id": "12664",
    "Sentence": "In vitro and in vivo assays of proinflammatory cytokine production revealed that <\\entity><\\entity> diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of <\\entity><\\entity> on T cell function.",
    "Label": ""
  },
  {
    "id": "12665",
    "Sentence": "In vitro and in vivo assays of <\\entity><\\entity> production revealed that P2281 diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of P2281 on T cell function.",
    "Label": ""
  },
  {
    "id": "12667",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12668",
    "Sentence": "In the dextran sulfate sodium (DSS) model of <\\entity><\\entity>, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12670",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12671",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved <\\entity><\\entity> index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12673",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12674",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced <\\entity><\\entity>, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12676",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12677",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced <\\entity><\\entity>; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12679",
    "Sentence": "In the <\\entity><\\entity> (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12680",
    "Sentence": "In the dextran sulfate sodium (DSS) model of <\\entity><\\entity>, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12682",
    "Sentence": "In the <\\entity><\\entity> (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12683",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved <\\entity><\\entity> index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12685",
    "Sentence": "In the <\\entity><\\entity> (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12686",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced <\\entity><\\entity>, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12688",
    "Sentence": "In the <\\entity><\\entity> (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12689",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced <\\entity><\\entity>; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12691",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that <\\entity><\\entity> significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that <\\entity><\\entity> distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that <\\entity><\\entity> blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12692",
    "Sentence": "In the dextran sulfate sodium (DSS) model of <\\entity><\\entity>, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12694",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that <\\entity><\\entity> significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that <\\entity><\\entity> distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that <\\entity><\\entity> blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12695",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved <\\entity><\\entity> index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12697",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that <\\entity><\\entity> significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that <\\entity><\\entity> distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that <\\entity><\\entity> blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12698",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced <\\entity><\\entity>, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12700",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that <\\entity><\\entity> significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that <\\entity><\\entity> distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that <\\entity><\\entity> blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12701",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced <\\entity><\\entity>; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12703",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12704",
    "Sentence": "In the dextran sulfate sodium (DSS) model of <\\entity><\\entity>, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12706",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12707",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved <\\entity><\\entity> index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12709",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12710",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced <\\entity><\\entity>, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12712",
    "Sentence": "In the dextran sulfate sodium (<\\entity><\\entity>) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited <\\entity><\\entity>-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed <\\entity><\\entity>-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated <\\entity><\\entity>-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against <\\entity><\\entity>-induced crypt damage; and 3) Western blot analysis showed that P2281 blocks <\\entity><\\entity>-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12713",
    "Sentence": "In the dextran sulfate sodium (DSS) model of colitis, 1) macroscopic colon observations demonstrated that P2281 significantly inhibited DSS-induced weight loss, improved rectal bleeding index, decreased disease activity index, and reversed DSS-induced shortening of the colon; 2) histological analyses of colonic tissues revealed that P2281 distinctly attenuated DSS-induced edema, prominently diminished the leukocyte infiltration in the colonic mucosa, and resulted in protection against DSS-induced <\\entity><\\entity>; and 3) Western blot analysis showed that P2281 blocks DSS-induced activation of mTOR.",
    "Label": ""
  },
  {
    "id": "12715",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel <\\entity><\\entity>, suppresses DSS-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": ""
  },
  {
    "id": "12716",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses DSS-induced <\\entity><\\entity> by inhibiting T cell function and is a potential therapeutic for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12718",
    "Sentence": "Collectively, these results provide direct evidence that <\\entity><\\entity>, a novel mTOR inhibitor, suppresses DSS-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": ""
  },
  {
    "id": "12719",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel <\\entity><\\entity>, suppresses DSS-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": ""
  },
  {
    "id": "12721",
    "Sentence": "Collectively, these results provide direct evidence that <\\entity><\\entity>, a novel mTOR inhibitor, suppresses DSS-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": ""
  },
  {
    "id": "12722",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses DSS-induced <\\entity><\\entity> by inhibiting T cell function and is a potential therapeutic for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12724",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses <\\entity><\\entity>-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": ""
  },
  {
    "id": "12725",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel <\\entity><\\entity>, suppresses DSS-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": ""
  },
  {
    "id": "12727",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses <\\entity><\\entity>-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": ""
  },
  {
    "id": "12728",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses DSS-induced <\\entity><\\entity> by inhibiting T cell function and is a potential therapeutic for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12730",
    "Sentence": "In vitro and in vivo assays of proinflammatory cytokine production revealed that <\\entity><\\entity> diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of <\\entity><\\entity> on T cell function.",
    "Label": ""
  },
  {
    "id": "12731",
    "Sentence": "In vitro and in vivo assays of proinflammatory cytokine production revealed that P2281 diminishes induced IFN-gamma production but not TNF-alpha production, indicating preferential inhibitory effects of P2281 on <\\entity><\\entity> function.",
    "Label": ""
  },
  {
    "id": "12733",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel <\\entity><\\entity>, suppresses DSS-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": ""
  },
  {
    "id": "12734",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses DSS-induced colitis by inhibiting <\\entity><\\entity> function and is a potential therapeutic for colitis.",
    "Label": ""
  },
  {
    "id": "12736",
    "Sentence": "Collectively, these results provide direct evidence that <\\entity><\\entity>, a novel mTOR inhibitor, suppresses DSS-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": ""
  },
  {
    "id": "12737",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses DSS-induced colitis by inhibiting <\\entity><\\entity> function and is a potential therapeutic for colitis.",
    "Label": ""
  },
  {
    "id": "12739",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses <\\entity><\\entity>-induced colitis by inhibiting T cell function and is a potential therapeutic for colitis.",
    "Label": ""
  },
  {
    "id": "12740",
    "Sentence": "Collectively, these results provide direct evidence that P2281, a novel mTOR inhibitor, suppresses DSS-induced colitis by inhibiting <\\entity><\\entity> function and is a potential therapeutic for colitis.",
    "Label": ""
  },
  {
    "id": "12746",
    "Sentence": "The significant improvement in pediatric cancer survival over the past few decades is the result of optimized <\\entity><\\entity> drug dosing, timing, and intensity; however, further alterations in traditional <\\entity><\\entity> agents are unlikely to produce substantially better outcomes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12747",
    "Sentence": "The significant improvement in pediatric cancer survival over the past few decades is the result of optimized chemotherapy drug dosing, timing, and intensity; however, further alterations in traditional <\\entity><\\entity> are unlikely to produce substantially better outcomes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12748",
    "Sentence": "These novel agents <\\entity><\\entity> the promise for continuing to drive forward improvements in patient survival, with potentially less toxicity than exists with traditional chemotherapy drugs.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12749",
    "Sentence": "These novel agents hold the promise for continuing to drive forward improvements in patient survival, with potentially less toxicity than exists with traditional <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12754",
    "Sentence": "Drug related genetic polymorphisms affecting adverse reactions to <\\entity><\\entity>, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer.PURPOSE: There is considerable interindividual diversity in the development of adverse reactions during chemotherapy for cancers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12755",
    "Sentence": "Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with <\\entity><\\entity>.PURPOSE: There is considerable interindividual diversity in the development of adverse reactions during chemotherapy for cancers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12756",
    "Sentence": "Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer.PURPOSE: There is considerable interindividual diversity in the development of <\\entity><\\entity> for cancers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12757",
    "Sentence": "Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer.PURPOSE: There is considerable interindividual diversity in the development of adverse reactions during chemotherapy for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12758",
    "Sentence": "In this study we evaluated the possible association of polymorphisms of genes involved in the metabolism, detoxification and transport of the agents with adverse reactions to <\\entity><\\entity>, vinblastine, doxorubicin and cisplatin therapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12759",
    "Sentence": "MATERIALS AND METHODS: A total of 40 patients with <\\entity><\\entity> who received methotrexate, vinblastine, doxorubicin and cisplatin or high dose methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy between 1996 and 2005 at Akita University Medical Center were included in this study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12760",
    "Sentence": "Four genetic polymorphisms (<\\entity><\\entity>, GSTP1, CYP3A5 and MTHFR) and clinical parameters were included in the analysis to determine whether there was any association with the grade of adverse reactions at the first cycle and the worst grade of each adverse reaction throughout the chemotherapy period.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12761",
    "Sentence": "Four genetic polymorphisms (ABCB1, <\\entity><\\entity>, CYP3A5 and MTHFR) and clinical parameters were included in the analysis to determine whether there was any association with the grade of adverse reactions at the first cycle and the worst grade of each adverse reaction throughout the chemotherapy period.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12762",
    "Sentence": "Four genetic polymorphisms (ABCB1, GSTP1, <\\entity><\\entity> and MTHFR) and clinical parameters were included in the analysis to determine whether there was any association with the grade of adverse reactions at the first cycle and the worst grade of each adverse reaction throughout the chemotherapy period.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12763",
    "Sentence": "Four genetic polymorphisms (ABCB1, GSTP1, CYP3A5 and <\\entity><\\entity>) and clinical parameters were included in the analysis to determine whether there was any association with the grade of adverse reactions at the first cycle and the worst grade of each adverse reaction throughout the chemotherapy period.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12764",
    "Sentence": "Four genetic polymorphisms (ABCB1, GSTP1, CYP3A5 and MTHFR) and clinical parameters were included in the analysis to determine whether there was any association with the grade of adverse reactions at the first cycle and the worst grade of each <\\entity><\\entity> period.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12765",
    "Sentence": "RESULTS: On multivariate analysis the <\\entity><\\entity> (OR 8.205, 95% CI 1.616-41.667, p = 0.011) and smaller number of treatment cycles (OR 0.156, 95% CI 0.037-0.659, p = 0.011) were independent factors for leukocytopenia (grade 3 or greater) throughout the period of chemotherapy.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12766",
    "Sentence": "RESULTS: On multivariate analysis the <\\entity><\\entity> (OR 8.205, 95% CI 1.616-41.667, p = 0.011) and smaller number of treatment cycles (OR 0.156, 95% CI 0.037-0.659, p = 0.011) were independent factors for leukocytopenia (grade 3 or greater) throughout the period of chemotherapy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12767",
    "Sentence": "RESULTS: On multivariate analysis the CYP3A5 <\\entity><\\entity> genotype *3/*3 (OR 8.205, 95% CI 1.616-41.667, p = 0.011) and smaller number of treatment cycles (OR 0.156, 95% CI 0.037-0.659, p = 0.011) were independent factors for leukocytopenia (grade 3 or greater) throughout the period of chemotherapy.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12768",
    "Sentence": "RESULTS: On multivariate analysis the CYP3A5 A6986G genotype *3/*3 (OR 8.205, 95% CI 1.616-41.667, p = 0.011) and smaller number of treatment cycles (OR 0.156, 95% CI 0.037-0.659, p = 0.011) were independent factors for <\\entity><\\entity> (grade 3 or greater) throughout the period of chemotherapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12769",
    "Sentence": "The mean white blood cell count nadir in patients with <\\entity><\\entity> was significantly lower than that in those with the *1 allele (1,542 +/- 903 vs 2,431 +/- 973/mm(3), p = 0.009).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12770",
    "Sentence": "The mean white blood cell count nadir in patients with genotype *3/*3 was significantly lower than that in those with the <\\entity><\\entity> (1,542 +/- 903 vs 2,431 +/- 973/mm(3), p = 0.009).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12771",
    "Sentence": "CONCLUSIONS: The <\\entity><\\entity>, which is involved in the metabolism of vinblastine and doxorubicin, might be a genetic predictor of the severity of leukocytopenia induced by chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12772",
    "Sentence": "CONCLUSIONS: The <\\entity><\\entity>, which is involved in the metabolism of vinblastine and doxorubicin, might be a genetic predictor of the severity of leukocytopenia induced by chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12773",
    "Sentence": "CONCLUSIONS: The A6986G polymorphism of CYP3A5, which is involved in the metabolism of vinblastine and doxorubicin, might be a genetic predictor of the severity of <\\entity><\\entity> induced by chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12774",
    "Sentence": "RESULTS: On multivariate analysis the <\\entity><\\entity> (OR 8.205, 95% CI 1.616-41.667, p = 0.011) and smaller number of treatment cycles (OR 0.156, 95% CI 0.037-0.659, p = 0.011) were independent factors for leukocytopenia (grade 3 or greater) throughout the period of chemotherapy.",
    "Label": ""
  },
  {
    "id": "12775",
    "Sentence": "RESULTS: On multivariate analysis the CYP3A5 A6986G genotype *3/*3 (OR 8.205, 95% CI 1.616-41.667, p = 0.011) and smaller number of treatment cycles (OR 0.156, 95% CI 0.037-0.659, p = 0.011) were independent factors for <\\entity><\\entity> (grade 3 or greater) throughout the period of chemotherapy.",
    "Label": ""
  },
  {
    "id": "12777",
    "Sentence": "CONCLUSIONS: The <\\entity><\\entity>, which is involved in the metabolism of vinblastine and doxorubicin, might be a genetic predictor of the severity of leukocytopenia induced by chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin.",
    "Label": ""
  },
  {
    "id": "12778",
    "Sentence": "CONCLUSIONS: The A6986G polymorphism of CYP3A5, which is involved in the metabolism of vinblastine and doxorubicin, might be a genetic predictor of the severity of <\\entity><\\entity> induced by chemotherapy with methotrexate, vinblastine, doxorubicin and cisplatin.",
    "Label": ""
  },
  {
    "id": "12780",
    "Sentence": "RESULTS: On multivariate analysis the CYP3A5 <\\entity><\\entity> genotype *3/*3 (OR 8.205, 95% CI 1.616-41.667, p = 0.011) and smaller number of treatment cycles (OR 0.156, 95% CI 0.037-0.659, p = 0.011) were independent factors for leukocytopenia (grade 3 or greater) throughout the period of chemotherapy.",
    "Label": ""
  },
  {
    "id": "12781",
    "Sentence": "RESULTS: On multivariate analysis the CYP3A5 A6986G genotype *3/*3 (OR 8.205, 95% CI 1.616-41.667, p = 0.011) and smaller number of treatment cycles (OR 0.156, 95% CI 0.037-0.659, p = 0.011) were independent factors for <\\entity><\\entity> (grade 3 or greater) throughout the period of chemotherapy.",
    "Label": ""
  },
  {
    "id": "12787",
    "Sentence": "The role of <\\entity><\\entity> and ceramide-1-phosphate in calcium homeostasis.During the last several years, sphingolipids have been identified as a source of important signaling molecules.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12788",
    "Sentence": "The role of <\\entity><\\entity> and ceramide-1-phosphate in calcium homeostasis.During the last several years, sphingolipids have been identified as a source of important signaling molecules.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12789",
    "Sentence": "The role of sphingosine-1-phosphate and <\\entity><\\entity> in calcium homeostasis.During the last several years, sphingolipids have been identified as a source of important signaling molecules.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12790",
    "Sentence": "The role of sphingosine-1-phosphate and <\\entity><\\entity> in calcium homeostasis.During the last several years, sphingolipids have been identified as a source of important signaling molecules.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12791",
    "Sentence": "The role of sphingosine-1-phosphate and ceramide-1-phosphate in <\\entity><\\entity> homeostasis.During the last several years, sphingolipids have been identified as a source of important signaling molecules.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12792",
    "Sentence": "The role of sphingosine-1-phosphate and ceramide-1-phosphate in calcium homeostasis.During the last several years, <\\entity><\\entity> have been identified as a source of important signaling molecules.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12793",
    "Sentence": "The role of sphingosine-1-phosphate and ceramide-1-phosphate in calcium homeostasis.During the last several years, <\\entity><\\entity> have been identified as a source of important signaling molecules.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12794",
    "Sentence": "Particularly, the understanding of the distinct biological roles of <\\entity><\\entity>, sphingosine-1-phosphate (S1P), <\\entity><\\entity>-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12795",
    "Sentence": "Particularly, the understanding of the distinct biological roles of <\\entity><\\entity>, sphingosine-1-phosphate (S1P), <\\entity><\\entity>-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12796",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, <\\entity><\\entity> (S1P), ceramide-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12797",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, <\\entity><\\entity> (S1P), ceramide-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12798",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (<\\entity><\\entity>), ceramide-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12799",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (<\\entity><\\entity>), ceramide-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12800",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), <\\entity><\\entity> (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12801",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), <\\entity><\\entity> (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12802",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), ceramide-1-phosphate (<\\entity><\\entity>) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12803",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), ceramide-1-phosphate (<\\entity><\\entity>) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12804",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P) and <\\entity><\\entity> in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12805",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P) and <\\entity><\\entity> in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12806",
    "Sentence": "Additional studies have elucidated the biological roles of <\\entity><\\entity> in maintaining a homeostatic environment in cells, as well as in regulating numerous cellular responses to environmental stimuli.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12807",
    "Sentence": "Additional studies have elucidated the biological roles of <\\entity><\\entity> in maintaining a homeostatic environment in cells, as well as in regulating numerous cellular responses to environmental stimuli.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12808",
    "Sentence": "This review focuses on the role of <\\entity><\\entity> and C1P in maintaining Ca2+ homeostasis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12809",
    "Sentence": "This review focuses on the role of <\\entity><\\entity> and C1P in maintaining Ca2+ homeostasis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12810",
    "Sentence": "This review focuses on the role of S1P and <\\entity><\\entity> in maintaining Ca2+ homeostasis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12811",
    "Sentence": "This review focuses on the role of S1P and <\\entity><\\entity> in maintaining Ca2+ homeostasis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12812",
    "Sentence": "This review focuses on the role of S1P and C1P in maintaining <\\entity><\\entity> homeostasis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12813",
    "Sentence": "By studying changes in the metabolism of <\\entity><\\entity> and C1P in pathological conditions, it is hoped that altered sphingolipid-metabolizing enzymes and their metabolites can be used as therapeutic targets.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12814",
    "Sentence": "By studying changes in the metabolism of <\\entity><\\entity> and C1P in pathological conditions, it is hoped that altered sphingolipid-metabolizing enzymes and their metabolites can be used as therapeutic targets.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12815",
    "Sentence": "By studying changes in the metabolism of S1P and <\\entity><\\entity> in pathological conditions, it is hoped that altered sphingolipid-metabolizing enzymes and their metabolites can be used as therapeutic targets.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12816",
    "Sentence": "By studying changes in the metabolism of S1P and <\\entity><\\entity> in pathological conditions, it is hoped that altered sphingolipid-metabolizing enzymes and their metabolites can be used as therapeutic targets.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12817",
    "Sentence": "By studying changes in the metabolism of S1P and C1P in pathological conditions, it is hoped that altered <\\entity><\\entity> and their metabolites can be used as therapeutic targets.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12818",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, <\\entity><\\entity> (S1P), ceramide-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": ""
  },
  {
    "id": "12819",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, <\\entity><\\entity>, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": ""
  },
  {
    "id": "12821",
    "Sentence": "Particularly, the understanding of the distinct biological roles of <\\entity><\\entity>, sphingosine-1-phosphate (S1P), <\\entity><\\entity>-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": ""
  },
  {
    "id": "12822",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, <\\entity><\\entity>, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": ""
  },
  {
    "id": "12824",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (<\\entity><\\entity>), ceramide-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": ""
  },
  {
    "id": "12825",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, <\\entity><\\entity>, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": ""
  },
  {
    "id": "12827",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), <\\entity><\\entity> (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": ""
  },
  {
    "id": "12828",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, <\\entity><\\entity>, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": ""
  },
  {
    "id": "12830",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), ceramide-1-phosphate (<\\entity><\\entity>) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": ""
  },
  {
    "id": "12831",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, <\\entity><\\entity>, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": ""
  },
  {
    "id": "12833",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P) and <\\entity><\\entity> in the regulation of cell growth, death, senescence, adhesion, migration, inflammation, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": ""
  },
  {
    "id": "12834",
    "Sentence": "Particularly, the understanding of the distinct biological roles of ceramide, sphingosine-1-phosphate (S1P), ceramide-1-phosphate (C1P) and lyso-sphingomyelin in the regulation of cell growth, death, senescence, adhesion, migration, <\\entity><\\entity>, angiogenesis and intracellular trafficking has rapidly expanded.",
    "Label": ""
  },
  {
    "id": "12836",
    "Sentence": "This review focuses on the role of S1P and C1P in maintaining <\\entity><\\entity> homeostasis.",
    "Label": ""
  },
  {
    "id": "12837",
    "Sentence": "This review focuses on the role of <\\entity><\\entity> and C1P in maintaining Ca2+ homeostasis.",
    "Label": ""
  },
  {
    "id": "12839",
    "Sentence": "This review focuses on the role of S1P and C1P in maintaining <\\entity><\\entity> homeostasis.",
    "Label": ""
  },
  {
    "id": "12840",
    "Sentence": "This review focuses on the role of S1P and <\\entity><\\entity> in maintaining Ca2+ homeostasis.",
    "Label": ""
  },
  {
    "id": "12846",
    "Sentence": "<\\entity><\\entity> combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12847",
    "Sentence": "High-dose methotrexate combined with <\\entity><\\entity> and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with <\\entity><\\entity> and CCNU.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12848",
    "Sentence": "High-dose methotrexate combined with procarbazine and <\\entity><\\entity> for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12849",
    "Sentence": "High-dose methotrexate combined with procarbazine and CCNU for <\\entity><\\entity> in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12850",
    "Sentence": "High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with <\\entity><\\entity> (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12851",
    "Sentence": "High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (<\\entity><\\entity>), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12852",
    "Sentence": "High-dose <\\entity><\\entity> combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose <\\entity><\\entity> (MTX) combined with procarbazine and CCNU.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12853",
    "Sentence": "High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (<\\entity><\\entity>) combined with procarbazine and CCNU.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12854",
    "Sentence": "High-dose methotrexate combined with <\\entity><\\entity> and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with <\\entity><\\entity> and CCNU.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12855",
    "Sentence": "High-dose methotrexate combined with procarbazine and <\\entity><\\entity> for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12856",
    "Sentence": "To reduce <\\entity><\\entity>, whole-brain irradiation was reserved for patients not responding to chemotherapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12857",
    "Sentence": "To reduce neurotoxicity, whole-brain irradiation was reserved for patients not responding to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12858",
    "Sentence": "PATIENTS AND METHODS: <\\entity><\\entity> was applied on days 1, 15, and 30, procarbazine on days 1-10, and CCNU on day 1.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12859",
    "Sentence": "PATIENTS AND METHODS: High-dose MTX was applied on days 1, 15, and 30, <\\entity><\\entity> on days 1-10, and CCNU on day 1.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12860",
    "Sentence": "PATIENTS AND METHODS: High-dose MTX was applied on days 1, 15, and 30, procarbazine on days 1-10, and <\\entity><\\entity> on day 1.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12861",
    "Sentence": "RESULTS: Thirty patients with <\\entity><\\entity> (n = 29) or primary ocular lymphoma (n = 1) were included (median age 70 years, range 57-79 years).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12862",
    "Sentence": "RESULTS: Thirty patients with PCNSL (n = 29) or <\\entity><\\entity> (n = 1) were included (median age 70 years, range 57-79 years).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12863",
    "Sentence": "<\\entity><\\entity> documented response in 27 assessable patients were 12 of 27 (44.4%) complete remissions, 7 of 27 (25.9%) partial remissions, and 8 of 27 (29.6%) disease progressions.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12864",
    "Sentence": "Best documented response in 27 assessable patients were 12 of 27 (44.4%) complete remissions, 7 of 27 (25.9%) partial remissions, and 8 of 27 (29.6%) <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12865",
    "Sentence": "Eight of 30 patients (26.7%) are currently alive and well, six without <\\entity><\\entity> of leukoencephalopathy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12866",
    "Sentence": "Eight of 30 patients (26.7%) are currently alive and well, six without signs of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12867",
    "Sentence": "CONCLUSION: The combination of <\\entity><\\entity> with procarbazine and CCNU is feasible and effective and results in a low rate of leukoencephalopathy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12868",
    "Sentence": "CONCLUSION: The combination of high-dose MTX with <\\entity><\\entity> and CCNU is feasible and effective and results in a low rate of leukoencephalopathy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12869",
    "Sentence": "CONCLUSION: The combination of high-dose MTX with procarbazine and <\\entity><\\entity> is feasible and effective and results in a low rate of leukoencephalopathy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12870",
    "Sentence": "CONCLUSION: The combination of high-dose MTX with procarbazine and CCNU is feasible and effective and results in a low rate of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12871",
    "Sentence": "Comorbidity and <\\entity><\\entity> remain of concern when treating PCNSL in elderly patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12872",
    "Sentence": "Comorbidity and toxicity remain of concern when treating <\\entity><\\entity> in elderly patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12873",
    "Sentence": "CONCLUSION: The combination of high-dose MTX with <\\entity><\\entity> and CCNU is feasible and effective and results in a low rate of leukoencephalopathy.",
    "Label": ""
  },
  {
    "id": "12874",
    "Sentence": "CONCLUSION: The combination of high-dose MTX with procarbazine and CCNU is feasible and effective and results in a low rate of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12876",
    "Sentence": "CONCLUSION: The combination of high-dose MTX with procarbazine and <\\entity><\\entity> is feasible and effective and results in a low rate of leukoencephalopathy.",
    "Label": ""
  },
  {
    "id": "12877",
    "Sentence": "CONCLUSION: The combination of high-dose MTX with procarbazine and CCNU is feasible and effective and results in a low rate of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12879",
    "Sentence": "CONCLUSION: The combination of <\\entity><\\entity> with procarbazine and CCNU is feasible and effective and results in a low rate of leukoencephalopathy.",
    "Label": ""
  },
  {
    "id": "12880",
    "Sentence": "CONCLUSION: The combination of high-dose MTX with procarbazine and CCNU is feasible and effective and results in a low rate of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12882",
    "Sentence": "High-dose methotrexate combined with procarbazine and <\\entity><\\entity> for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12883",
    "Sentence": "High-dose methotrexate combined with procarbazine and CCNU for <\\entity><\\entity> in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU.",
    "Label": ""
  },
  {
    "id": "12885",
    "Sentence": "<\\entity><\\entity> combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU.",
    "Label": ""
  },
  {
    "id": "12886",
    "Sentence": "High-dose methotrexate combined with procarbazine and CCNU for <\\entity><\\entity> in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU.",
    "Label": ""
  },
  {
    "id": "12888",
    "Sentence": "High-dose methotrexate combined with <\\entity><\\entity> and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with <\\entity><\\entity> and CCNU.",
    "Label": ""
  },
  {
    "id": "12889",
    "Sentence": "High-dose methotrexate combined with procarbazine and CCNU for <\\entity><\\entity> in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU.",
    "Label": ""
  },
  {
    "id": "12891",
    "Sentence": "High-dose methotrexate combined with procarbazine and <\\entity><\\entity> for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12892",
    "Sentence": "High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with <\\entity><\\entity> (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU.",
    "Label": ""
  },
  {
    "id": "12894",
    "Sentence": "High-dose <\\entity><\\entity> combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose <\\entity><\\entity> (MTX) combined with procarbazine and CCNU.",
    "Label": ""
  },
  {
    "id": "12895",
    "Sentence": "High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with <\\entity><\\entity> (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU.",
    "Label": ""
  },
  {
    "id": "12897",
    "Sentence": "High-dose methotrexate combined with <\\entity><\\entity> and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with primary central nervous system lymphoma (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with <\\entity><\\entity> and CCNU.",
    "Label": ""
  },
  {
    "id": "12898",
    "Sentence": "High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.BACKGROUND: To improve survival of elderly patients with <\\entity><\\entity> (PCNSL), we conducted a phase II study with high-dose methotrexate (MTX) combined with procarbazine and CCNU.",
    "Label": ""
  },
  {
    "id": "12900",
    "Sentence": "To reduce neurotoxicity, whole-brain irradiation was reserved for patients not responding to <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "12901",
    "Sentence": "To reduce <\\entity><\\entity>, whole-brain irradiation was reserved for patients not responding to chemotherapy.",
    "Label": ""
  },
  {
    "id": "12907",
    "Sentence": "Understanding <\\entity><\\entity>.The purpose of this review is to describe the clinical features, pathology and molecular biology of <\\entity><\\entity>, which represent a heterogenous group of malignant neoplasms; to propose an anatomical classification of these tumours according to whether they occur in the retina or uvea; and to overview laboratory investigations and highlight factors required for successful biopsy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12908",
    "Sentence": "Understanding <\\entity><\\entity>.The purpose of this review is to describe the clinical features, pathology and molecular biology of <\\entity><\\entity>, which represent a heterogenous group of malignant neoplasms; to propose an anatomical classification of these tumours according to whether they occur in the retina or uvea; and to overview laboratory investigations and highlight factors required for successful biopsy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12909",
    "Sentence": "Understanding intraocular lymphomas.The purpose of this review is to describe the clinical features, pathology and molecular biology of intraocular lymphomas, which represent a heterogenous group of <\\entity><\\entity>; to propose an anatomical classification of these tumours according to whether they occur in the retina or uvea; and to overview laboratory investigations and highlight factors required for successful biopsy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12910",
    "Sentence": "Understanding intraocular lymphomas.The purpose of this review is to describe the clinical features, pathology and molecular biology of intraocular lymphomas, which represent a heterogenous group of malignant neoplasms; to propose an anatomical classification of these <\\entity><\\entity> according to whether they occur in the retina or uvea; and to overview laboratory investigations and highlight factors required for successful biopsy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12911",
    "Sentence": "Recent findings show that <\\entity><\\entity> are high-grade (i.e.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12912",
    "Sentence": "<\\entity><\\entity>), B-cell malignancies and are associated with a poor prognosis, with most patients dying of central nervous system disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12913",
    "Sentence": "aggressive), B-cell <\\entity><\\entity> and are associated with a poor prognosis, with most patients dying of central nervous system disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12914",
    "Sentence": "aggressive), B-cell malignancies and are associated with a poor prognosis, with most patients dying of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12915",
    "Sentence": "Immunophenotyping and <\\entity><\\entity> analyses indicate that these lymphomas are probably derived from early post-germinal centre cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12916",
    "Sentence": "Immunophenotyping and somatic mutation analyses indicate that these <\\entity><\\entity> are probably derived from early post-germinal centre cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12917",
    "Sentence": "<\\entity><\\entity> are typically low-grade (i.e.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12918",
    "Sentence": "Primary <\\entity><\\entity> lymphomas are typically low-grade (i.e.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12919",
    "Sentence": "indolent), B-cell <\\entity><\\entity> with morphological, immunophenotypical and genotypic features similar to extranodal marginal zone B-cell lymphomas (EMZL) elsewhere in the body.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12920",
    "Sentence": "indolent), B-cell tumours with morphological, immunophenotypical and genotypic features similar to <\\entity><\\entity> (EMZL) elsewhere in the body.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12921",
    "Sentence": "indolent), B-cell tumours with morphological, immunophenotypical and genotypic features similar to extranodal marginal zone B-cell lymphomas (<\\entity><\\entity>) elsewhere in the body.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12922",
    "Sentence": "<\\entity><\\entity> are very rare, with an equal distribution of B- and T-cell types and with a variable clinical course, most patients succumbing to their disease as a result of systemic dissemination.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12923",
    "Sentence": "Primary <\\entity><\\entity> lymphomas are very rare, with an equal distribution of B- and T-cell types and with a variable clinical course, most patients succumbing to their disease as a result of systemic dissemination.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12924",
    "Sentence": "Primary iridal lymphomas are very rare, with an equal distribution of B- and T-cell types and with a variable clinical course, most patients succumbing to their <\\entity><\\entity> as a result of systemic dissemination.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12925",
    "Sentence": "<\\entity><\\entity> limited to the ciliary body are exceptionally rare.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12926",
    "Sentence": "Primary lymphomas limited to the <\\entity><\\entity> body are exceptionally rare.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12927",
    "Sentence": "<\\entity><\\entity>/leukaemias occur in patients with advanced systemic lymphoma or leukaemia, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12928",
    "Sentence": "Secondary uveal lymphomas/<\\entity><\\entity> occur in patients with advanced systemic lymphoma or leukaemia, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12929",
    "Sentence": "Secondary uveal lymphomas/leukaemias occur in patients with advanced <\\entity><\\entity> or leukaemia, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12930",
    "Sentence": "Secondary uveal lymphomas/<\\entity><\\entity>s occur in patients with advanced systemic lymphoma or <\\entity><\\entity>, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12931",
    "Sentence": "In summary, the term <\\entity><\\entity> (PIOL)' is imprecise.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12932",
    "Sentence": "In summary, the term 'primary intraocular lymphoma (<\\entity><\\entity>)' is imprecise.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12933",
    "Sentence": "It would be preferable to refer to the various forms of <\\entity><\\entity> according to whether they are retinal, choroidal, ciliary or iridal and whether they are primary or secondary in these locations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12934",
    "Sentence": "It would be preferable to refer to the various forms of intraocular lymphoma according to whether they are <\\entity><\\entity>, choroidal, ciliary or iridal and whether they are primary or secondary in these locations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12935",
    "Sentence": "It would be preferable to refer to the various forms of intraocular lymphoma according to whether they are retinal, <\\entity><\\entity>, ciliary or iridal and whether they are primary or secondary in these locations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12936",
    "Sentence": "It would be preferable to refer to the various forms of intraocular lymphoma according to whether they are retinal, choroidal, <\\entity><\\entity> or iridal and whether they are primary or secondary in these locations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12937",
    "Sentence": "It would be preferable to refer to the various forms of intraocular lymphoma according to whether they are retinal, choroidal, ciliary or <\\entity><\\entity> and whether they are primary or secondary in these locations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12938",
    "Sentence": "It would be preferable to refer to the various forms of intraocular lymphoma according to whether they are retinal, choroidal, ciliary or iridal and whether they are primary or <\\entity><\\entity> in these locations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12943",
    "Sentence": "A critical role for <\\entity><\\entity> in the aggresome pathway.Recent evidence suggests that aggresome formation is a physiologic stress response not limited to misfolded proteins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12944",
    "Sentence": "That stress response, termed \"physiologic aggresome,\" is exemplified by aggresome formation of <\\entity><\\entity> (iNOS), an important host defense protein.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12945",
    "Sentence": "That stress response, termed \"physiologic aggresome,\" is exemplified by aggresome formation of inducible <\\entity><\\entity> synthase (iNOS), an important host defense protein.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12946",
    "Sentence": "That stress response, termed \"physiologic aggresome,\" is exemplified by aggresome formation of inducible nitric oxide synthase (<\\entity><\\entity>), an important host defense protein.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12947",
    "Sentence": "<\\entity><\\entity> (carboxy terminus of Hsp70-interacting protein) is a highly conserved protein that has been shown to mediate substrate ubiquitination and degradation by the proteasome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12948",
    "Sentence": "CHIP (<\\entity><\\entity>) is a highly conserved protein that has been shown to mediate substrate ubiquitination and degradation by the proteasome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12949",
    "Sentence": "In this study, we show that <\\entity><\\entity> has a previously unexpected critical role in the aggresome pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12950",
    "Sentence": "<\\entity><\\entity> interacts with iNOS and promotes its ubiquitination and degradation by the proteasome as well as its sequestration to the aggresome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12951",
    "Sentence": "CHIP interacts with <\\entity><\\entity> and promotes its ubiquitination and degradation by the proteasome as well as its sequestration to the aggresome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12952",
    "Sentence": "<\\entity><\\entity>-mediated iNOS targeting to the proteasome sequentially precedes <\\entity><\\entity>-mediated iNOS sequestration to the aggresome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12953",
    "Sentence": "CHIP-mediated <\\entity><\\entity> targeting to the proteasome sequentially precedes CHIP-mediated <\\entity><\\entity> sequestration to the aggresome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12954",
    "Sentence": "<\\entity><\\entity>-mediated iNOS targeting to the proteasome sequentially precedes <\\entity><\\entity>-mediated iNOS sequestration to the aggresome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12955",
    "Sentence": "CHIP-mediated <\\entity><\\entity> targeting to the proteasome sequentially precedes CHIP-mediated <\\entity><\\entity> sequestration to the aggresome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12956",
    "Sentence": "<\\entity><\\entity> is required for iNOS preaggresome structures to form a mature aggresome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12957",
    "Sentence": "CHIP is required for <\\entity><\\entity> preaggresome structures to form a mature aggresome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12958",
    "Sentence": "Furthermore, <\\entity><\\entity> is required for targeting the mutant form of cystic fibrosis transconductance regulator (CFTRDeltaF508) to the aggresome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12959",
    "Sentence": "Furthermore, CHIP is required for targeting the mutant form of <\\entity><\\entity> (CFTRDeltaF508) to the aggresome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12960",
    "Sentence": "Furthermore, CHIP is required for targeting the mutant form of cystic fibrosis transconductance regulator (<\\entity><\\entity>) to the aggresome.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "12961",
    "Sentence": "Importantly, the <\\entity><\\entity> function of CHIP is required in targeting preaggresomal structures to the aggresome by promoting an iNOS interaction with histone deacetylase 6, which serves as an adaptor between ubiquitinated proteins and the dynein motor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12962",
    "Sentence": "Importantly, the ubiquitin ligase function of <\\entity><\\entity> is required in targeting preaggresomal structures to the aggresome by promoting an iNOS interaction with histone deacetylase 6, which serves as an adaptor between ubiquitinated proteins and the dynein motor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12963",
    "Sentence": "Importantly, the ubiquitin ligase function of CHIP is required in targeting preaggresomal structures to the aggresome by promoting an <\\entity><\\entity> interaction with histone deacetylase 6, which serves as an adaptor between ubiquitinated proteins and the dynein motor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12964",
    "Sentence": "Importantly, the ubiquitin ligase function of CHIP is required in targeting preaggresomal structures to the aggresome by promoting an iNOS interaction with <\\entity><\\entity>, which serves as an adaptor between ubiquitinated proteins and the dynein motor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12965",
    "Sentence": "Importantly, the ubiquitin ligase function of CHIP is required in targeting preaggresomal structures to the aggresome by promoting an iNOS interaction with histone deacetylase 6, which serves as an adaptor between ubiquitinated proteins and the <\\entity><\\entity> motor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12966",
    "Sentence": "This study reveals a critical role for <\\entity><\\entity> in the aggresome pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "12971",
    "Sentence": "Identification of <\\entity><\\entity> evolution patterns by means of inductive logic programming.In considering key events of genomic disorders in the development and progression of cancer, the correlation between genomic instability and carcinogenesis is currently under investigation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12972",
    "Sentence": "Identification of tumor evolution patterns by means of inductive logic programming.In considering key events of <\\entity><\\entity> in the development and progression of cancer, the correlation between genomic instability and carcinogenesis is currently under investigation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12973",
    "Sentence": "Identification of tumor evolution patterns by means of inductive logic programming.In considering key events of genomic disorders in the development and progression of <\\entity><\\entity>, the correlation between genomic instability and carcinogenesis is currently under investigation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12974",
    "Sentence": "Identification of tumor evolution patterns by means of inductive logic programming.In considering key events of genomic disorders in the development and progression of cancer, the correlation between <\\entity><\\entity> and carcinogenesis is currently under investigation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12975",
    "Sentence": "Identification of tumor evolution patterns by means of inductive logic programming.In considering key events of genomic disorders in the development and progression of cancer, the correlation between genomic instability and <\\entity><\\entity> is currently under investigation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12976",
    "Sentence": "In this work, we propose an inductive logic programming approach to the problem of modeling evolution patterns for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12977",
    "Sentence": "Using this approach, it is possible to extract fingerprints of stages of the <\\entity><\\entity> that can be used in order to develop and deliver the most adequate therapies to patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12978",
    "Sentence": "Furthermore, such a model can help physicians and biologists in the elucidation of molecular dynamics underlying the aberrations-waterfall model behind <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12983",
    "Sentence": "Effects of <\\entity><\\entity> versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of <\\entity><\\entity>, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12984",
    "Sentence": "Effects of febuxostat versus <\\entity><\\entity> and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, <\\entity><\\entity>, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12985",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with <\\entity><\\entity> and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with <\\entity><\\entity> and gout, including persons with impaired renal function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12986",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and <\\entity><\\entity>: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and <\\entity><\\entity>, including persons with impaired renal function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12987",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-<\\entity><\\entity>, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12988",
    "Sentence": "Effects of <\\entity><\\entity> versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of <\\entity><\\entity>, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12989",
    "Sentence": "Effects of febuxostat versus <\\entity><\\entity> and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, <\\entity><\\entity>, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12990",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with <\\entity><\\entity> and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with <\\entity><\\entity> and gout, including persons with impaired renal function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12991",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and <\\entity><\\entity>: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and <\\entity><\\entity>, including persons with impaired renal function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12992",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12993",
    "Sentence": "METHODS: Subjects (n = 1,072) with <\\entity><\\entity> (serum urate level > or = 8.0 mg/dl) and gout with normal or impaired (serum creatinine level >1.5 to < or = 2.0 mg/dl) renal function were randomized to receive once-daily febuxostat (80 mg, 120 mg, or 240 mg), allopurinol (300 or 100 mg, based on renal function), or placebo for 28 weeks.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12994",
    "Sentence": "METHODS: Subjects (n = 1,072) with hyperuricemia (serum urate level > or = 8.0 mg/dl) and <\\entity><\\entity> with normal or impaired (serum creatinine level >1.5 to < or = 2.0 mg/dl) renal function were randomized to receive once-daily febuxostat (80 mg, 120 mg, or 240 mg), allopurinol (300 or 100 mg, based on renal function), or placebo for 28 weeks.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "12995",
    "Sentence": "METHODS: Subjects (n = 1,072) with hyperuricemia (serum urate level > or = 8.0 mg/dl) and gout with normal or impaired (serum creatinine level >1.5 to < or = 2.0 mg/dl) renal function were randomized to receive once-daily <\\entity><\\entity> (80 mg, 120 mg, or 240 mg), allopurinol (300 or 100 mg, based on renal function), or placebo for 28 weeks.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12996",
    "Sentence": "METHODS: Subjects (n = 1,072) with hyperuricemia (serum urate level > or = 8.0 mg/dl) and gout with normal or impaired (serum creatinine level >1.5 to < or = 2.0 mg/dl) renal function were randomized to receive once-daily febuxostat (80 mg, 120 mg, or 240 mg), <\\entity><\\entity> (300 or 100 mg, based on renal function), or placebo for 28 weeks.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12997",
    "Sentence": "RESULTS: Significantly (P < or = 0.05) higher percentages of subjects treated with <\\entity><\\entity> 80 mg (48%), 120 mg (65%), and 240 mg (69%) attained the primary end point of last 3 monthly serum urate levels <6.0 mg/dl compared with allopurinol (22%) and placebo (0%).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12998",
    "Sentence": "RESULTS: Significantly (P < or = 0.05) higher percentages of subjects treated with febuxostat 80 mg (48%), 120 mg (65%), and 240 mg (69%) attained the primary end point of last 3 monthly serum urate levels <6.0 mg/dl compared with <\\entity><\\entity> (22%) and placebo (0%).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "12999",
    "Sentence": "A significantly (P < 0.05) higher percentage of subjects with <\\entity><\\entity> treated with febuxostat 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of allopurinol (0 [0%] of 10).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13000",
    "Sentence": "A significantly (P < 0.05) higher percentage of subjects with impaired renal function treated with <\\entity><\\entity> 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of allopurinol (0 [0%] of 10).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13001",
    "Sentence": "A significantly (P < 0.05) higher percentage of subjects with impaired renal function treated with febuxostat 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of <\\entity><\\entity> (0 [0%] of 10).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13002",
    "Sentence": "Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although <\\entity><\\entity> and dizziness were more frequent in the febuxostat 240 mg group.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13003",
    "Sentence": "Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although diarrhea and <\\entity><\\entity> were more frequent in the febuxostat 240 mg group.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13004",
    "Sentence": "Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although diarrhea and dizziness were more frequent in the <\\entity><\\entity> 240 mg group.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13005",
    "Sentence": "The primary reasons for withdrawal were similar across groups except for <\\entity><\\entity>, which were more frequent with febuxostat than with allopurinol.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13006",
    "Sentence": "The primary reasons for withdrawal were similar across groups except for gout flares, which were more frequent with <\\entity><\\entity> than with allopurinol.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13007",
    "Sentence": "The primary reasons for withdrawal were similar across groups except for gout flares, which were more frequent with febuxostat than with <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13008",
    "Sentence": "CONCLUSION: At all doses studied, <\\entity><\\entity> more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13009",
    "Sentence": "CONCLUSION: At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did <\\entity><\\entity> (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13010",
    "Sentence": "CONCLUSION: At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with <\\entity><\\entity> and gout, including those with mild to moderately impaired renal function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13011",
    "Sentence": "CONCLUSION: At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and <\\entity><\\entity>, including those with mild to moderately impaired renal function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13012",
    "Sentence": "CONCLUSION: At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13013",
    "Sentence": "A significantly (P < 0.05) higher percentage of subjects with impaired renal function treated with <\\entity><\\entity> 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of allopurinol (0 [0%] of 10).",
    "Label": ""
  },
  {
    "id": "13014",
    "Sentence": "A significantly (P < 0.05) higher percentage of subjects with <\\entity><\\entity> treated with febuxostat 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of allopurinol (0 [0%] of 10).",
    "Label": ""
  },
  {
    "id": "13016",
    "Sentence": "A significantly (P < 0.05) higher percentage of subjects with impaired renal function treated with febuxostat 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of <\\entity><\\entity> (0 [0%] of 10).",
    "Label": ""
  },
  {
    "id": "13017",
    "Sentence": "A significantly (P < 0.05) higher percentage of subjects with <\\entity><\\entity> treated with febuxostat 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of allopurinol (0 [0%] of 10).",
    "Label": ""
  },
  {
    "id": "13019",
    "Sentence": "Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although diarrhea and dizziness were more frequent in the <\\entity><\\entity> 240 mg group.",
    "Label": ""
  },
  {
    "id": "13020",
    "Sentence": "Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although <\\entity><\\entity> and dizziness were more frequent in the febuxostat 240 mg group.",
    "Label": ""
  },
  {
    "id": "13022",
    "Sentence": "Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although diarrhea and dizziness were more frequent in the <\\entity><\\entity> 240 mg group.",
    "Label": ""
  },
  {
    "id": "13023",
    "Sentence": "Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although diarrhea and <\\entity><\\entity> were more frequent in the febuxostat 240 mg group.",
    "Label": ""
  },
  {
    "id": "13025",
    "Sentence": "The primary reasons for withdrawal were similar across groups except for gout flares, which were more frequent with <\\entity><\\entity> than with allopurinol.",
    "Label": ""
  },
  {
    "id": "13026",
    "Sentence": "The primary reasons for withdrawal were similar across groups except for <\\entity><\\entity>, which were more frequent with febuxostat than with allopurinol.",
    "Label": ""
  },
  {
    "id": "13028",
    "Sentence": "CONCLUSION: At all doses studied, <\\entity><\\entity> more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.",
    "Label": ""
  },
  {
    "id": "13029",
    "Sentence": "CONCLUSION: At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with <\\entity><\\entity> and gout, including those with mild to moderately impaired renal function.",
    "Label": ""
  },
  {
    "id": "13031",
    "Sentence": "CONCLUSION: At all doses studied, <\\entity><\\entity> more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.",
    "Label": ""
  },
  {
    "id": "13032",
    "Sentence": "CONCLUSION: At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and <\\entity><\\entity>, including those with mild to moderately impaired renal function.",
    "Label": ""
  },
  {
    "id": "13034",
    "Sentence": "CONCLUSION: At all doses studied, <\\entity><\\entity> more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.",
    "Label": ""
  },
  {
    "id": "13035",
    "Sentence": "CONCLUSION: At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13037",
    "Sentence": "The primary reasons for withdrawal were similar across groups except for gout flares, which were more frequent with febuxostat than with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13038",
    "Sentence": "The primary reasons for withdrawal were similar across groups except for <\\entity><\\entity>, which were more frequent with febuxostat than with allopurinol.",
    "Label": ""
  },
  {
    "id": "13040",
    "Sentence": "CONCLUSION: At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did <\\entity><\\entity> (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.",
    "Label": ""
  },
  {
    "id": "13041",
    "Sentence": "CONCLUSION: At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with <\\entity><\\entity> and gout, including those with mild to moderately impaired renal function.",
    "Label": ""
  },
  {
    "id": "13043",
    "Sentence": "CONCLUSION: At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did <\\entity><\\entity> (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.",
    "Label": ""
  },
  {
    "id": "13044",
    "Sentence": "CONCLUSION: At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and <\\entity><\\entity>, including those with mild to moderately impaired renal function.",
    "Label": ""
  },
  {
    "id": "13046",
    "Sentence": "Effects of <\\entity><\\entity> versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of <\\entity><\\entity>, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13047",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with <\\entity><\\entity> and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with <\\entity><\\entity> and gout, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13049",
    "Sentence": "Effects of <\\entity><\\entity> versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of <\\entity><\\entity>, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13050",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and <\\entity><\\entity>: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and <\\entity><\\entity>, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13052",
    "Sentence": "Effects of febuxostat versus <\\entity><\\entity> and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, <\\entity><\\entity>, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13053",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with <\\entity><\\entity> and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with <\\entity><\\entity> and gout, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13055",
    "Sentence": "Effects of febuxostat versus <\\entity><\\entity> and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, <\\entity><\\entity>, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13056",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and <\\entity><\\entity>: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and <\\entity><\\entity>, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13058",
    "Sentence": "Effects of <\\entity><\\entity> versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of <\\entity><\\entity>, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13059",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with <\\entity><\\entity> and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with <\\entity><\\entity> and gout, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13061",
    "Sentence": "Effects of <\\entity><\\entity> versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of <\\entity><\\entity>, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13062",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and <\\entity><\\entity>: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and <\\entity><\\entity>, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13064",
    "Sentence": "Effects of <\\entity><\\entity> versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of <\\entity><\\entity>, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13065",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13067",
    "Sentence": "Effects of febuxostat versus <\\entity><\\entity> and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, <\\entity><\\entity>, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13068",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with <\\entity><\\entity> and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with <\\entity><\\entity> and gout, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13070",
    "Sentence": "Effects of febuxostat versus <\\entity><\\entity> and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, <\\entity><\\entity>, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13071",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and <\\entity><\\entity>: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and <\\entity><\\entity>, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13073",
    "Sentence": "Effects of febuxostat versus <\\entity><\\entity> and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, <\\entity><\\entity>, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function.",
    "Label": ""
  },
  {
    "id": "13074",
    "Sentence": "Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13076",
    "Sentence": "METHODS: Subjects (n = 1,072) with hyperuricemia (serum urate level > or = 8.0 mg/dl) and gout with normal or impaired (serum creatinine level >1.5 to < or = 2.0 mg/dl) renal function were randomized to receive once-daily <\\entity><\\entity> (80 mg, 120 mg, or 240 mg), allopurinol (300 or 100 mg, based on renal function), or placebo for 28 weeks.",
    "Label": ""
  },
  {
    "id": "13077",
    "Sentence": "METHODS: Subjects (n = 1,072) with <\\entity><\\entity> (serum urate level > or = 8.0 mg/dl) and gout with normal or impaired (serum creatinine level >1.5 to < or = 2.0 mg/dl) renal function were randomized to receive once-daily febuxostat (80 mg, 120 mg, or 240 mg), allopurinol (300 or 100 mg, based on renal function), or placebo for 28 weeks.",
    "Label": ""
  },
  {
    "id": "13079",
    "Sentence": "METHODS: Subjects (n = 1,072) with hyperuricemia (serum urate level > or = 8.0 mg/dl) and gout with normal or impaired (serum creatinine level >1.5 to < or = 2.0 mg/dl) renal function were randomized to receive once-daily <\\entity><\\entity> (80 mg, 120 mg, or 240 mg), allopurinol (300 or 100 mg, based on renal function), or placebo for 28 weeks.",
    "Label": ""
  },
  {
    "id": "13080",
    "Sentence": "METHODS: Subjects (n = 1,072) with hyperuricemia (serum urate level > or = 8.0 mg/dl) and <\\entity><\\entity> with normal or impaired (serum creatinine level >1.5 to < or = 2.0 mg/dl) renal function were randomized to receive once-daily febuxostat (80 mg, 120 mg, or 240 mg), allopurinol (300 or 100 mg, based on renal function), or placebo for 28 weeks.",
    "Label": ""
  },
  {
    "id": "13082",
    "Sentence": "METHODS: Subjects (n = 1,072) with hyperuricemia (serum urate level > or = 8.0 mg/dl) and gout with normal or impaired (serum creatinine level >1.5 to < or = 2.0 mg/dl) renal function were randomized to receive once-daily febuxostat (80 mg, 120 mg, or 240 mg), <\\entity><\\entity> (300 or 100 mg, based on renal function), or placebo for 28 weeks.",
    "Label": ""
  },
  {
    "id": "13083",
    "Sentence": "METHODS: Subjects (n = 1,072) with <\\entity><\\entity> (serum urate level > or = 8.0 mg/dl) and gout with normal or impaired (serum creatinine level >1.5 to < or = 2.0 mg/dl) renal function were randomized to receive once-daily febuxostat (80 mg, 120 mg, or 240 mg), allopurinol (300 or 100 mg, based on renal function), or placebo for 28 weeks.",
    "Label": ""
  },
  {
    "id": "13085",
    "Sentence": "METHODS: Subjects (n = 1,072) with hyperuricemia (serum urate level > or = 8.0 mg/dl) and gout with normal or impaired (serum creatinine level >1.5 to < or = 2.0 mg/dl) renal function were randomized to receive once-daily febuxostat (80 mg, 120 mg, or 240 mg), <\\entity><\\entity> (300 or 100 mg, based on renal function), or placebo for 28 weeks.",
    "Label": ""
  },
  {
    "id": "13086",
    "Sentence": "METHODS: Subjects (n = 1,072) with hyperuricemia (serum urate level > or = 8.0 mg/dl) and <\\entity><\\entity> with normal or impaired (serum creatinine level >1.5 to < or = 2.0 mg/dl) renal function were randomized to receive once-daily febuxostat (80 mg, 120 mg, or 240 mg), allopurinol (300 or 100 mg, based on renal function), or placebo for 28 weeks.",
    "Label": ""
  },
  {
    "id": "13088",
    "Sentence": "CONCLUSION: At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did <\\entity><\\entity> (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.",
    "Label": ""
  },
  {
    "id": "13089",
    "Sentence": "CONCLUSION: At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13095",
    "Sentence": "<\\entity><\\entity>: update on classification and treatment.A significant proportion of patients with depressive disorders suffer from chronic conditions.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13096",
    "Sentence": "Chronic depression: update on classification and treatment.A significant proportion of patients with <\\entity><\\entity> suffer from chronic conditions.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13097",
    "Sentence": "Chronic depression: update on classification and treatment.A significant proportion of patients with depressive disorders <\\entity><\\entity> from chronic conditions.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13098",
    "Sentence": "The DSM-IV recognizes several forms of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13099",
    "Sentence": "<\\entity><\\entity> differ from nonchronic major depressive disorder (MDD) on many clinical, psychosocial, and familial variables.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13100",
    "Sentence": "Chronic depressions differ from nonchronic <\\entity><\\entity> (MDD) on many clinical, psychosocial, and familial variables.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13101",
    "Sentence": "Chronic depressions differ from nonchronic major depressive disorder (<\\entity><\\entity>) on many clinical, psychosocial, and familial variables.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13102",
    "Sentence": "However, less support exists for current distinctions between the various forms of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13103",
    "Sentence": "<\\entity><\\entity> medications and at least some forms of psychotherapy are efficacious in treating chronic depression, and the combination of pharmacotherapy and psychotherapy appears to be superior to either monotherapy alone.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13104",
    "Sentence": "Antidepressant medications and at least some forms of psychotherapy are efficacious in treating <\\entity><\\entity>, and the combination of pharmacotherapy and psychotherapy appears to be superior to either monotherapy alone.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13105",
    "Sentence": "<\\entity><\\entity>, chronic depression is often inadequately treated, and many patients fail to respond or continue to experience residual symptoms after treatment.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13106",
    "Sentence": "Still, <\\entity><\\entity> is often inadequately treated, and many patients fail to respond or continue to experience residual symptoms after treatment.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13107",
    "Sentence": "Still, chronic depression is often inadequately treated, and many patients fail to respond or continue to experience residual <\\entity><\\entity> after treatment.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13108",
    "Sentence": "An important direction for future research is to elucidate the multiple pathways to <\\entity><\\entity> and to tailor treatments to specific etiopathogenetic subgroups.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13109",
    "Sentence": "<\\entity><\\entity> medications and at least some forms of psychotherapy are efficacious in treating chronic depression, and the combination of pharmacotherapy and psychotherapy appears to be superior to either monotherapy alone.",
    "Label": ""
  },
  {
    "id": "13110",
    "Sentence": "Antidepressant medications and at least some forms of psychotherapy are efficacious in treating <\\entity><\\entity>, and the combination of pharmacotherapy and psychotherapy appears to be superior to either monotherapy alone.",
    "Label": ""
  },
  {
    "id": "13116",
    "Sentence": "Immune control of an <\\entity><\\entity> challenge by a T-cell-based vaccine in rhesus monkeys.A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13117",
    "Sentence": "Immune control of an <\\entity><\\entity> challenge by a T-cell-based vaccine in rhesus monkeys.A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13118",
    "Sentence": "Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.A recombinant <\\entity><\\entity> serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13119",
    "Sentence": "Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.A recombinant <\\entity><\\entity> serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13120",
    "Sentence": "Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.A recombinant adenovirus serotype 5 (<\\entity><\\entity>) vector-based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13121",
    "Sentence": "Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for <\\entity><\\entity> has recently failed in a phase 2b efficacy study in humans.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13122",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that <\\entity><\\entity> vectors expressing simian immunodeficiency virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13123",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian <\\entity><\\entity> virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13124",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency <\\entity><\\entity> (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13125",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (<\\entity><\\entity>) Gag failed to reduce peak or setpoint viral loads after <\\entity><\\entity> challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13126",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (<\\entity><\\entity>) Gag failed to reduce peak or setpoint viral loads after <\\entity><\\entity> challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13127",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (<\\entity><\\entity>) Gag failed to reduce peak or setpoint viral loads after <\\entity><\\entity> challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13128",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (<\\entity><\\entity>) Gag failed to reduce peak or setpoint viral loads after <\\entity><\\entity> challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13129",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective <\\entity><\\entity> (ref.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13130",
    "Sentence": "Here we show that an improved T-cell-based vaccine regimen using two serologically distinct <\\entity><\\entity> vectors afforded substantially improved protective efficacy in this challenge model.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13131",
    "Sentence": "In particular, a heterologous <\\entity><\\entity> prime/rAd5 boost vaccine regimen expressing SIV Gag elicited cellular immune responses with augmented magnitude, breadth and polyfunctionality as compared with the homologous rAd5 regimen.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13132",
    "Sentence": "In particular, a heterologous rAd26 prime/rAd5 boost vaccine regimen expressing <\\entity><\\entity> Gag elicited cellular immune responses with augmented magnitude, breadth and polyfunctionality as compared with the homologous rAd5 regimen.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13133",
    "Sentence": "In particular, a heterologous rAd26 prime/rAd5 boost vaccine regimen expressing <\\entity><\\entity> Gag elicited cellular immune responses with augmented magnitude, breadth and polyfunctionality as compared with the homologous rAd5 regimen.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13134",
    "Sentence": "In particular, a heterologous rAd26 prime/<\\entity><\\entity> boost vaccine regimen expressing SIV Gag elicited cellular immune responses with augmented magnitude, breadth and polyfunctionality as compared with the homologous <\\entity><\\entity> regimen.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13135",
    "Sentence": "After <\\entity><\\entity>(MAC251) challenge, monkeys vaccinated with the rAd26/rAd5 regimen showed a 1.4 log reduction of peak and a 2.4 log reduction of setpoint viral loads as well as decreased AIDS-related mortality as compared with control animals.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13136",
    "Sentence": "After SIV(<\\entity><\\entity>) challenge, monkeys vaccinated with the rAd26/rAd5 regimen showed a 1.4 log reduction of peak and a 2.4 log reduction of setpoint viral loads as well as decreased AIDS-related mortality as compared with control animals.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13137",
    "Sentence": "After SIV(MAC251) challenge, monkeys vaccinated with the <\\entity><\\entity>/rAd5 regimen showed a 1.4 log reduction of peak and a 2.4 log reduction of setpoint viral loads as well as decreased AIDS-related mortality as compared with control animals.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13138",
    "Sentence": "After SIV(MAC251) challenge, monkeys vaccinated with the rAd26/rAd5 regimen showed a 1.4 log reduction of peak and a 2.4 log reduction of setpoint viral loads as well as decreased <\\entity><\\entity>-related mortality as compared with control animals.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13139",
    "Sentence": "These data demonstrate that durable partial immune control of a pathogenic <\\entity><\\entity> challenge for more than 500 days can be achieved by a T-cell-based vaccine in Mamu-A*01-negative rhesus monkeys in the absence of a homologous Env antigen.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13140",
    "Sentence": "These data demonstrate that durable partial immune control of a pathogenic <\\entity><\\entity> challenge for more than 500 days can be achieved by a T-cell-based vaccine in Mamu-A*01-negative rhesus monkeys in the absence of a homologous Env antigen.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13141",
    "Sentence": "These data demonstrate that durable partial immune control of a pathogenic SIV challenge for more than 500 days can be achieved by a T-cell-based vaccine in Mamu-A*01-negative rhesus monkeys in the <\\entity><\\entity> of a homologous Env antigen.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13142",
    "Sentence": "These findings have important implications for the development of next-generation T-cell-based vaccine candidates for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13143",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (<\\entity><\\entity>) Gag failed to reduce peak or setpoint viral loads after <\\entity><\\entity> challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": ""
  },
  {
    "id": "13144",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian <\\entity><\\entity> virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": ""
  },
  {
    "id": "13146",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (<\\entity><\\entity>) Gag failed to reduce peak or setpoint viral loads after <\\entity><\\entity> challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": ""
  },
  {
    "id": "13147",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency <\\entity><\\entity> (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": ""
  },
  {
    "id": "13149",
    "Sentence": "After SIV(MAC251) challenge, monkeys vaccinated with the <\\entity><\\entity>/rAd5 regimen showed a 1.4 log reduction of peak and a 2.4 log reduction of setpoint viral loads as well as decreased AIDS-related mortality as compared with control animals.",
    "Label": ""
  },
  {
    "id": "13150",
    "Sentence": "After SIV(MAC251) challenge, monkeys vaccinated with the rAd26/rAd5 regimen showed a 1.4 log reduction of peak and a 2.4 log reduction of setpoint viral loads as well as decreased <\\entity><\\entity>-related mortality as compared with control animals.",
    "Label": ""
  },
  {
    "id": "13152",
    "Sentence": "Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.A recombinant adenovirus serotype 5 (<\\entity><\\entity>) vector-based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans.",
    "Label": ""
  },
  {
    "id": "13153",
    "Sentence": "Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for <\\entity><\\entity> has recently failed in a phase 2b efficacy study in humans.",
    "Label": ""
  },
  {
    "id": "13155",
    "Sentence": "Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.A recombinant <\\entity><\\entity> serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans.",
    "Label": ""
  },
  {
    "id": "13156",
    "Sentence": "Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for <\\entity><\\entity> has recently failed in a phase 2b efficacy study in humans.",
    "Label": ""
  },
  {
    "id": "13158",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that <\\entity><\\entity> vectors expressing simian immunodeficiency virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": ""
  },
  {
    "id": "13159",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian <\\entity><\\entity> virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": ""
  },
  {
    "id": "13161",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that <\\entity><\\entity> vectors expressing simian immunodeficiency virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": ""
  },
  {
    "id": "13162",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (<\\entity><\\entity>) Gag failed to reduce peak or setpoint viral loads after <\\entity><\\entity> challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": ""
  },
  {
    "id": "13164",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective <\\entity><\\entity> (ref.",
    "Label": ""
  },
  {
    "id": "13165",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian <\\entity><\\entity> virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": ""
  },
  {
    "id": "13167",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective <\\entity><\\entity> (ref.",
    "Label": ""
  },
  {
    "id": "13168",
    "Sentence": "Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (<\\entity><\\entity>) Gag failed to reduce peak or setpoint viral loads after <\\entity><\\entity> challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref.",
    "Label": ""
  },
  {
    "id": "13170",
    "Sentence": "In particular, a heterologous rAd26 prime/<\\entity><\\entity> boost vaccine regimen expressing SIV Gag elicited cellular immune responses with augmented magnitude, breadth and polyfunctionality as compared with the homologous <\\entity><\\entity> regimen.",
    "Label": ""
  },
  {
    "id": "13171",
    "Sentence": "In particular, a heterologous rAd26 prime/rAd5 boost vaccine regimen expressing <\\entity><\\entity> Gag elicited cellular immune responses with augmented magnitude, breadth and polyfunctionality as compared with the homologous rAd5 regimen.",
    "Label": ""
  },
  {
    "id": "13173",
    "Sentence": "In particular, a heterologous <\\entity><\\entity> prime/rAd5 boost vaccine regimen expressing SIV Gag elicited cellular immune responses with augmented magnitude, breadth and polyfunctionality as compared with the homologous rAd5 regimen.",
    "Label": ""
  },
  {
    "id": "13174",
    "Sentence": "In particular, a heterologous rAd26 prime/rAd5 boost vaccine regimen expressing <\\entity><\\entity> Gag elicited cellular immune responses with augmented magnitude, breadth and polyfunctionality as compared with the homologous rAd5 regimen.",
    "Label": ""
  },
  {
    "id": "13176",
    "Sentence": "After SIV(MAC251) challenge, monkeys vaccinated with the <\\entity><\\entity>/rAd5 regimen showed a 1.4 log reduction of peak and a 2.4 log reduction of setpoint viral loads as well as decreased AIDS-related mortality as compared with control animals.",
    "Label": ""
  },
  {
    "id": "13177",
    "Sentence": "After SIV(<\\entity><\\entity>) challenge, monkeys vaccinated with the rAd26/rAd5 regimen showed a 1.4 log reduction of peak and a 2.4 log reduction of setpoint viral loads as well as decreased AIDS-related mortality as compared with control animals.",
    "Label": ""
  },
  {
    "id": "13179",
    "Sentence": "After SIV(MAC251) challenge, monkeys vaccinated with the <\\entity><\\entity>/rAd5 regimen showed a 1.4 log reduction of peak and a 2.4 log reduction of setpoint viral loads as well as decreased AIDS-related mortality as compared with control animals.",
    "Label": ""
  },
  {
    "id": "13180",
    "Sentence": "After <\\entity><\\entity>(MAC251) challenge, monkeys vaccinated with the rAd26/rAd5 regimen showed a 1.4 log reduction of peak and a 2.4 log reduction of setpoint viral loads as well as decreased AIDS-related mortality as compared with control animals.",
    "Label": ""
  },
  {
    "id": "13186",
    "Sentence": "<\\entity><\\entity> following second unrelated cord blood transplantation for acute myelogenous leukemia.Here we report the case of a 43-year-old Japanese woman with acute myelogenous leukemia who underwent 2 unrelated cord blood transplantations (UCBT), terminating in fatal disseminated tuberculosis (TB).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13187",
    "Sentence": "Disseminated tuberculosis following second unrelated cord blood transplantation for <\\entity><\\entity>.Here we report the case of a 43-year-old Japanese woman with <\\entity><\\entity> who underwent 2 unrelated cord blood transplantations (UCBT), terminating in fatal disseminated tuberculosis (TB).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13188",
    "Sentence": "Disseminated tuberculosis following second unrelated cord blood transplantation for <\\entity><\\entity>.Here we report the case of a 43-year-old Japanese woman with <\\entity><\\entity> who underwent 2 unrelated cord blood transplantations (UCBT), terminating in fatal disseminated tuberculosis (TB).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13189",
    "Sentence": "Disseminated tuberculosis following second unrelated cord blood transplantation for acute myelogenous leukemia.Here we report the case of a 43-year-old Japanese woman with acute myelogenous leukemia who underwent 2 unrelated cord blood transplantations (UCBT), terminating in fatal <\\entity><\\entity> (TB).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13190",
    "Sentence": "Disseminated tuberculosis following second unrelated cord blood transplantation for acute myelogenous leukemia.Here we report the case of a 43-year-old Japanese woman with acute myelogenous leukemia who underwent 2 unrelated cord blood transplantations (UCBT), terminating in fatal disseminated tuberculosis (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13191",
    "Sentence": "The patient did not achieve remission despite intensive <\\entity><\\entity>, and subsequently underwent UCBT with a standard conditioning regimen.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13192",
    "Sentence": "She developed a pre-engraftment <\\entity><\\entity>, which responded well to prednisolone, and engraftment was documented.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13193",
    "Sentence": "She developed a pre-engraftment immune reaction, which responded well to <\\entity><\\entity>, and engraftment was documented.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13194",
    "Sentence": "However, 50 days after the second UCBT, the patient presented with <\\entity><\\entity> and developed pneumonia despite antibiotic and antifungal treatments.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13195",
    "Sentence": "However, 50 days after the second UCBT, the patient presented with high fever and developed <\\entity><\\entity> despite antibiotic and antifungal treatments.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13196",
    "Sentence": "However, 50 days after the second UCBT, the patient presented with high fever and developed pneumonia despite <\\entity><\\entity> and antifungal treatments.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13197",
    "Sentence": "However, 50 days after the second UCBT, the patient presented with high fever and developed pneumonia despite <\\entity><\\entity> and antifungal treatments.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13198",
    "Sentence": "However, 50 days after the second UCBT, the patient presented with high fever and developed pneumonia despite antibiotic and <\\entity><\\entity> treatments.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13199",
    "Sentence": "However, 50 days after the second UCBT, the patient presented with high fever and developed pneumonia despite antibiotic and <\\entity><\\entity> treatments.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13200",
    "Sentence": "Thereafter, <\\entity><\\entity> was detected in blood cultures and specimens of bronchoalveolar lavage, thus indicating disseminated TB.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13201",
    "Sentence": "Thereafter, Mycobacterium tuberculosis was detected in blood cultures and specimens of bronchoalveolar lavage, thus indicating <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13202",
    "Sentence": "Despite <\\entity><\\entity> treatment, she died on day 85.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13203",
    "Sentence": "<\\entity><\\entity> should always be considered as a possible diagnosis when treating febrile immunocompromised patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13204",
    "Sentence": "TB should always be considered as a possible diagnosis when treating <\\entity><\\entity> patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13205",
    "Sentence": "She developed a pre-engraftment immune reaction, which responded well to <\\entity><\\entity>, and engraftment was documented.",
    "Label": ""
  },
  {
    "id": "13206",
    "Sentence": "She developed a pre-engraftment <\\entity><\\entity>, which responded well to prednisolone, and engraftment was documented.",
    "Label": ""
  },
  {
    "id": "13212",
    "Sentence": "Vicarious excretion of <\\entity><\\entity> after endovascular abdominal aortic aneurysm repair.The aim of this study is to describe the finding of vicarious excretion of intravascular contrast media in association with endovascular management of an aortic aneurysm and to discuss the clinical significance.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13213",
    "Sentence": "Vicarious excretion of parenteral contrast material after endovascular <\\entity><\\entity> repair.The aim of this study is to describe the finding of vicarious excretion of intravascular contrast media in association with endovascular management of an aortic aneurysm and to discuss the clinical significance.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13214",
    "Sentence": "Vicarious excretion of parenteral contrast material after endovascular abdominal aortic aneurysm repair.The aim of this study is to describe the finding of vicarious excretion of <\\entity><\\entity> in association with endovascular management of an aortic aneurysm and to discuss the clinical significance.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13215",
    "Sentence": "Vicarious excretion of parenteral contrast material after endovascular abdominal <\\entity><\\entity> repair.The aim of this study is to describe the finding of vicarious excretion of intravascular contrast media in association with endovascular management of an <\\entity><\\entity> and to discuss the clinical significance.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13216",
    "Sentence": "Vicarious excretion of <\\entity><\\entity> through the hepatobiliary system will be encountered occasionally following endovascular procedures.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13217",
    "Sentence": "Vicarious hepatobiliary excretion of parenteral <\\entity><\\entity>, while associated with renal obstruction or parenchymal pathology, is not pathognomonic for renal pathology.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13218",
    "Sentence": "Vicarious hepatobiliary excretion of parenteral contrast media, while associated with <\\entity><\\entity> or parenchymal pathology, is not pathognomonic for renal pathology.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13219",
    "Sentence": "Vicarious hepatobiliary excretion of parenteral contrast media, while associated with renal obstruction or <\\entity><\\entity>, is not pathognomonic for renal pathology.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13220",
    "Sentence": "Vicarious hepatobiliary excretion of parenteral contrast media, while associated with renal obstruction or parenchymal pathology, is not pathognomonic for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13221",
    "Sentence": "Vicarious excretion of parenteral contrast material after endovascular abdominal aortic aneurysm repair.The aim of this study is to describe the finding of vicarious excretion of <\\entity><\\entity> in association with endovascular management of an aortic aneurysm and to discuss the clinical significance.",
    "Label": ""
  },
  {
    "id": "13222",
    "Sentence": "Vicarious excretion of parenteral contrast material after endovascular abdominal <\\entity><\\entity> repair.The aim of this study is to describe the finding of vicarious excretion of intravascular contrast media in association with endovascular management of an <\\entity><\\entity> and to discuss the clinical significance.",
    "Label": ""
  },
  {
    "id": "13224",
    "Sentence": "Vicarious hepatobiliary excretion of parenteral <\\entity><\\entity>, while associated with renal obstruction or parenchymal pathology, is not pathognomonic for renal pathology.",
    "Label": ""
  },
  {
    "id": "13225",
    "Sentence": "Vicarious hepatobiliary excretion of parenteral contrast media, while associated with <\\entity><\\entity> or parenchymal pathology, is not pathognomonic for renal pathology.",
    "Label": ""
  },
  {
    "id": "13227",
    "Sentence": "Vicarious hepatobiliary excretion of parenteral <\\entity><\\entity>, while associated with renal obstruction or parenchymal pathology, is not pathognomonic for renal pathology.",
    "Label": ""
  },
  {
    "id": "13228",
    "Sentence": "Vicarious hepatobiliary excretion of parenteral contrast media, while associated with renal obstruction or parenchymal pathology, is not pathognomonic for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13230",
    "Sentence": "Vicarious hepatobiliary excretion of parenteral <\\entity><\\entity>, while associated with renal obstruction or parenchymal pathology, is not pathognomonic for renal pathology.",
    "Label": ""
  },
  {
    "id": "13231",
    "Sentence": "Vicarious hepatobiliary excretion of parenteral contrast media, while associated with renal obstruction or <\\entity><\\entity>, is not pathognomonic for renal pathology.",
    "Label": ""
  },
  {
    "id": "13237",
    "Sentence": "pylori selectively blocks <\\entity><\\entity> endocytosis via the non-receptor kinase c-Abl and CagA.Helicobacter pylori infection is a primary cause of peptic ulcers and is associated with gastric carcinogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13238",
    "Sentence": "pylori selectively blocks EGFR endocytosis via the <\\entity><\\entity> and CagA.Helicobacter pylori infection is a primary cause of peptic ulcers and is associated with gastric carcinogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13239",
    "Sentence": "pylori selectively blocks EGFR endocytosis via the non-receptor kinase c-Abl and <\\entity><\\entity>.Helicobacter pylori infection is a primary cause of peptic ulcers and is associated with gastric carcinogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13240",
    "Sentence": "pylori-induced pathophysiology may be linked to the deregulation of <\\entity><\\entity> signalling.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13241",
    "Sentence": "Elevated mucosal levels of <\\entity><\\entity> and the <\\entity><\\entity>R have been found in antral gastric biopsies of H.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13242",
    "Sentence": "Elevated mucosal levels of EGF and the <\\entity><\\entity> have been found in antral gastric biopsies of H.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13243",
    "Sentence": "A critical mechanism for regulating <\\entity><\\entity> signalling is ligand-induced endocytosis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13244",
    "Sentence": "pylori blocks <\\entity><\\entity> endocytosis and receptor degradation upon prolonged infection of gastric epithelial cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13245",
    "Sentence": "Moreover, this inhibition occurs via a <\\entity><\\entity>-dependent, but <\\entity><\\entity> phosphorylation-independent activation of the non-receptor kinase c-Abl, which in turn phosphorylates the EGFR target site pY1173.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13246",
    "Sentence": "Moreover, this inhibition occurs via a <\\entity><\\entity>-dependent, but <\\entity><\\entity> phosphorylation-independent activation of the non-receptor kinase c-Abl, which in turn phosphorylates the EGFR target site pY1173.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13247",
    "Sentence": "Moreover, this inhibition occurs via a CagA-dependent, but CagA phosphorylation-independent activation of the <\\entity><\\entity>, which in turn phosphorylates the EGFR target site pY1173.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13248",
    "Sentence": "Moreover, this inhibition occurs via a CagA-dependent, but CagA phosphorylation-independent activation of the non-receptor kinase c-Abl, which in turn phosphorylates the <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13249",
    "Sentence": "This suggests a novel <\\entity><\\entity>-induced host cell response that is independent of <\\entity><\\entity> tyrosine phosphorylation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13250",
    "Sentence": "This suggests a novel <\\entity><\\entity>-induced host cell response that is independent of <\\entity><\\entity> tyrosine phosphorylation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13251",
    "Sentence": "pylori in host cell manipulations by altering selective receptor populations via a <\\entity><\\entity>-dependent endocytic mechanism.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13252",
    "Sentence": "Furthermore, we identified a new role for <\\entity><\\entity> in phosphorylation of the EGFR target site pY1173 during H.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13253",
    "Sentence": "Furthermore, we identified a new role for c-Abl in phosphorylation of the <\\entity><\\entity> during H.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13254",
    "Sentence": "pylori blocks <\\entity><\\entity> endocytosis and receptor degradation upon prolonged infection of gastric epithelial cells.",
    "Label": ""
  },
  {
    "id": "13255",
    "Sentence": "pylori blocks EGFR endocytosis and receptor degradation upon prolonged <\\entity><\\entity> epithelial cells.",
    "Label": ""
  },
  {
    "id": "13257",
    "Sentence": "Furthermore, we identified a new role for c-Abl in phosphorylation of the <\\entity><\\entity> during H.",
    "Label": ""
  },
  {
    "id": "13258",
    "Sentence": "pylori <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13260",
    "Sentence": "Furthermore, we identified a new role for <\\entity><\\entity> in phosphorylation of the EGFR target site pY1173 during H.",
    "Label": ""
  },
  {
    "id": "13261",
    "Sentence": "pylori <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13267",
    "Sentence": "Antitumor activity of <\\entity><\\entity>, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13268",
    "Sentence": "Antitumor activity of F90, an <\\entity><\\entity>, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13269",
    "Sentence": "Antitumor activity of F90, an <\\entity><\\entity>, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13270",
    "Sentence": "Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line <\\entity><\\entity>.BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13271",
    "Sentence": "Antitumor activity of F90, an <\\entity><\\entity> tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of <\\entity><\\entity> (EGFR) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13272",
    "Sentence": "Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (<\\entity><\\entity>) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13273",
    "Sentence": "Forty percent to fifty percent of glioblastoma multiforme (GBM) possess deregulated <\\entity><\\entity>, which may contribute to the aggressive and refractory course of GBM.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13274",
    "Sentence": "Therefore, blockade of <\\entity><\\entity> signal transduction may be a promising treatment strategy for GBM.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13275",
    "Sentence": "METHODS: MTT assay, cell growth curve assay and tumor xenograft model were used to evaluate the antitumor activity of <\\entity><\\entity> against SHG-44 in vitro and in vivo.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13276",
    "Sentence": "METHODS: MTT assay, cell growth curve assay and tumor xenograft model were used to evaluate the antitumor activity of F90 against <\\entity><\\entity> in vitro and in vivo.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13277",
    "Sentence": "Western blot assay was applied to evaluate the expression of <\\entity><\\entity>, p-ERK1, p-JNK, p-P38, Bcl2 and P53 proteins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13278",
    "Sentence": "Western blot assay was applied to evaluate the expression of p-EGFR, <\\entity><\\entity>, p-JNK, p-P38, Bcl2 and P53 proteins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13279",
    "Sentence": "Western blot assay was applied to evaluate the expression of p-EGFR, p-ERK1, <\\entity><\\entity>, p-P38, Bcl2 and P53 proteins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13280",
    "Sentence": "Western blot assay was applied to evaluate the expression of p-EGFR, p-ERK1, p-JNK, <\\entity><\\entity>, Bcl2 and P53 proteins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13281",
    "Sentence": "Western blot assay was applied to evaluate the expression of p-EGFR, p-ERK1, p-JNK, p-P38, <\\entity><\\entity> and P53 proteins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13282",
    "Sentence": "Western blot assay was applied to evaluate the expression of p-EGFR, p-ERK1, p-JNK, p-P38, Bcl2 and <\\entity><\\entity> proteins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13283",
    "Sentence": "RESULTS: <\\entity><\\entity> inhibited the cell proliferation in a dose-dependent manner in vitro.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13284",
    "Sentence": "The growth of <\\entity><\\entity> tumor xenografts was suppressed by F90 at a high dose level (100 mg x kg(-1) x d(-1)).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13285",
    "Sentence": "The growth of SHG-44 tumor xenografts was suppressed by <\\entity><\\entity> at a high dose level (100 mg x kg(-1) x d(-1)).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13286",
    "Sentence": "Phosphorylation of <\\entity><\\entity> and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with F90 for 48 hours in vitro.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13287",
    "Sentence": "Phosphorylation of EGFR and activated downstream signaling proteins, such as <\\entity><\\entity>, JNK and P38, were found to be depressed after incubation with F90 for 48 hours in vitro.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13288",
    "Sentence": "Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, <\\entity><\\entity> and P38, were found to be depressed after incubation with F90 for 48 hours in vitro.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13289",
    "Sentence": "Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and <\\entity><\\entity>, were found to be depressed after incubation with F90 for 48 hours in vitro.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13290",
    "Sentence": "Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with <\\entity><\\entity> for 48 hours in vitro.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13291",
    "Sentence": "Down-regulated <\\entity><\\entity> protein and up-regulated P53 protein were also observed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13292",
    "Sentence": "Down-regulated Bcl2 protein and up-regulated <\\entity><\\entity> protein were also observed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13293",
    "Sentence": "CONCLUSIONS: The results demonstrate that <\\entity><\\entity> is effective in inhibiting the proliferation of SHG-44 cells in vitro and tumor growth in vivo, suggesting that <\\entity><\\entity> may be a new therapeutic option for treatment of GBM.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13294",
    "Sentence": "CONCLUSIONS: The results demonstrate that F90 is effective in inhibiting the proliferation of <\\entity><\\entity> cells in vitro and tumor growth in vivo, suggesting that F90 may be a new therapeutic option for treatment of GBM.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13295",
    "Sentence": "CONCLUSIONS: The results demonstrate that <\\entity><\\entity> is effective in inhibiting the proliferation of SHG-44 cells in vitro and tumor growth in vivo, suggesting that <\\entity><\\entity> may be a new therapeutic option for treatment of GBM.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13296",
    "Sentence": "Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with <\\entity><\\entity> for 48 hours in vitro.",
    "Label": ""
  },
  {
    "id": "13297",
    "Sentence": "Phosphorylation of <\\entity><\\entity> and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with F90 for 48 hours in vitro.",
    "Label": ""
  },
  {
    "id": "13299",
    "Sentence": "Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with <\\entity><\\entity> for 48 hours in vitro.",
    "Label": ""
  },
  {
    "id": "13300",
    "Sentence": "Phosphorylation of EGFR and activated downstream signaling proteins, such as <\\entity><\\entity>, JNK and P38, were found to be depressed after incubation with F90 for 48 hours in vitro.",
    "Label": ""
  },
  {
    "id": "13302",
    "Sentence": "Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with <\\entity><\\entity> for 48 hours in vitro.",
    "Label": ""
  },
  {
    "id": "13303",
    "Sentence": "Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, <\\entity><\\entity> and P38, were found to be depressed after incubation with F90 for 48 hours in vitro.",
    "Label": ""
  },
  {
    "id": "13305",
    "Sentence": "Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and P38, were found to be depressed after incubation with <\\entity><\\entity> for 48 hours in vitro.",
    "Label": ""
  },
  {
    "id": "13306",
    "Sentence": "Phosphorylation of EGFR and activated downstream signaling proteins, such as ERK1, JNK and <\\entity><\\entity>, were found to be depressed after incubation with F90 for 48 hours in vitro.",
    "Label": ""
  },
  {
    "id": "13308",
    "Sentence": "Antitumor activity of F90, an <\\entity><\\entity>, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": ""
  },
  {
    "id": "13309",
    "Sentence": "Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on <\\entity><\\entity> cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": ""
  },
  {
    "id": "13311",
    "Sentence": "Antitumor activity of <\\entity><\\entity>, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": ""
  },
  {
    "id": "13312",
    "Sentence": "Antitumor activity of F90, an <\\entity><\\entity>, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": ""
  },
  {
    "id": "13314",
    "Sentence": "Antitumor activity of <\\entity><\\entity>, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": ""
  },
  {
    "id": "13315",
    "Sentence": "Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on <\\entity><\\entity> cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": ""
  },
  {
    "id": "13317",
    "Sentence": "Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (<\\entity><\\entity>) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": ""
  },
  {
    "id": "13318",
    "Sentence": "Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, <\\entity><\\entity>, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": ""
  },
  {
    "id": "13320",
    "Sentence": "Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (<\\entity><\\entity>) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": ""
  },
  {
    "id": "13321",
    "Sentence": "Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13323",
    "Sentence": "Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (<\\entity><\\entity>) is thought to be related to cell proliferation, invasion, metastasis, resistance to chemoradiotherapy and poor prognosis of various human cancers.",
    "Label": ""
  },
  {
    "id": "13324",
    "Sentence": "Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.BACKGROUND: Over-expression of epidermal growth factor receptor (EGFR) is thought to be related to cell proliferation, invasion, metastasis, <\\entity><\\entity> and poor prognosis of various human cancers.",
    "Label": ""
  },
  {
    "id": "13326",
    "Sentence": "Forty percent to fifty percent of glioblastoma multiforme (GBM) possess deregulated <\\entity><\\entity>, which may contribute to the aggressive and refractory course of GBM.",
    "Label": ""
  },
  {
    "id": "13327",
    "Sentence": "Forty percent to fifty percent of glioblastoma multiforme (<\\entity><\\entity>) possess deregulated EGFR, which may contribute to the aggressive and refractory course of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13329",
    "Sentence": "Therefore, blockade of <\\entity><\\entity> signal transduction may be a promising treatment strategy for GBM.",
    "Label": ""
  },
  {
    "id": "13330",
    "Sentence": "Therefore, blockade of EGFR signal transduction may be a promising treatment strategy for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13332",
    "Sentence": "CONCLUSIONS: The results demonstrate that <\\entity><\\entity> is effective in inhibiting the proliferation of SHG-44 cells in vitro and tumor growth in vivo, suggesting that <\\entity><\\entity> may be a new therapeutic option for treatment of GBM.",
    "Label": ""
  },
  {
    "id": "13333",
    "Sentence": "CONCLUSIONS: The results demonstrate that F90 is effective in inhibiting the proliferation of SHG-44 cells in vitro and tumor growth in vivo, suggesting that F90 may be a new therapeutic option for treatment of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13335",
    "Sentence": "METHODS: MTT assay, cell growth curve assay and tumor xenograft model were used to evaluate the antitumor activity of <\\entity><\\entity> against SHG-44 in vitro and in vivo.",
    "Label": ""
  },
  {
    "id": "13336",
    "Sentence": "METHODS: MTT assay, cell growth curve assay and tumor xenograft model were used to evaluate the antitumor activity of F90 against <\\entity><\\entity> in vitro and in vivo.",
    "Label": ""
  },
  {
    "id": "13338",
    "Sentence": "The growth of SHG-44 tumor xenografts was suppressed by <\\entity><\\entity> at a high dose level (100 mg x kg(-1) x d(-1)).",
    "Label": ""
  },
  {
    "id": "13339",
    "Sentence": "The growth of <\\entity><\\entity> tumor xenografts was suppressed by F90 at a high dose level (100 mg x kg(-1) x d(-1)).",
    "Label": ""
  },
  {
    "id": "13341",
    "Sentence": "CONCLUSIONS: The results demonstrate that <\\entity><\\entity> is effective in inhibiting the proliferation of SHG-44 cells in vitro and tumor growth in vivo, suggesting that <\\entity><\\entity> may be a new therapeutic option for treatment of GBM.",
    "Label": ""
  },
  {
    "id": "13342",
    "Sentence": "CONCLUSIONS: The results demonstrate that F90 is effective in inhibiting the proliferation of <\\entity><\\entity> cells in vitro and tumor growth in vivo, suggesting that F90 may be a new therapeutic option for treatment of GBM.",
    "Label": ""
  },
  {
    "id": "13348",
    "Sentence": "Safety of regular use of <\\entity><\\entity> as monotherapy or added to inhaled corticosteroids in asthma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13349",
    "Sentence": "Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled <\\entity><\\entity> in asthma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13350",
    "Sentence": "Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13351",
    "Sentence": "A systematic review.BACKGROUND: Safety of <\\entity><\\entity> (LABA) has been questioned and recent evidence suggested a detrimental effect on asthma control as well as an increased risk of death.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13352",
    "Sentence": "A systematic review.BACKGROUND: Safety of long-acting beta agonists (<\\entity><\\entity>) has been questioned and recent evidence suggested a detrimental effect on asthma control as well as an increased risk of death.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13353",
    "Sentence": "A systematic review.BACKGROUND: Safety of long-acting beta agonists (LABA) has been questioned and recent evidence suggested a detrimental effect on <\\entity><\\entity> control as well as an increased risk of death.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13354",
    "Sentence": "A systematic review.BACKGROUND: Safety of long-acting beta agonists (LABA) has been questioned and recent evidence suggested a detrimental effect on asthma control as well as an increased risk of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13355",
    "Sentence": "OBJECTIVE: To evaluate the safety of regular use of <\\entity><\\entity> compared with placebo or <\\entity><\\entity> added to inhaled corticosteroids (ICS) compared with ICS in persistent asthma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13356",
    "Sentence": "OBJECTIVE: To evaluate the safety of regular use of <\\entity><\\entity> compared with placebo or <\\entity><\\entity> added to inhaled corticosteroids (ICS) compared with ICS in persistent asthma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13357",
    "Sentence": "OBJECTIVE: To evaluate the safety of regular use of LABA compared with placebo or LABA added to <\\entity><\\entity> (ICS) compared with ICS in persistent asthma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13358",
    "Sentence": "OBJECTIVE: To evaluate the safety of regular use of LABA compared with placebo or LABA added to inhaled corticosteroids (<\\entity><\\entity>) compared with <\\entity><\\entity> in persistent asthma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13359",
    "Sentence": "OBJECTIVE: To evaluate the safety of regular use of LABA compared with placebo or LABA added to inhaled corticosteroids (<\\entity><\\entity>) compared with <\\entity><\\entity> in persistent asthma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13360",
    "Sentence": "OBJECTIVE: To evaluate the safety of regular use of LABA compared with placebo or LABA added to inhaled corticosteroids (<\\entity><\\entity>) compared with <\\entity><\\entity> in persistent asthma.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13361",
    "Sentence": "OBJECTIVE: To evaluate the safety of regular use of LABA compared with placebo or LABA added to inhaled corticosteroids (<\\entity><\\entity>) compared with <\\entity><\\entity> in persistent asthma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13362",
    "Sentence": "OBJECTIVE: To evaluate the safety of regular use of LABA compared with placebo or LABA added to inhaled corticosteroids (ICS) compared with ICS in persistent <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13363",
    "Sentence": "Additionally, AstraZeneca, GlaxoSmithKline, <\\entity><\\entity> and FDA clinical trials databases were searched.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13364",
    "Sentence": "Primary outcomes were <\\entity><\\entity> (AE) requiring systemic corticosteroids or hospitalization, life-threatening exacerbations and asthma-related deaths.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13365",
    "Sentence": "Primary outcomes were asthma exacerbations (<\\entity><\\entity>) requiring systemic corticosteroids or hospitalization, life-threatening exacerbations and asthma-related deaths.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13366",
    "Sentence": "Primary outcomes were asthma exacerbations (AE) requiring systemic <\\entity><\\entity> or hospitalization, life-threatening exacerbations and asthma-related deaths.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13367",
    "Sentence": "Primary outcomes were asthma exacerbations (AE) requiring systemic corticosteroids or hospitalization, <\\entity><\\entity> and asthma-related deaths.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13368",
    "Sentence": "Primary outcomes were asthma exacerbations (AE) requiring systemic corticosteroids or hospitalization, life-threatening exacerbations and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13369",
    "Sentence": "<\\entity><\\entity> (as monotherapy) reduced exacerbations requiring corticosteroids (Relative Risk [RR]=0.80; 95% CI, 0.73-0.88), without detrimental effects on hospitalizations or life-threatening episodes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13370",
    "Sentence": "LABA (as monotherapy) reduced exacerbations requiring <\\entity><\\entity> (Relative Risk [RR]=0.80; 95% CI, 0.73-0.88), without detrimental effects on hospitalizations or life-threatening episodes.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13371",
    "Sentence": "LABA (as monotherapy) reduced exacerbations requiring corticosteroids (Relative Risk [RR]=0.80; 95% CI, 0.73-0.88), without detrimental effects on hospitalizations or <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13372",
    "Sentence": "Contrarily, <\\entity><\\entity> showed a significant increase in asthma-related deaths (Relative Risk=3.83; 95% CI, 1.21-12.14).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13373",
    "Sentence": "Contrarily, LABA showed a significant increase in <\\entity><\\entity> (Relative Risk=3.83; 95% CI, 1.21-12.14).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13374",
    "Sentence": "Subgroup analysis suggests that children, patients receiving <\\entity><\\entity>, and a duration of treatment>12 weeks are associated with a higher risk of serious adverse effects; also there was a protective effect of concomitant use of ICS.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13375",
    "Sentence": "Subgroup analysis suggests that children, patients receiving salmeterol, and a duration of treatment>12 weeks are associated with a higher risk of serious <\\entity><\\entity>; also there was a protective effect of concomitant use of ICS.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13376",
    "Sentence": "Subgroup analysis suggests that children, patients receiving salmeterol, and a duration of treatment>12 weeks are associated with a higher risk of serious adverse effects; also there was a protective effect of concomitant use of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13377",
    "Sentence": "Subgroup analysis suggests that children, patients receiving salmeterol, and a duration of treatment>12 weeks are associated with a higher risk of serious adverse effects; also there was a protective effect of concomitant use of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13378",
    "Sentence": "On the other hand, combination of <\\entity><\\entity> reduced exacerbations (RR=0.73; 95% CI, 0.67-0.79), and hospitalizations (RR=0.58, 95% CI, 0.45-0.74).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13379",
    "Sentence": "On the other hand, combination of <\\entity><\\entity> reduced exacerbations (RR=0.73; 95% CI, 0.67-0.79), and hospitalizations (RR=0.58, 95% CI, 0.45-0.74).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13380",
    "Sentence": "Combined therapy was also equivalent to <\\entity><\\entity> in terms of life-threatening episodes and asthma-related deaths.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13381",
    "Sentence": "Combined therapy was also equivalent to <\\entity><\\entity> in terms of life-threatening episodes and asthma-related deaths.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13382",
    "Sentence": "Combined therapy was also equivalent to ICS in terms of <\\entity><\\entity> and asthma-related deaths.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13383",
    "Sentence": "Combined therapy was also equivalent to ICS in terms of life-threatening episodes and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13384",
    "Sentence": "Again, children and use of <\\entity><\\entity> were associated with an increased risk of some severe outcomes as compared with adults and formoterol users, respectively.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13385",
    "Sentence": "Again, children and use of salmeterol were associated with an increased risk of some severe outcomes as compared with adults and <\\entity><\\entity> users, respectively.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13386",
    "Sentence": "CONCLUSIONS: This review reinforced the international recommendations in terms of the use of <\\entity><\\entity> remains the preferred add-on therapy to ICS for patients whose disease cannot adequately controlled with ICS, and that <\\entity><\\entity> cannot be prescribed as a monotherapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13387",
    "Sentence": "CONCLUSIONS: This review reinforced the international recommendations in terms of the use of LABA remains the preferred add-on therapy to <\\entity><\\entity> for patients whose disease cannot adequately controlled with <\\entity><\\entity>, and that LABA cannot be prescribed as a monotherapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13388",
    "Sentence": "CONCLUSIONS: This review reinforced the international recommendations in terms of the use of LABA remains the preferred add-on therapy to <\\entity><\\entity> for patients whose disease cannot adequately controlled with <\\entity><\\entity>, and that LABA cannot be prescribed as a monotherapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13389",
    "Sentence": "CONCLUSIONS: This review reinforced the international recommendations in terms of the use of LABA remains the preferred add-on therapy to ICS for patients whose <\\entity><\\entity> cannot adequately controlled with ICS, and that LABA cannot be prescribed as a monotherapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13390",
    "Sentence": "CONCLUSIONS: This review reinforced the international recommendations in terms of the use of LABA remains the preferred add-on therapy to <\\entity><\\entity> for patients whose disease cannot adequately controlled with <\\entity><\\entity>, and that LABA cannot be prescribed as a monotherapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13391",
    "Sentence": "CONCLUSIONS: This review reinforced the international recommendations in terms of the use of LABA remains the preferred add-on therapy to <\\entity><\\entity> for patients whose disease cannot adequately controlled with <\\entity><\\entity>, and that LABA cannot be prescribed as a monotherapy.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13392",
    "Sentence": "CONCLUSIONS: This review reinforced the international recommendations in terms of the use of <\\entity><\\entity> remains the preferred add-on therapy to ICS for patients whose disease cannot adequately controlled with ICS, and that <\\entity><\\entity> cannot be prescribed as a monotherapy.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13393",
    "Sentence": "Nevertheless, in spite of the protective effect of the <\\entity><\\entity>, children and salmeterol use still show an increased risk of non-fatal serious adverse events.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13394",
    "Sentence": "Nevertheless, in spite of the protective effect of the <\\entity><\\entity>, children and salmeterol use still show an increased risk of non-fatal serious adverse events.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13395",
    "Sentence": "Nevertheless, in spite of the protective effect of the ICS, children and <\\entity><\\entity> use still show an increased risk of non-fatal serious adverse events.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13396",
    "Sentence": "Nevertheless, in spite of the protective effect of the ICS, children and salmeterol use <\\entity><\\entity> show an increased risk of non-fatal serious adverse events.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13397",
    "Sentence": "Nevertheless, in spite of the protective effect of the ICS, children and salmeterol use still show an increased risk of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13398",
    "Sentence": "A systematic review.BACKGROUND: Safety of <\\entity><\\entity> (LABA) has been questioned and recent evidence suggested a detrimental effect on asthma control as well as an increased risk of death.",
    "Label": ""
  },
  {
    "id": "13399",
    "Sentence": "A systematic review.BACKGROUND: Safety of long-acting beta agonists (LABA) has been questioned and recent evidence suggested a detrimental effect on asthma control as well as an increased risk of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13401",
    "Sentence": "A systematic review.BACKGROUND: Safety of long-acting beta agonists (<\\entity><\\entity>) has been questioned and recent evidence suggested a detrimental effect on asthma control as well as an increased risk of death.",
    "Label": ""
  },
  {
    "id": "13402",
    "Sentence": "A systematic review.BACKGROUND: Safety of long-acting beta agonists (LABA) has been questioned and recent evidence suggested a detrimental effect on asthma control as well as an increased risk of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13404",
    "Sentence": "Primary outcomes were asthma exacerbations (AE) requiring systemic <\\entity><\\entity> or hospitalization, life-threatening exacerbations and asthma-related deaths.",
    "Label": ""
  },
  {
    "id": "13405",
    "Sentence": "Primary outcomes were <\\entity><\\entity> (AE) requiring systemic corticosteroids or hospitalization, life-threatening exacerbations and asthma-related deaths.",
    "Label": ""
  },
  {
    "id": "13407",
    "Sentence": "<\\entity><\\entity> (as monotherapy) reduced exacerbations requiring corticosteroids (Relative Risk [RR]=0.80; 95% CI, 0.73-0.88), without detrimental effects on hospitalizations or life-threatening episodes.",
    "Label": ""
  },
  {
    "id": "13408",
    "Sentence": "LABA (as monotherapy) reduced exacerbations requiring corticosteroids (Relative Risk [RR]=0.80; 95% CI, 0.73-0.88), without detrimental effects on hospitalizations or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13410",
    "Sentence": "Contrarily, <\\entity><\\entity> showed a significant increase in asthma-related deaths (Relative Risk=3.83; 95% CI, 1.21-12.14).",
    "Label": ""
  },
  {
    "id": "13411",
    "Sentence": "Contrarily, LABA showed a significant increase in <\\entity><\\entity> (Relative Risk=3.83; 95% CI, 1.21-12.14).",
    "Label": ""
  },
  {
    "id": "13413",
    "Sentence": "Nevertheless, in spite of the protective effect of the ICS, children and <\\entity><\\entity> use still show an increased risk of non-fatal serious adverse events.",
    "Label": ""
  },
  {
    "id": "13414",
    "Sentence": "Nevertheless, in spite of the protective effect of the ICS, children and salmeterol use still show an increased risk of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13416",
    "Sentence": "Nevertheless, in spite of the protective effect of the ICS, children and <\\entity><\\entity> use still show an increased risk of non-fatal serious adverse events.",
    "Label": ""
  },
  {
    "id": "13417",
    "Sentence": "Nevertheless, in spite of the protective effect of the ICS, children and salmeterol use <\\entity><\\entity> show an increased risk of non-fatal serious adverse events.",
    "Label": ""
  },
  {
    "id": "13419",
    "Sentence": "Safety of regular use of <\\entity><\\entity> as monotherapy or added to inhaled corticosteroids in asthma.",
    "Label": ""
  },
  {
    "id": "13420",
    "Sentence": "Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13422",
    "Sentence": "Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled <\\entity><\\entity> in asthma.",
    "Label": ""
  },
  {
    "id": "13423",
    "Sentence": "Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13425",
    "Sentence": "A systematic review.BACKGROUND: Safety of long-acting beta agonists (<\\entity><\\entity>) has been questioned and recent evidence suggested a detrimental effect on asthma control as well as an increased risk of death.",
    "Label": ""
  },
  {
    "id": "13426",
    "Sentence": "A systematic review.BACKGROUND: Safety of long-acting beta agonists (LABA) has been questioned and recent evidence suggested a detrimental effect on <\\entity><\\entity> control as well as an increased risk of death.",
    "Label": ""
  },
  {
    "id": "13428",
    "Sentence": "A systematic review.BACKGROUND: Safety of <\\entity><\\entity> (LABA) has been questioned and recent evidence suggested a detrimental effect on asthma control as well as an increased risk of death.",
    "Label": ""
  },
  {
    "id": "13429",
    "Sentence": "A systematic review.BACKGROUND: Safety of long-acting beta agonists (LABA) has been questioned and recent evidence suggested a detrimental effect on <\\entity><\\entity> control as well as an increased risk of death.",
    "Label": ""
  },
  {
    "id": "13431",
    "Sentence": "OBJECTIVE: To evaluate the safety of regular use of <\\entity><\\entity> compared with placebo or <\\entity><\\entity> added to inhaled corticosteroids (ICS) compared with ICS in persistent asthma.",
    "Label": ""
  },
  {
    "id": "13432",
    "Sentence": "OBJECTIVE: To evaluate the safety of regular use of LABA compared with placebo or LABA added to inhaled corticosteroids (ICS) compared with ICS in persistent <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13434",
    "Sentence": "OBJECTIVE: To evaluate the safety of regular use of LABA compared with placebo or LABA added to inhaled corticosteroids (<\\entity><\\entity>) compared with <\\entity><\\entity> in persistent asthma.",
    "Label": ""
  },
  {
    "id": "13435",
    "Sentence": "OBJECTIVE: To evaluate the safety of regular use of LABA compared with placebo or LABA added to inhaled corticosteroids (ICS) compared with ICS in persistent <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13437",
    "Sentence": "OBJECTIVE: To evaluate the safety of regular use of LABA compared with placebo or LABA added to <\\entity><\\entity> (ICS) compared with ICS in persistent asthma.",
    "Label": ""
  },
  {
    "id": "13438",
    "Sentence": "OBJECTIVE: To evaluate the safety of regular use of LABA compared with placebo or LABA added to inhaled corticosteroids (ICS) compared with ICS in persistent <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13440",
    "Sentence": "Primary outcomes were asthma exacerbations (AE) requiring systemic <\\entity><\\entity> or hospitalization, life-threatening exacerbations and asthma-related deaths.",
    "Label": ""
  },
  {
    "id": "13441",
    "Sentence": "Primary outcomes were asthma exacerbations (AE) requiring systemic corticosteroids or hospitalization, life-threatening exacerbations and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13443",
    "Sentence": "Combined therapy was also equivalent to <\\entity><\\entity> in terms of life-threatening episodes and asthma-related deaths.",
    "Label": ""
  },
  {
    "id": "13444",
    "Sentence": "Combined therapy was also equivalent to ICS in terms of life-threatening episodes and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13450",
    "Sentence": "Comparison of the Bath <\\entity><\\entity> Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.OBJECTIVE: To compare the original Bath <\\entity><\\entity> Disease Activity Index (BASDAI) with a modified BASDAI without questions about peripheral arthritis (question 3) and enthesitis (question 4), here termed the mini-BASDAI, as an instrument to assess disease activity in patients with ankylosing spondylitis (AS) without peripheral manifestations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13451",
    "Sentence": "Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with <\\entity><\\entity> without peripheral manifestations.OBJECTIVE: To compare the original Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) with a modified BASDAI without questions about peripheral arthritis (question 3) and enthesitis (question 4), here termed the mini-BASDAI, as an instrument to assess disease activity in patients with <\\entity><\\entity> (AS) without peripheral manifestations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13452",
    "Sentence": "Comparison of the Bath <\\entity><\\entity> Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.OBJECTIVE: To compare the original Bath <\\entity><\\entity> Disease Activity Index (BASDAI) with a modified BASDAI without questions about peripheral arthritis (question 3) and enthesitis (question 4), here termed the mini-BASDAI, as an instrument to assess disease activity in patients with ankylosing spondylitis (AS) without peripheral manifestations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13453",
    "Sentence": "Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with <\\entity><\\entity> without peripheral manifestations.OBJECTIVE: To compare the original Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) with a modified BASDAI without questions about peripheral arthritis (question 3) and enthesitis (question 4), here termed the mini-BASDAI, as an instrument to assess disease activity in patients with <\\entity><\\entity> (AS) without peripheral manifestations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13454",
    "Sentence": "The correlation of the original BASDAI and the mini-BASDAI with patient global and other disease parameters was assessed in a total of 692 patients from three AS cohorts including one observational AS cohort and two clinical trial populations treated with <\\entity><\\entity> and tumour necrosis factor alpha inhibitors.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13455",
    "Sentence": "The correlation of the original BASDAI and the mini-BASDAI with patient global and other disease parameters was assessed in a total of 692 patients from three AS cohorts including one observational AS cohort and two clinical trial populations treated with non-steroidal anti-inflammatory drugs and <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13456",
    "Sentence": "The correlation of the original BASDAI and the mini-BASDAI with patient global and other disease parameters was assessed in a total of 692 patients from three AS cohorts including one observational AS cohort and two clinical trial populations treated with <\\entity><\\entity> and tumour necrosis factor alpha inhibitors.",
    "Label": ""
  },
  {
    "id": "13457",
    "Sentence": "The correlation of the original B<\\entity><\\entity>DAI and the mini-B<\\entity><\\entity>DAI with patient global and other disease parameters was assessed in a total of 692 patients from three <\\entity><\\entity> cohorts including one observational <\\entity><\\entity> cohort and two clinical trial populations treated with non-steroidal anti-inflammatory drugs and tumour necrosis factor alpha inhibitors.",
    "Label": ""
  },
  {
    "id": "13459",
    "Sentence": "The correlation of the original BASDAI and the mini-BASDAI with patient global and other disease parameters was assessed in a total of 692 patients from three AS cohorts including one observational AS cohort and two clinical trial populations treated with non-steroidal anti-inflammatory drugs and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13460",
    "Sentence": "The correlation of the original B<\\entity><\\entity>DAI and the mini-B<\\entity><\\entity>DAI with patient global and other disease parameters was assessed in a total of 692 patients from three <\\entity><\\entity> cohorts including one observational <\\entity><\\entity> cohort and two clinical trial populations treated with non-steroidal anti-inflammatory drugs and tumour necrosis factor alpha inhibitors.",
    "Label": ""
  },
  {
    "id": "13466",
    "Sentence": "Elevation of <\\entity><\\entity> expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation.Growth hormone-releasing hormone (GHRH) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13467",
    "Sentence": "Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in <\\entity><\\entity> with Gsalpha protein mutation.Growth hormone-releasing hormone (GHRH) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13468",
    "Sentence": "Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with <\\entity><\\entity>.Growth hormone-releasing hormone (GHRH) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13469",
    "Sentence": "Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with <\\entity><\\entity>.Growth hormone-releasing hormone (GHRH) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13470",
    "Sentence": "Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with <\\entity><\\entity>.Growth hormone-releasing hormone (GHRH) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13471",
    "Sentence": "Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation.<\\entity><\\entity> (GHRH) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13472",
    "Sentence": "Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation.Growth hormone-releasing hormone (<\\entity><\\entity>) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13473",
    "Sentence": "Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation.Growth hormone-releasing hormone (<\\entity><\\entity>RH) stimulates not only the synthesis and secretion of <\\entity><\\entity> but also the proliferation of normal somatotrophs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13474",
    "Sentence": "The expression of <\\entity><\\entity> (GHRHR) is regulated by GHRH, both of which are known to be expressed in human GH-secreting pituitary adenoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13475",
    "Sentence": "The expression of GHRH receptor (<\\entity><\\entity>) is regulated by GHRH, both of which are known to be expressed in human GH-secreting pituitary adenoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13476",
    "Sentence": "The expression of <\\entity><\\entity> receptor (<\\entity><\\entity>R) is regulated by <\\entity><\\entity>, both of which are known to be expressed in human GH-secreting pituitary adenoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13477",
    "Sentence": "The expression of GHRH receptor (GHRHR) is regulated by GHRH, both of which are known to be expressed in human <\\entity><\\entity> cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13478",
    "Sentence": "The expression of GHRH receptor (GHRHR) is regulated by GHRH, both of which are known to be expressed in human <\\entity><\\entity> cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13479",
    "Sentence": "<\\entity><\\entity> (gsp), lead to the constitutive activation of adenylyl cyclase in pituitary adenomas that secrete GH.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13480",
    "Sentence": "<\\entity><\\entity> (gsp), lead to the constitutive activation of adenylyl cyclase in pituitary adenomas that secrete GH.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13481",
    "Sentence": "Somatic mutations in the subunit of <\\entity><\\entity> protein (gsp), lead to the constitutive activation of adenylyl cyclase in pituitary adenomas that secrete GH.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13482",
    "Sentence": "Somatic mutations in the subunit of Gsalpha protein (<\\entity><\\entity>), lead to the constitutive activation of adenylyl cyclase in pituitary adenomas that secrete GH.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13483",
    "Sentence": "Somatic mutations in the subunit of Gsalpha protein (gsp), lead to the constitutive activation of <\\entity><\\entity> in pituitary adenomas that secrete GH.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13484",
    "Sentence": "Somatic mutations in the subunit of Gsalpha protein (gsp), lead to the constitutive activation of adenylyl cyclase in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13485",
    "Sentence": "Somatic mutations in the subunit of Gsalpha protein (gsp), lead to the constitutive activation of adenylyl cyclase in <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13486",
    "Sentence": "It has not been examined how <\\entity><\\entity> influence GHRHR expression in GH-secreting adenomas.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13487",
    "Sentence": "It has not been examined how <\\entity><\\entity> influence GHRHR expression in GH-secreting adenomas.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13488",
    "Sentence": "It has not been examined how <\\entity><\\entity> influence GHRHR expression in GH-secreting adenomas.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13489",
    "Sentence": "It has not been examined how gsp mutations influence <\\entity><\\entity> expression in GH-secreting adenomas.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13490",
    "Sentence": "It has not been examined how gsp mutations influence GHRHR expression in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13491",
    "Sentence": "It has not been examined how gsp mutations influence GHRHR expression in <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13492",
    "Sentence": "We therefore analyzed the expression levels of <\\entity><\\entity> (mRNA) in GH-secreting pituitary adenomas focusing on a gsp mutation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13493",
    "Sentence": "We therefore analyzed the expression levels of GHRHR messenger ribonucleic acid (mRNA) in <\\entity><\\entity> focusing on a gsp mutation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13494",
    "Sentence": "We therefore analyzed the expression levels of GHRHR messenger ribonucleic acid (mRNA) in <\\entity><\\entity> focusing on a gsp mutation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13495",
    "Sentence": "We therefore analyzed the expression levels of GHRHR messenger ribonucleic acid (mRNA) in GH-secreting pituitary adenomas focusing on a <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13496",
    "Sentence": "We therefore analyzed the expression levels of GHRHR messenger ribonucleic acid (mRNA) in GH-secreting pituitary adenomas focusing on a <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13497",
    "Sentence": "We therefore analyzed the expression levels of GHRHR messenger ribonucleic acid (mRNA) in GH-secreting pituitary adenomas focusing on a <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13498",
    "Sentence": "Furthermore, we investigated the effect of <\\entity><\\entity> on the expression of <\\entity><\\entity>R mRNA in primary cultures of GH-secreting pituitary adenoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13499",
    "Sentence": "Furthermore, we investigated the effect of GHRH on the expression of <\\entity><\\entity> in primary cultures of GH-secreting pituitary adenoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13500",
    "Sentence": "Furthermore, we investigated the effect of GHRH on the expression of GHRHR mRNA in primary cultures of <\\entity><\\entity> cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13501",
    "Sentence": "Furthermore, we investigated the effect of GHRH on the expression of GHRHR mRNA in primary cultures of <\\entity><\\entity> cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13502",
    "Sentence": "<\\entity><\\entity> expression levels were significantly elevated in gsp mutation-positive GH-secreting adenomas compared with those in gsp mutation-negative ones.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13503",
    "Sentence": "GHRHR mRNA expression levels were significantly elevated in <\\entity><\\entity> GH-secreting adenomas compared with those in gsp mutation-negative ones.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13504",
    "Sentence": "GHRHR mRNA expression levels were significantly elevated in <\\entity><\\entity> GH-secreting adenomas compared with those in gsp mutation-negative ones.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13505",
    "Sentence": "GHRHR mRNA expression levels were significantly elevated in <\\entity><\\entity> GH-secreting adenomas compared with those in gsp mutation-negative ones.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13506",
    "Sentence": "GHRHR mRNA expression levels were significantly elevated in gsp <\\entity><\\entity>-positive GH-secreting adenomas compared with those in gsp <\\entity><\\entity>-negative ones.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13507",
    "Sentence": "<\\entity><\\entity>RHR mRNA expression levels were significantly elevated in gsp mutation-positive <\\entity><\\entity>-secreting adenomas compared with those in gsp mutation-negative ones.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13508",
    "Sentence": "GHRHR mRNA expression levels were significantly elevated in gsp mutation-positive GH-secreting <\\entity><\\entity> compared with those in gsp mutation-negative ones.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13509",
    "Sentence": "GHRHR mRNA expression levels were significantly elevated in gsp mutation-positive GH-secreting adenomas compared with those in <\\entity><\\entity> ones.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13510",
    "Sentence": "GHRHR mRNA expression levels were significantly elevated in gsp mutation-positive GH-secreting adenomas compared with those in <\\entity><\\entity> ones.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13511",
    "Sentence": "GHRHR mRNA expression levels were significantly elevated in gsp <\\entity><\\entity>-positive GH-secreting adenomas compared with those in gsp <\\entity><\\entity>-negative ones.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13512",
    "Sentence": "In primary-cultured <\\entity><\\entity> cells, the increase of GH secretion in response to GHRH was shown in both gsp mutation-positive and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13513",
    "Sentence": "In primary-cultured <\\entity><\\entity> cells, the increase of GH secretion in response to GHRH was shown in both gsp mutation-positive and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13514",
    "Sentence": "In primary-cultured <\\entity><\\entity>-secreting adenoma cells, the increase of <\\entity><\\entity> secretion in response to <\\entity><\\entity>RH was shown in both gsp mutation-positive and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13515",
    "Sentence": "In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to <\\entity><\\entity> was shown in both gsp mutation-positive and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13516",
    "Sentence": "In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to GHRH was shown in both <\\entity><\\entity> and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13517",
    "Sentence": "In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to GHRH was shown in both <\\entity><\\entity> and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13518",
    "Sentence": "In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to GHRH was shown in both <\\entity><\\entity> and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13519",
    "Sentence": "In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to GHRH was shown in both gsp <\\entity><\\entity>-positive and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13520",
    "Sentence": "In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to GHRH was shown in both gsp mutation-positive and <\\entity><\\entity> adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13521",
    "Sentence": "In primary-cultured GH-secreting <\\entity><\\entity> cells, the increase of GH secretion in response to GHRH was shown in both gsp mutation-positive and -negative <\\entity><\\entity> cells with a significantly higher response in the latter <\\entity><\\entity> cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13522",
    "Sentence": "In primary-cultured GH-secreting <\\entity><\\entity> cells, the increase of GH secretion in response to GHRH was shown in both gsp mutation-positive and -negative <\\entity><\\entity> cells with a significantly higher response in the latter <\\entity><\\entity> cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13523",
    "Sentence": "<\\entity><\\entity> increased <\\entity><\\entity>R mRNA expression level in gsp mutation-negative adenoma cells while it was not influenced by <\\entity><\\entity> in gsp mutation-positive adenoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13524",
    "Sentence": "GHRH increased <\\entity><\\entity> expression level in gsp mutation-negative adenoma cells while it was not influenced by GHRH in gsp mutation-positive adenoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13525",
    "Sentence": "GHRH increased GHRHR mRNA expression level in <\\entity><\\entity> adenoma cells while it was not influenced by GHRH in gsp mutation-positive adenoma cells.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13526",
    "Sentence": "GHRH increased GHRHR mRNA expression level in <\\entity><\\entity> adenoma cells while it was not influenced by GHRH in gsp mutation-positive adenoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13527",
    "Sentence": "GHRH increased GHRHR mRNA expression level in <\\entity><\\entity> adenoma cells while it was not influenced by GHRH in gsp mutation-positive adenoma cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13528",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp <\\entity><\\entity>-negative adenoma cells while it was not influenced by GHRH in gsp <\\entity><\\entity>-positive adenoma cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13529",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp mutation-negative <\\entity><\\entity> cells while it was not influenced by GHRH in gsp mutation-positive <\\entity><\\entity> cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13530",
    "Sentence": "<\\entity><\\entity> increased <\\entity><\\entity>R mRNA expression level in gsp mutation-negative adenoma cells while it was not influenced by <\\entity><\\entity> in gsp mutation-positive adenoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13531",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp mutation-negative adenoma cells while it was not influenced by GHRH in <\\entity><\\entity> adenoma cells.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13532",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp mutation-negative adenoma cells while it was not influenced by GHRH in <\\entity><\\entity> adenoma cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13533",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp mutation-negative adenoma cells while it was not influenced by GHRH in <\\entity><\\entity> adenoma cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13534",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp <\\entity><\\entity>-negative adenoma cells while it was not influenced by GHRH in gsp <\\entity><\\entity>-positive adenoma cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13535",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp mutation-negative <\\entity><\\entity> cells while it was not influenced by GHRH in gsp mutation-positive <\\entity><\\entity> cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13536",
    "Sentence": "These results suggest that <\\entity><\\entity> up-regulate GHRHR mRNA expression in GH-secreting pituitary adenoma cells, and that <\\entity><\\entity> desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13537",
    "Sentence": "These results suggest that <\\entity><\\entity> up-regulate GHRHR mRNA expression in GH-secreting pituitary adenoma cells, and that <\\entity><\\entity> desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13538",
    "Sentence": "These results suggest that <\\entity><\\entity> up-regulate GHRHR mRNA expression in GH-secreting pituitary adenoma cells, and that <\\entity><\\entity> desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13539",
    "Sentence": "These results suggest that gsp mutations up-regulate <\\entity><\\entity> expression in GH-secreting pituitary adenoma cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their <\\entity><\\entity> expression probably because of their saturation of GHRH signaling.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13540",
    "Sentence": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in <\\entity><\\entity> cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13541",
    "Sentence": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in <\\entity><\\entity> cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13542",
    "Sentence": "These results suggest that <\\entity><\\entity> up-regulate GHRHR mRNA expression in GH-secreting pituitary adenoma cells, and that <\\entity><\\entity> desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13543",
    "Sentence": "These results suggest that <\\entity><\\entity> up-regulate GHRHR mRNA expression in GH-secreting pituitary adenoma cells, and that <\\entity><\\entity> desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13544",
    "Sentence": "These results suggest that <\\entity><\\entity> up-regulate GHRHR mRNA expression in GH-secreting pituitary adenoma cells, and that <\\entity><\\entity> desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13545",
    "Sentence": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in GH-secreting pituitary <\\entity><\\entity> cells, and that gsp mutations desensitize the <\\entity><\\entity> cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13546",
    "Sentence": "These results suggest that gsp mutations up-regulate <\\entity><\\entity>R mRNA expression in GH-secreting pituitary adenoma cells, and that gsp mutations desensitize the adenoma cells to <\\entity><\\entity> in terms of their <\\entity><\\entity>R mRNA expression probably because of their saturation of <\\entity><\\entity> signaling.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13547",
    "Sentence": "These results suggest that gsp mutations up-regulate <\\entity><\\entity> expression in GH-secreting pituitary adenoma cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their <\\entity><\\entity> expression probably because of their saturation of GHRH signaling.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13548",
    "Sentence": "These results suggest that gsp mutations up-regulate <\\entity><\\entity>R mRNA expression in GH-secreting pituitary adenoma cells, and that gsp mutations desensitize the adenoma cells to <\\entity><\\entity> in terms of their <\\entity><\\entity>R mRNA expression probably because of their saturation of <\\entity><\\entity> signaling.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13549",
    "Sentence": "The expression of <\\entity><\\entity> receptor (<\\entity><\\entity>R) is regulated by <\\entity><\\entity>, both of which are known to be expressed in human GH-secreting pituitary adenoma cells.",
    "Label": ""
  },
  {
    "id": "13550",
    "Sentence": "The expression of GHRH receptor (GHRHR) is regulated by GHRH, both of which are known to be expressed in human <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13552",
    "Sentence": "The expression of <\\entity><\\entity> (GHRHR) is regulated by GHRH, both of which are known to be expressed in human GH-secreting pituitary adenoma cells.",
    "Label": ""
  },
  {
    "id": "13553",
    "Sentence": "The expression of GHRH receptor (GHRHR) is regulated by GHRH, both of which are known to be expressed in human <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13555",
    "Sentence": "The expression of GHRH receptor (<\\entity><\\entity>) is regulated by GHRH, both of which are known to be expressed in human GH-secreting pituitary adenoma cells.",
    "Label": ""
  },
  {
    "id": "13556",
    "Sentence": "The expression of GHRH receptor (GHRHR) is regulated by GHRH, both of which are known to be expressed in human <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13558",
    "Sentence": "<\\entity><\\entity> (gsp), lead to the constitutive activation of adenylyl cyclase in pituitary adenomas that secrete GH.",
    "Label": ""
  },
  {
    "id": "13559",
    "Sentence": "Somatic mutations in the subunit of Gsalpha protein (gsp), lead to the constitutive activation of adenylyl cyclase in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13561",
    "Sentence": "These results suggest that <\\entity><\\entity> up-regulate GHRHR mRNA expression in GH-secreting pituitary adenoma cells, and that <\\entity><\\entity> desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13562",
    "Sentence": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in <\\entity><\\entity> cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13564",
    "Sentence": "Elevation of <\\entity><\\entity> expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation.Growth hormone-releasing hormone (GHRH) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs.",
    "Label": ""
  },
  {
    "id": "13565",
    "Sentence": "Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in <\\entity><\\entity> with Gsalpha protein mutation.Growth hormone-releasing hormone (GHRH) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs.",
    "Label": ""
  },
  {
    "id": "13567",
    "Sentence": "Elevation of <\\entity><\\entity> expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation.Growth hormone-releasing hormone (GHRH) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs.",
    "Label": ""
  },
  {
    "id": "13568",
    "Sentence": "Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with <\\entity><\\entity>.Growth hormone-releasing hormone (GHRH) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs.",
    "Label": ""
  },
  {
    "id": "13570",
    "Sentence": "Somatic mutations in the subunit of Gsalpha protein (gsp), lead to the constitutive activation of <\\entity><\\entity> in pituitary adenomas that secrete GH.",
    "Label": ""
  },
  {
    "id": "13571",
    "Sentence": "Somatic mutations in the subunit of Gsalpha protein (gsp), lead to the constitutive activation of adenylyl cyclase in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13573",
    "Sentence": "Somatic mutations in the subunit of Gsalpha protein (gsp), lead to the constitutive activation of <\\entity><\\entity> in pituitary adenomas that secrete GH.",
    "Label": ""
  },
  {
    "id": "13574",
    "Sentence": "<\\entity><\\entity> (gsp), lead to the constitutive activation of adenylyl cyclase in pituitary adenomas that secrete GH.",
    "Label": ""
  },
  {
    "id": "13576",
    "Sentence": "It has not been examined how gsp mutations influence <\\entity><\\entity> expression in GH-secreting adenomas.",
    "Label": ""
  },
  {
    "id": "13577",
    "Sentence": "It has not been examined how <\\entity><\\entity> influence GHRHR expression in GH-secreting adenomas.",
    "Label": ""
  },
  {
    "id": "13579",
    "Sentence": "It has not been examined how gsp mutations influence <\\entity><\\entity> expression in GH-secreting adenomas.",
    "Label": ""
  },
  {
    "id": "13580",
    "Sentence": "It has not been examined how gsp mutations influence GHRHR expression in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13582",
    "Sentence": "We therefore analyzed the expression levels of <\\entity><\\entity> (mRNA) in GH-secreting pituitary adenomas focusing on a gsp mutation.",
    "Label": ""
  },
  {
    "id": "13583",
    "Sentence": "We therefore analyzed the expression levels of GHRHR messenger ribonucleic acid (mRNA) in GH-secreting pituitary adenomas focusing on a <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13585",
    "Sentence": "We therefore analyzed the expression levels of <\\entity><\\entity> (mRNA) in GH-secreting pituitary adenomas focusing on a gsp mutation.",
    "Label": ""
  },
  {
    "id": "13586",
    "Sentence": "We therefore analyzed the expression levels of GHRHR messenger ribonucleic acid (mRNA) in <\\entity><\\entity> focusing on a gsp mutation.",
    "Label": ""
  },
  {
    "id": "13588",
    "Sentence": "Furthermore, we investigated the effect of GHRH on the expression of <\\entity><\\entity> in primary cultures of GH-secreting pituitary adenoma cells.",
    "Label": ""
  },
  {
    "id": "13589",
    "Sentence": "Furthermore, we investigated the effect of GHRH on the expression of GHRHR mRNA in primary cultures of <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13591",
    "Sentence": "Furthermore, we investigated the effect of <\\entity><\\entity> on the expression of <\\entity><\\entity>R mRNA in primary cultures of GH-secreting pituitary adenoma cells.",
    "Label": ""
  },
  {
    "id": "13592",
    "Sentence": "Furthermore, we investigated the effect of GHRH on the expression of GHRHR mRNA in primary cultures of <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13594",
    "Sentence": "<\\entity><\\entity> expression levels were significantly elevated in gsp mutation-positive GH-secreting adenomas compared with those in gsp mutation-negative ones.",
    "Label": ""
  },
  {
    "id": "13595",
    "Sentence": "GHRHR mRNA expression levels were significantly elevated in gsp <\\entity><\\entity>-positive GH-secreting adenomas compared with those in gsp <\\entity><\\entity>-negative ones.",
    "Label": ""
  },
  {
    "id": "13597",
    "Sentence": "<\\entity><\\entity> expression levels were significantly elevated in gsp mutation-positive GH-secreting adenomas compared with those in gsp mutation-negative ones.",
    "Label": ""
  },
  {
    "id": "13598",
    "Sentence": "GHRHR mRNA expression levels were significantly elevated in gsp mutation-positive GH-secreting <\\entity><\\entity> compared with those in gsp mutation-negative ones.",
    "Label": ""
  },
  {
    "id": "13600",
    "Sentence": "In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to <\\entity><\\entity> was shown in both gsp mutation-positive and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": ""
  },
  {
    "id": "13601",
    "Sentence": "In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to GHRH was shown in both gsp <\\entity><\\entity>-positive and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": ""
  },
  {
    "id": "13603",
    "Sentence": "In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to <\\entity><\\entity> was shown in both gsp mutation-positive and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": ""
  },
  {
    "id": "13604",
    "Sentence": "In primary-cultured GH-secreting <\\entity><\\entity> cells, the increase of GH secretion in response to GHRH was shown in both gsp mutation-positive and -negative <\\entity><\\entity> cells with a significantly higher response in the latter <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13606",
    "Sentence": "GHRH increased <\\entity><\\entity> expression level in gsp mutation-negative adenoma cells while it was not influenced by GHRH in gsp mutation-positive adenoma cells.",
    "Label": ""
  },
  {
    "id": "13607",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp <\\entity><\\entity>-negative adenoma cells while it was not influenced by GHRH in gsp <\\entity><\\entity>-positive adenoma cells.",
    "Label": ""
  },
  {
    "id": "13609",
    "Sentence": "GHRH increased <\\entity><\\entity> expression level in gsp mutation-negative adenoma cells while it was not influenced by GHRH in gsp mutation-positive adenoma cells.",
    "Label": ""
  },
  {
    "id": "13610",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp mutation-negative <\\entity><\\entity> cells while it was not influenced by GHRH in gsp mutation-positive <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13612",
    "Sentence": "<\\entity><\\entity> increased <\\entity><\\entity>R mRNA expression level in gsp mutation-negative adenoma cells while it was not influenced by <\\entity><\\entity> in gsp mutation-positive adenoma cells.",
    "Label": ""
  },
  {
    "id": "13613",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp <\\entity><\\entity>-negative adenoma cells while it was not influenced by GHRH in gsp <\\entity><\\entity>-positive adenoma cells.",
    "Label": ""
  },
  {
    "id": "13615",
    "Sentence": "<\\entity><\\entity> increased <\\entity><\\entity>R mRNA expression level in gsp mutation-negative adenoma cells while it was not influenced by <\\entity><\\entity> in gsp mutation-positive adenoma cells.",
    "Label": ""
  },
  {
    "id": "13616",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp mutation-negative <\\entity><\\entity> cells while it was not influenced by GHRH in gsp mutation-positive <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13618",
    "Sentence": "These results suggest that gsp mutations up-regulate <\\entity><\\entity> expression in GH-secreting pituitary adenoma cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their <\\entity><\\entity> expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13619",
    "Sentence": "These results suggest that <\\entity><\\entity> up-regulate GHRHR mRNA expression in GH-secreting pituitary adenoma cells, and that <\\entity><\\entity> desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13621",
    "Sentence": "These results suggest that gsp mutations up-regulate <\\entity><\\entity> expression in GH-secreting pituitary adenoma cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their <\\entity><\\entity> expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13622",
    "Sentence": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in <\\entity><\\entity> cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13624",
    "Sentence": "These results suggest that gsp mutations up-regulate <\\entity><\\entity> expression in GH-secreting pituitary adenoma cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their <\\entity><\\entity> expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13625",
    "Sentence": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in GH-secreting pituitary <\\entity><\\entity> cells, and that gsp mutations desensitize the <\\entity><\\entity> cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13627",
    "Sentence": "These results suggest that gsp mutations up-regulate <\\entity><\\entity>R mRNA expression in GH-secreting pituitary adenoma cells, and that gsp mutations desensitize the adenoma cells to <\\entity><\\entity> in terms of their <\\entity><\\entity>R mRNA expression probably because of their saturation of <\\entity><\\entity> signaling.",
    "Label": ""
  },
  {
    "id": "13628",
    "Sentence": "These results suggest that <\\entity><\\entity> up-regulate GHRHR mRNA expression in GH-secreting pituitary adenoma cells, and that <\\entity><\\entity> desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13630",
    "Sentence": "These results suggest that gsp mutations up-regulate <\\entity><\\entity>R mRNA expression in GH-secreting pituitary adenoma cells, and that gsp mutations desensitize the adenoma cells to <\\entity><\\entity> in terms of their <\\entity><\\entity>R mRNA expression probably because of their saturation of <\\entity><\\entity> signaling.",
    "Label": ""
  },
  {
    "id": "13631",
    "Sentence": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in <\\entity><\\entity> cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13633",
    "Sentence": "These results suggest that gsp mutations up-regulate <\\entity><\\entity>R mRNA expression in GH-secreting pituitary adenoma cells, and that gsp mutations desensitize the adenoma cells to <\\entity><\\entity> in terms of their <\\entity><\\entity>R mRNA expression probably because of their saturation of <\\entity><\\entity> signaling.",
    "Label": ""
  },
  {
    "id": "13634",
    "Sentence": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in GH-secreting pituitary <\\entity><\\entity> cells, and that gsp mutations desensitize the <\\entity><\\entity> cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13636",
    "Sentence": "Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with <\\entity><\\entity>.Growth hormone-releasing hormone (GHRH) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs.",
    "Label": ""
  },
  {
    "id": "13637",
    "Sentence": "Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in <\\entity><\\entity> with Gsalpha protein mutation.Growth hormone-releasing hormone (GHRH) stimulates not only the synthesis and secretion of GH but also the proliferation of normal somatotrophs.",
    "Label": ""
  },
  {
    "id": "13639",
    "Sentence": "The expression of GHRH receptor (GHRHR) is regulated by GHRH, both of which are known to be expressed in human <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13640",
    "Sentence": "The expression of GHRH receptor (GHRHR) is regulated by GHRH, both of which are known to be expressed in human <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13642",
    "Sentence": "Somatic mutations in the subunit of <\\entity><\\entity> protein (gsp), lead to the constitutive activation of adenylyl cyclase in pituitary adenomas that secrete GH.",
    "Label": ""
  },
  {
    "id": "13643",
    "Sentence": "Somatic mutations in the subunit of Gsalpha protein (gsp), lead to the constitutive activation of adenylyl cyclase in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13645",
    "Sentence": "Somatic mutations in the subunit of Gsalpha protein (gsp), lead to the constitutive activation of adenylyl cyclase in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13646",
    "Sentence": "Somatic mutations in the subunit of Gsalpha protein (gsp), lead to the constitutive activation of adenylyl cyclase in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13648",
    "Sentence": "Somatic mutations in the subunit of Gsalpha protein (<\\entity><\\entity>), lead to the constitutive activation of adenylyl cyclase in pituitary adenomas that secrete GH.",
    "Label": ""
  },
  {
    "id": "13649",
    "Sentence": "Somatic mutations in the subunit of Gsalpha protein (gsp), lead to the constitutive activation of adenylyl cyclase in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13651",
    "Sentence": "It has not been examined how gsp mutations influence GHRHR expression in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13652",
    "Sentence": "It has not been examined how gsp mutations influence GHRHR expression in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13654",
    "Sentence": "It has not been examined how <\\entity><\\entity> influence GHRHR expression in GH-secreting adenomas.",
    "Label": ""
  },
  {
    "id": "13655",
    "Sentence": "It has not been examined how gsp mutations influence GHRHR expression in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13657",
    "Sentence": "We therefore analyzed the expression levels of GHRHR messenger ribonucleic acid (mRNA) in <\\entity><\\entity> focusing on a gsp mutation.",
    "Label": ""
  },
  {
    "id": "13658",
    "Sentence": "We therefore analyzed the expression levels of GHRHR messenger ribonucleic acid (mRNA) in <\\entity><\\entity> focusing on a gsp mutation.",
    "Label": ""
  },
  {
    "id": "13660",
    "Sentence": "We therefore analyzed the expression levels of GHRHR messenger ribonucleic acid (mRNA) in GH-secreting pituitary adenomas focusing on a <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13661",
    "Sentence": "We therefore analyzed the expression levels of GHRHR messenger ribonucleic acid (mRNA) in <\\entity><\\entity> focusing on a gsp mutation.",
    "Label": ""
  },
  {
    "id": "13663",
    "Sentence": "Furthermore, we investigated the effect of GHRH on the expression of GHRHR mRNA in primary cultures of <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13664",
    "Sentence": "Furthermore, we investigated the effect of GHRH on the expression of GHRHR mRNA in primary cultures of <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13666",
    "Sentence": "<\\entity><\\entity>RHR mRNA expression levels were significantly elevated in gsp mutation-positive <\\entity><\\entity>-secreting adenomas compared with those in gsp mutation-negative ones.",
    "Label": ""
  },
  {
    "id": "13667",
    "Sentence": "GHRHR mRNA expression levels were significantly elevated in gsp mutation-positive GH-secreting <\\entity><\\entity> compared with those in gsp mutation-negative ones.",
    "Label": ""
  },
  {
    "id": "13669",
    "Sentence": "GHRHR mRNA expression levels were significantly elevated in gsp mutation-positive GH-secreting adenomas compared with those in <\\entity><\\entity> ones.",
    "Label": ""
  },
  {
    "id": "13670",
    "Sentence": "GHRHR mRNA expression levels were significantly elevated in gsp mutation-positive GH-secreting <\\entity><\\entity> compared with those in gsp mutation-negative ones.",
    "Label": ""
  },
  {
    "id": "13672",
    "Sentence": "In primary-cultured <\\entity><\\entity>-secreting adenoma cells, the increase of <\\entity><\\entity> secretion in response to <\\entity><\\entity>RH was shown in both gsp mutation-positive and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": ""
  },
  {
    "id": "13673",
    "Sentence": "In primary-cultured GH-secreting <\\entity><\\entity> cells, the increase of GH secretion in response to GHRH was shown in both gsp mutation-positive and -negative <\\entity><\\entity> cells with a significantly higher response in the latter <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13675",
    "Sentence": "In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to GHRH was shown in both <\\entity><\\entity> and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": ""
  },
  {
    "id": "13676",
    "Sentence": "In primary-cultured GH-secreting <\\entity><\\entity> cells, the increase of GH secretion in response to GHRH was shown in both gsp mutation-positive and -negative <\\entity><\\entity> cells with a significantly higher response in the latter <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13678",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp mutation-negative adenoma cells while it was not influenced by GHRH in <\\entity><\\entity> adenoma cells.",
    "Label": ""
  },
  {
    "id": "13679",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp mutation-negative <\\entity><\\entity> cells while it was not influenced by GHRH in gsp mutation-positive <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13681",
    "Sentence": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in <\\entity><\\entity> cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13682",
    "Sentence": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in <\\entity><\\entity> cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13684",
    "Sentence": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in <\\entity><\\entity> cells, and that gsp mutations desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13685",
    "Sentence": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in GH-secreting pituitary <\\entity><\\entity> cells, and that gsp mutations desensitize the <\\entity><\\entity> cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13687",
    "Sentence": "These results suggest that <\\entity><\\entity> up-regulate GHRHR mRNA expression in GH-secreting pituitary adenoma cells, and that <\\entity><\\entity> desensitize the adenoma cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13688",
    "Sentence": "These results suggest that gsp mutations up-regulate GHRHR mRNA expression in GH-secreting pituitary <\\entity><\\entity> cells, and that gsp mutations desensitize the <\\entity><\\entity> cells to GHRH in terms of their GHRHR mRNA expression probably because of their saturation of GHRH signaling.",
    "Label": ""
  },
  {
    "id": "13690",
    "Sentence": "<\\entity><\\entity> expression levels were significantly elevated in gsp mutation-positive GH-secreting adenomas compared with those in gsp mutation-negative ones.",
    "Label": ""
  },
  {
    "id": "13691",
    "Sentence": "GHRHR mRNA expression levels were significantly elevated in <\\entity><\\entity> GH-secreting adenomas compared with those in gsp mutation-negative ones.",
    "Label": ""
  },
  {
    "id": "13693",
    "Sentence": "In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to <\\entity><\\entity> was shown in both gsp mutation-positive and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": ""
  },
  {
    "id": "13694",
    "Sentence": "In primary-cultured <\\entity><\\entity> cells, the increase of GH secretion in response to GHRH was shown in both gsp mutation-positive and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": ""
  },
  {
    "id": "13696",
    "Sentence": "In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to <\\entity><\\entity> was shown in both gsp mutation-positive and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": ""
  },
  {
    "id": "13697",
    "Sentence": "In primary-cultured GH-secreting adenoma cells, the increase of GH secretion in response to GHRH was shown in both <\\entity><\\entity> and -negative adenoma cells with a significantly higher response in the latter adenoma cells.",
    "Label": ""
  },
  {
    "id": "13699",
    "Sentence": "<\\entity><\\entity> increased <\\entity><\\entity>R mRNA expression level in gsp mutation-negative adenoma cells while it was not influenced by <\\entity><\\entity> in gsp mutation-positive adenoma cells.",
    "Label": ""
  },
  {
    "id": "13700",
    "Sentence": "GHRH increased GHRHR mRNA expression level in <\\entity><\\entity> adenoma cells while it was not influenced by GHRH in gsp mutation-positive adenoma cells.",
    "Label": ""
  },
  {
    "id": "13702",
    "Sentence": "<\\entity><\\entity> increased <\\entity><\\entity>R mRNA expression level in gsp mutation-negative adenoma cells while it was not influenced by <\\entity><\\entity> in gsp mutation-positive adenoma cells.",
    "Label": ""
  },
  {
    "id": "13703",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp mutation-negative adenoma cells while it was not influenced by GHRH in <\\entity><\\entity> adenoma cells.",
    "Label": ""
  },
  {
    "id": "13705",
    "Sentence": "GHRH increased <\\entity><\\entity> expression level in gsp mutation-negative adenoma cells while it was not influenced by GHRH in gsp mutation-positive adenoma cells.",
    "Label": ""
  },
  {
    "id": "13706",
    "Sentence": "GHRH increased GHRHR mRNA expression level in <\\entity><\\entity> adenoma cells while it was not influenced by GHRH in gsp mutation-positive adenoma cells.",
    "Label": ""
  },
  {
    "id": "13708",
    "Sentence": "GHRH increased <\\entity><\\entity> expression level in gsp mutation-negative adenoma cells while it was not influenced by GHRH in gsp mutation-positive adenoma cells.",
    "Label": ""
  },
  {
    "id": "13709",
    "Sentence": "GHRH increased GHRHR mRNA expression level in gsp mutation-negative adenoma cells while it was not influenced by GHRH in <\\entity><\\entity> adenoma cells.",
    "Label": ""
  },
  {
    "id": "13715",
    "Sentence": "Characteristics of <\\entity><\\entity> following intravitreal injection of bevacizumab (Avastin).BACKGROUND/AIMS: To report a series of severe intraocular inflammatory events following intravitreal injections of bevacizumab (Avastin).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13716",
    "Sentence": "Characteristics of severe intraocular inflammation following intravitreal injection of <\\entity><\\entity> (Avastin).BACKGROUND/AIMS: To report a series of severe intraocular inflammatory events following intravitreal injections of <\\entity><\\entity> (Avastin).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13717",
    "Sentence": "Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (<\\entity><\\entity>).BACKGROUND/AIMS: To report a series of severe intraocular inflammatory events following intravitreal injections of bevacizumab (<\\entity><\\entity>).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13718",
    "Sentence": "Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin).BACKGROUND/AIMS: To report a series of <\\entity><\\entity> following intravitreal injections of bevacizumab (Avastin).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13719",
    "Sentence": "Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin).BACKGROUND/AIMS: To report a series of severe <\\entity><\\entity> events following intravitreal injections of bevacizumab (Avastin).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13720",
    "Sentence": "Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin).BACKGROUND/AIMS: To report a series of severe intraocular inflammatory events following <\\entity><\\entity> (Avastin).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13721",
    "Sentence": "Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (<\\entity><\\entity>).BACKGROUND/AIMS: To report a series of severe intraocular inflammatory events following intravitreal injections of bevacizumab (<\\entity><\\entity>).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13722",
    "Sentence": "This procedure is performed on a rapidly increasing number worldwide, and rare <\\entity><\\entity> such as intraocular inflammation, endophthalmitis or intraocular haemorrhage are gaining in importance in clinical routine.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13723",
    "Sentence": "This procedure is performed on a rapidly increasing number worldwide, and rare complications such as <\\entity><\\entity>, endophthalmitis or intraocular haemorrhage are gaining in importance in clinical routine.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13724",
    "Sentence": "This procedure is performed on a rapidly increasing number worldwide, and rare complications such as intraocular inflammation, <\\entity><\\entity> or intraocular haemorrhage are gaining in importance in clinical routine.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13725",
    "Sentence": "This procedure is performed on a rapidly increasing number worldwide, and rare complications such as intraocular inflammation, endophthalmitis or <\\entity><\\entity> are gaining in importance in clinical routine.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13726",
    "Sentence": "METHODS: This is a single-centre retrospective interventional case series of eight patients with <\\entity><\\entity> after intravitreal injection of bevacizumab at one referral centre consecutively seen out of approximately a total of 2500 injections performed in that time period.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13727",
    "Sentence": "METHODS: This is a single-centre retrospective interventional case series of eight patients with severe intraocular inflammation after intravitreal injection of <\\entity><\\entity> at one referral centre consecutively seen out of approximately a total of 2500 injections performed in that time period.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13728",
    "Sentence": "Patients who developed <\\entity><\\entity> after intravitreal injection were evaluated clinically, including slit-lamp examination, best-corrected Snellen visual acuity (VA), slit-lamp photography, optical coherence tomography and fluorescein angiography prior to the event and during follow-up.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13729",
    "Sentence": "Patients who developed severe intraocular inflammation after intravitreal injection were evaluated clinically, including slit-lamp examination, best-corrected Snellen visual acuity (<\\entity><\\entity>), slit-lamp photography, optical coherence tomography and fluorescein angiography prior to the event and during follow-up.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13730",
    "Sentence": "Patients who developed severe intraocular inflammation after intravitreal injection were evaluated clinically, including slit-lamp examination, best-corrected Snellen visual acuity (VA), slit-lamp photography, optical coherence tomography and <\\entity><\\entity> angiography prior to the event and during follow-up.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13731",
    "Sentence": "RESULTS: Patients noticed a painless drop in <\\entity><\\entity> up to 2 days following the injection.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13732",
    "Sentence": "All patients had a marked <\\entity><\\entity> chamber reaction with increased flare and cells, but no hypopyon.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13733",
    "Sentence": "All patients had a marked anterior chamber reaction with increased <\\entity><\\entity> and cells, but no hypopyon.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13734",
    "Sentence": "All patients had a marked anterior chamber reaction with increased flare and cells, but no <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13735",
    "Sentence": "Typical <\\entity><\\entity> segment findings included vitreous cellular infiltrates of pseudogranulomatous aspect.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13736",
    "Sentence": "Typical posterior segment findings included vitreous <\\entity><\\entity> of pseudogranulomatous aspect.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13737",
    "Sentence": "Due to their initial clinical aspect suspicious of an <\\entity><\\entity>, three cases were treated with systemic antibiotics, but the final diagnosis was uveitis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13738",
    "Sentence": "Due to their initial clinical aspect suspicious of an endophthalmitis, three cases were treated with <\\entity><\\entity> antibiotics, but the final diagnosis was uveitis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13739",
    "Sentence": "Due to their initial clinical aspect suspicious of an endophthalmitis, three cases were treated with systemic <\\entity><\\entity>, but the final diagnosis was uveitis.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13740",
    "Sentence": "Due to their initial clinical aspect suspicious of an endophthalmitis, three cases were treated with systemic antibiotics, but the final diagnosis was <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13741",
    "Sentence": "Five cases showed a characteristic <\\entity><\\entity> as seen in vitritis and were treated only topically.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13742",
    "Sentence": "Five cases showed a characteristic pseudogranulomatous vitreous infiltration as seen in <\\entity><\\entity> and were treated only topically.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13743",
    "Sentence": "CONCLUSIONS: Characteristic features of an <\\entity><\\entity> induced by bevacizumab injection include an early onset with painless loss in VA mostly without conjunctival or ciliary injection.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13744",
    "Sentence": "CONCLUSIONS: Characteristic features of an inflammation induced by <\\entity><\\entity> injection include an early onset with painless loss in VA mostly without conjunctival or ciliary injection.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13745",
    "Sentence": "CONCLUSIONS: Characteristic features of an inflammation induced by bevacizumab injection include an early onset with painless loss in <\\entity><\\entity> mostly without conjunctival or ciliary injection.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13746",
    "Sentence": "CONCLUSIONS: Characteristic features of an inflammation induced by bevacizumab injection include an early onset with painless loss in VA mostly without conjunctival or <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13747",
    "Sentence": "Patients respond to <\\entity><\\entity> or topical cortisone treatment with slow recovery but without permanent damage.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13748",
    "Sentence": "Patients respond to systemic or <\\entity><\\entity> treatment with slow recovery but without permanent damage.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13749",
    "Sentence": "<\\entity><\\entity> and infectious endophthalmitis might be differentiated by time course and symptoms.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13750",
    "Sentence": "Vitreous haemorrhage and <\\entity><\\entity> might be differentiated by time course and symptoms.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13751",
    "Sentence": "Vitreous haemorrhage and infectious endophthalmitis might be differentiated by time course and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13752",
    "Sentence": "Due to their initial clinical aspect suspicious of an endophthalmitis, three cases were treated with <\\entity><\\entity> antibiotics, but the final diagnosis was uveitis.",
    "Label": ""
  },
  {
    "id": "13753",
    "Sentence": "Due to their initial clinical aspect suspicious of an endophthalmitis, three cases were treated with systemic antibiotics, but the final diagnosis was <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13755",
    "Sentence": "Due to their initial clinical aspect suspicious of an endophthalmitis, three cases were treated with <\\entity><\\entity> antibiotics, but the final diagnosis was uveitis.",
    "Label": ""
  },
  {
    "id": "13756",
    "Sentence": "Due to their initial clinical aspect suspicious of an <\\entity><\\entity>, three cases were treated with systemic antibiotics, but the final diagnosis was uveitis.",
    "Label": ""
  },
  {
    "id": "13758",
    "Sentence": "CONCLUSIONS: Characteristic features of an inflammation induced by <\\entity><\\entity> injection include an early onset with painless loss in VA mostly without conjunctival or ciliary injection.",
    "Label": ""
  },
  {
    "id": "13759",
    "Sentence": "CONCLUSIONS: Characteristic features of an <\\entity><\\entity> induced by bevacizumab injection include an early onset with painless loss in VA mostly without conjunctival or ciliary injection.",
    "Label": ""
  },
  {
    "id": "13761",
    "Sentence": "Characteristics of severe intraocular inflammation following intravitreal injection of <\\entity><\\entity> (Avastin).BACKGROUND/AIMS: To report a series of severe intraocular inflammatory events following intravitreal injections of <\\entity><\\entity> (Avastin).",
    "Label": ""
  },
  {
    "id": "13762",
    "Sentence": "Characteristics of <\\entity><\\entity> following intravitreal injection of bevacizumab (Avastin).BACKGROUND/AIMS: To report a series of severe intraocular inflammatory events following intravitreal injections of bevacizumab (Avastin).",
    "Label": ""
  },
  {
    "id": "13764",
    "Sentence": "METHODS: This is a single-centre retrospective interventional case series of eight patients with severe intraocular inflammation after intravitreal injection of <\\entity><\\entity> at one referral centre consecutively seen out of approximately a total of 2500 injections performed in that time period.",
    "Label": ""
  },
  {
    "id": "13765",
    "Sentence": "METHODS: This is a single-centre retrospective interventional case series of eight patients with <\\entity><\\entity> after intravitreal injection of bevacizumab at one referral centre consecutively seen out of approximately a total of 2500 injections performed in that time period.",
    "Label": ""
  },
  {
    "id": "13767",
    "Sentence": "Patients who developed severe intraocular inflammation after intravitreal injection were evaluated clinically, including slit-lamp examination, best-corrected Snellen visual acuity (<\\entity><\\entity>), slit-lamp photography, optical coherence tomography and fluorescein angiography prior to the event and during follow-up.",
    "Label": ""
  },
  {
    "id": "13768",
    "Sentence": "Patients who developed <\\entity><\\entity> after intravitreal injection were evaluated clinically, including slit-lamp examination, best-corrected Snellen visual acuity (VA), slit-lamp photography, optical coherence tomography and fluorescein angiography prior to the event and during follow-up.",
    "Label": ""
  },
  {
    "id": "13770",
    "Sentence": "Patients who developed severe intraocular inflammation after intravitreal injection were evaluated clinically, including slit-lamp examination, best-corrected Snellen visual acuity (VA), slit-lamp photography, optical coherence tomography and <\\entity><\\entity> angiography prior to the event and during follow-up.",
    "Label": ""
  },
  {
    "id": "13771",
    "Sentence": "Patients who developed <\\entity><\\entity> after intravitreal injection were evaluated clinically, including slit-lamp examination, best-corrected Snellen visual acuity (VA), slit-lamp photography, optical coherence tomography and fluorescein angiography prior to the event and during follow-up.",
    "Label": ""
  },
  {
    "id": "13773",
    "Sentence": "CONCLUSIONS: Characteristic features of an inflammation induced by <\\entity><\\entity> injection include an early onset with painless loss in VA mostly without conjunctival or ciliary injection.",
    "Label": ""
  },
  {
    "id": "13774",
    "Sentence": "CONCLUSIONS: Characteristic features of an inflammation induced by bevacizumab injection include an early onset with painless loss in VA mostly without conjunctival or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13776",
    "Sentence": "CONCLUSIONS: Characteristic features of an inflammation induced by bevacizumab injection include an early onset with painless loss in <\\entity><\\entity> mostly without conjunctival or ciliary injection.",
    "Label": ""
  },
  {
    "id": "13777",
    "Sentence": "CONCLUSIONS: Characteristic features of an <\\entity><\\entity> induced by bevacizumab injection include an early onset with painless loss in VA mostly without conjunctival or ciliary injection.",
    "Label": ""
  },
  {
    "id": "13779",
    "Sentence": "CONCLUSIONS: Characteristic features of an inflammation induced by bevacizumab injection include an early onset with painless loss in <\\entity><\\entity> mostly without conjunctival or ciliary injection.",
    "Label": ""
  },
  {
    "id": "13780",
    "Sentence": "CONCLUSIONS: Characteristic features of an inflammation induced by bevacizumab injection include an early onset with painless loss in VA mostly without conjunctival or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13782",
    "Sentence": "Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (<\\entity><\\entity>).BACKGROUND/AIMS: To report a series of severe intraocular inflammatory events following intravitreal injections of bevacizumab (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "13783",
    "Sentence": "Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin).BACKGROUND/AIMS: To report a series of <\\entity><\\entity> following intravitreal injections of bevacizumab (Avastin).",
    "Label": ""
  },
  {
    "id": "13785",
    "Sentence": "Due to their initial clinical aspect suspicious of an endophthalmitis, three cases were treated with systemic <\\entity><\\entity>, but the final diagnosis was uveitis.",
    "Label": ""
  },
  {
    "id": "13786",
    "Sentence": "Due to their initial clinical aspect suspicious of an endophthalmitis, three cases were treated with systemic antibiotics, but the final diagnosis was <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13788",
    "Sentence": "Due to their initial clinical aspect suspicious of an endophthalmitis, three cases were treated with systemic <\\entity><\\entity>, but the final diagnosis was uveitis.",
    "Label": ""
  },
  {
    "id": "13789",
    "Sentence": "Due to their initial clinical aspect suspicious of an <\\entity><\\entity>, three cases were treated with systemic antibiotics, but the final diagnosis was uveitis.",
    "Label": ""
  },
  {
    "id": "13795",
    "Sentence": "Polymorphism <\\entity><\\entity> of COL1A2 and sporadic intracranial aneurysms in the Chinese population.OBJECT: The COL1A2 gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (IAs) in the Japanese population.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13796",
    "Sentence": "Polymorphism rs42524 of <\\entity><\\entity> and sporadic intracranial aneurysms in the Chinese population.OBJECT: The <\\entity><\\entity> gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (IAs) in the Japanese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13797",
    "Sentence": "Polymorphism rs42524 of COL1A2 and <\\entity><\\entity> in the Chinese population.OBJECT: The COL1A2 gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (IAs) in the Japanese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13798",
    "Sentence": "Polymorphism rs42524 of <\\entity><\\entity> and sporadic intracranial aneurysms in the Chinese population.OBJECT: The <\\entity><\\entity> gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (IAs) in the Japanese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13799",
    "Sentence": "Polymorphism rs42524 of COL1A2 and sporadic <\\entity><\\entity> in the Chinese population.OBJECT: The COL1A2 gene at 7q22.1 has been shown to be associated with familial <\\entity><\\entity> (IAs) in the Japanese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13800",
    "Sentence": "Polymorphism rs42524 of COL1A2 and sporadic intracranial aneurysms in the Chinese population.OBJECT: The COL1A2 gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (<\\entity><\\entity>) in the Japanese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13801",
    "Sentence": "In the present study, the authors investigated the correlation between the presence of the <\\entity><\\entity> polymorphism in COL1A2 and the occurrence of sporadic IAs in Chinese patients.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13802",
    "Sentence": "In the present study, the authors investigated the correlation between the presence of the rs42524 polymorphism in <\\entity><\\entity> and the occurrence of sporadic IAs in Chinese patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13803",
    "Sentence": "In the present study, the authors investigated the correlation between the presence of the rs42524 polymorphism in COL1A2 and the occurrence of sporadic <\\entity><\\entity> in Chinese patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13804",
    "Sentence": "METHODS: The polymorphism <\\entity><\\entity> of the COL1A2 gene was identified by polymerase chain reaction-based restriction analysis in genomic DNA from 226 patients with sporadic IAs (mean age 51.49 +/- 11.47 years) and 326 control participants (mean age 52.33 +/- 10.50 years).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13805",
    "Sentence": "METHODS: The polymorphism rs42524 of the <\\entity><\\entity> gene was identified by polymerase chain reaction-based restriction analysis in genomic DNA from 226 patients with sporadic IAs (mean age 51.49 +/- 11.47 years) and 326 control participants (mean age 52.33 +/- 10.50 years).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13806",
    "Sentence": "METHODS: The polymorphism rs42524 of the COL1A2 gene was identified by polymerase chain reaction-based restriction analysis in genomic DNA from 226 patients with sporadic <\\entity><\\entity> (mean age 51.49 +/- 11.47 years) and 326 control participants (mean age 52.33 +/- 10.50 years).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13807",
    "Sentence": "RESULTS: There was a significant difference in either the genotype distribution (chi(2) = 11.99, p = 0.002) or allelic frequencies (chi(2) = 11.96, p = 0.001, odds ratio 2.579, 95% confidence interval 1.486-4.476) between patients with <\\entity><\\entity> and patients in the control group.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13808",
    "Sentence": "CONCLUSIONS: The <\\entity><\\entity> polymorphism of COL1A2 could be a genetic risk factor for sporadic IAs among individuals of Chinese Han ethnicity.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "13809",
    "Sentence": "CONCLUSIONS: The rs42524 polymorphism of <\\entity><\\entity> could be a genetic risk factor for sporadic IAs among individuals of Chinese Han ethnicity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13810",
    "Sentence": "CONCLUSIONS: The rs42524 polymorphism of COL1A2 could be a genetic risk factor for sporadic <\\entity><\\entity> among individuals of Chinese Han ethnicity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13811",
    "Sentence": "This study is the first to confirm the association between <\\entity><\\entity> and IAs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13812",
    "Sentence": "This study is the first to confirm the association between COL1A2 and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13813",
    "Sentence": "Polymorphism rs42524 of <\\entity><\\entity> and sporadic intracranial aneurysms in the Chinese population.OBJECT: The <\\entity><\\entity> gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (IAs) in the Japanese population.",
    "Label": ""
  },
  {
    "id": "13814",
    "Sentence": "Polymorphism rs42524 of COL1A2 and sporadic <\\entity><\\entity> in the Chinese population.OBJECT: The COL1A2 gene at 7q22.1 has been shown to be associated with familial <\\entity><\\entity> (IAs) in the Japanese population.",
    "Label": ""
  },
  {
    "id": "13816",
    "Sentence": "Polymorphism rs42524 of <\\entity><\\entity> and sporadic intracranial aneurysms in the Chinese population.OBJECT: The <\\entity><\\entity> gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (IAs) in the Japanese population.",
    "Label": ""
  },
  {
    "id": "13817",
    "Sentence": "Polymorphism rs42524 of COL1A2 and sporadic intracranial aneurysms in the Chinese population.OBJECT: The COL1A2 gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (<\\entity><\\entity>) in the Japanese population.",
    "Label": ""
  },
  {
    "id": "13819",
    "Sentence": "In the present study, the authors investigated the correlation between the presence of the rs42524 polymorphism in <\\entity><\\entity> and the occurrence of sporadic IAs in Chinese patients.",
    "Label": ""
  },
  {
    "id": "13820",
    "Sentence": "In the present study, the authors investigated the correlation between the presence of the rs42524 polymorphism in COL1A2 and the occurrence of sporadic <\\entity><\\entity> in Chinese patients.",
    "Label": ""
  },
  {
    "id": "13822",
    "Sentence": "CONCLUSIONS: The <\\entity><\\entity> polymorphism of COL1A2 could be a genetic risk factor for sporadic IAs among individuals of Chinese Han ethnicity.",
    "Label": ""
  },
  {
    "id": "13823",
    "Sentence": "CONCLUSIONS: The rs42524 polymorphism of COL1A2 could be a genetic risk factor for sporadic <\\entity><\\entity> among individuals of Chinese Han ethnicity.",
    "Label": ""
  },
  {
    "id": "13825",
    "Sentence": "This study is the first to confirm the association between <\\entity><\\entity> and IAs.",
    "Label": ""
  },
  {
    "id": "13826",
    "Sentence": "This study is the first to confirm the association between COL1A2 and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13828",
    "Sentence": "Polymorphism rs42524 of <\\entity><\\entity> and sporadic intracranial aneurysms in the Chinese population.OBJECT: The <\\entity><\\entity> gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (IAs) in the Japanese population.",
    "Label": ""
  },
  {
    "id": "13829",
    "Sentence": "Polymorphism rs42524 of COL1A2 and <\\entity><\\entity> in the Chinese population.OBJECT: The COL1A2 gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (IAs) in the Japanese population.",
    "Label": ""
  },
  {
    "id": "13831",
    "Sentence": "Polymorphism <\\entity><\\entity> of COL1A2 and sporadic intracranial aneurysms in the Chinese population.OBJECT: The COL1A2 gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (IAs) in the Japanese population.",
    "Label": ""
  },
  {
    "id": "13832",
    "Sentence": "Polymorphism rs42524 of COL1A2 and <\\entity><\\entity> in the Chinese population.OBJECT: The COL1A2 gene at 7q22.1 has been shown to be associated with familial intracranial aneurysms (IAs) in the Japanese population.",
    "Label": ""
  },
  {
    "id": "13834",
    "Sentence": "In the present study, the authors investigated the correlation between the presence of the <\\entity><\\entity> polymorphism in COL1A2 and the occurrence of sporadic IAs in Chinese patients.",
    "Label": ""
  },
  {
    "id": "13835",
    "Sentence": "In the present study, the authors investigated the correlation between the presence of the rs42524 polymorphism in COL1A2 and the occurrence of sporadic <\\entity><\\entity> in Chinese patients.",
    "Label": ""
  },
  {
    "id": "13837",
    "Sentence": "METHODS: The polymorphism rs42524 of the <\\entity><\\entity> gene was identified by polymerase chain reaction-based restriction analysis in genomic DNA from 226 patients with sporadic IAs (mean age 51.49 +/- 11.47 years) and 326 control participants (mean age 52.33 +/- 10.50 years).",
    "Label": ""
  },
  {
    "id": "13838",
    "Sentence": "METHODS: The polymorphism rs42524 of the COL1A2 gene was identified by polymerase chain reaction-based restriction analysis in genomic DNA from 226 patients with sporadic <\\entity><\\entity> (mean age 51.49 +/- 11.47 years) and 326 control participants (mean age 52.33 +/- 10.50 years).",
    "Label": ""
  },
  {
    "id": "13840",
    "Sentence": "METHODS: The polymorphism <\\entity><\\entity> of the COL1A2 gene was identified by polymerase chain reaction-based restriction analysis in genomic DNA from 226 patients with sporadic IAs (mean age 51.49 +/- 11.47 years) and 326 control participants (mean age 52.33 +/- 10.50 years).",
    "Label": ""
  },
  {
    "id": "13841",
    "Sentence": "METHODS: The polymorphism rs42524 of the COL1A2 gene was identified by polymerase chain reaction-based restriction analysis in genomic DNA from 226 patients with sporadic <\\entity><\\entity> (mean age 51.49 +/- 11.47 years) and 326 control participants (mean age 52.33 +/- 10.50 years).",
    "Label": ""
  },
  {
    "id": "13843",
    "Sentence": "CONCLUSIONS: The rs42524 polymorphism of <\\entity><\\entity> could be a genetic risk factor for sporadic IAs among individuals of Chinese Han ethnicity.",
    "Label": ""
  },
  {
    "id": "13844",
    "Sentence": "CONCLUSIONS: The rs42524 polymorphism of COL1A2 could be a genetic risk factor for sporadic <\\entity><\\entity> among individuals of Chinese Han ethnicity.",
    "Label": ""
  },
  {
    "id": "13850",
    "Sentence": "A review of <\\entity><\\entity>.The first article in this supplement is an overall review of the first glycylcycline, <\\entity><\\entity>, which includes a brief overview of the problem of tetracycline resistance as well as <\\entity><\\entity>'s mode of action, antibacterial activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13851",
    "Sentence": "A review of tigecycline.The first article in this supplement is an overall review of the first <\\entity><\\entity>, tigecycline, which includes a brief overview of the problem of tetracycline resistance as well as tigecycline's mode of action, antibacterial activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13852",
    "Sentence": "A review of <\\entity><\\entity>.The first article in this supplement is an overall review of the first glycylcycline, <\\entity><\\entity>, which includes a brief overview of the problem of tetracycline resistance as well as <\\entity><\\entity>'s mode of action, antibacterial activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13853",
    "Sentence": "A review of tigecycline.The first article in this supplement is an overall review of the first glycylcycline, tigecycline, which includes a brief overview of the problem of <\\entity><\\entity> resistance as well as tigecycline's mode of action, antibacterial activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13854",
    "Sentence": "A review of <\\entity><\\entity>.The first article in this supplement is an overall review of the first glycylcycline, <\\entity><\\entity>, which includes a brief overview of the problem of tetracycline resistance as well as <\\entity><\\entity>'s mode of action, antibacterial activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13855",
    "Sentence": "The remaining articles in the supplement report the European clinical experience from the pivotal clinical trials in <\\entity><\\entity>, complicated skin and skin structure infections and community acquired pneumonia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13856",
    "Sentence": "The remaining articles in the supplement report the European clinical experience from the pivotal clinical trials in complicated intra-abdominal infections, <\\entity><\\entity> and skin structure infections and community acquired pneumonia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13857",
    "Sentence": "The remaining articles in the supplement report the European clinical experience from the pivotal clinical trials in complicated intra-abdominal infections, complicated skin and <\\entity><\\entity> and community acquired pneumonia.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13858",
    "Sentence": "The remaining articles in the supplement report the European clinical experience from the pivotal clinical trials in complicated intra-abdominal infections, complicated skin and skin structure infections and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13863",
    "Sentence": "Estrogen-dependent downregulation of <\\entity><\\entity> gene expression in breast cancer cells is mediated via a 3' distal element.Regulation of hairy and enhancer of split homologue-1 (HES-1) by estradiol and all-trans retinoic acid affects proliferation of human breast cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13864",
    "Sentence": "Estrogen-dependent downregulation of hairy and enhancer of split homolog-1 gene expression in <\\entity><\\entity> cells is mediated via a 3' distal element.Regulation of hairy and enhancer of split homologue-1 (HES-1) by estradiol and all-trans retinoic acid affects proliferation of human <\\entity><\\entity> cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13865",
    "Sentence": "Estrogen-dependent downregulation of hairy and enhancer of split homolog-1 gene expression in breast cancer cells is mediated via a 3' distal element.Regulation of <\\entity><\\entity> (HES-1) by estradiol and all-trans retinoic acid affects proliferation of human breast cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13866",
    "Sentence": "Estrogen-dependent downregulation of hairy and enhancer of split homolog-1 gene expression in breast cancer cells is mediated via a 3' distal element.Regulation of hairy and enhancer of split homologue-1 (<\\entity><\\entity>) by estradiol and all-trans retinoic acid affects proliferation of human breast cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13867",
    "Sentence": "Estrogen-dependent downregulation of hairy and enhancer of split homolog-1 gene expression in breast cancer cells is mediated via a 3' distal element.Regulation of hairy and enhancer of split homologue-1 (HES-1) by <\\entity><\\entity> and all-trans retinoic acid affects proliferation of human breast cancer cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13868",
    "Sentence": "Estrogen-dependent downregulation of hairy and enhancer of split homolog-1 gene expression in <\\entity><\\entity> cells is mediated via a 3' distal element.Regulation of hairy and enhancer of split homologue-1 (HES-1) by estradiol and all-trans retinoic acid affects proliferation of human <\\entity><\\entity> cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13869",
    "Sentence": "Here, we identify and characterize <\\entity><\\entity> involved in HES-1 regulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13870",
    "Sentence": "Here, we identify and characterize cis-regulatory elements involved in <\\entity><\\entity> regulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13871",
    "Sentence": "In the distal 5' promoter of the <\\entity><\\entity> gene, we found a retinoic acid response element and in the distal 3' region, an estrogen receptor alpha(ER)alpha binding site.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13872",
    "Sentence": "In the distal 5' promoter of the HES-1 gene, we found a <\\entity><\\entity> response element and in the distal 3' region, an estrogen receptor alpha(ER)alpha binding site.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13873",
    "Sentence": "In the distal 5' promoter of the HES-1 gene, we found a retinoic acid response element and in the distal 3' region, an <\\entity><\\entity>(ER)alpha binding site.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13874",
    "Sentence": "In the distal 5' promoter of the HES-1 gene, we found a retinoic acid response element and in the distal 3' region, an estrogen receptor alpha(<\\entity><\\entity> binding site.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13875",
    "Sentence": "The <\\entity><\\entity> binding site, composed of an estrogen response element (ERE) and an ERE half-site, is important for both <\\entity><\\entity> binding and transcriptional regulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13876",
    "Sentence": "The ERalpha binding site, composed of an <\\entity><\\entity> (ERE) and an ERE half-site, is important for both ERalpha binding and transcriptional regulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13877",
    "Sentence": "The ERalpha binding site, composed of an estrogen response element (<\\entity><\\entity>) and an <\\entity><\\entity> half-site, is important for both ERalpha binding and transcriptional regulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13878",
    "Sentence": "The ERalpha binding site, composed of an estrogen response element (<\\entity><\\entity>) and an <\\entity><\\entity> half-site, is important for both ERalpha binding and transcriptional regulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13879",
    "Sentence": "The <\\entity><\\entity> binding site, composed of an estrogen response element (ERE) and an ERE half-site, is important for both <\\entity><\\entity> binding and transcriptional regulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13880",
    "Sentence": "<\\entity><\\entity> immunoprecipitation assays revealed that ERalpha is recruited to the ERE and associates with the HES-1 promoter.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13881",
    "Sentence": "Chromatin immunoprecipitation assays revealed that <\\entity><\\entity> is recruited to the ERE and associates with the HES-1 promoter.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13882",
    "Sentence": "Chromatin immunoprecipitation assays revealed that ERalpha is recruited to the <\\entity><\\entity> and associates with the HES-1 promoter.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13883",
    "Sentence": "Chromatin immunoprecipitation assays revealed that ERalpha is recruited to the ERE and associates with the <\\entity><\\entity> promoter.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13884",
    "Sentence": "We also show <\\entity><\\entity> of nuclear receptor co-regulators to the ERE in response to estradiol, followed by a decrease in histone acetylation and RNA polymerase II docking in the HES-1 promoter region.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13885",
    "Sentence": "We also show recruitment of nuclear receptor co-regulators to the <\\entity><\\entity> in response to estradiol, followed by a decrease in histone acetylation and RNA polymerase II docking in the HES-1 promoter region.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13886",
    "Sentence": "We also show recruitment of nuclear receptor co-regulators to the ERE in response to <\\entity><\\entity>, followed by a decrease in histone acetylation and RNA polymerase II docking in the HES-1 promoter region.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13887",
    "Sentence": "We also show recruitment of nuclear receptor co-regulators to the ERE in response to estradiol, followed by a decrease in <\\entity><\\entity> acetylation and RNA polymerase II docking in the HES-1 promoter region.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13888",
    "Sentence": "We also show recruitment of nuclear receptor co-regulators to the ERE in response to estradiol, followed by a decrease in histone acetylation and <\\entity><\\entity> docking in the HES-1 promoter region.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13889",
    "Sentence": "We also show recruitment of nuclear receptor co-regulators to the ERE in response to estradiol, followed by a decrease in histone acetylation and RNA polymerase II docking in the <\\entity><\\entity> promoter region.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13890",
    "Sentence": "Our findings are consistent with a novel type of repressive <\\entity><\\entity> in the distal 3' region of the HES-1 gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13891",
    "Sentence": "Our findings are consistent with a novel type of repressive <\\entity><\\entity> in the distal 3' region of the HES-1 gene.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "13892",
    "Sentence": "Our findings are consistent with a novel type of repressive estrogen response element in the distal 3' region of the <\\entity><\\entity> gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13893",
    "Sentence": "Estrogen-dependent downregulation of hairy and enhancer of split homolog-1 gene expression in breast cancer cells is mediated via a 3' distal element.Regulation of hairy and enhancer of split homologue-1 (<\\entity><\\entity>) by estradiol and all-trans retinoic acid affects proliferation of human breast cancer cells.",
    "Label": ""
  },
  {
    "id": "13894",
    "Sentence": "Estrogen-dependent downregulation of hairy and enhancer of split homolog-1 gene expression in <\\entity><\\entity> cells is mediated via a 3' distal element.Regulation of hairy and enhancer of split homologue-1 (HES-1) by estradiol and all-trans retinoic acid affects proliferation of human <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13896",
    "Sentence": "We also show recruitment of nuclear receptor co-regulators to the ERE in response to estradiol, followed by a decrease in histone acetylation and RNA polymerase II docking in the <\\entity><\\entity> promoter region.",
    "Label": ""
  },
  {
    "id": "13897",
    "Sentence": "We also show <\\entity><\\entity> of nuclear receptor co-regulators to the ERE in response to estradiol, followed by a decrease in histone acetylation and RNA polymerase II docking in the HES-1 promoter region.",
    "Label": ""
  },
  {
    "id": "13899",
    "Sentence": "Estrogen-dependent downregulation of <\\entity><\\entity> gene expression in breast cancer cells is mediated via a 3' distal element.Regulation of hairy and enhancer of split homologue-1 (HES-1) by estradiol and all-trans retinoic acid affects proliferation of human breast cancer cells.",
    "Label": ""
  },
  {
    "id": "13900",
    "Sentence": "Estrogen-dependent downregulation of hairy and enhancer of split homolog-1 gene expression in <\\entity><\\entity> cells is mediated via a 3' distal element.Regulation of hairy and enhancer of split homologue-1 (HES-1) by estradiol and all-trans retinoic acid affects proliferation of human <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13902",
    "Sentence": "Estrogen-dependent downregulation of hairy and enhancer of split homolog-1 gene expression in breast cancer cells is mediated via a 3' distal element.Regulation of <\\entity><\\entity> (HES-1) by estradiol and all-trans retinoic acid affects proliferation of human breast cancer cells.",
    "Label": ""
  },
  {
    "id": "13903",
    "Sentence": "Estrogen-dependent downregulation of hairy and enhancer of split homolog-1 gene expression in <\\entity><\\entity> cells is mediated via a 3' distal element.Regulation of hairy and enhancer of split homologue-1 (HES-1) by estradiol and all-trans retinoic acid affects proliferation of human <\\entity><\\entity> cells.",
    "Label": ""
  },
  {
    "id": "13905",
    "Sentence": "Our findings are consistent with a novel type of repressive estrogen response element in the distal 3' region of the <\\entity><\\entity> gene.",
    "Label": ""
  },
  {
    "id": "13906",
    "Sentence": "Our findings are consistent with a novel type of repressive <\\entity><\\entity> in the distal 3' region of the HES-1 gene.",
    "Label": ""
  },
  {
    "id": "13912",
    "Sentence": "Evidence that resistance to <\\entity><\\entity> may be due to BCR-ABL, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-positive acute lymphoblastic leukemia.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13913",
    "Sentence": "Evidence that resistance to nilotinib may be due to <\\entity><\\entity>, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-positive acute lymphoblastic leukemia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13914",
    "Sentence": "Evidence that resistance to nilotinib may be due to BCR-ABL, <\\entity><\\entity>, or Src kinase overexpression.Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-positive acute lymphoblastic leukemia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13915",
    "Sentence": "Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or <\\entity><\\entity> overexpression.Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-positive acute lymphoblastic leukemia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13916",
    "Sentence": "Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of <\\entity><\\entity> is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in <\\entity><\\entity>-positive acute lymphoblastic leukemia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13917",
    "Sentence": "Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (<\\entity><\\entity>) and in Bcr-Abl-positive acute lymphoblastic leukemia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13918",
    "Sentence": "Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of <\\entity><\\entity> is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in <\\entity><\\entity>-positive acute lymphoblastic leukemia.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13919",
    "Sentence": "Whereas <\\entity><\\entity>, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of <\\entity><\\entity>-resistant or <\\entity><\\entity>-intolerant disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13920",
    "Sentence": "Whereas imatinib, a <\\entity><\\entity> tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13921",
    "Sentence": "Whereas imatinib, a <\\entity><\\entity> tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13922",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for <\\entity><\\entity>, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13923",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, <\\entity><\\entity> tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13924",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, <\\entity><\\entity> tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13925",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as <\\entity><\\entity> or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13926",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or <\\entity><\\entity> have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13927",
    "Sentence": "Whereas <\\entity><\\entity>, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of <\\entity><\\entity>-resistant or <\\entity><\\entity>-intolerant disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13928",
    "Sentence": "Whereas <\\entity><\\entity>, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of <\\entity><\\entity>-resistant or <\\entity><\\entity>-intolerant disease.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13929",
    "Sentence": "In the current study, we generated <\\entity><\\entity>-resistant cell lines and investigated their mechanism of resistance.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13930",
    "Sentence": "Overexpression of <\\entity><\\entity> and multidrug resistance gene (MDR-1) were found among the investigated mechanisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13931",
    "Sentence": "Overexpression of BCR-ABL and <\\entity><\\entity> (MDR-1) were found among the investigated mechanisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13932",
    "Sentence": "Overexpression of BCR-ABL and multidrug resistance gene (<\\entity><\\entity>) were found among the investigated mechanisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13933",
    "Sentence": "We showed that <\\entity><\\entity> is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13934",
    "Sentence": "We showed that nilotinib is a substrate of the <\\entity><\\entity> product, P-glycoprotein, using verapamil or PSC833 to block binding.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13935",
    "Sentence": "We showed that nilotinib is a substrate of the multidrug resistance gene product, <\\entity><\\entity>, using verapamil or PSC833 to block binding.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13936",
    "Sentence": "We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using <\\entity><\\entity> or PSC833 to block binding.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13937",
    "Sentence": "We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or <\\entity><\\entity> to block binding.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13938",
    "Sentence": "Up-regulated expression of <\\entity><\\entity> kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to nilotinib.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13939",
    "Sentence": "Up-regulated expression of p53/56 <\\entity><\\entity> kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and <\\entity><\\entity> silencing by small interfering RNA restored sensitivity to nilotinib.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13940",
    "Sentence": "Up-regulated expression of p53/56 Lyn kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13941",
    "Sentence": "Moreover, failure of <\\entity><\\entity> treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant CML.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13942",
    "Sentence": "Moreover, failure of nilotinib treatment was accompanied by an increase of <\\entity><\\entity> expression in patients with resistant CML.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13943",
    "Sentence": "Moreover, failure of nilotinib treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13944",
    "Sentence": "Two <\\entity><\\entity> (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13945",
    "Sentence": "Two <\\entity><\\entity> (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13946",
    "Sentence": "Two Src kinase inhibitors (<\\entity><\\entity> and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13947",
    "Sentence": "Two Src kinase inhibitors (<\\entity><\\entity> and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13948",
    "Sentence": "Two Src kinase inhibitors (PP1 and <\\entity><\\entity>) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13949",
    "Sentence": "Two Src kinase inhibitors (PP1 and <\\entity><\\entity>) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13950",
    "Sentence": "Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit <\\entity><\\entity> tyrosine kinase activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13951",
    "Sentence": "In contrast, <\\entity><\\entity>, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13952",
    "Sentence": "In contrast, dasatinib, a <\\entity><\\entity>, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13953",
    "Sentence": "In contrast, dasatinib, a dual <\\entity><\\entity> and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the <\\entity><\\entity> cell line overexpressing p53/56 Lyn.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13954",
    "Sentence": "In contrast, dasatinib, a dual Bcr-Abl and <\\entity><\\entity> kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13955",
    "Sentence": "In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both <\\entity><\\entity> and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13956",
    "Sentence": "In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and <\\entity><\\entity>, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13957",
    "Sentence": "In contrast, dasatinib, a dual <\\entity><\\entity> and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the <\\entity><\\entity> cell line overexpressing p53/56 Lyn.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13958",
    "Sentence": "In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13959",
    "Sentence": "Such mechanisms of resistance are close to those observed in <\\entity><\\entity>-resistant cell lines and emphasize the critical role of Lyn in nilotinib resistance.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13960",
    "Sentence": "Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of <\\entity><\\entity> in nilotinib resistance.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "13961",
    "Sentence": "Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of Lyn in <\\entity><\\entity> resistance.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "13962",
    "Sentence": "Evidence that resistance to <\\entity><\\entity> may be due to BCR-ABL, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-positive acute lymphoblastic leukemia.",
    "Label": ""
  },
  {
    "id": "13963",
    "Sentence": "Evidence that resistance to nilotinib may be due to BCR-ABL, <\\entity><\\entity>, or Src kinase overexpression.Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-positive acute lymphoblastic leukemia.",
    "Label": ""
  },
  {
    "id": "13965",
    "Sentence": "Evidence that resistance to <\\entity><\\entity> may be due to BCR-ABL, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-positive acute lymphoblastic leukemia.",
    "Label": ""
  },
  {
    "id": "13966",
    "Sentence": "Evidence that resistance to nilotinib may be due to <\\entity><\\entity>, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-positive acute lymphoblastic leukemia.",
    "Label": ""
  },
  {
    "id": "13968",
    "Sentence": "Evidence that resistance to <\\entity><\\entity> may be due to BCR-ABL, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-positive acute lymphoblastic leukemia.",
    "Label": ""
  },
  {
    "id": "13969",
    "Sentence": "Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or <\\entity><\\entity> overexpression.Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl-positive acute lymphoblastic leukemia.",
    "Label": ""
  },
  {
    "id": "13971",
    "Sentence": "We showed that <\\entity><\\entity> is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding.",
    "Label": ""
  },
  {
    "id": "13972",
    "Sentence": "We showed that nilotinib is a substrate of the multidrug resistance gene product, <\\entity><\\entity>, using verapamil or PSC833 to block binding.",
    "Label": ""
  },
  {
    "id": "13974",
    "Sentence": "We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using <\\entity><\\entity> or PSC833 to block binding.",
    "Label": ""
  },
  {
    "id": "13975",
    "Sentence": "We showed that nilotinib is a substrate of the multidrug resistance gene product, <\\entity><\\entity>, using verapamil or PSC833 to block binding.",
    "Label": ""
  },
  {
    "id": "13977",
    "Sentence": "We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or <\\entity><\\entity> to block binding.",
    "Label": ""
  },
  {
    "id": "13978",
    "Sentence": "We showed that nilotinib is a substrate of the multidrug resistance gene product, <\\entity><\\entity>, using verapamil or PSC833 to block binding.",
    "Label": ""
  },
  {
    "id": "13980",
    "Sentence": "Up-regulated expression of p53/56 Lyn kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13981",
    "Sentence": "Up-regulated expression of p53/56 <\\entity><\\entity> kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and <\\entity><\\entity> silencing by small interfering RNA restored sensitivity to nilotinib.",
    "Label": ""
  },
  {
    "id": "13983",
    "Sentence": "Moreover, failure of <\\entity><\\entity> treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant CML.",
    "Label": ""
  },
  {
    "id": "13984",
    "Sentence": "Moreover, failure of nilotinib treatment was accompanied by an increase of <\\entity><\\entity> expression in patients with resistant CML.",
    "Label": ""
  },
  {
    "id": "13986",
    "Sentence": "Two Src kinase inhibitors (<\\entity><\\entity> and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.",
    "Label": ""
  },
  {
    "id": "13987",
    "Sentence": "Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit <\\entity><\\entity> tyrosine kinase activity.",
    "Label": ""
  },
  {
    "id": "13989",
    "Sentence": "Two Src kinase inhibitors (PP1 and <\\entity><\\entity>) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.",
    "Label": ""
  },
  {
    "id": "13990",
    "Sentence": "Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit <\\entity><\\entity> tyrosine kinase activity.",
    "Label": ""
  },
  {
    "id": "13992",
    "Sentence": "Two <\\entity><\\entity> (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.",
    "Label": ""
  },
  {
    "id": "13993",
    "Sentence": "Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit <\\entity><\\entity> tyrosine kinase activity.",
    "Label": ""
  },
  {
    "id": "13995",
    "Sentence": "In contrast, <\\entity><\\entity>, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.",
    "Label": ""
  },
  {
    "id": "13996",
    "Sentence": "In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and <\\entity><\\entity>, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "13998",
    "Sentence": "In contrast, <\\entity><\\entity>, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.",
    "Label": ""
  },
  {
    "id": "13999",
    "Sentence": "In contrast, dasatinib, a dual <\\entity><\\entity> and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the <\\entity><\\entity> cell line overexpressing p53/56 Lyn.",
    "Label": ""
  },
  {
    "id": "14001",
    "Sentence": "In contrast, <\\entity><\\entity>, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.",
    "Label": ""
  },
  {
    "id": "14002",
    "Sentence": "In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14004",
    "Sentence": "In contrast, dasatinib, a <\\entity><\\entity>, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.",
    "Label": ""
  },
  {
    "id": "14005",
    "Sentence": "In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and <\\entity><\\entity>, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14007",
    "Sentence": "In contrast, dasatinib, a <\\entity><\\entity>, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.",
    "Label": ""
  },
  {
    "id": "14008",
    "Sentence": "In contrast, dasatinib, a dual <\\entity><\\entity> and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the <\\entity><\\entity> cell line overexpressing p53/56 Lyn.",
    "Label": ""
  },
  {
    "id": "14010",
    "Sentence": "In contrast, dasatinib, a <\\entity><\\entity>, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.",
    "Label": ""
  },
  {
    "id": "14011",
    "Sentence": "In contrast, dasatinib, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14013",
    "Sentence": "Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of Lyn in <\\entity><\\entity> resistance.",
    "Label": ""
  },
  {
    "id": "14014",
    "Sentence": "Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of <\\entity><\\entity> in nilotinib resistance.",
    "Label": ""
  },
  {
    "id": "14016",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as <\\entity><\\entity> or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": ""
  },
  {
    "id": "14017",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for <\\entity><\\entity>, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": ""
  },
  {
    "id": "14019",
    "Sentence": "Whereas <\\entity><\\entity>, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of <\\entity><\\entity>-resistant or <\\entity><\\entity>-intolerant disease.",
    "Label": ""
  },
  {
    "id": "14020",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for <\\entity><\\entity>, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": ""
  },
  {
    "id": "14022",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or <\\entity><\\entity> have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": ""
  },
  {
    "id": "14023",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for <\\entity><\\entity>, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": ""
  },
  {
    "id": "14025",
    "Sentence": "Up-regulated expression of p53/56 Lyn kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14026",
    "Sentence": "Up-regulated expression of <\\entity><\\entity> kinase, both at the mRNA and protein level, was found in one of the resistant cell lines and Lyn silencing by small interfering RNA restored sensitivity to nilotinib.",
    "Label": ""
  },
  {
    "id": "14028",
    "Sentence": "Moreover, failure of <\\entity><\\entity> treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant CML.",
    "Label": ""
  },
  {
    "id": "14029",
    "Sentence": "Moreover, failure of nilotinib treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14031",
    "Sentence": "In contrast, <\\entity><\\entity>, a dual Bcr-Abl and Src kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.",
    "Label": ""
  },
  {
    "id": "14032",
    "Sentence": "In contrast, dasatinib, a dual Bcr-Abl and <\\entity><\\entity> kinase inhibitor, inhibited the phosphorylation of both BCR-ABL and Lyn, and induced apoptosis of the Bcr-Abl cell line overexpressing p53/56 Lyn.",
    "Label": ""
  },
  {
    "id": "14034",
    "Sentence": "Such mechanisms of resistance are close to those observed in <\\entity><\\entity>-resistant cell lines and emphasize the critical role of Lyn in nilotinib resistance.",
    "Label": ""
  },
  {
    "id": "14035",
    "Sentence": "Such mechanisms of resistance are close to those observed in imatinib-resistant cell lines and emphasize the critical role of <\\entity><\\entity> in nilotinib resistance.",
    "Label": ""
  },
  {
    "id": "14037",
    "Sentence": "Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of <\\entity><\\entity> is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in <\\entity><\\entity>-positive acute lymphoblastic leukemia.",
    "Label": ""
  },
  {
    "id": "14038",
    "Sentence": "Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in <\\entity><\\entity> (CML) and in Bcr-Abl-positive acute lymphoblastic leukemia.",
    "Label": ""
  },
  {
    "id": "14040",
    "Sentence": "Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of <\\entity><\\entity> is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in <\\entity><\\entity>-positive acute lymphoblastic leukemia.",
    "Label": ""
  },
  {
    "id": "14041",
    "Sentence": "Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (<\\entity><\\entity>) and in Bcr-Abl-positive acute lymphoblastic leukemia.",
    "Label": ""
  },
  {
    "id": "14043",
    "Sentence": "Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of <\\entity><\\entity> is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in <\\entity><\\entity>-positive acute lymphoblastic leukemia.",
    "Label": ""
  },
  {
    "id": "14044",
    "Sentence": "Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.Targeting the tyrosine kinase activity of <\\entity><\\entity> is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in <\\entity><\\entity>-positive acute lymphoblastic leukemia.",
    "Label": ""
  },
  {
    "id": "14046",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as <\\entity><\\entity> or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": ""
  },
  {
    "id": "14047",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, <\\entity><\\entity> tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": ""
  },
  {
    "id": "14049",
    "Sentence": "Whereas <\\entity><\\entity>, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of <\\entity><\\entity>-resistant or <\\entity><\\entity>-intolerant disease.",
    "Label": ""
  },
  {
    "id": "14050",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, <\\entity><\\entity> tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": ""
  },
  {
    "id": "14052",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or <\\entity><\\entity> have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": ""
  },
  {
    "id": "14053",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, <\\entity><\\entity> tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": ""
  },
  {
    "id": "14055",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for CML, <\\entity><\\entity> tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": ""
  },
  {
    "id": "14056",
    "Sentence": "Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is now used in frontline therapy for <\\entity><\\entity>, second-generation inhibitors of Bcr-Abl tyrosine kinase such as nilotinib or dasatinib have been developed for the treatment of imatinib-resistant or imatinib-intolerant disease.",
    "Label": ""
  },
  {
    "id": "14058",
    "Sentence": "We showed that <\\entity><\\entity> is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or PSC833 to block binding.",
    "Label": ""
  },
  {
    "id": "14059",
    "Sentence": "We showed that nilotinib is a substrate of the <\\entity><\\entity> product, P-glycoprotein, using verapamil or PSC833 to block binding.",
    "Label": ""
  },
  {
    "id": "14061",
    "Sentence": "We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using <\\entity><\\entity> or PSC833 to block binding.",
    "Label": ""
  },
  {
    "id": "14062",
    "Sentence": "We showed that nilotinib is a substrate of the <\\entity><\\entity> product, P-glycoprotein, using verapamil or PSC833 to block binding.",
    "Label": ""
  },
  {
    "id": "14064",
    "Sentence": "We showed that nilotinib is a substrate of the multidrug resistance gene product, P-glycoprotein, using verapamil or <\\entity><\\entity> to block binding.",
    "Label": ""
  },
  {
    "id": "14065",
    "Sentence": "We showed that nilotinib is a substrate of the <\\entity><\\entity> product, P-glycoprotein, using verapamil or PSC833 to block binding.",
    "Label": ""
  },
  {
    "id": "14067",
    "Sentence": "Moreover, failure of nilotinib treatment was accompanied by an increase of <\\entity><\\entity> expression in patients with resistant CML.",
    "Label": ""
  },
  {
    "id": "14068",
    "Sentence": "Moreover, failure of nilotinib treatment was accompanied by an increase of Lyn mRNA expression in patients with resistant <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14070",
    "Sentence": "Two <\\entity><\\entity> (PP1 and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.",
    "Label": ""
  },
  {
    "id": "14071",
    "Sentence": "Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit <\\entity><\\entity> tyrosine kinase activity.",
    "Label": ""
  },
  {
    "id": "14073",
    "Sentence": "Two Src kinase inhibitors (<\\entity><\\entity> and PP2) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.",
    "Label": ""
  },
  {
    "id": "14074",
    "Sentence": "Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit <\\entity><\\entity> tyrosine kinase activity.",
    "Label": ""
  },
  {
    "id": "14076",
    "Sentence": "Two Src kinase inhibitors (PP1 and <\\entity><\\entity>) partially removed resistance but did not significantly inhibit Bcr-Abl tyrosine kinase activity.",
    "Label": ""
  },
  {
    "id": "14077",
    "Sentence": "Two Src kinase inhibitors (PP1 and PP2) partially removed resistance but did not significantly inhibit <\\entity><\\entity> tyrosine kinase activity.",
    "Label": ""
  },
  {
    "id": "14083",
    "Sentence": "However, several problems continue to impose serious limits on LTx today, including a shortage of donor livers, recurrence of disease (eg, hepatitis, hepatocellular cancer), preservation of long-term allograft function and the side effects of <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14084",
    "Sentence": "However, several problems continue to impose serious limits on LTx today, including a shortage of donor livers, recurrence of disease (eg, hepatitis, hepatocellular cancer), preservation of long-term allograft function and the side effects of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14085",
    "Sentence": "However, several problems continue to impose serious limits on LTx today, including a shortage of donor livers, recurrence of disease (eg, <\\entity><\\entity>, hepatocellular cancer), preservation of long-term allograft function and the side effects of anti-rejection drugs.",
    "Label": ""
  },
  {
    "id": "14087",
    "Sentence": "However, several problems continue to impose serious limits on LTx today, including a shortage of donor livers, recurrence of disease (eg, hepatitis, hepatocellular cancer), preservation of long-term allograft function and the side effects of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14088",
    "Sentence": "However, several problems continue to impose serious limits on LTx today, including a shortage of donor livers, recurrence of disease (eg, hepatitis, hepatocellular <\\entity><\\entity>), preservation of long-term allograft function and the side effects of anti-rejection drugs.",
    "Label": ""
  },
  {
    "id": "14094",
    "Sentence": "<\\entity><\\entity> induce intestinal transient receptor potential vanilloid type 6 expression in rats and Caco-2 cells.Fructooligosaccharides (FOS) are indigestible oligosaccharides that increase calcium absorption by the colorectum in rats, but the underlying mechanisms remain unclear.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14095",
    "Sentence": "<\\entity><\\entity> induce intestinal transient receptor potential vanilloid type 6 expression in rats and Caco-2 cells.Fructooligosaccharides (FOS) are indigestible oligosaccharides that increase calcium absorption by the colorectum in rats, but the underlying mechanisms remain unclear.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14096",
    "Sentence": "Short-chain fatty acids induce <\\entity><\\entity> expression in rats and Caco-2 cells.Fructooligosaccharides (FOS) are indigestible oligosaccharides that increase calcium absorption by the colorectum in rats, but the underlying mechanisms remain unclear.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14097",
    "Sentence": "Short-chain fatty acids induce intestinal transient receptor potential vanilloid type 6 expression in rats and Caco-2 cells.<\\entity><\\entity> (FOS) are indigestible oligosaccharides that increase calcium absorption by the colorectum in rats, but the underlying mechanisms remain unclear.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14098",
    "Sentence": "Short-chain fatty acids induce intestinal transient receptor potential vanilloid type 6 expression in rats and Caco-2 cells.Fructooligosaccharides (<\\entity><\\entity>) are indigestible oligosaccharides that increase calcium absorption by the colorectum in rats, but the underlying mechanisms remain unclear.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14099",
    "Sentence": "Short-chain fatty acids induce intestinal transient receptor potential vanilloid type 6 expression in rats and Caco-2 cells.Fructooligosaccharides (<\\entity><\\entity>) are indigestible oligosaccharides that increase calcium absorption by the colorectum in rats, but the underlying mechanisms remain unclear.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14100",
    "Sentence": "Short-chain fatty acids induce intestinal transient receptor potential vanilloid type 6 expression in rats and Caco-2 cells.Fructooligosaccharides (FOS) are <\\entity><\\entity> that increase calcium absorption by the colorectum in rats, but the underlying mechanisms remain unclear.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14101",
    "Sentence": "Short-chain fatty acids induce intestinal transient receptor potential vanilloid type 6 expression in rats and Caco-2 cells.Fructooligosaccharides (FOS) are indigestible oligosaccharides that increase <\\entity><\\entity> absorption by the colorectum in rats, but the underlying mechanisms remain unclear.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14102",
    "Sentence": "We therefore investigated the effects of <\\entity><\\entity> on expressions of genes involved with calcium absorption in rat colorectal mucosa cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14103",
    "Sentence": "We therefore investigated the effects of <\\entity><\\entity> on expressions of genes involved with calcium absorption in rat colorectal mucosa cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14104",
    "Sentence": "We therefore investigated the effects of FOS on expressions of genes involved with <\\entity><\\entity> absorption in rat colorectal mucosa cells.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14105",
    "Sentence": "After feeding a diet containing <\\entity><\\entity> (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14106",
    "Sentence": "After feeding a diet containing <\\entity><\\entity> (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14107",
    "Sentence": "After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of <\\entity><\\entity> (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14108",
    "Sentence": "After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (<\\entity><\\entity>), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14109",
    "Sentence": "After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), <\\entity><\\entity>, and plasma membrane calcium-ATPase 1b (PMCA1b).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14110",
    "Sentence": "After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and <\\entity><\\entity> (PMCA1b).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14111",
    "Sentence": "After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14112",
    "Sentence": "The <\\entity><\\entity> diet increased expression of TRPV6 and calbindin-D9k but did not affect PMCA1b expression.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14113",
    "Sentence": "The <\\entity><\\entity> diet increased expression of TRPV6 and calbindin-D9k but did not affect PMCA1b expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14114",
    "Sentence": "The FOS diet increased expression of <\\entity><\\entity> and calbindin-D9k but did not affect PMCA1b expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14115",
    "Sentence": "The FOS diet increased expression of TRPV6 and <\\entity><\\entity> but did not affect PMCA1b expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14116",
    "Sentence": "The FOS diet increased expression of TRPV6 and calbindin-D9k but did not affect <\\entity><\\entity> expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14117",
    "Sentence": "Because <\\entity><\\entity> could not directly affect gene expression, SCFA formed as fermentation products of <\\entity><\\entity> were considered as likely intermediates.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14118",
    "Sentence": "Because <\\entity><\\entity> could not directly affect gene expression, SCFA formed as fermentation products of <\\entity><\\entity> were considered as likely intermediates.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14119",
    "Sentence": "Because FOS could not directly affect gene expression, <\\entity><\\entity> formed as fermentation products of FOS were considered as likely intermediates.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14120",
    "Sentence": "Because FOS could not directly affect gene expression, <\\entity><\\entity> formed as fermentation products of FOS were considered as likely intermediates.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14121",
    "Sentence": "Because <\\entity><\\entity> could not directly affect gene expression, SCFA formed as fermentation products of <\\entity><\\entity> were considered as likely intermediates.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14122",
    "Sentence": "Because <\\entity><\\entity> could not directly affect gene expression, SCFA formed as fermentation products of <\\entity><\\entity> were considered as likely intermediates.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14123",
    "Sentence": "<\\entity><\\entity> (2.0 mmol/L) were thus added to Caco-2 human colonic epithelial cells, resulting in significantly increased mRNA expression of TRPV6.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14124",
    "Sentence": "<\\entity><\\entity> (2.0 mmol/L) were thus added to Caco-2 human colonic epithelial cells, resulting in significantly increased mRNA expression of TRPV6.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14125",
    "Sentence": "SCFA (2.0 mmol/L) were thus added to Caco-2 human colonic epithelial cells, resulting in significantly increased <\\entity><\\entity> expression of TRPV6.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14126",
    "Sentence": "SCFA (2.0 mmol/L) were thus added to Caco-2 human colonic epithelial cells, resulting in significantly increased mRNA expression of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14127",
    "Sentence": "To ascertain the effects of <\\entity><\\entity> on mRNA expression, a genomic clone of TRPV6 was isolated.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14128",
    "Sentence": "To ascertain the effects of <\\entity><\\entity> on mRNA expression, a genomic clone of TRPV6 was isolated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14129",
    "Sentence": "To ascertain the effects of SCFA on <\\entity><\\entity> expression, a genomic clone of TRPV6 was isolated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14130",
    "Sentence": "To ascertain the effects of SCFA on mRNA expression, a genomic clone of <\\entity><\\entity> was isolated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14131",
    "Sentence": "Using luciferase reporter assay, a segment between -71 nucleotides and the translation start site was found to contain a positive responsive element to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14132",
    "Sentence": "Using luciferase reporter assay, a segment between -71 nucleotides and the translation start site was found to contain a positive responsive element to <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14133",
    "Sentence": "These results suggest that <\\entity><\\entity> increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of <\\entity><\\entity>, are involved in the increased mRNA expression of TRPV6.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14134",
    "Sentence": "These results suggest that <\\entity><\\entity> increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of <\\entity><\\entity>, are involved in the increased mRNA expression of TRPV6.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14135",
    "Sentence": "These results suggest that FOS increase <\\entity><\\entity> absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased mRNA expression of TRPV6.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14136",
    "Sentence": "These results suggest that FOS increase calcium absorption by increasing <\\entity><\\entity> expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased <\\entity><\\entity> expression of TRPV6.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14137",
    "Sentence": "These results suggest that FOS increase calcium absorption by increasing mRNA expression of <\\entity><\\entity> in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased mRNA expression of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14138",
    "Sentence": "These results suggest that FOS increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that <\\entity><\\entity>, as fermentation products of FOS, are involved in the increased mRNA expression of TRPV6.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14139",
    "Sentence": "These results suggest that FOS increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that <\\entity><\\entity>, as fermentation products of FOS, are involved in the increased mRNA expression of TRPV6.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14140",
    "Sentence": "These results suggest that <\\entity><\\entity> increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of <\\entity><\\entity>, are involved in the increased mRNA expression of TRPV6.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14141",
    "Sentence": "These results suggest that <\\entity><\\entity> increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of <\\entity><\\entity>, are involved in the increased mRNA expression of TRPV6.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14142",
    "Sentence": "These results suggest that FOS increase calcium absorption by increasing <\\entity><\\entity> expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased <\\entity><\\entity> expression of TRPV6.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14143",
    "Sentence": "These results suggest that FOS increase calcium absorption by increasing mRNA expression of <\\entity><\\entity> in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased mRNA expression of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14144",
    "Sentence": "We found for the first time, to our knowledge, that regulation of <\\entity><\\entity> gene expression by SCFA may be a molecular mechanism involved in the promotion of calcium absorption by FOS in rats.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14145",
    "Sentence": "We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by <\\entity><\\entity> may be a molecular mechanism involved in the promotion of calcium absorption by FOS in rats.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14146",
    "Sentence": "We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by <\\entity><\\entity> may be a molecular mechanism involved in the promotion of calcium absorption by FOS in rats.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14147",
    "Sentence": "We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by SCFA may be a molecular mechanism involved in the promotion of <\\entity><\\entity> absorption by FOS in rats.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14148",
    "Sentence": "We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by SCFA may be a molecular mechanism involved in the promotion of calcium absorption by <\\entity><\\entity> in rats.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "14149",
    "Sentence": "We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by SCFA may be a molecular mechanism involved in the promotion of calcium absorption by <\\entity><\\entity> in rats.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14150",
    "Sentence": "<\\entity><\\entity> induce intestinal transient receptor potential vanilloid type 6 expression in rats and Caco-2 cells.Fructooligosaccharides (FOS) are indigestible oligosaccharides that increase calcium absorption by the colorectum in rats, but the underlying mechanisms remain unclear.",
    "Label": ""
  },
  {
    "id": "14151",
    "Sentence": "Short-chain fatty acids induce <\\entity><\\entity> expression in rats and Caco-2 cells.Fructooligosaccharides (FOS) are indigestible oligosaccharides that increase calcium absorption by the colorectum in rats, but the underlying mechanisms remain unclear.",
    "Label": ""
  },
  {
    "id": "14153",
    "Sentence": "After feeding a diet containing <\\entity><\\entity> (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b).",
    "Label": ""
  },
  {
    "id": "14154",
    "Sentence": "After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (<\\entity><\\entity>), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b).",
    "Label": ""
  },
  {
    "id": "14156",
    "Sentence": "After feeding a diet containing <\\entity><\\entity> (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b).",
    "Label": ""
  },
  {
    "id": "14157",
    "Sentence": "After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), <\\entity><\\entity>, and plasma membrane calcium-ATPase 1b (PMCA1b).",
    "Label": ""
  },
  {
    "id": "14159",
    "Sentence": "After feeding a diet containing <\\entity><\\entity> (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b).",
    "Label": ""
  },
  {
    "id": "14160",
    "Sentence": "After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "14162",
    "Sentence": "The <\\entity><\\entity> diet increased expression of TRPV6 and calbindin-D9k but did not affect PMCA1b expression.",
    "Label": ""
  },
  {
    "id": "14163",
    "Sentence": "The FOS diet increased expression of <\\entity><\\entity> and calbindin-D9k but did not affect PMCA1b expression.",
    "Label": ""
  },
  {
    "id": "14165",
    "Sentence": "The <\\entity><\\entity> diet increased expression of TRPV6 and calbindin-D9k but did not affect PMCA1b expression.",
    "Label": ""
  },
  {
    "id": "14166",
    "Sentence": "The FOS diet increased expression of TRPV6 and <\\entity><\\entity> but did not affect PMCA1b expression.",
    "Label": ""
  },
  {
    "id": "14168",
    "Sentence": "The <\\entity><\\entity> diet increased expression of TRPV6 and calbindin-D9k but did not affect PMCA1b expression.",
    "Label": ""
  },
  {
    "id": "14169",
    "Sentence": "The FOS diet increased expression of TRPV6 and calbindin-D9k but did not affect <\\entity><\\entity> expression.",
    "Label": ""
  },
  {
    "id": "14171",
    "Sentence": "<\\entity><\\entity> (2.0 mmol/L) were thus added to Caco-2 human colonic epithelial cells, resulting in significantly increased mRNA expression of TRPV6.",
    "Label": ""
  },
  {
    "id": "14172",
    "Sentence": "SCFA (2.0 mmol/L) were thus added to Caco-2 human colonic epithelial cells, resulting in significantly increased mRNA expression of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14174",
    "Sentence": "These results suggest that <\\entity><\\entity> increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of <\\entity><\\entity>, are involved in the increased mRNA expression of TRPV6.",
    "Label": ""
  },
  {
    "id": "14175",
    "Sentence": "These results suggest that FOS increase calcium absorption by increasing mRNA expression of <\\entity><\\entity> in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased mRNA expression of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14177",
    "Sentence": "These results suggest that FOS increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that <\\entity><\\entity>, as fermentation products of FOS, are involved in the increased mRNA expression of TRPV6.",
    "Label": ""
  },
  {
    "id": "14178",
    "Sentence": "These results suggest that FOS increase calcium absorption by increasing mRNA expression of <\\entity><\\entity> in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased mRNA expression of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14180",
    "Sentence": "We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by SCFA may be a molecular mechanism involved in the promotion of calcium absorption by <\\entity><\\entity> in rats.",
    "Label": ""
  },
  {
    "id": "14181",
    "Sentence": "We found for the first time, to our knowledge, that regulation of <\\entity><\\entity> gene expression by SCFA may be a molecular mechanism involved in the promotion of calcium absorption by FOS in rats.",
    "Label": ""
  },
  {
    "id": "14183",
    "Sentence": "We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by <\\entity><\\entity> may be a molecular mechanism involved in the promotion of calcium absorption by FOS in rats.",
    "Label": ""
  },
  {
    "id": "14184",
    "Sentence": "We found for the first time, to our knowledge, that regulation of <\\entity><\\entity> gene expression by SCFA may be a molecular mechanism involved in the promotion of calcium absorption by FOS in rats.",
    "Label": ""
  },
  {
    "id": "14186",
    "Sentence": "After feeding a diet containing <\\entity><\\entity> (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b).",
    "Label": ""
  },
  {
    "id": "14187",
    "Sentence": "After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and <\\entity><\\entity> (PMCA1b).",
    "Label": ""
  },
  {
    "id": "14189",
    "Sentence": "After feeding a diet containing <\\entity><\\entity> (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b).",
    "Label": ""
  },
  {
    "id": "14190",
    "Sentence": "After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "14192",
    "Sentence": "We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by SCFA may be a molecular mechanism involved in the promotion of <\\entity><\\entity> absorption by FOS in rats.",
    "Label": ""
  },
  {
    "id": "14193",
    "Sentence": "We found for the first time, to our knowledge, that regulation of <\\entity><\\entity> gene expression by SCFA may be a molecular mechanism involved in the promotion of calcium absorption by FOS in rats.",
    "Label": ""
  },
  {
    "id": "14195",
    "Sentence": "After feeding a diet containing <\\entity><\\entity> (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of transient receptor potential vanilloid type 6 (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b).",
    "Label": ""
  },
  {
    "id": "14196",
    "Sentence": "After feeding a diet containing FOS (100 g/kg diet) to rats for 2 d, we investigated gene transcripts of <\\entity><\\entity> (TRPV6), calbindin-D9k, and plasma membrane calcium-ATPase 1b (PMCA1b).",
    "Label": ""
  },
  {
    "id": "14198",
    "Sentence": "The <\\entity><\\entity> diet increased expression of TRPV6 and calbindin-D9k but did not affect PMCA1b expression.",
    "Label": ""
  },
  {
    "id": "14199",
    "Sentence": "The FOS diet increased expression of TRPV6 and calbindin-D9k but did not affect <\\entity><\\entity> expression.",
    "Label": ""
  },
  {
    "id": "14201",
    "Sentence": "Because <\\entity><\\entity> could not directly affect gene expression, SCFA formed as fermentation products of <\\entity><\\entity> were considered as likely intermediates.",
    "Label": ""
  },
  {
    "id": "14202",
    "Sentence": "Because FOS could not directly affect gene expression, <\\entity><\\entity> formed as fermentation products of FOS were considered as likely intermediates.",
    "Label": ""
  },
  {
    "id": "14204",
    "Sentence": "These results suggest that FOS increase <\\entity><\\entity> absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased mRNA expression of TRPV6.",
    "Label": ""
  },
  {
    "id": "14205",
    "Sentence": "These results suggest that FOS increase calcium absorption by increasing mRNA expression of <\\entity><\\entity> in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased mRNA expression of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14207",
    "Sentence": "These results suggest that FOS increase <\\entity><\\entity> absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased mRNA expression of TRPV6.",
    "Label": ""
  },
  {
    "id": "14208",
    "Sentence": "These results suggest that FOS increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that <\\entity><\\entity>, as fermentation products of FOS, are involved in the increased mRNA expression of TRPV6.",
    "Label": ""
  },
  {
    "id": "14210",
    "Sentence": "These results suggest that FOS increase <\\entity><\\entity> absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased mRNA expression of TRPV6.",
    "Label": ""
  },
  {
    "id": "14211",
    "Sentence": "These results suggest that FOS increase calcium absorption by increasing <\\entity><\\entity> expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased <\\entity><\\entity> expression of TRPV6.",
    "Label": ""
  },
  {
    "id": "14213",
    "Sentence": "These results suggest that <\\entity><\\entity> increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of <\\entity><\\entity>, are involved in the increased mRNA expression of TRPV6.",
    "Label": ""
  },
  {
    "id": "14214",
    "Sentence": "These results suggest that FOS increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that <\\entity><\\entity>, as fermentation products of FOS, are involved in the increased mRNA expression of TRPV6.",
    "Label": ""
  },
  {
    "id": "14216",
    "Sentence": "These results suggest that <\\entity><\\entity> increase calcium absorption by increasing mRNA expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of <\\entity><\\entity>, are involved in the increased mRNA expression of TRPV6.",
    "Label": ""
  },
  {
    "id": "14217",
    "Sentence": "These results suggest that FOS increase calcium absorption by increasing <\\entity><\\entity> expression of TRPV6 in rat colorectum, and cell culture analysis indicated that SCFA, as fermentation products of FOS, are involved in the increased <\\entity><\\entity> expression of TRPV6.",
    "Label": ""
  },
  {
    "id": "14219",
    "Sentence": "We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by SCFA may be a molecular mechanism involved in the promotion of <\\entity><\\entity> absorption by FOS in rats.",
    "Label": ""
  },
  {
    "id": "14220",
    "Sentence": "We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by <\\entity><\\entity> may be a molecular mechanism involved in the promotion of calcium absorption by FOS in rats.",
    "Label": ""
  },
  {
    "id": "14222",
    "Sentence": "We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by SCFA may be a molecular mechanism involved in the promotion of calcium absorption by <\\entity><\\entity> in rats.",
    "Label": ""
  },
  {
    "id": "14223",
    "Sentence": "We found for the first time, to our knowledge, that regulation of TRPV6 gene expression by <\\entity><\\entity> may be a molecular mechanism involved in the promotion of calcium absorption by FOS in rats.",
    "Label": ""
  },
  {
    "id": "14229",
    "Sentence": "<\\entity><\\entity> contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population.Genetic polymorphisms of DNA repair genes seem to determine the DNA repair capacity.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14230",
    "Sentence": "<\\entity><\\entity> contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population.Genetic polymorphisms of DNA repair genes seem to determine the DNA repair capacity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14231",
    "Sentence": "RAD52 polymorphisms contribute to the development of <\\entity><\\entity> susceptibility in Middle Eastern population.Genetic polymorphisms of DNA repair genes seem to determine the DNA repair capacity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14232",
    "Sentence": "We hypothesized that polymorphisms of genes responsible for DNA repair may be associated with risk of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14233",
    "Sentence": "To evaluate the role of genetic polymorphisms of DNA repair genes in <\\entity><\\entity>, we conducted a hospital-based case-control study in Saudi population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14234",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14235",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes <\\entity><\\entity> (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14236",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (<\\entity><\\entity>, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14237",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (<\\entity><\\entity>, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14238",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, <\\entity><\\entity>, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14239",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, <\\entity><\\entity>), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14240",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), <\\entity><\\entity> Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14241",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), <\\entity><\\entity> Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14242",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice <\\entity><\\entity> and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14243",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and <\\entity><\\entity> ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14244",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and <\\entity><\\entity> ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14245",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 <\\entity><\\entity>; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14246",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes <\\entity><\\entity> ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14247",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes <\\entity><\\entity> ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14248",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 <\\entity><\\entity> and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14249",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and <\\entity><\\entity>, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14250",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, <\\entity><\\entity> UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14251",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, <\\entity><\\entity> UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14252",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 <\\entity><\\entity>, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14253",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 <\\entity><\\entity>, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14254",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, <\\entity><\\entity>, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14255",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, <\\entity><\\entity> and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14256",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, <\\entity><\\entity> and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14257",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and <\\entity><\\entity>, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14258",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved <\\entity><\\entity> response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14259",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene <\\entity><\\entity> PRO47SER, PRO72ARG, <\\entity><\\entity> UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14260",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene <\\entity><\\entity> PRO47SER, PRO72ARG, <\\entity><\\entity> UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14261",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 <\\entity><\\entity>, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14262",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, <\\entity><\\entity>, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14263",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene <\\entity><\\entity> PRO47SER, PRO72ARG, <\\entity><\\entity> UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14264",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene <\\entity><\\entity> PRO47SER, PRO72ARG, <\\entity><\\entity> UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14265",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 <\\entity><\\entity> and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14266",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 <\\entity><\\entity> and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14267",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene <\\entity><\\entity> ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14268",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene <\\entity><\\entity> ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14269",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 <\\entity><\\entity>, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14270",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, <\\entity><\\entity>, ARG399GLN, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14271",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, <\\entity><\\entity>, ARG559GLN.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14272",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14273",
    "Sentence": "<\\entity><\\entity> genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14274",
    "Sentence": "<\\entity><\\entity> genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14275",
    "Sentence": "RAD52 GLN221GLU genotypes <\\entity><\\entity> and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [<\\entity><\\entity> vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, <\\entity><\\entity>+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14276",
    "Sentence": "RAD52 GLN221GLU genotypes CG and variants carrying <\\entity><\\entity> showed statistical significance and very high risk of developing thyroid cancer compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14277",
    "Sentence": "RAD52 GLN221GLU genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing <\\entity><\\entity> compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14278",
    "Sentence": "RAD52 GLN221GLU genotypes <\\entity><\\entity> and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [<\\entity><\\entity> vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, <\\entity><\\entity>+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14279",
    "Sentence": "RAD52 GLN221GLU genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [CG vs <\\entity><\\entity>; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs <\\entity><\\entity>; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14280",
    "Sentence": "RAD52 GLN221GLU genotypes <\\entity><\\entity> and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [<\\entity><\\entity> vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, <\\entity><\\entity>+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14281",
    "Sentence": "RAD52 GLN221GLU genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+<\\entity><\\entity> vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14282",
    "Sentence": "RAD52 GLN221GLU genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [CG vs <\\entity><\\entity>; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs <\\entity><\\entity>; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14283",
    "Sentence": "Similarly, <\\entity><\\entity> genotypes CT and variant allele T showed a significant difference in terms of risk estimation (CT vs CC; p<0.05, OR=1.53, 95% CI=1.03-2.28, CT+TT vs CC; p<0.001, OR=1.922, 95% CI=1.31-2.82).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14284",
    "Sentence": "Similarly, <\\entity><\\entity> genotypes CT and variant allele T showed a significant difference in terms of risk estimation (CT vs CC; p<0.05, OR=1.53, 95% CI=1.03-2.28, CT+TT vs CC; p<0.001, OR=1.922, 95% CI=1.31-2.82).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14285",
    "Sentence": "Similarly, RAD52 2259 genotypes <\\entity><\\entity> and variant allele T showed a significant difference in terms of risk estimation (<\\entity><\\entity> vs CC; p<0.05, OR=1.53, 95% CI=1.03-2.28, <\\entity><\\entity>+TT vs CC; p<0.001, OR=1.922, 95% CI=1.31-2.82).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14286",
    "Sentence": "Similarly, RAD52 2259 genotypes CT and variant <\\entity><\\entity> showed a significant difference in terms of risk estimation (CT vs CC; p<0.05, OR=1.53, 95% CI=1.03-2.28, CT+TT vs CC; p<0.001, OR=1.922, 95% CI=1.31-2.82).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14287",
    "Sentence": "Similarly, RAD52 2259 genotypes <\\entity><\\entity> and variant allele T showed a significant difference in terms of risk estimation (<\\entity><\\entity> vs CC; p<0.05, OR=1.53, 95% CI=1.03-2.28, <\\entity><\\entity>+TT vs CC; p<0.001, OR=1.922, 95% CI=1.31-2.82).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14288",
    "Sentence": "Similarly, RAD52 2259 genotypes CT and variant allele T showed a significant difference in terms of risk estimation (CT vs <\\entity><\\entity>; p<0.05, OR=1.53, 95% CI=1.03-2.28, CT+TT vs <\\entity><\\entity>; p<0.001, OR=1.922, 95% CI=1.31-2.82).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14289",
    "Sentence": "Similarly, RAD52 2259 genotypes <\\entity><\\entity> and variant allele T showed a significant difference in terms of risk estimation (<\\entity><\\entity> vs CC; p<0.05, OR=1.53, 95% CI=1.03-2.28, <\\entity><\\entity>+TT vs CC; p<0.001, OR=1.922, 95% CI=1.31-2.82).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14290",
    "Sentence": "Similarly, RAD52 2259 genotypes CT and variant allele T showed a significant difference in terms of risk estimation (CT vs CC; p<0.05, OR=1.53, 95% CI=1.03-2.28, CT+<\\entity><\\entity> vs CC; p<0.001, OR=1.922, 95% CI=1.31-2.82).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14291",
    "Sentence": "Similarly, RAD52 2259 genotypes CT and variant allele T showed a significant difference in terms of risk estimation (CT vs <\\entity><\\entity>; p<0.05, OR=1.53, 95% CI=1.03-2.28, CT+TT vs <\\entity><\\entity>; p<0.001, OR=1.922, 95% CI=1.31-2.82).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14292",
    "Sentence": "Of the 21 loci screened, <\\entity><\\entity> and RAD52 GLN221GLU may be of importance to disease process and may be associated with papillary thyroid cancer risk in Saudi Arabian population.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14293",
    "Sentence": "Of the 21 loci screened, <\\entity><\\entity> and RAD52 GLN221GLU may be of importance to disease process and may be associated with papillary thyroid cancer risk in Saudi Arabian population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14294",
    "Sentence": "Of the 21 loci screened, RAD52 2259 and <\\entity><\\entity> may be of importance to disease process and may be associated with papillary thyroid cancer risk in Saudi Arabian population.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14295",
    "Sentence": "Of the 21 loci screened, RAD52 2259 and <\\entity><\\entity> may be of importance to disease process and may be associated with papillary thyroid cancer risk in Saudi Arabian population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14296",
    "Sentence": "Of the 21 loci screened, RAD52 2259 and RAD52 GLN221GLU may be of importance to <\\entity><\\entity> process and may be associated with papillary thyroid cancer risk in Saudi Arabian population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14297",
    "Sentence": "Of the 21 loci screened, RAD52 2259 and RAD52 GLN221GLU may be of importance to disease process and may be associated with <\\entity><\\entity> risk in Saudi Arabian population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14298",
    "Sentence": "<\\entity><\\entity> contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population.Genetic polymorphisms of DNA repair genes seem to determine the DNA repair capacity.",
    "Label": ""
  },
  {
    "id": "14299",
    "Sentence": "RAD52 polymorphisms contribute to the development of <\\entity><\\entity> susceptibility in Middle Eastern population.Genetic polymorphisms of DNA repair genes seem to determine the DNA repair capacity.",
    "Label": ""
  },
  {
    "id": "14301",
    "Sentence": "<\\entity><\\entity> genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": ""
  },
  {
    "id": "14302",
    "Sentence": "RAD52 GLN221GLU genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing <\\entity><\\entity> compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": ""
  },
  {
    "id": "14304",
    "Sentence": "RAD52 GLN221GLU genotypes <\\entity><\\entity> and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [<\\entity><\\entity> vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, <\\entity><\\entity>+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": ""
  },
  {
    "id": "14305",
    "Sentence": "RAD52 GLN221GLU genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing <\\entity><\\entity> compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": ""
  },
  {
    "id": "14307",
    "Sentence": "RAD52 GLN221GLU genotypes CG and variants carrying <\\entity><\\entity> showed statistical significance and very high risk of developing thyroid cancer compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": ""
  },
  {
    "id": "14308",
    "Sentence": "RAD52 GLN221GLU genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing <\\entity><\\entity> compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": ""
  },
  {
    "id": "14310",
    "Sentence": "Of the 21 loci screened, RAD52 2259 and <\\entity><\\entity> may be of importance to disease process and may be associated with papillary thyroid cancer risk in Saudi Arabian population.",
    "Label": ""
  },
  {
    "id": "14311",
    "Sentence": "Of the 21 loci screened, RAD52 2259 and RAD52 GLN221GLU may be of importance to disease process and may be associated with <\\entity><\\entity> risk in Saudi Arabian population.",
    "Label": ""
  },
  {
    "id": "14313",
    "Sentence": "Of the 21 loci screened, <\\entity><\\entity> and RAD52 GLN221GLU may be of importance to disease process and may be associated with papillary thyroid cancer risk in Saudi Arabian population.",
    "Label": ""
  },
  {
    "id": "14314",
    "Sentence": "Of the 21 loci screened, RAD52 2259 and RAD52 GLN221GLU may be of importance to disease process and may be associated with <\\entity><\\entity> risk in Saudi Arabian population.",
    "Label": ""
  },
  {
    "id": "14316",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, <\\entity><\\entity> and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14317",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14319",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, <\\entity><\\entity> and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14320",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved <\\entity><\\entity> response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14322",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 <\\entity><\\entity> and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14323",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14325",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 <\\entity><\\entity> and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14326",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved <\\entity><\\entity> response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14328",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), <\\entity><\\entity> Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14329",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14331",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), <\\entity><\\entity> Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14332",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved <\\entity><\\entity> response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14334",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and <\\entity><\\entity> ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14335",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14337",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and <\\entity><\\entity> ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14338",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved <\\entity><\\entity> response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14340",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes <\\entity><\\entity> ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14341",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14343",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes <\\entity><\\entity> ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14344",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved <\\entity><\\entity> response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14346",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, <\\entity><\\entity> UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14347",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14349",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, <\\entity><\\entity> UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14350",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved <\\entity><\\entity> response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14352",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene <\\entity><\\entity> PRO47SER, PRO72ARG, <\\entity><\\entity> UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14353",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14355",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene <\\entity><\\entity> PRO47SER, PRO72ARG, <\\entity><\\entity> UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14356",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved <\\entity><\\entity> response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14358",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene <\\entity><\\entity> ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14359",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14361",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene <\\entity><\\entity> ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14362",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved <\\entity><\\entity> response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14364",
    "Sentence": "Of the 21 loci screened, RAD52 2259 and <\\entity><\\entity> may be of importance to disease process and may be associated with papillary thyroid cancer risk in Saudi Arabian population.",
    "Label": ""
  },
  {
    "id": "14365",
    "Sentence": "Of the 21 loci screened, RAD52 2259 and RAD52 GLN221GLU may be of importance to <\\entity><\\entity> process and may be associated with papillary thyroid cancer risk in Saudi Arabian population.",
    "Label": ""
  },
  {
    "id": "14367",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes <\\entity><\\entity> (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14368",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14370",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (<\\entity><\\entity>, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14371",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14373",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, <\\entity><\\entity>, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14374",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14376",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, <\\entity><\\entity>), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14377",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14379",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice <\\entity><\\entity> and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14380",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14382",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 <\\entity><\\entity>; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14383",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14385",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 <\\entity><\\entity> and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14386",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14388",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and <\\entity><\\entity>, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14389",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14391",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 <\\entity><\\entity>, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14392",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14394",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, <\\entity><\\entity>, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14395",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14397",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and <\\entity><\\entity>, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14398",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14400",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 <\\entity><\\entity>, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14401",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14403",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, <\\entity><\\entity>, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14404",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14406",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 <\\entity><\\entity>, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14407",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14409",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, <\\entity><\\entity>, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14410",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14412",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, <\\entity><\\entity>, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14413",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14415",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14416",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14418",
    "Sentence": "Two hundred and twenty-three incident papillary thyroid cancer cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene <\\entity><\\entity> PRO47SER, PRO72ARG, <\\entity><\\entity> UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14419",
    "Sentence": "Two hundred and twenty-three incident <\\entity><\\entity> cases and 229 controls recruited from Saudi Arabian population were analyzed for 21 loci in 8 selected DNA repair genes by PCR-restriction fragment length polymorphism including non-homologous end joining pathway genes LIGIV (LIGlV ASP62HIS, PRO231SER, TRP46TER), XRCC4 Splice 33243301G>A and XRCC7 ILE3434THR; homologous recombination pathway genes XRCC3 ARG94HIS and THR241MET, RAD51 UTR 15452658T>C, 15455419A>G, RAD52 2259 and GLN221GLU, conserved DNA damage response gene Tp53 PRO47SER, PRO72ARG, Tp53 UTR 7178189A>C and base excision repair gene XRCC1 ARG194TRP, ARG280HIS, ARG399GLN, ARG559GLN.",
    "Label": ""
  },
  {
    "id": "14421",
    "Sentence": "RAD52 GLN221GLU genotypes <\\entity><\\entity> and variants carrying G allele showed statistical significance and very high risk of developing thyroid cancer compared to wild type [<\\entity><\\entity> vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, <\\entity><\\entity>+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": ""
  },
  {
    "id": "14422",
    "Sentence": "RAD52 GLN221GLU genotypes CG and variants carrying G allele showed statistical significance and very high risk of developing <\\entity><\\entity> compared to wild type [CG vs CC; p<0.001, odds ratio (OR)=15.57, 95% confidence interval (CI)=6.56-36.98, CG+GG vs CC; p<0.001, OR=17.58, 95% CI=7.44-41.58].",
    "Label": ""
  },
  {
    "id": "14428",
    "Sentence": "Replication of the <\\entity><\\entity> (OX40L) promoter region association with systemic lupus erythematosus.The tumor necrosis factor ligand superfamily member 4 gene (<\\entity><\\entity>) encodes the OX40 ligand (OX40L), a costimulatory molecule involved in T-cell activation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14429",
    "Sentence": "Replication of the TNFSF4 (<\\entity><\\entity>) promoter region association with systemic lupus erythematosus.The tumor necrosis factor ligand superfamily member 4 gene (TNFSF4) encodes the OX40 ligand (<\\entity><\\entity>), a costimulatory molecule involved in T-cell activation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14430",
    "Sentence": "Replication of the TNFSF4 (OX40L) promoter region association with <\\entity><\\entity>.The tumor necrosis factor ligand superfamily member 4 gene (TNFSF4) encodes the OX40 ligand (OX40L), a costimulatory molecule involved in T-cell activation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14431",
    "Sentence": "Replication of the TNFSF4 (OX40L) promoter region association with systemic lupus erythematosus.The <\\entity><\\entity> gene (TNFSF4) encodes the OX40 ligand (OX40L), a costimulatory molecule involved in T-cell activation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14432",
    "Sentence": "Replication of the <\\entity><\\entity> (OX40L) promoter region association with systemic lupus erythematosus.The tumor necrosis factor ligand superfamily member 4 gene (<\\entity><\\entity>) encodes the OX40 ligand (OX40L), a costimulatory molecule involved in T-cell activation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14433",
    "Sentence": "Replication of the TNFSF4 (OX40L) promoter region association with systemic lupus erythematosus.The tumor necrosis factor ligand superfamily member 4 gene (TNFSF4) encodes the <\\entity><\\entity> (OX40L), a costimulatory molecule involved in T-cell activation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14434",
    "Sentence": "Replication of the TNFSF4 (<\\entity><\\entity>) promoter region association with systemic lupus erythematosus.The tumor necrosis factor ligand superfamily member 4 gene (TNFSF4) encodes the OX40 ligand (<\\entity><\\entity>), a costimulatory molecule involved in T-cell activation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14435",
    "Sentence": "Replication of the TNFSF4 (OX40L) promoter region association with systemic lupus erythematosus.The tumor necrosis factor ligand superfamily member 4 gene (TNFSF4) encodes the OX40 ligand (OX40L), a <\\entity><\\entity> involved in T-cell activation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14436",
    "Sentence": "A recent study demonstrated the association of <\\entity><\\entity> located in the upstream region with risk for or protection from systemic lupus erythematosus (SLE).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14437",
    "Sentence": "A recent study demonstrated the association of <\\entity><\\entity> located in the upstream region with risk for or protection from systemic lupus erythematosus (SLE).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14438",
    "Sentence": "A recent study demonstrated the association of TNFSF4 haplotypes located in the upstream region with risk for or protection from <\\entity><\\entity> (SLE).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14439",
    "Sentence": "A recent study demonstrated the association of TNFSF4 haplotypes located in the upstream region with risk for or protection from systemic lupus erythematosus (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14440",
    "Sentence": "To replicate this association, five single nucleotide polymorphisms (SNPs) <\\entity><\\entity> the previously associated haplotypes and passing the proper quality-control filters were tested in 1312 cases and 1801 controls from Germany, Italy, Spain and Argentina.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14441",
    "Sentence": "The association of <\\entity><\\entity> with SLE was replicated in all the sets except Spain.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14442",
    "Sentence": "The association of TNFSF4 with <\\entity><\\entity> was replicated in all the sets except Spain.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14443",
    "Sentence": "There was a unique risk haplotype <\\entity><\\entity> by the minor alleles of the SNPs rs1234317 (pooled odds ratio (OR)=1.39, P=0.0009) and rs12039904 (pooled OR=1.38, P=0.0012).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14444",
    "Sentence": "There was a unique risk haplotype tagged by the <\\entity><\\entity> alleles of the SNPs rs1234317 (pooled odds ratio (OR)=1.39, P=0.0009) and rs12039904 (pooled OR=1.38, P=0.0012).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14445",
    "Sentence": "There was a unique risk haplotype tagged by the minor alleles of the SNPs <\\entity><\\entity> (pooled odds ratio (OR)=1.39, P=0.0009) and rs12039904 (pooled OR=1.38, P=0.0012).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14446",
    "Sentence": "There was a unique risk haplotype tagged by the minor alleles of the SNPs rs1234317 (pooled odds ratio (OR)=1.39, P=0.0009) and <\\entity><\\entity> (pooled OR=1.38, P=0.0012).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14447",
    "Sentence": "We did not observe association to a single protective marker (<\\entity><\\entity>) or haplotype as the first study reported; instead, we observed different protective haplotypes, all carrying the major alleles of both SNPs rs1234317 and rs12039904.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14448",
    "Sentence": "We did not observe association to a single protective marker (rs844644) or haplotype as the first study reported; instead, we observed different protective haplotypes, all carrying the major alleles of both SNPs <\\entity><\\entity> and rs12039904.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14449",
    "Sentence": "We did not observe association to a single protective marker (rs844644) or haplotype as the first study reported; instead, we observed different protective haplotypes, all carrying the major alleles of both SNPs rs1234317 and <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14450",
    "Sentence": "This first replication study confirms the association of genetic variation in the upstream region of <\\entity><\\entity> with susceptibility to SLE.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14451",
    "Sentence": "This first replication study confirms the association of genetic variation in the upstream region of TNFSF4 with susceptibility to <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14452",
    "Sentence": "A recent study demonstrated the association of <\\entity><\\entity> located in the upstream region with risk for or protection from systemic lupus erythematosus (SLE).",
    "Label": ""
  },
  {
    "id": "14453",
    "Sentence": "A recent study demonstrated the association of TNFSF4 haplotypes located in the upstream region with risk for or protection from <\\entity><\\entity> (SLE).",
    "Label": ""
  },
  {
    "id": "14455",
    "Sentence": "A recent study demonstrated the association of <\\entity><\\entity> located in the upstream region with risk for or protection from systemic lupus erythematosus (SLE).",
    "Label": ""
  },
  {
    "id": "14456",
    "Sentence": "A recent study demonstrated the association of TNFSF4 haplotypes located in the upstream region with risk for or protection from systemic lupus erythematosus (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "14458",
    "Sentence": "The association of <\\entity><\\entity> with SLE was replicated in all the sets except Spain.",
    "Label": ""
  },
  {
    "id": "14459",
    "Sentence": "The association of TNFSF4 with <\\entity><\\entity> was replicated in all the sets except Spain.",
    "Label": ""
  },
  {
    "id": "14461",
    "Sentence": "This first replication study confirms the association of genetic variation in the upstream region of <\\entity><\\entity> with susceptibility to SLE.",
    "Label": ""
  },
  {
    "id": "14462",
    "Sentence": "This first replication study confirms the association of genetic variation in the upstream region of TNFSF4 with susceptibility to <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14464",
    "Sentence": "Replication of the TNFSF4 (<\\entity><\\entity>) promoter region association with systemic lupus erythematosus.The tumor necrosis factor ligand superfamily member 4 gene (TNFSF4) encodes the OX40 ligand (<\\entity><\\entity>), a costimulatory molecule involved in T-cell activation.",
    "Label": ""
  },
  {
    "id": "14465",
    "Sentence": "Replication of the TNFSF4 (OX40L) promoter region association with <\\entity><\\entity>.The tumor necrosis factor ligand superfamily member 4 gene (TNFSF4) encodes the OX40 ligand (OX40L), a costimulatory molecule involved in T-cell activation.",
    "Label": ""
  },
  {
    "id": "14471",
    "Sentence": "Polymorphisms in the regulatory region of the <\\entity><\\entity> gene influence the susceptibility for HIV-1 infection.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of <\\entity><\\entity> (CypA) and susceptibility to both HIV-1 infection and disease progression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14472",
    "Sentence": "Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 <\\entity><\\entity>.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of Cyclophilin A (CypA) and susceptibility to both HIV-1 <\\entity><\\entity> and disease progression.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14473",
    "Sentence": "Polymorphisms in the regulatory region of the <\\entity><\\entity> gene influence the susceptibility for HIV-1 infection.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of <\\entity><\\entity> (CypA) and susceptibility to both HIV-1 infection and disease progression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14474",
    "Sentence": "Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 infection.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of Cyclophilin A (<\\entity><\\entity>) and susceptibility to both HIV-1 infection and disease progression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14475",
    "Sentence": "Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 <\\entity><\\entity>.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of Cyclophilin A (CypA) and susceptibility to both HIV-1 <\\entity><\\entity> and disease progression.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14476",
    "Sentence": "Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 infection.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of Cyclophilin A (CypA) and susceptibility to both HIV-1 infection and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14477",
    "Sentence": "Here we studied whether these polymorphisms are associated with susceptibility to HIV-1 <\\entity><\\entity> and disease progression in the Amsterdam Cohort on HIV-1 <\\entity><\\entity> and AIDS (ACS) in a group of men having sex with men (MSM) and drug users (DU).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14478",
    "Sentence": "Here we studied whether these polymorphisms are associated with susceptibility to HIV-1 infection and <\\entity><\\entity> in the Amsterdam Cohort on HIV-1 infection and AIDS (ACS) in a group of men having sex with men (MSM) and drug users (DU).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14479",
    "Sentence": "Here we studied whether these polymorphisms are associated with susceptibility to HIV-1 <\\entity><\\entity> and disease progression in the Amsterdam Cohort on HIV-1 <\\entity><\\entity> and AIDS (ACS) in a group of men having sex with men (MSM) and drug users (DU).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14480",
    "Sentence": "Here we studied whether these polymorphisms are associated with susceptibility to HIV-1 infection and disease progression in the Amsterdam Cohort on HIV-1 infection and <\\entity><\\entity> (ACS) in a group of men having sex with men (MSM) and drug users (DU).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14481",
    "Sentence": "Here we studied whether these polymorphisms are associated with susceptibility to HIV-1 infection and disease progression in the Amsterdam Cohort on HIV-1 infection and AIDS (<\\entity><\\entity>) in a group of men having sex with men (MSM) and drug users (DU).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14482",
    "Sentence": "METHODOLOGY/PRINCIPAL FINDINGS: We screened participants of the <\\entity><\\entity> for the C1604G and A1650G polymorphisms in the regulatory regions of CypA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14483",
    "Sentence": "METHODOLOGY/PRINCIPAL FINDINGS: We screened participants of the ACS for the <\\entity><\\entity> and A1650G polymorphisms in the regulatory regions of CypA.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14484",
    "Sentence": "METHODOLOGY/PRINCIPAL FINDINGS: We screened participants of the ACS for the C1604G and <\\entity><\\entity> polymorphisms in the regulatory regions of CypA.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14485",
    "Sentence": "METHODOLOGY/PRINCIPAL FINDINGS: We screened participants of the ACS for the C1604G and A1650G polymorphisms in the regulatory regions of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14486",
    "Sentence": "The prevalence of the <\\entity><\\entity> was significantly higher in high risk seronegative MSM than in HIV-1 infected MSM.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14487",
    "Sentence": "The prevalence of the 1650G allele was significantly higher in high risk <\\entity><\\entity> than in HIV-1 infected MSM.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14488",
    "Sentence": "The prevalence of the 1650G allele was significantly higher in high risk seronegative MSM than in <\\entity><\\entity> MSM.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14489",
    "Sentence": "However, <\\entity><\\entity> or A1650G were not associated with the clinical course of infection in MSM of the ACS.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14490",
    "Sentence": "However, C1604G or <\\entity><\\entity> were not associated with the clinical course of infection in MSM of the ACS.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14491",
    "Sentence": "However, C1604G or A1650G were not associated with the clinical course of <\\entity><\\entity> in MSM of the ACS.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14492",
    "Sentence": "However, C1604G or A1650G were not associated with the clinical course of infection in MSM of the <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14493",
    "Sentence": "Interestingly, participants of the ACS-DU who carried the <\\entity><\\entity> showed a significantly accelerated progression when viral RNA load above 10(4.5) copies per ml plasma was used as an endpoint in survival analysis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14494",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the <\\entity><\\entity> polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 infection, while the 1604G allele may have a weak association with the clinical course of infection in DU.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14495",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the <\\entity><\\entity> gene may be associated with protection from HIV-1 infection, while the 1604G allele may have a weak association with the clinical course of infection in DU.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14496",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 <\\entity><\\entity>, while the 1604G allele may have a weak association with the clinical course of <\\entity><\\entity> in DU.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14497",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 infection, while the <\\entity><\\entity> may have a weak association with the clinical course of infection in DU.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14498",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 infection, while the 1604G allele may have a <\\entity><\\entity> association with the clinical course of infection in DU.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14499",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 <\\entity><\\entity>, while the 1604G allele may have a weak association with the clinical course of <\\entity><\\entity> in DU.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14500",
    "Sentence": "Polymorphisms in the regulatory region of the <\\entity><\\entity> gene influence the susceptibility for HIV-1 infection.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of <\\entity><\\entity> (CypA) and susceptibility to both HIV-1 infection and disease progression.",
    "Label": ""
  },
  {
    "id": "14501",
    "Sentence": "Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 <\\entity><\\entity>.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of Cyclophilin A (CypA) and susceptibility to both HIV-1 <\\entity><\\entity> and disease progression.",
    "Label": ""
  },
  {
    "id": "14503",
    "Sentence": "Polymorphisms in the regulatory region of the <\\entity><\\entity> gene influence the susceptibility for HIV-1 infection.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of <\\entity><\\entity> (CypA) and susceptibility to both HIV-1 infection and disease progression.",
    "Label": ""
  },
  {
    "id": "14504",
    "Sentence": "Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 <\\entity><\\entity>.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of Cyclophilin A (CypA) and susceptibility to both HIV-1 <\\entity><\\entity> and disease progression.",
    "Label": ""
  },
  {
    "id": "14506",
    "Sentence": "Polymorphisms in the regulatory region of the <\\entity><\\entity> gene influence the susceptibility for HIV-1 infection.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of <\\entity><\\entity> (CypA) and susceptibility to both HIV-1 infection and disease progression.",
    "Label": ""
  },
  {
    "id": "14507",
    "Sentence": "Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 infection.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of Cyclophilin A (CypA) and susceptibility to both HIV-1 infection and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14509",
    "Sentence": "Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 infection.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of Cyclophilin A (<\\entity><\\entity>) and susceptibility to both HIV-1 infection and disease progression.",
    "Label": ""
  },
  {
    "id": "14510",
    "Sentence": "Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 <\\entity><\\entity>.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of Cyclophilin A (CypA) and susceptibility to both HIV-1 <\\entity><\\entity> and disease progression.",
    "Label": ""
  },
  {
    "id": "14512",
    "Sentence": "Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 infection.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of Cyclophilin A (<\\entity><\\entity>) and susceptibility to both HIV-1 infection and disease progression.",
    "Label": ""
  },
  {
    "id": "14513",
    "Sentence": "Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 infection.BACKGROUND: Previous studies have demonstrated an association between polymorphisms in the regulatory regions of Cyclophilin A (CypA) and susceptibility to both HIV-1 infection and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14515",
    "Sentence": "Here we studied whether these polymorphisms are associated with susceptibility to HIV-1 infection and disease progression in the Amsterdam Cohort on HIV-1 infection and AIDS (<\\entity><\\entity>) in a group of men having sex with men (MSM) and drug users (DU).",
    "Label": ""
  },
  {
    "id": "14516",
    "Sentence": "Here we studied whether these polymorphisms are associated with susceptibility to HIV-1 <\\entity><\\entity> and disease progression in the Amsterdam Cohort on HIV-1 <\\entity><\\entity> and AIDS (ACS) in a group of men having sex with men (MSM) and drug users (DU).",
    "Label": ""
  },
  {
    "id": "14518",
    "Sentence": "Here we studied whether these polymorphisms are associated with susceptibility to HIV-1 infection and disease progression in the Amsterdam Cohort on HIV-1 infection and AIDS (<\\entity><\\entity>) in a group of men having sex with men (MSM) and drug users (DU).",
    "Label": ""
  },
  {
    "id": "14519",
    "Sentence": "Here we studied whether these polymorphisms are associated with susceptibility to HIV-1 infection and <\\entity><\\entity> in the Amsterdam Cohort on HIV-1 infection and AIDS (ACS) in a group of men having sex with men (MSM) and drug users (DU).",
    "Label": ""
  },
  {
    "id": "14521",
    "Sentence": "Here we studied whether these polymorphisms are associated with susceptibility to HIV-1 infection and disease progression in the Amsterdam Cohort on HIV-1 infection and AIDS (<\\entity><\\entity>) in a group of men having sex with men (MSM) and drug users (DU).",
    "Label": ""
  },
  {
    "id": "14522",
    "Sentence": "Here we studied whether these polymorphisms are associated with susceptibility to HIV-1 infection and disease progression in the Amsterdam Cohort on HIV-1 infection and <\\entity><\\entity> (ACS) in a group of men having sex with men (MSM) and drug users (DU).",
    "Label": ""
  },
  {
    "id": "14524",
    "Sentence": "However, C1604G or A1650G were not associated with the clinical course of infection in MSM of the <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14525",
    "Sentence": "However, C1604G or A1650G were not associated with the clinical course of <\\entity><\\entity> in MSM of the ACS.",
    "Label": ""
  },
  {
    "id": "14527",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the <\\entity><\\entity> gene may be associated with protection from HIV-1 infection, while the 1604G allele may have a weak association with the clinical course of infection in DU.",
    "Label": ""
  },
  {
    "id": "14528",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 <\\entity><\\entity>, while the 1604G allele may have a weak association with the clinical course of <\\entity><\\entity> in DU.",
    "Label": ""
  },
  {
    "id": "14530",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the <\\entity><\\entity> gene may be associated with protection from HIV-1 infection, while the 1604G allele may have a weak association with the clinical course of infection in DU.",
    "Label": ""
  },
  {
    "id": "14531",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 infection, while the 1604G allele may have a <\\entity><\\entity> association with the clinical course of infection in DU.",
    "Label": ""
  },
  {
    "id": "14533",
    "Sentence": "The prevalence of the <\\entity><\\entity> was significantly higher in high risk seronegative MSM than in HIV-1 infected MSM.",
    "Label": ""
  },
  {
    "id": "14534",
    "Sentence": "The prevalence of the 1650G allele was significantly higher in high risk seronegative MSM than in <\\entity><\\entity> MSM.",
    "Label": ""
  },
  {
    "id": "14536",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the <\\entity><\\entity> gene may be associated with protection from HIV-1 infection, while the 1604G allele may have a weak association with the clinical course of infection in DU.",
    "Label": ""
  },
  {
    "id": "14537",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 <\\entity><\\entity>, while the 1604G allele may have a weak association with the clinical course of <\\entity><\\entity> in DU.",
    "Label": ""
  },
  {
    "id": "14539",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the <\\entity><\\entity> polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 infection, while the 1604G allele may have a weak association with the clinical course of infection in DU.",
    "Label": ""
  },
  {
    "id": "14540",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 <\\entity><\\entity>, while the 1604G allele may have a weak association with the clinical course of <\\entity><\\entity> in DU.",
    "Label": ""
  },
  {
    "id": "14542",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 infection, while the <\\entity><\\entity> may have a weak association with the clinical course of infection in DU.",
    "Label": ""
  },
  {
    "id": "14543",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 <\\entity><\\entity>, while the 1604G allele may have a weak association with the clinical course of <\\entity><\\entity> in DU.",
    "Label": ""
  },
  {
    "id": "14545",
    "Sentence": "The prevalence of the <\\entity><\\entity> was significantly higher in high risk seronegative MSM than in HIV-1 infected MSM.",
    "Label": ""
  },
  {
    "id": "14546",
    "Sentence": "The prevalence of the 1650G allele was significantly higher in high risk <\\entity><\\entity> than in HIV-1 infected MSM.",
    "Label": ""
  },
  {
    "id": "14548",
    "Sentence": "However, <\\entity><\\entity> or A1650G were not associated with the clinical course of infection in MSM of the ACS.",
    "Label": ""
  },
  {
    "id": "14549",
    "Sentence": "However, C1604G or A1650G were not associated with the clinical course of <\\entity><\\entity> in MSM of the ACS.",
    "Label": ""
  },
  {
    "id": "14551",
    "Sentence": "However, C1604G or <\\entity><\\entity> were not associated with the clinical course of infection in MSM of the ACS.",
    "Label": ""
  },
  {
    "id": "14552",
    "Sentence": "However, C1604G or A1650G were not associated with the clinical course of <\\entity><\\entity> in MSM of the ACS.",
    "Label": ""
  },
  {
    "id": "14554",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 infection, while the <\\entity><\\entity> may have a weak association with the clinical course of infection in DU.",
    "Label": ""
  },
  {
    "id": "14555",
    "Sentence": "CONCLUSION/SIGNIFICANCE: The results obtained in this study suggest that the A1650G polymorphism in the regulatory region of the CypA gene may be associated with protection from HIV-1 <\\entity><\\entity>, while the 1604G allele may have a weak association with the clinical course of <\\entity><\\entity> in DU.",
    "Label": ""
  },
  {
    "id": "14561",
    "Sentence": "Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in <\\entity><\\entity> patients among Indians.OBJECTIVE: Methotrexate (MTX) is the drug of choice for <\\entity><\\entity> (RA) but is effective only in around 60% of treated patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14562",
    "Sentence": "Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians.OBJECTIVE: Methotrexate (<\\entity><\\entity>) is the drug of choice for rheumatoid arthritis (RA) but is effective only in around 60% of treated patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14563",
    "Sentence": "Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in <\\entity><\\entity> patients among Indians.OBJECTIVE: Methotrexate (MTX) is the drug of choice for <\\entity><\\entity> (RA) but is effective only in around 60% of treated patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14564",
    "Sentence": "Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians.OBJECTIVE: Methotrexate (MTX) is the drug of choice for rheumatoid arthritis (<\\entity><\\entity>) but is effective only in around 60% of treated patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14565",
    "Sentence": "Bioavailability of <\\entity><\\entity> may be a major determinant of response status and this may be governed by variations in <\\entity><\\entity> receptor and transporter genes and genes responsible for polyglutamation and deconjugation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14566",
    "Sentence": "Bioavailability of MTX may be a major determinant of response status and this may be governed by variations in <\\entity><\\entity> and transporter genes and genes responsible for polyglutamation and deconjugation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14567",
    "Sentence": "Bioavailability of MTX may be a major determinant of response status and this may be governed by variations in MTX receptor and transporter genes and <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14568",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in <\\entity><\\entity>, FOLR1, FPGS, GGH and MDR1 genes to MTX response in RA patients from North India.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14569",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, <\\entity><\\entity>, FPGS, GGH and MDR1 genes to MTX response in RA patients from North India.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14570",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, FOLR1, <\\entity><\\entity>, GGH and MDR1 genes to MTX response in RA patients from North India.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14571",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, FOLR1, FPGS, <\\entity><\\entity> and MDR1 genes to MTX response in RA patients from North India.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14572",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, FOLR1, FPGS, GGH and <\\entity><\\entity> genes to MTX response in RA patients from North India.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14573",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, FOLR1, FPGS, GGH and MDR1 genes to <\\entity><\\entity> response in RA patients from North India.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14574",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, FOLR1, FPGS, GGH and MDR1 genes to <\\entity><\\entity> response in RA patients from North India.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14575",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, FOLR1, FPGS, GGH and MDR1 genes to MTX response in <\\entity><\\entity> patients from North India.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14576",
    "Sentence": "METHODS: <\\entity><\\entity> patients recruited using American College of Rheumatology criteria, were categorized into good and poor responders to MTX, based on disease activity score.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14577",
    "Sentence": "METHODS: RA patients recruited using American College of Rheumatology criteria, were categorized into good and poor responders to <\\entity><\\entity>, based on disease activity score.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14578",
    "Sentence": "METHODS: RA patients recruited using American College of Rheumatology criteria, were categorized into good and poor responders to MTX, based on <\\entity><\\entity> activity score.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14579",
    "Sentence": "A total of 17 SNPs from the above mentioned genes were genotyped and tested for association with <\\entity><\\entity> response using [chi]2 test; logistic regression along with clinical variables; and gene-gene interaction using multifactor dimensionality reduction (MDR).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14580",
    "Sentence": "A total of 17 SNPs from the above mentioned genes were genotyped and tested for association with <\\entity><\\entity> response using [chi]2 test; logistic regression along with clinical variables; and gene-gene interaction using multifactor dimensionality reduction (MDR).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14581",
    "Sentence": "A total of 17 SNPs from the above mentioned genes were genotyped and tested for association with MTX response using [chi]2 test; logistic <\\entity><\\entity> along with clinical variables; and gene-gene interaction using multifactor dimensionality reduction (MDR).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14582",
    "Sentence": "RESULTS: One novel synonymous SNP <\\entity><\\entity> (972 G > A) was identified in RFC gene.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14583",
    "Sentence": "RESULTS: One novel synonymous SNP Ala324Ala (<\\entity><\\entity>) was identified in RFC gene.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14584",
    "Sentence": "RESULTS: One novel synonymous SNP Ala324Ala (972 G > A) was identified in <\\entity><\\entity> gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14585",
    "Sentence": "The <\\entity><\\entity> genotype of C3435T in MDR1 gene conferred almost twice the risk of poor response [[chi]2 = 5.85, P = 0.01, odds ratio (95% confidence interval) = 1.97 (1.13-3.42)] and was retained in binary logistic regression [B = 0.66, P = 0.025, adjusted odds ratio (95% confidence interval) = 1.93(1.09-3.42)].",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14586",
    "Sentence": "The CT genotype of <\\entity><\\entity> in MDR1 gene conferred almost twice the risk of poor response [[chi]2 = 5.85, P = 0.01, odds ratio (95% confidence interval) = 1.97 (1.13-3.42)] and was retained in binary logistic regression [B = 0.66, P = 0.025, adjusted odds ratio (95% confidence interval) = 1.93(1.09-3.42)].",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14587",
    "Sentence": "The CT genotype of C3435T in <\\entity><\\entity> gene conferred almost twice the risk of poor response [[chi]2 = 5.85, P = 0.01, odds ratio (95% confidence interval) = 1.97 (1.13-3.42)] and was retained in binary logistic regression [B = 0.66, P = 0.025, adjusted odds ratio (95% confidence interval) = 1.93(1.09-3.42)].",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14588",
    "Sentence": "The CT genotype of C3435T in MDR1 gene conferred almost twice the risk of poor response [[chi]2 = 5.85, P = 0.01, odds ratio (95% confidence interval) = 1.97 (1.13-3.42)] and was retained in binary logistic <\\entity><\\entity> [B = 0.66, P = 0.025, adjusted odds ratio (95% confidence interval) = 1.93(1.09-3.42)].",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14589",
    "Sentence": "Significant interaction between SNPs in <\\entity><\\entity> and MDR1 genes seems promising.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14590",
    "Sentence": "Significant interaction between SNPs in GGH and <\\entity><\\entity> genes seems promising.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14591",
    "Sentence": "CONCLUSION: Interactions between genes coding for deconjugation and transporter seem to be important determinants of <\\entity><\\entity> response in RA but replication and functional studies would be confirmatory.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14592",
    "Sentence": "CONCLUSION: Interactions between genes coding for deconjugation and transporter seem to be important determinants of <\\entity><\\entity> response in RA but replication and functional studies would be confirmatory.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14593",
    "Sentence": "CONCLUSION: Interactions between genes coding for deconjugation and transporter seem to be important determinants of MTX response in <\\entity><\\entity> but replication and functional studies would be confirmatory.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14594",
    "Sentence": "The CT genotype of C3435T in <\\entity><\\entity> gene conferred almost twice the risk of poor response [[chi]2 = 5.85, P = 0.01, odds ratio (95% confidence interval) = 1.97 (1.13-3.42)] and was retained in binary logistic regression [B = 0.66, P = 0.025, adjusted odds ratio (95% confidence interval) = 1.93(1.09-3.42)].",
    "Label": ""
  },
  {
    "id": "14595",
    "Sentence": "The CT genotype of C3435T in MDR1 gene conferred almost twice the risk of poor response [[chi]2 = 5.85, P = 0.01, odds ratio (95% confidence interval) = 1.97 (1.13-3.42)] and was retained in binary logistic <\\entity><\\entity> [B = 0.66, P = 0.025, adjusted odds ratio (95% confidence interval) = 1.93(1.09-3.42)].",
    "Label": ""
  },
  {
    "id": "14597",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in <\\entity><\\entity>, FOLR1, FPGS, GGH and MDR1 genes to MTX response in RA patients from North India.",
    "Label": ""
  },
  {
    "id": "14598",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, FOLR1, FPGS, GGH and MDR1 genes to MTX response in <\\entity><\\entity> patients from North India.",
    "Label": ""
  },
  {
    "id": "14600",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, <\\entity><\\entity>, FPGS, GGH and MDR1 genes to MTX response in RA patients from North India.",
    "Label": ""
  },
  {
    "id": "14601",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, FOLR1, FPGS, GGH and MDR1 genes to MTX response in <\\entity><\\entity> patients from North India.",
    "Label": ""
  },
  {
    "id": "14603",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, FOLR1, <\\entity><\\entity>, GGH and MDR1 genes to MTX response in RA patients from North India.",
    "Label": ""
  },
  {
    "id": "14604",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, FOLR1, FPGS, GGH and MDR1 genes to MTX response in <\\entity><\\entity> patients from North India.",
    "Label": ""
  },
  {
    "id": "14606",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, FOLR1, FPGS, <\\entity><\\entity> and MDR1 genes to MTX response in RA patients from North India.",
    "Label": ""
  },
  {
    "id": "14607",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, FOLR1, FPGS, GGH and MDR1 genes to MTX response in <\\entity><\\entity> patients from North India.",
    "Label": ""
  },
  {
    "id": "14609",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, FOLR1, FPGS, GGH and <\\entity><\\entity> genes to MTX response in RA patients from North India.",
    "Label": ""
  },
  {
    "id": "14610",
    "Sentence": "We investigated the contribution of single nucleotide polymorphisms (SNPs) in RFC, FOLR1, FPGS, GGH and MDR1 genes to MTX response in <\\entity><\\entity> patients from North India.",
    "Label": ""
  },
  {
    "id": "14616",
    "Sentence": "<\\entity><\\entity>-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways.Pattern recognition receptors (PRRs) are an integral part of the innate immune system and govern the early control of foreign microorganisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14617",
    "Sentence": "Toll-like receptor-induced <\\entity><\\entity> secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways.Pattern recognition receptors (PRRs) are an integral part of the innate immune system and govern the early control of foreign microorganisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14618",
    "Sentence": "Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in <\\entity><\\entity> by nucleotide oligomerization domain 2-dependent and -independent pathways.Pattern recognition receptors (PRRs) are an integral part of the innate immune system and govern the early control of foreign microorganisms.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14619",
    "Sentence": "Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by <\\entity><\\entity>-dependent and -independent pathways.Pattern recognition receptors (PRRs) are an integral part of the innate immune system and govern the early control of foreign microorganisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14620",
    "Sentence": "Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways.<\\entity><\\entity> (PRRs) are an integral part of the innate immune system and govern the early control of foreign microorganisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14621",
    "Sentence": "Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways.Pattern recognition receptors (<\\entity><\\entity>) are an integral part of the innate immune system and govern the early control of foreign microorganisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14622",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor <\\entity><\\entity> (NOD2, nucleotide oligomerization domain 2) are associated with Crohn's disease (CD).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14623",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (<\\entity><\\entity>, nucleotide oligomerization domain 2) are associated with Crohn's disease (CD).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14624",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, <\\entity><\\entity>) are associated with Crohn's disease (CD).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14625",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, nucleotide oligomerization domain 2) are associated with <\\entity><\\entity> (CD).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14626",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, nucleotide oligomerization domain 2) are associated with Crohn's disease (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14627",
    "Sentence": "We investigated the impact of <\\entity><\\entity> on cytokine secretion and proliferation of peripheral blood mononuclear cells (PBMCs) in response to Toll-like receptor (TLR) and NOD2 ligands.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14628",
    "Sentence": "We investigated the impact of <\\entity><\\entity> on cytokine secretion and proliferation of peripheral blood mononuclear cells (PBMCs) in response to Toll-like receptor (TLR) and NOD2 ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14629",
    "Sentence": "We investigated the impact of NOD2 polymorphisms on <\\entity><\\entity> secretion and proliferation of peripheral blood mononuclear cells (PBMCs) in response to Toll-like receptor (TLR) and NOD2 ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14630",
    "Sentence": "We investigated the impact of NOD2 polymorphisms on cytokine secretion and proliferation of peripheral blood mononuclear cells (PBMCs) in response to <\\entity><\\entity> (TLR) and NOD2 ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14631",
    "Sentence": "We investigated the impact of NOD2 polymorphisms on cytokine secretion and proliferation of peripheral blood mononuclear cells (PBMCs) in response to Toll-like receptor (<\\entity><\\entity>) and NOD2 ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14632",
    "Sentence": "We investigated the impact of <\\entity><\\entity> polymorphisms on cytokine secretion and proliferation of peripheral blood mononuclear cells (PBMCs) in response to Toll-like receptor (TLR) and <\\entity><\\entity> ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14633",
    "Sentence": "Based on <\\entity><\\entity> analyses, 41 CD patients and 12 healthy controls were studied.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14634",
    "Sentence": "Based on <\\entity><\\entity> analyses, 41 CD patients and 12 healthy controls were studied.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14635",
    "Sentence": "Based on NOD2 SNP analyses, 41 <\\entity><\\entity> patients and 12 healthy controls were studied.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14636",
    "Sentence": "<\\entity><\\entity> were stimulated with NOD2 and TLR ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14637",
    "Sentence": "PBMCs were stimulated with <\\entity><\\entity> and TLR ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14638",
    "Sentence": "PBMCs were stimulated with NOD2 and <\\entity><\\entity> ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14639",
    "Sentence": "After 18 h culture supernatants were measured using multiplex assays for the presence of human <\\entity><\\entity> granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-1 beta and tumour necrosis factor (TNF)-alpha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14640",
    "Sentence": "After 18 h culture supernatants were measured using multiplex assays for the presence of human cytokines <\\entity><\\entity> (GM-CSF), interleukin (IL)-1 beta and tumour necrosis factor (TNF)-alpha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14641",
    "Sentence": "After 18 h culture supernatants were measured using multiplex assays for the presence of human cytokines granulocyte-macrophage colony-stimulating factor (<\\entity><\\entity>), interleukin (IL)-1 beta and tumour necrosis factor (TNF)-alpha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14642",
    "Sentence": "After 18 h culture supernatants were measured using multiplex assays for the presence of human cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF), <\\entity><\\entity> (IL)-1 beta and tumour necrosis factor (TNF)-alpha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14643",
    "Sentence": "After 18 h culture supernatants were measured using multiplex assays for the presence of human cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (<\\entity><\\entity> and tumour necrosis factor (TNF)-alpha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14644",
    "Sentence": "After 18 h culture supernatants were measured using multiplex assays for the presence of human cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-1 beta and <\\entity><\\entity> (TNF)-alpha.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14645",
    "Sentence": "After 18 h culture supernatants were measured using multiplex assays for the presence of human cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-1 beta and <\\entity><\\entity> (TNF)-alpha.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14646",
    "Sentence": "After 18 h culture supernatants were measured using multiplex assays for the presence of human cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-1 beta and tumour necrosis factor (<\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14647",
    "Sentence": "In <\\entity><\\entity> patients, TLR-induced GM-CSF secretion was impaired by both NOD2-dependent and -independent mechanisms.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14648",
    "Sentence": "In CD patients, <\\entity><\\entity>-induced GM-CSF secretion was impaired by both NOD2-dependent and -independent mechanisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14649",
    "Sentence": "In CD patients, TLR-induced <\\entity><\\entity> secretion was impaired by both NOD2-dependent and -independent mechanisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14650",
    "Sentence": "In CD patients, TLR-induced GM-CSF secretion was impaired by both <\\entity><\\entity>-dependent and -independent mechanisms.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14651",
    "Sentence": "Moreover, <\\entity><\\entity> production was induced by a TLR-2 ligand, but a down-regulatory function by the NOD2 ligand, muramyl dipeptide, was impaired significantly in CD patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14652",
    "Sentence": "Moreover, TNF-alpha production was induced by a <\\entity><\\entity>-2 ligand, but a down-regulatory function by the NOD2 ligand, muramyl dipeptide, was impaired significantly in CD patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14653",
    "Sentence": "Moreover, TNF-alpha production was induced by a TLR-2 ligand, but a down-regulatory function by the <\\entity><\\entity> ligand, muramyl dipeptide, was impaired significantly in CD patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14654",
    "Sentence": "Moreover, TNF-alpha production was induced by a TLR-2 ligand, but a down-regulatory function by the NOD2 ligand, <\\entity><\\entity>, was impaired significantly in CD patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14655",
    "Sentence": "Moreover, TNF-alpha production was induced by a TLR-2 ligand, but a down-regulatory function by the NOD2 ligand, muramyl dipeptide, was impaired significantly in <\\entity><\\entity> patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14656",
    "Sentence": "Intracellular <\\entity><\\entity> ligands had minimal effect on GM-CSF, TNF-alpha and IL-1beta secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14657",
    "Sentence": "Intracellular TLR ligands had minimal effect on <\\entity><\\entity>, TNF-alpha and IL-1beta secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14658",
    "Sentence": "Intracellular TLR ligands had minimal effect on GM-CSF, <\\entity><\\entity> and IL-1beta secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14659",
    "Sentence": "Intracellular TLR ligands had minimal effect on GM-CSF, TNF-alpha and <\\entity><\\entity> secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14660",
    "Sentence": "<\\entity><\\entity> patients with NOD2 mutations were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14661",
    "Sentence": "CD patients with <\\entity><\\entity> were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14662",
    "Sentence": "CD patients with <\\entity><\\entity> were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14663",
    "Sentence": "CD patients with <\\entity><\\entity> were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14664",
    "Sentence": "CD patients with NOD2 mutations were able to secrete <\\entity><\\entity>, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14665",
    "Sentence": "CD patients with NOD2 mutations were able to secrete TNF-alpha, but not <\\entity><\\entity>, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14666",
    "Sentence": "CD patients with <\\entity><\\entity> mutations were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with <\\entity><\\entity> and TLR-7 ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14667",
    "Sentence": "CD patients with NOD2 mutations were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and <\\entity><\\entity>-7 ligands.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14668",
    "Sentence": "<\\entity><\\entity> patients have impaired GM-CSF secretion via NOD2-dependent and -independent pathways and display an impaired NOD2-dependent down-regulation of TNF-alpha secretion.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14669",
    "Sentence": "CD patients have impaired <\\entity><\\entity> secretion via NOD2-dependent and -independent pathways and display an impaired NOD2-dependent down-regulation of TNF-alpha secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14670",
    "Sentence": "CD patients have impaired GM-CSF secretion via <\\entity><\\entity>-dependent and -independent pathways and display an impaired <\\entity><\\entity>-dependent down-regulation of TNF-alpha secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14671",
    "Sentence": "CD patients have impaired GM-CSF secretion via <\\entity><\\entity>-dependent and -independent pathways and display an impaired <\\entity><\\entity>-dependent down-regulation of TNF-alpha secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14672",
    "Sentence": "CD patients have impaired GM-CSF secretion via NOD2-dependent and -independent pathways and display an impaired NOD2-dependent down-regulation of <\\entity><\\entity> secretion.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14673",
    "Sentence": "The defect in <\\entity><\\entity> secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of CD and is consistent with the hypothesis that impaired <\\entity><\\entity> secretion in part constitutes a NOD2-dependent disease risk factor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14674",
    "Sentence": "The defect in GM-CSF secretion suggests a hitherto unknown role of <\\entity><\\entity> in the pathogenesis of CD and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a <\\entity><\\entity>-dependent disease risk factor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14675",
    "Sentence": "The defect in GM-CSF secretion suggests a hitherto unknown role of NOD2 in the <\\entity><\\entity> of CD and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a NOD2-dependent disease risk factor.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14676",
    "Sentence": "The defect in GM-CSF secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of <\\entity><\\entity> and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a NOD2-dependent disease risk factor.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14677",
    "Sentence": "The defect in <\\entity><\\entity> secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of CD and is consistent with the hypothesis that impaired <\\entity><\\entity> secretion in part constitutes a NOD2-dependent disease risk factor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14678",
    "Sentence": "The defect in GM-CSF secretion suggests a hitherto unknown role of <\\entity><\\entity> in the pathogenesis of CD and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a <\\entity><\\entity>-dependent disease risk factor.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14679",
    "Sentence": "The defect in GM-CSF secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of CD and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a NOD2-dependent <\\entity><\\entity> risk factor.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14680",
    "Sentence": "Toll-like receptor-induced <\\entity><\\entity> secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways.Pattern recognition receptors (PRRs) are an integral part of the innate immune system and govern the early control of foreign microorganisms.",
    "Label": ""
  },
  {
    "id": "14681",
    "Sentence": "Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in <\\entity><\\entity> by nucleotide oligomerization domain 2-dependent and -independent pathways.Pattern recognition receptors (PRRs) are an integral part of the innate immune system and govern the early control of foreign microorganisms.",
    "Label": ""
  },
  {
    "id": "14683",
    "Sentence": "<\\entity><\\entity>-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways.Pattern recognition receptors (PRRs) are an integral part of the innate immune system and govern the early control of foreign microorganisms.",
    "Label": ""
  },
  {
    "id": "14684",
    "Sentence": "Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in <\\entity><\\entity> by nucleotide oligomerization domain 2-dependent and -independent pathways.Pattern recognition receptors (PRRs) are an integral part of the innate immune system and govern the early control of foreign microorganisms.",
    "Label": ""
  },
  {
    "id": "14686",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (<\\entity><\\entity>, nucleotide oligomerization domain 2) are associated with Crohn's disease (CD).",
    "Label": ""
  },
  {
    "id": "14687",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, nucleotide oligomerization domain 2) are associated with <\\entity><\\entity> (CD).",
    "Label": ""
  },
  {
    "id": "14689",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (<\\entity><\\entity>, nucleotide oligomerization domain 2) are associated with Crohn's disease (CD).",
    "Label": ""
  },
  {
    "id": "14690",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, nucleotide oligomerization domain 2) are associated with Crohn's disease (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "14692",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, <\\entity><\\entity>) are associated with Crohn's disease (CD).",
    "Label": ""
  },
  {
    "id": "14693",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, nucleotide oligomerization domain 2) are associated with <\\entity><\\entity> (CD).",
    "Label": ""
  },
  {
    "id": "14695",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, <\\entity><\\entity>) are associated with Crohn's disease (CD).",
    "Label": ""
  },
  {
    "id": "14696",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, nucleotide oligomerization domain 2) are associated with Crohn's disease (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "14698",
    "Sentence": "In CD patients, TLR-induced <\\entity><\\entity> secretion was impaired by both NOD2-dependent and -independent mechanisms.",
    "Label": ""
  },
  {
    "id": "14699",
    "Sentence": "In <\\entity><\\entity> patients, TLR-induced GM-CSF secretion was impaired by both NOD2-dependent and -independent mechanisms.",
    "Label": ""
  },
  {
    "id": "14701",
    "Sentence": "In CD patients, <\\entity><\\entity>-induced GM-CSF secretion was impaired by both NOD2-dependent and -independent mechanisms.",
    "Label": ""
  },
  {
    "id": "14702",
    "Sentence": "In <\\entity><\\entity> patients, TLR-induced GM-CSF secretion was impaired by both NOD2-dependent and -independent mechanisms.",
    "Label": ""
  },
  {
    "id": "14704",
    "Sentence": "Moreover, TNF-alpha production was induced by a TLR-2 ligand, but a down-regulatory function by the <\\entity><\\entity> ligand, muramyl dipeptide, was impaired significantly in CD patients.",
    "Label": ""
  },
  {
    "id": "14705",
    "Sentence": "Moreover, TNF-alpha production was induced by a TLR-2 ligand, but a down-regulatory function by the NOD2 ligand, muramyl dipeptide, was impaired significantly in <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "14707",
    "Sentence": "CD patients with <\\entity><\\entity> were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14708",
    "Sentence": "<\\entity><\\entity> patients with NOD2 mutations were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14710",
    "Sentence": "CD patients have impaired <\\entity><\\entity> secretion via NOD2-dependent and -independent pathways and display an impaired NOD2-dependent down-regulation of TNF-alpha secretion.",
    "Label": ""
  },
  {
    "id": "14711",
    "Sentence": "<\\entity><\\entity> patients have impaired GM-CSF secretion via NOD2-dependent and -independent pathways and display an impaired NOD2-dependent down-regulation of TNF-alpha secretion.",
    "Label": ""
  },
  {
    "id": "14713",
    "Sentence": "CD patients have impaired GM-CSF secretion via NOD2-dependent and -independent pathways and display an impaired NOD2-dependent down-regulation of <\\entity><\\entity> secretion.",
    "Label": ""
  },
  {
    "id": "14714",
    "Sentence": "<\\entity><\\entity> patients have impaired GM-CSF secretion via NOD2-dependent and -independent pathways and display an impaired NOD2-dependent down-regulation of TNF-alpha secretion.",
    "Label": ""
  },
  {
    "id": "14716",
    "Sentence": "CD patients have impaired GM-CSF secretion via <\\entity><\\entity>-dependent and -independent pathways and display an impaired <\\entity><\\entity>-dependent down-regulation of TNF-alpha secretion.",
    "Label": ""
  },
  {
    "id": "14717",
    "Sentence": "<\\entity><\\entity> patients have impaired GM-CSF secretion via NOD2-dependent and -independent pathways and display an impaired NOD2-dependent down-regulation of TNF-alpha secretion.",
    "Label": ""
  },
  {
    "id": "14719",
    "Sentence": "The defect in <\\entity><\\entity> secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of CD and is consistent with the hypothesis that impaired <\\entity><\\entity> secretion in part constitutes a NOD2-dependent disease risk factor.",
    "Label": ""
  },
  {
    "id": "14720",
    "Sentence": "The defect in GM-CSF secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of <\\entity><\\entity> and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a NOD2-dependent disease risk factor.",
    "Label": ""
  },
  {
    "id": "14722",
    "Sentence": "The defect in GM-CSF secretion suggests a hitherto unknown role of <\\entity><\\entity> in the pathogenesis of CD and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a <\\entity><\\entity>-dependent disease risk factor.",
    "Label": ""
  },
  {
    "id": "14723",
    "Sentence": "The defect in GM-CSF secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of <\\entity><\\entity> and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a NOD2-dependent disease risk factor.",
    "Label": ""
  },
  {
    "id": "14725",
    "Sentence": "After 18 h culture supernatants were measured using multiplex assays for the presence of human cytokines granulocyte-macrophage colony-stimulating factor (<\\entity><\\entity>), interleukin (IL)-1 beta and tumour necrosis factor (TNF)-alpha.",
    "Label": ""
  },
  {
    "id": "14726",
    "Sentence": "After 18 h culture supernatants were measured using multiplex assays for the presence of human cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-1 beta and <\\entity><\\entity> (TNF)-alpha.",
    "Label": ""
  },
  {
    "id": "14728",
    "Sentence": "CD patients with NOD2 mutations were able to secrete TNF-alpha, but not <\\entity><\\entity>, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14729",
    "Sentence": "CD patients with <\\entity><\\entity> were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14731",
    "Sentence": "CD patients with <\\entity><\\entity> mutations were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with <\\entity><\\entity> and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14732",
    "Sentence": "CD patients with <\\entity><\\entity> were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14734",
    "Sentence": "CD patients with NOD2 mutations were able to secrete <\\entity><\\entity>, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14735",
    "Sentence": "CD patients with <\\entity><\\entity> were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14737",
    "Sentence": "CD patients with NOD2 mutations were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and <\\entity><\\entity>-7 ligands.",
    "Label": ""
  },
  {
    "id": "14738",
    "Sentence": "CD patients with <\\entity><\\entity> were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14740",
    "Sentence": "The defect in <\\entity><\\entity> secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of CD and is consistent with the hypothesis that impaired <\\entity><\\entity> secretion in part constitutes a NOD2-dependent disease risk factor.",
    "Label": ""
  },
  {
    "id": "14741",
    "Sentence": "The defect in GM-CSF secretion suggests a hitherto unknown role of NOD2 in the <\\entity><\\entity> of CD and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a NOD2-dependent disease risk factor.",
    "Label": ""
  },
  {
    "id": "14743",
    "Sentence": "The defect in <\\entity><\\entity> secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of CD and is consistent with the hypothesis that impaired <\\entity><\\entity> secretion in part constitutes a NOD2-dependent disease risk factor.",
    "Label": ""
  },
  {
    "id": "14744",
    "Sentence": "The defect in GM-CSF secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of CD and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a NOD2-dependent <\\entity><\\entity> risk factor.",
    "Label": ""
  },
  {
    "id": "14746",
    "Sentence": "The defect in GM-CSF secretion suggests a hitherto unknown role of <\\entity><\\entity> in the pathogenesis of CD and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a <\\entity><\\entity>-dependent disease risk factor.",
    "Label": ""
  },
  {
    "id": "14747",
    "Sentence": "The defect in GM-CSF secretion suggests a hitherto unknown role of NOD2 in the <\\entity><\\entity> of CD and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a NOD2-dependent disease risk factor.",
    "Label": ""
  },
  {
    "id": "14749",
    "Sentence": "The defect in GM-CSF secretion suggests a hitherto unknown role of <\\entity><\\entity> in the pathogenesis of CD and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a <\\entity><\\entity>-dependent disease risk factor.",
    "Label": ""
  },
  {
    "id": "14750",
    "Sentence": "The defect in GM-CSF secretion suggests a hitherto unknown role of NOD2 in the pathogenesis of CD and is consistent with the hypothesis that impaired GM-CSF secretion in part constitutes a NOD2-dependent <\\entity><\\entity> risk factor.",
    "Label": ""
  },
  {
    "id": "14752",
    "Sentence": "Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by <\\entity><\\entity>-dependent and -independent pathways.Pattern recognition receptors (PRRs) are an integral part of the innate immune system and govern the early control of foreign microorganisms.",
    "Label": ""
  },
  {
    "id": "14753",
    "Sentence": "Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in <\\entity><\\entity> by nucleotide oligomerization domain 2-dependent and -independent pathways.Pattern recognition receptors (PRRs) are an integral part of the innate immune system and govern the early control of foreign microorganisms.",
    "Label": ""
  },
  {
    "id": "14755",
    "Sentence": "Based on <\\entity><\\entity> analyses, 41 CD patients and 12 healthy controls were studied.",
    "Label": ""
  },
  {
    "id": "14756",
    "Sentence": "Based on NOD2 SNP analyses, 41 <\\entity><\\entity> patients and 12 healthy controls were studied.",
    "Label": ""
  },
  {
    "id": "14758",
    "Sentence": "In CD patients, TLR-induced GM-CSF secretion was impaired by both <\\entity><\\entity>-dependent and -independent mechanisms.",
    "Label": ""
  },
  {
    "id": "14759",
    "Sentence": "In <\\entity><\\entity> patients, TLR-induced GM-CSF secretion was impaired by both NOD2-dependent and -independent mechanisms.",
    "Label": ""
  },
  {
    "id": "14761",
    "Sentence": "Moreover, TNF-alpha production was induced by a <\\entity><\\entity>-2 ligand, but a down-regulatory function by the NOD2 ligand, muramyl dipeptide, was impaired significantly in CD patients.",
    "Label": ""
  },
  {
    "id": "14762",
    "Sentence": "Moreover, TNF-alpha production was induced by a TLR-2 ligand, but a down-regulatory function by the NOD2 ligand, muramyl dipeptide, was impaired significantly in <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "14764",
    "Sentence": "CD patients with NOD2 mutations were able to secrete TNF-alpha, but not <\\entity><\\entity>, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14765",
    "Sentence": "<\\entity><\\entity> patients with NOD2 mutations were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14767",
    "Sentence": "CD patients with NOD2 mutations were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and <\\entity><\\entity>-7 ligands.",
    "Label": ""
  },
  {
    "id": "14768",
    "Sentence": "<\\entity><\\entity> patients with NOD2 mutations were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14770",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor <\\entity><\\entity> (NOD2, nucleotide oligomerization domain 2) are associated with Crohn's disease (CD).",
    "Label": ""
  },
  {
    "id": "14771",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, nucleotide oligomerization domain 2) are associated with <\\entity><\\entity> (CD).",
    "Label": ""
  },
  {
    "id": "14773",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor <\\entity><\\entity> (NOD2, nucleotide oligomerization domain 2) are associated with Crohn's disease (CD).",
    "Label": ""
  },
  {
    "id": "14774",
    "Sentence": "Single nucleotide polymorphisms (SNPs) in the intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing protein (NOD2, nucleotide oligomerization domain 2) are associated with Crohn's disease (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "14776",
    "Sentence": "Moreover, <\\entity><\\entity> production was induced by a TLR-2 ligand, but a down-regulatory function by the NOD2 ligand, muramyl dipeptide, was impaired significantly in CD patients.",
    "Label": ""
  },
  {
    "id": "14777",
    "Sentence": "Moreover, TNF-alpha production was induced by a TLR-2 ligand, but a down-regulatory function by the NOD2 ligand, muramyl dipeptide, was impaired significantly in <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "14779",
    "Sentence": "Moreover, TNF-alpha production was induced by a TLR-2 ligand, but a down-regulatory function by the NOD2 ligand, <\\entity><\\entity>, was impaired significantly in CD patients.",
    "Label": ""
  },
  {
    "id": "14780",
    "Sentence": "Moreover, TNF-alpha production was induced by a TLR-2 ligand, but a down-regulatory function by the NOD2 ligand, muramyl dipeptide, was impaired significantly in <\\entity><\\entity> patients.",
    "Label": ""
  },
  {
    "id": "14782",
    "Sentence": "CD patients with NOD2 mutations were able to secrete TNF-alpha, but not <\\entity><\\entity>, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14783",
    "Sentence": "<\\entity><\\entity> patients with NOD2 mutations were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14785",
    "Sentence": "CD patients with <\\entity><\\entity> mutations were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with <\\entity><\\entity> and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14786",
    "Sentence": "<\\entity><\\entity> patients with NOD2 mutations were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14788",
    "Sentence": "CD patients with NOD2 mutations were able to secrete <\\entity><\\entity>, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14789",
    "Sentence": "<\\entity><\\entity> patients with NOD2 mutations were able to secrete TNF-alpha, but not GM-CSF, upon stimulation with NOD2 and TLR-7 ligands.",
    "Label": ""
  },
  {
    "id": "14795",
    "Sentence": "Genome wide association for <\\entity><\\entity>: convergent results from epidemiologic and research volunteer samples.BACKGROUND: Dependences on addictive substances are substantially-heritable complex disorders whose molecular genetic bases have been partially elucidated by studies that have largely focused on research volunteers, including those recruited in Baltimore.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14796",
    "Sentence": "Genome wide association for substance dependence: convergent results from epidemiologic and research volunteer samples.BACKGROUND: <\\entity><\\entity> addictive substances are substantially-heritable complex disorders whose molecular genetic bases have been partially elucidated by studies that have largely focused on research volunteers, including those recruited in Baltimore.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14797",
    "Sentence": "Genome wide association for substance dependence: convergent results from epidemiologic and research volunteer samples.BACKGROUND: Dependences on addictive substances are substantially-heritable complex <\\entity><\\entity> whose molecular genetic bases have been partially elucidated by studies that have largely focused on research volunteers, including those recruited in Baltimore.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14798",
    "Sentence": "Subjects recruited from the Baltimore site of the Epidemiological Catchment Area (ECA) study provide a potentially-useful comparison group for possible confounding features that might arise from selecting research volunteer samples of <\\entity><\\entity> and control individuals.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14799",
    "Sentence": "We now report novel SNP (single nucleotide polymorphism) genome wide association (GWA) results for vulnerability to <\\entity><\\entity> in ECA participants, who were initially ascertained as members of a probability sample from Baltimore, and compare the results to those from ethnically-matched Baltimore research volunteers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14800",
    "Sentence": "We find overlapping clusters of SNPs whose allele frequencies differ with nominal significance between <\\entity><\\entity> vs control individuals in both samples.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14801",
    "Sentence": "Comparison with data from human expressed sequence <\\entity><\\entity> suggests that these genes are expressed in brain, especially in hippocampus and amygdala, to extents that are greater than chance.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14802",
    "Sentence": "They fail to support the idea that large portions of the molecular genetic results for vulnerability to <\\entity><\\entity> derive from factors that are limited to research volunteers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14807",
    "Sentence": "Relation of genetic variation in the gene coding for <\\entity><\\entity> with its plasma protein concentrations: findings from the Women's Health Initiative Observational Cohort.BACKGROUND: Although common genetic variants of the CRP gene (<\\entity><\\entity>, pentraxin related) have been associated with plasma concentrations of high-sensitivity CRP (hsCRP) in several cohorts of European Americans, relatively few studies have comprehensively assessed this association in well-characterized multiethnic populations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14808",
    "Sentence": "Relation of genetic variation in the gene coding for C-reactive protein with its plasma protein concentrations: findings from the Women's Health Initiative Observational Cohort.BACKGROUND: Although common genetic variants of the <\\entity><\\entity> gene (C-reactive protein, pentraxin related) have been associated with plasma concentrations of high-sensitivity <\\entity><\\entity> (hs<\\entity><\\entity>) in several cohorts of European Americans, relatively few studies have comprehensively assessed this association in well-characterized multiethnic populations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14809",
    "Sentence": "Relation of genetic variation in the gene coding for <\\entity><\\entity> with its plasma protein concentrations: findings from the Women's Health Initiative Observational Cohort.BACKGROUND: Although common genetic variants of the CRP gene (<\\entity><\\entity>, pentraxin related) have been associated with plasma concentrations of high-sensitivity CRP (hsCRP) in several cohorts of European Americans, relatively few studies have comprehensively assessed this association in well-characterized multiethnic populations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14810",
    "Sentence": "Relation of genetic variation in the gene coding for C-reactive protein with its plasma protein concentrations: findings from the Women's Health Initiative Observational Cohort.BACKGROUND: Although common genetic variants of the CRP gene (C-reactive protein, pentraxin related) have been associated with plasma concentrations of <\\entity><\\entity> (hsCRP) in several cohorts of European Americans, relatively few studies have comprehensively assessed this association in well-characterized multiethnic populations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14811",
    "Sentence": "Relation of genetic variation in the gene coding for C-reactive protein with its plasma protein concentrations: findings from the Women's Health Initiative Observational Cohort.BACKGROUND: Although common genetic variants of the CRP gene (C-reactive protein, pentraxin related) have been associated with plasma concentrations of high-sensitivity CRP (<\\entity><\\entity>) in several cohorts of European Americans, relatively few studies have comprehensively assessed this association in well-characterized multiethnic populations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14812",
    "Sentence": "METHODS: In a case-control study of <\\entity><\\entity> nested in the Women's Health Initiative Observational Cohort, we comprehensively evaluated the association of genetic variation in CRP with plasma hsCRP concentrations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14813",
    "Sentence": "METHODS: In a case-control study of diabetes nested in the Women's Health Initiative Observational Cohort, we comprehensively evaluated the association of genetic variation in <\\entity><\\entity> with plasma hs<\\entity><\\entity> concentrations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14814",
    "Sentence": "METHODS: In a case-control study of diabetes nested in the Women's Health Initiative Observational Cohort, we comprehensively evaluated the association of genetic variation in CRP with plasma <\\entity><\\entity> concentrations.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14815",
    "Sentence": "RESULTS: The allele frequencies for these tSNPs and the haplotype <\\entity><\\entity> defined by these tSNPs varied significantly by ethnic group (P < 0.0001).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14816",
    "Sentence": "Consistent with prior studies of whites, <\\entity><\\entity>, rs1130864, and rs1417938 were significantly associated with higher hsCRP concentrations (geometric-mean increase per minor-allele change, 1.20-1.25 mg/L), and rs1205 and rs1800947 were significantly associated with lower hsCRP values (decrease of 1.28-1.48 mg/L).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14817",
    "Sentence": "Consistent with prior studies of whites, rs3093068, <\\entity><\\entity>, and rs1417938 were significantly associated with higher hsCRP concentrations (geometric-mean increase per minor-allele change, 1.20-1.25 mg/L), and rs1205 and rs1800947 were significantly associated with lower hsCRP values (decrease of 1.28-1.48 mg/L).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14818",
    "Sentence": "Consistent with prior studies of whites, rs3093068, rs1130864, and <\\entity><\\entity> were significantly associated with higher hsCRP concentrations (geometric-mean increase per minor-allele change, 1.20-1.25 mg/L), and rs1205 and rs1800947 were significantly associated with lower hsCRP values (decrease of 1.28-1.48 mg/L).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14819",
    "Sentence": "Consistent with prior studies of whites, rs3093068, rs1130864, and rs1417938 were significantly associated with higher <\\entity><\\entity> concentrations (geometric-mean increase per minor-allele change, 1.20-1.25 mg/L), and rs1205 and rs1800947 were significantly associated with lower <\\entity><\\entity> values (decrease of 1.28-1.48 mg/L).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14820",
    "Sentence": "Consistent with prior studies of whites, rs3093068, rs1130864, and rs1417938 were significantly associated with higher hsCRP concentrations (geometric-mean increase per minor-allele change, 1.20-1.25 mg/L), and <\\entity><\\entity> and rs1800947 were significantly associated with lower hsCRP values (decrease of 1.28-1.48 mg/L).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14821",
    "Sentence": "Consistent with prior studies of whites, rs3093068, rs1130864, and rs1417938 were significantly associated with higher hsCRP concentrations (geometric-mean increase per minor-allele change, 1.20-1.25 mg/L), and rs1205 and <\\entity><\\entity> were significantly associated with lower hsCRP values (decrease of 1.28-1.48 mg/L).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14822",
    "Sentence": "Consistent with prior studies of whites, rs3093068, rs1130864, and rs1417938 were significantly associated with higher <\\entity><\\entity> concentrations (geometric-mean increase per minor-allele change, 1.20-1.25 mg/L), and rs1205 and rs1800947 were significantly associated with lower <\\entity><\\entity> values (decrease of 1.28-1.48 mg/L).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14823",
    "Sentence": "The associations with <\\entity><\\entity> and rs1205 appeared to be stronger in Asians/Pacific Islanders than in whites (geometric-mean increase, 1.65 mg/L vs 1.25 mg/L, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14824",
    "Sentence": "The associations with rs3093068 and <\\entity><\\entity> appeared to be stronger in Asians/Pacific Islanders than in whites (geometric-mean increase, 1.65 mg/L vs 1.25 mg/L, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14825",
    "Sentence": "<\\entity><\\entity> alleles at rs3093075 and rs3093059 were associated with substantially increased hsCRP concentrations, whereas rs1800947 was associated with lower hsCRP values.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14826",
    "Sentence": "Minor alleles at <\\entity><\\entity> and rs3093059 were associated with substantially increased hsCRP concentrations, whereas rs1800947 was associated with lower hsCRP values.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14827",
    "Sentence": "Minor alleles at rs3093075 and <\\entity><\\entity> were associated with substantially increased hsCRP concentrations, whereas rs1800947 was associated with lower hsCRP values.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14828",
    "Sentence": "Minor alleles at rs3093075 and rs3093059 were associated with substantially increased <\\entity><\\entity> concentrations, whereas rs1800947 was associated with lower <\\entity><\\entity> values.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14829",
    "Sentence": "Minor alleles at rs3093075 and rs3093059 were associated with substantially increased hsCRP concentrations, whereas <\\entity><\\entity> was associated with lower hsCRP values.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14830",
    "Sentence": "Minor alleles at rs3093075 and rs3093059 were associated with substantially increased <\\entity><\\entity> concentrations, whereas rs1800947 was associated with lower <\\entity><\\entity> values.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14831",
    "Sentence": "All haplotype-based association results tended to be consistent with the associations seen with single <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14832",
    "Sentence": "All haplotype-based association results tended to be consistent with the associations seen with single <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14833",
    "Sentence": "CONCLUSIONS: Our large multiethnic case-control study of postmenopausal women provides evidence that common genetic variants in the <\\entity><\\entity> gene are substantially associated with plasma hs<\\entity><\\entity> concentrations in this case-control subcohort.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14834",
    "Sentence": "CONCLUSIONS: Our large multiethnic case-control study of postmenopausal women provides evidence that common genetic variants in the CRP gene are substantially associated with plasma <\\entity><\\entity> concentrations in this case-control subcohort.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14835",
    "Sentence": "METHODS: In a case-control study of diabetes nested in the Women's Health Initiative Observational Cohort, we comprehensively evaluated the association of genetic variation in <\\entity><\\entity> with plasma hs<\\entity><\\entity> concentrations.",
    "Label": ""
  },
  {
    "id": "14836",
    "Sentence": "METHODS: In a case-control study of <\\entity><\\entity> nested in the Women's Health Initiative Observational Cohort, we comprehensively evaluated the association of genetic variation in CRP with plasma hsCRP concentrations.",
    "Label": ""
  },
  {
    "id": "14838",
    "Sentence": "METHODS: In a case-control study of diabetes nested in the Women's Health Initiative Observational Cohort, we comprehensively evaluated the association of genetic variation in CRP with plasma <\\entity><\\entity> concentrations.",
    "Label": ""
  },
  {
    "id": "14839",
    "Sentence": "METHODS: In a case-control study of <\\entity><\\entity> nested in the Women's Health Initiative Observational Cohort, we comprehensively evaluated the association of genetic variation in CRP with plasma hsCRP concentrations.",
    "Label": ""
  },
  {
    "id": "14845",
    "Sentence": "Susceptibility of <\\entity><\\entity>, XPD, and XOBJECTIVE: DNA repair genes play a key role in maintaining genomic stability and integrity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14846",
    "Sentence": "Susceptibility of XRCC3, <\\entity><\\entity>, and XOBJECTIVE: DNA repair genes play a key role in maintaining genomic stability and integrity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14847",
    "Sentence": "Susceptibility of XRCC3, <\\entity><\\entity>, and XOBJECTIVE: DNA repair genes play a key role in maintaining genomic stability and integrity.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14848",
    "Sentence": "Susceptibility of XRCC3, <\\entity><\\entity>, and XOBJECTIVE: DNA repair genes play a key role in maintaining genomic stability and integrity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14849",
    "Sentence": "Susceptibility of XRCC3, XPD, and XOBJECTIVE: DNA repair genes play a key role in maintaining genomic stability and integrity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14850",
    "Sentence": "Susceptibility of XRCC3, XPD, and XOBJECTIVE: DNA repair genes play a key role in maintaining genomic stability and integrity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14851",
    "Sentence": "Susceptibility of XRCC3, XPD, and XOBJECTIVE: DNA repair <\\entity><\\entity>ole in maintaining genomic stability and integrity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14852",
    "Sentence": "DNA repair gene polymorphisms, such as those of XRCC3 and xeroderma pigmentosum, complemen<\\entity><\\entity>n group D and G (XPD, XPG), contribute to carcinogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14853",
    "Sentence": "DNA repair gene polymorphisms, such as those of XRCC3 and xeroderma pigmentosum, complementation gro<\\entity><\\entity>, contribute to carcinogenesis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14854",
    "Sentence": "DNA repair gene polymorphisms, such as those of XRCC3 and xeroderma pigmentosum, complementation gro<\\entity><\\entity>, contribute to carcinogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14855",
    "Sentence": "I<\\entity><\\entity>his study, we investigated the correlation between cervical carcinoma risk and XRCC3, XPD, XPG genetic variants.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14856",
    "Sentence": "I<\\entity><\\entity>his study, we investigated the correlation between cervical carcinoma risk and XRCC3, XPD, XPG genetic variants.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14857",
    "Sentence": "I<\\entity><\\entity>his study, we investigated the correlation between cervical carcinoma risk and XRCC3, XPD, XPG genetic variants.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14858",
    "Sentence": "In thi<\\entity><\\entity>tudy, we investigated the correlation between cervical carcinoma risk and XRCC3, XPD, XPG genetic variants.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14859",
    "Sentence": "In thi<\\entity><\\entity>tudy, we investigated the correlation between cervical carcinoma risk and XRCC3, XPD, XPG genetic variants.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14860",
    "Sentence": "In this study, we investig<\\entity><\\entity>lation between cervical carcinoma risk and XRCC3, XPD, XPG genetic variants.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14861",
    "Sentence": "In this study, we investigated the correlation between cervical carcinoma risk and XRCC3, XPD, XP<\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14862",
    "Sentence": "METHODS:<\\entity><\\entity>se-control study of 400 cases including 200 carcinoma, 200 cervical intraepithelial neoplasia (CIN) and 200 normal women was performed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14863",
    "Sentence": "METHODS: A case<\\entity><\\entity>ntrol study of 400 cases including 200 carcinoma, 200 cervical intraepithelial neoplasia (CIN) and 200 normal women was performed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14864",
    "Sentence": "METHODS: A case<\\entity><\\entity>ntrol study of 400 cases including 200 carcinoma, 200 cervical intraepithelial neoplasia (CIN) and 200 normal women was performed.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14865",
    "Sentence": "METHODS: A case<\\entity><\\entity>ntrol study of 400 cases including 200 carcinoma, 200 cervical intraepithelial neoplasia (CIN) and 200 normal women was performed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14866",
    "Sentence": "METHODS: A case-cont<\\entity><\\entity> study of 400 cases including 200 carcinoma, 200 cervical intraepithelial neoplasia (CIN) and 200 normal women was performed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14867",
    "Sentence": "METHODS: A case-cont<\\entity><\\entity> study of 400 cases including 200 carcinoma, 200 cervical intraepithelial neoplasia (CIN) and 200 normal women was performed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14868",
    "Sentence": "METHODS: A case-control study of 400 cases including 200 carcinoma, 200 cervical intraepithelial ne<\\entity><\\entity>CIN) and 200 normal women was performed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14869",
    "Sentence": "METHODS: A case-control study of 400 cases including 200 carcinoma, 200 cervical intraepithelial neoplasia (CIN) a<\\entity><\\entity>",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14870",
    "Sentence": "F<\\entity><\\entity> single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys751Gln) were genotyped by mismatch amplification polymerase chain reaction.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14871",
    "Sentence": "F<\\entity><\\entity> single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys751Gln) were genotyped by mismatch amplification polymerase chain reaction.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14872",
    "Sentence": "Four single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp31<\\entity><\\entity>ys751Gln) were genotyped by mismatch amplification polymerase chain reaction.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14873",
    "Sentence": "Four single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp31<\\entity><\\entity>ys751Gln) were genotyped by mismatch amplification polymerase chain reaction.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14874",
    "Sentence": "Four single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys<\\entity><\\entity>enotyped by mismatch amplification polymerase chain reaction.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14875",
    "Sentence": "Four single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys<\\entity><\\entity>enotyped by mismatch amplification polymerase chain reaction.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14876",
    "Sentence": "Four single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys<\\entity><\\entity>enotyped by mismatch amplification polymerase chain reaction.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14877",
    "Sentence": "Four single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys751Gln) were gen<\\entity><\\entity>match amplification polymerase chain reaction.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14878",
    "Sentence": "Four single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys751Gln) were gen<\\entity><\\entity>match amplification polymerase chain reaction.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14879",
    "Sentence": "Four single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys751Gln) were gen<\\entity><\\entity>match amplification polymerase chain reaction.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14880",
    "Sentence": "Four single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys751Gln) were genotyped by mismatch <\\entity><\\entity> polymerase chain reaction.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14881",
    "Sentence": "Four single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys751Gln) were genotyped by mismatch <\\entity><\\entity> polymerase chain reaction.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14882",
    "Sentence": "Four single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys751Gln) were genotyped by mismatch <\\entity><\\entity> polymerase chain reaction.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14883",
    "Sentence": "R<\\entity><\\entity> carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcinoma compared to His1104Asp or His1104His genotypes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14884",
    "Sentence": "RESULTS: Women carrying homozygous Asp1104Asp genotypes had a significantly d<\\entity><\\entity>isk of cervical or cervical squamous cell carcinoma compared to His1104Asp or His1104His genotypes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14885",
    "Sentence": "RESULTS: Women carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcino<\\entity><\\entity>red to His1104Asp or His1104His genotypes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14886",
    "Sentence": "RESULTS: Women carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcinoma compared <\\entity><\\entity>types.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14887",
    "Sentence": "Simila<\\entity><\\entity>sn312Asn (AA) reduced the risk of cervical or cervical squamous cell carcinoma.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14888",
    "Sentence": "Similarly, XPD Asn31<\\entity><\\entity>reduced the risk of cervical or cervical squamous cell carcinoma.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14889",
    "Sentence": "Similarly, XPD Asn312Asn (AA) reduced the risk of cer<\\entity><\\entity>ical squamous cell carcinoma.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14890",
    "Sentence": "Similarly, XPD Asn312Asn (AA) reduced the risk of cer<\\entity><\\entity>ical squamous cell carcinoma.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14891",
    "Sentence": "Similarly, XPD Asn312Asn (AA) reduced the risk of cer<\\entity><\\entity>ical squamous cell carcinoma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14892",
    "Sentence": "Similarly, XPD Asn312Asn (AA) reduced the risk of cervic<\\entity><\\entity> or cervic<\\entity><\\entity> squamous cell carcinoma.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14893",
    "Sentence": "Similarly, XPD Asn312Asn (AA) reduced the risk of cervical or cervical squamous cell carcinoma.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14894",
    "Sentence": "No assoc<\\entity><\\entity> Lys751Gln and cervical carcinoma was found.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14895",
    "Sentence": "No association of XRCC3 Thr241Met or XPD Lys751Gln and cervi<\\entity><\\entity>as found.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14896",
    "Sentence": "No association of XRCC3 Thr241Met or XPD Lys751Gln and cervi<\\entity><\\entity>as found.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14897",
    "Sentence": "No association of XRCC3 Thr241Met or XPD Lys751Gln and cervical carcinoma was found.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "14898",
    "Sentence": "No association of XRCC3 Thr241Met or XPD Lys751Gln and cervical carcinoma was found.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14899",
    "Sentence": "No association of XRCC3 Thr241Met or XPD Lys751Gln and cervical carcinoma was found.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14900",
    "Sentence": "None of the <\\entity><\\entity>the risk of CIN in our study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14901",
    "Sentence": "CONCLUSION: Our results <\\entity><\\entity>port the hypothesis that genetic variations in DNA repair genes may contribute to an inherited genetic susceptibility to cervical carcinoma.CI - Copyright 2008 S.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "14902",
    "Sentence": "CONCLUSION: Our results <\\entity><\\entity>port the hypothesis that genetic variations in DNA repair genes may contribute to an inherited genetic susceptibility to cervical carcinoma.CI - Copyright 2008 S.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14903",
    "Sentence": "<\\entity><\\entity>",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "14904",
    "Sentence": "I<\\entity><\\entity>his study, we investigated the correlation between cervical carcinoma risk and XRCC3, XPD, XPG genetic variants.",
    "Label": ""
  },
  {
    "id": "14905",
    "Sentence": "In this study, we investig<\\entity><\\entity>lation between cervical carcinoma risk and XRCC3, XPD, XPG genetic variants.",
    "Label": ""
  },
  {
    "id": "14907",
    "Sentence": "In thi<\\entity><\\entity>tudy, we investigated the correlation between cervical carcinoma risk and XRCC3, XPD, XPG genetic variants.",
    "Label": ""
  },
  {
    "id": "14908",
    "Sentence": "In this study, we investig<\\entity><\\entity>lation between cervical carcinoma risk and XRCC3, XPD, XPG genetic variants.",
    "Label": ""
  },
  {
    "id": "14910",
    "Sentence": "DNA repair gene polymorphisms, such as those of XRCC3 and xeroderma pigmentosum, complemen<\\entity><\\entity>n group D and G (XPD, XPG), contribute to carcinogenesis.",
    "Label": ""
  },
  {
    "id": "14911",
    "Sentence": "In this study, we investig<\\entity><\\entity>lation between cervical carcinoma risk and XRCC3, XPD, XPG genetic variants.",
    "Label": ""
  },
  {
    "id": "14913",
    "Sentence": "F<\\entity><\\entity> single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys751Gln) were genotyped by mismatch amplification polymerase chain reaction.",
    "Label": ""
  },
  {
    "id": "14914",
    "Sentence": "METHODS: A case-control study of 400 cases including 200 carcinoma, 200 cervical intraepithelial ne<\\entity><\\entity>CIN) and 200 normal women was performed.",
    "Label": ""
  },
  {
    "id": "14916",
    "Sentence": "F<\\entity><\\entity> single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys751Gln) were genotyped by mismatch amplification polymerase chain reaction.",
    "Label": ""
  },
  {
    "id": "14917",
    "Sentence": "METHODS: A case-control study of 400 cases including 200 carcinoma, 200 cervical intraepithelial neoplasia (CIN) a<\\entity><\\entity>",
    "Label": ""
  },
  {
    "id": "14919",
    "Sentence": "RESULTS: Women carrying homozygous Asp1104Asp genotypes had a significantly d<\\entity><\\entity>isk of cervical or cervical squamous cell carcinoma compared to His1104Asp or His1104His genotypes.",
    "Label": ""
  },
  {
    "id": "14920",
    "Sentence": "RESULTS: Women carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcino<\\entity><\\entity>red to His1104Asp or His1104His genotypes.",
    "Label": ""
  },
  {
    "id": "14922",
    "Sentence": "RESULTS: Women carrying homozygous Asp1104Asp genotypes had a significantly d<\\entity><\\entity>isk of cervical or cervical squamous cell carcinoma compared to His1104Asp or His1104His genotypes.",
    "Label": ""
  },
  {
    "id": "14923",
    "Sentence": "RESULTS: Women carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcinoma compared <\\entity><\\entity>types.",
    "Label": ""
  },
  {
    "id": "14925",
    "Sentence": "Similarly, XPD Asn312Asn (AA) reduced the risk of cer<\\entity><\\entity>ical squamous cell carcinoma.",
    "Label": ""
  },
  {
    "id": "14926",
    "Sentence": "Similarly, XPD Asn312Asn (AA) reduced the risk of cervical or cervical squamous cell carcinoma.",
    "Label": ""
  },
  {
    "id": "14928",
    "Sentence": "Similarly, XPD Asn312Asn (AA) reduced the risk of cer<\\entity><\\entity>ical squamous cell carcinoma.",
    "Label": ""
  },
  {
    "id": "14929",
    "Sentence": "No assoc<\\entity><\\entity> Lys751Gln and cervical carcinoma was found.",
    "Label": ""
  },
  {
    "id": "14931",
    "Sentence": "No association of XRCC3 Thr241Met or XPD Lys751Gln and cervical carcinoma was found.",
    "Label": ""
  },
  {
    "id": "14932",
    "Sentence": "None of the <\\entity><\\entity>the risk of CIN in our study.",
    "Label": ""
  },
  {
    "id": "14934",
    "Sentence": "No association of XRCC3 Thr241Met or XPD Lys751Gln and cervi<\\entity><\\entity>as found.",
    "Label": ""
  },
  {
    "id": "14935",
    "Sentence": "None of the <\\entity><\\entity>the risk of CIN in our study.",
    "Label": ""
  },
  {
    "id": "14937",
    "Sentence": "Susceptibility of XRCC3, <\\entity><\\entity>, and XOBJECTIVE: DNA repair genes play a key role in maintaining genomic stability and integrity.",
    "Label": ""
  },
  {
    "id": "14938",
    "Sentence": "Susceptibility of XRCC3, XPD, and XOBJECTIVE: DNA repair <\\entity><\\entity>ole in maintaining genomic stability and integrity.",
    "Label": ""
  },
  {
    "id": "14940",
    "Sentence": "Susceptibility of XRCC3, XPD, and XOBJECTIVE: DNA repair genes play a key role in maintaining genomic stability and integrity.",
    "Label": ""
  },
  {
    "id": "14941",
    "Sentence": "Susceptibility of XRCC3, XPD, and XOBJECTIVE: DNA repair <\\entity><\\entity>ole in maintaining genomic stability and integrity.",
    "Label": ""
  },
  {
    "id": "14943",
    "Sentence": "Susceptibility of <\\entity><\\entity>, XPD, and XOBJECTIVE: DNA repair genes play a key role in maintaining genomic stability and integrity.",
    "Label": ""
  },
  {
    "id": "14944",
    "Sentence": "Susceptibility of XRCC3, XPD, and XOBJECTIVE: DNA repair <\\entity><\\entity>ole in maintaining genomic stability and integrity.",
    "Label": ""
  },
  {
    "id": "14946",
    "Sentence": "I<\\entity><\\entity>his study, we investigated the correlation between cervical carcinoma risk and XRCC3, XPD, XPG genetic variants.",
    "Label": ""
  },
  {
    "id": "14947",
    "Sentence": "DNA repair gene polymorphisms, such as those of XRCC3 and xeroderma pigmentosum, complementation gro<\\entity><\\entity>, contribute to carcinogenesis.",
    "Label": ""
  },
  {
    "id": "14949",
    "Sentence": "In thi<\\entity><\\entity>tudy, we investigated the correlation between cervical carcinoma risk and XRCC3, XPD, XPG genetic variants.",
    "Label": ""
  },
  {
    "id": "14950",
    "Sentence": "DNA repair gene polymorphisms, such as those of XRCC3 and xeroderma pigmentosum, complementation gro<\\entity><\\entity>, contribute to carcinogenesis.",
    "Label": ""
  },
  {
    "id": "14952",
    "Sentence": "DNA repair gene polymorphisms, such as those of XRCC3 and xeroderma pigmentosum, complemen<\\entity><\\entity>n group D and G (XPD, XPG), contribute to carcinogenesis.",
    "Label": ""
  },
  {
    "id": "14953",
    "Sentence": "DNA repair gene polymorphisms, such as those of XRCC3 and xeroderma pigmentosum, complementation gro<\\entity><\\entity>, contribute to carcinogenesis.",
    "Label": ""
  },
  {
    "id": "14955",
    "Sentence": "METHODS: A case<\\entity><\\entity>ntrol study of 400 cases including 200 carcinoma, 200 cervical intraepithelial neoplasia (CIN) and 200 normal women was performed.",
    "Label": ""
  },
  {
    "id": "14956",
    "Sentence": "In this study, we investigated the correlation between cervical carcinoma risk and XRCC3, XPD, XP<\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14958",
    "Sentence": "METHODS: A case-cont<\\entity><\\entity> study of 400 cases including 200 carcinoma, 200 cervical intraepithelial neoplasia (CIN) and 200 normal women was performed.",
    "Label": ""
  },
  {
    "id": "14959",
    "Sentence": "In this study, we investigated the correlation between cervical carcinoma risk and XRCC3, XPD, XP<\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14961",
    "Sentence": "METHODS:<\\entity><\\entity>se-control study of 400 cases including 200 carcinoma, 200 cervical intraepithelial neoplasia (CIN) and 200 normal women was performed.",
    "Label": ""
  },
  {
    "id": "14962",
    "Sentence": "In this study, we investigated the correlation between cervical carcinoma risk and XRCC3, XPD, XP<\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "14964",
    "Sentence": "Four single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys751Gln) were genotyped by mismatch <\\entity><\\entity> polymerase chain reaction.",
    "Label": ""
  },
  {
    "id": "14965",
    "Sentence": "R<\\entity><\\entity> carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcinoma compared to His1104Asp or His1104His genotypes.",
    "Label": ""
  },
  {
    "id": "14967",
    "Sentence": "Four single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp312Asn, and XPD Lys<\\entity><\\entity>enotyped by mismatch amplification polymerase chain reaction.",
    "Label": ""
  },
  {
    "id": "14968",
    "Sentence": "R<\\entity><\\entity> carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcinoma compared to His1104Asp or His1104His genotypes.",
    "Label": ""
  },
  {
    "id": "14970",
    "Sentence": "Four single nucleotide polymorphisms (SNPs) (XRCC3 Thr241Met, XPG His1104Asp, XPD Asp31<\\entity><\\entity>ys751Gln) were genotyped by mismatch amplification polymerase chain reaction.",
    "Label": ""
  },
  {
    "id": "14971",
    "Sentence": "R<\\entity><\\entity> carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcinoma compared to His1104Asp or His1104His genotypes.",
    "Label": ""
  },
  {
    "id": "14973",
    "Sentence": "No association of XRCC3 Thr241Met or XPD Lys751Gln and cervical carcinoma was found.",
    "Label": ""
  },
  {
    "id": "14974",
    "Sentence": "None of the <\\entity><\\entity>the risk of CIN in our study.",
    "Label": ""
  },
  {
    "id": "14976",
    "Sentence": "No association of XRCC3 Thr241Met or XPD Lys751Gln and cervi<\\entity><\\entity>as found.",
    "Label": ""
  },
  {
    "id": "14977",
    "Sentence": "None of the <\\entity><\\entity>the risk of CIN in our study.",
    "Label": ""
  },
  {
    "id": "14979",
    "Sentence": "DNA repair gene polymorphisms, such as those of XRCC3 and xeroderma pigmentosum, complementation gro<\\entity><\\entity>, contribute to carcinogenesis.",
    "Label": ""
  },
  {
    "id": "14980",
    "Sentence": "In this study, we investig<\\entity><\\entity>lation between cervical carcinoma risk and XRCC3, XPD, XPG genetic variants.",
    "Label": ""
  },
  {
    "id": "14982",
    "Sentence": "Simila<\\entity><\\entity>sn312Asn (AA) reduced the risk of cervical or cervical squamous cell carcinoma.",
    "Label": ""
  },
  {
    "id": "14983",
    "Sentence": "RESULTS: Women carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcinoma compared <\\entity><\\entity>types.",
    "Label": ""
  },
  {
    "id": "14985",
    "Sentence": "Similarly, XPD Asn31<\\entity><\\entity>reduced the risk of cervical or cervical squamous cell carcinoma.",
    "Label": ""
  },
  {
    "id": "14986",
    "Sentence": "RESULTS: Women carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcinoma compared <\\entity><\\entity>types.",
    "Label": ""
  },
  {
    "id": "14988",
    "Sentence": "Simila<\\entity><\\entity>sn312Asn (AA) reduced the risk of cervical or cervical squamous cell carcinoma.",
    "Label": ""
  },
  {
    "id": "14989",
    "Sentence": "RESULTS: Women carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcino<\\entity><\\entity>red to His1104Asp or His1104His genotypes.",
    "Label": ""
  },
  {
    "id": "14991",
    "Sentence": "Similarly, XPD Asn31<\\entity><\\entity>reduced the risk of cervical or cervical squamous cell carcinoma.",
    "Label": ""
  },
  {
    "id": "14992",
    "Sentence": "RESULTS: Women carrying homozygous Asp1104Asp genotypes had a significantly decreased risk of cervical or cervical squamous cell carcino<\\entity><\\entity>red to His1104Asp or His1104His genotypes.",
    "Label": ""
  },
  {
    "id": "14994",
    "Sentence": "Similarly, XPD Asn312Asn (AA) reduced the risk of cervic<\\entity><\\entity> or cervic<\\entity><\\entity> squamous cell carcinoma.",
    "Label": ""
  },
  {
    "id": "14995",
    "Sentence": "Similarly, XPD Asn312Asn (AA) reduced the risk of cervical or cervical squamous cell carcinoma.",
    "Label": ""
  },
  {
    "id": "14997",
    "Sentence": "Similarly, XPD Asn312Asn (AA) reduced the risk of cervic<\\entity><\\entity> or cervic<\\entity><\\entity> squamous cell carcinoma.",
    "Label": ""
  },
  {
    "id": "14998",
    "Sentence": "No assoc<\\entity><\\entity> Lys751Gln and cervical carcinoma was found.",
    "Label": ""
  },
  {
    "id": "15004",
    "Sentence": "A haplotype of the <\\entity><\\entity> gene associated with myocardial infarction in Japanese men.This study assessed associations between the <\\entity><\\entity> gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15005",
    "Sentence": "A haplotype of the CYP4F2 gene associated with <\\entity><\\entity> in Japanese men.This study assessed associations between the CYP4F2 gene and <\\entity><\\entity> (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15006",
    "Sentence": "A haplotype of the <\\entity><\\entity> gene associated with myocardial infarction in Japanese men.This study assessed associations between the <\\entity><\\entity> gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15007",
    "Sentence": "A haplotype of the CYP4F2 gene associated with <\\entity><\\entity> in Japanese men.This study assessed associations between the CYP4F2 gene and <\\entity><\\entity> (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15008",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (<\\entity><\\entity>), using a haplotype-based case-control study of 234 <\\entity><\\entity> patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15009",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (<\\entity><\\entity>), using a haplotype-based case-control study of 234 <\\entity><\\entity> patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15010",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (<\\entity><\\entity>, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15011",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, <\\entity><\\entity>, rs1558139, rs2108622, rs3093200).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15012",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, <\\entity><\\entity>, rs2108622, rs3093200).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15013",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, <\\entity><\\entity>, rs3093200).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15014",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, <\\entity><\\entity>).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15015",
    "Sentence": "For men, <\\entity><\\entity> frequency of rs2108622 and frequency of the T-C-G haplotype were significantly higher, and frequency of the T-C-A haplotype was significantly lower for MI patients than for controls (P=0.006, P=0.001 and P=0.002, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15016",
    "Sentence": "For men, G allele frequency of <\\entity><\\entity> and frequency of the T-C-G haplotype were significantly higher, and frequency of the T-C-A haplotype was significantly lower for MI patients than for controls (P=0.006, P=0.001 and P=0.002, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15017",
    "Sentence": "For men, G allele frequency of rs2108622 and frequency of the <\\entity><\\entity> were significantly higher, and frequency of the T-C-A haplotype was significantly lower for MI patients than for controls (P=0.006, P=0.001 and P=0.002, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15018",
    "Sentence": "For men, G allele frequency of rs2108622 and frequency of the T-C-G haplotype were significantly higher, and frequency of the <\\entity><\\entity> was significantly lower for MI patients than for controls (P=0.006, P=0.001 and P=0.002, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15019",
    "Sentence": "For men, G allele frequency of rs2108622 and frequency of the T-C-G haplotype were significantly higher, and frequency of the T-C-A haplotype was significantly lower for <\\entity><\\entity> patients than for controls (P=0.006, P=0.001 and P=0.002, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15020",
    "Sentence": "A haplotype of the <\\entity><\\entity> gene associated with myocardial infarction in Japanese men.This study assessed associations between the <\\entity><\\entity> gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15021",
    "Sentence": "A haplotype of the CYP4F2 gene associated with <\\entity><\\entity> in Japanese men.This study assessed associations between the CYP4F2 gene and <\\entity><\\entity> (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15023",
    "Sentence": "A haplotype of the <\\entity><\\entity> gene associated with myocardial infarction in Japanese men.This study assessed associations between the <\\entity><\\entity> gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15024",
    "Sentence": "A haplotype of the CYP4F2 gene associated with <\\entity><\\entity> in Japanese men.This study assessed associations between the CYP4F2 gene and <\\entity><\\entity> (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15026",
    "Sentence": "A haplotype of the <\\entity><\\entity> gene associated with myocardial infarction in Japanese men.This study assessed associations between the <\\entity><\\entity> gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15027",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (<\\entity><\\entity>), using a haplotype-based case-control study of 234 <\\entity><\\entity> patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15029",
    "Sentence": "For men, G allele frequency of <\\entity><\\entity> and frequency of the T-C-G haplotype were significantly higher, and frequency of the T-C-A haplotype was significantly lower for MI patients than for controls (P=0.006, P=0.001 and P=0.002, respectively).",
    "Label": ""
  },
  {
    "id": "15030",
    "Sentence": "For men, G allele frequency of rs2108622 and frequency of the T-C-G haplotype were significantly higher, and frequency of the T-C-A haplotype was significantly lower for <\\entity><\\entity> patients than for controls (P=0.006, P=0.001 and P=0.002, respectively).",
    "Label": ""
  },
  {
    "id": "15032",
    "Sentence": "For men, <\\entity><\\entity> frequency of rs2108622 and frequency of the T-C-G haplotype were significantly higher, and frequency of the T-C-A haplotype was significantly lower for MI patients than for controls (P=0.006, P=0.001 and P=0.002, respectively).",
    "Label": ""
  },
  {
    "id": "15033",
    "Sentence": "For men, G allele frequency of rs2108622 and frequency of the T-C-G haplotype were significantly higher, and frequency of the T-C-A haplotype was significantly lower for <\\entity><\\entity> patients than for controls (P=0.006, P=0.001 and P=0.002, respectively).",
    "Label": ""
  },
  {
    "id": "15035",
    "Sentence": "For men, G allele frequency of rs2108622 and frequency of the <\\entity><\\entity> were significantly higher, and frequency of the T-C-A haplotype was significantly lower for MI patients than for controls (P=0.006, P=0.001 and P=0.002, respectively).",
    "Label": ""
  },
  {
    "id": "15036",
    "Sentence": "For men, G allele frequency of rs2108622 and frequency of the T-C-G haplotype were significantly higher, and frequency of the T-C-A haplotype was significantly lower for <\\entity><\\entity> patients than for controls (P=0.006, P=0.001 and P=0.002, respectively).",
    "Label": ""
  },
  {
    "id": "15038",
    "Sentence": "For men, G allele frequency of rs2108622 and frequency of the T-C-G haplotype were significantly higher, and frequency of the <\\entity><\\entity> was significantly lower for MI patients than for controls (P=0.006, P=0.001 and P=0.002, respectively).",
    "Label": ""
  },
  {
    "id": "15039",
    "Sentence": "For men, G allele frequency of rs2108622 and frequency of the T-C-G haplotype were significantly higher, and frequency of the T-C-A haplotype was significantly lower for <\\entity><\\entity> patients than for controls (P=0.006, P=0.001 and P=0.002, respectively).",
    "Label": ""
  },
  {
    "id": "15041",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (<\\entity><\\entity>, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15042",
    "Sentence": "A haplotype of the CYP4F2 gene associated with <\\entity><\\entity> in Japanese men.This study assessed associations between the CYP4F2 gene and <\\entity><\\entity> (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15044",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (<\\entity><\\entity>, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15045",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (<\\entity><\\entity>), using a haplotype-based case-control study of 234 <\\entity><\\entity> patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15047",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, <\\entity><\\entity>, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15048",
    "Sentence": "A haplotype of the CYP4F2 gene associated with <\\entity><\\entity> in Japanese men.This study assessed associations between the CYP4F2 gene and <\\entity><\\entity> (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15050",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, <\\entity><\\entity>, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15051",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (<\\entity><\\entity>), using a haplotype-based case-control study of 234 <\\entity><\\entity> patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15053",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, <\\entity><\\entity>, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15054",
    "Sentence": "A haplotype of the CYP4F2 gene associated with <\\entity><\\entity> in Japanese men.This study assessed associations between the CYP4F2 gene and <\\entity><\\entity> (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15056",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, <\\entity><\\entity>, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15057",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (<\\entity><\\entity>), using a haplotype-based case-control study of 234 <\\entity><\\entity> patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15059",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, <\\entity><\\entity>, rs3093200).",
    "Label": ""
  },
  {
    "id": "15060",
    "Sentence": "A haplotype of the CYP4F2 gene associated with <\\entity><\\entity> in Japanese men.This study assessed associations between the CYP4F2 gene and <\\entity><\\entity> (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15062",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, <\\entity><\\entity>, rs3093200).",
    "Label": ""
  },
  {
    "id": "15063",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (<\\entity><\\entity>), using a haplotype-based case-control study of 234 <\\entity><\\entity> patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15065",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, <\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "15066",
    "Sentence": "A haplotype of the CYP4F2 gene associated with <\\entity><\\entity> in Japanese men.This study assessed associations between the CYP4F2 gene and <\\entity><\\entity> (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15068",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (MI), using a haplotype-based case-control study of 234 MI patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, <\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "15069",
    "Sentence": "A haplotype of the CYP4F2 gene associated with myocardial infarction in Japanese men.This study assessed associations between the CYP4F2 gene and myocardial infarction (<\\entity><\\entity>), using a haplotype-based case-control study of 234 <\\entity><\\entity> patients and 248 controls genotyped for 5 single-nucleotide polymorphisms (rs3093105, rs3093135, rs1558139, rs2108622, rs3093200).",
    "Label": ""
  },
  {
    "id": "15075",
    "Sentence": "Development of predictive models of <\\entity><\\entity> based on genetic variables: the Retina 4 project.PURPOSE: Machine learning techniques were used to identify which of 14 algorithms best predicts the genetic risk for development of <\\entity><\\entity> (PVR) in patients who are experiencing primary rhegmatogenous retinal detachment (RD).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15076",
    "Sentence": "Development of predictive models of proliferative vitreoretinopathy based on genetic variables: the Retina 4 project.PURPOSE: Machine learning techniques were used to identify which of 14 algorithms <\\entity><\\entity> predicts the genetic risk for development of proliferative vitreoretinopathy (PVR) in patients who are experiencing primary rhegmatogenous retinal detachment (RD).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15077",
    "Sentence": "Development of predictive models of <\\entity><\\entity> based on genetic variables: the Retina 4 project.PURPOSE: Machine learning techniques were used to identify which of 14 algorithms best predicts the genetic risk for development of <\\entity><\\entity> (PVR) in patients who are experiencing primary rhegmatogenous retinal detachment (RD).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15078",
    "Sentence": "Development of predictive models of proliferative vitreoretinopathy based on genetic variables: the Retina 4 project.PURPOSE: Machine learning techniques were used to identify which of 14 algorithms best predicts the genetic risk for development of proliferative vitreoretinopathy (<\\entity><\\entity>) in patients who are experiencing primary rhegmatogenous retinal detachment (RD).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15079",
    "Sentence": "Development of predictive models of proliferative vitreoretinopathy based on genetic variables: the Retina 4 project.PURPOSE: Machine learning techniques were used to identify which of 14 algorithms best predicts the genetic risk for development of proliferative vitreoretinopathy (<\\entity><\\entity>) in patients who are experiencing primary rhegmatogenous retinal detachment (RD).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15080",
    "Sentence": "Development of predictive models of proliferative vitreoretinopathy based on genetic variables: the Retina 4 project.PURPOSE: Machine learning techniques were used to identify which of 14 algorithms best predicts the genetic risk for development of proliferative vitreoretinopathy (PVR) in patients who are experiencing <\\entity><\\entity> (RD).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15081",
    "Sentence": "Development of predictive models of proliferative vitreoretinopathy based on genetic variables: the Retina 4 project.PURPOSE: Machine learning techniques were used to identify which of 14 algorithms best predicts the genetic risk for development of proliferative vitreoretinopathy (PVR) in patients who are experiencing primary rhegmatogenous retinal detachment (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15082",
    "Sentence": "The genotypic profile of 138 patients with <\\entity><\\entity> following primary rhegmatogenous RD and 312 patients without <\\entity><\\entity> RD were analyzed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15083",
    "Sentence": "The genotypic profile of 138 patients with <\\entity><\\entity> following primary rhegmatogenous RD and 312 patients without <\\entity><\\entity> RD were analyzed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15084",
    "Sentence": "The genotypic profile of 138 patients with PVR following <\\entity><\\entity> and 312 patients without PVR RD were analyzed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15085",
    "Sentence": "The genotypic profile of 138 patients with PVR following primary rhegmatogenous RD and 312 patients without <\\entity><\\entity> were analyzed.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15086",
    "Sentence": "The genotypic profile of 138 patients with PVR following primary rhegmatogenous RD and 312 patients without <\\entity><\\entity> were analyzed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15087",
    "Sentence": "RESULTS: The three <\\entity><\\entity> predictive models were the lineal kernel based on the Support Vector Machine (SMV), the radial kernel based on the SVM, and the Random Forest.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15088",
    "Sentence": "The <\\entity><\\entity> individually predictor marker was rs2229094 in the tumor necrosis factor locus.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15089",
    "Sentence": "The best individually predictor marker was <\\entity><\\entity> in the tumor necrosis factor locus.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15090",
    "Sentence": "The best individually predictor marker was rs2229094 in the <\\entity><\\entity> locus.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15091",
    "Sentence": "CONCLUSION: Genetic variables may be useful to predict the likelihood of the development of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15092",
    "Sentence": "CONCLUSION: Genetic variables may be useful to predict the likelihood of the development of <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15093",
    "Sentence": "The best individually predictor marker was rs2229094 in the <\\entity><\\entity> locus.",
    "Label": ""
  },
  {
    "id": "15094",
    "Sentence": "The <\\entity><\\entity> individually predictor marker was rs2229094 in the tumor necrosis factor locus.",
    "Label": ""
  },
  {
    "id": "15100",
    "Sentence": "Common variants in the <\\entity><\\entity> region contribute to Crohn's disease susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of <\\entity><\\entity> (previously known as CIAS1 and NALP3) that are associated with Crohn's disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15101",
    "Sentence": "Common variants in the NLRP3 region contribute to <\\entity><\\entity> susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of NLRP3 (previously known as CIAS1 and NALP3) that are associated with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15102",
    "Sentence": "Common variants in the NLRP3 region contribute to Crohn's disease susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome <\\entity><\\entity> downstream of NLRP3 (previously known as CIAS1 and NALP3) that are associated with Crohn's disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15103",
    "Sentence": "Common variants in the <\\entity><\\entity> region contribute to Crohn's disease susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of <\\entity><\\entity> (previously known as CIAS1 and NALP3) that are associated with Crohn's disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15104",
    "Sentence": "Common variants in the NLRP3 region contribute to Crohn's disease susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of NLRP3 (previously known as <\\entity><\\entity> and NALP3) that are associated with Crohn's disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15105",
    "Sentence": "Common variants in the NLRP3 region contribute to Crohn's disease susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of NLRP3 (previously known as CIAS1 and <\\entity><\\entity>) that are associated with Crohn's disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15106",
    "Sentence": "Common variants in the NLRP3 region contribute to <\\entity><\\entity> susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of NLRP3 (previously known as CIAS1 and NALP3) that are associated with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15107",
    "Sentence": "In the combined analysis of all samples (710 father-mother-child trios, 239 cases and 107 controls), these SNPs were strongly associated with risk of <\\entity><\\entity> (P(combined) = 3.49 x 10(-9), odds ratio = 1.78, confidence interval = 1.47-2.16 for rs10733113), reaching a level consistent with the stringent significance thresholds imposed by whole-genome association studies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15108",
    "Sentence": "In addition, we observed significant associations between SNPs in the associated regions and <\\entity><\\entity> expression and IL-1beta production.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15109",
    "Sentence": "In addition, we observed significant associations between SNPs in the associated regions and NLRP3 expression and <\\entity><\\entity> production.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15110",
    "Sentence": "<\\entity><\\entity> are known to be responsible for three rare autoinflammatory disorders.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15111",
    "Sentence": "<\\entity><\\entity> are known to be responsible for three rare autoinflammatory disorders.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15112",
    "Sentence": "<\\entity><\\entity> are known to be responsible for three rare autoinflammatory disorders.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15113",
    "Sentence": "Mutations in NLRP3 are known to be responsible for three <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15114",
    "Sentence": "These results suggest that the <\\entity><\\entity> region is also implicated in the susceptibility of more common inflammatory diseases such as Crohn's disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15115",
    "Sentence": "These results suggest that the NLRP3 region is also implicated in the susceptibility of more common <\\entity><\\entity> such as Crohn's disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15116",
    "Sentence": "These results suggest that the NLRP3 region is also implicated in the susceptibility of more common inflammatory diseases such as <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15117",
    "Sentence": "Common variants in the <\\entity><\\entity> region contribute to Crohn's disease susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of <\\entity><\\entity> (previously known as CIAS1 and NALP3) that are associated with Crohn's disease.",
    "Label": ""
  },
  {
    "id": "15118",
    "Sentence": "Common variants in the NLRP3 region contribute to <\\entity><\\entity> susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of NLRP3 (previously known as CIAS1 and NALP3) that are associated with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15120",
    "Sentence": "Common variants in the NLRP3 region contribute to Crohn's disease susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of NLRP3 (previously known as CIAS1 and <\\entity><\\entity>) that are associated with Crohn's disease.",
    "Label": ""
  },
  {
    "id": "15121",
    "Sentence": "Common variants in the NLRP3 region contribute to <\\entity><\\entity> susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of NLRP3 (previously known as CIAS1 and NALP3) that are associated with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15123",
    "Sentence": "Common variants in the <\\entity><\\entity> region contribute to Crohn's disease susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of <\\entity><\\entity> (previously known as CIAS1 and NALP3) that are associated with Crohn's disease.",
    "Label": ""
  },
  {
    "id": "15124",
    "Sentence": "Common variants in the NLRP3 region contribute to <\\entity><\\entity> susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of NLRP3 (previously known as CIAS1 and NALP3) that are associated with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15126",
    "Sentence": "Common variants in the NLRP3 region contribute to Crohn's disease susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome <\\entity><\\entity> downstream of NLRP3 (previously known as CIAS1 and NALP3) that are associated with Crohn's disease.",
    "Label": ""
  },
  {
    "id": "15127",
    "Sentence": "Common variants in the NLRP3 region contribute to <\\entity><\\entity> susceptibility.We used a candidate gene approach to identify a set of SNPs, located in a predicted regulatory region on chromosome 1q44 downstream of NLRP3 (previously known as CIAS1 and NALP3) that are associated with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15129",
    "Sentence": "<\\entity><\\entity> are known to be responsible for three rare autoinflammatory disorders.",
    "Label": ""
  },
  {
    "id": "15130",
    "Sentence": "Mutations in NLRP3 are known to be responsible for three <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15132",
    "Sentence": "These results suggest that the <\\entity><\\entity> region is also implicated in the susceptibility of more common inflammatory diseases such as Crohn's disease.",
    "Label": ""
  },
  {
    "id": "15133",
    "Sentence": "These results suggest that the NLRP3 region is also implicated in the susceptibility of more common inflammatory diseases such as <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15135",
    "Sentence": "These results suggest that the <\\entity><\\entity> region is also implicated in the susceptibility of more common inflammatory diseases such as Crohn's disease.",
    "Label": ""
  },
  {
    "id": "15136",
    "Sentence": "These results suggest that the NLRP3 region is also implicated in the susceptibility of more common <\\entity><\\entity> such as Crohn's disease.",
    "Label": ""
  },
  {
    "id": "15142",
    "Sentence": "Evaluation of <\\entity><\\entity> in primary open-angle glaucoma in southern and northern Chinese.PURPOSE: The lysyl oxidase-like protein 1 (LOXL1) gene is strongly associated with exfoliation glaucoma, which is very rare in the Chinese population.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15143",
    "Sentence": "Evaluation of <\\entity><\\entity> in primary open-angle glaucoma in southern and northern Chinese.PURPOSE: The lysyl oxidase-like protein 1 (LOXL1) gene is strongly associated with exfoliation glaucoma, which is very rare in the Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15144",
    "Sentence": "Evaluation of LOXL1 polymorphisms in <\\entity><\\entity> in southern and northern Chinese.PURPOSE: The lysyl oxidase-like protein 1 (LOXL1) gene is strongly associated with exfoliation glaucoma, which is very rare in the Chinese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15145",
    "Sentence": "Evaluation of LOXL1 polymorphisms in primary open-angle glaucoma in southern and northern Chinese.PURPOSE: The <\\entity><\\entity> (LOXL1) gene is strongly associated with exfoliation glaucoma, which is very rare in the Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15146",
    "Sentence": "Evaluation of <\\entity><\\entity> polymorphisms in primary open-angle glaucoma in southern and northern Chinese.PURPOSE: The lysyl oxidase-like protein 1 (<\\entity><\\entity>) gene is strongly associated with exfoliation glaucoma, which is very rare in the Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15147",
    "Sentence": "Evaluation of LOXL1 polymorphisms in primary open-angle glaucoma in southern and northern Chinese.PURPOSE: The lysyl oxidase-like protein 1 (LOXL1) gene is strongly associated with <\\entity><\\entity>, which is very rare in the Chinese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15148",
    "Sentence": "The implicated <\\entity><\\entity> have not been associated with primary open-angle glaucoma (POAG).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15149",
    "Sentence": "The implicated <\\entity><\\entity> have not been associated with primary open-angle glaucoma (POAG).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15150",
    "Sentence": "The implicated LOXL1 polymorphisms have not been associated with <\\entity><\\entity> (POAG).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15151",
    "Sentence": "The implicated LOXL1 polymorphisms have not been associated with primary open-angle glaucoma (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15152",
    "Sentence": "In this study, we investigated three of the <\\entity><\\entity> in POAG in a southern Chinese population of Hong Kong and northern Chinese from Beijing.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15153",
    "Sentence": "In this study, we investigated three of the <\\entity><\\entity> in POAG in a southern Chinese population of Hong Kong and northern Chinese from Beijing.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15154",
    "Sentence": "In this study, we investigated three of the LOXL1 polymorphisms in <\\entity><\\entity> in a southern Chinese population of Hong Kong and northern Chinese from Beijing.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15155",
    "Sentence": "METHODS: The Hong Kong group included 293 <\\entity><\\entity> patients and 250 controls, and the Beijing group included 169 <\\entity><\\entity> patients and 197 controls.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15156",
    "Sentence": "METHODS: The Hong Kong group included 293 <\\entity><\\entity> patients and 250 controls, and the Beijing group included 169 <\\entity><\\entity> patients and 197 controls.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15157",
    "Sentence": "<\\entity><\\entity> single nucleotide polymorphisms (SNPs), rs1048661, rs3825942, and rs2165241, were genotyped by direct DNA sequencing.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15158",
    "Sentence": "LOXL1 single nucleotide polymorphisms (SNPs), <\\entity><\\entity>, rs3825942, and rs2165241, were genotyped by direct DNA sequencing.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15159",
    "Sentence": "LOXL1 single nucleotide polymorphisms (SNPs), rs1048661, <\\entity><\\entity>, and rs2165241, were genotyped by direct DNA sequencing.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15160",
    "Sentence": "LOXL1 single nucleotide polymorphisms (SNPs), rs1048661, rs3825942, and <\\entity><\\entity>, were genotyped by direct DNA sequencing.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15161",
    "Sentence": "RESULTS: Each of the candidate SNPs was not statistically associated with <\\entity><\\entity> in either group (p>0.017, Bonferroni correction).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15162",
    "Sentence": "Haplotype-based association analysis had identified a significant omnibus association (Omnibus chi(2)=18.16, p=0.00115) between these SNPs and <\\entity><\\entity> in the Hong Kong group.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15163",
    "Sentence": "A <\\entity><\\entity> haplotype (T-G-T) showed significant statistical association with POAG.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15164",
    "Sentence": "A minor haplotype (<\\entity><\\entity>) showed significant statistical association with POAG.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15165",
    "Sentence": "A minor haplotype (T-G-T) showed significant statistical association with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15166",
    "Sentence": "It presented in 2.1% of cases and 0.4% of controls, conferring a 5.24 fold of increased risk to the <\\entity><\\entity> (95% CI: 1.17-23.54, P(perm)=0.00108).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15167",
    "Sentence": "CONCLUSIONS: Individual <\\entity><\\entity> SNPs, rs1048661, rs3825942, and rs2165241, were not associated with POAG in the Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15168",
    "Sentence": "CONCLUSIONS: Individual LOXL1 SNPs, <\\entity><\\entity>, rs3825942, and rs2165241, were not associated with POAG in the Chinese population.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15169",
    "Sentence": "CONCLUSIONS: Individual LOXL1 SNPs, rs1048661, <\\entity><\\entity>, and rs2165241, were not associated with POAG in the Chinese population.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15170",
    "Sentence": "CONCLUSIONS: Individual LOXL1 SNPs, rs1048661, rs3825942, and <\\entity><\\entity>, were not associated with POAG in the Chinese population.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15171",
    "Sentence": "CONCLUSIONS: Individual LOXL1 SNPs, rs1048661, rs3825942, and rs2165241, were not associated with <\\entity><\\entity> in the Chinese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15172",
    "Sentence": "However, a <\\entity><\\entity> haplotype T-G-T was found to be associated with the disorder in the southern Chinese.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15173",
    "Sentence": "However, a minor <\\entity><\\entity> was found to be associated with the disorder in the southern Chinese.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15174",
    "Sentence": "However, a minor haplotype T-G-T was found to be associated with the <\\entity><\\entity> in the southern Chinese.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15175",
    "Sentence": "The low frequencies of the at-risk alleles at <\\entity><\\entity> and rs2165241 may be one of the factors that led to the low prevalence of exfoliation syndrome in the general populations of the Chinese.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15176",
    "Sentence": "The low frequencies of the at-risk alleles at rs1048661 and <\\entity><\\entity> may be one of the factors that led to the low prevalence of exfoliation syndrome in the general populations of the Chinese.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15177",
    "Sentence": "The low frequencies of the at-risk alleles at rs1048661 and rs2165241 may be one of the factors that led to the low prevalence of <\\entity><\\entity> in the general populations of the Chinese.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15178",
    "Sentence": "Evaluation of <\\entity><\\entity> polymorphisms in primary open-angle glaucoma in southern and northern Chinese.PURPOSE: The lysyl oxidase-like protein 1 (<\\entity><\\entity>) gene is strongly associated with exfoliation glaucoma, which is very rare in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15179",
    "Sentence": "Evaluation of LOXL1 polymorphisms in primary open-angle glaucoma in southern and northern Chinese.PURPOSE: The lysyl oxidase-like protein 1 (LOXL1) gene is strongly associated with <\\entity><\\entity>, which is very rare in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15181",
    "Sentence": "A minor haplotype (<\\entity><\\entity>) showed significant statistical association with POAG.",
    "Label": ""
  },
  {
    "id": "15182",
    "Sentence": "A minor haplotype (T-G-T) showed significant statistical association with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15184",
    "Sentence": "CONCLUSIONS: Individual LOXL1 SNPs, <\\entity><\\entity>, rs3825942, and rs2165241, were not associated with POAG in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15185",
    "Sentence": "CONCLUSIONS: Individual LOXL1 SNPs, rs1048661, rs3825942, and rs2165241, were not associated with <\\entity><\\entity> in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15187",
    "Sentence": "CONCLUSIONS: Individual LOXL1 SNPs, rs1048661, <\\entity><\\entity>, and rs2165241, were not associated with POAG in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15188",
    "Sentence": "CONCLUSIONS: Individual LOXL1 SNPs, rs1048661, rs3825942, and rs2165241, were not associated with <\\entity><\\entity> in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15190",
    "Sentence": "CONCLUSIONS: Individual LOXL1 SNPs, rs1048661, rs3825942, and <\\entity><\\entity>, were not associated with POAG in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15191",
    "Sentence": "CONCLUSIONS: Individual LOXL1 SNPs, rs1048661, rs3825942, and rs2165241, were not associated with <\\entity><\\entity> in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15193",
    "Sentence": "The low frequencies of the at-risk alleles at <\\entity><\\entity> and rs2165241 may be one of the factors that led to the low prevalence of exfoliation syndrome in the general populations of the Chinese.",
    "Label": ""
  },
  {
    "id": "15194",
    "Sentence": "The low frequencies of the at-risk alleles at rs1048661 and rs2165241 may be one of the factors that led to the low prevalence of <\\entity><\\entity> in the general populations of the Chinese.",
    "Label": ""
  },
  {
    "id": "15196",
    "Sentence": "The low frequencies of the at-risk alleles at rs1048661 and <\\entity><\\entity> may be one of the factors that led to the low prevalence of exfoliation syndrome in the general populations of the Chinese.",
    "Label": ""
  },
  {
    "id": "15197",
    "Sentence": "The low frequencies of the at-risk alleles at rs1048661 and rs2165241 may be one of the factors that led to the low prevalence of <\\entity><\\entity> in the general populations of the Chinese.",
    "Label": ""
  },
  {
    "id": "15199",
    "Sentence": "Evaluation of <\\entity><\\entity> in primary open-angle glaucoma in southern and northern Chinese.PURPOSE: The lysyl oxidase-like protein 1 (LOXL1) gene is strongly associated with exfoliation glaucoma, which is very rare in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15200",
    "Sentence": "Evaluation of LOXL1 polymorphisms in <\\entity><\\entity> in southern and northern Chinese.PURPOSE: The lysyl oxidase-like protein 1 (LOXL1) gene is strongly associated with exfoliation glaucoma, which is very rare in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15202",
    "Sentence": "The implicated <\\entity><\\entity> have not been associated with primary open-angle glaucoma (POAG).",
    "Label": ""
  },
  {
    "id": "15203",
    "Sentence": "The implicated LOXL1 polymorphisms have not been associated with primary open-angle glaucoma (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "15205",
    "Sentence": "In this study, we investigated three of the <\\entity><\\entity> in POAG in a southern Chinese population of Hong Kong and northern Chinese from Beijing.",
    "Label": ""
  },
  {
    "id": "15206",
    "Sentence": "In this study, we investigated three of the LOXL1 polymorphisms in <\\entity><\\entity> in a southern Chinese population of Hong Kong and northern Chinese from Beijing.",
    "Label": ""
  },
  {
    "id": "15208",
    "Sentence": "CONCLUSIONS: Individual <\\entity><\\entity> SNPs, rs1048661, rs3825942, and rs2165241, were not associated with POAG in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15209",
    "Sentence": "CONCLUSIONS: Individual LOXL1 SNPs, rs1048661, rs3825942, and rs2165241, were not associated with <\\entity><\\entity> in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15211",
    "Sentence": "Evaluation of LOXL1 polymorphisms in primary open-angle glaucoma in southern and northern Chinese.PURPOSE: The <\\entity><\\entity> (LOXL1) gene is strongly associated with exfoliation glaucoma, which is very rare in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15212",
    "Sentence": "Evaluation of LOXL1 polymorphisms in primary open-angle glaucoma in southern and northern Chinese.PURPOSE: The lysyl oxidase-like protein 1 (LOXL1) gene is strongly associated with <\\entity><\\entity>, which is very rare in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15214",
    "Sentence": "The implicated <\\entity><\\entity> have not been associated with primary open-angle glaucoma (POAG).",
    "Label": ""
  },
  {
    "id": "15215",
    "Sentence": "The implicated LOXL1 polymorphisms have not been associated with primary open-angle glaucoma (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "15217",
    "Sentence": "The implicated <\\entity><\\entity> have not been associated with primary open-angle glaucoma (POAG).",
    "Label": ""
  },
  {
    "id": "15218",
    "Sentence": "The implicated LOXL1 polymorphisms have not been associated with <\\entity><\\entity> (POAG).",
    "Label": ""
  },
  {
    "id": "15220",
    "Sentence": "CONCLUSIONS: Individual <\\entity><\\entity> SNPs, rs1048661, rs3825942, and rs2165241, were not associated with POAG in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15221",
    "Sentence": "CONCLUSIONS: Individual LOXL1 SNPs, rs1048661, rs3825942, and rs2165241, were not associated with <\\entity><\\entity> in the Chinese population.",
    "Label": ""
  },
  {
    "id": "15227",
    "Sentence": "<\\entity><\\entity>: reading the enemy's playbook.BACKGROUND: At the Yale University Center for Thoracic Aortic Disease, we have been using our clinical experience and laboratory investigations to shed light on the pathophysiology of thoracic aortic aneurysm (TAA), the clinical behavior of thoracic aortic aneurysm, and the optimal clinical management.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15228",
    "Sentence": "<\\entity><\\entity> aortic aneurysm: reading the enemy's playbook.BACKGROUND: At the Yale University Center for <\\entity><\\entity> Aortic Disease, we have been using our clinical experience and laboratory investigations to shed light on the pathophysiology of thoracic aortic aneurysm (TAA), the clinical behavior of thoracic aortic aneurysm, and the optimal clinical management.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15229",
    "Sentence": "Thoracic aortic aneurysm: reading the enemy's playbook.BACKGROUND: At the Yale University Center for Thoracic <\\entity><\\entity>, we have been using our clinical experience and laboratory investigations to shed light on the pathophysiology of thoracic aortic aneurysm (TAA), the clinical behavior of thoracic aortic aneurysm, and the optimal clinical management.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15230",
    "Sentence": "Thoracic aortic aneurysm: reading the enemy's playbook.BACKGROUND: At the Yale University Center for Thoracic Aortic Disease, we have been using our clinical experience and laboratory investigations to shed light on the <\\entity><\\entity> of thoracic aortic aneurysm (TAA), the clinical behavior of thoracic aortic aneurysm, and the optimal clinical management.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15231",
    "Sentence": "Thoracic aortic aneurysm: reading the enemy's playbook.BACKGROUND: At the Yale University Center for Thoracic Aortic Disease, we have been using our clinical experience and laboratory investigations to shed light on the pathophysiology of <\\entity><\\entity> (TAA), the clinical behavior of <\\entity><\\entity>, and the optimal clinical management.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15232",
    "Sentence": "Thoracic aortic aneurysm: reading the enemy's playbook.BACKGROUND: At the Yale University Center for Thoracic Aortic Disease, we have been using our clinical experience and laboratory investigations to shed light on the pathophysiology of thoracic aortic aneurysm (<\\entity><\\entity>), the clinical behavior of thoracic aortic aneurysm, and the optimal clinical management.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15233",
    "Sentence": "Thoracic aortic aneurysm: reading the enemy's playbook.BACKGROUND: At the Yale University Center for Thoracic Aortic Disease, we have been using our clinical experience and laboratory investigations to shed light on the pathophysiology of <\\entity><\\entity> (TAA), the clinical behavior of <\\entity><\\entity>, and the optimal clinical management.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15234",
    "Sentence": "MATERIALS AND METHODS: The Yale database contains information on 3,000 patients with <\\entity><\\entity>, with 9,000 patient-years of follow-up and 9,000 imaging studies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15235",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) <\\entity><\\entity> is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of <\\entity><\\entity>; (3) wall tension in <\\entity><\\entity> approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a <\\entity><\\entity> reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to <\\entity><\\entity> and can serve as biomarkers for screening for this virulent disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15236",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) TAA is a <\\entity><\\entity> with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of TAA; (3) wall tension in TAA approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a TAA reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to TAA and can serve as biomarkers for screening for this virulent disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15237",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) TAA is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) <\\entity><\\entity> (MMP) enzymes are activated in the pathogenesis of TAA; (3) wall tension in TAA approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a TAA reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to TAA and can serve as biomarkers for screening for this virulent disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15238",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) TAA is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (<\\entity><\\entity>) enzymes are activated in the pathogenesis of TAA; (3) wall tension in TAA approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a TAA reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to TAA and can serve as biomarkers for screening for this virulent disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15239",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) TAA is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the <\\entity><\\entity> of TAA; (3) wall tension in TAA approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a TAA reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to TAA and can serve as biomarkers for screening for this virulent disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15240",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) <\\entity><\\entity> is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of <\\entity><\\entity>; (3) wall tension in <\\entity><\\entity> approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a <\\entity><\\entity> reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to <\\entity><\\entity> and can serve as biomarkers for screening for this virulent disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15241",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) TAA is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of TAA; (3) wall <\\entity><\\entity> in TAA approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a TAA reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to TAA and can serve as biomarkers for screening for this virulent disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15242",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) <\\entity><\\entity> is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of <\\entity><\\entity>; (3) wall tension in <\\entity><\\entity> approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a <\\entity><\\entity> reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to <\\entity><\\entity> and can serve as biomarkers for screening for this virulent disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15243",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) <\\entity><\\entity> is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of <\\entity><\\entity>; (3) wall tension in <\\entity><\\entity> approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a <\\entity><\\entity> reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to <\\entity><\\entity> and can serve as biomarkers for screening for this virulent disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15244",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) TAA is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of TAA; (3) wall tension in TAA approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a TAA reaches a clinical diameter of 6 cm, 34 percent of affected patients have <\\entity><\\entity> dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to TAA and can serve as biomarkers for screening for this virulent disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15245",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) TAA is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of TAA; (3) wall tension in TAA approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a TAA reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered <\\entity><\\entity> or rupture; (5) extreme physical exertion or severe emotion often precipitate acute <\\entity><\\entity>; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to TAA and can serve as biomarkers for screening for this virulent disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15246",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) TAA is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of TAA; (3) wall tension in TAA approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a TAA reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or <\\entity><\\entity>; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to TAA and can serve as biomarkers for screening for this virulent disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15247",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) TAA is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of TAA; (3) wall tension in TAA approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a TAA reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate <\\entity><\\entity>; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to TAA and can serve as biomarkers for screening for this virulent disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15248",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) <\\entity><\\entity> is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of <\\entity><\\entity>; (3) wall tension in <\\entity><\\entity> approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a <\\entity><\\entity> reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to <\\entity><\\entity> and can serve as biomarkers for screening for this virulent disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15249",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) TAA is a genetic <\\entity><\\entity> with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of TAA; (3) wall tension in TAA approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a TAA reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to TAA and can serve as biomarkers for screening for this virulent <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15250",
    "Sentence": "CONCLUSIONS: The \"playbook\" of <\\entity><\\entity> is gradually being read, with the help of scientific investigations, positioning practitioners to combat this lethal disease more effectively than ever before.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15251",
    "Sentence": "CONCLUSIONS: The \"playbook\" of TAA is gradually being read, with the help of scientific investigations, positioning practitioners to combat this lethal <\\entity><\\entity> more effectively than ever before.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15252",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) TAA is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) <\\entity><\\entity> (MMP) enzymes are activated in the pathogenesis of TAA; (3) wall tension in TAA approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a TAA reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to TAA and can serve as biomarkers for screening for this virulent disease.",
    "Label": ""
  },
  {
    "id": "15253",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) <\\entity><\\entity> is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of <\\entity><\\entity>; (3) wall tension in <\\entity><\\entity> approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a <\\entity><\\entity> reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to <\\entity><\\entity> and can serve as biomarkers for screening for this virulent disease.",
    "Label": ""
  },
  {
    "id": "15255",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) TAA is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (<\\entity><\\entity>) enzymes are activated in the pathogenesis of TAA; (3) wall tension in TAA approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a TAA reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to TAA and can serve as biomarkers for screening for this virulent disease.",
    "Label": ""
  },
  {
    "id": "15256",
    "Sentence": "RESULTS: Analysis yielded the following Yale-generated observations: (1) <\\entity><\\entity> is a genetic disease with a predominantly autosomal dominant mode of inheritance; (2) matrix metalloproteinase (MMP) enzymes are activated in the pathogenesis of <\\entity><\\entity>; (3) wall tension in <\\entity><\\entity> approaches the tensile limits of aortic tissue at a diameter of 6 cm; (4) by the time a <\\entity><\\entity> reaches a clinical diameter of 6 cm, 34 percent of affected patients have suffered dissection or rupture; (5) extreme physical exertion or severe emotion often precipitate acute dissection; and (6) single nucleotide polymorphisms (SNPs) and RNA expression profile changes are being identified that predispose a patient to <\\entity><\\entity> and can serve as biomarkers for screening for this virulent disease.",
    "Label": ""
  },
  {
    "id": "15262",
    "Sentence": "Clinical utility of genetic tests for <\\entity><\\entity> and dilated cardiomyopathies.Genetic testing has become an increasingly important part of medical practice for heritable form of cardiomyopathies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15263",
    "Sentence": "Clinical utility of genetic tests for inherited hypertrophic and <\\entity><\\entity>.Genetic testing has become an increasingly important part of medical practice for heritable form of cardiomyopathies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15264",
    "Sentence": "Clinical utility of genetic tests for inherited hypertrophic and dilated <\\entity><\\entity>.Genetic testing has become an increasingly important part of medical practice for heritable form of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15265",
    "Sentence": "<\\entity><\\entity> and about 50% of idiopathic dilatative cardiomyopathy are familial diseases, with an autosomal dominant pattern of inheritance.Some genotype-phenotype correlations can provide important information to target DNA analyses in specific genes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15266",
    "Sentence": "Hypertrophic cardiomyopathy and about 50% of <\\entity><\\entity> are familial diseases, with an autosomal dominant pattern of inheritance.Some genotype-phenotype correlations can provide important information to target DNA analyses in specific genes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15267",
    "Sentence": "Hypertrophic cardiomyopathy and about 50% of idiopathic dilatative cardiomyopathy are <\\entity><\\entity>, with an autosomal dominant pattern of inheritance.Some genotype-phenotype correlations can provide important information to target DNA analyses in specific genes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15268",
    "Sentence": "In addition, genetic screening of first-degree relatives can help early identification and diagnosis of individuals at greatest risk for developing <\\entity><\\entity>, allowing to focus clinical resources on high-risk family members.This paper provides a concise overview of the genetic etiology as well as the clinical utilities and limitations of genetic testing for the heritable cardiomyopathies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15269",
    "Sentence": "In addition, genetic screening of first-degree relatives can help early identification and diagnosis of individuals at greatest risk for developing cardiomyopathy, allowing to focus clinical resources on high-risk family members.This paper provides a concise overview of the genetic etiology as well as the clinical utilities and limitations of genetic testing for the <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15274",
    "Sentence": "Influence of single-nucleotide polymorphisms on <\\entity><\\entity> levels in chronic kidney disease before and after kidney transplantation.INTRODUCTION: We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the <\\entity><\\entity> (CRP) gene promoter region for their effects on CRP levels in chronic kidney disease (CKD) patients before and after a successful kidney transplantation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15275",
    "Sentence": "Influence of single-nucleotide polymorphisms on C-reactive protein levels in <\\entity><\\entity> before and after kidney transplantation.INTRODUCTION: We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the C-reactive protein (CRP) gene promoter region for their effects on CRP levels in <\\entity><\\entity> (CKD) patients before and after a successful kidney transplantation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15276",
    "Sentence": "Influence of single-nucleotide polymorphisms on <\\entity><\\entity> levels in chronic kidney disease before and after kidney transplantation.INTRODUCTION: We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the <\\entity><\\entity> (CRP) gene promoter region for their effects on CRP levels in chronic kidney disease (CKD) patients before and after a successful kidney transplantation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15277",
    "Sentence": "Influence of single-nucleotide polymorphisms on C-reactive protein levels in chronic kidney disease before and after kidney transplantation.INTRODUCTION: We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the C-reactive protein (<\\entity><\\entity>) gene promoter region for their effects on <\\entity><\\entity> levels in chronic kidney disease (CKD) patients before and after a successful kidney transplantation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15278",
    "Sentence": "Influence of single-nucleotide polymorphisms on C-reactive protein levels in chronic kidney disease before and after kidney transplantation.INTRODUCTION: We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the C-reactive protein (<\\entity><\\entity>) gene promoter region for their effects on <\\entity><\\entity> levels in chronic kidney disease (CKD) patients before and after a successful kidney transplantation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15279",
    "Sentence": "Influence of single-nucleotide polymorphisms on C-reactive protein levels in <\\entity><\\entity> before and after kidney transplantation.INTRODUCTION: We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the C-reactive protein (CRP) gene promoter region for their effects on CRP levels in <\\entity><\\entity> (CKD) patients before and after a successful kidney transplantation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15280",
    "Sentence": "Influence of single-nucleotide polymorphisms on C-reactive protein levels in chronic kidney disease before and after kidney transplantation.INTRODUCTION: We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the C-reactive protein (CRP) gene promoter region for their effects on CRP levels in chronic kidney disease (<\\entity><\\entity>) patients before and after a successful kidney transplantation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15281",
    "Sentence": "METHODS: Fifty <\\entity><\\entity> patients were evaluated before and at the first and second years after the graft.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15282",
    "Sentence": "Two SNPs were studied, a bi-allelic (G-->A) at the <\\entity><\\entity> and a tri-allelic (C-->T-->A) variation at the -390 position in the CRP gene.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15283",
    "Sentence": "Two SNPs were studied, a bi-allelic (G-->A) at the -409 and a tri-allelic (C-->T-->A) variation at the <\\entity><\\entity> position in the CRP gene.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15284",
    "Sentence": "Two SNPs were studied, a bi-allelic (G-->A) at the -409 and a tri-allelic (C-->T-->A) variation at the -390 position in the <\\entity><\\entity> gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15285",
    "Sentence": "RESULTS: All patients presented the <\\entity><\\entity> genotype.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15286",
    "Sentence": "At the <\\entity><\\entity> position, the \"A\" allele was not found; there were 15 \"CC\" patients, 11 \"TT\" patients, and 24 \"CT\" patients.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15287",
    "Sentence": "<\\entity><\\entity> levels were different among patients with various genotypes (P < .019).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15288",
    "Sentence": "Also the presence of the allele \"T\" was sufficient to determine differences in <\\entity><\\entity> levels both in pretransplantation (P = .045) and at 1 year posttransplantation (P = .011), but not at the second year (P = .448).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15289",
    "Sentence": "Also the presence of the allele \"T\" was sufficient to determine differences in CRP levels both in pretransplantation (P = .045) and at <\\entity><\\entity> (P = .011), but not at the second year (P = .448).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15290",
    "Sentence": "CONCLUSION: SNPs at the <\\entity><\\entity> position of the CRP gene promoter region influence CRP basal levels in such a way that the \"C\" allele correlated with the lowest and the \"T\" with the highest.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15291",
    "Sentence": "CONCLUSION: SNPs at the -390 position of the <\\entity><\\entity> gene promoter region influence <\\entity><\\entity> basal levels in such a way that the \"C\" allele correlated with the lowest and the \"T\" with the highest.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15292",
    "Sentence": "CONCLUSION: SNPs at the -390 position of the <\\entity><\\entity> gene promoter region influence <\\entity><\\entity> basal levels in such a way that the \"C\" allele correlated with the lowest and the \"T\" with the highest.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15293",
    "Sentence": "We did not observe this influence in our patients at the second year <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15294",
    "Sentence": "Influence of single-nucleotide polymorphisms on <\\entity><\\entity> levels in chronic kidney disease before and after kidney transplantation.INTRODUCTION: We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the <\\entity><\\entity> (CRP) gene promoter region for their effects on CRP levels in chronic kidney disease (CKD) patients before and after a successful kidney transplantation.",
    "Label": ""
  },
  {
    "id": "15295",
    "Sentence": "Influence of single-nucleotide polymorphisms on C-reactive protein levels in <\\entity><\\entity> before and after kidney transplantation.INTRODUCTION: We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the C-reactive protein (CRP) gene promoter region for their effects on CRP levels in <\\entity><\\entity> (CKD) patients before and after a successful kidney transplantation.",
    "Label": ""
  },
  {
    "id": "15297",
    "Sentence": "Influence of single-nucleotide polymorphisms on C-reactive protein levels in chronic kidney disease before and after kidney transplantation.INTRODUCTION: We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the C-reactive protein (<\\entity><\\entity>) gene promoter region for their effects on <\\entity><\\entity> levels in chronic kidney disease (CKD) patients before and after a successful kidney transplantation.",
    "Label": ""
  },
  {
    "id": "15298",
    "Sentence": "Influence of single-nucleotide polymorphisms on C-reactive protein levels in <\\entity><\\entity> before and after kidney transplantation.INTRODUCTION: We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the C-reactive protein (CRP) gene promoter region for their effects on CRP levels in <\\entity><\\entity> (CKD) patients before and after a successful kidney transplantation.",
    "Label": ""
  },
  {
    "id": "15300",
    "Sentence": "Influence of single-nucleotide polymorphisms on C-reactive protein levels in chronic kidney disease before and after kidney transplantation.INTRODUCTION: We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the C-reactive protein (<\\entity><\\entity>) gene promoter region for their effects on <\\entity><\\entity> levels in chronic kidney disease (CKD) patients before and after a successful kidney transplantation.",
    "Label": ""
  },
  {
    "id": "15301",
    "Sentence": "Influence of single-nucleotide polymorphisms on C-reactive protein levels in chronic kidney disease before and after kidney transplantation.INTRODUCTION: We sought to evaluate 2 single-nucleotide polymorphisms (SNPs) in the C-reactive protein (CRP) gene promoter region for their effects on CRP levels in chronic kidney disease (<\\entity><\\entity>) patients before and after a successful kidney transplantation.",
    "Label": ""
  },
  {
    "id": "15303",
    "Sentence": "Also the presence of the allele \"T\" was sufficient to determine differences in <\\entity><\\entity> levels both in pretransplantation (P = .045) and at 1 year posttransplantation (P = .011), but not at the second year (P = .448).",
    "Label": ""
  },
  {
    "id": "15304",
    "Sentence": "Also the presence of the allele \"T\" was sufficient to determine differences in CRP levels both in pretransplantation (P = .045) and at <\\entity><\\entity> (P = .011), but not at the second year (P = .448).",
    "Label": ""
  },
  {
    "id": "15310",
    "Sentence": "Conversion to <\\entity><\\entity> in kidney-pancreas and pancreas transplantation.Reports on the use of <\\entity><\\entity> (SRL) in pancreas transplantation are still limited.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15311",
    "Sentence": "Conversion to <\\entity><\\entity> in kidney-pancreas and pancreas transplantation.Reports on the use of <\\entity><\\entity> (SRL) in pancreas transplantation are still limited.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15312",
    "Sentence": "Conversion to sirolimus in kidney-pancreas and pancreas transplantation.Reports on the use of sirolimus (<\\entity><\\entity>) in pancreas transplantation are still limited.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15313",
    "Sentence": "Conversion to sirolimus in kidney-pancreas and pancreas transplantation.Reports on the use of sirolimus (SRL) in pancreas transplantation are <\\entity><\\entity> limited.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15314",
    "Sentence": "The aim of this study was to evaluate the outcome of <\\entity><\\entity> conversion in pancreas transplant patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15315",
    "Sentence": "Among 247 patients undergoing simultaneous kidney-pancreas or solitary pancreas transplantation, 33 (13%) were converted to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15316",
    "Sentence": "The reasons for conversion were <\\entity><\\entity> (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15317",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (<\\entity><\\entity>) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to <\\entity><\\entity> (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15318",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) <\\entity><\\entity> (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15319",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe <\\entity><\\entity> owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15320",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (<\\entity><\\entity>) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to <\\entity><\\entity> (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15321",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent <\\entity><\\entity> episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15322",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), <\\entity><\\entity> (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15323",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (<\\entity><\\entity> of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15324",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of <\\entity><\\entity> (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15325",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (<\\entity><\\entity>; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15326",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and <\\entity><\\entity> (n = 4; 12%).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15327",
    "Sentence": "Before conversion, all patients were maintained on a <\\entity><\\entity>, MMF, and low-dose steroids.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15328",
    "Sentence": "Before conversion, all patients were maintained on a CNI, <\\entity><\\entity>, and low-dose steroids.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15329",
    "Sentence": "Before conversion, all patients were maintained on a CNI, MMF, and low-dose <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15330",
    "Sentence": "They were gradually converted to <\\entity><\\entity> associated with either CNI or MMF withdrawal.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15331",
    "Sentence": "They were gradually converted to SRL associated with either <\\entity><\\entity> or MMF withdrawal.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15332",
    "Sentence": "They were gradually converted to SRL associated with either CNI or <\\entity><\\entity> withdrawal.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15333",
    "Sentence": "Sixty-three percent (n = 15) of patients who were converted owing to <\\entity><\\entity> nephrotoxicity, showed stable or improved renal function.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15334",
    "Sentence": "Sixty-three percent (n = 15) of patients who were converted owing to CNI <\\entity><\\entity>, showed stable or improved renal function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15335",
    "Sentence": "The only patient with <\\entity><\\entity> showed improved neurologic status after SRL conversion.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15336",
    "Sentence": "The only patient with leucoencephalopathy showed improved neurologic status after <\\entity><\\entity> conversion.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15337",
    "Sentence": "All patients converted to <\\entity><\\entity> because of GI side effects of MMF showed improvements, and none of those converted because of hyperglycemia experienced improvement.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15338",
    "Sentence": "All patients converted to SRL because of <\\entity><\\entity> of MMF showed improvements, and none of those converted because of hyperglycemia experienced improvement.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15339",
    "Sentence": "All patients converted to SRL because of GI side effects of <\\entity><\\entity> showed improvements, and none of those converted because of hyperglycemia experienced improvement.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15340",
    "Sentence": "All patients converted to SRL because of GI side effects of MMF showed improvements, and none of those converted because of <\\entity><\\entity> experienced improvement.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15341",
    "Sentence": "There were no episodes of <\\entity><\\entity> after conversion.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15342",
    "Sentence": "We concluded that conversion to <\\entity><\\entity> in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and neurotoxicity, and in cases of severe diarrhea due to MMF.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15343",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for <\\entity><\\entity> nephrotoxicity and neurotoxicity, and in cases of severe diarrhea due to MMF.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15344",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI <\\entity><\\entity> and neurotoxicity, and in cases of severe diarrhea due to MMF.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15345",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and <\\entity><\\entity>, and in cases of severe diarrhea due to MMF.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15346",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and neurotoxicity, and in cases of <\\entity><\\entity> due to MMF.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15347",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and neurotoxicity, and in cases of severe diarrhea due to <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "15348",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (<\\entity><\\entity>; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15349",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), <\\entity><\\entity> (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15351",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (<\\entity><\\entity>; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15352",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (<\\entity><\\entity> of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15354",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (<\\entity><\\entity>) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to <\\entity><\\entity> (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15355",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (<\\entity><\\entity> of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15357",
    "Sentence": "The only patient with leucoencephalopathy showed improved neurologic status after <\\entity><\\entity> conversion.",
    "Label": ""
  },
  {
    "id": "15358",
    "Sentence": "The only patient with <\\entity><\\entity> showed improved neurologic status after SRL conversion.",
    "Label": ""
  },
  {
    "id": "15360",
    "Sentence": "All patients converted to SRL because of GI side effects of <\\entity><\\entity> showed improvements, and none of those converted because of hyperglycemia experienced improvement.",
    "Label": ""
  },
  {
    "id": "15361",
    "Sentence": "All patients converted to SRL because of <\\entity><\\entity> of MMF showed improvements, and none of those converted because of hyperglycemia experienced improvement.",
    "Label": ""
  },
  {
    "id": "15363",
    "Sentence": "All patients converted to <\\entity><\\entity> because of GI side effects of MMF showed improvements, and none of those converted because of hyperglycemia experienced improvement.",
    "Label": ""
  },
  {
    "id": "15364",
    "Sentence": "All patients converted to SRL because of <\\entity><\\entity> of MMF showed improvements, and none of those converted because of hyperglycemia experienced improvement.",
    "Label": ""
  },
  {
    "id": "15366",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and neurotoxicity, and in cases of severe diarrhea due to <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15367",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and neurotoxicity, and in cases of <\\entity><\\entity> due to MMF.",
    "Label": ""
  },
  {
    "id": "15369",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of <\\entity><\\entity> (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15370",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) <\\entity><\\entity> (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15372",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of <\\entity><\\entity> (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15373",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), <\\entity><\\entity> (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15375",
    "Sentence": "The reasons for conversion were <\\entity><\\entity> (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15376",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) <\\entity><\\entity> (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15378",
    "Sentence": "The reasons for conversion were <\\entity><\\entity> (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15379",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), <\\entity><\\entity> (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15381",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (<\\entity><\\entity>) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to <\\entity><\\entity> (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15382",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe <\\entity><\\entity> owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15384",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (<\\entity><\\entity>) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to <\\entity><\\entity> (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15385",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) <\\entity><\\entity> (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15387",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (<\\entity><\\entity>) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to <\\entity><\\entity> (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15388",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), <\\entity><\\entity> (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15390",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe <\\entity><\\entity> owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15391",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) <\\entity><\\entity> (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15393",
    "Sentence": "Sixty-three percent (n = 15) of patients who were converted owing to <\\entity><\\entity> nephrotoxicity, showed stable or improved renal function.",
    "Label": ""
  },
  {
    "id": "15394",
    "Sentence": "Sixty-three percent (n = 15) of patients who were converted owing to CNI <\\entity><\\entity>, showed stable or improved renal function.",
    "Label": ""
  },
  {
    "id": "15396",
    "Sentence": "We concluded that conversion to <\\entity><\\entity> in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and neurotoxicity, and in cases of severe diarrhea due to MMF.",
    "Label": ""
  },
  {
    "id": "15397",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and neurotoxicity, and in cases of <\\entity><\\entity> due to MMF.",
    "Label": ""
  },
  {
    "id": "15399",
    "Sentence": "We concluded that conversion to <\\entity><\\entity> in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and neurotoxicity, and in cases of severe diarrhea due to MMF.",
    "Label": ""
  },
  {
    "id": "15400",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI <\\entity><\\entity> and neurotoxicity, and in cases of severe diarrhea due to MMF.",
    "Label": ""
  },
  {
    "id": "15402",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for <\\entity><\\entity> nephrotoxicity and neurotoxicity, and in cases of severe diarrhea due to MMF.",
    "Label": ""
  },
  {
    "id": "15403",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and neurotoxicity, and in cases of <\\entity><\\entity> due to MMF.",
    "Label": ""
  },
  {
    "id": "15405",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for <\\entity><\\entity> nephrotoxicity and neurotoxicity, and in cases of severe diarrhea due to MMF.",
    "Label": ""
  },
  {
    "id": "15406",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and <\\entity><\\entity>, and in cases of severe diarrhea due to MMF.",
    "Label": ""
  },
  {
    "id": "15408",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for <\\entity><\\entity> nephrotoxicity and neurotoxicity, and in cases of severe diarrhea due to MMF.",
    "Label": ""
  },
  {
    "id": "15409",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI <\\entity><\\entity> and neurotoxicity, and in cases of severe diarrhea due to MMF.",
    "Label": ""
  },
  {
    "id": "15411",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and <\\entity><\\entity>, and in cases of severe diarrhea due to MMF.",
    "Label": ""
  },
  {
    "id": "15412",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI <\\entity><\\entity> and neurotoxicity, and in cases of severe diarrhea due to MMF.",
    "Label": ""
  },
  {
    "id": "15414",
    "Sentence": "Conversion to <\\entity><\\entity> in kidney-pancreas and pancreas transplantation.Reports on the use of <\\entity><\\entity> (SRL) in pancreas transplantation are still limited.",
    "Label": ""
  },
  {
    "id": "15415",
    "Sentence": "Conversion to sirolimus in kidney-pancreas and pancreas transplantation.Reports on the use of sirolimus (SRL) in pancreas transplantation are <\\entity><\\entity> limited.",
    "Label": ""
  },
  {
    "id": "15417",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (<\\entity><\\entity>; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15418",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and <\\entity><\\entity> (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15420",
    "Sentence": "All patients converted to SRL because of GI side effects of <\\entity><\\entity> showed improvements, and none of those converted because of hyperglycemia experienced improvement.",
    "Label": ""
  },
  {
    "id": "15421",
    "Sentence": "All patients converted to SRL because of GI side effects of MMF showed improvements, and none of those converted because of <\\entity><\\entity> experienced improvement.",
    "Label": ""
  },
  {
    "id": "15423",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (<\\entity><\\entity>; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15424",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent <\\entity><\\entity> episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15426",
    "Sentence": "The reasons for conversion were <\\entity><\\entity> (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15427",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and <\\entity><\\entity> (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15429",
    "Sentence": "The reasons for conversion were <\\entity><\\entity> (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15430",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe <\\entity><\\entity> owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15432",
    "Sentence": "The reasons for conversion were <\\entity><\\entity> (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15433",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent <\\entity><\\entity> episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15435",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (<\\entity><\\entity>) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to <\\entity><\\entity> (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15436",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and <\\entity><\\entity> (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15438",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (<\\entity><\\entity>) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to <\\entity><\\entity> (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15439",
    "Sentence": "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent <\\entity><\\entity> episodes (n = 7; 21%), gastrointestinal (GI) side effects of mycophenolate mofetil (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).",
    "Label": ""
  },
  {
    "id": "15441",
    "Sentence": "All patients converted to <\\entity><\\entity> because of GI side effects of MMF showed improvements, and none of those converted because of hyperglycemia experienced improvement.",
    "Label": ""
  },
  {
    "id": "15442",
    "Sentence": "All patients converted to SRL because of GI side effects of MMF showed improvements, and none of those converted because of <\\entity><\\entity> experienced improvement.",
    "Label": ""
  },
  {
    "id": "15444",
    "Sentence": "We concluded that conversion to <\\entity><\\entity> in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and neurotoxicity, and in cases of severe diarrhea due to MMF.",
    "Label": ""
  },
  {
    "id": "15445",
    "Sentence": "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and <\\entity><\\entity>, and in cases of severe diarrhea due to MMF.",
    "Label": ""
  },
  {
    "id": "15451",
    "Sentence": "Analysis of DNA variations in promoter region of <\\entity><\\entity> gene with Alzheimer's disease.Hippocampal cholinergic neurostimulating peptide (<\\entity><\\entity>), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from <\\entity><\\entity> precursor protein (<\\entity><\\entity>pp), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (RKIP).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15452",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with <\\entity><\\entity>.Hippocampal cholinergic neurostimulating peptide (HCNP), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from HCNP precursor protein (HCNPpp), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (RKIP).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15453",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with Alzheimer's disease.<\\entity><\\entity> (HCNP), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from HCNP precursor protein (HCNPpp), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (RKIP).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15454",
    "Sentence": "Analysis of DNA variations in promoter region of <\\entity><\\entity> gene with Alzheimer's disease.Hippocampal cholinergic neurostimulating peptide (<\\entity><\\entity>), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from <\\entity><\\entity> precursor protein (<\\entity><\\entity>pp), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (RKIP).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15455",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with Alzheimer's disease.Hippocampal cholinergic neurostimulating peptide (HCNP), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from <\\entity><\\entity> (HCNPpp), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (RKIP).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15456",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with Alzheimer's disease.Hippocampal cholinergic neurostimulating peptide (HCNP), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from HCNP precursor protein (<\\entity><\\entity>), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (RKIP).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15457",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with Alzheimer's disease.Hippocampal cholinergic neurostimulating peptide (HCNP), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from HCNP precursor protein (HCNPpp), also known as <\\entity><\\entity> (PEBP) and Raf kinase inhibitor protein (RKIP).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15458",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with Alzheimer's disease.Hippocampal cholinergic neurostimulating peptide (HCNP), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from HCNP precursor protein (HCNPpp), also known as phosphatidylethanolamine binding protein (<\\entity><\\entity>) and Raf kinase inhibitor protein (RKIP).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15459",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with Alzheimer's disease.Hippocampal cholinergic neurostimulating peptide (HCNP), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from HCNP precursor protein (HCNPpp), also known as phosphatidylethanolamine binding protein (PEBP) and <\\entity><\\entity> (RKIP).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15460",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with Alzheimer's disease.Hippocampal cholinergic neurostimulating peptide (HCNP), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from HCNP precursor protein (HCNPpp), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15461",
    "Sentence": "Our previous study demonstrated that expression of <\\entity><\\entity> mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of HCNP with the pathogenesis of AD.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15462",
    "Sentence": "Our previous study demonstrated that expression of HCNPpp mRNA was decreased in the hippocampi of autopsied brains of <\\entity><\\entity> (AD) patients, indicating the association of HCNP with the pathogenesis of AD.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15463",
    "Sentence": "Our previous study demonstrated that expression of HCNPpp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (<\\entity><\\entity>) patients, indicating the association of HCNP with the pathogenesis of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15464",
    "Sentence": "Our previous study demonstrated that expression of <\\entity><\\entity>pp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of <\\entity><\\entity> with the pathogenesis of AD.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15465",
    "Sentence": "Our previous study demonstrated that expression of HCNPpp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of HCNP with the <\\entity><\\entity> of AD.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15466",
    "Sentence": "Our previous study demonstrated that expression of HCNPpp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (<\\entity><\\entity>) patients, indicating the association of HCNP with the pathogenesis of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15467",
    "Sentence": "To clarify the involvement of gene variations in the promoter region of the gene encoding <\\entity><\\entity> in this mRNA reduction, we analyzed DNA polymorphisms or mutations within this gene promoter region in AD patients by direct sequencing.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15468",
    "Sentence": "To clarify the involvement of gene variations in the promoter region of the gene encoding HCNPpp in this mRNA reduction, we analyzed DNA polymorphisms or <\\entity><\\entity> within this gene promoter region in AD patients by direct sequencing.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15469",
    "Sentence": "To clarify the involvement of gene variations in the promoter region of the gene encoding HCNPpp in this mRNA reduction, we analyzed DNA polymorphisms or mutations within this gene promoter region in <\\entity><\\entity> patients by direct sequencing.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15470",
    "Sentence": "The promoter was found to contain a <\\entity><\\entity> without a TATA box, an element of housekeeping gene promoters.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15471",
    "Sentence": "The promoter was found to contain a CpG island without a <\\entity><\\entity>, an element of housekeeping gene promoters.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15472",
    "Sentence": "Moreover, no <\\entity><\\entity>-specific polymorphisms or mutations were identified, suggesting that the decrease of mRNA can be ascribed to transcriptional or posttranscriptional changes in activity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15473",
    "Sentence": "Moreover, no disease-specific polymorphisms or <\\entity><\\entity> were identified, suggesting that the decrease of mRNA can be ascribed to transcriptional or posttranscriptional changes in activity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15474",
    "Sentence": "Our previous study demonstrated that expression of <\\entity><\\entity>pp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of <\\entity><\\entity> with the pathogenesis of AD.",
    "Label": ""
  },
  {
    "id": "15475",
    "Sentence": "Our previous study demonstrated that expression of HCNPpp mRNA was decreased in the hippocampi of autopsied brains of <\\entity><\\entity> (AD) patients, indicating the association of HCNP with the pathogenesis of AD.",
    "Label": ""
  },
  {
    "id": "15477",
    "Sentence": "Our previous study demonstrated that expression of <\\entity><\\entity>pp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of <\\entity><\\entity> with the pathogenesis of AD.",
    "Label": ""
  },
  {
    "id": "15478",
    "Sentence": "Our previous study demonstrated that expression of HCNPpp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (<\\entity><\\entity>) patients, indicating the association of HCNP with the pathogenesis of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15480",
    "Sentence": "Our previous study demonstrated that expression of <\\entity><\\entity> mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of HCNP with the pathogenesis of AD.",
    "Label": ""
  },
  {
    "id": "15481",
    "Sentence": "Our previous study demonstrated that expression of HCNPpp mRNA was decreased in the hippocampi of autopsied brains of <\\entity><\\entity> (AD) patients, indicating the association of HCNP with the pathogenesis of AD.",
    "Label": ""
  },
  {
    "id": "15483",
    "Sentence": "Our previous study demonstrated that expression of <\\entity><\\entity> mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of HCNP with the pathogenesis of AD.",
    "Label": ""
  },
  {
    "id": "15484",
    "Sentence": "Our previous study demonstrated that expression of HCNPpp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (<\\entity><\\entity>) patients, indicating the association of HCNP with the pathogenesis of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15486",
    "Sentence": "Analysis of DNA variations in promoter region of <\\entity><\\entity> gene with Alzheimer's disease.Hippocampal cholinergic neurostimulating peptide (<\\entity><\\entity>), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from <\\entity><\\entity> precursor protein (<\\entity><\\entity>pp), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (RKIP).",
    "Label": ""
  },
  {
    "id": "15487",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with <\\entity><\\entity>.Hippocampal cholinergic neurostimulating peptide (HCNP), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from HCNP precursor protein (HCNPpp), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (RKIP).",
    "Label": ""
  },
  {
    "id": "15489",
    "Sentence": "Our previous study demonstrated that expression of <\\entity><\\entity>pp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of <\\entity><\\entity> with the pathogenesis of AD.",
    "Label": ""
  },
  {
    "id": "15490",
    "Sentence": "Our previous study demonstrated that expression of HCNPpp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of HCNP with the <\\entity><\\entity> of AD.",
    "Label": ""
  },
  {
    "id": "15492",
    "Sentence": "Our previous study demonstrated that expression of <\\entity><\\entity> mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of HCNP with the pathogenesis of AD.",
    "Label": ""
  },
  {
    "id": "15493",
    "Sentence": "Our previous study demonstrated that expression of HCNPpp mRNA was decreased in the hippocampi of autopsied brains of Alzheimer's disease (AD) patients, indicating the association of HCNP with the <\\entity><\\entity> of AD.",
    "Label": ""
  },
  {
    "id": "15495",
    "Sentence": "To clarify the involvement of gene variations in the promoter region of the gene encoding <\\entity><\\entity> in this mRNA reduction, we analyzed DNA polymorphisms or mutations within this gene promoter region in AD patients by direct sequencing.",
    "Label": ""
  },
  {
    "id": "15496",
    "Sentence": "To clarify the involvement of gene variations in the promoter region of the gene encoding HCNPpp in this mRNA reduction, we analyzed DNA polymorphisms or <\\entity><\\entity> within this gene promoter region in AD patients by direct sequencing.",
    "Label": ""
  },
  {
    "id": "15498",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with Alzheimer's disease.Hippocampal cholinergic neurostimulating peptide (HCNP), which enhances <\\entity><\\entity> synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from HCNP precursor protein (HCNPpp), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (RKIP).",
    "Label": ""
  },
  {
    "id": "15499",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with Alzheimer's disease.Hippocampal cholinergic neurostimulating peptide (HCNP), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from <\\entity><\\entity> (HCNPpp), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (RKIP).",
    "Label": ""
  },
  {
    "id": "15501",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with Alzheimer's disease.Hippocampal cholinergic neurostimulating peptide (HCNP), which enhances <\\entity><\\entity> synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from HCNP precursor protein (HCNPpp), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (RKIP).",
    "Label": ""
  },
  {
    "id": "15502",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with Alzheimer's disease.Hippocampal cholinergic neurostimulating peptide (HCNP), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from HCNP precursor protein (HCNPpp), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "15504",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with Alzheimer's disease.Hippocampal cholinergic neurostimulating peptide (HCNP), which enhances <\\entity><\\entity> synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from HCNP precursor protein (HCNPpp), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (RKIP).",
    "Label": ""
  },
  {
    "id": "15505",
    "Sentence": "Analysis of DNA variations in promoter region of HCNP gene with Alzheimer's disease.<\\entity><\\entity> (HCNP), which enhances acetylcholine synthesis and induces cholinergic phenotype development of the septohippocampal system, is derived from HCNP precursor protein (HCNPpp), also known as phosphatidylethanolamine binding protein (PEBP) and Raf kinase inhibitor protein (RKIP).",
    "Label": ""
  },
  {
    "id": "15507",
    "Sentence": "To clarify the involvement of gene variations in the promoter region of the gene encoding <\\entity><\\entity> in this mRNA reduction, we analyzed DNA polymorphisms or mutations within this gene promoter region in AD patients by direct sequencing.",
    "Label": ""
  },
  {
    "id": "15508",
    "Sentence": "To clarify the involvement of gene variations in the promoter region of the gene encoding HCNPpp in this mRNA reduction, we analyzed DNA polymorphisms or mutations within this gene promoter region in <\\entity><\\entity> patients by direct sequencing.",
    "Label": ""
  },
  {
    "id": "15514",
    "Sentence": "Association analysis between the <\\entity><\\entity> polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma.Cdc6 play crucial roles in DNA replication and carcinogenesis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15515",
    "Sentence": "Association analysis between the <\\entity><\\entity> polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma.Cdc6 play crucial roles in DNA replication and carcinogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15516",
    "Sentence": "Association analysis between the Cdc6 G1321A polymorphism and the risk for <\\entity><\\entity> and hepatocellular carcinoma.Cdc6 play crucial roles in DNA replication and carcinogenesis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15517",
    "Sentence": "Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and <\\entity><\\entity>.Cdc6 play crucial roles in DNA replication and carcinogenesis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15518",
    "Sentence": "Association analysis between the <\\entity><\\entity> G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma.<\\entity><\\entity> play crucial roles in DNA replication and carcinogenesis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15519",
    "Sentence": "Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma.Cdc6 play crucial roles in DNA replication and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15520",
    "Sentence": "The biological significance of the <\\entity><\\entity> polymorphism (V441I, rs13706) is still not elucidated.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15521",
    "Sentence": "The biological significance of the <\\entity><\\entity> polymorphism (V441I, rs13706) is still not elucidated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15522",
    "Sentence": "The biological significance of the Cdc6 G1321A polymorphism (<\\entity><\\entity>, rs13706) is still not elucidated.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15523",
    "Sentence": "The biological significance of the Cdc6 G1321A polymorphism (V441I, <\\entity><\\entity>) is still not elucidated.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15524",
    "Sentence": "The biological significance of the Cdc6 G1321A polymorphism (V441I, rs13706) is <\\entity><\\entity> not elucidated.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15525",
    "Sentence": "Here we examined the influence of this polymorphism on the function of <\\entity><\\entity> and the individual's susceptibility to non-Hodgkin lymphoma (NHL) and hepatocellular carcinoma (HCC).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15526",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to <\\entity><\\entity> (NHL) and hepatocellular carcinoma (HCC).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15527",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to non-Hodgkin lymphoma (<\\entity><\\entity>) and hepatocellular carcinoma (HCC).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15528",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to non-Hodgkin lymphoma (<\\entity><\\entity>) and hepatocellular carcinoma (HCC).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15529",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to non-Hodgkin lymphoma (NHL) and <\\entity><\\entity> (HCC).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15530",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to non-Hodgkin lymphoma (NHL) and hepatocellular carcinoma (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15531",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to non-Hodgkin lymphoma (NHL) and hepatocellular carcinoma (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15532",
    "Sentence": "Unconditional logistic <\\entity><\\entity> analysis revealed that the risk for NHL was significantly reduced in both AG heterozygotes [odds ratio (OR)=0.67, P=0.019] and AA homozygotes (OR=0.54, P=0.026), compared with GG homozygotes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15533",
    "Sentence": "Unconditional logistic regression analysis revealed that the risk for <\\entity><\\entity> was significantly reduced in both AG heterozygotes [odds ratio (OR)=0.67, P=0.019] and AA homozygotes (OR=0.54, P=0.026), compared with GG homozygotes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15534",
    "Sentence": "Unconditional logistic regression analysis revealed that the risk for <\\entity><\\entity> was significantly reduced in both AG heterozygotes [odds ratio (OR)=0.67, P=0.019] and AA homozygotes (OR=0.54, P=0.026), compared with GG homozygotes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15535",
    "Sentence": "Unconditional logistic regression analysis revealed that the risk for NHL was significantly reduced in both <\\entity><\\entity> heterozygotes [odds ratio (OR)=0.67, P=0.019] and AA homozygotes (OR=0.54, P=0.026), compared with GG homozygotes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15536",
    "Sentence": "Unconditional logistic regression analysis revealed that the risk for NHL was significantly reduced in both AG heterozygotes [odds ratio (OR)=0.67, P=0.019] and <\\entity><\\entity> homozygotes (OR=0.54, P=0.026), compared with GG homozygotes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15537",
    "Sentence": "Unconditional logistic regression analysis revealed that the risk for NHL was significantly reduced in both AG heterozygotes [odds ratio (OR)=0.67, P=0.019] and AA homozygotes (OR=0.54, P=0.026), compared with <\\entity><\\entity> homozygotes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15538",
    "Sentence": "Further stratification by subtypes of <\\entity><\\entity> showed that the AG as well as combined AA/AG genotypes were associated with decreased risk for B-cell-<\\entity><\\entity> (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15539",
    "Sentence": "Further stratification by subtypes of <\\entity><\\entity> showed that the AG as well as combined AA/AG genotypes were associated with decreased risk for B-cell-<\\entity><\\entity> (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15540",
    "Sentence": "Further stratification by subtypes of NHL showed that the <\\entity><\\entity> as well as combined AA/<\\entity><\\entity> genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15541",
    "Sentence": "Further stratification by subtypes of NHL showed that the AG as well as combined <\\entity><\\entity> genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15542",
    "Sentence": "Further stratification by subtypes of NHL showed that the AG as well as combined AA/AG genotypes were associated with decreased risk for <\\entity><\\entity> (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15543",
    "Sentence": "Further stratification by subtypes of NHL showed that the AG as well as combined AA/AG genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for <\\entity><\\entity> (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15544",
    "Sentence": "Further stratification by subtypes of NHL showed that the AG as well as combined AA/AG genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (<\\entity><\\entity>, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15545",
    "Sentence": "In addition, male individuals with the <\\entity><\\entity> genotype displayed borderline significantly reduced risk for HCC (OR=0.48, P=0.054).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15546",
    "Sentence": "In addition, male individuals with the AA genotype displayed borderline significantly reduced risk for <\\entity><\\entity> (OR=0.48, P=0.054).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15547",
    "Sentence": "In addition, male individuals with the AA genotype displayed borderline significantly reduced risk for <\\entity><\\entity> (OR=0.48, P=0.054).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15548",
    "Sentence": "Interestingly, the <\\entity><\\entity> polymorphism did not affect caspase-mediated cleavage of Cdc6 during etoposide-induced apoptosis, but it was predicted to alter the secondary structure of Cdc6 mRNA.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15549",
    "Sentence": "Interestingly, the G1321A polymorphism did not affect caspase-mediated cleavage of <\\entity><\\entity> during etoposide-induced apoptosis, but it was predicted to alter the secondary structure of <\\entity><\\entity> mRNA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15550",
    "Sentence": "Interestingly, the G1321A polymorphism did not affect caspase-mediated cleavage of Cdc6 during <\\entity><\\entity>-induced apoptosis, but it was predicted to alter the secondary structure of Cdc6 mRNA.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15551",
    "Sentence": "Interestingly, the G1321A polymorphism did not affect caspase-mediated cleavage of Cdc6 during etoposide-induced apoptosis, but it was predicted to alter the <\\entity><\\entity> structure of Cdc6 mRNA.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15552",
    "Sentence": "Interestingly, the G1321A polymorphism did not affect caspase-mediated cleavage of <\\entity><\\entity> during etoposide-induced apoptosis, but it was predicted to alter the secondary structure of <\\entity><\\entity> mRNA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15553",
    "Sentence": "Our data provide the first evidence that the <\\entity><\\entity> polymorphism is associated with decreased risk of cancer.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15554",
    "Sentence": "Our data provide the first evidence that the <\\entity><\\entity> polymorphism is associated with decreased risk of cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15555",
    "Sentence": "Our data provide the first evidence that the Cdc6 G1321A polymorphism is associated with decreased risk of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15556",
    "Sentence": "Association analysis between the <\\entity><\\entity> G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma.<\\entity><\\entity> play crucial roles in DNA replication and carcinogenesis.",
    "Label": ""
  },
  {
    "id": "15557",
    "Sentence": "Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma.Cdc6 play crucial roles in DNA replication and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15559",
    "Sentence": "Unconditional logistic regression analysis revealed that the risk for NHL was significantly reduced in both <\\entity><\\entity> heterozygotes [odds ratio (OR)=0.67, P=0.019] and AA homozygotes (OR=0.54, P=0.026), compared with GG homozygotes.",
    "Label": ""
  },
  {
    "id": "15560",
    "Sentence": "Unconditional logistic regression analysis revealed that the risk for <\\entity><\\entity> was significantly reduced in both AG heterozygotes [odds ratio (OR)=0.67, P=0.019] and AA homozygotes (OR=0.54, P=0.026), compared with GG homozygotes.",
    "Label": ""
  },
  {
    "id": "15562",
    "Sentence": "Unconditional logistic regression analysis revealed that the risk for NHL was significantly reduced in both AG heterozygotes [odds ratio (OR)=0.67, P=0.019] and <\\entity><\\entity> homozygotes (OR=0.54, P=0.026), compared with GG homozygotes.",
    "Label": ""
  },
  {
    "id": "15563",
    "Sentence": "Unconditional logistic regression analysis revealed that the risk for <\\entity><\\entity> was significantly reduced in both AG heterozygotes [odds ratio (OR)=0.67, P=0.019] and AA homozygotes (OR=0.54, P=0.026), compared with GG homozygotes.",
    "Label": ""
  },
  {
    "id": "15565",
    "Sentence": "Further stratification by subtypes of NHL showed that the <\\entity><\\entity> as well as combined AA/<\\entity><\\entity> genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": ""
  },
  {
    "id": "15566",
    "Sentence": "Further stratification by subtypes of NHL showed that the AG as well as combined AA/AG genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (<\\entity><\\entity>, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": ""
  },
  {
    "id": "15568",
    "Sentence": "Further stratification by subtypes of NHL showed that the <\\entity><\\entity> as well as combined AA/<\\entity><\\entity> genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": ""
  },
  {
    "id": "15569",
    "Sentence": "Further stratification by subtypes of NHL showed that the AG as well as combined AA/AG genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for <\\entity><\\entity> (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": ""
  },
  {
    "id": "15571",
    "Sentence": "Further stratification by subtypes of NHL showed that the <\\entity><\\entity> as well as combined AA/<\\entity><\\entity> genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": ""
  },
  {
    "id": "15572",
    "Sentence": "Further stratification by subtypes of NHL showed that the AG as well as combined AA/AG genotypes were associated with decreased risk for <\\entity><\\entity> (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": ""
  },
  {
    "id": "15574",
    "Sentence": "Further stratification by subtypes of NHL showed that the AG as well as combined <\\entity><\\entity> genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": ""
  },
  {
    "id": "15575",
    "Sentence": "Further stratification by subtypes of NHL showed that the AG as well as combined AA/AG genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (<\\entity><\\entity>, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": ""
  },
  {
    "id": "15577",
    "Sentence": "Further stratification by subtypes of NHL showed that the AG as well as combined <\\entity><\\entity> genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": ""
  },
  {
    "id": "15578",
    "Sentence": "Further stratification by subtypes of NHL showed that the AG as well as combined AA/AG genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for <\\entity><\\entity> (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": ""
  },
  {
    "id": "15580",
    "Sentence": "Further stratification by subtypes of NHL showed that the AG as well as combined <\\entity><\\entity> genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": ""
  },
  {
    "id": "15581",
    "Sentence": "Further stratification by subtypes of NHL showed that the AG as well as combined AA/AG genotypes were associated with decreased risk for <\\entity><\\entity> (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": ""
  },
  {
    "id": "15583",
    "Sentence": "In addition, male individuals with the <\\entity><\\entity> genotype displayed borderline significantly reduced risk for HCC (OR=0.48, P=0.054).",
    "Label": ""
  },
  {
    "id": "15584",
    "Sentence": "In addition, male individuals with the AA genotype displayed borderline significantly reduced risk for <\\entity><\\entity> (OR=0.48, P=0.054).",
    "Label": ""
  },
  {
    "id": "15586",
    "Sentence": "Our data provide the first evidence that the <\\entity><\\entity> polymorphism is associated with decreased risk of cancer.",
    "Label": ""
  },
  {
    "id": "15587",
    "Sentence": "Our data provide the first evidence that the Cdc6 G1321A polymorphism is associated with decreased risk of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15589",
    "Sentence": "Association analysis between the <\\entity><\\entity> polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma.Cdc6 play crucial roles in DNA replication and carcinogenesis.",
    "Label": ""
  },
  {
    "id": "15590",
    "Sentence": "Association analysis between the Cdc6 G1321A polymorphism and the risk for <\\entity><\\entity> and hepatocellular carcinoma.Cdc6 play crucial roles in DNA replication and carcinogenesis.",
    "Label": ""
  },
  {
    "id": "15592",
    "Sentence": "Association analysis between the <\\entity><\\entity> polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma.Cdc6 play crucial roles in DNA replication and carcinogenesis.",
    "Label": ""
  },
  {
    "id": "15593",
    "Sentence": "Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and <\\entity><\\entity>.Cdc6 play crucial roles in DNA replication and carcinogenesis.",
    "Label": ""
  },
  {
    "id": "15595",
    "Sentence": "The biological significance of the <\\entity><\\entity> polymorphism (V441I, rs13706) is still not elucidated.",
    "Label": ""
  },
  {
    "id": "15596",
    "Sentence": "The biological significance of the Cdc6 G1321A polymorphism (V441I, rs13706) is <\\entity><\\entity> not elucidated.",
    "Label": ""
  },
  {
    "id": "15598",
    "Sentence": "Here we examined the influence of this polymorphism on the function of <\\entity><\\entity> and the individual's susceptibility to non-Hodgkin lymphoma (NHL) and hepatocellular carcinoma (HCC).",
    "Label": ""
  },
  {
    "id": "15599",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to <\\entity><\\entity> (NHL) and hepatocellular carcinoma (HCC).",
    "Label": ""
  },
  {
    "id": "15601",
    "Sentence": "Here we examined the influence of this polymorphism on the function of <\\entity><\\entity> and the individual's susceptibility to non-Hodgkin lymphoma (NHL) and hepatocellular carcinoma (HCC).",
    "Label": ""
  },
  {
    "id": "15602",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to non-Hodgkin lymphoma (NHL) and <\\entity><\\entity> (HCC).",
    "Label": ""
  },
  {
    "id": "15604",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to non-Hodgkin lymphoma (<\\entity><\\entity>) and hepatocellular carcinoma (HCC).",
    "Label": ""
  },
  {
    "id": "15605",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to <\\entity><\\entity> (NHL) and hepatocellular carcinoma (HCC).",
    "Label": ""
  },
  {
    "id": "15607",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to non-Hodgkin lymphoma (<\\entity><\\entity>) and hepatocellular carcinoma (HCC).",
    "Label": ""
  },
  {
    "id": "15608",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to non-Hodgkin lymphoma (NHL) and <\\entity><\\entity> (HCC).",
    "Label": ""
  },
  {
    "id": "15610",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to non-Hodgkin lymphoma (NHL) and hepatocellular carcinoma (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "15611",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to <\\entity><\\entity> (NHL) and hepatocellular carcinoma (HCC).",
    "Label": ""
  },
  {
    "id": "15613",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to non-Hodgkin lymphoma (NHL) and hepatocellular carcinoma (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "15614",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to non-Hodgkin lymphoma (NHL) and <\\entity><\\entity> (HCC).",
    "Label": ""
  },
  {
    "id": "15616",
    "Sentence": "Unconditional logistic regression analysis revealed that the risk for <\\entity><\\entity> was significantly reduced in both AG heterozygotes [odds ratio (OR)=0.67, P=0.019] and AA homozygotes (OR=0.54, P=0.026), compared with GG homozygotes.",
    "Label": ""
  },
  {
    "id": "15617",
    "Sentence": "Unconditional logistic <\\entity><\\entity> analysis revealed that the risk for NHL was significantly reduced in both AG heterozygotes [odds ratio (OR)=0.67, P=0.019] and AA homozygotes (OR=0.54, P=0.026), compared with GG homozygotes.",
    "Label": ""
  },
  {
    "id": "15619",
    "Sentence": "Further stratification by subtypes of <\\entity><\\entity> showed that the AG as well as combined AA/AG genotypes were associated with decreased risk for B-cell-<\\entity><\\entity> (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (DLBCL, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": ""
  },
  {
    "id": "15620",
    "Sentence": "Further stratification by subtypes of NHL showed that the AG as well as combined AA/AG genotypes were associated with decreased risk for B-cell-NHL (OR=0.62, P=0.011 and OR=0.61, P=0.006, respectively), especially for diffuse large B-cell lymphoma (<\\entity><\\entity>, OR=0.63, P=0.025 and OR=0.62, P=0.012, respectively).",
    "Label": ""
  },
  {
    "id": "15622",
    "Sentence": "Interestingly, the G1321A polymorphism did not affect caspase-mediated cleavage of <\\entity><\\entity> during etoposide-induced apoptosis, but it was predicted to alter the secondary structure of <\\entity><\\entity> mRNA.",
    "Label": ""
  },
  {
    "id": "15623",
    "Sentence": "Interestingly, the G1321A polymorphism did not affect caspase-mediated cleavage of Cdc6 during etoposide-induced apoptosis, but it was predicted to alter the <\\entity><\\entity> structure of Cdc6 mRNA.",
    "Label": ""
  },
  {
    "id": "15625",
    "Sentence": "Here we examined the influence of this polymorphism on the function of <\\entity><\\entity> and the individual's susceptibility to non-Hodgkin lymphoma (NHL) and hepatocellular carcinoma (HCC).",
    "Label": ""
  },
  {
    "id": "15626",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to non-Hodgkin lymphoma (<\\entity><\\entity>) and hepatocellular carcinoma (HCC).",
    "Label": ""
  },
  {
    "id": "15628",
    "Sentence": "Here we examined the influence of this polymorphism on the function of <\\entity><\\entity> and the individual's susceptibility to non-Hodgkin lymphoma (NHL) and hepatocellular carcinoma (HCC).",
    "Label": ""
  },
  {
    "id": "15629",
    "Sentence": "Here we examined the influence of this polymorphism on the function of Cdc6 and the individual's susceptibility to non-Hodgkin lymphoma (NHL) and hepatocellular carcinoma (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "15631",
    "Sentence": "Unconditional logistic regression analysis revealed that the risk for NHL was significantly reduced in both AG heterozygotes [odds ratio (OR)=0.67, P=0.019] and AA homozygotes (OR=0.54, P=0.026), compared with <\\entity><\\entity> homozygotes.",
    "Label": ""
  },
  {
    "id": "15632",
    "Sentence": "Unconditional logistic regression analysis revealed that the risk for <\\entity><\\entity> was significantly reduced in both AG heterozygotes [odds ratio (OR)=0.67, P=0.019] and AA homozygotes (OR=0.54, P=0.026), compared with GG homozygotes.",
    "Label": ""
  },
  {
    "id": "15638",
    "Sentence": "Expansion of the human <\\entity><\\entity> gene architecture: novel functional variants.The <\\entity><\\entity> (OPRM1) is the principal receptor target for both endogenous and exogenous opioid analgesics.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15639",
    "Sentence": "Expansion of the human <\\entity><\\entity> gene architecture: novel functional variants.The <\\entity><\\entity> (OPRM1) is the principal receptor target for both endogenous and exogenous opioid analgesics.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15640",
    "Sentence": "Expansion of the human mu-opioid receptor gene architecture: novel functional variants.The mu-opioid receptor (<\\entity><\\entity>) is the principal receptor target for both endogenous and exogenous opioid analgesics.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15641",
    "Sentence": "There are substantial individual differences in human <\\entity><\\entity> and to opiate drugs that are attributed to genetic variations in OPRM1.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15642",
    "Sentence": "There are substantial individual differences in human responses to painful stimuli and to opiate drugs that are attributed to genetic variations in <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15643",
    "Sentence": "In searching for new functional variants, we employed comparative genome analysis and obtained evidence for the existence of an expanded human <\\entity><\\entity> gene locus with new promoters, alternative exons and regulatory elements.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15644",
    "Sentence": "Examination of polymorphisms within the human <\\entity><\\entity> gene locus identified strong association between single nucleotide polymorphism (SNP) rs563649 and individual variations in pain perception.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15645",
    "Sentence": "Examination of polymorphisms within the human OPRM1 gene locus identified strong association between single nucleotide polymorphism (SNP) <\\entity><\\entity> and individual variations in pain perception.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15646",
    "Sentence": "Examination of polymorphisms within the human OPRM1 gene locus identified strong association between single nucleotide polymorphism (SNP) rs563649 and individual variations in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15647",
    "Sentence": "SNP <\\entity><\\entity> is located within a structurally conserved internal ribosome entry site (IRES) in the 5'-UTR of a novel exon 13-containing OPRM1 isoforms (MOR-1K) and affects both mRNA levels and translation efficiency of these variants.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15648",
    "Sentence": "SNP rs563649 is located within a structurally conserved <\\entity><\\entity> (IRES) in the 5'-UTR of a novel exon 13-containing OPRM1 isoforms (MOR-1K) and affects both mRNA levels and translation efficiency of these variants.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15649",
    "Sentence": "SNP rs563649 is located within a structurally conserved internal ribosome entry site (<\\entity><\\entity>) in the 5'-UTR of a novel exon 13-containing OPRM1 isoforms (MOR-1K) and affects both mRNA levels and translation efficiency of these variants.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15650",
    "Sentence": "SNP rs563649 is located within a structurally conserved internal ribosome entry site (IRES) in the <\\entity><\\entity> of a novel exon 13-containing OPRM1 isoforms (MOR-1K) and affects both mRNA levels and translation efficiency of these variants.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15651",
    "Sentence": "SNP rs563649 is located within a structurally conserved internal ribosome entry site (IRES) in the 5'-UTR of a novel exon 13-containing <\\entity><\\entity> isoforms (MOR-1K) and affects both mRNA levels and translation efficiency of these variants.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15652",
    "Sentence": "SNP rs563649 is located within a structurally conserved internal ribosome entry site (IRES) in the 5'-UTR of a novel exon 13-containing OPRM1 isoforms (<\\entity><\\entity>) and affects both mRNA levels and translation efficiency of these variants.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15653",
    "Sentence": "SNP rs563649 is located within a structurally conserved internal ribosome entry site (IRES) in the 5'-UTR of a novel exon 13-containing OPRM1 isoforms (<\\entity><\\entity>) and affects both mRNA levels and translation efficiency of these variants.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15654",
    "Sentence": "Furthermore, <\\entity><\\entity> exhibits very strong linkage disequilibrium throughout the entire OPRM1 gene locus and thus affects the functional contribution of the corresponding haplotype that includes other functional OPRM1 SNPs.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15655",
    "Sentence": "Furthermore, rs563649 exhibits very strong linkage disequilibrium throughout the entire <\\entity><\\entity> gene locus and thus affects the functional contribution of the corresponding haplotype that includes other functional <\\entity><\\entity> SNPs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15656",
    "Sentence": "Furthermore, rs563649 exhibits very strong linkage disequilibrium throughout the entire OPRM1 gene locus and thus affects the functional contribution of the corresponding haplotype that includes other functional <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15657",
    "Sentence": "Furthermore, rs563649 exhibits very strong linkage disequilibrium throughout the entire OPRM1 gene locus and thus affects the functional contribution of the corresponding haplotype that includes other functional <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15658",
    "Sentence": "Our results provide evidence for an essential role for <\\entity><\\entity> isoforms in nociceptive signaling and suggest that genetic variations in alternative OPRM1 isoforms may contribute to individual differences in opiate responses.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15659",
    "Sentence": "Our results provide evidence for an essential role for <\\entity><\\entity> isoforms in nociceptive signaling and suggest that genetic variations in alternative OPRM1 isoforms may contribute to individual differences in opiate responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15660",
    "Sentence": "Our results provide evidence for an essential role for MOR-1K isoforms in <\\entity><\\entity> and suggest that genetic variations in alternative OPRM1 isoforms may contribute to individual differences in opiate responses.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15661",
    "Sentence": "Our results provide evidence for an essential role for MOR-1K isoforms in nociceptive signaling and suggest that genetic variations in alternative <\\entity><\\entity> isoforms may contribute to individual differences in opiate responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15662",
    "Sentence": "Our results provide evidence for an essential role for MOR-1K isoforms in nociceptive signaling and suggest that genetic variations in alternative OPRM1 isoforms may contribute to individual differences in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15663",
    "Sentence": "There are substantial individual differences in human responses to painful stimuli and to opiate drugs that are attributed to genetic variations in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15664",
    "Sentence": "There are substantial individual differences in human <\\entity><\\entity> and to opiate drugs that are attributed to genetic variations in OPRM1.",
    "Label": ""
  },
  {
    "id": "15666",
    "Sentence": "Examination of polymorphisms within the human <\\entity><\\entity> gene locus identified strong association between single nucleotide polymorphism (SNP) rs563649 and individual variations in pain perception.",
    "Label": ""
  },
  {
    "id": "15667",
    "Sentence": "Examination of polymorphisms within the human OPRM1 gene locus identified strong association between single nucleotide polymorphism (SNP) rs563649 and individual variations in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15669",
    "Sentence": "Examination of polymorphisms within the human OPRM1 gene locus identified strong association between single nucleotide polymorphism (SNP) <\\entity><\\entity> and individual variations in pain perception.",
    "Label": ""
  },
  {
    "id": "15670",
    "Sentence": "Examination of polymorphisms within the human OPRM1 gene locus identified strong association between single nucleotide polymorphism (SNP) rs563649 and individual variations in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15672",
    "Sentence": "Our results provide evidence for an essential role for MOR-1K isoforms in nociceptive signaling and suggest that genetic variations in alternative <\\entity><\\entity> isoforms may contribute to individual differences in opiate responses.",
    "Label": ""
  },
  {
    "id": "15673",
    "Sentence": "Our results provide evidence for an essential role for MOR-1K isoforms in nociceptive signaling and suggest that genetic variations in alternative OPRM1 isoforms may contribute to individual differences in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15675",
    "Sentence": "Our results provide evidence for an essential role for <\\entity><\\entity> isoforms in nociceptive signaling and suggest that genetic variations in alternative OPRM1 isoforms may contribute to individual differences in opiate responses.",
    "Label": ""
  },
  {
    "id": "15676",
    "Sentence": "Our results provide evidence for an essential role for MOR-1K isoforms in <\\entity><\\entity> and suggest that genetic variations in alternative OPRM1 isoforms may contribute to individual differences in opiate responses.",
    "Label": ""
  },
  {
    "id": "15682",
    "Sentence": "Association between donor <\\entity><\\entity> and graft survival and the development of BOS after lung transplantation.BACKGROUND: Lung transplantation is a well accepted therapy for end-stage lung disease, despite high mortality rates.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15683",
    "Sentence": "Association between donor <\\entity><\\entity> and graft survival and the development of BOS after lung transplantation.BACKGROUND: Lung transplantation is a well accepted therapy for end-stage lung disease, despite high mortality rates.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15684",
    "Sentence": "Association between donor MBL promoter haplotype and graft survival and the development of <\\entity><\\entity> after lung transplantation.BACKGROUND: Lung transplantation is a well accepted therapy for end-stage lung disease, despite high mortality rates.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15685",
    "Sentence": "Association between donor MBL promoter haplotype and graft survival and the development of BOS after lung transplantation.BACKGROUND: Lung transplantation is a well accepted therapy for <\\entity><\\entity>, despite high mortality rates.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15686",
    "Sentence": "<\\entity><\\entity> (MBL), a recognition molecule of innate immunity, has been associated with transplant outcome in other solid organ transplantation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15687",
    "Sentence": "Mannose binding lectin (<\\entity><\\entity>), a recognition molecule of innate immunity, has been associated with transplant outcome in other solid organ transplantation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15688",
    "Sentence": "In this study, the effect of donor- and recipient-<\\entity><\\entity> genotype on lung transplant outcome was investigated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15689",
    "Sentence": "Genotyping of the <\\entity><\\entity> variants (promoter: L/H, Y/X, and P/Q allele and exon 1: A/D, A/B, and A/C allele) was performed in donor and recipient DNA.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15690",
    "Sentence": "Genotyping of the MBL2 variants (promoter: <\\entity><\\entity>, Y/X, and P/Q allele and exon 1: A/D, A/B, and A/C allele) was performed in donor and recipient DNA.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15691",
    "Sentence": "Genotyping of the MBL2 variants (promoter: L/H, <\\entity><\\entity>, and P/Q allele and exon 1: A/D, A/B, and A/C allele) was performed in donor and recipient DNA.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15692",
    "Sentence": "Genotyping of the MBL2 variants (promoter: L/H, Y/X, and <\\entity><\\entity> and exon 1: A/D, A/B, and A/C allele) was performed in donor and recipient DNA.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15693",
    "Sentence": "Genotyping of the MBL2 variants (promoter: L/H, Y/X, and P/Q allele and exon 1: <\\entity><\\entity>, A/B, and A/C allele) was performed in donor and recipient DNA.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15694",
    "Sentence": "Genotyping of the MBL2 variants (promoter: L/H, Y/X, and P/Q allele and exon 1: A/D, <\\entity><\\entity>, and A/C allele) was performed in donor and recipient DNA.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15695",
    "Sentence": "Genotyping of the MBL2 variants (promoter: L/H, Y/X, and P/Q allele and exon 1: A/D, A/B, and <\\entity><\\entity>) was performed in donor and recipient DNA.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15696",
    "Sentence": "Analyses on graft survival and the development of <\\entity><\\entity> were performed with Kaplan-Meier (log rank) survival analysis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15697",
    "Sentence": "Analyses on graft survival and the development of bronchiolitis obliterans syndrome were performed with Kaplan-Meier (log <\\entity><\\entity>) survival analysis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15698",
    "Sentence": "Patients who received a graft from a donor with an <\\entity><\\entity> had better graft survival (P=0.007) and bronchiolitis obliterans syndrome free survival (P=0.007).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15699",
    "Sentence": "Patients who received a graft from a donor with an X-allele had better graft survival (P=0.007) and <\\entity><\\entity> free survival (P=0.007).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15700",
    "Sentence": "Recipient <\\entity><\\entity> genotype was not associated with transplant outcome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15701",
    "Sentence": "CONCLUSION: The donor <\\entity><\\entity>, which corresponds to the LXPA haplotype is associated with superior lung transplant outcome.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15702",
    "Sentence": "CONCLUSION: The donor X-allele, which corresponds to the <\\entity><\\entity> is associated with superior lung transplant outcome.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15703",
    "Sentence": "CONCLUSION: The donor X-allele, which corresponds to the <\\entity><\\entity> is associated with superior lung transplant outcome.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15704",
    "Sentence": "Association between donor <\\entity><\\entity> and graft survival and the development of BOS after lung transplantation.BACKGROUND: Lung transplantation is a well accepted therapy for end-stage lung disease, despite high mortality rates.",
    "Label": ""
  },
  {
    "id": "15705",
    "Sentence": "Association between donor MBL promoter haplotype and graft survival and the development of <\\entity><\\entity> after lung transplantation.BACKGROUND: Lung transplantation is a well accepted therapy for end-stage lung disease, despite high mortality rates.",
    "Label": ""
  },
  {
    "id": "15707",
    "Sentence": "Patients who received a graft from a donor with an <\\entity><\\entity> had better graft survival (P=0.007) and bronchiolitis obliterans syndrome free survival (P=0.007).",
    "Label": ""
  },
  {
    "id": "15708",
    "Sentence": "Patients who received a graft from a donor with an X-allele had better graft survival (P=0.007) and <\\entity><\\entity> free survival (P=0.007).",
    "Label": ""
  },
  {
    "id": "15710",
    "Sentence": "Analyses on graft survival and the development of bronchiolitis obliterans syndrome were performed with Kaplan-Meier (log <\\entity><\\entity>) survival analysis.",
    "Label": ""
  },
  {
    "id": "15711",
    "Sentence": "Analyses on graft survival and the development of <\\entity><\\entity> were performed with Kaplan-Meier (log rank) survival analysis.",
    "Label": ""
  },
  {
    "id": "15717",
    "Sentence": "<\\entity><\\entity> genomics: towards a new understanding.Recent genetics and genomics studies of prostate cancer have helped to clarify the genetic basis of this common but complex disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15718",
    "Sentence": "Prostate cancer genomics: towards a new understanding.Recent genetics and genomics studies of <\\entity><\\entity> have helped to clarify the genetic basis of this common but complex disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15719",
    "Sentence": "Prostate cancer genomics: towards a new understanding.Recent genetics and genomics studies of prostate cancer have helped to clarify the genetic basis of this common but complex <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15720",
    "Sentence": "Genome-wide studies have detected numerous variants associated with <\\entity><\\entity> as well as common gene fusions and expression 'signatures' in prostate tumours.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15721",
    "Sentence": "Genome-wide studies have detected numerous variants associated with disease as well as common <\\entity><\\entity> and expression 'signatures' in prostate tumours.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15722",
    "Sentence": "Genome-wide studies have detected numerous variants associated with disease as well as common <\\entity><\\entity> and expression 'signatures' in prostate tumours.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15723",
    "Sentence": "Genome-wide studies have detected numerous variants associated with disease as well as common gene fusions and <\\entity><\\entity> in prostate tumours.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15724",
    "Sentence": "Genome-wide studies have detected numerous variants associated with disease as well as common gene fusions and expression 'signatures' in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15725",
    "Sentence": "On the basis of these results, some advocate gene-based individualized screening for <\\entity><\\entity>, although such testing might only be worthwhile to distinguish disease aggressiveness.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15726",
    "Sentence": "On the basis of these results, some advocate gene-based individualized screening for prostate cancer, although such testing might only be worthwhile to distinguish <\\entity><\\entity> aggressiveness.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15727",
    "Sentence": "On the basis of these results, some advocate gene-based individualized screening for prostate cancer, although such testing might only be worthwhile to distinguish disease <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15728",
    "Sentence": "Lessons learned from these studies provide strategies for further deciphering the genetic causes of <\\entity><\\entity> and other diseases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15729",
    "Sentence": "Lessons learned from these studies provide strategies for further deciphering the genetic causes of prostate cancer and other <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15730",
    "Sentence": "Genome-wide studies have detected numerous variants associated with disease as well as common <\\entity><\\entity> and expression 'signatures' in prostate tumours.",
    "Label": ""
  },
  {
    "id": "15731",
    "Sentence": "Genome-wide studies have detected numerous variants associated with disease as well as common gene fusions and expression 'signatures' in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15733",
    "Sentence": "Genome-wide studies have detected numerous variants associated with disease as well as common gene fusions and <\\entity><\\entity> in prostate tumours.",
    "Label": ""
  },
  {
    "id": "15734",
    "Sentence": "Genome-wide studies have detected numerous variants associated with disease as well as common gene fusions and expression 'signatures' in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15740",
    "Sentence": "Variations in the <\\entity><\\entity> gene impact on survival of patients with advanced colorectal cancer.The <\\entity><\\entity> (IL-1RA) cytokine is thought to counteract tumor angiogenesis/metastasis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15741",
    "Sentence": "Variations in the interleukin-1 receptor antagonist gene impact on <\\entity><\\entity> of patients with advanced colorectal cancer.The interleukin-1 receptor antagonist (IL-1RA) cytokine is thought to counteract tumor angiogenesis/metastasis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15742",
    "Sentence": "Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced <\\entity><\\entity>.The interleukin-1 receptor antagonist (IL-1RA) cytokine is thought to counteract tumor angiogenesis/metastasis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15743",
    "Sentence": "Variations in the <\\entity><\\entity> gene impact on survival of patients with advanced colorectal cancer.The <\\entity><\\entity> (IL-1RA) cytokine is thought to counteract tumor angiogenesis/metastasis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15744",
    "Sentence": "Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer.The interleukin-1 receptor antagonist (<\\entity><\\entity>) cytokine is thought to counteract tumor angiogenesis/metastasis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15745",
    "Sentence": "Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer.The interleukin-1 receptor antagonist (IL-1RA) cytokine is thought to counteract <\\entity><\\entity>/metastasis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15746",
    "Sentence": "Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer.The interleukin-1 receptor antagonist (IL-1RA) cytokine is thought to counteract tumor angiogenesis/<\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15747",
    "Sentence": "Two single nucleotide polymorphisms in the <\\entity><\\entity> gene (rs4251961 T/C and rs579543 C/T) influence <\\entity><\\entity> circulating levels with highest production in carriers of the homozygous rs4251961 T/T and rs579543 T/T genotypes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15748",
    "Sentence": "Two single nucleotide polymorphisms in the IL-1RA gene (<\\entity><\\entity> and rs579543 C/T) influence IL-1RA circulating levels with highest production in carriers of the homozygous rs4251961 T/T and rs579543 T/T genotypes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15749",
    "Sentence": "Two single nucleotide polymorphisms in the IL-1RA gene (rs4251961 T/C and <\\entity><\\entity>) influence IL-1RA circulating levels with highest production in carriers of the homozygous rs4251961 T/T and rs579543 T/T genotypes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15750",
    "Sentence": "Two single nucleotide polymorphisms in the <\\entity><\\entity> gene (rs4251961 T/C and rs579543 C/T) influence <\\entity><\\entity> circulating levels with highest production in carriers of the homozygous rs4251961 T/T and rs579543 T/T genotypes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15751",
    "Sentence": "Two single nucleotide polymorphisms in the IL-1RA gene (rs4251961 T/C and rs579543 C/T) influence IL-1RA circulating levels with highest production in carriers of the homozygous <\\entity><\\entity> and rs579543 T/T genotypes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15752",
    "Sentence": "Two single nucleotide polymorphisms in the IL-1RA gene (rs4251961 T/C and rs579543 C/T) influence IL-1RA circulating levels with highest production in carriers of the homozygous rs4251961 T/T and <\\entity><\\entity> genotypes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15753",
    "Sentence": "A total of 180 patients with <\\entity><\\entity> were categorized as high IL-1RA producers if they were carriers of at least one of the rs4251961 T/T or rs579543 T/T genotypes (T/T carriers).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15754",
    "Sentence": "A total of 180 patients with metastatic colorectal cancer were categorized as high <\\entity><\\entity> producers if they were carriers of at least one of the rs4251961 T/T or rs579543 T/T genotypes (T/T carriers).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15755",
    "Sentence": "A total of 180 patients with metastatic colorectal cancer were categorized as high IL-1RA producers if they were carriers of at least one of the <\\entity><\\entity> or rs579543 T/T genotypes (T/T carriers).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15756",
    "Sentence": "A total of 180 patients with metastatic colorectal cancer were categorized as high IL-1RA producers if they were carriers of at least one of the rs4251961 T/T or <\\entity><\\entity> genotypes (T/T carriers).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15757",
    "Sentence": "A total of 180 patients with metastatic colorectal cancer were categorized as high IL-1RA producers if they were carriers of at least one of the rs4251961 <\\entity><\\entity> or rs579543 <\\entity><\\entity> genotypes (<\\entity><\\entity> carriers).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15758",
    "Sentence": "Median <\\entity><\\entity> times were 35.8 months (95% confidence interval: 29.7-43.7 months) and 28.6 months (95% confidence interval: 25.6-30 months) in 56 T/T carriers and in 124 non-T/T carriers, respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15759",
    "Sentence": "Median survival times were 35.8 months (95% confidence interval: 29.7-43.7 months) and 28.6 months (95% confidence interval: 25.6-30 months) in 56 <\\entity><\\entity> carriers and in 124 non-<\\entity><\\entity> carriers, respectively.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15760",
    "Sentence": "Median survival times were 35.8 months (95% confidence interval: 29.7-43.7 months) and 28.6 months (95% confidence interval: 25.6-30 months) in 56 T/T carriers and in 124 <\\entity><\\entity> carriers, respectively.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15761",
    "Sentence": "The favorable association between <\\entity><\\entity> carriers' status and survival was significant in the multivariate analysis (P=0.018).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15762",
    "Sentence": "The favorable association between T/T carriers' status and <\\entity><\\entity> was significant in the multivariate analysis (P=0.018).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15763",
    "Sentence": "Also, <\\entity><\\entity> carriers and non-<\\entity><\\entity> carriers were prevalent among patients with Karnofsky performance status 90-100 and 70-80, respectively (P=0.002).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15764",
    "Sentence": "Also, T/T carriers and <\\entity><\\entity> carriers were prevalent among patients with Karnofsky performance status 90-100 and 70-80, respectively (P=0.002).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15765",
    "Sentence": "Also, T/T carriers and non-T/T carriers were prevalent among patients with Karnofsky <\\entity><\\entity> 90-100 and 70-80, respectively (P=0.002).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15766",
    "Sentence": "These findings encourage additional studies in this field and the evaluation of a recombinant-<\\entity><\\entity> for anticancer activity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15767",
    "Sentence": "These findings encourage additional studies in this field and the evaluation of a recombinant-IL-1RA for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15768",
    "Sentence": "Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer.The interleukin-1 receptor antagonist (<\\entity><\\entity>) cytokine is thought to counteract tumor angiogenesis/metastasis.",
    "Label": ""
  },
  {
    "id": "15769",
    "Sentence": "Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer.The interleukin-1 receptor antagonist (IL-1RA) cytokine is thought to counteract <\\entity><\\entity>/metastasis.",
    "Label": ""
  },
  {
    "id": "15771",
    "Sentence": "Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer.The interleukin-1 receptor antagonist (<\\entity><\\entity>) cytokine is thought to counteract tumor angiogenesis/metastasis.",
    "Label": ""
  },
  {
    "id": "15772",
    "Sentence": "Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer.The interleukin-1 receptor antagonist (IL-1RA) cytokine is thought to counteract tumor angiogenesis/<\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15774",
    "Sentence": "Variations in the <\\entity><\\entity> gene impact on survival of patients with advanced colorectal cancer.The <\\entity><\\entity> (IL-1RA) cytokine is thought to counteract tumor angiogenesis/metastasis.",
    "Label": ""
  },
  {
    "id": "15775",
    "Sentence": "Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced <\\entity><\\entity>.The interleukin-1 receptor antagonist (IL-1RA) cytokine is thought to counteract tumor angiogenesis/metastasis.",
    "Label": ""
  },
  {
    "id": "15777",
    "Sentence": "A total of 180 patients with metastatic colorectal cancer were categorized as high <\\entity><\\entity> producers if they were carriers of at least one of the rs4251961 T/T or rs579543 T/T genotypes (T/T carriers).",
    "Label": ""
  },
  {
    "id": "15778",
    "Sentence": "A total of 180 patients with <\\entity><\\entity> were categorized as high IL-1RA producers if they were carriers of at least one of the rs4251961 T/T or rs579543 T/T genotypes (T/T carriers).",
    "Label": ""
  },
  {
    "id": "15780",
    "Sentence": "A total of 180 patients with metastatic colorectal cancer were categorized as high IL-1RA producers if they were carriers of at least one of the <\\entity><\\entity> or rs579543 T/T genotypes (T/T carriers).",
    "Label": ""
  },
  {
    "id": "15781",
    "Sentence": "A total of 180 patients with <\\entity><\\entity> were categorized as high IL-1RA producers if they were carriers of at least one of the rs4251961 T/T or rs579543 T/T genotypes (T/T carriers).",
    "Label": ""
  },
  {
    "id": "15783",
    "Sentence": "A total of 180 patients with metastatic colorectal cancer were categorized as high IL-1RA producers if they were carriers of at least one of the rs4251961 T/T or <\\entity><\\entity> genotypes (T/T carriers).",
    "Label": ""
  },
  {
    "id": "15784",
    "Sentence": "A total of 180 patients with <\\entity><\\entity> were categorized as high IL-1RA producers if they were carriers of at least one of the rs4251961 T/T or rs579543 T/T genotypes (T/T carriers).",
    "Label": ""
  },
  {
    "id": "15786",
    "Sentence": "Variations in the <\\entity><\\entity> gene impact on survival of patients with advanced colorectal cancer.The <\\entity><\\entity> (IL-1RA) cytokine is thought to counteract tumor angiogenesis/metastasis.",
    "Label": ""
  },
  {
    "id": "15787",
    "Sentence": "Variations in the interleukin-1 receptor antagonist gene impact on <\\entity><\\entity> of patients with advanced colorectal cancer.The interleukin-1 receptor antagonist (IL-1RA) cytokine is thought to counteract tumor angiogenesis/metastasis.",
    "Label": ""
  },
  {
    "id": "15789",
    "Sentence": "Variations in the <\\entity><\\entity> gene impact on survival of patients with advanced colorectal cancer.The <\\entity><\\entity> (IL-1RA) cytokine is thought to counteract tumor angiogenesis/metastasis.",
    "Label": ""
  },
  {
    "id": "15790",
    "Sentence": "Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer.The interleukin-1 receptor antagonist (IL-1RA) cytokine is thought to counteract <\\entity><\\entity>/metastasis.",
    "Label": ""
  },
  {
    "id": "15792",
    "Sentence": "Variations in the <\\entity><\\entity> gene impact on survival of patients with advanced colorectal cancer.The <\\entity><\\entity> (IL-1RA) cytokine is thought to counteract tumor angiogenesis/metastasis.",
    "Label": ""
  },
  {
    "id": "15793",
    "Sentence": "Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer.The interleukin-1 receptor antagonist (IL-1RA) cytokine is thought to counteract tumor angiogenesis/<\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15795",
    "Sentence": "A total of 180 patients with metastatic colorectal cancer were categorized as high IL-1RA producers if they were carriers of at least one of the rs4251961 <\\entity><\\entity> or rs579543 <\\entity><\\entity> genotypes (<\\entity><\\entity> carriers).",
    "Label": ""
  },
  {
    "id": "15796",
    "Sentence": "A total of 180 patients with <\\entity><\\entity> were categorized as high IL-1RA producers if they were carriers of at least one of the rs4251961 T/T or rs579543 T/T genotypes (T/T carriers).",
    "Label": ""
  },
  {
    "id": "15798",
    "Sentence": "The favorable association between <\\entity><\\entity> carriers' status and survival was significant in the multivariate analysis (P=0.018).",
    "Label": ""
  },
  {
    "id": "15799",
    "Sentence": "The favorable association between T/T carriers' status and <\\entity><\\entity> was significant in the multivariate analysis (P=0.018).",
    "Label": ""
  },
  {
    "id": "15801",
    "Sentence": "Also, <\\entity><\\entity> carriers and non-<\\entity><\\entity> carriers were prevalent among patients with Karnofsky performance status 90-100 and 70-80, respectively (P=0.002).",
    "Label": ""
  },
  {
    "id": "15802",
    "Sentence": "Also, T/T carriers and non-T/T carriers were prevalent among patients with Karnofsky <\\entity><\\entity> 90-100 and 70-80, respectively (P=0.002).",
    "Label": ""
  },
  {
    "id": "15804",
    "Sentence": "Also, T/T carriers and <\\entity><\\entity> carriers were prevalent among patients with Karnofsky performance status 90-100 and 70-80, respectively (P=0.002).",
    "Label": ""
  },
  {
    "id": "15805",
    "Sentence": "Also, T/T carriers and non-T/T carriers were prevalent among patients with Karnofsky <\\entity><\\entity> 90-100 and 70-80, respectively (P=0.002).",
    "Label": ""
  },
  {
    "id": "15807",
    "Sentence": "These findings encourage additional studies in this field and the evaluation of a recombinant-<\\entity><\\entity> for anticancer activity.",
    "Label": ""
  },
  {
    "id": "15808",
    "Sentence": "These findings encourage additional studies in this field and the evaluation of a recombinant-IL-1RA for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15814",
    "Sentence": "Genetic analysis of the <\\entity><\\entity> gene in two epithelial cancers: melanoma and breast cancer case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, cancer risk.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15815",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial <\\entity><\\entity>: melanoma and breast cancer case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, cancer risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15816",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial cancers: <\\entity><\\entity> and breast cancer case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, cancer risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15817",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and <\\entity><\\entity> case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, cancer risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15818",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies.BACKGROUND: <\\entity><\\entity> serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, cancer risk.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15819",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with <\\entity><\\entity>, growth control and consequently, cancer risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15820",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell differentiation, <\\entity><\\entity> control and consequently, cancer risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15821",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial <\\entity><\\entity>s: melanoma and breast <\\entity><\\entity> case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, <\\entity><\\entity> risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15822",
    "Sentence": "<\\entity><\\entity> (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15823",
    "Sentence": "Vitamin D receptor (<\\entity><\\entity>) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15824",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence <\\entity><\\entity> risk; however, no epidemiological studies in sporadic breast <\\entity><\\entity> (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15825",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in <\\entity><\\entity> (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15826",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (<\\entity><\\entity>) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15827",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or <\\entity><\\entity> (MM) have been performed in a southern European population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15828",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (<\\entity><\\entity>) have been performed in a southern European population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15829",
    "Sentence": "In this study, the <\\entity><\\entity> gene has been evaluated in two epithelial cancers BC and MM.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15830",
    "Sentence": "In this study, the VDR gene has been evaluated in two epithelial <\\entity><\\entity> BC and MM.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15831",
    "Sentence": "In this study, the VDR gene has been evaluated in two epithelial cancers <\\entity><\\entity> and MM.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15832",
    "Sentence": "In this study, the VDR gene has been evaluated in two epithelial cancers BC and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15833",
    "Sentence": "METHODS: We have conducted an analysis in 549 consecutive and non-related <\\entity><\\entity> cases and 556 controls, all from the Spanish population, and 283 MM cases and 245 controls.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15834",
    "Sentence": "METHODS: We have conducted an analysis in 549 consecutive and non-related sporadic BC cases and 556 controls, all from the Spanish population, and 283 <\\entity><\\entity> cases and 245 controls.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15835",
    "Sentence": "Genotyping analyses were carried out on four putatively functional SNPs within the <\\entity><\\entity> gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15836",
    "Sentence": "RESULTS: An association with the <\\entity><\\entity> of the non-synonymous SNP rs2228570 (rs10735810, FokI, Met1Thr) was observed for BC, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15837",
    "Sentence": "RESULTS: An association with the <\\entity><\\entity> of the non-synonymous SNP rs2228570 (rs10735810, FokI, Met1Thr) was observed for BC, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15838",
    "Sentence": "RESULTS: An association with the minor allele A of the non-synonymous SNP <\\entity><\\entity> (rs10735810, FokI, Met1Thr) was observed for BC, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15839",
    "Sentence": "RESULTS: An association with the minor allele A of the non-synonymous SNP rs2228570 (<\\entity><\\entity>, FokI, Met1Thr) was observed for BC, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15840",
    "Sentence": "RESULTS: An association with the minor allele A of the non-synonymous SNP rs2228570 (rs10735810, <\\entity><\\entity>, Met1Thr) was observed for BC, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15841",
    "Sentence": "RESULTS: An association with the minor allele A of the non-synonymous SNP rs2228570 (rs10735810, FokI, <\\entity><\\entity>) was observed for BC, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15842",
    "Sentence": "RESULTS: An association with the minor allele A of the non-synonymous SNP rs2228570 (rs10735810, FokI, <\\entity><\\entity>) was observed for BC, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15843",
    "Sentence": "RESULTS: An association with the minor allele A of the non-synonymous SNP rs2228570 (rs10735810, FokI, Met1Thr) was observed for <\\entity><\\entity>, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15844",
    "Sentence": "The synonymous variant <\\entity><\\entity> (TaqI) appeared to be associated with protection from BC (OR = 0.80, 95%CI = 0.64-0.99; p = 0.047).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15845",
    "Sentence": "The synonymous variant rs731236 (<\\entity><\\entity>) appeared to be associated with protection from BC (OR = 0.80, 95%CI = 0.64-0.99; p = 0.047).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15846",
    "Sentence": "The synonymous variant rs731236 (TaqI) appeared to be associated with protection from <\\entity><\\entity> (OR = 0.80, 95%CI = 0.64-0.99; p = 0.047).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15847",
    "Sentence": "No statistically significant associations with <\\entity><\\entity> were observed for any SNP.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15848",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between <\\entity><\\entity> (FokI) and absence of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more aggressive tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15849",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (<\\entity><\\entity>) and absence of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more aggressive tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15850",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (FokI) and <\\entity><\\entity> of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more aggressive tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15851",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (FokI) and absence of <\\entity><\\entity> (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more aggressive tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15852",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (FokI) and absence of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr SNP <\\entity><\\entity> (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more aggressive tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15853",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (FokI) and absence of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (<\\entity><\\entity>) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more aggressive tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15854",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (FokI) and absence of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP <\\entity><\\entity> and the more aggressive tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15855",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (FokI) and absence of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more <\\entity><\\entity> tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15856",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (FokI) and absence of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more aggressive <\\entity><\\entity> location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15857",
    "Sentence": "CONCLUSION: In summary, we observed associations between <\\entity><\\entity> gene and BC risk, and a comprehensive analysis using clinical and tumour characteristics as outcome variables has revealed potential associations with MM.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15858",
    "Sentence": "CONCLUSION: In summary, we observed associations between <\\entity><\\entity> gene and BC risk, and a comprehensive analysis using clinical and tumour characteristics as outcome variables has revealed potential associations with MM.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15859",
    "Sentence": "CONCLUSION: In summary, we observed associations between SNPs in the VDR gene and <\\entity><\\entity> risk, and a comprehensive analysis using clinical and tumour characteristics as outcome variables has revealed potential associations with MM.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15860",
    "Sentence": "CONCLUSION: In summary, we observed associations between SNPs in the VDR gene and BC risk, and a comprehensive analysis using clinical and <\\entity><\\entity> characteristics as outcome variables has revealed potential associations with MM.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15861",
    "Sentence": "CONCLUSION: In summary, we observed associations between SNPs in the VDR gene and BC risk, and a comprehensive analysis using clinical and tumour characteristics as outcome variables has revealed potential associations with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15862",
    "Sentence": "Vitamin D receptor (<\\entity><\\entity>) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15863",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in <\\entity><\\entity> (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15865",
    "Sentence": "Vitamin D receptor (<\\entity><\\entity>) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15866",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or <\\entity><\\entity> (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15868",
    "Sentence": "Vitamin D receptor (<\\entity><\\entity>) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15869",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (<\\entity><\\entity>) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15871",
    "Sentence": "Vitamin D receptor (<\\entity><\\entity>) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15872",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (<\\entity><\\entity>) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15874",
    "Sentence": "RESULTS: An association with the minor allele A of the non-synonymous SNP rs2228570 (<\\entity><\\entity>, FokI, Met1Thr) was observed for BC, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": ""
  },
  {
    "id": "15875",
    "Sentence": "RESULTS: An association with the minor allele A of the non-synonymous SNP rs2228570 (rs10735810, FokI, Met1Thr) was observed for <\\entity><\\entity>, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": ""
  },
  {
    "id": "15877",
    "Sentence": "The synonymous variant <\\entity><\\entity> (TaqI) appeared to be associated with protection from BC (OR = 0.80, 95%CI = 0.64-0.99; p = 0.047).",
    "Label": ""
  },
  {
    "id": "15878",
    "Sentence": "The synonymous variant rs731236 (TaqI) appeared to be associated with protection from <\\entity><\\entity> (OR = 0.80, 95%CI = 0.64-0.99; p = 0.047).",
    "Label": ""
  },
  {
    "id": "15880",
    "Sentence": "CONCLUSION: In summary, we observed associations between <\\entity><\\entity> gene and BC risk, and a comprehensive analysis using clinical and tumour characteristics as outcome variables has revealed potential associations with MM.",
    "Label": ""
  },
  {
    "id": "15881",
    "Sentence": "CONCLUSION: In summary, we observed associations between SNPs in the VDR gene and BC risk, and a comprehensive analysis using clinical and tumour characteristics as outcome variables has revealed potential associations with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15883",
    "Sentence": "CONCLUSION: In summary, we observed associations between <\\entity><\\entity> gene and BC risk, and a comprehensive analysis using clinical and tumour characteristics as outcome variables has revealed potential associations with MM.",
    "Label": ""
  },
  {
    "id": "15884",
    "Sentence": "CONCLUSION: In summary, we observed associations between SNPs in the VDR gene and <\\entity><\\entity> risk, and a comprehensive analysis using clinical and tumour characteristics as outcome variables has revealed potential associations with MM.",
    "Label": ""
  },
  {
    "id": "15886",
    "Sentence": "Genetic analysis of the <\\entity><\\entity> gene in two epithelial cancers: melanoma and breast cancer case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, cancer risk.",
    "Label": ""
  },
  {
    "id": "15887",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial <\\entity><\\entity>: melanoma and breast cancer case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, cancer risk.",
    "Label": ""
  },
  {
    "id": "15889",
    "Sentence": "Genetic analysis of the <\\entity><\\entity> gene in two epithelial cancers: melanoma and breast cancer case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, cancer risk.",
    "Label": ""
  },
  {
    "id": "15890",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial cancers: <\\entity><\\entity> and breast cancer case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, cancer risk.",
    "Label": ""
  },
  {
    "id": "15892",
    "Sentence": "Genetic analysis of the <\\entity><\\entity> gene in two epithelial cancers: melanoma and breast cancer case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, cancer risk.",
    "Label": ""
  },
  {
    "id": "15893",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and <\\entity><\\entity> case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, cancer risk.",
    "Label": ""
  },
  {
    "id": "15895",
    "Sentence": "Vitamin D receptor (<\\entity><\\entity>) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15896",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence <\\entity><\\entity> risk; however, no epidemiological studies in sporadic breast <\\entity><\\entity> (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15898",
    "Sentence": "In this study, the <\\entity><\\entity> gene has been evaluated in two epithelial cancers BC and MM.",
    "Label": ""
  },
  {
    "id": "15899",
    "Sentence": "In this study, the VDR gene has been evaluated in two epithelial <\\entity><\\entity> BC and MM.",
    "Label": ""
  },
  {
    "id": "15901",
    "Sentence": "CONCLUSION: In summary, we observed associations between <\\entity><\\entity> gene and BC risk, and a comprehensive analysis using clinical and tumour characteristics as outcome variables has revealed potential associations with MM.",
    "Label": ""
  },
  {
    "id": "15902",
    "Sentence": "CONCLUSION: In summary, we observed associations between SNPs in the VDR gene and BC risk, and a comprehensive analysis using clinical and <\\entity><\\entity> characteristics as outcome variables has revealed potential associations with MM.",
    "Label": ""
  },
  {
    "id": "15904",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies.BACKGROUND: <\\entity><\\entity> serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, cancer risk.",
    "Label": ""
  },
  {
    "id": "15905",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial <\\entity><\\entity>s: melanoma and breast <\\entity><\\entity> case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, <\\entity><\\entity> risk.",
    "Label": ""
  },
  {
    "id": "15907",
    "Sentence": "In this study, the <\\entity><\\entity> gene has been evaluated in two epithelial cancers BC and MM.",
    "Label": ""
  },
  {
    "id": "15908",
    "Sentence": "In this study, the VDR gene has been evaluated in two epithelial cancers <\\entity><\\entity> and MM.",
    "Label": ""
  },
  {
    "id": "15910",
    "Sentence": "In this study, the <\\entity><\\entity> gene has been evaluated in two epithelial cancers BC and MM.",
    "Label": ""
  },
  {
    "id": "15911",
    "Sentence": "In this study, the VDR gene has been evaluated in two epithelial cancers BC and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "15913",
    "Sentence": "RESULTS: An association with the minor allele A of the non-synonymous SNP <\\entity><\\entity> (rs10735810, FokI, Met1Thr) was observed for BC, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": ""
  },
  {
    "id": "15914",
    "Sentence": "RESULTS: An association with the minor allele A of the non-synonymous SNP rs2228570 (rs10735810, FokI, Met1Thr) was observed for <\\entity><\\entity>, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": ""
  },
  {
    "id": "15916",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between <\\entity><\\entity> (FokI) and absence of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more aggressive tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": ""
  },
  {
    "id": "15917",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (FokI) and absence of <\\entity><\\entity> (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more aggressive tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": ""
  },
  {
    "id": "15919",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (FokI) and absence of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP <\\entity><\\entity> and the more aggressive tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": ""
  },
  {
    "id": "15920",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (FokI) and absence of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more <\\entity><\\entity> tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": ""
  },
  {
    "id": "15922",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies.BACKGROUND: <\\entity><\\entity> serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, cancer risk.",
    "Label": ""
  },
  {
    "id": "15923",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell differentiation, <\\entity><\\entity> control and consequently, cancer risk.",
    "Label": ""
  },
  {
    "id": "15925",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies.BACKGROUND: <\\entity><\\entity> serum levels have been found to be related to sun exposure and diet, together with cell differentiation, growth control and consequently, cancer risk.",
    "Label": ""
  },
  {
    "id": "15926",
    "Sentence": "Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies.BACKGROUND: Vitamin D serum levels have been found to be related to sun exposure and diet, together with <\\entity><\\entity>, growth control and consequently, cancer risk.",
    "Label": ""
  },
  {
    "id": "15928",
    "Sentence": "<\\entity><\\entity> (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15929",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (<\\entity><\\entity>) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15931",
    "Sentence": "<\\entity><\\entity> (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15932",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (<\\entity><\\entity>) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15934",
    "Sentence": "<\\entity><\\entity> (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15935",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or <\\entity><\\entity> (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15937",
    "Sentence": "<\\entity><\\entity> (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15938",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence <\\entity><\\entity> risk; however, no epidemiological studies in sporadic breast <\\entity><\\entity> (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15940",
    "Sentence": "<\\entity><\\entity> (VDR) genotypes may influence cancer risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15941",
    "Sentence": "Vitamin D receptor (VDR) genotypes may influence cancer risk; however, no epidemiological studies in <\\entity><\\entity> (BC) or malignant melanoma (MM) have been performed in a southern European population.",
    "Label": ""
  },
  {
    "id": "15943",
    "Sentence": "RESULTS: An association with the minor allele A of the non-synonymous SNP rs2228570 (rs10735810, <\\entity><\\entity>, Met1Thr) was observed for BC, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": ""
  },
  {
    "id": "15944",
    "Sentence": "RESULTS: An association with the minor allele A of the non-synonymous SNP rs2228570 (rs10735810, FokI, Met1Thr) was observed for <\\entity><\\entity>, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": ""
  },
  {
    "id": "15946",
    "Sentence": "RESULTS: An association with the minor allele A of the non-synonymous SNP rs2228570 (rs10735810, FokI, <\\entity><\\entity>) was observed for BC, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": ""
  },
  {
    "id": "15947",
    "Sentence": "RESULTS: An association with the minor allele A of the non-synonymous SNP rs2228570 (rs10735810, FokI, Met1Thr) was observed for <\\entity><\\entity>, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02-1.57; p = 0.036).",
    "Label": ""
  },
  {
    "id": "15949",
    "Sentence": "The synonymous variant rs731236 (<\\entity><\\entity>) appeared to be associated with protection from BC (OR = 0.80, 95%CI = 0.64-0.99; p = 0.047).",
    "Label": ""
  },
  {
    "id": "15950",
    "Sentence": "The synonymous variant rs731236 (TaqI) appeared to be associated with protection from <\\entity><\\entity> (OR = 0.80, 95%CI = 0.64-0.99; p = 0.047).",
    "Label": ""
  },
  {
    "id": "15952",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (FokI) and absence of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP <\\entity><\\entity> and the more aggressive tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": ""
  },
  {
    "id": "15953",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (FokI) and absence of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more aggressive <\\entity><\\entity> location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": ""
  },
  {
    "id": "15955",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (<\\entity><\\entity>) and absence of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more aggressive tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": ""
  },
  {
    "id": "15956",
    "Sentence": "Nevertheless, sub-group analyses revealed an association between rs2228570 (FokI) and absence of <\\entity><\\entity> (OR = 0.65, p = 0.003), between the 3'utr SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more aggressive tumour location in head-neck and trunk (OR = 1.54, p = 0.020).",
    "Label": ""
  },
  {
    "id": "15962",
    "Sentence": "<\\entity><\\entity> gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the <\\entity><\\entity> gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15963",
    "Sentence": "INSIG2 gene polymorphism is associated with increased <\\entity><\\entity> in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the INSIG2 gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15964",
    "Sentence": "INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and <\\entity><\\entity> in men.BACKGROUND: A common SNP upstream of the INSIG2 gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15965",
    "Sentence": "<\\entity><\\entity> gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the <\\entity><\\entity> gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15966",
    "Sentence": "INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the INSIG2 gene, <\\entity><\\entity> (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15967",
    "Sentence": "INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the INSIG2 gene, rs7566605 (<\\entity><\\entity>, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15968",
    "Sentence": "INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the INSIG2 gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with <\\entity><\\entity> (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15969",
    "Sentence": "As BMI is a relatively insensitive measure of <\\entity><\\entity> that is subject to many confounding variables, we sought to determine the relationship between the INSIG2 SNP and subcutaneous fat volumes measured by MRI in a young adult population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15970",
    "Sentence": "As BMI is a relatively insensitive measure of adiposity that is subject to many confounding variables, we sought to determine the relationship between the <\\entity><\\entity> and subcutaneous fat volumes measured by MRI in a young adult population.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15971",
    "Sentence": "As BMI is a relatively insensitive measure of adiposity that is subject to many confounding variables, we sought to determine the relationship between the <\\entity><\\entity> and subcutaneous fat volumes measured by MRI in a young adult population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15972",
    "Sentence": "As BMI is a relatively insensitive measure of adiposity that is subject to many confounding variables, we sought to determine the relationship between the INSIG2 SNP and <\\entity><\\entity> volumes measured by MRI in a young adult population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15973",
    "Sentence": "METHODS: We genotyped the <\\entity><\\entity> rs7566605 in college-aged population enrolled in a controlled resistance-training program, (the Functional Polymorphism Associated with Human Muscle Size and Strength, FAMuSS cohort, n = 752 volunteers 18-40 yrs).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15974",
    "Sentence": "METHODS: We genotyped the <\\entity><\\entity> rs7566605 in college-aged population enrolled in a controlled resistance-training program, (the Functional Polymorphism Associated with Human Muscle Size and Strength, FAMuSS cohort, n = 752 volunteers 18-40 yrs).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15975",
    "Sentence": "METHODS: We genotyped the INSIG2 SNP <\\entity><\\entity> in college-aged population enrolled in a controlled resistance-training program, (the Functional Polymorphism Associated with Human Muscle Size and Strength, FAMuSS cohort, n = 752 volunteers 18-40 yrs).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15976",
    "Sentence": "METHODS: We genotyped the INSIG2 SNP rs7566605 in college-aged population enrolled in a controlled resistance-training program, (the Functional Polymorphism Associated with Human Muscle Size and Strength, FAMuSS cohort, n = 752 volunteers 18-40 <\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15977",
    "Sentence": "In this longitudinal study, we examined the effect of the <\\entity><\\entity> on subcutaneous fat and muscle volumes of the upper arm measured by magnetic resonance imaging (MRI) before and after 12 wks of resistance training.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15978",
    "Sentence": "In this longitudinal study, we examined the effect of the <\\entity><\\entity> on subcutaneous fat and muscle volumes of the upper arm measured by magnetic resonance imaging (MRI) before and after 12 wks of resistance training.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15979",
    "Sentence": "In this longitudinal study, we examined the effect of the INSIG2 polymorphism on <\\entity><\\entity> and muscle volumes of the upper arm measured by magnetic resonance imaging (MRI) before and after 12 wks of resistance training.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15980",
    "Sentence": "In this longitudinal study, we examined the effect of the INSIG2 polymorphism on subcutaneous fat and muscle volumes of the upper arm measured by magnetic resonance imaging (MRI) before and after 12 wks of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15981",
    "Sentence": "Gene/phenotype associations were tested using an analysis of covariance model with age and <\\entity><\\entity> as covariates.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15982",
    "Sentence": "RESULTS: Women with a copy of the <\\entity><\\entity> had higher levels of baseline subcutaneous fat (GG: n = 139; 243473 +/- 5713 mm3 vs.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15983",
    "Sentence": "RESULTS: Women with a copy of the C allele had higher levels of baseline <\\entity><\\entity> (GG: n = 139; 243473 +/- 5713 mm3 vs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15984",
    "Sentence": "RESULTS: Women with a copy of the C allele had higher levels of baseline subcutaneous fat (<\\entity><\\entity>: n = 139; 243473 +/- 5713 mm3 vs.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15985",
    "Sentence": "<\\entity><\\entity>: n = 181; 268521 +/- 5003 mm3; p = 0.0011); but men did not show any such association.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15986",
    "Sentence": "Men homozygous for the <\\entity><\\entity> showed a loss of subcutaneous fat, while those with one or two copies of the C allele gained a greater percentage of subcutaneous fat with resistance training (GG: n = 103; 1.02% +/- 1.74% vs.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15987",
    "Sentence": "Men homozygous for the G ancestral allele showed a loss of <\\entity><\\entity>, while those with one or two copies of the C allele gained a greater percentage of <\\entity><\\entity> with resistance training (GG: n = 103; 1.02% +/- 1.74% vs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15988",
    "Sentence": "Men homozygous for the G ancestral allele showed a loss of subcutaneous fat, while those with one or two copies of the <\\entity><\\entity> gained a greater percentage of subcutaneous fat with resistance training (GG: n = 103; 1.02% +/- 1.74% vs.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15989",
    "Sentence": "Men homozygous for the G ancestral allele showed a loss of <\\entity><\\entity>, while those with one or two copies of the C allele gained a greater percentage of <\\entity><\\entity> with resistance training (GG: n = 103; 1.02% +/- 1.74% vs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15990",
    "Sentence": "Men homozygous for the G ancestral allele showed a loss of subcutaneous fat, while those with one or two copies of the C allele gained a greater percentage of subcutaneous fat with <\\entity><\\entity> (GG: n = 103; 1.02% +/- 1.74% vs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15991",
    "Sentence": "Men homozygous for the G ancestral allele showed a loss of subcutaneous fat, while those with one or two copies of the C allele gained a greater percentage of subcutaneous fat with resistance training (<\\entity><\\entity>: n = 103; 1.02% +/- 1.74% vs.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15992",
    "Sentence": "<\\entity><\\entity>: n = 93; 6.39% +/- 1.82%; p = 0.035).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15993",
    "Sentence": "CONCLUSION: Our results show that the <\\entity><\\entity> polymorphism underlies variation in subcutaneous adiposity in young adult women and suppresses the positive effects of resistance training on men.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15994",
    "Sentence": "CONCLUSION: Our results show that the <\\entity><\\entity> polymorphism underlies variation in subcutaneous adiposity in young adult women and suppresses the positive effects of resistance training on men.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "15995",
    "Sentence": "CONCLUSION: Our results show that the INSIG2 rs7566605 polymorphism underlies variation in subcutaneous <\\entity><\\entity> in young adult women and suppresses the positive effects of resistance training on men.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15996",
    "Sentence": "CONCLUSION: Our results show that the INSIG2 rs7566605 polymorphism underlies variation in subcutaneous adiposity in young adult women and suppresses the positive effects of <\\entity><\\entity> on men.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15997",
    "Sentence": "This supports and extends the original finding that there is an association between measures of <\\entity><\\entity> and INSIG2 rs7566605 and further implicates this polymorphism in fat regulation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "15998",
    "Sentence": "This supports and extends the original finding that there is an association between measures of obesity and <\\entity><\\entity> and further implicates this polymorphism in fat regulation.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "15999",
    "Sentence": "This supports and extends the original finding that there is an association between measures of obesity and <\\entity><\\entity> and further implicates this polymorphism in fat regulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16000",
    "Sentence": "<\\entity><\\entity> gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the <\\entity><\\entity> gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": ""
  },
  {
    "id": "16001",
    "Sentence": "INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the INSIG2 gene, <\\entity><\\entity> (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": ""
  },
  {
    "id": "16003",
    "Sentence": "This supports and extends the original finding that there is an association between measures of obesity and <\\entity><\\entity> and further implicates this polymorphism in fat regulation.",
    "Label": ""
  },
  {
    "id": "16004",
    "Sentence": "This supports and extends the original finding that there is an association between measures of <\\entity><\\entity> and INSIG2 rs7566605 and further implicates this polymorphism in fat regulation.",
    "Label": ""
  },
  {
    "id": "16006",
    "Sentence": "<\\entity><\\entity> gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the <\\entity><\\entity> gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": ""
  },
  {
    "id": "16007",
    "Sentence": "INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the INSIG2 gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with <\\entity><\\entity> (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": ""
  },
  {
    "id": "16009",
    "Sentence": "As BMI is a relatively insensitive measure of adiposity that is subject to many confounding variables, we sought to determine the relationship between the <\\entity><\\entity> and subcutaneous fat volumes measured by MRI in a young adult population.",
    "Label": ""
  },
  {
    "id": "16010",
    "Sentence": "As BMI is a relatively insensitive measure of <\\entity><\\entity> that is subject to many confounding variables, we sought to determine the relationship between the INSIG2 SNP and subcutaneous fat volumes measured by MRI in a young adult population.",
    "Label": ""
  },
  {
    "id": "16012",
    "Sentence": "CONCLUSION: Our results show that the <\\entity><\\entity> polymorphism underlies variation in subcutaneous adiposity in young adult women and suppresses the positive effects of resistance training on men.",
    "Label": ""
  },
  {
    "id": "16013",
    "Sentence": "CONCLUSION: Our results show that the INSIG2 rs7566605 polymorphism underlies variation in subcutaneous <\\entity><\\entity> in young adult women and suppresses the positive effects of resistance training on men.",
    "Label": ""
  },
  {
    "id": "16015",
    "Sentence": "INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the INSIG2 gene, <\\entity><\\entity> (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": ""
  },
  {
    "id": "16016",
    "Sentence": "INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the INSIG2 gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with <\\entity><\\entity> (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": ""
  },
  {
    "id": "16018",
    "Sentence": "INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the INSIG2 gene, rs7566605 (<\\entity><\\entity>, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": ""
  },
  {
    "id": "16019",
    "Sentence": "INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the INSIG2 gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with <\\entity><\\entity> (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": ""
  },
  {
    "id": "16021",
    "Sentence": "<\\entity><\\entity> gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the <\\entity><\\entity> gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": ""
  },
  {
    "id": "16022",
    "Sentence": "INSIG2 gene polymorphism is associated with increased <\\entity><\\entity> in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the INSIG2 gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": ""
  },
  {
    "id": "16024",
    "Sentence": "<\\entity><\\entity> gene polymorphism is associated with increased subcutaneous fat in women and poor response to resistance training in men.BACKGROUND: A common SNP upstream of the <\\entity><\\entity> gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": ""
  },
  {
    "id": "16025",
    "Sentence": "INSIG2 gene polymorphism is associated with increased subcutaneous fat in women and <\\entity><\\entity> in men.BACKGROUND: A common SNP upstream of the INSIG2 gene, rs7566605 (g.-10,1025G>C, Chr2:118,552,255, NT_022135.15), was reported to be associated with obesity (Body Mass Index, [BMI]) in a genome-wide association scan using the Framingham Heart Study but has not been reproduced in other cohorts.",
    "Label": ""
  },
  {
    "id": "16027",
    "Sentence": "As BMI is a relatively insensitive measure of adiposity that is subject to many confounding variables, we sought to determine the relationship between the <\\entity><\\entity> and subcutaneous fat volumes measured by MRI in a young adult population.",
    "Label": ""
  },
  {
    "id": "16028",
    "Sentence": "As BMI is a relatively insensitive measure of adiposity that is subject to many confounding variables, we sought to determine the relationship between the INSIG2 SNP and <\\entity><\\entity> volumes measured by MRI in a young adult population.",
    "Label": ""
  },
  {
    "id": "16030",
    "Sentence": "RESULTS: Women with a copy of the <\\entity><\\entity> had higher levels of baseline subcutaneous fat (GG: n = 139; 243473 +/- 5713 mm3 vs.",
    "Label": ""
  },
  {
    "id": "16031",
    "Sentence": "RESULTS: Women with a copy of the C allele had higher levels of baseline <\\entity><\\entity> (GG: n = 139; 243473 +/- 5713 mm3 vs.",
    "Label": ""
  },
  {
    "id": "16033",
    "Sentence": "Men homozygous for the G ancestral allele showed a loss of subcutaneous fat, while those with one or two copies of the <\\entity><\\entity> gained a greater percentage of subcutaneous fat with resistance training (GG: n = 103; 1.02% +/- 1.74% vs.",
    "Label": ""
  },
  {
    "id": "16034",
    "Sentence": "Men homozygous for the G ancestral allele showed a loss of <\\entity><\\entity>, while those with one or two copies of the C allele gained a greater percentage of <\\entity><\\entity> with resistance training (GG: n = 103; 1.02% +/- 1.74% vs.",
    "Label": ""
  },
  {
    "id": "16036",
    "Sentence": "Men homozygous for the G ancestral allele showed a loss of subcutaneous fat, while those with one or two copies of the <\\entity><\\entity> gained a greater percentage of subcutaneous fat with resistance training (GG: n = 103; 1.02% +/- 1.74% vs.",
    "Label": ""
  },
  {
    "id": "16037",
    "Sentence": "Men homozygous for the G ancestral allele showed a loss of subcutaneous fat, while those with one or two copies of the C allele gained a greater percentage of subcutaneous fat with <\\entity><\\entity> (GG: n = 103; 1.02% +/- 1.74% vs.",
    "Label": ""
  },
  {
    "id": "16039",
    "Sentence": "Men homozygous for the <\\entity><\\entity> showed a loss of subcutaneous fat, while those with one or two copies of the C allele gained a greater percentage of subcutaneous fat with resistance training (GG: n = 103; 1.02% +/- 1.74% vs.",
    "Label": ""
  },
  {
    "id": "16040",
    "Sentence": "Men homozygous for the G ancestral allele showed a loss of <\\entity><\\entity>, while those with one or two copies of the C allele gained a greater percentage of <\\entity><\\entity> with resistance training (GG: n = 103; 1.02% +/- 1.74% vs.",
    "Label": ""
  },
  {
    "id": "16042",
    "Sentence": "Men homozygous for the <\\entity><\\entity> showed a loss of subcutaneous fat, while those with one or two copies of the C allele gained a greater percentage of subcutaneous fat with resistance training (GG: n = 103; 1.02% +/- 1.74% vs.",
    "Label": ""
  },
  {
    "id": "16043",
    "Sentence": "Men homozygous for the G ancestral allele showed a loss of subcutaneous fat, while those with one or two copies of the C allele gained a greater percentage of subcutaneous fat with <\\entity><\\entity> (GG: n = 103; 1.02% +/- 1.74% vs.",
    "Label": ""
  },
  {
    "id": "16045",
    "Sentence": "CONCLUSION: Our results show that the <\\entity><\\entity> polymorphism underlies variation in subcutaneous adiposity in young adult women and suppresses the positive effects of resistance training on men.",
    "Label": ""
  },
  {
    "id": "16046",
    "Sentence": "CONCLUSION: Our results show that the INSIG2 rs7566605 polymorphism underlies variation in subcutaneous adiposity in young adult women and suppresses the positive effects of <\\entity><\\entity> on men.",
    "Label": ""
  },
  {
    "id": "16052",
    "Sentence": "Genetic association between the <\\entity><\\entity> gene and mode of onset of type 1 diabetes in the Japanese population.CONTEXT/OBJECTIVE: The IL-2 receptor-alpha (IL2RA), also known as CD25, is expressed on the regulatory T cells, which play an important role in the control of immune responses and the maintenance of immune homeostasis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16053",
    "Sentence": "Genetic association between the interleukin-2 receptor-alpha gene and mode of onset of <\\entity><\\entity> in the Japanese population.CONTEXT/OBJECTIVE: The IL-2 receptor-alpha (IL2RA), also known as CD25, is expressed on the regulatory T cells, which play an important role in the control of immune responses and the maintenance of immune homeostasis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16054",
    "Sentence": "Genetic association between the interleukin-2 receptor-alpha gene and mode of onset of type 1 diabetes in the Japanese population.CONTEXT/OBJECTIVE: The <\\entity><\\entity> (IL2RA), also known as CD25, is expressed on the regulatory T cells, which play an important role in the control of immune responses and the maintenance of immune homeostasis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16055",
    "Sentence": "Genetic association between the interleukin-2 receptor-alpha gene and mode of onset of type 1 diabetes in the Japanese population.CONTEXT/OBJECTIVE: The IL-2 receptor-alpha (<\\entity><\\entity>), also known as CD25, is expressed on the regulatory T cells, which play an important role in the control of immune responses and the maintenance of immune homeostasis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16056",
    "Sentence": "Genetic association between the interleukin-2 receptor-alpha gene and mode of onset of type 1 diabetes in the Japanese population.CONTEXT/OBJECTIVE: The IL-2 receptor-alpha (IL2RA), also known as <\\entity><\\entity>, is expressed on the regulatory T cells, which play an important role in the control of immune responses and the maintenance of immune homeostasis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16057",
    "Sentence": "Our objective was to determine whether variants in the <\\entity><\\entity> gene are associated with type 1 diabetes in the Japanese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16058",
    "Sentence": "Our objective was to determine whether variants in the IL2RA gene are associated with <\\entity><\\entity> in the Japanese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16059",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (<\\entity><\\entity>, rs3118470, ss52580101, and rs11594656) of the IL2RA in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16060",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (rs706778, <\\entity><\\entity>, ss52580101, and rs11594656) of the IL2RA in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16061",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, <\\entity><\\entity>, and rs11594656) of the IL2RA in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16062",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and <\\entity><\\entity>) of the IL2RA in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16063",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and rs11594656) of the <\\entity><\\entity> in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16064",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and rs11594656) of the IL2RA in 885 patients with <\\entity><\\entity> and 606 control subjects of Japanese origin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16065",
    "Sentence": "RESULTS: We found evidence of association with acute-onset, but not slow-onset and fulminant, <\\entity><\\entity> for two of the four single-nucleotide polymorphisms genotyped (rs706778 and rs3118470).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16066",
    "Sentence": "RESULTS: We found evidence of association with acute-onset, but not slow-onset and fulminant, type 1 diabetes for two of the four single-nucleotide polymorphisms genotyped (<\\entity><\\entity> and rs3118470).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16067",
    "Sentence": "RESULTS: We found evidence of association with acute-onset, but not slow-onset and fulminant, type 1 diabetes for two of the four single-nucleotide polymorphisms genotyped (rs706778 and <\\entity><\\entity>).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16068",
    "Sentence": "The <\\entity><\\entity> allele and the rs3118470 G allele were associated with an increased disease risk [odds ratio (OR) for <\\entity><\\entity>A genotype 1.54, P = 4.2 x 10(-4) and OR for rs3118470 GG genotype 1.50, P = 0.0019, respectively].",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16069",
    "Sentence": "The rs706778 A allele and the <\\entity><\\entity> allele were associated with an increased disease risk [odds ratio (OR) for rs706778 AA genotype 1.54, P = 4.2 x 10(-4) and OR for <\\entity><\\entity>G genotype 1.50, P = 0.0019, respectively].",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16070",
    "Sentence": "The rs706778 A allele and the rs3118470 G allele were associated with an increased <\\entity><\\entity> risk [odds ratio (OR) for rs706778 AA genotype 1.54, P = 4.2 x 10(-4) and OR for rs3118470 GG genotype 1.50, P = 0.0019, respectively].",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16071",
    "Sentence": "The rs706778 A allele and the rs3118470 G allele were associated with an increased disease risk [odds ratio (OR) for <\\entity><\\entity> genotype 1.54, P = 4.2 x 10(-4) and OR for rs3118470 GG genotype 1.50, P = 0.0019, respectively].",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16072",
    "Sentence": "The rs706778 A allele and the rs3118470 G allele were associated with an increased disease risk [odds ratio (OR) for rs706778 AA genotype 1.54, P = 4.2 x 10(-4) and OR for <\\entity><\\entity> genotype 1.50, P = 0.0019, respectively].",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16073",
    "Sentence": "Furthermore, the <\\entity><\\entity> was associated with increased type 1 diabetes risk in the acute-onset form (OR 1.30, P = 0.002).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16074",
    "Sentence": "Furthermore, the <\\entity><\\entity> was associated with increased type 1 diabetes risk in the acute-onset form (OR 1.30, P = 0.002).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16075",
    "Sentence": "Furthermore, the A-G haplotype was associated with increased <\\entity><\\entity> risk in the acute-onset form (OR 1.30, P = 0.002).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16076",
    "Sentence": "CONCLUSIONS: The present data confirm the <\\entity><\\entity> association with IL2RA and provide evidence that the different contributions of the IL2RA in the susceptibility to acute-onset and other forms of <\\entity><\\entity> in the Japanese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16077",
    "Sentence": "CONCLUSIONS: The present data confirm the type 1 diabetes association with <\\entity><\\entity> and provide evidence that the different contributions of the <\\entity><\\entity> in the susceptibility to acute-onset and other forms of type 1 diabetes in the Japanese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16078",
    "Sentence": "CONCLUSIONS: The present data confirm the type 1 diabetes association with <\\entity><\\entity> and provide evidence that the different contributions of the <\\entity><\\entity> in the susceptibility to acute-onset and other forms of type 1 diabetes in the Japanese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16079",
    "Sentence": "CONCLUSIONS: The present data confirm the <\\entity><\\entity> association with IL2RA and provide evidence that the different contributions of the IL2RA in the susceptibility to acute-onset and other forms of <\\entity><\\entity> in the Japanese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16080",
    "Sentence": "RESULTS: We found evidence of association with acute-onset, but not slow-onset and fulminant, type 1 diabetes for two of the four single-nucleotide polymorphisms genotyped (<\\entity><\\entity> and rs3118470).",
    "Label": ""
  },
  {
    "id": "16081",
    "Sentence": "RESULTS: We found evidence of association with acute-onset, but not slow-onset and fulminant, <\\entity><\\entity> for two of the four single-nucleotide polymorphisms genotyped (rs706778 and rs3118470).",
    "Label": ""
  },
  {
    "id": "16083",
    "Sentence": "RESULTS: We found evidence of association with acute-onset, but not slow-onset and fulminant, type 1 diabetes for two of the four single-nucleotide polymorphisms genotyped (rs706778 and <\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "16084",
    "Sentence": "RESULTS: We found evidence of association with acute-onset, but not slow-onset and fulminant, <\\entity><\\entity> for two of the four single-nucleotide polymorphisms genotyped (rs706778 and rs3118470).",
    "Label": ""
  },
  {
    "id": "16086",
    "Sentence": "Furthermore, the <\\entity><\\entity> was associated with increased type 1 diabetes risk in the acute-onset form (OR 1.30, P = 0.002).",
    "Label": ""
  },
  {
    "id": "16087",
    "Sentence": "Furthermore, the A-G haplotype was associated with increased <\\entity><\\entity> risk in the acute-onset form (OR 1.30, P = 0.002).",
    "Label": ""
  },
  {
    "id": "16089",
    "Sentence": "CONCLUSIONS: The present data confirm the type 1 diabetes association with <\\entity><\\entity> and provide evidence that the different contributions of the <\\entity><\\entity> in the susceptibility to acute-onset and other forms of type 1 diabetes in the Japanese population.",
    "Label": ""
  },
  {
    "id": "16090",
    "Sentence": "CONCLUSIONS: The present data confirm the <\\entity><\\entity> association with IL2RA and provide evidence that the different contributions of the IL2RA in the susceptibility to acute-onset and other forms of <\\entity><\\entity> in the Japanese population.",
    "Label": ""
  },
  {
    "id": "16092",
    "Sentence": "Genetic association between the <\\entity><\\entity> gene and mode of onset of type 1 diabetes in the Japanese population.CONTEXT/OBJECTIVE: The IL-2 receptor-alpha (IL2RA), also known as CD25, is expressed on the regulatory T cells, which play an important role in the control of immune responses and the maintenance of immune homeostasis.",
    "Label": ""
  },
  {
    "id": "16093",
    "Sentence": "Genetic association between the interleukin-2 receptor-alpha gene and mode of onset of <\\entity><\\entity> in the Japanese population.CONTEXT/OBJECTIVE: The IL-2 receptor-alpha (IL2RA), also known as CD25, is expressed on the regulatory T cells, which play an important role in the control of immune responses and the maintenance of immune homeostasis.",
    "Label": ""
  },
  {
    "id": "16095",
    "Sentence": "Our objective was to determine whether variants in the <\\entity><\\entity> gene are associated with type 1 diabetes in the Japanese population.",
    "Label": ""
  },
  {
    "id": "16096",
    "Sentence": "Our objective was to determine whether variants in the IL2RA gene are associated with <\\entity><\\entity> in the Japanese population.",
    "Label": ""
  },
  {
    "id": "16098",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and rs11594656) of the <\\entity><\\entity> in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin.",
    "Label": ""
  },
  {
    "id": "16099",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and rs11594656) of the IL2RA in 885 patients with <\\entity><\\entity> and 606 control subjects of Japanese origin.",
    "Label": ""
  },
  {
    "id": "16101",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (<\\entity><\\entity>, rs3118470, ss52580101, and rs11594656) of the IL2RA in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin.",
    "Label": ""
  },
  {
    "id": "16102",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and rs11594656) of the IL2RA in 885 patients with <\\entity><\\entity> and 606 control subjects of Japanese origin.",
    "Label": ""
  },
  {
    "id": "16104",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (rs706778, <\\entity><\\entity>, ss52580101, and rs11594656) of the IL2RA in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin.",
    "Label": ""
  },
  {
    "id": "16105",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and rs11594656) of the IL2RA in 885 patients with <\\entity><\\entity> and 606 control subjects of Japanese origin.",
    "Label": ""
  },
  {
    "id": "16107",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, <\\entity><\\entity>, and rs11594656) of the IL2RA in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin.",
    "Label": ""
  },
  {
    "id": "16108",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and rs11594656) of the IL2RA in 885 patients with <\\entity><\\entity> and 606 control subjects of Japanese origin.",
    "Label": ""
  },
  {
    "id": "16110",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and <\\entity><\\entity>) of the IL2RA in 885 patients with type 1 diabetes and 606 control subjects of Japanese origin.",
    "Label": ""
  },
  {
    "id": "16111",
    "Sentence": "DESIGN/PATIENTS: We genotyped the four single-nucleotide polymorphisms (rs706778, rs3118470, ss52580101, and rs11594656) of the IL2RA in 885 patients with <\\entity><\\entity> and 606 control subjects of Japanese origin.",
    "Label": ""
  },
  {
    "id": "16113",
    "Sentence": "The rs706778 A allele and the rs3118470 G allele were associated with an increased disease risk [odds ratio (OR) for <\\entity><\\entity> genotype 1.54, P = 4.2 x 10(-4) and OR for rs3118470 GG genotype 1.50, P = 0.0019, respectively].",
    "Label": ""
  },
  {
    "id": "16114",
    "Sentence": "The rs706778 A allele and the rs3118470 G allele were associated with an increased <\\entity><\\entity> risk [odds ratio (OR) for rs706778 AA genotype 1.54, P = 4.2 x 10(-4) and OR for rs3118470 GG genotype 1.50, P = 0.0019, respectively].",
    "Label": ""
  },
  {
    "id": "16116",
    "Sentence": "The rs706778 A allele and the rs3118470 G allele were associated with an increased disease risk [odds ratio (OR) for rs706778 AA genotype 1.54, P = 4.2 x 10(-4) and OR for <\\entity><\\entity> genotype 1.50, P = 0.0019, respectively].",
    "Label": ""
  },
  {
    "id": "16117",
    "Sentence": "The rs706778 A allele and the rs3118470 G allele were associated with an increased <\\entity><\\entity> risk [odds ratio (OR) for rs706778 AA genotype 1.54, P = 4.2 x 10(-4) and OR for rs3118470 GG genotype 1.50, P = 0.0019, respectively].",
    "Label": ""
  },
  {
    "id": "16119",
    "Sentence": "CONCLUSIONS: The present data confirm the type 1 diabetes association with <\\entity><\\entity> and provide evidence that the different contributions of the <\\entity><\\entity> in the susceptibility to acute-onset and other forms of type 1 diabetes in the Japanese population.",
    "Label": ""
  },
  {
    "id": "16120",
    "Sentence": "CONCLUSIONS: The present data confirm the <\\entity><\\entity> association with IL2RA and provide evidence that the different contributions of the IL2RA in the susceptibility to acute-onset and other forms of <\\entity><\\entity> in the Japanese population.",
    "Label": ""
  },
  {
    "id": "16126",
    "Sentence": "Genetic variation in the promoter region of <\\entity><\\entity> is associated with atopy.RATIONALE: Atopy or atopic syndrome is an allergic hypersensitivity subject to hereditary influences.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16127",
    "Sentence": "Genetic variation in the promoter region of chitinase 3-like 1 is associated with <\\entity><\\entity>.RATIONALE: Atopy or atopic syndrome is an allergic hypersensitivity subject to hereditary influences.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16128",
    "Sentence": "Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy.RATIONALE: <\\entity><\\entity> or atopic syndrome is an allergic hypersensitivity subject to hereditary influences.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16129",
    "Sentence": "Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy.RATIONALE: Atopy or <\\entity><\\entity> is an allergic hypersensitivity subject to hereditary influences.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16130",
    "Sentence": "Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy.RATIONALE: Atopy or atopic syndrome is an allergic <\\entity><\\entity> subject to hereditary influences.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16131",
    "Sentence": "Aberrant expression of <\\entity><\\entity> (CHI3L1), also known as YKL-40 or HC gp-39, is involved in the pathogenesis of inflammatory and allergic diseases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16132",
    "Sentence": "Aberrant expression of chitinase 3-like 1 (<\\entity><\\entity>), also known as YKL-40 or HC gp-39, is involved in the pathogenesis of inflammatory and allergic diseases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16133",
    "Sentence": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as <\\entity><\\entity> or HC gp-39, is involved in the pathogenesis of inflammatory and allergic diseases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16134",
    "Sentence": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as YKL-40 or <\\entity><\\entity>, is involved in the pathogenesis of inflammatory and allergic diseases.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16135",
    "Sentence": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as YKL-40 or HC gp-39, is involved in the <\\entity><\\entity> of inflammatory and allergic diseases.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16136",
    "Sentence": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as YKL-40 or HC gp-39, is involved in the pathogenesis of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16137",
    "Sentence": "OBJECTIVES: The genetic contribution of <\\entity><\\entity> gene to atopic susceptibility was investigated using an integrated population genetic and molecular analysis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16138",
    "Sentence": "OBJECTIVES: The genetic contribution of CHI3L1 gene to <\\entity><\\entity> susceptibility was investigated using an integrated population genetic and molecular analysis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16139",
    "Sentence": "METHODS: Genetic variations in <\\entity><\\entity> were identified and genotyped in 295 unrelated patients with atopy and 180 control subjects.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16140",
    "Sentence": "METHODS: Genetic variations in CHI3L1 were identified and genotyped in 295 unrelated patients with <\\entity><\\entity> and 180 control subjects.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16141",
    "Sentence": "Serum <\\entity><\\entity> and IgE levels were analyzed according to genotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16142",
    "Sentence": "Serum YKL-40 and <\\entity><\\entity> levels were analyzed according to genotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16143",
    "Sentence": "The effects of a promoter polymorphism (<\\entity><\\entity>) on promoter activity were examined in reporter and protein binding assays.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16144",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the <\\entity><\\entity> polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with atopy.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16145",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (<\\entity><\\entity>; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with atopy.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16146",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the <\\entity><\\entity> polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with atopy.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16147",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the <\\entity><\\entity> polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with atopy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16148",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (<\\entity><\\entity>; P = 0.0056) of CHI3L1 showed a significant association with atopy.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16149",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of <\\entity><\\entity> showed a significant association with atopy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16150",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16151",
    "Sentence": "Subjects with the <\\entity><\\entity> risk allele had significantly higher serum YKL-40 (P < 0.0001) and IgE (P = 0.012) levels.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16152",
    "Sentence": "Subjects with the g.-247T risk allele had significantly higher serum <\\entity><\\entity> (P < 0.0001) and IgE (P = 0.012) levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16153",
    "Sentence": "Subjects with the g.-247T risk allele had significantly higher serum YKL-40 (P < 0.0001) and <\\entity><\\entity> (P = 0.012) levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16154",
    "Sentence": "An in vitro promoter assay using <\\entity><\\entity> human monocyte cells revealed that the C to T conversion at g.-247 induced a more than twofold increase of reporter gene expression.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16155",
    "Sentence": "An in vitro promoter assay using THP-1 human monocyte cells revealed that the <\\entity><\\entity> induced a more than twofold increase of reporter gene expression.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16156",
    "Sentence": "Moreover, the <\\entity><\\entity> allele showed an increased affinity for CCAAT enhancer-binding protein, a well known transcriptional activator, by electrophoretic mobility shift assay.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16157",
    "Sentence": "Moreover, the g.-247T allele showed an increased affinity for <\\entity><\\entity>, a well known transcriptional activator, by electrophoretic mobility shift assay.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16158",
    "Sentence": "Accordingly, subjects with the <\\entity><\\entity> genotype showed a 2.5-fold increase in CHI3L1 mRNA expression in peripheral blood cells compared with those with the g.-247CC genotype.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16159",
    "Sentence": "Accordingly, subjects with the g.-247TT genotype showed a 2.5-fold increase in <\\entity><\\entity> mRNA expression in peripheral blood cells compared with those with the g.-247CC genotype.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16160",
    "Sentence": "Accordingly, subjects with the g.-247TT genotype showed a 2.5-fold increase in CHI3L1 mRNA expression in peripheral blood cells compared with those with the <\\entity><\\entity> genotype.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16161",
    "Sentence": "CONCLUSIONS: These results strongly suggest that the <\\entity><\\entity> polymorphism in the CHI3L1 promoter region is associated with the risk of atopy.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16162",
    "Sentence": "CONCLUSIONS: These results strongly suggest that the g.-247C/T polymorphism in the <\\entity><\\entity> promoter region is associated with the risk of atopy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16163",
    "Sentence": "CONCLUSIONS: These results strongly suggest that the g.-247C/T polymorphism in the CHI3L1 promoter region is associated with the risk of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16164",
    "Sentence": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as YKL-40 or <\\entity><\\entity>, is involved in the pathogenesis of inflammatory and allergic diseases.",
    "Label": ""
  },
  {
    "id": "16165",
    "Sentence": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as YKL-40 or HC gp-39, is involved in the pathogenesis of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16167",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the <\\entity><\\entity> polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with atopy.",
    "Label": ""
  },
  {
    "id": "16168",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16170",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (<\\entity><\\entity>; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with atopy.",
    "Label": ""
  },
  {
    "id": "16171",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16173",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the <\\entity><\\entity> polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with atopy.",
    "Label": ""
  },
  {
    "id": "16174",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16176",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (<\\entity><\\entity>; P = 0.0056) of CHI3L1 showed a significant association with atopy.",
    "Label": ""
  },
  {
    "id": "16177",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16179",
    "Sentence": "CONCLUSIONS: These results strongly suggest that the <\\entity><\\entity> polymorphism in the CHI3L1 promoter region is associated with the risk of atopy.",
    "Label": ""
  },
  {
    "id": "16180",
    "Sentence": "CONCLUSIONS: These results strongly suggest that the g.-247C/T polymorphism in the CHI3L1 promoter region is associated with the risk of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16182",
    "Sentence": "Genetic variation in the promoter region of <\\entity><\\entity> is associated with atopy.RATIONALE: Atopy or atopic syndrome is an allergic hypersensitivity subject to hereditary influences.",
    "Label": ""
  },
  {
    "id": "16183",
    "Sentence": "Genetic variation in the promoter region of chitinase 3-like 1 is associated with <\\entity><\\entity>.RATIONALE: Atopy or atopic syndrome is an allergic hypersensitivity subject to hereditary influences.",
    "Label": ""
  },
  {
    "id": "16185",
    "Sentence": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as YKL-40 or <\\entity><\\entity>, is involved in the pathogenesis of inflammatory and allergic diseases.",
    "Label": ""
  },
  {
    "id": "16186",
    "Sentence": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as YKL-40 or HC gp-39, is involved in the <\\entity><\\entity> of inflammatory and allergic diseases.",
    "Label": ""
  },
  {
    "id": "16188",
    "Sentence": "OBJECTIVES: The genetic contribution of <\\entity><\\entity> gene to atopic susceptibility was investigated using an integrated population genetic and molecular analysis.",
    "Label": ""
  },
  {
    "id": "16189",
    "Sentence": "OBJECTIVES: The genetic contribution of CHI3L1 gene to <\\entity><\\entity> susceptibility was investigated using an integrated population genetic and molecular analysis.",
    "Label": ""
  },
  {
    "id": "16191",
    "Sentence": "METHODS: Genetic variations in <\\entity><\\entity> were identified and genotyped in 295 unrelated patients with atopy and 180 control subjects.",
    "Label": ""
  },
  {
    "id": "16192",
    "Sentence": "METHODS: Genetic variations in CHI3L1 were identified and genotyped in 295 unrelated patients with <\\entity><\\entity> and 180 control subjects.",
    "Label": ""
  },
  {
    "id": "16194",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of <\\entity><\\entity> showed a significant association with atopy.",
    "Label": ""
  },
  {
    "id": "16195",
    "Sentence": "MEASUREMENTS AND MAIN RESULTS: In the case-control association analysis, the g.-247C/T polymorphism at the promoter region (rs10399805; P = 0.0062) and the IVS7+82C/T polymorphism at intron 7 (rs2275353; P = 0.0056) of CHI3L1 showed a significant association with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16197",
    "Sentence": "CONCLUSIONS: These results strongly suggest that the g.-247C/T polymorphism in the <\\entity><\\entity> promoter region is associated with the risk of atopy.",
    "Label": ""
  },
  {
    "id": "16198",
    "Sentence": "CONCLUSIONS: These results strongly suggest that the g.-247C/T polymorphism in the CHI3L1 promoter region is associated with the risk of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16200",
    "Sentence": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as <\\entity><\\entity> or HC gp-39, is involved in the pathogenesis of inflammatory and allergic diseases.",
    "Label": ""
  },
  {
    "id": "16201",
    "Sentence": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as YKL-40 or HC gp-39, is involved in the pathogenesis of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16203",
    "Sentence": "Aberrant expression of <\\entity><\\entity> (CHI3L1), also known as YKL-40 or HC gp-39, is involved in the pathogenesis of inflammatory and allergic diseases.",
    "Label": ""
  },
  {
    "id": "16204",
    "Sentence": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as YKL-40 or HC gp-39, is involved in the pathogenesis of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16206",
    "Sentence": "Aberrant expression of chitinase 3-like 1 (<\\entity><\\entity>), also known as YKL-40 or HC gp-39, is involved in the pathogenesis of inflammatory and allergic diseases.",
    "Label": ""
  },
  {
    "id": "16207",
    "Sentence": "Aberrant expression of chitinase 3-like 1 (CHI3L1), also known as YKL-40 or HC gp-39, is involved in the pathogenesis of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16213",
    "Sentence": "Distinct genetic loci control plasma <\\entity><\\entity> and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study.Previous studies of the HIV-1 disease have shown that HLA and Chemokine receptor genetic variants influence disease progression and early viral load.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16214",
    "Sentence": "Distinct genetic loci control plasma HIV-RNA and cellular <\\entity><\\entity> levels in HIV-1 infection: the ANRS Genome Wide Association 01 study.Previous studies of the HIV-1 disease have shown that HLA and Chemokine receptor genetic variants influence disease progression and early viral load.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16215",
    "Sentence": "Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in <\\entity><\\entity> infection: the ANRS Genome Wide Association 01 study.Previous studies of the <\\entity><\\entity> disease have shown that HLA and Chemokine receptor genetic variants influence disease progression and early viral load.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16216",
    "Sentence": "Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 <\\entity><\\entity>: the ANRS Genome Wide Association 01 study.Previous studies of the HIV-1 disease have shown that HLA and Chemokine receptor genetic variants influence disease progression and early viral load.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16217",
    "Sentence": "Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study.Previous studies of the <\\entity><\\entity> have shown that HLA and Chemokine receptor genetic variants influence disease progression and early viral load.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16218",
    "Sentence": "Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study.Previous studies of the HIV-1 disease have shown that <\\entity><\\entity> and Chemokine receptor genetic variants influence disease progression and early viral load.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16219",
    "Sentence": "Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study.Previous studies of the HIV-1 disease have shown that HLA and <\\entity><\\entity> genetic variants influence disease progression and early viral load.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16220",
    "Sentence": "Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study.Previous studies of the HIV-1 disease have shown that HLA and Chemokine receptor genetic variants influence <\\entity><\\entity> and early viral load.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16221",
    "Sentence": "We performed a Genome Wide Association study in a cohort of 605 <\\entity><\\entity> for detection of novel genetic factors that influence plasma HIV-RNA and cellular HIV-DNA levels.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16222",
    "Sentence": "We performed a Genome Wide Association study in a cohort of 605 HIV-1-infected seroconverters for detection of novel genetic factors that influence plasma <\\entity><\\entity> and cellular HIV-DNA levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16223",
    "Sentence": "We performed a Genome Wide Association study in a cohort of 605 HIV-1-infected seroconverters for detection of novel genetic factors that influence plasma HIV-RNA and cellular <\\entity><\\entity> levels.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16224",
    "Sentence": "Most of the SNPs strongly associated with <\\entity><\\entity> levels were localised in the 6p21 major histocompatibility complex (MHC) region and were in the vicinity of class I and III genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16225",
    "Sentence": "Most of the SNPs strongly associated with HIV-RNA levels were localised in the <\\entity><\\entity> (MHC) region and were in the vicinity of class I and III genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16226",
    "Sentence": "Most of the SNPs strongly associated with HIV-RNA levels were localised in the 6p21 major histocompatibility complex (<\\entity><\\entity>) region and were in the vicinity of class I and III genes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16227",
    "Sentence": "Moreover, protective alleles for four <\\entity><\\entity>-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16228",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the <\\entity><\\entity> locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16229",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (<\\entity><\\entity>, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16230",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, <\\entity><\\entity>, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16231",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, <\\entity><\\entity> and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16232",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and <\\entity><\\entity>) were strikingly over-represented among forty-five Long Term HIV controllers.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16233",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term <\\entity><\\entity> controllers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16234",
    "Sentence": "Furthermore, we show that the <\\entity><\\entity> levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16235",
    "Sentence": "Furthermore, we show that the <\\entity><\\entity>-DNA levels (reflecting the <\\entity><\\entity> reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16236",
    "Sentence": "Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on <\\entity><\\entity> (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16237",
    "Sentence": "Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (<\\entity><\\entity>; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16238",
    "Sentence": "Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the <\\entity><\\entity> and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16239",
    "Sentence": "Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and <\\entity><\\entity> genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16240",
    "Sentence": "Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and <\\entity><\\entity> (rs2575735; within the Syndecan 2 gene).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16241",
    "Sentence": "Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (<\\entity><\\entity>; within the Syndecan 2 gene).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16242",
    "Sentence": "Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the <\\entity><\\entity> gene).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16243",
    "Sentence": "Our data provide evidence that the <\\entity><\\entity> controls both HIV replication and HIV reservoir.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16244",
    "Sentence": "Our data provide evidence that the MHC controls both <\\entity><\\entity> replication and <\\entity><\\entity> reservoir.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16245",
    "Sentence": "Our data provide evidence that the MHC controls both <\\entity><\\entity> replication and <\\entity><\\entity> reservoir.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16246",
    "Sentence": "They also indicate that two additional genomic loci may influence the <\\entity><\\entity> reservoir.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16247",
    "Sentence": "Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study.Previous studies of the HIV-1 disease have shown that <\\entity><\\entity> and Chemokine receptor genetic variants influence disease progression and early viral load.",
    "Label": ""
  },
  {
    "id": "16248",
    "Sentence": "Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study.Previous studies of the <\\entity><\\entity> have shown that HLA and Chemokine receptor genetic variants influence disease progression and early viral load.",
    "Label": ""
  },
  {
    "id": "16250",
    "Sentence": "Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study.Previous studies of the HIV-1 disease have shown that HLA and <\\entity><\\entity> genetic variants influence disease progression and early viral load.",
    "Label": ""
  },
  {
    "id": "16251",
    "Sentence": "Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study.Previous studies of the <\\entity><\\entity> have shown that HLA and Chemokine receptor genetic variants influence disease progression and early viral load.",
    "Label": ""
  },
  {
    "id": "16253",
    "Sentence": "Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the <\\entity><\\entity> and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": ""
  },
  {
    "id": "16254",
    "Sentence": "Furthermore, we show that the <\\entity><\\entity>-DNA levels (reflecting the <\\entity><\\entity> reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": ""
  },
  {
    "id": "16256",
    "Sentence": "Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and <\\entity><\\entity> genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": ""
  },
  {
    "id": "16257",
    "Sentence": "Furthermore, we show that the <\\entity><\\entity>-DNA levels (reflecting the <\\entity><\\entity> reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": ""
  },
  {
    "id": "16259",
    "Sentence": "Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the <\\entity><\\entity> gene).",
    "Label": ""
  },
  {
    "id": "16260",
    "Sentence": "Furthermore, we show that the <\\entity><\\entity>-DNA levels (reflecting the <\\entity><\\entity> reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": ""
  },
  {
    "id": "16262",
    "Sentence": "Distinct genetic loci control plasma <\\entity><\\entity> and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study.Previous studies of the HIV-1 disease have shown that HLA and Chemokine receptor genetic variants influence disease progression and early viral load.",
    "Label": ""
  },
  {
    "id": "16263",
    "Sentence": "Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in <\\entity><\\entity> infection: the ANRS Genome Wide Association 01 study.Previous studies of the <\\entity><\\entity> disease have shown that HLA and Chemokine receptor genetic variants influence disease progression and early viral load.",
    "Label": ""
  },
  {
    "id": "16265",
    "Sentence": "Distinct genetic loci control plasma HIV-RNA and cellular <\\entity><\\entity> levels in HIV-1 infection: the ANRS Genome Wide Association 01 study.Previous studies of the HIV-1 disease have shown that HLA and Chemokine receptor genetic variants influence disease progression and early viral load.",
    "Label": ""
  },
  {
    "id": "16266",
    "Sentence": "Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in <\\entity><\\entity> infection: the ANRS Genome Wide Association 01 study.Previous studies of the <\\entity><\\entity> disease have shown that HLA and Chemokine receptor genetic variants influence disease progression and early viral load.",
    "Label": ""
  },
  {
    "id": "16268",
    "Sentence": "We performed a Genome Wide Association study in a cohort of 605 HIV-1-infected seroconverters for detection of novel genetic factors that influence plasma <\\entity><\\entity> and cellular HIV-DNA levels.",
    "Label": ""
  },
  {
    "id": "16269",
    "Sentence": "We performed a Genome Wide Association study in a cohort of 605 <\\entity><\\entity> for detection of novel genetic factors that influence plasma HIV-RNA and cellular HIV-DNA levels.",
    "Label": ""
  },
  {
    "id": "16271",
    "Sentence": "We performed a Genome Wide Association study in a cohort of 605 HIV-1-infected seroconverters for detection of novel genetic factors that influence plasma HIV-RNA and cellular <\\entity><\\entity> levels.",
    "Label": ""
  },
  {
    "id": "16272",
    "Sentence": "We performed a Genome Wide Association study in a cohort of 605 <\\entity><\\entity> for detection of novel genetic factors that influence plasma HIV-RNA and cellular HIV-DNA levels.",
    "Label": ""
  },
  {
    "id": "16274",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the <\\entity><\\entity> locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers.",
    "Label": ""
  },
  {
    "id": "16275",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term <\\entity><\\entity> controllers.",
    "Label": ""
  },
  {
    "id": "16277",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (<\\entity><\\entity>, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers.",
    "Label": ""
  },
  {
    "id": "16278",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term <\\entity><\\entity> controllers.",
    "Label": ""
  },
  {
    "id": "16280",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, <\\entity><\\entity>, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers.",
    "Label": ""
  },
  {
    "id": "16281",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term <\\entity><\\entity> controllers.",
    "Label": ""
  },
  {
    "id": "16283",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, <\\entity><\\entity> and rs3093662) were strikingly over-represented among forty-five Long Term HIV controllers.",
    "Label": ""
  },
  {
    "id": "16284",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term <\\entity><\\entity> controllers.",
    "Label": ""
  },
  {
    "id": "16286",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and <\\entity><\\entity>) were strikingly over-represented among forty-five Long Term HIV controllers.",
    "Label": ""
  },
  {
    "id": "16287",
    "Sentence": "Moreover, protective alleles for four disease-associated SNPs in the MHC locus (rs2395029, rs13199524, rs12198173 and rs3093662) were strikingly over-represented among forty-five Long Term <\\entity><\\entity> controllers.",
    "Label": ""
  },
  {
    "id": "16289",
    "Sentence": "Furthermore, we show that the <\\entity><\\entity> levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": ""
  },
  {
    "id": "16290",
    "Sentence": "Furthermore, we show that the <\\entity><\\entity>-DNA levels (reflecting the <\\entity><\\entity> reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": ""
  },
  {
    "id": "16292",
    "Sentence": "Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (<\\entity><\\entity>; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": ""
  },
  {
    "id": "16293",
    "Sentence": "Furthermore, we show that the <\\entity><\\entity>-DNA levels (reflecting the <\\entity><\\entity> reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": ""
  },
  {
    "id": "16295",
    "Sentence": "Furthermore, we show that the HIV-DNA levels (reflecting the HIV reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (<\\entity><\\entity>; within the Syndecan 2 gene).",
    "Label": ""
  },
  {
    "id": "16296",
    "Sentence": "Furthermore, we show that the <\\entity><\\entity>-DNA levels (reflecting the <\\entity><\\entity> reservoir) are associated with the same four SNPs, but also with two additional SNPs on chromosome 17 (rs6503919; intergenic region flanked by the DDX40 and YPEL2 genes) and chromosome 8 (rs2575735; within the Syndecan 2 gene).",
    "Label": ""
  },
  {
    "id": "16298",
    "Sentence": "Our data provide evidence that the <\\entity><\\entity> controls both HIV replication and HIV reservoir.",
    "Label": ""
  },
  {
    "id": "16299",
    "Sentence": "Our data provide evidence that the MHC controls both <\\entity><\\entity> replication and <\\entity><\\entity> reservoir.",
    "Label": ""
  },
  {
    "id": "16301",
    "Sentence": "Our data provide evidence that the <\\entity><\\entity> controls both HIV replication and HIV reservoir.",
    "Label": ""
  },
  {
    "id": "16302",
    "Sentence": "Our data provide evidence that the MHC controls both <\\entity><\\entity> replication and <\\entity><\\entity> reservoir.",
    "Label": ""
  },
  {
    "id": "16308",
    "Sentence": "Association of a genetic polymorphism in <\\entity><\\entity> with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic hepatitis C virus (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16309",
    "Sentence": "Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with <\\entity><\\entity> and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic hepatitis C virus (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16310",
    "Sentence": "Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with <\\entity><\\entity> virus infection and <\\entity><\\entity> virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic <\\entity><\\entity> virus (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16311",
    "Sentence": "Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with <\\entity><\\entity> virus infection and <\\entity><\\entity> virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic <\\entity><\\entity> virus (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16312",
    "Sentence": "Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C <\\entity><\\entity> infection and hepatitis C <\\entity><\\entity> core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic hepatitis C <\\entity><\\entity> (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16313",
    "Sentence": "Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of <\\entity><\\entity> (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16314",
    "Sentence": "Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with <\\entity><\\entity> virus infection and <\\entity><\\entity> virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic <\\entity><\\entity> virus (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16315",
    "Sentence": "Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic hepatitis C virus (<\\entity><\\entity> is strongly associated with insulin resistance and obesity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16316",
    "Sentence": "Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic hepatitis C virus (HCV) infection is strongly associated with <\\entity><\\entity> and obesity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16317",
    "Sentence": "Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic hepatitis C virus (HCV) infection is strongly associated with insulin resistance and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16318",
    "Sentence": "The <\\entity><\\entity> polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16319",
    "Sentence": "The K121Q polymorphism in the <\\entity><\\entity> (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16320",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (<\\entity><\\entity> gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16321",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the <\\entity><\\entity> genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16322",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near <\\entity><\\entity> have been shown to be associated with insulin resistance and obesity.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16323",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with <\\entity><\\entity> and obesity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16324",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16325",
    "Sentence": "This study examined whether the <\\entity><\\entity> polymorphism in ENPP1 or the rs7566605 genotype is associated with the clinical course of HCV infection.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16326",
    "Sentence": "This study examined whether the K121Q polymorphism in <\\entity><\\entity> or the rs7566605 genotype is associated with the clinical course of HCV infection.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16327",
    "Sentence": "This study examined whether the K121Q polymorphism in ENPP1 or the <\\entity><\\entity> genotype is associated with the clinical course of HCV infection.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16328",
    "Sentence": "This study examined whether the K121Q polymorphism in ENPP1 or the rs7566605 genotype is associated with the clinical course of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16329",
    "Sentence": "METHODS: The relationships between the clinical characteristics of 469 <\\entity><\\entity>-seropositive subjects (353 were positive for HCV core antigen or RNA, whereas 116 were negative for HCV RNA) and the polymorphisms were analyzed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16330",
    "Sentence": "METHODS: The relationships between the clinical characteristics of 469 anti-HCV antibody-seropositive subjects (353 were positive for <\\entity><\\entity> or RNA, whereas 116 were negative for HCV RNA) and the polymorphisms were analyzed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16331",
    "Sentence": "METHODS: The relationships between the clinical characteristics of 469 anti-HCV antibody-seropositive subjects (353 were positive for HCV core antigen or RNA, whereas 116 were negative for <\\entity><\\entity>) and the polymorphisms were analyzed.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16332",
    "Sentence": "RESULTS: No significant differences in <\\entity><\\entity>, plasma glucose level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the K121Q polymorphism or rs7566605.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16333",
    "Sentence": "RESULTS: No significant differences in body mass index, plasma <\\entity><\\entity> level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the K121Q polymorphism or rs7566605.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16334",
    "Sentence": "RESULTS: No significant differences in body mass index, plasma glucose level, serum <\\entity><\\entity> level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the K121Q polymorphism or rs7566605.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16335",
    "Sentence": "RESULTS: No significant differences in body mass index, plasma glucose level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the <\\entity><\\entity> polymorphism or rs7566605.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16336",
    "Sentence": "RESULTS: No significant differences in body mass index, plasma glucose level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the K121Q polymorphism or <\\entity><\\entity>.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16337",
    "Sentence": "The frequency of the homozygous wild-type genotype at <\\entity><\\entity> in HCV carriers, however, was significantly higher than that in subjects who were negative for HCV RNA (84.5% vs.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16338",
    "Sentence": "The frequency of the homozygous wild-type genotype at K121Q in <\\entity><\\entity> carriers, however, was significantly higher than that in subjects who were negative for <\\entity><\\entity> RNA (84.5% vs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16339",
    "Sentence": "The frequency of the homozygous wild-type genotype at K121Q in HCV carriers, however, was significantly higher than that in subjects who were negative for <\\entity><\\entity> (84.5% vs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16340",
    "Sentence": "Moreover, in <\\entity><\\entity> carriers, <\\entity><\\entity> core antigen levels in subjects homozygous for the wild-type genotype at K121Q were significantly higher than in heterozygous carriers of K121Q (5358 fmol/l vs.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16341",
    "Sentence": "Moreover, in HCV carriers, <\\entity><\\entity> levels in subjects homozygous for the wild-type genotype at K121Q were significantly higher than in heterozygous carriers of K121Q (5358 fmol/l vs.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16342",
    "Sentence": "Moreover, in HCV carriers, HCV core antigen levels in subjects homozygous for the wild-type genotype at <\\entity><\\entity> were significantly higher than in heterozygous carriers of <\\entity><\\entity> (5358 fmol/l vs.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16343",
    "Sentence": "Moreover, in HCV carriers, HCV core antigen levels in subjects homozygous for the wild-type genotype at <\\entity><\\entity> were significantly higher than in heterozygous carriers of <\\entity><\\entity> (5358 fmol/l vs.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16344",
    "Sentence": "In contrast, the <\\entity><\\entity> genotype was not associated with hepatitis C viremia or with the HCV core antigen level.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16345",
    "Sentence": "In contrast, the rs7566605 genotype was not associated with <\\entity><\\entity> viremia or with the HCV core antigen level.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16346",
    "Sentence": "In contrast, the rs7566605 genotype was not associated with hepatitis C <\\entity><\\entity> or with the HCV core antigen level.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16347",
    "Sentence": "In contrast, the rs7566605 genotype was not associated with hepatitis C viremia or with the <\\entity><\\entity> level.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16348",
    "Sentence": "CONCLUSIONS: The <\\entity><\\entity> variant of ENPP1 may be associated with hepatitis C viremia and core antigen levels in HCV carriers.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16349",
    "Sentence": "CONCLUSIONS: The K121Q variant of <\\entity><\\entity> may be associated with hepatitis C viremia and core antigen levels in HCV carriers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16350",
    "Sentence": "CONCLUSIONS: The K121Q variant of ENPP1 may be associated with <\\entity><\\entity> viremia and core antigen levels in HCV carriers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16351",
    "Sentence": "CONCLUSIONS: The K121Q variant of ENPP1 may be associated with hepatitis C <\\entity><\\entity> and core antigen levels in HCV carriers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16352",
    "Sentence": "CONCLUSIONS: The K121Q variant of ENPP1 may be associated with hepatitis C viremia and <\\entity><\\entity> levels in HCV carriers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16353",
    "Sentence": "CONCLUSIONS: The K121Q variant of ENPP1 may be associated with hepatitis C viremia and core antigen levels in <\\entity><\\entity> carriers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16354",
    "Sentence": "The <\\entity><\\entity> polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16355",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with <\\entity><\\entity> and obesity.",
    "Label": ""
  },
  {
    "id": "16357",
    "Sentence": "The <\\entity><\\entity> polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16358",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16360",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the <\\entity><\\entity> genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16361",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with <\\entity><\\entity> and obesity.",
    "Label": ""
  },
  {
    "id": "16363",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the <\\entity><\\entity> genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16364",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16366",
    "Sentence": "This study examined whether the <\\entity><\\entity> polymorphism in ENPP1 or the rs7566605 genotype is associated with the clinical course of HCV infection.",
    "Label": ""
  },
  {
    "id": "16367",
    "Sentence": "This study examined whether the K121Q polymorphism in ENPP1 or the rs7566605 genotype is associated with the clinical course of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16369",
    "Sentence": "This study examined whether the K121Q polymorphism in ENPP1 or the <\\entity><\\entity> genotype is associated with the clinical course of HCV infection.",
    "Label": ""
  },
  {
    "id": "16370",
    "Sentence": "This study examined whether the K121Q polymorphism in ENPP1 or the rs7566605 genotype is associated with the clinical course of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16372",
    "Sentence": "Association of a genetic polymorphism in <\\entity><\\entity> with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic hepatitis C virus (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16373",
    "Sentence": "Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with <\\entity><\\entity> virus infection and <\\entity><\\entity> virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic <\\entity><\\entity> virus (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16375",
    "Sentence": "Association of a genetic polymorphism in <\\entity><\\entity> with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic hepatitis C virus (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16376",
    "Sentence": "Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C <\\entity><\\entity> infection and hepatitis C <\\entity><\\entity> core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic hepatitis C <\\entity><\\entity> (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16378",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near <\\entity><\\entity> have been shown to be associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16379",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with <\\entity><\\entity> and obesity.",
    "Label": ""
  },
  {
    "id": "16381",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near <\\entity><\\entity> have been shown to be associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16382",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16384",
    "Sentence": "This study examined whether the K121Q polymorphism in <\\entity><\\entity> or the rs7566605 genotype is associated with the clinical course of HCV infection.",
    "Label": ""
  },
  {
    "id": "16385",
    "Sentence": "This study examined whether the K121Q polymorphism in ENPP1 or the rs7566605 genotype is associated with the clinical course of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16387",
    "Sentence": "CONCLUSIONS: The K121Q variant of <\\entity><\\entity> may be associated with hepatitis C viremia and core antigen levels in HCV carriers.",
    "Label": ""
  },
  {
    "id": "16388",
    "Sentence": "CONCLUSIONS: The K121Q variant of ENPP1 may be associated with <\\entity><\\entity> viremia and core antigen levels in HCV carriers.",
    "Label": ""
  },
  {
    "id": "16390",
    "Sentence": "CONCLUSIONS: The K121Q variant of <\\entity><\\entity> may be associated with hepatitis C viremia and core antigen levels in HCV carriers.",
    "Label": ""
  },
  {
    "id": "16391",
    "Sentence": "CONCLUSIONS: The K121Q variant of ENPP1 may be associated with hepatitis C <\\entity><\\entity> and core antigen levels in HCV carriers.",
    "Label": ""
  },
  {
    "id": "16393",
    "Sentence": "Association of a genetic polymorphism in <\\entity><\\entity> with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic hepatitis C virus (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16394",
    "Sentence": "Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with <\\entity><\\entity> and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic hepatitis C virus (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16396",
    "Sentence": "Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with <\\entity><\\entity> virus infection and <\\entity><\\entity> virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic <\\entity><\\entity> virus (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16397",
    "Sentence": "Association of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with <\\entity><\\entity> and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan.BACKGROUND: The clinical course of chronic hepatitis C virus (HCV) infection is strongly associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16399",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (<\\entity><\\entity> gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16400",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with <\\entity><\\entity> and obesity.",
    "Label": ""
  },
  {
    "id": "16402",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (<\\entity><\\entity> gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16403",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16405",
    "Sentence": "In contrast, the <\\entity><\\entity> genotype was not associated with hepatitis C viremia or with the HCV core antigen level.",
    "Label": ""
  },
  {
    "id": "16406",
    "Sentence": "In contrast, the rs7566605 genotype was not associated with <\\entity><\\entity> viremia or with the HCV core antigen level.",
    "Label": ""
  },
  {
    "id": "16408",
    "Sentence": "CONCLUSIONS: The <\\entity><\\entity> variant of ENPP1 may be associated with hepatitis C viremia and core antigen levels in HCV carriers.",
    "Label": ""
  },
  {
    "id": "16409",
    "Sentence": "CONCLUSIONS: The K121Q variant of ENPP1 may be associated with <\\entity><\\entity> viremia and core antigen levels in HCV carriers.",
    "Label": ""
  },
  {
    "id": "16411",
    "Sentence": "The K121Q polymorphism in the <\\entity><\\entity> (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16412",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with <\\entity><\\entity> and obesity.",
    "Label": ""
  },
  {
    "id": "16414",
    "Sentence": "The K121Q polymorphism in the <\\entity><\\entity> (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and obesity.",
    "Label": ""
  },
  {
    "id": "16415",
    "Sentence": "The K121Q polymorphism in the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP)-1 gene and the rs7566605 genotype located near insulin-induced gene 2 have been shown to be associated with insulin resistance and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16417",
    "Sentence": "RESULTS: No significant differences in body mass index, plasma glucose level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the <\\entity><\\entity> polymorphism or rs7566605.",
    "Label": ""
  },
  {
    "id": "16418",
    "Sentence": "RESULTS: No significant differences in <\\entity><\\entity>, plasma glucose level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the K121Q polymorphism or rs7566605.",
    "Label": ""
  },
  {
    "id": "16420",
    "Sentence": "RESULTS: No significant differences in body mass index, plasma glucose level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the <\\entity><\\entity> polymorphism or rs7566605.",
    "Label": ""
  },
  {
    "id": "16421",
    "Sentence": "RESULTS: No significant differences in body mass index, plasma <\\entity><\\entity> level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the K121Q polymorphism or rs7566605.",
    "Label": ""
  },
  {
    "id": "16423",
    "Sentence": "RESULTS: No significant differences in body mass index, plasma glucose level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the <\\entity><\\entity> polymorphism or rs7566605.",
    "Label": ""
  },
  {
    "id": "16424",
    "Sentence": "RESULTS: No significant differences in body mass index, plasma glucose level, serum <\\entity><\\entity> level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the K121Q polymorphism or rs7566605.",
    "Label": ""
  },
  {
    "id": "16426",
    "Sentence": "RESULTS: No significant differences in body mass index, plasma glucose level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the K121Q polymorphism or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16427",
    "Sentence": "RESULTS: No significant differences in <\\entity><\\entity>, plasma glucose level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the K121Q polymorphism or rs7566605.",
    "Label": ""
  },
  {
    "id": "16429",
    "Sentence": "RESULTS: No significant differences in body mass index, plasma glucose level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the K121Q polymorphism or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16430",
    "Sentence": "RESULTS: No significant differences in body mass index, plasma <\\entity><\\entity> level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the K121Q polymorphism or rs7566605.",
    "Label": ""
  },
  {
    "id": "16432",
    "Sentence": "RESULTS: No significant differences in body mass index, plasma glucose level, serum insulin level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the K121Q polymorphism or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16433",
    "Sentence": "RESULTS: No significant differences in body mass index, plasma glucose level, serum <\\entity><\\entity> level, and other biochemical markers were observed between subgroups of subjects with different genotypes at the K121Q polymorphism or rs7566605.",
    "Label": ""
  },
  {
    "id": "16435",
    "Sentence": "The frequency of the homozygous wild-type genotype at <\\entity><\\entity> in HCV carriers, however, was significantly higher than that in subjects who were negative for HCV RNA (84.5% vs.",
    "Label": ""
  },
  {
    "id": "16436",
    "Sentence": "The frequency of the homozygous wild-type genotype at K121Q in <\\entity><\\entity> carriers, however, was significantly higher than that in subjects who were negative for <\\entity><\\entity> RNA (84.5% vs.",
    "Label": ""
  },
  {
    "id": "16438",
    "Sentence": "The frequency of the homozygous wild-type genotype at K121Q in HCV carriers, however, was significantly higher than that in subjects who were negative for <\\entity><\\entity> (84.5% vs.",
    "Label": ""
  },
  {
    "id": "16439",
    "Sentence": "The frequency of the homozygous wild-type genotype at K121Q in <\\entity><\\entity> carriers, however, was significantly higher than that in subjects who were negative for <\\entity><\\entity> RNA (84.5% vs.",
    "Label": ""
  },
  {
    "id": "16441",
    "Sentence": "Moreover, in HCV carriers, HCV core antigen levels in subjects homozygous for the wild-type genotype at <\\entity><\\entity> were significantly higher than in heterozygous carriers of <\\entity><\\entity> (5358 fmol/l vs.",
    "Label": ""
  },
  {
    "id": "16442",
    "Sentence": "Moreover, in <\\entity><\\entity> carriers, <\\entity><\\entity> core antigen levels in subjects homozygous for the wild-type genotype at K121Q were significantly higher than in heterozygous carriers of K121Q (5358 fmol/l vs.",
    "Label": ""
  },
  {
    "id": "16444",
    "Sentence": "Moreover, in HCV carriers, <\\entity><\\entity> levels in subjects homozygous for the wild-type genotype at K121Q were significantly higher than in heterozygous carriers of K121Q (5358 fmol/l vs.",
    "Label": ""
  },
  {
    "id": "16445",
    "Sentence": "Moreover, in <\\entity><\\entity> carriers, <\\entity><\\entity> core antigen levels in subjects homozygous for the wild-type genotype at K121Q were significantly higher than in heterozygous carriers of K121Q (5358 fmol/l vs.",
    "Label": ""
  },
  {
    "id": "16447",
    "Sentence": "CONCLUSIONS: The K121Q variant of <\\entity><\\entity> may be associated with hepatitis C viremia and core antigen levels in HCV carriers.",
    "Label": ""
  },
  {
    "id": "16448",
    "Sentence": "CONCLUSIONS: The K121Q variant of ENPP1 may be associated with hepatitis C viremia and core antigen levels in <\\entity><\\entity> carriers.",
    "Label": ""
  },
  {
    "id": "16450",
    "Sentence": "CONCLUSIONS: The <\\entity><\\entity> variant of ENPP1 may be associated with hepatitis C viremia and core antigen levels in HCV carriers.",
    "Label": ""
  },
  {
    "id": "16451",
    "Sentence": "CONCLUSIONS: The K121Q variant of ENPP1 may be associated with hepatitis C viremia and core antigen levels in <\\entity><\\entity> carriers.",
    "Label": ""
  },
  {
    "id": "16457",
    "Sentence": "Hidden <\\entity><\\entity> and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16458",
    "Sentence": "Hidden abnormalities and novel classification of <\\entity><\\entity> (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16459",
    "Sentence": "Hidden abnormalities and novel classification of t(<\\entity><\\entity>) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(<\\entity><\\entity>), resulting in the formation of the PML-RARA gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16460",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (<\\entity><\\entity>) based on genomic alterations.Acute promyelocytic leukemia (<\\entity><\\entity>) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16461",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (<\\entity><\\entity>) based on genomic alterations.Acute promyelocytic leukemia (<\\entity><\\entity>) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16462",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.<\\entity><\\entity> (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16463",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (<\\entity><\\entity>) based on genomic alterations.Acute promyelocytic leukemia (<\\entity><\\entity>) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16464",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (<\\entity><\\entity>) based on genomic alterations.Acute promyelocytic leukemia (<\\entity><\\entity>) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16465",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant <\\entity><\\entity> characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16466",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the <\\entity><\\entity> t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16467",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the <\\entity><\\entity> t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16468",
    "Sentence": "Hidden abnormalities and novel classification of <\\entity><\\entity> acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation <\\entity><\\entity>, resulting in the formation of the PML-RARA gene.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16469",
    "Sentence": "Hidden abnormalities and novel classification of t(<\\entity><\\entity>) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(<\\entity><\\entity>), resulting in the formation of the PML-RARA gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16470",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the <\\entity><\\entity> gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16471",
    "Sentence": "Here, 47 <\\entity><\\entity> samples were analyzed with high-density single-nucleotide polymorphism microarray (50-K and 250-K SNP-chips) using the new algorithm AsCNAR (allele-specific copy-number analysis using anonymous references).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16472",
    "Sentence": "Here, 47 <\\entity><\\entity> samples were analyzed with high-density single-nucleotide polymorphism microarray (50-K and 250-K SNP-chips) using the new algorithm AsCNAR (allele-specific copy-number analysis using anonymous references).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16473",
    "Sentence": "Here, 47 t(<\\entity><\\entity>) APL samples were analyzed with high-density single-nucleotide polymorphism microarray (50-K and 250-K SNP-chips) using the new algorithm AsCNAR (allele-specific copy-number analysis using anonymous references).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16474",
    "Sentence": "<\\entity><\\entity> (CNN-LOH) was identified at chromosomes 10q (3 cases), 11p (3 cases), and 19q (1 case).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16475",
    "Sentence": "Copy-number-neutral loss of heterozygosity (<\\entity><\\entity>) was identified at chromosomes 10q (3 cases), 11p (3 cases), and 19q (1 case).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16476",
    "Sentence": "Copy-number-neutral loss of heterozygosity (<\\entity><\\entity>) was identified at chromosomes 10q (3 cases), 11p (3 cases), and 19q (1 case).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16477",
    "Sentence": "Copy-number-neutral loss of heterozygosity (CNN-LOH) was identified at chromosomes <\\entity><\\entity> (3 cases), 11p (3 cases), and 19q (1 case).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16478",
    "Sentence": "Copy-number-neutral loss of heterozygosity (CNN-LOH) was identified at chromosomes 10q (3 cases), <\\entity><\\entity> (3 cases), and 19q (1 case).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16479",
    "Sentence": "Copy-number-neutral loss of heterozygosity (CNN-LOH) was identified at chromosomes 10q (3 cases), 11p (3 cases), and <\\entity><\\entity> (1 case).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16480",
    "Sentence": "Nineteen samples (40%) showed either one or more genomic <\\entity><\\entity>: 8 samples (17%) had trisomy 8 either with or without an additional duplication, deletion, or CNN-LOH (+8 group); and 11 samples (23%) had genomic <\\entity><\\entity> without trisomy 8 (other <\\entity><\\entity> group).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16481",
    "Sentence": "Nineteen samples (40%) showed either one or more genomic abnormalities: 8 samples (17%) had <\\entity><\\entity> either with or without an additional duplication, deletion, or CNN-LOH (+8 group); and 11 samples (23%) had genomic abnormalities without <\\entity><\\entity> (other abnormalities group).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16482",
    "Sentence": "Nineteen samples (40%) showed either one or more genomic abnormalities: 8 samples (17%) had <\\entity><\\entity> either with or without an additional duplication, deletion, or CNN-LOH (+8 group); and 11 samples (23%) had genomic abnormalities without <\\entity><\\entity> (other abnormalities group).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16483",
    "Sentence": "Nineteen samples (40%) showed either one or more genomic abnormalities: 8 samples (17%) had trisomy 8 either with or without an additional <\\entity><\\entity>, deletion, or CNN-LOH (+8 group); and 11 samples (23%) had genomic abnormalities without trisomy 8 (other abnormalities group).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16484",
    "Sentence": "Nineteen samples (40%) showed either one or more genomic abnormalities: 8 samples (17%) had trisomy 8 either with or without an additional duplication, <\\entity><\\entity>, or CNN-LOH (+8 group); and 11 samples (23%) had genomic abnormalities without trisomy 8 (other abnormalities group).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16485",
    "Sentence": "Nineteen samples (40%) showed either one or more genomic abnormalities: 8 samples (17%) had trisomy 8 either with or without an additional duplication, deletion, or <\\entity><\\entity> (+8 group); and 11 samples (23%) had genomic abnormalities without trisomy 8 (other abnormalities group).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16486",
    "Sentence": "Nineteen samples (40%) showed either one or more genomic abnormalities: 8 samples (17%) had trisomy 8 either with or without an additional duplication, deletion, or <\\entity><\\entity> (+8 group); and 11 samples (23%) had genomic abnormalities without trisomy 8 (other abnormalities group).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16487",
    "Sentence": "Nineteen samples (40%) showed either one or more genomic <\\entity><\\entity>: 8 samples (17%) had trisomy 8 either with or without an additional duplication, deletion, or CNN-LOH (+8 group); and 11 samples (23%) had genomic <\\entity><\\entity> without trisomy 8 (other <\\entity><\\entity> group).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16488",
    "Sentence": "Nineteen samples (40%) showed either one or more genomic abnormalities: 8 samples (17%) had <\\entity><\\entity> either with or without an additional duplication, deletion, or CNN-LOH (+8 group); and 11 samples (23%) had genomic abnormalities without <\\entity><\\entity> (other abnormalities group).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16489",
    "Sentence": "Nineteen samples (40%) showed either one or more genomic abnormalities: 8 samples (17%) had <\\entity><\\entity> either with or without an additional duplication, deletion, or CNN-LOH (+8 group); and 11 samples (23%) had genomic abnormalities without <\\entity><\\entity> (other abnormalities group).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16490",
    "Sentence": "Nineteen samples (40%) showed either one or more genomic <\\entity><\\entity>: 8 samples (17%) had trisomy 8 either with or without an additional duplication, deletion, or CNN-LOH (+8 group); and 11 samples (23%) had genomic <\\entity><\\entity> without trisomy 8 (other <\\entity><\\entity> group).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16491",
    "Sentence": "These <\\entity><\\entity> were acquired somatic mutations.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16492",
    "Sentence": "These chromosomal abnormalities were acquired <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16493",
    "Sentence": "Interestingly, <\\entity><\\entity> mutations (11/47 cases) occurred only in the group with no genomic alteration (NC group).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16494",
    "Sentence": "Interestingly, <\\entity><\\entity> mutations (11/47 cases) occurred only in the group with no genomic alteration (NC group).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16495",
    "Sentence": "Interestingly, FLT3-ITD <\\entity><\\entity> (11/47 cases) occurred only in the group with no genomic alteration (NC group).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16496",
    "Sentence": "Taken together, these results suggest that the pathway of development of <\\entity><\\entity> differs in each group: FLT3-ITD, trisomy 8, and other genomic changes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16497",
    "Sentence": "Taken together, these results suggest that the pathway of development of <\\entity><\\entity> differs in each group: FLT3-ITD, trisomy 8, and other genomic changes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16498",
    "Sentence": "Taken together, these results suggest that the pathway of development of APL differs in each group: <\\entity><\\entity>, trisomy 8, and other genomic changes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16499",
    "Sentence": "Taken together, these results suggest that the pathway of development of APL differs in each group: <\\entity><\\entity>, trisomy 8, and other genomic changes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16500",
    "Sentence": "Taken together, these results suggest that the pathway of development of APL differs in each group: FLT3-ITD, <\\entity><\\entity>, and other genomic changes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16501",
    "Sentence": "Taken together, these results suggest that the pathway of development of APL differs in each group: FLT3-ITD, <\\entity><\\entity>, and other genomic changes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16502",
    "Sentence": "Here, we showed for the first time hidden <\\entity><\\entity> and novel disease-related genomic changes in t(15;17) APL.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16503",
    "Sentence": "Here, we showed for the first time hidden abnormalities and novel <\\entity><\\entity>-related genomic changes in t(15;17) APL.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16504",
    "Sentence": "Here, we showed for the first time hidden abnormalities and novel disease-related genomic changes in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16505",
    "Sentence": "Here, we showed for the first time hidden abnormalities and novel disease-related genomic changes in <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16506",
    "Sentence": "Here, we showed for the first time hidden abnormalities and novel disease-related genomic changes in t(<\\entity><\\entity>) APL.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16507",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the <\\entity><\\entity> t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16508",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (<\\entity><\\entity>) based on genomic alterations.Acute promyelocytic leukemia (<\\entity><\\entity>) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16510",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the <\\entity><\\entity> t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16511",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.<\\entity><\\entity> (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16513",
    "Sentence": "Hidden abnormalities and novel classification of <\\entity><\\entity> acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation <\\entity><\\entity>, resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16514",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (<\\entity><\\entity>) based on genomic alterations.Acute promyelocytic leukemia (<\\entity><\\entity>) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16516",
    "Sentence": "Hidden abnormalities and novel classification of <\\entity><\\entity> acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation <\\entity><\\entity>, resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16517",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.<\\entity><\\entity> (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16519",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (<\\entity><\\entity>) based on genomic alterations.Acute promyelocytic leukemia (<\\entity><\\entity>) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16520",
    "Sentence": "Hidden <\\entity><\\entity> and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16522",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (<\\entity><\\entity>) based on genomic alterations.Acute promyelocytic leukemia (<\\entity><\\entity>) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16523",
    "Sentence": "Hidden abnormalities and novel classification of <\\entity><\\entity> (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16525",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (<\\entity><\\entity>) based on genomic alterations.Acute promyelocytic leukemia (<\\entity><\\entity>) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16526",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.<\\entity><\\entity> (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16528",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (<\\entity><\\entity>) based on genomic alterations.Acute promyelocytic leukemia (<\\entity><\\entity>) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16529",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant <\\entity><\\entity> characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16531",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (<\\entity><\\entity>) based on genomic alterations.Acute promyelocytic leukemia (<\\entity><\\entity>) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16532",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the <\\entity><\\entity> t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16534",
    "Sentence": "Taken together, these results suggest that the pathway of development of <\\entity><\\entity> differs in each group: FLT3-ITD, trisomy 8, and other genomic changes.",
    "Label": ""
  },
  {
    "id": "16535",
    "Sentence": "Taken together, these results suggest that the pathway of development of APL differs in each group: FLT3-ITD, <\\entity><\\entity>, and other genomic changes.",
    "Label": ""
  },
  {
    "id": "16537",
    "Sentence": "Here, we showed for the first time hidden abnormalities and novel disease-related genomic changes in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16538",
    "Sentence": "Here, we showed for the first time hidden <\\entity><\\entity> and novel disease-related genomic changes in t(15;17) APL.",
    "Label": ""
  },
  {
    "id": "16540",
    "Sentence": "Here, we showed for the first time hidden abnormalities and novel disease-related genomic changes in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16541",
    "Sentence": "Here, we showed for the first time hidden abnormalities and novel <\\entity><\\entity>-related genomic changes in t(15;17) APL.",
    "Label": ""
  },
  {
    "id": "16543",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the <\\entity><\\entity> gene.",
    "Label": ""
  },
  {
    "id": "16544",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (<\\entity><\\entity>) based on genomic alterations.Acute promyelocytic leukemia (<\\entity><\\entity>) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16546",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the <\\entity><\\entity> gene.",
    "Label": ""
  },
  {
    "id": "16547",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.<\\entity><\\entity> (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16549",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the <\\entity><\\entity> gene.",
    "Label": ""
  },
  {
    "id": "16550",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the <\\entity><\\entity> t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16552",
    "Sentence": "Interestingly, <\\entity><\\entity> mutations (11/47 cases) occurred only in the group with no genomic alteration (NC group).",
    "Label": ""
  },
  {
    "id": "16553",
    "Sentence": "Interestingly, FLT3-ITD <\\entity><\\entity> (11/47 cases) occurred only in the group with no genomic alteration (NC group).",
    "Label": ""
  },
  {
    "id": "16555",
    "Sentence": "Taken together, these results suggest that the pathway of development of APL differs in each group: <\\entity><\\entity>, trisomy 8, and other genomic changes.",
    "Label": ""
  },
  {
    "id": "16556",
    "Sentence": "Taken together, these results suggest that the pathway of development of <\\entity><\\entity> differs in each group: FLT3-ITD, trisomy 8, and other genomic changes.",
    "Label": ""
  },
  {
    "id": "16558",
    "Sentence": "Hidden abnormalities and novel classification of t(<\\entity><\\entity>) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(<\\entity><\\entity>), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16559",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.<\\entity><\\entity> (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16561",
    "Sentence": "Hidden abnormalities and novel classification of t(<\\entity><\\entity>) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(<\\entity><\\entity>), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16562",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the <\\entity><\\entity> t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16564",
    "Sentence": "Hidden abnormalities and novel classification of t(<\\entity><\\entity>) acute promyelocytic leukemia (APL) based on genomic alterations.Acute promyelocytic leukemia (APL) is a hematopoietic malignant disease characterized by the chromosomal translocation t(<\\entity><\\entity>), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16565",
    "Sentence": "Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (<\\entity><\\entity>) based on genomic alterations.Acute promyelocytic leukemia (<\\entity><\\entity>) is a hematopoietic malignant disease characterized by the chromosomal translocation t(15;17), resulting in the formation of the PML-RARA gene.",
    "Label": ""
  },
  {
    "id": "16567",
    "Sentence": "Here, 47 t(<\\entity><\\entity>) APL samples were analyzed with high-density single-nucleotide polymorphism microarray (50-K and 250-K SNP-chips) using the new algorithm AsCNAR (allele-specific copy-number analysis using anonymous references).",
    "Label": ""
  },
  {
    "id": "16568",
    "Sentence": "Here, 47 <\\entity><\\entity> samples were analyzed with high-density single-nucleotide polymorphism microarray (50-K and 250-K SNP-chips) using the new algorithm AsCNAR (allele-specific copy-number analysis using anonymous references).",
    "Label": ""
  },
  {
    "id": "16570",
    "Sentence": "Nineteen samples (40%) showed either one or more genomic abnormalities: 8 samples (17%) had trisomy 8 either with or without an additional duplication, deletion, or <\\entity><\\entity> (+8 group); and 11 samples (23%) had genomic abnormalities without trisomy 8 (other abnormalities group).",
    "Label": ""
  },
  {
    "id": "16571",
    "Sentence": "Nineteen samples (40%) showed either one or more genomic abnormalities: 8 samples (17%) had <\\entity><\\entity> either with or without an additional duplication, deletion, or CNN-LOH (+8 group); and 11 samples (23%) had genomic abnormalities without <\\entity><\\entity> (other abnormalities group).",
    "Label": ""
  },
  {
    "id": "16573",
    "Sentence": "Taken together, these results suggest that the pathway of development of APL differs in each group: <\\entity><\\entity>, trisomy 8, and other genomic changes.",
    "Label": ""
  },
  {
    "id": "16574",
    "Sentence": "Taken together, these results suggest that the pathway of development of APL differs in each group: FLT3-ITD, <\\entity><\\entity>, and other genomic changes.",
    "Label": ""
  },
  {
    "id": "16580",
    "Sentence": "<\\entity><\\entity> and arterial stiffness in patients with normal kidney function.AIM: To evaluate the association between fetuin-A level (AHSG), its encoding gene (Thr256Ser) and arterial function in subjects with normal kidney function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16581",
    "Sentence": "Fetuin-A and <\\entity><\\entity> in patients with normal kidney function.AIM: To evaluate the association between fetuin-A level (AHSG), its encoding gene (Thr256Ser) and arterial function in subjects with normal kidney function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16582",
    "Sentence": "Fetuin-A and arterial stiffness in patients with normal kidney function.AIM: To evaluate the association between <\\entity><\\entity> level (AHSG), its encoding gene (Thr256Ser) and arterial function in subjects with normal kidney function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16583",
    "Sentence": "Fetuin-A and arterial stiffness in patients with normal kidney function.AIM: To evaluate the association between fetuin-A level (<\\entity><\\entity>), its encoding gene (Thr256Ser) and arterial function in subjects with normal kidney function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16584",
    "Sentence": "Fetuin-A and arterial stiffness in patients with normal kidney function.AIM: To evaluate the association between fetuin-A level (AHSG), its encoding gene (<\\entity><\\entity>) and arterial function in subjects with normal kidney function.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16585",
    "Sentence": "Fetuin-A and arterial stiffness in patients with normal kidney function.AIM: To evaluate the association between fetuin-A level (AHSG), its encoding gene (<\\entity><\\entity>) and arterial function in subjects with normal kidney function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16586",
    "Sentence": "Fetuin-A and arterial stiffness in patients with normal kidney function.AIM: To evaluate the association between fetuin-A level (AHSG), its encoding gene (Thr256Ser) and <\\entity><\\entity> in subjects with normal kidney function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16587",
    "Sentence": "INTRODUCTION: The aortic pulse wave velocity (<\\entity><\\entity>) is a predictor for cardiovascular mortality.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16588",
    "Sentence": "INTRODUCTION: The aortic pulse wave velocity (aPWV) is a predictor for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16589",
    "Sentence": "<\\entity><\\entity> is a calcification inhibitor and correlates negatively with increased vascular stiffness in dialysis patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16590",
    "Sentence": "Fetuin-A is a <\\entity><\\entity> and correlates negatively with increased vascular stiffness in dialysis patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16591",
    "Sentence": "Fetuin-A is a <\\entity><\\entity> and correlates negatively with increased vascular stiffness in dialysis patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16592",
    "Sentence": "Fetuin-A is a calcification inhibitor and correlates negatively with increased <\\entity><\\entity> in dialysis patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16593",
    "Sentence": "The <\\entity><\\entity> polymorphism (Thr256Ser) is associated with reduced fetuin levels and accelerated vascular calcification in dialysis patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16594",
    "Sentence": "The fetuin-A polymorphism (<\\entity><\\entity>) is associated with reduced fetuin levels and accelerated vascular calcification in dialysis patients.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16595",
    "Sentence": "The fetuin-A polymorphism (<\\entity><\\entity>) is associated with reduced fetuin levels and accelerated vascular calcification in dialysis patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16596",
    "Sentence": "The fetuin-A polymorphism (Thr256Ser) is associated with reduced <\\entity><\\entity> and accelerated vascular calcification in dialysis patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16597",
    "Sentence": "The fetuin-A polymorphism (Thr256Ser) is associated with reduced fetuin levels and accelerated <\\entity><\\entity> in dialysis patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16598",
    "Sentence": "<\\entity><\\entity> is known about the role of fetuin-A as an independent predictor for the development of arterial stiffness in healthy subjects.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16599",
    "Sentence": "Little is known about the role of <\\entity><\\entity> as an independent predictor for the development of arterial stiffness in healthy subjects.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16600",
    "Sentence": "Little is known about the role of fetuin-A as an independent predictor for the development of <\\entity><\\entity> in healthy subjects.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16601",
    "Sentence": "Calcium measurements, plasma <\\entity><\\entity>, its encoding gene (Thr256Ser) and indexes of arterial stiffness, such as aPWV and arterial distensibility, were determined.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16602",
    "Sentence": "Calcium measurements, plasma fetuin-A, its encoding gene (<\\entity><\\entity>) and indexes of arterial stiffness, such as aPWV and arterial distensibility, were determined.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16603",
    "Sentence": "Calcium measurements, plasma fetuin-A, its encoding gene (<\\entity><\\entity>) and indexes of arterial stiffness, such as aPWV and arterial distensibility, were determined.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16604",
    "Sentence": "Calcium measurements, plasma fetuin-A, its encoding gene (Thr256Ser) and indexes of <\\entity><\\entity>, such as aPWV and arterial distensibility, were determined.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16605",
    "Sentence": "Calcium measurements, plasma fetuin-A, its encoding gene (Thr256Ser) and indexes of arterial stiffness, such as <\\entity><\\entity> and arterial distensibility, were determined.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16606",
    "Sentence": "Calcium measurements, plasma fetuin-A, its encoding gene (Thr256Ser) and indexes of arterial stiffness, such as aPWV and <\\entity><\\entity>, were determined.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16607",
    "Sentence": "RESULTS: <\\entity><\\entity> levels were negatively correlated with aPWV (r=-0.21, p=0.029).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16608",
    "Sentence": "RESULTS: Fetuin-A levels were negatively correlated with <\\entity><\\entity> (r=-0.21, p=0.029).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16609",
    "Sentence": "After an adjustment for multiple covariables, <\\entity><\\entity> levels were independently associated with aPWV (r=-0.30, p=0.022) in males but not in females.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16610",
    "Sentence": "After an adjustment for multiple covariables, fetuin-A levels were independently associated with <\\entity><\\entity> (r=-0.30, p=0.022) in males but not in females.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16611",
    "Sentence": "<\\entity><\\entity> had lower fetuin-A levels and higher aPWV (fetuin-A: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16612",
    "Sentence": "Male <\\entity><\\entity> SerSer carrier had lower <\\entity><\\entity> levels and higher aPWV (<\\entity><\\entity>: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (<\\entity><\\entity>: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (<\\entity><\\entity>: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16613",
    "Sentence": "Male fetuin-A <\\entity><\\entity> carrier had lower fetuin-A levels and higher aPWV (fetuin-A: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16614",
    "Sentence": "Male fetuin-A <\\entity><\\entity> carrier had lower fetuin-A levels and higher aPWV (fetuin-A: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16615",
    "Sentence": "Male <\\entity><\\entity> SerSer carrier had lower <\\entity><\\entity> levels and higher aPWV (<\\entity><\\entity>: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (<\\entity><\\entity>: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (<\\entity><\\entity>: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16616",
    "Sentence": "Male fetuin-A SerSer carrier had lower fetuin-A levels and higher <\\entity><\\entity> (fetuin-A: 61.9+/-29.0 microg/ml; <\\entity><\\entity>: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; <\\entity><\\entity>: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; <\\entity><\\entity>: 6.6+/-1.3 m/s).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16617",
    "Sentence": "Male <\\entity><\\entity> SerSer carrier had lower <\\entity><\\entity> levels and higher aPWV (<\\entity><\\entity>: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (<\\entity><\\entity>: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (<\\entity><\\entity>: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16618",
    "Sentence": "Male fetuin-A SerSer carrier had lower fetuin-A levels and higher <\\entity><\\entity> (fetuin-A: 61.9+/-29.0 microg/ml; <\\entity><\\entity>: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; <\\entity><\\entity>: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; <\\entity><\\entity>: 6.6+/-1.3 m/s).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16619",
    "Sentence": "Male fetuin-A SerSer carrier had lower fetuin-A levels and higher aPWV (fetuin-A: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to <\\entity><\\entity> (fetuin-A: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16620",
    "Sentence": "Male fetuin-A SerSer carrier had lower fetuin-A levels and higher aPWV (fetuin-A: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to <\\entity><\\entity> (fetuin-A: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16621",
    "Sentence": "Male <\\entity><\\entity> SerSer carrier had lower <\\entity><\\entity> levels and higher aPWV (<\\entity><\\entity>: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (<\\entity><\\entity>: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (<\\entity><\\entity>: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16622",
    "Sentence": "Male fetuin-A SerSer carrier had lower fetuin-A levels and higher <\\entity><\\entity> (fetuin-A: 61.9+/-29.0 microg/ml; <\\entity><\\entity>: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; <\\entity><\\entity>: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; <\\entity><\\entity>: 6.6+/-1.3 m/s).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16623",
    "Sentence": "Male fetuin-A SerSer carrier had lower fetuin-A levels and higher aPWV (fetuin-A: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and <\\entity><\\entity> (fetuin-A: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16624",
    "Sentence": "Male fetuin-A SerSer carrier had lower fetuin-A levels and higher aPWV (fetuin-A: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and <\\entity><\\entity> (fetuin-A: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16625",
    "Sentence": "Male <\\entity><\\entity> SerSer carrier had lower <\\entity><\\entity> levels and higher aPWV (<\\entity><\\entity>: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (<\\entity><\\entity>: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (<\\entity><\\entity>: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16626",
    "Sentence": "Male fetuin-A SerSer carrier had lower fetuin-A levels and higher <\\entity><\\entity> (fetuin-A: 61.9+/-29.0 microg/ml; <\\entity><\\entity>: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; <\\entity><\\entity>: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; <\\entity><\\entity>: 6.6+/-1.3 m/s).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16627",
    "Sentence": "Other calcium variables were not significantly associated with arterial <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16628",
    "Sentence": "CONCLUSION: With respect to common calcium variables, only <\\entity><\\entity> level showed an inverse relation with aPWV in men with normal renal function.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16629",
    "Sentence": "CONCLUSION: With respect to common calcium variables, only fetuin-A level showed an inverse relation with <\\entity><\\entity> in men with normal renal function.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16630",
    "Sentence": "<\\entity><\\entity> demonstrate particularly high aortic stiffness, possibly implying a status of increased cardiovascular risk.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16631",
    "Sentence": "Male <\\entity><\\entity> SerSer carriers demonstrate particularly high aortic stiffness, possibly implying a status of increased cardiovascular risk.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16632",
    "Sentence": "Male fetuin-A <\\entity><\\entity> carriers demonstrate particularly high aortic stiffness, possibly implying a status of increased cardiovascular risk.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16633",
    "Sentence": "Male fetuin-A <\\entity><\\entity> carriers demonstrate particularly high aortic stiffness, possibly implying a status of increased cardiovascular risk.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16634",
    "Sentence": "Male fetuin-A SerSer carriers demonstrate particularly high <\\entity><\\entity>, possibly implying a status of increased cardiovascular risk.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16635",
    "Sentence": "Male fetuin-A SerSer carriers demonstrate particularly high aortic stiffness, possibly implying a status of increased <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16636",
    "Sentence": "<\\entity><\\entity> is a calcification inhibitor and correlates negatively with increased vascular stiffness in dialysis patients.",
    "Label": ""
  },
  {
    "id": "16637",
    "Sentence": "Fetuin-A is a calcification inhibitor and correlates negatively with increased <\\entity><\\entity> in dialysis patients.",
    "Label": ""
  },
  {
    "id": "16639",
    "Sentence": "The fetuin-A polymorphism (<\\entity><\\entity>) is associated with reduced fetuin levels and accelerated vascular calcification in dialysis patients.",
    "Label": ""
  },
  {
    "id": "16640",
    "Sentence": "The fetuin-A polymorphism (Thr256Ser) is associated with reduced fetuin levels and accelerated <\\entity><\\entity> in dialysis patients.",
    "Label": ""
  },
  {
    "id": "16642",
    "Sentence": "Little is known about the role of <\\entity><\\entity> as an independent predictor for the development of arterial stiffness in healthy subjects.",
    "Label": ""
  },
  {
    "id": "16643",
    "Sentence": "Little is known about the role of fetuin-A as an independent predictor for the development of <\\entity><\\entity> in healthy subjects.",
    "Label": ""
  },
  {
    "id": "16645",
    "Sentence": "<\\entity><\\entity> demonstrate particularly high aortic stiffness, possibly implying a status of increased cardiovascular risk.",
    "Label": ""
  },
  {
    "id": "16646",
    "Sentence": "Male fetuin-A SerSer carriers demonstrate particularly high <\\entity><\\entity>, possibly implying a status of increased cardiovascular risk.",
    "Label": ""
  },
  {
    "id": "16648",
    "Sentence": "<\\entity><\\entity> demonstrate particularly high aortic stiffness, possibly implying a status of increased cardiovascular risk.",
    "Label": ""
  },
  {
    "id": "16649",
    "Sentence": "Male fetuin-A SerSer carriers demonstrate particularly high aortic stiffness, possibly implying a status of increased <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16651",
    "Sentence": "<\\entity><\\entity> and arterial stiffness in patients with normal kidney function.AIM: To evaluate the association between fetuin-A level (AHSG), its encoding gene (Thr256Ser) and arterial function in subjects with normal kidney function.",
    "Label": ""
  },
  {
    "id": "16652",
    "Sentence": "Fetuin-A and <\\entity><\\entity> in patients with normal kidney function.AIM: To evaluate the association between fetuin-A level (AHSG), its encoding gene (Thr256Ser) and arterial function in subjects with normal kidney function.",
    "Label": ""
  },
  {
    "id": "16654",
    "Sentence": "<\\entity><\\entity> is a calcification inhibitor and correlates negatively with increased vascular stiffness in dialysis patients.",
    "Label": ""
  },
  {
    "id": "16655",
    "Sentence": "Fetuin-A is a <\\entity><\\entity> and correlates negatively with increased vascular stiffness in dialysis patients.",
    "Label": ""
  },
  {
    "id": "16657",
    "Sentence": "The <\\entity><\\entity> polymorphism (Thr256Ser) is associated with reduced fetuin levels and accelerated vascular calcification in dialysis patients.",
    "Label": ""
  },
  {
    "id": "16658",
    "Sentence": "The fetuin-A polymorphism (Thr256Ser) is associated with reduced fetuin levels and accelerated <\\entity><\\entity> in dialysis patients.",
    "Label": ""
  },
  {
    "id": "16660",
    "Sentence": "Little is known about the role of <\\entity><\\entity> as an independent predictor for the development of arterial stiffness in healthy subjects.",
    "Label": ""
  },
  {
    "id": "16661",
    "Sentence": "<\\entity><\\entity> is known about the role of fetuin-A as an independent predictor for the development of arterial stiffness in healthy subjects.",
    "Label": ""
  },
  {
    "id": "16663",
    "Sentence": "Calcium measurements, plasma <\\entity><\\entity>, its encoding gene (Thr256Ser) and indexes of arterial stiffness, such as aPWV and arterial distensibility, were determined.",
    "Label": ""
  },
  {
    "id": "16664",
    "Sentence": "Calcium measurements, plasma fetuin-A, its encoding gene (Thr256Ser) and indexes of <\\entity><\\entity>, such as aPWV and arterial distensibility, were determined.",
    "Label": ""
  },
  {
    "id": "16666",
    "Sentence": "Male <\\entity><\\entity> SerSer carriers demonstrate particularly high aortic stiffness, possibly implying a status of increased cardiovascular risk.",
    "Label": ""
  },
  {
    "id": "16667",
    "Sentence": "Male fetuin-A SerSer carriers demonstrate particularly high <\\entity><\\entity>, possibly implying a status of increased cardiovascular risk.",
    "Label": ""
  },
  {
    "id": "16669",
    "Sentence": "Male fetuin-A <\\entity><\\entity> carriers demonstrate particularly high aortic stiffness, possibly implying a status of increased cardiovascular risk.",
    "Label": ""
  },
  {
    "id": "16670",
    "Sentence": "Male fetuin-A SerSer carriers demonstrate particularly high <\\entity><\\entity>, possibly implying a status of increased cardiovascular risk.",
    "Label": ""
  },
  {
    "id": "16672",
    "Sentence": "Fetuin-A and arterial stiffness in patients with normal kidney function.AIM: To evaluate the association between fetuin-A level (<\\entity><\\entity>), its encoding gene (Thr256Ser) and arterial function in subjects with normal kidney function.",
    "Label": ""
  },
  {
    "id": "16673",
    "Sentence": "Fetuin-A and arterial stiffness in patients with normal kidney function.AIM: To evaluate the association between fetuin-A level (AHSG), its encoding gene (Thr256Ser) and <\\entity><\\entity> in subjects with normal kidney function.",
    "Label": ""
  },
  {
    "id": "16675",
    "Sentence": "Fetuin-A and arterial stiffness in patients with normal kidney function.AIM: To evaluate the association between fetuin-A level (AHSG), its encoding gene (<\\entity><\\entity>) and arterial function in subjects with normal kidney function.",
    "Label": ""
  },
  {
    "id": "16676",
    "Sentence": "Fetuin-A and arterial stiffness in patients with normal kidney function.AIM: To evaluate the association between fetuin-A level (AHSG), its encoding gene (Thr256Ser) and <\\entity><\\entity> in subjects with normal kidney function.",
    "Label": ""
  },
  {
    "id": "16678",
    "Sentence": "Fetuin-A is a <\\entity><\\entity> and correlates negatively with increased vascular stiffness in dialysis patients.",
    "Label": ""
  },
  {
    "id": "16679",
    "Sentence": "Fetuin-A is a calcification inhibitor and correlates negatively with increased <\\entity><\\entity> in dialysis patients.",
    "Label": ""
  },
  {
    "id": "16681",
    "Sentence": "The <\\entity><\\entity> polymorphism (Thr256Ser) is associated with reduced fetuin levels and accelerated vascular calcification in dialysis patients.",
    "Label": ""
  },
  {
    "id": "16682",
    "Sentence": "The fetuin-A polymorphism (Thr256Ser) is associated with reduced <\\entity><\\entity> and accelerated vascular calcification in dialysis patients.",
    "Label": ""
  },
  {
    "id": "16684",
    "Sentence": "The fetuin-A polymorphism (<\\entity><\\entity>) is associated with reduced fetuin levels and accelerated vascular calcification in dialysis patients.",
    "Label": ""
  },
  {
    "id": "16685",
    "Sentence": "The fetuin-A polymorphism (Thr256Ser) is associated with reduced <\\entity><\\entity> and accelerated vascular calcification in dialysis patients.",
    "Label": ""
  },
  {
    "id": "16687",
    "Sentence": "RESULTS: <\\entity><\\entity> levels were negatively correlated with aPWV (r=-0.21, p=0.029).",
    "Label": ""
  },
  {
    "id": "16688",
    "Sentence": "RESULTS: Fetuin-A levels were negatively correlated with <\\entity><\\entity> (r=-0.21, p=0.029).",
    "Label": ""
  },
  {
    "id": "16690",
    "Sentence": "After an adjustment for multiple covariables, <\\entity><\\entity> levels were independently associated with aPWV (r=-0.30, p=0.022) in males but not in females.",
    "Label": ""
  },
  {
    "id": "16691",
    "Sentence": "After an adjustment for multiple covariables, fetuin-A levels were independently associated with <\\entity><\\entity> (r=-0.30, p=0.022) in males but not in females.",
    "Label": ""
  },
  {
    "id": "16693",
    "Sentence": "Male <\\entity><\\entity> SerSer carrier had lower <\\entity><\\entity> levels and higher aPWV (<\\entity><\\entity>: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (<\\entity><\\entity>: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (<\\entity><\\entity>: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": ""
  },
  {
    "id": "16694",
    "Sentence": "Male fetuin-A SerSer carrier had lower fetuin-A levels and higher <\\entity><\\entity> (fetuin-A: 61.9+/-29.0 microg/ml; <\\entity><\\entity>: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; <\\entity><\\entity>: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; <\\entity><\\entity>: 6.6+/-1.3 m/s).",
    "Label": ""
  },
  {
    "id": "16696",
    "Sentence": "Male fetuin-A <\\entity><\\entity> carrier had lower fetuin-A levels and higher aPWV (fetuin-A: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": ""
  },
  {
    "id": "16697",
    "Sentence": "Male fetuin-A SerSer carrier had lower fetuin-A levels and higher <\\entity><\\entity> (fetuin-A: 61.9+/-29.0 microg/ml; <\\entity><\\entity>: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; <\\entity><\\entity>: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; <\\entity><\\entity>: 6.6+/-1.3 m/s).",
    "Label": ""
  },
  {
    "id": "16699",
    "Sentence": "Male fetuin-A SerSer carrier had lower fetuin-A levels and higher aPWV (fetuin-A: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to <\\entity><\\entity> (fetuin-A: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": ""
  },
  {
    "id": "16700",
    "Sentence": "Male fetuin-A SerSer carrier had lower fetuin-A levels and higher <\\entity><\\entity> (fetuin-A: 61.9+/-29.0 microg/ml; <\\entity><\\entity>: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; <\\entity><\\entity>: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; <\\entity><\\entity>: 6.6+/-1.3 m/s).",
    "Label": ""
  },
  {
    "id": "16702",
    "Sentence": "Male fetuin-A SerSer carrier had lower fetuin-A levels and higher aPWV (fetuin-A: 61.9+/-29.0 microg/ml; aPWV: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; aPWV: 6.4+/-1.3 m/s) and <\\entity><\\entity> (fetuin-A: 100.8+/-52.5 microg/ml; aPWV: 6.6+/-1.3 m/s).",
    "Label": ""
  },
  {
    "id": "16703",
    "Sentence": "Male fetuin-A SerSer carrier had lower fetuin-A levels and higher <\\entity><\\entity> (fetuin-A: 61.9+/-29.0 microg/ml; <\\entity><\\entity>: 14.3+/-0.9 m/s) as compared to ThrThr (fetuin-A: 109.9+/-54.9 microg/ml; <\\entity><\\entity>: 6.4+/-1.3 m/s) and ThrSer carrier (fetuin-A: 100.8+/-52.5 microg/ml; <\\entity><\\entity>: 6.6+/-1.3 m/s).",
    "Label": ""
  },
  {
    "id": "16705",
    "Sentence": "CONCLUSION: With respect to common calcium variables, only <\\entity><\\entity> level showed an inverse relation with aPWV in men with normal renal function.",
    "Label": ""
  },
  {
    "id": "16706",
    "Sentence": "CONCLUSION: With respect to common calcium variables, only fetuin-A level showed an inverse relation with <\\entity><\\entity> in men with normal renal function.",
    "Label": ""
  },
  {
    "id": "16708",
    "Sentence": "Male <\\entity><\\entity> SerSer carriers demonstrate particularly high aortic stiffness, possibly implying a status of increased cardiovascular risk.",
    "Label": ""
  },
  {
    "id": "16709",
    "Sentence": "Male fetuin-A SerSer carriers demonstrate particularly high aortic stiffness, possibly implying a status of increased <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16711",
    "Sentence": "Male fetuin-A <\\entity><\\entity> carriers demonstrate particularly high aortic stiffness, possibly implying a status of increased cardiovascular risk.",
    "Label": ""
  },
  {
    "id": "16712",
    "Sentence": "Male fetuin-A SerSer carriers demonstrate particularly high aortic stiffness, possibly implying a status of increased <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16718",
    "Sentence": "Common genetic variations of the <\\entity><\\entity> gene and risk of hepatocellular carcinoma in a Chinese population.Cytochrome P450 1A1 is a major enzyme in the bioactivation of exogenous procarcinogens of hepatocellular carcinoma (HCC).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16719",
    "Sentence": "Common genetic variations of the cytochrome P450 1A1 gene and risk of <\\entity><\\entity> in a Chinese population.Cytochrome P450 1A1 is a major enzyme in the bioactivation of exogenous procarcinogens of <\\entity><\\entity> (HCC).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16720",
    "Sentence": "Common genetic variations of the cytochrome P450 1A1 gene and risk of hepatocellular carcinoma in a Chinese population.<\\entity><\\entity> is a major enzyme in the bioactivation of exogenous procarcinogens of hepatocellular carcinoma (HCC).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16721",
    "Sentence": "Common genetic variations of the cytochrome P450 1A1 gene and risk of <\\entity><\\entity> in a Chinese population.Cytochrome P450 1A1 is a major enzyme in the bioactivation of exogenous procarcinogens of <\\entity><\\entity> (HCC).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16722",
    "Sentence": "Common genetic variations of the cytochrome P450 1A1 gene and risk of hepatocellular carcinoma in a Chinese population.Cytochrome P450 1A1 is a major enzyme in the bioactivation of exogenous procarcinogens of hepatocellular carcinoma (<\\entity><\\entity>).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16723",
    "Sentence": "Common genetic variations of the cytochrome P450 1A1 gene and risk of hepatocellular carcinoma in a Chinese population.Cytochrome P450 1A1 is a major enzyme in the bioactivation of exogenous procarcinogens of hepatocellular carcinoma (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16724",
    "Sentence": "However, the contribution of common genetic variants in <\\entity><\\entity> to the HCC risk in Chinese populations has not been thoroughly investigated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16725",
    "Sentence": "However, the contribution of common genetic variants in CYP1A1 to the <\\entity><\\entity> risk in Chinese populations has not been thoroughly investigated.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16726",
    "Sentence": "However, the contribution of common genetic variants in CYP1A1 to the <\\entity><\\entity> risk in Chinese populations has not been thoroughly investigated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16727",
    "Sentence": "In this study, we examined the association between <\\entity><\\entity> and four selected tagging single nucleotide polymorphisms (SNPs) of CYP1A1, and the risk of CYP1A1 haplotypes/diplotypes in 1006 pathologically confirmed <\\entity><\\entity> patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16728",
    "Sentence": "In this study, we examined the association between <\\entity><\\entity> and four selected tagging single nucleotide polymorphisms (SNPs) of CYP1A1, and the risk of CYP1A1 haplotypes/diplotypes in 1006 pathologically confirmed <\\entity><\\entity> patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16729",
    "Sentence": "In this study, we examined the association between HCC and four selected <\\entity><\\entity> single nucleotide polymorphisms (SNPs) of CYP1A1, and the risk of CYP1A1 haplotypes/diplotypes in 1006 pathologically confirmed HCC patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16730",
    "Sentence": "In this study, we examined the association between HCC and four selected tagging single nucleotide polymorphisms (SNPs) of <\\entity><\\entity>, and the risk of <\\entity><\\entity> haplotypes/diplotypes in 1006 pathologically confirmed HCC patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16731",
    "Sentence": "In this study, we examined the association between HCC and four selected tagging single nucleotide polymorphisms (SNPs) of <\\entity><\\entity>, and the risk of <\\entity><\\entity> haplotypes/diplotypes in 1006 pathologically confirmed HCC patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16732",
    "Sentence": "In this study, we examined the association between <\\entity><\\entity> and four selected tagging single nucleotide polymorphisms (SNPs) of CYP1A1, and the risk of CYP1A1 haplotypes/diplotypes in 1006 pathologically confirmed <\\entity><\\entity> patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16733",
    "Sentence": "In this study, we examined the association between <\\entity><\\entity> and four selected tagging single nucleotide polymorphisms (SNPs) of CYP1A1, and the risk of CYP1A1 haplotypes/diplotypes in 1006 pathologically confirmed <\\entity><\\entity> patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16734",
    "Sentence": "In this study, we examined the association between HCC and four selected tagging single nucleotide polymorphisms (SNPs) of CYP1A1, and the risk of CYP1A1 haplotypes/diplotypes in 1006 pathologically confirmed HCC patients and 1015 <\\entity><\\entity>-free controls, from a Han Chinese population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16735",
    "Sentence": "Relative risk was estimated by using multivariable logistic <\\entity><\\entity> method.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16736",
    "Sentence": "To summarise, we detected an increased <\\entity><\\entity> risk in rs4646421 variant carriers (OR 1.30, 95% CI 1.05-1.61) and rs2198843 variant carriers (OR 1.33, 95% CI 1.05-1.69), and a reduced risk of <\\entity><\\entity> (OR 0.70.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16737",
    "Sentence": "To summarise, we detected an increased <\\entity><\\entity> risk in rs4646421 variant carriers (OR 1.30, 95% CI 1.05-1.61) and rs2198843 variant carriers (OR 1.33, 95% CI 1.05-1.69), and a reduced risk of <\\entity><\\entity> (OR 0.70.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16738",
    "Sentence": "To summarise, we detected an increased HCC risk in <\\entity><\\entity> variant carriers (OR 1.30, 95% CI 1.05-1.61) and rs2198843 variant carriers (OR 1.33, 95% CI 1.05-1.69), and a reduced risk of HCC (OR 0.70.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16739",
    "Sentence": "To summarise, we detected an increased HCC risk in rs4646421 variant carriers (OR 1.30, 95% CI 1.05-1.61) and <\\entity><\\entity> variant carriers (OR 1.33, 95% CI 1.05-1.69), and a reduced risk of HCC (OR 0.70.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16740",
    "Sentence": "To summarise, we detected an increased <\\entity><\\entity> risk in rs4646421 variant carriers (OR 1.30, 95% CI 1.05-1.61) and rs2198843 variant carriers (OR 1.33, 95% CI 1.05-1.69), and a reduced risk of <\\entity><\\entity> (OR 0.70.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16741",
    "Sentence": "To summarise, we detected an increased <\\entity><\\entity> risk in rs4646421 variant carriers (OR 1.30, 95% CI 1.05-1.61) and rs2198843 variant carriers (OR 1.33, 95% CI 1.05-1.69), and a reduced risk of <\\entity><\\entity> (OR 0.70.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16742",
    "Sentence": "95% CI 0.52-0.94) associated with homozygote carriers of <\\entity><\\entity> variant.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16743",
    "Sentence": "These association signals were also observed in non-smokers with <\\entity><\\entity> (OR 1.56, 95% CI 1.16-2.08) and rs4886605 (OR 0.61, 95% CI 0.40-0.91).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16744",
    "Sentence": "These association signals were also observed in non-smokers with rs4646421 (OR 1.56, 95% CI 1.16-2.08) and <\\entity><\\entity> (OR 0.61, 95% CI 0.40-0.91).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16745",
    "Sentence": "Compared to the most common <\\entity><\\entity> haplotype CCAG, the haplotype TTGC conferred an increased risk of HCC (OR 1.26, 95% CI 1.04-1.52).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16746",
    "Sentence": "Compared to the most common CYP1A1 haplotype <\\entity><\\entity>, the haplotype TTGC conferred an increased risk of HCC (OR 1.26, 95% CI 1.04-1.52).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16747",
    "Sentence": "Compared to the most common CYP1A1 haplotype <\\entity><\\entity>, the haplotype TTGC conferred an increased risk of HCC (OR 1.26, 95% CI 1.04-1.52).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16748",
    "Sentence": "Compared to the most common CYP1A1 haplotype CCAG, the haplotype <\\entity><\\entity> conferred an increased risk of HCC (OR 1.26, 95% CI 1.04-1.52).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16749",
    "Sentence": "Compared to the most common CYP1A1 haplotype CCAG, the haplotype <\\entity><\\entity> conferred an increased risk of HCC (OR 1.26, 95% CI 1.04-1.52).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16750",
    "Sentence": "Compared to the most common CYP1A1 haplotype CCAG, the haplotype TTGC conferred an increased risk of <\\entity><\\entity> (OR 1.26, 95% CI 1.04-1.52).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16751",
    "Sentence": "Compared to the most common CYP1A1 haplotype CCAG, the haplotype TTGC conferred an increased risk of <\\entity><\\entity> (OR 1.26, 95% CI 1.04-1.52).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16752",
    "Sentence": "Similarly, the <\\entity><\\entity> diplotype conferred an increased risk of HCC compared with diplotype CCAG/CCAG (OR 2.06, 95% CI 1.23-3.45, P=0.006).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16753",
    "Sentence": "Similarly, the <\\entity><\\entity> diplotype conferred an increased risk of HCC compared with diplotype CCAG/CCAG (OR 2.06, 95% CI 1.23-3.45, P=0.006).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16754",
    "Sentence": "Similarly, the TTGC/TTGC diplotype conferred an increased risk of <\\entity><\\entity> compared with diplotype CCAG/CCAG (OR 2.06, 95% CI 1.23-3.45, P=0.006).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16755",
    "Sentence": "Similarly, the TTGC/TTGC diplotype conferred an increased risk of <\\entity><\\entity> compared with diplotype CCAG/CCAG (OR 2.06, 95% CI 1.23-3.45, P=0.006).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16756",
    "Sentence": "Similarly, the TTGC/TTGC diplotype conferred an increased risk of HCC compared with diplotype <\\entity><\\entity> (OR 2.06, 95% CI 1.23-3.45, P=0.006).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16757",
    "Sentence": "Similarly, the TTGC/TTGC diplotype conferred an increased risk of HCC compared with diplotype <\\entity><\\entity> (OR 2.06, 95% CI 1.23-3.45, P=0.006).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16758",
    "Sentence": "Interestingly, the diplotype <\\entity><\\entity> also conferred an increased risk of HCC (OR 1.76, 95% CI 1.22-2.54, P=0.003).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16759",
    "Sentence": "Interestingly, the diplotype <\\entity><\\entity> also conferred an increased risk of HCC (OR 1.76, 95% CI 1.22-2.54, P=0.003).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16760",
    "Sentence": "Interestingly, the diplotype TTAC/CCAG also conferred an increased risk of <\\entity><\\entity> (OR 1.76, 95% CI 1.22-2.54, P=0.003).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16761",
    "Sentence": "Interestingly, the diplotype TTAC/CCAG also conferred an increased risk of <\\entity><\\entity> (OR 1.76, 95% CI 1.22-2.54, P=0.003).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16762",
    "Sentence": "Our results suggested that common genetic variants in <\\entity><\\entity> may modulate the risk of developing HCC in the study population, particularly in non-smokers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16763",
    "Sentence": "Our results suggested that common genetic variants in CYP1A1 may modulate the risk of developing <\\entity><\\entity> in the study population, particularly in non-smokers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16764",
    "Sentence": "Our results suggested that common genetic variants in CYP1A1 may modulate the risk of developing <\\entity><\\entity> in the study population, particularly in non-smokers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16765",
    "Sentence": "Common genetic variations of the cytochrome P450 1A1 gene and risk of hepatocellular carcinoma in a Chinese population.<\\entity><\\entity> is a major enzyme in the bioactivation of exogenous procarcinogens of hepatocellular carcinoma (HCC).",
    "Label": ""
  },
  {
    "id": "16766",
    "Sentence": "Common genetic variations of the cytochrome P450 1A1 gene and risk of hepatocellular carcinoma in a Chinese population.Cytochrome P450 1A1 is a major enzyme in the bioactivation of exogenous procarcinogens of hepatocellular carcinoma (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "16768",
    "Sentence": "Common genetic variations of the cytochrome P450 1A1 gene and risk of hepatocellular carcinoma in a Chinese population.<\\entity><\\entity> is a major enzyme in the bioactivation of exogenous procarcinogens of hepatocellular carcinoma (HCC).",
    "Label": ""
  },
  {
    "id": "16769",
    "Sentence": "Common genetic variations of the cytochrome P450 1A1 gene and risk of <\\entity><\\entity> in a Chinese population.Cytochrome P450 1A1 is a major enzyme in the bioactivation of exogenous procarcinogens of <\\entity><\\entity> (HCC).",
    "Label": ""
  },
  {
    "id": "16771",
    "Sentence": "However, the contribution of common genetic variants in <\\entity><\\entity> to the HCC risk in Chinese populations has not been thoroughly investigated.",
    "Label": ""
  },
  {
    "id": "16772",
    "Sentence": "However, the contribution of common genetic variants in CYP1A1 to the <\\entity><\\entity> risk in Chinese populations has not been thoroughly investigated.",
    "Label": ""
  },
  {
    "id": "16774",
    "Sentence": "To summarise, we detected an increased HCC risk in <\\entity><\\entity> variant carriers (OR 1.30, 95% CI 1.05-1.61) and rs2198843 variant carriers (OR 1.33, 95% CI 1.05-1.69), and a reduced risk of HCC (OR 0.70.",
    "Label": ""
  },
  {
    "id": "16775",
    "Sentence": "To summarise, we detected an increased <\\entity><\\entity> risk in rs4646421 variant carriers (OR 1.30, 95% CI 1.05-1.61) and rs2198843 variant carriers (OR 1.33, 95% CI 1.05-1.69), and a reduced risk of <\\entity><\\entity> (OR 0.70.",
    "Label": ""
  },
  {
    "id": "16777",
    "Sentence": "To summarise, we detected an increased HCC risk in rs4646421 variant carriers (OR 1.30, 95% CI 1.05-1.61) and <\\entity><\\entity> variant carriers (OR 1.33, 95% CI 1.05-1.69), and a reduced risk of HCC (OR 0.70.",
    "Label": ""
  },
  {
    "id": "16778",
    "Sentence": "To summarise, we detected an increased <\\entity><\\entity> risk in rs4646421 variant carriers (OR 1.30, 95% CI 1.05-1.61) and rs2198843 variant carriers (OR 1.33, 95% CI 1.05-1.69), and a reduced risk of <\\entity><\\entity> (OR 0.70.",
    "Label": ""
  },
  {
    "id": "16780",
    "Sentence": "95% CI 0.52-0.94) associated with homozygote carriers of <\\entity><\\entity> variant.",
    "Label": ""
  },
  {
    "id": "16781",
    "Sentence": "To summarise, we detected an increased <\\entity><\\entity> risk in rs4646421 variant carriers (OR 1.30, 95% CI 1.05-1.61) and rs2198843 variant carriers (OR 1.33, 95% CI 1.05-1.69), and a reduced risk of <\\entity><\\entity> (OR 0.70.",
    "Label": ""
  },
  {
    "id": "16783",
    "Sentence": "Compared to the most common CYP1A1 haplotype CCAG, the haplotype <\\entity><\\entity> conferred an increased risk of HCC (OR 1.26, 95% CI 1.04-1.52).",
    "Label": ""
  },
  {
    "id": "16784",
    "Sentence": "Compared to the most common CYP1A1 haplotype CCAG, the haplotype TTGC conferred an increased risk of <\\entity><\\entity> (OR 1.26, 95% CI 1.04-1.52).",
    "Label": ""
  },
  {
    "id": "16786",
    "Sentence": "Similarly, the <\\entity><\\entity> diplotype conferred an increased risk of HCC compared with diplotype CCAG/CCAG (OR 2.06, 95% CI 1.23-3.45, P=0.006).",
    "Label": ""
  },
  {
    "id": "16787",
    "Sentence": "Similarly, the TTGC/TTGC diplotype conferred an increased risk of <\\entity><\\entity> compared with diplotype CCAG/CCAG (OR 2.06, 95% CI 1.23-3.45, P=0.006).",
    "Label": ""
  },
  {
    "id": "16789",
    "Sentence": "Interestingly, the diplotype <\\entity><\\entity> also conferred an increased risk of HCC (OR 1.76, 95% CI 1.22-2.54, P=0.003).",
    "Label": ""
  },
  {
    "id": "16790",
    "Sentence": "Interestingly, the diplotype TTAC/CCAG also conferred an increased risk of <\\entity><\\entity> (OR 1.76, 95% CI 1.22-2.54, P=0.003).",
    "Label": ""
  },
  {
    "id": "16792",
    "Sentence": "Our results suggested that common genetic variants in <\\entity><\\entity> may modulate the risk of developing HCC in the study population, particularly in non-smokers.",
    "Label": ""
  },
  {
    "id": "16793",
    "Sentence": "Our results suggested that common genetic variants in CYP1A1 may modulate the risk of developing <\\entity><\\entity> in the study population, particularly in non-smokers.",
    "Label": ""
  },
  {
    "id": "16795",
    "Sentence": "Common genetic variations of the <\\entity><\\entity> gene and risk of hepatocellular carcinoma in a Chinese population.Cytochrome P450 1A1 is a major enzyme in the bioactivation of exogenous procarcinogens of hepatocellular carcinoma (HCC).",
    "Label": ""
  },
  {
    "id": "16796",
    "Sentence": "Common genetic variations of the cytochrome P450 1A1 gene and risk of <\\entity><\\entity> in a Chinese population.Cytochrome P450 1A1 is a major enzyme in the bioactivation of exogenous procarcinogens of <\\entity><\\entity> (HCC).",
    "Label": ""
  },
  {
    "id": "16798",
    "Sentence": "Common genetic variations of the cytochrome P450 1A1 gene and risk of hepatocellular carcinoma in a Chinese population.Cytochrome P450 1A1 is a major enzyme in the bioactivation of exogenous procarcinogens of hepatocellular carcinoma (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "16799",
    "Sentence": "Common genetic variations of the cytochrome P450 1A1 gene and risk of <\\entity><\\entity> in a Chinese population.Cytochrome P450 1A1 is a major enzyme in the bioactivation of exogenous procarcinogens of <\\entity><\\entity> (HCC).",
    "Label": ""
  },
  {
    "id": "16801",
    "Sentence": "In this study, we examined the association between HCC and four selected tagging single nucleotide polymorphisms (SNPs) of <\\entity><\\entity>, and the risk of <\\entity><\\entity> haplotypes/diplotypes in 1006 pathologically confirmed HCC patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": ""
  },
  {
    "id": "16802",
    "Sentence": "In this study, we examined the association between HCC and four selected <\\entity><\\entity> single nucleotide polymorphisms (SNPs) of CYP1A1, and the risk of CYP1A1 haplotypes/diplotypes in 1006 pathologically confirmed HCC patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": ""
  },
  {
    "id": "16804",
    "Sentence": "In this study, we examined the association between HCC and four selected tagging single nucleotide polymorphisms (SNPs) of <\\entity><\\entity>, and the risk of <\\entity><\\entity> haplotypes/diplotypes in 1006 pathologically confirmed HCC patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": ""
  },
  {
    "id": "16805",
    "Sentence": "In this study, we examined the association between HCC and four selected tagging single nucleotide polymorphisms (SNPs) of CYP1A1, and the risk of CYP1A1 haplotypes/diplotypes in 1006 pathologically confirmed HCC patients and 1015 <\\entity><\\entity>-free controls, from a Han Chinese population.",
    "Label": ""
  },
  {
    "id": "16807",
    "Sentence": "In this study, we examined the association between <\\entity><\\entity> and four selected tagging single nucleotide polymorphisms (SNPs) of CYP1A1, and the risk of CYP1A1 haplotypes/diplotypes in 1006 pathologically confirmed <\\entity><\\entity> patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": ""
  },
  {
    "id": "16808",
    "Sentence": "In this study, we examined the association between HCC and four selected <\\entity><\\entity> single nucleotide polymorphisms (SNPs) of CYP1A1, and the risk of CYP1A1 haplotypes/diplotypes in 1006 pathologically confirmed HCC patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": ""
  },
  {
    "id": "16810",
    "Sentence": "In this study, we examined the association between <\\entity><\\entity> and four selected tagging single nucleotide polymorphisms (SNPs) of CYP1A1, and the risk of CYP1A1 haplotypes/diplotypes in 1006 pathologically confirmed <\\entity><\\entity> patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": ""
  },
  {
    "id": "16811",
    "Sentence": "In this study, we examined the association between HCC and four selected tagging single nucleotide polymorphisms (SNPs) of CYP1A1, and the risk of CYP1A1 haplotypes/diplotypes in 1006 pathologically confirmed HCC patients and 1015 <\\entity><\\entity>-free controls, from a Han Chinese population.",
    "Label": ""
  },
  {
    "id": "16813",
    "Sentence": "In this study, we examined the association between HCC and four selected tagging single nucleotide polymorphisms (SNPs) of <\\entity><\\entity>, and the risk of <\\entity><\\entity> haplotypes/diplotypes in 1006 pathologically confirmed HCC patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": ""
  },
  {
    "id": "16814",
    "Sentence": "In this study, we examined the association between <\\entity><\\entity> and four selected tagging single nucleotide polymorphisms (SNPs) of CYP1A1, and the risk of CYP1A1 haplotypes/diplotypes in 1006 pathologically confirmed <\\entity><\\entity> patients and 1015 cancer-free controls, from a Han Chinese population.",
    "Label": ""
  },
  {
    "id": "16816",
    "Sentence": "Compared to the most common <\\entity><\\entity> haplotype CCAG, the haplotype TTGC conferred an increased risk of HCC (OR 1.26, 95% CI 1.04-1.52).",
    "Label": ""
  },
  {
    "id": "16817",
    "Sentence": "Compared to the most common CYP1A1 haplotype CCAG, the haplotype TTGC conferred an increased risk of <\\entity><\\entity> (OR 1.26, 95% CI 1.04-1.52).",
    "Label": ""
  },
  {
    "id": "16819",
    "Sentence": "Compared to the most common CYP1A1 haplotype <\\entity><\\entity>, the haplotype TTGC conferred an increased risk of HCC (OR 1.26, 95% CI 1.04-1.52).",
    "Label": ""
  },
  {
    "id": "16820",
    "Sentence": "Compared to the most common CYP1A1 haplotype CCAG, the haplotype TTGC conferred an increased risk of <\\entity><\\entity> (OR 1.26, 95% CI 1.04-1.52).",
    "Label": ""
  },
  {
    "id": "16822",
    "Sentence": "Similarly, the TTGC/TTGC diplotype conferred an increased risk of HCC compared with diplotype <\\entity><\\entity> (OR 2.06, 95% CI 1.23-3.45, P=0.006).",
    "Label": ""
  },
  {
    "id": "16823",
    "Sentence": "Similarly, the TTGC/TTGC diplotype conferred an increased risk of <\\entity><\\entity> compared with diplotype CCAG/CCAG (OR 2.06, 95% CI 1.23-3.45, P=0.006).",
    "Label": ""
  },
  {
    "id": "16829",
    "Sentence": "Genetic, epidemiological and biological analysis of <\\entity><\\entity> suggests a definitive role for -819C/T in leprosy susceptibility.Leprosy is a complex infectious disease influenced by genetic and environmental factors.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16830",
    "Sentence": "Genetic, epidemiological and biological analysis of <\\entity><\\entity> suggests a definitive role for -819C/T in leprosy susceptibility.Leprosy is a complex infectious disease influenced by genetic and environmental factors.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16831",
    "Sentence": "Genetic, epidemiological and biological analysis of interleukin-10 promoter single-nucleotide polymorphisms suggests a definitive role for <\\entity><\\entity> in leprosy susceptibility.Leprosy is a complex infectious disease influenced by genetic and environmental factors.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16832",
    "Sentence": "Genetic, epidemiological and biological analysis of interleukin-10 promoter single-nucleotide polymorphisms suggests a definitive role for -819C/T in <\\entity><\\entity> susceptibility.Leprosy is a complex infectious disease influenced by genetic and environmental factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16833",
    "Sentence": "Genetic, epidemiological and biological analysis of interleukin-10 promoter single-nucleotide polymorphisms suggests a definitive role for -819C/T in leprosy susceptibility.<\\entity><\\entity> is a complex infectious disease influenced by genetic and environmental factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16834",
    "Sentence": "Genetic, epidemiological and biological analysis of interleukin-10 promoter single-nucleotide polymorphisms suggests a definitive role for -819C/T in leprosy susceptibility.Leprosy is a complex <\\entity><\\entity> influenced by genetic and environmental factors.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16835",
    "Sentence": "The genetic contributing factors are considered heterogeneous and several genes have been consistently associated with susceptibility like <\\entity><\\entity>, tumor necrosis factor (TNF), lymphotoxin-alpha (LTA) and vitamin-D receptor (VDR).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16836",
    "Sentence": "The genetic contributing factors are considered heterogeneous and several genes have been consistently associated with susceptibility like <\\entity><\\entity>, tumor necrosis factor (TNF), lymphotoxin-alpha (LTA) and vitamin-D receptor (VDR).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16837",
    "Sentence": "The genetic contributing factors are considered heterogeneous and several genes have been consistently associated with susceptibility like PARK2, <\\entity><\\entity> (TNF), lymphotoxin-alpha (LTA) and vitamin-D receptor (VDR).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16838",
    "Sentence": "The genetic contributing factors are considered heterogeneous and several genes have been consistently associated with susceptibility like PARK2, tumor necrosis factor (<\\entity><\\entity>), lymphotoxin-alpha (LTA) and vitamin-D receptor (VDR).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16839",
    "Sentence": "The genetic contributing factors are considered heterogeneous and several genes have been consistently associated with susceptibility like PARK2, tumor necrosis factor (TNF), <\\entity><\\entity> (LTA) and vitamin-D receptor (VDR).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16840",
    "Sentence": "The genetic contributing factors are considered heterogeneous and several genes have been consistently associated with susceptibility like PARK2, tumor necrosis factor (TNF), lymphotoxin-alpha (<\\entity><\\entity>) and vitamin-D receptor (VDR).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16841",
    "Sentence": "The genetic contributing factors are considered heterogeneous and several genes have been consistently associated with susceptibility like PARK2, tumor necrosis factor (TNF), lymphotoxin-alpha (LTA) and <\\entity><\\entity> (VDR).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16842",
    "Sentence": "The genetic contributing factors are considered heterogeneous and several genes have been consistently associated with susceptibility like PARK2, tumor necrosis factor (TNF), lymphotoxin-alpha (LTA) and vitamin-D receptor (<\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16843",
    "Sentence": "Here, we combined a case-control study (374 patients and 380 controls), with meta-analysis (5 studies; 2702 individuals) and biological study to test the epidemiological and physiological relevance of the <\\entity><\\entity> (IL-10) genetic markers in leprosy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16844",
    "Sentence": "Here, we combined a case-control study (374 patients and 380 controls), with meta-analysis (5 studies; 2702 individuals) and biological study to test the epidemiological and physiological relevance of the interleukin-10 (<\\entity><\\entity>) genetic markers in leprosy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16845",
    "Sentence": "Here, we combined a case-control study (374 patients and 380 controls), with meta-analysis (5 studies; 2702 individuals) and biological study to test the epidemiological and physiological relevance of the interleukin-10 (IL-10) genetic markers in <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16846",
    "Sentence": "We observed that the <\\entity><\\entity> allele is associated with leprosy susceptibility either in the case-control or in the meta-analysis studies.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16847",
    "Sentence": "We observed that the -819T allele is associated with <\\entity><\\entity> susceptibility either in the case-control or in the meta-analysis studies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16848",
    "Sentence": "Haplotypes combining promoter single-nucleotide polymorphisms also implicated a haplotype carrying the <\\entity><\\entity> allele in leprosy susceptibility (odds ratio (OR)=1.40; P=0.01).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16849",
    "Sentence": "Haplotypes combining promoter single-nucleotide polymorphisms also implicated a haplotype carrying the -819T allele in <\\entity><\\entity> susceptibility (odds ratio (OR)=1.40; P=0.01).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16850",
    "Sentence": "Finally, we tested <\\entity><\\entity> production in peripheral blood mononuclear cells stimulated with Mycobacterium leprae antigens and found that -819T carriers produced lower levels of <\\entity><\\entity> when compared with non-carriers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16851",
    "Sentence": "Finally, we tested IL-10 production in peripheral blood mononuclear cells stimulated with <\\entity><\\entity> and found that -819T carriers produced lower levels of IL-10 when compared with non-carriers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16852",
    "Sentence": "Finally, we tested IL-10 production in peripheral blood mononuclear cells stimulated with <\\entity><\\entity> and found that -819T carriers produced lower levels of IL-10 when compared with non-carriers.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16853",
    "Sentence": "Finally, we tested IL-10 production in peripheral blood mononuclear cells stimulated with Mycobacterium leprae antigens and found that <\\entity><\\entity> carriers produced lower levels of IL-10 when compared with non-carriers.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16854",
    "Sentence": "Finally, we tested <\\entity><\\entity> production in peripheral blood mononuclear cells stimulated with Mycobacterium leprae antigens and found that -819T carriers produced lower levels of <\\entity><\\entity> when compared with non-carriers.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16855",
    "Sentence": "Taken together, these data suggest that low levels of <\\entity><\\entity> during the disease outcome can drive patients to a chronic and unprotective response that culminates with leprosy.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16856",
    "Sentence": "Taken together, these data suggest that low levels of IL-10 during the disease outcome can drive patients to a chronic and unprotective response that culminates with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16857",
    "Sentence": "Genetic, epidemiological and biological analysis of interleukin-10 promoter single-nucleotide polymorphisms suggests a definitive role for <\\entity><\\entity> in leprosy susceptibility.Leprosy is a complex infectious disease influenced by genetic and environmental factors.",
    "Label": ""
  },
  {
    "id": "16858",
    "Sentence": "Genetic, epidemiological and biological analysis of interleukin-10 promoter single-nucleotide polymorphisms suggests a definitive role for -819C/T in <\\entity><\\entity> susceptibility.Leprosy is a complex infectious disease influenced by genetic and environmental factors.",
    "Label": ""
  },
  {
    "id": "16860",
    "Sentence": "Genetic, epidemiological and biological analysis of <\\entity><\\entity> suggests a definitive role for -819C/T in leprosy susceptibility.Leprosy is a complex infectious disease influenced by genetic and environmental factors.",
    "Label": ""
  },
  {
    "id": "16861",
    "Sentence": "Genetic, epidemiological and biological analysis of interleukin-10 promoter single-nucleotide polymorphisms suggests a definitive role for -819C/T in <\\entity><\\entity> susceptibility.Leprosy is a complex infectious disease influenced by genetic and environmental factors.",
    "Label": ""
  },
  {
    "id": "16863",
    "Sentence": "We observed that the <\\entity><\\entity> allele is associated with leprosy susceptibility either in the case-control or in the meta-analysis studies.",
    "Label": ""
  },
  {
    "id": "16864",
    "Sentence": "We observed that the -819T allele is associated with <\\entity><\\entity> susceptibility either in the case-control or in the meta-analysis studies.",
    "Label": ""
  },
  {
    "id": "16866",
    "Sentence": "Haplotypes combining promoter single-nucleotide polymorphisms also implicated a haplotype carrying the <\\entity><\\entity> allele in leprosy susceptibility (odds ratio (OR)=1.40; P=0.01).",
    "Label": ""
  },
  {
    "id": "16867",
    "Sentence": "Haplotypes combining promoter single-nucleotide polymorphisms also implicated a haplotype carrying the -819T allele in <\\entity><\\entity> susceptibility (odds ratio (OR)=1.40; P=0.01).",
    "Label": ""
  },
  {
    "id": "16869",
    "Sentence": "Taken together, these data suggest that low levels of <\\entity><\\entity> during the disease outcome can drive patients to a chronic and unprotective response that culminates with leprosy.",
    "Label": ""
  },
  {
    "id": "16870",
    "Sentence": "Taken together, these data suggest that low levels of IL-10 during the disease outcome can drive patients to a chronic and unprotective response that culminates with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16872",
    "Sentence": "The genetic contributing factors are considered heterogeneous and several genes have been consistently associated with susceptibility like PARK2, tumor necrosis factor (<\\entity><\\entity>), lymphotoxin-alpha (LTA) and vitamin-D receptor (VDR).",
    "Label": ""
  },
  {
    "id": "16873",
    "Sentence": "The genetic contributing factors are considered heterogeneous and several genes have been consistently associated with susceptibility like <\\entity><\\entity>, tumor necrosis factor (TNF), lymphotoxin-alpha (LTA) and vitamin-D receptor (VDR).",
    "Label": ""
  },
  {
    "id": "16875",
    "Sentence": "The genetic contributing factors are considered heterogeneous and several genes have been consistently associated with susceptibility like PARK2, tumor necrosis factor (TNF), lymphotoxin-alpha (<\\entity><\\entity>) and vitamin-D receptor (VDR).",
    "Label": ""
  },
  {
    "id": "16876",
    "Sentence": "The genetic contributing factors are considered heterogeneous and several genes have been consistently associated with susceptibility like <\\entity><\\entity>, tumor necrosis factor (TNF), lymphotoxin-alpha (LTA) and vitamin-D receptor (VDR).",
    "Label": ""
  },
  {
    "id": "16878",
    "Sentence": "The genetic contributing factors are considered heterogeneous and several genes have been consistently associated with susceptibility like PARK2, tumor necrosis factor (TNF), lymphotoxin-alpha (LTA) and vitamin-D receptor (<\\entity><\\entity>).",
    "Label": ""
  },
  {
    "id": "16879",
    "Sentence": "The genetic contributing factors are considered heterogeneous and several genes have been consistently associated with susceptibility like <\\entity><\\entity>, tumor necrosis factor (TNF), lymphotoxin-alpha (LTA) and vitamin-D receptor (VDR).",
    "Label": ""
  },
  {
    "id": "16881",
    "Sentence": "Here, we combined a case-control study (374 patients and 380 controls), with meta-analysis (5 studies; 2702 individuals) and biological study to test the epidemiological and physiological relevance of the interleukin-10 (<\\entity><\\entity>) genetic markers in leprosy.",
    "Label": ""
  },
  {
    "id": "16882",
    "Sentence": "Here, we combined a case-control study (374 patients and 380 controls), with meta-analysis (5 studies; 2702 individuals) and biological study to test the epidemiological and physiological relevance of the interleukin-10 (IL-10) genetic markers in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16884",
    "Sentence": "Finally, we tested <\\entity><\\entity> production in peripheral blood mononuclear cells stimulated with Mycobacterium leprae antigens and found that -819T carriers produced lower levels of <\\entity><\\entity> when compared with non-carriers.",
    "Label": ""
  },
  {
    "id": "16885",
    "Sentence": "Finally, we tested IL-10 production in peripheral blood mononuclear cells stimulated with <\\entity><\\entity> and found that -819T carriers produced lower levels of IL-10 when compared with non-carriers.",
    "Label": ""
  },
  {
    "id": "16887",
    "Sentence": "Finally, we tested IL-10 production in peripheral blood mononuclear cells stimulated with Mycobacterium leprae antigens and found that <\\entity><\\entity> carriers produced lower levels of IL-10 when compared with non-carriers.",
    "Label": ""
  },
  {
    "id": "16888",
    "Sentence": "Finally, we tested IL-10 production in peripheral blood mononuclear cells stimulated with <\\entity><\\entity> and found that -819T carriers produced lower levels of IL-10 when compared with non-carriers.",
    "Label": ""
  },
  {
    "id": "16890",
    "Sentence": "Here, we combined a case-control study (374 patients and 380 controls), with meta-analysis (5 studies; 2702 individuals) and biological study to test the epidemiological and physiological relevance of the <\\entity><\\entity> (IL-10) genetic markers in leprosy.",
    "Label": ""
  },
  {
    "id": "16891",
    "Sentence": "Here, we combined a case-control study (374 patients and 380 controls), with meta-analysis (5 studies; 2702 individuals) and biological study to test the epidemiological and physiological relevance of the interleukin-10 (IL-10) genetic markers in <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16897",
    "Sentence": "Role of <\\entity><\\entity> gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.The expression of <\\entity><\\entity> receptors in normal and tumor cells of the pancreas, the type and incidence of EGFR gene polymorphism were studied.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16898",
    "Sentence": "Role of epidermal growth factor gene in the development of <\\entity><\\entity> and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.The expression of epidermal growth factor receptors in normal and tumor cells of the pancreas, the type and incidence of EGFR gene polymorphism were studied.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16899",
    "Sentence": "Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of <\\entity><\\entity>.The expression of epidermal growth factor receptors in normal and tumor cells of the pancreas, the type and incidence of EGFR gene polymorphism were studied.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16900",
    "Sentence": "Role of <\\entity><\\entity> gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.The expression of <\\entity><\\entity> receptors in normal and tumor cells of the pancreas, the type and incidence of EGFR gene polymorphism were studied.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16901",
    "Sentence": "Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.The expression of epidermal growth factor receptors in normal and <\\entity><\\entity> cells of the pancreas, the type and incidence of EGFR gene polymorphism were studied.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16902",
    "Sentence": "Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.The expression of epidermal growth factor receptors in normal and tumor cells of the pancreas, the type and incidence of <\\entity><\\entity> gene polymorphism were studied.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16903",
    "Sentence": "<\\entity><\\entity> gene expression in pancreatic adenocarcinoma cells significantly surpassed that in normal pancreatic cells.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16904",
    "Sentence": "EGFR gene expression in <\\entity><\\entity> cells significantly surpassed that in normal pancreatic cells.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16905",
    "Sentence": "On the other hand, <\\entity><\\entity> and A allele polymorphism in the EGF gene nucleotide pair G-A 61 is a significant risk factor for pancreatic cancer.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16906",
    "Sentence": "On the other hand, AA genome and <\\entity><\\entity> in the EGF gene nucleotide pair G-A 61 is a significant risk factor for pancreatic cancer.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16907",
    "Sentence": "On the other hand, AA genome and A allele polymorphism in the <\\entity><\\entity> gene nucleotide pair G-A 61 is a significant risk factor for pancreatic cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16908",
    "Sentence": "On the other hand, AA genome and A allele polymorphism in the <\\entity><\\entity> gene nucleotide pair G-A 61 is a significant risk factor for pancreatic cancer.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16909",
    "Sentence": "On the other hand, AA genome and A allele polymorphism in the EGF gene nucleotide pair <\\entity><\\entity> is a significant risk factor for pancreatic cancer.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16910",
    "Sentence": "On the other hand, AA genome and A allele polymorphism in the EGF gene nucleotide pair <\\entity><\\entity> is a significant risk factor for pancreatic cancer.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16911",
    "Sentence": "On the other hand, AA genome and A allele polymorphism in the EGF gene nucleotide pair G-A 61 is a significant risk factor for <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16912",
    "Sentence": "The effect of AG-1478 preparation (a new-generation inhibitor of <\\entity><\\entity>) on apoptosis and cell proliferation in pancreatic cancer was evaluated.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16913",
    "Sentence": "The effect of AG-1478 preparation (a new-generation inhibitor of EGFR) on apoptosis and cell proliferation in <\\entity><\\entity> was evaluated.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16914",
    "Sentence": "Role of <\\entity><\\entity> gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.The expression of <\\entity><\\entity> receptors in normal and tumor cells of the pancreas, the type and incidence of EGFR gene polymorphism were studied.",
    "Label": ""
  },
  {
    "id": "16915",
    "Sentence": "Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of <\\entity><\\entity>.The expression of epidermal growth factor receptors in normal and tumor cells of the pancreas, the type and incidence of EGFR gene polymorphism were studied.",
    "Label": ""
  },
  {
    "id": "16917",
    "Sentence": "<\\entity><\\entity> gene expression in pancreatic adenocarcinoma cells significantly surpassed that in normal pancreatic cells.",
    "Label": ""
  },
  {
    "id": "16918",
    "Sentence": "EGFR gene expression in <\\entity><\\entity> cells significantly surpassed that in normal pancreatic cells.",
    "Label": ""
  },
  {
    "id": "16920",
    "Sentence": "On the other hand, <\\entity><\\entity> and A allele polymorphism in the EGF gene nucleotide pair G-A 61 is a significant risk factor for pancreatic cancer.",
    "Label": ""
  },
  {
    "id": "16921",
    "Sentence": "On the other hand, AA genome and A allele polymorphism in the EGF gene nucleotide pair G-A 61 is a significant risk factor for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16923",
    "Sentence": "On the other hand, AA genome and <\\entity><\\entity> in the EGF gene nucleotide pair G-A 61 is a significant risk factor for pancreatic cancer.",
    "Label": ""
  },
  {
    "id": "16924",
    "Sentence": "On the other hand, AA genome and A allele polymorphism in the EGF gene nucleotide pair G-A 61 is a significant risk factor for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16926",
    "Sentence": "Role of <\\entity><\\entity> gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.The expression of <\\entity><\\entity> receptors in normal and tumor cells of the pancreas, the type and incidence of EGFR gene polymorphism were studied.",
    "Label": ""
  },
  {
    "id": "16927",
    "Sentence": "Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.The expression of epidermal growth factor receptors in normal and <\\entity><\\entity> cells of the pancreas, the type and incidence of EGFR gene polymorphism were studied.",
    "Label": ""
  },
  {
    "id": "16929",
    "Sentence": "Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.The expression of epidermal growth factor receptors in normal and tumor cells of the pancreas, the type and incidence of <\\entity><\\entity> gene polymorphism were studied.",
    "Label": ""
  },
  {
    "id": "16930",
    "Sentence": "Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.The expression of epidermal growth factor receptors in normal and <\\entity><\\entity> cells of the pancreas, the type and incidence of EGFR gene polymorphism were studied.",
    "Label": ""
  },
  {
    "id": "16932",
    "Sentence": "On the other hand, AA genome and A allele polymorphism in the <\\entity><\\entity> gene nucleotide pair G-A 61 is a significant risk factor for pancreatic cancer.",
    "Label": ""
  },
  {
    "id": "16933",
    "Sentence": "On the other hand, AA genome and A allele polymorphism in the EGF gene nucleotide pair G-A 61 is a significant risk factor for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16935",
    "Sentence": "The effect of AG-1478 preparation (a new-generation inhibitor of <\\entity><\\entity>) on apoptosis and cell proliferation in pancreatic cancer was evaluated.",
    "Label": ""
  },
  {
    "id": "16936",
    "Sentence": "The effect of AG-1478 preparation (a new-generation inhibitor of EGFR) on apoptosis and cell proliferation in <\\entity><\\entity> was evaluated.",
    "Label": ""
  },
  {
    "id": "16938",
    "Sentence": "On the other hand, AA genome and A allele polymorphism in the EGF gene nucleotide pair <\\entity><\\entity> is a significant risk factor for pancreatic cancer.",
    "Label": ""
  },
  {
    "id": "16939",
    "Sentence": "On the other hand, AA genome and A allele polymorphism in the EGF gene nucleotide pair G-A 61 is a significant risk factor for <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "16945",
    "Sentence": "Lack of association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16946",
    "Sentence": "Lack of association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16947",
    "Sentence": "Lack of association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16948",
    "Sentence": "Lack of association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16949",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and <\\entity><\\entity>, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to <\\entity><\\entity> on chromosome 1q21-25.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16950",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, <\\entity><\\entity>, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16951",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, <\\entity><\\entity> and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16952",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related <\\entity><\\entity> in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16953",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative <\\entity><\\entity>.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16954",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and <\\entity><\\entity>, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to <\\entity><\\entity> on chromosome 1q21-25.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16955",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16956",
    "Sentence": "Both <\\entity><\\entity> encoding the liver pyruvate kinase and NOS1AP encoding the nitric oxide synthase 1 (neuronal) adaptor protein (CAPON) are positioned within this chromosomal region and are thus positional candidates for the observed linkage peak.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16957",
    "Sentence": "Both PKLR encoding the <\\entity><\\entity> and NOS1AP encoding the nitric oxide synthase 1 (neuronal) adaptor protein (CAPON) are positioned within this chromosomal region and are thus positional candidates for the observed linkage peak.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16958",
    "Sentence": "Both PKLR encoding the liver pyruvate kinase and <\\entity><\\entity> encoding the nitric oxide synthase 1 (neuronal) adaptor protein (CAPON) are positioned within this chromosomal region and are thus positional candidates for the observed linkage peak.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16959",
    "Sentence": "Both PKLR encoding the liver pyruvate kinase and NOS1AP encoding the <\\entity><\\entity> (CAPON) are positioned within this chromosomal region and are thus positional candidates for the observed linkage peak.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16960",
    "Sentence": "Both PKLR encoding the liver pyruvate kinase and NOS1AP encoding the nitric oxide synthase 1 (neuronal) adaptor protein (<\\entity><\\entity>) are positioned within this chromosomal region and are thus positional candidates for the observed linkage peak.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16961",
    "Sentence": "The <\\entity><\\entity> and the T-allele of NOS1AP rs7538490 are reported to strongly associate with type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16962",
    "Sentence": "The C-allele of <\\entity><\\entity> rs3020781 and the T-allele of NOS1AP rs7538490 are reported to strongly associate with type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16963",
    "Sentence": "The C-allele of PKLR rs3020781 and the <\\entity><\\entity> are reported to strongly associate with type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16964",
    "Sentence": "The C-allele of PKLR rs3020781 and the T-allele of <\\entity><\\entity> rs7538490 are reported to strongly associate with type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16965",
    "Sentence": "The C-allele of PKLR rs3020781 and the T-allele of NOS1AP rs7538490 are reported to strongly associate with <\\entity><\\entity> in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16966",
    "Sentence": "Our aim was to validate these findings by investigating the impact of the two variants on <\\entity><\\entity> and related quantitative metabolic phenotypes in a large study sample of Danes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16967",
    "Sentence": "Our aim was to validate these findings by investigating the impact of the two variants on type 2 diabetes and related quantitative <\\entity><\\entity> in a large study sample of Danes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16968",
    "Sentence": "Further, we intended to expand the analyses by examining the effect of the variants in relation to <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16969",
    "Sentence": "METHODS: <\\entity><\\entity> and NOS1AP rs7538490 were genotyped, using TaqMan allelic discrimination, in a combined study sample comprising a total of 16,801 and 16,913 individuals, respectively.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16970",
    "Sentence": "METHODS: <\\entity><\\entity> and NOS1AP rs7538490 were genotyped, using TaqMan allelic discrimination, in a combined study sample comprising a total of 16,801 and 16,913 individuals, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16971",
    "Sentence": "METHODS: PKLR rs3020781 and <\\entity><\\entity> were genotyped, using TaqMan allelic discrimination, in a combined study sample comprising a total of 16,801 and 16,913 individuals, respectively.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16972",
    "Sentence": "METHODS: PKLR rs3020781 and <\\entity><\\entity> were genotyped, using TaqMan allelic discrimination, in a combined study sample comprising a total of 16,801 and 16,913 individuals, respectively.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16973",
    "Sentence": "The participants were ascertained from four different study groups; the population-based Inter99 cohort (<\\entity><\\entity> = 5,962, nNOS1AP = 6,008), a type 2 diabetic patient group (<\\entity><\\entity> = 1,873, nNOS1AP = 1,874) from Steno Diabetes Center, a population-based study sample (<\\entity><\\entity> = 599, nNOS1AP = 596) from Steno Diabetes Center and the ADDITION Denmark screening study cohort (<\\entity><\\entity> = 8,367, nNOS1AP = 8,435).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16974",
    "Sentence": "The participants were ascertained from four different study groups; the population-based Inter99 cohort (nPKLR = 5,962, <\\entity><\\entity> = 6,008), a type 2 diabetic patient group (nPKLR = 1,873, <\\entity><\\entity> = 1,874) from Steno Diabetes Center, a population-based study sample (nPKLR = 599, <\\entity><\\entity> = 596) from Steno Diabetes Center and the ADDITION Denmark screening study cohort (nPKLR = 8,367, <\\entity><\\entity> = 8,435).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16975",
    "Sentence": "The participants were ascertained from four different study groups; the population-based Inter99 cohort (<\\entity><\\entity> = 5,962, nNOS1AP = 6,008), a type 2 diabetic patient group (<\\entity><\\entity> = 1,873, nNOS1AP = 1,874) from Steno Diabetes Center, a population-based study sample (<\\entity><\\entity> = 599, nNOS1AP = 596) from Steno Diabetes Center and the ADDITION Denmark screening study cohort (<\\entity><\\entity> = 8,367, nNOS1AP = 8,435).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16976",
    "Sentence": "The participants were ascertained from four different study groups; the population-based Inter99 cohort (nPKLR = 5,962, <\\entity><\\entity> = 6,008), a type 2 diabetic patient group (nPKLR = 1,873, <\\entity><\\entity> = 1,874) from Steno Diabetes Center, a population-based study sample (nPKLR = 599, <\\entity><\\entity> = 596) from Steno Diabetes Center and the ADDITION Denmark screening study cohort (nPKLR = 8,367, <\\entity><\\entity> = 8,435).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16977",
    "Sentence": "The participants were ascertained from four different study groups; the population-based Inter99 cohort (nPKLR = 5,962, nNOS1AP = 6,008), a type 2 diabetic patient group (nPKLR = 1,873, nNOS1AP = 1,874) from Steno <\\entity><\\entity> Center, a population-based study sample (nPKLR = 599, nNOS1AP = 596) from Steno <\\entity><\\entity> Center and the ADDITION Denmark screening study cohort (nPKLR = 8,367, nNOS1AP = 8,435).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16978",
    "Sentence": "The participants were ascertained from four different study groups; the population-based Inter99 cohort (<\\entity><\\entity> = 5,962, nNOS1AP = 6,008), a type 2 diabetic patient group (<\\entity><\\entity> = 1,873, nNOS1AP = 1,874) from Steno Diabetes Center, a population-based study sample (<\\entity><\\entity> = 599, nNOS1AP = 596) from Steno Diabetes Center and the ADDITION Denmark screening study cohort (<\\entity><\\entity> = 8,367, nNOS1AP = 8,435).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16979",
    "Sentence": "The participants were ascertained from four different study groups; the population-based Inter99 cohort (nPKLR = 5,962, <\\entity><\\entity> = 6,008), a type 2 diabetic patient group (nPKLR = 1,873, <\\entity><\\entity> = 1,874) from Steno Diabetes Center, a population-based study sample (nPKLR = 599, <\\entity><\\entity> = 596) from Steno Diabetes Center and the ADDITION Denmark screening study cohort (nPKLR = 8,367, <\\entity><\\entity> = 8,435).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16980",
    "Sentence": "The participants were ascertained from four different study groups; the population-based Inter99 cohort (nPKLR = 5,962, nNOS1AP = 6,008), a type 2 diabetic patient group (nPKLR = 1,873, nNOS1AP = 1,874) from Steno <\\entity><\\entity> Center, a population-based study sample (nPKLR = 599, nNOS1AP = 596) from Steno <\\entity><\\entity> Center and the ADDITION Denmark screening study cohort (nPKLR = 8,367, nNOS1AP = 8,435).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16981",
    "Sentence": "The participants were ascertained from four different study groups; the population-based Inter99 cohort (<\\entity><\\entity> = 5,962, nNOS1AP = 6,008), a type 2 diabetic patient group (<\\entity><\\entity> = 1,873, nNOS1AP = 1,874) from Steno Diabetes Center, a population-based study sample (<\\entity><\\entity> = 599, nNOS1AP = 596) from Steno Diabetes Center and the ADDITION Denmark screening study cohort (<\\entity><\\entity> = 8,367, nNOS1AP = 8,435).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16982",
    "Sentence": "The participants were ascertained from four different study groups; the population-based Inter99 cohort (nPKLR = 5,962, <\\entity><\\entity> = 6,008), a type 2 diabetic patient group (nPKLR = 1,873, <\\entity><\\entity> = 1,874) from Steno Diabetes Center, a population-based study sample (nPKLR = 599, <\\entity><\\entity> = 596) from Steno Diabetes Center and the ADDITION Denmark screening study cohort (nPKLR = 8,367, <\\entity><\\entity> = 8,435).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16983",
    "Sentence": "RESULTS: In case-control studies we evaluated the potential association between <\\entity><\\entity> and rs7538490 and type 2 diabetes and obesity.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16984",
    "Sentence": "RESULTS: In case-control studies we evaluated the potential association between rs3020781 and <\\entity><\\entity> and type 2 diabetes and obesity.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16985",
    "Sentence": "RESULTS: In case-control studies we evaluated the potential association between rs3020781 and rs7538490 and <\\entity><\\entity> and obesity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16986",
    "Sentence": "RESULTS: In case-control studies we evaluated the potential association between rs3020781 and rs7538490 and type 2 diabetes and <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16987",
    "Sentence": "No significant associations were observed for <\\entity><\\entity> (rs3020781: pAF = 0.49, OR = 1.02 [0.96-1.10]; rs7538490: pAF = 0.84, OR = 0.99 [0.93-1.06]).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16988",
    "Sentence": "No significant associations were observed for type 2 diabetes (<\\entity><\\entity>: pAF = 0.49, OR = 1.02 [0.96-1.10]; rs7538490: pAF = 0.84, OR = 0.99 [0.93-1.06]).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16989",
    "Sentence": "No significant associations were observed for type 2 diabetes (rs3020781: pAF = 0.49, OR = 1.02 [0.96-1.10]; <\\entity><\\entity>: pAF = 0.84, OR = 0.99 [0.93-1.06]).",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16990",
    "Sentence": "Neither did we show association with <\\entity><\\entity> or obesity.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16991",
    "Sentence": "Neither did we show association with overweight or <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16992",
    "Sentence": "Additionally, the <\\entity><\\entity> and the NOS1AP genotypes were demonstrated not to have a major influence on diabetes-related quantitative metabolic phenotypes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16993",
    "Sentence": "Additionally, the PKLR and the <\\entity><\\entity> genotypes were demonstrated not to have a major influence on diabetes-related quantitative metabolic phenotypes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16994",
    "Sentence": "Additionally, the PKLR and the NOS1AP genotypes were demonstrated not to have a major influence on <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "16995",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16996",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16997",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "16998",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "16999",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and <\\entity><\\entity>, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17000",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, <\\entity><\\entity>, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17001",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, <\\entity><\\entity> or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17002",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative <\\entity><\\entity> in large-scale studies of Danes.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17003",
    "Sentence": "Lack of association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17004",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and <\\entity><\\entity>, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to <\\entity><\\entity> on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17006",
    "Sentence": "Lack of association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17007",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and <\\entity><\\entity>, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to <\\entity><\\entity> on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17009",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17010",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and <\\entity><\\entity>, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to <\\entity><\\entity> on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17012",
    "Sentence": "The <\\entity><\\entity> and the T-allele of NOS1AP rs7538490 are reported to strongly associate with type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively.",
    "Label": ""
  },
  {
    "id": "17013",
    "Sentence": "The C-allele of PKLR rs3020781 and the T-allele of NOS1AP rs7538490 are reported to strongly associate with <\\entity><\\entity> in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively.",
    "Label": ""
  },
  {
    "id": "17015",
    "Sentence": "The C-allele of PKLR rs3020781 and the <\\entity><\\entity> are reported to strongly associate with type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively.",
    "Label": ""
  },
  {
    "id": "17016",
    "Sentence": "The C-allele of PKLR rs3020781 and the T-allele of NOS1AP rs7538490 are reported to strongly associate with <\\entity><\\entity> in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively.",
    "Label": ""
  },
  {
    "id": "17018",
    "Sentence": "No significant associations were observed for type 2 diabetes (<\\entity><\\entity>: pAF = 0.49, OR = 1.02 [0.96-1.10]; rs7538490: pAF = 0.84, OR = 0.99 [0.93-1.06]).",
    "Label": ""
  },
  {
    "id": "17019",
    "Sentence": "No significant associations were observed for <\\entity><\\entity> (rs3020781: pAF = 0.49, OR = 1.02 [0.96-1.10]; rs7538490: pAF = 0.84, OR = 0.99 [0.93-1.06]).",
    "Label": ""
  },
  {
    "id": "17021",
    "Sentence": "No significant associations were observed for type 2 diabetes (rs3020781: pAF = 0.49, OR = 1.02 [0.96-1.10]; <\\entity><\\entity>: pAF = 0.84, OR = 0.99 [0.93-1.06]).",
    "Label": ""
  },
  {
    "id": "17022",
    "Sentence": "No significant associations were observed for <\\entity><\\entity> (rs3020781: pAF = 0.49, OR = 1.02 [0.96-1.10]; rs7538490: pAF = 0.84, OR = 0.99 [0.93-1.06]).",
    "Label": ""
  },
  {
    "id": "17024",
    "Sentence": "Additionally, the <\\entity><\\entity> and the NOS1AP genotypes were demonstrated not to have a major influence on diabetes-related quantitative metabolic phenotypes.",
    "Label": ""
  },
  {
    "id": "17025",
    "Sentence": "Additionally, the PKLR and the NOS1AP genotypes were demonstrated not to have a major influence on <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17027",
    "Sentence": "Additionally, the PKLR and the <\\entity><\\entity> genotypes were demonstrated not to have a major influence on diabetes-related quantitative metabolic phenotypes.",
    "Label": ""
  },
  {
    "id": "17028",
    "Sentence": "Additionally, the PKLR and the NOS1AP genotypes were demonstrated not to have a major influence on <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17030",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17031",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and <\\entity><\\entity>, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17033",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17034",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and <\\entity><\\entity>, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17036",
    "Sentence": "Lack of association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17037",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and <\\entity><\\entity>, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to <\\entity><\\entity> on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17039",
    "Sentence": "Lack of association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17040",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, <\\entity><\\entity>, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17042",
    "Sentence": "Lack of association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17043",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, <\\entity><\\entity> and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17045",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative <\\entity><\\entity>.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17046",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and <\\entity><\\entity>, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to <\\entity><\\entity> on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17048",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative <\\entity><\\entity>.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17049",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, <\\entity><\\entity>, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17051",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative <\\entity><\\entity>.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17052",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, <\\entity><\\entity> and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17054",
    "Sentence": "Lack of association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17055",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and <\\entity><\\entity>, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to <\\entity><\\entity> on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17057",
    "Sentence": "Lack of association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17058",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, <\\entity><\\entity>, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17060",
    "Sentence": "Lack of association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17061",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, <\\entity><\\entity> and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17063",
    "Sentence": "The C-allele of <\\entity><\\entity> rs3020781 and the T-allele of NOS1AP rs7538490 are reported to strongly associate with type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively.",
    "Label": ""
  },
  {
    "id": "17064",
    "Sentence": "The C-allele of PKLR rs3020781 and the T-allele of NOS1AP rs7538490 are reported to strongly associate with <\\entity><\\entity> in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively.",
    "Label": ""
  },
  {
    "id": "17066",
    "Sentence": "The C-allele of PKLR rs3020781 and the T-allele of <\\entity><\\entity> rs7538490 are reported to strongly associate with type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively.",
    "Label": ""
  },
  {
    "id": "17067",
    "Sentence": "The C-allele of PKLR rs3020781 and the T-allele of NOS1AP rs7538490 are reported to strongly associate with <\\entity><\\entity> in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively.",
    "Label": ""
  },
  {
    "id": "17069",
    "Sentence": "Additionally, the <\\entity><\\entity> and the NOS1AP genotypes were demonstrated not to have a major influence on diabetes-related quantitative metabolic phenotypes.",
    "Label": ""
  },
  {
    "id": "17070",
    "Sentence": "Additionally, the PKLR and the NOS1AP genotypes were demonstrated not to have a major influence on <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17072",
    "Sentence": "Additionally, the PKLR and the <\\entity><\\entity> genotypes were demonstrated not to have a major influence on diabetes-related quantitative metabolic phenotypes.",
    "Label": ""
  },
  {
    "id": "17073",
    "Sentence": "Additionally, the PKLR and the NOS1AP genotypes were demonstrated not to have a major influence on <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17075",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17076",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and <\\entity><\\entity>, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17078",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17079",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, <\\entity><\\entity>, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17081",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17082",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, <\\entity><\\entity> or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17084",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17085",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and <\\entity><\\entity>, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17087",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17088",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, <\\entity><\\entity>, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17090",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17091",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, <\\entity><\\entity> or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17093",
    "Sentence": "Lack of association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17094",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, <\\entity><\\entity>, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17096",
    "Sentence": "Lack of association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17097",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, <\\entity><\\entity> and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17099",
    "Sentence": "Lack of association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17100",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, <\\entity><\\entity>, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17102",
    "Sentence": "Lack of association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17103",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, <\\entity><\\entity> and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17105",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17106",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, <\\entity><\\entity>, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17108",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17109",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, <\\entity><\\entity> or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17111",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17112",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, <\\entity><\\entity>, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17114",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17115",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, <\\entity><\\entity> or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17117",
    "Sentence": "Lack of association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17118",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related <\\entity><\\entity> in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17120",
    "Sentence": "Lack of association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17121",
    "Sentence": "Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related <\\entity><\\entity> in a Danish large-scale study: case-control studies and analyses of quantitative traits.BACKGROUND: Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25.",
    "Label": ""
  },
  {
    "id": "17123",
    "Sentence": "RESULTS: In case-control studies we evaluated the potential association between <\\entity><\\entity> and rs7538490 and type 2 diabetes and obesity.",
    "Label": ""
  },
  {
    "id": "17124",
    "Sentence": "RESULTS: In case-control studies we evaluated the potential association between rs3020781 and rs7538490 and type 2 diabetes and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17126",
    "Sentence": "RESULTS: In case-control studies we evaluated the potential association between <\\entity><\\entity> and rs7538490 and type 2 diabetes and obesity.",
    "Label": ""
  },
  {
    "id": "17127",
    "Sentence": "RESULTS: In case-control studies we evaluated the potential association between rs3020781 and rs7538490 and <\\entity><\\entity> and obesity.",
    "Label": ""
  },
  {
    "id": "17129",
    "Sentence": "RESULTS: In case-control studies we evaluated the potential association between rs3020781 and <\\entity><\\entity> and type 2 diabetes and obesity.",
    "Label": ""
  },
  {
    "id": "17130",
    "Sentence": "RESULTS: In case-control studies we evaluated the potential association between rs3020781 and rs7538490 and type 2 diabetes and <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17132",
    "Sentence": "RESULTS: In case-control studies we evaluated the potential association between rs3020781 and <\\entity><\\entity> and type 2 diabetes and obesity.",
    "Label": ""
  },
  {
    "id": "17133",
    "Sentence": "RESULTS: In case-control studies we evaluated the potential association between rs3020781 and rs7538490 and <\\entity><\\entity> and obesity.",
    "Label": ""
  },
  {
    "id": "17135",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between <\\entity><\\entity> and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17136",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative <\\entity><\\entity> in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17138",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and <\\entity><\\entity> and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17139",
    "Sentence": "CONCLUSION: We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative <\\entity><\\entity> in large-scale studies of Danes.",
    "Label": ""
  },
  {
    "id": "17145",
    "Sentence": "<\\entity><\\entity> and TGF-beta 1 gene in black South Africans.Limited literature is available on the epidemiology and genetics of otosclerosis in South African blacks, among whom it is extremely rare.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17146",
    "Sentence": "Otosclerosis and <\\entity><\\entity> gene in black South Africans.Limited literature is available on the epidemiology and genetics of otosclerosis in South African blacks, among whom it is extremely rare.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17147",
    "Sentence": "Otosclerosis and TGF-beta 1 gene in black South Africans.Limited literature is available on the epidemiology and genetics of <\\entity><\\entity> in South African blacks, among whom it is extremely rare.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17148",
    "Sentence": "We undertook this study because we had documented and surgically confirmed cases of clinical oval window <\\entity><\\entity> in this population.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17149",
    "Sentence": "Otosclerosis and <\\entity><\\entity> gene in black South Africans.Limited literature is available on the epidemiology and genetics of otosclerosis in South African blacks, among whom it is extremely rare.",
    "Label": ""
  },
  {
    "id": "17150",
    "Sentence": "<\\entity><\\entity> and TGF-beta 1 gene in black South Africans.Limited literature is available on the epidemiology and genetics of otosclerosis in South African blacks, among whom it is extremely rare.",
    "Label": ""
  },
  {
    "id": "17156",
    "Sentence": "From the Cover: Whole-genome association study identifies <\\entity><\\entity> as a hypertension susceptibility gene.Hypertension places a major burden on individual and public health, but the genetic basis of this complex disorder is poorly understood.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17157",
    "Sentence": "From the Cover: Whole-genome association study identifies STK39 as a <\\entity><\\entity> susceptibility gene.Hypertension places a major burden on individual and public health, but the genetic basis of this complex disorder is poorly understood.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17158",
    "Sentence": "From the Cover: Whole-genome association study identifies STK39 as a hypertension susceptibility gene.<\\entity><\\entity> places a major burden on individual and public health, but the genetic basis of this complex disorder is poorly understood.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17159",
    "Sentence": "From the Cover: Whole-genome association study identifies STK39 as a hypertension susceptibility gene.Hypertension places a major burden on individual and public health, but the genetic basis of this complex <\\entity><\\entity> is poorly understood.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17160",
    "Sentence": "We conducted a genome-wide association study of systolic and diastolic blood pressure (<\\entity><\\entity> and DBP) in Amish subjects and found strong association signals with common variants in a serine/threonine kinase gene, STK39.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17161",
    "Sentence": "We conducted a genome-wide association study of systolic and diastolic blood pressure (<\\entity><\\entity> and DBP) in Amish subjects and found strong association signals with common variants in a serine/threonine kinase gene, STK39.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17162",
    "Sentence": "We conducted a genome-wide association study of systolic and diastolic blood pressure (SBP and <\\entity><\\entity>) in Amish subjects and found strong association signals with common variants in a serine/threonine kinase gene, STK39.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17163",
    "Sentence": "We conducted a genome-wide association study of systolic and diastolic blood pressure (SBP and <\\entity><\\entity>) in Amish subjects and found strong association signals with common variants in a serine/threonine kinase gene, STK39.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17164",
    "Sentence": "We conducted a genome-wide association study of systolic and diastolic blood pressure (SBP and DBP) in Amish subjects and found strong association signals with common variants in a <\\entity><\\entity> gene, STK39.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17165",
    "Sentence": "We conducted a genome-wide association study of systolic and diastolic blood pressure (SBP and DBP) in Amish subjects and found strong association signals with common variants in a serine/threonine kinase gene, <\\entity><\\entity>.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17166",
    "Sentence": "We confirmed this association in an independent Amish and 4 non-Amish Caucasian samples including the <\\entity><\\entity> Genetics Initiative, Framingham Heart Study, GenNet, and Hutterites (meta-analysis combining all studies: n = 7,125, P < 10(-6)).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17167",
    "Sentence": "The higher <\\entity><\\entity>-associated alleles have frequencies > 0.09 and were associated with increases of 3.3/1.3 mm Hg in S<\\entity><\\entity>/D<\\entity><\\entity>, respectively, in the Amish subjects and with smaller but consistent effects across the non-Amish studies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17168",
    "Sentence": "The higher BP-associated alleles have frequencies > 0.09 and were associated with increases of 3.3/1.3 mm Hg in <\\entity><\\entity>/DBP, respectively, in the Amish subjects and with smaller but consistent effects across the non-Amish studies.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17169",
    "Sentence": "The higher BP-associated alleles have frequencies > 0.09 and were associated with increases of 3.3/1.3 mm Hg in <\\entity><\\entity>/DBP, respectively, in the Amish subjects and with smaller but consistent effects across the non-Amish studies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17170",
    "Sentence": "The higher BP-associated alleles have frequencies > 0.09 and were associated with increases of 3.3/1.3 mm Hg in SBP/<\\entity><\\entity>, respectively, in the Amish subjects and with smaller but consistent effects across the non-Amish studies.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17171",
    "Sentence": "The higher BP-associated alleles have frequencies > 0.09 and were associated with increases of 3.3/1.3 mm Hg in SBP/<\\entity><\\entity>, respectively, in the Amish subjects and with smaller but consistent effects across the non-Amish studies.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17172",
    "Sentence": "Cell-based functional studies showed that <\\entity><\\entity> interacts with WNK kinases and cation-chloride cotransporters, mutations in which cause monogenic forms of BP dysregulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17173",
    "Sentence": "Cell-based functional studies showed that STK39 interacts with <\\entity><\\entity> kinases and cation-chloride cotransporters, mutations in which cause monogenic forms of BP dysregulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17174",
    "Sentence": "Cell-based functional studies showed that STK39 interacts with WNK kinases and <\\entity><\\entity>, mutations in which cause monogenic forms of BP dysregulation.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17175",
    "Sentence": "Cell-based functional studies showed that STK39 interacts with WNK kinases and cation-chloride cotransporters, <\\entity><\\entity> in which cause monogenic forms of BP dysregulation.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17176",
    "Sentence": "Cell-based functional studies showed that STK39 interacts with WNK kinases and cation-chloride cotransporters, mutations in which cause monogenic forms of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17177",
    "Sentence": "We demonstrate that in vivo, <\\entity><\\entity> is expressed in the distal nephron, where it may interact with these proteins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17178",
    "Sentence": "Thus, variants in <\\entity><\\entity> may influence BP by increasing <\\entity><\\entity> expression and consequently altering renal Na(+) excretion, thus unifying rare and common BP-regulating alleles in the same physiological pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17179",
    "Sentence": "Thus, variants in STK39 may influence <\\entity><\\entity> by increasing STK39 expression and consequently altering renal Na(+) excretion, thus unifying rare and common <\\entity><\\entity>-regulating alleles in the same physiological pathway.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17180",
    "Sentence": "Thus, variants in <\\entity><\\entity> may influence BP by increasing <\\entity><\\entity> expression and consequently altering renal Na(+) excretion, thus unifying rare and common BP-regulating alleles in the same physiological pathway.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17181",
    "Sentence": "Thus, variants in STK39 may influence BP by increasing STK39 expression and consequently altering <\\entity><\\entity>(+) excretion, thus unifying rare and common BP-regulating alleles in the same physiological pathway.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17182",
    "Sentence": "Thus, variants in STK39 may influence <\\entity><\\entity> by increasing STK39 expression and consequently altering renal Na(+) excretion, thus unifying rare and common <\\entity><\\entity>-regulating alleles in the same physiological pathway.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17183",
    "Sentence": "From the Cover: Whole-genome association study identifies <\\entity><\\entity> as a hypertension susceptibility gene.Hypertension places a major burden on individual and public health, but the genetic basis of this complex disorder is poorly understood.",
    "Label": ""
  },
  {
    "id": "17184",
    "Sentence": "From the Cover: Whole-genome association study identifies STK39 as a <\\entity><\\entity> susceptibility gene.Hypertension places a major burden on individual and public health, but the genetic basis of this complex disorder is poorly understood.",
    "Label": ""
  },
  {
    "id": "17186",
    "Sentence": "Cell-based functional studies showed that STK39 interacts with WNK kinases and <\\entity><\\entity>, mutations in which cause monogenic forms of BP dysregulation.",
    "Label": ""
  },
  {
    "id": "17187",
    "Sentence": "Cell-based functional studies showed that STK39 interacts with WNK kinases and cation-chloride cotransporters, mutations in which cause monogenic forms of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17189",
    "Sentence": "Cell-based functional studies showed that <\\entity><\\entity> interacts with WNK kinases and cation-chloride cotransporters, mutations in which cause monogenic forms of BP dysregulation.",
    "Label": ""
  },
  {
    "id": "17190",
    "Sentence": "Cell-based functional studies showed that STK39 interacts with WNK kinases and cation-chloride cotransporters, <\\entity><\\entity> in which cause monogenic forms of BP dysregulation.",
    "Label": ""
  },
  {
    "id": "17192",
    "Sentence": "We conducted a genome-wide association study of systolic and diastolic blood pressure (SBP and DBP) in Amish subjects and found strong association signals with common variants in a serine/threonine kinase gene, <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17193",
    "Sentence": "We conducted a genome-wide association study of systolic and diastolic blood pressure (SBP and <\\entity><\\entity>) in Amish subjects and found strong association signals with common variants in a serine/threonine kinase gene, STK39.",
    "Label": ""
  },
  {
    "id": "17195",
    "Sentence": "We conducted a genome-wide association study of systolic and diastolic blood pressure (SBP and DBP) in Amish subjects and found strong association signals with common variants in a serine/threonine kinase gene, <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17196",
    "Sentence": "We conducted a genome-wide association study of systolic and diastolic blood pressure (<\\entity><\\entity> and DBP) in Amish subjects and found strong association signals with common variants in a serine/threonine kinase gene, STK39.",
    "Label": ""
  },
  {
    "id": "17198",
    "Sentence": "We conducted a genome-wide association study of systolic and diastolic blood pressure (SBP and DBP) in Amish subjects and found strong association signals with common variants in a <\\entity><\\entity> gene, STK39.",
    "Label": ""
  },
  {
    "id": "17199",
    "Sentence": "We conducted a genome-wide association study of systolic and diastolic blood pressure (SBP and <\\entity><\\entity>) in Amish subjects and found strong association signals with common variants in a serine/threonine kinase gene, STK39.",
    "Label": ""
  },
  {
    "id": "17201",
    "Sentence": "We conducted a genome-wide association study of systolic and diastolic blood pressure (SBP and DBP) in Amish subjects and found strong association signals with common variants in a <\\entity><\\entity> gene, STK39.",
    "Label": ""
  },
  {
    "id": "17202",
    "Sentence": "We conducted a genome-wide association study of systolic and diastolic blood pressure (<\\entity><\\entity> and DBP) in Amish subjects and found strong association signals with common variants in a serine/threonine kinase gene, STK39.",
    "Label": ""
  },
  {
    "id": "17204",
    "Sentence": "Cell-based functional studies showed that <\\entity><\\entity> interacts with WNK kinases and cation-chloride cotransporters, mutations in which cause monogenic forms of BP dysregulation.",
    "Label": ""
  },
  {
    "id": "17205",
    "Sentence": "Cell-based functional studies showed that STK39 interacts with WNK kinases and cation-chloride cotransporters, mutations in which cause monogenic forms of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17207",
    "Sentence": "Cell-based functional studies showed that STK39 interacts with <\\entity><\\entity> kinases and cation-chloride cotransporters, mutations in which cause monogenic forms of BP dysregulation.",
    "Label": ""
  },
  {
    "id": "17208",
    "Sentence": "Cell-based functional studies showed that STK39 interacts with WNK kinases and cation-chloride cotransporters, mutations in which cause monogenic forms of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17210",
    "Sentence": "Thus, variants in <\\entity><\\entity> may influence BP by increasing <\\entity><\\entity> expression and consequently altering renal Na(+) excretion, thus unifying rare and common BP-regulating alleles in the same physiological pathway.",
    "Label": ""
  },
  {
    "id": "17211",
    "Sentence": "Thus, variants in STK39 may influence <\\entity><\\entity> by increasing STK39 expression and consequently altering renal Na(+) excretion, thus unifying rare and common <\\entity><\\entity>-regulating alleles in the same physiological pathway.",
    "Label": ""
  },
  {
    "id": "17213",
    "Sentence": "Thus, variants in <\\entity><\\entity> may influence BP by increasing <\\entity><\\entity> expression and consequently altering renal Na(+) excretion, thus unifying rare and common BP-regulating alleles in the same physiological pathway.",
    "Label": ""
  },
  {
    "id": "17214",
    "Sentence": "Thus, variants in STK39 may influence BP by increasing STK39 expression and consequently altering <\\entity><\\entity>(+) excretion, thus unifying rare and common BP-regulating alleles in the same physiological pathway.",
    "Label": ""
  },
  {
    "id": "17216",
    "Sentence": "Thus, variants in <\\entity><\\entity> may influence BP by increasing <\\entity><\\entity> expression and consequently altering renal Na(+) excretion, thus unifying rare and common BP-regulating alleles in the same physiological pathway.",
    "Label": ""
  },
  {
    "id": "17217",
    "Sentence": "Thus, variants in STK39 may influence <\\entity><\\entity> by increasing STK39 expression and consequently altering renal Na(+) excretion, thus unifying rare and common <\\entity><\\entity>-regulating alleles in the same physiological pathway.",
    "Label": ""
  },
  {
    "id": "17219",
    "Sentence": "Thus, variants in <\\entity><\\entity> may influence BP by increasing <\\entity><\\entity> expression and consequently altering renal Na(+) excretion, thus unifying rare and common BP-regulating alleles in the same physiological pathway.",
    "Label": ""
  },
  {
    "id": "17220",
    "Sentence": "Thus, variants in STK39 may influence BP by increasing STK39 expression and consequently altering <\\entity><\\entity>(+) excretion, thus unifying rare and common BP-regulating alleles in the same physiological pathway.",
    "Label": ""
  },
  {
    "id": "17226",
    "Sentence": "Effects of polymorphism in <\\entity><\\entity> triallelic region of MDR1 gene in Turkish patients with inflammatory bowel disease.BACKGROUND/AIMS: Crohn's disease and ulcerative colitis are both chronic inflammatory disorders of the gastrointestinal tract, the main causes of which remain unknown.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "17227",
    "Sentence": "Effects of polymorphism in G2677T/A triallelic region of <\\entity><\\entity> gene in Turkish patients with inflammatory bowel disease.BACKGROUND/AIMS: Crohn's disease and ulcerative colitis are both chronic inflammatory disorders of the gastrointestinal tract, the main causes of which remain unknown.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17228",
    "Sentence": "Effects of polymorphism in G2677T/A triallelic region of MDR1 gene in Turkish patients with <\\entity><\\entity>.BACKGROUND/AIMS: Crohn's disease and ulcerative colitis are both chronic inflammatory disorders of the gastrointestinal tract, the main causes of which remain unknown.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17229",
    "Sentence": "Effects of polymorphism in G2677T/A triallelic region of MDR1 gene in Turkish patients with inflammatory bowel disease.BACKGROUND/AIMS: <\\entity><\\entity> and ulcerative colitis are both chronic inflammatory disorders of the gastrointestinal tract, the main causes of which remain unknown.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17230",
    "Sentence": "Effects of polymorphism in G2677T/A triallelic region of MDR1 gene in Turkish patients with inflammatory bowel disease.BACKGROUND/AIMS: Crohn's disease and <\\entity><\\entity> are both chronic inflammatory disorders of the gastrointestinal tract, the main causes of which remain unknown.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17231",
    "Sentence": "Effects of polymorphism in G2677T/A triallelic region of MDR1 gene in Turkish patients with inflammatory bowel disease.BACKGROUND/AIMS: Crohn's disease and ulcerative colitis are both <\\entity><\\entity> of the gastrointestinal tract, the main causes of which remain unknown.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17232",
    "Sentence": "<\\entity><\\entity> and ulcerative colitis are characterized by cell-mediated immune response against the luminal bacteria.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17233",
    "Sentence": "Crohn's disease and <\\entity><\\entity> are characterized by cell-mediated immune response against the luminal bacteria.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17234",
    "Sentence": "It is suggested that expression levels and function of <\\entity><\\entity>, encoded by the MDR1 gene, are important for protection of the gut against xenobiotics and bacterial toxins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17235",
    "Sentence": "It is suggested that expression levels and function of P-glycoprotein, encoded by the <\\entity><\\entity> gene, are important for protection of the gut against xenobiotics and bacterial toxins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17236",
    "Sentence": "It is suggested that expression levels and function of P-glycoprotein, encoded by the MDR1 gene, are important for protection of the <\\entity><\\entity> against xenobiotics and bacterial toxins.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17237",
    "Sentence": "Therefore, the <\\entity><\\entity> of the MDR1 gene are thought to be related with the pathogenesis of inflammatory bowel disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17238",
    "Sentence": "Therefore, the mutations of the <\\entity><\\entity> gene are thought to be related with the pathogenesis of inflammatory bowel disease.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17239",
    "Sentence": "Therefore, the mutations of the <\\entity><\\entity> gene are thought to be related with the pathogenesis of inflammatory bowel disease.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "17240",
    "Sentence": "Therefore, the mutations of the MDR1 gene are thought to be related with the <\\entity><\\entity> of inflammatory bowel disease.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17241",
    "Sentence": "Therefore, the mutations of the MDR1 gene are thought to be related with the pathogenesis of <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17242",
    "Sentence": "The aim of this study was to investigate the <\\entity><\\entity> polymorphism in the MDR1 gene in Turkish patients with inflammatory bowel disease and a healthy control group.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "17243",
    "Sentence": "The aim of this study was to investigate the G2677T/A polymorphism in the <\\entity><\\entity> gene in Turkish patients with inflammatory bowel disease and a healthy control group.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17244",
    "Sentence": "The aim of this study was to investigate the G2677T/A polymorphism in the MDR1 gene in Turkish patients with <\\entity><\\entity> and a healthy control group.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17245",
    "Sentence": "METHODS: In our study, the genotypes of endoscopically or histopathologically diagnosed <\\entity><\\entity> (n: 35; 14 F, 21 M) and ulcerative colitis (n: 82; 36 F, 46 M) patients and of 70 healthy individuals (39 F, 31 M) were compared.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17246",
    "Sentence": "METHODS: In our study, the genotypes of endoscopically or histopathologically diagnosed Crohn's disease (n: 35; 14 F, 21 M) and <\\entity><\\entity> (n: 82; 36 F, 46 M) patients and of 70 healthy individuals (39 F, 31 M) were compared.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17247",
    "Sentence": "In the patient and control groups, polymerase chain reaction restriction fragment length polymorphism analysis was performed for two polymorphisms (<\\entity><\\entity> and G2677A) of the MDR1 gene.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "17248",
    "Sentence": "In the patient and control groups, polymerase chain reaction restriction fragment length polymorphism analysis was performed for two polymorphisms (G2677T and <\\entity><\\entity>) of the MDR1 gene.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "17249",
    "Sentence": "In the patient and control groups, polymerase chain reaction restriction fragment length polymorphism analysis was performed for two polymorphisms (G2677T and G2677A) of the <\\entity><\\entity> gene.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17250",
    "Sentence": "RESULTS: In this study, the frequency of <\\entity><\\entity> of the MDR1 gene, which has a triallelic polymorphism, was not found to be significantly different between the patient and the healthy control groups.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "17251",
    "Sentence": "RESULTS: In this study, the frequency of alleles at position 2677 of the <\\entity><\\entity> gene, which has a triallelic polymorphism, was not found to be significantly different between the patient and the healthy control groups.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17252",
    "Sentence": "Moreover, the <\\entity><\\entity> allele was not detected in either the patient group or the healthy control group.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "17253",
    "Sentence": "CONCLUSIONS: In this study, the <\\entity><\\entity> polymorphism observed in the MDR1 gene was not found to be a risk factor for Crohn's disease or ulcerative colitis.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "17254",
    "Sentence": "CONCLUSIONS: In this study, the G2677T/A polymorphism observed in the <\\entity><\\entity> gene was not found to be a risk factor for Crohn's disease or ulcerative colitis.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17255",
    "Sentence": "CONCLUSIONS: In this study, the G2677T/A polymorphism observed in the MDR1 gene was not found to be a risk factor for <\\entity><\\entity> or ulcerative colitis.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17256",
    "Sentence": "CONCLUSIONS: In this study, the G2677T/A polymorphism observed in the MDR1 gene was not found to be a risk factor for Crohn's disease or <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17257",
    "Sentence": "Therefore, the mutations of the <\\entity><\\entity> gene are thought to be related with the pathogenesis of inflammatory bowel disease.",
    "Label": ""
  },
  {
    "id": "17258",
    "Sentence": "Therefore, the mutations of the MDR1 gene are thought to be related with the pathogenesis of <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17260",
    "Sentence": "CONCLUSIONS: In this study, the <\\entity><\\entity> polymorphism observed in the MDR1 gene was not found to be a risk factor for Crohn's disease or ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "17261",
    "Sentence": "CONCLUSIONS: In this study, the G2677T/A polymorphism observed in the MDR1 gene was not found to be a risk factor for <\\entity><\\entity> or ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "17263",
    "Sentence": "CONCLUSIONS: In this study, the <\\entity><\\entity> polymorphism observed in the MDR1 gene was not found to be a risk factor for Crohn's disease or ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "17264",
    "Sentence": "CONCLUSIONS: In this study, the G2677T/A polymorphism observed in the MDR1 gene was not found to be a risk factor for Crohn's disease or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17266",
    "Sentence": "Effects of polymorphism in G2677T/A triallelic region of <\\entity><\\entity> gene in Turkish patients with inflammatory bowel disease.BACKGROUND/AIMS: Crohn's disease and ulcerative colitis are both chronic inflammatory disorders of the gastrointestinal tract, the main causes of which remain unknown.",
    "Label": ""
  },
  {
    "id": "17267",
    "Sentence": "Effects of polymorphism in G2677T/A triallelic region of MDR1 gene in Turkish patients with <\\entity><\\entity>.BACKGROUND/AIMS: Crohn's disease and ulcerative colitis are both chronic inflammatory disorders of the gastrointestinal tract, the main causes of which remain unknown.",
    "Label": ""
  },
  {
    "id": "17269",
    "Sentence": "Therefore, the mutations of the <\\entity><\\entity> gene are thought to be related with the pathogenesis of inflammatory bowel disease.",
    "Label": ""
  },
  {
    "id": "17270",
    "Sentence": "Therefore, the <\\entity><\\entity> of the MDR1 gene are thought to be related with the pathogenesis of inflammatory bowel disease.",
    "Label": ""
  },
  {
    "id": "17272",
    "Sentence": "Therefore, the mutations of the <\\entity><\\entity> gene are thought to be related with the pathogenesis of inflammatory bowel disease.",
    "Label": ""
  },
  {
    "id": "17273",
    "Sentence": "Therefore, the mutations of the MDR1 gene are thought to be related with the <\\entity><\\entity> of inflammatory bowel disease.",
    "Label": ""
  },
  {
    "id": "17275",
    "Sentence": "The aim of this study was to investigate the G2677T/A polymorphism in the <\\entity><\\entity> gene in Turkish patients with inflammatory bowel disease and a healthy control group.",
    "Label": ""
  },
  {
    "id": "17276",
    "Sentence": "The aim of this study was to investigate the G2677T/A polymorphism in the MDR1 gene in Turkish patients with <\\entity><\\entity> and a healthy control group.",
    "Label": ""
  },
  {
    "id": "17278",
    "Sentence": "CONCLUSIONS: In this study, the G2677T/A polymorphism observed in the <\\entity><\\entity> gene was not found to be a risk factor for Crohn's disease or ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "17279",
    "Sentence": "CONCLUSIONS: In this study, the G2677T/A polymorphism observed in the MDR1 gene was not found to be a risk factor for <\\entity><\\entity> or ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "17281",
    "Sentence": "CONCLUSIONS: In this study, the G2677T/A polymorphism observed in the <\\entity><\\entity> gene was not found to be a risk factor for Crohn's disease or ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "17282",
    "Sentence": "CONCLUSIONS: In this study, the G2677T/A polymorphism observed in the MDR1 gene was not found to be a risk factor for Crohn's disease or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17284",
    "Sentence": "Effects of polymorphism in <\\entity><\\entity> triallelic region of MDR1 gene in Turkish patients with inflammatory bowel disease.BACKGROUND/AIMS: Crohn's disease and ulcerative colitis are both chronic inflammatory disorders of the gastrointestinal tract, the main causes of which remain unknown.",
    "Label": ""
  },
  {
    "id": "17285",
    "Sentence": "Effects of polymorphism in G2677T/A triallelic region of MDR1 gene in Turkish patients with <\\entity><\\entity>.BACKGROUND/AIMS: Crohn's disease and ulcerative colitis are both chronic inflammatory disorders of the gastrointestinal tract, the main causes of which remain unknown.",
    "Label": ""
  },
  {
    "id": "17287",
    "Sentence": "The aim of this study was to investigate the <\\entity><\\entity> polymorphism in the MDR1 gene in Turkish patients with inflammatory bowel disease and a healthy control group.",
    "Label": ""
  },
  {
    "id": "17288",
    "Sentence": "The aim of this study was to investigate the G2677T/A polymorphism in the MDR1 gene in Turkish patients with <\\entity><\\entity> and a healthy control group.",
    "Label": ""
  },
  {
    "id": "17290",
    "Sentence": "CONCLUSIONS: In this study, the G2677T/A polymorphism observed in the <\\entity><\\entity> gene was not found to be a risk factor for Crohn's disease or ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "17291",
    "Sentence": "CONCLUSIONS: In this study, the G2677T/A polymorphism observed in the MDR1 gene was not found to be a risk factor for <\\entity><\\entity> or ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "17293",
    "Sentence": "CONCLUSIONS: In this study, the G2677T/A polymorphism observed in the <\\entity><\\entity> gene was not found to be a risk factor for Crohn's disease or ulcerative colitis.",
    "Label": ""
  },
  {
    "id": "17294",
    "Sentence": "CONCLUSIONS: In this study, the G2677T/A polymorphism observed in the MDR1 gene was not found to be a risk factor for Crohn's disease or <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17300",
    "Sentence": "<\\entity><\\entity> implant in women with diabetes mellitus.OBJECTIVES: To evaluate the effect of etonogestrel implant on the control of the carbohydrate and lipid metabolism and on the progression of vascular complications in diabetic women treated with insulin, and to assess the acceptability of this modality of contraception in these patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17301",
    "Sentence": "Etonogestrel implant in women with <\\entity><\\entity>.OBJECTIVES: To evaluate the effect of etonogestrel implant on the control of the carbohydrate and lipid metabolism and on the progression of vascular complications in diabetic women treated with insulin, and to assess the acceptability of this modality of contraception in these patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17302",
    "Sentence": "Etonogestrel implant in women with diabetes mellitus.OBJECTIVES: To evaluate the effect of <\\entity><\\entity> implant on the control of the carbohydrate and lipid metabolism and on the progression of vascular complications in diabetic women treated with insulin, and to assess the acceptability of this modality of contraception in these patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17303",
    "Sentence": "Etonogestrel implant in women with diabetes mellitus.OBJECTIVES: To evaluate the effect of etonogestrel implant on the control of the carbohydrate and lipid metabolism and on the progression of <\\entity><\\entity> in diabetic women treated with insulin, and to assess the acceptability of this modality of contraception in these patients.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17304",
    "Sentence": "Etonogestrel implant in women with diabetes mellitus.OBJECTIVES: To evaluate the effect of etonogestrel implant on the control of the carbohydrate and lipid metabolism and on the progression of vascular complications in diabetic women treated with <\\entity><\\entity>, and to assess the acceptability of this modality of contraception in these patients.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17305",
    "Sentence": "METHODS: Prospective-observational study of 23 women with <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17306",
    "Sentence": "METHODS: Prospective-observational study of 23 women with <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17307",
    "Sentence": "Clinical and metabolic evaluation was performed before and at 3, 6, 12, and 24 months after implant <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17308",
    "Sentence": "RESULTS: There were no significant changes in BMI, in daily <\\entity><\\entity> requirement and in mean HbA1c.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17309",
    "Sentence": "There was a significant reduction of total serum cholesterol (<\\entity><\\entity>) at 6 and 12 months, of triglyceride levels at 6, 12 and 24 months, and of high-density lipoprotein cholesterol (HDL-C) at 6, 12 and 24 months.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17310",
    "Sentence": "Neither the low-density lipoprotein (LDL) levels nor the HDL/<\\entity><\\entity> ratio changed.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17311",
    "Sentence": "<\\entity><\\entity> decreased significantly at 12 and 24 months.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17312",
    "Sentence": "No <\\entity><\\entity> was observed over the study period.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17313",
    "Sentence": "<\\entity><\\entity> and infrequent bleeding were the most common menstrual bleeding patterns.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17314",
    "Sentence": "Amenorrhoea and infrequent <\\entity><\\entity> were the most common menstrual <\\entity><\\entity> patterns.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17315",
    "Sentence": "Amenorrhoea and infrequent <\\entity><\\entity> were the most common menstrual <\\entity><\\entity> patterns.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17316",
    "Sentence": "One woman discontinued the method due to frequent <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17317",
    "Sentence": "CONCLUSION: We found no evidence of impaired control of the carbohydrate and lipid metabolism or aggravation of <\\entity><\\entity> during the two years an etonogestrel implant was used by diabetic women.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17318",
    "Sentence": "CONCLUSION: We found no evidence of impaired control of the carbohydrate and lipid metabolism or aggravation of vascular lesions during the two years an <\\entity><\\entity> implant was used by diabetic women.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17319",
    "Sentence": "CONCLUSION: We found no evidence of impaired control of the carbohydrate and lipid metabolism or aggravation of vascular lesions during the two years an <\\entity><\\entity> implant was used by diabetic women.",
    "Label": ""
  },
  {
    "id": "17320",
    "Sentence": "CONCLUSION: We found no evidence of impaired control of the carbohydrate and lipid metabolism or aggravation of <\\entity><\\entity> during the two years an etonogestrel implant was used by diabetic women.",
    "Label": ""
  },
  {
    "id": "17322",
    "Sentence": "<\\entity><\\entity> implant in women with diabetes mellitus.OBJECTIVES: To evaluate the effect of etonogestrel implant on the control of the carbohydrate and lipid metabolism and on the progression of vascular complications in diabetic women treated with insulin, and to assess the acceptability of this modality of contraception in these patients.",
    "Label": ""
  },
  {
    "id": "17323",
    "Sentence": "Etonogestrel implant in women with <\\entity><\\entity>.OBJECTIVES: To evaluate the effect of etonogestrel implant on the control of the carbohydrate and lipid metabolism and on the progression of vascular complications in diabetic women treated with insulin, and to assess the acceptability of this modality of contraception in these patients.",
    "Label": ""
  },
  {
    "id": "17325",
    "Sentence": "Etonogestrel implant in women with diabetes mellitus.OBJECTIVES: To evaluate the effect of <\\entity><\\entity> implant on the control of the carbohydrate and lipid metabolism and on the progression of vascular complications in diabetic women treated with insulin, and to assess the acceptability of this modality of contraception in these patients.",
    "Label": ""
  },
  {
    "id": "17326",
    "Sentence": "Etonogestrel implant in women with diabetes mellitus.OBJECTIVES: To evaluate the effect of etonogestrel implant on the control of the carbohydrate and lipid metabolism and on the progression of <\\entity><\\entity> in diabetic women treated with insulin, and to assess the acceptability of this modality of contraception in these patients.",
    "Label": ""
  },
  {
    "id": "17328",
    "Sentence": "CONCLUSION: We found no evidence of impaired control of the carbohydrate and lipid metabolism or aggravation of vascular lesions during the two years an <\\entity><\\entity> implant was used by diabetic women.",
    "Label": ""
  },
  {
    "id": "17329",
    "Sentence": "CONCLUSION: We found no evidence of impaired control of the carbohydrate and lipid metabolism or aggravation of <\\entity><\\entity> during the two years an etonogestrel implant was used by diabetic women.",
    "Label": ""
  },
  {
    "id": "17331",
    "Sentence": "Etonogestrel implant in women with diabetes mellitus.OBJECTIVES: To evaluate the effect of etonogestrel implant on the control of the carbohydrate and lipid metabolism and on the progression of vascular complications in diabetic women treated with <\\entity><\\entity>, and to assess the acceptability of this modality of contraception in these patients.",
    "Label": ""
  },
  {
    "id": "17332",
    "Sentence": "Etonogestrel implant in women with diabetes mellitus.OBJECTIVES: To evaluate the effect of etonogestrel implant on the control of the carbohydrate and lipid metabolism and on the progression of <\\entity><\\entity> in diabetic women treated with insulin, and to assess the acceptability of this modality of contraception in these patients.",
    "Label": ""
  },
  {
    "id": "17334",
    "Sentence": "METHODS: Prospective-observational study of 23 women with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17335",
    "Sentence": "METHODS: Prospective-observational study of 23 women with <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17341",
    "Sentence": "From Hans Selye's discovery of biological stress to the identification of <\\entity><\\entity> signaling pathways: implication in stress-related functional bowel diseases.Selye pioneered the concept of biological stress in 1936, culminating in the identification of the <\\entity><\\entity> (CRF) signaling pathways by Vale's group in the last two decades.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17342",
    "Sentence": "From Hans Selye's discovery of biological stress to the identification of <\\entity><\\entity> signaling pathways: implication in stress-related functional bowel diseases.Selye pioneered the concept of biological stress in 1936, culminating in the identification of the <\\entity><\\entity> (CRF) signaling pathways by Vale's group in the last two decades.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17343",
    "Sentence": "From Hans Selye's discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related functional bowel diseases.Selye pioneered the concept of biological stress in 1936, culminating in the identification of the corticotropin-releasing factor (<\\entity><\\entity>) signaling pathways by Vale's group in the last two decades.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17344",
    "Sentence": "The characterization of the 41 amino-acid <\\entity><\\entity> and other peptide members of the mammalian <\\entity><\\entity> family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of <\\entity><\\entity>(1) and <\\entity><\\entity>(2) receptors, which display distinct affinity for <\\entity><\\entity> ligands, combined with the development of selective <\\entity><\\entity> receptor antagonists enable us to unravel the importance of <\\entity><\\entity>(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17345",
    "Sentence": "The characterization of the 41 amino-acid <\\entity><\\entity> and other peptide members of the mammalian <\\entity><\\entity> family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of <\\entity><\\entity>(1) and <\\entity><\\entity>(2) receptors, which display distinct affinity for <\\entity><\\entity> ligands, combined with the development of selective <\\entity><\\entity> receptor antagonists enable us to unravel the importance of <\\entity><\\entity>(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17346",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, <\\entity><\\entity>, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17347",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, <\\entity><\\entity>, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17348",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and <\\entity><\\entity>, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17349",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of <\\entity><\\entity> and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of <\\entity><\\entity> receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17350",
    "Sentence": "The characterization of the 4<\\entity><\\entity> amino-acid CRF and other peptide members of the mammalian CRF family, urocortin <\\entity><\\entity>, urocortin 2, and urocortin 3, and the cloning of CRF(<\\entity><\\entity>) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(<\\entity><\\entity>) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17351",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and <\\entity><\\entity>, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17352",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for <\\entity><\\entity>, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17353",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for <\\entity><\\entity>, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17354",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of <\\entity><\\entity> enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17355",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of <\\entity><\\entity> enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17356",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of <\\entity><\\entity> in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17357",
    "Sentence": "The activation of <\\entity><\\entity> receptors is also one of the key mechanisms through which various stressors impact the gut to stimulate colonic propulsive motor function and to induce hypersensitivity to colorectal distension as shown by the efficacy of the <\\entity><\\entity> receptor antagonists in blunting these stress-related components.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17358",
    "Sentence": "The activation of CRF(1) <\\entity><\\entity> is also one of the key mechanisms through which various stressors impact the gut to stimulate colonic propulsive motor function and to induce hypersensitivity to colorectal distension as shown by the efficacy of the CRF(1) receptor antagonists in blunting these stress-related components.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17359",
    "Sentence": "The activation of CRF(1) receptors is also one of the key mechanisms through which various stressors impact the <\\entity><\\entity> to stimulate colonic propulsive motor function and to induce hypersensitivity to colorectal distension as shown by the efficacy of the CRF(1) receptor antagonists in blunting these stress-related components.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17360",
    "Sentence": "The activation of CRF(1) receptors is also one of the key mechanisms through which various stressors impact the gut to stimulate colonic propulsive motor function and to induce hypersensitivity to colorectal distension as shown by the efficacy of the <\\entity><\\entity> in blunting these stress-related components.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17361",
    "Sentence": "The activation of CRF(1) receptors is also one of the key mechanisms through which various stressors impact the gut to stimulate colonic propulsive motor function and to induce hypersensitivity to colorectal distension as shown by the efficacy of the <\\entity><\\entity> in blunting these stress-related components.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17362",
    "Sentence": "The activation of CRF(<\\entity><\\entity>s is also one of the key mechanisms through which various stressors impact the gut to stimulate colonic propulsive motor function and to induce hypersensitivity to colorectal distension as shown by the efficacy of the CRF(<\\entity><\\entity> antagonists in blunting these stress-related components.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17363",
    "Sentence": "The importance of <\\entity><\\entity> signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17364",
    "Sentence": "The importance of CRF(<\\entity><\\entity>) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17365",
    "Sentence": "From Hans Selye's discovery of biological stress to the identification of <\\entity><\\entity> signaling pathways: implication in stress-related functional bowel diseases.Selye pioneered the concept of biological stress in 1936, culminating in the identification of the <\\entity><\\entity> (CRF) signaling pathways by Vale's group in the last two decades.",
    "Label": ""
  },
  {
    "id": "17366",
    "Sentence": "From Hans Selye's discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related <\\entity><\\entity>.Selye pioneered the concept of biological stress in 1936, culminating in the identification of the corticotropin-releasing factor (CRF) signaling pathways by Vale's group in the last two decades.",
    "Label": ""
  },
  {
    "id": "17368",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, <\\entity><\\entity>, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17369",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (<\\entity><\\entity>, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17371",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and <\\entity><\\entity>, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17372",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (<\\entity><\\entity>, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17374",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and <\\entity><\\entity>, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17375",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (<\\entity><\\entity>, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17377",
    "Sentence": "The characterization of the 4<\\entity><\\entity> amino-acid CRF and other peptide members of the mammalian CRF family, urocortin <\\entity><\\entity>, urocortin 2, and urocortin 3, and the cloning of CRF(<\\entity><\\entity>) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(<\\entity><\\entity>) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17378",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (<\\entity><\\entity>, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17380",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of <\\entity><\\entity> in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17381",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (<\\entity><\\entity>, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17383",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for <\\entity><\\entity>, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17384",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, <\\entity><\\entity>, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17386",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for <\\entity><\\entity>, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17387",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and <\\entity><\\entity>, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17389",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for <\\entity><\\entity>, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17390",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (<\\entity><\\entity>, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17392",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for <\\entity><\\entity>, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17393",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of <\\entity><\\entity> in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17395",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for <\\entity><\\entity>, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17396",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, <\\entity><\\entity>, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17398",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of <\\entity><\\entity> enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17399",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, <\\entity><\\entity>, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17401",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of <\\entity><\\entity> enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17402",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and <\\entity><\\entity>, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17404",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of <\\entity><\\entity> enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17405",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and <\\entity><\\entity>, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17407",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of <\\entity><\\entity> enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17408",
    "Sentence": "The characterization of the 4<\\entity><\\entity> amino-acid CRF and other peptide members of the mammalian CRF family, urocortin <\\entity><\\entity>, urocortin 2, and urocortin 3, and the cloning of CRF(<\\entity><\\entity>) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(<\\entity><\\entity>) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17410",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of <\\entity><\\entity> enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17411",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of <\\entity><\\entity> in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17413",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of <\\entity><\\entity> enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17414",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (<\\entity><\\entity>, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17416",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of <\\entity><\\entity> enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17417",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, <\\entity><\\entity>, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17419",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, <\\entity><\\entity>, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (anxiety/depression, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17420",
    "Sentence": "The characterization of the 41 amino-acid CRF and other peptide members of the mammalian CRF family, urocortin 1, urocortin 2, and urocortin 3, and the cloning of CRF(1) and CRF(2) receptors, which display distinct affinity for CRF ligands, combined with the development of selective CRF receptor antagonists enable us to unravel the importance of CRF(1) receptor in the stress-related endocrine (activation of pituitary-adrenal axis), behavioral (<\\entity><\\entity>, altered feeding), autonomic (activation of sympathetic nervous system), and immune responses.",
    "Label": ""
  },
  {
    "id": "17422",
    "Sentence": "The activation of CRF(<\\entity><\\entity>s is also one of the key mechanisms through which various stressors impact the gut to stimulate colonic propulsive motor function and to induce hypersensitivity to colorectal distension as shown by the efficacy of the CRF(<\\entity><\\entity> antagonists in blunting these stress-related components.",
    "Label": ""
  },
  {
    "id": "17423",
    "Sentence": "The activation of CRF(1) receptors is also one of the key mechanisms through which various stressors impact the gut to stimulate colonic propulsive motor function and to induce <\\entity><\\entity> to colorectal distension as shown by the efficacy of the CRF(1) receptor antagonists in blunting these stress-related components.",
    "Label": ""
  },
  {
    "id": "17425",
    "Sentence": "The activation of CRF(<\\entity><\\entity>s is also one of the key mechanisms through which various stressors impact the gut to stimulate colonic propulsive motor function and to induce hypersensitivity to colorectal distension as shown by the efficacy of the CRF(<\\entity><\\entity> antagonists in blunting these stress-related components.",
    "Label": ""
  },
  {
    "id": "17426",
    "Sentence": "The activation of CRF(1) receptors is also one of the key mechanisms through which various stressors impact the gut to stimulate colonic propulsive motor function and to induce hypersensitivity to colorectal <\\entity><\\entity> as shown by the efficacy of the CRF(1) receptor antagonists in blunting these stress-related components.",
    "Label": ""
  },
  {
    "id": "17428",
    "Sentence": "The activation of CRF(1) receptors is also one of the key mechanisms through which various stressors impact the gut to stimulate colonic propulsive motor function and to induce hypersensitivity to colorectal distension as shown by the efficacy of the <\\entity><\\entity> in blunting these stress-related components.",
    "Label": ""
  },
  {
    "id": "17429",
    "Sentence": "The activation of CRF(1) receptors is also one of the key mechanisms through which various stressors impact the gut to stimulate colonic propulsive motor function and to induce <\\entity><\\entity> to colorectal distension as shown by the efficacy of the CRF(1) receptor antagonists in blunting these stress-related components.",
    "Label": ""
  },
  {
    "id": "17431",
    "Sentence": "The activation of CRF(1) receptors is also one of the key mechanisms through which various stressors impact the gut to stimulate colonic propulsive motor function and to induce hypersensitivity to colorectal distension as shown by the efficacy of the <\\entity><\\entity> in blunting these stress-related components.",
    "Label": ""
  },
  {
    "id": "17432",
    "Sentence": "The activation of CRF(1) receptors is also one of the key mechanisms through which various stressors impact the gut to stimulate colonic propulsive motor function and to induce hypersensitivity to colorectal <\\entity><\\entity> as shown by the efficacy of the CRF(1) receptor antagonists in blunting these stress-related components.",
    "Label": ""
  },
  {
    "id": "17434",
    "Sentence": "The importance of CRF(<\\entity><\\entity>) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17435",
    "Sentence": "The importance of CRF(1) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as <\\entity><\\entity>, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17437",
    "Sentence": "The importance of CRF(<\\entity><\\entity>) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17438",
    "Sentence": "The importance of CRF(1) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of <\\entity><\\entity> such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17440",
    "Sentence": "The importance of CRF(<\\entity><\\entity>) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17441",
    "Sentence": "The importance of CRF(1) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by <\\entity><\\entity> and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17443",
    "Sentence": "The importance of CRF(<\\entity><\\entity>) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17444",
    "Sentence": "The importance of CRF(1) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and <\\entity><\\entity>, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17446",
    "Sentence": "The importance of CRF(<\\entity><\\entity>) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17447",
    "Sentence": "The importance of CRF(1) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated <\\entity><\\entity> in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17449",
    "Sentence": "The importance of <\\entity><\\entity> signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17450",
    "Sentence": "The importance of CRF(1) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as <\\entity><\\entity>, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17452",
    "Sentence": "The importance of <\\entity><\\entity> signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17453",
    "Sentence": "The importance of CRF(1) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of <\\entity><\\entity> such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17455",
    "Sentence": "The importance of <\\entity><\\entity> signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17456",
    "Sentence": "The importance of CRF(1) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by <\\entity><\\entity> and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17458",
    "Sentence": "The importance of <\\entity><\\entity> signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17459",
    "Sentence": "The importance of CRF(1) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and <\\entity><\\entity>, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17461",
    "Sentence": "The importance of <\\entity><\\entity> signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated with anxiety-depression in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17462",
    "Sentence": "The importance of CRF(1) signaling pathway in the visceral response to stress in experimental animals provided new therapeutic approaches for treatment of functional bowel disorder such as irritable bowel syndrome, a multifactor functional disorder characterized by altered bowel habits and visceral pain, for which stress has been implicated in the pathophysiology and is associated <\\entity><\\entity> in a subset of patients.",
    "Label": ""
  },
  {
    "id": "17468",
    "Sentence": "Improved virologic response in <\\entity><\\entity> treated with nitazoxanide, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with <\\entity><\\entity> treated with peginterferon plus ribavirin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17469",
    "Sentence": "Improved virologic response in chronic <\\entity><\\entity> genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic <\\entity><\\entity> genotype 4 treated with peginterferon plus ribavirin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17470",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with <\\entity><\\entity>, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus ribavirin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17471",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, <\\entity><\\entity>, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with <\\entity><\\entity> plus ribavirin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17472",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and <\\entity><\\entity>.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17473",
    "Sentence": "Improved virologic response in <\\entity><\\entity> treated with nitazoxanide, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with <\\entity><\\entity> treated with peginterferon plus ribavirin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17474",
    "Sentence": "Improved virologic response in chronic <\\entity><\\entity> genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic <\\entity><\\entity> genotype 4 treated with peginterferon plus ribavirin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17475",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, <\\entity><\\entity>, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with <\\entity><\\entity> plus ribavirin.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17476",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and <\\entity><\\entity>.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17477",
    "Sentence": "The safety and efficacy of <\\entity><\\entity> plus peginterferon alfa-2a, with or without ribavirin, were evaluated in a randomized controlled trial at 2 centers in Egypt.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17478",
    "Sentence": "The safety and efficacy of nitazoxanide plus <\\entity><\\entity>, with or without ribavirin, were evaluated in a randomized controlled trial at 2 centers in Egypt.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17479",
    "Sentence": "The safety and efficacy of nitazoxanide plus peginterferon alfa-2a, with or without <\\entity><\\entity>, were evaluated in a randomized controlled trial at 2 centers in Egypt.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17480",
    "Sentence": "METHODS: Previously untreated patients with <\\entity><\\entity> C and genotype 4 infection were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17481",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and <\\entity><\\entity> were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17482",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (<\\entity><\\entity> and ribavirin for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus <\\entity><\\entity> for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus <\\entity><\\entity> and ribavirin for 36 weeks (n = 28).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17483",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and <\\entity><\\entity> for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a and <\\entity><\\entity> for 36 weeks (n = 28).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17484",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40), <\\entity><\\entity> monotherapy for 12 weeks followed by <\\entity><\\entity> plus peginterferon alfa-2a for 36 weeks (n = 28), or <\\entity><\\entity> monotherapy for 12 weeks followed by <\\entity><\\entity> plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17485",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40), <\\entity><\\entity> monotherapy for 12 weeks followed by <\\entity><\\entity> plus peginterferon alfa-2a for 36 weeks (n = 28), or <\\entity><\\entity> monotherapy for 12 weeks followed by <\\entity><\\entity> plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17486",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (<\\entity><\\entity> and ribavirin for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus <\\entity><\\entity> for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus <\\entity><\\entity> and ribavirin for 36 weeks (n = 28).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17487",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40), <\\entity><\\entity> monotherapy for 12 weeks followed by <\\entity><\\entity> plus peginterferon alfa-2a for 36 weeks (n = 28), or <\\entity><\\entity> monotherapy for 12 weeks followed by <\\entity><\\entity> plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17488",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40), <\\entity><\\entity> monotherapy for 12 weeks followed by <\\entity><\\entity> plus peginterferon alfa-2a for 36 weeks (n = 28), or <\\entity><\\entity> monotherapy for 12 weeks followed by <\\entity><\\entity> plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17489",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (<\\entity><\\entity> and ribavirin for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus <\\entity><\\entity> for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus <\\entity><\\entity> and ribavirin for 36 weeks (n = 28).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17490",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and <\\entity><\\entity> for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a and <\\entity><\\entity> for 36 weeks (n = 28).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17491",
    "Sentence": "Therapeutics included <\\entity><\\entity> (500 mg) twice daily, peginterferon alfa-2a (180 microg) once weekly, and weight-based ribavirin (1000-1200 mg/day).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17492",
    "Sentence": "Therapeutics included nitazoxanide (500 mg) twice daily, <\\entity><\\entity> (180 microg) once weekly, and weight-based ribavirin (1000-1200 mg/day).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17493",
    "Sentence": "Therapeutics included nitazoxanide (500 mg) twice daily, peginterferon alfa-2a (180 microg) once weekly, and <\\entity><\\entity>-based ribavirin (1000-1200 mg/day).",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17494",
    "Sentence": "Therapeutics included nitazoxanide (500 mg) twice daily, peginterferon alfa-2a (180 microg) once weekly, and weight-based <\\entity><\\entity> (1000-1200 mg/day).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17495",
    "Sentence": "Patients given <\\entity><\\entity> plus peginterferon alfa-2a had intermediate rates of RVR (54%) and SVR (61%).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17496",
    "Sentence": "Patients given nitazoxanide plus <\\entity><\\entity> had intermediate rates of RVR (54%) and SVR (61%).",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17497",
    "Sentence": "Adverse events were similar across treatment groups except for higher rates of <\\entity><\\entity> in the groups receiving ribavirin.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17498",
    "Sentence": "Adverse events were similar across treatment groups except for higher rates of anemia in the groups receiving <\\entity><\\entity>.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17499",
    "Sentence": "CONCLUSIONS: The combination of <\\entity><\\entity>, peginterferon alfa-2a, and ribavirin increased the percentages of patients with RVR and SVR, compared with patients given peginterferon plus ribavirin, without an increase in adverse events.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17500",
    "Sentence": "CONCLUSIONS: The combination of nitazoxanide, <\\entity><\\entity>, and ribavirin increased the percentages of patients with RVR and SVR, compared with patients given peginterferon plus ribavirin, without an increase in adverse events.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17501",
    "Sentence": "CONCLUSIONS: The combination of nitazoxanide, peginterferon alfa-2a, and <\\entity><\\entity> increased the percentages of patients with RVR and SVR, compared with patients given peginterferon plus <\\entity><\\entity>, without an increase in adverse events.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17502",
    "Sentence": "CONCLUSIONS: The combination of nitazoxanide, <\\entity><\\entity> alfa-2a, and ribavirin increased the percentages of patients with RVR and SVR, compared with patients given <\\entity><\\entity> plus ribavirin, without an increase in adverse events.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17503",
    "Sentence": "CONCLUSIONS: The combination of nitazoxanide, peginterferon alfa-2a, and <\\entity><\\entity> increased the percentages of patients with RVR and SVR, compared with patients given peginterferon plus <\\entity><\\entity>, without an increase in adverse events.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17504",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and <\\entity><\\entity>.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17505",
    "Sentence": "Improved virologic response in <\\entity><\\entity> treated with nitazoxanide, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with <\\entity><\\entity> treated with peginterferon plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17507",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, <\\entity><\\entity>, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with <\\entity><\\entity> plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17508",
    "Sentence": "Improved virologic response in <\\entity><\\entity> treated with nitazoxanide, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with <\\entity><\\entity> treated with peginterferon plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17510",
    "Sentence": "Adverse events were similar across treatment groups except for higher rates of anemia in the groups receiving <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17511",
    "Sentence": "Adverse events were similar across treatment groups except for higher rates of <\\entity><\\entity> in the groups receiving ribavirin.",
    "Label": ""
  },
  {
    "id": "17513",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with <\\entity><\\entity>, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17514",
    "Sentence": "Improved virologic response in <\\entity><\\entity> treated with nitazoxanide, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with <\\entity><\\entity> treated with peginterferon plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17516",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with <\\entity><\\entity>, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17517",
    "Sentence": "Improved virologic response in chronic <\\entity><\\entity> genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic <\\entity><\\entity> genotype 4 treated with peginterferon plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17519",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and <\\entity><\\entity>.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17520",
    "Sentence": "Improved virologic response in <\\entity><\\entity> treated with nitazoxanide, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with <\\entity><\\entity> treated with peginterferon plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17522",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and <\\entity><\\entity>.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17523",
    "Sentence": "Improved virologic response in chronic <\\entity><\\entity> genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic <\\entity><\\entity> genotype 4 treated with peginterferon plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17525",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and <\\entity><\\entity>.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with peginterferon plus <\\entity><\\entity>.",
    "Label": ""
  },
  {
    "id": "17526",
    "Sentence": "Improved virologic response in chronic <\\entity><\\entity> genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic <\\entity><\\entity> genotype 4 treated with peginterferon plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17528",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40), <\\entity><\\entity> monotherapy for 12 weeks followed by <\\entity><\\entity> plus peginterferon alfa-2a for 36 weeks (n = 28), or <\\entity><\\entity> monotherapy for 12 weeks followed by <\\entity><\\entity> plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28).",
    "Label": ""
  },
  {
    "id": "17529",
    "Sentence": "METHODS: Previously untreated patients with <\\entity><\\entity> C and genotype 4 infection were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28).",
    "Label": ""
  },
  {
    "id": "17531",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40), <\\entity><\\entity> monotherapy for 12 weeks followed by <\\entity><\\entity> plus peginterferon alfa-2a for 36 weeks (n = 28), or <\\entity><\\entity> monotherapy for 12 weeks followed by <\\entity><\\entity> plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28).",
    "Label": ""
  },
  {
    "id": "17532",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and <\\entity><\\entity> were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28).",
    "Label": ""
  },
  {
    "id": "17534",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and <\\entity><\\entity> for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a and <\\entity><\\entity> for 36 weeks (n = 28).",
    "Label": ""
  },
  {
    "id": "17535",
    "Sentence": "METHODS: Previously untreated patients with <\\entity><\\entity> C and genotype 4 infection were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28).",
    "Label": ""
  },
  {
    "id": "17537",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and <\\entity><\\entity> for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a and <\\entity><\\entity> for 36 weeks (n = 28).",
    "Label": ""
  },
  {
    "id": "17538",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and <\\entity><\\entity> were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28).",
    "Label": ""
  },
  {
    "id": "17540",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (<\\entity><\\entity> and ribavirin for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus <\\entity><\\entity> for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus <\\entity><\\entity> and ribavirin for 36 weeks (n = 28).",
    "Label": ""
  },
  {
    "id": "17541",
    "Sentence": "METHODS: Previously untreated patients with <\\entity><\\entity> C and genotype 4 infection were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28).",
    "Label": ""
  },
  {
    "id": "17543",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and genotype 4 infection were assigned randomly to groups that were given standard of care (<\\entity><\\entity> and ribavirin for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus <\\entity><\\entity> for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus <\\entity><\\entity> and ribavirin for 36 weeks (n = 28).",
    "Label": ""
  },
  {
    "id": "17544",
    "Sentence": "METHODS: Previously untreated patients with chronic hepatitis C and <\\entity><\\entity> were assigned randomly to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40), nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a for 36 weeks (n = 28), or nitazoxanide monotherapy for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28).",
    "Label": ""
  },
  {
    "id": "17546",
    "Sentence": "Therapeutics included <\\entity><\\entity> (500 mg) twice daily, peginterferon alfa-2a (180 microg) once weekly, and weight-based ribavirin (1000-1200 mg/day).",
    "Label": ""
  },
  {
    "id": "17547",
    "Sentence": "Therapeutics included nitazoxanide (500 mg) twice daily, peginterferon alfa-2a (180 microg) once weekly, and <\\entity><\\entity>-based ribavirin (1000-1200 mg/day).",
    "Label": ""
  },
  {
    "id": "17549",
    "Sentence": "Therapeutics included nitazoxanide (500 mg) twice daily, peginterferon alfa-2a (180 microg) once weekly, and weight-based <\\entity><\\entity> (1000-1200 mg/day).",
    "Label": ""
  },
  {
    "id": "17550",
    "Sentence": "Therapeutics included nitazoxanide (500 mg) twice daily, peginterferon alfa-2a (180 microg) once weekly, and <\\entity><\\entity>-based ribavirin (1000-1200 mg/day).",
    "Label": ""
  },
  {
    "id": "17552",
    "Sentence": "Therapeutics included nitazoxanide (500 mg) twice daily, <\\entity><\\entity> (180 microg) once weekly, and weight-based ribavirin (1000-1200 mg/day).",
    "Label": ""
  },
  {
    "id": "17553",
    "Sentence": "Therapeutics included nitazoxanide (500 mg) twice daily, peginterferon alfa-2a (180 microg) once weekly, and <\\entity><\\entity>-based ribavirin (1000-1200 mg/day).",
    "Label": ""
  },
  {
    "id": "17555",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, <\\entity><\\entity>, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with <\\entity><\\entity> plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17556",
    "Sentence": "Improved virologic response in <\\entity><\\entity> treated with nitazoxanide, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with <\\entity><\\entity> treated with peginterferon plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17558",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, <\\entity><\\entity>, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with <\\entity><\\entity> plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17559",
    "Sentence": "Improved virologic response in chronic <\\entity><\\entity> genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic <\\entity><\\entity> genotype 4 treated with peginterferon plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17561",
    "Sentence": "Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, <\\entity><\\entity>, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic hepatitis C genotype 4 treated with <\\entity><\\entity> plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17562",
    "Sentence": "Improved virologic response in chronic <\\entity><\\entity> genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.BACKGROUND & AIMS: Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with chronic <\\entity><\\entity> genotype 4 treated with peginterferon plus ribavirin.",
    "Label": ""
  },
  {
    "id": "17568",
    "Sentence": "Analysis of additional virulence genes and <\\entity><\\entity> confirms the epidemiologic relevance of multi-virulence-locus sequence typing.Previous molecular subtyping studies have defined four epidemic clones (ECs) of Listeria monocytogenes (ECI, ECII, ECIII, and ECIV).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17569",
    "Sentence": "Analysis of additional virulence genes and virulence gene regions in Listeria monocytogenes confirms the epidemiologic relevance of multi-virulence-locus sequence typing.Previous molecular subtyping studies have defined four epidemic clones (ECs) of Listeria monocytogenes (<\\entity><\\entity>, <\\entity><\\entity>I, <\\entity><\\entity>II, and <\\entity><\\entity>V).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17570",
    "Sentence": "Analysis of additional virulence genes and virulence gene regions in Listeria monocytogenes confirms the epidemiologic relevance of multi-virulence-locus sequence typing.Previous molecular subtyping studies have defined four epidemic clones (ECs) of Listeria monocytogenes (ECI, <\\entity><\\entity>, <\\entity><\\entity>I, and ECIV).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17571",
    "Sentence": "Analysis of additional virulence genes and virulence gene regions in Listeria monocytogenes confirms the epidemiologic relevance of multi-virulence-locus sequence typing.Previous molecular subtyping studies have defined four epidemic clones (ECs) of Listeria monocytogenes (ECI, ECII, <\\entity><\\entity>, and ECIV).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17572",
    "Sentence": "Analysis of additional virulence genes and virulence gene regions in Listeria monocytogenes confirms the epidemiologic relevance of multi-virulence-locus sequence typing.Previous molecular subtyping studies have defined four epidemic clones (ECs) of Listeria monocytogenes (ECI, ECII, ECIII, and <\\entity><\\entity>).",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17573",
    "Sentence": "Six additional virulence genes--<\\entity><\\entity>, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17574",
    "Sentence": "Six additional virulence genes--bsh, <\\entity><\\entity>, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17575",
    "Sentence": "Six additional virulence genes--bsh, hly, <\\entity><\\entity>, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17576",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, <\\entity><\\entity>, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17577",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, <\\entity><\\entity>, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17578",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and <\\entity><\\entity>--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17579",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of <\\entity><\\entity>, inlA, and inlB were selected based on their role in L.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17580",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, <\\entity><\\entity>, and inlB were selected based on their role in L.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17581",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and <\\entity><\\entity> were selected based on their role in L.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17582",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17583",
    "Sentence": "monocytogenes <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17584",
    "Sentence": "Results demonstrated that the sequenced regions of the <\\entity><\\entity> were identical within each of the ECs, and 257 new single nucleotide polymorphism (SNPs) were identified.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17585",
    "Sentence": "<\\entity><\\entity> (lineage II) was easily distinguishable from the other ECs, as 238 SNPs were observed in <\\entity><\\entity> due to its significant evolutionary divergence from lineage I.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17586",
    "Sentence": "<\\entity><\\entity> (lineage II) was easily distinguishable from the other ECs, as 238 SNPs were observed in <\\entity><\\entity> due to its significant evolutionary divergence from lineage I.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17587",
    "Sentence": "With regard to the other ECs, there were 5 SNPs that represented an informative set, since these SNPs were able to differentiate specific ECs from all other unrelated <\\entity><\\entity> used in this study.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17588",
    "Sentence": "monocytogenes from each other and from other diverse <\\entity><\\entity>.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17589",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, <\\entity><\\entity>, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17590",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17592",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of <\\entity><\\entity>, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17593",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17595",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, <\\entity><\\entity>, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17596",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17598",
    "Sentence": "Six additional virulence genes--bsh, <\\entity><\\entity>, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17599",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17601",
    "Sentence": "Six additional virulence genes--bsh, hly, <\\entity><\\entity>, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17602",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17604",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, <\\entity><\\entity>, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17605",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17607",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and <\\entity><\\entity>--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17608",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17610",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and <\\entity><\\entity> were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17611",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17613",
    "Sentence": "Six additional virulence genes--<\\entity><\\entity>, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17614",
    "Sentence": "Six additional virulence genes--bsh, hly, inlJ, IplA1, pgdA, and srtA--and three additional virulence gene regions of actA, inlA, and inlB were selected based on their role in L.",
    "Label": ""
  },
  {
    "id": "17620",
    "Sentence": "Mass defect filtering on high resolution LC/MS data as a methodology for detecting metabolites with unpredictable structures: identification of <\\entity><\\entity>.This study describes the application of the mass defect filter method for the detection of two unpredicted <\\entity><\\entity> in the feces of humans following oral administration.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17621",
    "Sentence": "Mass defect filtering on high resolution LC/MS data as a methodology for detecting metabolites with unpredictable structures: identification of <\\entity><\\entity>.This study describes the application of the mass defect filter method for the detection of two unpredicted <\\entity><\\entity> in the feces of humans following oral administration.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17622",
    "Sentence": "Unlike other <\\entity><\\entity>, these metabolites formed little to no protonated ions, and the NH(4)(+) or Na(+) adduct ions that were formed were weak and not discernible from fecal interferences even after background subtraction.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17623",
    "Sentence": "Unlike other muraglitazar metabolites, these metabolites formed little to no protonated ions, and the <\\entity><\\entity> or Na(+) adduct ions that were formed were weak and not discernible from fecal interferences even after background subtraction.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17624",
    "Sentence": "Unlike other muraglitazar metabolites, these metabolites formed little to no protonated ions, and the NH(4)(+) or <\\entity><\\entity> adduct ions that were formed were weak and not discernible from fecal interferences even after background subtraction.",
    "Label": "Chemicals & Drugs"
  },
  {
    "id": "17629",
    "Sentence": "Compound heterozygosity for the <\\entity><\\entity> and A1298C mutations of the MTHFR gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "17630",
    "Sentence": "Compound heterozygosity for the C677T and <\\entity><\\entity> gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": "SNP & Sequence variations"
  },
  {
    "id": "17631",
    "Sentence": "Compound heterozygosity for the C677T and <\\entity><\\entity> gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17632",
    "Sentence": "Compound heterozygosity for the C677T and A1298C <\\entity><\\entity> of the MTHFR gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17633",
    "Sentence": "Compound heterozygosity for the C677T and A1298C mutations of the MTHFR gene in a case of <\\entity><\\entity> with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17634",
    "Sentence": "Compound heterozygosity for the C677T and A1298C mutations of the MTHFR gene in a case of hyperhomocysteinemia with recurrent <\\entity><\\entity> at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17635",
    "Sentence": "Compound heterozygosity for the C677T and A1298C mutations of the MTHFR gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent <\\entity><\\entity> (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17636",
    "Sentence": "Compound heterozygosity for the C677T and A1298C mutations of the MTHFR gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (<\\entity><\\entity>) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17637",
    "Sentence": "All blood investigations for etiology of recurrent <\\entity><\\entity> were normal except for serum homocysteine level, which was mildly increased.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17638",
    "Sentence": "All blood investigations for etiology of recurrent DVT were normal except for serum <\\entity><\\entity> level, which was mildly increased.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17639",
    "Sentence": "The three main causes of <\\entity><\\entity> are genetic defects, nutritional deficiencies and insufficient elimination.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17640",
    "Sentence": "The three main causes of hyperhomocysteinemia are genetic defects, <\\entity><\\entity> and insufficient elimination.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17641",
    "Sentence": "In our case a genetic defect for one of the key enzymes of <\\entity><\\entity> metabolism was found to be the underlying cause.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17642",
    "Sentence": "Oral anticoagulation and supplementation with pyridoxine, cyanocobalamine and <\\entity><\\entity> was recommended.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17643",
    "Sentence": "Whether therapy with <\\entity><\\entity> and folate can substantially reduce the recurrence of venous thromboembolic disease remains to be established.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17644",
    "Sentence": "Whether therapy with B vitamins and <\\entity><\\entity> can substantially reduce the recurrence of venous thromboembolic disease remains to be established.",
    "Label": "Genes & Molecular Sequences"
  },
  {
    "id": "17645",
    "Sentence": "Whether therapy with B vitamins and folate can substantially reduce the recurrence of <\\entity><\\entity> remains to be established.",
    "Label": "Diseases & Disorders"
  },
  {
    "id": "17646",
    "Sentence": "Whether therapy with <\\entity><\\entity> and folate can substantially reduce the recurrence of venous thromboembolic disease remains to be established.",
    "Label": ""
  },
  {
    "id": "17647",
    "Sentence": "Whether therapy with B vitamins and folate can substantially reduce the recurrence of <\\entity><\\entity> remains to be established.",
    "Label": ""
  },
  {
    "id": "17649",
    "Sentence": "Whether therapy with B vitamins and <\\entity><\\entity> can substantially reduce the recurrence of venous thromboembolic disease remains to be established.",
    "Label": ""
  },
  {
    "id": "17650",
    "Sentence": "Whether therapy with B vitamins and folate can substantially reduce the recurrence of <\\entity><\\entity> remains to be established.",
    "Label": ""
  },
  {
    "id": "17652",
    "Sentence": "Compound heterozygosity for the C677T and <\\entity><\\entity> gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": ""
  },
  {
    "id": "17653",
    "Sentence": "Compound heterozygosity for the C677T and A1298C <\\entity><\\entity> of the MTHFR gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": ""
  },
  {
    "id": "17655",
    "Sentence": "Compound heterozygosity for the C677T and <\\entity><\\entity> gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": ""
  },
  {
    "id": "17656",
    "Sentence": "Compound heterozygosity for the C677T and A1298C mutations of the MTHFR gene in a case of <\\entity><\\entity> with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": ""
  },
  {
    "id": "17658",
    "Sentence": "Compound heterozygosity for the C677T and <\\entity><\\entity> gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": ""
  },
  {
    "id": "17659",
    "Sentence": "Compound heterozygosity for the C677T and A1298C mutations of the MTHFR gene in a case of hyperhomocysteinemia with recurrent <\\entity><\\entity> at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": ""
  },
  {
    "id": "17661",
    "Sentence": "Compound heterozygosity for the <\\entity><\\entity> and A1298C mutations of the MTHFR gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": ""
  },
  {
    "id": "17662",
    "Sentence": "Compound heterozygosity for the C677T and A1298C mutations of the MTHFR gene in a case of <\\entity><\\entity> with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": ""
  },
  {
    "id": "17664",
    "Sentence": "Compound heterozygosity for the <\\entity><\\entity> and A1298C mutations of the MTHFR gene in a case of hyperhomocysteinemia with recurrent deep thrombosis at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": ""
  },
  {
    "id": "17665",
    "Sentence": "Compound heterozygosity for the C677T and A1298C mutations of the MTHFR gene in a case of hyperhomocysteinemia with recurrent <\\entity><\\entity> at young age.We report a case of a young woman with an extensive, recurrent deep vein thrombosis (DVT) diagnosed by CT scan and duplex ultrasound examination.",
    "Label": ""
  }
]